<SEC-DOCUMENT>0001628280-22-004291.txt : 20220228
<SEC-HEADER>0001628280-22-004291.hdr.sgml : 20220228
<ACCEPTANCE-DATETIME>20220228172054
ACCESSION NUMBER:		0001628280-22-004291
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220228
DATE AS OF CHANGE:		20220228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		22691540

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ameh-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:56a96635-232a-499f-a03d-15d085375db3,g:3c5e1a1a-f2ce-472c-bc52-288bd5b84a32,d:796d62c2eb674b8c9edd48d78ebf1f96--><html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ameh="http://www.apollomed.net/20211231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ameh-20211231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV8zLTEtMS0xLTA_0f3855e7-9d58-4a94-97a8-b7baf56faa84">false</ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV80LTEtMS0xLTA_66f4422f-a161-43df-9c71-cb88caaa3a17">2021</ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV81LTEtMS0xLTA_b8a923d9-c53b-4c7f-a284-3b7d225c7afa">FY</ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV82LTEtMS0xLTA_7b75b2fb-c44a-47cb-8511-b8bdd4a83b29">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231" name="ameh:AccountsReceivableExpectedToBeCollectedPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5OTk_64bfc1bc-0468-44da-ae64-8adbf345015b">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMDk1_890dedd3-9639-4f3d-a087-9691ad4f5456">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="icfa29991cc184f5ab71a9689f9e7cbb3_I20191231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MDUx_13452d7a-ce48-4cb1-9932-b9a62aad18dd">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i889c185a8f9149ea80fad8d3964a0104_I20211231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MTA3_7004a731-22ef-4a6d-af57-dbde08754dca">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjU2_c963fd5b-c811-4093-81f8-04122b4eaed7">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzEx_0992ad4a-a700-4f32-8ee4-5af8a166e27a">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzgy_218c2412-51ed-4adf-8fb2-fba58a465401">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzY0OQ_c2588d0e-53b8-4fa3-9a93-34c4f0d89c10" escape="true">Subsequent Events<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Orma Health, Inc., and Provider Growth Solutions LLC (together, "Orma Health")</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company announced that it acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#8220;Orma Health&#8221;) in accordance with an agreement between ApolloMed, Orma, and certain equity holders of Orma Health. Per the agreement, the purchase price consists of $2.0 million in cash and shares. Through its suite of AI-driven solutions, Orma Health currently serves over 4,000 aligned Medicare beneficiaries in a Direct Contracting Entity (&#8220;DCE&#8221;) and over 2,500 patients in California, Nevada, Arizona, and Texas through its remote patient monitoring ("RPM") platform.</span></div></ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ic8994136231a429187388373d060ea08_I20220131" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzYwNDczMTM5NTUzNTg_091ab6eb-48a1-4381-b862-a1ee2bf1ba85">100</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ia9cc68c974834aefa2ce53b34b45264a_D20220101-20220131" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzEwOTk1MTE2MzEzNDQ_648e4a1f-7151-473b-91b2-25a96b7739a1">2.0</ix:nonFraction><ix:nonFraction unitRef="patient" contextRef="ic8994136231a429187388373d060ea08_I20220131" decimals="INF" name="ameh:NumberOfDirectContractingEntityPatients" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzYwNDczMTM5NTUzNjQ_87ae507c-2078-472f-a2f5-f8ba9b5909a3">4,000</ix:nonFraction><ix:nonFraction unitRef="patient" contextRef="ic8994136231a429187388373d060ea08_I20220131" decimals="INF" name="ameh:NumberOfRemotePatientMonitoringPatients" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzYwNDczMTM5NTUzNzE_d63830c0-700c-4182-89a6-4a73428dc93d">2,500</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ameh-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc6ae380313d4f9e9297cfdbf9b997ac_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ib7afb98c0185462db67289bfa9ee20c8_I20220216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8759c801140b4316acf0688d1a7d8073_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a3083cbe3b4707adbb02b65c588a45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d8f20402a94db18c5d908913c78e54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0648fafc89a544e7a200bb47e8fe8e6e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae936f11a7bb4e4c99d3fe13851ffc0b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830aa1f9bb124cffa1eb7bbc0aff0ad3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bca0ca7ef34b17b7aa1fbeb535bbf0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id541469a4a79478381a9bc7f4f5a6536_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb259c5215b44e0591d9d9fe4eca90e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i612cc8b6b50c4dd986466df93d1b6382_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dc831eca8c24ab395130475d7b38dd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea8035697aa431d99f99268b6c7d832_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2efb609fa90049de89473edcbce394a5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i872c7cf84d474bde9cbecebf6dc0d987_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2292f34b157f4b3b842835c609844787_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id823cee670274003a572be40978abfb9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38935258fdd640ccbf3015940e510e1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea80e278e3444cafa519677345773d02_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69d3506ad61545a28e82fbaea4860bd7_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i238ec269dd2b4e39bf78ffb28244ae9f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dc7a8bb404d44d6a025101ce145ebcb_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1890ce55fe054d5fb8532b6899d89386_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64bc2b851e8049a69e6c4252d1789f5a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51d91826c13e48f9ac3b196f1709cf0c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69343d65ad324809810e1b1eda1dbc7d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:HoldbackSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i6084317bda0d48f9b2293ce7324d000d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae93612a82b454fad4c214ad4fbe93f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59f1b5c490b84fb7bcd0e27816f8a1fd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic665959fd8094aba83a52190f5ce2a29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7108c557e599411aa1a3345423fbcaf2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2666f9aebddc43b295ec38700190d8f9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd090b6a4d07450b83ab3ba19b8a8b82_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcca7582879a462a8ca400618dab2e16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbb14ec4c3d04df498362b3ff2649443_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ebd2bb3cc9f4ccfb1e9e646ea718b5a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b34f542dee746a88ed1f03df4889be3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76474cb8ad064d37a1739d166c60efc9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0752ab08774f379384a68ffb9687d6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92f73d2de50b4e529703a74542535701_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02229923c53147db941db9c29b48ab30_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic922097b0d6044c2893f7d407499ba35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c75cb4bf9e4ad79f118905ac2df40d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0088a70f180a4664865e2acb1ce90bce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97a105ebf2734bc999cb1eda989a2bf9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca318fe85484ec8995fd60b38993065_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f341ffb85ca4a0a9602302c5c3d5969_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a787853fb4e44ab97a431b68a27e17f_D19990701-19990731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-07-01</xbrli:startDate><xbrli:endDate>1999-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075d8ca8fc3540c08520741050fea395_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2b7ab46ec1f4230b17c5bc1355ea969_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb9136ad4e1240bd8120581c09a56b83_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic93862edf0d94e38a0905a9d5e2a7e97_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i730fecde417c468e90d3113624967018_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7b9267d39a0457aa1e20e58ddb345e4_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2380fc33084f94b7a593212ef66566_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439aed610b4a4563872164ecdf084f75_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica1cde9ee4cb4494b58321188ad95db5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4bb40e84ae24fb4b5080af0965a1437_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c3dd0689a5341d584d1b40693f33ff1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5742adc9978b45aaa40335db8f9111dd_D20190531-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-31</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ba50ac0812478a8bf374d9030b66b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ameh:plan</xbrli:measure></xbrli:unit><xbrli:context id="i82f8e127a67545b3bdfa58cfd22513c0_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f4a82d79e57442f9d6db8a9a608f3ff_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide47e2643c3c4ee5a76d35bfdd8a6db7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>ameh:clinic</xbrli:measure></xbrli:unit><xbrli:context id="ia8e95cb40b2041898bc0dd250b3bf3a3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eb95e4e08f44ee1bbc425d9152ac541_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i971fe048ecb4482193d9bb6633606328_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c118bd8bb54e4d9429b7ddcd63c503_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa8a8f6914b344759eab7b2e8596a641_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47097cefe18c427f8543ad5cd7663066_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fb44b3ad67c4065a24264c841b2285a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff99085ba68941a1a5742e3e59299a26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bb290c80ed04d9284ae72a27d2b780d_I20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e863e59c64443d08c0faadab68620e3_I20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie58240bdc60b46879e56e7842cd94022_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ameh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i843561394b2844a9b8120f9bad1daee3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56fd8a6fc7d245bdbb1e814caed96cee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d60f7810f154d9185d11b65f7a20684_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f06cfd6220a4db180cc0a47fb336fc4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i302d9a0e032749edb6f74c01755fae4b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac5f8642c01d4d23bd5b08e841100c8c_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2fdbacce1904cf3912b442f8c709d96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32f8e0c168ce444ca00cbd5129aa617a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0587413f1c6a47c099219d283492a39a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16b60c8d266045aa80eb56cf8c52109f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i745de55cc97343cf9f5cd4dd3f327d33_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c70a6d6fd1473aa3326d1e1d7c1a0b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id30a014ea9a543089265dbe3894f75f9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68bb08ba38e94f7bb612b424801b2a5c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d8221e56424d85ab5b7cc79c7ebe1e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022a5fa7aae74c619acb43e67e97eda4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2e545c192042c0a652056f20110ef6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8391dd985bc48f89be89e25c7043816_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9926274bc8d84660ae987c991d85aa80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4300a3b054a47eb9093ebb87d484b6d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic95b069367b24fd890ebdca632ea58eb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ce2f24276fa40f1bac2f8b82eb3561d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c991f317b8a4c638731da2d2c41fbf7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943dfe63e2ab45ca9f085402af19715d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fc1a4e79592432dbc61f090c132bdce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ca388db64744f11a4ecfa00deef6721_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056d175194ad41b1a26e434846bc2bb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic80816a284004c57bc9d57607f50fae6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc61efd9b3fb4b72af24435b0ac021d3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f42dcbfcf6e414f9c2f53ca2fd539fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib36036ab49044648a373020e6e50c5c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6bca11224045aab99c0deaf9679a62_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43b900167e4147608494071af8a327e5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e05dc98d4304124b10db253c8d59d8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a462e81bf45445cb29240d95de98506_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1797fd6783dd4f6a8e55c48ac402e7d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice50008825b6453b900419be6e538d60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f29656902d24bac845ed6c3e1313c72_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i724f9c4c78a84bb5b1cf0f0c80000aa7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a44a937b1d142b3bfe3aa76130e4ed1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e0046d91fd144e69bc896e9a3d03eb3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb3ead10c02740de85a4ae1939f70f28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8cc51db51b6476f9350d45ef801fbe2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ameh:unit</xbrli:measure></xbrli:unit><xbrli:context id="i015c75fcf61d4986bcc5f227b6c412de_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62aa39d44086415d845d34f0d7dc7a73_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i144871d547d04bfcb5651aa2b05ed3f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8abaa0013749f6a54d7e3495c4052d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a8b2897992491a9bba33dd880b5e6f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f20c7ee23624be2a07a0c15e0ad0c80_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa29991cc184f5ab71a9689f9e7cbb3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i889c185a8f9149ea80fad8d3964a0104_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id558792183dd45c2a570c57e2912737a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i332f5bcb413946b09f9ee77d790f9a78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86e83dd845b24aafb3a23652cf069056_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd3bc75cd44b41e18d64665e42101205_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2125de0047684f7088debca1f678a717_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee954aec3cb404a92c9fa15cd03d7f5_D20210731-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-31</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839af06b2bf7483780595e14fb317ba9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75a131bd7e744b5a823cd87fdb684fe_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id201e64241bd4df388bd1b11f4019ca1_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51111a66dda4ebb9aba6212e6167b7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia31747ce9de543bc82b00188c7aa83e7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b2e1de018d94f24b2a76496127751c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e99a95143da4c8eaf2dd4d3559ccdbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5051abc09bc4fa69a0f957f3c5b0241_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f0ad5790334506970900a82f46c08f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i487033aa27ad4f9b9271e75aa8aa3a91_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaff2efa428034a01ba020fb02de6fc10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifea711226dc146e9810f79de10c986d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c77143a62554eab971843dd2d16ee2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27538f0196b542fc85d8c25bf235059d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c3bdf2fd4b4890ae012255fe841f5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i024a6dcb30a242cb813e9f1ccb581b12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i676fdea1181f4e9193158b995298022b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53efa605f72144cf9c19b468aa9c14af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2582d81f93dc42f1a148af1c328393bb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88445e03e6ca41139c3da34cf3553c19_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf6b316b9ec34ba09028e2941bda64c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b75bb3419b74b6db04ab86aac159bb2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4cabdf561f47f68984b36789e4965c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42823650eb854b4f9ee2477d31236773_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13a44368edd4777a7c9cfc306a21f2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d8e768a8482425ba021a05970238a2f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008c29b02c5e4ce5a69883a33d891ded_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2878f7db1e942a9b61dbbd3d355573f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdc0c8a020740599e30d4e0c3298af2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia10dba65880142848189a35b3d649ae5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35497baacaae4c5f8085541195e2dbab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7fa92aa24446d18fe184c6400b9ba3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ebf6aeee1a415ca258abe927ecdc64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia464591a552f4ad4a88bc800875941fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9eee87a655349b195602787d695ad5b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40c3a0315be548acb27758e893a56720_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i749dc1caa7f94b5a8d9ae541374197c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb8f4c6415114fdab30e95d035c48f77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e30d0a130514a509245b1d72aa48f0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74208b2350a54619bb22d219854dc476_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f9f2d34982748f39594f8bbf5d26296_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49479cdc0b20425392e36614906e56d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic77befc8ecf64d6390b3232a58d0202f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503c88657b144f3aab4aa1799044b19f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefca0b3acca84ef39bac26666af72183_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc7ce9f2aefb4de8b0e4a49738897718_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b87107110124a33ad3ed49dca12817e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f9c8db35dd1455cbb9efcf67a63698b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110382789db14433b603074a67e42a36_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13903951d2fc4cb3a6f3cc653bc12796_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i898d05e125bd4e44b591badacf6f75fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731e915d69124743b66363b19a199dda_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ca09a27d4e24e43ac205809e114b053_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f6c47496c364a6b8c27c34e249b3a21_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cce677040344f7c94c12092ed289604_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i273a684a3d8b492283839a5d9ccc76b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa85536a036b46379cea77c234a086b4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf87ab1f75b4885966e552286174dd2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c28398a7a274eb28a70bc44722ecef4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id52e19518ae34e748e1b53e56a606015_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id249748cb92647bcb3ae2fe466c5b254_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="provider"><xbrli:measure>ameh:provider</xbrli:measure></xbrli:unit><xbrli:context id="i0412a16b622b47b881cd9067167d397e_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i198ab6e687c84de2a822e8318e6dfb6d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbbeb1f862bf450891db9fb5dfd9a221_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cb8cf60062647d29f8c59848644f427_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03f22c6e36ab4bd4853b9f3b723fc918_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic37f82250e404856a1dcea1915c8a4f9_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee587da7f4aa43ada9b4e8471a61bc94_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c187ffabbda44aca5a5d84550b8aa79_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib555dbec242444c28b4456bb93f2b6f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9a36e1a441145a19e883235e84ce38a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if37956fe79bf4000a19ec8e8571ca1cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d99fc8fa9b454a8bd0c6ed6faa3ba9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5061a26c78b5403a92ef0a14467a0063_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc98f3cf1ce4c1d8a0b83f75ea36297_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad767e257dc04de09097654e8d9ea038_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d13a567771417b82eab2d872ffeddd_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e772255fe246ffa225f111f36bbee4_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id948340a0f0b4857bed7bfd4a5db9f4c_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib63764ca4e84414c81bcc395ce6a0848_I20190423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1111e9e2a048a785ec584e3a23c0db_I20190423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8eb23240eab47278ba31489ec5f4074_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie652a00fea2c45bba68f168cd6fd0326_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4819e77fc964fe284f83cd52ffd9bed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice49c40a4d0b40009b5fc8fabf4890d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a5796b7a274d6dac1cfafd9d65e199_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1154256fe1de45f59c9c10c10c8ab21b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic23531b109fe425ea37a2b8d6a5e782b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0037e84ba38f4a3e9dfb06a8532434cb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8e6770db7ed467b9bfa172bb05c7567_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id671637d094b4da9baff3726eb0bb9ef_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fd1339411804f9e8ee4a8aaa22a5cc7_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i100c286c449b435198ed0d3c17cfbda1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ab282e08eee4f75b09eb011582c6e08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81be945f4a484abab03ca823d400fb2d_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0caec3bea3f4eaa9e7ff87ad11adae8_D20190701-20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib53fcc8b36514b66982fc74e646bd81d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef9d826ba6d40728e8ea8794c1ba388_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604b63e710a74052bd5134a326c3b521_I20181218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2dacf52383a475da0334f0ba9ad8b31_I20181218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3069a2df4dba45069c16005bfe7c95a9_I20181218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1195755b784aa8b53f18c076ac879d_I20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9d54cb427946a28f7ce5949115e202_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1e6664f4ef468db3a85b5fe37e8ad0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ec0825cadd340a0b4abec77e08752ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1018ea938faa4df890ec9e0a02e9cd39_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i805098d929664b258e9e02430e3446f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2087645dd294b50b435fd15e8f370f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79361bf90da942189dd476704c690d21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eba764439774dedac07edaac463b53b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife653c4fcbb243abb96d4ba2a5ef5c68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9caf120fa2d4bb9a623a159c3d8cb6b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae23f71d35ba49afac259c7ec4de8fd2_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief487b48631e4a36972039b3bafdc0c5_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00679cfa5a534ce9a92bdb137b52ec50_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie551eb427ed34af7aa4c793742c0e19a_I20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a6bb0cac4404e838f3cb21cb1f78f8a_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87ee29c5cb344aa98db576466c4bfb91_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d5ec03a2b04b30a66a4a30c5784f2b_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfb4fbfb2ec34149b57c0fb417d25c41_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf89debf8d114314b44b8b7514c5ed0e_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9c42d5297743dda47552322302b667_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6900356a9b954339b957ad128fe7fb9e_D20210616-20210616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-16</xbrli:startDate><xbrli:endDate>2021-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac4990f656442ea8b9d9d247491dc90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financial_ratio"><xbrli:measure>ameh:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="i4c7dc17bcbe04fb4904d893562ad225d_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e78513b2a054c24a539e76d8c9ed784_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61742fc5636f4d02a62b8ec226f2b8a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib09048f44b5646e98a8d38401a6e9317_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabfdc0514ad04c73ab76b77f6739e8e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i447604f483784ad082efe8790195e57c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d459770fc824dfd85b90f08dcfec692_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b39ded9aa144fe959c2e5f7e0cdc81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031524a8f2864901a900ba1a85eaecbf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b9e264b58ec4372891355322134a590_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie560514b2ee1454a9f9e0ab9ae48bb1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86ab3861fcda413d815e58a991ea9bf7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92cd58fb0c7d4588b4469022555c03b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd4ffb9558045b08ca6250bddb77123_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7511f70c51f546fab2df45ef49ea60d1_D20230101-20231201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22b6c0d320cb4d01aef31c88d0405025_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df55a8afb084316ae481f2b066f353f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42cdd50cdf8449ea72386bfca57f57e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53c301d60fb84feb86e40458baac030a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f03a46a00b3442fa2d6f0b063116153_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d5181abc61c4949b5e2bb84d79457b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia61a2888862d4451867b421f57199890_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dbe830985b3456088798fdc58aa9daf_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92adc7af35ce442586e7f832696d8083_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718ff6d9aae440bfbe2ebdfa0389b7f9_I20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if827ee4c779a4b57ab9eeeb719e06b2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f6447a0def84811a339a66cb7ac0e7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87791bdb507743179b1b6187068193d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a226f12905c46efbbd050421af8eea6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87bcea25b6704ede86f7f3a191ef629d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdc79f5d00754b61ab7e3baaf585df20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7f59b7851384b0d91511c5a20b67577_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e116c4ba416435f84ab15341357ee49_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id187f254b8f044069cf6e62f7dd23492_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f27f189d204a99bb6fbd309638d302_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bf49749cfa4149bfcc21376770c3d7_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i736e3fec90114a5aa4409b6b2e10ee3d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6be868f31ad04ccd92b62a8b53e31994_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:Warrant2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idafaa881ac7c4f0ea1acfd5e7bac657c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6c9410eee65468595d358150c9017de_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9926c974cf3347f388bb822becf71f99_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:FormerShareholdersOfNmmMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36c4f94c659e40378bce5560a8288c13_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eff2864c695401fb93686780342c192_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i601de355c37d4e38a5ea8fffe8e17e9d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81990f1f745c424ca090209239fb9e19_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011724573aa749b2834cc036d67d7006_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40fc578ddc114d17b7d8aa16f28a9b27_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5cc5d815cc04d21bef7fb998c409f3d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i163cc47f491d41b392adbb6959d8f774_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04943825157d4043aa0fb2fe8723b079_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4774888a4f484996ad1923628b04af51_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificofCaliforniaBrokerageAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5005e6c965ce49078328bedec974e062_I20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyThirteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a44ec4586564a71b632ebd24b41a548_I20171208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9540bba78a40aa9b698767130e5df9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f37aecb480c4ca4bdaabd1cc01c6d74_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69e0bb8c26da401f981101891ef4858c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5a872d4cb64a1795a11e4a6a81b2cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d0316c954743c68575e89e641ec7ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92bee5c5555f4c9bb28b959713ee742c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55c7e2bb01da4cb8a05eeb09f96b7145_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida71012f2abb40c3bb3b97875ac19fd1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia48d331e72ef4c45922e796a5ec33fe2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id34b814b72a749ff9980e038fe3de780_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e60e144eae847ee8431a5c5918fdb83_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2b2b020931f4f90afee0ac9784f1f61_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f05771c561640aaab3a2c2c0e44330b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb2c1e084a049cd8af7b6044a0c177e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibef63d60b9e947eead74bdfd0b22345e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie160814e72a34eebb359d61571716c26_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e9c3a5ed3424d31b9ae24620d3bb654_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31c542aee5d1477695e59726049c8b71_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ExecutiveOfficerAndDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc47b22c80ae4ba5a6046042c4073438_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31caf7183734c75a34b0c38fefd09f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife3ade634e3f411d8ff9d287f7f6ccfc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ed9f8ac2bd41ad84ee70e5cec56071_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i670fb4a8ae4c408681d8b085578171d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic130048652fd4ae89ae9be7d998b753c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b029890b2714cffb3297481713b140b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f1ff2005de4e06ab13d40c18783c14_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia49fab4addb846b78532141505ad76c8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39d667c80e24f60a2821321e2d966cc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eae915be53045f6bb1b2c554e86ccb5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifebcbe81b7cb4bb1b35b8f52f712e985_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0fafa1dea0849b1b343ca69489e8c78_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d3bbb3ca7dd4c24bc7e516e958c13e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7edf78b63c6f4e08805f86b4036d2e81_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A11CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f12986e0b9048669859a5f857899013_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A11CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i779a53f850a8409dbd4e696d526532c9_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A10CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie312f8b83db04cdcb3b524d5a3a6ba12_I20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A10CommonStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66cd6792e85c49d7a61ed092edae091c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia90a6c2a97b64a389f5c927fc93bf96a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if46b72f6abf844e9879f71846c8b9b66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08aaa85087aa4345a9007df6c4591fd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b537ba452f949228e951dcdfcef32e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53187ce216524aa3b307b37805167d6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b1cfd32fb714d1b80f4201a5deed2a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bab33a21a0648868b28fc7d50f54158_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d72bc8610fd48128d879bda262dfe43_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie254787cc84c48bd84c74b128e2266d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15d1c54ce99042c1b561ab2ee11ee78e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i129f6a3461cf4f1ab4901b6a723c2efa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9270b7467dd044688bc0a7eb2e2ca95b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2b387c30626438ebb40b9bca7610e32_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e46c773fc154de4bf33cdae598f28cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b8910f127dd44bf93a735ed77e16ac9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic79962b6add548d1a0a0800ef768b995_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63281dcdd4a140dbb747619db7d8c8a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70d92535c55249a8847213ad5c2a502c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bad5438ff3a4f74a3d70bcaa21c6c0f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5679f2c797347059c1225b32fbb6b13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie849991976b847cf90334bfe31a52480_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf99075624e6433ba75a5f77dc805f15_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13f9af073384d4c9e1929dc51068830_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2133589307c47dcbdf2e41c006a5957_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e8615520d1c460abd7740668e7eccb7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bcb63ad4a3840f5972376ef0ad45c77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c960befa3cb4c8481200d45bd9ea49e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3bb44ce70f74f858de6d865daacc078_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66a2b156a58d4e41b8c652fbfc2b1dc3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725de084f7484bf2b557e23683209c2f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48ce8008a9aa413bbc0d854c5c099a7b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ad1a32d47d24ebd9e398feacbdef5da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i345508df7f534ec186d436d698300127_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17a3d24c34e24e4bbb0b52e9864a691c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e413d93a45413e867b6c43dcbcb16f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56618b59636c41de889fa82a7f480457_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i885597d6544c4e3abef7773242454b2b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i962c50aee1e348aba05114edeaee56c5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72264584776344db971c065a8fce37ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9f3ec8accf2446a924e82c4b5f8ccfb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia561e5c258f2485694a76848bb8b6a1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e4b1ef0f59e450b996daa00631fb6ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413b4eb991864312abee85b2aa4136a2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaf783f1db0c4787a4a69fb6282d4e02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaFamilyHealthCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac72b50c95e94fc09e52a827a55332b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaFamilyHealthCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia53e8f382a2e4439b60240b8915724ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd656c250ce4150a6a1a1fceb8542ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2192a286cf646ccab3788f074402528_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i134932193dfa499ca1b1effba3b95a14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia409ec0563224e55807090c8d3e6ede7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9cdce4ca78b41e0a57fc6795290012c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ec1d618774465c8dea886fe213dfe7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a2b3509507d4d48912d14647a92e623_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3a8211eb68b4df0b319ce09e3b1f902_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30eb97f7c32744b7b15f7e0871ad0fbb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a4c5277f7fe49faac858648aba110d4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d6fef6bdcd4ea5849d94a4db61a9e0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75f1a347fb7b4952812981c95e91f55d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id64373440d04487abfcbb1c9c106cd2a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibea0b347dab449ca8628a24054c9a91c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib376d31c4e7c47d1adb2a6a237f9cc09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ConsultingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09eece4c427740f687d9a6fadb11f1ff_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ConsultingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802eb21bde26452ba2c3f5659cee4c04_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ConsultingServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65dded2172ef422fb17e1d0fce8b7249_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69c49049ebbc47528adaa662d73d39ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2e7d052ba2b4395b0f60a17ae65a0f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14cb455ba05463cb1678b216ef7075f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae3db4ca1e34c708b94c52c71ad2914_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd421eb1df5c49939ff1803196eb2a86_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i208f479f75974f779de286c45d4474bf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6adcc0aa230f41fd87e0b1d0454f2be7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f8971b99a7041a48f19c1d1278bc25b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f8d61c8ab544a5b3f23e1be85c5358_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44bf6e3eefc4f64a56179122b3b4d22_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7308475feed14b639f9c04dfe2ffc4d7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28dfed083b894f49a515b929d24e2c7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283b7bc3b0dc4508af91c59f486c2adf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8994136231a429187388373d060ea08_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9cc68c974834aefa2ce53b34b45264a_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>ameh:patient</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTQtMS0xLTA_d2add495-3187-4214-9620-f3aacb32a074 id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTItMS0xLTA_88f8d027-0dcd-4f98-8e05-61d92fffcfaf id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTItMS0xLTA_7bcc9575-21a7-4a27-a77e-32e7a3454581 id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTQtMS0xLTA_a79fca52-6e1e-45fb-b0a3-d2e1a70dd11d" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQy_88abd94d-5de3-4675-adbd-bf3bb33c4c2b">10-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YzE5MTNmYTZmZjAyNDhmNmE0NjU2Mzc2OGYxZDY2ZDAvdGFibGVyYW5nZTpjMTkxM2ZhNmZmMDI0OGY2YTQ2NTYzNzY4ZjFkNjZkMF8wLTAtMS0xLTA_160594e0-d191-493d-a955-e101f2d61326">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8xMjk_50a026c9-9901-4c95-b593-8a1f70fcda51"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8xMjk_54cbf30a-1dfc-4779-a53d-ef8d4aae6291">December 31</ix:nonNumeric>, 2021</ix:nonNumeric> </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.433%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YmMzNmI2NmVkNTEzNDgxYWJiOWVkNmY1YTdhODVlY2QvdGFibGVyYW5nZTpiYzM2YjY2ZWQ1MTM0ODFhYmI5ZWQ2ZjVhN2E4NWVjZF8wLTAtMS0xLTA_100f84c9-6a28-4792-9baf-dcf58d4b8178">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF<br/>1934 </span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">for the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___&#160;to ___</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number:&#160; <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQz_c0d4075a-6de3-494f-87bd-74824d9fcb8b">001-37392</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTUx_451c3301-6f43-42b5-977f-d5c154efb700">Apollo Medical Holdings, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.071%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YTM1NThlYWVjYzFjNGVkZjg1OTRmODNjZDIzNWYwNDAvdGFibGVyYW5nZTphMzU1OGVhZWNjMWM0ZWRmODU5NGY4M2NkMjM1ZjA0MF8wLTAtMS0xLTA_de96649b-7b65-4a3c-8e7d-cf0f822c6e5d">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YTM1NThlYWVjYzFjNGVkZjg1OTRmODNjZDIzNWYwNDAvdGFibGVyYW5nZTphMzU1OGVhZWNjMWM0ZWRmODU5NGY4M2NkMjM1ZjA0MF8wLTItMS0xLTA_18a187ac-bbd1-41a2-8ba4-52a6e530aa5e">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTUz_8d4ff6d3-7bab-4754-87d8-fa43f8db4a69">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTM3_88f2b622-9624-456f-b97c-def50cbbcf5c">2nd Floor</ix:nonNumeric>, <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ2_2a72b214-d4c1-4114-8102-4e890aa717cb">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTM4_38cfafde-de9c-4666-b569-8ce0c81633db">California</ix:nonNumeric> <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTM5_47e9e876-0621-4c19-b5ac-fdcdb962ad73">91801</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTU0_38bc7908-03f4-45e2-8432-0bbc1e1edbc4">626</ix:nonNumeric>) <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ3_af933a54-e871-45d0-95d3-ab01a262e1db">282-0288</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.751%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6NDMzMzcyMzcxODA4NDUwNTgxOWM2ZTUzZWY0YzU2YTYvdGFibGVyYW5nZTo0MzMzNzIzNzE4MDg0NTA1ODE5YzZlNTNlZjRjNTZhNl8xLTAtMS0xLTA_20902b9b-5fb8-4c1a-b35a-e0db943d9d01">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6NDMzMzcyMzcxODA4NDUwNTgxOWM2ZTUzZWY0YzU2YTYvdGFibGVyYW5nZTo0MzMzNzIzNzE4MDg0NTA1ODE5YzZlNTNlZjRjNTZhNl8xLTItMS0xLTA_66a529a4-0096-4841-a93b-4aa886bdd84e">AMEH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Title of class)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl82MDQ3MzEzOTU2NDI1_5d7ee590-28b7-4854-8ebe-864d02e374d7">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Exchange Act. Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ5_a6c8df7a-8054-46f0-bf81-44a95f3dbbfc">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTU1_14d417aa-a489-4234-8228-35f155f9962e">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTUw_37c2694d-481c-4982-9781-41efa46363fe">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.579%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6Mjc1ZjFhMTEyMTBhNDQyZDhhNTRmZGZmYmMyZjk1ZWUvdGFibGVyYW5nZToyNzVmMWExMTIxMGE0NDJkOGE1NGZkZmZiYzJmOTVlZV8wLTAtMS0xLTQzNDEy_92f1bb77-9b44-4844-ae64-aa6b5dcc635d">Large accelerated filer</ix:nonNumeric>&#160;&#160; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer&#160;&#160; </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6Mjc1ZjFhMTEyMTBhNDQyZDhhNTRmZGZmYmMyZjk1ZWUvdGFibGVyYW5nZToyNzVmMWExMTIxMGE0NDJkOGE1NGZkZmZiYzJmOTVlZV8xLTMtMS0xLTA_3ff54b88-bbb1-4837-a0e1-64c8080dde23">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6Mjc1ZjFhMTEyMTBhNDQyZDhhNTRmZGZmYmMyZjk1ZWUvdGFibGVyYW5nZToyNzVmMWExMTIxMGE0NDJkOGE1NGZkZmZiYzJmOTVlZV8yLTMtMS0xLTA_408f923b-7c28-44d4-8eee-ce690ff1d791">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ1_89a7e5d3-a71d-4e46-9c64-bf6efdb5ef42">&#9746;</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQw_152a17bd-5ca5-40a2-90e0-6afbdbe55c40">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Yes&#160;&#9746; No</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of common stock held by non-affiliates of the registrant, as of June 30, 2021, the last day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="icc6ae380313d4f9e9297cfdbf9b997ac_I20210630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8yODYy_35612549-cd38-4d52-882e-6de746e6f7b9">2.4</ix:nonFraction>&#160;billion (based on the closing price for shares of the registrant&#8217;s common stock as reported by the NASDAQ Capital Market on June 30, 2021). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;16, 2022, there were <ix:nonFraction unitRef="shares" contextRef="ib7afb98c0185462db67289bfa9ee20c8_I20220216" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zMDE5_276a2d17-7d80-4c6c-ac9c-7da38eac87d4">55,956,280</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQx_acbb21e0-4e75-4f2b-9678-c1dad389a73c" escape="true">Portions of the registrant&#8217;s definitive Proxy Statement for the 2022 annual meeting of the stockholders of the registrant are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2021.</ix:nonNumeric></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Table of Contents</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Ended December&#160;31, 2021</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_13">Introductory Note</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_16">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_16">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_19">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_22">ITEM 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_22">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_28">ITEM 1A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_28">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_28">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_31">ITEM 1B</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_31">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_31">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_34">ITEM 2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_34">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_34">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_37">ITEM 3</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_37">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_37">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_40">ITEM 4</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_40">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_40">47</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_43">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_43">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_46">ITEM 5</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_46">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_46">48</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_55">ITEM 6</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_55">Reserved</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_52">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_58">ITEM 7</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_58">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_58">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_91">ITEM 7A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_91">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_91">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_94">ITEM 8</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_94">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_94">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_229">ITEM 9</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_229">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_229">128</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_232">ITEM 9A</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_232">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_232">129</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_235">ITEM 9B</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_235">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_235">131</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_2162">ITEM 9C</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_2162">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_2162">131</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_238">PART III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_238">133</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_241">ITEM 10</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_241">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_241">133</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_244">ITEM 11</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_244">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_244">133</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_247">ITEM 12</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_247">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_247">133</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_250">ITEM 13</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_250">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_250">133</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_253">ITEM 14</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_253">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_253">133</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_256">PART IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_256">134</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_259">ITEM 15</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_259">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_259">134</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_262">ITEM 16</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_262">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_262">141</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glossary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care IPA, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIPBP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG Properties, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Hospitalists, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP - AMH 2 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP - AMH 2 Medical Corporation </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians of California, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Access Primary Care Medical Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bay Area Hospitalist Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDSC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concourse Diagnostic Surgery Center, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CQMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Quality Management Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">College Street Investment LP, a California limited partnership</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Department of Managed Healthcare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Medical Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC International Cancer Center, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">independent practice association</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maverick Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MPP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Property Partners</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MSSP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare Shared Savings Program </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PASC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Ambulatory Health Care, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMIOC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern California Heart Centers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Labs</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sun Clinical Labs</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-6 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag 8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tag-8 Medical Investments Group, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care Acquisition Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable interest entity</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ZLL Partners, LLC</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTORY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE</span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in this Annual Report on Form 10-K to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation (&#8220;ApolloMed&#8221;), and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of our results of operations and financial performance. This discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere herein, and with our prior filings with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Report, including statements describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the next generation accountable care organization (&#8220;NGACO&#8221;) model, or the Global and Professional Direct Contracting (&#8220;GPDC&#8221;) model. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names and trademarks of ApolloMed and its subsidiaries referred to herein and their respective logos, are our property. This Annual Report on Form 10-K may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, any statements about our business, financial condition, operating results, plans, objectives, expectations, and intentions, any projections of earnings, revenue, or other financial items, such as our projected capitation from CMS&#160;and our future liquidity; any statements of any plans, strategies, and objectives of management for future operations,&#160;such as the material opportunities that we believe exist for our company; any statements concerning proposed services, developments, mergers, or acquisitions;&#160;any statements regarding the outlook on our NGACO or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms, such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases, or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Annual Report on Form 10-K and are subject to change.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations, and certain assumptions of management. Some or all of such beliefs, expectations, and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental, and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and significant risks and uncertainties that could cause actual conditions, outcomes, and results to differ materially from those indicated by such statements. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_22"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. We, together with our affiliated physician groups and consolidated entities, provide coordinated outcomes-based medical care primarily serving patients in California, the majority of whom are covered by private or public insurance provided through Medicare, Medicaid, and health maintenance organizations (&#8220;HMOs&#8221;), with a small portion of our revenue coming from non-insured patients. We provide care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Our physician network consists of primary care physicians, specialist physicians, physician and specialist extenders, and hospitalists. We operate primarily through Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) and the following subsidiaries: Network Medical Management, Inc. (&#8220;NMM&#8221;), Apollo Medical Management, Inc. (&#8220;AMM&#8221;), and APAACO, and their consolidated entities, including consolidated VIEs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Led by a management team with several decades of experience, we have built a company and culture that is focused on physicians providing high-quality medical care, population health management, and care coordination for patients. As a result, we are well-positioned to take advantage of the shift in the U.S. healthcare industry toward providing value-based and results-oriented healthcare with a focus on patient satisfaction, high-quality care, and cost efficiency.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, ApolloMed merged with NMM, a California corporation formed in 1994 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed. The combined company operates under the Apollo Medical Holdings, Inc. name, but NMM is the larger entity in terms of assets, revenues, and earnings. In addition, as of the closing of the 2017 Merger, the majority of the board of directors of the combined company was comprised of former NMM directors and directors nominated for election by NMM. Accordingly, ApolloMed is considered to be the legal acquirer (and accounting acquiree), whereas NMM is considered to be the accounting acquirer (and legal acquiree).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We implement and operate different innovative healthcare models, primarily including the following integrated operations:</span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Independent practice associations (&#8220;IPAs&#8221;), which contract with physicians and provide care to Medicare, Medicaid, and commercial and dual-eligible patients on a risk- and value-based fee basis;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:32.5pt">Management service organizations (&#8220;MSOs&#8221;), which provide management, administrative and other support services to our affiliated physician groups such as IPAs;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">APAACO, which participates in the Next Generation ACO Model sponsored by CMS, and focuses on providing high-quality and cost-efficient care to Medicare fee-for-service (&#8220;FFS&#8221;) patients;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Outpatient clinics providing specialty care, including an ambulatory surgery center and a specialty clinic that focuses on cardiac care and diagnostic testing; and</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Hospitalists, which include our contracted physicians who focus on the delivery of comprehensive medical care to hospitalized patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate under one reportable segment, the healthcare delivery segment. Our revenue streams are diversified among our various operations and contract types, and include:</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Capitation payments, including payments made by CMS from the Next Generation Accountable Care Organization (&#8220;NGACO&#8221;) Model;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Risk pool settlements and incentives;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Management fees, including stipends from hospitals and percentages of collections; and</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">FFS reimbursements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed&#8217;s common stock is listed on the NASDAQ Capital Market and trades under the symbol &#8220;AMEH.&#8221;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsidiaries</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate through our subsidiaries, including:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">NMM;</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">AMM; and</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">APAACO.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of NMM and AMM operates as a management services organization (&#8220;MSO&#8221;) and is in the business of providing management services to physician practice corporations under long-term management and/or administrative services agreements (&#8220;MSAs&#8221;), pursuant to which the MSO manages certain non-medical services for the physician groups and have exclusive authority over all non-medical decision-making related to ongoing business operations. The MSAs generally provide for management fees that are recognized as earned based on a percentage of revenue or cash collections generated by the physician practices.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO has participated in the NGACO Model of CMS since January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our NGACO model, that operates under APAACO, and a network of IPAs with more than approximately 9,900 contracted healthcare providers, which have agreements with various health plans, hospitals, and other HMOs, we are responsible for coordinating the care of over 1.2&#160;million patients, as of December&#160;31, 2021. These patients are comprised of managed care members whose health coverage is provided through their employers, or who have acquired health coverage directly from a health plan or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to provide high-quality, cost-effective care. To implement a patient-centered, physician-centric experience, we also have other integrated and synergistic operations, including (i) MSOs that provide management and other services to our affiliated IPAs, (ii) outpatient clinics, and (iii) hospitalists that coordinate the care of patients in hospitals.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, we evaluate whether we are the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and benefits. We consolidate a VIE if we have both power and benefits &#8211; that is, (i) we have the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance, and (ii) we have the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE. See Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to our consolidated financial statements for information on our entities that qualify as consolidated VIEs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states have laws that prohibit business entities with non-physician owners from practicing medicine, which are generally referred to as the corporate practice of medicine laws. States that have corporate practice of medicine laws require that only physicians can practice medicine, exercise control over medical decisions, or engage in certain arrangements with other physicians, such as fee-splitting. California is a corporate practice of medicine state.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, in addition to our subsidiaries, we mainly operate by maintaining long-term MSAs with our affiliated IPAs, which are owned and operated by a network of independent primary care physicians and specialists, and which employ or contract with additional physicians to provide medical services. Under such agreements, we provide and perform non-medical management and administrative services, including financial management, information systems, marketing, risk management, and administrative support.<br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM has entered into MSAs with several affiliated IPAs, including Allied Physicians of California IPA d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;). APC contracts with various HMOs or licensed healthcare service plans, each of which pays a fixed capitation payment. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. The risk is subject to stop-loss provisions in contracts with HMOs. Some risk is transferred to the contracted physicians or professional corporations. The physicians in the IPA are exclusively in control of, and responsible for, all aspects of the practice of medicine for enrolled patients. In accordance with relevant accounting guidance, APC has been determined to be a VIE of NMM, as NMM is its primary beneficiary with the ability, through majority representation on the APC Joint Planning Board and otherwise, to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance. Therefore, APC and its consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;), APC&#8217;s consolidated VIEs, Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;), APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;), AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;), and APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;), and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;) are consolidated in the accompanying financial statements.<br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDSC is an ambulatory surgery center in City of Industry, California. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare. CDSC is consolidated as a VIE by APC, as it was determined that APC has a controlling financial interest in CDSC and is the primary beneficiary of CDSC. ICC provides comprehensive, compassionate post-cancer diagnosis care and a wide range of support services. ICC was determined to be a VIE of APC and is consolidated by APC, as it was determined that APC is the primary beneficiary of ICC through its power and obligation to absorb losses and rights to receive benefits that could potentially be significant to ICC. <br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and the Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments, and receives all distributions from the investments. APC has the obligation to absorb losses and the right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA, and its consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG are controlled and consolidated by APC as the primary beneficiary.<br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through AMM, we manage a number of our affiliates pursuant to their long-term MSAs, including: ApolloMed Hospitalists (&#8220;AMH&#8221;), a physician group that provides hospitalist, intensivist, and physician advisor services, and Southern California Heart Centers (&#8220;SCHC&#8221;), a specialty clinic that focuses on cardiac care and diagnostic testing.  AMH and SCHC are VIEs of AMM. We have determined that AMM is the primary beneficiary of such entities. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) were formed in May 2019 and July 2021, respectively, as designated shareholder professional corporations. Dr. Thomas Lam is the sole shareholder of AP-AMH and AP-AMH 2. In accordance with relevant accounting guidance, AP-AMH and AP-AMH 2 are determined to be VIEs of ApolloMed. Therefore, AP-AMH, AP-AMH 2, and AP-AMH 2&#8217;s consolidated subsidiary, Access Primary Care Medical Group (&#8220;APCMG&#8221;), are consolidated in the accompanying financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sun Clinical Labs (&#8220;Sun Labs&#8221;) is a Clinical Laboratory Improvement Amendments-certified full-service lab that operates across the San Gabriel Valley in Southern California. In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diagnostic Medical Group (&#8220;DMG&#8221;) is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, has the ability to exercise significant influence, but not control over DMG&#8217;s operations. However, in October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate its consolidation of DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2021, ApolloMed and its subsidiaries&#8217; consolidated VIEs, and their consolidated subsidiaries, included the following entities: (1) ApolloMed&#8217;s consolidated VIEs, AP-AMH, AP-AMH2, Sun Labs, DMG, AMH, SCHC, and APC; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) APC&#8217;s subsidiaries, UCAP, MPP, AMG Properties, ZLL, APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (4) APC-LSMA&#8217;s consolidated subsidiaries Alpha Care, Accountable Health Care, and AMG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invested in several entities in the healthcare and real estate industries. APC holds a 50% interest in each of the following real estate entities: 531 W. College LLC, One MSO LLC (&#8220;One MSO&#8221;), and Tag-6 Medical Investment Group LLC (&#8220;Tag 6&#8221;). ApolloMed holds a 30% interest in CAIPA MSO, LLC (&#8220;CAIPA MSO&#8221;). CAIPA MSO is a New York-based management services organization affiliated with Chinese-American IPA d.b.a. Coalition of Asian-American IPA (&#8220;CAIPA&#8221;), a leading independent practice association serving the greater New York City area.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to laws prohibiting a California professional corporation that has more than one shareholder (such as APC) from being a shareholder in another California professional corporation, APC cannot directly own shares in other professional corporations in which APC has invested. An exception to this prohibition, however, permits a professional corporation that has only one shareholder to own shares in another professional corporation. In reliance on this exception, APC-LSMA holds controlling and non-controlling ownership interests in several medical corporations. APC-LSMA holds non-controlling interests in the IPA line of business of LaSalle Medical Associates (&#8220;LMA&#8221;) and Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;) and holds controlling interests in Alpha Care, Accountable Health Care, and AMG. In addition, AP-AMH holds preferred shares of APC and AP-AMH 2 holds a controlling interest in APCMG. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC holds a 2.8% membership interests of MediPortal LLC, a New York limited liability company, and NMM holds a 10% interest in AchievaMed, Inc., a California corporation. The Company also holds equity securities that are primarily comprised of common stock of a payor partner that completed its initial public offering (&#8220;IPO&#8221;) in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). As of December&#160;31, 2021, the value of the equity securities was $28.4 million. As of December&#160;31, 2021, APC also holds a 19.68% ownership interest in ApolloMed. APC&#8217;s ownership interest in ApolloMed is eliminated upon consolidation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Industry</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Industry Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. healthcare spending has increased steadily over the past approximately two decades. CMS estimates that total U.S. healthcare expenditures are expected to grow at an average annual rate of 5.4% from 2019 to 2028 and will reach $6.2 trillion by 2028. Health spending is projected to grow 1.1% faster than the U.S. gross domestic product per year on average over 2019-2028, and as a result, the healthcare share of gross domestic product is expected to rise from 17.7% in 2018 to 19.7% by 2028. Medicare spending increased by 3.5% to $829.5 billion and Medicaid spending increased by 9.2% to $671.2 billion in 2020, which accounted for 20% and 16% of total health expenditures, respectively. Private health insurance spending declined 1.2% to $1.2 trillion in 2020, accounting for 28% of total health expenditures. Medicare spending is expected to have the fastest growth (7.6% per year for 2019-2028) primarily due to the projected enrollment growth. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care health plans were developed in the U.S., primarily during the 1980s, in an attempt to mitigate the rising cost of providing healthcare to populations covered by health insurance. These managed care health plans enroll members through their employers in connection with federal Medicare benefits or state Medicaid programs. As a result of the prevalence of these health plans, many seniors now becoming eligible for Medicare have been interacting with managed care companies through their employers for the last 30 years. Individuals now turning 65 are likely more familiar with the managed care setting than previous Medicare populations. The healthcare industry, however, is highly regulated by various government agencies and heavily relies on reimbursement and payments from government-sponsored programs such as Medicare and Medicaid. Companies in the healthcare industry therefore have to organize, operate around, and face challenges from idiosyncratic laws and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many health plans recognize both the opportunity for growth from adding members, as well as the potential risks and costs associated with managing additional members. In California, many health plans subcontract a significant portion of the responsibility for managing patient care to integrated medical systems such as ApolloMed and our affiliated physician groups. These integrated healthcare systems offer a comprehensive medical delivery system, sophisticated care management know-how, and infrastructure to more efficiently provide for the healthcare needs of the population enrolled with that health plan. While reimbursement models for these arrangements vary around the U.S., health plans often prospectively pay the integrated healthcare system a fixed capitation payment, which is frequently based on a percentage of the amount received by the health plan. Capitation payments to integrated healthcare systems, in the aggregate, represent a prospective budget from which the system manages care-related expenses on behalf of the population enrolled with that system. To the extent that these systems manage such expenses under the capitated levels, the system realizes an operating profit. On the other hand, if the expenses exceed projected levels, the system will realize an operating deficit. Since premiums paid represent a substantial amount per person, there is a significant revenue opportunity for an integrated medical system that is able to effectively manage healthcare costs for the capitated arrangements entered into by its affiliated physician groups.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Industry Trends and Demand Drivers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the healthcare industry is undergoing a significant transformation and the demand for our offerings is driven by the confluence of a number of fundamental healthcare industry trends, including:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shift to Value-Based and Results-Oriented Models.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> According to the 2020 National Health Expenditure Historical Data prepared by CMS, healthcare spending in the U.S. increased 9.7% to $4.1 trillion in 2020, representing 19.7% of U.S. Gross Domestic Product. CMS projects healthcare spending in the U.S. to increase at an average rate of 5.4% for 2019-2028 and to reach approximately $6.2 trillion by 2028. To address this expected significant rise in healthcare costs, the U.S. healthcare market is seeking more efficient and effective methods of delivering care. The fee-for-service reimbursement model has arguably played a major role in increasing the level and growth rate of healthcare spending. In response, both the public and private sectors are shifting away from the fee-for-service reimbursement model toward value-based, capitated payment models that are designed to incentivize value and quality at an individual patient level. The number of Americans covered by capitated payment programs continues to increase, which drives more coordinated and outcomes-based patient care.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Increasingly Patient-Centered</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. More patients are becoming actively involved and taking an informed role in how their own healthcare is delivered resulting in the healthcare marketplace becoming increasingly patient-centered, and thus requiring providers to deliver team-based, coordinated, and accessible care to stay competitive.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Added Complexity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the healthcare space, more sophisticated technology has been employed, new diagnostics and treatments have been introduced, research and development has expanded, and regulations have multiplied. This expanding complexity drives a growing and continuous need for integrated care delivery systems.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Integration of Healthcare Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Across the healthcare landscape, a significant amount of data is being created every day, driven by patient care, payment systems, regulatory compliance, and record keeping. As the amount of healthcare data continues to grow, it becomes increasingly important to connect disparate data and apply insights in a targeted manner in order to better achieve the goals of higher quality and more efficient care.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Integrated Medical Systems</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Integrated medical systems that are able to pool a large number of patients, such as the Company and its affiliated physician groups, are positioned to take advantage of industry trends, meet patient and government demands, and benefit from cost advantages resulting from their scale of operation and integrated approach of care delivery. In addition, integrated medical systems with years of managed care experience can leverage their expertise and sizeable medical data to identify specific treatment strategies and interventions, improve the quality of medical care and lower cost. Many integrated medical systems have also established physician performance metrics that allow them to monitor quality and service outcomes achieved by participating physicians in order to reward efficient, high-quality care delivered to members and initiate improvement efforts for physicians whose performance can be enhanced.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPAs and MSOs</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IPA is an association of independent physicians, or other organization that contracts with independent physicians, and provides services to HMOs, which are medical insurance groups that provide health services generally for a fixed annual fee, on a negotiated per capita rate, flat retainer fee, or negotiated FFS basis. Because of the prohibition against corporate practice of medicine under certain state laws, MSOs are formed to provide management and administrative support services to affiliated physician groups such as IPAs. These services include payroll, benefits, human resource services, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding, and other consulting services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NGACOs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS established the NGACO Model to test whether health outcomes will improve and Medicare Parts A and B expenditures for Medicare beneficiaries will decrease if Accountable Care Organizations (&#8220;ACOs&#8221;) (1) accept a higher level of financial risk compared to the existing MSSP model, and (2) are permitted to select certain innovative Medicare payment arrangements and offer certain additional benefit enhancements to their assigned Medicare beneficiaries. As a result, ACOs generally assume higher levels of financial risk and reward under the NGACO Model. CMS also established the MSSP to improve the care quality and reduce costs for beneficiaries in the Medicare FFS program. MSSP promotes accountability, facilitates coordination and cooperation among care providers, and encourages investment in infrastructure and redesign of care processes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outpatient Clinics</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ambulatory surgery centers and other outpatient clinics are healthcare facilities that specialize in performing outpatient surgeries, ambulatory treatments, and diagnostic and other services in local communities. As medical care has increasingly been delivered in clinic settings, many integrated medical systems also operate healthcare facilities primarily focused on the diagnosis and/or care of outpatients, including those with chronic conditions such as heart disease and diabetes, to cover the primary healthcare needs of local communities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hospitalists</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hospitalists are doctors specialized in the care of patients in the hospital. Hospitalists assume the inpatient care responsibilities otherwise provided by primary care or other attending physicians and are reimbursed through the same billing procedures as other physicians. Hospitalists tend to focus exclusively on inpatient care. By practicing in the same facilities, hospitalists perform consistent functions, interact regularly with the same healthcare professionals, and thus are familiar with specific and unique hospital processes, which can result in greater efficiency, less process variability, and better outcomes. Through managing the treatment of a large number of patients with similar clinical needs, hospitalists generally develop practice expertise in both the diagnosis and treatment of common conditions that require hospitalization. For these reasons, hospitalists have an increasingly important role in improving care quality. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Population Health Management</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Population health management (&#8220;PHM&#8221;) is a central trend within healthcare delivery, which includes the aggregation of patient data across multiple health information technology resources, the analysis of that data into a single, actionable patient record, and the actions through which care providers can improve both clinical and financial outcomes. PHM seeks to improve the health outcomes by monitoring and identifying individual patients, aggregating data, and providing a comprehensive clinical picture of each patient. Using that data, providers can track, and hopefully improve, clinical outcomes while lowering costs. A successful PHM platform requires a robust care and risk management infrastructure, a cohesive delivery system, and a well-managed partnership network.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Business Operations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPAs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our affiliated IPAs comprises a network of independent primary care physicians and specialists who collectively care for patients and contract with HMOs to provide physician services to their enrollees typically under capitated arrangements. Under the capitated model, an HMO pays the IPA a capitation payment and assigns it the responsibility for providing physician services required by patients. The IPA physicians are exclusively in control of, and responsible for, all aspects of the practice of medicine for enrolled patients. Most of the HMO agreements have an initial term of two years renewing automatically for successive one-year terms. The HMO agreements generally allow either party to terminate the HMO agreements without cause typically with a four to six months advance notice and provide for a termination for cause by the HMO at any time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MSOs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MSOs generally provide services to our affiliated IPAs or ACOs under long-term MSAs, pursuant to which they manage certain non-medical services for the physician groups and have exclusive authority over all non-medical decision-making related to ongoing business operations. These services include but are not limited to:</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Physician recruiting;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Physician and health plan contracting;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medical management, including utilization management and quality assurance;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provider relations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Member services, including annual wellness evaluations; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pre-negotiating contracts with specialists, labs, imaging centers, nursing homes, and other vendors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NGACO</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, CMS announced that APAACO was approved to participate in the NGACO Model and APAACO began operations under this new model. We have devoted significant effort and resources, financial and otherwise, to the NGACO Model. APAACO finished its last year of participation under its Participation Agreement with CMS. The Company continues to be eligible in receiving any shared savings or deficit under the NGACO Model for performance year 2021</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In advance of its participation in the NGACO Model, APAACO entered into agreements with over 750 medical care providers, including physicians, hospitals, nursing facilities and multiple labs, radiology centers, outpatient surgery centers, dialysis clinics, and other service providers. APAACO negotiated discounted rates and such providers agreed to receive 100% of their claims for beneficiaries reimbursed by APAACO.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among many requirements to be eligible to participate in the NGACO Model, ACOs must have at least 10,000 assigned Medicare beneficiaries and must maintain that number throughout each performance year. APAACO&#8217;s aligned beneficiaries totaled approximately 29,000 in 2021 and 2020. This number may decrease if beneficiaries join a managed care plan, pass away, or move out of the service area.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Participation Agreement, APAACO must require its participants and preferred providers to make medically necessary covered services available to beneficiaries in accordance with applicable laws, regulations, and guidance, and APAACO and its participants may not participate in any other Medicare shared savings initiatives.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are different levels of financial risk and reward that an ACO may select under the NGACO Model, and the extent of risk and reward may be limited on a percentage basis. The NGACO Model offers two risk arrangement options. In Arrangement A, the ACO takes 80% of Medicare Part A and Part B risk. In Arrangement B, the ACO takes 100% of Medicare Part A and Part B risk. Under each risk arrangement, the ACO can cap aggregate savings and losses anywhere between 5% to 15%. The cap is elected annually by the ACO. APAACO has opted for Risk Arrangement B and a higher risk track for performance year 2021 increasing the Company&#8217;s shared savings and losses cap from 5% to 15%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NGACO Model offers four payment mechanisms:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payment Mechanism #1: Normal FFS.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payment Mechanism #2: Normal FFS plus Infrastructure payments of $6 Per Beneficiary Per Month (&#8220;PBPM&#8221;).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payment Mechanism #3: Population-Based Payments (&#8220;PBP&#8221;). PBP provide ACOs with a monthly payment to support ongoing ACO activities. ACO participants and preferred providers must agree to percentage payment fee reductions, which are then used to estimate a monthly PBP to be received by the ACO.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Payment Mechanism #4: All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;). Under this mechanism, CMS will estimate the total annual expenditures of the ACO&#8217;s aligned beneficiaries and pay that projected amount in PBPM payments. ACOs in AIPBP may have alternative compensation arrangements with their providers, including 100% FFS, discounted FFS, capitation, or case rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO opted for, and was approved by CMS effective on April 1, 2017 to participate in, the AIPBP track, which is the most advanced risk-taking payment model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s beneficiaries and then pays that projected amount to APAACO on a PBPM basis. APAACO is responsible for paying all Part A and Part B costs for in-network participating providers and preferred providers with whom it has contracted. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Revenue Streams</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue reflected in the accompanying consolidated financial statements includes revenue generated by our subsidiaries and consolidated entities. Revenue generated by consolidated entities, however, does not necessarily result in available or distributable cash for ApolloMed. Some revenue is generated from Excluded Assets that remain solely for the benefit of APC and its shareholders. Our revenue streams flow from various multi-year renewable contractual arrangements&#160;that vary by type of business operation as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capitation Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capitation revenue consists primarily of capitated fees for medical services we provide under capitated arrangements made directly with various managed care providers, including HMOs. Capitation revenue is typically prepaid monthly to us based on the number of enrollees selecting us as their healthcare provider. Capitation is a fixed payment amount per patient per unit of time paid in advance for the delivery of healthcare services, whereby the service providers are generally liable for excess medical costs. The actual amount paid is determined by the ranges of services provided, the number of patients enrolled, and the period of time during which the services are provided. Capitation rates are generally based on local costs and average utilization of services. Because Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care providers based on the health status (acuity) of each individual enrollee, managed care providers with higher acuity enrollees receive more, and those with lower acuity enrollees receive less, capitation that can be allocated to service providers. Under the Risk Adjustment model, capitation is paid on an interim basis based on enrollee data submitted for the preceding year and is adjusted in subsequent periods after the final data is compiled.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Per member per month (&#8220;PMPM&#8221;) managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable, as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the term of the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk shares. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation arrangements are supplemented by risk-sharing arrangements. We have two different types of capitation risk-sharing arrangements: full-risk and shared-risk arrangements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a related party, where the hospital is responsible for providing, arranging, and paying for institutional risk. We are responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, we generally receive a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospital&#8217;s costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. Risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for medical loss ratios (&#8220;MLR&#8221;), incurred but not reported (&#8220;IBNR&#8221;) completion factor and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitation arrangements with certain HMOs, we participate in one or more shared-risk arrangements relating to the provision of institutional services to enrollees (shared-risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where we are responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore, the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, we also receive incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate us for our efforts to improve the quality of services and to promote the efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to us based on the performance measures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management Fee Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by us to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue, or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits, or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NGACO Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through APAACO, we participate in the AIPBP track of the NGACO Model sponsored by CMS. Under the NGACO Model, CMS grants us a pool of patients to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. We are ultimately responsible for managing the medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. Under the AIPBP track, CMS estimates an average of monthly expenditures&#160;for the previous calendar year for APAACO&#8217;s aligned&#160;beneficiaries and pays that projected amount to us in monthly installments, and&#160;we are responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by&#160;us to provide services to the aligned beneficiaries. Claims from out-of-network providers are processed and paid by CMS, our shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to our risk-share agreement with CMS, we will be eligible to receive the surplus or be liable for the deficit according to the budgetary benchmark established by CMS based on our efficiency or lack thereof, in managing how the beneficiaries aligned to us by CMS are served by in-network and out-of-network providers. Our shared savings or losses on providing such services are both capped by CMS. We recognize such savings or deficit upon substantial completion of reconciliation and determination of the amounts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the AIPBP agreement we received $21.8 million and $19.8 million in risk pool savings related to the 2020 and 2019 performance years, respectively, and have recognized such amounts as revenue in the risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December&#160;31, 2021 and 2020, respectively.<br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The monthly AIPBP received by the Company for performance year 2020 was approximately $7.2 million per month.  For performance year 2021, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.7 million per month from CMS. The Company has recorded a deferred revenue amount of $16.3 million related under the NGACO alternative payment arrangement as of December&#160;31, 2021. The deferred revenue amount will be earned or repaid back to CMS based on a settlement that will occur after the standard run-out period.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fee For Service Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which we bill and collect the professional component of charges for medical services rendered by our contracted physicians and employed physicians. Under the FFS arrangements, we bill, and receive payments from, the hospitals and third-party payors for physician staffing and further bill patients or their third-party payors for patient care services provided.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Key Payors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A limited number of payors represent a significant portion of our net revenue. For the years ended December 31, 2021, 2020 and 2019, four payors accounted for an aggregate of 49.6%, 53.4%, and 51.6% of our total net revenue, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strengths and Advantages</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are some of the material opportunities that we believe exist for our company:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Combination of Clinical, Administrative and Technology Capabilities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our key strength lies in our combined clinical, administrative, and technology capabilities. While many companies separately provide clinical, MSO, or technology support services, to our knowledge there are currently very few organizations like us that provide all three types of services to approximately 1.2 million patients as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversification</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our subsidiaries, consolidated affiliates, and invested entities, we have been able to reduce our business risk and increase revenue opportunities by diversifying our service offerings and expanding our ability to manage patient care across a horizontally integrated care network. Our revenue is spread across our operations. Additionally, with our ability to monitor and manage care within our wide network, we are an attractive business partner to health plans, hospitals, IPAs, and other medical groups seeking to provide better care at lower costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strong Management Team</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management team has, collectively, several decades of experience managing physician practices, risk-based organizations, health plans, hospitals, and health systems, a deep understanding of the healthcare marketplace and emerging trends, and a vision for the future of healthcare delivery led by physician-driven healthcare networks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Robust Physician Network</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our physician network consisted of over approximately 9,900 contracted physicians, including primary care physicians, specialist physicians, and hospitalists, through our affiliated physician groups and ACOs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cultural Affinities with Patients</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to delivering premium healthcare, we believe in the importance of providing services that are sensitive to the needs of local communities, including their cultural affinities. This value is shared by physicians within our affiliated IPAs and medical groups, and promotes patient comfort in communicating with care providers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Standing Relationships with Partners</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed long-standing relationships with and have earned trust from multiple health plans, hospitals, IPAs, and other medical groups that have helped to generate recurring contractual revenue for us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive and Effective Healthcare Management Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer comprehensive and effective healthcare management programs to patients. We have developed expertise in population health management and care coordination, and in proper medical coding, which results in improved Risk Adjustment Factor (&#8220;RAF&#8221;) scores and higher payments from health plans, and in improving quality metrics in both inpatient and outpatient settings and thus patient satisfaction and CMS scores. Using our own proprietary risk assessment scoring tool, we have also developed our own protocol for identifying high-risk patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is highly competitive and fragmented. We compete for customers across all of our services with other healthcare management companies, including MSOs and healthcare providers, such as local, regional, and national networks of physicians, medical groups, and hospitals, many of which are substantially larger than us and have significantly greater financial and other resources, including personnel, than we have.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPAs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our affiliated IPAs compete with other IPAs, medical groups, and hospitals, many of which have greater financial, personnel, and other resources available to them. In the greater Los Angeles area, such competitors include Regal Medical Group and Lakeside Medical Group, which are part of Heritage Provider Network (&#8220;Heritage&#8221;), as well as Optum (f.k.a. HealthCare Partners), a subsidiary of UnitedHealth Group.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ACOs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our NGACO, APAACO, competes with sophisticated provider groups in the creation, administration, and management of ACOs, including MSSP ACOs and NGACOs, many of which have greater financial, personnel, and other resources available to them. In the greater Los Angeles area, major competitors of APAACO include Heritage California ACO and DaVita Medical ACO California.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Outpatient Clinics</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our outpatient clinics compete with large ambulatory surgery centers and/or diagnostic centers such as Foothill Cardiology (California Heart Medical Group), RadNet, and Envision Healthcare, many of which have greater financial, personnel, and other resources available to them, as well as smaller clinics that have ties to local communities. Optum (f.k.a. HealthCare Partners) also has its own urgent care centers, clinics, and diagnostic centers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hospitalists</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because individual physicians may provide hospitalist services if they have necessary credentials and privileges, the markets for hospitalist services are highly fragmented. Our affiliated hospitalist groups face competition primarily from numerous small inpatient practices in existing and expanding markets, but also compete with large physician groups, many of which have greater financial, personnel, and other resources available to them. Some of such competitors operate on a national level, including EmCare, Team Health, and Sound Physicians.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a healthcare company, our operations and relationships with healthcare providers, such as hospitals, other healthcare facilities, and healthcare professionals, are subject to extensive and increasing regulation by numerous federal, state, and local government agencies, including the Office of Inspector General , the Department of Justice, CMS, and various state authorities. These laws and regulations often are interpreted broadly and enforced aggressively. Imposition of liabilities associated with a violation of any of these healthcare laws and regulations could have a material adverse effect on our business, financial condition, or results of operations. We cannot guarantee that our practices will not be subject to government scrutiny or be found to violate certain healthcare laws. Government investigations and prosecutions, even if we are ultimately found to be without fault, can be costly and disruptive to our business. Moreover, changes in healthcare legislation or government regulation may restrict our existing operations, limit our expansion, or impose additional compliance requirements and costs, any of which could have a material adverse effect on our business, financial condition, or results of operations. Below are brief descriptions of some, but not all, of such laws and regulations that affect our business operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Practice of Medicine</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our subsidiaries and VIEs. Some states have laws that prohibit business entities with non-physician owners, such as ApolloMed and its subsidiaries, from practicing medicine, employing physicians to practice medicine, or exercising control over medical decisions by physicians. These laws are generally referred to as corporate practice of medicine laws. States that have corporate practice of medicine laws permit only physicians to practice medicine, exercise control over medical decisions, or engage in certain arrangements, such as fee-splitting, with physicians. In these states, a violation of the corporate practice of medicine prohibition constitutes the unlawful practice of medicine, which is a public offense punishable by fines and other criminal penalties. In addition, any physician who participates in a scheme that violates the state&#8217;s corporate practice of medicine prohibition may be punished for aiding and abetting a lay entity in the unlawful practice of medicine.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California is a corporate practice of medicine state and we operate by maintaining long-term MSAs with our affiliated IPAs and medical groups, each of which is owned and operated by physicians only, and employs or contracts with additional physicians to provide medical services. Under such MSAs, our wholly owned MSOs are contracted to provide non-medical management and administrative services, such as financial and risk management, as well as information systems, marketing, and administrative support to the IPAs and medical groups. The MSAs typically have an initial term of 3-30 years and are generally not terminable by our affiliated IPAs and medical groups except in the case of bankruptcy, gross negligence, fraud, or other illegal acts by the contracting MSO.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the MSAs and the relationship with the physician owners of our medical affiliates, we have exclusive authority over all non-medical decisions related to the ongoing business operations of those affiliates. Consequently, ApolloMed consolidates the revenue and expenses of such affiliates as their primary beneficiary from the date of execution of the applicable MSA. When necessary, our Co-Chief Executive Officer, Dr. Thomas Lam, serves as nominee shareholder of affiliated medical practices on ApolloMed&#8217;s behalf, in order to comply with corporate practice of medicine laws&#160;and certain accounting rules applicable to consolidated financial reporting by our affiliates as VIEs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these arrangements, our MSOs perform only non-medical functions, do not represent to offer medical services, and do not exercise influence or control over the practice of medicine by physicians. The California Medical Board, as well as other states&#8217; regulatory bodies, has taken the position that MSAs that confer too much control over a physician practice to MSOs may violate the prohibition against corporate practice of medicine. Some of the relevant laws, regulations, and agency interpretations in California and other states that have corporate practice prohibitions have been subject to limited judicial and regulatory interpretation. Moreover, state laws and regulatory interpretations are subject to change. Other parties, including our affiliated physicians, may assert that, despite these arrangements, ApolloMed and its subsidiaries are engaged in the prohibited corporate practice of medicine or that such arrangements constitute unlawful fee-splitting between physicians and non-physicians. If this occurred, we could be subject to civil or criminal penalties, our MSAs could be found legally invalid and unenforceable in whole or in part, and we could be required to restructure arrangements with our affiliated IPAs and medical groups. If we were required to change our operating structures due to determination that a corporate practice of medicine violation existed, such a restructuring might require revising our MSOs&#8217; management fees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">False Claims Acts</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The False Claims Act, 31 U.S.C. &#167;&#167; 3729 - 3733, imposes civil liability on individuals or entities that submit false or fraudulent claims for payment to the federal government. The False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim for payment approved. Private parties may initiate qui tam whistleblower lawsuits against any person or entity under the False Claims Act in the name of the federal government and may share in the proceeds of a successful suit. The federal government has used the False Claims Act to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs. By way of illustration, these prosecutions may be based upon alleged coding errors, billing for services not rendered, billing services at a higher payment rate than appropriate, and billing for care that is not considered medically necessary. The federal government and a number of courts have taken the position that claims presented in violation of certain other statutes, including the federal Anti-Kickback Statute or the Stark Law, can also be considered a violation of the False Claims Act based on the theory that a provider impliedly certifies compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penalties for False Claims Act violations include substantial fines for each false claim, plus up to three times the amount of damages sustained by the government. A False Claims Act violation may provide the basis for the imposition of administrative penalties as well as exclusion from participation in governmental healthcare programs, including Medicare and Medicaid. In addition to the provisions of the False Claims Act, which provide for civil enforcement, the federal government also can use several criminal statutes to prosecute persons who are alleged to have submitted false or fraudulent claims to the government for payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of states including California have enacted laws that are similar to the federal False Claims Act. Under Section 6031 of the Deficit Reduction Act of 2005 (&#8220;DRA&#8221;), as amended, if a state enacts a false claims act that is at least as stringent as the federal statute and that also meets certain other requirements, the state will be eligible to receive a greater share of any monetary recovery obtained pursuant to certain actions brought under the state&#8217;s false claims act. As a result, more states are expected to enact laws that are similar to the federal False Claims Act in the future along with a corresponding increase in state false claims enforcement efforts. In addition, section 6032 of the DRA requires entities that make or receive annual Medicaid payments of $5.0 million or more from any one state to provide their employees, contractors, and agents with written policies and employee handbook materials on federal and state False Claims Acts and related statues. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Kickback Statutes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute is a provision of the Social Security Act of 1972 that prohibits as a felony offense the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce, (1) the referral of a patient for items or services for which payment may be made in whole or part under Medicare, Medicaid, or other federal healthcare programs, (2) the furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid, or other federal healthcare programs or (3) the purchase, lease, or order or arranging or recommending the purchasing, leasing, or ordering of any item or service reimbursable under Medicare, Medicaid, or other federal healthcare programs. The Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) amended section 1128B of the Social Security Act to make it clear that a person need not have actual knowledge of the statute, or specific intent to violate the statute, as a predicate for a violation. The OIG, which has the authority to impose administrative sanctions for violation of the statute, has adopted as its standard for review a judicial interpretation, which concludes that the statute prohibits any arrangement where even one purpose of the remuneration is to induce or reward referrals. A violation of the Anti-Kickback Statute is a felony punishable by imprisonment, criminal fines, civil fines, and three times the amount of the unlawful remuneration. A violation also can result in exclusion from Medicare, Medicaid, or other federal healthcare programs. In addition, pursuant to the changes of the ACA, a claim that includes items or services resulting from a violation of the Anti-Kickback Statute is a false claim for purposes of the False Claims Act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the breadth of the Anti-Kickback Statute&#8217;s broad prohibitions, statutory exceptions exist that protect certain arrangements from prosecution. In addition, the OIG has published safe harbor regulations that specify arrangements that are deemed protected from prosecution under the Anti-Kickback Statute, provided all applicable criteria are met. The failure of an activity to meet all of the applicable safe harbor criteria does not necessarily mean that the particular arrangement violates the Anti-Kickback Statute, but these arrangements may be subject to scrutiny and prosecution by enforcement agencies. We may be less willing than some competitors to take actions or enter into arrangements that do not clearly satisfy the OIG safe harbors and suffer a competitive disadvantage.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 2, 2020, in conjunction with HHS&#8217;s Regulatory Sprint to Coordinated Care, the OIG finalized modifications to existing safe harbors to the Anti-Kickback Statute and added new safe harbors and a new exception to the civil monetary penalty provision prohibiting inducements to beneficiaries, the purpose of which was to remove potential barriers to more effective coordination and management of patient care and delivery of value-based care. The changes implemented by the final rules went into effect on January 19, 2021. These or other changes implemented by OIG in the future may impact our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states have enacted statutes and regulations similar to the Anti-Kickback Statute, but which may be applicable regardless of the payor source for the patient. These state laws may contain exceptions and safe harbors that are different from and/or more limited than those of the federal law and that may vary from state to state. For example, California has adopted the Physician Ownership and Referral Act of 1993 (&#8220;PORA&#8221;). PORA makes it unlawful for physicians, surgeons, and other licensed professionals to refer a person for certain healthcare services if they have a financial interest with the person or entity that receives the referral. While PORA also provides certain exemptions from this prohibition, failure to fit within an exemption in violation of PORA can lead to a misdemeanor offense that may subject a physician to civil penalties and disciplinary action by the Medical Board of California.<br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, Section 445 of the California Health and Safety Code, provides that &#8220;no person, firm, partnership, association or corporation, or agent or employee thereof, shall for profit refer or recommend a person to a physician, hospital, health-related facility, or dispensary for any form of medical care or treatment of any ailment or physical condition. The imposition of a fee or charge of any such referral or recommendation creates a presumption that the referral or recommendation is for profit.&#8221; A violation of Section 445 is a misdemeanor and may subject the offender to imprisonment and/or monetary fines. Further, a violation of Section 445 may be enjoined by the California Attorney General. Section 650 of the California Business and Professions Code contains prohibitions against self-referral and kickbacks. Business &amp; Professions Code Section 650 makes it unlawful for a &#8220;licensee,&#8221; including a physician, to pay or receive any compensation or inducement for referring patients, clients, or customers to any person or entity, irrespective of any membership or proprietary interest in or with the person or entity receiving the referral. Violation of the statute is a public offense punishable by imprisonment and/or monetary fines. Section 650 further provides that it is not unlawful for a physician to refer a patient to a healthcare facility solely because the physician has a proprietary interest or co-ownership in a healthcare facility, provided that (1) the physician&#8217;s return on investment for that proprietary interest or co-ownership is based upon the amount of capital investment or proportional ownership of the physician; and (2) the ownership interest is not based on the number or value of any patients referred. A violation of Section 650 is a misdemeanor and may subject the offender to imprisonment and/or monetary fines.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure that the applicable regulatory authorities will not determine that some of our arrangements with physicians violate the federal Anti-Kickback Statute or other applicable laws. An adverse determination could subject us to different liabilities, including criminal penalties, civil monetary penalties, and exclusion from participation in Medicare, Medicaid, or other healthcare programs, any of which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stark Laws</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Stark Law, 42 U.S.C. 1395nn, also known as the physician self-referral law, generally prohibits a physician from referring Medicare and Medicaid patients to an entity (including hospitals) providing &#8220;designated health services,&#8221; if the physician or a member of the physician&#8217;s immediate family has a &#8220;financial relationship&#8221; with the entity, unless a specific exception applies. Designated health services include, among other services, inpatient hospital services, outpatient prescription drug services, clinical laboratory services, certain imaging services (e.g., MRI, CT, ultrasound), and other services that our affiliated physicians may order for their patients. The prohibition applies regardless of the reasons for the financial relationship and the referral, and therefore, unlike the federal Anti-Kickback Statute, intent to violate the law is not required. Like the Anti-Kickback Statute, the Stark Law contains statutory and regulatory exceptions intended to protect certain types of transactions and arrangements. Unlike safe harbors under the Anti-Kickback Statute with which compliance is voluntary, an arrangement must comply with every requirement of a Stark Law exception or the arrangement is in violation of the Stark Law.<br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the Stark Law and implementing regulations continue to evolve and are detailed and complex, while we attempt to structure its relationships to meet an exception to the Stark Law, there can be no assurance that the arrangements entered into by us with affiliated physicians and facilities will be found to be in compliance with the Stark Law, as it ultimately may be implemented or interpreted. The penalties for violating the Stark Law can include the denial of payment for services ordered in violation of the statute, mandatory refunds of any sums paid for such services, and civil penalties for each violation, double damages, and possible exclusion from future participation in the governmental healthcare programs. A person who engages in a scheme to circumvent the Stark Law&#8217;s prohibitions may face substantial fines for each applicable arrangement or scheme. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 2, 2020, in conjunction with HHS&#8217;s Regulatory Sprint to Coordinated Care, CMS issued a final rule intended to address the regulatory impact and burden of the Stark Law that impeded the healthcare system&#8217;s move toward value-based reimbursement. CMS added new exceptions to attempt to address potential barriers to coordinated care and value-based care. The changes implemented by the final rules went into effect on January 19, 2021. These or other changes implemented by CMS in the future may impact our business, results of operations, and financial condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some states have enacted statutes and regulations against self-referral arrangements similar to the federal Stark Law, but which may be applicable to the referral of patients regardless of their payor source and which may apply to different types of services. These state laws may contain statutory and regulatory exceptions that are different from those of the federal law and that may vary from state to state. For example, California has adopted the Physician Ownership and Referral Act of 1993 (&#8220;PORA&#8221;). PORA makes it unlawful for physicians, surgeons, and other licensed professionals to refer a person for certain healthcare services if they have a financial interest with the person or entity that receives the referral. While PORA also provides certain exemptions from this prohibition, failure to fit within an exemption in violation of PORA can lead to a misdemeanor offense that may subject a physician to civil penalties and disciplinary action by the Medical Board of California.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An adverse determination under these state laws and/or the federal Stark Law could subject us to different liabilities, including criminal penalties, civil monetary penalties, and exclusion from participation in Medicare, Medicaid, or other healthcare programs, any of which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Information Privacy and Security Standards<br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The privacy regulations promulgated under the  Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended, contain detailed requirements concerning the use and disclosure of individually identifiable patient health information (&#8220;PHI&#8221;) by entities like our MSOs and affiliated IPAs and medical groups. HIPAA covered entities must implement certain administrative, physical, and technical security standards to protect the integrity, confidentiality, and availability of certain electronic health information received, maintained, or transmitted. HIPAA also implemented standard transaction code sets and standard identifiers that covered entities must use when submitting or receiving certain electronic healthcare transactions, including billing and claim collection activities. New health information standards could have a significant effect on the manner in which we do business, and the cost of complying with new standards could be significant.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the HIPAA privacy and security rules may result in civil and criminal penalties, including a tiered system of civil money penalties. A HIPAA-covered entity must also promptly notify affected individuals where a breach affects more than 500 individuals and report annually any breaches affecting fewer than 500 individuals.<br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State attorneys general may bring civil actions on behalf of state residents for violations of the HIPAA privacy and security rules, obtain damages on behalf of state residents, and enjoin further violations. Many states also have laws that protect the privacy and security of confidential, personal information, which may be similar to or even more stringent than HIPAA. Where state laws are more protective than HIPAA, we have to comply with the stricter provisions. Some of these state laws may impose fines and penalties on violators and may afford private rights of action to individuals who believe their personal information has been misused. California&#8217;s patient privacy laws, for example, provide for monetary penalties and permit injured parties to sue for damages. Both state and federal laws are subject to modification or enhancement of privacy protection at any time.<br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with HIPAA or similar state laws, we could incur substantial civil monetary or criminal penalties. We expect increased federal and state privacy and security enforcement efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knox-Keene Act and State Insurance Laws<br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Knox-Keene Health Care Service Plan Act of 1975 (Health and Safety Code Section 1340, et seq.), as amended (the &#8220;Knox-Keene Act&#8221;), is the California law that regulates managed care plans. Neither our MSOs nor their managed medical groups and IPAs hold a Knox-Keene license. Some of the medical groups and IPAs that have entered into MSAs with our MSOs have historically contracted with health plans and other payors to receive capitation payments and assumed the financial responsibility for professional services. In many of these cases, the health plans or other payors separately enter into contracts with hospitals that receive payments and assume some type of contractual financial responsibility for their institutional services. In some instances, our affiliated medical groups and IPAs have been paid by their contracting payors or hospitals for the financial outcome of managing the care costs associated with both the professional and institutional services received by patients and have recognized a percentage of the surplus of institutional revenues less institutional expense as the medical groups&#8217; and IPAs&#8217; net revenues and, under certain circumstances, may be responsible for a percentage of any shortfall in the event that institutional expenses exceed institutional revenues. While our MSOs and their managed medical groups and IPAs are not contractually obligated to pay claims to hospitals or other institutions under these arrangements, if it is determined that our MSOs or the medical groups and IPAs have been inappropriately taking financial risk for institutional and professional services without Knox-Keene license or regulatory exemption as a result of their hospital and physician arrangements, we may be required to obtain a restricted Knox-Keene license to resolve such violations and we could be subject to civil and criminal liability, any of which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, some states require ACOs to be registered or otherwise comply with state insurance laws. Our ACOs are not registered with any state insurance agency. If it is determined that we have been inappropriately operating an ACO without state registration or licensure, we may be required to obtain such registration or licensure to resolve such violations and we could be subject to liability, which could have a material adverse effect on our business,&#160;financial condition, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental and Occupational Safety and Health Administration Regulations</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal, state, and local regulations governing the storage, use, and disposal of waste materials and products. Although we believe that our safety procedures for storing, handling, and disposing of these materials and products comply with the standards prescribed by law and regulation, we cannot eliminate the risk of accidental contamination or injury from those hazardous materials. In the event of an accident, we could be held liable for any damages that result and any liability could exceed the limits or fall outside the coverage of our insurance policies, which we may not be able to maintain on acceptable terms, or at all. We could incur significant costs and the attention of our management could be diverted to comply with current or future environmental laws and regulations. Federal regulations promulgated by the Occupational Safety and Health Administration impose additional requirements on us, including those protecting employees from exposure to elements such as blood-borne pathogens. We cannot predict the frequency of compliance, monitoring, or enforcement actions to which we may be subject as those regulations are being implemented, which could adversely affect our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Federal and State Healthcare Laws</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other federal and state healthcare laws that could have a material adverse effect on our business, financial condition, or results of operations. The Health Care Fraud Statute prohibits any person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, which can be either a government or private payor plan. Violation of this statute, even in the absence of actual knowledge of or specific intent to violate the statute, may be charged as a felony offense and may result in fines, imprisonment, or both. The Health Care False Statement Statute prohibits, in any matter involving a federal healthcare program, anyone from knowingly and willfully falsifying, concealing, or covering up, by any trick, scheme, or device, a material fact, or making any materially false, fictitious, or fraudulent statement or representation, or making or using any materially false writing or document knowing that it contains a materially false or fraudulent statement. A violation of this statute may be charged as a felony offense and may result in fines, imprisonment, or both. Under the Civil Monetary Penalties Law of the Social Security Act, a person (including an organization) is prohibited from knowingly presenting or causing to be presented to any United States officer, employee, agent, or department, or any state agency, a claim for payment for medical or other items or services where the person knows or should know (a) the items or services were not provided as described in the coding of the claim, (b) the claim is a false or fraudulent claim, (c) the claim is for a service furnished by an unlicensed physician, (d) the claim is for medical or other items or service furnished by a person or an entity that is in a period of exclusion from the program, or (e) the items or services are medically unnecessary items or services. Violations of the law may result in substantial penalties, treble damages, and exclusion from federal healthcare programs. In addition, the OIG may impose civil monetary penalties against any physician who knowingly accepts payment from a hospital (as well as against the hospital making the payment) as an inducement to reduce or limit medically necessary services provided to Medicare or Medicaid program beneficiaries. Further, except as permitted under the Civil Monetary Penalties Law, a person who offers or transfers to a Medicare or Medicaid beneficiary any remuneration that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular provider of Medicare or Medicaid payable items or services may be liable for civil money penalties for each wrongful act.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the state laws previously described, we may also be subject to other state fraud and abuse statutes and regulations if we expand our operations beyond California. Many states have adopted a form of anti-kickback law, self-referral prohibition, and false claims and insurance fraud prohibition. The scope of these laws and the interpretations of them vary from state to state and are enforced by state courts and regulatory authorities, each with broad discretion. Generally, state laws reach to all healthcare services and not just those covered under a governmental healthcare program. A determination of liability under any of these laws could result in fines and penalties and restrictions on our ability to operate in these states. We cannot assure that our arrangements or business practices will not be subject to government scrutiny or be found to violate applicable fraud and abuse laws.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Licensure, Certification, Accreditation, and Related Laws and Guidelines</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical personnel are subject to numerous federal, state, and local licensing laws and regulations, relating to, among other things, professional credentialing and professional ethics. Clinical professionals are also subject to state and federal regulation regarding prescribing medication and controlled substances. Our affiliated physicians and hospitalists must satisfy and maintain their individual professional licensing in each state where they practice medicine, including California, and many states require that nurse practitioners and physician assistants work in collaboration with or under the supervision of a physician. Each state defines the scope of practice of clinical professionals through legislation and through the respective Boards of Medicine and Nursing. Activities that qualify as professional misconduct under state law may subject our clinical personnel to sanctions, or to even lose their license and could, possibly, subject us to sanctions as well. Some state boards of medicine impose reciprocal discipline, that is, if a physician is disciplined for having committed professional misconduct in one state where they are licensed, another state where they are also licensed may impose the same discipline even though the conduct occurred in another state. Since we and our affiliated medical groups perform services at hospitals and other healthcare facilities, we may indirectly be subject to laws, ethical guidelines, and operating standards of professional trade associations and private accreditation commissions (such as the American Medical Association and The Joint Commission) applicable to those entities. Penalties for non-compliance with these laws and standards include loss of professional license, civil or criminal fines and penalties, loss of hospital admitting privileges, and exclusion from participation in various governmental and other third-party healthcare programs. In addition, our affiliated facilities are subject to state and local licensing regulations ranging from the adequacy of medical care, to compliance with building codes and environmental protection laws. Our ability to operate profitably will depend, in part, upon our ability and the ability of our affiliated physicians and facilities to obtain and maintain all necessary licenses and other approvals and operate in compliance with applicable healthcare and other laws and regulations that evolve rapidly. We provide home health, hospice, and palliative care, which require compliance with additional regulatory requirements. Reimbursement for palliative care and house call services is generally conditioned on clinical professionals providing the correct procedure and diagnosis codes and properly documenting both the service and the medical necessity for the service. Incorrect or incomplete documentation and billing information, or the incorrect selection of codes for the level and type of service provided, could result in non-payment for services rendered or lead to allegations of billing fraud. We must also comply with laws relating to hospice care eligibility, development, and maintenance of care plans and coordination with nursing homes or assisted living facilities where patients live.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Professional Liability and Other Insurance Coverage</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has an inherent and significant risk of claims of medical malpractice against us and our affiliated physicians. We and our affiliated physician groups pay premiums for third-party professional liability insurance that provides indemnification on a claims-made basis for losses incurred related to medical malpractice litigation in order to carry out our operations. Our physicians are required to carry first dollar coverage with limits of liability equal to not less than $1.0 million for claims based on occurrence up to an aggregate of $3.0 million per year. Our IPAs purchase stop-loss insurance, which will reimburse them for claims from service providers on a per enrollee basis. The specific retention amount per enrollee per policy period is $45,000 to $70,000 for professional coverage. We also maintain worker&#8217;s compensation, director and officer, and other third-party insurance coverage subject to deductibles and other restrictions that we believe are in accordance with industry standards. While we believe that our insurance coverage is adequate based upon claims experience and the nature and risks of our business, we cannot be certain that our insurance coverage will be adequate to cover liabilities arising out of pending or future claims asserted against us or our affiliated physician groups in the future where the outcomes of such claims are unfavorable. The ultimate resolution of pending and future claims in excess of our insurance coverage, may have a material adverse effect on our business, financial position, results of operations, or cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, ApolloMed, its subsidiaries, and consolidated VIEs had 1,133 employees. None of our employees are members of a labor union, and we have not experienced any work stoppage. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are committed to supporting the professional development of our employees, providing competitive compensation and benefits and a safe and inclusive workplace. We measure employee engagement on an ongoing basis to create a more innovative, productive, and profitable company. The results from engagement surveys are used to implement programs and processes designed to support employee retention and satisfaction. The Company believes a diverse workforce fosters innovation and cultivates an environment filled with unique perspectives and growth. Respect for human rights is fundamental to the Company&#8217;s business and its commitment to ethical business conduct.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Available Information</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a website at www.apollomed.net and make available there, free of charge, our periodic reports filed with the SEC, as soon as is reasonably practicable after filing. The SEC maintains a website at http://www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers such as us that file electronically with the SEC.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7, and our consolidated financial statements and related notes, before making a decision to invest in our common stock. The risks and uncertainties described below may not be the only ones we face. If any of the risks actually occur, our business, financial condition, operating results, and prospects could be materially and adversely affected. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Summary of Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ongoing coronavirus (COVID-19) pandemic may negatively impact certain aspects of our business, financial condition, results of operations, and growth.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to raise additional capital to grow, which might not be available.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential changes in laws, accounting principles, and regulations related to VIEs could impact our consolidation of total revenues derived from our affiliated physician groups.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The arrangements we have with our VIEs are not as secure as direct ownership of such entities.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently derive a substantial portion of our revenues in California and are vulnerable to changes in that state.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business strategy involves acquisitions and strategic partnerships, which can be costly, risky, and complex. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth, and the nature of our business and rapid changes in the healthcare industry make it difficult to reliably predict future growth and operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We could experience significant losses under capitation contracts if our expenses exceed revenues.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our agreements with affiliated physician groups are deemed invalid or are terminated under applicable law, our results of operations and financial condition will be materially impaired.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our revenues and operations are dependent on a limited number of key payors.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be impacted by a shift in payor mix, including eligibility changes to government and private insurance programs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our agreements with hospitals and medical groups have limited durations, may be terminated without cause by them, and prohibit us from acquiring physicians or patients from or competing with them.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to federal, state, and local healthcare law, including the ACA and/or the adoption of a primarily publicly funded healthcare system, may negatively impact our business. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The success of our emphasis on the NGACO Model is not guaranteed, due to political risks, uncertainties of NGACO administration, and the requirement of the Company to maintain significant capital reserves. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business and the failure to comply with such laws could subject us to penalties and restructuring.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The healthcare industry is intensely regulated at the federal, state, and local levels, and government authorities may determine that we fail to comply with applicable laws or regulations and take actions against us.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Controls designed to reduce inpatient services and associated costs may reduce our revenues.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our affiliated physician groups are not able to satisfy California financial solvency regulations, they could become subject to sanctions and their ability to do business in California could be limited or terminated.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our current principal stockholders, executive officers, and directors have significant influence over our operations and strategic direction and they could cause us to take actions with which other stockholders might not agree and could delay, deter, or prevent a change of control or a business combination with respect to us.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Our General Business and Operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;In 2019, the Company, AP-AMH, and APC consummated a series of interrelated transactions that may expose the Company and its subsidiaries and VIEs to additional risks, including the inability to repay a significant loan made in connection with such transactions.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, the Company, AP-AMH and APC, concurrently consummated a series of interrelated transactions (collectively, the &#8220;APC Transactions&#8221;).</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed elsewhere in this Annual Report on Form 10-K and in the Company&#8217;s other reports on file with the SEC, the APC Transactions included the following agreements and transactions: (i) the Company made a $545.0 million ten-year secured loan to AP-AMH; (ii) AP-AMH used all of the proceeds of that loan to purchase 1,000,000 shares of Series A Preferred Stock of APC; (iii) the Company obtained the funds to make the AP-AMH Loan (x) by entering into a credit agreement with Truist Bank, in its capacity as administrative agent for various lenders, and the lenders from time to time party thereto, for a $290.0 million senior secured credit facility (the &#8220;Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Credit Facility&#8221;), and then immediately drawing down $250.0 million in cash, and (y) by selling $300.0 million shares of the Company&#8217;s common stock to APC, the purchase price of which was offset against $300.0 million of AP-AMH&#8217;s purchase price for its APC Preferred Stock.</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM guaranteed the obligations of the Company under the Credit Facility, and both the Company and NMM have granted the lenders a security interest in all of their assets, including, without limitation, in all stock and other equity issued by their subsidiaries (including the shares of NMM) and all rights with respect to the AP-AMH Loan. The Credit Agreement was amended and restated </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on June 16, 2021 by an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) among the Company, Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and a lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The APC Transactions may expose the Company, its subsidiaries and its VIEs to additional risks, including without limitation, the following: AP-AMH may never be able to repay the AP-AMH Loan; even if AP-AMH does not, or cannot repay the loan, the Company will be obligated to pay principal and interest on the Amended Credit Facility; in connection with the Credit Facility, the lenders were granted a first priority perfected security interest over all of the assets of the Company and its subsidiaries, and such lenders have the right to foreclose on those assets if the Company defaults on its obligations under the Amended Credit Facility; a disconnect could arise between APC achieving net income, declaring and paying dividends to AP-AMH, and AP-AMH making its required payments to the Company, which disconnect could materially impact the Company&#8217;s financial results and its ability to make its required payments under the Amended Credit Facility; APC may be prohibited from paying, or may be unable to pay the dividends on its Series A Preferred Stock, including under the California Corporations Code; regulators could determine that the current, post-APC Transactions consolidated structure amounts to the Company violating California&#8217;s corporate practice of medicine doctrine; and the Company may be deemed an investment company, which could impose burdensome compliance requirements on the Company and restrict its future activities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;Risk Factors&#8221; section of the definitive proxy statement of the Company&#8217;s board of directors that the Company filed with the SEC on July 31, 2019 (the &#8220;2019 Proxy Statement&#8221;) described these and certain other risks related to the APC Transactions, which are hereby incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our internal controls over financial reporting are not considered effective, our business and stock price could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 404 of the Sarbanes-Oxley Act of 2002 requires us to evaluate the effectiveness of our internal controls over financial reporting as of the end of each fiscal year, and to include a management report assessing the effectiveness of our internal controls over financial reporting in our Annual Report on Form 10-K for that fiscal year. Section 404 also requires our independent registered public accounting firm to attest to, and report on, management&#8217;s assessment of our internal controls over financial reporting.&#160;Our management, including our principal executive officer and principal financial officer, does not expect that our internal controls over financial reporting will prevent all errors and all fraud. A control system, no matter how well-designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud involving a company have been, or will be, detected. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and we cannot assure you that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become ineffective because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. We cannot assure you that we or our independent registered public accounting firm will not identify a material weakness in our internal controls in the future. A material weakness in our internal controls over financial reporting would require management and our independent registered public accounting firm to consider our internal controls as ineffective. If our internal controls over financial reporting are not considered effective, we may experience a loss of public confidence, which could have an adverse effect on our business and on the market price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to raise additional capital to grow, which might not be available.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may in the future require additional capital to grow our business and may have to raise additional funds by selling equity, issuing debt, borrowing, refinancing our existing debt, or selling assets or subsidiaries. These alternatives may not be available on acceptable terms to us or in amounts sufficient to meet our needs. The failure to obtain any required future financing may require us to reduce or curtail certain existing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our&#160;net operating loss carryforwards and certain other tax attributes will be subject to limitations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a corporation undergoes an &#8220;ownership change&#8221; within the meaning of Section&#160;382 of the Internal Revenue Code of 1986, as amended, its net operating loss carryforwards and certain other tax attributes arising from before the ownership change are subject to limitations on use after the ownership change. In general, an ownership change occurs if there is a cumulative change in the corporation&#8217;s equity ownership by certain stockholders that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. Additional ownership changes in the future could result in additional limitations on our net operating loss carryforwards. Consequently, we may not be able to utilize a material portion of our net operating loss carryforwards and other tax attributes, to offset our tax liabilities, which could have a material adverse effect on our cash flows and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertain or adverse economic conditions could adversely impact us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A downturn in economic conditions could have a material adverse effect on our results of operations, financial condition, business prospects, and stock price. Historically, government budget limitations have resulted in reduced spending. Given that Medicaid is a significant component of state budgets, an economic downturn would put continued cost containment pressures on Medicaid outlays for healthcare services in California. The existing federal deficit and continued deficit spending by the federal government can lead to reduced government expenditures, including for government-funded programs in which we participate such as Medicare. An economic downturn and sustained unemployment may also impact the number of enrollees in managed care programs and the profitability of managed care companies, which could result in reduced reimbursement rates. Although we attempt to stay informed, any sustained failure to identify and respond to these trends could have a material adverse effect on our results of operations, financial condition, business, and prospects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may impact certain aspects of our business, financial condition, results of operation, and growth. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global spread of the COVID-19 pandemic and measures introduced by local, state, and federal governments to contain the virus and mitigate its public health effects have created significant impact to the global economy. We expect the evolving COVID-19 pandemic to continue to impact certain aspects of our business, results of operations, and financial condition and liquidity, but given the uncertainty around the duration and severity of the pandemic, we cannot accurately predict at this time the future potential impact on our business, results of operations, financial condition, and liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the pandemic, COVID-19 impacted certain aspects of our business as community self-isolation practices and shelter-in-place requirements reduced our inpatient visits. Continued shelter-in-place, quarantine, executive order, or related measures to combat the spread of COVID-19, as well as the perceived need by individuals to continue such practices to avoid infection, among other factors, have impacted and are expected to continue to impact certain aspects of our results of operations, business, and financial condition. These measures and practices resulted in temporary closures of outpatient clinics, and may result in delays in entry into new markets and expansion in existing markets. Governmental authorities in California began reopening and lifting or relaxing shelter-in-place and quarantine measures only to revert back to such restrictions in the face of increases in new COVID-19 cases. In addition, due to the shelter-in-place orders across the country, we have implemented work-from-home policies for many employees, which may impact productivity and disrupt our business operations. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare organizations around the world, including our medical offices, have faced, and will continue to face, substantial challenges in treating patients with COVID-19, such as the diversion of hospital staff and resources from ordinary functions to the treatment of COVID-19, supply, resource, and capital shortages, and overburdening of staff and resource capacity. In the United States, governmental authorities have also recommended, and in certain cases required, that elective, specialty, and other procedures and appointments, including certain primary care services, be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19, and to focus limited resources and personnel capacity toward the treatment of COVID-19. Some of these measures and challenges will likely continue for the duration of the pandemic, which is uncertain, and will harm the results of operations, liquidity, and financial condition of these healthcare organizations, including certain of our health network partners. We cannot accurately predict at this time the ultimate severity or duration that the foregoing measures and challenges may have on these healthcare organizations, including us and our health network partners. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic and similar crises could also diminish the public&#8217;s trust in healthcare facilities, especially facilities that fail to accurately or timely diagnose, or are treating (or have treated) patients affected by infectious diseases. As certain of our medical offices treat patients with COVID-19 or other infectious disease, patients may be discouraged from visiting our offices, including cancelling appointments. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our affiliated physician groups also face an increased risk of infection with COVID-19, which may result in staffing shortages at our offices or increased workers&#8217; compensation claims. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by and the duration of COVID-19 may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, potentially reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global outbreak of COVID-19 continues to rapidly evolve. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We cannot at this time precisely predict what effects the COVID-19 outbreak will have on certain aspects of our business, results of operations, and financial condition, including due to uncertainties relating to the severity of the disease, the duration of the pandemic, and the governmental responses to the pandemic.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to take write-downs or write-offs, restructuring, and impairment or other charges that could have a significant negative effect on our financial condition, results of operations, and stock price.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that all material issues that may be present in our operations, including from prior to the 2017 Merger, have been uncovered, or that factors outside of our control will not later arise. As a result, we may be forced to write-down or write-off assets, restructure operations, or incur impairment or other charges that could result in losses. Unexpected risks may arise and previously known risks may materialize in a manner not consistent with each company&#8217;s preliminary risk analysis. Even though these charges may not have an immediate impact on our liquidity, the fact that we report charges of this nature could contribute to negative market perceptions about us or our securities and may make our future financing difficult to obtain on favorable terms or at all.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our intangible assets are subject to impairment testing. Under current accounting standards, our goodwill, including acquired goodwill, is tested for impairment on an annual basis and may be subject to impairment losses as circumstances change (e.g., after an acquisition). If we record an impairment loss, it could have a material adverse effect on our results of operations for the year in which the impairment is recorded.&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A prolonged disruption of or any actual or perceived difficulties in the capital and credit markets may adversely affect our future access to capital, our cost of capital, and our ability to continue operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and performance depend primarily on California and U.S. economic conditions and their impact on purchases of, or capitated rates for, our healthcare services, and our business is significantly exposed to risks associated with government spending and private payor reimbursement rates. As a result of inflation and the current impact on the market and the COVID-19-related 2020 recession, general economic conditions deteriorated significantly. Although the markets have improved significantly, the overall economic recovery since that time has been uneven. Declines in consumer and business confidence, as well as private and government spending, together with significant reductions in the availability and increases in the cost of credit and volatility in the capital and credit markets, have adversely affected the business and economic environment in which we operate and our profitability. Market disruption, increases in interest rates, and/or sluggish economic growth in any future period could adversely affect our patients&#8217; spending habits, private payors&#8217; access to capital, and governmental budgetary processes, which, in turn, could result in reduced revenue for us. The continuation or recurrence of any of these conditions may adversely affect our cash flows, results of operations, and financial condition. As economic uncertainty may continue in future periods, our patients, private payors, and government payors may alter their purchasing activities of healthcare services. Our patients may scale back healthcare spending, and private and government payors may reduce reimbursement rates, which may also cause delay or cancellation of consumer spending for discretionary and non-reimbursed healthcare. This uncertainty may also affect our ability to prepare accurate financial forecasts or meet specific forecasted results, and we may be unable to adequately respond to or forecast further changes in demand for healthcare services. Volatility and disruption of capital and credit markets may adversely affect our access to capital and increase our cost of capital. Should current economic and market conditions deteriorate, our ability to finance ongoing operations and our expansion may be adversely affected, we may be unable to raise necessary funds, our cost of debt or equity capital may increase significantly, and future access to capital markets may be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If there is a change in accounting principles or the interpretation thereof affecting consolidation of VIEs, it could impact our consolidation of total revenues derived from our affiliated physician groups.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements are consolidated and include the accounts of our majority-owned subsidiaries and various non-owned affiliated physician groups that are VIEs, which consolidation is effectuated in accordance with applicable accounting rules promulgated by the Financial Accounting Standards Board (&#8220;FASB&#8221;). Such accounting rules require that, under some circumstances, the VIE consolidation model be applied when a reporting enterprise holds a variable interest (e.g., equity interests, debt obligations, certain management, and service contracts) in a legal entity. Under this model, an enterprise must assess the entity in which it holds a variable interest to determine whether it meets the criteria to be consolidated as a VIE. If the entity is a VIE, the consolidation framework next identifies the party, if one exists, that possesses a controlling financial interest in the VIE, and then requires that party to consolidate as the primary beneficiary. An enterprise&#8217;s determination of whether it has a controlling financial interest in a VIE requires that a qualitative determination be made, and is not solely based on voting rights. If an enterprise determines the entity in which it holds a variable interest is not subject to the VIE consolidation model, the enterprise should apply the traditional voting control model which focuses on voting rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our case, the VIE consolidation model applies to our controlled, but not owned, physician-affiliated entities. Our determination regarding the consolidation of our affiliates, however, could be challenged, which could have a material adverse effect on our operations. In addition, in the event of a change in accounting rules or FASB&#8217;s interpretations thereof, or if there were an adverse determination by a regulatory agency or a court or a change in state or federal law relating to the ability to maintain present agreements or arrangements with our affiliated physician groups, we may not be permitted to continue to consolidate the revenues of our VIEs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breaches or compromises of our information security systems or our information technology systems or infrastructure could result in exposure of private information, disruption of our business, and damage to our reputation, which could harm our business, results of operation, and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a routine part of our business, we utilize information security and information technology systems and websites that allow for the secure storage and transmission of proprietary or private information regarding our patients, employees, vendors, and others, including individually identifiable health information. A security breach of our network, hosted service providers, or vendor systems, may expose us to a risk of loss or misuse of this information, litigation, and potential liability. Hackers and data thieves are increasingly sophisticated and operate large-scale and complex automated attacks, including on companies within the healthcare industry. Although we believe that we take appropriate measures to safeguard sensitive information within our possession, we may not have the resources or technical sophistication to anticipate or prevent rapidly evolving types of cyber-attacks targeted at us, our patients, or others who have entrusted us with information. Actual or anticipated attacks may cause us to incur costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants. We invest in industry-standard security technology to protect personal information. Advances in computer capabilities, new technological discoveries, or other developments may result in the technology used by us to protect personal information or other data being breached or compromised. In addition, data and security breaches can also occur as a result of non-technical failures. To our knowledge, we have not experienced any material breach of our cybersecurity systems. If we or our third-party service providers systems fail to operate effectively or are damaged, destroyed, or shut down, or there are problems with transitioning to upgraded or replacement systems, or there are security breaches in these systems, any of the aforementioned could occur as a result of natural disasters, software or equipment failures, telecommunications failures, loss or theft of equipment, acts of terrorism, circumvention of security systems, or other cyberattacks, we could experience delays or decreases in service, and reduced efficiency of our operations. Additionally, any of these events could lead to violations of privacy laws, loss of customers, or loss, misappropriation or corruption of confidential information, trade secrets or data, which could expose us to potential litigation, regulatory actions, sanctions, or other statutory penalties, any or all of which could adversely affect our business, and cause it to incur significant losses and remediation costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on complex software systems and hosted applications to operate our business, and our business may be disrupted if we are unable to successfully or efficiently update these systems or convert to new systems.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on technology systems to operate our business, reduce costs, and enhance customer service. These systems include complex software systems and hosted applications that are provided by third parties. Software systems need to be updated on a regular basis with patches, bug fixes, and other modifications. Hosted applications are subject to service availability and reliability of hosting environments. We also migrate from legacy systems to new systems from time to time. Maintaining existing software systems, implementing upgrades, and converting to new systems are costly and require personnel and other resources. The implementation of these systems upgrades, and conversions is a complex and time-consuming project involving substantial expenditures for implementation activities, consultants, system hardware and software, often requires transforming our current business and processes to conform to new systems, and therefore, may take longer, be more disruptive, and cost more than forecast and may not be successful. If the implementation is delayed or otherwise is not successful, it may hinder our business operations and negatively affect our financial condition and results of operations. There are many factors that may materially and adversely affect the schedule, cost, and execution of the implementation process, including, without limitation, problems in the design and testing of new systems; system delays and malfunctions; the deviation by suppliers and contractors from the required performance under their contracts with us; the diversion of management attention from our daily operations to the implementation project; reworks due to unanticipated changes in business processes; difficulty in training employees in the operation of new systems and maintaining internal control while converting from legacy systems to new systems; and integration with our existing systems. Some of such factors may not be reasonably anticipated or may be beyond our control.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to renew our leases on favorable terms or at all as our leases expire, which could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate several leased premises. There is no assurance that we will be able to continue to occupy such premises in the future. For example, we currently rent our corporate headquarters on a month-to-month basis. We could thus spend substantial resources to meet the current landlords&#8217; demands or look for other premises. We may be unable to timely renew such leases or renew them on favorable terms, if at all. If any current lease is terminated or not renewed, we may be required to relocate our operations at substantial costs or incur increased rental expenses, which could adversely affect our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently derive a substantial portion of our revenues in California and are vulnerable to changes in that state.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We primarily operate in California. Any material changes with respect to consumer preferences, taxation, reimbursements, financial requirements, or other aspects of the healthcare delivery in California or the state&#8217;s economic conditions could have an adverse effect on our business, results of operations, and financial condition.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends, to a significant degree, upon our ability to adapt to the ever-changing healthcare industry and continued development of additional services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect to provide a broad and competitive range of services, there can be no assurance of acceptance of current services by the marketplace. Our ability to procure new contracts&#160;may be dependent upon the continuing results achieved at the current facilities, upon pricing and operational considerations, and the potential need for continuing improvement to our existing services. Moreover, the markets for our new services may not develop as expected nor can there be any assurance that we will be successful in marketing any such services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Our Growth Strategy and Business Model.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth strategy may not prove viable and we may not realize expected results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is to grow rapidly by building a network of medical groups and integrated physician networks and is significantly dependent on locating and acquiring, partnering or contracting with medical practices to provide healthcare delivery services. We seek growth opportunities both organically and through acquisitions of or alliances with other medical service providers. As part of our growth strategy, we regularly review potential strategic opportunities. Identifying and establishing suitable strategic relationships are time-consuming and costly. There can be no assurance that we will be successful. We cannot guarantee that we will be successful in pursuing such strategic opportunities or assure the consequences of any strategic transactions. If we fail to evaluate and execute strategic transactions properly, we may not achieve anticipated benefits and may incur increased costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic transactions involve a number of risks and uncertainties, including that:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to successfully identify suitable strategic opportunities, complete desired strategic transactions, or realize their expected benefits. In addition, we compete for strategic transactions with other potential players, some of whom may have greater resources than we do. This competition may intensify due to the ongoing consolidation in the healthcare industry, which may increase our costs to pursue such opportunities.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to establish suitable strategic relationships and may fail to integrate them into our business. We cannot be certain of the extent of any unknown, undisclosed or contingent liabilities of any acquired business, including liabilities for failure to comply with applicable laws. We may incur material liabilities for past activities from strategic relationships. Also, depending on the location of the strategic transactions, we may be required to comply with laws and regulations that may differ from those of California, the state in which we currently operate.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may form strategic relationships with medical practices that operate with lower profit margins as compared with ours or which have a different payor mix than our other practice groups, which would reduce our overall profit margin. Depending upon the nature of the local market, we may not be able to implement our business model in every local market that we enter, which could negatively impact our revenues and financial condition.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may incur substantial costs to complete strategic transactions, integrate strategic relationships into our business, or expand our operations, including hiring more employees and engaging other personnel, to provide services to additional patients that we are responsible for managing pursuant to the new relationships. If such relationships terminate or diminish before we can realize their expected benefits, any costs that we have already incurred may not be recovered.</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we finance strategic transactions by issuing our equity securities or securities convertible thereto, our existing stockholders could be diluted. If we finance strategic transactions with debt, it could result in higher leverage and interest costs for us.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not successful in our efforts to identify and execute strategic transactions on beneficial terms, our ability to implement our business plan and achieve our targets could be adversely affected.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of integrating strategic relationships also involves significant risks, including:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in coping with demands on management related to the increased size of our business;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in not diverting management&#8217;s attention from our daily operations;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in assimilating different corporate cultures and business practices;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in converting other entities&#8217; books and records and conforming their practices to ours;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in integrating operating, accounting, and information technology systems of other entities with ours and in maintaining uniform procedures, policies, and standards such as internal accounting controls;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in retaining employees who may be vital to the integration of the acquired entities; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in maintaining contracts and relationships with payors of other entities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to make certain contingent payments in connection with strategic transactions from time to time. The fair value of such payments is reevaluated periodically based on changes in our estimate of future operating results and changes in market discount rates. Any changes in our estimated fair value are recognized in our results of operations. The actual payments, however, may exceed our estimated fair value. Increases in actual contingent payments compared to the amounts recognized may have an adverse effect on our financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to effectively integrate strategic relationships into our business, which may negatively impact our business model, revenues, results of operations, and financial condition. In addition, strategic transactions are time-intensive, requiring significant commitment of our management&#8217;s focus. If our management spends too much time on assessing potential opportunities, completing strategic transactions, and integrating strategic relationships, our management may not have sufficient time to focus on our existing operations. This diversion of attention could have material and adverse consequences on our operations and profitability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obligations in our credit or loan documents could restrict our operations, particularly our ability to respond to changes in our business or to take specified actions. An event of default could harm our business, and creditors having security interests over our assets would be able to foreclose on our assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of our credit agreements and other indebtedness from time to time require us to comply with a number of financial and other obligations, which may include maintaining debt service coverage and leverage ratios and maintaining insurance coverage, that impose significant operating and financial restrictions on us, including restrictions on our ability to take actions that may be in our interests. These obligations may limit our flexibility in our operations, and breaches of these obligations could result in defaults under the agreements or instruments governing the indebtedness, even if we had satisfied our payment obligations. Moreover, if we defaulted on these obligations, creditors having security interests over our assets could exercise various remedies, including foreclosing on and selling our assets. Unless waived by creditors, for which no assurance can be given, defaulting on these obligations could result in a material adverse effect on our financial condition and ability to continue our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth, and the nature of our business and rapid changes in the healthcare industry makes it difficult to reliably predict future growth and operating results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to successfully grow and expand. Successful implementation of our business plan will require management of growth, including potentially rapid and substantial growth, which could result in an increase in the level of responsibility for management personnel and strain on our human and capital resources. To manage growth effectively, we will be required, among other things, to continue to implement and improve our operating and financial systems, procedures, and controls and to expand, train, and manage our employee base. If we are unable to implement and scale improvements to our existing systems and controls in an efficient and timely manner or if we encounter deficiencies, we will not be able to successfully execute our business plans. Failure to attract and retain sufficient numbers of qualified personnel could also impede our growth. If we are unable to manage our growth effectively, it will have a material adverse effect on its business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The evolving nature of our business and rapid changes in the healthcare industry makes it difficult to anticipate the nature and amount of medical reimbursements, third-party private payments, and participation in certain government programs and thus to reliably predict our future growth and operating results.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could experience significant losses under capitation contracts if our expenses exceed revenues.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under a capitation contract, a health plan typically prospectively pays an IPA periodic capitation payments based on a percentage of the amount received by the health plan. Capitation payments, in the aggregate, represent a prospective budget from which an IPA manages care-related expenses on behalf of the population enrolled with that IPA. If our affiliated IPAs are able to manage care-related expenses under the capitated levels, we realize operating profits from capitation contracts. However, if care-related expenses exceed projected levels, our affiliated IPAs may realize substantial operating deficits, which are not capped and could lead to substantial losses. Additionally, factors beyond our control, such as natural disasters, the potential effects of climate change, major epidemics, pandemics, or newly emergent viruses (such as COVID-19), could reduce our ability to effectively manage the costs of providing healthcare.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our agreements with affiliated physician groups are deemed invalid or are terminated under applicable law, our results of operations and financial condition will be materially impaired.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various state laws, including laws in California, regulating the corporate practice of medicine, which prohibit us from directly owning medical professional entities. These prohibitions are intended to prevent unlicensed persons from interfering with or inappropriately influencing a physician&#8217;s professional judgment. These and other laws may also prevent fee-splitting, which is the sharing of professional service income with non-professional or business interests. The interpretation and enforcement of these laws vary significantly from state to state. We currently derive revenues from MSAs or similar arrangements with our affiliated IPAs, whereby we provide management and administrative services to them. If these agreements and arrangements were held to be invalid under laws prohibiting the corporate practice of medicine and other laws or if there are new laws that prohibit such agreements or arrangements, a significant portion of our revenues will be lost, resulting in a material adverse effect on our results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The arrangements we have with our VIEs are not as secure as direct ownership of such entities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of corporate practice of medicine laws, we entered into contractual arrangements to manage certain affiliated physician practice groups, which allow us to consolidate those groups for financial reporting purposes. We do not have direct ownership interests in any of our VIEs and are not able to exercise rights as an equity holder to directly change the members of the boards of directors of these entities so as to affect changes at the management and operational level. Under our arrangements with our VIEs, we must rely on their equity holders to exercise our control over the entities. If our affiliated entities or their equity holders fail to perform as expected, we may have to incur substantial costs and expend additional resources to enforce such arrangements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure by our affiliated entities or their owners to perform their obligations under their agreements with us would have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our affiliated physician practice groups are owned by individual physicians who could die, become incapacitated, or become no longer affiliated with us. Although our MSAs with these affiliates provide that they will be binding on successors of current owners, as the successors are not parties to the MSAs, it is uncertain in case of the death, bankruptcy, or divorce of a current owner whether their successors would be subject to such MSAs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenues and operations are dependent on a limited number of key payors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are dependent on a concentrated number of payors. Four payors accounted for an aggregate of 49.6% and 53.4% of our total net revenue for the years ended December&#160;31, 2021 and 2020, respectively. We believe that a majority of our revenues will continue to be derived from a limited number of key payors, which may terminate their contracts with us or our physicians credentialed by them upon the occurrence of certain events. They may also amend the material terms of the contracts under certain circumstances. Failure to maintain such contracts on favorable terms, or at all, would materially and adversely affect our results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An exodus of our patients could have a material adverse effect on our results of operations. We may also be impacted by a shift in payor mix, including eligibility changes to government and private insurance programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material decline in the number of patients that we and our affiliated physician groups serve, whether a government or a private entity is paying for their healthcare, could have a material adverse effect on our results of operations and financial condition, which could result from increased competition, new developments in the healthcare industry, or regulatory overhauls. In light of the repeal of the individual mandate requirement under the Patient Protection and Affordable Care Act of 2010 (also known as Affordable Care Act or Obamacare) via the Tax Cuts and Jobs Act of 2017, some people are expected to lose their health insurance and thus may not continue to afford services by our managed medical groups. In addition, due to potential decreased availability of healthcare through private employers, the number of patients who are uninsured or participate in governmental programs may increase. A shift in payor mix from managed care and other private payors to government payors or the uninsured may result in a reduction in our rates of reimbursement or an increase in our uncollectible receivables or uncompensated care, with a corresponding decrease our net revenue. Changes in the eligibility requirements for governmental programs could also change the number of patients who participate in such programs or the number of uninsured patients. For those patients who remain with private insurance, changes in those programs could increase patient responsibility amounts, resulting in a greater risk for uncollectible receivables. Such events could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth could be harmed if we lose the services of our key management personnel.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends to a significant extent on the continued contributions of our key management personnel, particularly our Executive Chairman and Co-Chief Executive Officer, Dr. Sim, and our Co-Chief Executive Officer and President, Dr. Lam, for the management of our business and implementation of our business strategy. The loss of their services could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If having our key management personnel serving as nominee equity holders of our VIEs is invalid under applicable laws, or if we lost the services of key management personnel for any reason, it could have a material adverse impact on our results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various state laws, including laws in California, regulating the corporate practice of medicine, which prohibit us from owning various healthcare entities. These corporate practice of medicine prohibitions are intended to prevent unlicensed persons from interfering with or inappropriately influencing a physician&#8217;s professional judgment. The interpretation and enforcement of these laws vary significantly from state to state. As a result, many of our affiliated physician practice groups are either wholly owned or primarily owned by Dr. Lam as the nominee shareholder for our benefit. If these arrangements were held to be invalid under applicable laws, which may change from time to time, a significant portion of our consolidated revenues would be affected, which may result in a material adverse effect on our results of operations and financial condition. Similarly, if Dr. Lam died, was incapacitated, or otherwise was no longer affiliated with us, our relationships and arrangements with those VIEs could be in jeopardy, and our business could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent in part on referrals from third parties and preferred provider status with payors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business relies in part on referrals from third parties for our services. We receive referrals from community medical providers, emergency departments, payors, and hospitals in the same manner as other medical professionals receive patient referrals. We do not provide compensation or other remuneration to referral sources for referring patients to us. A decrease in these referrals due to competition, concerns about our services and other factors could result in a significant decrease in our revenues and adversely impact our financial condition. Similarly, we cannot assure that we will be able to obtain or maintain preferred provider status with significant third-party payors in the communities where we operate. If we are unable to maintain our referral base or our preferred provider status with significant third-party payors, it may negatively impact our revenues and financial performance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partner facilities may terminate agreements with our affiliated physician groups or reduce their fees.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hospitalist physician services net revenue is derived from contracts directly with hospitals and other inpatient and post-acute care facilities. Our current partner facilities may decide not to renew contracts with, impose unfavorable terms on, or reduce fees paid to our affiliated physician groups. Any of these events may impact the ability of our affiliated physician groups to operate at such facilities, which would negatively impact our revenues, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Many of our agreements with hospitals and medical groups have limited durations, may be terminated without cause by them, and prohibit us from acquiring physicians or patients from or competing with them.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our agreements with hospitals and medical groups are limited in their terms or may be terminated without cause by providing advance notice. If such agreements are not renewed or terminated, we would lose the revenue generated by them. Any such events could have a material adverse effect on our results of operations, financial condition, and future business plans. Because many of such agreements with hospitals and medical groups prohibit us from acquiring physicians or patients from or competing with them, our ability to hire physicians, attract patients, or conduct business in certain areas may be limited in some cases.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business model depends on numerous complex management information systems, and any failure to successfully maintain these systems or implement new systems could undermine our ability to receive payments and otherwise materially harm our operations and may result in violations of healthcare laws and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on a complex, specialized, integrated management information system and standardized procedures for operational and financial information, as well as for our billing operations. We may be unable to enhance existing management information systems or implement new management information systems when necessary. We may experience unanticipated delays, complications, or expenses in implementing, integrating, and operating our systems. Our management information systems may require modifications, improvements, or replacements that may require both substantial expenditures, as well as interruptions in operations. Our ability to create and implement these systems depends on the availability of technology and skilled personnel. Our failure to successfully implement and maintain all of our systems could undermine our ability to receive payments and otherwise have a material adverse effect on our business, results of operations, and financial condition. Our failure to successfully operate our billing systems could also lead to potential violations of healthcare laws and regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to the Healthcare Industry.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare industry is highly competitive.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete directly with national, regional, and local providers of inpatient healthcare for patients and physicians. There are many other companies and individuals currently providing healthcare services, many of which have been in business longer and/or have substantially more resources. Since there are virtually no substantial capital expenditures required for providing healthcare services, there are few financial barriers to entry the healthcare industry. Other companies could enter the healthcare industry in the future and divert some or all of our business. On a national basis, our competitors include, but are not limited to, Team Health, EmCare, Optum, and Heritage, each of which has greater financial and other resources available to them. We also compete with physician groups and privately-owned healthcare companies in local markets. In addition, our relationships with governmental and private third-party payors are not exclusive and our competitors have established or could seek to establish relationships with such payors to serve their covered patients. Competitors may also seek to compete with us for acquisitions, which could have the effect of increasing the price and reducing the number of suitable acquisitions, which would have an adverse impact on our growth strategy. Individual physicians, physician groups, and companies in other healthcare industry segments, including those with which we have contracts, and some of which have greater financial, marketing, and staffing resources, may become competitors in providing healthcare services, and this competition may have a material adverse effect on our business operations and financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We therefore may be unable to compete successfully and even after we expend significant resources.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New physicians and other providers must be properly enrolled in governmental healthcare programs before we can receive reimbursement for their services, and there may be delays in the enrollment process.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each time a new physician joins us or our affiliated groups, we must enroll the physician under our applicable group identification number for Medicare and Medicaid programs and for certain managed care and private insurance programs before we can receive reimbursement for services the physician renders to beneficiaries of those programs. The estimated time to receive approval for the enrollment is sometimes difficult to predict and, in recent years, the Medicare program carriers often have not issued these numbers to our affiliated physicians in a timely manner. These practices result in delayed reimbursement that may adversely affect our cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hospitals where our affiliated physicians provide services may deny privileges to our physicians.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, our affiliated physicians may only provide services in a hospital where they have maintained certain credentials, also known as privileges, which are granted by the medical staff according to the bylaws of the hospital. The medical staff could decide that our affiliated physicians can no longer receive privileges to practice there. Such a decision would limit our ability to furnish services at the hospital, decrease the number of our affiliated physicians, or preclude us from entering new hospitals. In addition, hospitals may attempt to enter into exclusive contracts for certain physician services, which would reduce our access to patient populations within the hospital.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes associated with reimbursements by third-party payors may adversely affect our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical services industry is undergoing significant changes with government and other third-party payors that are taking measures to reduce reimbursement rates or, in some cases, denying reimbursement altogether. There is no assurance that government or other third-party payors will continue to pay for the services provided by our affiliated medical groups. Furthermore, there has been, and continues to be, a great deal of discussion and debate about the repeal and replacement of existing government reimbursement programs, such as the ACA. As a result, the future of healthcare reimbursement programs is uncertain, making long-term business planning difficult and imprecise. The failure of government or other third-party payors to cover adequately the medical services provided by us could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business may be significantly and adversely affected by legislative initiatives aimed at or having the effect of reducing healthcare costs associated with Medicare and other government healthcare programs and changes in reimbursement policies. In order to participate in the Medicare program, we must comply with stringent and often complex enrollment and reimbursement requirements. These programs generally provide for reimbursement on a fee-schedule basis rather than on a charge-related basis. As a result, we cannot increase our revenue by increasing the amount that we and our affiliates charge for services. To the extent that our costs increase, we may not be able to recover the increased costs from these programs. In addition, cost containment measures in non-governmental insurance plans have generally restricted our ability to recover, or shift to non-governmental payors, these increased costs. In attempts to limit federal and state spending, there have been, and we expect that there will continue to be, a number of proposals to limit or reduce Medicare reimbursement for various services. For example, the Medicare Access and CHIP Reauthorization Act of 2015 made numerous changes to Medicare, Medicaid, and other healthcare-related programs, including new systems for establishing annual updates to Medicare rates for physicians&#8217; services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have difficulty collecting payments from third-party payors in a timely manner.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive significant revenue from third-party payors, and delays in payment or refunds to payors may adversely impact our net revenue. We assume the financial risks relating to uncollectible and delayed payments. In particular, we rely on some key governmental payors. Governmental payors typically pay on a more extended payment cycle, which could require us to incur substantial expenses prior to receiving corresponding payments. In the current healthcare environment, as payors continue to control expenditures for healthcare services, including through revising their coverage and reimbursement policies, we may continue to experience difficulties in collecting payments from payors that may seek to reduce or delay such payments. If we are not timely paid in full or if we need to refund some payments, our revenues, cash flows, and financial condition could be adversely affected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Decreases in payor rates could adversely affect us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decreases in payor rates, either prospectively or retroactively, could have a significant adverse effect on our revenues, cash flows, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and state laws may limit our ability to collect monies owed by patients.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third-party collection agencies whom we do not control to collect from patients any co-payments and other payments for services that our physicians provide. The federal Fair Debt Collection Practices Act of 1977 (the &#8220;FDCPA&#8221;) restricts the methods that third-party collection companies may use to contact and seek payment from consumer debtors regarding past due accounts. State laws vary with respect to debt collection practices, although most state requirements are similar to those under the FDCPA. Therefore, such agencies may not be successful in collecting payments owed to us and our affiliated physician groups. If practices of collection agencies utilized by us are inconsistent with these standards, we may be subject to actual damages and penalties. These factors and events could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have established reserves for our potential medical claim losses, which are subject to inherent uncertainties, and a deficiency in the established reserves may lead to a reduction in our assets or net incomes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We establish reserves for estimated IBNR claims. IBNR estimates are developed using actuarial methods and are based on many variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such interpretations may not come to light until a substantial period of time has passed. The inherent difficulty in interpreting contracts and estimating necessary reserves could result in significant fluctuations in our estimates from period to period. Our actual losses and related expenses therefore may differ, even substantially, from the reserve estimates reflected in our financial statements. If actual claims exceed our estimated reserves, we may be required to increase reserves, which would lead to a reduction in our assets or net income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition for qualified physicians, employees, and management personnel is intense in the healthcare industry, and we may not be able to hire and retain qualified physicians and other personnel.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our affiliated physicians to provide services and generate revenue. We compete with many types of healthcare providers, including teaching, research and government institutions, hospitals, and other practice groups, for the services of clinicians and management personnel. The limited number of residents and other licensed providers on the job market with the expertise necessary to provide services within our business makes it challenging to meet our hiring needs and may require us to train new employees, contract temporary physicians, or offer more attractive wage and benefit packages to experienced professionals, which could decrease our profit margins. The limited number of available residents and other licensed providers also impacts our ability to renew contracts with existing physicians on acceptable terms. As a result, our ability to provide services could be adversely affected. Even though our physician turnover rate has remained stable over the last three years, if the turnover rate were to increase significantly, our growth could be adversely affected. Moreover, unlike some of our competitors who sometimes pay additional compensation to physicians who agree to provide services exclusively to that competitor, our affiliated IPAs have historically not entered into such exclusivity agreements and have allowed our affiliated physicians to affiliate with multiple IPAs. This practice may place us at a competitive disadvantage regarding the hiring and retention of physicians relative to those competitors who do enter into such exclusivity agreements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare industry is increasingly reliant on technology, which could increase our risks.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The role of technology is greatly increasing in the delivery of healthcare, which makes it difficult for traditional physician-driven companies, such as us, to adopt and integrate electronic health records, databases, cloud-based billing systems, and many other technology applications in the delivery of healthcare services. Additionally, consumers are using mobile applications and care and cost research in selecting and usage of healthcare services. We may need to incur significant costs to implement these technology applications and comply with applicable laws. For example, the nature of our business and the requirements of healthcare privacy laws impose significant obligations on us to maintain privacy and protection of patient medical information. We rely on employees and third parties with technology knowledge and expertise and could be at risk if technology applications are not properly established, maintained, or secured. Any cybersecurity incident, even unintended, could expose us to significant fines and remediation costs and materially impair our business operations and financial position.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting the U.S. healthcare reform, our business may be harmed.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the importance of the healthcare industry in the lives of all Americans, federal, state, and local legislative bodies frequently pass legislation and promulgate regulations relating to healthcare reform or that affect the healthcare industry. As has been the trend in recent years, it is reasonable to assume that there will continue to be increased government oversight and regulation of the healthcare industry in the future. We cannot assure our stockholders as to the ultimate content, timing, or effect of any new healthcare legislation or regulations, nor is it possible at this time to estimate the impact of potential new legislation or regulations on our business. It is possible that future legislation enacted by Congress or state legislatures, or regulations promulgated by regulatory authorities at the federal or state level, could adversely affect our business or could change the operating environment of the hospitals and other facilities where our affiliated physicians provide services. It is possible that the changes to the Medicare, Medicaid, or other governmental healthcare program reimbursements may serve as precedent to possible changes in other payors&#8217; reimbursement policies in a manner adverse to us. Similarly, changes in private payor reimbursements could lead to adverse changes in Medicare, Medicaid, and other governmental healthcare programs, which could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not anticipate that a single-payer national health insurance system will be enacted by the current Congress, several legislative initiatives have been proposed by members of Congress and presidential candidates that would establish some form of a single public or quasi-public agency that organizes healthcare financing, but under which healthcare delivery would remain private. If enacted, such a system could adversely affect our business.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation in the healthcare industry could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many healthcare industry participants and payers are consolidating to create larger and more integrated healthcare delivery systems with greater market power. We expect regulatory and economic conditions to result in additional consolidation in the healthcare industry in the future. As consolidation accelerates, the economies of scale of our partners&#8217; organizations may grow. If a partner experiences sizable growth following consolidation, it may determine that it no longer needs to rely on us and may reduce its demand for our products and services. In addition, as healthcare providers consolidate to create larger and more integrated healthcare delivery systems with greater market power, these providers may try to use their market power to negotiate fee reductions for our products and services. Finally, consolidation may also result in the acquisition or future development by our partners of products and services that compete with our products and services. Any of these potential results of consolidation could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to NGACO.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The success of our emphasis on the NGACO Model is uncertain.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, CMS approved APAACO, our subsidiary, to participate in the NGACO Model. To position us to participate in the NGACO Model and meet its requirements, we have invested significant resources in reshaping our business and organizations and in establishing related infrastructure, and expect to continue to devote, significant financial and other resources to the NGACO Model. These efforts have required us to refocus away from certain other parts of our historic business and revenue streams, which will receive less emphasis and could result in reduced revenue from these activities for us. For example, we have converted physicians and patients from our MSSP ACOs to our NGACO. It is unknown whether this strategic decision will be eventually successful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The NGACO Model has certain political risks and is undergoing changes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Patient Protection and the ACA is amended, repealed, declared unconstitutional, or replaced, or if The Center for Medicare and Medicaid Innovation (&#8220;CMMI&#8221;) is terminated, the NGACO Model program could be discontinued or significantly altered. In addition, CMS and CMMI leadership could be changed and influenced by Congress or the current Biden Administration, and may elect to combine any existing programs, including bundled payments, which could greatly alter the NGACO Model program. The rules regarding NGACOs have also been altered and may be further altered in the future. Any material change to the NGACO requirements and governing rules or the discontinuation of the program as a whole could create significant uncertainties for us and alter our strategic direction, thereby increasing financial risks for our stockholders.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are uncertainties regarding the design and administration of the NGACO Model and CMS&#8217; initial financial reports to NGACO participants, which could negatively impact our results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the newness of the NGACO Model, and due to being the only participant in the AIPBP track, we are subject to initial program challenges, including, but not limited to, process design, data, and other related aspects. We rely on CMS for design, oversight, and governance of the NGACO Model. If CMS cannot provide accurate data, claims benchmarking and calculations, make timely payments, and conduct periodic process reviews, our results of operations and financial condition could be materially and adversely affected. CMS relies on various third parties to effect the NGACO program, including other departments of the U.S. government, such as CMMI. CMS also relies on multiple third-party contractors to manage the NGACO Model program, including claims and auditing. As a result, there is the potential for errors, delays, and poor communication among the differing entities involved, which are beyond our control. As CMS is implementing extensive reporting protocols for the NGACO Model, CMS has indicated that because of inherent biases in reporting the results, its initial financial reports under the NGACO Model may not be indicative of final results of actual risk sharing and revenues that we receive. Were that to be the case, we might not report accurately our revenues for relevant periods, which could result in adjustment in a later period when we receive final results from CMS. We and our contracted providers have experienced various apparent errors in the NGACO Model, resulting in some providers terminating their relationships with us, and the resolution of these issues and impact on us remains uncertain. If we continue to experience such issues or new issues emerge, this could have a material adverse effect on our results of operations on a consolidated basis.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We chose to participate in the AIPBP mechanism, which entails certain special risks.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the AIPBP mechanism, CMS estimates the total annual Part A and Part B Medicare expenditures of our assigned Medicare beneficiaries and pay us that projected amount in per beneficiary per month payments. We chose &#8220;Risk Arrangement B,&#8221; comprising 100% risk for Part A and Part B Medicare expenditures and a shared savings and losses cap of 15% (or a 15% effective shared savings and losses cap when factoring in 100% risk impact). Our benchmark Medicare Part A and Part B expenditures for beneficiaries for the 2021 performance year are approximately $436.4&#160;million, and under &#8220;Risk Arrangement B&#8221; of the AIPBP mechanism we could therefore have profits or be liable for losses of up to 15% of such benchmarked expenditures, or approximately $65.5&#160;million. While performance can be monitored throughout the year, end results for the 2021 performance year will not be known until late-2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AIPBP operations and benchmarking calculations are complex and could result in uncertainties for us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AIPBP operations and benchmarking calculations are complex and can lead to errors in the application of the NGACO Model, which could create reimbursement delays to our contracted, in-network providers and adversely affect our performance and results of operations. For example, we discovered a feature in the AIPBP claim processing system that does not allow us to break down certain claims amounts by individual patient codes. This has created confusion for our in-network providers in reconciling payments, causing some providers to terminate their agreements with us. This feature and other complexities within the AIPBP mechanism could also create uncertainties for our operations, including under agreements with our contracted, in-network providers&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may suffer losses and may not generate savings through our participation in the NGACO Model.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the NGACO Model, CMS provides an opportunity to provider groups that are willing to assume higher levels of financial risk and reward, to participate in this new attribution-based risk-sharing model. The NGACO Model uses a prospectively-set cost benchmark, which is established prior to the start of each performance year. The benchmark is based on various factors, including baseline expenditures with the baseline updated each year to reflect the NGACO&#8217;s participant list for the given year. Our 2021 performance year baseline is based on calendar year 2020 expenditures that are risk-adjusted and trended. A discount is then applied that incorporates regional and national efficiency. The benchmarked expenditures therefore could potentially underestimate our actual expenditures for assigned Medicare beneficiaries and there can be no assurance that we could successfully adjust such benchmarked expenditures. Under the NGACO Model, we are responsible for savings and losses related to care received by assigned patients by covering claims from physicians, nurses, and other medical professionals. If claim costs exceed the benchmarked expenditures, or the baseline years are statistical anomalies, we could experience losses, which could be significant. Among other things, this could result from factors beyond our control, such as natural disasters, the potential effects of climate change, major epidemics, pandemics, or newly emergent viruses (such as COVID-19). As we are providing care coordination through APAACO, but do not provide direct patient care, our influence could be limited. Because of our limited influence, it is possible that we may not be able to control care providers&#8217; behavior, utilization, and costs. As a result, we may not be able to generate savings through our participation in the NGACO Model to cover our administrative and care coordination operating costs, and any savings generated, if at all, will be earned in arrears and uncertain in both timing and amount.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not control, but are responsible for savings and losses related to, care received by assigned patients at out-of-network providers, which could negatively impact our ability to control claim costs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare beneficiaries in the NGACO Model are not required to receive care from a specified network of contracted providers and facilities, which could make it difficult for us to control the financial risks of those beneficiaries. CMS notified us that its Medicare beneficiaries historically had received approximately 62% of care at non-contracted, out-of-network (&#8220;OON&#8221;) providers. While we are not responsible for directly paying claims for OON providers, we may have difficulty managing patient care and costs in relation to such OON providers as compared to contracted, in-network providers, which, could adversely impact our financial results as we are responsible for savings and losses of assigned beneficiaries, irrespective of whether they are using in-network or OON providers. In addition, even if we are successful in encouraging more assigned patients to receive care from our contracted, in-network providers, there is the possibility that the monthly AIPBP from CMS will be insufficient to cover our expenditures, since the AIPBP is generally based on historical in-network/out-of-network ratios. If CMS fails to monitor the in-network/OON provider ratio for our assigned patients on a frequent basis or CMS&#8217; reconciliation payments to us are not timely made, this could result in negative cash flows for us, especially if increased payments will need to be made to our contracted, in-network providers.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties used by us could hinder our performance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use third parties to perform certain administrative and care coordination tasks. We have contracted with participating Part A and Part B providers and sometimes with discounted rates. This could, however, create operational and performance risk; for example, if a third party does not perform its responsibilities properly. In addition, such providers could increase their current rates or discontinue their agreements with us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from traditional MSSP ACOs and other NGACOs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care providers experienced in coordinating care for populations of patients compete with each other to be selected by CMS to participate in the NGACO Model. Since MSSP and pioneer ACOs began in 2012, the number of Medicare ACOs continues to rise and have grown to several hundred nationwide, but there are still a growing number of ACOs in different program types that compete with us for resources and patients.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Following CMS&#8217;s termination of the NGACO Model, our continued participation in other CMS Advanced Alternative Payment Models, such as the GPDC Model, cannot be guaranteed.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">APAACO and CMS entered into a Next Generation ACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with a term of four performance years through December 31, 2020. Subsequently due to the COVID-19 Public Health Emergency (the &#8220;PHE&#8221;), CMS offered APAACO to amend the Participation Agreement to add one additional 12-month Performance Year, extending the term of the Participation Agreement by one calendar year, such that the final Performance Year ended on December 31, 2021. In addition, the Participation Agreement may be terminated sooner by CMS as specified therein and CMS has the flexibility to alter or change the program over time. Among many requirements to be eligible to participate in the NGACO Model, we must have at least 10,000 aligned Medicare beneficiaries and must maintain that number throughout each performance year. Although we started the 2021 performance year with approximately 30,000 aligned Medicare beneficiaries, there can be no assurance that we will maintain the required number of assigned Medicare beneficiaries. If that number were not maintained, we would become ineligible for the NGACO Model. In addition, we are required to comply with all applicable laws and regulations regarding provider-based risk-bearing entities. If these laws or regulations change, for example, to require a Knox-Keene license in California, which we do not currently have, we could be required to cease our NGACO operations. We could be terminated from the NGACO Model at any time if we do not continue to comply with the NGACO participation requirements. In October 2017, CMS notified us that our participation in the AIPBP mechanism for performance year 2018 would not be renewed due to alleged deficiencies in performance by us. We submitted a request for reconsideration to CMS. In December 2017, we received the official decision on our reconsideration request that CMS reversed the prior decision against our continued participation in the AIPBP mechanism. As a result, we were again eligible to receive monthly AIPBP from CMS. We, however, will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. If future compliance or performance issues arise, we may lose our current eligibility and may be subject to CMS&#8217; enforcement or contract actions, including our potential inability to participate in the AIPBP mechanism (where the payment mechanism would default to traditional fee for service) or dismissal from the NGACO Model, which would have a material adverse effect on our revenues and cash flows. In addition, the payments from CMS to us will decrease if the number of beneficiaries assigned to our NGACO declines, or the contracted providers terminate their relationships with us, which could have a material adverse effect on our results of operations on a consolidated basis.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With the ending of the NGACO Model on December 31, 2021, CMS is allowing former NGACO participants including APAACO to apply to participate as a Direct Contracting Entity (&#8220;DCE&#8221;) in the standard track of CMS&#8217;s Global and Professional Direct Contracting (&#8220;GPDC&#8221;) Model (formerly known as the Direct Contracting Model for Global and Professional Options). APAACO has applied for the GPDC Model for Performance Year 2022 (&#8220;PY22&#8221;) with CMS releasing the PY22 GPDC Model Participants at </span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">https://innovation.cms.gov/media/document/gpdc-model-participant-summary. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CMS has redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, stakeholder feedback, and participant experience. They have renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model. The ACO REACH Model will begin participation on January 1, 2023. Any change to the transition from GPDC to ACO REACH could have a material adverse effect on our revenues and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to Regulatory Compliance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws regulating the corporate practice of medicine could restrict the manner in which we are permitted to conduct our business and the failure to comply with such laws could subject us to penalties and restructuring.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states have laws that prohibit business entities from practicing medicine, employing physicians to practice medicine, exercising control over medical decisions by physicians (also known collectively as the corporate practice of medicine) or engaging in some arrangements, such as fee-splitting, with physicians. In some states these prohibitions are expressly stated in a statute or regulation, while in other states the prohibition is a matter of judicial or regulatory interpretation. California is one of the states that prohibit the corporate practice of medicine.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In California, we operate by maintaining contracts with our affiliated physician groups, which are each owned and operated by physicians and which employ or contract with additional physicians to provide physician services. Under these arrangements, we or our subsidiaries provide management services, receive a management fee for providing management services, do not represent to offer medical services, and do not exercise influence or control over the practice of medicine by the physicians or the affiliated physician groups.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above management arrangements, in certain instances, we have contractual rights relating to the transfer of equity interests in our affiliated physician groups under physician shareholder agreements that we entered into with the controlling equity holder of such affiliated physician groups. However, even in such instances, such equity interests cannot be transferred to or held by us or by any non-professional organization. Accordingly, we do not directly own any equity interests in any affiliated physician groups in California. In the event that any of these affiliated physician groups or their equity holders fail to comply with these management or ownership transfer arrangements, these arrangements are terminated, we are unable to enforce such arrangements, or these arrangements are invalidated under applicable laws, there could be a material adverse effect on our business, results of operations, and financial condition and we may have to restructure our organization and change our arrangements with our affiliated physician groups, which may not be successful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare industry is intensely regulated at the federal, state, and local levels and government authorities may determine that we fail to comply with applicable laws or regulations and take actions against us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company involved in providing healthcare services, we are subject to numerous federal, state, and local laws and regulations. There are significant costs involved in complying with these laws and regulations. If we are found to have violated any applicable laws or regulations, we could be subject to civil and/or criminal damages, fines, sanctions, or penalties, including exclusion from participation in governmental healthcare programs, such as Medicare and Medicaid, and we may be required to change our method of operations and business strategy. These consequences could be the result of our current conduct or even conduct that occurred a number of years ago, including prior to the completion of the 2017 Merger. We could incur significant costs to defend ourselves if we become the subject of an investigation or legal proceeding alleging a violation of these laws and regulations. We cannot predict whether a federal, state, or local government will determine that we are not operating in accordance with law, or whether, when or how the laws will change in the future and impact our business. The following is a non-exhaustive list of some of the more significant healthcare laws and regulations that could affect us:</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the False Claims Act, that provides for penalties against entities and individuals who knowingly or recklessly make claims to Medicare, Medicaid, and other governmental healthcare programs, as well as third-party payors, that contain or are based upon false or fraudulent information;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a provision of the Social Security Act, commonly referred to as the &#8220;Anti-Kickback Statute,&#8221; that prohibits the knowing and willful offering, payment, solicitation, or receipt of any bribe, kickback, rebate, or other remuneration, in cash or in kind, in return for the referral or recommendation of patients for items and services covered, in or in part, by federal healthcare programs such as Medicare and Medicaid;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a provision of the Social Security Act, commonly referred to as the Stark Law or physician self-referral law, that (subject to limited exceptions) prohibits physicians from referring Medicare patients to an entity for the provision of specific &#8220;designated health services&#8221; if the physician or a member of such physician&#8217;s immediate family has a direct or indirect financial relationship with the entity, and prohibits the entity from billing for services arising out of such prohibited referrals;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a provision of the Social Security Act that provides for criminal penalties on healthcare providers who fail to disclose known overpayments;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">a provision of the Social Security Act that provides for civil monetary penalties on healthcare providers who fail to repay known overpayments within 60 days of identification or the date any corresponding cost report was due, if applicable, and also allows improper retention of known overpayments to serve as a basis for False Claims Act violations;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions of the Social Security Act (emanating from the DRA) that require entities that make or receive annual Medicaid payments of $5 million or more from a single Medicaid program to provide its employees, contractors, and agents with written policies and employee handbook materials on federal and state false claims acts and related statutes, that establish a new Medicaid Integrity Program designed to enhance federal and state efforts to detect Medicaid fraud, waste, and abuse, and that increase financial incentives for both states and individuals to bring fraud and abuse claims against healthcare companies;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state law provisions pertaining to anti-kickback, self-referral, and false claims issues;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions of, and regulations relating to, HIPAA that provide penalties for knowingly and willfully executing a scheme or artifice to defraud a healthcare benefit program or falsifying, concealing, or covering up a material fact or making any material false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions of HIPAA and the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) limiting how covered entities, business associates, and business associate sub-contractors may use and disclose PHI and the security measures that must be taken in connection with protecting that information and related systems, as well as similar or more stringent state laws;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state laws that provide penalties for providers for billing and receiving payments from a governmental healthcare program for services unless the services are medically necessary and reasonable, adequately and accurately documented, and billed using codes that accurately reflect the type and level of services rendered;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state laws that provide for financial solvency requirements relating to risk-bearing organizations (&#8220;RBOs&#8221;), plan operations, plan-affiliate operations and transactions, plan-provider contractual relationships, and provider-affiliate operations and transactions, such as California Business &amp; Professions Code Section 1375.4 (&#167; 1375.4; Cal. Code Regs., tit. 28, &#167; 1300.75.4 et seq.);</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal laws that provide for administrative sanctions, including civil monetary penalties for, among other violations, inappropriate billing of services to federal healthcare programs, payments by hospitals to physicians for reducing or limiting services to Medicare or Medicaid patients, or employing or contracting with individuals or entities who/which are excluded from participation in federal healthcare programs;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state laws and policies that require healthcare providers to enroll in the Medicare and Medicaid programs before submitting any claims for services, to promptly report certain changes in its operations to the agencies that administer these programs, and to re-enroll in these programs when changes in direct or indirect ownership occur or in response to revalidation requests from Medicare and Medicaid;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state laws that prohibit general business entities from practicing medicine, controlling physicians&#8217; medical decisions or engaging in certain practices, such as splitting fees with physicians;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state laws that require timely payment of claims, including &#167;1371.38, et al, of the California Health &amp; Safety Code, which imposes time limits for the payment of uncontested covered claims and required healthcare service plans to pay interest on uncontested claims not paid promptly within the required time period;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">laws in some states that prohibit non-domiciled entities from owning and operating medical practices in such states;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">federal and state laws and regulations restricting the techniques that may be used to collect past due accounts from consumers, such as our patients, for services provided to the consumer; and</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">state laws that require healthcare providers that assume professional and institutional risk (i.e., global risk) to either obtain a license under the Knox-Keene Health Care Service Plan Act of 1975 or receive an exemption from the California Department of Managed Healthcare (&#8220;DMHC&#8221;) for the contract(s) under which the entity assumes global risk.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any violation or alleged violation of any of these laws or regulations by us or our affiliates could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in healthcare laws could create an uncertain environment and materially impact us. We cannot predict the effect that the ACA (also known as Obamacare) and its implementation, amendment, or repeal and replacement, may have on our business, results of operations, or financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any changes in healthcare laws or regulations that reduce, curtail, or eliminate payments, government-subsidized programs, government-sponsored programs, and/or the expansion of Medicare or Medicaid, among other actions, could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the ACA dramatically changed how healthcare services are covered, delivered, and reimbursed. The ACA requires insurers to accept all applicants, regardless of pre-existing conditions, cover an extensive list of conditions and treatments, and charge the same rates, regardless of pre-existing condition or gender. The ACA and the Health Care and Education Reconciliation Act of 2010 (collectively, the &#8220;Health Care Reform Acts&#8221;) also mandated changes specific to home health and hospice benefits under Medicare. In 2012, the U.S. Supreme Court upheld the constitutionality of the ACA, including the &#8220;individual mandate&#8221; provisions of the ACA that generally require all individuals to obtain healthcare insurance or pay a penalty. However, the U.S. Supreme Court also held that the provision of the ACA that authorized the Secretary of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) to penalize states that choose not to participate in the expansion of the Medicaid program by removing all of its existing Medicaid funding was unconstitutional. In response to the ruling, a number of state governors opposed its state&#8217;s participation in the expanded Medicaid program, which resulted in the ACA not providing coverage to some low-income persons in those states. In addition, several bills have been, and are continuing to be, introduced in U.S. Congress to amend all or significant provisions of the ACA, or repeal and replace the ACA with another law. In December 2017, the individual mandate was repealed via the Tax Cuts and Jobs Act of 2017. Afterwards, legal and political challenges as to the constitutionality of the remaining provisions of the ACA resumed. Just as the fate of the ACA is uncertain, so is the future of care organizations established under the ACA such as ACOs and NGACOs. Under its NGACO Participation Agreement with CMS, our operations are always subject to the nation&#8217;s healthcare laws, as amended, repealed, or replaced from time to time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net effect of the ACA on our business is subject to numerous variables, including the law&#8217;s complexity, lack of complete implementing regulations and interpretive guidance, gradual and potentially delayed implementation, or possible amendment, as well as the uncertainty as to the extent to which states will choose to participate in the expanded Medicaid program. The continued implementation of provisions of the ACA, the adoption of new regulations thereunder and ongoing challenges thereto, also added uncertainty about the current state of U.S. healthcare laws and could negatively impact our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare providers could be subject to federal and state investigations and payor audits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our and our affiliates&#8217; participation in government and private healthcare programs, we are from time to time involved in inquiries, reviews, audits, and investigations by governmental agencies and private payors of our business practices, including assessments of our compliance with coding, billing, and documentation requirements. Federal and state government agencies have active civil and criminal enforcement efforts against healthcare companies, and their executives and managers. The DRA, which provides a financial incentive to states to enact their own false claims acts, and similar laws encourage investigations against healthcare companies by different agencies. These investigations could also be initiated by private whistleblowers. Responding to audit and investigative activities are costly and disruptive to our business operations, even when the allegations are without merit. If we are subject to an audit or investigation, a finding could be made that we or our affiliates erroneously billed or were incorrectly reimbursed, and we may be required to repay such agencies or payors, may be subjected to pre-payment reviews, which can be time-consuming and result in non-payment or delayed payments for the services we or our affiliates provide, and may be subject to financial sanctions or required to modify our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls designed to reduce inpatient services and associated costs may reduce our revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Controls imposed by Medicare, Medicaid, and private payors designed to reduce admissions and lengths of stay, commonly referred to as &#8220;utilization review,&#8221; have affected and are expected to continue to affect our operations. Federal law contains numerous provisions designed to ensure that services rendered by hospitals and other care providers to Medicare and Medicaid patients meet professionally recognized standards and are medically necessary and that claims for reimbursement are properly filed. These provisions include a requirement that a sampling of admissions of Medicare and Medicaid patients must be reviewed by quality improvement organizations, which review the appropriateness of Medicare and Medicaid patient admissions and discharges, the quality of care provided, and the appropriateness of cases of extraordinary length of stay or cost on a post-discharge basis. Quality improvement organizations may deny payment for services or assess fines and also have the authority to recommend to the HHS that a provider is in substantial non-compliance with the standards of the quality improvement organization and should be excluded from participation in the Medicare program. The ACA potentially expands the use of prepayment review by Medicare contractors by eliminating statutory restrictions on its use, and, as a result, efforts to impose more stringent cost controls are expected to continue. Utilization review is also a requirement of most non-governmental managed care organizations and other third-party payors. Inpatient utilization, average lengths of stay and occupancy rates continue to be negatively affected by payor-required pre-admission authorization and utilization review and by third-party payor pressure to maximize outpatient and alternative healthcare delivery services for less acutely ill patients. Although we are unable to predict the effect these controls and any changes thereto may have on our operations, significant limits on the scope of our services reimbursed and on reimbursement rates and fees could have a material, adverse effect on our business, financial position, and results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not have a Knox-Keene license.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Knox-Keene Health Care Service Plan Act of 1975 was passed by the California State Legislature to regulate California managed care plans and is currently administered by the DMHC. A Knox-Keene Act license is required to operate a healthcare service plan, e.g., an HMO, or an organization that accepts global risk, i.e., accepts full risk for a patient population, including risk related to institutional services, e.g., hospital, and professional services. Applying for and obtaining such a license is a time-consuming and detail-oriented undertaking. We currently do not hold any Knox-Keene license. If the DMHC were to determine that we have been inappropriately taking risk for institutional and professional services as a result of our various hospital and physician arrangements without having any Knox-Keene license or applicable regulatory exemption, we may be required to obtain a Knox-Keene license and could be subject to civil and criminal liability, any of which could have a material adverse effect on our business, results of operations, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Knox-Keene Act license </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">or exemption from licensure, where applicable, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is required to operate a healthcare service plan, e.g., an HMO, or an organization that accepts global risk, i.e., accepts full risk for a patient population, including risk related to institutional services, e.g., hospital, and professional services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our affiliated physician groups are not able to satisfy California financial solvency regulations, they could become subject to sanctions and their ability to do business in California could be limited or terminated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DMHC has instituted financial solvency regulations. The regulations are intended to provide a formal mechanism for monitoring the financial solvency of a RBO in California, including capitated physician groups. Under current DMHC regulations, our affiliated physician groups, as applicable, are required to, among other things:</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Maintain, at all times, a minimum &#8220;cash-to-claims ratio&#8221; (which means the organization&#8217;s cash, marketable securities, and certain qualified receivables, divided by the organization&#8217;s total unpaid claims liability) of 0.75; and</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">Submit periodic reports to the DMHC containing various data and attestations regarding their performance and financial solvency, including IBNR calculations and documentation and attestations as to whether or not the organization (i) was in compliance with the &#8220;Knox-Keene Act&#8221; requirements related to claims payment timeliness, (ii) had maintained positive tangible net equity (&#8220;TNE&#8221;), and (iii) had maintained positive working capital.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that a physician group is not in compliance with any of the above criteria, it would be required to describe in a report submitted to the DMHC the reasons for non-compliance and actions to be taken to bring it into compliance. Under such regulations, the DMHC can also make some of the information contained in the reports public, including, but not limited to, whether or not a particular physician organization met each of the criteria. In the event any of our affiliated physician groups are not able to meet certain of the financial solvency requirements, and fail to meet subsequent corrective action plans, it could be subject to sanctions, or limitations on, or removal of, its ability to do business in California. There can be no assurance that our affiliated physician groups, such as our IPAs, will remain in compliance with DMHC requirements or be able to timely and adequately rectify non-compliance. To the extent that we need to provide additional capital to our affiliated physician groups in the future in order to comply with DMHC regulations, we would have less cash available for other parts of our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue will be negatively impacted if our physicians fail to appropriately document their services.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon our affiliated physicians to appropriately and accurately complete necessary medical record documentation and assign appropriate reimbursement codes for their services. Reimbursement is conditioned upon, in part, our affiliated physicians providing the correct procedure and diagnosis codes and properly documenting the services themselves, including the level of service provided and the medical necessity for the services. If our affiliated physicians have provided incorrect or incomplete documentation or selected inaccurate reimbursement codes, this could result in non-payment for services rendered or lead to allegations of billing fraud. This could subsequently lead to civil and criminal penalties, including exclusion from government healthcare programs, such as Medicare and Medicaid. In addition, third-party payors may disallow, in whole or in part, requests for reimbursement based on determinations that certain amounts are not covered, services provided were not medically necessary, or supporting documentation was not adequate. Retroactive adjustments may change amounts realized from third-party payors and result in recoupments or refund demands, affecting revenue already received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Primary care physicians may seek to affiliate with our and our competitors&#8217; IPAs at the same time.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is common in the medical services industry for primary care physicians to be affiliated with multiple IPAs. Our affiliated IPAs therefore may enter into agreements with physicians who are also affiliated with our competitors. However, some of our competitors at times have agreements with physicians that require the physician to provide exclusive services. Our affiliated IPAs often have no knowledge, and no way of knowing, whether a physician is subject to an exclusivity agreement without being informed by the physician. Competitors have initiated lawsuits against us alleging in part interference with such exclusivity arrangements, and may do so again in the future. An adverse outcome from any such lawsuit could adversely affect our business, cash flows and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we inadvertently employ or contract with an excluded person, we may face government sanctions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individuals and entities can be excluded from participating in the Medicare and Medicaid programs for violating certain laws and regulations, or for other reasons such as the loss of a license in any state, even if the person retains other licensure. This means that the excluded person and others are prohibited from receiving payments for such person&#8217;s services rendered to Medicare or Medicaid beneficiaries, and if the excluded person is a physician, all services ordered (not just provided) by such physician are also non-covered and non-payable. Entities that employ or contract with excluded individuals are prohibited from billing the Medicare or Medicaid programs for the excluded individual&#8217;s services, and are subject to civil penalties if it does. The U.S. Department of Health and Human Services Office of the Inspector General maintains a list of excluded persons. Although we have instituted policies and procedures to minimize such risks, there can be no assurance that we will not inadvertently hire or contract with an excluded person, or that our employees or contracts will not become excluded in the future without our knowledge. If this occurs, we may be subject to substantial repayments and civil penalties, and the hospitals at which we furnish services may also be subject to repayments and sanctions, for which they may seek recovery from us, which could adversely affect our business, cash flows, and financial condition.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with federal and state privacy and data security laws is expensive, and we may be subject to government or private actions due to privacy and security breaches.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with various federal and state laws and regulations governing the collection, dissemination, access, use, security, and confidentiality of PHI, including HIPAA and HITECH. As part of our medical record keeping, third-party billing, and other services, we collect and maintain PHI in paper and electronic format. Privacy and data security laws and regulations thus could have a significant effect on the manner in which we handle healthcare-related data and communicates with payors. In addition, compliance with these standards could limit our ability to offer services, thereby negatively impacting the business opportunities available to us. Despite our efforts to prevent privacy and security breaches, it may still occur. If any non-compliance with such laws and regulations results in privacy or security breaches, we could be subject to monetary fines, suits, penalties, or sanctions. As a result of the expanded scope of HIPAA through HITECH, we may incur significant costs in order to minimize the amount of &#8220;unsecured PHI&#8221; that we handle and retain and/or to implement improved administrative, technical, or physical safeguards to protect PHI. We may have to demonstrate and document our compliance efforts, even if there is a low probability that PHI has been compromised, in order to overcome the presumption that an impermissible use or disclosure of PHI results in a reportable breach. We may incur significant costs to notify the relevant individuals, government entities and, in some cases, the media, in the event of a breach and to provide appropriate remediation and monitoring to mitigate any potential damage.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to liability for failure to fully comply with applicable corporate and securities laws.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various corporate and securities laws. Any failure to comply with such laws could cause government agencies to take action against us, which could restrict our ability to issue securities and result in fines or penalties. Any claim brought by such an agency could also cause us to expend resources to defend ourselves, divert the attention of our management from our business and could significantly harm our business, operating results, and financial condition, even if the claim is resolved in our favor.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A plaintiffs&#8217; securities law firm announced that it was investigating ApolloMed and its pre-2017 Merger board of directors for potential federal law violations and breaches of fiduciary duties in connection with the 2017 Merger. This investigation purportedly focused on whether ApolloMed and its board of directors violated federal securities laws or breached their fiduciary duties to ApolloMed&#8217;s stockholders by failing to properly value the 2017 Merger and failing to disclose all material information in connection with the 2017 Merger. As of filing of this Annual Report on Form 10-K, no lawsuit has been filed against us by that firm.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot preclude the possibility that claims or lawsuits brought relating to any alleged securities law violations or breaches of fiduciary duty in connection with the 2017 Merger could potentially require significant time and resources to defend and/or settle and distract our management and board of directors from focusing on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face lawsuits not covered by insurance and related expenses may be material. Our failure to avoid, defend, and accrue for claims and litigation could negatively impact our results of operations or cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to and become involved in various litigation matters arising out of our business, including from time to time, actual or threatened lawsuits. Malpractice lawsuits are common in the healthcare industry. The medical malpractice legal environment varies greatly by state. The status of tort reform, availability of non-economic damages, or the presence or absence of other statutes, such as elder abuse or vulnerable adult statutes, influence the incidence and severity of malpractice litigation. We may also be subject to other types of lawsuits, such as those initiated by our competitors, stockholders, employees, service providers, contractors, or by government agencies, including when we terminate relationships with them, which may involve large claims and significant defense costs. Many states have joint and several liabilities for providers who deliver care to a patient and are at least partially liable. As a result, if one provider is found liable for medical malpractice for the provision of care to a particular patient, all other providers who furnished care to that same patient, including possibly us and our affiliated physicians, may also share in the liability, which could be substantial individually or in aggregate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The defense of litigation, including fees of legal counsel, expert witnesses, and related costs, is expensive and difficult to forecast accurately. Such costs may be unrecoverable even if we ultimately prevail in litigation and could consume a significant portion of our limited capital resources. To defend lawsuits, it may also be necessary for us to divert officers and other employees from our normal business functions to gather evidence, give testimony, and otherwise support litigation efforts. If we lose any material litigation, we could face material judgments or awards against them. An unfavorable resolution of one or more of the proceedings in which we are involved now or in the future could have a material adverse effect on our business, cash flows, and financial condition. We may also in the future find it necessary to file lawsuits to recover damages or protect our interests. The cost of such litigation could also be significant and unrecoverable, which may also deter us from aggressively pursuing even legitimate claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain malpractice liability insurance coverage to cover professional liability and other claims for certain hospitalists and clinic physicians. All of our affiliated physicians are required to carry first dollar coverage with limits of coverage equal to $1.0 million for all claims based on occurrence up to an aggregate of $3.0 million per year. We cannot be certain that our insurance coverage will be adequate to cover liabilities arising out of claims asserted against us, our affiliated professional organizations, or our affiliated physicians. Liabilities incurred by us or our affiliates in excess of our insurance coverage, including coverage for professional liability and other claims, could have a material adverse effect on our business, financial condition, and results of operations. Our professional liability insurance coverage generally must be renewed annually and may not continue to be available to us in future years at acceptable costs and on favorable terms, which could increase our exposure to litigation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may also be subject to laws and regulations not specifically targeting the healthcare industry.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain regulations not specifically targeting the healthcare industry also could have material effects on our operations. For example, the California Finance Lenders Law (the &#8220;CFLL&#8221;), Division 9, Sections 22000-22780 of the California Financial Code, could be applied to us as a result of our various affiliate and subsidiary loans and similar arrangements. If a regulator were to take the position that such loans were covered by the California Finance Lenders Law, we could be subject to regulatory action that could impair our ability to continue to operate and may have a material adverse effect on our profitability and business as we currently do not hold a CFLL licensure. Pursuant to an exemption under the CFLL, a person may make five or fewer commercial loans in a 12-month period without a CFLL licensure if the loans are &#8220;incidental&#8221; to the business of the person. This exemption, however, creates some uncertainty as to which loans could be deemed as incidental to our business. In addition, a person without a CFLL licensure may also make a single commercial loan in a 12-month period without the loan being &#8220;incidental&#8221; to such person&#8217;s business but this single-loan exemption is currently set to expire on January 1, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Risks Relating to the Ownership of ApolloMed&#8217;s Common Stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have to meet certain requirements in order to remain as a NASDAQ-listed public company.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, ApolloMed is required to comply with various regulatory and reporting requirements, including those required by the SEC. After ApolloMed uplisted to NASDAQ in December 2017, it is also subject to NASDAQ listing rules. Complying with these requirements is time-consuming and expensive. No assurance can be given that ApolloMed can continue to meet the SEC reporting and NASDAQ listing requirements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ApolloMed&#8217;s common stock may continue to be thinly traded and its market price may be subject to fluctuations and volatility. Stockholders may be unable to sell their shares at a profit and might incur losses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of ApolloMed&#8217;s common stock was volatile and may continue to be so from time to time. The price at which ApolloMed&#8217;s common stock trades could be subject to significant fluctuation and may be affected by a variety of factors, including the trading volume, our results of operations, the announcement and consummation of certain transactions, our ability or inability to raise additional capital and the terms thereof, and therefore could fluctuate, and decline, significantly. Other factors that may cause the market price of ApolloMed&#8217;s common stock to fluctuate include:</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">variations in our operating results, such as actual or anticipated quarterly and annual increases or decreases in revenue, gross margin or earnings;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in our business, operations, or prospects, including announcements relating to strategic relationships, mergers, acquisitions, partnerships, collaborations, joint ventures, capital commitments, or other events by us or our competitors;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">announcements of acquisitions, dispositions, and other corporate transactions, as well as financings and other capital-raising transactions;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments, conditions, or trends in the healthcare industry;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in the economic performance or market valuations of other healthcare-related companies;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">general market conditions or domestic or international macroeconomic and geopolitical factors unrelated to our performance or financial condition, including economic or political instability, wars, civil unrest, terrorism, epidemics (including COVID-19), outbreak, and natural disasters;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">sales of stock by ApolloMed&#8217;s stockholders generally and ApolloMed&#8217;s larger stockholders, including insiders, in particular, including sale or distributions of large blocks of common stock by our executives and directors;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">volatility and limitations in trading volumes of ApolloMed&#8217;s common stock and the stock market;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">approval, maintenance, and withdrawal of our and our affiliates&#8217; certificates, permits, registration, licensure, certification, and accreditation by the applicable regulatory or other oversight bodies;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our financing activities, including our ability to obtain financings and prices that we sell our equity securities, including notes convertible to and warrants to purchase shares of ApolloMed&#8217;s common stock;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">failures to meet external expectations or management guidance;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in our capital structure and cash position;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">analyst research reports on ApolloMed&#8217;s common stock, including analysts&#8217; recommendations and changes in recommendations, price targets, and withdrawals of coverage;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">departures and additions of our key personnel, including our officers or directors;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">disputes and litigations related to intellectual properties, proprietary rights, and contractual obligations;</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in applicable laws, rules, regulations, or accounting practices and other dynamics; and</span></div><div style="margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">other events or factors, many of which may be out of our control.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may continue to be a limited trading market for ApolloMed&#8217;s common stock. A lack of an active market may contribute to stock price volatility or supply/demand imbalances, make an investment in ApolloMed&#8217;s common stock less attractive to certain investors, impair the ability of ApolloMed&#8217;s stockholders to sell shares at the time they desire or at a price that they consider favorable. The lack of an active market may also reduce the fair market value of ApolloMed&#8217;s common stock, impair our ability to raise capital by selling shares of ApolloMed&#8217;s common stock or use such stock as consideration to attract and retain talent or engage in business transactions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If analysts do not report about us, or negatively evaluate us, ApolloMed&#8217;s stock price could decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for ApolloMed&#8217;s common stock will rely in part on the availability of research and reports that third-party analysts publish about us. There are many large companies active in the healthcare industry, which make it more difficult for us to receive widespread coverage. Furthermore, if one or more of the analysts who do cover us downgrade ApolloMed&#8217;s common stock, its price would likely decline. If one or more of these analysts cease coverage of us, we could lose market visibility, which in turn could cause ApolloMed&#8217;s stock price to decline.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current principal stockholders, executive officers, and directors have significant influence over our operations and strategic direction and they could cause us to take actions with which other stockholders might not agree and could delay, deter, or prevent a change of control or a business combination with respect to us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, our executive officers, directors, five percent or greater stockholders, and their respective affiliated entities in the aggregate own approximately 29.9% of our outstanding common stock. As a result, these stockholders, who are entitled to vote their shares in their own interests, acting together, exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control, merger, consolidation, sale of all or substantially all of our assets or other corporate transactions that other stockholders may view as beneficial, or conversely, this concentrated control could result in the consummation of a transaction that other stockholders may not support. This may harm the value of our shares and discourage investors from investing in us.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions under Delaware law and ApolloMed&#8217;s charter and bylaws could deter takeover attempts or attempts to remove its board members or management that might otherwise be beneficial to its stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed is subject to Section 203 of the Delaware General Corporation Law, which makes the acquisition of ApolloMed and the removal of its incumbent officers and directors more difficult for potential acquirers by prohibiting stockholders holding 15% or more of its outstanding voting stock from acquiring it without the consent of its board of directors for at least three years from the date they first hold 15% or more of the voting stock. These provisions and others that could be adopted in the future could deter unsolicited takeovers or delay or prevent changes in ApolloMed&#8217;s control or management, including transactions in which ApolloMed&#8217;s stockholders might otherwise receive a premium for their shares over then current market prices. These provisions may also limit the ability of ApolloMed&#8217;s stockholders to approve transactions that they may deem to be in their best interests.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, ApolloMed&#8217;s charter and bylaws contain additional provisions, such as the authorization for its board of directors to issue one or more classes of preferred stock and determine the rights, preferences, and privileges of the preferred stock, which could cause substantial dilution to a person or group that attempts to acquire ApolloMed on terms not approved by the board, and the ownership requirement for ApolloMed&#8217;s stockholders to call special meetings, that could deter, discourage, or make it more difficult for a change in control of ApolloMed or for a third party to acquire ApolloMed, even if such a change in control could be deemed in the interest of ApolloMed&#8217;s stockholders, or if such an acquisition would provide ApolloMed&#8217;s stockholders with a substantial premium for their shares over the market price of ApolloMed&#8217;s common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As such, these provisions could discourage a potential acquirer from acquiring us or otherwise attempting to obtain our control and increase the likelihood that our incumbent directors and officers will retain their positions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may issue additional equity securities in the future, which may result in dilution to existing investors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If ApolloMed issues additional equity securities, its existing stockholders may experience substantial dilution. ApolloMed may sell equity securities and may issue convertible notes and warrants in one or more transactions at prices and manners as we may determine from time to time, including at prices (or exercise prices) below the market price of ApolloMed&#8217;s common stock, for capital-raising purposes, including in any debt financing, registered offering, or private placement, and new investors could have superior rights such as liquidation and other preferences. To attract and retain the right talent, ApolloMed may also issue equity awards under its equity compensation plans to its officers, other employees, directors, and consultants from time to time. ApolloMed may also issue additional shares of its common stock or other securities that are convertible into or exercisable for common stock in connection with future acquisitions or for other business purposes. In addition, the exercise or conversion of outstanding options or warrants to purchase shares of ApolloMed&#8217;s stock may result in dilution to its existing stockholders upon any such exercise or conversion. </span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_31"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_34"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;Properties</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our corporate headquarters are located in Alhambra, California, where we lease approximately 35,000 square feet of office spaces in two adjacent buildings from an entity that is wholly owned and consolidated by APC as a result of an acquisition that occurred on December 31, 2020. We also lease approximately 47,500 square feet of office space in Monterey Park, California, from an entity that is partially owned by APC. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain other offices, medical spaces, and a warehouse located in Monterey Park, Alhambra, City of Industry, Arcadia, Glendale, Daly City, San Gabriel, Pasadena, and El Monte, California. These leases require monthly rental payments ranging from approximately $3,000 to $34,000 and have terms that expire between July 2022, subject to options to extend provided thereunder, and May 2027.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing facilities are in good condition and are suitable and adequate for our current requirements. Based on current information and subject to future events and circumstances, we anticipate that we may extend leases on our various facilities as necessary, as they expire, and lease additional facilities to accommodate possible future growth.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_37"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the pending or threatened legal proceedings or claims in which we are involved are discussed under Note 14 - &#8220;Commitments and Contingencies,&#8221; to our consolidated financial statements in this Annual Report on Form 10-K, which disclosure is incorporated by reference herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety Disclosures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_46"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information presented below is our historical data and not necessarily indicative of our future financial condition or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed&#8217;s common stock is listed on the NASDAQ Capital Market, under the symbol, &#8220;AMEH.&#8221; </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Record Holders</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;16, 2022, there were approximately 575 holders of record of ApolloMed&#8217;s common stock based on its transfer agent&#8217;s report. Because many shares of ApolloMed&#8217;s common stock are held by brokers and other nominees on behalf of stockholders, including in trust, we are unable to estimate the total number of stockholders represented by these record holders.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date we have not paid any cash dividends on ApolloMed&#8217;s common stock and we do not contemplate the payment of cash dividends thereon in the foreseeable future. Our future dividend policy will depend on our earnings, capital requirements, financial condition, and other factors relevant to our ability to pay dividends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None during the three months ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Measurement Comparison</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following chart compares the cumulative total return of our common stock with the cumulative total return of the Russell 3000 Index and the S&amp;P 500 Healthcare Index, from December 31, 2016 to December&#160;31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">              We believe the Russell 3000 Index is an appropriate independent broad market index, because it measures the performance of similar-sized companies in numerous sectors. In addition, we believe the S&amp;P 500 Healthcare Index is an appropriate third-party published industry index because it measures the performance of healthcare companies.</span></div><div style="margin-top:12pt;text-align:center"><img src="ameh-20211231_g1.jpg" alt="ameh-20211231_g1.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.559%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indexed Returns for the Years Ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Company/Index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Base Period<br/>12/31/2016</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russell 3000 Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S&amp;P 500 Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_52"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Reserved</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_58"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following management&#8217;s discussion and analysis should be read in conjunction with the audited consolidated financial statements and the notes thereto included in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In this section, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; refer to Apollo Medical Holdings, Inc. (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloMed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">) and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VIEs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">).</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. We, together with our affiliated physician groups and consolidated entities, provide coordinated outcomes-based medical care in a cost-effective manner.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our NGACO model and our network of IPAs we were responsible for coordinating the care for approximately 1.2 million patients primarily in California as of December&#160;31, 2021. These covered patients are comprised of managed care members whose health coverage is provided either through their employers, acquired directly from a health plan, or as a result of their eligibility for Medicaid or Medicare benefits. Our managed patients benefit from an integrated approach that places physicians at the center of patient care and utilizes sophisticated risk management techniques and clinical protocols to provide high-quality, cost-effective care. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2017, ApolloMed completed its business combination with NMM (i.e., the &#8220;2017 Merger&#8221;). The combination of ApolloMed and NMM brought together two complementary healthcare organizations to form one of the nation&#8217;s largest integrated population health management companies. As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed and the former NMM shareholders received a majority of the issued and outstanding common stock of ApolloMed. For accounting purposes, NMM was considered the accounting acquirer and accordingly, as of the closing of the 2017 Merger, NMM&#8217;s historical results of operations replaced ApolloMed&#8217;s historical results of operations for periods prior to the 2017 Merger, and the results of operations of both companies are included in the accompanying consolidated financial statements for periods following the 2017 Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Highlights</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shared Savings from Centers for Medicare and Medicaid Services for 2020 Performance Year</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the end of each performance year and at such other times as may be required under the NGACO Participation Agreement between APAACO and CMS (the &#8220;Participation Agreement&#8221;), CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared-risk pool revenue is considered fully constrained until it is settled. The settlement for the 2020 performance year was finalized in October 2021 and the Company recognized $21.8 million related to savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the year ended December&#160;31, 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into the Amended Credit Agreement. The Amended Credit Agreement and Amended Credit Facility thereunder provides for a five-year revolving credit facility to the Company of $400.0 million, which includes a letter of credit sub-facility of up to $25.0 million and a swingline loan sub-facility of $25.0 million. The Amended Credit Facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, NMM, and Truist Bank remains in effect, pursuant to which, among other things, NMM guarantees the obligations of the Company under the Amended Credit Agreement and the lenders under the Amended Credit Agreement have a security interest over all of the assets of the Company and NMM. As of December&#160;31, 2021, the Company had $180.0 million outstanding under the Amended Credit Facility. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business and Asset Acquisitions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag 8</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% interest in Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). Tag 8 has vacant land, which they plan to develop in the future. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate the accounting for the Company&#8217;s investment in Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APCMG</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;), a VIE of the Company, purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company.  As part of the transaction, the Company paid $1.0 million in cash and the remaining $1.0 million will be paid out in cash as a contingent consideration related to APCMG&#8217;s financial performance for fiscal year 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sun Labs</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments-certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DMG</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_64"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Jade Health Care Medical Group (&#8220;Jade Health&#8221;) </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company announced that AP-AMH 2 has entered into a definitive agreement to acquire 100% of the capital stock of Jade Health Care Medical Group (&#8220;Jade Health&#8221;), a primary and specialty care physicians&#8217; group focused on providing high-quality care to its local communities. The Company anticipates closing this transaction by the end of the second quarter of 2022 and will fund the transaction from cash on hand.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orma Health, Inc., and Provider Growth Solutions LLC (together, &#8220;Orma Health&#8221;)</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company announced that it acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#8220;Orma Health&#8221;) in accordance with an agreement between ApolloMed, Orma, and certain equity holders of Orma Health. Through its suite of AI-driven solutions, Orma Health currently serves over 4,000 aligned Medicare beneficiaries in a Direct Contracting Entity (&#8220;DCE&#8221;) and over 2,500 patients in California, Nevada, Arizona, and Texas through its remote patient monitoring (&#8220;RPM&#8221;) platform.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Direct Contracting Model</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO has applied for the GPDC Model for Performance Year 2022 (&#8220;PY22&#8221;) with CMS releasing the PY22 GPDC Model Participants at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">https://innovation.cms.gov/media/document/gpdc-model-participant-summary</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. CMS has redesigned the GPDC Model in response to Administration priorities, including their commitment to advancing health equity, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stakeholder feedback, and participant experience. They have renamed the GPDC Model to ACO Realizing Equity, Access, and Community Health (&#8220;ACO REACH&#8221;) Model. The ACO REACH Model will  begin participation on January 1, 2023.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Measures and Indicators</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our revenue, which is recorded in the period in which services are rendered and earned, primarily consists of capitation revenue, risk pool settlements and incentives, NGACO AIPBP revenue, management fee income, and fee-for-services (&#8220;FFS&#8221;) revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest expenses consist of the cost of: (1) patient care paid to contracted physicians; (2) information technology equipment and software and; (3) hiring staff to provide management and administrative support services to our affiliated physician groups, as further described in the following sections. These services include payroll, benefits, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services, and other consulting services.</span></div><div><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_70"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Compared to 2020</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated operating results for the year ended December&#160;31, 2021, as compared to the year ended December&#160;31, 2020 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income (in thousands)</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">593,224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">557,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,260&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">773,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">687,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86,735&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">675,736&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">606,677&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,059&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (expense) income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(97,646)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(98)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,394)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(44)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,745)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,750)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,827)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(20,431)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(118,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,427&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100,679)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,653)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122,320&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,026)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(60)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net (loss) income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,564)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(109,018)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income in 2021 was $49.3 million, as compared to $122.3 million in 2020, a decrease of $73.0 million or 60%. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the total number of affiliated physician groups we managed were 12 groups and 14 groups, respectively, and the total number of patients for whom we managed the delivery of healthcare services was 1.2 million and 1.1 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenue in 2021 was $773.9 million, as compared to $687.2 million in 2020, an increase of $86.7 million or 13%. The increase in total revenue was primarily attributable to the following:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) An overall increase of $35.9 million in capitation revenue primarily driven by membership growth at APC and Alpha Care and higher average capitation rate at APC. APC and Alpha Care contributed additional capitation revenue of approximately $38.2 million and $7.0 million, respectively. This was offset with a decrease in capitation revenue of $11.5 million at Accountable Health Care due to decreased membership.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) An increase of $34.3 million in risk pool settlements and incentives revenue due to an increase of $14.7 million in shared savings generated from our full risk pool arrangements driven by reduced utilization at ApolloMed&#8217;s partner hospitals resulting from the suspension of non-emergency medical procedures in early 2020 when the COVID-19 pandemic first began, revenues from ApolloMed&#8217;s partner hospitals reflect a 15-18 month lag, $13.1 million from health plan incentives and settlements from various payor partners, which was mainly attributable to increased membership and timing of settlements, $4.5 million resulting from a settlement with a health plan within our full risk pool arrangement, and a $2.0 million increase in the shared savings settlement earned from ApolloMed&#8217;s participation in an ACO related to performance year 2020 as compared to prior year.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) An increase of $13.9 million in fee-for-services revenue attributable to fees generated from Sun Labs and DMG totaling $7.2 million due to the consolidation of Sun Labs in August 2021 and DMG in October 2021. In addition, there was an increase of $5.4 million from increased visits to our surgery and heart centers, which were partially closed in the prior year due COVID-19.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services, Excluding Depreciation and Amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services, excluding depreciation and amortization, in 2021 were $596.1 million, as compared to $539.2 million in 2020, an increase of $56.9 million or 11%. The overall increase was due to an increase in medical claims incurred of $33.4 million, $12.1 million in additional costs as a result of the consolidation of Sun Labs in August 2021 and DMG in October 2021, and $8.3 million in increased sub-capitation payments due to a new oncology vendor joining in November 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses in 2021 were $62.1 million, as compared to $49.1 million in 2020, an increase of $13.0 million or 26%. This increase was primarily due to an $8.9 million increase in personnel-related costs to support the continued growth in the depth and breadth of our operations and $2.7 million in one time cost related to vendor settlement and execution of the Amended Credit Facility agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $17.5 million and $18.4 million for the years ended December&#160;31, 2021 and 2020, respectively. These amounts included depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Expense) Income </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income represents income, or loss, from equity method investments, gain, or loss, on sale of equity method investment, interest expense, interest income, unrealized loss on investments, and other (expense) income. Our total other expense in 2021 was $20.4 million compared to other income of $97.9 million in 2020, a decrease of $118.4 million. The decrease in other income was due to a decrease of $97.6 million resulting from the gain on sale of equity method investment in 2020, unrealized loss on investments of $10.7 million, and a decrease in income from equity method investments of $8.0 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $97.6 million decrease in sale of equity method investment is primarily driven by a $99.6 million gain from the sale of UCI in 2020 as compared to a $2.2 million gain from sale of 21.25% interest in LMA in 2021. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $10.7 million unrealized loss on investments is primarily driven by an unrealized loss of $12.1 million due to fluctuations in the stock price of a payor partner in which we hold shares in. These shares are recorded as marketable securities and deemed an Excluded Assets that are solely for the benefit of APC and its shareholders. Any resulting gain or loss does not impact net income attributable to Apollo Medical Holdings, Inc.  The unrealized loss was partial offset by an unrealized gain of $1.3 million due to fluctuations in the stock price of our equity holdings in Clinigence.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $8.0 million decrease in income from equity method investments was primarily due to the sale of UCI in April 2020. For the nine months ended September 30, 2020, UCI contributed equity earnings of $3.6 million. The additional decrease is from our investment in LMA. The Company incurred a loss of $5.8 million from LMA as a result of increased claims expense for the year ended December&#160;31, 2021 as compared to equity earnings of $0.3 million for the year ended December&#160;31, 2020. The loss was partially offset by increases in income from One MSO, Tag 6, and CAIPA MSO of $0.5 million, $0.3 million, and $0.3 million, respectively. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $28.5 million in 2021, as compared to $56.1 million in 2020, a decrease of $27.7 million or 49%. This was primarily attributable to the decrease in pre-tax income in 2021, as compared to 2020, due to the factors described above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net (Loss) Income Attributable to Noncontrolling Interests</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to non-controlling interests was $24.6 million in 2021, as compared to net income of $84.5 million in 2020, a decrease of $109.0 million. The decrease was primarily due to unrealized loss on investment recognized for the year ended December&#160;31, 2021 related to a payor partner as compared to the gain on sale of UCI in April 2020.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Compared to 2019</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated operating results for the year ended December&#160;31, 2020, as compared to the year ended December&#160;31, 2019 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income (in thousands)</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">557,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">454,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fee-for-services, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,792)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">687,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">560,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services, excluding depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,363)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of goodwill and intangibles assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">606,677&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">528,198&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,479&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,694&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,901)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(154)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,733)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,766)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,580)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104,504&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">591&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">587&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122,320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,866&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,116&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,750&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:17pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*    Percentage change of over 1000% </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income in 2020 was $122.3 million, as compared to $17.7 million in 2019, an increase of $104.6 million or 592%.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, the total number of affiliated physician groups we managed were 14 groups and 13 groups, respectively, and the total number of patients for whom we managed the delivery of healthcare services was 1.1 million and 0.9 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenue in 2020 was $687.2 million, as compared to $560.6 million in 2019, an increase of $126.6 million or 23%. The increase in total revenue was primarily attributable to the following:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) An overall increase of $103.2 million in capitation revenue primarily driven by the acquisition of Alpha Care and Accountable Health Care in August 2019 and September 2019, respectively. For the full year ended December 31, 2020, Alpha Care and Accountable Health Care contributed additional capitation revenues of $52.4 million and $29.0 million, respectively. In addition, capitation revenue at APC increased by $16.4 million due to increased rates from incentives being met and increased patient lives under management. Lastly, capitation revenue at APAACO increased by $5.3 million as a result of organic growth and expansion of the ACO program. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) An increase of $26.3 million in risk pool settlements and incentives revenue due to the settlement of the 2019 ACO Performance Year, resulting in a shared-risk settlement of $19.8 million recognized during the third quarter of 2020, as compared to $0.9 million in shared-risk settlement related to the 2018 performance year and recognized during the year ended December 31, 2019. In addition, during the year ended December 31, 2020, risk pool revenues increased by $6.2 million primarily driven by reduced hospital costs as a result of COVID-19. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) A decrease in fees-for-services revenue of $2.8 million primarily due to the COVID-19 pandemic that resulted in the closure of our surgery centers and heart center from March 2020 to May 2020 and fewer procedures completed in 2020.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services, Excluding Depreciation and Amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services, excluding depreciation and amortization, in 2020 were $539.2 million, as compared to $467.8 million in 2019, an increase of $71.4 million or 15%. The increase was due primarily to the acquisitions of Alpha Care and Accountable Health Care in May 2019 and September 2019, respectively, which provided for a full year of costs for the year ended December 31, 2020. Cost of services, excluding depreciation and amortization, related to Alpha Care and Accountable Health Care contributed $52.2 million and $28.0 million, respectively, to the overall increase. Furthermore, there was an $8.6 million increase at our APAACO entity resulting from a full year of services in the 2020 performance year as compared to nine months of services under the 2019 performance year due to the delayed commencement by CMS of APAACO&#8217;s 2019 Next Generation ACO performance year from January 1, 2019 to April 1, 2019. Lastly, cost of sales increased by $5.6 million at NMM to support the continued growth of the Company. These increases were offset by a reduction in claims costs totaling approximately $25.1 million as a result of the COVID-19 pandemic, which caused a decrease in office visits and a reduction in non-emergency procedures. We do not expect similar decreases in claims costs as a result of COVID-19 to occur again in fiscal 2021.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses in 2020 were $49.1 million, as compared to $41.5 million in 2019, an increase of $7.6 million or 18%. This increase was primarily due to $4.5 million in additional provider bonuses and $2.4 million from share-based compensation related to stock options and restricted stock awards granted in 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $18.4 million and $18.3 million for the years ended December 31, 2020 and 2019, respectively. These amounts included depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Doubtful Accounts</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, we released reserves related to certain management fees in the amount of approximately $1.4 million as collectability of the outstanding amount was no longer in doubt. These reserves were related to various preacquisition obligations of Accountable Health Care and were no longer necessary as a result of our acquisition of Accountable Health Care.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill and Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no impairment of goodwill and intangible assets for the year ended December 31, 2020, as compared to $2.0 million for the year ended December 31, 2019, which related to a write-off of Medicare licenses that were acquired as part of the 2017 Merger between ApolloMed and NMM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) represents income, or loss, from equity method investments, interest expense, interest income, gain on sale of equity method investment, and other income. Total other income in 2020 was income of $97.9 million compared to other expense of $6.6 million in 2019, an increase of $104.5 million. The increase in other income was primarily due to a $99.8 million gain on sale of our UCI equity method investment and an increase of $10.6 million from income from equity method investments. This was partially offset by an increase of $4.8 million in interest expense. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $10.6 million in income from equity method investments was primarily due to equity earnings recognized related to Universal Care Inc, of $3.6 million compared to a loss of $1.2 million in 2019. During the year ended December 31, 2020, we recognized equity earnings from our investment of LSMA of $0.3 million as compared to an equity loss of $2.8 million in 2019. Further, we recognized an equity loss of $2.5 million related to our investment in Accountable Health Care during the year ended December 31, 2019, which was acquired in August 2019 and is now a consolidated entity of APC.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense of $4.8 million was primarily due to interest incurred from a new credit facility we secured in September 2019 to fund growth, primarily through acquisitions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $56.1 million in 2020, as compared to $8.2 million in 2019, an increase of $47.9 million or 587%. This was primarily attributable to the increase in pre-tax income in 2020, as compared to 2019, due to the factors described above.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to non-controlling interests was $84.5 million in 2020, as compared to $3.6 million in 2019, an increase of $80.9 million. The increase was primarily due to the sale of UCI in April 2020 where the gain, net of tax, remained strictly with the APC Excluded Assets and increased consolidated net income generated in the current period, which resulted in additional income allocated to the non-controlling interest.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_73"></div><div><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Guidance</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed anticipates full-year 2022 total revenue of between $1.03 billion and $1.08 billion, based on the Company&#8217;s existing business, current view of existing market conditions, and assumptions for the year ending December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is providing projections for total revenue only at this time due to uncertainties related to its participation in a Centers for Medicare &amp; Medicaid Services Innovation Center (&#8220;CMMI&#8221;) innovation model, ongoing investment in staff to support future growth, and certain investments that depend on unpredictable macroeconomic factors.</span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_2181"></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.414%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>&#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,813)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Benefit from) provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,454&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,517&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense (income)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,839)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider bonus payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC excluded assets costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,190&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Other expense (income) excludes the impact of fair value of certain equity securities held by the Company and the gain resulting from the consolidation of an equity method investment as of December 31, 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Non-GAAP Financial Measures&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with generally accepted accounting principles (&#8220;GAAP&#8221;) is net income. These measures are not in accordance with, or an alternative to, U.S. GAAP, and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations,&#160;for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income from equity method investments, provider bonuses, impairment of intangibles, provision of doubtful accounts, and other income earned that is not related to the Company&#8217;s normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of ApolloMed&#8217;s ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and investment in marketable securities at December&#160;31, 2021 totaled $286.5 million. Working capital totaled $283.4 million at December&#160;31, 2021, compared to $223.6 million at December&#160;31, 2020, an increase of $59.8 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitations, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups, as well as FFS reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations at least through February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents and restricted cash increased by $39.1 million from $194.0 million at December&#160;31, 2020 to $233.1 million at December&#160;31, 2021. Cash provided by operating activities during the year ended December&#160;31, 2021 was $70.3 million, as compared to $46.2 million during the year ended December&#160;31, 2020. Cash provided by operating activities during the year ended December&#160;31, 2021 was due to net income of $49.3 million with adjustments to reconcile net income to net cash provided by operating activities. For the year ended December&#160;31, 2021 adjustments from depreciation and amortization of $17.5 million, share-based compensation of $6.7 million, unrealized loss on investments of $10.8 million, impairment of beneficial interest of $15.7 million, loss from equity method investments of $4.3 million, $4.1 million change in accounts payable and accrued expenses and fiduciary payable, $5.3 million change in medical liabilities, and $2.7 million change in prepaid expenses and other current assets increased cash provided by operating activities. This was offset by adjustments from gain on sale of equity method investment of $2.2 million, gain on consolidation of equity method investment of $2.8 million, gain on purchase of warrants of $1.1 million, gain on contingent equity securities of $4.3 million, $27.0 million change in receivable, net, receivable, net - related parties, and other receivable, and $5.2 million change in other assets and income taxes payable. This is compared to cash provided by operating activities during the year ended December&#160;31, 2020 as a result of net income of $122.3 million adjusted to reconcile net income to net cash provided by operating activities. Adjustments from depreciation and amortization of $18.4 million, share-based compensation of $3.4 million, $15.6 million change in receivable, net, receivable, net - related parties, and other receivable, and $15.8 million change in accounts payable and accrued expenses and fiduciary payable increased cash provided by operating activities. This was offset by adjustments from income from equity method investments of $3.7 million, gain on sale of UCI equity method investments of $99.8 million, $6.4 million change in prepaid expenses and other current assets,  $14.5 million change in other assets, medical liabilities, and income taxes payable.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities during the year ended December&#160;31, 2021 was $16.5 million, as compared to cash provided by investing activities of $95.5 million during the year ended December&#160;31, 2020. Cash provided by investing activities during the year ended December&#160;31, 2021 was primarily due to proceeds from sale of marketable securities of $67.6 million, proceeds from sale of equity method investment totaling $6.4 million, and cash recognized from consolidation of VIE of $5.9 million. These were offset by purchases of equity method investments of $13.6 million, purchases of property and equipment of $19.2 million, payments for business acquisition, net of cash acquired of $2.6 million, and purchases of marketable securities of $28.0 million. This is compared to cash provided in investing activities for the year ended December&#160;31, 2020 primarily due to proceeds of marketable securities of $50.6 million, proceeds from sale of equity method investment totaling $52.7 million, and proceeds from repayment of loans receivable of $16.5 million. These were offset by purchases of equity method investments of $10.0 million, payments for business acquisitions of $11.4 million, and purchases of marketable securities of $1.8 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the year ended December&#160;31, 2021 was $47.7 million, as compared to cash used in financing activities of $51.7 million for the year ended December&#160;31, 2020. Cash used in financing activities during the year ended December&#160;31, 2021 was primarily attributable to repayment of Credit Facility and other debt of $238.3 million, the payments of dividends totaling $31.1 million, payment of debt issuance cost related to the Amended Credit Facility of $0.7 million, distribution to noncontrolling interests of $1.5 million, and repurchases of shares totaling $5.7 million. This was offset by proceeds from the exercise of stock options and warrants of $9.1 million, borrowings on the Amended Credit Facility of $180.0 million, borrowings on Tag 8&#8217;s Construction Loan of $0.6 million, and proceeds from sale of shares of $40.1 million. This is compared to cash used in financing activities for the year ended December&#160;31, 2020 for payments of dividends totaling $51.3 million, repayment on our term loan totaling $9.5 million, distribution to non-controlling interests of $1.0 million, and repurchases of shares totaling $0.5 million. Cash used was offset with the proceeds from the exercise of stock options and warrants of $10.8 million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excluded Assets</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, APC and AP-AMH entered into the Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term Excluded Assets. &#8220;Excluded Assets&#8221; means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Excluded Assets as of December&#160;31, 2021, are primarily comprised of assets and liabilities from operating real estate and proceeds from the sale of UCI. Any dividends issued to APC shareholders are paid using cash from Excluded Assets. Excluded Assets consisted of the following (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable and assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,178)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,645)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total excluded assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,087&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_79"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consisted of the following (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction loan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized financing cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Long-term debt </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis.</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Coverage Ratios </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Requirement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated leverage ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 3.75 to 1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated interest coverage ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 3.25 to 1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.44</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All covenant ratio titles utilize terms as defined in the respective debt agreements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information on the Amended Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to its entry into the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7 million related to its entry into the Amended Credit Facility. Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related to the Credit Facility and the new costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the years ended December&#160;31, 2021, 2020, and 2019 was 2.06%, 3.48%, and 3.39%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the years ended December&#160;31, 2021, 2020, and 2019 of $1.2 million, $1.4 million, and $0.5 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in MPP, AMG Properties, and ZLL. As a result of the purchase, the Company assumed $6.4 million, $0.7 million, and $0.7 million of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">existing loans held by MPP, AMG Properties, and ZLL, respectively, on the day of acquisition. Refer to Note 10 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;) that allows Tag 8 to borrow up to $10.7&#160;million. Tag 8 is a VIE consolidated by the Company. Refer to Note 10 &#8211; &#8220;Credit Facility, Bank Loans, and Lines of Credit&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;10, 2019, APC amended its promissory note agreement with Preferred Bank (&#8220;APC Business Loan Agreement&#8221;), which is affiliated with one of the Company&#8217;s board members, to modify loan availability to $4.1 million. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019 securing APC&#8217;s obligations to NMM under, and as required pursuant to, that certain Management Services Agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Loans</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of AMH, Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Bay Area Hospitalist Associates (&#8220;BAHA&#8221;), AKM Medical Group, Inc. (&#8220;AKM&#8221;), and SCHC has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each of the affiliated entities in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM&#8217;s obligation to make any advances automatically terminates concurrently with the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December&#160;31, 2021 (in thousands)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Entity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intercompany Credit Facility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Per Annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maximum Balance During Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal Paid During Period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Paid During Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,679&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,558&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;), which require management to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and to the reported amounts of revenues and expenses during the period. The Company bases its estimates on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. Changes in estimates are recorded if and when better information becomes available. Actual results could differ from those estimates under different assumptions and conditions. The Company believes that the accounting policies discussed below are those that are most important to the presentation of its financial condition and results of operations and that require its management&#8217;s most difficult, subjective, and complex judgments. Our significant accounting policies are described in Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221; to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">             Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of December&#160;31, 2021 and 2020 and consolidated statements of income for the years ended December&#160;31, 2021, 2020, and 2019 include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">             The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (IBNR claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors and historical margins), income tax  valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables and Receivables &#8211; Related Parties</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation, and claims receivable, risk pool settlements and incentive receivables, management fee income, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements and incentive receivables, management fee income, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivable relate to each health plan&#8217;s capitation, which is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full-risk pool receivable that is recorded quarterly based on reports received from our hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables include FFS reimbursement for patient care, certain expense reimbursements, and stop-loss insurance premium reimbursements from IPAs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/>&#160;&#160;&#160;&#160;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable &#8211; related parties, accounts payable, certain accrued expenses, capital lease obligations, bank loan, line of credit &#8211; related party, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amount of the loan receivables &#8211; related parties, net of current portion, bank loan, capital lease obligations line of credit - related party, and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality. The FASB ASC 820, Fair Value Measurement (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosures of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business Combinations</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate. Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<br/><br/>&#160;&#160;&#160;&#160;Goodwill and Intangible Assets </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under FASB ASC 350,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles &#8211; Goodwill and Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASC 350&#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner, if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units, (1) management services, (2) IPA, and (3) ACO. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accrual of Medical Liabilities</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, and APAACO provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may not come to light until a substantial period of time has passed following the contract implementation. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full-risk pool-sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.<br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs APC participates in one or more shared-risk arrangements relating to the provision of institutional services to enrollees (shared-risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>&#160;&#160;&#160;&#160;The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk-share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally fully settled in the third or fourth quarter of the following year.<br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-Based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards, such as options, is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Leases<br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and right-of-use asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under 12 months term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform a primary beneficiary analysis on all our identified variable interest entities, which comprises a qualitative analysis based on power and economics. We consolidate a VIE if both power and benefits belong to us &#8211; that is, we (i) have the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) have the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). We consolidate VIEs whenever it is determined that we are the primary beneficiary.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in Other Entities - Equity Method</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for certain investments using the equity method of accounting when it is determined that the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize our share of net earnings or losses of the investee and is recognized in the consolidated statements of income under &#8220;Income from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. During the period ended December&#160;31, 2021, the Company recognized no impairment loss. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including certain VIEs) in the Company&#8217;s consolidated entities. The amount of net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the shareholder agreements for APC, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from their respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. APC&#8217;s shares were not redeemable and it was not probable that the shares would become redeemable as of December&#160;31, 2021 and 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, &#8220;Revenue from Contracts with Customers (Topic 606),&#8221; using the modified retrospective method on January 1, 2018. Modified retrospective adoption required entities to apply the standard retrospectively to the most current period presented in the financial statements, requiring the cumulative effect of the retrospective application as an adjustment to the opening balance of retained earnings and non-controlling interests at the date of initial application. Revenue from substantially all of the Company&#8217;s contracts with customers continues to be recognized over time as services are rendered.  <br/><br/>&#160;&#160;&#160;&#160;Income Taxes<br/><br/>&#160;&#160;&#160;&#160;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.<br/><br/>&#160;&#160;&#160;&#160;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effect of New Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Refer to &#8220;Recent Accounting Pronouncements&#8221; under Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements under Item 8 in this Annual Report on Form 10-K for additional information.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_91"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:13pt;padding-left:31.5pt;text-indent:-31.5pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Borrowings under our Amended Credit Agreement exposed us to interest rate risk. As of December&#160;31, 2021, we had $180.0 million in outstanding borrowings under our Amended Credit Agreement. The amount borrowed under the Amended Credit Agreement bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR. In addition, as of December&#160;31, 2021, Tag 8, a VIE consolidated by the Company, had $0.6 million in outstanding borrowings for the Construction Loan. Interest rate on the &#8220;Construction Loan&#8221; is equal to an index rate determined by the bank. Furthermore, as of December&#160;31, 2021, APC had $7.4 million in outstanding borrowings for real estate loans related to ZLL, MPP, and AMG Properties (&#8220;Real Estate Loans&#8221;). Each agreement bears interest that is subject to change from time to time based on changes in an independent index, which is the daily Wall Street Journal Prime Rate, as quoted in the &#8220;Money Rates&#8221; column of The Wall Street Journal (Western edition) as determined by the Lender (the &#8220;Index&#8221;). On the dates of the agreement, the Index is 3.25% per annum. Under no circumstances will the interest rate on this loan be less than 3.50% per annum or more than the maximum rate allowed by applicable law. The Company has entered into interest rate swap agreements for certain of these agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. A hypothetical 1% change in our interest rates for our outstanding borrowings under our Credit Agreement, Construction Loan, and Real Estate Loans would have increased or decreased our interest expense for the year ended December&#160;31, 2021, by $1.9 million.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to the Consolidated Financial Statements</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_97">Reports of Independent Registered Public Accounting Firms</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMwODI_1f3fcea7-3c9d-4dea-9876-bde9d46cc155">Ernst and Young, LLP</ix:nonNumeric> PCAOB ID No. <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMxMTM_e6f71d57-65d0-462b-89e1-027c49af7aff">42</ix:nonNumeric> and <ix:nonNumeric contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMxMjg_6f16572d-f835-45d8-8ca2-e1279d92d9e7">BDO USA, LLP</ix:nonNumeric> PCAOB ID No. <ix:nonNumeric contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMxNjA_a60f5916-53e1-480c-9bcb-37b9c6b63ffa">243</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_97">71</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_103">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_103">75</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_106">Consolidated Statements of Income for the Years Ended December 31, 2021, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_106">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_106"> and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_106">78</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_109">Consolidated Statements of Mezzanine and Stockholders&#8217; Equity for the Years Ended December 31, 2021, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_109">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_109"> and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_109">79</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_112">Consolidated Statements of Cash Flows for the Years Ended December 31, 2021, 2020</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_112">,</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_112"> and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_112">81</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_115">Notes to the Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_115">84</a></span></div></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Apollo Medical Holdings, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Apollo Medical Holdings, Inc. (the Company) as of December 31, 2021 and 2020, and the related consolidated statements of income, mezzanine and stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;28, 2022 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Critical Audit Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Risk Pool Settlements and Related Receivables</span></div><div style="padding-left:108pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in Note 2 of the consolidated financial statements, the Company enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and the Company is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, the Company generally receives a percentage of the net surplus from the affiliated hospitals&#8217; risk pools with health plans after deductions for the affiliated hospitals&#8217; costs. The Company estimated risk pool settlements relating to such arrangements using the most likely amount methodology and amounts are only included in revenues to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The amount of such risk pool settlements recorded is driven by an expected margin factor calculated by the Company using historical utilization data, historical margin trends, constraint percentages and various data and information provided by the affiliated hospitals.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing management&#8217;s estimate of the risk pool settlements and related receivables involved a high degree of subjectivity used by management and the nature of the significant assumptions, which include a margin factor based on historical trends, volume data and other available information. The Company relied on data provided by other parties in its estimation model. Additionally, judgment is used to develop the margin factor used to account for the expected performance of the risk pools for each settlement year and is derived based on an evaluation of historical data provided by the hospital, publicly available information, and communications between the Company and the affiliated hospital.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We <br/>Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls over the Company&#8217;s process for estimating risk pool settlements and related receivable amounts. This included testing management review controls over the reasonableness of the data (including capitation revenue and related claims and other administrative expenses) underlying the risk pool calculations provided by the affiliated hospitals, and analyzing the historical trends and appropriateness of the method used in determining the estimated risk pool surplus. We also reviewed relevant Service Organization Control (SOC) 1 reports to evaluate that such affiliated hospitals and administrator have effective controls over the completeness and accuracy of the data they process and provide to the Company. We also assessed and tested complementary user entity controls relevant to the SOC 1 reports.<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit procedures included, among others, confirming the external data used in the calculations of risk pools directly with the affiliated hospitals, testing the revenue amount by comparing it to subsequent cash receipts, and testing the margin factor used by the Company in its estimate. In order to test the margin factor, we evaluated historical margin trends within the risk pools, reviewed the Company&#8217;s own volumes and margins, and evaluated other publicly available information to identify any trends which may provide contrary evidence. Additionally, we performed a hindsight analysis to assess how precise the Company&#8217;s prior year estimates were compared to the final settled amounts.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Valuation of Incurred but not Reported (IBNR) Claims Liability </span></div><div style="padding-left:108pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At December 31, 2021, the Company&#8217;s medical liabilities totaled $55.8 million. As discussed in Note 2 of the consolidated financial statements, medical liabilities include reserves for incurred but not reported (&#8220;IBNR&#8221;) claims. The IBNR liability is an estimate that management developed using actuarial methods and is based on numerous variables, including the utilization of health care services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing management&#8217;s estimate of the IBNR liability involved a high degree of subjectivity due to the complexity of the models used by management and the nature of the significant assumptions used in the estimation of the liability. We involved our actuarial specialists to assist with the testing due to the highly judgmental nature of assumptions used in the valuation process, including completion factors and per member per month trend factors. These assumptions have a significant effect on the valuation of the IBNR liability.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company&#8217;s controls over the process for estimating the IBNR liability. This included testing management review controls over completion factor and per member per month trend factor assumptions, and management&#8217;s review of actuarial methods used to calculate the IBNR liability, including the completeness and accuracy of data inputs and outputs of those models. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To test the IBNR liability, our audit procedures included, among others, testing the completeness and accuracy of data used in the Company&#8217;s models by testing reconciliations of underlying claims and membership data recorded in source systems to the actuarial reserve models, and comparing claims to source documentation. With the assistance of our actuarial specialists, we compared management&#8217;s methods and assumptions used in their analysis with historical experience, consistency with generally accepted actuarial methodologies used within the industry, and observable healthcare trend levels within the markets the Company operates. With the assistance of our actuarial specialists, we used the Company&#8217;s underlying claims and membership data to develop an independent range of IBNR estimates and compared management&#8217;s recorded IBNR liability to our range. Additionally, we performed a hindsight review of prior period estimates using subsequent claims development, and we evaluated management&#8217;s disclosures surrounding IBNR.</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst and Young LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company&#8217;s auditor since 2020.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85Ny9mcmFnOjdkNWE3MDBkNjRkYTRkYmQ5ZTljNDQyMDI5ZDc3ZTViL3RhYmxlOmUwODUyMDRmYWJjNTRmNThhNGYxMjljNjE0ZGFmYTc3L3RhYmxlcmFuZ2U6ZTA4NTIwNGZhYmM1NGY1OGE0ZjEyOWM2MTRkYWZhNzdfNC0wLTEtMS02NDIzOS90ZXh0cmVnaW9uOjkzNDgyZDdmMzg1ZjQ1OTU4MmVhMmM2OGU1Y2UxNzcwXzYwNDczMTM5NTI4MTg_e61aa64e-6a34-4469-bd34-6050f12beebe">Los Angeles, California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders and Board of Directors</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alhambra, California</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated statements of income, mezzanine and stockholders&#8217; equity, and cash flows for the year ended December 31, 2019, of Apollo Medical Holdings, Inc. (the &#8220;Company&#8221;) and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the results of the Company&#8217;s operations and its cash flows for the year ended December 31, 2019, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BDO USA, LLP</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We served as the Company&#8217;s auditor from 2014 to 2020.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDAvZnJhZzpmYTNmNGI5NDE3YTg0YmQ2YTQyZmQ3ZDJlZjliOTZkNC90YWJsZTo5NDlmNzg0OWQ1ZDE0OWJiOTY5MTRiODQ0ZWIwM2ZiMC90YWJsZXJhbmdlOjk0OWY3ODQ5ZDVkMTQ5YmI5NjkxNGI4NDRlYjAzZmIwXzQtMC0xLTEtNjQyNDcvdGV4dHJlZ2lvbjpmZGY2M2ZlZjQ1NmM0OTY2YTc4ZDBmYWEzYTFiODAxMF82MDQ3MzEzOTUyODE4_139d0156-ac4d-4e93-b74d-5947d46af551">Los Angeles, California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 16, 2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;CONSOLIDATED BALANCE SHEETS</span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzktMi0xLTEtMA_340b52d2-4e6e-4388-ac0b-9957196958b9">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzktNC0xLTEtMA_f61b8ac7-e297-4b22-b2f0-a88f2be0ad33">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzExLTItMS0xLTA_ac0bf856-b3aa-450e-9b7c-95e5d625cedb">53,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzExLTQtMS0xLTA_df627b0a-ab1a-48f8-a38a-4c6faf6049c2">67,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEyLTItMS0xLTA_509470f9-312e-4a58-b623-c4fbc8638427">10,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEyLTQtMS0xLTA_24c074b3-0de7-497e-b778-6a4ddc1323a4">7,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEzLTItMS0xLTA_6c097f24-f330-45c1-b1bd-370e829a2f8f">69,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEzLTQtMS0xLTA_d12458ed-42ba-4fca-b703-2ac977716fd7">49,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE0LTItMS0xLTA_1d97999e-a7ae-4c3e-b141-d7debffd6923">9,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE0LTQtMS0xLTA_d58e93c0-28c7-489b-9b94-9d44071702a1">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE1LTItMS0xLTA_10cbf361-0c74-47e1-b4b9-f35719905c88">18,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE1LTQtMS0xLTA_64984d77-9ff9-4a13-999e-b620a7e994f2">16,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable - related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE2LTItMS0xLTA_682bea18-6fe7-443b-be80-18755bba0c7f">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE2LTQtMS0xLTA_d5c31590-286a-44a4-a838-f3eaa4435f3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE4LTItMS0xLTA_b37ccd2b-6b13-4128-b578-965b2aa3ed56">398,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE4LTQtMS0xLTA_2cb063c7-b7fe-4d12-b9fa-100d57f03459">338,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIxLTItMS0xLTA_66bf8581-9d31-461c-a161-b4a11fdc4fac">53,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIxLTQtMS0xLTA_b53c01c7-b4bd-47af-bf0c-b92587572391">29,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIyLTItMS0xLTA_bbcb79ec-3c83-4394-9986-4b8c250acb1b">82,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIyLTQtMS0xLTA_e56feb02-8654-410e-82fa-ca0d27359950">86,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIzLTItMS0xLTA_31994818-98fa-4198-820e-4b3a43fe7944">253,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIzLTQtMS0xLTA_7281d788-bfcc-494b-8edd-6da1e56e3b58">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI0LTItMS0xLTA_cb6810f9-3bfb-4820-9a1d-0a4774ebfb94">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI0LTQtMS0xLTA_35390c7f-f7f8-4583-a70b-7e6d5e90c8e4">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI1LTItMS0xLTA_178a7031-d3ae-4cfa-8311-a049a82fc3d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI1LTQtMS0xLTA_03595b8e-b0a3-4dfe-9c1a-955872190e62">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI2LTItMS0xLTA_2af51476-b530-4e21-b5d2-1eb56938133b">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI2LTQtMS0xLTA_fd905bda-e37e-4c15-addf-f28be0ac23c0">43,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI3LTItMS0xLTA_88cb9631-ac38-466f-84b4-cf2b33d28bd5">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI3LTQtMS0xLTA_a32e7292-bae1-4421-a044-edbc5fb301d7">37,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI4LTItMS0xLTA_03a8415b-b804-4af5-bda9-c372a29d84eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI4LTQtMS0xLTA_dc7db8fb-c8e7-4711-98bf-d794c0f84f1b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI5LTItMS0xLTA_a3c12cf9-b685-4bd0-ae95-876b9d1ee3e8">15,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI5LTQtMS0xLTA_834f5de9-0e18-40fa-8ee3-0c102a0b00a9">18,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMwLTItMS0xLTA_4aa9ad5c-528b-490a-b032-2abc5f749f0a">5,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMwLTQtMS0xLTA_d46ccab1-ce3c-4560-94ac-26ba355e60fd">18,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMyLTItMS0xLTA_3c3cd6b7-c5eb-40ac-880d-7605d2554a6c">453,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMyLTQtMS0xLTA_d461ce1d-cb87-404e-a4cc-233be6ba5c79">478,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTItMS0xLTA_7bcc9575-21a7-4a27-a77e-32e7a3454581">852,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTQtMS0xLTA_d2add495-3187-4214-9620-f3aacb32a074">817,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED BALANCE SHEETS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Continued)</span></div></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except share data)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities, Mezzanine Equity, and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzktMi0xLTEtMA_3732b2f1-ef5d-46c6-b6b9-591677048ef3">43,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzktNC0xLTEtMA_ca173616-1fef-4777-aeca-e9837aaf4aa1">36,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEwLTItMS0xLTA_c523ae19-94b6-4ab2-9107-7a6974aa5ef0">10,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEwLTQtMS0xLTA_6e08c140-ef6b-4272-9015-d08cb566e18c">9,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:MedicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzExLTItMS0xLTA_408d62c8-60c1-4627-9e0b-94ee8d552ede">55,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:MedicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzExLTQtMS0xLTA_57d3a797-90fa-493b-8068-a7b388628f26">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEyLTItMS0xLTA_292ce126-4440-4517-a393-ca38b7813474">652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEyLTQtMS0xLTA_2000cd92-2696-4772-a45d-a261b15e1da4">4,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEzLTItMS0xLTA_156faffa-3305-42c7-ac8b-4a608a23e9d0">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEzLTQtMS0xLTA_a3eb0311-dc93-48eb-8851-a0470161149c">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE0LTItMS0xLTA_7590c5f0-b732-43a8-a088-e1af8ee2f5ec">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE0LTQtMS0xLTA_cb46f684-a21c-42f2-b38f-05746416b96b">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE1LTItMS0xLTA_ddb71357-96b7-4bd9-90eb-1ec1c3c1d5c9">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE1LTQtMS0xLTA_71e0b7e4-4aea-4de4-ad41-1f1212591d0f">3,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE2LTItMS0xLTA_1d0f5829-2995-4993-b717-6600671db2c3">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE2LTQtMS0xLTA_14bba95e-37fa-4f95-8a85-97ec355b6825">10,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE4LTItMS0xLTA_b3c11552-d39e-4f97-8d8e-de2d5b889acd">115,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE4LTQtMS0xLTA_aea1bd2a-c711-44d2-84ac-cd43d29830ec">114,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIxLTItMS0xLTA_96975791-398e-45c8-946a-5e24909d77e6">9,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIxLTQtMS0xLTA_421493fe-31b6-47ec-9809-42764a8f83ac">10,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIyLTItMS0xLTA_8e0c8a2b-f23e-412d-be9e-4f6949f1c83d">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIyLTQtMS0xLTA_2bf18304-7c4d-41b3-a418-1a16a1116c44">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIzLTItMS0xLTA_9de3aa1d-d7b6-4f2e-a98d-cbe541b1f75a">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIzLTQtMS0xLTA_88ac1981-3830-4dd0-871e-081634d96198">15,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI0LTItMS0xLTA_55d2a1d8-1605-4e20-9829-1bd2ae2235f0">182,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI0LTQtMS0xLTA_23608805-65c0-4001-9c9c-08d82a60e2ef">230,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTItMS0xLTQzOTA5_ed8bae1c-5822-419e-bb3f-328689e69e6e">14,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTQtMS0xLTQzOTA5_086c1b9a-ce42-4d99-a358-878d741c23be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTItMS0xLTA_72fef86f-e773-400b-bfa4-35dde7591f16">220,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTQtMS0xLTA_34b37a2e-cdd4-4b1b-b59c-329817e222f4">257,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTItMS0xLTA_88f8d027-0dcd-4f98-8e05-61d92fffcfaf">336,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTQtMS0xLTA_a79fca52-6e1e-45fb-b0a3-d2e1a70dd11d">372,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (Note 14)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMwLTItMS0xLTA_f7fe8067-6ec8-412a-bfac-6513a9f9afe5"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMwLTQtMS0xLTA_f9ad7a83-dedc-4228-a77c-6610340d0f46"></ix:nonFraction></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mezzanine equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (&#8220;APC&#8221;)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMzLTItMS0xLTA_37f068df-676c-43a4-a91f-f65d85edd9d9">55,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMzLTQtMS0xLTA_b467bfa5-d693-473a-aa29-ee4a362408d5">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80MA_62a05e33-45a9-4925-9fb6-8849c7c46302"><ix:nonFraction unitRef="usdPerShare" contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80MA_95f704da-f016-4ed1-95f0-a9c7118838f1">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80NA_37d40ccc-3ca3-4ffd-a850-448e5050cb74"><ix:nonFraction unitRef="shares" contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80NA_c3e67ba0-71a3-4065-a546-168e2b1780bb">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMDY_2faff5dc-5e2d-4d94-8847-feea8942a5ef"><ix:nonFraction unitRef="shares" contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMDY_c03bd823-b3da-419f-9589-b1082e5c9bcc">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMjA_b3f0634e-dd24-493b-ab8a-3811ce0c25b8"><ix:nonFraction unitRef="shares" contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMjA_f3eb6abe-648c-41f2-a921-3bfdc2d8c620">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTItMS0xLTA_c074c4a8-e5e1-4eac-bc69-6d8671da5142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTQtMS0xLTA_b35f3463-0af3-4cd2-a952-73f182c300e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80MA_5ad718a2-c4c5-4615-8c7c-6851d824416f"><ix:nonFraction unitRef="usdPerShare" contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80MA_cc867601-49d9-4901-aa33-56aaf2b960ed">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80NA_08f3498b-b42c-40d0-a626-bf84e47386f6"><ix:nonFraction unitRef="shares" contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80NA_1429f82e-e3d1-47d1-a7c2-780b09620beb">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMDY_18617bd7-db40-46d9-9d0c-7d56187baa6c"><ix:nonFraction unitRef="shares" contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMDY_7e3cd650-718e-409d-959e-5d01851105f3">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMjA_33fe03d3-68d3-4deb-8411-5b3bac0f3a88"><ix:nonFraction unitRef="shares" contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMjA_c8477edf-61d7-4ed7-8dce-5e9ed7ebb3db">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTItMS0xLTA_c5cc5717-cc6a-4f5b-8ba3-686ba3824154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTQtMS0xLTA_bc2a3cdf-5ca1-4e12-8e26-45d196e8aed6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yOA_8ee43eeb-53dc-487b-9f87-1c3de2567414"><ix:nonFraction unitRef="usdPerShare" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yOA_bbf05a51-7384-4c18-a716-562cbf1aa42e">0.001</ix:nonFraction></ix:nonFraction>; <ix:nonFraction unitRef="shares" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8zMg_adb1ae0a-18fa-4e2c-becf-3832a54762b6"><ix:nonFraction unitRef="shares" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8zMg_dfe68d70-8f61-4644-b7e9-a7887e37778e">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized,<ix:nonFraction unitRef="shares" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yNzQ4Nzc5MDY5NjE2_a7068b7b-27b9-4bdf-b895-c174ffeea017">44,630,873</ix:nonFraction>and <ix:nonFraction unitRef="shares" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yNzQ4Nzc5MDY5NjIw_94b841c7-790e-4130-a5d4-76153a4f9ec1">42,249,137</ix:nonFraction> shares outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF85NA_cc893a97-9d2a-485e-94f5-8266e81085d6">10,925,702</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8xMDE_60a5da2b-b4a4-47b9-ba13-61156b91303f">12,323,164</ix:nonFraction> treasury shares, at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTItMS0xLTA_202f9ecc-5e63-45bd-8bf8-1628b8dfda3b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTQtMS0xLTA_c4ad7c59-5d98-4a81-993b-a10be0cac045">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM5LTItMS0xLTA_62353f04-0901-4c1c-a0d0-52e74640fa1a">310,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM5LTQtMS0xLTA_782ea5af-828d-47d5-b865-c608aa97a100">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQwLTItMS0xLTA_4e47237d-7fe1-4ff1-bdb5-1dd06cef9ee5">143,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQwLTQtMS0xLTA_550f866a-0996-41e2-afeb-724868d98a39">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQxLTItMS0xLTA_ce69675f-1678-42e0-9867-afe03841033b">454,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQxLTQtMS0xLTA_24fde083-7e4d-4295-91ac-c77b3ebcf9cc">330,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQzLTItMS0xLTA_a34fdc46-83bc-457b-8dca-cfd79c5ecabd">5,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQzLTQtMS0xLTA_67d80690-cd5b-49bb-81e6-af07f8929375">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ1LTItMS0xLTA_12d5fc04-7f45-4284-90e5-d1554b36231a">460,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ1LTQtMS0xLTA_39caddb9-3b7d-495d-9b01-4b12122c1836">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities, mezzanine equity, and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ3LTItMS0xLTA_5b4c320a-ec5d-41d5-b671-bf66bc7826ea">852,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ3LTQtMS0xLTA_59ddecac-ea69-48a7-ba7d-13e77f82e6ac">817,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00" footnoteRole="http://www.xbrl.org/2003/role/footnote">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNzU_15ac2327-2a6b-4756-8ecc-ac30caaf82ad">567.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNjE_7e4532d7-54c5-4276-a66e-1c733b53e0f4">576.1</ix:nonFraction>&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNzk_5f7068f2-9104-4622-aa44-0b4d75001561">91.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNjU_9ca6ccda-be3e-489c-bb22-1caa7b2cc359">88.6</ix:nonFraction>&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively. These VIE balances do not include $<ix:nonFraction unitRef="usd" contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkwOTk_89b6cbf2-f3b3-4a52-b753-20b494c5737d">802.8</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231" decimals="-5" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkxMzQ_6ce4175b-d598-4e59-8859-db7a7362bd2f">6.6</ix:nonFraction>&#160;million of amounts due from affiliates as of December&#160;31, 2021 and $<ix:nonFraction unitRef="usd" contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231" decimals="-5" name="us-gaap:DueFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyMzY_1eecbd2c-b343-4cb9-b7b1-f7ea12b05532">225.1</ix:nonFraction>&#160;million of investment in affiliates and $<ix:nonFraction unitRef="usd" contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231" decimals="-5" name="us-gaap:DueFromAffiliates" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNDg_a8f82e76-6e41-41b3-a97e-7475630c62dd">22.7</ix:nonFraction>&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</ix:footnote></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF INCOME</span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except per share data)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0648fafc89a544e7a200bb47e8fe8e6e_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzYtMi0xLTEtMA_dc10b9fe-4a72-4542-8033-f2d942c5b3e5">593,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae936f11a7bb4e4c99d3fe13851ffc0b_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzYtNC0xLTEtMA_23a24c89-29f7-454d-a539-d2dfd82f42a0">557,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830aa1f9bb124cffa1eb7bbc0aff0ad3_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzYtNi0xLTEtMA_09916749-db7b-4726-9cc5-b727c7b7a397">454,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0bca0ca7ef34b17b7aa1fbeb535bbf0_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzctMi0xLTEtMA_3a626d50-d2f5-4f24-b0c5-306dd9cc213b">111,627</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id541469a4a79478381a9bc7f4f5a6536_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzctNC0xLTEtMA_f9702bab-7059-4039-b455-a494201ed3e2">77,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb259c5215b44e0591d9d9fe4eca90e5_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzctNi0xLTEtMA_685477d5-4fce-43e4-b197-94289f6d4004">51,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i612cc8b6b50c4dd986466df93d1b6382_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzgtMi0xLTEtMA_f70deaa9-f02a-4875-9505-ec00e337b30b">35,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dc831eca8c24ab395130475d7b38dd7_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzgtNC0xLTEtMA_599e6972-601e-4bcf-aff8-a079bf94a0e1">34,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea8035697aa431d99f99268b6c7d832_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzgtNi0xLTEtMA_0f5896c8-721d-4cd5-9c11-b7c6ed515be6">34,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2efb609fa90049de89473edcbce394a5_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzktMi0xLTEtMA_b88b5624-00b2-43f5-b094-499aa82f1ae9">26,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872c7cf84d474bde9cbecebf6dc0d987_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzktNC0xLTEtMA_e26604a9-dbe4-4af0-9b3e-4df4f251a1fe">12,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2292f34b157f4b3b842835c609844787_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzktNi0xLTEtMA_c196c91f-7330-4b1e-88df-39ac499a661d">15,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id823cee670274003a572be40978abfb9_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEwLTItMS0xLTA_fc5c032f-1751-4749-b4dd-d5fdc0dc9eef">6,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38935258fdd640ccbf3015940e510e1d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEwLTQtMS0xLTA_af46794c-b4d8-47d2-b7a4-ae284c282f34">4,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea80e278e3444cafa519677345773d02_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEwLTYtMS0xLTA_babb4322-8d56-40b1-a1f4-035a41cfb566">5,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEyLTItMS0xLTA_61083131-0994-4bbe-bd94-e3933e9128c1">773,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEyLTQtMS0xLTA_173a1fef-1ef8-45ee-91e5-d4733592b28b">687,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEyLTYtMS0xLTA_2b2bdab3-a1ca-48bd-ae80-12f8195d25f6">560,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services, excluding depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE1LTItMS0xLTA_83a0dfef-fb1b-422f-ba77-3eb3b28603b5">596,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE1LTQtMS0xLTA_423db96f-7fa6-408d-a123-0908fcc48f0e">539,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE1LTYtMS0xLTA_ac02ab18-0546-4046-8ea8-c0d85752770e">467,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE2LTItMS0xLTA_4f4704b1-2588-4556-b2d1-07b906038e7e">62,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE2LTQtMS0xLTA_e7de7e6e-31e5-46ab-8e47-9ff88f68d144">49,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE2LTYtMS0xLTA_b9cb7348-a903-422f-835e-e072961dcaa9">41,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE3LTItMS0xLTA_1f3827d0-8719-4536-bb33-316aaefff8df">17,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE3LTQtMS0xLTA_777e79da-f677-4dd8-ac91-d23145fcae6b">18,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE3LTYtMS0xLTA_88eca1aa-b65c-4b8a-9797-0f1bccfc81fd">18,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE4LTItMS0xLTUzNDQ0_eb2469d5-dfa1-4298-92ec-44252a9d7d62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE4LTQtMS0xLTUzNDQ3_6efe2edb-ab88-4d82-ad9d-66acc6092ab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE4LTYtMS0xLTUzNDUw_7c7be6e5-6882-40b1-9026-1a11a09f4df5">1,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE5LTItMS0xLTUzNDQ0_f858590a-fe9e-40b5-9460-227bbee3f767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE5LTQtMS0xLTUzNDQ3_dfa5c0e2-d7b9-4dd5-b0ca-b479be8b3387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE5LTYtMS0xLTUzNDUw_0e0fa775-be03-497b-b52d-7a7fea453ad9">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIxLTItMS0xLTA_6a964ee1-8e00-4a65-840c-914b4dce2172">675,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIxLTQtMS0xLTA_dbdbf9fa-1cfd-4bc1-81ac-9b9309a9581d">606,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIxLTYtMS0xLTA_3b9292c3-dafb-4963-8e8b-478b6826ec56">528,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIzLTItMS0xLTA_ae8512aa-be76-485e-a90a-d28012a9aa92">98,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIzLTQtMS0xLTA_d20bd7a1-56d9-42c5-8980-2336be4fb0bc">80,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIzLTYtMS0xLTA_c344a049-4453-41f0-babe-68acf3a68b95">32,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) income from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI2LTItMS0xLTA_0b21e403-ca66-4a17-82d7-66b1c7da7d4a">4,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI2LTQtMS0xLTA_9e6f038c-2e08-4bd6-889b-3409cd4032a7">3,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI2LTYtMS0xLTA_f47c81d7-6783-46ec-9b11-afc1ca898050">6,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI3LTItMS0xLTA_5e240719-2bd2-47a6-93a1-a7fc904c11ce">2,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI3LTQtMS0xLTA_a4cdd048-ef34-43e8-8014-bb31bf854d0d">99,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI3LTYtMS0xLTA_61ef4cc0-6189-418e-b7cc-957298461135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI4LTItMS0xLTA_adf3cd62-62fb-45e0-bb0d-20cda211077d">5,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI4LTQtMS0xLTA_f6ef636d-2efa-45a0-9449-1f7277459f83">9,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI4LTYtMS0xLTA_2ff258cc-48b6-4144-b75a-0262f6925086">4,733</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI5LTItMS0xLTA_b9915b1e-1d8c-456a-85ee-ab06d751efca">1,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI5LTQtMS0xLTA_9ce1a328-aac0-4157-ac0e-db310b33986b">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI5LTYtMS0xLTA_a6570573-578a-4a13-a944-313c58f14627">2,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMwLTItMS0xLTA_a5d9c22c-178b-4e34-865e-2774f4c23d49">10,745</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMwLTQtMS0xLTA_ed9781fa-5a61-489c-8e78-a3d8ce3858d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMwLTYtMS0xLTA_f90392e7-692f-48a0-882f-b43b2311644f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMxLTItMS0xLTQ3NDMy_16702a52-8a7e-43c2-be06-fd53d799e251">3,750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMxLTQtMS0xLTQ3NDQ1_ec54a2e4-1cd4-46ef-9407-de487b71906c">1,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMxLTYtMS0xLTQ3NDU3_67a362d4-18f7-40aa-b206-58b0d8ea62eb">3,030</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMyLTItMS0xLTA_e80add7d-5cd6-4f7c-ac23-1f1158d066ba">20,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMyLTQtMS0xLTA_40258d9a-dfb9-40ac-850c-cdad5689e605">97,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMyLTYtMS0xLTA_9c88a544-543f-4931-b153-872719f47701">6,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM0LTItMS0xLTA_f71ca901-8258-4d7b-aa88-256b83e74bf8">77,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM0LTQtMS0xLTA_9458415c-8666-4118-bea1-36ec552c318c">178,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM0LTYtMS0xLTA_a5f95df5-2ffa-45cd-a46c-d7b853a0f68a">25,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM2LTItMS0xLTA_8b315dda-f5c9-46a4-88fe-eb141f2a9732">28,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM2LTQtMS0xLTA_8f3f6360-bd24-4e27-825c-5f0873bd6e69">56,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM2LTYtMS0xLTA_7028b4db-47d4-48bc-9a98-c16a190bdae4">8,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM4LTItMS0xLTA_364a6d8b-e6a1-491e-b729-106ef48da381">49,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM4LTQtMS0xLTA_9c0d78b7-74ff-47c5-9cd2-17ac348fd930">122,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM4LTYtMS0xLTA_2036d44f-6c20-4cdf-a93d-1a3e35611e19">17,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQwLTItMS0xLTA_605a91ad-5fa8-4738-b18b-df4a9838cb0b">24,564</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQwLTQtMS0xLTA_7c7e5be8-ba0a-4408-ad2e-da6a7e16b89c">84,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQwLTYtMS0xLTA_0fcbab2c-e0b4-4ded-a0fc-e19251e3a05e">3,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQyLTItMS0xLTA_f4f699f5-c108-491d-9687-30876c8d763f">73,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQyLTQtMS0xLTA_18cf4aff-4a0d-406b-9b90-c3083b9ec680">37,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQyLTYtMS0xLTA_1d08cd35-2a74-4a7e-889a-31596adf83f5">14,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTItMS0xLTA_57ed5f7a-186e-4c00-af0b-ec15e458aee2">1.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTQtMS0xLTA_5ca414fe-74d9-43ba-b1e3-515192dd333c"><ix:nonFraction unitRef="usdPerShare" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTQtMS0xLTA_d102e43f-969b-4c76-961f-55c29d2b6f56">1.04</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTYtMS0xLTA_a02d5581-b5fb-4f54-b286-f3fa06c0bd5a">0.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTItMS0xLTA_4cc08e02-a9ed-4aba-ac19-153240ebe555">1.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTQtMS0xLTA_2017a725-0eaa-4ad2-a164-a319967f755c"><ix:nonFraction unitRef="usdPerShare" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTQtMS0xLTA_476da3fc-2223-4d51-a0be-020e1ff9ed13">1.01</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTYtMS0xLTA_20cc52cf-b0e7-43a0-a18b-bc467a36b65e">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="42" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except share data)</span></td></tr><tr style="height:16pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mezzanine<br/>Equity&#160;&#8211;<br/>Non-controlling<br/>Interest&#160;in&#160;APC</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional<br/>Paid-in&#160;Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained<br/>Earnings<br/>(Accumulated<br/>Deficit)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common&#160;Stock&#160;Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d3506ad61545a28e82fbaea4860bd7_I20181231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTEtMS0xLTA_8d4436fd-7433-4140-bf75-8a3f3e4762e2">225,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i238ec269dd2b4e39bf78ffb28244ae9f_I20181231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTMtMS0xLTA_a7dfb47b-1540-4bb1-8c50-12efe32c3614">34,578,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i238ec269dd2b4e39bf78ffb28244ae9f_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTUtMS0xLTA_2a4d680a-38bf-49ce-ba01-a9fed2ed949a">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc7a8bb404d44d6a025101ce145ebcb_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTctMS0xLTA_876ed514-e797-4e35-9531-5cca877fcc27">162,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1890ce55fe054d5fb8532b6899d89386_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTktMS0xLTA_94f0d888-57fd-4e11-ba94-bd92e79570f6">17,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64bc2b851e8049a69e6c4252d1789f5a_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTExLTEtMS0w_ecbf0b9b-34ae-4fd2-b3c6-a976abef2a0f">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d3506ad61545a28e82fbaea4860bd7_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTEzLTEtMS0w_f7475fae-bd8b-4969-8ac0-8d9810298ddc">181,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTEtMS0xLTA_9ea76744-a018-4d48-b81d-ee968c7a031a">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51d91826c13e48f9ac3b196f1709cf0c_D20190101-20191231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTktMS0xLTA_f7d5164c-8808-418b-aa4f-0255dd3ee0c9">14,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTExLTEtMS0w_d3680d64-d16e-4490-83aa-c38cc680188d">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTEzLTEtMS0w_0f53bcfc-95e1-4c23-89f1-fef1e69d022b">15,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:TemporaryEquityRepurchaseOfTreasuryShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTEtMS0xLTA_86809fca-bedf-450e-8719-996763d853b5">283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTMtMS0xLTA_7a6ad25e-c966-4c9b-a883-4a8cb0ea96c6">601,581</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTUtMS0xLTA_f7366558-46da-4a6a-a4c6-d0cc76eb3ab9">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTctMS0xLTA_a4149d43-7ed5-4d33-845e-707d97185b60">7,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTEzLTEtMS0w_777213ef-8451-47db-ae23-70965fdd8780">7,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIwLTMtMS0xLTA_922abf92-72c6-4eab-aae3-0bd8df23d3c5">418,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIwLTctMS0xLTA_59bc7973-6e34-4861-8a0c-34e36762035f">3,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIwLTEzLTEtMS0w_34696a84-a5ab-4dac-9ba8-4b803f7e2a6a">3,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:TemporaryEquityShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTEtMS0xLTA_2a50aada-9ced-41d2-9843-71147fbe355c">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTMtMS0xLTA_be04a136-4774-48c7-ac1f-6c344f5df033">1,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTctMS0xLTA_687475a9-ad33-4274-af3d-6a261bc93442">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTEzLTEtMS0w_45ae7619-2d3f-4f88-8bba-ed9bcd0fe781">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock subscription</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:TemporaryEquityStockSubscription" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIyLTEtMS0xLTA_d786a1ae-7a32-4e26-a031-600a1c3d3e0a">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued in connection with business acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIzLTEtMS0xLTA_7bebdb00-bdff-4dfb-8366-2d9581552fd2">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of equity issuance of preferred shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="ameh:TemporaryEquityCostOfEquityIssuanceOfPreferredShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI0LTEtMS0xLTA_87f1352d-68af-4ed2-a1c5-3312a90e92da">878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest capital change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231" decimals="-3" name="ameh:NoncontrollingInterestIncreaseFromCapitalCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI1LTExLTEtMS0w_b65f740b-f218-4f99-9099-dd9c505e924b">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:NoncontrollingInterestIncreaseFromCapitalCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI1LTEzLTEtMS0w_12567bb8-e6eb-41ac-a3bf-dfe6186035d7">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:TemporaryEquityAccretionOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI2LTEtMS0xLTA_92dc8ead-70e1-42e4-8b7b-a3c2f15d7409">60,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI2LTExLTEtMS0w_2fe6f790-ad52-49a4-8d5f-49737eaf8999">1,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI2LTEzLTEtMS0w_130d153e-c425-43ea-85c4-5e8296916bdf">1,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of options liability to equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI3LTEtMS0xLTA_13d7a4dd-476c-4071-ae63-d6f72e494f06">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI3LTEzLTEtMS0w_950ab715-7a4a-4b23-b3c9-aa7d5aac003c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of <ix:nonFraction unitRef="number" contextRef="i69343d65ad324809810e1b1eda1dbc7d_D20190101-20191231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MmZjZWMzMDI2Y2M0MzhjYTMzODA5MWI0ZjZkZmUzNF82MDQ3MzEzOTUyODA2_5d69c990-acaf-43ed-b3f4-fee3ebdf1686">50</ix:nonFraction>% holdback shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231" decimals="INF" name="ameh:StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTMtMS0xLTA_fd170b49-c144-47cb-a68a-cc9b8ef6086b">1,511,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231" decimals="-3" name="ameh:StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTUtMS0xLTA_774c3994-6cbe-42f5-8020-0b731eafbb71">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231" decimals="-3" sign="-" name="ameh:StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTctMS0xLTA_1cc8aa00-e427-4559-8f3c-22bb42f43fc0">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTEtMS0xLTA_c84dcca8-8f11-4f79-ad90-7a0adc702a70">168,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibae93612a82b454fad4c214ad4fbe93f_I20191231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTMtMS0xLTA_85f91c4e-112c-497a-9966-2869abb24b97">35,908,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae93612a82b454fad4c214ad4fbe93f_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTUtMS0xLTA_672e125a-bd10-41d2-b1e1-248530c47173">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f1b5c490b84fb7bcd0e27816f8a1fd_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTctMS0xLTA_d5ee432f-4f99-4187-af56-f1497d46d40d">159,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic665959fd8094aba83a52190f5ce2a29_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTktMS0xLTA_bd5cc407-3930-48c2-ab7b-de14c1f501a6">31,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7108c557e599411aa1a3345423fbcaf2_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTExLTEtMS0w_d02474a1-9fb4-4e32-ac58-243a09154495">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTEzLTEtMS0w_1b7d8094-a80c-4964-9410-41f7ce022071">192,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEtMS0xLTA_43dbf99a-08d7-49b6-a8d5-e5df25c1fc11">83,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2666f9aebddc43b295ec38700190d8f9_D20200101-20201231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTktMS0xLTA_1db3f453-9bb5-4d19-83a5-0de1a525091f">37,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd090b6a4d07450b83ab3ba19b8a8b82_D20200101-20201231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTExLTEtMS0w_ed00ea1c-5d8a-48b6-b1b6-0343f8af76b5">833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEzLTEtMS0w_b62c06f3-6964-4780-9114-06f954c90ca8">38,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTMtMS0xLTA_84439b25-255f-44cd-ad3a-f21a8213c7d4">16,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTUtMS0xLTA_107b4188-b6ae-4a1e-991c-fc9ccf78cf2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTctMS0xLTA_00774938-9a10-4211-afe9-0ed7dc3dc800">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTEzLTEtMS0w_9cdb9786-1ca3-4a51-959f-8eb5e0c72d2e">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:TemporaryEquityDistributionToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMyLTEtMS0xLTA_7d67ebc4-9098-47b8-a337-4cd66d7c872b">1,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMzLTMtMS0xLTA_d53facc5-ccf4-480f-a75c-634948e7a480">66,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMzLTEzLTEtMS0w_7d40a125-7fdd-4c34-9f46-c6ac20177eab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for cashless exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="INF" name="ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTMtMS0xLTA_d430e59a-e56a-4bc4-a8c1-79d461dcd807">66,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTEzLTEtMS0w_7d8c6b96-3e3c-4e33-86b7-4e25cca61bcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTMtMS0xLTA_90b77d89-d6a4-4ca8-ba15-9a0b70e45b5e">1,240,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTUtMS0xLTA_b85e1883-752f-4fde-b1fb-1dc3e4fe70d0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTctMS0xLTA_f41f6888-cec9-4099-b969-7dcad768112e">11,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTEzLTEtMS0w_bdd1df14-2c53-4440-8d43-92dd9d23b6da">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM2LTctMS0xLTA_143f55a7-6df1-4c79-86ce-24c2d29f4102">3,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM2LTEzLTEtMS0w_aa44240e-5bdf-49c3-8ba1-2afaa64ae8dd">3,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTctMS0xLTQzMDIy_c947f5f7-1445-4d00-b454-08c50bd348a1">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTEzLTEtMS00MzA1NQ_8498e83c-14fc-414a-b2c7-b89cd8e08ba1">236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:TemporaryEquityAccretionOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEtMS0xLTQyOTg5_d84bc3e9-7549-4200-bf52-a384302194db">137,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="INF" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTMtMS0xLTQzMDAw_31345a7b-9534-45c7-95e6-a8bd1419036c">4,984,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231" decimals="-3" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTUtMS0xLTQzMDEx_3e4d57be-5e4d-424e-b861-9bd73b909e48">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231" decimals="-3" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTctMS0xLTQzMDIy_63fd8214-1d0f-443d-93bb-04ba64f0d785">87,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd090b6a4d07450b83ab3ba19b8a8b82_D20200101-20201231" decimals="-3" sign="-" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTExLTEtMS00MzA0NA_55f180b2-3942-422f-87f6-c3deab808e37">1,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEzLTEtMS00MzA1NQ_60330767-2213-4ab8-9692-4c36fbdf9aa4">85,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTEtMS0xLTA_87d3b574-25e6-4c89-858a-e588517abb6e">114,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcca7582879a462a8ca400618dab2e16_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTMtMS0xLTA_fd44811f-11ae-44a1-970a-2d3553438d4a">42,249,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcca7582879a462a8ca400618dab2e16_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTUtMS0xLTA_2dc0286b-b12e-4da5-a214-8893fa99c503">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbb14ec4c3d04df498362b3ff2649443_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTctMS0xLTA_61133e4e-2738-4906-b918-3d5ddf5413df">261,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ebd2bb3cc9f4ccfb1e9e646ea718b5a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTktMS0xLTA_42011c94-eafa-4eef-af5a-b923034c6c1b">69,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b34f542dee746a88ed1f03df4889be3_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTExLTEtMS0w_1eae3f9d-bac3-4146-91bd-c0aedd85baee">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTEzLTEtMS0w_8a8cba26-4aec-43a8-afeb-d787c112b50c">330,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:TemporaryEquityNetIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTEtMS0xLTQzMjAy_5c1a0cd7-b016-47b3-82ba-4921c0a2861e">27,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76474cb8ad064d37a1739d166c60efc9_D20210101-20211231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTktMS0xLTQzMjI1_2049e2bf-501c-49b9-8efb-d509eec8ba24">73,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTExLTEtMS00MzIzMg_96984807-3f59-4f16-8486-1fe482d89db7">2,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTEzLTEtMS00MzI0OA_30e749cd-c55f-4ec9-91ad-251ea074ff34">76,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c0752ab08774f379384a68ffb9687d6_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTEtMS0xLTQzMjAy_cb7a674a-4ace-4d22-acdb-9fb0b107acf4">1,546</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTExLTEtMS00MzIzMg_17588ab5-dcae-49e3-b163-1e6e4e93f6fd">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTEzLTEtMS00MzI0OA_2fb3d2c3-c3d4-4824-906a-4e710f5de0fd">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.614%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.617%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of non-controlling interest </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0752ab08774f379384a68ffb9687d6_D20210101-20211231" decimals="-3" sign="-" name="ameh:TemporaryEquityIncreaseFromSaleOfNonControllingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM2LTEtMS0xLTQzMjAy_cbd8b5ac-5ee7-447c-a088-7f49e6d1e128">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of shares by non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231" decimals="INF" name="ameh:StockIssuedDuringPeriodSharesNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMyLTMtMS0xLTUyOTUx_3daa9a94-5d82-4985-bf2d-c42ea3b36dca">1,638,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231" decimals="-3" name="ameh:StockIssuedDuringPeriodValueNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM3LTUtMS0xLTQzMjEx_e1d81529-7af2-45e0-92d3-c4f7e6debcd4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231" decimals="-3" name="ameh:StockIssuedDuringPeriodValueNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM3LTctMS0xLTQzMjE4_107d827c-9b47-42bc-8287-7dfe1ecbe392">40,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:StockIssuedDuringPeriodValueNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM3LTEzLTEtMS00MzI0OA_6f0857de-22b4-45a2-b36b-03f1b2ccfa17">40,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMzLTMtMS0xLTUyOTUx_6b9082ff-654c-47db-b45e-64157c5adbcb">29,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM4LTEzLTEtMS00MzI0OA_7cd4d52a-02ef-423d-ac4c-50e409e7ff70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231" decimals="INF" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTMtMS0xLTUyOTUx_e3595b4c-ff08-45fe-ad34-c86e39a5adae">898,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTUtMS0xLTQzMjEx_4b783af0-8019-429e-a1e8-3e2eea3c17a8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTctMS0xLTQzMjE4_1dacdfb1-104f-4bd7-9d35-351e73841312">9,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTEzLTEtMS00MzI0OA_0de5765c-2153-4652-917b-17e9268afb14">9,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTMtMS0xLTUyOTUx_2808664d-7cd0-4e06-ba0f-b2e7adc8e0f0">174,158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQwLTctMS0xLTQzMjE4_f3cff771-9545-4976-9140-b59128f39a20">5,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQwLTEzLTEtMS00MzgyMw_43128f32-6606-4834-b68b-e98319aaab33">5,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQxLTctMS0xLTQzMjE4_7217597e-d4bb-4daa-bf5d-a2e4117fdeca">6,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQxLTEzLTEtMS00MzI0OA_99a81ab0-32af-47db-9c1c-27aa92cd136f">6,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQyLTExLTEtMS00MzIzMg_667cb577-a24f-4f19-85bf-2f0f66eaba2d">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQyLTEzLTEtMS00MzI0OA_bc3d1a20-7433-48ae-9425-e5f36409cf2c">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQzLTExLTEtMS00MzIzMg_26582e1a-3f0c-4834-9fad-7966f7dff667">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQzLTEzLTEtMS00MzgyMw_dbf7cd9d-5f0e-4d59-bc76-847c928cc6f7">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTMtMS0xLTUyOTUx_4a30706c-c9b4-4a1e-918e-8a22c3034fa6">10,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ0LTctMS0xLTQzMjE4_e1ae1282-01b0-47aa-bd77-eaf2d3f8548b">334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ0LTEzLTEtMS00MzgyMw_edd0afe7-bd5a-4f3f-9a32-c13d3bdd4dee">334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest capital change</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231" decimals="-3" name="ameh:NoncontrollingInterestIncreaseFromCapitalCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ1LTExLTEtMS00MzIzMg_eaccd5f4-b652-4687-88b6-e28df821d908">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:NoncontrollingInterestIncreaseFromCapitalCharge" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ1LTEzLTEtMS00MzI0OA_fe4c64b6-8afe-4b84-920c-a9a4119166d3">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:TemporaryEquityAccretionOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ2LTEtMS0xLTQzMjAy_a0890f9b-9c4a-49d4-aceb-4ef474ed759a">30,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ2LTExLTEtMS00MzIzMg_994dd97c-446c-4aed-affd-26618c164b15">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ2LTEzLTEtMS00MzI0OA_96912cfd-3aaf-463a-ab0d-865edf58c67a">1,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTEtMS0xLTQzMjY0_b533dcd0-dd00-41d1-893e-d724d40c0f0a">55,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i02229923c53147db941db9c29b48ab30_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTMtMS0xLTQzMjY5_90eaebea-6956-4cf6-9697-0a89a5b42fb1">44,630,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02229923c53147db941db9c29b48ab30_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTUtMS0xLTQzMjcy_63c00680-89b8-49b9-9a8e-6d893be327cb">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic922097b0d6044c2893f7d407499ba35_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTctMS0xLTQzMjc3_da8b87e5-d117-46e5-b200-4812d78023ea">310,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c75cb4bf9e4ad79f118905ac2df40d_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTktMS0xLTQzMjgy_12847355-b80b-4a54-b472-cd4bac3a1580">143,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0088a70f180a4664865e2acb1ce90bce_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTExLTEtMS00MzI4Nw_65f5cb90-6e1d-4353-87f0-5679ac665023">5,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTEzLTEtMS00MzI5Mg_46139da2-a5df-450e-b259-8bafffeb967f">460,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYtMi0xLTEtMA_88660091-9e1c-48b8-ac42-c1588dcece84">49,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYtNC0xLTEtMA_15c1140b-1318-4da1-8cd8-c7f8c7c3462d">122,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYtNi0xLTEtMA_1f6f70b7-eddc-4dd7-90b9-df2fa0d496e0">17,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgtMi0xLTEtMA_75da68a3-1462-4bf1-9d61-253ad5e36bcc">17,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgtNC0xLTEtMA_1f6cf19b-54fe-45ed-adbb-880a83dca202">18,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgtNi0xLTEtMA_ddbc09d7-2faa-48d5-9a3c-fe569073c4ad">18,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzktMi0xLTEtMA_af5a6647-4b11-43fd-afe4-00c52203a57c">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzktNC0xLTEtMA_c4c8206f-cb4c-4a08-ab12-91c5e216451e">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzktNi0xLTEtMA_e6900b18-f550-4640-8f30-2ea09326118c">473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTItMS0xLTU2OTY2_0fa5180f-93b1-4d51-80ce-6535b0708d6b">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTQtMS0xLTU2OTc3_f23dd644-797b-4e20-8157-af65b77167d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromOtherOperatingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTYtMS0xLTU2OTg0_363ace60-ee59-4df7-b9fa-5ea5c2bd3731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss of disposal of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTItMS0xLTA_aa63e8bd-0ca1-40a8-a4f7-542e71710a3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTQtMS0xLTA_76cb9fcd-e68e-4c1d-9913-75e612e9fdf3">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTYtMS0xLTA_08f0f1e9-5997-4398-9319-6da179746e78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of goodwill and intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzExLTItMS0xLTA_a0244f3f-4e65-4996-8359-3fc8743d2c11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzExLTQtMS0xLTA_aca69346-bd5b-4e1c-bd25-1ef76089fb4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzExLTYtMS0xLTA_4528f48c-c13b-4997-b4aa-f29fb570eeb2">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEyLTItMS0xLTA_83c5bcc6-044a-4cc3-a3f4-a706606f536d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEyLTQtMS0xLTA_d3c7ed50-3f35-4d78-b7d9-0446cef578a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEyLTYtMS0xLTA_987026d0-250d-4fa7-9052-675764f29939">1,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEzLTItMS0xLTA_657f6baf-c8a9-4e1f-8234-36bb11ff2718">6,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEzLTQtMS0xLTA_ecdb4789-cabf-4857-b940-f209951e5cc5">3,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEzLTYtMS0xLTA_ecee3514-8b9e-4d1b-838d-ce0741db3b2f">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE0LTItMS0xLTA_1d4a9367-cf74-4394-b2f7-241118001b5e">2,193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE0LTQtMS0xLTA_3f03564a-7124-48bf-9f84-adfee4a716c3">99,839</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE0LTYtMS0xLTA_ba085385-9253-4699-b9ad-ab07dc08646c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on consolidation of equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:GainLossOnConsolidationOfEquityMethodInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTItMS0xLTYzNTU0_9c6d6043-3b8f-482a-a6d2-3d1383c3948b">2,752</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:GainLossOnConsolidationOfEquityMethodInvestment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTQtMS0xLTYzNTY0_e846b6f3-2e90-4e08-919b-0e0815093d11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:GainLossOnConsolidationOfEquityMethodInvestment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTYtMS0xLTYzNTcy_76fc422e-a6a1-444f-b3bf-43fce9d91b06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on contingent equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:GainLossOnEquityReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTItMS0xLTU3MDEw_468a9240-8629-4ae8-bb58-01c4c5dad57c">4,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:GainLossOnEquityReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTQtMS0xLTU3MDE5_9915e51d-4060-4bdc-909e-aa4b1dacd193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:GainLossOnEquityReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTYtMS0xLTU3MDI2_3468426b-ea30-47f3-a76c-197156e75b3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on loan assumption</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:GainLossOnAssumptionOfLoan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE1LTItMS0xLTA_0eb6401b-2e94-4925-bb6f-8c9d1a981f69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:GainLossOnAssumptionOfLoan" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE1LTQtMS0xLTA_34ae5eb0-f89d-4786-9129-e1e03ea6acaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:GainLossOnAssumptionOfLoan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE1LTYtMS0xLTA_56dcc0e8-443c-4856-a5df-4ef1dfb2d701">2,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss (gain) from investment in equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTItMS0xLTA_debbcfa5-cf08-4fee-b16b-faf2895ab38a">10,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTQtMS0xLTA_e5aed621-da1e-48f9-a4fd-e334b54756f3">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTYtMS0xLTA_9c6fbbd8-de15-441e-b504-4388e80e0c00">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from investment in warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTItMS0xLTY0OTM2_02de63fd-f6f4-4676-b111-a2e56a477027">1,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" xsi:nil="true" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTQtMS0xLTY0OTQz_09f486c3-36d6-47bc-9b07-766c3afa587b"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTYtMS0xLTY0OTUw_49169aac-b0c1-476a-9254-ac06946a7593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss in interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:DerivativeLossOnDerivative" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE5LTItMS0xLTU3MTA2_9df39dd6-36ef-4d10-aed8-c08bbd48c02a">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:DerivativeLossOnDerivative" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE5LTQtMS0xLTU3MTE1_86b121e9-56ed-43ae-805f-1a03fd757dbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:DerivativeLossOnDerivative" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE5LTYtMS0xLTU3MTI0_a899051e-20a2-4204-b1dc-fbbc5ab0f9d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of beneficial interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTItMS0xLTU3MTA2_806eb04e-e689-407c-89b4-7b6f960b7c9e">15,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTQtMS0xLTU3MTE1_a5976b33-a4ed-4c52-b686-f2f5e9350e1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTYtMS0xLTU3MTI0_6f43403b-428c-495a-8d4f-2ba536501fa8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from equity method investments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE3LTItMS0xLTA_abf87456-59b2-47e0-881b-705191cf7acb">4,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE3LTQtMS0xLTA_b24c97ec-21b5-4608-9df0-c7cf97947fa0">3,694</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE3LTYtMS0xLTA_f3272d99-73eb-487e-a6c9-2bf0d88b18a2">6,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE4LTItMS0xLTA_932ed0c8-b882-4b79-bef9-e54b527c1433">5,952</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE4LTQtMS0xLTA_5eb90734-523d-4cd2-ae50-89e3c6cd5421">6,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE4LTYtMS0xLTA_c7b381f2-4e16-46af-a3ee-13ae3ef526d0">6,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisition amounts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTItMS0xLTA_cd9839ca-c59b-4dbf-b923-7768263c4171">1,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTQtMS0xLTA_eb982cf3-cd9f-4838-9154-e7c56f857c3c">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTYtMS0xLTA_1c55b5bb-a585-40ea-aaf8-9aaae69ab725">10,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivable, net &#8211; related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIxLTItMS0xLTA_47c996fe-b903-44b0-aaca-868b8a0736a0">20,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIxLTQtMS0xLTA_ec23a801-0439-47f6-84fb-6b6a997d6c0d">1,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIxLTYtMS0xLTA_fe552626-0cdb-46b2-944a-775c7dc2a431">1,435</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIyLTItMS0xLTA_4ff33b26-4b7b-4a6a-9dbd-b6cb28fd7964">5,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIyLTQtMS0xLTA_b3f1164c-edf3-4b41-af5d-af1f560939d1">12,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIyLTYtMS0xLTA_ab086b46-6958-48cd-b7aa-5ee5817a55bf">15,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIzLTItMS0xLTA_122d457c-8679-4cb3-8290-876079cacc3c">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIzLTQtMS0xLTA_9b94ecf1-728e-49e7-9932-04d8abc74062">6,432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIzLTYtMS0xLTA_a60eedb2-aad2-4185-99f0-eedde6ded6fe">2,756</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI0LTItMS0xLTA_ebf70a61-1c6d-4baa-9218-ef9364555b1a">3,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI0LTQtMS0xLTA_218c7b23-f32f-4319-90ef-297a9d591a84">3,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI0LTYtMS0xLTA_ec034afb-d6dd-4b97-93f6-0934f9b2a25d">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI1LTItMS0xLTA_c7c52027-8b0e-4e19-b4f0-eb26319a2759">1,529</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI1LTQtMS0xLTA_b64c3339-a9a5-4dc4-8811-0ffcc8c6dd11">5,530</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI1LTYtMS0xLTA_a5fb729b-0b31-419c-b07a-8cb9cba2eeae">572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI2LTItMS0xLTA_e3058d93-b427-4b3d-940d-c22b0ff76dfd">3,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI2LTQtMS0xLTA_186ab10e-15e1-4f97-8b60-1a3af093ac82">8,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI2LTYtMS0xLTA_250bf5e3-fd1e-45f6-b372-c0eede20a521">4,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI3LTItMS0xLTA_838bb5e3-1af9-4fbb-86cf-d04252dd171c">892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI3LTQtMS0xLTA_656e3755-2ed7-418f-98aa-b15c53643946">7,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI3LTYtMS0xLTA_030f76f0-e25b-457f-84fc-79bdf6c9bfc9">488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI5LTItMS0xLTA_267fae67-b112-4b5d-b6db-9acd525187e4">5,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI5LTQtMS0xLTA_ed86b2fb-6df8-4cfb-aa0b-da035168ef11">8,691</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInMedicalLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI5LTYtMS0xLTA_373a1dd7-dbe0-4e34-bb9d-6316487a5ac3">2,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMwLTItMS0xLTA_b35d5474-3553-46e9-82da-6db88f476473">3,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMwLTQtMS0xLTA_bae9541f-159d-4f8b-9038-cb623cc258b3">304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMwLTYtMS0xLTA_a350e291-1115-4b49-89dc-aa12665a0299">7,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMxLTItMS0xLTA_445055b0-6814-4eac-acfe-9edea3b71999">3,215</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMxLTQtMS0xLTA_f4c4bcee-1751-4afb-9a77-1ba5d89c2ed5">2,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMxLTYtMS0xLTA_a87bd63b-1b2e-4c6c-bced-b76d8dbe4377">2,244</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMyLTItMS0xLTA_badeaad9-6a23-4b04-b639-b5da80f1323f">70,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMyLTQtMS0xLTA_236467a2-d958-44f2-910a-3326a32e3a01">46,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMyLTYtMS0xLTA_23c96cc1-dc83-4c2b-81e4-97306cbe59b4">13,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM1LTItMS0xLTA_b12d2744-c460-4ae8-8493-082fb6acd2de">28,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM1LTQtMS0xLTA_3f2c1992-527b-4d48-937a-745c4c41f527">1,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM1LTYtMS0xLTA_f5764a14-6bb5-449e-9293-8c3daa245432">115,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM2LTItMS0xLTA_39e6ab10-5c87-455d-821a-2f805a252621">67,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM2LTQtMS0xLTA_6a6dfa58-a11d-4a8b-b981-7b047b3b8ff5">50,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM2LTYtMS0xLTA_963cc66a-ddde-476d-96d7-3f3a083bbd2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from repayment of loans receivable - related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM3LTItMS0xLTA_b033a112-9de6-4d72-9c47-2be7cf47cf6c">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM3LTQtMS0xLTA_e999fa07-5b53-44e2-8a25-617f69425a67">16,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM3LTYtMS0xLTA_71839a22-ea0e-4f75-8d1f-cd338edd17da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances on loans receivable </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM4LTItMS0xLTA_e42a1793-0a9d-481d-a4a3-80b911756809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM4LTQtMS0xLTA_160f4b40-1dd8-4c29-9091-3d2cb8a635f6">145</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM4LTYtMS0xLTA_2fa1d2d4-8eee-4030-adc9-f73ed2035800">11,425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends received from equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM5LTItMS0xLTA_aeca5254-a55d-4eab-b7cb-772728f5763d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM5LTQtMS0xLTA_cfc78184-8bf0-4491-8c20-ebc886f49bad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM5LTYtMS0xLTA_48f38cd1-b668-4c0d-9af9-14ac02885414">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of fixed assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQwLTItMS0xLTA_49cdf276-ea60-4ff8-9c7d-266a05704b28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQwLTQtMS0xLTA_ff44f449-4baf-4a76-87d3-279150832a48">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQwLTYtMS0xLTA_ce1d9e09-b8bf-4897-8711-b0ca29fc0958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for business acquisition, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQxLTItMS0xLTA_177bced4-99b3-4ac0-ac51-f2052f7cbb92">2,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQxLTQtMS0xLTA_ecbacba5-53d0-4756-8a0a-b904b6a5cbde">11,354</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQxLTYtMS0xLTA_3c1d5150-ea4c-4aa3-8a01-ea1f187861c9">49,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments in privately held entities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQyLTItMS0xLTA_4b04c28f-8414-4816-bb5b-f7530964bfcf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQyLTQtMS0xLTA_83556d04-64e5-440c-a459-2404af5334d7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQyLTYtMS0xLTA_204a2143-e7be-4af8-97dd-fe7ebb03cc48">491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQzLTItMS0xLTA_7a8e151f-e9e5-4f78-977a-36a137359bab">6,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQzLTQtMS0xLTA_8009109f-3455-4ae4-896a-b0bcff2add66">52,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQzLTYtMS0xLTA_7cd48b62-7da8-402e-85e9-802f751e0757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments &#8211; equity method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ0LTItMS0xLTA_91e91337-2691-401e-bdb2-c4905b3af458">13,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ0LTQtMS0xLTA_c209acf4-ddda-477f-890c-2098e4ea960c">9,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ0LTYtMS0xLTA_f27b6c50-8e3f-4a1e-8c1a-3fd51a1e3e2f">3,108</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ1LTItMS0xLTA_4e9a701e-705c-439e-8d0f-9f6129de127b">19,223</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ1LTQtMS0xLTA_18688269-9945-47f9-9d5e-7473ba53be5a">1,164</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ1LTYtMS0xLTA_c75b351d-53f0-490c-98e9-7ca7f79fb203">1,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash recorded from consolidation of VIE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTItMS0xLTU3NDA1_dd84942c-3895-4e89-a674-9d14fc6fc7b1">5,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTQtMS0xLTU4Nzk2_60029cf7-9c82-4ce0-b06c-c16c42006aa2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTYtMS0xLTU4Nzk2_8a3d0468-62e6-4529-813d-df42ba266a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ2LTItMS0xLTA_6b7a749f-b650-4d96-ab94-13590c46c7d7">16,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ2LTQtMS0xLTA_67cb02a6-ee4c-43a5-8ce5-39ce103a1cba">95,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ2LTYtMS0xLTA_5f61cbff-9185-4aae-94ed-479f3dc2421a">180,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ5LTItMS0xLTA_148ccf24-a888-4d28-a64b-d27b297ab86f">31,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ5LTQtMS0xLTA_dc78c088-8f54-4cb6-9e38-d09ec26316e3">51,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ5LTYtMS0xLTA_15516c4b-e828-428e-806d-6a475134d3e1">61,717</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTItMS0xLTA_fdd69168-0f03-4433-aed7-40f0a00db0b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTQtMS0xLTA_4d96ca10-1b56-4df2-bd51-905abc39c807">9,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTYtMS0xLTA_1d5e9836-7e11-4ea1-a1d7-3589966f90ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-controlling interest capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUxLTItMS0xLTA_98c4dd11-db3f-486a-a1ab-4024ca97ae34">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUxLTQtMS0xLTA_f650067b-f857-4904-9b9c-b0e310600b03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUxLTYtMS0xLTA_31e439aa-70ed-4faf-9a7f-08bd08067f12">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUyLTItMS0xLTA_82c5e328-b49b-448c-8b95-fe161c906a35">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUyLTQtMS0xLTA_3649b35b-0b02-464c-b9a8-eb13d8c8cfb1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUyLTYtMS0xLTA_0c90e499-8daa-49e6-98da-586022bced3e">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUzLTItMS0xLTA_b40bb9b4-1e41-4181-b0f6-25c6259f055b">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUzLTQtMS0xLTA_68df605b-5c9f-4773-9210-1479a39a67b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUzLTYtMS0xLTA_95d42e71-14b4-4676-97e8-11c76f736c40">39,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU0LTItMS0xLTA_62d20c84-e553-4e4a-9e81-d0bbcf84159c">201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU0LTQtMS0xLTA_306d7379-3810-4d19-a356-a898e37acad5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU0LTYtMS0xLTA_51059f19-3a07-4fab-bf6d-a9cac0ee58a3">2,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments on bank loan and lines of credit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:RepaymentsOfBankLoanAndLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU1LTItMS0xLTA_c617f686-7afa-4445-9e25-2965289f97d2">238,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:RepaymentsOfBankLoanAndLinesOfCredit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU1LTQtMS0xLTA_5545d094-afa2-485f-9858-8ba5755fcd8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:RepaymentsOfBankLoanAndLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU1LTYtMS0xLTA_e300cc29-dc59-433e-81b6-7ec61e713111">52,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of capital lease obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU2LTItMS0xLTA_7c042160-0de0-4c06-9822-a93cd1728347">208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU2LTQtMS0xLTA_6ee6d21d-83bc-4d8b-94db-2662f62b5d9c">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU2LTYtMS0xLTA_7b0e59ca-ebb1-4ec0-afdb-6401ae3ea86e">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU3LTItMS0xLTA_df35bd02-2b1b-4eec-a79b-dfa671e7c4ad">9,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU3LTQtMS0xLTA_6f05d726-e78a-4b78-bb74-fd1c04955b87">10,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU3LTYtMS0xLTA_ea1aa591-fe1a-4c53-8f3a-030fce9e870c">3,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTItMS0xLTU3NTAw_3076c026-92a6-4400-b699-accec6d7cbb2">40,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTQtMS0xLTU3NTA5_4bf9be6c-0edc-4b8b-b4ae-c88af42fb463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTYtMS0xLTU3NTE2_0f208076-c3f7-4ad7-bee9-716248c867d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from common stock offering</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:ProceedsFromEquityOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU4LTItMS0xLTA_7a21b9c2-3076-4a9e-a24d-045c3f0d0047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:ProceedsFromEquityOffering" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU4LTQtMS0xLTA_6dee4a75-7796-43e9-862a-659dd8399bb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:ProceedsFromEquityOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU4LTYtMS0xLTA_3ae3ea0b-ed19-458d-92fc-aaad49947893">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU5LTItMS0xLTA_56038668-e4df-4330-8f05-c407d886e9df">5,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU5LTQtMS0xLTA_a333b64c-b3d7-4dc7-805f-fd4129ae6f59">537</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU5LTYtMS0xLTA_5e7894f1-0246-4a0e-b474-8c473042682d">7,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution to non-controlling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfDividendsMinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYwLTItMS0xLTA_270f4c2c-e49d-4992-a7dd-3af1bdeab221">1,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsOfDividendsMinorityInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYwLTQtMS0xLTA_7cd48175-2f83-430d-ae57-0a9114f03ab3">1,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsOfDividendsMinorityInterest" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYwLTYtMS0xLTA_6e661260-15fa-42b5-8f41-1e4485036e23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of debt and equity issuances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYxLTItMS0xLTA_b8f467a2-3dc0-4e4c-9838-d4e3a53657e7">727</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYxLTQtMS0xLTA_2fe0311a-8d94-412a-af8c-0c411b111ef0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYxLTYtMS0xLTA_af9d2101-3252-4d18-b82c-4f49644cc08d">5,771</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYyLTItMS0xLTA_dee493d3-c8df-4ddf-816d-55d78354babb">47,748</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYyLTQtMS0xLTA_915097eb-f203-4b4c-9c2b-24919155b800">51,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYyLTYtMS0xLTA_d870a776-0b13-4780-ab25-40ff3517c542">163,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTItMS0xLTA_ed0f24f9-b817-4546-8896-ecd75d7aedf9">39,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTQtMS0xLTA_9d467e06-8a78-48f1-b1e5-e3ab0331e3af">89,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTYtMS0xLTA_f6867771-19d3-47b7-8f58-c3a7142038a7">3,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY2LTItMS0xLTA_2e1bfa09-6030-49d8-bb90-f9f2528b52ff">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY2LTQtMS0xLTA_f84fb3af-a26b-45df-aff7-99f8a452788a">104,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69d3506ad61545a28e82fbaea4860bd7_I20181231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY2LTYtMS0xLTA_e632fcaa-2b50-4c9a-9460-5c58730f393f">107,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY4LTItMS0xLTA_d5bb75d3-4f73-462c-8e07-c3bb13f2f9b7">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY4LTQtMS0xLTA_ae8b7388-30a6-4cb7-a1de-c2bf0e6913c9">193,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY4LTYtMS0xLTA_e15ac8b7-6324-4326-a2f6-bc9762947b75">104,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcxLTItMS0xLTA_d87628a3-f8e2-4ca5-8119-9725a49f0d90">37,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcxLTQtMS0xLTA_f0debaf3-4533-4ea2-a02f-a8fdb4172ab7">62,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcxLTYtMS0xLTA_2d418ce8-9d26-4fd6-8b6c-75b4b9a28453">20,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcyLTItMS0xLTA_83e0b772-3614-42ad-bc24-b1b9989ae630">4,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcyLTQtMS0xLTA_0cfca526-c20f-4b74-a394-d713397afb9e">8,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcyLTYtMS0xLTA_a904a0f2-6c45-4213-b36b-652a5b381df9">4,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosures of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of financing obligation for business combinations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:IssuanceOfFinancingObligationForBusinessCombination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgyLTItMS0xLTY5NTA0_85472788-0b68-4d12-94a5-be786ecb237c">12,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:IssuanceOfFinancingObligationForBusinessCombination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgyLTQtMS0xLTY5NTEy_57114cd8-cae8-43a9-a53e-f92574517387">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:IssuanceOfFinancingObligationForBusinessCombination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgyLTYtMS0xLTY5NTE5_65fc8ddc-bf8b-41f6-9868-666af3f7b49d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cashless exercise of warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:CashlessExerciseOfStockOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc1LTItMS0xLTA_eaa050b7-5a09-4fe7-96fe-f7fb61a43e12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:CashlessExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc1LTQtMS0xLTA_9894246c-107f-48f6-b374-baafac9befab">599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:CashlessExerciseOfStockOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc1LTYtMS0xLTA_981ea7b2-ac0c-4494-ab83-61452b0f9af6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancellation of Restricted Stock Awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:CancellationOfRestrictedStockAwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgzLTItMS0xLTU3NTQx_276eac04-43ee-4008-a2c2-944715054530">334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:CancellationOfRestrictedStockAwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgzLTQtMS0xLTU3NTQ4_bbad32a7-4b8d-472d-832e-69a3778b463a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:CancellationOfRestrictedStockAwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgzLTYtMS0xLTU3NTU4_b2897ac8-48d8-4c26-83c3-3b593ab52165">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend declared included in dividend payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc2LTItMS0xLTA_1f16de84-37ce-43ca-9f3d-4c88b121b786">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc2LTQtMS0xLTA_3c141b79-fabe-4960-a9f2-80f8c8c61d63">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc2LTYtMS0xLTA_822da011-eac7-487f-9150-909b79427814">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC stock issued in exchange for AMG</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a105ebf2734bc999cb1eda989a2bf9_D20210101-20211231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc3LTItMS0xLTA_5964342b-e227-45c1-b43b-f5f2a45bd6ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca318fe85484ec8995fd60b38993065_D20200101-20201231" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc3LTQtMS0xLTA_a091681e-a415-4957-afcc-fac768cd81a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f341ffb85ca4a0a9602302c5c3d5969_D20190101-20191231" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc3LTYtMS0xLTA_dbe345d3-6ab1-404f-8d8b-7633a839bc0d">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification of liability for equity shares </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:ReclassificationOfLiabilityForEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc5LTItMS0xLTA_519a2c6b-68a8-4efc-8308-78f4385dd7f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:ReclassificationOfLiabilityForEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc5LTQtMS0xLTA_2d5c98db-c19a-43bf-9182-4826f745ad6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="ameh:ReclassificationOfLiabilityForEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc5LTYtMS0xLTA_36717fec-fee7-4c6c-ab2e-831cf4376316">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Deferred tax liability adjustment related to warrant exercises</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg0LTItMS0xLTA_2041d872-b333-4c5f-979c-1543a9336b0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg0LTQtMS0xLTA_127f619f-066d-4a2b-b2e1-927bcbd9c37a">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentOfWarrantsGrantedForServices" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg0LTYtMS0xLTA_6ba9b5b8-99f6-469d-a06d-938a21b0f416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Preferred shares received from sale of equity method investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg1LTItMS0xLTA_0baf88b1-c17c-4609-bcf1-87d66223066f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg1LTQtMS0xLTA_709d2026-2871-4d40-b41d-25193186f1f6">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ConversionOfStockAmountIssued1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg1LTYtMS0xLTA_b477f5f2-0792-4d25-a851-85ce08716450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Beneficial interest acquired from sale of equity method investment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg2LTItMS0xLTA_87f6a958-0158-467b-804e-37c8fa5f4bf6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg2LTQtMS0xLTA_2e7f9dc8-ddbb-41bc-8dec-0e9568cd40e6">15,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg2LTYtMS0xLTA_4be5112f-e52f-41a2-ac01-42594f8f5859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents, and restricted cash shown in the consolidated statements of cash flows (in thousands).</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:58.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzItMS0xLTEtMA_d639ae01-f4d2-46b6-88f8-5f5ecb6c49d7">233,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzItMy0xLTEtMA_50ac3082-0bb0-44b2-9f8f-8477c3bff218">193,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzItNS0xLTEtMA_be83bca8-99cf-4605-8f43-d745294d07f5">103,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; long-term - letters of credit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzMtMS0xLTEtMA_69bff7b8-79f2-4c4c-91bb-f7b97804f557">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzMtMy0xLTEtMA_621abcbb-d512-48b7-9540-27a2f0587a43">500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzMtNS0xLTEtMA_b2901397-fd52-4887-8126-da8debf73eef">746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; short-term</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzQtMS0xLTEtMA_0e5608ad-0a67-4c4a-982b-03cd78ca3242">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzQtMy0xLTEtMA_abb7a0e0-0fb8-4918-accb-1ae0a254c461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzQtNS0xLTEtMA_905385e5-70e9-4ace-bdaf-ece43f2cee8f">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzUtMS0xLTEtMA_9e5c19ca-3b05-459b-902a-24c351070b16">233,097</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzUtMy0xLTEtMA_7dce339c-6f82-4bfb-8331-052434afad09">193,970</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzUtNS0xLTEtMA_b8e7557a-a898-452d-8bb2-1b474c6bda94">104,010</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_115"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_118"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzE1NDI4_9212eaa5-b7c3-4c8b-b4c1-d46d672a2fba" continuedAt="idb9b650ea10f41abaa3f8e8f63ead389" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="idb9b650ea10f41abaa3f8e8f63ead389" continuedAt="iaa5fa40b94b843b89ccd011a7fb47bc3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;) and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually. Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA (&#8220;Accountable Health Care&#8221;), and Access Primary Care Medical Group (&#8220;APCMG&#8221;) are the affiliated IPA groups that provide medical services. These affiliated IPAs are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, AMH and SCHC. AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly owned subsidiary of ApolloMed in December 2017. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (amending an initial management services agreement that was entered into in 1997) for an initial fixed term of <ix:nonNumeric contextRef="i0a787853fb4e44ab97a431b68a27e17f_D19990701-19990731" name="ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzM4NjA_b17a91f4-68ce-4be0-a2fe-f31e3bad1fc8">30</ix:nonNumeric> years. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="iaa5fa40b94b843b89ccd011a7fb47bc3" continuedAt="i2c10c6bb8c0546dcbc9428fa7b4d49f6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) were formed in May 2019 and July 2021, respectively, as a designated shareholder&#160;professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. ApolloMed makes all the decisions on behalf of AP-AMH and AP-AMH 2 and funds and receives all the distributions from its operations. ApolloMed has the right to receive benefits from the operations of AP-AMH and AP-AMH 2 and has the option, but not the obligation, to cover its losses. Therefore, AP-AMH and AP-AMH 2 is controlled by and consolidated by ApolloMed as the primary beneficiary of this VIE. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzUxNjA_1349d560-53ff-44c4-8601-863124513c16">545.0</ix:nonFraction> million loan to AP-AMH, pursuant to a <ix:nonNumeric contextRef="i075d8ca8fc3540c08520741050fea395_D20190901-20190930" name="ameh:FinanceReceivableTermOfReceivable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzE1NDMw_9615e901-80ae-41aa-b0da-53fe9e5382fa">10-year</ix:nonNumeric> secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930" decimals="INF" name="ameh:FinanceReceivableStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzUyNjY_080e80fd-69a8-4231-8834-58b94b01d32d">10</ix:nonFraction>% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#8217;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930" decimals="INF" name="ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzU5Njc_86f6d9df-000a-415c-97a6-3188c861b10f">10.75</ix:nonFraction>% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDY0Mjc_1349d560-53ff-44c4-8601-863124513c16">545.0</ix:nonFraction> million private placement, where AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="ia2b7ab46ec1f4230b17c5bc1355ea969_D20190901-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwMTQ_117325c0-1706-4c31-aff6-d862d4e43593">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. During the year ended December&#160;31, 2021 and 2020, APC distributed $<ix:nonFraction unitRef="usd" contextRef="ibb9136ad4e1240bd8120581c09a56b83_D20210101-20211231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDYyNzE_452a9cff-dbf9-4fa9-889e-4106b892be14">55.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic93862edf0d94e38a0905a9d5e2a7e97_D20200101-20201231" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDYyNzg_886295b5-6723-4cb4-b569-6fd9fece5cce">30.4</ix:nonFraction> million, respectively, as preferred returns.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $<ix:nonFraction unitRef="usd" contextRef="i730fecde417c468e90d3113624967018_I20190930" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDcwMDg_2328d2fb-8951-4405-aba3-2f8e111f6b47">300.0</ix:nonFraction>&#160;million private placement, where APC purchased <ix:nonFraction unitRef="shares" contextRef="ia7b9267d39a0457aa1e20e58ddb345e4_D20190901-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzY3NjY_a409c6c1-3808-496b-9363-9dce35352bc4">15,015,015</ix:nonFraction> shares of the Company&#8217;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.  During the year ended December&#160;31, 2020, APC distributed approximately <ix:nonFraction unitRef="shares" contextRef="i9d2380fc33084f94b7a593212ef66566_D20200101-20201231" decimals="-5" name="ameh:NoncontrollingInterestSharesDistributed" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzQzOTgwNDY1MzgyNTg_759c68a1-1f01-4b31-97e2-6be680412d4e">5.0</ix:nonFraction>&#160;million shares of the Company&#8217;s common stock to APC shareholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#8220;Excluded Assets&#8221;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC's ownership in ApolloMed was <ix:nonFraction unitRef="number" contextRef="i439aed610b4a4563872164ecdf084f75_I20211231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzg5MDQ_ad64d8b5-7caf-4055-a734-90965963f070">19.68</ix:nonFraction>% and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ica1cde9ee4cb4494b58321188ad95db5_I20201231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzg5MTE_dacf40a0-a20a-4bb3-8791-06e42f7225eb">22.58</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2021 and 2020, respectively.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, organized by a group of highly qualified physicians, with a surgical center that utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of December&#160;31, 2021, APC owned <ix:nonFraction unitRef="number" contextRef="ie4bb40e84ae24fb4b5080af0965a1437_I20211231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzk0MzQ_53ea1069-caa7-4d50-9a5d-bd8c3d8cc039">44.50</ix:nonFraction>% of CDSC&#8217;s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#8217;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i2c10c6bb8c0546dcbc9428fa7b4d49f6" continuedAt="i24492127451646cf9f116f8d85079c10"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and the right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a <ix:nonFraction unitRef="number" contextRef="i8c3dd0689a5341d584d1b40693f33ff1_I20211231" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwODY5_6e3475de-6088-4aa4-be78-304f2af3cb84">100</ix:nonFraction>% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;), and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA, was acquired by APC-LSMA in May 2019 for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i5742adc9978b45aaa40335db8f9111dd_D20190531-20190531" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzExMjE4_ee35d1ff-5fc7-4859-b5f6-7222bdc097f5">45.1</ix:nonFraction> million in cash, has been operating in California since 1993, and is a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, Medicare, and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through <ix:nonFraction unitRef="plan" contextRef="i45ba50ac0812478a8bf374d9030b66b3_I20211231" decimals="INF" name="ameh:NumberOfFederallyQualifiedHealthPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTQwMDE5NzE_a47bfe56-394c-4a5d-8dda-60a013b90712">three</ix:nonFraction> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare, and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock they did not already own (comprising <ix:nonFraction unitRef="number" contextRef="i82f8e127a67545b3bdfa58cfd22513c0_I20190831" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyNTE0_95cc4058-1061-40f5-8ee2-1c781bc351a0">75</ix:nonFraction>%) for $<ix:nonFraction unitRef="usd" contextRef="i2f4a82d79e57442f9d6db8a9a608f3ff_D20190801-20190831" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyNTIy_629f5308-da29-4040-9e4d-6c180343c172">7.3</ix:nonFraction> million in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating in <ix:nonFraction unitRef="clinic" contextRef="ide47e2643c3c4ee5a76d35bfdd8a6db7_I20211231" decimals="INF" name="ameh:NumberOfFamilyPracticeClinics" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyNjE1_c1983def-355b-44b2-80e7-81533de27c55">three</ix:nonFraction> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its networks of doctors and nurse practitioners. In September 2019, APC-LSMA acquired <ix:nonFraction unitRef="number" contextRef="ia8e95cb40b2041898bc0dd250b3bf3a3_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyODY2_6b40bfd0-852e-44ff-863a-1ca73b31cf16">100</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of AMG for $<ix:nonFraction unitRef="usd" contextRef="i6eb95e4e08f44ee1bbc425d9152ac541_D20190901-20190930" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyOTQ0_bd6ed291-3dfd-444e-a15b-d3fc228d29b7">1.2</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="i971fe048ecb4482193d9bb6633606328_D20190901-20190930" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyOTU5_66f2bfff-e1a7-4021-883a-c14c938e60e6">0.4</ix:nonFraction> million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its <ix:nonFraction unitRef="number" contextRef="i38c118bd8bb54e4d9429b7ddcd63c503_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTQwMDE5NjA_b7968eec-e02c-4ace-9bc9-8d15c2c6b25e">40</ix:nonFraction>% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, has the ability to exercise significant influence, but not control over DMG&#8217;s operations. However, in October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="iaa8a8f6914b344759eab7b2e8596a641_D20210101-20211231" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTQwMDE5NTQ_0b18c766-f9a1-442d-aba8-2db1fec23571">three years</ix:nonNumeric> from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="i47097cefe18c427f8543ad5cd7663066_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTM5Nzk_fa7743a4-55db-4371-8ba2-725802128385">8.5</ix:nonFraction>&#160;million at December&#160;31, 2021. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="i8fb44b3ad67c4065a24264c841b2285a_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzY5NTg_44f5cfb7-3ff0-42bf-a01b-42b482591154">100</ix:nonFraction>% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a <ix:nonFraction unitRef="number" contextRef="iff99085ba68941a1a5742e3e59299a26_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzY5NjQ_36039ab4-aac6-436f-bbc2-d57a2e1e4d09">50</ix:nonFraction>% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants, as well as vacant land that they plan to develop in the future. MPP, AMG Properties, and ZLL are <ix:nonFraction unitRef="number" contextRef="i8fb44b3ad67c4065a24264c841b2285a_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzY5Njk_3f732b57-6214-45f9-9306-bd917037df5f">100</ix:nonFraction>% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate the accounting for the Company&#8217;s investment in Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i24492127451646cf9f116f8d85079c10" continuedAt="i2f1979543f0a4d8bb7de9671384208f7"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2 purchased an <ix:nonFraction unitRef="number" contextRef="i2bb290c80ed04d9284ae72a27d2b780d_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTQ1ODA_d9f80b33-4e73-452a-a351-a81037df4c39">80</ix:nonFraction>% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Apollo Medical Holdings, Inc. acquired <ix:nonFraction unitRef="number" contextRef="i6e863e59c64443d08c0faadab68620e3_I20210801" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTQ1NzY_bb685719-718a-4c24-84cf-51668fa85550">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTQ1NzI_53b60b2f-24e7-4ab9-8b92-7c4b1fd26ff5">4.0</ix:nonFraction> million. Sun Labs is a Clinical Laboratory Improvement Amendments-certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzcwMjc_e458a269-aa50-4e6e-ab43-986f96d2b287">three years</ix:nonNumeric> from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="ie58240bdc60b46879e56e7842cd94022_I20211231" decimals="-5" name="ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTM5NzE_f724b504-8ea2-4ca5-b19f-5ec2b4511c08">4.2</ix:nonFraction>&#160;million at December&#160;31, 2021. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f1979543f0a4d8bb7de9671384208f7">APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_124"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQx_426180ea-c9c7-4acd-b0c3-305299f003a0" continuedAt="i35c941f562d04429b8aa2eddcf79d9c1" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i35c941f562d04429b8aa2eddcf79d9c1" continuedAt="i5fdc960800b0411993b5367c2479f687"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUy_61cdeb6f-7152-4fd4-8fc3-c22e16f1ec06" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared by management in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU0_9cb51c38-9ffd-4b31-9109-56082f2742c7" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of December&#160;31, 2021 and 2020 and consolidated statements of income for the years ended December&#160;31, 2021, 2020 and 2019 include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY1_bd08c6e4-3bb2-410a-8aea-869f641856f7" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment, accrual of medical liabilities (IBNR claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors, and historical margins), income tax  valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ1_3fa4ef03-943b-4999-96a2-85031f5551d1" continuedAt="i9a4e51ac001a41a68c6d9276c5954ced" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by it in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements (&#8220;MSA&#8221;). To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i5fdc960800b0411993b5367c2479f687" continuedAt="ib9f629f2c06846828f93b37b7ff2ca3c"><ix:continuation id="i9a4e51ac001a41a68c6d9276c5954ced"><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company concludes that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 6 &#8211; &#8220;Investments in Other Entities&#8221; for entities that qualify as VIEs but the Company is not the primary beneficiary.</span></div></ix:continuation><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU5_30cf1bc5-003d-4610-8ea1-02bd10d7e9c2" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="ib9f629f2c06846828f93b37b7ff2ca3c" continuedAt="i80409ab07a664fb3b02f4b8c808f9c9a"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU2_3ae599a9-e4b3-40e1-84dc-d5fb7dcfebef" continuedAt="i221b5a7846b2476da324821ae4f70b37" escape="true">Reportable Segments</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i221b5a7846b2476da324821ae4f70b37">The Company operates as <ix:nonFraction unitRef="segment" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYzODg_8469423e-85d6-431d-a79e-73052ff9ddf4">one</ix:nonFraction> reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in <ix:nonFraction unitRef="segment" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzY2NjU_e9a81eb5-5bcd-4c79-a9fd-53d4c49827c8">one</ix:nonFraction> reportable segment.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDM4_24cc35b9-6111-412f-9f4f-1cb9148f6828" continuedAt="ifd70635b4f50414f8296f6b82f437913" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifd70635b4f50414f8296f6b82f437913">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</ix:continuation> As of December&#160;31, 2021 and 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzc4NTg_e9cbe513-a188-4b95-b5f4-046cb09127c1">285.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzc4NjU_8e2c23a4-c62e-4ecd-9980-d1ffc85931ee">294.9</ix:nonFraction> million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU3_b9e5e7d7-a648-4b4b-99da-ae27ab693624" continuedAt="i18b074845aef4015977a88e0935089b8" escape="true">Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i18b074845aef4015977a88e0935089b8">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</ix:continuation> </span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYy_19be3e6a-94e8-4011-8ad7-bc59d73bb9a0" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of December&#160;31, 2021 and 2020, investments in marketable securities were approximately $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzg2Njg_4dbba808-3316-4da0-b05c-8a4693263905">53.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzg2NzU_a7b5aecc-67fc-4577-8326-d83bf92518f4">67.7</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from <ix:nonNumeric contextRef="i843561394b2844a9b8120f9bad1daee3_D20210101-20211231" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2NTU_ce4cb9af-4339-4bc0-940d-d1c80b805aaa">four months</ix:nonNumeric> to <ix:nonNumeric contextRef="i56fd8a6fc7d245bdbb1e814caed96cee_D20210101-20211231" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2NzY_3a9cfc6b-6c02-4e4c-89af-0a2695103cef">twenty-four months</ix:nonNumeric> (see fair value measurements of financial instruments below). As of December&#160;31, 2021 and 2020, certificates of deposit amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i8d60f7810f154d9185d11b65f7a20684_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2MDg_38e12ae8-f90c-4d56-81d3-ffb881e12443">25.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5f06cfd6220a4db180cc0a47fb336fc4_I20201231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2Mjk_e54d2da6-314c-4ae5-ba53-984564e0d86f">67.6</ix:nonFraction> million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted-average share prices from observable market data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The common stock of a payor partner were acquired as a result of UCAP selling its <ix:nonFraction unitRef="number" contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2ODI_2c07a05a-0345-48c0-ae72-b3dd42d0e5ff">48.9</ix:nonFraction>% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. As of December&#160;31, 2021, the equity securities from the payor partner amounted to $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2NzA_94333efe-ecc5-4b23-9f41-528188dbc8c4">24.0</ix:nonFraction> million. As of December&#160;31, 2020, prior to our payor partner&#8217;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2ODY_6587b830-5e4e-43a0-ac14-d189470e6a36">36.2</ix:nonFraction> million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#8220;contingent equity securities&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="iac5f8642c01d4d23bd5b08e841100c8c_D20210901-20210930" decimals="-5" name="ameh:PaymentsToAcquireCommonStockAndWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk4ODQ_9f624d72-c51b-49a6-88f2-96a34544046e">3.0</ix:nonFraction> million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 - &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#8221; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognized unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk5MDM_b09bc795-d9ec-45cf-ba22-5a4ef6316ac6">10.7</ix:nonFraction> million during the year ended December&#160;31, 2021 in unrealized gain or loss on investments in the accompanying consolidated statements of income.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i80409ab07a664fb3b02f4b8c808f9c9a" continuedAt="i52ef4a943950410fb2290f04e0f97cad"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY2_958ad082-f1b9-499f-ab64-0e7caa8f0659" continuedAt="i32fec1b3b93b48fc895d457eeb9f491e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, management fee income, incentive receivables, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements and incentive receivables, management fee income and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s loan receivable - related party consists of promissory notes from payees that are expected to be collected between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5OTk_64bfc1bc-0468-44da-ae64-8adbf345015b">two</span> to <ix:nonNumeric contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231" name="ameh:AccountsReceivableExpectedToBeCollectedPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjMwMTg_0320ae9f-af8a-42c8-90ba-52e7760fee43">four years</ix:nonNumeric> and accrue interest per annum. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full-risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5ODY_0a674dc8-5dcd-486d-9b63-7286e99f767e">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, FFS reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32fec1b3b93b48fc895d457eeb9f491e">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.</ix:continuation> </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYw_656258e1-ba6c-4696-9de6-1a98f4a497de" continuedAt="ia62f30b632c44e2595209d1f7da6b54a" escape="true">Concentrations of Risks</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia62f30b632c44e2595209d1f7da6b54a">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts.</ix:continuation> The consolidated statements of income present disaggregated revenue by service type. <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUz_7898db7d-0dcd-4896-abdb-c58c39b0de68" continuedAt="i39ec3760955f4869b82247dc11838e55" escape="true">The following table presents disaggregated revenue generated by each payor type (in thousands):</ix:nonNumeric></span></div><div style="margin-top:17pt;text-align:center"><ix:continuation id="i39ec3760955f4869b82247dc11838e55"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.144%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.002%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2fdbacce1904cf3912b442f8c709d96_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzItMS0xLTEtMA_5546a221-f158-4efc-a0ca-ec24c7b47da1">138,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32f8e0c168ce444ca00cbd5129aa617a_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzItMy0xLTEtMA_5b2392ed-218b-4763-97ad-fa286318e8c2">108,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0587413f1c6a47c099219d283492a39a_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzItNS0xLTEtMA_7ce5dc71-caeb-4d3f-bdb0-3a956f4a7777">107,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16b60c8d266045aa80eb56cf8c52109f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzMtMS0xLTEtMA_51db2d11-7134-4113-82e7-18c283714685">307,286</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745de55cc97343cf9f5cd4dd3f327d33_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzMtMy0xLTEtMA_264d665c-f28e-4c3d-bcda-3c4806c833a7">271,596</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56c70a6d6fd1473aa3326d1e1d7c1a0b_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzMtNS0xLTEtMA_7e669411-9464-43ce-ab4c-6b8229f81cc5">226,002</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id30a014ea9a543089265dbe3894f75f9_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzQtMS0xLTEtMA_30bbfb58-49c5-41db-940f-ce3fb2db5e79">283,311</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bb08ba38e94f7bb612b424801b2a5c_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzQtMy0xLTEtMA_3ddbb0d5-4416-4007-9c59-24f0319e0fcf">269,079</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d8221e56424d85ab5b7cc79c7ebe1e_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzQtNS0xLTEtMA_fd94ed5b-55c3-4ced-ac47-f59b6675fa64">192,596</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third parties</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022a5fa7aae74c619acb43e67e97eda4_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzUtMS0xLTEtMA_96c9f81b-f3d6-410e-aaca-efc369431ff7">44,985</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2e545c192042c0a652056f20110ef6_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzUtMy0xLTEtMA_43b5a36e-257c-4eca-abfe-cd6b73bc6378">37,654</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8391dd985bc48f89be89e25c7043816_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzUtNS0xLTEtMA_256e8833-8935-47ba-9d5c-89b1c3bfd2db">34,680</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzYtMS0xLTEtMA_5b924c4b-551d-4f16-a05f-bc56881cd37a">773,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzYtMy0xLTEtMA_dbc09a1a-7c76-44c6-8111-7c70d1bffb6d">687,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzYtNS0xLTEtMA_2ed3be24-a2a9-483e-bbb7-98348dc2546e">560,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ3_81dd4573-812a-4162-873e-360cb2d3b525" continuedAt="i6584d5fdfaa2444bb550815202da8b0b" escape="true">The Company had major payors that contributed the following percentages of net revenue:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i52ef4a943950410fb2290f04e0f97cad" continuedAt="i961ad0981fff43e6b662a24a65d63242"><ix:continuation id="i6584d5fdfaa2444bb550815202da8b0b"><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9926274bc8d84660ae987c991d85aa80_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzItMS0xLTEtMA_c3a32d8c-fbcc-471b-9981-137e03a85996">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic4300a3b054a47eb9093ebb87d484b6d_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzItMy0xLTEtMA_a127c576-55fa-4f9b-bddf-9c63f75530c0">12.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic95b069367b24fd890ebdca632ea58eb_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzItNS0xLTEtMA_85b59674-a74d-46a4-901d-9fa1e1b063f5">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ce2f24276fa40f1bac2f8b82eb3561d_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzMtMy0xLTEtMA_47f4ecb0-138d-41b5-bc95-5841bfdab7d2">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c991f317b8a4c638731da2d2c41fbf7_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzMtNS0xLTEtMA_ac55de94-96d2-4991-b341-f051b971f6f9">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i943dfe63e2ab45ca9f085402af19715d_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzUtMS0xLTEtMA_4a421631-6dbd-4b9a-b2e2-61e9a6b89798">11.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fc1a4e79592432dbc61f090c132bdce_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzUtMy0xLTEtMA_e37f9a47-11dd-40f5-be02-f090421e31c6">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2ca388db64744f11a4ecfa00deef6721_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzUtNS0xLTEtMA_0f84895e-415c-4302-ba33-8527942bde1c">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i056d175194ad41b1a26e434846bc2bb8_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzYtMS0xLTEtMA_a4100da3-66ac-4f06-9a09-326a058d64d5">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic80816a284004c57bc9d57607f50fae6_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzYtMy0xLTEtMA_4cc99dba-b52e-49a6-b080-aa9261e6bbff">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idc61efd9b3fb4b72af24435b0ac021d3_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzYtNS0xLTEtMA_f48da1a6-00f6-4a3d-8eb2-191e19cbc7fb">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total net revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties :</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:73.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f42dcbfcf6e414f9c2f53ca2fd539fb_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzItMi0xLTEtMA_1e623e96-dd8c-4598-a3b6-dde8050c16e1">45.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib36036ab49044648a373020e6e50c5c9_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzItNC0xLTEtMA_86eb3e20-50a6-4436-9d7b-9378ec1648c0">43.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor F</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8b6bca11224045aab99c0deaf9679a62_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzMtMi0xLTEtMA_c1677e66-4e5e-4561-a830-cb6e69d8480b">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43b900167e4147608494071af8a327e5_D20200101-20201231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzMtNC0xLTEtMA_423208e9-8226-4743-978a-3de3dcc1b702">36.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ4_71795ca2-ba1c-4daa-9716-cfa8b0991d46" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Land, Property, and Equipment, Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMDk1_890dedd3-9639-4f3d-a087-9691ad4f5456">three</span> to <ix:nonNumeric contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMTAx_c7bdf9c4-75ab-438c-a4fb-ee58aa9b5b53">thirty-nine years</ix:nonNumeric>. Leasehold improvements are amortized on a straight-line basis over the shorter of the terms of the respective leases or the expected useful lives of those improvements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDM5_31f4b501-8fd5-45a0-a705-5116e84eaabe" continuedAt="i3de40fa08e164dcda3f2e34ac9365549" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i961ad0981fff43e6b662a24a65d63242" continuedAt="ib70a4184f0d44c999e75f629e21094ed"><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><ix:continuation id="i3de40fa08e164dcda3f2e34ac9365549"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></ix:continuation></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUw_db16492f-b6e0-45be-8812-13b90a61301d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021 are presented below (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtMi0xLTEtMA_c29c3b12-ef9d-44df-910d-d4422a31fa13">114,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtNC0xLTEtMA_b6d3f0bd-3ad6-4f29-8989-0a17f9d3fe4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtNi0xLTEtMA_eac7cad0-da30-4d22-85c4-5d60f8b6f9e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtOC0xLTEtMA_0c9dbaea-d772-4611-a1f3-5a640a09a2a5">114,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtMi0xLTEtMA_a8c5261c-e432-4045-aa41-e00c75da6f6f">25,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtNC0xLTEtMA_97b5a64e-6112-4801-b0b1-13fb042f19ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtNi0xLTEtMA_8a748026-a879-4d10-96bf-2bb4892f1186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtOC0xLTEtMA_56f7be8f-5d5f-47c0-81cd-9580ddb9dddf">25,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtMi0xLTEtMA_0afb0f42-a956-4611-9c57-304eca7e278f">24,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtNC0xLTEtMA_81617f2c-5b7e-4e82-a540-65dc291b33e2">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtNi0xLTEtMA_252473d4-a0e9-4193-b509-f083eaf917e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtOC0xLTEtMA_69b1f1d2-086d-45d3-83a7-36d1157e597c">28,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a462e81bf45445cb29240d95de98506_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtMi0xLTEtNTMwOTA_b24a0e41-1eba-4ccb-bbe1-4aaded4b1b4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1797fd6783dd4f6a8e55c48ac402e7d7_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNC0xLTEtNTMwOTA_41e66566-e7ea-46db-bc4f-8cdf744b11a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice50008825b6453b900419be6e538d60_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNi0xLTEtNTMwOTA_16023222-42a3-45aa-a462-35e35f9e66ec">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f29656902d24bac845ed6c3e1313c72_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtOC0xLTEtNTMwOTA_a28d4ca0-07e0-4726-b398-6223291097b5">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i724f9c4c78a84bb5b1cf0f0c80000aa7_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtMi0xLTEtMzUyODM_9ff52430-378b-4658-bf31-27bd591b59b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a44a937b1d142b3bfe3aa76130e4ed1_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNC0xLTEtMzUyODM_e346e88b-1484-4efd-bbc1-20316012f450">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0046d91fd144e69bc896e9a3d03eb3_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNi0xLTEtMzUyODM_4dc524c8-41ce-4a0f-89bd-40c1d9d9682c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb3ead10c02740de85a4ae1939f70f28_I20211231" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtOC0xLTEtMzUyODM_aa318c2b-5328-4022-ba5b-21e11e676f16">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctMi0xLTEtMA_05830bdc-c5a4-4f99-be8c-260eaa58247b">163,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctNC0xLTEtMA_ebc1b2e5-2324-4baf-8e65-3e885be94dcd">5,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctNi0xLTEtMA_bddfcca9-0d80-4b08-914d-2c3732842b5f">4,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctOC0xLTEtMA_67d9fb28-bbc3-4c7a-aa44-8828ee31d64f">173,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTItMS0xLTM1OTQw_bc42dc28-f2e5-4562-8a6b-22c0e9093250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTQtMS0xLTM1OTQw_502467ef-ecfe-445f-ae95-718bfeedecd2">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTYtMS0xLTM1OTQw_456fccbb-9033-4a9b-8f4a-8c3240e47239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTgtMS0xLTM1OTQw_be701af8-bab8-4e58-bba2-43101f525257">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTItMS0xLTM1OTQw_de7a41d0-bcc7-43d8-9ea2-c9b93aa52ed3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTQtMS0xLTM1OTQw_39a04386-4b3f-4668-b513-4231d3d8044e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTYtMS0xLTM1OTQw_687d70c5-215d-4a2a-8d74-3da03ea3dd56">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTgtMS0xLTM1OTQw_035088a4-2f6e-4a81-8295-e8c162122793">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTItMS0xLTM1OTQw_1291d9a5-8e29-4c7b-972e-4f4e6c308cd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTQtMS0xLTM1OTQw_39663233-6d40-4d74-94a2-02a221c8aef5">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTYtMS0xLTM1OTQw_43d5283b-bd11-48c7-b0dc-dbd092804f9a">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTgtMS0xLTM1OTQw_d59df8d8-ebe1-4dd2-bf70-497c1ee6dc47">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020 are presented below (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.098%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtMi0xLTEtMA_1549e8c7-9183-4b28-8f04-5ffb19336f89">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtNC0xLTEtMA_1901292d-8ee1-4c61-9d19-56ad9a6b7c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtNi0xLTEtMA_3f914980-27be-4603-afb3-c03a88d6d04b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtOC0xLTEtMA_2823d9fa-1c12-4d54-891b-f834da00b5de">115,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtMi0xLTEtMA_7651e59b-5731-4692-b94c-332ed6a12bf5">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtNC0xLTEtMA_230380fa-e443-4187-af1a-917afc54ef91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtNi0xLTEtMA_9d62f5dd-d56f-429f-82a6-cd6d4d271214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtOC0xLTEtMA_0b52df7b-700c-4841-8748-37d5f6b6da3f">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtMi0xLTEtMA_d3c47864-0a77-4905-bc40-6baac845d70e">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtNC0xLTEtMA_497cd5e1-edec-4ef1-a861-a57c97efd2a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtNi0xLTEtMA_dc2fd3a8-660d-4312-b6bd-61ece7fcc765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtOC0xLTEtMA_a69d7040-5ae0-40e7-8174-cd2d2b6ae72d">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctMi0xLTEtMA_921a345e-66bd-4e74-bebd-fde788ccdd84">183,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctNC0xLTEtMA_2c148842-788c-477e-8c99-8f22eef12ebd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctNi0xLTEtMA_119c85c8-94d0-46ef-8334-274698319d93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctOC0xLTEtMA_c9f66049-ce89-4116-bbcb-bc42b4f6479e">183,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:31pt">Included in cash and cash equivalents</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the year ended December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYz_4c648f0f-1749-4360-b572-bace857cde67" continuedAt="i6bd42758aa6448fb8a22815468f56380" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, and member relationships and are stated at cost, less accumulated amortization, and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization, and impairment losses, and are amortized using the straight-line method.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6bd42758aa6448fb8a22815468f56380">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="ib70a4184f0d44c999e75f629e21094ed" continuedAt="i366ab66e95bd407b9c641fe565f22b2f"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU1_e21027ca-daf3-41e0-80dc-83b97fc27d66" continuedAt="i5d913bec93cb48c2bcb4d97df2938888" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 350&#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s <ix:nonFraction unitRef="unit" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE4MDgy_98cf7b9f-88d5-4632-bd0b-536f498b9abd">three</ix:nonFraction> reporting units (1) MSOs, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5d913bec93cb48c2bcb4d97df2938888">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</ix:continuation> <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2019, the Company wrote off indefinite-lived intangible assets of approximately $<ix:nonFraction unitRef="usd" contextRef="i015c75fcf61d4986bcc5f227b6c412de_D20190101-20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5NTAz_6b9edfef-247a-41b3-9580-b52ea7a0245b">2.0</ix:nonFraction> million related to Medicare licenses, acquired as part of the 2017 Merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom. The write-off is included in impairment of goodwill and intangible assets in the accompanying consolidated statements of income. There was <ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_3a4d9bd2-30bb-41c5-ae06-87d54c23f6ee"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_7e3120c8-6608-4f95-a4d3-7404e957db55"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_c53a5281-0b5f-45dc-b67a-8ff0e68f6e78"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_e7796800-1cb0-4d29-9efa-75eaae8212f9">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment loss recorded related to goodwill and intangibles during the years ended December&#160;31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUx_82935112-09b6-4c0c-8a29-3a0e36fbba29" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8211; Equity Method</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are subject to impairment evaluation. During the years ended December&#160;31, 2019, the Company recognized an impairment loss of approximately $<ix:nonFraction unitRef="usd" contextRef="i62aa39d44086415d845d34f0d7dc7a73_D20190101-20191231" decimals="-5" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzIxMTcy_6fdb310d-293d-4e9a-82a0-d113cd1f95bb">0.3</ix:nonFraction> million related to its investment in Pacific Ambulatory Health Care, LLC as the Company does not believe it will recover its investment balance. Such impairment loss is included in loss from equity method investments in the accompanying consolidated statements of income. There was <ix:nonFraction unitRef="usd" contextRef="i144871d547d04bfcb5651aa2b05ed3f2_D20210101-20211231" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzIxNDE4_c5f47e1f-5aad-40b6-95d7-aef7f812fb6c"><ix:nonFraction unitRef="usd" contextRef="iba8abaa0013749f6a54d7e3495c4052d_D20200101-20201231" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzIxNDE4_f7b59d94-9c9b-4b42-97cc-987676df3b61">no</ix:nonFraction></ix:nonFraction> impairment loss recorded related to equity method investments for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY3_35fa464e-d834-4e6d-8478-9f42a5b039b2" continuedAt="i7cd51f154caa4784abcbe71266292993" escape="true">Medical Liabilities</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i366ab66e95bd407b9c641fe565f22b2f" continuedAt="i1984a52e24f948749035be84ee4aac35"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7cd51f154caa4784abcbe71266292993" continuedAt="i12f2dba5c8e74839a5b264e143cb7c28">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. The consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.</ix:continuation></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i12f2dba5c8e74839a5b264e143cb7c28">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:FiduciaryCashAndPayablePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2ODg_2b45e38a-6a8e-4d4b-91fb-37c82bd4bcac" continuedAt="i2ce91586a32d467aaf9f17ea7e36aa5e" escape="true">Fiduciary Cash and Payable</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2ce91586a32d467aaf9f17ea7e36aa5e">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ix:continuation> The fiduciary cash balance of $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI2MDQ_227188fb-7dcc-4906-a586-fd5a3eb75c74">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI2MTk_7d6e69d8-6147-409c-8b5c-87e010f6ef6f">9.6</ix:nonFraction> million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2ODk_91be1f33-7987-4894-96f8-cc01ca9d7de6" continuedAt="i8186ca172bf6455d9c99a2a875ea08ba" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 10 - &#8220;Credit Facility, Bank Loan, and Lines of Credit,&#8221; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of December&#160;31, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i04a8b2897992491a9bba33dd880b5e6f_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI3Mzc_afbc67a9-ee51-46ad-a73f-5c8aa55b1325">1.1</ix:nonFraction> million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement which included the Company purchasing warrants. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI4Mzc_401bcf6e-5fa4-483e-ba17-4abd645bd9dd">1.1</ix:nonFraction> million and is presented within other assets in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The Company determined the fair value of the contingent equity security using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i1984a52e24f948749035be84ee4aac35" continuedAt="i3673c6ad347848f5b5f49c9bc0e939ff"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8186ca172bf6455d9c99a2a875ea08ba">considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $<ix:nonFraction unitRef="usd" contextRef="i9f29656902d24bac845ed6c3e1313c72_I20211231" decimals="-5" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE3MTE2NDQ_06a10e6e-2bd0-4019-a7bf-1a3db239c2e6">4.3</ix:nonFraction> million and is presented within prepaid and other current assets in the accompanying consolidated balance sheets.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQy_8e0e1610-5ba0-4ffd-baf7-a58c3e64c280" continuedAt="ie1e295ac340a4f4ba711a580e240c342" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. The Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company&#8217;s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of <ix:nonNumeric contextRef="i9f20c7ee23624be2a07a0c15e0ad0c80_D20210101-20211231" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzI4NjQ1_43f41697-22ca-4bda-8e9b-1bc7d70f77b9">one year</ix:nonNumeric> or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i3673c6ad347848f5b5f49c9bc0e939ff" continuedAt="i0bc6193381b2424c909159015a7958b5"><ix:continuation id="ie1e295ac340a4f4ba711a580e240c342" continuedAt="ibb6105fdd95045fca9883ca020585e19"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions on factors, including but not limited to, historical margin, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared-risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk-share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MDUx_13452d7a-ce48-4cb1-9932-b9a62aad18dd">two</span> performance years through December&#160;31, 2019, which was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MTA3_7004a731-22ef-4a6d-af57-dbde08754dca">two</span> additional renewal years through December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company submitted to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company obtained CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i0bc6193381b2424c909159015a7958b5" continuedAt="i27871214f8cb4f28a2e0cc40a108112b"><ix:continuation id="ibb6105fdd95045fca9883ca020585e19" continuedAt="ie5eb32711c7e43a69f89e8e014504261"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk-share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency, in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 9 - &#8220;Medical Liabilities&#8221;), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there was any excess AIPBPs for the performance year and the excess is refunded to CMS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within <ix:nonNumeric contextRef="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM3MzU0_fa8739a8-edf3-4579-a81a-49aaa547222e">30</ix:nonNumeric> days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within <ix:nonNumeric contextRef="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM3NjE0_98051a56-25d0-498b-a025-56678ce3d3a5">30</ix:nonNumeric> days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within <ix:nonNumeric contextRef="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM3NzM3_98051a56-25d0-498b-a025-56678ce3d3a5">30</ix:nonNumeric> days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared-risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit for the performance year and therefore this shared-risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="ameh:RiskPoolSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM5MDU1_aad9ede4-a96e-440e-aff2-f71c9690e2fa">21.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-5" name="ameh:RiskPoolSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NjY3NDM_0a72e636-8ea8-454a-b5a8-6fe4db28e897">19.8</ix:nonFraction> million in risk pool savings, related to the 2020 and 2019 performance years, respectively, and has recognized such savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be eligible in receiving AIPBP under the NGACO Model for performance year 2021, with the effective date of the performance year beginning January 1, 2021. For performance year 2021, the Company received monthly AIPBP payments at a rate of approximately $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="ameh:PaymentOfRevenueMonthlyAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM5ODIz_c80292cd-02d1-4a9d-84f0-e325df42329f">7.7</ix:nonFraction> million per month from CMS. The monthly AIPBP received by the Company for performance year 2020 was approximately $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="ameh:PaymentOfRevenueMonthlyAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NjY5ODU_a622e132-7077-4537-b5dd-6d637b09a3ea">7.2</ix:nonFraction> million per month. The Company has received approximately $<ix:nonFraction unitRef="usd" contextRef="id558792183dd45c2a570c57e2912737a_D20210101-20211231" decimals="-5" name="ameh:PaymentOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQwMTkz_13acfef4-b215-4c7e-939b-58906a304678">92.4</ix:nonFraction> million in total AIPBP for the year ended December&#160;31, 2021 of which $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="ameh:PaymentOfRevenueRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQwMjQy_07be0074-0fc8-420e-82a2-845aead33e68">59.2</ix:nonFraction> million has been recognized as revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i27871214f8cb4f28a2e0cc40a108112b" continuedAt="i2a334c1531d74e91b9855bd12a6b8403"><ix:continuation id="ie5eb32711c7e43a69f89e8e014504261" continuedAt="i6533555032d7440f93597534231429a3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors, such as hours staffed, patient visits, or collections per visit, against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., <ix:nonNumeric contextRef="i612cc8b6b50c4dd986466df93d1b6382_D20210101-20211231" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQyNjU5_418b6cb2-3efa-4759-9eae-49736a06565c">ten years</ix:nonNumeric>), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients, and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i2a334c1531d74e91b9855bd12a6b8403" continuedAt="i09c3591c22ba430a9717245ff08e563c"><ix:continuation id="i6533555032d7440f93597534231429a3" continuedAt="i39f2ffd8c65e4948bf10886155d2c1f6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company does not have any contract assets since all obligations have been performed when revenue was recognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39f2ffd8c65e4948bf10886155d2c1f6">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</ix:continuation> As of December&#160;31, 2021, the Company&#8217;s contract liability balance was $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQ4OTc4_67879eb7-12b9-4c19-8ad9-38bae44b2fec">16.8</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="i332f5bcb413946b09f9ee77d790f9a78_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQ4OTkx_d9d172d1-247a-484a-9d1e-6a3dcc592264">16.3</ix:nonFraction> million was related to the Company&#8217;s NGACO. Contract liability was $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3Njc4NzQ_636c169a-d5b6-4f3a-ae24-a10b3136f006">13.0</ix:nonFraction>&#160;million as of December&#160;31, 2020, of which $<ix:nonFraction unitRef="usd" contextRef="i86e83dd845b24aafb3a23652cf069056_I20201231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3Njc4ODE_799da796-e345-46ac-9a3c-13415a68efa0">12.6</ix:nonFraction>&#160;million was related to NGACO. Contract liability is presented within the accounts payable and accrued expenses in the accompanying consolidated balance sheets. Approximately $<ix:nonFraction unitRef="usd" contextRef="id558792183dd45c2a570c57e2912737a_D20210101-20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQ5MjU2_1e9a649a-370d-4e58-aedc-d2c74b3880ee">0.4</ix:nonFraction> million of the Company&#8217;s contracted liability accrued in 2020 has been recognized as revenue during the year ended December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY0_15867157-3b18-48cf-9279-cc36a65b86b8" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQz_92024f40-377e-4302-96d1-f29744b311b6" continuedAt="i7d5beddcbc724dccb021aee8f55cbdea" escape="true">Share-Based Compensation</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i09c3591c22ba430a9717245ff08e563c" continuedAt="ic4ab8aee3efe4823b7279369e3d896d4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7d5beddcbc724dccb021aee8f55cbdea">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</ix:continuation></span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYx_55bc0846-750d-41ab-ab95-c222a2b97063" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to the holders of the Company&#8217;s common stock by the weighted-average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted-average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 17 &#8212;  &#8220;Earnings Per Share&#8221; for a discussion of shares treated as treasury shares for accounting purposes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:MinorityInterestPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ0_c3b49834-41ee-4be8-872c-441a85184651" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than <ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzUyMTg2_f60390d1-9a26-4fde-9559-17c99f90d69a">50</ix:nonFraction>% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:TemporaryEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU4_1d215ef6-5fb8-499d-a031-1686c84be58f" continuedAt="if7689b9a1ad148729abe75b2ecbd11f6" escape="true">Mezzanine Equity</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if7689b9a1ad148729abe75b2ecbd11f6">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements.</ix:continuation> As of December&#160;31, 2021 and 2020, APC&#8217;s shares were not redeemable nor was it probable the shares would become redeemable.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQw_7b8e2192-e343-425c-966a-7274526ce4d8" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and ROU asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under twelve month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="ic4ab8aee3efe4823b7279369e3d896d4"><div style="margin-top:10pt;text-align:justify"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:BeneficialInterestPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMzAzNjk_93404ca9-bed9-4e86-9cf9-fd87c486f8a2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a <ix:nonFraction unitRef="number" contextRef="icd3bc75cd44b41e18d64665e42101205_I20200430" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1Mzg_1e2d2e70-7f01-433e-a6a2-0417b2c39b25">100</ix:nonFraction>% owned subsidiary of APC, sold its <ix:nonFraction unitRef="number" contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1NDY_98c7dd62-55ce-4824-bf97-90c3b47c2461">48.9</ix:nonFraction>% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020 was&#160;$<ix:nonFraction unitRef="usd" contextRef="i2125de0047684f7088debca1f678a717_D20200401-20200430" decimals="-5" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1NjM_6d67a8a6-208e-46cb-94b6-1c5b24533eeb">15.7</ix:nonFraction>&#160;million and was included in other assets in the accompanying consolidated balance sheets. The beneficial interest was the result of a gross margin provision in the stock purchase agreement, which entitled UCAP to potentially receive additional cash and preferred shares (cash of $<ix:nonFraction unitRef="usd" contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430" decimals="-5" name="ameh:EquityMethodInvestmentSaleContingentConsiderationCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1OTg_c5afd403-856f-4090-be11-daa9fce97cff">15.6</ix:nonFraction>&#160;million and preferred shares with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430" decimals="-5" name="ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1Njk_216d532e-ba24-49d3-bc97-fa2f3895de3a">6.4</ix:nonFraction>&#160;million, total estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430" decimals="-5" name="ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1ODM_86ceb07f-d47a-44b6-9b11-110d2650da56">22.0</ix:nonFraction>&#160;million on the date of sale, were held in an escrow account) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varied dependent upon the gross margin as compared to the target but cannot exceed the amounts that were in the escrow account. Additionally, the stock purchase agreement included a tangible net equity provision that could have resulted in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. The Company determined the fair value of the beneficial interest using an income approach, which included significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value, which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment was defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $<ix:nonFraction unitRef="usd" contextRef="i2125de0047684f7088debca1f678a717_D20200401-20200430" decimals="-5" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ2MjY_6d67a8a6-208e-46cb-94b6-1c5b24533eeb">15.7</ix:nonFraction>&#160;million was written off and expensed in other income in the accompanying consolidated statements of income during the year ended December&#160;31, 2021.</span></ix:nonNumeric></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY4_99e2ce53-8e5b-4f61-a2fc-48414285e347" escape="true"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMzY4Njg_2bbf2363-1bf6-4661-9945-b3063cf3b5d4" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently assessing the impact of that adoption of ASU 2021-08 will have on the Company&#8217;s consolidated financial statements. <br/><br/>With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_2103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTYyNDQy_8d76b077-dab4-4353-b0d6-f17f5251017b" continuedAt="i86204976f5a64e4e927b31fc72205669" escape="true">Business Combinations and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i86204976f5a64e4e927b31fc72205669" continuedAt="ie8d81b28fe4b4c0d8ffd8bc7ea411f56"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company acquired an <ix:nonFraction unitRef="number" contextRef="i2bb290c80ed04d9284ae72a27d2b780d_I20210731" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzMx_d9f80b33-4e73-452a-a351-a81037df4c39">80</ix:nonFraction>% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i1ee954aec3cb404a92c9fa15cd03d7f5_D20210731-20210731" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3Mzk3_8304f57e-db49-4c9b-806e-68a304440cdf">2.0</ix:nonFraction> million. As part of the transaction, the Company paid $<ix:nonFraction unitRef="usd" contextRef="i1ee954aec3cb404a92c9fa15cd03d7f5_D20210731-20210731" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzQ2_a94a7624-5e12-4ca8-a6a1-e0828f218492">1.0</ix:nonFraction> million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#8217;s financial performance for fiscal year 2022 (&#8220;APCMG contingent consideration&#8221;). The APCMG contingent consideration is met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#8220;EBITDA&#8221;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $<ix:nonFraction unitRef="usd" contextRef="i839af06b2bf7483780595e14fb317ba9_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzYx_1007b08e-89bc-4d47-b3a5-c0d3dd9d1d45">1.0</ix:nonFraction> million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company acquired <ix:nonFraction unitRef="number" contextRef="i6e863e59c64443d08c0faadab68620e3_I20210801" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzI1_bb685719-718a-4c24-84cf-51668fa85550">49</ix:nonFraction>% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzE5_53b60b2f-24e7-4ab9-8b92-7c4b1fd26ff5">4.0</ix:nonFraction> million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="if75a131bd7e744b5a823cd87fdb684fe_D20210801-20210831" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTYyNDU5_8ccd2a48-5d40-4391-b1ab-24acd4a27006">three years</ix:nonNumeric> from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DMG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within <ix:nonNumeric contextRef="id201e64241bd4df388bd1b11f4019ca1_D20211001-20211031" name="ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTczNTIx_95d49a5c-828f-4b9e-b40d-c793e4afbbaf">three years</ix:nonNumeric> from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of APCMG, Sun Labs, and DMG have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie8d81b28fe4b4c0d8ffd8bc7ea411f56"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTYyNDQz_671a4c0d-48c5-4ebf-ab89-532c2b2ec78c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of goodwill activity for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN18yLTEtMS0xLTM2ODc2_75984b42-3079-4f87-8d6e-93e0df9b120e">238,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN18zLTEtMS0xLTM2ODc2_95dde043-d68f-4752-8b78-8d08a450b3f7">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN180LTEtMS0xLTM2ODc2_01f4c9aa-969a-4c64-a4d8-345b4ae52990">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN181LTEtMS0xLTM2OTIw_0e0a0e76-3976-49d6-b661-d1a0b8f037c3">13,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN182LTEtMS0xLTM2ODc2_e022cee6-b25a-4885-b6e1-e8ab5c1867a0">253,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_136"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzEzMzU_c971e637-8a3e-4e5a-8e96-6efe82100f66" continuedAt="i6f76c088a1e5495482a5cb65bb5cdfe5" escape="true">Land, Property, and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="i6f76c088a1e5495482a5cb65bb5cdfe5" continuedAt="i7771786fb1d54a9abe7a41cda8df6942"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzEzMzY_7d91630f-762b-4e78-b454-8c38045afc33" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land, property, and equipment, net consisted of (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51111a66dda4ebb9aba6212e6167b7f_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzItMy0xLTEtMA_8ff543a5-4b51-4b74-9f0a-cdde73096af0">20,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia31747ce9de543bc82b00188c7aa83e7_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzItNS0xLTEtMA_2470a8e8-fc00-4ca1-9200-a0c72a72165b">9,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0b2e1de018d94f24b2a76496127751c1_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzMtMS0xLTEtMA_d871d5ee-0ff8-4b09-b448-5e6725fd9731">39</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e99a95143da4c8eaf2dd4d3559ccdbc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzMtMy0xLTEtMA_90ae3882-aac3-4baa-b764-986c723c808e">21,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5051abc09bc4fa69a0f957f3c5b0241_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzMtNS0xLTEtMA_a5d1dd1b-f9b6-4109-b55a-86ede47a7ed5">15,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie4f0ad5790334506970900a82f46c08f_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjdhZmIxNTQyMmNhMzQ2YWU4MjQwMGIwN2E3ZDI0NjNjXzQ_5101f659-fad5-4219-9a59-add06b216022">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i487033aa27ad4f9b9271e75aa8aa3a91_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjdhZmIxNTQyMmNhMzQ2YWU4MjQwMGIwN2E3ZDI0NjNjXzk_ddb23984-c33e-46c9-80a4-5f8a0ff82fb0">5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaff2efa428034a01ba020fb02de6fc10_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtMy0xLTEtMA_ff33bf9e-1f27-4781-af86-edfd964d82b7">3,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifea711226dc146e9810f79de10c986d4_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtNS0xLTEtMA_a36c3dc0-fb8c-4f3a-ad01-00486076e532">3,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9c77143a62554eab971843dd2d16ee2a_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmZiMzBlOWQ0MjA0ZjQ2OWI5NDU0M2I4MzY3YmQ3OTkwXzQ_96727fe5-d4e0-4c81-8b76-6b1b263a97b4">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i27538f0196b542fc85d8c25bf235059d_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmZiMzBlOWQ0MjA0ZjQ2OWI5NDU0M2I4MzY3YmQ3OTkwXzk_8f92f411-74a1-43be-a1da-adae3006c76c">7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c3bdf2fd4b4890ae012255fe841f5d_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtMy0xLTEtMA_af0e3a3b-5ec9-4d54-999f-abfd07198148">15,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024a6dcb30a242cb813e9f1ccb581b12_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtNS0xLTEtMA_69d56dac-00ff-4667-8a50-dce338a10dd7">13,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i676fdea1181f4e9193158b995298022b_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzYtMy0xLTEtMA_c4c4d2b0-d56c-4c91-85e0-d51c83dee4f0">4,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53efa605f72144cf9c19b468aa9c14af_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzYtNS0xLTEtMA_92639b8b-1565-4170-b92f-058bf153d535">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2582d81f93dc42f1a148af1c328393bb_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctMS0xLTEtMC90ZXh0cmVnaW9uOjkyYTY5MzhhYmE2NzRmYjk4NzBiMTMwMGRlZDA1MmUxXzQ_6c716e2f-9932-4dd4-9fef-d50036f6a61b">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i88445e03e6ca41139c3da34cf3553c19_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctMS0xLTEtMC90ZXh0cmVnaW9uOjkyYTY5MzhhYmE2NzRmYjk4NzBiMTMwMGRlZDA1MmUxXzk_6e6f129f-2293-4263-8aa6-e59bce851a0e">39</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf6b316b9ec34ba09028e2941bda64c2_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctMy0xLTEtMA_c48caf8a-22e0-403f-8b50-7014b4f9be5a">7,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b75bb3419b74b6db04ab86aac159bb2_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctNS0xLTEtMA_d7d7be2b-dad9-4ac1-bb04-7a7cd5393acd">6,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzktMy0xLTEtMA_fdb80711-aec9-43fe-b174-d24af883a9a4">73,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzktNS0xLTEtMA_bfe010e3-8467-4e9e-b3c9-606eac142ed9">48,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzExLTMtMS0xLTA_0cec4cd3-d9df-4cec-aa3c-00f54786e95a">20,382</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzExLTUtMS0xLTA_a77922c0-1a66-45e8-9e00-50f8693cad8e">18,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzEzLTMtMS0xLTA_4fec9ca3-e7e1-409d-ade4-362a78ed1c1a">53,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzEzLTUtMS0xLTA_8a829b91-923d-4024-a855-37ef8fb7c581">29,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had finance leases totaling $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzE2NA_a3878f45-4b46-4af2-8ce1-453e0810dc34">1.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzE3MQ_93a8d47c-a2e4-487e-b409-be4d2a1aa6dd">0.4</ix:nonFraction> million, respectively, included in land, property, and equipment, net in the accompanying consolidated balance sheets.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><ix:continuation id="i7771786fb1d54a9abe7a41cda8df6942" continuedAt="i51fc0a903dc543819cb39baa1030c900"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzMwOQ_0cdd7fe4-7a71-4e98-9d70-fb4834a9c19e">2.1</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i51fc0a903dc543819cb39baa1030c900"> $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzMxMw_0f4da910-b6e1-45af-8141-b9125159dbd3">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-5" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzMyMA_b4b29705-8cac-4667-828f-e04032b2c598">2.0</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020, and 2019, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income.</ix:continuation> </span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_139"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgzMQ_c648c200-6037-4d07-8c2e-1563d16638a0" continuedAt="i80990f5a9ddb4ee08aafe976a2b91c2b" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="i80990f5a9ddb4ee08aafe976a2b91c2b" continuedAt="i6da414bcea364b31b1a43f1de360afc0"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgyOQ_6af7fcb7-71e5-4f67-ac39-a4b7e8790345" continuedAt="ib988b4d98a124512ba148f28d119a7c9" escape="true"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgzMg_71a7eb1e-8862-48f5-b6bf-086dca249d09" continuedAt="i50c2a7ba6df64f35bb2df4973584a0bb" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4cabdf561f47f68984b36789e4965c_I20201231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMy0xLTEtMzgyNjk_a9ad7429-af1e-4f47-b65c-937ab3ba5867">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42823650eb854b4f9ee2477d31236773_D20210101-20211231" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNS0xLTEtMzgyNjk_4a9d4b3f-fb7d-447c-a3e5-e9634807a9ed">2,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42823650eb854b4f9ee2477d31236773_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNy0xLTEtMzgyNjk_cecb69ab-0fea-4ffc-ac15-afd081f516c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13a44368edd4777a7c9cfc306a21f2d_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItOS0xLTEtMzgyNjk_1bdd7b57-3cde-4c6d-a483-8d4c6edb7311">2,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib13a44368edd4777a7c9cfc306a21f2d_I20211231" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMTMtMS0xLTM4MjY5_60ad6736-9813-44f1-8f86-cb7f60e60653">2,150</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6d8e768a8482425ba021a05970238a2f_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY1YTc3MWYxMTc0NjQxNGJiZGQ4MGY2YzRlNDFkYWQzXzQ_23d62e82-cdec-45a5-bbf3-b679972e3cf9">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i008c29b02c5e4ce5a69883a33d891ded_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY1YTc3MWYxMTc0NjQxNGJiZGQ4MGY2YzRlNDFkYWQzXzc_4b91ef55-c9ed-4743-a1b3-5bb20d735419">15</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMy0xLTEtMA_1c87a8b1-35df-4ebf-9e3b-f3ab1d62c45e">143,930</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNS0xLTEtMA_a603b0f5-bcc0-41e4-94be-8038547c9c49">6,749</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNy0xLTEtMA_05b0f68f-e9a6-44d7-8894-1623d1b1db40">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdc0c8a020740599e30d4e0c3298af2_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItOS0xLTEtMA_8a54b6e1-b4e8-4bde-9df2-de54dbbfb1b2">150,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cdc0c8a020740599e30d4e0c3298af2_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMTEtMS0xLTA_8e558860-25f9-4377-8297-0331180db034">84,865</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdc0c8a020740599e30d4e0c3298af2_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMTMtMS0xLTA_26a42293-3060-45ab-91f3-fe6c650ffcd6">65,814</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMS0xLTEtMA_582d129f-cf1e-47ff-9a26-39493c12ad72">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMy0xLTEtMA_93063574-0ef3-4afa-b4df-f5da484e15e0">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtNS0xLTEtMA_d7fb117f-6cdb-498a-8428-b4a68f0ea422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtNy0xLTEtMA_30f96a20-90fc-4bf6-b5b5-521fd247b09c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7fa92aa24446d18fe184c6400b9ba3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtOS0xLTEtMA_2dedbb13-ce07-478a-84bc-4992358b14fa">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab7fa92aa24446d18fe184c6400b9ba3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMTEtMS0xLTA_10159ef3-efc6-406f-a8a2-077dc08bc8ca">13,563</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7fa92aa24446d18fe184c6400b9ba3_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMTMtMS0xLTA_8c32b23c-e4da-4494-aaf1-7ea5e01b8e0e">9,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMS0xLTEtMA_1d6375a5-8b1e-44d8-8b40-c0e378f38810">12</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMy0xLTEtMA_9d6c5257-6d51-4ae3-b895-6adf00d747b6">6,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtNS0xLTEtMA_0fd30855-fea0-421f-9034-e9eee6c22fb2">2,301</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtNy0xLTEtMA_6dd6a72d-d8b8-49bb-a076-7c693c940e09">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtOS0xLTEtMA_1325898a-b322-4eba-aa37-d0b3773cc8dc">8,997</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMTEtMS0xLTA_6bef57d5-7bc2-4125-8da0-6c8393f4826f">4,606</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMTMtMS0xLTA_ff4ef54f-b68f-4cf6-9609-23203ac6d020">4,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMS0xLTEtMA_562f28a8-425a-4644-8d29-7185388817e8">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMy0xLTEtMA_79d3fb1f-79cf-4409-b121-ae3de6a3fc7a">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtNS0xLTEtMA_b0e4584b-7573-4a10-91d2-f5bd8060ef84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtNy0xLTEtMA_360e0140-5f04-4e2c-9ba9-22ae0de9935d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtOS0xLTEtMA_541f9c9c-1f5e-4a6b-ba18-a53e36cfdb1e">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMTEtMS0xLTA_c9ec5497-d164-4360-accf-48b8ab739832">1,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMTMtMS0xLTA_a471e4cf-a3b7-40c8-b2fe-076e3cba6bd7">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMS0xLTEtMA_6f8ff2a1-d156-4fcc-801a-bcb9883573d8">20</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMy0xLTEtMA_5e9b1d0d-9e0f-4e5f-b657-e764a80ae2a4">1,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtNS0xLTEtMA_832fb8eb-f960-4885-847b-ec2873a0b75e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtNy0xLTEtMA_6d2f2d8b-fcee-4e7e-a79c-78313e342593">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia464591a552f4ad4a88bc800875941fc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtOS0xLTEtMA_5bb183ce-1ce2-4786-91cf-f4efdfde6630">1,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia464591a552f4ad4a88bc800875941fc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMTEtMS0xLTA_a1869fc8-cb4b-4822-bf57-ae7a5bca46a9">206</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia464591a552f4ad4a88bc800875941fc_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMTMtMS0xLTA_3178d6f8-0be3-45e7-baa3-00245dbaf117">805</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctMy0xLTEtMA_18a1c350-83f3-4204-99a8-09a98b73413e">176,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:FiniteAndIndefiniteLivedIntangibleAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctNS0xLTEtMA_dd719470-a90a-44e0-8f94-00cc1ec8425a">11,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctNy0xLTEtMA_1c756da4-5328-433c-b0d2-3c483938f620">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctOS0xLTEtMA_3cc6216f-f6c7-40bc-8537-a9ba0af2d6cb">187,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctMTEtMS0xLTA_e2e0be01-da13-41cb-89fd-4ebe59b043c6">104,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctMTMtMS0xLTA_20fba9ef-ca9e-4cc6-915a-f17b3a181a32">82,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i6da414bcea364b31b1a43f1de360afc0"><ix:continuation id="ib988b4d98a124512ba148f28d119a7c9"><ix:continuation id="i50c2a7ba6df64f35bb2df4973584a0bb"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:19.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if9eee87a655349b195602787d695ad5b_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzOTczNmQ4ZDJjYjQyZDE4ZTdkMTBlNmI1NzljNjU0XzQ_ad617aca-6ea1-4a34-a155-5f8725e3beba">11</ix:nonNumeric>-<ix:nonNumeric contextRef="i40c3a0315be548acb27758e893a56720_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzOTczNmQ4ZDJjYjQyZDE4ZTdkMTBlNmI1NzljNjU0Xzc_d9b42f8a-4f8f-4773-82f2-b29a3fc68915">15</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749dc1caa7f94b5a8d9ae541374197c3_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMy0xLTEtMA_70546750-f77e-45d5-8612-cde48ff89bba">143,930</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f4c6415114fdab30e95d035c48f77_D20200101-20201231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzItNS0xLTEtNDkxNTM_2cbb58c2-8d56-4a52-8c77-7c9bf8621840">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb8f4c6415114fdab30e95d035c48f77_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzItNy0xLTEtNDkxNTg_622b73eb-42b4-4ce5-b6ff-0c63b979a42f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtOS0xLTEtMA_40998102-1d6a-42be-b071-73ad5b0d0bf9">143,930</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMTEtMS0xLTA_54e94b16-a70c-466b-929d-5490f63fdb81">73,169</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMTMtMS0xLTA_97311d2e-266a-4461-bbb7-8503c9397e07">70,761</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMS0xLTEtMA_78af7b01-46b1-42a1-b363-adcc04816fca">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e30d0a130514a509245b1d72aa48f0f_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMy0xLTEtMA_62a0e1da-4e53-4505-a5d8-9b1000e979c4">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzMtNS0xLTEtNDkxNTM_c948be29-6ab7-4935-9faa-2ee942c23628">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzMtNy0xLTEtNDkxNTg_5138100f-9e99-4d7b-bd3a-d7ebee8af209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtOS0xLTEtMA_16cbba03-25b6-48bd-a94f-46abdab0afcd">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMTEtMS0xLTA_fa307bc4-e75d-4189-b34f-5e55024b3939">11,715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMTMtMS0xLTA_f1c2adb9-a160-444d-8649-4fcd0b2e498f">11,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMS0xLTEtMA_18b347db-ccec-4fc4-8810-00d03b8e3e8c">12</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74208b2350a54619bb22d219854dc476_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMy0xLTEtMA_1b60a6d7-c7af-434f-bdd2-37339ee09c2e">6,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtNS0xLTEtNDkxNTM_3b727f66-f507-4ae7-8b40-0e621392a359">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtNy0xLTEtNDkxNTg_92b2ce84-b8a3-4e47-9852-4fbefd529048">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtOS0xLTEtMA_f02198ee-5b07-4ded-9119-8c7ff6ae7ff0">6,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMTEtMS0xLTA_886dfaae-4d85-4c85-94d6-aadf8c2815ad">3,234</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMTMtMS0xLTA_68888c2b-3815-4a9e-9f97-aa82d3464280">3,462</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMS0xLTEtMA_d97d1453-c25b-4f83-bef1-65c178a28819">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f9f2d34982748f39594f8bbf5d26296_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMy0xLTEtMA_5c8ddbf2-be70-4f14-9b19-b8662550742b">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtNS0xLTEtNDkxNTM_89097c67-84bc-499b-a5d7-5396853fa76c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtNy0xLTEtNDkxNTg_f3b21171-fcff-4e8c-b72b-f24c4983fd75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctOS0xLTEtMA_39610e8d-aa47-4118-b17d-491e32f95c19">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMTEtMS0xLTA_aac91326-7596-4087-93ff-f31a82889891">1,270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMTMtMS0xLTA_b721a62f-e2bc-47cc-9b21-5f0a48bd4295">790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMS0xLTEtMA_376c1087-ce76-4bc4-92ac-e8d363aa232f">20</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49479cdc0b20425392e36614906e56d6_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMy0xLTEtMA_d77d1af6-3928-44f4-b2f2-a79fa12f63d2">1,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231" decimals="-3" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtNS0xLTEtNDkxNTM_c0fc46df-293b-42cb-ad20-10ba10207e48">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtNy0xLTEtNDkxNTg_3eaeacbe-a61b-41d3-b4f4-e8772d4094ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtOS0xLTEtMA_0d8f9bd9-329d-46bf-9e40-8d36d72bb2d4">1,011</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMTEtMS0xLTA_c6314eb7-a807-4c84-aade-bcf2a82decd4">156</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMTMtMS0xLTA_709a29dc-2ab1-4720-8c26-857567c0bc9f">855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktMy0xLTEtMA_29e94972-488f-4961-813d-e17b0dceb255">176,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="ameh:FiniteAndIndefiniteLivedIntangibleAssetsAcquired" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctNS0xLTEtNDkxNTM_12273b92-68d2-4a83-93cf-30d209a19366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctNy0xLTEtNDkxNTg_c197f5ee-9253-4d65-bbc0-1b5dfe0a700d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktOS0xLTEtMA_7f1bea48-91d1-43a3-bed1-ee26bbc5b9a6">176,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktMTEtMS0xLTA_9ad49649-92ce-4574-b5b2-da85f85a29bd">89,544</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktMTMtMS0xLTA_95337d6d-8c5f-42df-bcf4-ed5983e213c7">86,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, network relationships, management contracts, member relationships, patient management platform, and tradename/trademarks had weighted-average remaining useful lives of <ix:nonNumeric contextRef="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1MTM_cf44962c-ca56-4d58-9d23-ab15751e202e">10.5</ix:nonNumeric> years, <ix:nonNumeric contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1MTg_376e80e5-8ea1-4b40-aad5-475081927056">8.5</ix:nonNumeric> years, <ix:nonNumeric contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1MjM_438c83d5-28be-476b-a11f-dd69718da00b">8.3</ix:nonNumeric> years, <ix:nonNumeric contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1Mjg_7467267e-2578-4e95-98e5-b2c0caf89fa0">0.9</ix:nonNumeric> years, and <ix:nonNumeric contextRef="ic77befc8ecf64d6390b3232a58d0202f_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1Mzc_72dfffa9-4b68-4349-8a93-544f88877688">15.9</ix:nonNumeric> years, respectively. Amortization expense was $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzIwNg_61d97354-52b1-4b4c-be60-85fe44090e53">15.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzIxMA_93a434eb-1288-4c36-add7-7f2ebc9d8eee">16.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzIxNw_2e80cf9a-a02b-463a-b513-d7a8faa6d2e0">16.3</ix:nonFraction> million for the years ended December&#160;31, 2021, 2020, and 2019, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company wrote off indefinite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i015c75fcf61d4986bcc5f227b6c412de_D20190101-20191231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzQ2Mg_f1a4c320-4f20-48cb-ae6b-26440a60aef0">2.0</ix:nonFraction> million related to Medicare licenses it acquired as part of the 2017 Merger. The Company will no longer utilize these licenses and as such the Company will not receive future economic benefits. There was no impairment loss recorded related to intangibles for the year ended December&#160;31, 2021 and 2020.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgzMA_4660ceea-32a2-4c23-b0fa-b45e35cfb2dd" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands):</span></div><div style="margin-top:17pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzItMS0xLTEtMA_6854a938-25f0-4c98-963d-3d6c57cf9031">13,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzMtMS0xLTEtMA_cd3f0656-3fdd-4e24-97ab-e19dad9665ef">11,661</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzQtMS0xLTEtMA_5f245be4-d741-4227-9684-a9c1285b9c6d">10,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzUtMS0xLTEtMA_bdcf1c78-01d9-4d54-afd7-4af85c2fec6a">9,414</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzYtMS0xLTEtMA_395d02aa-6e3d-4964-8e24-03289e854cb5">8,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzctMS0xLTEtMA_f47a629f-22b2-4cbf-a277-9fddb9089c79">26,908</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzgtMS0xLTEtMA_e3d37887-f16a-4d1e-9d22-893d4ade8894">80,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_145"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE1OTQ0_a1b924ba-e09a-40bd-bba7-f8980808eaec" continuedAt="ia62e62d642d6427d86ab942c288fd76e" escape="true">Investments in Other Entities</ix:nonNumeric></span></div><ix:continuation id="ia62e62d642d6427d86ab942c288fd76e" continuedAt="i16f2d265ed4e4cd0a33c54fa827777bd"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE1OTQz_ca9f4320-dca0-4ef4-874b-cba36774422a" continuedAt="i14f964d7270d49848ba0031c7e20b39b" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contribution</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidation of Entity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i503c88657b144f3aab4aa1799044b19f_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMi0xLTEtMA_251e155c-7107-40c7-aaed-958d697a77ed">13,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtNC0xLTEtMA_ba11a932-4754-4b18-b159-47463f953363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtNi0xLTEtMA_be3a43d2-2155-421d-afda-b1aca2aadd67">5,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtOC0xLTEtMA_6969388b-612a-40ed-bf40-6e477e3b9201">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMTAtMS0xLTA_50a27dd3-363d-4953-a69d-d0f01b4a40b9">4,182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMTItMS0xLTQwMTU1_8c9dac0b-1ec5-4d38-bb07-94217f2296b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefca0b3acca84ef39bac26666af72183_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMTItMS0xLTA_5fa147f4-ac93-47f9-b762-88dd25b3caf3">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc7ce9f2aefb4de8b0e4a49738897718_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMi0xLTEtMA_874a825c-a349-4e03-800e-b3ac8191d1c7">1,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItNC0xLTEtMA_e4ba2a3a-9523-4743-bffb-72a8a058d3cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItNi0xLTEtMA_aa3a3475-85f3-491b-9387-c4f8dec2eb85">306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItOC0xLTEtMA_1d89126a-c1db-480e-8bc0-78f1cb62267e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMTAtMS0xLTA_aaa1b398-4999-4ecc-bda7-8905fd54005b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMTItMS0xLTQwMTU1_a8b00320-4643-4a87-9570-e5a4acd60bd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b87107110124a33ad3ed49dca12817e_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMTItMS0xLTA_457d000e-b58d-479b-914a-6a5c35d55abd">1,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f9c8db35dd1455cbb9efcf67a63698b_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMi0xLTEtMA_bd5265f4-8d3b-40fb-af57-4178b0a2a355">2,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtNC0xLTEtMA_e4f4d448-4292-409a-9241-bce1b325d451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtNi0xLTEtMA_48968667-06ff-4b10-8719-40b89858fc56">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtOC0xLTEtMA_2d45c62e-b62a-4eb7-a742-61e38f1475e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMTAtMS0xLTA_2b99ffe5-cc79-4401-b924-a2a5ccd9dbdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzMtMTItMS0xLTQwMTU1_2f88959e-47ca-4f67-8b16-96415be18e28">2,943</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110382789db14433b603074a67e42a36_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMTItMS0xLTA_b88ffec8-c385-43fe-bf28-587e65d45444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13903951d2fc4cb3a6f3cc653bc12796_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMi0xLTEtMA_486f6d43-8e38-4b98-8877-09b11439bb93">17,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtNC0xLTEtMA_710745f0-b7bf-4b69-8f3f-13a52ee08660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtNi0xLTEtMA_a16cd3fc-1809-403f-a489-78de4696867a">208</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtOC0xLTEtMA_3e365a85-fd83-4570-9c8c-53049925ec52">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMTAtMS0xLTA_3011ae91-0f19-46e0-a005-64c785a2d568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMTItMS0xLTQwMTU1_522a7047-a85a-486d-b331-07641bb7a2aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898d05e125bd4e44b591badacf6f75fe_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMTItMS0xLTA_79a1a533-8c91-42e5-a581-695085dfc9a4">17,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One MSO, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i731e915d69124743b66363b19a199dda_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMi0xLTEtMA_dccf423f-b40a-408b-b2b6-cf850ba02d1e">2,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctNC0xLTEtMA_6431e20a-6507-44da-b654-7281c7972938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctNi0xLTEtMA_70e9b72a-2727-46e7-9e9d-a6c87c7b67df">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctOC0xLTEtMA_962259e6-683c-49c8-bb26-15e6ad9aab69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMTAtMS0xLTA_55b94877-628f-47bf-8644-4a504442d2c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMTItMS0xLTQwMTU1_aed32c55-fd45-45cf-bcc3-8391b0ecfe7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ca09a27d4e24e43ac205809e114b053_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMTItMS0xLTA_1da0603d-db61-4ef3-b0f8-091976d7f0c7">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6c47496c364a6b8c27c34e249b3a21_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMi0xLTEtMA_ca3df851-10e6-44cd-bcd5-52610d708bc5">4,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNC0xLTEtMA_251147df-f8b7-4f86-90ac-a39403e7852e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNi0xLTEtMA_be550ee2-87cb-4f2b-a363-e2c0a923a03f">314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtOC0xLTEtMA_0987abd2-4e41-4d5e-9d6d-1470035aead9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTAtMS0xLTA_44fe348b-52b3-4601-860b-26c7fdadea12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzYtMTItMS0xLTQwMTU1_5719b627-f29f-4e67-8709-eb510fcf236f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cce677040344f7c94c12092ed289604_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTItMS0xLTA_208e6637-a7d4-46ac-96a2-5f08eb79d3ad">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i273a684a3d8b492283839a5d9ccc76b3_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktMi0xLTEtMA_e57df2ec-d4f3-44ec-90bb-a00d85c2f5f0">2,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktNC0xLTEtMA_f0d3e852-a980-4670-b4cb-1968a08d07ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktNi0xLTEtMA_1eda32ef-66ea-4b7c-8f12-201c683d79be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktOC0xLTEtMA_e4117537-b6c5-4053-be9b-ed6649355c21">1,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktMTAtMS0xLTA_328a2fa6-4498-4260-8cd4-7c53666677c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMTItMS0xLTQwMTU1_479848b5-749f-4c85-9510-0d951c2b2be1">3,768</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf87ab1f75b4885966e552286174dd2_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktMTItMS0xLTA_362f7e27-be5b-4b3f-9a34-31e46f3a6d4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c28398a7a274eb28a70bc44722ecef4_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMi0xLTEtNDAyMjE_1dd118de-fc4a-420f-b645-c9070ec924d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNC0xLTEtNDAxNTU_b44d9802-7f5d-4a8e-85f7-63c2cb320b4d">11,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNi0xLTEtNDAxNTU_3c15e62b-8ba9-4122-89db-88d621352756">268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtOC0xLTEtNDAxNTU_4bf0433c-1fc6-4a4b-b927-2c6a4d932cee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTAtMS0xLTQwMTU1_c2ed90fe-dfab-4426-b88e-d29e0a75c105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTItMS0xLTQwMTU1_109a63a0-6256-4436-9b1f-63a323f1916d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id249748cb92647bcb3ae2fe466c5b254_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTQtMS0xLTQwMjIx_25fadf36-d2a9-4b38-93ab-c5585291ca81">11,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTItMS0xLTA_c59c9edc-cb80-4c3f-b609-e4912b02e8f1">43,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentInvestmentInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTQtMS0xLTA_e6f59e4a-65d4-4c02-938d-13c92fb59747">11,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTYtMS0xLTA_5dbb6578-2516-4e2a-a770-c9bba3f36e5f">4,306</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTgtMS0xLTA_2e53b0f4-c4d5-4f44-b51c-4d517fae3780">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTEwLTEtMS0w_33cf6d68-d331-4cfd-9077-9234b4b958d7">4,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="ameh:EquityMethodInvestmentsConsolidated" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEwLTEyLTEtMS00MDE1NQ_a14d2562-e33d-45b4-9108-22fcbee684c7">6,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTEyLTEtMS0w_b391b4b6-93cf-430b-a275-c7576f87593b">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; IPA Line of Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino, and Tulare Counties through its network of approximately <ix:nonFraction unitRef="provider" contextRef="iefca0b3acca84ef39bac26666af72183_I20211231" decimals="INF" name="ameh:NumberOfEmployees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2Nzg4MTc_19ba5978-ecde-452c-9c0a-00b84468cd2d">2,400</ix:nonFraction> independently contracted primary care physicians and specialist providers. LMA&#8217;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net, and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="i0412a16b622b47b881cd9067167d397e_I20121231" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzg4MQ_36c716b5-3f0a-48ae-9878-1edb81e519dd">5.0</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i198ab6e687c84de2a822e8318e6dfb6d_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzg5MA_804699e2-aa96-4d49-ab7b-54e8647238d1">25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. NMM has a management services agreement with LMA. In December 2020, the Company exercised its option to convert a promissory note totaling $<ix:nonFraction unitRef="usd" contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNzg_68f33184-2e12-4aac-9a17-97ed1600f127">6.4</ix:nonFraction>&#160;million due from Dr. Arteaga into an additional <ix:nonFraction unitRef="number" contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMjE_938d426f-abf9-49db-b1d5-42998dafc370">21.25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. As a result, APC-LSMA&#8217;s interest in LMA&#8217;s IPA line of business increased to <ix:nonFraction unitRef="number" contextRef="idbbeb1f862bf450891db9fb5dfd9a221_I20201231" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzY1OTcwNjk3OTQyMjc_1a6dbfe8-34cc-4105-9ec5-4caf537eaac0">46.25</ix:nonFraction>%. In September 2021, APC-LSMA sold <ix:nonFraction unitRef="number" contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2NzkyNzg_938d426f-abf9-49db-b1d5-42998dafc370">21.25</ix:nonFraction>% of its interest in LMA back to Dr. Arteaga for $<ix:nonFraction unitRef="usd" contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2NzkzMjk_68f33184-2e12-4aac-9a17-97ed1600f127">6.4</ix:nonFraction>&#160;million, which resulted in APC-LSMA owning a <ix:nonFraction unitRef="number" contextRef="i198ab6e687c84de2a822e8318e6dfb6d_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2NzkzNzA_804699e2-aa96-4d49-ab7b-54e8647238d1">25</ix:nonFraction>% interest in LMA as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the year ended December&#160;31, 2021, APC recorded net loss of $<ix:nonFraction unitRef="usd" contextRef="i8cb8cf60062647d29f8c59848644f427_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0ODI_17fadfae-3dd1-4201-8810-03d0a18bcde2">5.8</ix:nonFraction> million from its investment in LMA as compared to a net income of $<ix:nonFraction unitRef="usd" contextRef="i03f22c6e36ab4bd4853b9f3b723fc918_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE1NDE_52709f84-2a2a-46e8-adf5-bdedf5128c28">0.3</ix:nonFraction> million for the year ended December&#160;31, 2020, in the accompanying consolidated statements of income. The investment balance was $<ix:nonFraction unitRef="usd" contextRef="iefca0b3acca84ef39bac26666af72183_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE2NDk_02bfe176-9238-47cd-8612-aa1d10955994">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i503c88657b144f3aab4aa1799044b19f_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE2NTY_8c5177b8-40e2-43d3-94d3-5a5db2c14895">13.0</ix:nonFraction> million at December&#160;31, 2021 and 2020, respectively.</span></div><ix:continuation id="i14f964d7270d49848ba0031c7e20b39b" continuedAt="i49983cf06fce4ccc85aca144667243fc"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s unaudited summarized balance sheets at December&#160;31, 2021 and 2020 and unaudited summarized statements of operations for the years ended December&#160;31, 2021, 2020, and 2019 are as follows (in thousands):</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i16f2d265ed4e4cd0a33c54fa827777bd" continuedAt="i4b7f293a261849e0a71037d9dc001848"><ix:continuation id="i49983cf06fce4ccc85aca144667243fc"><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020<br/>(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzMtMi0xLTEtMA_435d8344-1853-4696-9e9d-038c31a27c84">6,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzMtNC0xLTEtMA_fe793263-bba5-4965-9dc8-6ac4b48c5e91">9,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzQtMi0xLTEtMA_a400689c-d1af-4078-9524-ed523793f089">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzQtNC0xLTEtMA_2363d141-b48a-419e-bc67-a9edcdf090f7">3,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzUtMi0xLTEtMA_180734b9-72b1-4652-90e7-d4fe42f64a8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzUtNC0xLTEtMA_2dc2b3a6-fb20-4a26-802a-d4d250e0cbc1">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzYtMi0xLTEtMA_88d73897-6285-4682-99bb-5755b4487a68">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzYtNC0xLTEtMA_bdbbcbeb-998d-4ed2-a332-00e9fb7b4e7b">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzctMi0xLTEtMA_61bf8089-7282-4b54-963b-faa1fa709aa0">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzctNC0xLTEtMA_4d0d4dbf-f4e9-441e-aa52-70eeb6c5477d">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzktMi0xLTEtMA_1bf3d245-b458-4263-8e91-85380b45575f">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzktNC0xLTEtMA_15adfa21-8f8d-4809-a377-5c93daabb321">17,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEyLTItMS0xLTA_3ce74770-4e77-4ac8-a43b-723232cc8efd">32,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEyLTQtMS0xLTA_ecb09a0e-5cf1-4d6d-b98f-58b28f11c878">21,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEzLTItMS0xLTA_74e8f03f-e24e-489a-af1d-6adc4c68b186">20,571</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEzLTQtMS0xLTA_7f5b04b1-2705-4de3-8292-85f4905ab34d">4,499</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzE1LTItMS0xLTA_ea5bc264-e4ca-4726-b00a-138a0f6bc5c9">11,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzE1LTQtMS0xLTA_ce585ead-df4e-4d86-b8b9-695e7f64ab3f">17,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2021<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2019<br/>(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzItMi0xLTEtMA_57dd5cc0-6853-450a-92ae-65c6092a5c8c">204,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzItNC0xLTEtMA_21bf2cc0-8750-44b9-b668-229ff65050bb">186,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzItNi0xLTEtMzk5NDg_e23f7af1-9b99-468f-ab9d-989f1c996129">194,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzMtMi0xLTEtMA_34da640e-9941-4eaa-bb07-f14eee7ef585">220,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzMtNC0xLTEtMA_2dc71281-d029-4b33-b7fb-947e72bbaa47">185,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzMtNi0xLTEtMzk5NDg_d3fc6b0e-f0f4-4b8e-aebb-4f9e761a4a9d">205,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzUtMi0xLTEtMA_4e3247d2-bde9-467c-be19-596d84999eee">16,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzUtNC0xLTEtMA_131b906e-e9dc-4a60-bf21-f732b904388d">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzUtNi0xLTEtMzk5NTU_32e65700-6509-427e-9d74-a76527c052f2">11,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzctMi0xLTEtMA_29712c70-c502-4836-9990-1bac01c743be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzctNC0xLTEtMA_326634bb-2f94-42e3-89dc-ea0acc0f30f5">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzctNi0xLTEtMzk5NTU_8e6b9606-f758-436c-abe2-473e4b15909c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzEzLTItMS0xLTA_3cf89d73-503c-4faf-8947-9650ce0c4bb2">16,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzEzLTQtMS0xLTA_78ffe9de-2af4-4bff-ac66-a055072ffea6">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzEzLTYtMS0xLTM5OTU1_53509845-9c2a-48ea-9ca0-39f176a9af4e">11,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMIOC was incorporated in 2004 in the state of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at their facilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="ic37f82250e404856a1dcea1915c8a4f9_I20150731" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzIzODE_536336a2-c5df-44ec-a629-ade3b34dcaaa">1.2</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="ic37f82250e404856a1dcea1915c8a4f9_I20150731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzIzOTA_6bfb0f34-4deb-477c-98ea-ab96530e585a">40</ix:nonFraction>% ownership in PMIOC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract APC paid PMIOC fees of $<ix:nonFraction unitRef="usd" contextRef="iee587da7f4aa43ada9b4e8471a61bc94_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsForFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI2MjI_0801b47b-3b85-4706-8e2f-d2fa3b05b02e">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2c187ffabbda44aca5a5d84550b8aa79_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsForFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI2Mjk_80c47b9a-4006-4e93-9fa5-9ef0ef301f43">2.2</ix:nonFraction> million for the years ended December&#160;31, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. During the year ended December&#160;31, 2021, APC recorded net income of $<ix:nonFraction unitRef="usd" contextRef="ib555dbec242444c28b4456bb93f2b6f5_D20210101-20211231" decimals="0" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI5MDg_88dafe2b-8082-47d0-8f0b-f2105dbd6def">0.3</ix:nonFraction> million from its investment as compared to net income of $<ix:nonFraction unitRef="usd" contextRef="ic9a36e1a441145a19e883235e84ce38a_D20200101-20201231" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI5NTg_16a2b07c-0723-4bba-924c-b1abf7025568">17,000</ix:nonFraction> for the year ended December&#160;31, 2020 in the accompanying consolidated statements of income and has an investment balance of $<ix:nonFraction unitRef="usd" contextRef="if37956fe79bf4000a19ec8e8571ca1cc_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzMwNzA_537499d8-30d4-44aa-ba80-26535ee0a070">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i18d99fc8fa9b454a8bd0c6ed6faa3ba9_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzMwNzc_96a0cc53-18e5-42b9-89cb-3990975d9ca7">1.4</ix:nonFraction> million at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i4b7f293a261849e0a71037d9dc001848" continuedAt="i5d72b043e9f24275920d9c80e6172c9d"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounted for its <ix:nonFraction unitRef="number" contextRef="i5061a26c78b5403a92ef0a14467a0063_I20211231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzcwNjc_5e2389f7-e40c-4fe3-aba8-2c4db27c6188">40</ix:nonFraction>% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, had the ability to exercise significant influence, but not control over DMG&#8217;s operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; therefore DMG is consolidated. As a result of the consolidation, the Company recognized a gain of $<ix:nonFraction unitRef="usd" contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231" decimals="-5" name="us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzM4NDgyOTA3NjE0MDU_14c6ee7f-a180-4bdd-9b2b-e9d471a87045">2.8</ix:nonFraction> million for the year ended December&#160;31, 2021 in other income in the accompanying consolidated statement of income, representing the difference between the fair value and the carrying value of the previously held noncontrolling interest in DMG on the date of consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, and prior to consolidation of DMG, APC recorded income from this investment of $<ix:nonFraction unitRef="usd" contextRef="ibdc98f3cf1ce4c1d8a0b83f75ea36297_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzczMjU_a4837707-f0a8-4feb-bc0a-97b8bf1eac5e">0.3</ix:nonFraction> million as compared to income of $<ix:nonFraction unitRef="usd" contextRef="iad767e257dc04de09097654e8d9ea038_D20200101-20201231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODc2NjI_597e093b-415a-43a3-98a4-df34abeb34f6">0.3</ix:nonFraction> million during the year ended December&#160;31, 2020 in the accompanying consolidated statements of income.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), a related party, APC and NMM, entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owns <ix:nonFraction unitRef="number" contextRef="ib0d13a567771417b82eab2d872ffeddd_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk4Nzc_9da2a9b9-7bf9-42f3-ba2f-07461d6aaf67">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i00e772255fe246ffa225f111f36bbee4_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk4ODE_35096f50-9390-4c61-aa70-f9775a9ed220">25</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="id948340a0f0b4857bed7bfd4a5db9f4c_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk4ODg_e74d3ff9-6365-4b1b-aff8-e0db021f88f1">25</ix:nonFraction>%, respectively, of member units based on initial capital contributions of $<ix:nonFraction unitRef="usd" contextRef="ib0d13a567771417b82eab2d872ffeddd_I20180630" decimals="-5" name="us-gaap:MembersCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk5NjQ_264e5574-a8e7-4a43-8961-8a8018ec3540">16.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i00e772255fe246ffa225f111f36bbee4_I20180630" decimals="-5" name="us-gaap:MembersCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk5Njg_6a54cf6d-abde-42b5-ab4b-37c86e99f0b0">8.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id948340a0f0b4857bed7bfd4a5db9f4c_I20180630" decimals="-5" name="us-gaap:MembersCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk5NzY_5faa2be1-adff-4f09-b194-aa15e753e8bb">8.3</ix:nonFraction> million, respectively. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s&#160;<ix:nonFraction unitRef="number" contextRef="ib63764ca4e84414c81bcc395ce6a0848_I20190423" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNjEz_6a04ad4b-dfc7-4dcd-a723-af7f3fed6ea6">25</ix:nonFraction>%&#160;membership interest in 531 W. College, LLC for approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="ib63764ca4e84414c81bcc395ce6a0848_I20190423" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNjc3_10ed5da4-1e9e-48f7-ab9e-a113435c8b32">8.3</ix:nonFraction> million. Subsequently, APC has a&#160;<ix:nonFraction unitRef="number" contextRef="ief1111e9e2a048a785ec584e3a23c0db_I20190423" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNzA1_5f648cfe-070c-4e8b-a975-39ca7e8c0945">50</ix:nonFraction>%&#160;ownership in 531 W. College LLC. APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, APC recorded losses from its investment in 531 W. College LLC of $<ix:nonFraction unitRef="usd" contextRef="ib8eb23240eab47278ba31489ec5f4074_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMjQw_b5fba5e7-f9e3-4e14-a184-94f7393ffe73">0.2</ix:nonFraction> million and loss of $<ix:nonFraction unitRef="usd" contextRef="ie652a00fea2c45bba68f168cd6fd0326_D20200101-20201231" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMjQ3_3ac52a65-c6cd-43cd-a902-27ca9448846d">0.4</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. During the year ended December&#160;31, 2021 and 2020, APC contributed $<ix:nonFraction unitRef="usd" contextRef="ie4819e77fc964fe284f83cd52ffd9bed_D20210101-20211231" decimals="-5" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE3MDY0Mjc_28a0a292-6ce6-4059-938e-585fbfb8bd28">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ice49c40a4d0b40009b5fc8fabf4890d2_D20200101-20201231" decimals="-5" name="ameh:EquityMethodInvestmentsContribution" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMzg3_094bb598-450b-4f54-9dfb-0b85fe5ea354">1.0</ix:nonFraction>&#160;million, respectively, to 531 W. College, LLC as part of its <ix:nonFraction unitRef="number" contextRef="i28a5796b7a274d6dac1cfafd9d65e199_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExNDQ5_6c4e5303-4600-4fa4-b36f-66d354b7796b">50</ix:nonFraction>% interest.  The accompanying consolidated balance sheets include the related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i1154256fe1de45f59c9c10c10c8ab21b_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExNTUw_4fa7c5bb-3c91-444c-92fd-2da8f7bacef0">17.2</ix:nonFraction> million</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i28a5796b7a274d6dac1cfafd9d65e199_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExNTU3_63b88aec-56d4-4c06-8b79-287a6d373c7c">17.2</ix:nonFraction> million, respectively, related to APC's investment at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One MSO LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a <ix:nonFraction unitRef="number" contextRef="ic23531b109fe425ea37a2b8d6a5e782b_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEyNjc0_4a073ca8-f558-4cab-88d4-ffaffcbf2648">50</ix:nonFraction>% membership interest in One MSO LLC (&#8220;One MSO&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i731e915d69124743b66363b19a199dda_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEyNzI4_05d22591-1e40-4271-9922-f52d784e41fe">2.4</ix:nonFraction>&#160;million. APC accounts for its investment in One MSO under the equity method of accounting as APC has the ability to exercise significant influence, but not control over One MSO&#8217;s operations. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. During the year ended December&#160;31, 2021, APC recorded income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODM3OTQ_2ce1e51a-9380-409a-a67c-9260d124c152">0.5</ix:nonFraction> million in the accompanying consolidated statements of income. The investment balance was $<ix:nonFraction unitRef="usd" contextRef="i4ca09a27d4e24e43ac205809e114b053_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODM3OTA_115342c8-9da0-404a-ba1d-9747fb5f8026">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i731e915d69124743b66363b19a199dda_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODM3NzQ_ce2e8f81-03b1-45a0-9d14-7ec90b31ead4">2.4</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, APC purchased a <ix:nonFraction unitRef="number" contextRef="i0037e84ba38f4a3e9dfb06a8532434cb_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEyOTY1_1a1cff1f-8f35-446e-9445-3d95ff592219">50</ix:nonFraction>% member interest in Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i9f6c47496c364a6b8c27c34e249b3a21_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzMDM3_fc73ee7e-8182-4194-858d-4b734e74d0e0">4.5</ix:nonFraction> million and a <ix:nonFraction unitRef="number" contextRef="if8e6770db7ed467b9bfa172bb05c7567_I20201231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzMDc3_af885500-1e30-409a-8b50-290289353ff5">50</ix:nonFraction>% member interest in Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="i273a684a3d8b492283839a5d9ccc76b3_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzMTQ5_754cc19e-fc9d-427d-8c80-cf54adf221db">2.1</ix:nonFraction> million. Tag 6 leases their building to tenants and Tag 8 has vacant land with plans to develop medical offices in the future. In April 2021, the Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in Tag 6 under the equity method of accounting as APC has the ability to exercise significant influence, but not control over Tag 6&#8217;s operations. Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. During the year ended December&#160;31, 2021, APC recorded income from this investment of $<ix:nonFraction unitRef="usd" contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODQzOTQ_1324167b-de7d-441b-876b-e81ea35ce40e">0.3</ix:nonFraction> million in the accompanying consolidated statements of income. The investment balance was $<ix:nonFraction unitRef="usd" contextRef="i6cce677040344f7c94c12092ed289604_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODQzOTg_3a6563e4-bf20-4b57-b411-5c64e8ec2eef">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9f6c47496c364a6b8c27c34e249b3a21_I20201231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODQ0MDI_91c7e000-99f0-4346-9169-e31c04e6e5c8">4.5</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i5d72b043e9f24275920d9c80e6172c9d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased a <ix:nonFraction unitRef="number" contextRef="id671637d094b4da9baff3726eb0bb9ef_I20210831" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODEzODA_4b6eba8f-524c-4f6e-b9ff-8804bbe6c7a0">30</ix:nonFraction>% interest in CAIPA MSO, LLC for $<ix:nonFraction unitRef="usd" contextRef="i8fd1339411804f9e8ee4a8aaa22a5cc7_I20210831" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODEzOTY_520fe6ad-11eb-49a5-9f3a-6319131db338">11.7</ix:nonFraction> million. CAIPA MSO, LLC (&#8220;CAIPA MSO&#8221;) is a New York-based management services organization affiliated with Chinese-American IPA d.b.a. Coalition of Asian-American IPA , a leading independent practice association serving the greater New York City area.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. During the year ended December&#160;31, 2021, ApolloMed recorded income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i100c286c449b435198ed0d3c17cfbda1_D20210101-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODMxNjY_709d2570-cf5d-42fe-acf2-ef9cb336019e">0.3</ix:nonFraction> million in the accompanying consolidated statements of income. The investment balance was $<ix:nonFraction unitRef="usd" contextRef="i2ab282e08eee4f75b09eb011582c6e08_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODMxMjA_590c2c3e-a0d1-4a5a-b2e3-39b9f3b893af">12.0</ix:nonFraction> million as of December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased <ix:nonFraction unitRef="shares" contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNDcx_7559bfbd-81d3-4236-af42-ffc2a3ba765b">270,000</ix:nonFraction> membership interests of MediPortal LLC, a New York limited liability company, for $<ix:nonFraction unitRef="usd" contextRef="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531" decimals="-5" name="ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNTU2_18eec776-cf91-454d-8243-e008653a3b0e">0.4</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNTYy_27bd608e-7fe3-4dfd-bc24-706f2e462194">1.50</ix:nonFraction> per membership interest, which represented approximately <ix:nonFraction unitRef="number" contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531" decimals="3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjIy_67040b99-33d6-4063-a751-b513b66ab140">2.8</ix:nonFraction>% ownership. APC also received a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjU2_c963fd5b-c811-4093-81f8-04122b4eaed7">five</span>-year warrant to purchase <ix:nonFraction unitRef="shares" contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531" decimals="-3" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjg0_44b2dba9-7a7f-45d9-b7f3-93f5983b26ed">270,000</ix:nonFraction> membership interests. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzEx_0992ad4a-a700-4f32-8ee4-5af8a166e27a">five</span>-year option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531" decimals="-3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzUy_5616b2c9-4daa-4b02-abfc-f42b638f2a0e">380,000</ix:nonFraction> membership interests and a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzgy_218c2412-51ed-4adf-8fb2-fba58a465401">five</span>-year warrant to purchase <ix:nonFraction unitRef="shares" contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531" decimals="0" name="ameh:EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzODEw_b9646671-07d9-4b36-868a-bc4c24fd8652">480,000</ix:nonFraction> membership interests were contingent upon the portal completion date, however, the Company did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December&#160;31, 2021 and 2020, there were no observable price changes to APC&#8217;s investment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase up to <ix:nonFraction unitRef="number" contextRef="i81be945f4a484abab03ca823d400fb2d_I20190701" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0NTM2_a12a2f54-5a91-4549-a80c-a063dfa67bf5">50</ix:nonFraction>% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed <ix:nonNumeric contextRef="id0caec3bea3f4eaa9e7ff87ad11adae8_D20190701-20190701" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0NjMw_5fab91f5-a299-480b-b981-10954978fc6f">five years</ix:nonNumeric>. As a result of this transaction, NMM invested $<ix:nonFraction unitRef="usd" contextRef="i81be945f4a484abab03ca823d400fb2d_I20190701" decimals="-5" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0Njgw_5f47b626-baa6-47c0-ae32-3478accb7216">0.5</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i81be945f4a484abab03ca823d400fb2d_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0Njg5_e4bdeb18-bfeb-4b88-84a9-5bd2bc5fea32">10</ix:nonFraction>% interest. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="ib53fcc8b36514b66982fc74e646bd81d_I20211231" decimals="-5" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0NzM2_c417c850-bc9a-45d3-bcc7-8e08662dc305">0.5</ix:nonFraction>&#160;million is included in &#8220;Investment in a privately held entities&#8221; in the accompanying consolidated balance sheets as of December&#160;31, 2021. As NMM does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December&#160;31, 2021 and 2020, there were no observable price changes to NMM&#8217;s investment.</span></div></ix:continuation><div id="i796d62c2eb674b8c9edd48d78ebf1f96_151"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:LoanReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzMwMjU_483db4b1-8768-4537-b112-20fce918ec7e" continuedAt="i28e3d2d2db6645e28478c301dfd054fa" escape="true">Loans Receivable and Loans Receivable &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="i28e3d2d2db6645e28478c301dfd054fa" continuedAt="i308e28c2c83f455cabc0fb95039fe5c5"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loans Receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 Enterprises (&#8220;Pacific6&#8221;) totaling $<ix:nonFraction unitRef="usd" contextRef="ieef9d826ba6d40728e8ea8794c1ba388_I20201031" decimals="-5" name="us-gaap:NotesReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzE3Nzc_d70cd624-a636-4e9b-835f-c9b645b713b1">0.5</ix:nonFraction>&#160;million as a result of the sale of the Company&#8217;s <ix:nonFraction unitRef="number" contextRef="i604b63e710a74052bd5134a326c3b521_I20181218" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzEwOTk1MTE2MzMyNTc_208b7eb1-ced0-446e-9282-c7dd88ade3be"><ix:nonFraction unitRef="number" contextRef="ie2dacf52383a475da0334f0ba9ad8b31_I20181218" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzEwOTk1MTE2MzMyNTc_40ad2811-6607-4d89-86dc-08c2140b1c6a"><ix:nonFraction unitRef="number" contextRef="i3069a2df4dba45069c16005bfe7c95a9_I20181218" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzEwOTk1MTE2MzMyNTc_48938be1-844f-43e5-8f70-42908f284f65">33.3</ix:nonFraction></ix:nonFraction></ix:nonFraction>% interest in MWN. Interest accrues at a rate of <ix:nonFraction unitRef="number" contextRef="idb1195755b784aa8b53f18c076ac879d_I20201030" decimals="2" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzE4Njg_da6a8a65-bc2d-400f-9128-6c043385be5b">5</ix:nonFraction>% per annum and is payable monthly through the maturity date of December 1, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan Receivable &#8212; Related Party</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC Healthcare Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC Healthcare Inc. (&#8220;AHMC&#8221;), a related party of the Company, (the &#8220;AHMC Note&#8221;) for a principal sum of $<ix:nonFraction unitRef="usd" contextRef="i2c9d54cb427946a28f7ce5949115e202_I20201031" decimals="-5" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzIxMjc_ffe7d83a-9f9e-41c2-a3a8-9cdf8722e796">4.0</ix:nonFraction>&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is <ix:nonFraction unitRef="number" contextRef="i2c9d54cb427946a28f7ce5949115e202_I20201031" decimals="INF" name="ameh:FinanceReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzIyMzk_b9a6a5ea-0289-42f4-9d73-eddaee4b1b72">3.75</ix:nonFraction>% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of December&#160;31, 2021, the total principal of $<ix:nonFraction unitRef="usd" contextRef="i3f1e6664f4ef468db3a85b5fe37e8ad0_I20211231" decimals="-5" name="us-gaap:NotesReceivableGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzI0NDg_65548fbd-d376-406b-87f1-78201c6a8fe3">4.0</ix:nonFraction>&#160;million remains outstanding. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable and loan receivable &#8212; related parties under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i308e28c2c83f455cabc0fb95039fe5c5">estimates an expected credit loss based on the remittance schedule of the note. <ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:NotesReceivableRelatedPartiesNoncurrentGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzI5MTk_60fcd83c-052b-430b-b6db-17b62eb1eb9f"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzI5MTk_6ef6e9c2-6c66-4c6b-a3ad-bae9bded7568">No</ix:nonFraction></ix:nonFraction> losses were recorded for loan receivable and loan receivable &#8212; related parties as of December&#160;31, 2021.</ix:continuation> </span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_157"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90ZXh0cmVnaW9uOjI0N2NjNzVhNDlhZjQ0MzhhOWQxMDNmNTFiYjgzNDQ3XzEyOA_73e8bfca-68cc-41e4-a610-648badddd0e6" continuedAt="ia0d1051cd09a459395ed686769090d5f" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ia0d1051cd09a459395ed686769090d5f"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90ZXh0cmVnaW9uOjI0N2NjNzVhNDlhZjQ0MzhhOWQxMDNmNTFiYjgzNDQ3XzEyOQ_c02ccb7c-7938-4e59-bb77-65b41b1cac93" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzItMi0xLTEtMA_01190d73-7dc2-4bac-b56a-550ed30a4748">9,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzItNC0xLTEtMA_b7e51871-612a-4f60-abd9-c17bad91ae76">9,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzMtMi0xLTEtMA_92d1943d-a72f-4383-a03a-2e5e0455bb00">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:SpecialtyCapitationPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzMtNC0xLTEtMA_1f17b22d-c601-4c65-b5fa-55c6fae46aa3">3,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor IPA payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:SubcontractorIpaRiskPoolPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzQtMi0xLTEtMA_c6be5cd4-fa30-48d3-a5e0-9bbaff8ee7f3">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:SubcontractorIpaRiskPoolPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzQtNC0xLTEtMA_9b41d4b3-8391-478e-a4e8-0e3651eb0236">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzUtMi0xLTEtMA_d002a8e2-5f14-4467-adc0-cd5014b3afb9">878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzUtNC0xLTEtMA_474a2228-fe23-4c18-b053-a6f00f4d8720">1,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzYtMi0xLTEtMA_b5408c74-bac8-4d51-b52a-294212cb541f">2,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzYtNC0xLTEtMA_59694f5a-0a15-43e1-8029-db4ee7253cc8">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzctMi0xLTEtMA_05d06ba3-7811-4677-a9b2-c60f42ea4a23">16,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzctNC0xLTEtMA_32ac2f7d-90c3-476d-b075-926055a4fcea">12,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzgtMi0xLTEtMA_e8cf10cf-5da4-4e6e-98c3-2181a7520a9e">10,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzgtNC0xLTEtMA_f83872fd-44e7-4f46-a119-b34b07d4c80c">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzktMi0xLTEtMA_9448564e-0a40-49ae-a5cb-ef16b3563c6e">43,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzktNC0xLTEtMA_d899c1dd-dd61-406d-91b9-08496c1743d5">36,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_160"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90ZXh0cmVnaW9uOmUwNWEyZGIyNTFiNjQ3MjhiYjg1YWJiM2NlNmMwMThkXzEwNg_b8d7aa7f-6317-43e2-aeb1-763ff8fb2f79" continuedAt="i80c4cf8d7ef641ada8af83a576d7258d" escape="true">Medical Liabilities</ix:nonNumeric></span></div><ix:continuation id="i80c4cf8d7ef641ada8af83a576d7258d"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90ZXh0cmVnaW9uOmUwNWEyZGIyNTFiNjQ3MjhiYjg1YWJiM2NlNmMwMThkXzEwNw_c3997010-6854-4f1c-881b-8f1082cca390" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzItMi0xLTEtMA_637886bc-89ce-4003-a89e-6b568d3b6e2d">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzItNC0xLTEtMA_5b92b1b4-3290-4ada-84d0-863b3e0b7f3a">58,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzMtMi0xLTEtMA_6c5336e0-2089-463f-ae50-9822f918293b">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzMtNC0xLTEtMA_1a7edcae-741d-4d7a-b8e2-d5420f7c2291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzUtMi0xLTEtMA_ae51292b-1398-4efa-b4fe-59f6100c7f63">347,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzUtNC0xLTEtMA_6e2e1aae-de92-470a-ab5e-d2f98ac8300a">309,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzYtMi0xLTEtMA_417866ca-95a7-4750-b1fa-282033aebbad">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzYtNC0xLTEtMA_f925f62c-bc3c-4c87-8cb1-9e48dadfc4c4">3,258</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzctMi0xLTEtMA_771211a2-b47c-415a-9e2a-e2ce6cb59e8e">348,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzctNC0xLTEtMA_1f3fcb6d-55ae-4ff8-8331-1f14b1f4d174">306,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzktMi0xLTEtMA_ed9c1c6e-9880-4fd5-9738-228ee5f10712">291,243</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzktNC0xLTEtMA_297c9c7d-eb4e-4b9e-871b-530651c53e68">261,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEwLTItMS0xLTA_1fba9335-71e9-45a4-8329-c3161ad348ea">51,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEwLTQtMS0xLTA_5aae7917-de2c-4c99-b49b-06a378c48259">54,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzExLTItMS0xLTA_437c5e99-28b1-411a-a661-36a70fa46b2c">342,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzExLTQtMS0xLTA_e4141672-0473-4616-8d81-89f7be3c0f28">315,118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEyLTItMS0xLTA_c15310fe-8027-4396-823b-36c0bb20ae59">521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEyLTQtMS0xLTA_c3ba0374-9ce2-40c3-a291-e48b362bc02e">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzE0LTItMS0xLTA_ec7b1dc6-1aa8-41c5-acc3-d4c4baa52673">55,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzE0LTQtMS0xLTA_0d1b2112-7ce5-411f-9111-0cec1eba34c7">50,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_163"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4ODA4_d9c46b2b-79c1-49b6-a890-752c803cf6d8" continuedAt="ied56ee42d764433ea2e13c8e03efcefe" escape="true">Credit Facility, Bank Loans, and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="ied56ee42d764433ea2e13c8e03efcefe" continuedAt="ie762c7f342934e748ee89616c3f86a7b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4ODA5_c838e21c-035f-479c-bf1a-4b20e306fcf9" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ec0825cadd340a0b4abec77e08752ba_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzItMS0xLTEtMA_7bcdc06c-2a41-40bf-a443-67714d87d18d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1018ea938faa4df890ec9e0a02e9cd39_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzItMy0xLTEtMA_e7247fa8-4135-4022-bfaf-0d355dd96b86">178,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i805098d929664b258e9e02430e3446f0_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzMtMS0xLTEtMA_b7caa316-a062-4309-a20c-be56f3061815">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2087645dd294b50b435fd15e8f370f1_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzMtMy0xLTEtMA_23366b77-8aec-43c1-a4fa-c97cd3f1e2e4">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79361bf90da942189dd476704c690d21_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzQtMS0xLTEtMA_80015cbf-b99c-44cf-877e-af3b3d525c52">7,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eba764439774dedac07edaac463b53b_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzQtMy0xLTEtMA_eb1c3e88-c5d1-445c-8239-b0d4d0471f99">7,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction loan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife653c4fcbb243abb96d4ba2a5ef5c68_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMS0xLTEtMzk0MjU_3d2d0cda-076a-46e9-b48d-0cd148700554">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9caf120fa2d4bb9a623a159c3d8cb6b_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMy0xLTEtMzk0MDI_47d8b03c-e3c5-4dfc-968a-a1ef251bfc94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMS0xLTEtMA_7b4bd3c1-2e69-4e00-8a87-0f6202d2a5f7">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMy0xLTEtMA_e08adbf0-dc6c-49f7-b889-db5b313c404f">245,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzctMS0xLTEtMA_55ed9ed1-1cc4-47ab-b96d-0aa5357fe78f">780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzctMy0xLTEtMA_95fe82a2-7487-41ed-b3e6-865692bf2179">10,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized financing cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzgtMS0xLTEtMA_03c459b5-7753-42e4-bc62-0d6a0aa5fc19">4,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzgtMy0xLTEtMA_0aaf8b44-4568-48d4-b84b-5d70df56a608">4,605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Long-term debt </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzEwLTEtMS0xLTA_e42025c3-d993-4798-bc40-e4accc22838e">182,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzEwLTMtMS0xLTA_16f8273d-2f42-4614-9569-5abc9a4b9421">230,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of December&#160;31, 2021 and 2020, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4NzAy_315468d3-9d10-40bc-a305-a637f5ba8371" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzEtMS0xLTEtMA_7a9f9d1e-9103-44ed-90f3-a805af11dddf">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzItMS0xLTEtMA_a1b96c38-fc3c-4a8e-8b2b-e8035c14095a">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzMtMS0xLTEtMA_156b9b04-f79e-45da-b72b-280925ff5033">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzQtMS0xLTEtMA_d4c6bc28-c710-4364-9d45-cb58533efd19">6,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:LongTermDebtMaturityAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzUtMS0xLTEtMA_9511bf16-efce-4a67-9315-716a946c7fdc">180,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzctMS0xLTEtMA_1143fda7-eb85-4587-84ac-fe6c6a87c049">187,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie762c7f342934e748ee89616c3f86a7b" continuedAt="ib08e559c39b841d2af43e76a2567dc54"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#8220;Credit Facility&#8221;), in its entirety. The Amended Credit Agreement provides for a <ix:nonNumeric contextRef="iae23f71d35ba49afac259c7ec4de8fd2_D20210616-20210616" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI2Mzg4Mjc5MTc4MTEx_bce93083-241b-4039-a3f4-925b086798ac">five-year</ix:nonNumeric> revolving credit facility to the Company of $<ix:nonFraction unitRef="usd" contextRef="ief487b48631e4a36972039b3bafdc0c5_I20210616" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI3NDg3NzkxNTcyNTI_88d31634-c6cc-486b-87c4-f7f89336de7f">400</ix:nonFraction> million, which includes a letter of credit sub-facility of up to $<ix:nonFraction unitRef="usd" contextRef="i00679cfa5a534ce9a92bdb137b52ec50_I20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI3NDg3NzkxNTcyNzI_5b2ab0cc-db7d-492a-941d-fd17b842eeb7">25</ix:nonFraction> million and a swingline loan sub-facility of $<ix:nonFraction unitRef="usd" contextRef="ie551eb427ed34af7aa4c793742c0e19a_I20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI3NDg3NzkxNTcyOTI_c8ab868b-d8d0-420f-8072-3c8ec04349ae">25</ix:nonFraction> million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, NMM and Truist Bank remain in effect.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $<ix:nonFraction unitRef="usd" contextRef="i0a6bb0cac4404e838f3cb21cb1f78f8a_D20210616-20210616" decimals="-3" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0NDk_0e960bbb-9b68-40e1-aee2-3714b548adef">50,000</ix:nonFraction> and an annual facility fee of <ix:nonFraction unitRef="number" contextRef="i87ee29c5cb344aa98db576466c4bfb91_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0MTY_96d9718b-8a20-457f-9eae-585141293241">0.175</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id3d5ec03a2b04b30a66a4a30c5784f2b_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0MjQ_22f5017e-0469-40f0-8c9c-6032c4b2d846">0.35</ix:nonFraction>% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to <ix:nonFraction unitRef="number" contextRef="idfb4fbfb2ec34149b57c0fb417d25c41_D20210616-20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0MzI_4a75c0d6-3aba-40c2-b977-9de29edba3c8">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ibf89debf8d114314b44b8b7514c5ed0e_D20210616-20210616" decimals="4" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0Mzk_9e09fc7d-a978-44d1-abff-94fd63b0ae7d">2.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from <ix:nonFraction unitRef="number" contextRef="i4b9c42d5297743dda47552322302b667_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4MTI_d1bc5745-c61d-4db1-9aa7-e1357dd07d26">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6900356a9b954339b957ad128fe7fb9e_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4MTk_6eb8bbd4-a32f-46c3-8cb8-24f401848ff1">2.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of <ix:nonFraction unitRef="number" contextRef="i87ee29c5cb344aa98db576466c4bfb91_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4Mjc_0d46bd89-34f5-4d5a-8793-dbf2398214d4">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id3d5ec03a2b04b30a66a4a30c5784f2b_D20210616-20210616" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4MzQ_0816d05e-597f-444a-abf3-38fd43c1ba55">1.50</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio.  As of December&#160;31, 2021, the interest rate on the Credit Agreement was <ix:nonFraction unitRef="number" contextRef="i5ac4990f656442ea8b9d9d247491dc90_I20211231" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODUxNTk_f7378fde-4b85-4f6f-b70e-f209befbb634">1.71</ix:nonFraction>%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231" decimals="INF" name="ameh:DebtInstrumentNumberOfKeyFinancialRatios" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwNDQ_472497d5-6a96-4375-9bc3-e212cc263ddc">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2MDQ_7075e6d3-ba1d-4668-a15f-7447f9a5dc11">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $<ix:nonFraction unitRef="usd" contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231" decimals="-5" name="ameh:DebtCovenantAggregatePurchasePriceMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2Mjg_334b04bf-b378-478b-95ab-52ffea7f684a">75.0</ix:nonFraction> million, the maximum consolidated total net leverage ratio may temporarily increase by <ix:nonFraction unitRef="number" contextRef="i4c7dc17bcbe04fb4904d893562ad225d_I20220101" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2NDQ_18cf4965-457b-43ed-9ba4-bcb31c515286">0.25</ix:nonFraction> to 1.00 to <ix:nonFraction unitRef="number" contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2NTA_f6cdec4b-3fa4-4939-b814-59a45ab3375c">4.00</ix:nonFraction> to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231" decimals="INF" name="ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2MTg_b3570f22-ec9e-4993-bd20-907638ed5b02">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company purchased <ix:nonFraction unitRef="number" contextRef="i1e78513b2a054c24a539e76d8c9ed784_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzExNzcy_7cc85422-e161-4dc1-8a11-1a8064a97511"><ix:nonFraction unitRef="number" contextRef="i61742fc5636f4d02a62b8ec226f2b8a3_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzExNzcy_d0a54315-9028-46e1-94a4-0842efb35f3b"><ix:nonFraction unitRef="number" contextRef="ib09048f44b5646e98a8d38401a6e9317_I20201231" decimals="INF" name="ameh:AssetAcquisitionPercentageOfSharesAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzExNzcy_dc849d56-f132-42c5-b724-4b41d0db1351">100</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of MPP, AMG Properties, and ZLL. As a result of the purchase, the Company assumed $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzQzOTgwNDY1OTM0MzI_40851bae-daa7-4e70-8bfc-5cad28554d37">6.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzQzOTgwNDY1OTM0NjI_21753228-15fd-4a69-a454-e7cf750cf738">0.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-5" name="us-gaap:LiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzQzOTgwNDY1OTM0NDc_6cd29518-94a7-4c2c-8c44-1d63384dfe5d">0.7</ix:nonFraction> million of existing loans held by MPP, AMG Properties, and ZLL, respectively, on the day of acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="ib08e559c39b841d2af43e76a2567dc54" continuedAt="i832293f08f66469bb033679d4e62e590"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $<ix:nonFraction unitRef="usd" contextRef="iabfdc0514ad04c73ab76b77f6739e8e4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjA2MzI_9e23406e-dcc3-4e9a-b4aa-bab67007d64e">6.1</ix:nonFraction> million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i447604f483784ad082efe8790195e57c_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEyMTI0_b8120e70-e7ef-48cd-a472-9d43f8907358">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i8d459770fc824dfd85b90f08dcfec692_D20210101-20211231" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEyNTcy_0fba27fb-ed18-4941-b496-b847d181b35a">1.25</ix:nonFraction> to 1.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $<ix:nonFraction unitRef="usd" contextRef="if9b39ded9aa144fe959c2e5f7e0cdc81_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjA2NDA_6ae64aa4-7abb-4f18-85b4-f31ca70b98f2">0.7</ix:nonFraction> million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i031524a8f2864901a900ba1a85eaecbf_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEyNzk5_fc84d4e0-e0d4-483e-aa4c-387744a97a7c">0.30</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i6b9e264b58ec4372891355322134a590_D20210101-20211231" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEzMjY5_978c3841-61ad-4001-8757-f4137729a7d0">1.25</ix:nonFraction> to 1.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $<ix:nonFraction unitRef="usd" contextRef="ie560514b2ee1454a9f9e0ab9ae48bb1e_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjA2MzY_2cbe2272-7790-474e-8138-30eec44d489c">0.6</ix:nonFraction> million with a variable interest rate of <ix:nonFraction unitRef="number" contextRef="i86ab3861fcda413d815e58a991ea9bf7_D20210101-20211231" decimals="INF" sign="-" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEzNDg0_859ed44b-9313-4b06-a507-bf2320280009">0.50</ix:nonFraction>% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i92cd58fb0c7d4588b4469022555c03b1_D20210101-20211231" decimals="INF" name="ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEzOTQz_a1e172d7-6d3b-471d-b8cb-6bf6a6c33730">1.25</ix:nonFraction> to 1.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $<ix:nonFraction unitRef="usd" contextRef="i9bd4ffb9558045b08ca6250bddb77123_I20210430" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwNDg_3ea4325b-356f-4327-af2a-f87744211e9c">10.7</ix:nonFraction>&#160;million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be <ix:nonFraction unitRef="number" contextRef="i7511f70c51f546fab2df45ef49ea60d1_D20230101-20231201" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwNjM_11e01621-8e0c-46c4-b1a5-aa6910874cd7">2.0</ix:nonFraction>% per annum in excess of the LIBOR rate. As of December&#160;31, 2021, the likelihood of the construction being completed by the maturity date is remote. The outstanding balance as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ife653c4fcbb243abb96d4ba2a5ef5c68_I20211231" decimals="-5" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE3MDI3Njk_7aaf5169-2af4-494f-b88a-e0d542ae9625">0.6</ix:nonFraction> million and was recorded as current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than <ix:nonFraction unitRef="number" contextRef="i22b6c0d320cb4d01aef31c88d0405025_I20211231" decimals="INF" name="ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwODM_383a54ac-fd1b-4431-aa04-568d305c01f4">1.25</ix:nonFraction> to 1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i4df55a8afb084316ae481f2b066f353f_I20211231" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjM3ODU_419affc3-91fe-4b4e-b0e4-a9168893634e">6.5</ix:nonFraction> million related to the issuance of the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="ib42cdd50cdf8449ea72386bfca57f57e_I20210630" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjM5MTE_1bcb2dc5-7ac8-45b3-a059-0c5361ea48c9">0.7</ix:nonFraction> million related to its entry into the Amended Credit Facility.  Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related Credit Facility and the costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility.  As of December&#160;31, 2021 and 2020, unamortized deferred financing costs were $<ix:nonFraction unitRef="usd" contextRef="i53c301d60fb84feb86e40458baac030a_I20200930" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQzNjY_fba73297-453a-4602-a668-043e1fa62606">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7f03a46a00b3442fa2d6f0b063116153_I20201231" decimals="-5" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQzNzQ_8fa9a6af-5116-460e-99fe-11c29a89f368">4.6</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i832293f08f66469bb033679d4e62e590"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the years ended December&#160;31, 2021, 2020, and 2019 was <ix:nonFraction unitRef="number" contextRef="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ1Mjg_22fc3c6b-0e8c-4460-b579-05fa19d94754">2.06</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i7d5181abc61c4949b5e2bb84d79457b5_D20200101-20201231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ1MzM_63a15327-897e-4bd9-8780-b9aca970487f">3.48</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="ia61a2888862d4451867b421f57199890_D20190101-20191231" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ1NDI_390fd46d-a1e5-45fd-afeb-e5e1e989335b">3.39</ix:nonFraction>%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the years ended December&#160;31, 2021, 2020, and 2019 of $<ix:nonFraction unitRef="usd" contextRef="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ3MTQ_7c8041d1-0025-4176-adda-56192e48d181">1.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i7d5181abc61c4949b5e2bb84d79457b5_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ3MTk_97e3adf9-8203-4494-9422-32d33c7c04e8">1.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ia61a2888862d4451867b421f57199890_D20190101-20191231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ3Mjg_2e79c0c7-a902-4b34-9086-53035fcc22fe">0.5</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, APC amended its promissory note agreement with Preferred Bank (&#8220;APC Business Loan Agreement&#8221;), which is affiliated with one of the Company&#8217;s board members, to modify loan availability to $<ix:nonFraction unitRef="usd" contextRef="i1dbe830985b3456088798fdc58aa9daf_I20190910" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE2MDQw_929d13a9-9e81-4ce6-b34f-ef5ab78da242">4.1</ix:nonFraction> million. This further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019 securing APC&#8217;s obligations to NMM under, and as required pursuant to, that certain Management Services Agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#8217;s board members, totaling $<ix:nonFraction unitRef="usd" contextRef="i92adc7af35ce442586e7f832696d8083_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3MjM3_a607c56e-4c80-4b2d-be56-00a778f7d8e0">14.8</ix:nonFraction>&#160;million for the benefit of CMS. In September 2019, these letters were terminated with Preferred Bank and reissued under the Credit Agreement. In August 2020, $<ix:nonFraction unitRef="usd" contextRef="i718ff6d9aae440bfbe2ebdfa0389b7f9_I20200731" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3NzM3_4eba0672-ecfd-4864-a338-56b6e9a586df">14.8</ix:nonFraction>&#160;million of the irrevocable standby letters of credit were released by CMS. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="i92adc7af35ce442586e7f832696d8083_I20211231" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3ODEw_019b1969-0c59-4caf-98e4-46aecc8480aa">no</ix:nonFraction> outstanding letters of credit and the Company had $<ix:nonFraction unitRef="usd" contextRef="i00679cfa5a534ce9a92bdb137b52ec50_I20210616" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE3MDgzNzM_5b2ab0cc-db7d-492a-941d-fd17b842eeb7">25.0</ix:nonFraction> million available under the Amended Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with a financial institution for a total of $<ix:nonFraction unitRef="usd" contextRef="if827ee4c779a4b57ab9eeeb719e06b2a_I20211231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3OTYz_ab2ce96d-8399-409d-b73a-ee63231405c7">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i7f6447a0def84811a339a66cb7ac0e7e_D20210101-20211231" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4Nzg0_c9be7d7f-10d6-4b9f-b44b-952a3989ec1a">one year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i87791bdb507743179b1b6187068193d1_I20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4NDAw_40043666-454c-4927-ac65-542a89614f3b">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i0a226f12905c46efbbd050421af8eea6_D20210101-20211231" name="us-gaap:LineOfCreditFacilityExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4ODMw_30ac672b-45dc-4928-ba83-2c605f185f3b">one year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div id="i796d62c2eb674b8c9edd48d78ebf1f96_169"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjM_0f6e0f49-e74a-4482-b12b-71558c1ea3f5" continuedAt="iec8638bf09004c909eef2295cec0e777" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="iec8638bf09004c909eef2295cec0e777" continuedAt="i30b7b42a58104d3d8e062e56c1172f0a"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjQ_f4357106-4639-4a43-9a7b-0af4876abd9d" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzMtMS0xLTEtMA_6abc794c-4f4a-45ef-8f93-9c8f71fbb8f7">22,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzMtMy0xLTEtMA_36217449-3f08-44e5-b028-a6c95d6bb533">43,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzMtNS0xLTEtMA_a3908c2c-ff4d-4ded-a2db-331ac0829e19">9,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzQtMS0xLTEtMA_5ce6adcb-d984-4d4d-8c94-96369bac5a5a">11,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzQtMy0xLTEtMA_cce94d04-8ebc-4c5a-9a48-64a91ea87893">19,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzQtNS0xLTEtMA_a25a7360-ab35-4529-b9fe-21a676b42a12">5,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzUtMS0xLTEtMA_1266cd5d-1e3d-4b93-a0cf-f6a03e0d2c74">34,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzUtMy0xLTEtMA_25e3a624-046e-4dca-bb96-63334a376881">62,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzUtNS0xLTEtMA_3aebe2a0-9af3-4b5c-b147-cb0e80737900">14,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzgtMS0xLTEtMA_a92b92e7-a322-40d4-b83f-7cb45a619bc8">3,794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzgtMy0xLTEtMA_bc2f85ee-056e-4751-a5b0-8147c3a75cee">4,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzgtNS0xLTEtMA_09f94f90-7d00-434a-9926-5a6b63e390e0">3,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzktMS0xLTEtMA_6d861a1a-9c19-4bee-aa5a-5b360aea1835">2,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzktMy0xLTEtMA_6f4fde12-93ba-4bb1-af81-1afef10f897b">1,657</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzktNS0xLTEtMA_97ef0c29-08e2-4fee-98b0-d9569a77bc8e">3,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEwLTEtMS0xLTA_9adf337b-7ea3-4709-bc65-d7c1adc83fdb">5,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEwLTMtMS0xLTA_0eeadb54-dcf3-4be7-8b24-d08741a0e058">6,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEwLTUtMS0xLTA_77eb39f5-22bb-4512-b0c2-b9fadc89040b">6,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEyLTEtMS0xLTA_8420e38a-d00c-4a0e-be18-0bf753295c76">28,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEyLTMtMS0xLTA_e75e547c-a55b-4b89-b3a6-57a4354e5766">56,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEyLTUtMS0xLTA_5e0c4d17-e0e8-4965-b76b-0b6ee0179a2d">8,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i30b7b42a58104d3d8e062e56c1172f0a" continuedAt="i034ee789bcb74455955fc081a22837c9"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates. As of December&#160;31, 2021, the Company had federal and California net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i87bcea25b6704ede86f7f3a191ef629d_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzQ2NQ_91adb713-f687-40d3-b31a-5248e9e34749">97.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icdc79f5d00754b61ab7e3baaf585df20_I20211231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzQ3Mg_a34d2694-d38c-49e6-9cd0-8b2eceb85d33">120.8</ix:nonFraction> million, respectively. The federal and California net operating loss carryforwards will expire at various dates from <ix:nonNumeric contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231" name="ameh:OperatingLossCarryforwardsExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzU4NA_df79133d-e965-4571-92d0-a2b812181303">2027</ix:nonNumeric> through <ix:nonNumeric contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231" name="ameh:OperatingLossCarryforwardsExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzU5NQ_0e246985-664d-4d51-a439-62fafab7c0bf">2040</ix:nonNumeric>; however, $<ix:nonFraction unitRef="usd" contextRef="i87bcea25b6704ede86f7f3a191ef629d_I20211231" decimals="-5" name="ameh:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzYwOA_7ad8a54e-987d-404b-a2f0-94c2bb17587c">77.7</ix:nonFraction> million of the federal operating loss do not expire and can be carried forward indefinitely. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company&#8217;s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three years&#8217; period since the last ownership change. </span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjU_8dfb6f7a-41b4-4402-b93d-265fd097deb3" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets (liabilities) as of December&#160;31, 2021 and 2020 are shown below (in thousands). A valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzExMDc_81cd0083-a45f-468b-a6bd-41113bd70fe3">22.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzExMTQ_878dc2f9-6fa2-41d7-97c1-5edd28cbe168">15.5</ix:nonFraction> million as of December&#160;31, 2021 and 2020, respectively, has been established against the Company&#8217;s deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzEwOTk1MTE2MzA1MTU_64d0dcd6-08e5-479b-896d-cba244ba68df">6.8</ix:nonFraction> million in 2021.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsStateTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzItMS0xLTEtMA_ec9633a2-d9cf-465c-acb5-051b979d54ff">2,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsStateTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzItMy0xLTEtMA_d6564b1d-8cb1-427d-b867-5412741b3e33">3,932</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzMtMS0xLTEtMA_1e4575b5-38f2-4833-bba0-0a3797ac6e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzMtMy0xLTEtMA_1293660d-14b7-4ca5-a743-e2f79ae7fab7">461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzQtMS0xLTEtMA_44b9ff01-144a-4e6b-84f5-31c043ec7bfe">1,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzQtMy0xLTEtMA_0d4b6561-ed0d-43a5-9e1c-4b2aa461ed28">3,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for bad debts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzUtMS0xLTEtMA_432b8c27-841e-49f9-8286-2fe0dcfe272b">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzUtMy0xLTEtMA_45704d2e-c132-4fed-a556-187e7054645b">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in other entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:DeferredTaxAssetsInvestment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzYtMS0xLTEtMA_e7632a4e-00dd-4f09-8fbc-983ba676ce1d">3,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:DeferredTaxAssetsInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzYtMy0xLTEtMA_dca62591-8e21-443a-a8fb-9290bdddc375">702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzctMS0xLTEtMA_7789a718-dbad-4fb5-9569-2f60bf212e06">28,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzctMy0xLTEtMA_ba3f8264-420d-4b26-b8c0-34c9038949c7">20,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMS0xLTEtNjE4MjU_4356378c-8e51-4d0d-9778-7550e02aa895">4,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:DeferredTaxAssetsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMy0xLTEtNjE4MjU_b7445d1f-aaa0-463c-9828-c3b4d0f44ad6">4,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMS0xLTEtNjE1NDk_8c35e0d9-f887-4109-8959-6d88e36a6e77">3,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMy0xLTEtNjE1NTg_cc753911-ac35-49c1-83ff-fc1bf7012a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzktMS0xLTEtMA_442746d7-591b-4a63-9b9f-a3e7ebfa75d5">705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzktMy0xLTEtMA_d2e42df3-6dc2-43f2-963d-64dda1fb79f3">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEwLTEtMS0xLTA_f6664662-2d6d-4bdc-8bc4-bd9ace3df6ad">44,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEwLTMtMS0xLTA_eabc9534-e39f-4695-9014-e36e20062334">35,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzExLTEtMS0xLTA_4e52eca5-1b91-41ef-a681-092fcab2e3a3">22,351</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzExLTMtMS0xLTA_00e3f12e-d1cc-4eb7-aa18-648c5bc3dd5d">15,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEyLTEtMS0xLTA_8346165d-f4f6-419e-8db5-a21166011c5f">22,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEyLTMtMS0xLTA_5f056547-100a-4167-8c50-871ccfaee41e">20,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE1LTEtMS0xLTA_7f869d9e-4862-45c0-a3d1-5cae03c6138e">777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE1LTMtMS0xLTA_a9afc550-58b3-4a01-9d4a-c0e04d989ea4">661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE2LTEtMS0xLTA_4f8c3625-7d1f-4630-a15f-c7fd634c4768">23,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE2LTMtMS0xLTA_fb580bbe-af92-43bd-a000-e623aac84860">24,661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:DeferredTaxLiabilitiesStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTEtMS0xLTYxNTc1_6a86b0f0-7db4-418c-aaf0-4296d6deb6eb">1,641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:DeferredTaxLiabilitiesStockOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTMtMS0xLTYxNTc5_74de4634-488a-454c-a4dd-865efa00732c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE3LTEtMS0xLTA_8f746060-75eb-40fb-8e33-712cdee9e6ec">4,117</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE3LTMtMS0xLTA_8127722e-bca7-4dce-b88f-8dacbe2ee92c">4,888</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTEtMS0xLTY0NjM0_6f75f34d-7154-4d09-b1d0-2f95e763a7da">988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTMtMS0xLTY0NjQx_7175135a-a2be-4d0f-8cf4-f2560f489fa7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481(a) adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="ameh:DeferredTaxLiabilities481aAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTEtMS0xLTA_d32f3cf9-ff1b-432b-8eb4-cb1213942b7c">87</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="ameh:DeferredTaxLiabilities481aAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTMtMS0xLTA_337973a2-3b2e-450a-8184-036450995843">985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTEtMS0xLTA_31a425a0-6b66-40f7-8d7f-d859b98d7c04">31,373</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTMtMS0xLTA_8caefb56-f8a3-43d6-965e-ab61c3ebae8c">31,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIyLTEtMS0xLTA_77d92a11-b0b4-44b7-a71d-949b27a669ec">9,127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIyLTMtMS0xLTA_798a09d0-c6b3-44cd-89a4-eefb75cabf65">10,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjI_86c684ef-0935-44e3-bd61-fabce78b1f3d" continuedAt="i763d6431fa354b77a55ee44bbe806ccc" escape="true">The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December&#160;31:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i034ee789bcb74455955fc081a22837c9" continuedAt="ibd67347abc7a47c1809ee96cd2e650b8"><div style="margin-top:5pt"><ix:continuation id="i763d6431fa354b77a55ee44bbe806ccc"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision at U.S. federal statutory rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzMtMS0xLTEtMA_3dc1dea3-1ef9-4ab3-b00d-a09b17a5068e">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzMtMy0xLTEtMA_fd14e995-81fc-4290-b7f9-4ed0ea6283af">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzMtNS0xLTEtMA_c2b6b610-e581-4a73-b24a-f4bde0bc6001">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzQtMS0xLTEtMA_6b71ec27-447a-4e02-bad4-59b2af3206ca">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzQtMy0xLTEtMA_dbe757e0-7219-48dc-a8e2-64db0bcddce8">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzQtNS0xLTEtMA_21d19fd7-ad31-4589-b1da-8b5ea2bace54">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" name="ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzUtMS0xLTEtMA_f2ab874c-d821-4e23-bf0f-6547efa2bc67">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" name="ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzUtMy0xLTEtMA_c925b342-e01f-4bce-ba90-513cc104e1bb">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" name="ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzUtNS0xLTEtMA_05c7daaa-16d3-426a-8bcc-2be83566ef27">3.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable interest entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzYtMS0xLTEtMA_84946b73-4e5e-491c-abfc-d6c1a3810481">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzYtMy0xLTEtMA_58dfa5c1-7d74-49b4-8a77-50d03b3e5986">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzYtNS0xLTEtMA_9e707250-7d46-44b3-8488-8d0081f15f82">2.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzctMS0xLTEtMA_b7f4185c-c73b-4b83-8d3c-f25b38994455">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzctMy0xLTEtMA_5626f2e6-5f8b-4bd9-86b3-043a85a87b79">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzctNS0xLTEtMA_cb81403f-d0c9-48c4-b0b0-76864b8f5f89">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzgtMS0xLTEtMA_9fde4756-337f-4191-8cf6-1436165f0bd9">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzgtMy0xLTEtMA_abf47d1a-4c57-4204-aa5a-871978112141">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzgtNS0xLTEtMA_a503a658-4a9b-4034-a27d-4fb01cd88800">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" sign="-" name="ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMS0xLTEtNjgwOTY_28afcf5c-d9eb-471f-acf1-7decbd4c1fb7">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" name="ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMy0xLTEtNjgxMDM_c626a244-6f5e-4824-9a0e-eb5f4a2adac4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" name="ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktNS0xLTEtNjgxMTA_7e89138a-779a-40a1-bba8-e55352a50c35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMS0xLTEtMA_596626dd-3c55-422f-8231-80dbede29deb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMy0xLTEtMA_4bdc093b-9aab-424b-8b29-c8be5963572d">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktNS0xLTEtMA_938e1009-7484-4443-8943-d79ecf8f5110">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzExLTEtMS0xLTA_ffe1f62f-fce1-4325-a893-985af7e4f8e6">36.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzExLTMtMS0xLTA_e4399dd3-9f01-49df-b4ac-2c7f0ef6a834">31.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzExLTUtMS0xLTA_83027a0a-16ce-4775-bebb-08c30591dda3">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate is different from the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzE2MjI_d21f3a2f-175c-4edc-a6b2-0db7f7c1a409">21</ix:nonFraction>% due primarily to state taxes, change in valuation allowance, and permanent adjustments. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law. The CARES Act, among other things, permits net operating loss carryovers and carrybacks and modifications on the limitation of business interests.  As of December&#160;31, 2021, the Company does not expect the CARES Act to result in any material impact on the Company&#8217;s effective tax rate. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd67347abc7a47c1809ee96cd2e650b8">The Company is subject to U.S. federal income tax, as well as income tax in California. The Company and its subsidiaries&#8217; state&#160;and federal income tax returns are open to audit under the statute of limitations for the years ended December&#160;31, 2017 through December&#160;31, 2020 and for the years ended December&#160;31, 2018 through December&#160;31, 2020, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.</ix:continuation> </span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_175"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzgwNDk_5255caef-4ad0-4eac-9f5b-23f933e7235f" continuedAt="id09d5d543adf45158113f5659c3259fd" escape="true">Mezzanine and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="id09d5d543adf45158113f5659c3259fd" continuedAt="i508937b8ba114f14a087eddd4b9b927b"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Mezzanine Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature (see Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221;) of APC&#8217;s shares of common stock is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interests in mezzanine or temporary equity. APC&#8217;s shares were not redeemable and it was not probable that the shares would become redeemable as of December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="ib7f59b7851384b0d91511c5a20b67577_D20190901-20190930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzY0NA_de9adf20-f6ec-4961-917c-07420deb572d">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock for aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="ib7f59b7851384b0d91511c5a20b67577_D20190901-20190930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxNw_58b06fa0-1b82-4b7b-a873-a93cf2a42a79">545.0</ix:nonFraction> million in a private placement. This investment was eliminated in consolidation. In relation to the issuance of APC Series A Preferred Stock, APC incurred $<ix:nonFraction unitRef="usd" contextRef="i8e116c4ba416435f84ab15341357ee49_D20190901-20190930" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3Xzg2Nw_975348d8-51be-42b0-b90e-29568c522073">0.9</ix:nonFraction> million in cost (see Note 1 &#8212; &#8220;Description of Business&#8221;). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Stockholders&#8217; Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock &#8211; Series A</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, <ix:nonFraction unitRef="shares" contextRef="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzExMTU_f51acdd4-cfcb-4a77-9a29-796e269e4b63">1,111,111</ix:nonFraction> units, each unit consisting of one share of ApolloMed&#8217;s Series A Preferred Stock and a common stock warrant to purchase one share of ApolloMed&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id187f254b8f044069cf6e62f7dd23492_I20151031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzEzMDA_76826167-68b2-44d1-bf66-1142418a2762">9.00</ix:nonFraction> per share. NMM paid ApolloMed an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzEzNDk_d8c3f4f6-60c3-4592-b0a1-a88c3a21657f">10.0</ix:nonFraction> million for the units.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i508937b8ba114f14a087eddd4b9b927b" continuedAt="i017ea38c3d004dc993cc6386fa91cb21"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock &#8211; Series B</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, <ix:nonFraction unitRef="shares" contextRef="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzE1NjY_6e88f9f3-e517-476b-9108-36431d0e232e">555,555</ix:nonFraction> units, each unit consisting of one share of ApolloMed&#8217;s Series B Preferred Stock and a common stock warrant to purchase one share of ApolloMed&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="id8f27f189d204a99bb6fbd309638d302_I20160331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzE3NTE_a30ad749-c8ba-4448-9b6d-c8eb3239951b">10.00</ix:nonFraction> per share. NMM paid ApolloMed an aggregate $<ix:nonFraction unitRef="usd" contextRef="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzE3OTc_912cd240-ffde-4bac-9ed8-ea5119700106">5.0</ix:nonFraction> million for the units.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Share Issuances and Repurchases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, ApolloMed completed its business combination with NMM following the satisfaction or waiver of the conditions set forth in the Merger Agreement, pursuant to which Merger Subsidiary merged with and into NMM, with NMM surviving as a wholly owned subsidiary of ApolloMed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2017 Merger and as of the effective time of the 2017 Merger (the &#8220;Effective Time&#8221;):</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">each issued and outstanding share of NMM common stock was converted into the right to receive such number of shares of common stock of ApolloMed that results in the former NMM shareholders who did not dissent from the 2017 Merger (&#8220;former NMM Shareholders&#8221;) having a right to receive an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic9bf49749cfa4149bfcc21376770c3d7_D20171201-20171231" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI1NDE_7b516bf3-69e7-4275-a596-06fc15780db7">30,397,489</ix:nonFraction> shares of common stock of ApolloMed, subject to the <ix:nonFraction unitRef="number" contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231" decimals="2" name="ameh:NumberOfSharesHoldbackPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI1OTY_d6bc1d20-d2ab-4cdb-8236-fa8910e91c36">10</ix:nonFraction>% holdback pursuant to the Merger Agreement;</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ApolloMed issued to former NMM Shareholders each former NMM Shareholder&#8217;s pro rata portion of (i) warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i736e3fec90114a5aa4409b6b2e10ee3d_I20171231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI3Nzc_d8f58ecc-c795-4825-9a80-bc02b14cf1b1">850,000</ix:nonFraction> shares of common stock of ApolloMed, exercisable at $<ix:nonFraction unitRef="usdPerShare" contextRef="i736e3fec90114a5aa4409b6b2e10ee3d_I20171231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI4MzI_e5b71eb9-4a18-49b5-a92e-d3c8d8ed1b86">11.00</ix:nonFraction> per share, and (ii) warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i6be868f31ad04ccd92b62a8b53e31994_I20171231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI4OTI_3a5e29e9-f5b7-4b2d-b36f-83bff6aa7b5b">900,000</ix:nonFraction> shares of common stock of ApolloMed, exercisable at $<ix:nonFraction unitRef="usdPerShare" contextRef="i6be868f31ad04ccd92b62a8b53e31994_I20171231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI5NDc_2f7c8ea1-0330-4eee-b855-1d409d8cda67">10.00</ix:nonFraction> per share; and</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ApolloMed held back an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic9bf49749cfa4149bfcc21376770c3d7_D20171201-20171231" decimals="INF" name="ameh:BusinessCombinationNumberOfSharesHeldBack" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzMwMDE_d49cceaf-1ac3-4248-bda4-54c371c3a141">3,039,749</ix:nonFraction> shares of common stock issuable to former NMM Shareholders, representing <ix:nonFraction unitRef="number" contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231" decimals="2" name="ameh:NumberOfSharesHoldbackPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzMwNzc_06019460-5a1b-4a0c-b12a-67e0874648bb">10</ix:nonFraction>% of the total number of shares of ApolloMed common stock issuable to former NMM Shareholders, to secure indemnification rights of AMEH and its affiliates under the Merger Agreement (the &#8220;Holdback Shares&#8221;). The Holdback Shares were issued and outstanding as of December&#160;31, 2021. The first tranche of <ix:nonFraction unitRef="shares" contextRef="idafaa881ac7c4f0ea1acfd5e7bac657c_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzMzNjQ_7c9701d7-e8b5-4f06-8fa9-066ded080c0b">1,519,805</ix:nonFraction> shares were issued in December 2018 and the remaining <ix:nonFraction unitRef="shares" contextRef="id6c9410eee65468595d358150c9017de_I20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM0MjE_72777726-47c0-481c-b98b-19f0dc4d297f">1,511,380</ix:nonFraction> were issued in December 2019, net of shares repurchase.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of common stock issuable to former NMM shareholders in the exchange were <ix:nonFraction unitRef="shares" contextRef="i9926c974cf3347f388bb822becf71f99_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM1NjQ_acfd6cea-343b-4d0b-87df-cb35f9043599">25,675,630</ix:nonFraction> (net of <ix:nonFraction unitRef="number" contextRef="i36c4f94c659e40378bce5560a8288c13_D20210101-20211231" decimals="2" name="ameh:NumberOfSharesHoldbackPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM1NzU_da514a9c-3199-49e7-9082-9b6bc770c9a8">10</ix:nonFraction>% holdback and Treasury Shares). The <ix:nonFraction unitRef="number" contextRef="i36c4f94c659e40378bce5560a8288c13_D20210101-20211231" decimals="2" name="ameh:NumberOfSharesHoldbackPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM2MTM_da514a9c-3199-49e7-9082-9b6bc770c9a8">10</ix:nonFraction>% holdback shares were released to all the former NMM shareholders based on their respective pro rata ownership interest in NMM at the Effective Time without regard to whether the former NMM shareholders are providing any services to the Company at the time of this distribution. This holdback accommodation was made as indemnification protection to the accounting acquiree (ApolloMed), and as such, is not considered compensatory. At the time when these holdback shares were issued to the former NMM shareholders, the Company recorded the stock issuance with a reduction to additional paid-in capital to properly reflect the shares outstanding.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the 2017 Merger, the Company issued <ix:nonFraction unitRef="shares" contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231" decimals="INF" name="ameh:StockIssuedDuringPeriodShareConversionOfNotes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzQzMjE_1b7ce519-9db0-41fa-98d9-18dee0bd6987">520,081</ix:nonFraction> shares of its common stock with a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231" decimals="-5" name="ameh:StockIssuedDuringPeriodValueConversionOfNotes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzQzODY_e14be780-2372-420d-8288-11c3547697e8">5.4</ix:nonFraction> million from the conversion of a convertible promissory note issued by the Company in 2017.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:StockIssuedDuringPeriodSharesMerger" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzQ0OTY_9dbc1ca5-8847-4c56-b4de-e05a135b4970">140,954</ix:nonFraction> holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the Merger Agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, NMM did not pay any dividends.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i017ea38c3d004dc993cc6386fa91cb21" continuedAt="ibd124bea0652495291a3048cbfc6d79b"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i1eff2864c695401fb93686780342c192_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxMDY_c7c9fd67-944f-4075-9178-fa8117fd4daf">29.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i601de355c37d4e38a5ea8fffe8e17e9d_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxMTA_0d04389c-1d55-4df8-b643-9d1c1dfb4137">136.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81990f1f745c424ca090209239fb9e19_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxMTc_ce2893db-2794-458c-8aef-464ffc38cd1d">60.0</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, CDSC paid distributions of $<ix:nonFraction unitRef="usd" contextRef="i011724573aa749b2834cc036d67d7006_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM4NDgyOTA3MDgwMTM_18828d0d-9563-4cd8-9c01-bb9102215f8f">1.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i40fc578ddc114d17b7d8aa16f28a9b27_D20200101-20201231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcyMDQ_93b0103c-bd60-45a3-899d-f70fcdd7f5a3">2.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id5cc5d815cc04d21bef7fb998c409f3d_D20190101-20191231" decimals="-5" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcyMTE_8f1d6521-a156-4e07-a198-a078489c1fdc">2.6</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned <ix:nonFraction unitRef="shares" contextRef="i163cc47f491d41b392adbb6959d8f774_I20211231" decimals="0" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcyNTQ_4a8f6990-b1b9-46ea-9cfc-5a1e95ca0f3d">10,925,702</ix:nonFraction> shares of ApolloMed&#8217;s common stock as of December&#160;31, 2021, and <ix:nonFraction unitRef="shares" contextRef="i04943825157d4043aa0fb2fe8723b079_I20201231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzczMDY_795d041e-fd78-4493-ad90-b3fcea98984b">12,323,164</ix:nonFraction> shares of ApolloMed&#8217;s common stock as of December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1 &#8212; &#8220;Description of Business&#8221;).</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd124bea0652495291a3048cbfc6d79b">During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board, of which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of December&#160;31, 2020, the brokerage account only held shares of ApolloMed, as such the brokerage account totaling $<ix:nonFraction unitRef="usd" contextRef="i4774888a4f484996ad1923628b04af51_I20201231" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI3NDg3NzkwNzg5NTY_1e947b9f-bd94-497a-9941-9514a9aaf4c5">7.7</ix:nonFraction> million was recorded as treasury shares. As of April 2021, the brokerage account has been closed.</ix:continuation> </span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_199"></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODg_cbafba91-4f4b-4d6d-b09f-a18fcc3b04cd" continuedAt="i36b9df913d4948baaa2a0ec468f147eb" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i36b9df913d4948baaa2a0ec468f147eb" continuedAt="i3ebe0a21462b434183ef068c0f786420"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2017 Merger, the Company assumed ApolloMed&#8217;s 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;), pursuant to which <ix:nonFraction unitRef="shares" contextRef="i5005e6c965ce49078328bedec974e062_I20171208" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE4NQ_97bb7c98-3707-425c-9845-810073fbf38a">500,000</ix:nonFraction> shares of the Company&#8217;s common stock were reserved for issuance thereunder. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of December&#160;31, 2021, there were no shares available for future grants under the 2013 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2017 Merger, the Company assumed ApolloMed&#8217;s 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;), pursuant to which <ix:nonFraction unitRef="shares" contextRef="i0a44ec4586564a71b632ebd24b41a548_I20171208" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU2OA_ac6dfdcd-b8da-493c-aae3-fc1fe31245e1">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were reserved for issuance thereunder. In addition, shares that are subject to outstanding grants under the Company&#8217;s 2013 Plan, but that ordinarily would have been restored to such plans reserve due to award forfeitures and terminations, were rolled into and become available for awards under the 2015 Plan. The 2015 Plan provides for awards, including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. The 2015 Plan was approved by ApolloMed&#8217;s stockholders at ApolloMed&#8217;s 2016 annual meeting of stockholders that was held in September 2016. As of December&#160;31, 2021, 2020, and 2019, there were approximately <ix:nonFraction unitRef="shares" contextRef="iec9540bba78a40aa9b698767130e5df9_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEyNDk_6e2977a2-731b-4807-995d-bf419dc5e645">1.7</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="i9f37aecb480c4ca4bdaabd1cc01c6d74_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEyNTM_a7a221b9-85f4-4a08-b54b-387193ecdcc5">0.1</ix:nonFraction> million and <ix:nonFraction unitRef="shares" contextRef="i69e0bb8c26da401f981101891ef4858c_I20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEyNjA_42cebe11-386f-469c-9c97-65df956ae4e2">0.5</ix:nonFraction> million shares available for future grants under the 2015 Plan, respectively.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODQ_3e6e3be0-4ef9-41c7-a56a-99c9f0f86b9b" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans in 2021, 2020, and 2019 and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5a872d4cb64a1795a11e4a6a81b2cd_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzItMi0xLTEtMA_58c06697-12f6-448a-98c6-3fd673016d49">2,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d0316c954743c68575e89e641ec7ec_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzItNC0xLTEtMA_98be9e2d-cbba-440c-bb2c-38c6208a148a">1,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92bee5c5555f4c9bb28b959713ee742c_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzItNi0xLTEtMA_0b22f73b-320d-4154-9d7c-19eaae913f7f">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55c7e2bb01da4cb8a05eeb09f96b7145_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzMtMi0xLTEtMA_a4c1e645-a5ef-4c45-9b25-6883d73c8725">4,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida71012f2abb40c3bb3b97875ac19fd1_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzMtNC0xLTEtMA_b25578d1-d14b-43b2-a17a-96f8aae1ce18">1,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48d331e72ef4c45922e796a5ec33fe2_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzMtNi0xLTEtMA_386c9a7a-d7c0-4b27-838a-38a11ace4a86">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id34b814b72a749ff9980e038fe3de780_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzQtMi0xLTEtMA_132523f3-8506-4d13-b03d-5db392b5e807">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e60e144eae847ee8431a5c5918fdb83_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzQtNC0xLTEtMA_7cbe370a-429f-44cd-abae-03db4815c4f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b2b020931f4f90afee0ac9784f1f61_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzQtNi0xLTEtMA_0b3c5f46-3001-409a-a7fc-ed65ee8711ca">607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzUtMi0xLTEtMA_592a5d0c-96ab-4b10-9dfe-211a97e7d9ea">6,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzUtNC0xLTEtMA_e6defa17-d4f0-46c0-8361-3606b484c989">3,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzUtNi0xLTEtMA_f83d48bc-8a77-43f2-9149-2879221d83a9">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of December&#160;31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="iec9540bba78a40aa9b698767130e5df9_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzg4Mjc_71902771-1896-42e4-aa42-ee469c20b02a">21.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODU_5e5ffd9a-550e-45b5-85c6-0b72664cbb66" continuedAt="i6081473aec064cd696569ddd35c8ded3" escape="true">The Company&#8217;s outstanding stock options consisted of the following:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i3ebe0a21462b434183ef068c0f786420" continuedAt="ifb4828aa06aa46f798e1ef446c8ccd16"><div style="margin-top:17pt"><ix:continuation id="i6081473aec064cd696569ddd35c8ded3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItMS0xLTEtMA_bf4c3922-400a-456b-b633-a9eb6b0a330d">725,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItMy0xLTEtMA_90092442-8d58-416e-85bf-b5e717ac42fe">13.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItNS0xLTEtMA_0e43e1f2-c7dc-43b9-821f-9b72feb0291d">3.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItNy0xLTEtMA_29e7648d-0236-4e97-8b63-29596e836478">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzMtMS0xLTEtMA_7b75c285-cef5-4560-a03d-0acd620846fe">137,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzMtMy0xLTEtMA_a21ab59f-96d6-45c9-9ba2-331ccfb1413d">66.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzQtMS0xLTEtMA_cf815231-1ecb-432e-b085-9d6b1e6dac01">40,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzQtMy0xLTEtMA_65cadc40-c09a-4e82-90cc-d738ca131a81">5.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzQtNy0xLTEtMA_52d01090-6680-48ab-bdd2-5064d1109bf1">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzUtMS0xLTEtMA_d3a2ecd4-945a-469e-a528-8c7a740ca48d">9,826</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzUtMy0xLTEtMA_9dad1865-85a2-4c05-914d-b4388a054329">3.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtMS0xLTEtMA_cdea8806-8aec-4f26-ae71-88ce39d0f36e">813,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtMy0xLTEtMA_1a72a61d-5e2d-4cb9-92e3-aca63780b178">22.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtNS0xLTEtMA_387b9ee0-5f6f-454d-8d8a-60c3b6c895e2">3.20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtNy0xLTEtMA_6a1d8054-99b4-4b07-99ce-e0f56d38a94b">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtMS0xLTEtMA_e3337537-1bdb-43df-8eab-2049ec3cd6a2">618,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtMy0xLTEtMA_32c9ff46-b67a-4290-b530-eb61fd55ca33">10.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtNS0xLTEtMA_69ff41a1-6233-465b-8602-bbdcbe3a7c66">2.14</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtNy0xLTEtMA_d19a2fb0-36b9-4078-834d-7665e9fddacd">37.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, stock options were exercised for <ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE4NjA_f7fe8e61-d59f-4fb1-97bf-d11e956ac7b6">40,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE4Njc_f7d89983-428e-4b65-b269-9440ef5249fe">0.1</ix:nonFraction> million shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i0f05771c561640aaab3a2c2c0e44330b_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE5Njc_5ed8fd1c-326c-409b-8736-c97a310c1674">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8bb2c1e084a049cd8af7b6044a0c177e_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE5NzQ_72c7fed2-d180-42f5-a313-85fe570fdd64">0.3</ix:nonFraction> million, respectively. The exercise price was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibef63d60b9e947eead74bdfd0b22345e_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIwMzA_e9e80a0c-5376-444c-ab9a-c536fea63b95">5.20</ix:nonFraction> per share for the exercises during the year ended December&#160;31, 2021 and ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="ie160814e72a34eebb359d61571716c26_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIxMDI_6ed70609-6271-469c-b65b-6073549fe550">2.10</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i3e9c3a5ed3424d31b9ae24620d3bb654_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIxMDg_abc0330e-3d6b-477f-b4a5-b8a567d52486">5.00</ix:nonFraction> per share for the exercises during the year ended December&#160;31, 2020. During the year ended December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjUzMzA_c24bb71c-cc3f-4418-9c48-2481365ccd47">no</ix:nonFraction> stock options were exercised pursuant the cashless exercise provision. The total intrinsic value of stock options exercised was $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3MDE_0be8bbce-bac9-48b4-8279-a8605df97428">2.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3MTY_0a168b46-b5d1-42a1-87b5-26fadfde08b6">1.8</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3MzI_26dcc813-1c64-4d94-951b-d04cab59b82c">2.7</ix:nonFraction> million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. The intrinsic value of stock options is defined as the difference between the Company&#8217;s stock price on the exercise date and the grant date exercise price. </span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODY_21046691-19b0-4b87-9b23-6950b096345e" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company granted <ix:nonFraction unitRef="shares" contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIzMTk_b6689eca-3391-46ed-a98e-5a78f8435e2f">0.1</ix:nonFraction> million <ix:nonNumeric contextRef="i31c542aee5d1477695e59726049c8b71_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODc_36447cc8-b1ac-4bbf-a746-4bbfb1ea9f79">five-year</ix:nonNumeric> stock options to certain ApolloMed executives with exercise price ranging from $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc47b22c80ae4ba5a6046042c4073438_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI0NTI_eaf1a502-f4da-46f0-971a-528a2bde9126">23.24</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ie31caf7183734c75a34b0c38fefd09f8_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzY5ODU_b0b1a509-206b-44a3-906f-1be72368d1de">80.00</ix:nonFraction>. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2021, 2020, and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzcxODE_07e57571-425b-4d3b-a571-3c17aeca91c1">32.63</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzcxODY_ca9b6eef-a7b8-4e25-b6fd-331274860394">9.89</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzM4NDgyOTA3MDkzNDI_84da59df-cdb4-41ff-b432-1fc36dcf2c75">11.33</ix:nonFraction>, respectively. The options granted during the year ended December&#160;31, 2021 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzEtNC0xLTEtMA_245246f8-2cdb-438a-a733-ea98226c40a4">3.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ife3ade634e3f411d8ff9d287f7f6ccfc_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzItNC0xLTEtMC90ZXh0cmVnaW9uOjgzMDdkMGNlMGY1ZDRiNWViNjE2NjEzZTEyNGZkZTUyXzk4OTU2MDQ2NTAwMjI_59b16b3c-3683-400f-8b39-e6e67c2330a9">75.45</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i88ed9f8ac2bd41ad84ee70e5cec56071_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzItNC0xLTEtMC90ZXh0cmVnaW9uOjgzMDdkMGNlMGY1ZDRiNWViNjE2NjEzZTEyNGZkZTUyXzk4OTU2MDQ2NTAwMzI_faf95ee5-eabc-48b4-a6db-3beae5a08490">81.10</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ife3ade634e3f411d8ff9d287f7f6ccfc_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzMtNC0xLTEtMC90ZXh0cmVnaW9uOmE2M2U5ZDY2Y2NiMzRhMWQ4OGU5ZTY3NjRlNTYwN2ZjXzk4OTU2MDQ2NTAwMTk_2292b82f-f37c-4f11-bdd2-6dae6dd4905e">0.19</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i88ed9f8ac2bd41ad84ee70e5cec56071_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzMtNC0xLTEtMC90ZXh0cmVnaW9uOmE2M2U5ZDY2Y2NiMzRhMWQ4OGU5ZTY3NjRlNTYwN2ZjXzk4OTU2MDQ2NTAwMjg_bb25dba3-f5a7-4778-a25a-a81f61bcdc43">1.15</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc47b22c80ae4ba5a6046042c4073438_I20211231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzQtNC0xLTEtMC90ZXh0cmVnaW9uOmQxZmM5ODdmMjc3YTRkNzZhNDExNDJlZjFiYWE1OGZiXzk4OTU2MDQ2NTAwMTk_5058b813-b3d3-4a22-afbf-aeb62ae0c076">12.86</ix:nonFraction>-<ix:nonFraction unitRef="usdPerShare" contextRef="ie31caf7183734c75a34b0c38fefd09f8_I20211231" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzQtNC0xLTEtMC90ZXh0cmVnaW9uOmQxZmM5ODdmMjc3YTRkNzZhNDExNDJlZjFiYWE1OGZiXzk4OTU2MDQ2NTAwMzE_ad6e49d7-b693-475f-9641-034cddb5b6c3">37.82</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzUtNC0xLTEtMA_452022ba-2fde-460d-a11b-a0de7c51bcb2">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231" decimals="2" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzYtNC0xLTEtMA_b08dc655-9b55-4690-a7c0-8325edf73707">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjAwOTk_b8efc1bf-c23a-4e55-b43c-7793da8ce351" continuedAt="i53c3c9a8f3e445569865b82d8a82a0fd" escape="true">The Company&#8217;s unvested restricted stock award activity for the year ended December&#160;31, 2021 consisted of the following:</ix:nonNumeric></span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="ifb4828aa06aa46f798e1ef446c8ccd16" continuedAt="i98a29f122ce042e3986345cff53a86b0"><div style="text-align:justify"><ix:continuation id="i53c3c9a8f3e445569865b82d8a82a0fd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.276%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted  Average <br/>Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i670fb4a8ae4c408681d8b085578171d6_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzItMS0xLTEtNDEyMjQ_7f8f5cfc-c933-45c8-8a52-04c9c0b8903b">262,419</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i670fb4a8ae4c408681d8b085578171d6_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzItMy0xLTEtNDEyMjQ_0526b7d3-3820-4321-a439-9fce2e628b57">17.96</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzMtMS0xLTEtNDEyMjQ_25925ee8-f19f-4860-8eb6-514f6f232174">332,202</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzMtMy0xLTEtNDEyMjQ_26436a31-df54-4a3f-8729-5ae7202ad9ed">50.73</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzQtMS0xLTEtNDEyMjQ_81fdafb4-bf87-4c5e-bcea-c0f3b5e9c0fb">39,910</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzQtMy0xLTEtNDEyMjQ_5c3458fa-9dec-4f62-8365-e529ea4394cf">17.03</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzUtMS0xLTEtNDEyMjQ_c3f4ca23-f3f0-4e3f-8728-e5ea8e805d72">13,204</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzUtMy0xLTEtNDEyMjQ_9a410f64-344e-464c-9869-89f5c58dc89f">29.88</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic130048652fd4ae89ae9be7d998b753c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzYtMS0xLTEtNDEyMjQ_1f6e937a-6f1c-46a2-a085-208bfc7d382d">541,507</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic130048652fd4ae89ae9be7d998b753c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzYtMy0xLTEtNDEyMjQ_277c12f7-ded8-4a10-a207-262600eb78ee">37.84</ix:nonFraction></span></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to employees and executives, which are earned based on service conditions. The awards will vest over a period of <ix:nonNumeric contextRef="i2b029890b2714cffb3297481713b140b_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjYzODk_df7649ae-cea3-4bae-8c6d-3e0cbb2b3110">six months</ix:nonNumeric> to <ix:nonNumeric contextRef="i21f1ff2005de4e06ab13d40c18783c14_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjY0MDk_59792be8-a3a4-49e8-8e12-a981250120ec">three years</ix:nonNumeric> in accordance with the terms of those plans. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the year ended December&#160;31, 2021, the Company granted restricted stock awards for employees totaling <ix:nonFraction unitRef="shares" contextRef="ia49fab4addb846b78532141505ad76c8_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3NDU_e07f471e-f262-460f-be0a-b8987b3408d8">0.3</ix:nonFraction> million shares with a weighted-average grant-date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia49fab4addb846b78532141505ad76c8_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3NDk_0864ec7b-e082-4478-a257-37941034ef11">50.73</ix:nonFraction>. The  weighted-average grant-date fair value of restricted stock awards granted during the years ended December&#160;31, 2020, and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="id39d667c80e24f60a2821321e2d966cc_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzg3MDc_eff4dc0c-cdc2-4a3b-8c98-815fb32582fe">17.56</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9eae915be53045f6bb1b2c554e86ccb5_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzg3MTE_4ecbdfaf-c49c-48bb-84d9-538cf38dff95">18.65</ix:nonFraction>, respectively. The total fair value of restricted stock awards, as of their respective vesting dates during the years ended December&#160;31, 2021, 2020, and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="ifebcbe81b7cb4bb1b35b8f52f712e985_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyNDg_ad816c33-ec49-4417-8468-3104c0c537f1">1.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0fafa1dea0849b1b343ca69489e8c78_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyNjQ_043548b1-4d2a-4477-b8ad-a306713e871b">1.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i1d3bbb3ca7dd4c24bc7e516e958c13e6_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyODA_5681813e-5b67-4e29-b166-1d65ecaa7c36">0</ix:nonFraction>, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants, to purchase <ix:nonFraction unitRef="shares" contextRef="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzUwODk_f51acdd4-cfcb-4a77-9a29-796e269e4b63">1,111,111</ix:nonFraction> shares of ApolloMed common stock, issued to NMM in connection with the Series A Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $<ix:nonFraction unitRef="usdPerShare" contextRef="id187f254b8f044069cf6e62f7dd23492_I20151031" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzUyODk_76826167-68b2-44d1-bf66-1142418a2762">9.00</ix:nonFraction> per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants, to purchase <ix:nonFraction unitRef="shares" contextRef="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzU2MzE_6e88f9f3-e517-476b-9108-36431d0e232e">555,555</ix:nonFraction> shares of ApolloMed common stock, issued to NMM in connection with the Series B Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $<ix:nonFraction unitRef="usdPerShare" contextRef="id8f27f189d204a99bb6fbd309638d302_I20160331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyOTQ_a30ad749-c8ba-4448-9b6d-c8eb3239951b">10.00</ix:nonFraction> per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants, to purchase <ix:nonFraction unitRef="shares" contextRef="i7edf78b63c6f4e08805f86b4036d2e81_D20160301-20160331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0MzA_eefd38e7-9499-4ddf-9bbc-948da4bbebc9">850,000</ix:nonFraction> shares, for $<ix:nonFraction unitRef="usdPerShare" contextRef="i5f12986e0b9048669859a5f857899013_I20160331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0Mzk_a90c3b61-2cd1-4c1b-8ceb-be7ae76804ef">11.00</ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="i779a53f850a8409dbd4e696d526532c9_D20160301-20160331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0NDk_f17d8ed2-d140-4c6a-99e0-d75f63c85174">900,000</ix:nonFraction> shares, for $<ix:nonFraction unitRef="usdPerShare" contextRef="ie312f8b83db04cdcb3b524d5a3a6ba12_I20160331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0NTg_fe232e03-0664-4628-aac9-fa47be996e03">10.00</ix:nonFraction> per share, of ApolloMed common stock, issued to former NMM shareholders on a pro-rata basis in connection with the Merger, may be exercised at any time after issuance and through December 8, 2022, subject to adjustment in the event of stock dividends and stock splits. </span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzY1OTcwNjk3NzU4NTY_5f1f1544-ad2e-407b-8580-d3c09c34ae43" continuedAt="i9c4cc1841efe4824a0d6a7e3e72ae402" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtMS0xLTEtNDEwNzk_7f8a3c29-1abb-4267-ab69-3e98c17c3720">1,878,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtMy0xLTEtNDEwNzk_403b923c-0bea-4916-89b7-f6e1d0988640">10.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtNS0xLTEtNDEwNzk_5ee34dee-9dfd-4d6e-ab62-5e0f9f9b7a6b">1.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtNy0xLTEtNDEwNzk_632b200f-7d49-48bd-a1db-cebe5189f469">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:NumberOfWarrantsGranted" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzktMS0xLTEtNDEwNzk_c303967d-2f5e-43c7-9499-8744e29c3978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzktMy0xLTEtNDEwNzk_4daecf76-bea8-45d5-9343-7996259d1e60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzktNy0xLTEtNDEwNzk_74947ae2-31e8-47e8-9b84-eb2a8450822d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:NumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEwLTEtMS0xLTQxMDc5_14531960-6531-416b-9a85-0c5227224a93">858,583</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEwLTMtMS0xLTQxMDc5_5b3bdf0d-f3ea-4368-bade-5950e2e07c16">10.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEwLTctMS0xLTQxMDc5_f58c4035-286c-41db-8a1b-d2222775c61a">41.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:ClassOfWarrantOrRightCancelledInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzExLTEtMS0xLTQxMDc5_2de8235a-1982-467e-a30e-a0c07b430dd6">17,803</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzExLTMtMS0xLTQxMDc5_fb115bfc-7256-43ff-bca1-d2b9bcbe4304">9.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzExLTctMS0xLTQxMDc5_1f03caea-b221-4547-8c87-5b977281f6f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTEtMS0xLTQxMDc5_e1d6e842-2714-44ef-9438-717409c7d2db">1,001,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTMtMS0xLTQxMDc5_b06254b7-a58c-4d0e-a280-6a648f3aeda5">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTUtMS0xLTQxMDc5_8c9cf0ac-25d8-4511-992e-873051a9237f">0.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTctMS0xLTQxMDc5_6084b169-4c90-44f7-bfa9-951dda3f0965">63.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i98a29f122ce042e3986345cff53a86b0"><div style="margin-top:12pt"><ix:continuation id="i9c4cc1841efe4824a0d6a7e3e72ae402"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.665%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.229%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise&#160;Price&#160;Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br/>Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>Per<br/>Share</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtMC0xLTEtNDEwNzk_de5e45a0-c67d-43fc-ad38-60a9193443c3">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66cd6792e85c49d7a61ed092edae091c_D20210101-20211231" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtMi0xLTEtNDEwNzk_fbfac083-b9fc-4957-a8f1-c86db5208c78">515,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66cd6792e85c49d7a61ed092edae091c_D20210101-20211231" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtNC0xLTEtNDEwNzk_02a6ae1c-31e8-4015-bf5b-d04dc9391387">0.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtNi0xLTEtNDEwNzk_39f4f0b1-2c30-4766-92b8-46a8c3afbae3">515,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtOC0xLTEtNDEwNzk_46e90052-a854-4215-95e9-1c1fc3fb7cea">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtMC0xLTEtNDEwNzk_9afec95c-004f-47d3-ab26-affd87f7f1d4">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia90a6c2a97b64a389f5c927fc93bf96a_D20210101-20211231" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtMi0xLTEtNDEwNzk_efc96c41-4dac-4cd6-83e4-8ee46edfd351">486,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia90a6c2a97b64a389f5c927fc93bf96a_D20210101-20211231" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtNC0xLTEtNDEwNzk_bbdf5577-29ee-4e88-9452-683001af1ab9">0.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtNi0xLTEtNDEwNzk_2c076080-ef7d-4328-8895-d1dc8fdce795">486,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtOC0xLTEtNDEwNzk_db1685fa-c825-4752-b63f-12413de96f9f">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if46b72f6abf844e9879f71846c8b9b66_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtMC0xLTEtNDEwNzkvdGV4dHJlZ2lvbjpmNThkZTM5NDQ5M2Q0MTNkOGNhMjBjMDhmNmEyMmY3M180_ede00109-c2ea-43c2-9fcb-f3c31354e40c">10.00</ix:nonFraction> &#8211; $<ix:nonFraction unitRef="usdPerShare" contextRef="i08aaa85087aa4345a9007df6c4591fd1_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtMC0xLTEtNDEwNzkvdGV4dHJlZ2lvbjpmNThkZTM5NDQ5M2Q0MTNkOGNhMjBjMDhmNmEyMmY3M185_f22f7081-762e-4737-9d68-c51e979221cd">11.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b537ba452f949228e951dcdfcef32e0_D20210101-20211231" decimals="INF" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtMi0xLTEtNDEwNzk_0eba1fa5-7395-4479-bfbf-5208e3d9efa9">1,001,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3b537ba452f949228e951dcdfcef32e0_D20210101-20211231" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtNC0xLTEtNDEwNzk_fcbb35e1-cfe0-4468-b54e-b9784063bb2b">0.94</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53187ce216524aa3b307b37805167d6b_I20211231" decimals="INF" name="ameh:ClassOfWarrantOrRightExercisable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtNi0xLTEtNDEwNzk_665c41e2-3177-4217-9d21-4365b24be5f5">1,001,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53187ce216524aa3b307b37805167d6b_I20211231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtOC0xLTEtNDEwNzk_47ec9143-06f1-45a2-982f-96b85c46cd89">10.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, common stock warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="INF" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYyODI_ebb300db-cbf3-4e65-bbe4-f9180b127ada">0.9</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYyOTA_c44977f3-b97d-4a8b-bed6-1354ece5b593">1.2</ix:nonFraction> million shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYzODk_584a387d-d7cb-4ea0-8de7-f230eafb0ed7">8.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYzOTc_badc2701-661d-4637-a73b-8abfaa45dcbc">10.5</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i3b1cfd32fb714d1b80f4201a5deed2a1_D20200101-20201231" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NDc_3b76a9ef-2052-434a-ac1d-e5e9d3784b1c"><ix:nonFraction unitRef="usdPerShare" contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NDc_c5a936ac-ce7d-45a9-97bb-b4c37b15711b">9.00</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NTQ_1989b4f2-501f-46cb-887c-e0e7f782890c"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bab33a21a0648868b28fc7d50f54158_D20200101-20201231" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NTQ_274f5fd2-4a7c-453b-bf9e-121610a74ad7">10.00</ix:nonFraction></ix:nonFraction> per share during year ended December&#160;31, 2021 and December&#160;31, 2020.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_181"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzM4Mjg_90df191e-5bfc-4486-b6d2-cb70ebecfdbe" continuedAt="ie82485be370748b9bd51d51618472192" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ie82485be370748b9bd51d51618472192" continuedAt="i4c32d2206c104ac4b90ee021b6a56739"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care (&#8220;DMHC&#8221;). The Company must comply with a minimum working capital requirement, tangible net equity (&#8220;TNE&#8221;) requirement, cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. At December&#160;31, 2021 and 2020, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount of <ix:nonFraction unitRef="number" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="ameh:PercentageOfFinancialGuaranteeBenchmarkAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzE4NjE_a1c0e148-6bb3-444e-b4e3-9d3aac0ddd2f">2</ix:nonFraction>% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. In August 2020, $<ix:nonFraction unitRef="usd" contextRef="i5d72bc8610fd48128d879bda262dfe43_I20200831" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzE5NDg_dcb2b55d-a422-44ed-9e13-cdb3eeb7f77a">14.8</ix:nonFraction>&#160;million of the irrevocable standby letters of credit were released by CMS and $<ix:nonFraction unitRef="usd" contextRef="i92adc7af35ce442586e7f832696d8083_I20211231" decimals="-5" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzE5NTI_019b1969-0c59-4caf-98e4-46aecc8480aa">0</ix:nonFraction> remain outstanding as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with Preferred Bank for a total of $<ix:nonFraction unitRef="usd" contextRef="ie254787cc84c48bd84c74b128e2266d7_I20211231" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzIwNjM_bd32a70e-c571-4040-99cb-06d9a9cf3961">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15d1c54ce99042c1b561ab2ee11ee78e_I20211231" decimals="-5" name="us-gaap:LineOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzIwNzA_d746ed28-4e43-47bc-b761-e62f63c9ad4d">3.8</ix:nonFraction> million, respectively, for the benefit of certain health plans (see Note 10 &#8212; &#8220;Credit Facility, Bank Loan, and Lines of Credit&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i4c32d2206c104ac4b90ee021b6a56739"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div></ix:continuation><div id="i796d62c2eb674b8c9edd48d78ebf1f96_187"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQyOTg_88b60b0f-334a-4ee2-9acd-bd558f3566e9" continuedAt="i47c35e0a6b684891a553684ec9d04111" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i47c35e0a6b684891a553684ec9d04111" continuedAt="icf5b5ce7d40d4f29b8c8775350184aa5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, NMM earned approximately $<ix:nonFraction unitRef="usd" contextRef="i129f6a3461cf4f1ab4901b6a723c2efa_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEwMg_6fb2cb20-a6cb-47fc-b18a-aebb7a589686">18.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9270b7467dd044688bc0a7eb2e2ca95b_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEwNg_841e80df-cb97-4e0d-bc54-4c85cf16d8f8">16.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ic2b387c30626438ebb40b9bca7610e32_D20190101-20191231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExNA_977116e8-f0fe-44be-a0cd-600609e460c6">17.3</ix:nonFraction>&#160;million, respectively, in management fees, of which $<ix:nonFraction unitRef="usd" contextRef="i4e46c773fc154de4bf33cdae598f28cd_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE2MQ_4d011b9c-1daf-46f5-8014-f2a9b3e437cf">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7b8910f127dd44bf93a735ed77e16ac9_I20201231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE2OA_eac5e704-458e-40a6-8eb7-edaec02e9278">2.3</ix:nonFraction> million, remained outstanding, at December&#160;31, 2021 and 2020 respectively, from LMA, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="ic79962b6add548d1a0a0800ef768b995_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI4Nw_9d73444b-b927-4b9b-b98b-28c4406a16b6">25</ix:nonFraction>% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i63281dcdd4a140dbb747619db7d8c8a4_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQwNg_a15b7470-d44d-4bcc-8125-bb60a1858750">2.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i70d92535c55249a8847213ad5c2a502c_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQxMA_d50c1c61-4b28-4bd0-bd13-1fbf8e649f9d">2.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i4bad5438ff3a4f74a3d70bcaa21c6c0f_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQxOA_ea8d8a58-1670-4d08-9e7f-b19fd4edb6c6">2.7</ix:nonFraction>&#160;million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="ia5679f2c797347059c1225b32fbb6b13_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzUyNA_e0d4592e-2b79-436a-a5e2-59922bf87235">40</ix:nonFraction>% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ie849991976b847cf90334bfe31a52480_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzY0Mw_92a49d59-e074-4226-b85e-88a62188a4ea">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="icf99075624e6433ba75a5f77dc805f15_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzY0Nw_e68bcb44-9e69-4def-880b-f567a1ad1b00">6.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ib13f9af073384d4c9e1929dc51068830_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzY1NQ_0575fcef-a6cf-4e7b-975c-7f7c7c8891f3">7.8</ix:nonFraction>&#160;million, respectively, to DMG for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="ic2133589307c47dcbdf2e41c006a5957_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzc1OQ_57cd94c4-395b-4efc-a800-b0459f6ceed1">40</ix:nonFraction>% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;). In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8e8615520d1c460abd7740668e7eccb7_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzg3OA_786bfaa6-75ac-4fb6-b458-1250ab5a481a">0.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0bcb63ad4a3840f5972376ef0ad45c77_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzg4Mg_a457f919-f5f9-43e9-bd81-45aff224c2e1">0.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3c960befa3cb4c8481200d45bd9ea49e_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzg4Ng_d4af4412-1046-4153-8b57-3be55dfcd70d">0.4</ix:nonFraction>&#160;million, respectively, to Advance Diagnostic Surgery Center for services as a provider. Advance Diagnostic Surgery Center shares common ownership with certain board members of APC. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="id3bb44ce70f74f858de6d865daacc078_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExMjY_bcd66abc-0102-41ae-80e9-9d36f2070076">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i66a2b156a58d4e41b8c652fbfc2b1dc3_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExMzA_0c88c1d6-712d-4c5d-89a5-d215626580c9">0.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i725de084f7484bf2b557e23683209c2f_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExMzg_2ea73476-0e49-417d-bda1-963c306dc753">0.1</ix:nonFraction>&#160;million respectively, to Fresenius and their subsidiaries for services as a provider. During the year ended December&#160;31, 2021 and 2020, APAACO paid approximately $<ix:nonFraction unitRef="usd" contextRef="i48ce8008a9aa413bbc0d854c5c099a7b_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEyNzg_aa3a6abd-3720-48d4-9b19-ff8e8720c3db">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9ad1a32d47d24ebd9e398feacbdef5da_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEyODU_09575f02-f3df-49de-8f92-33a533eb9b2a">0.7</ix:nonFraction> million, respectively, to Fresenius and their subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius and their subsidiaries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i345508df7f534ec186d436d698300127_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE1MTE_57ffb23f-4ff5-44a0-aa70-fdd3d6417530">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i17a3d24c34e24e4bbb0b52e9864a691c_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE1MTg_6b9fd8bc-6b7b-4466-b96d-f13d7893bde4">0.3</ix:nonFraction> million, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shares common a board member with the Company starting in 2019. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="if2e413d93a45413e867b6c43dcbcb16f_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE5NTM_9feb2c4a-6477-4d4e-8bb3-b2641f969f77">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56618b59636c41de889fa82a7f480457_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE5NjA_5bfe38a8-c05e-45f1-9f14-fa777d08df06">1.4</ix:nonFraction> million, respectively, to One MSO, Inc. (&#8220;One MSO&#8221;) for an office lease. One MSO is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i885597d6544c4e3abef7773242454b2b_I20211231" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM4NDgyOTA3MDIyOTk_8f4e1805-2fb1-4f81-8a75-42b4d111e0b6">50</ix:nonFraction>% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="i962c50aee1e348aba05114edeaee56c5_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzIyNDg_d41aabcf-1225-4fc7-888c-afb6ef2d67b6">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i72264584776344db971c065a8fce37ec_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzIyNTI_5813e428-0f94-471f-adbd-10351313adcb">0.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id9f3ec8accf2446a924e82c4b5f8ccfb_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzIyNjA_275bb6bb-f4db-4fcd-a183-5e1039f80c2d">0.5</ix:nonFraction>&#160;million respectively, to Critical Quality Management Corp (&#8220;CQMC&#8221;) for an office lease. As of December 31, 2020, the office lease has ended. CQMC shares common ownership with certain board members of APC (see Note 19 &#8212; &#8220;Leases&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, SCHC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ia561e5c258f2485694a76848bb8b6a1b_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI0ODY_fb9bc4ae-001a-4554-a0b8-cd3ad7735edd">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3e4b1ef0f59e450b996daa00631fb6ca_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI0OTA_7d6a3532-4490-4412-b6e2-6ebc056b5413">0.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i413b4eb991864312abee85b2aa4136a2_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI0OTg_dc745c45-7b04-4ebd-b8f6-f8453f5bbbad">0.4</ix:nonFraction>&#160;million respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC (see Note 19 &#8212; &#8220;Leases&#8221;).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="icf5b5ce7d40d4f29b8c8775350184aa5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="icaf783f1db0c4787a4a69fb6282d4e02_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI3NDg3NzkwNzU4MDU_3bfc3518-fe63-4519-93f7-47b8fa120e31">15.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iac72b50c95e94fc09e52a827a55332b6_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI3NDg3NzkwNzU4MTM_4bb4c1d8-fdc6-49b7-a0ff-c5d57d120e00">0</ix:nonFraction>, respectively, to Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;) for services as a provider. The CEO of Arroyo Vista became a board member with the Company in 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQyOTk_7ea9ec52-8923-4c20-9f6b-7e34161c5545" continuedAt="i29a4bffa5c7d4b81b21fbe4ceb992903" escape="true">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion Corporation (in thousands):</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i29a4bffa5c7d4b81b21fbe4ceb992903"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:69.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.103%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC &#8211; Risk pool earnings net of claims payment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia53e8f382a2e4439b60240b8915724ee_D20210101-20211231" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzItMS0xLTEtMA_d1e1547b-862a-4c2b-b353-38f2f6ad1e91">46,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd656c250ce4150a6a1a1fceb8542ce_D20200101-20201231" decimals="-3" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzItMy0xLTEtMA_843ccc78-21da-4154-9264-ec21652c5784">28,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2192a286cf646ccab3788f074402528_D20210101-20211231" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzMtMS0xLTEtMA_c594be8f-23b3-49cd-929a-2618c1eebbc6">629</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i134932193dfa499ca1b1effba3b95a14_D20200101-20201231" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzMtMy0xLTEtMA_a89378cb-d7a1-40d7-a776-bad331b58345">949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia409ec0563224e55807090c8d3e6ede7_D20210101-20211231" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzQtMS0xLTEtMA_543559b4-1c74-48a2-a622-521419c08dce">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id9cdce4ca78b41e0a57fc6795290012c_D20200101-20201231" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzQtMy0xLTEtMA_61fc3a7d-ae8a-405a-8fa5-df029958866c">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipts, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzYtMS0xLTEtMA_6eb10aab-2026-405c-9b6d-a4c527c03e8e">45,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzYtMy0xLTEtMA_d2b678cc-b5e5-4a39-aa1f-a84dfef74738">27,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the years ended December&#160;31, 2021, 2020, and 2019, the Company has recognized risk pool revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="ia53e8f382a2e4439b60240b8915724ee_D20210101-20211231" decimals="-5" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyNTk_0309d818-b599-43af-b20d-b24677268d15">60.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i1cd656c250ce4150a6a1a1fceb8542ce_D20200101-20201231" decimals="-5" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyNjM_ff886b14-fcfb-4152-8c3b-86737abc666c">42.6</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i24ec1d618774465c8dea886fe213dfe7_D20190101-20191231" decimals="-5" name="us-gaap:InsuranceServicesRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyNzE_09d9a446-2b59-4da5-ae56-6384a160bea4">49.3</ix:nonFraction>&#160;million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="i2a2b3509507d4d48912d14647a92e623_I20211231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyOTg_a992eec3-4119-4ac8-9604-99dba4f535f4">58.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic3a8211eb68b4df0b319ce09e3b1f902_I20201231" decimals="-5" name="us-gaap:DeferredCreditsAndOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMzMDU_ba3226ac-e6c6-44ff-a943-9fd1e777420c">45.3</ix:nonFraction> million, remain outstanding as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="i30eb97f7c32744b7b15f7e0871ad0fbb_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM0Mzk_e2f64f33-e646-437a-babf-5058d1038f60">34.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i8a4c5277f7fe49faac858648aba110d4_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM0NDM_9bb2d060-2add-4b20-b229-f76c3c717050">33.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i14d6fef6bdcd4ea5849d94a4db61a9e0_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM0NTE_ff6d31c8-6895-411e-a51d-603b6c3e2798">30.8</ix:nonFraction>&#160;million, respectively, to shareholders of APC for provider services, which included approximately $<ix:nonFraction unitRef="usd" contextRef="i75f1a347fb7b4952812981c95e91f55d_D20210101-20211231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM1NDQ_53d2af10-8a48-4db5-b76b-f2747c4d43bc">8.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="id64373440d04487abfcbb1c9c106cd2a_D20200101-20201231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM1NDg_3095872f-1ca4-40dd-8548-d51cc9a237a5">9.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="ibea0b347dab449ca8628a24054c9a91c_D20190101-20191231" decimals="-5" name="ameh:PaymentMadeToRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM1NTY_fc8bb9c1-291a-45d1-9534-c382e932902c">8.8</ix:nonFraction>&#160;million, respectively, to shareholders who are also officers of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="ib376d31c4e7c47d1adb2a6a237f9cc09_D20210101-20211231" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM2Nzc_4370249b-925b-47ed-bf8c-deeacbc35892">44,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i09eece4c427740f687d9a6fadb11f1ff_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM2ODQ_be48e8a7-3d98-429b-ad71-e5de8f3329b8">0.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i802eb21bde26452ba2c3f5659cee4c04_D20190101-20191231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI3NDg3NzkwNzQ1ODc_a0bf4204-221b-40f1-9d4e-c750de0ae1c1">0.2</ix:nonFraction>&#160;million to an ApolloMed board member, Matthew Mazdyasni, for consulting services.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including Dr. Thomas Lam, ApolloMed&#8217;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable and line of credits from related parties, see Note 6 &#8212; &#8220;Investments in Other Entities,&#8221; Note 7 &#8212; &#8220;Loans Receivable &#8212; Related Parties,&#8221; and Note 10 &#8212;  &#8220;Credit Facility, Bank Loan, and Lines of Credit,&#8221;  respectively.</span></div></ix:continuation><div id="i796d62c2eb674b8c9edd48d78ebf1f96_193"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzUzOA_e8be5673-3045-42fe-904b-f4ca457c392b" continuedAt="ica91e6e56aea4f1aa5bde442a2cd5272" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ica91e6e56aea4f1aa5bde442a2cd5272">NMM has a qualified 401(k) plan that covers substantially all employees who have completed at least <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:DefinedContributionPlanServicePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzEzMQ_6b97b83a-7078-4297-b96b-62d49f11a5cc">six months</ix:nonNumeric> of service and meet minimum age requirements. Participants may&#160;contribute a portion of their compensation to the plan, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Participants become fully vested after <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:DefinedContributionPlanVestingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzM3OA_31e638b1-7b90-4718-b631-532e091d4544">six years</ix:nonNumeric> of service. NMM matches a portion of the participants&#8217; contributions. NMM&#8217;s matching contributions for the years ended December&#160;31, 2021 and 2020 were approximately $<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzUyOQ_fffae937-c93c-4738-89f8-eaf08a6d2e8c">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzUzNg_c1526416-1aa1-44ca-b55b-07aa046324c8">0.4</ix:nonFraction> million.</ix:continuation></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_205"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzIwOTI_6e38cbb7-4565-4479-81c9-4753d6b234e8" continuedAt="i9ed6ea5fe50b444abcd53bf27ff3f9f4" escape="true">Earnings Per Share</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9ed6ea5fe50b444abcd53bf27ff3f9f4" continuedAt="i212441ba692648bc8d2e24120aa80514">Basic net income per share is calculated by dividing net income by the weighted-average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period. Diluted net income per share is calculated using the weighted-average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for preferred stock and the treasury stock method for options and common stock warrants.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i212441ba692648bc8d2e24120aa80514"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, 2020, and 2019, APC held <ix:nonFraction unitRef="shares" contextRef="i1eff2864c695401fb93686780342c192_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzEyODc_27a9991b-b6f8-44c5-a422-b3060ea73603">10,925,702</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i601de355c37d4e38a5ea8fffe8e17e9d_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzEyOTE_c7efd69d-ce76-4fec-93dd-9141a5b2fe09">12,323,164</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i81990f1f745c424ca090209239fb9e19_D20190101-20191231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzEyOTg_13242a22-43a8-40a7-8303-e42cdb699a4e">17,290,317</ix:nonFraction> shares, respectively, of ApolloMed's common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share (see Note 12 &#8212; &#8220;Mezzanine and Shareholders&#8217; Equity&#8221;). The non-controlling interests in APC are allocated their share of ApolloMed&#8217;s income from APC&#8217;s ownership of ApolloMed common stock and this is included in the net income attributable to non-controlling interests on the consolidated statements of income. Therefore, none of the shares of ApolloMed held by APC are considered outstanding for the purposes of basic or diluted earnings per share computation. </span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzIwOTM_54af8444-1fdf-494e-8f99-35bfa0bf13de" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.029%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzMtMi0xLTEtMA_91661981-9b3e-4269-b352-b364cfa604d6">1.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzMtNC0xLTEtMA_2cce4aa0-32ca-4db1-9f87-169d2c28d4e7">1.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzMtNi0xLTEtMA_cf430905-2116-4b07-9af5-811596da5d34">0.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzQtMi0xLTEtMA_7b991bf8-2142-4a6a-9f72-c4d0c4d587d4">1.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzQtNC0xLTEtMA_33cbb798-6d3a-4cd8-9984-a516d2ce0248">1.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzQtNi0xLTEtMA_27dd02d1-1640-4059-a955-afc2ff7ba7bb">0.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzUtMi0xLTEtMA_daf8ec0a-2d39-4896-b4d0-c868e996bbc3">43,828,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzUtNC0xLTEtMA_a65d3dff-49c2-443d-bb8c-2fed854f2306">36,527,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzUtNi0xLTEtMA_8d2ca12c-b759-43d3-a7ea-27e909ec9fb7">34,708,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzYtMi0xLTEtMA_e14602e1-8369-4d19-8904-4aa6d7afe516">45,403,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzYtNC0xLTEtMA_bd9658fc-8506-424e-a00a-e90373e6b0d2">37,448,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzYtNi0xLTEtMA_179d0ba7-64ed-4557-92cc-8a16f1011e09">36,403,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzIwOTE_c35852ed-4de1-4bdc-a592-3911786f43b9" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.589%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzMtMi0xLTEtMA_0c3bd503-6876-4b38-bf81-f47b6b9c49be">43,828,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzMtNC0xLTEtMA_b770a8b0-162f-4156-b0ac-6b3c077858ad">36,527,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzMtNi0xLTEtMA_9880718f-c2be-4012-8c98-db366763cb0b">34,708,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65dded2172ef422fb17e1d0fce8b7249_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzUtMi0xLTEtMA_46ab2610-f9e4-4df2-ae33-912528b50307">495,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69c49049ebbc47528adaa662d73d39ec_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzUtNC0xLTEtMA_d216bc2d-f234-4542-a833-e4d7a81b6be5">182,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2e7d052ba2b4395b0f60a17ae65a0f2_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzUtNi0xLTEtMA_d20e6707-279e-4d13-af4e-13e4d9cd5c3f">295,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic14cb455ba05463cb1678b216ef7075f_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzYtMi0xLTEtMA_4d9ae896-1d86-4578-a921-3524e63146e2">819,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ae3db4ca1e34c708b94c52c71ad2914_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzYtNC0xLTEtMA_71f7ab8a-3eb0-4101-8a46-25865990ea94">717,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibd421eb1df5c49939ff1803196eb2a86_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzYtNi0xLTEtMA_cf6db97b-a709-4041-a0dd-a18d5891cba9">1,384,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i208f479f75974f779de286c45d4474bf_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzctMi0xLTEtMA_068705d6-9865-45b2-8c01-bb5ead79bc28">23,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6adcc0aa230f41fd87e0b1d0454f2be7_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzctNC0xLTEtMA_6a29ab2f-9614-479e-84fd-d0324f1c266a">7,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0f8971b99a7041a48f19c1d1278bc25b_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzctNi0xLTEtMA_cacbe718-022b-47e6-b4ab-54bef7395f88">15,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib0f8d61c8ab544a5b3f23e1be85c5358_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzgtMi0xLTEtMA_73927943-bff5-4fb1-86fc-9ed78a7fc734">235,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia44bf6e3eefc4f64a56179122b3b4d22_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzgtNC0xLTEtMA_d5cbc438-4f87-4fd5-a410-08dc07b68bbf">13,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7308475feed14b639f9c04dfe2ffc4d7_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzgtNi0xLTEtMA_a97fe5fc-c30a-407c-8ddd-0b994757d148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzktMi0xLTEtMA_eba3dc58-77ab-490f-a0ed-b97a4a4d57ba">45,403,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzktNC0xLTEtMA_84948431-3a69-41d2-a06c-1bd7b2d91b09">37,448,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzktNi0xLTEtMA_675c402b-ac7d-4697-8dca-9da68956b1b0">36,403,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_208"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90ZXh0cmVnaW9uOmVjOTJkOWQ0ZTU5MzQ1ZjBhZDJmZjNlYzI0NmM5ZmQ1XzE2ODg_69a88e0e-ded8-4ad3-b283-fde032ac5a48" continuedAt="iba5fe5b9b22c41b58a391c5e2e14b726" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><ix:continuation id="iba5fe5b9b22c41b58a391c5e2e14b726" continuedAt="i32e42cba354f48ec9c124514913c144e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies &#8212; Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90ZXh0cmVnaW9uOmVjOTJkOWQ0ZTU5MzQ1ZjBhZDJmZjNlYzI0NmM5ZmQ1XzE2ODk_f849d48b-dcd7-45cd-aea5-582f175a426a" continuedAt="ic2de9eee331b4196be31965511bf50d7" escape="true">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant.</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt"><ix:continuation id="i32e42cba354f48ec9c124514913c144e" continuedAt="i410e1ea658f44e318b05cd568d1cb432"><ix:continuation id="ic2de9eee331b4196be31965511bf50d7" continuedAt="ic7b27ae1ff16482888f7c4734b5e51c4"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzYtMi0xLTEtMA_7a66ea3c-b19d-4fd0-8cdf-e9e31130e6d0">161,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzYtNC0xLTEtMA_a5887ff5-9472-49fb-8525-63cea47cb14f">126,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzgtMi0xLTEtMA_04e8a08a-62e7-4de9-8d99-7950b27f06c4">49,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzgtNC0xLTEtMA_0664e2b5-49c5-4c1a-aad4-8e30ea1977bf">67,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzktMi0xLTEtMA_a11670fc-5d2a-4348-bd05-f7df42e2a91a">7,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzktNC0xLTEtMA_692d452a-8ace-44ac-8869-73cbe1bd4fed">5,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEwLTItMS0xLTA_2fff612a-f295-4803-a51a-950c093fdd6d">62,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEwLTQtMS0xLTA_808b0bfc-7e0d-4f42-bbec-067a395ade7c">46,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTItMS0xLTYyMDUy_41d4189c-3d36-48fe-b595-d7dfb48277ff">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTQtMS0xLTYyMDU5_12e69afc-eee3-4f30-8a77-3719a4ccadb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTItMS0xLTA_2639a89c-df3c-444c-a006-810c2136d217">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTQtMS0xLTA_fa7416b0-d369-4ffd-9a9d-32fc6480a81b">1,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEyLTItMS0xLTA_bd9c973b-9eec-4244-8b40-dae2d60ba1e7">11,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEyLTQtMS0xLTA_ae24daec-8374-4fef-9839-913627e1825c">14,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8212; related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE0LTItMS0xLTA_be8663a6-8374-42fb-add7-7df32fd88228">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:NotesReceivableRelatedPartiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE0LTQtMS0xLTA_d11d7e34-d620-47cf-a45d-b326ae4e84ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:DueFromAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE1LTItMS0xLTYxNzA2_1e11a221-02cd-4d28-85bf-d98197262ac1">6,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:DueFromAffiliates" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE1LTQtMS0xLTYxNzEz_17cbbb53-de0a-4815-8a27-2c3d75ce908a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE2LTItMS0xLTA_05dcc9df-b6c1-4e44-89c4-6399a180e152">305,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE2LTQtMS0xLTA_429aa5c6-fe9b-4130-a13e-f9996244b03e">261,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE5LTItMS0xLTA_5349c34d-0deb-48d6-8b4f-83f73936e334">49,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE5LTQtMS0xLTA_c110aafd-7aa9-45e5-891d-a3a12fcb3811">27,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIwLTItMS0xLTA_0ef26c3e-f3bd-48dd-9f74-530c95f1808c">58,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIwLTQtMS0xLTA_7423cde0-911d-436a-9c77-d2480b2dd641">69,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIxLTItMS0xLTA_ed7a8233-f63e-425a-b689-703d08a5c081">109,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIxLTQtMS0xLTA_8870ab32-36de-4358-86e2-5d1abda801f6">109,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:DueFromRelatedPartiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIyLTItMS0xLTA_de27dfdf-f06e-482c-90b2-ab8aee9e8700">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:DueFromRelatedPartiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIyLTQtMS0xLTA_ef0f81ec-0e82-4674-8620-057d44c1f41e">4,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIzLTItMS0xLTA_6d488e4a-1cc8-4ec0-a582-520113e11d62">41,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIzLTQtMS0xLTA_8a1dad74-ff18-4b79-af26-d14afd80693a">43,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in a privately held entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI0LTItMS0xLTA_93869503-cd64-4e31-b63c-4fd8fd2f2c0b">405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI0LTQtMS0xLTA_409b4d35-b3c3-4971-a632-aadef1d7c3e8">36,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI1LTItMS0xLTA_177a3824-3c3c-4080-8177-dc5a0a93ae22">802,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:OtherLongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI1LTQtMS0xLTA_2de187f5-be7b-43c5-89d2-985d269729d5">225,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI2LTItMS0xLTA_dee712d2-2721-4b31-b696-93f6ffc62a97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI2LTQtMS0xLTA_31bcbe2b-f348-4d2f-b649-b3eaa10b9fe8">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI3LTItMS0xLTA_74a98b8e-bfa2-4712-8a94-8587ce176216">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI3LTQtMS0xLTA_8229e421-08fc-496c-9308-17e4bf9a14b7">6,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI4LTItMS0xLTA_7dfa2f6c-53d5-4b86-89ad-61be3e39f230">3,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI4LTQtMS0xLTA_bfe1ba4c-ee9a-4bb9-87e4-55ccc6922cd0">17,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMwLTItMS0xLTA_e37ffff5-4e85-4de1-8b49-55bc5eaf65a1">1,070,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMwLTQtMS0xLTA_7d0207f2-f2e0-4277-a10c-00353b771b80">539,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMyLTItMS0xLTA_ca5cd44a-3715-4c33-9ca4-a08a81752f56">1,376,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMyLTQtMS0xLTA_6962958f-1087-4219-9c8d-313db2a70631">801,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM1LTItMS0xLTA_15ed6d54-e1bd-49ce-8e29-f3f6ed5d171b">11,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM1LTQtMS0xLTA_7bb09b93-86e4-47c5-907b-3502a238e461">12,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM2LTItMS0xLTA_d6952d7c-9ad1-4b79-b275-949655a1e7a0">10,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="ameh:FiduciaryAccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM2LTQtMS0xLTA_77e5d803-16fc-4160-a3eb-114a8cf6c0be">9,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="ameh:MedicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM3LTItMS0xLTA_851ee1c0-c7c6-4677-baa2-87db41481fbf">44,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="ameh:MedicalLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM3LTQtMS0xLTA_1a3da0bc-0ce9-488c-b88c-28ad27777400">37,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM4LTItMS0xLTA_04ab771c-8b86-4c83-a9f4-3f8237d2ce04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM4LTQtMS0xLTA_cb15f39f-36d6-4d57-8aba-c9cf2cb916ee">4,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM5LTItMS0xLTA_06fddcfb-835a-4904-83ff-c2a3fd7f1416">556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM5LTQtMS0xLTA_a014d574-5679-4a5c-ada9-a977b5e093d7">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:DueToAffiliateCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQwLTItMS0xLTA_998391fd-d0ec-4ed2-bce7-12aeaeb40e92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:DueToAffiliateCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQwLTQtMS0xLTA_e5308b06-c5ed-48ae-bc15-7e06a5c21328">22,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQxLTItMS0xLTA_9e539bac-ec6f-4a84-8bb8-2dc8ee615612">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQxLTQtMS0xLTA_1cb27c40-12a0-43a4-bc87-ed792bf337a7">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQyLTItMS0xLTA_db55c82d-13ea-4f60-8a14-31f04e400497">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQyLTQtMS0xLTA_dc0cea5f-dfd8-44a4-aa4e-311c15a6c22b">1,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQzLTItMS0xLTA_ed99c436-821f-4da1-b13a-f4842f4df7ce">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQzLTQtMS0xLTA_37fd52a6-7cab-4c1c-b219-62279489f9ba">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ1LTItMS0xLTA_58292372-0010-46b5-b169-3951b30d287f">68,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ1LTQtMS0xLTA_dc6834e6-be72-41fc-869f-cbb227ad7fdc">89,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ4LTItMS0xLTA_83846aa3-933a-4f7c-9db4-fb313f5f2751">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ4LTQtMS0xLTA_86b44ad1-f808-4b4c-8291-7ce29831602a">9,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ5LTItMS0xLTA_ca2b4568-214f-45e6-ae75-a5bf0016adf1">193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ5LTQtMS0xLTA_54a059fd-c746-45f4-95cc-41e55ba1b879">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUwLTItMS0xLTA_324ab5b6-585e-4614-a237-675d8bb26b9e">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUwLTQtMS0xLTA_f6842ca3-d374-4a24-bdfb-a839d7f7c8b2">5,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUyLTItMS0xLTA_d8aff236-f42e-4335-bfe5-586d257fc5c0">7,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUyLTQtMS0xLTA_331ffecf-b431-41bb-ba93-8ca843ddc680">7,379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i410e1ea658f44e318b05cd568d1cb432"><ix:continuation id="ic7b27ae1ff16482888f7c4734b5e51c4"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.999%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUzLTItMS0xLTQ0MjE2_b91e53e8-893a-4e2a-ace3-d82e69f18dcd">9,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUzLTQtMS0xLTQ0MjI3_0f63a850-30d2-4a47-91c6-cfaf46db7a23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU0LTItMS0xLTA_99ea0fec-ef07-4e36-90cc-c0369ed9488c">22,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU0LTQtMS0xLTA_d4c84644-186a-4e5a-82b0-2895f2039d95">22,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU2LTItMS0xLTA_497fd46c-123c-4f17-8bb8-6ca5683c714b">91,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU2LTQtMS0xLTA_243ec097-d0f5-42f4-9772-1ad29b4490bd">111,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investment in affiliates include APC&#8217;s investment in ApolloMed, which is reflected as treasury shares and eliminated upon consolidation. Amount due to, or due from, affiliates are payables and receivables with ApolloMed&#8217;s subsidiaries and consolidated VIEs. As a result, these balances are eliminated upon consolidation and are not reflected on ApolloMed&#8217;s consolidated balance sheets as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and 2020.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMzA_9f7042e8-66cd-47c3-9cad-09448798c7bd" continuedAt="i425f6c2b4a8e4332b67fdc2f76c426c6" escape="true"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMzE_4a3155ed-f08b-40e3-88da-6bb2a3e8f3a6" continuedAt="i4b2032aa354947ef8fde1fc9e358cc13" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i425f6c2b4a8e4332b67fdc2f76c426c6" continuedAt="i0672f94088d746f9bd05325be13ff560"><ix:continuation id="i4b2032aa354947ef8fde1fc9e358cc13" continuedAt="i38de3218782545ac89277c708e9e6ca7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms ranging from <ix:nonNumeric contextRef="i283b7bc3b0dc4508af91c59f486c2adf_I20211231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4Mg_18b81b0d-fa87-467a-9d3a-6a47b47a12dd"><ix:nonNumeric contextRef="i283b7bc3b0dc4508af91c59f486c2adf_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4Mg_1b7463d1-fc0e-4bd1-803f-f911a97d89b0">seven months</ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="ibef63d60b9e947eead74bdfd0b22345e_I20211231" name="us-gaap:LesseeFinanceLeaseTermOfContract1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4OA_612810fc-17d3-4dbb-a746-443bdb1ba28e"><ix:nonNumeric contextRef="ibef63d60b9e947eead74bdfd0b22345e_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4OA_7a7ad439-6ed3-42a6-9104-ddb7a63bad44">eight years</ix:nonNumeric></ix:nonNumeric>, some of which may include options to extend the leases for up to <ix:nonNumeric contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzI1Nw_2b4a27a6-5173-46cf-b8f3-877f79a7aa03"><ix:nonNumeric contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzI1Nw_394f0bff-a876-4a2c-9937-7a19d3ca7e1e">ten years</ix:nonNumeric></ix:nonNumeric>, and some of which may include options to terminate the leases within <ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzMzMA_5bc8f1df-6b07-42e4-a2ee-b154e9521cad"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzMzMA_da373d40-64b5-4f33-9fb8-d6a7e7135031">one year</ix:nonNumeric></ix:nonNumeric>. As of December&#160;31, 2021 and December&#160;31, 2020, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzM5Mw_a3878f45-4b46-4af2-8ce1-453e0810dc34">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzQwMA_93a8d47c-a2e4-487e-b409-be4d2a1aa6dd">0.4</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases was $<ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzQ4Mg_a06c46e0-78ec-4823-9432-67c7a0c43b3e">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzQ4OQ_b8d599ea-62d6-4afc-abaa-818c09018a8a">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMzI_bbad78e7-e36c-42b2-8a1d-9bbbb985d26e" continuedAt="i41ae7da459cb4f8eb20b6111575b506b" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzItMS0xLTEtMA_bd99ac84-3761-4fa6-8933-37e4ac4a8ef1">6,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzItMy0xLTEtMA_d57fa590-4496-4dd2-a5a1-eee7fcbf576b">6,589</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzUtMS0xLTEtMA_cc41ee65-a969-4065-a679-ea7b7c766a65">208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzUtMy0xLTEtMA_40e0405c-256b-49f9-a302-0a577965ecd5">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzYtMS0xLTEtMA_d4679480-3c7d-413c-856b-1633f3d16b9e">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzYtMy0xLTEtMA_ffbb2be4-5cc3-4478-ad18-02093cfd2a85">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzgtMS0xLTEtMA_c3559adf-b600-46d5-be35-14841c8d4185">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzgtMy0xLTEtMA_14c89557-ee9c-43e8-9921-a540b06a31eb">784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzEwLTEtMS0xLTA_4b2c659b-714a-4e24-b56a-5e59a866b6e5">5,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzEwLTMtMS0xLTA_14ef86b0-0b41-49b5-ba60-505a94697412">5,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span></div></div><ix:continuation id="i0672f94088d746f9bd05325be13ff560"><ix:continuation id="i38de3218782545ac89277c708e9e6ca7"><ix:continuation id="i41ae7da459cb4f8eb20b6111575b506b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Other information related to leases was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzUtMS0xLTEtMA_b19101df-fa47-460a-be81-96e00194ac6c">6,083</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzUtMy0xLTEtMA_500e844e-99f1-4b22-97c2-ed292e7c746b">5,804</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzYtMS0xLTEtMA_4c3e4fea-37de-4ef5-a54b-b73a8ff84835">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzYtMy0xLTEtMA_b45d3762-0d75-420f-8c51-780dc4458d31">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzctMS0xLTEtMA_ab849d55-5b7c-4c51-8196-952e4649d2b1">208</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzctMy0xLTEtMA_d4706a3a-8047-4592-9ef1-e2b4866f85e6">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzEwLTEtMS0xLTA_fe6becd9-b8b5-41ed-8f14-25babf4883a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzEwLTMtMS0xLTA_71f5a787-2e47-4e46-94b5-4c11d1988b4d">7,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzExLTEtMS0xLTA_c6c8a4f3-4117-4659-a5f6-178391a1f6e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzExLTMtMS0xLTA_4a7cadea-59a9-48cb-b279-ad3720e49657">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE3LTEtMS0xLTA_52e1c7e7-7185-4f2d-a0b7-3cea5d2f71a1">6.27</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE3LTMtMS0xLTA_45c7b31c-bb02-4fba-941c-269498290a10">6.80</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE4LTEtMS0xLTA_f91b18e6-82df-4c73-8dd1-bca880321681">3.26</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE4LTMtMS0xLTA_25a4de0d-1f18-4149-af52-6b4a3c38e1f7">3.67</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIyLTEtMS0xLTA_62788bbe-bf1e-40a2-87e8-0f5142f22a23">6.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIyLTMtMS0xLTA_b519aac9-75cb-4343-be1a-c7c89c1767ec">6.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIzLTEtMS0xLTA_99ef301d-8383-482b-bcde-0992da424ec3">4.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIzLTMtMS0xLTA_2599ae6c-ec17-4e9f-8aa7-74013dfaece9">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMjg_6a935754-2490-431d-8d14-94de40b9cde5" escape="true"><ix:nonNumeric contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMjk_1dd5222d-f19a-4e47-8399-479820bc4931" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.225%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEtMS0xLTEtMA_badc122f-1d16-4d86-a82d-5a24d64d28c0">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEtMy0xLTEtMA_f9f5730c-b860-499e-8a71-e9dad5afc209">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzItMS0xLTEtMA_ea471196-013f-4c4c-91d1-f60f1b9297d6">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzItMy0xLTEtMA_b07b967c-cf34-4625-9a98-74d58638035b">443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzMtMS0xLTEtMA_38b3719f-e5f7-4d6f-85e4-2655daa78f4c">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzMtMy0xLTEtMA_d69d707f-ce8c-473d-aab0-0f18f341978d">377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzQtMS0xLTEtMA_ba3a1779-22df-4d71-b36f-a7cc4a966261">2,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzQtMy0xLTEtMA_7dab60ce-2856-4111-a504-27c24f28b47a">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzUtMS0xLTEtMA_2bc16039-c172-47cf-9c24-30e0b9475329">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzUtMy0xLTEtMA_f7c92222-0e0e-480b-ab99-304eda4662fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzYtMS0xLTEtMA_0122c610-1b94-4f9f-8245-386479df623a">4,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzYtMy0xLTEtMA_f59a2451-d92b-48d4-bba5-b6f705361963">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzgtMS0xLTEtMA_cf2c815d-a238-4048-8191-27dda641e43a">19,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzgtMy0xLTEtMA_b5911dd4-0152-4342-99e4-b1f0a9941fbc">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzktMS0xLTEtMA_ae1ba630-1be1-47bf-9dfd-b3585dc26306">3,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzktMy0xLTEtMA_97c7c603-c88c-494b-8a3f-f4dcb27f2d98">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEwLTEtMS0xLTA_41f5ea67-8d0e-4dfb-a3b1-1e3920d61508">15,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEwLTMtMS0xLTA_cd828c1d-8d01-460e-a915-a677f471ebff">1,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzExLTEtMS0xLTA_aa25d78c-812d-451c-91cb-bfe1de119ce5">2,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzExLTMtMS0xLTA_4be1210a-0890-4f31-9ab1-c3890a892f90">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEyLTEtMS0xLTA_5c581a85-0411-4105-9627-d7ea65be4964">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEyLTMtMS0xLTA_75154cc0-6c8b-438b-ad77-5df297f627d1">973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company does not have additional operating or finance leases that have not yet commenced.</span><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_229"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_232"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.&#160;&#160;&#160;&#160;Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures were effective as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule&#160;13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company&#8217;s principal executive and principal financial officers and effected by the Company&#8217;s board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Co-Chief Executive Officers and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2021, the end of our fiscal year. Our management based its assessment on criteria established in&#160;Internal Control&#8212;Integrated Framework&#160;(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Our management&#8217;s assessment included evaluation and testing of the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our management&#8217;s assessment, our management has concluded that our internal control over financial reporting was effective as of December&#160;31, 2021. Our management communicated the results of its assessment to the Audit Committee of our Board of Directors.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Ernst &amp; Young, LLP, audited our consolidated financial statements for the fiscal year ended December&#160;31, 2021 included in this Annual Report on Form&#160;10-K, and has issued an audit report with respect to the effectiveness of the Company&#8217;s internal control over financial reporting, a copy of which is included below in this Annual Report on Form&#160;10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting during our fourth quarter of 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Apollo Medical Holdings, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have audited Apollo Medical Holdings, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2021, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2013 framework), (the COSO criteria). In our opinion, Apollo Medical Holdings, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2021, based on the COSO criteria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, and the related consolidated statements of income, mezzanine and stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2021, and our report dated February&#160;28, 2022 expressed an unqualified opinion thereon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.164%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernst and Young LLP</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;28, 2022</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.&#160;&#160;&#160;&#160;Other Information</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt;text-indent:36pt"><span><br/></span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_2162"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_238"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_241"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.&#160;&#160;&#160;&#160;Directors, Executive Officers, and Corporate Governance</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be contained in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting to be filed with the SEC not later than 120 days following the end of the Company&#8217;s fiscal year ended December&#160;31, 2021, which information is incorporated herein by reference.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_244"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.&#160;&#160;&#160;&#160;Executive Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be contained in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting to be filed with the SEC not later than 120 days following the end of the Company&#8217;s fiscal year ended December&#160;31, 2021, which information is incorporated herein by reference.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_247"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be contained in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting to be filed with the SEC not later than 120 days following the end of the Company&#8217;s fiscal year ended December&#160;31, 2021, which information is incorporated herein by reference.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_250"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be contained in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting to be filed with the SEC not later than 120 days following the end of the Company&#8217;s fiscal year ended December&#160;31, 2021, which information is incorporated herein by reference.</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_253"></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.&#160;&#160;&#160;&#160;Principal Accounting Fees and Services</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item will be contained in the Company&#8217;s Proxy Statement for the 2022 Annual Meeting to be filed with the SEC not later than 120 days following the end of the Company&#8217;s fiscal year ended December&#160;31, 2021, which information is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_259"></div><div style="-sec-extract:summary;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.&#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:12pt;padding-left:76.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Consolidated financial statements</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements and notes thereto contained herein are as listed on the &#8220;Index to Consolidated Financial Statements&#8221; in Part II, Item&#160;8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;padding-left:76.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Financial Statement Schedules</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted, since the required information is not applicable or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements and notes thereto included in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;padding-left:76.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15pt">Exhibits required by Item 601 of Regulation S-K.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Agreement and Plan of Merger, dated December&#160;21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex&#160;A to the joint proxy statement/prospectus filed pursuant to Rule&#160;424(b)(3) on November&#160;15, 2017 that is a part of a Registration Statement on Form&#160;S-4).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexa">Amendment to the Agreement and Plan of Merger, dated March&#160;30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex&#160;A to the joint proxy statement/prospectus filed pursuant to Rule&#160;424(b)(3) on November&#160;15, 2017 that is a part of a Registration Statement on Form&#160;S-4).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420417053488/tv477411_ex10-1.htm#:~:text=2%20TO%20AGREEMENT%20AND%20PLAN%20OF%20MERGER%20.,%E2%80%9CCompany%E2%80%9D),%20and%20Kenneth%20Sim,%20M.D.%20(the%20%E2%80%9CShareholders%E2%80%99%20Representative%E2%80%9D).">Amendment No.&#160;2 to the Agreement and Plan of Merger, dated October&#160;17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex&#160;A to the joint proxy statement/prospectus filed pursuant to Rule&#160;424(b)(3) on November&#160;15, 2017 that is a part of a Registration Statement on Form&#160;S-4).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock purchase agreement dated March 15, 2019 (incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465920057432/tm2018794d1_ex2-1.htm">Stock Purchase Agreement, dated as of December 31, 2019, among Universal Care Acquisition Partners, LLC, a Delaware limited liability company, Bright Health Company of California, Inc., a California corporation, Bright Health, Inc., a Delaware corporation (solely for purposes of section 13.22 thereto), Universal Care, Inc., a California corporation doing business as Brand New Day, Howard E. And Elaine H. Davis Family Trust, Howard E. And Elaine H. Davis Grandchildren&#8217;s Trust, Jeffrey V. Davis, Jay B. Davis, Laura Davis-Loschiavo, Marc M. Davis, Peter And Helen Lee Family Trust, and, in their respective capacities as seller representatives, Kenneth Sim, M.D., Thomas Lam, M.D., Jay Davis and Jeffrey Davis. (incorporated herein by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on May 6, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 21, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 16, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex3-1.htm">Certificate of Designation of Series A Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex3-1.htm">Amended and Restated Certificate of Designation of Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-1.htm">Form of Certificate for Common Stock of Apollo Medical Holdings, Inc., par value $0.001 per share (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-3.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $11.00 per share (incorporated herein by reference to Exhibit 4.3 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-4.htm">Form of Warrant issued as Merger Consideration pursuant to the Merger Agreement for the purchase of Common Stock of Apollo Medical Holdings, Inc., exercisable at $10.00 per share (incorporated herein by reference to Exhibit 4.4 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415059991/v422440_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series A Warrant&#8221;) dated October 14, 2015, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 1,111,111 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on October 19, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-6.htm">Form of Assignment of Series A Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.6 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420416092455/v436045_ex4-1.htm">Common Stock Purchase Warrant (&#8220;Series B Warrant&#8221;) dated March 30, 2016, originally issued by Apollo Medical Holdings, Inc. to Network Medical Management, Inc. to purchase 555,555 shares of common stock and subsequently issued as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K filed on April 4, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex4-8.htm">Form of Assignment of Series B Warrant as Merger Consideration pursuant to the Merger Agreement (incorporated herein by reference to Exhibit 4.8 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020003626/ameh-20191231xexx410.htm">Description of Registered Securities</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420410045126/v194384_def14c.htm">2010 Equity Incentive Plan of the Company (incorporated herein by reference to Appendix&#160;A to Schedule&#160;14C Information Statement filed on August&#160;17, 2010).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420414028378/v374384_ex10-13.htm">2013 Equity Incentive Plan of the Company (incorporated herein by reference to Exhibit 10.13 to the Company&#8217;s Annual Report on Form&#160;10-K filed on May&#160;8, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex10-3.htm">2015 Equity Incentive Plan of the Company. (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420414028378/v374384_ex10-14.htm">Board of Directors Agreement dated May&#160;22, 2013 by and between Apollo Medical Holdings, Inc., and David Schmidt (incorporated herein by reference to Exhibit 10.14 to the Company&#8217;s Annual Report on Form&#160;10-K filed on May&#160;8, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420416076130/v429126_ex10-2.htm">Board of Directors Agreement between Apollo Medical Holdings, Inc. and Thomas S. Lam, M.D. dated January&#160;19, 2016 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form&#160;8-K filed on January&#160;19, 2016.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420416078529/v430394_ex10-1.htm">Board of Directors Agreement dated January&#160;12, 2016 between Apollo Medical Holdings, Inc. and Mark Fawcett (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K/A filed on February&#160;2, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex10-1.htm">Form of Board of Directors Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K filed on December&#160;13, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex10-2.htm">Form of Director Proprietary Information Agreement (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form&#160;8-K filed on December&#160;13, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex10-3.htm">Form of Indemnification Agreement (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form&#160;8-K filed on December&#160;13, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420414020524/v373739_ex10-24.htm">Physician Shareholder Agreement, granted and delivered by Warren Hosseinion, M.D., in favor of Apollo Medical Management, Inc. and Apollo Medical Holdings, Inc., for the account of ApolloMed Hospitalists, dated March&#160;28, 2014 (incorporated herein by reference to Exhibit 10.24 to the Company&#8217;s Current Report on Form&#160;8-K/A filed on April&#160;3, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420414068523/v393189_ex10-5.htm">Second Amendment to Lease Agreement dated October&#160;14, 2014 by and between Apollo Medical Holdings, Inc. and EOP-700 North Brand,&#160;LLC (incorporated herein by reference to Exhibit 10.5 on Quarterly Report on Form&#160;10-Q filed on November&#160;14, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420414072756/v395966_ex10-01.htm">Lease Agreement, dated July&#160;22, 2014, by and between Numen,&#160;LLC and Apollo Medical Management, Inc. (incorporated herein by reference to Exhibit 10.01 to the Company&#8217;s Current Report on Form&#160;8-K/A filed on December&#160;8, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex10-27.htm">Lease Agreement, dated August 1, 2002, by and between Network Medical Management, Inc. and Medical Property Partner. (incorporated herein by reference to Exhibit 10.27 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex10-28.htm">Lease Agreement, dated August 1, 2002, by and between Network Medical Management, Inc. and Medical Property Partner. (incorporated herein by reference to Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex10-29.htm">Lease Agreement Addendum, dated February 1, 2013, by and between Network Medical Management, Inc. and Medical Property Partner. (incorporated herein by reference to Exhibit 10.29 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex10-30.htm">Change in Terms Agreement and Business Loan Agreement, dated April 9, 2016, by and between Network Medical Management, Inc. and Preferred Bank. (incorporated herein by reference to Exhibit 10.30 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex10-31.htm">Change in Terms Agreement and Business Loan Agreement, dated April 7, 2017, by and between Network Medical Management, Inc. and Preferred Bank. (incorporated herein by reference to Exhibit 10.31 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420416110594/v442479_ex10-69.htm">Amended and Restated Hospitalist Participation Service Agreement made as of June 29, 2016 by and between ApolloMed Hospitalists, a Medical Corporation, and Warren Hosseinion, M.D. (incorporated herein by reference to Exhibit 10.69 to the Company&#8217;s Annual Report on Form 10-K filed on June 29, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420416110594/v442479_ex10-70.htm">Amended and Restated Hospitalist Participation Service Agreement made as of June 29, 2016 by and between ApolloMed Hospitalists, a Medical Corporation, and Adrian Vazquez, M.D. (incorporated herein by reference to Exhibit 10.70 to the Company&#8217;s Annual Report on Form 10-K filed on June 29, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417003013/v456696_ex10-1.htm">Next Generation ACO Model Participation Agreement (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form&#160;8-K filed on January&#160;20, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm#a_annexd">Form of Stockholder Lock-Up Agreement (incorporated herein by reference to Annex&#160;D to the joint proxy statement/prospectus filed pursuant to Rule&#160;424(b)(3) on November&#160;15, 2017 that is a part of a Registration Statement on Form S-4).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418018690/tv489499_ex10-40.htm">Convertible Secured Promissory Note made as of October 13, 2017 by George M. Jayatilaka, M.D. (incorporated herein by reference to Exhibit 10.40 to the Company&#8217;s Annual Report on Form 10-K filed on April 2, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035699/tv497161_ex10-1.htm">Board of Directors Agreement, dated June 21, 2018, between Apollo Medical Holdings, Inc. and Ernest A. Bates, M.D. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on June 26, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000155335019000061/ameh_ex10z1.htm">Board of Directors Agreement, dated January 11, 2019, between Apollo Medical Holdings, Inc. and Linda Marsh. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on January 17, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000155335019000061/ameh_ex10z2.htm">Board of Directors Agreement, dated January 11, 2019, between Apollo Medical Holdings, Inc. and John Chiang. (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed on January 17, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025470/tv521268_ex10-1.htm">Loan Agreement, dated May 10, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on May 13, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025470/tv521268_ex10-3.htm">Tradename Licensing Agreement, dated May 10, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on May 13, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025470/tv521268_ex10-4.htm">Administrative Services Agreement, dated May 10, 2019, by and between Network Medical Management, Inc., a California corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Current Report on Form 8-K filed on May 13, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025470/tv521268_ex10-5.htm">Physician Shareholder Agreement, dated May 10, 2019, by and between Thomas Lam, M.D., Apollo Medical Holdings, Inc., a Delaware corporation, Network Medical Management, Inc., a California corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Current Report on Form 8-K filed on May 13, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025470/tv521268_ex10-6.htm">Series A Preferred Stock Purchase Agreement, dated May 10, 2019, by and between AP-AMH Medical Corporation, a California professional medical corporation and Allied Physicians of California, a Professional Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed on May 13, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025470/tv521268_ex10-7.htm">Special Purpose Shareholder Agreement, dated May 10, 2019, by and between Allied Physicians of California, a Professional Medical Corporation, a California professional medical corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.7 to the Company&#8217;s Current Report on Form 8-K filed on May 13, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025470/tv521268_ex10-8.htm">Stock Purchase Agreement, dated May 10, 2019, by and between Allied Physicians of California, a Professional Medical Corporation, a California professional medical corporation and Apollo Medical Holdings, Inc., a Delaware corporation (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Current Report on Form 8-K filed on May 13, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000162828019010579/ex1010q22019amendment.htm">Form of Amendment to Stockholder Lock-up Agreement (incorporated herein by reference to Exhibit 10.10 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 9, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000114420419042604/tv528615_ex10-1.htm">First Amendment to the Stock Purchase Agreement dated August 26, 2019, by and between Allied Physicians of California, a California Professional Medical Corporation and Apollo Medical Holdings, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 29, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419042604/tv528615_ex10-2.htm">First Amendment to the Series A Preferred Stock Purchase Agreement dated August 26, 2019, by and between Allied Physicians of California, a California Professional Medical Corporation and AP-AMH Medical Corporation, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on August 29, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419042604/tv528615_ex10-3.htm">First Amendment to the Loan Agreement dated August 26, 2019, by and between Apollo Medical Holdings, Inc. and AP-AMH Medical Corporation, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on August 29, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-2.htm">Guaranty and Security Agreement dated as of September 11, 2019, by and among Apollo Medical Holdings, Inc., as Borrower, and Network Medical Management, Inc., as Guarantor, in favor of SunTrust Bank, as administrative agent for the Secured Parties (incorporated herein by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-3.htm">Second Amendment to Series A Stock Purchase Agreement dated as of September 9, 2019, by and between Allied Physicians of California, a Professional Medical Corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-4.htm">First Amendment to Special Purpose Shareholder Agreement, dated as of September 11, 2019, by and between Allied Physicians of California, a Professional Medical Corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-5.htm">First Amendment to Tradename Licensing Agreement, dated as of September 10, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.5 to the Company's Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-6.htm">First Amendment to Administrative Services Agreement, dated as of September 10, 2019, by and between Network Medical Management, Inc., a California corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-7.htm">Security Agreement, dated as of September 11, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation, and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.7 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-8.htm">Certificate of Determination of Preferences of Series A Preferred Stock of Allied Physicians of California, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-9.htm">Voting and Registration Rights Agreement, dated as of September 11, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation, and Allied Physicians of California, a Professional Medical Corporation (incorporated herein by reference to Exhibit 10.9 to the Company&#8217;s Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419044449/tv529206_ex10-10.htm">Second Amendment to Loan Agreement, dated September 11, 2019, by and between Apollo Medical Holdings, Inc., a Delaware corporation and AP-AMH Medical Corporation, a California professional medical corporation (incorporated herein by reference to Exhibit 10.10 to the Company's Current Report on Form 8-K filed on September 12, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000162828019013826/ex1014q32019amendment.htm">Form of Amendment to Stockholder Lock-up Agreement entered into on or about September 26, 2019 (incorporated herein by reference to Exhibit 10.14 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 8, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419046557/tv530294_ex10-1.htm">Board of Directors Agreement, dated September 29, 2019, with Matthew Mazdyasni (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on September 30, 2019).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020012247/ex1012020063010-qngksim.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Kenneth Sim, M.D. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020012247/ex1022020063010qngtlam.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Thomas Lam, M.D. (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020012247/ex1032020063010qngechin.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Eric Chin (incorporated herein by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020012247/ex1042020063010qngavaz.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Adrian Vazquez, M.D. (incorporated herein by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020012247/ex1052020063010qngayou.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Albert Young, M.D. (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.53+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000162828020012247/ex1062020063010qngbsim.htm">Employment Agreement, dated June 8, 2020, between Network Medical Management, Inc. and Brandon Sim (incorporated herein by reference to Exhibit 10.6 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 10, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.54</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001083446/000162828021016083/ex102021063010-q.htm">Amended and Restated Credit Agreement dated as of June 16,2021, by and among Apollo Medical Holdings Inc., as Borrower, the Lenders from time to time party thereto, and Truist Bank, in its capacity as administrative agent for the Lenders, as issuing bank and as swingline lender. (incorporated herein by reference to Exhibit 10 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 6,2021).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx141.htm">The Company's Code of Ethics.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1083446/000110465920052240/tm2017841d1_ex16-1.htm">Letter, dated April 27, 2020, from BDO USA, LLP to the Securities and Exchange Commission (incorporated herein by reference to Exhibit 16.1 to the Company&#8217;s Current Report on Form 8-K filed on April 28, 2020).</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx211.htm">Subsidiaries of Apollo Medical Holdings, Inc.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx231.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx232.htm">Consent of BDO USA,&#160;LLP, Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i796d62c2eb674b8c9edd48d78ebf1f96_268">Power of Attorney (included on the signatures page of this Annual Report on Form 10-K).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx311.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx312.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx313.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ameh-20211231xexx32.htm">Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Management contract or compensatory plan, contract or arrangement</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;The schedules and exhibits thereof have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APOLLO&#160;MEDICAL&#160;HOLDINGS,&#160;INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Lam </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brandon Sim </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon Sim</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><div id="i796d62c2eb674b8c9edd48d78ebf1f96_268"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, jointly and severally, Thomas Lam, M.D., M.P.H. and Brandon Sim, and each of them, as their true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:4.248%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.425%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.582%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas Lam</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive&#160;Officer (Principal Executive Officer), President, and Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Brandon Sim</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive&#160;Officer (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon Sim</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Eric Chin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Chin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kenneth Sim</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman, Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth Sim, M.D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ernest Bates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ernest Bates, M.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Chiang</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Chiang</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Weili Dai</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weili Dai</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael Eng</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Eng</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ J. Lorraine Estradas</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Lorraine Estradas</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Fawcett</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Fawcett&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mitchell Kitayama</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mitchell Kitayama</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Linda Marsh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda Marsh</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Matthew Mazdyasni</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Mazdyasni</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ David Schmidt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">David Schmidt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-14.1
<SEQUENCE>2
<FILENAME>ameh-20211231xexx141.htm
<DESCRIPTION>EX-14.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i18dbd10a86be4c7f81f5d551f3494f2f_1"></div><div style="min-height:69.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CODE OF ETHICS</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(adopted April 19, 2018)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Introduction</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The Board of Directors of Apollo Medical Holdings, Inc. (the &#8220;Company&#8221;) has adopted this Code of Ethics (this &#8220;Code&#8221;) for its directors, officers and other employees (individually, an &#8220;Apollo Party&#8221; and collectively, &#8220;Apollo Parties&#8221;).  As used herein, any principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions are sometimes also referred to as the &#8220;Senior Financial Officers.&#8221;</font></div><div><font><br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Code has been reasonably designed to deter wrongdoing and to promote&#58;</font></div><div style="margin-top:1pt"><font><br></font></div><div style="padding-left:58.5pt;padding-right:2.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;&#160;&#160;&#160;&#160;Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships&#59;</font></div><div style="margin-top:1pt"><font><br></font></div><div style="padding-left:58.5pt;padding-right:2.25pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">&#8226;&#160;&#160;&#160;&#160;Full, fair, accurate, timely and understandable disclosure in reports and documents that a registrant files with, or submits to, the Securities and Exchange Commission and in other public communications made by the Company&#59;</font></div><div><font><br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Compliance with applicable governmental laws, rules and regulations&#59;</font></div><div style="margin-top:1pt"><font><br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;The prompt internal reporting to an appropriate person or persons identified in this</font></div><div style="margin-top:2pt;padding-left:58.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Code of violations of this Code&#59; and</font></div><div style="margin-top:1pt"><font><br></font></div><div style="padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Accountability for adherence to this Code.</font></div><div style="padding-left:40.5pt"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">I. Honest and Ethical Conduct</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Apollo Parties are expected to act and perform their duties ethically, honestly and with the utmost integrity. Honest conduct is free from fraud and deception. Ethical conduct conforms to accepted professional standards and includes the ethical handling of actual and apparent conflicts of interest between personal and professional relationships, as discussed in greater detail below.</font></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font><br></font></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">II. Compliance with Laws, Rules and Regulations</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">It is the policy of the Company to comply with all applicable laws, rules and regulations, and it is the personal responsibility of each Apollo Party to adhere to all standards and restrictions imposed by these laws, rules and regulations. In particular, each Apollo Party will adhere to all laws, rules and regulations relating to accounting and auditing matters. Any Apollo Party with questions about applicability or interpretation of any law, rule or regulation should contact a member of the Company&#8217;s upper management.</font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">III. Conflicts of Interest</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">In performing their job duties, Apollo Parties are expected to use good judgment to act, at all times and in all ways, in the best interests of the Company. A &#8220;conflict of interest&#8221; exists where an Apollo Party&#8217;s personal interest, or the interest of a family member, comes into conflict with or interferes with the best interests of the Company. For example, a conflict of interest may occur when an Apollo Party or family member receives a personal </font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">benefit as a result of the Apollo Party&#8217;s position with the Company.  A conflict of interest may also arise from an Apollo Party&#8217;s business or personal relationship with a competitor, supplier, customer, business partner or other Apollo Party if the relationship impairs the Apollo Party&#8217;s objective business judgment, or from the receipt of gifts or services in certain situations.</font></div><div><font><br></font></div><div style="padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Any Apollo Party who is aware of a conflict of interest, or is concerned that a conflict of interest might develop, must discuss the matter with a supervisor or a member of the Company&#8217;s upper management promptly. Senior Financial Officers may, in addition, discuss the matter with the Audit Committee of the Board of Directors of the Company (the &#8220;Audit Committee&#8221;).</font></div><div style="padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">IV. Insider Trading</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Federal and state laws prohibit trading in securities by persons who have material information that is not generally known or available to the public. Apollo Parties may not (a) trade in stock or other securities while in possession of material nonpublic information, (b) pass such information on to others without the express authorization of the Company, or (c) recommend to others that they trade in stock or other securities of any company based on material nonpublic information.</font></div><div><font><br></font></div><div style="padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The Company has adopted an Insider Trading Policy to implement this policy and assist in compliance with insider trading laws.  All Apollo Parties are required to review and follow the Company&#8217;s Insider Trading Policy, and certain Apollo Parties must comply with designated blackout periods for trading described in the Insider Trading Policy when trading in Company securities.</font></div><div style="padding-right:2.25pt;text-align:justify"><font><br></font></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">V. Discrimination and Harassment</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The Company provides equal opportunity in all aspects of employment and will not tolerate any illegal discrimination or harassment of any kind.</font></div><div style="margin-top:1pt;padding-right:2.25pt"><font><br></font></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">VI. Health and Safety</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company strives to provide a clean, safe and healthy work environment to all Apollo</font></div><div style="margin-top:2pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties.  Each Apollo Party is responsible for maintaining a safe and healthy workplace for all other Apollo Parties by following safety and health rules and practices, and reporting any accidents or injuries, and any unsafe equipment, practices or conditions.</font></div><div style="margin-top:2pt;padding-left:4.5pt"><font><br></font></div><div style="margin-top:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">VII. Bribery&#59; Payments to Government Personnel</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Apollo Parties may not bribe anyone for any reason, whether in dealings with governments or in the private sector. The United States Foreign Corrupt Practices Act, and similar laws in other countries, prohibit offering or giving anything of value to government officials in order to secure business. Apollo Parties may not make any illegal payments to government personnel, whether directly or through a third party, and should contact a member of upper management for guidance when conducting business with government officials of any country.</font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">VIII. Recordkeeping, Reporting and Financial Integrity</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The Company&#8217;s books, records, accounts and financial statements must be appropriately maintained in reasonable detail at all times, and must properly reflect the Company&#8217;s transactions and conform to the Company&#8217;s system of internal controls and applicable law.  The Company&#8217;s public financial reports must contain full, fair, accurate, timely and understandable disclosure, as required by law.</font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:69.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:1pt;padding-right:2.25pt;text-align:justify"><font><br></font></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">IX. Additional Provisions Applicable to Senior Financial Officers</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Senior Financial Officers are responsible for ensuring that the disclosures in the Company&#8217;s periodic reports are full, fair, accurate, timely, and understandable, as required by law. In doing so, Senior Financial Officers must take all such action reasonably necessary to (I) establish  and  comply  with  disclosure  controls  and  procedures,  as  well  as  accounting  and financial  controls,  that  are  designed  to  ensure  that  all  material  information  related  to  the Company is made known to them&#59; (ii) confirm that the Company&#8217;s periodic reports comply with the requirements of Sections 13(a) and&#47;or 15(d) of the Securities Exchange Act of 1934&#59; and (iii) ensure that the information in the Company&#8217;s periodic reports fairly presents in all material respects the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Senior Financial Officers shall not knowingly (I) make, or permit or direct any other person to make, materially false or misleading entries in the financial statements or records of the Company or any of its subsidiaries&#59; (ii) sign, or permit or direct another person to sign, a document containing materially false and misleading information&#59; or (iv) falsely respond, or fail to respond, to specific inquiries from the Company&#8217;s independent auditor or outside counsel.</font></div><div style="padding-right:2.25pt;text-align:justify"><font><br></font></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">X. Internal Reporting</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Parties shall take all appropriate actions to stop known misconduct by fellow </font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Parties that violate this Code.  Apollo Parties shall report any known or suspected misconduct to their supervisors or a member of the Company&#8217;s upper management, or, in the case of misconduct by a Senior Financial Officer, to the Chair of the Audit Committee.</font></div><div><font><br></font></div><div style="padding-left:4.5pt;padding-right:2.25pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Apollo Parties are encouraged to report any breach of this Code. The Company will not retaliate or allow retaliation for any reports made in good faith.</font></div><div style="padding-right:2.25pt"><font><br></font></div><div style="padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">XI. Accountability</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">All Apollo Parties will be held strictly accountable for adherence to this Code. Questions concerning this Code may be directed to a member of upper management or the Audit Committee. Violations of this Code may result in disciplinary action, including termination, and if warranted, legal proceedings. This Code is a statement of certain fundamental principles that govern the Apollo Parties in the conduct of the Company&#8217;s business. It does not create any rights in any employee, customer, supplier, competitor, stockholder or any other person or entity. The Audit Committee will investigate violations and appropriate action will be taken in the event of any violation of this Code.</font></div><div style="margin-top:1pt;padding-right:2.25pt;text-align:justify"><font><br></font></div><div style="margin-top:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%;text-decoration:underline">XII. Waivers and Amendments</font></div><div style="margin-top:1pt"><font><br></font></div><div style="margin-top:1pt;padding-left:4.5pt;padding-right:2.25pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The Board of Directors shall have the sole authority to approve any waiver or deviation from this Code for any Apollo Party, and any amendment or waiver of this Code shall be promptly disclosed as required by law. Specifically, any waiver or modification of this Code for a Senior Financial Officer will be promptly disclosed to stockholders as required by law, regulation or rule of a stock exchange on which the Company&#8217;s securities are traded.</font></div><div style="height:56.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ameh-20211231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if0b6022a538f4a149165a9adb0412bc4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">Subsidiaries</font></div><div style="margin-bottom:7pt;text-align:center"><font><br></font></div><div style="margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:58.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.320%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Entity</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network Medical Management, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Medical Management, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Care Connect, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Accountable Care Organization, Inc.*</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Pacific Hospice, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians ACO, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCN-ACO, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99 Medical Equipment, Healthcare Supplies &#38; Wheelchair Center</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Palliative Services, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Best Choice Hospice Care, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Holistic Care Home Health Agency, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pulmonary Critical Care Management, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Verdugo Medical Management, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Imaging, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Laboratories, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP Healthcare System </font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo-DMG Management, LLC**</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo-Sun Labs Management LLC**</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt 0 3.25pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 3.25pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt 0 3.25pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt 0 3.25pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:7pt;margin-top:3pt"><font><br></font></div><div style="margin-top:5pt;padding-left:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80% ownership</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</font></td><td colspan="3" style="padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51% ownership</font></td></tr></table></div><div style="margin-top:4pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ameh-20211231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2b281b3e02a148a88a40bb862d1ff9b8_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br>Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We consent to the incorporation by reference in the following Registration Statements&#58;           </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-231109) of Apollo Medical Holdings, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333-229895) of Apollo Medical Holdings, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-4 No. 333-219898) of Apollo Medical Holdings, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-153138) pertaining to the 2008 Professional&#47;Consultant Stock Compensation Plan of Apollo Medical Holdings, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-217719) pertaining to the 2010 Equity Incentive Plan and 2015 Equity Incentive Plan of Apollo Medical Holdings, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-221900) pertaining to the 2013 Equity Incentive Plan of Apollo Medical Holdings, Inc., and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-221915) pertaining to Written Compensation Contracts Between the Registrant and Certain Directors, Employees and Consultants of Apollo Medical Holdings, Inc.&#59;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;28, 2022, with respect to the consolidated financial statements of Apollo Medical Holdings, Inc. and the effectiveness of internal control over financial reporting of Apollo Medical Holdings, Inc. included in this Annual Report (Form 10-K) of Apollo Medical Holdings, Inc. for the year ended December 31, 2021.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ameh-20211231xexx232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib512b4eb633f4d938b24b3d32f2bbd50_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:right"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 23.2</font></div><div style="text-align:center"><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br>Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Apollo Medical Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alhambra, California</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-4 (No. 333-219898), Form S-8 (No. 333-217719, 333-153138, 333-221915 and 333-221900), and Form S-3 (No. 333-229895 and 333-231109) of Apollo Medical Holdings, Inc. of our report dated March 16, 2020, relating to the consolidated financial statements, which appears in this Form 10-K. </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#47;s&#47; BDO USA, LLP                                                </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Los Angeles, California</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February&#160;28, 2022</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ameh-20211231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib767435b09154ce8897e9d91dfff732d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., M.P.H., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this annual report on Form 10-K of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam </font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ameh-20211231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i00b0698a4ffe46f4847ecc46f5231e2c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this annual report on Form 10-K of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon Sim</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>8
<FILENAME>ameh-20211231xexx313.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id4d6c38c0a4441d6b43d573b977a9b0d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.3</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this annual report on Form 10-K of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Chin</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>ameh-20211231xexx32.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="idd712dcd7ed943fd9624d0dae8c8385d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., M.P.H., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Apollo Medical Holdings, Inc. for the year ended December&#160;31, 2021, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.036%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam </font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brandon Sim, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Apollo Medical Holdings, Inc. for the year ended December&#160;31, 2021, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Brandon Sim</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brandon Sim </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer </font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of Apollo Medical Holdings, Inc. for the year ended December&#160;31, 2021, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:7.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Chin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ameh-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56a96635-232a-499f-a03d-15d085375db3,g:3c5e1a1a-f2ce-472c-bc52-288bd5b84a32-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ameh="http://www.apollomed.net/20211231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20211231">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.apollomed.net/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.apollomed.net/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1003005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
        <link:definition>1004006 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1005007 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Payor Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails">
        <link:definition>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwill" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill">
        <link:definition>2111103 - Disclosure - Business Combinations and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillTables" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables">
        <link:definition>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillGoodwillRollForwardDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails">
        <link:definition>2414408 - Disclosure - Business Combinations and Goodwill - Goodwill Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LandPropertyandEquipmentNet" roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNet">
        <link:definition>2115104 - Disclosure - Land, Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LandPropertyandEquipmentNetTables" roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetTables">
        <link:definition>2316303 - Disclosure - Land, Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails" roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails">
        <link:definition>2417409 - Disclosure - Land, Property and Equipment, Net - Schedule of Land, Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LandPropertyandEquipmentNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetAdditionalInformationDetails">
        <link:definition>2418410 - Disclosure - Land, Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>2119105 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>2320304 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>2421411 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>2421411 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2422412 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails">
        <link:definition>2423413 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntities" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities">
        <link:definition>2124106 - Disclosure - Investments in Other Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables">
        <link:definition>2325305 - Disclosure - Investments in Other Entities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails">
        <link:definition>2426414 - Disclosure - Investments in Other Entities - Equity Method (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails">
        <link:definition>2427415 - Disclosure - Investments in Other Entities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>2428416 - Disclosure - Investments in Other Entities &#8212; Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansReceivableandLoansReceivableRelatedParties" roleURI="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedParties">
        <link:definition>2129107 - Disclosure - Loans Receivable and Loans Receivable - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails">
        <link:definition>2430417 - Disclosure - Loans Receivable and Loans Receivable - Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>2131108 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2332306 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>2433418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>2134109 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>2335307 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails">
        <link:definition>2436419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit">
        <link:definition>2137110 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables">
        <link:definition>2338308 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails">
        <link:definition>2439420 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>2440421 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail">
        <link:definition>2441422 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>2142111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.apollomed.net/role/IncomeTaxesTables">
        <link:definition>2343309 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxProvisionBenefitDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails">
        <link:definition>2444423 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2445424 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2446425 - Disclosure - Income Taxes - Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>2447426 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>2148112 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails">
        <link:definition>2449427 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.apollomed.net/role/StockBasedCompensation">
        <link:definition>2150113 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.apollomed.net/role/StockBasedCompensationTables">
        <link:definition>2351310 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails">
        <link:definition>2452428 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>2453429 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionActivityDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails">
        <link:definition>2454430 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
        <link:definition>2455431 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRestrictedStockActivityDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails">
        <link:definition>2456432 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofWarrantDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails">
        <link:definition>2457433 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWarrantsDetails" roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails">
        <link:definition>2458434 - Disclosure - Stock-Based Compensation - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>2159114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2460435 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>2161115 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>2362311 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2463436 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails">
        <link:definition>2464437 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.apollomed.net/role/EmployeeBenefitPlan">
        <link:definition>2165116 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails">
        <link:definition>2466438 - Disclosure - Employee Benefit Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>2167117 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>2368312 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>2469439 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails">
        <link:definition>2470440 - Disclosure - Earnings Per Share - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails">
        <link:definition>2471441 - Disclosure - Earnings Per Share - Summary of Shares Included in Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>2172118 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>2373313 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails">
        <link:definition>2474442 - Disclosure - Variable Interest Entities (VIEs) - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>2175119 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>2376314 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>2477443 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2478444 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails">
        <link:definition>2479445 - Disclosure - Leases - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details">
        <link:definition>2480446 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1">
        <link:definition>2480446 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.apollomed.net/role/SubsequentEvents">
        <link:definition>2181120 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>2482447 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ameh_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_IssuanceOfFinancingObligationForBusinessCombination" abstract="false" name="IssuanceOfFinancingObligationForBusinessCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" abstract="false" name="StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityIncentivePlanTwentyFifteenMember" abstract="true" name="EquityIncentivePlanTwentyFifteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_TemporaryEquityPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentInvestmentInPeriod" abstract="false" name="EquityMethodInvestmentInvestmentInPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NumberOfRemotePatientMonitoringPatients" abstract="false" name="NumberOfRemotePatientMonitoringPatients" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_ClinigenceHoldingsIncMember" abstract="true" name="ClinigenceHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Warrant1Member" abstract="true" name="Warrant1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_TemporaryEquityShareBasedCompensation" abstract="false" name="TemporaryEquityShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AncillaryServiceContractMember" abstract="true" name="AncillaryServiceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PrimaryBeneficiaryMember" abstract="true" name="PrimaryBeneficiaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOInc.Member" abstract="true" name="OneMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeOneMember" abstract="true" name="WarrantExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_CMSMember" abstract="true" name="CMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" abstract="false" name="PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" abstract="false" name="AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_GainLossOnAssumptionOfLoan" abstract="false" name="GainLossOnAssumptionOfLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_GainLossOnConsolidationOfEquityMethodInvestment" abstract="false" name="GainLossOnConsolidationOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_FinanceReceivableInterestRateStatedPercentage" abstract="false" name="FinanceReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_MedicalCareCostsAbstract" abstract="true" name="MedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsContribution" abstract="false" name="EquityMethodInvestmentsContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeTwoMember" abstract="true" name="WarrantExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ContingentEquitySecuritiesMember" abstract="true" name="ContingentEquitySecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DeferredTaxLiabilities481aAdjustment" abstract="false" name="DeferredTaxLiabilities481aAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableStatedInterestRate" abstract="false" name="FinanceReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" abstract="false" name="StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueCashlessWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_FinanceReceivableTermOfReceivable" abstract="false" name="FinanceReceivableTermOfReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CAIPAMSOMember" abstract="true" name="CAIPAMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtCovenantAggregatePurchasePriceMaximum" abstract="false" name="DebtCovenantAggregatePurchasePriceMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentsToAcquireCommonStockAndWarrants" abstract="false" name="PaymentsToAcquireCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ConsultingServicesMember" abstract="true" name="ConsultingServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_GainLossOnEquityReceivable" abstract="false" name="GainLossOnEquityReceivable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentOfRevenueMonthlyAmount" abstract="false" name="PaymentOfRevenueMonthlyAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FulgentGeneticsIncMember" abstract="true" name="FulgentGeneticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AccountsReceivableExpectedToBeCollectedPeriod" abstract="false" name="AccountsReceivableExpectedToBeCollectedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" abstract="false" name="InsuranceServicesRevenueCapitationAndClaimsPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_TemporaryEquityStockSubscription" abstract="false" name="TemporaryEquityStockSubscription" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DefinedContributionPlanServicePeriod" abstract="false" name="DefinedContributionPlanServicePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_WeightedAverageExercisePriceWarrantsRollForward" abstract="true" name="WeightedAverageExercisePriceWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeThreeMember" abstract="true" name="WarrantExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Dr.ArteagaMember" abstract="true" name="Dr.ArteagaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" abstract="true" name="MPPAMGPropertiesAndZLLAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CashlessExerciseOfStockOptions" abstract="false" name="CashlessExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" abstract="false" name="ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ContractTypeAxis" abstract="true" name="ContractTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" abstract="false" name="FinanceReceivableModificationsSubsequentDefaultInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_LongTermDebtMaturityAfterYearFour" abstract="false" name="LongTermDebtMaturityAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_A11CommonStockWarrantsMember" abstract="true" name="A11CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" abstract="true" name="LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares" abstract="false" name="TemporaryEquityCostOfEquityIssuanceOfPreferredShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AccessPrimaryCareMedicalGroupMember" abstract="true" name="AccessPrimaryCareMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_APAMHMedicalCorporationMember" abstract="true" name="APAMHMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_Pacific6EnterprisesMember" abstract="true" name="Pacific6EnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessTable" abstract="true" name="DescriptionOfBusinessTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_SubcontractorIpaRiskPoolPayable" abstract="false" name="SubcontractorIpaRiskPoolPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicalPropertyPartnersLLCMember" abstract="true" name="MedicalPropertyPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApaacoMember" abstract="true" name="ApaacoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementIncMember" abstract="true" name="NetworkMedicalManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodShareConversionOfNotes" abstract="false" name="StockIssuedDuringPeriodShareConversionOfNotes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" abstract="true" name="OrmaHealthIncAndProviderGrowthSolutionsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_NumberOfEmployees" abstract="false" name="NumberOfEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_CriticalQualityManagementCorpMember" abstract="true" name="CriticalQualityManagementCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" abstract="false" name="FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NumberOfSharesHoldbackPercentage" abstract="false" name="NumberOfSharesHoldbackPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" abstract="false" name="PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_NoncontrollingInterestSharesDistributed" abstract="false" name="NoncontrollingInterestSharesDistributed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MWNCommunityHospitalLLCMember" abstract="true" name="MWNCommunityHospitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageDisposed" abstract="false" name="EquityMethodInvestmentOwnershipPercentageDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" abstract="false" name="StockIssuedDuringPeriodValueNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" abstract="false" name="TemporaryEquityIncreaseFromSaleOfNonControllingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_TemporaryEquityRepurchaseOfTreasuryShares" abstract="false" name="TemporaryEquityRepurchaseOfTreasuryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_Dr.JayMember" abstract="true" name="Dr.JayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationCash" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CAIPAMSOLLCMember" abstract="true" name="CAIPAMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AccountsPayableAndAccruedExpensesMember" abstract="true" name="AccountsPayableAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_TemporaryEquityDistributionToNoncontrollingInterest" abstract="false" name="TemporaryEquityDistributionToNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ContractTypeDomain" abstract="true" name="ContractTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessLineItems" abstract="true" name="DescriptionOfBusinessLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_OperatingLossCarryforwardsExpirationPeriod" abstract="false" name="OperatingLossCarryforwardsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:gYearItemType"/>
  <xs:element id="ameh_DefinedContributionPlanVestingPeriod" abstract="false" name="DefinedContributionPlanVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SCHCMember" abstract="true" name="SCHCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_LoanReceivableAbstract" abstract="true" name="LoanReceivableAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ProceedsFromEquityOffering" abstract="false" name="ProceedsFromEquityOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ApcShareholdersMember" abstract="true" name="ApcShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AlphaCareMedicalGroupInc.Member" abstract="true" name="AlphaCareMedicalGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NoncontrollingInterestIncreaseFromCapitalCharge" abstract="false" name="NoncontrollingInterestIncreaseFromCapitalCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_RepaymentsOfBankLoanAndLinesOfCredit" abstract="false" name="RepaymentsOfBankLoanAndLinesOfCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" abstract="false" name="DebtInstrumentCovenantLeverageRatioIncrementalChange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentOfRevenue" abstract="false" name="PaymentOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" abstract="true" name="AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" abstract="false" name="BusinessCombinationEquityInterestPurchaseObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApolloSunLabsManagementLLCMember" abstract="true" name="ApolloSunLabsManagementLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ReclassificationOfLiabilityForEquity" abstract="false" name="ReclassificationOfLiabilityForEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PacificAmbulatorySurgeryCenterLlcMember" abstract="true" name="PacificAmbulatorySurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_APCAndAPCLSMAMember" abstract="true" name="APCAndAPCLSMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ArroyoVistaFamilyHealthCenterMember" abstract="true" name="ArroyoVistaFamilyHealthCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ZLLPartnersLLCMember" abstract="true" name="ZLLPartnersLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DiagnosticMedicalGroupMember" abstract="true" name="DiagnosticMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOLLCMember" abstract="true" name="OneMSOLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" abstract="false" name="ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_BusinessCombinationNumberOfSharesHeldBack" abstract="false" name="BusinessCombinationNumberOfSharesHeldBack" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationPreferredShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ExecutiveOfficerAndDirectorMember" abstract="true" name="ExecutiveOfficerAndDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_UniversalCareIncMember" abstract="true" name="UniversalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicalLiabilitiesCurrent" abstract="false" name="MedicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss" abstract="false" name="NotesReceivableRelatedPartiesNoncurrentGainLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" abstract="false" name="DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_StockAwardsAndUnitsMember" abstract="true" name="StockAwardsAndUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesCashlessWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" abstract="false" name="NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CancellationOfRestrictedStockAwards" abstract="false" name="CancellationOfRestrictedStockAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MaverickMedicalGroupIncMember" abstract="true" name="MaverickMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AssetAcquisitionPercentageOfSharesAcquired" abstract="false" name="AssetAcquisitionPercentageOfSharesAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_NumenLLCMember" abstract="true" name="NumenLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AccountableHealthCareIPAMember" abstract="true" name="AccountableHealthCareIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_BeneficialInterestPolicyTextBlock" abstract="false" name="BeneficialInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_FiduciaryCashAndPayablePolicyTextBlock" abstract="false" name="FiduciaryCashAndPayablePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_NumberOfDirectContractingEntityPatients" abstract="false" name="NumberOfDirectContractingEntityPatients" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_SharesWarrantsRollForward" abstract="true" name="SharesWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AchievaMedInc.Member" abstract="true" name="AchievaMedInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_HealthSourceMSOInc.Member" abstract="true" name="HealthSourceMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" abstract="true" name="OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_Warrant2Member" abstract="true" name="Warrant2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOtherOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NumberOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" abstract="false" name="PercentageOfFinancialGuaranteeBenchmarkAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MedicareLicenseMember" abstract="true" name="MedicareLicenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_UniversalCareAcquisitionPartnersLlcMember" abstract="true" name="UniversalCareAcquisitionPartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorEMember" abstract="true" name="PayorEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_AMGPropertiesLLCMember" abstract="true" name="AMGPropertiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_PaymentOfRevenueRevenueRecognized" abstract="false" name="PaymentOfRevenueRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioAdjustedMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_Tag8MedicalInvestmentGroupLLCMember" abstract="true" name="Tag8MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CollegeStreetInvestmentLpMember" abstract="true" name="CollegeStreetInvestmentLpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightCancelledInPeriod" abstract="false" name="ClassOfWarrantOrRightCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsConsolidated" abstract="false" name="EquityMethodInvestmentsConsolidated" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantDebtCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_DeferredTaxAssetsInvestment" abstract="false" name="DeferredTaxAssetsInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_RiskPoolSettlement" abstract="false" name="RiskPoolSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_MinorityInterestPolicyPolicyTextBlock" abstract="false" name="MinorityInterestPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AmgIncMember" abstract="true" name="AmgIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" abstract="false" name="WarrantIssuedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MediPortalLLCMember" abstract="true" name="MediPortalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantCashFlowCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ApcStockOptionMember" abstract="true" name="ApcStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_A10CommonStockWarrantsMember" abstract="true" name="A10CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueConversionOfNotes" abstract="false" name="StockIssuedDuringPeriodValueConversionOfNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" abstract="false" name="EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AggregateintrinsicvalueAbstract" abstract="true" name="AggregateintrinsicvalueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" abstract="false" name="EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" abstract="false" name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_FormerShareholdersOfNmmMember" abstract="true" name="FormerShareholdersOfNmmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PerMemberPerMonthManagedCareContractMember" abstract="true" name="PerMemberPerMonthManagedCareContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NextGenerationACOModelParticipationAgreementMember" abstract="true" name="NextGenerationACOModelParticipationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" abstract="false" name="NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AlliedPacificofCaliforniaBrokerageAccountMember" abstract="true" name="AlliedPacificofCaliforniaBrokerageAccountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DeferredTaxLiabilitiesStockOptions" abstract="false" name="DeferredTaxLiabilitiesStockOptions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_Tag6MedicalInvestmentGroupLLCMember" abstract="true" name="Tag6MedicalInvestmentGroupLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AdvanceDiagnosticSurgeryCenterMember" abstract="true" name="AdvanceDiagnosticSurgeryCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PaymentMadeToRelatedParty" abstract="false" name="PaymentMadeToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" abstract="false" name="StockIssuedDuringPeriodSharesNoncontrollingInterest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ApaAcoIncMember" abstract="true" name="ApaAcoIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_ConstructionLoanMember" abstract="true" name="ConstructionLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ameh_NumberOfFamilyPracticeClinics" abstract="false" name="NumberOfFamilyPracticeClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_FreseniusMember" abstract="true" name="FreseniusMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" abstract="true" name="WeightedaverageremainingcontractualtermyearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" abstract="true" name="ConcourseDiagnosticSurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_EquityIncentivePlanTwentyThirteenMember" abstract="true" name="EquityIncentivePlanTwentyThirteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired" abstract="false" name="FiniteAndIndefiniteLivedIntangibleAssetsAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ApcLsmaMember" abstract="true" name="ApcLsmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" abstract="false" name="StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ameh_HoldbackSharesMember" abstract="true" name="HoldbackSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ameh_PayorFMember" abstract="true" name="PayorFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ameh-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56a96635-232a-499f-a03d-15d085375db3,g:3c5e1a1a-f2ce-472c-bc52-288bd5b84a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8ee61adf-1835-406e-8907-d8859f55e509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3e9ac70f-fc7e-4ad8-9f4b-43d8c123edb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ee61adf-1835-406e-8907-d8859f55e509" xlink:to="loc_us-gaap_LiabilitiesCurrent_3e9ac70f-fc7e-4ad8-9f4b-43d8c123edb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_9c2c6167-924c-46f2-8249-467f8ff55e16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8ee61adf-1835-406e-8907-d8859f55e509" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_9c2c6167-924c-46f2-8249-467f8ff55e16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_63216b73-3ede-44b8-b2df-5ad91845a964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_00193c04-c35b-46e6-8cff-93b1bc271073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_63216b73-3ede-44b8-b2df-5ad91845a964" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_00193c04-c35b-46e6-8cff-93b1bc271073" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e16c1e8e-ad1c-4406-9767-22667a2052b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_63216b73-3ede-44b8-b2df-5ad91845a964" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e16c1e8e-ad1c-4406-9767-22667a2052b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f648278-89f3-4db9-be9c-089f2ffa4fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_63216b73-3ede-44b8-b2df-5ad91845a964" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3f648278-89f3-4db9-be9c-089f2ffa4fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f570c89d-dd98-48a0-9181-c390f0f45a75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_63216b73-3ede-44b8-b2df-5ad91845a964" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f570c89d-dd98-48a0-9181-c390f0f45a75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_32a83c14-eca0-4f4a-87df-aef9c7d4c844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_63216b73-3ede-44b8-b2df-5ad91845a964" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_32a83c14-eca0-4f4a-87df-aef9c7d4c844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a4afaff7-6029-49cd-8695-445d75c9c740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_a4afaff7-6029-49cd-8695-445d75c9c740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a2106efb-d925-4f12-be48-f0a29caa58ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a2106efb-d925-4f12-be48-f0a29caa58ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b399ac9e-6df2-480d-a506-5d1a20c84ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_Goodwill_b399ac9e-6df2-480d-a506-5d1a20c84ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_fe5b30cb-dbc2-4329-813f-a6fb8c035fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_fe5b30cb-dbc2-4329-813f-a6fb8c035fe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_83ea106c-f2d0-4bf1-8f32-6c6c0d534816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_83ea106c-f2d0-4bf1-8f32-6c6c0d534816" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e0cccec-1e0b-4bd0-8a28-21b3b96552d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_EquityMethodInvestments_9e0cccec-1e0b-4bd0-8a28-21b3b96552d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_1e4fdec6-85bb-4628-8958-5d28e5a907cf" xlink:href="ameh-20211231.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_1e4fdec6-85bb-4628-8958-5d28e5a907cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_eb791a74-7f0a-437d-8204-821cde3885f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_eb791a74-7f0a-437d-8204-821cde3885f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e837e293-8b5b-4305-9452-dad6793b6360" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e837e293-8b5b-4305-9452-dad6793b6360" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_eececf76-3967-456e-a1f9-64b59f08689a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_d736182b-fddd-4fb5-80a0-fd2f153c20e2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_eececf76-3967-456e-a1f9-64b59f08689a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_05f4f095-028e-4c75-94d6-290b9dc2246e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_05f4f095-028e-4c75-94d6-290b9dc2246e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b3159da0-004e-487f-a768-ec63d21464e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_us-gaap_LongTermDebtCurrent_b3159da0-004e-487f-a768-ec63d21464e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_887784f7-8121-4f93-9c68-c538bbf3740a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_us-gaap_DueToAffiliateCurrent_887784f7-8121-4f93-9c68-c538bbf3740a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_aa601a7c-803e-418d-8b12-214669792fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_us-gaap_DividendsPayableCurrent_aa601a7c-803e-418d-8b12-214669792fcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_ed920388-4268-46ef-8db4-70216e7817ed" xlink:href="ameh-20211231.xsd#ameh_MedicalLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_ed920388-4268-46ef-8db4-70216e7817ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_45559fc7-be41-484f-a22c-8a29b1f263fe" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_45559fc7-be41-484f-a22c-8a29b1f263fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_3d92fca2-aafb-4dd8-b971-a00c1057d43b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_3d92fca2-aafb-4dd8-b971-a00c1057d43b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_15858f8c-4fb3-4f50-ab1e-3b76a2f145e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_15858f8c-4fb3-4f50-ab1e-3b76a2f145e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_44926a20-ca12-418b-bf8f-7bdf5b20ecaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d4dc9983-80d8-4d3b-a0ef-c4daabe4461a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_44926a20-ca12-418b-bf8f-7bdf5b20ecaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5aa45095-ea5e-40f7-9a1f-1bcc355c1111" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_01f994d4-c9cc-4984-adb9-c5c90c379d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5aa45095-ea5e-40f7-9a1f-1bcc355c1111" xlink:to="loc_us-gaap_AssetsCurrent_01f994d4-c9cc-4984-adb9-c5c90c379d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_369b98f6-f594-4c47-b096-215be1fef0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5aa45095-ea5e-40f7-9a1f-1bcc355c1111" xlink:to="loc_us-gaap_AssetsNoncurrent_369b98f6-f594-4c47-b096-215be1fef0a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3ad45559-7bac-4d8e-a997-3409d8e05348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3ebec483-06cc-456c-96fa-8374c504916e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3ad45559-7bac-4d8e-a997-3409d8e05348" xlink:to="loc_us-gaap_PreferredStockValue_3ebec483-06cc-456c-96fa-8374c504916e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_897975e9-82a5-4bfa-85fb-f0417244c653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3ad45559-7bac-4d8e-a997-3409d8e05348" xlink:to="loc_us-gaap_CommonStockValue_897975e9-82a5-4bfa-85fb-f0417244c653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6f21be6a-5587-432f-b788-65aa3bc24aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3ad45559-7bac-4d8e-a997-3409d8e05348" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6f21be6a-5587-432f-b788-65aa3bc24aaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_328e606d-c1a5-4a88-b409-2ae1476dee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_3ad45559-7bac-4d8e-a997-3409d8e05348" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_328e606d-c1a5-4a88-b409-2ae1476dee6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b85bf1af-d001-4799-8d2e-2c9bb6f5fe03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_14a1d92a-95e9-46b8-88dc-5948ff8059f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b85bf1af-d001-4799-8d2e-2c9bb6f5fe03" xlink:to="loc_us-gaap_StockholdersEquity_14a1d92a-95e9-46b8-88dc-5948ff8059f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_c1dec9a4-6e50-4077-843f-36c9b571cdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b85bf1af-d001-4799-8d2e-2c9bb6f5fe03" xlink:to="loc_us-gaap_MinorityInterest_c1dec9a4-6e50-4077-843f-36c9b571cdbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_045bc0f5-5424-4f22-b085-7310f0342e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_48b3b02e-ff2f-45b8-a32b-effa9b1db6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_045bc0f5-5424-4f22-b085-7310f0342e6b" xlink:to="loc_us-gaap_Liabilities_48b3b02e-ff2f-45b8-a32b-effa9b1db6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_03099762-5540-4ed4-a7f0-235e16ef1d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_045bc0f5-5424-4f22-b085-7310f0342e6b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_03099762-5540-4ed4-a7f0-235e16ef1d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7c13635b-b911-4442-aef4-089173b6a2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_045bc0f5-5424-4f22-b085-7310f0342e6b" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_7c13635b-b911-4442-aef4-089173b6a2f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90f25fcb-8268-4a7c-8c6c-8c65aa64f5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_045bc0f5-5424-4f22-b085-7310f0342e6b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_90f25fcb-8268-4a7c-8c6c-8c65aa64f5b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ed36fe39-fa9a-4975-9b94-2581ec567999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_10bc4b72-c28b-48bb-9c22-d86f3c782b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ed36fe39-fa9a-4975-9b94-2581ec567999" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_10bc4b72-c28b-48bb-9c22-d86f3c782b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_37ddfca4-bee2-4365-a883-c8922c863c12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ed36fe39-fa9a-4975-9b94-2581ec567999" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_37ddfca4-bee2-4365-a883-c8922c863c12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a15fb1af-d153-461c-9a30-3e9abb059324" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ed36fe39-fa9a-4975-9b94-2581ec567999" xlink:to="loc_us-gaap_InterestExpense_a15fb1af-d153-461c-9a30-3e9abb059324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cab33f81-d934-4f4b-9d40-9116acd186c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ed36fe39-fa9a-4975-9b94-2581ec567999" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cab33f81-d934-4f4b-9d40-9116acd186c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_f25d5e52-f83c-4561-9ede-d20e876ad703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ed36fe39-fa9a-4975-9b94-2581ec567999" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_f25d5e52-f83c-4561-9ede-d20e876ad703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_99458231-2ed9-4a9c-bf9b-9619f5cd68cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ed36fe39-fa9a-4975-9b94-2581ec567999" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_99458231-2ed9-4a9c-bf9b-9619f5cd68cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bd599955-99d5-4788-b935-ded382053efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a8d2564-5f16-4208-b966-3bffe9027d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bd599955-99d5-4788-b935-ded382053efd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9a8d2564-5f16-4208-b966-3bffe9027d7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b88ae21f-a47d-424b-9b50-0af10419215c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_bd599955-99d5-4788-b935-ded382053efd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b88ae21f-a47d-424b-9b50-0af10419215c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f9ef117c-055f-445a-8e75-f824aad3a285" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f805cc7a-c3c5-4445-b9be-7df562c3deaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9ef117c-055f-445a-8e75-f824aad3a285" xlink:to="loc_us-gaap_ProfitLoss_f805cc7a-c3c5-4445-b9be-7df562c3deaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b98c5f31-12d2-4b32-b251-242a6ef3bb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f9ef117c-055f-445a-8e75-f824aad3a285" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b98c5f31-12d2-4b32-b251-242a6ef3bb5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_39605b7f-7fda-4103-950d-540b1d540c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b91d3134-556c-4c1b-8c23-e6b50d3eaa3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39605b7f-7fda-4103-950d-540b1d540c76" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_b91d3134-556c-4c1b-8c23-e6b50d3eaa3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_f1868651-52fb-4fcc-9391-95a6fabc5958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39605b7f-7fda-4103-950d-540b1d540c76" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_f1868651-52fb-4fcc-9391-95a6fabc5958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_3c17f591-2224-4224-85a2-eefc21e29c77" xlink:href="ameh-20211231.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39605b7f-7fda-4103-950d-540b1d540c76" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_3c17f591-2224-4224-85a2-eefc21e29c77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_b734771b-54bf-4136-8051-a4e951d590ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39605b7f-7fda-4103-950d-540b1d540c76" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_b734771b-54bf-4136-8051-a4e951d590ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_df002c03-0411-4951-bde9-acd00e45454b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_39605b7f-7fda-4103-950d-540b1d540c76" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_df002c03-0411-4951-bde9-acd00e45454b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_504d09e0-7b3f-4480-b513-73fbcac246a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_caf7d6f2-b3ae-4cfd-99b3-1e5471431433" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_504d09e0-7b3f-4480-b513-73fbcac246a1" xlink:to="loc_us-gaap_OperatingIncomeLoss_caf7d6f2-b3ae-4cfd-99b3-1e5471431433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_38653dc2-6508-46a6-b73e-237d55c8310a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_504d09e0-7b3f-4480-b513-73fbcac246a1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_38653dc2-6508-46a6-b73e-237d55c8310a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4cdfeadd-ee4d-4ee7-accc-34fa1f93c3be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38ae7434-385f-4a02-9317-efebc5788719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4cdfeadd-ee4d-4ee7-accc-34fa1f93c3be" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38ae7434-385f-4a02-9317-efebc5788719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7fc0b487-fd31-4ec4-a367-a1885a10e7d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4cdfeadd-ee4d-4ee7-accc-34fa1f93c3be" xlink:to="loc_us-gaap_CostsAndExpenses_7fc0b487-fd31-4ec4-a367-a1885a10e7d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bf541221-11f1-406a-b904-043e2d3f16f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_ProfitLoss_bf541221-11f1-406a-b904-043e2d3f16f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ddee04b1-6949-4306-bf73-c187ba22fb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ddee04b1-6949-4306-bf73-c187ba22fb6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_2fb07ed6-44ed-42b8-8bf2-6b9341066ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_2fb07ed6-44ed-42b8-8bf2-6b9341066ff6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment_4c05828e-cd0e-4fc5-a64d-6c2b2d3a3ef8" xlink:href="ameh-20211231.xsd#ameh_GainLossOnConsolidationOfEquityMethodInvestment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment_4c05828e-cd0e-4fc5-a64d-6c2b2d3a3ef8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1ffa3bd0-de3d-49bf-a9a1-b1d35e7b3c93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1ffa3bd0-de3d-49bf-a9a1-b1d35e7b3c93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_7e827b18-34b9-4314-89f2-3f40d9cf3b08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_7e827b18-34b9-4314-89f2-3f40d9cf3b08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_bfbd1e55-3883-4b03-bcde-2fb296eb2808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_bfbd1e55-3883-4b03-bcde-2fb296eb2808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_824df8be-7654-479a-8ad5-c521f810c8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_824df8be-7654-479a-8ad5-c521f810c8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnEquityReceivable_ee7618ab-8a0e-496e-8909-2f8ab38a4b30" xlink:href="ameh-20211231.xsd#ameh_GainLossOnEquityReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_ameh_GainLossOnEquityReceivable_ee7618ab-8a0e-496e-8909-2f8ab38a4b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_f79f0dbd-920c-4d32-b06b-a413bd44c17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_f79f0dbd-920c-4d32-b06b-a413bd44c17d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_72cd8bfc-3628-406c-8057-db527006382c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_72cd8bfc-3628-406c-8057-db527006382c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f20b2740-a5b2-4b93-8296-34bc0a584ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_ShareBasedCompensation_f20b2740-a5b2-4b93-8296-34bc0a584ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_13a263ac-dde3-4519-9a88-b11b618dc249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_13a263ac-dde3-4519-9a88-b11b618dc249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_10832e69-d135-46c7-8035-79bfacce5d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_10832e69-d135-46c7-8035-79bfacce5d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnAssumptionOfLoan_83c74339-8d72-4415-9319-98f4e1a06ea0" xlink:href="ameh-20211231.xsd#ameh_GainLossOnAssumptionOfLoan"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_ameh_GainLossOnAssumptionOfLoan_83c74339-8d72-4415-9319-98f4e1a06ea0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c2b7cb5f-df59-4876-a203-89d44a5eb95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c2b7cb5f-df59-4876-a203-89d44a5eb95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_43576bae-18d7-4485-a642-600d2ec93dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_43576bae-18d7-4485-a642-600d2ec93dad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_be47a4ad-dd19-415a-9b6f-e0ee47de9268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_be47a4ad-dd19-415a-9b6f-e0ee47de9268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_121f6623-bab8-4405-8bef-d2841dca415e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_121f6623-bab8-4405-8bef-d2841dca415e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_8ae97e4a-7fb4-47f6-8339-9596ea0bb608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_8ae97e4a-7fb4-47f6-8339-9596ea0bb608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6d0fb3ed-4ff1-46f8-8945-6d8500ede367" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6d0fb3ed-4ff1-46f8-8945-6d8500ede367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_c0f4e32f-8170-4e83-8b27-aa6b12538f70" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_c0f4e32f-8170-4e83-8b27-aa6b12538f70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_7c63a29d-e7e6-4031-9d71-1abb85e3a55a" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_7c63a29d-e7e6-4031-9d71-1abb85e3a55a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bb85d6c3-b467-455c-b42d-687c52712447" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_bb85d6c3-b467-455c-b42d-687c52712447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8084b831-d36a-4382-910a-09290dff94b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="25" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8084b831-d36a-4382-910a-09290dff94b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_3d683672-b4ff-47f8-bd88-17c69a7ff3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="26" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_3d683672-b4ff-47f8-bd88-17c69a7ff3dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_56527979-b461-47cb-b678-669bf598bbe9" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="27" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_56527979-b461-47cb-b678-669bf598bbe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6d4d558a-e508-4527-8f81-a0d855fe4012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="28" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_6d4d558a-e508-4527-8f81-a0d855fe4012" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_be38720b-a1bf-42d9-9d72-c1ea4623105f" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:calculationArc order="29" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7f321cc9-012b-4de8-a9a0-cfb8c7de44b9" xlink:to="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_be38720b-a1bf-42d9-9d72-c1ea4623105f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_5fb1cad9-9b19-4d41-a7ae-f138a7f39794" xlink:href="ameh-20211231.xsd#ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_5fb1cad9-9b19-4d41-a7ae-f138a7f39794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d96ac646-48e4-4967-adf4-d0f4932bb451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d96ac646-48e4-4967-adf4-d0f4932bb451" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_fa4d833c-1abc-46f7-af0d-34d4c24bbb19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_fa4d833c-1abc-46f7-af0d-34d4c24bbb19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3d703c35-c360-499e-8e7c-c7ae94578f97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_3d703c35-c360-499e-8e7c-c7ae94578f97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_757c132a-4ef5-40a0-ac27-b036bb224672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_757c132a-4ef5-40a0-ac27-b036bb224672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_45626be5-7380-4cb9-9d10-a4550dfb9a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_45626be5-7380-4cb9-9d10-a4550dfb9a2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_571e5483-3e58-450e-892b-8678cdbd504b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_571e5483-3e58-450e-892b-8678cdbd504b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fdd015f6-ed86-49de-b126-12a5aed16dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fdd015f6-ed86-49de-b126-12a5aed16dcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_6d77b671-050e-447c-bf6e-c9c89a1f6f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_6d77b671-050e-447c-bf6e-c9c89a1f6f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_39f2c08d-5861-40cc-afe0-bb3a24f1985a" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_39f2c08d-5861-40cc-afe0-bb3a24f1985a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9be798fb-84d1-402a-b5d4-7d8f3045e9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9be798fb-84d1-402a-b5d4-7d8f3045e9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b2f7923a-89c3-416d-8479-7e473d538b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_87f48282-aaea-4e38-b844-0589efd70c22" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b2f7923a-89c3-416d-8479-7e473d538b7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_910136f4-ee99-4477-ad3a-9f0dc6fb4e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d54ef78-5a72-491f-b5ba-3c3ea7382f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_910136f4-ee99-4477-ad3a-9f0dc6fb4e56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3d54ef78-5a72-491f-b5ba-3c3ea7382f3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_788ec3c6-e3e6-44c2-b9c3-3e1d6284ba41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_910136f4-ee99-4477-ad3a-9f0dc6fb4e56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_788ec3c6-e3e6-44c2-b9c3-3e1d6284ba41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d682139-ef62-4469-936f-5fa47c1d994d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_910136f4-ee99-4477-ad3a-9f0dc6fb4e56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6d682139-ef62-4469-936f-5fa47c1d994d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_222c7c5c-2c92-4a4e-942a-c2c1872596f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_79b185a7-be75-4630-a9c3-c233833f9957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_222c7c5c-2c92-4a4e-942a-c2c1872596f7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_79b185a7-be75-4630-a9c3-c233833f9957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_43bfc4e4-fcee-4384-8630-eff89bda5c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_222c7c5c-2c92-4a4e-942a-c2c1872596f7" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_43bfc4e4-fcee-4384-8630-eff89bda5c4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_5ada6c5a-b708-4b42-8c5a-d013b3e6e21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_222c7c5c-2c92-4a4e-942a-c2c1872596f7" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_5ada6c5a-b708-4b42-8c5a-d013b3e6e21c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_c13aa70e-7d7b-4cd1-b126-3aa2afa9d450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_c13aa70e-7d7b-4cd1-b126-3aa2afa9d450" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_33f00db8-2b61-44b2-8aaf-0dd2fd066828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_33f00db8-2b61-44b2-8aaf-0dd2fd066828" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_fe039622-8b1e-4464-8a07-ac5a1eaf7dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_fe039622-8b1e-4464-8a07-ac5a1eaf7dfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_a5e2e497-636c-4425-bf85-fccd0a9eccb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_a5e2e497-636c-4425-bf85-fccd0a9eccb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_0d7c96c8-e7b8-4b6c-86a7-0a3cbc93c8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_0d7c96c8-e7b8-4b6c-86a7-0a3cbc93c8ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b5ab4082-a575-4606-98eb-7876072812a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b5ab4082-a575-4606-98eb-7876072812a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_bbf57e22-5e4f-454a-9959-e43b6090b73f" xlink:href="ameh-20211231.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_bbf57e22-5e4f-454a-9959-e43b6090b73f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2102bc60-b02f-4210-b25a-70ec4a6118af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_2102bc60-b02f-4210-b25a-70ec4a6118af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_dce4fce4-cc24-4385-abf3-9450609e0f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_dce4fce4-cc24-4385-abf3-9450609e0f84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9f53f43-3824-4c8f-8c7d-78f549d629f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9f53f43-3824-4c8f-8c7d-78f549d629f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromEquityOffering_40ed2841-0794-49de-80fb-8ef99ca01046" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromEquityOffering"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_ameh_ProceedsFromEquityOffering_40ed2841-0794-49de-80fb-8ef99ca01046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8fdbc05f-26be-4809-b8aa-bfdb149c68d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_8fdbc05f-26be-4809-b8aa-bfdb149c68d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_5bc7e7bf-c2dc-4863-a3ef-9279920c3d77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_5bc7e7bf-c2dc-4863-a3ef-9279920c3d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_bc2fa023-71e6-4990-ba51-02a50a5b9b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6dc07df9-0958-42cb-9319-40c6fcd8882b" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_bc2fa023-71e6-4990-ba51-02a50a5b9b96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d06581fc-f24b-49bf-9119-9c3a0b48cb41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fbab74ff-d717-472b-8c4b-11c4d1fb936a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d06581fc-f24b-49bf-9119-9c3a0b48cb41" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_fbab74ff-d717-472b-8c4b-11c4d1fb936a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8816e038-58c3-468b-9cc0-188dec42542f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d06581fc-f24b-49bf-9119-9c3a0b48cb41" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8816e038-58c3-468b-9cc0-188dec42542f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_5fd876ea-b490-4fd9-8041-7b0b0b386e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d06581fc-f24b-49bf-9119-9c3a0b48cb41" xlink:to="loc_us-gaap_DerivativeAssets_5fd876ea-b490-4fd9-8041-7b0b0b386e48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6b06e996-abbd-4f3c-ad8c-efb3036c3ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d06581fc-f24b-49bf-9119-9c3a0b48cb41" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6b06e996-abbd-4f3c-ad8c-efb3036c3ad8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_9da01545-5eaf-4846-b43a-3caa172fe249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6d9a2777-643c-4c2b-91c1-c1e662745cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_9da01545-5eaf-4846-b43a-3caa172fe249" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_6d9a2777-643c-4c2b-91c1-c1e662745cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_549dea44-1c0d-415e-8c58-ba91cde4a84e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_9da01545-5eaf-4846-b43a-3caa172fe249" xlink:to="loc_us-gaap_DerivativeLiabilities_549dea44-1c0d-415e-8c58-ba91cde4a84e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_68aa6da7-683e-4eb2-9064-a3b8d6308154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_1bd1c168-36be-4290-bb0b-722a5f7a05c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_68aa6da7-683e-4eb2-9064-a3b8d6308154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_1bd1c168-36be-4290-bb0b-722a5f7a05c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_66889b12-7f93-4af5-a768-0f1e8e0e8cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_68aa6da7-683e-4eb2-9064-a3b8d6308154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_66889b12-7f93-4af5-a768-0f1e8e0e8cad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d68ac8d8-5948-4bf5-be9d-170c43e9c65a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f8914af7-a92a-4fc6-a7d4-d84dd91d9957" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d68ac8d8-5948-4bf5-be9d-170c43e9c65a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f8914af7-a92a-4fc6-a7d4-d84dd91d9957" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7b1c9624-4fd2-4195-8013-afd8fbc1e474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_d68ac8d8-5948-4bf5-be9d-170c43e9c65a" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_7b1c9624-4fd2-4195-8013-afd8fbc1e474" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93d8351a-68d6-4d13-a6f6-1a09f818a63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_754a3498-7ac0-4ff1-9bdf-b0258cdd21e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93d8351a-68d6-4d13-a6f6-1a09f818a63c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_754a3498-7ac0-4ff1-9bdf-b0258cdd21e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6b3096f5-14e8-44cf-8707-ad137128ca18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_93d8351a-68d6-4d13-a6f6-1a09f818a63c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6b3096f5-14e8-44cf-8707-ad137128ca18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_6f8fe9b4-ca89-4c96-9371-2550236430de" xlink:href="ameh-20211231.xsd#ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_b00e13c0-77f1-49d6-b15c-b675d6e5a403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_6f8fe9b4-ca89-4c96-9371-2550236430de" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_b00e13c0-77f1-49d6-b15c-b675d6e5a403" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_04b56d44-2956-436a-88cc-d767d0f41f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_6f8fe9b4-ca89-4c96-9371-2550236430de" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_04b56d44-2956-436a-88cc-d767d0f41f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e6440bee-81d9-462e-8bbc-36b687f526b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e673293c-34fd-4a84-b08e-be84bd22a662" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e6440bee-81d9-462e-8bbc-36b687f526b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e673293c-34fd-4a84-b08e-be84bd22a662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0d05136e-2fe8-4a03-8d7c-de98a78a3a65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e6440bee-81d9-462e-8bbc-36b687f526b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0d05136e-2fe8-4a03-8d7c-de98a78a3a65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f8645415-2e23-42ff-9961-cb678c4e431e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f5cbf0b-75b0-4129-8719-a45898e453cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f8645415-2e23-42ff-9961-cb678c4e431e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5f5cbf0b-75b0-4129-8719-a45898e453cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b23eb785-549d-44b2-a963-fff7af31c618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f8645415-2e23-42ff-9961-cb678c4e431e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b23eb785-549d-44b2-a963-fff7af31c618" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3d78e54a-91e2-4dd7-8c52-64b41024dfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_91f19407-79f6-4688-ba07-276ded655856" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3d78e54a-91e2-4dd7-8c52-64b41024dfd6" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_91f19407-79f6-4688-ba07-276ded655856" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f24367cb-d92d-4171-bcfd-665e32e157e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_3d78e54a-91e2-4dd7-8c52-64b41024dfd6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f24367cb-d92d-4171-bcfd-665e32e157e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2d847dc-00be-4597-806f-aa6f67f51811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0e3ded49-4927-4d61-b46a-8d4834b308d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2d847dc-00be-4597-806f-aa6f67f51811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0e3ded49-4927-4d61-b46a-8d4834b308d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28dd821c-e5e6-4e48-9582-02c65ef86393" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2d847dc-00be-4597-806f-aa6f67f51811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_28dd821c-e5e6-4e48-9582-02c65ef86393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2c7a974d-cda5-4483-bcf1-d3f7b769061b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2d847dc-00be-4597-806f-aa6f67f51811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2c7a974d-cda5-4483-bcf1-d3f7b769061b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f29ddd40-6db9-49c1-a81d-fbdde9a27c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2d847dc-00be-4597-806f-aa6f67f51811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f29ddd40-6db9-49c1-a81d-fbdde9a27c6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b31b5c5a-19a0-47aa-8bd4-76c13c343f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2d847dc-00be-4597-806f-aa6f67f51811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_b31b5c5a-19a0-47aa-8bd4-76c13c343f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d683e6be-1a42-4554-8b90-bcb1a3badc14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e2d847dc-00be-4597-806f-aa6f67f51811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_d683e6be-1a42-4554-8b90-bcb1a3badc14" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c03dbcaf-9823-46e9-8b64-e9b2675c7958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_068995d8-4e94-4844-b11a-aea5a669a91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c03dbcaf-9823-46e9-8b64-e9b2675c7958" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_068995d8-4e94-4844-b11a-aea5a669a91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_b74c5c69-3e38-4d63-bb40-b96146980d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c03dbcaf-9823-46e9-8b64-e9b2675c7958" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_b74c5c69-3e38-4d63-bb40-b96146980d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_9cbf4557-ff96-4c21-afb8-da36e80367d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c03dbcaf-9823-46e9-8b64-e9b2675c7958" xlink:to="loc_us-gaap_OtherAssetsCurrent_9cbf4557-ff96-4c21-afb8-da36e80367d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1caf9490-4760-418f-b6a8-e7a0e6667769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c03dbcaf-9823-46e9-8b64-e9b2675c7958" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1caf9490-4760-418f-b6a8-e7a0e6667769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2ea44251-a00d-4fc5-977e-76f76dca74ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c03dbcaf-9823-46e9-8b64-e9b2675c7958" xlink:to="loc_us-gaap_RestrictedCashCurrent_2ea44251-a00d-4fc5-977e-76f76dca74ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_db32e250-2901-43e6-9abf-981353963b69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_db32e250-2901-43e6-9abf-981353963b69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_9624018a-4452-4ee3-9c27-229088a34a46" xlink:href="ameh-20211231.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_9624018a-4452-4ee3-9c27-229088a34a46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIpaRiskPoolPayable_8ead7435-c79e-46aa-b5a6-b08126aca5b4" xlink:href="ameh-20211231.xsd#ameh_SubcontractorIpaRiskPoolPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:to="loc_ameh_SubcontractorIpaRiskPoolPayable_8ead7435-c79e-46aa-b5a6-b08126aca5b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5117be1f-3c53-4d95-812f-6a5611855f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5117be1f-3c53-4d95-812f-6a5611855f0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_9a5c8ba0-530d-41d8-a447-a3e20e293bed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_9a5c8ba0-530d-41d8-a447-a3e20e293bed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_14779481-b149-4a13-b2e5-df4f5dd0bb40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_14779481-b149-4a13-b2e5-df4f5dd0bb40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_26148c9a-5c90-4e5f-ac3e-315a33e3afd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1bad432b-501f-4c67-b50c-4f26fcf9d8b7" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_26148c9a-5c90-4e5f-ac3e-315a33e3afd1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6e52ec0f-1fdf-45c3-833f-5d91508a59fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_ef8ecc39-6ed7-4f52-a15b-b076dafa25d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6e52ec0f-1fdf-45c3-833f-5d91508a59fe" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_ef8ecc39-6ed7-4f52-a15b-b076dafa25d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_e519c2bf-31c3-4e12-952f-ea812166d154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6e52ec0f-1fdf-45c3-833f-5d91508a59fe" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_e519c2bf-31c3-4e12-952f-ea812166d154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8b891d24-1d78-4c5b-b2b8-309f52d3a2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_0d408a0e-1b35-4714-8d81-70eb3976e3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8b891d24-1d78-4c5b-b2b8-309f52d3a2f8" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_0d408a0e-1b35-4714-8d81-70eb3976e3a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_e364dbe2-4b17-4e86-b958-ea622dca8d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_8b891d24-1d78-4c5b-b2b8-309f52d3a2f8" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_e364dbe2-4b17-4e86-b958-ea622dca8d5e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_3343cedb-05d9-4830-8607-6c3b73cc4dad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6eaed6eb-3132-41c2-ad51-08692a545649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_3343cedb-05d9-4830-8607-6c3b73cc4dad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6eaed6eb-3132-41c2-ad51-08692a545649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9ba14968-2152-48c9-889c-1f91595e4642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_3343cedb-05d9-4830-8607-6c3b73cc4dad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9ba14968-2152-48c9-889c-1f91595e4642" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_58e4543d-3524-44ba-baae-789882c54b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_3343cedb-05d9-4830-8607-6c3b73cc4dad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_58e4543d-3524-44ba-baae-789882c54b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0bc73808-76ec-4cdd-bf13-ec70e19cf35a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_3343cedb-05d9-4830-8607-6c3b73cc4dad" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_0bc73808-76ec-4cdd-bf13-ec70e19cf35a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_0808864e-b200-4431-923d-730bc432ebec" xlink:href="ameh-20211231.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_3343cedb-05d9-4830-8607-6c3b73cc4dad" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_0808864e-b200-4431-923d-730bc432ebec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesIncomeTaxProvisionBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a95a4c4a-2920-434a-a907-ed855fe21580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e5668ed2-9837-466e-a6a5-9a3ad8a7c292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a95a4c4a-2920-434a-a907-ed855fe21580" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_e5668ed2-9837-466e-a6a5-9a3ad8a7c292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7513d86-65a3-4fb3-84b1-d1e412acf03f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a95a4c4a-2920-434a-a907-ed855fe21580" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d7513d86-65a3-4fb3-84b1-d1e412acf03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0ad8bd14-3434-4a04-b10b-f03f1bcec41f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ab56b170-2331-4c11-8607-3d1a912667f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0ad8bd14-3434-4a04-b10b-f03f1bcec41f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ab56b170-2331-4c11-8607-3d1a912667f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_764c5416-7b85-4c10-ba9c-60368dda4bda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_0ad8bd14-3434-4a04-b10b-f03f1bcec41f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_764c5416-7b85-4c10-ba9c-60368dda4bda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b611aac4-14bd-4de4-ac8a-c5c5d0b340de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e6d8cfb5-d28e-44dd-9cd4-d006476cdc2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b611aac4-14bd-4de4-ac8a-c5c5d0b340de" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e6d8cfb5-d28e-44dd-9cd4-d006476cdc2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_937812b0-d9d6-4b41-8ea9-0fa368cefeea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b611aac4-14bd-4de4-ac8a-c5c5d0b340de" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_937812b0-d9d6-4b41-8ea9-0fa368cefeea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_105f0052-84a2-46c0-90e4-816ca6624f78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_94cbb9c8-bca5-4f64-9aa8-9133d737caa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_105f0052-84a2-46c0-90e4-816ca6624f78" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_94cbb9c8-bca5-4f64-9aa8-9133d737caa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_dfc4ca67-73fe-4536-bd56-3fea3d1fd87a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_105f0052-84a2-46c0-90e4-816ca6624f78" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_dfc4ca67-73fe-4536-bd56-3fea3d1fd87a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e7cb2185-2c10-4c63-8966-70391409ade3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9faab57a-ce4c-4272-a1e3-8c0cdd30822c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e7cb2185-2c10-4c63-8966-70391409ade3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9faab57a-ce4c-4272-a1e3-8c0cdd30822c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_de472014-b61b-4d7a-a18a-631b3be58c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e7cb2185-2c10-4c63-8966-70391409ade3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_de472014-b61b-4d7a-a18a-631b3be58c64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_97cb2b5c-601d-4cd6-8b16-b6e0f2ef0f15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e7cb2185-2c10-4c63-8966-70391409ade3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_97cb2b5c-601d-4cd6-8b16-b6e0f2ef0f15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesStockOptions_e9b19e5c-40f9-4c29-89d5-85e42bd21cf8" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxLiabilitiesStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e7cb2185-2c10-4c63-8966-70391409ade3" xlink:to="loc_ameh_DeferredTaxLiabilitiesStockOptions_e9b19e5c-40f9-4c29-89d5-85e42bd21cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4329808a-32fc-4ab5-9df7-7026fad5f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e7cb2185-2c10-4c63-8966-70391409ade3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_4329808a-32fc-4ab5-9df7-7026fad5f88e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilities481aAdjustment_a2443888-b6b5-4940-b9c1-f06d68eff595" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxLiabilities481aAdjustment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e7cb2185-2c10-4c63-8966-70391409ade3" xlink:to="loc_ameh_DeferredTaxLiabilities481aAdjustment_a2443888-b6b5-4940-b9c1-f06d68eff595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_518027e8-c951-46be-8d6b-bb569bb4f7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_42c017c5-9399-40cd-82fd-a799a946c3c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_518027e8-c951-46be-8d6b-bb569bb4f7aa" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_42c017c5-9399-40cd-82fd-a799a946c3c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b720e8f9-2c74-4126-aaba-035ace86354b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_518027e8-c951-46be-8d6b-bb569bb4f7aa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b720e8f9-2c74-4126-aaba-035ace86354b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_422cb220-5fc2-43b0-8de2-66efa54b4e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_422cb220-5fc2-43b0-8de2-66efa54b4e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_dc84b3a8-7c08-43bf-ab27-5cdf0aec076f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_dc84b3a8-7c08-43bf-ab27-5cdf0aec076f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_cf2f82df-531b-4875-bb4d-0739d3a6d9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_cf2f82df-531b-4875-bb4d-0739d3a6d9ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_7089db78-e902-4bb5-8fdd-2b8d605102e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_7089db78-e902-4bb5-8fdd-2b8d605102e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_85510aa2-2279-4656-a376-cff516f72546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_85510aa2-2279-4656-a376-cff516f72546" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxAssetsInvestment_b66862ff-ba12-4b2d-8ccd-d790d50a45c4" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxAssetsInvestment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_ameh_DeferredTaxAssetsInvestment_b66862ff-ba12-4b2d-8ccd-d790d50a45c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3e189232-6866-4862-9e16-5e6aab8d0d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3e189232-6866-4862-9e16-5e6aab8d0d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxAssetsLeaseLiability_30a276e6-b939-4eed-9f4c-3975e8ed4af8" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_ameh_DeferredTaxAssetsLeaseLiability_30a276e6-b939-4eed-9f4c-3975e8ed4af8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_9e064c51-6428-4360-b9a5-24329d2522e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_a968b25f-a727-4fbb-be76-e05056ba5fc2" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_9e064c51-6428-4360-b9a5-24329d2522e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_643e77a5-8078-4226-be57-e4a4afa40dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_643e77a5-8078-4226-be57-e4a4afa40dd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_48565b3c-0708-4f5e-be2e-eae159d5bd34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_48565b3c-0708-4f5e-be2e-eae159d5bd34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment_2f4523a1-06d3-4796-abb5-dc61b479e2ed" xlink:href="ameh-20211231.xsd#ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment_2f4523a1-06d3-4796-abb5-dc61b479e2ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_9bf6526d-cb68-4b9f-a6ec-c1a2405a4d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_9bf6526d-cb68-4b9f-a6ec-c1a2405a4d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_eaa28f48-5971-424b-a6cb-f82922cc645a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_eaa28f48-5971-424b-a6cb-f82922cc645a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4f0bd12a-edf4-4916-91a2-788f204d82ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4f0bd12a-edf4-4916-91a2-788f204d82ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent_bdc41cfd-6d40-48ef-a4dd-9146ec390000" xlink:href="ameh-20211231.xsd#ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent_bdc41cfd-6d40-48ef-a4dd-9146ec390000" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4738c4e5-5f08-4f35-a58e-948088b9d97c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a2b43eb1-ac01-42a6-baaf-6c643df30690" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_4738c4e5-5f08-4f35-a58e-948088b9d97c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f6b91f99-3c29-4fce-af3b-a5fea86b7be3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_2327e00b-7cb4-44a1-ae53-f365660efbc3" xlink:href="ameh-20211231.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f6b91f99-3c29-4fce-af3b-a5fea86b7be3" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_2327e00b-7cb4-44a1-ae53-f365660efbc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_36049ab6-5395-4dcf-bc12-db415660297b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_f6b91f99-3c29-4fce-af3b-a5fea86b7be3" xlink:to="loc_us-gaap_ManagementFeeExpense_36049ab6-5395-4dcf-bc12-db415660297b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a28238b-b41b-4c9c-bc87-b738f5f75ced" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e5e0a2a-2520-498a-b3eb-e8fdde4a6cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a28238b-b41b-4c9c-bc87-b738f5f75ced" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8e5e0a2a-2520-498a-b3eb-e8fdde4a6cd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_32633875-5ed8-4f9c-bd94-4b3ff0ec132d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9a28238b-b41b-4c9c-bc87-b738f5f75ced" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_32633875-5ed8-4f9c-bd94-4b3ff0ec132d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_6bd2f4d9-275d-4567-aa8e-50a8437a6f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_DueFromAffiliates_6bd2f4d9-275d-4567-aa8e-50a8437a6f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_5631ef71-01ba-4561-a4b8-6996e698374c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_IncomeTaxesReceivable_5631ef71-01ba-4561-a4b8-6996e698374c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_d2f506df-d649-4726-a0fd-a8be9db6dfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_d2f506df-d649-4726-a0fd-a8be9db6dfc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d97b205-ecb2-4c18-9a0f-cb5ee58c26b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2d97b205-ecb2-4c18-9a0f-cb5ee58c26b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_77ac5dc0-03af-49ef-913e-59c3e67332f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_77ac5dc0-03af-49ef-913e-59c3e67332f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b723da8a-ccea-43f1-9c06-1908962d3f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_b723da8a-ccea-43f1-9c06-1908962d3f2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ab4f1547-8873-4d11-b1af-474abff698c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ab4f1547-8873-4d11-b1af-474abff698c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_109b93c2-3f09-40c5-b09d-f6339d1b803d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_109b93c2-3f09-40c5-b09d-f6339d1b803d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_869dcc06-1c08-46e1-915b-7be84af07e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_351aa276-6ec1-495d-b9d3-69b1ec040939" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_869dcc06-1c08-46e1-915b-7be84af07e4c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_4544bf9a-e918-451e-bbdd-94222184c40c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b280aaf2-0f4b-4d5e-9e2e-ce874950466b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4544bf9a-e918-451e-bbdd-94222184c40c" xlink:to="loc_us-gaap_OperatingLeaseCost_b280aaf2-0f4b-4d5e-9e2e-ce874950466b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6b42b04-278d-43dd-8ed3-dca830d049b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4544bf9a-e918-451e-bbdd-94222184c40c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6b42b04-278d-43dd-8ed3-dca830d049b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ddff83b1-0b34-4ccc-ba7f-4f20e1bac09a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4544bf9a-e918-451e-bbdd-94222184c40c" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ddff83b1-0b34-4ccc-ba7f-4f20e1bac09a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_3b2d12a3-5d41-4cb2-babc-a6b5034ab310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_4544bf9a-e918-451e-bbdd-94222184c40c" xlink:to="loc_us-gaap_SubleaseIncome_3b2d12a3-5d41-4cb2-babc-a6b5034ab310" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4642f0f5-485f-425e-8e96-ee5d8d313826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_60fd406d-4793-4a8f-a835-960bcf28b497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4642f0f5-485f-425e-8e96-ee5d8d313826" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_60fd406d-4793-4a8f-a835-960bcf28b497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_774d263a-7f6d-492e-a685-b4a44cd09823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_4642f0f5-485f-425e-8e96-ee5d8d313826" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_774d263a-7f6d-492e-a685-b4a44cd09823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_390ee581-d625-42fb-b059-6906e6973c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_fe9ee84f-80a4-4a1d-ad83-9ff42208c766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_390ee581-d625-42fb-b059-6906e6973c2d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_fe9ee84f-80a4-4a1d-ad83-9ff42208c766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6af9335b-5fbe-43eb-aec4-47a146a1754c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_390ee581-d625-42fb-b059-6906e6973c2d" xlink:to="loc_us-gaap_FinanceLeaseLiability_6af9335b-5fbe-43eb-aec4-47a146a1754c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61757730-c429-4612-8313-707b0b895505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee639573-9441-491f-a732-964799b1c1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61757730-c429-4612-8313-707b0b895505" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ee639573-9441-491f-a732-964799b1c1e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a35a8db0-10ee-40d8-9eb3-ac2085d02a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61757730-c429-4612-8313-707b0b895505" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a35a8db0-10ee-40d8-9eb3-ac2085d02a68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f1df73c3-21f2-4995-8f88-cf463cfbde5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61757730-c429-4612-8313-707b0b895505" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f1df73c3-21f2-4995-8f88-cf463cfbde5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_249879ac-4e57-4318-8284-ab1ef9842306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61757730-c429-4612-8313-707b0b895505" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_249879ac-4e57-4318-8284-ab1ef9842306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6e93b134-0585-4299-94fa-5ba1b6fdbcac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61757730-c429-4612-8313-707b0b895505" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6e93b134-0585-4299-94fa-5ba1b6fdbcac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6c646981-75f2-4fbe-a5c4-1e63f5327ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_61757730-c429-4612-8313-707b0b895505" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_6c646981-75f2-4fbe-a5c4-1e63f5327ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d472c170-7a63-4f4f-9113-9bc64ab27b20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_04b7c99e-5358-4ce6-b984-e8c3b382a921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_d472c170-7a63-4f4f-9113-9bc64ab27b20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_04b7c99e-5358-4ce6-b984-e8c3b382a921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_fe600f4a-6809-4fbc-8c99-98a564b81a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_d472c170-7a63-4f4f-9113-9bc64ab27b20" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_fe600f4a-6809-4fbc-8c99-98a564b81a9d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_dfc7ea9a-441d-4199-9143-01312eb5c930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a52d95d8-fff9-4d1e-8afa-6200e684c05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_dfc7ea9a-441d-4199-9143-01312eb5c930" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a52d95d8-fff9-4d1e-8afa-6200e684c05f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_319fe7a8-6919-4fa3-8e5d-be89ecba19fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_dfc7ea9a-441d-4199-9143-01312eb5c930" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_319fe7a8-6919-4fa3-8e5d-be89ecba19fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a5923c7b-15c9-4f9c-8e05-627ac59d5b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_dfc7ea9a-441d-4199-9143-01312eb5c930" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_a5923c7b-15c9-4f9c-8e05-627ac59d5b3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4c533ee6-597e-4594-bb0e-b5b2e4058236" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_dfc7ea9a-441d-4199-9143-01312eb5c930" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4c533ee6-597e-4594-bb0e-b5b2e4058236" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c683bb19-1d9c-4ee2-beda-cce000134a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_dfc7ea9a-441d-4199-9143-01312eb5c930" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_c683bb19-1d9c-4ee2-beda-cce000134a62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_0afdf596-d885-4c9b-97c0-d46a8dc9c0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_dfc7ea9a-441d-4199-9143-01312eb5c930" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_0afdf596-d885-4c9b-97c0-d46a8dc9c0dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0945f61-8acd-4040-b546-1e9453c04714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0245f104-c226-4c70-98c1-10a942b0e91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0945f61-8acd-4040-b546-1e9453c04714" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0245f104-c226-4c70-98c1-10a942b0e91d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_7cf9ab27-6f18-4d84-9e20-86eceb054e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a0945f61-8acd-4040-b546-1e9453c04714" xlink:to="loc_us-gaap_OperatingLeaseLiability_7cf9ab27-6f18-4d84-9e20-86eceb054e43" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>ameh-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56a96635-232a-499f-a03d-15d085375db3,g:3c5e1a1a-f2ce-472c-bc52-288bd5b84a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="icc7b66b3bac746fb8b4a67b23475149c_CONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:to="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b1ce54eb-0bf6-4252-8f02-b3e5c1495b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b1ce54eb-0bf6-4252-8f02-b3e5c1495b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c0863114-563c-4426-955a-9f1389fcb3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c0863114-563c-4426-955a-9f1389fcb3e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_743b59db-74e2-4cbe-947f-a5bf39ccb65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_743b59db-74e2-4cbe-947f-a5bf39ccb65f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33be7faf-744c-44bb-889f-6b94190c1637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33be7faf-744c-44bb-889f-6b94190c1637" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_4e5569d1-d019-40c3-abce-7f6be72da5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_4e5569d1-d019-40c3-abce-7f6be72da5cf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8e72f13-07b7-4bd1-a36e-0772b65a70ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8e72f13-07b7-4bd1-a36e-0772b65a70ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5ba85f55-bdb1-4768-9e64-f497f1e38e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5ba85f55-bdb1-4768-9e64-f497f1e38e40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_020f0983-2f38-466e-9970-4720facdff6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_AssetsCurrent_020f0983-2f38-466e-9970-4720facdff6b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_45c17c51-8846-4366-9f6d-ae782c79e600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_45c17c51-8846-4366-9f6d-ae782c79e600" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1128c689-4efe-4bc1-8742-3f47a4eb1c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1128c689-4efe-4bc1-8742-3f47a4eb1c73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_108f19d3-a5c1-41a5-b067-ea44582d59d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_Goodwill_108f19d3-a5c1-41a5-b067-ea44582d59d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_e0ac4e41-0f43-4c28-87d3-33616337653d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_e0ac4e41-0f43-4c28-87d3-33616337653d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_04f42ecd-57fa-4c41-9a00-e8927b6e06b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_04f42ecd-57fa-4c41-9a00-e8927b6e06b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_49ad4830-716e-4754-aa44-422842566108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_EquityMethodInvestments_49ad4830-716e-4754-aa44-422842566108" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4059a433-6764-481a-9747-8c77a40f6b1b" xlink:href="ameh-20211231.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4059a433-6764-481a-9747-8c77a40f6b1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3ca11440-5f25-47a1-a117-c6558e782389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3ca11440-5f25-47a1-a117-c6558e782389" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e055c927-9543-4a57-82bd-2aad3e5ad6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e055c927-9543-4a57-82bd-2aad3e5ad6e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1f2b2395-b0b4-4541-83f7-9481775c130c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1f2b2395-b0b4-4541-83f7-9481775c130c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3ba47b11-50a1-4cde-8096-452d45bfc4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_AssetsNoncurrent_3ba47b11-50a1-4cde-8096-452d45bfc4f8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_572eece4-1c8e-4818-a99b-15df2a1b12a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:to="loc_us-gaap_Assets_572eece4-1c8e-4818-a99b-15df2a1b12a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c8516e3a-a7dd-4245-aa4b-1103d6ff6545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c8516e3a-a7dd-4245-aa4b-1103d6ff6545" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_db377982-c8ee-431a-8cf2-a224da8d17aa" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_db377982-c8ee-431a-8cf2-a224da8d17aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_8be53f89-2588-4648-8ca9-b20702a552a6" xlink:href="ameh-20211231.xsd#ameh_MedicalLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_8be53f89-2588-4648-8ca9-b20702a552a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_de509132-76c4-4b88-abaa-4b1594344ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_de509132-76c4-4b88-abaa-4b1594344ac3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_5ae32464-91d7-4e27-a1d9-12d4f7f4e244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_DividendsPayableCurrent_5ae32464-91d7-4e27-a1d9-12d4f7f4e244" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_bfbe4f7e-974e-4576-a810-14ff0057036b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_bfbe4f7e-974e-4576-a810-14ff0057036b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_07e9294b-42dd-4c1c-8a4f-088ec983caad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_07e9294b-42dd-4c1c-8a4f-088ec983caad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7f7cc0d7-51a6-48c9-add1-f08be485ec54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_LongTermDebtCurrent_7f7cc0d7-51a6-48c9-add1-f08be485ec54" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_410538d3-6809-46b1-bbdd-190170c1d192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_LiabilitiesCurrent_410538d3-6809-46b1-bbdd-190170c1d192" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_be509544-16af-41d4-95a8-c3d47cbd5ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_be509544-16af-41d4-95a8-c3d47cbd5ae8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8805701b-eb03-4d83-81ee-a1a52cbaebbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8805701b-eb03-4d83-81ee-a1a52cbaebbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbafc726-c85f-4abe-8a85-833139c9dd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbafc726-c85f-4abe-8a85-833139c9dd88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2a2b4d3f-673c-4f38-99f2-cd40cfe0d42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2a2b4d3f-673c-4f38-99f2-cd40cfe0d42d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3ab5cf9d-f2a5-46b4-b34f-02ee97abe8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3ab5cf9d-f2a5-46b4-b34f-02ee97abe8c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e44307e8-d1d9-4452-affc-02755b2b3f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e44307e8-d1d9-4452-affc-02755b2b3f24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c3187a61-59fa-4a27-bef1-73c9f8e9bb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_Liabilities_c3187a61-59fa-4a27-bef1-73c9f8e9bb6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f1238a4e-d4a9-4450-8991-7a21e70583a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f1238a4e-d4a9-4450-8991-7a21e70583a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_65da6b33-cbaf-4e85-8322-bfd74df7bbd9" xlink:href="ameh-20211231.xsd#ameh_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_ameh_MezzanineEquityAbstract_65da6b33-cbaf-4e85-8322-bfd74df7bbd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_95597118-7d3f-4850-a886-aa7f300df5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_65da6b33-cbaf-4e85-8322-bfd74df7bbd9" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_95597118-7d3f-4850-a886-aa7f300df5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_52eb1c83-9c2a-4060-a17a-73e54e238a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_PreferredStockValue_52eb1c83-9c2a-4060-a17a-73e54e238a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_aaeb46bc-4577-4c74-93be-03c6003b6ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_CommonStockValue_aaeb46bc-4577-4c74-93be-03c6003b6ab2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f49bfd6e-80ea-4661-98b2-8d7929132135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f49bfd6e-80ea-4661-98b2-8d7929132135" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b0176a6-a7e3-4018-beff-e506a284966f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b0176a6-a7e3-4018-beff-e506a284966f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8d02d1a-560e-4add-9e36-641223bf6f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_StockholdersEquity_a8d02d1a-560e-4add-9e36-641223bf6f2e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a737bfa5-bdd5-4473-8bc5-17e6a0f595e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_MinorityInterest_a737bfa5-bdd5-4473-8bc5-17e6a0f595e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0165e19-6c5b-46f7-bd5e-5cc9e694558f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0165e19-6c5b-46f7-bd5e-5cc9e694558f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd83684b-044a-42d4-b7b0-824bd9b361fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd83684b-044a-42d4-b7b0-824bd9b361fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_898b3b8e-ce5d-4b4f-b437-c347f5cd380a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:to="loc_us-gaap_StatementTable_898b3b8e-ce5d-4b4f-b437-c347f5cd380a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90638b13-cbe2-427e-af15-616c2f5282db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_898b3b8e-ce5d-4b4f-b437-c347f5cd380a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90638b13-cbe2-427e-af15-616c2f5282db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_90638b13-cbe2-427e-af15-616c2f5282db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90638b13-cbe2-427e-af15-616c2f5282db" xlink:to="loc_us-gaap_ClassOfStockDomain_90638b13-cbe2-427e-af15-616c2f5282db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90638b13-cbe2-427e-af15-616c2f5282db" xlink:to="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b1f03a76-6e71-45c3-84f4-cd5b1f94b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b1f03a76-6e71-45c3-84f4-cd5b1f94b6d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_fe25947b-e94f-45bc-ba2f-4314293b9fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_fe25947b-e94f-45bc-ba2f-4314293b9fdf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="iabea22e3d9f04a388e2414887025d635_CONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ef1b3640-374f-420d-ad0b-218e0bd0b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ef1b3640-374f-420d-ad0b-218e0bd0b8d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14926dc8-c575-4642-8a59-e8af17df4f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14926dc8-c575-4642-8a59-e8af17df4f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_40847620-5a1b-4821-b707-40dcc9c7767f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockSharesIssued_40847620-5a1b-4821-b707-40dcc9c7767f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4341b2fc-029c-46a5-bfee-ea1723c4f409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4341b2fc-029c-46a5-bfee-ea1723c4f409" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8a61e8c3-15ae-4ef5-9234-8a6d86deec95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8a61e8c3-15ae-4ef5-9234-8a6d86deec95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d52c0473-d3fa-41f6-8c54-f4c53b2025c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d52c0473-d3fa-41f6-8c54-f4c53b2025c3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9e991d17-9e74-4272-af74-55f1c783f677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_SharesOutstanding_9e991d17-9e74-4272-af74-55f1c783f677" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_22b2395b-41d2-4295-83f8-111489ace465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_TreasuryStockCommonShares_22b2395b-41d2-4295-83f8-111489ace465" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e15d3d46-c9b0-4482-be8c-17f94d589a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_Assets_e15d3d46-c9b0-4482-be8c-17f94d589a6c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6bc7daab-ed52-4f93-9b9d-4e95284837cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_Liabilities_6bc7daab-ed52-4f93-9b9d-4e95284837cf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f07a2d8-011f-4653-86af-68c027fc9546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f07a2d8-011f-4653-86af-68c027fc9546" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_8021fdef-f30c-467b-967a-6ee5ea0ebc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_DueFromAffiliates_8021fdef-f30c-467b-967a-6ee5ea0ebc5e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3c93d2af-1fc2-4ce3-8db5-83fa816234a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3c93d2af-1fc2-4ce3-8db5-83fa816234a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3c93d2af-1fc2-4ce3-8db5-83fa816234a3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3c93d2af-1fc2-4ce3-8db5-83fa816234a3" xlink:to="loc_us-gaap_ClassOfStockDomain_3c93d2af-1fc2-4ce3-8db5-83fa816234a3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3c93d2af-1fc2-4ce3-8db5-83fa816234a3" xlink:to="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_c8ae3533-05b2-4bbc-84ce-65b70035057c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_c8ae3533-05b2-4bbc-84ce-65b70035057c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_02ef6ad8-2950-4e00-8da2-4f0dea5bdd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_02ef6ad8-2950-4e00-8da2-4f0dea5bdd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:to="loc_srt_ConsolidatedEntitiesAxis_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_86e16335-ef7d-48c5-a45f-2863f56920ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_86e16335-ef7d-48c5-a45f-2863f56920ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrimaryBeneficiaryMember_f9230e60-d2de-425b-94d1-c748842bc64d" xlink:href="ameh-20211231.xsd#ameh_PrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_86e16335-ef7d-48c5-a45f-2863f56920ed" xlink:to="loc_ameh_PrimaryBeneficiaryMember_f9230e60-d2de-425b-94d1-c748842bc64d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a8f4c10c-dfbe-41c5-b19b-790ec660f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a8f4c10c-dfbe-41c5-b19b-790ec660f11f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a8f4c10c-dfbe-41c5-b19b-790ec660f11f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8f4c10c-dfbe-41c5-b19b-790ec660f11f" xlink:to="loc_us-gaap_EquityComponentDomain_a8f4c10c-dfbe-41c5-b19b-790ec660f11f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ba2c6374-66f2-4a6d-98f1-03ac14306400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8f4c10c-dfbe-41c5-b19b-790ec660f11f" xlink:to="loc_us-gaap_EquityComponentDomain_ba2c6374-66f2-4a6d-98f1-03ac14306400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d4236f8-25e7-4244-b4ea-1007ea378039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ba2c6374-66f2-4a6d-98f1-03ac14306400" xlink:to="loc_us-gaap_CommonStockMember_4d4236f8-25e7-4244-b4ea-1007ea378039" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="iecbadc59a53f4a90a0ef0b26e21aedea_CONSOLIDATEDSTATEMENTSOFINCOME">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2a28bed4-0b4a-449a-96b9-4baa91e5be93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_RevenuesAbstract_2a28bed4-0b4a-449a-96b9-4baa91e5be93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b7040f0-f751-47b8-8e77-ff0c3cb9b583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_2a28bed4-0b4a-449a-96b9-4baa91e5be93" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b7040f0-f751-47b8-8e77-ff0c3cb9b583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9c463b25-7e8a-4c55-a29b-ff7be4f3f7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9c463b25-7e8a-4c55-a29b-ff7be4f3f7be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_01539c08-c140-43ff-9f3a-1a77dd777cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_01539c08-c140-43ff-9f3a-1a77dd777cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_7ea152c5-6a64-4a5c-b023-496c10348df1" xlink:href="ameh-20211231.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_7ea152c5-6a64-4a5c-b023-496c10348df1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ed762f85-8d55-45ad-999e-1ffed7baa787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ed762f85-8d55-45ad-999e-1ffed7baa787" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_00df7ce6-82d6-47e9-b876-550c763cb06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_00df7ce6-82d6-47e9-b876-550c763cb06b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6256ff51-f82c-4fae-b7ef-600aadcca448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_CostsAndExpenses_6256ff51-f82c-4fae-b7ef-600aadcca448" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_44ea14ff-8730-47ef-919e-b7cc8b49e496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_OperatingIncomeLoss_44ea14ff-8730-47ef-919e-b7cc8b49e496" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8d46dc7a-46c2-40d9-96a0-0ded72bd77db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8d46dc7a-46c2-40d9-96a0-0ded72bd77db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f45f40a3-41ac-4c2e-bf1b-5e276ebdb4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f45f40a3-41ac-4c2e-bf1b-5e276ebdb4f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_081530b1-fd95-481b-9761-068c4e269b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_InterestExpense_081530b1-fd95-481b-9761-068c4e269b18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d26bef89-e21f-4b2a-9a43-d1eae17c3097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d26bef89-e21f-4b2a-9a43-d1eae17c3097" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_00d25490-abd2-4fa2-b375-87a36079d07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_00d25490-abd2-4fa2-b375-87a36079d07c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_22616674-40ba-450b-b2da-fd33e6b4a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_22616674-40ba-450b-b2da-fd33e6b4a9ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e47a9c83-0847-497e-b54b-5bc35234cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e47a9c83-0847-497e-b54b-5bc35234cc39" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_154da18e-bb84-4e92-ad05-5ee574bfc97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_154da18e-bb84-4e92-ad05-5ee574bfc97a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_923e59e2-223b-4fee-ab7c-5eb03099b8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_923e59e2-223b-4fee-ab7c-5eb03099b8d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f691741b-eb17-4b99-aecc-9be44340a504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_ProfitLoss_f691741b-eb17-4b99-aecc-9be44340a504" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_38103b60-953b-497e-a7cb-00908a0a899c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_38103b60-953b-497e-a7cb-00908a0a899c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11fae322-ce1b-4d9b-b1e9-ae4a9a20fcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_NetIncomeLoss_11fae322-ce1b-4d9b-b1e9-ae4a9a20fcf3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a4b56148-04cc-45a7-a7ab-4101bbcb32bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_EarningsPerShareBasic_a4b56148-04cc-45a7-a7ab-4101bbcb32bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4028f2c9-6f8c-4817-8742-984349d0a8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4028f2c9-6f8c-4817-8742-984349d0a8d7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54cb586b-f7db-4ecf-989d-5e7d0924b45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_StatementTable_54cb586b-f7db-4ecf-989d-5e7d0924b45a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_407b1c28-00ee-438b-ac81-586457d19d97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_54cb586b-f7db-4ecf-989d-5e7d0924b45a" xlink:to="loc_srt_ProductOrServiceAxis_407b1c28-00ee-438b-ac81-586457d19d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_407b1c28-00ee-438b-ac81-586457d19d97_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_407b1c28-00ee-438b-ac81-586457d19d97" xlink:to="loc_srt_ProductsAndServicesDomain_407b1c28-00ee-438b-ac81-586457d19d97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_407b1c28-00ee-438b-ac81-586457d19d97" xlink:to="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_d6eaed30-55ff-4e67-8167-54a744f14003" xlink:href="ameh-20211231.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_d6eaed30-55ff-4e67-8167-54a744f14003" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_e071a24a-6bee-469c-816a-8a48a6a1c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_HealthCareOtherMember_e071a24a-6bee-469c-816a-8a48a6a1c0ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_5bbaa7e0-f885-484c-aa2b-4adcec768dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_ManagementServiceMember_5bbaa7e0-f885-484c-aa2b-4adcec768dab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_3823c2a3-abbb-44b1-a4dc-9099dce0a024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_3823c2a3-abbb-44b1-a4dc-9099dce0a024" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_330ee679-00a6-4726-bcf3-282c936a517d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_330ee679-00a6-4726-bcf3-282c936a517d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended" id="ifb51dae7c2a24316b328d7b0a1adb485_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fdfc3aa1-66a9-45ee-9fbe-391a61f6dc60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fdfc3aa1-66a9-45ee-9fbe-391a61f6dc60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_269b1f43-2ee5-495c-b42f-93499b4106ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_269b1f43-2ee5-495c-b42f-93499b4106ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityRepurchaseOfTreasuryShares_2358b9a2-e852-452a-9cad-6cced0cb4283" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityRepurchaseOfTreasuryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityRepurchaseOfTreasuryShares_2358b9a2-e852-452a-9cad-6cced0cb4283" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityShareBasedCompensation_d3c295a0-c966-4012-bded-a5777b493ba1" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityShareBasedCompensation_d3c295a0-c966-4012-bded-a5777b493ba1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityStockSubscription_2e8f1d39-61c5-4015-b5be-2576516030ec" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityStockSubscription"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityStockSubscription_2e8f1d39-61c5-4015-b5be-2576516030ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_29dac533-9037-4c42-ace3-0a28dbb4cf1c" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_29dac533-9037-4c42-ace3-0a28dbb4cf1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityDistributionToNoncontrollingInterest_53087274-547a-46e2-a713-0b94d60430ed" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityDistributionToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityDistributionToNoncontrollingInterest_53087274-547a-46e2-a713-0b94d60430ed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1fd2175b-1a98-4d94-9dc4-627c3f79dd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1fd2175b-1a98-4d94-9dc4-627c3f79dd90" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares_f6ec5090-b72b-44a7-80da-f510a3936d3e" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares_f6ec5090-b72b-44a7-80da-f510a3936d3e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_66ec0b5f-31f2-4177-82a3-809c0e89abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_66ec0b5f-31f2-4177-82a3-809c0e89abdd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_31668542-1792-4876-9bba-7dc3bbd1d697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_31668542-1792-4876-9bba-7dc3bbd1d697" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_5f6409ce-9509-41bd-a110-cae79d15e7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a8fb396-3168-4e70-98be-4acf88616504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a8fb396-3168-4e70-98be-4acf88616504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_71ae9aae-b688-4407-9ecd-8cc45c568665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_SharesOutstanding_71ae9aae-b688-4407-9ecd-8cc45c568665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_53c4450d-3c84-4991-ac0b-5b56f8df2269" xlink:href="ameh-20211231.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_53c4450d-3c84-4991-ac0b-5b56f8df2269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_df0c2418-59b8-42f2-8494-05ec3e6a7755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_df0c2418-59b8-42f2-8494-05ec3e6a7755" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_2ee5f604-a3a3-47a0-ba28-03f1957b12b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_2ee5f604-a3a3-47a0-ba28-03f1957b12b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_8d328325-b291-4e3d-bcfc-8d936f7f9bb3" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestIncreaseFromCapitalCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_8d328325-b291-4e3d-bcfc-8d936f7f9bb3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d5b97b8a-d987-434c-9c1a-f0d1d37dbc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d5b97b8a-d987-434c-9c1a-f0d1d37dbc5a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_4e902322-9f27-4602-8243-5dc710301b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_4e902322-9f27-4602-8243-5dc710301b9c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_f50cc8b4-2eb6-4fae-af2c-01c5db16062e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_f50cc8b4-2eb6-4fae-af2c-01c5db16062e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e6610ae7-c151-45d2-a155-3e6f70313789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e6610ae7-c151-45d2-a155-3e6f70313789" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares_5011b84c-3d9e-4ed6-98a4-960b9e5f99a5" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares_5011b84c-3d9e-4ed6-98a4-960b9e5f99a5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_96605487-e7ae-4b19-bb94-023a83b0edb5" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_96605487-e7ae-4b19-bb94-023a83b0edb5" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4cf79475-b557-4fef-a793-6137effdde5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4cf79475-b557-4fef-a793-6137effdde5e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ebc93773-19ae-4798-84ea-74cc92d588d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ebc93773-19ae-4798-84ea-74cc92d588d2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_2cc6e467-df47-4e82-b988-baf5473a368e" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_2cc6e467-df47-4e82-b988-baf5473a368e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_b925b2a3-1519-4690-9ea8-eec35ca7f172" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_b925b2a3-1519-4690-9ea8-eec35ca7f172" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_2247622a-fb44-46d0-b0a6-df9e15826d71" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_2247622a-fb44-46d0-b0a6-df9e15826d71" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_8c8658bb-7b5c-48cd-980a-47ed41af716a" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_8c8658bb-7b5c-48cd-980a-47ed41af716a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_cb3fd4c3-a32a-493c-9d6b-0591a8d3a16d" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_cb3fd4c3-a32a-493c-9d6b-0591a8d3a16d" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_77a152bd-1d6e-465e-a844-67e4b22a2c64" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_77a152bd-1d6e-465e-a844-67e4b22a2c64" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_9298794d-8227-4298-a7ae-c4c9fa08fbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_9298794d-8227-4298-a7ae-c4c9fa08fbe7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_62e52b7b-afce-48ad-b876-8b7c2148435f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_62e52b7b-afce-48ad-b876-8b7c2148435f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c48ff2a8-85b0-43f2-8491-5de17a2aaf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c48ff2a8-85b0-43f2-8491-5de17a2aaf1f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity_0d1486c6-e90e-4163-8b27-5b7b5b57b7ba" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity_0d1486c6-e90e-4163-8b27-5b7b5b57b7ba" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares_a6dca88b-0a14-4963-a686-2eaf77a03c27" xlink:href="ameh-20211231.xsd#ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares_a6dca88b-0a14-4963-a686-2eaf77a03c27" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares_2490f541-9395-4de6-8a1c-669865aadb46" xlink:href="ameh-20211231.xsd#ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares_2490f541-9395-4de6-8a1c-669865aadb46" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca01b494-61f1-460e-a0c1-6b4743adc916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2b2bdf05-c64e-4908-82de-3b3d6670f228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:to="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b926f8da-1d4e-4b2e-a412-95d85920a180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b926f8da-1d4e-4b2e-a412-95d85920a180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b926f8da-1d4e-4b2e-a412-95d85920a180_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b926f8da-1d4e-4b2e-a412-95d85920a180" xlink:to="loc_us-gaap_EquityComponentDomain_b926f8da-1d4e-4b2e-a412-95d85920a180_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b926f8da-1d4e-4b2e-a412-95d85920a180" xlink:to="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_194fd3eb-5cdf-4855-b0c2-883b11b961e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_CommonStockMember_194fd3eb-5cdf-4855-b0c2-883b11b961e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3551628d-3bd2-43d6-bddf-ce5a1dfb2aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3551628d-3bd2-43d6-bddf-ce5a1dfb2aee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1d01c396-1f30-45a7-9ae0-23c0ebd758a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_RetainedEarningsMember_1d01c396-1f30-45a7-9ae0-23c0ebd758a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ed4c2a80-3f73-4d19-9873-3e0a538224e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ed4c2a80-3f73-4d19-9873-3e0a538224e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_24fd742a-fc88-4b67-81cd-49adf80c4ffc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:to="loc_dei_LegalEntityAxis_24fd742a-fc88-4b67-81cd-49adf80c4ffc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_24fd742a-fc88-4b67-81cd-49adf80c4ffc_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_24fd742a-fc88-4b67-81cd-49adf80c4ffc" xlink:to="loc_dei_EntityDomain_24fd742a-fc88-4b67-81cd-49adf80c4ffc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_55242de6-c819-40ca-a769-e4c32c01ca86" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_24fd742a-fc88-4b67-81cd-49adf80c4ffc" xlink:to="loc_dei_EntityDomain_55242de6-c819-40ca-a769-e4c32c01ca86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_1f5f873c-56b5-487e-8eac-f5fb062dfd8d" xlink:href="ameh-20211231.xsd#ameh_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_55242de6-c819-40ca-a769-e4c32c01ca86" xlink:to="loc_ameh_MezzanineMember_1f5f873c-56b5-487e-8eac-f5fb062dfd8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended" id="i199ca98d32454b62bcb602491618222e_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e35eb271-1ba3-4972-854f-a5cbb1274fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6885625d-d6d5-4f71-8e65-a3a98727829e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e35eb271-1ba3-4972-854f-a5cbb1274fc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6885625d-d6d5-4f71-8e65-a3a98727829e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_88ef2361-73ea-479e-b6c7-2a399f593243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e35eb271-1ba3-4972-854f-a5cbb1274fc4" xlink:to="loc_us-gaap_StatementTable_88ef2361-73ea-479e-b6c7-2a399f593243" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_635bae97-4518-4de1-aabb-2f4d6cac4b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_88ef2361-73ea-479e-b6c7-2a399f593243" xlink:to="loc_us-gaap_StatementClassOfStockAxis_635bae97-4518-4de1-aabb-2f4d6cac4b58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_635bae97-4518-4de1-aabb-2f4d6cac4b58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_635bae97-4518-4de1-aabb-2f4d6cac4b58" xlink:to="loc_us-gaap_ClassOfStockDomain_635bae97-4518-4de1-aabb-2f4d6cac4b58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_326c9722-2996-4ab3-945a-a680bf01bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_635bae97-4518-4de1-aabb-2f4d6cac4b58" xlink:to="loc_us-gaap_ClassOfStockDomain_326c9722-2996-4ab3-945a-a680bf01bb9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HoldbackSharesMember_36ed2cd2-31fb-47b7-9ea4-0302de78470b" xlink:href="ameh-20211231.xsd#ameh_HoldbackSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_326c9722-2996-4ab3-945a-a680bf01bb9f" xlink:to="loc_ameh_HoldbackSharesMember_36ed2cd2-31fb-47b7-9ea4-0302de78470b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="ic13270588da645a9806cec396673886c_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_45554ea0-9da4-4167-810f-f33b584bd88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:to="loc_us-gaap_ProfitLoss_45554ea0-9da4-4167-810f-f33b584bd88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4dfa6d28-a0e2-4b6c-b20f-e78b0b016b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4dfa6d28-a0e2-4b6c-b20f-e78b0b016b89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6fae85bf-96ac-428c-bdd6-5b6e9667c890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6fae85bf-96ac-428c-bdd6-5b6e9667c890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_9c2a2a80-a4ea-4933-99b5-b420756b438b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_9c2a2a80-a4ea-4933-99b5-b420756b438b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6a299d5f-942c-46ae-b8dd-8d734531453d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6a299d5f-942c-46ae-b8dd-8d734531453d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_615ab9fb-b2ae-4197-8ad2-5fd229f02a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_615ab9fb-b2ae-4197-8ad2-5fd229f02a9f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0cb81934-ad70-429f-88c6-9eca611679f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0cb81934-ad70-429f-88c6-9eca611679f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7d6b0cb0-982d-4668-8f1f-274440a4a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_ShareBasedCompensation_7d6b0cb0-982d-4668-8f1f-274440a4a879" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_1650c81c-d035-47a1-ac9a-687d2111bc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_1650c81c-d035-47a1-ac9a-687d2111bc85" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment_b5da50dd-1f88-4db8-a403-b7cfef66e83e" xlink:href="ameh-20211231.xsd#ameh_GainLossOnConsolidationOfEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment_b5da50dd-1f88-4db8-a403-b7cfef66e83e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnEquityReceivable_82f45b1b-8332-422e-b3f9-3063ec5620e9" xlink:href="ameh-20211231.xsd#ameh_GainLossOnEquityReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_ameh_GainLossOnEquityReceivable_82f45b1b-8332-422e-b3f9-3063ec5620e9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnAssumptionOfLoan_c61b4065-585f-43b9-b06d-5f58d4dcd00b" xlink:href="ameh-20211231.xsd#ameh_GainLossOnAssumptionOfLoan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_ameh_GainLossOnAssumptionOfLoan_c61b4065-585f-43b9-b06d-5f58d4dcd00b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c1d4d472-0050-4bb8-86ce-a17ed674bc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c1d4d472-0050-4bb8-86ce-a17ed674bc5c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f160b1b5-d0d1-40dd-a406-e6b864d7c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f160b1b5-d0d1-40dd-a406-e6b864d7c7fa" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_09c92c17-d7c6-4b42-9ac1-e63976aa1640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_09c92c17-d7c6-4b42-9ac1-e63976aa1640" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_e0de21ba-616d-4647-a2c8-b1744d727efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_e0de21ba-616d-4647-a2c8-b1744d727efd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d8da4566-b1cc-480d-a489-31611fb00b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d8da4566-b1cc-480d-a489-31611fb00b1c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b91cd6a9-16b2-4205-9fb1-59eee74954da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b91cd6a9-16b2-4205-9fb1-59eee74954da" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d7364bcf-c4f3-4a60-8b1d-da022bb41565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d7364bcf-c4f3-4a60-8b1d-da022bb41565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a7178a01-5ae2-4a67-8ebc-a6c8ae458e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a7178a01-5ae2-4a67-8ebc-a6c8ae458e7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_65969faa-650c-40cc-b4f1-2020c4379911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_65969faa-650c-40cc-b4f1-2020c4379911" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_cbf78704-a5a6-4c8d-a833-2184a4054c2f" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_cbf78704-a5a6-4c8d-a833-2184a4054c2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_65398c8b-19cd-4112-a6ba-d9e36c606cbe" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_65398c8b-19cd-4112-a6ba-d9e36c606cbe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_053eb185-01e7-4d63-aa49-3f2a46439a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_053eb185-01e7-4d63-aa49-3f2a46439a16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1405e825-0547-47ee-8e1a-20a64df6511b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1405e825-0547-47ee-8e1a-20a64df6511b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_bfec3230-a2b2-4639-a436-e369b6576738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_bfec3230-a2b2-4639-a436-e369b6576738" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_c8e3709c-fe82-4c1a-b5b1-cd4cbe7af66a" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_c8e3709c-fe82-4c1a-b5b1-cd4cbe7af66a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_43ff7270-bfa2-43fd-83c1-6e91166cb992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_43ff7270-bfa2-43fd-83c1-6e91166cb992" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_31e86268-9da5-41f9-a90f-acca84a0a1f0" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_31e86268-9da5-41f9-a90f-acca84a0a1f0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_219524dc-dfdf-4db5-8d7a-73d5f81f4826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_219524dc-dfdf-4db5-8d7a-73d5f81f4826" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dcccb813-197e-427d-87db-c9bff655b479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dcccb813-197e-427d-87db-c9bff655b479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8a879fc2-5e3f-4931-8fa6-8bf34b265d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8a879fc2-5e3f-4931-8fa6-8bf34b265d1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_9b671383-79d2-4637-a666-96eafad29bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_9b671383-79d2-4637-a666-96eafad29bcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_0a51badb-3f80-4916-a582-030920329be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_0a51badb-3f80-4916-a582-030920329be0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4eb64339-b123-4c6c-867d-e701a69a0672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4eb64339-b123-4c6c-867d-e701a69a0672" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_32666862-98a0-4b8c-9246-2fd52feafabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_32666862-98a0-4b8c-9246-2fd52feafabb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c7f0239b-ffd6-46fa-8094-a968b0684685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c7f0239b-ffd6-46fa-8094-a968b0684685" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_e3c8a771-6670-4862-98ac-582454c4aaa1" xlink:href="ameh-20211231.xsd#ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_e3c8a771-6670-4862-98ac-582454c4aaa1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_c51be980-4413-4fd2-9cb2-8bad64bf49ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_c51be980-4413-4fd2-9cb2-8bad64bf49ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3c78e442-adbc-4680-9c80-575f5042dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3c78e442-adbc-4680-9c80-575f5042dae8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fedecce0-ae4d-47ea-8c88-b76ab6944cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fedecce0-ae4d-47ea-8c88-b76ab6944cc9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_46e2b25d-f292-4070-b4af-8f5007625e9c" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_46e2b25d-f292-4070-b4af-8f5007625e9c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a774df7f-aca2-425b-bb4f-b2492164801b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a774df7f-aca2-425b-bb4f-b2492164801b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_d4e51417-c07e-42eb-8000-d1e2d65d8322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_d4e51417-c07e-42eb-8000-d1e2d65d8322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_665f2c84-edf0-4214-a5f8-b9ee1cd8ed99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_665f2c84-edf0-4214-a5f8-b9ee1cd8ed99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_546c1e80-cd3f-426b-9821-3cde86acdfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_546c1e80-cd3f-426b-9821-3cde86acdfbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_deb1ca99-cd84-4fed-9685-9f5ff58d2e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_deb1ca99-cd84-4fed-9685-9f5ff58d2e62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5d403430-e761-47fe-9038-af4e9c05da33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5d403430-e761-47fe-9038-af4e9c05da33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_5e465a35-0457-47fd-9197-48048a753259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_5e465a35-0457-47fd-9197-48048a753259" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_51a187b1-c053-4861-b75e-854f3d2deca5" xlink:href="ameh-20211231.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_51a187b1-c053-4861-b75e-854f3d2deca5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_b0745978-9031-45b1-a79d-5b5a54464673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_b0745978-9031-45b1-a79d-5b5a54464673" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ab8a4c48-bef2-459a-9d04-2c9c22d95c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ab8a4c48-bef2-459a-9d04-2c9c22d95c1f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dff5ad1e-f460-4015-a4af-c189a390f80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dff5ad1e-f460-4015-a4af-c189a390f80f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromEquityOffering_7e0923d0-4dc3-4718-88aa-2998808f4493" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromEquityOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_ameh_ProceedsFromEquityOffering_7e0923d0-4dc3-4718-88aa-2998808f4493" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_92db6676-1138-4a99-aea3-dfdca089fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_92db6676-1138-4a99-aea3-dfdca089fc74" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_a7ba04cb-2291-439b-91d7-3d2cfd2dd4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_a7ba04cb-2291-439b-91d7-3d2cfd2dd4b1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7d8dc122-398f-4d2a-ae78-bdfefac45c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7d8dc122-398f-4d2a-ae78-bdfefac45c19" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84ed71ae-6b47-4d47-a4fe-9a6d4b50ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84ed71ae-6b47-4d47-a4fe-9a6d4b50ccf5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87a84fa2-36af-435c-bd33-2179e95a3c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87a84fa2-36af-435c-bd33-2179e95a3c2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_753a8c96-5db5-4281-88e0-4a97002bf676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_753a8c96-5db5-4281-88e0-4a97002bf676" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3bb71d10-7e87-4f13-b0e8-972e6328dc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a3b5c883-f2f1-42e7-8b11-03d29e366e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:to="loc_us-gaap_IncomeTaxesPaid_a3b5c883-f2f1-42e7-8b11-03d29e366e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ed8fa690-8c6e-443d-b179-ae086f18a7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:to="loc_us-gaap_InterestPaidNet_ed8fa690-8c6e-443d-b179-ae086f18a7af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IssuanceOfFinancingObligationForBusinessCombination_a570ca69-a0e5-4c96-b587-a9d05ebd81d1" xlink:href="ameh-20211231.xsd#ameh_IssuanceOfFinancingObligationForBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_IssuanceOfFinancingObligationForBusinessCombination_a570ca69-a0e5-4c96-b587-a9d05ebd81d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashlessExerciseOfStockOptions_63184b90-a513-4606-9b63-9a116babaf4b" xlink:href="ameh-20211231.xsd#ameh_CashlessExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_CashlessExerciseOfStockOptions_63184b90-a513-4606-9b63-9a116babaf4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards_615dfe93-3a5f-4948-a7ed-65d05ab5db4b" xlink:href="ameh-20211231.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_CancellationOfRestrictedStockAwards_615dfe93-3a5f-4948-a7ed-65d05ab5db4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_9675a50a-33bd-4922-909c-9b08029e82f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_9675a50a-33bd-4922-909c-9b08029e82f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_fe1b8389-d69c-43dc-bdd8-df18a271abb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_StockIssued1_fe1b8389-d69c-43dc-bdd8-df18a271abb7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReclassificationOfLiabilityForEquity_5de1ef80-2847-4d4a-ba12-f354013466b6" xlink:href="ameh-20211231.xsd#ameh_ReclassificationOfLiabilityForEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_ReclassificationOfLiabilityForEquity_5de1ef80-2847-4d4a-ba12-f354013466b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_621c3547-b2bd-40e3-83cf-2c0cd4c94c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_621c3547-b2bd-40e3-83cf-2c0cd4c94c2a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_c5c0b327-9445-4b76-a009-0ec836e4a127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_c5c0b327-9445-4b76-a009-0ec836e4a127" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_697709c1-2fa0-429b-b1c9-07ef0b579e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_697709c1-2fa0-429b-b1c9-07ef0b579e94" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:href="ameh-20211231.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f612ce4a-a77d-49de-b190-83217e20fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f612ce4a-a77d-49de-b190-83217e20fa79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_71f6bb3a-e1e9-4b03-ae3d-2c4b6ab156a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_71f6bb3a-e1e9-4b03-ae3d-2c4b6ab156a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_d3dc1df9-d1e0-4d3f-b666-f671714046a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_d3dc1df9-d1e0-4d3f-b666-f671714046a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63f894e0-1842-4ab3-8c76-a6eef4aa05a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_069b3621-43d2-4925-b1a7-77cbddcb31f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_069b3621-43d2-4925-b1a7-77cbddcb31f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_069b3621-43d2-4925-b1a7-77cbddcb31f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_069b3621-43d2-4925-b1a7-77cbddcb31f6" xlink:to="loc_us-gaap_RelatedPartyDomain_069b3621-43d2-4925-b1a7-77cbddcb31f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b66e8f10-9eef-42e1-bffc-95d4cbfd51b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_069b3621-43d2-4925-b1a7-77cbddcb31f6" xlink:to="loc_us-gaap_RelatedPartyDomain_b66e8f10-9eef-42e1-bffc-95d4cbfd51b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d9dee59b-03c8-4ef7-b628-684cb4b0c383" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b66e8f10-9eef-42e1-bffc-95d4cbfd51b0" xlink:to="loc_srt_AffiliatedEntityMember_d9dee59b-03c8-4ef7-b628-684cb4b0c383" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1df742b7-e97a-4e62-9f6a-a449f67fb5bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:to="loc_srt_CounterpartyNameAxis_1df742b7-e97a-4e62-9f6a-a449f67fb5bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1df742b7-e97a-4e62-9f6a-a449f67fb5bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1df742b7-e97a-4e62-9f6a-a449f67fb5bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1df742b7-e97a-4e62-9f6a-a449f67fb5bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77ecaac-f13f-41a3-964c-92c75fcc641c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1df742b7-e97a-4e62-9f6a-a449f67fb5bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77ecaac-f13f-41a3-964c-92c75fcc641c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1a02ddf2-e2ad-4324-ac81-e9616ec7bf93" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77ecaac-f13f-41a3-964c-92c75fcc641c" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1a02ddf2-e2ad-4324-ac81-e9616ec7bf93" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="i7c247e4872f148db91a84ac6f7bd3b3f_DescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:href="ameh-20211231.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_bc714c1f-eff7-4a65-8fe5-d4f52a618e75" xlink:href="ameh-20211231.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_bc714c1f-eff7-4a65-8fe5-d4f52a618e75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_828913eb-4da7-4ae8-821f-1c7b91dc2f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_NotesReceivableNet_828913eb-4da7-4ae8-821f-1c7b91dc2f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_3ba2ec36-86b4-4af3-8c6a-723572179fed" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_3ba2ec36-86b4-4af3-8c6a-723572179fed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_b8b01ccc-484e-4720-b71b-d730c65db305" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_b8b01ccc-484e-4720-b71b-d730c65db305" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_a14ab3e0-dc88-4008-9fca-e9f103a5115d" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_a14ab3e0-dc88-4008-9fca-e9f103a5115d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51caeaeb-2ebe-4e77-bbca-3187439cdfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51caeaeb-2ebe-4e77-bbca-3187439cdfe1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2cb17494-df77-4db2-8997-9958f7fb2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2cb17494-df77-4db2-8997-9958f7fb2d04" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestSharesDistributed_0392d0b2-dba5-4bfa-8cf2-13e683ad7bdc" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestSharesDistributed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_NoncontrollingInterestSharesDistributed_0392d0b2-dba5-4bfa-8cf2-13e683ad7bdc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a1e31f-f5db-44cd-92d4-ed32db7e70d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a1e31f-f5db-44cd-92d4-ed32db7e70d7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_76e6b359-e54e-4943-9d88-89323e17655d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_76e6b359-e54e-4943-9d88-89323e17655d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_218ef68f-2a2e-474b-9133-11fc53058501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_218ef68f-2a2e-474b-9133-11fc53058501" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_0cceb20b-4232-4b48-a8c3-7594c1b43fbe" xlink:href="ameh-20211231.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_0cceb20b-4232-4b48-a8c3-7594c1b43fbe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f8351590-3a65-44b1-b1d3-1df1919fdc89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f8351590-3a65-44b1-b1d3-1df1919fdc89" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fff04e2b-79b1-4367-a86d-92fbf7fdff4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fff04e2b-79b1-4367-a86d-92fbf7fdff4e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_0df8db07-9247-41ba-9efa-f62764a91001" xlink:href="ameh-20211231.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_0df8db07-9247-41ba-9efa-f62764a91001" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fd91b28-1889-4243-8721-7a512720a213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fd91b28-1889-4243-8721-7a512720a213" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f911241a-976b-43ec-843b-5fd74594db56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f911241a-976b-43ec-843b-5fd74594db56" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3da97d48-774a-47e1-9b95-f6c9925a6150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_EquityMethodInvestments_3da97d48-774a-47e1-9b95-f6c9925a6150" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_164e69ac-25f2-432a-8047-b752ae1ae380" xlink:href="ameh-20211231.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_164e69ac-25f2-432a-8047-b752ae1ae380" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_e4ed30bf-3c8c-4850-9637-1abd50035241" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_e4ed30bf-3c8c-4850-9637-1abd50035241" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_a8409231-c733-4c84-8736-96ba4d2b5522" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_a8409231-c733-4c84-8736-96ba4d2b5522" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:href="ameh-20211231.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7df2e56c-2531-49e7-9c12-e8064feaaab8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_dei_LegalEntityAxis_7df2e56c-2531-49e7-9c12-e8064feaaab8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_7df2e56c-2531-49e7-9c12-e8064feaaab8_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_7df2e56c-2531-49e7-9c12-e8064feaaab8" xlink:to="loc_dei_EntityDomain_7df2e56c-2531-49e7-9c12-e8064feaaab8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_7df2e56c-2531-49e7-9c12-e8064feaaab8" xlink:to="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e3f3d371-2386-4b02-978d-8007a8b2c8d6" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e3f3d371-2386-4b02-978d-8007a8b2c8d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_33355393-00a6-4d99-ba7f-6ffa46bfc118" xlink:href="ameh-20211231.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_ApcLsmaMember_33355393-00a6-4d99-ba7f-6ffa46bfc118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_372431c2-6921-4262-b2d4-5e28630bbe59" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_372431c2-6921-4262-b2d4-5e28630bbe59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_ddaae660-72a5-4d82-99e6-bd4aa61b3cf4" xlink:href="ameh-20211231.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AccountableHealthCareIPAMember_ddaae660-72a5-4d82-99e6-bd4aa61b3cf4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_32dd1a1f-6ebe-44c5-bb7b-15a6b8d0446f" xlink:href="ameh-20211231.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AmgIncMember_32dd1a1f-6ebe-44c5-bb7b-15a6b8d0446f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_61a5f976-6769-4000-be5a-199f7a55264b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_61a5f976-6769-4000-be5a-199f7a55264b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_61a5f976-6769-4000-be5a-199f7a55264b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_61a5f976-6769-4000-be5a-199f7a55264b" xlink:to="loc_us-gaap_RelatedPartyDomain_61a5f976-6769-4000-be5a-199f7a55264b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_53bc7c2d-5c11-41ee-bf31-424df88aa701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_61a5f976-6769-4000-be5a-199f7a55264b" xlink:to="loc_us-gaap_RelatedPartyDomain_53bc7c2d-5c11-41ee-bf31-424df88aa701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_0809bc3c-a209-4434-ab73-48e72f20bbb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_53bc7c2d-5c11-41ee-bf31-424df88aa701" xlink:to="loc_srt_AffiliatedEntityMember_0809bc3c-a209-4434-ab73-48e72f20bbb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_srt_CounterpartyNameAxis_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_fa51eeb2-2ee5-4590-8780-87fccc022c7c" xlink:href="ameh-20211231.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:to="loc_ameh_APAMHMedicalCorporationMember_fa51eeb2-2ee5-4590-8780-87fccc022c7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_7e01d7b9-5419-4c8a-9f27-a98b25ca373b" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_7e01d7b9-5419-4c8a-9f27-a98b25ca373b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_40d76ae9-27cc-4a5d-8c91-76972bed09fe" xlink:href="ameh-20211231.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:to="loc_ameh_Dr.JayMember_40d76ae9-27cc-4a5d-8c91-76972bed09fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_71806c1b-731b-4eaf-839c-da3618ed29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_71806c1b-731b-4eaf-839c-da3618ed29c3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_71806c1b-731b-4eaf-839c-da3618ed29c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71806c1b-731b-4eaf-839c-da3618ed29c3" xlink:to="loc_us-gaap_ClassOfStockDomain_71806c1b-731b-4eaf-839c-da3618ed29c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f5969e6-f512-4517-af30-b712f144f3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71806c1b-731b-4eaf-839c-da3618ed29c3" xlink:to="loc_us-gaap_ClassOfStockDomain_7f5969e6-f512-4517-af30-b712f144f3d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4074eeab-11b1-4654-92c1-a9c0964cc73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7f5969e6-f512-4517-af30-b712f144f3d4" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4074eeab-11b1-4654-92c1-a9c0964cc73d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e9d1bae0-1025-4683-a295-d32692e8ff4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e9d1bae0-1025-4683-a295-d32692e8ff4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e9d1bae0-1025-4683-a295-d32692e8ff4e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e9d1bae0-1025-4683-a295-d32692e8ff4e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e9d1bae0-1025-4683-a295-d32692e8ff4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e9d1bae0-1025-4683-a295-d32692e8ff4e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_18f47d46-9e41-4b57-9bad-054e9c3eb9fe" xlink:href="ameh-20211231.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_18f47d46-9e41-4b57-9bad-054e9c3eb9fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_c34ab13f-5b1b-4afd-930e-ccdd39852b0c" xlink:href="ameh-20211231.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_c34ab13f-5b1b-4afd-930e-ccdd39852b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_20bb3e9e-9dd8-44c1-8ff9-009836d92157" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:to="loc_ameh_DmgMember_20bb3e9e-9dd8-44c1-8ff9-009836d92157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b4917ecf-a970-4789-b034-d072eb2a4e22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_srt_OwnershipAxis_b4917ecf-a970-4789-b034-d072eb2a4e22" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b4917ecf-a970-4789-b034-d072eb2a4e22_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_b4917ecf-a970-4789-b034-d072eb2a4e22" xlink:to="loc_srt_OwnershipDomain_b4917ecf-a970-4789-b034-d072eb2a4e22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_b4917ecf-a970-4789-b034-d072eb2a4e22" xlink:to="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_ef5b0c6e-8cfb-4f70-9755-01b05ad124d6" xlink:href="ameh-20211231.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_ef5b0c6e-8cfb-4f70-9755-01b05ad124d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_1b20212c-92fe-4266-80a0-7e4486074afd" xlink:href="ameh-20211231.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:to="loc_ameh_AccountableHealthCareIPAMember_1b20212c-92fe-4266-80a0-7e4486074afd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ab23cb91-828f-467e-9cce-078f929daa8f" xlink:href="ameh-20211231.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ab23cb91-828f-467e-9cce-078f929daa8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_10370b42-86c8-4b8e-86fe-e54eacf67bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_10370b42-86c8-4b8e-86fe-e54eacf67bb8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10370b42-86c8-4b8e-86fe-e54eacf67bb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10370b42-86c8-4b8e-86fe-e54eacf67bb8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_10370b42-86c8-4b8e-86fe-e54eacf67bb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10370b42-86c8-4b8e-86fe-e54eacf67bb8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_f2114634-2491-458f-acf1-fd6892215b12" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_f2114634-2491-458f-acf1-fd6892215b12" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_7390165e-bf26-4b36-9111-f560478c1931" xlink:href="ameh-20211231.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AccountableHealthCareIPAMember_7390165e-bf26-4b36-9111-f560478c1931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_924c16b7-c864-4174-b4df-d280b75e3cf4" xlink:href="ameh-20211231.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AmgIncMember_924c16b7-c864-4174-b4df-d280b75e3cf4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_002debbc-898e-4486-9d50-8d9ebe66c599" xlink:href="ameh-20211231.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_002debbc-898e-4486-9d50-8d9ebe66c599" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_9d0be98e-ee4d-4f03-bfed-0d84d96cfa98" xlink:href="ameh-20211231.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_9d0be98e-ee4d-4f03-bfed-0d84d96cfa98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ed46056f-069e-4b77-b6ec-e4b733ee09cd" xlink:href="ameh-20211231.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ed46056f-069e-4b77-b6ec-e4b733ee09cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_aba8ab0c-209b-4ca5-a350-d23e6f435998" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_aba8ab0c-209b-4ca5-a350-d23e6f435998" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ia581dfe1fe39407a936c93b7c558e0d2_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:href="ameh-20211231.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3a25b122-6b76-4b36-b75a-3ad086757e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3a25b122-6b76-4b36-b75a-3ad086757e6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_50e6f33d-e5d8-4c6c-a881-61267a02de5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_NumberOfReportableSegments_50e6f33d-e5d8-4c6c-a881-61267a02de5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_2bc0a9d4-1bb9-46c0-8d22-a3b5df7ef8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_CashUninsuredAmount_2bc0a9d4-1bb9-46c0-8d22-a3b5df7ef8ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7ad6e4fe-708e-4365-b351-5dd14998abae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7ad6e4fe-708e-4365-b351-5dd14998abae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_859b03d0-4779-48d7-8a66-a9feab845c97" xlink:href="ameh-20211231.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_859b03d0-4779-48d7-8a66-a9feab845c97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4b1c475-b9b5-41dd-a9d9-ebd005252a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4b1c475-b9b5-41dd-a9d9-ebd005252a05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_e8dc6888-bd6f-4589-b416-dbf60677131c" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_e8dc6888-bd6f-4589-b416-dbf60677131c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6b828f5e-1051-484f-a0f0-28e8d079e665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6b828f5e-1051-484f-a0f0-28e8d079e665" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_bf76d84d-e304-4691-a674-e67f6ec045a9" xlink:href="ameh-20211231.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_bf76d84d-e304-4691-a674-e67f6ec045a9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_52132803-d4d6-4fa5-bb55-e0bee83d6464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_52132803-d4d6-4fa5-bb55-e0bee83d6464" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableExpectedToBeCollectedPeriod_9ed67de2-96b7-4553-b0d8-65f22545f58d" xlink:href="ameh-20211231.xsd#ameh_AccountsReceivableExpectedToBeCollectedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_AccountsReceivableExpectedToBeCollectedPeriod_9ed67de2-96b7-4553-b0d8-65f22545f58d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_423565e9-69a4-4e60-ad90-eb25b4e5f226" xlink:href="ameh-20211231.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_423565e9-69a4-4e60-ad90-eb25b4e5f226" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aae8d9ba-a96c-4570-97b8-827f7ea3475e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aae8d9ba-a96c-4570-97b8-827f7ea3475e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_d9a72b09-9a2a-4e52-a0ee-7313a79f0639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_NumberOfReportingUnits_d9a72b09-9a2a-4e52-a0ee-7313a79f0639" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_e8d8cc17-abbe-4352-91a2-75dd514d180a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_e8d8cc17-abbe-4352-91a2-75dd514d180a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc3a19a4-d285-4e19-aa26-46f8267da262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc3a19a4-d285-4e19-aa26-46f8267da262" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_38d8d894-667d-4816-890a-da5c02fb6ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_38d8d894-667d-4816-890a-da5c02fb6ea9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_43e79e18-cacd-44ff-acc7-71f25c3f6f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_43e79e18-cacd-44ff-acc7-71f25c3f6f89" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_1069de2a-3906-433f-8baf-87484d020ac5" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_1069de2a-3906-433f-8baf-87484d020ac5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d875c887-a90a-4d66-b546-e2e5bcd976ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d875c887-a90a-4d66-b546-e2e5bcd976ff" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_b001d594-e73f-407c-8725-dad75e9eda4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_DerivativeAssets_b001d594-e73f-407c-8725-dad75e9eda4d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_a6da29e0-6f6f-434c-aa9f-d4fe8571fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_a6da29e0-6f6f-434c-aa9f-d4fe8571fff3" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e2f70a07-5fd6-431a-9f83-82b445a5307e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e2f70a07-5fd6-431a-9f83-82b445a5307e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_6d5c1343-39c5-4d36-84af-7bc630bbd1b5" xlink:href="ameh-20211231.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_6d5c1343-39c5-4d36-84af-7bc630bbd1b5" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSettlement_c2d5eca2-d59a-46e2-9718-0b40138fb60f" xlink:href="ameh-20211231.xsd#ameh_RiskPoolSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_RiskPoolSettlement_c2d5eca2-d59a-46e2-9718-0b40138fb60f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_e391a59a-c001-4182-b320-84cab0353ebc" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_e391a59a-c001-4182-b320-84cab0353ebc" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_bc2619d2-6e4c-4aba-880b-85552e053712" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentOfRevenue_bc2619d2-6e4c-4aba-880b-85552e053712" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized_9cbea239-ed23-4862-8f06-82e217ceb604" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentOfRevenueRevenueRecognized_9cbea239-ed23-4862-8f06-82e217ceb604" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5761c35-5f57-4f44-9563-28ca0df96e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5761c35-5f57-4f44-9563-28ca0df96e35" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5a6e4dee-c9f0-4c16-897b-04d227cba948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5a6e4dee-c9f0-4c16-897b-04d227cba948" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0132b656-f9cb-4e9b-950c-acb2fe79e329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0132b656-f9cb-4e9b-950c-acb2fe79e329" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_661e171f-2071-4772-8565-bf1cd5c7ea0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_661e171f-2071-4772-8565-bf1cd5c7ea0d" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_dd84257a-615c-4643-af60-e548e58eac74" xlink:href="ameh-20211231.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_dd84257a-615c-4643-af60-e548e58eac74" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_82e1cc5e-69a9-4857-8563-2d8415db7f68" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_82e1cc5e-69a9-4857-8563-2d8415db7f68" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_4a76210d-4ab4-434b-9324-1c154ae49f3e" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_4a76210d-4ab4-434b-9324-1c154ae49f3e" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9446d8e9-08de-4b57-b4da-8daa78c3312e" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9446d8e9-08de-4b57-b4da-8daa78c3312e" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:href="ameh-20211231.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_edcdfa51-a276-46f0-b0e6-7311ebde34f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_RangeAxis_edcdfa51-a276-46f0-b0e6-7311ebde34f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_edcdfa51-a276-46f0-b0e6-7311ebde34f4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_edcdfa51-a276-46f0-b0e6-7311ebde34f4" xlink:to="loc_srt_RangeMember_edcdfa51-a276-46f0-b0e6-7311ebde34f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_edcdfa51-a276-46f0-b0e6-7311ebde34f4" xlink:to="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_69c30c26-5d68-4746-aee3-3ee656aaea6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:to="loc_srt_MinimumMember_69c30c26-5d68-4746-aee3-3ee656aaea6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e60b90e2-8b75-4d3b-8c0a-b83f7af70802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:to="loc_srt_MaximumMember_e60b90e2-8b75-4d3b-8c0a-b83f7af70802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9072988c-965d-4a61-9423-bdd7e66fee66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9072988c-965d-4a61-9423-bdd7e66fee66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9072988c-965d-4a61-9423-bdd7e66fee66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9072988c-965d-4a61-9423-bdd7e66fee66" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_9072988c-965d-4a61-9423-bdd7e66fee66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2c7b1a22-91af-4cef-bb98-f6e679de4026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9072988c-965d-4a61-9423-bdd7e66fee66" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2c7b1a22-91af-4cef-bb98-f6e679de4026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareLicenseMember_06eacc49-24bc-41bb-bbbe-beafe8a5b7f2" xlink:href="ameh-20211231.xsd#ameh_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2c7b1a22-91af-4cef-bb98-f6e679de4026" xlink:to="loc_ameh_MedicareLicenseMember_06eacc49-24bc-41bb-bbbe-beafe8a5b7f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e80ca51-161a-442d-a243-a16b4051440e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e80ca51-161a-442d-a243-a16b4051440e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3e80ca51-161a-442d-a243-a16b4051440e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e80ca51-161a-442d-a243-a16b4051440e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3e80ca51-161a-442d-a243-a16b4051440e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e80ca51-161a-442d-a243-a16b4051440e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_e00bc33f-e0ea-4ded-bc0b-f0e6338ff6e7" xlink:href="ameh-20211231.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:to="loc_ameh_UniversalCareIncMember_e00bc33f-e0ea-4ded-bc0b-f0e6338ff6e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_ef4fe18c-1acf-4a7f-9666-2ca62dc10116" xlink:href="ameh-20211231.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_ef4fe18c-1acf-4a7f-9666-2ca62dc10116" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_687d75f5-2a9a-42de-94e4-745861763e3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_ProductOrServiceAxis_687d75f5-2a9a-42de-94e4-745861763e3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_687d75f5-2a9a-42de-94e4-745861763e3c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_687d75f5-2a9a-42de-94e4-745861763e3c" xlink:to="loc_srt_ProductsAndServicesDomain_687d75f5-2a9a-42de-94e4-745861763e3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_687d75f5-2a9a-42de-94e4-745861763e3c" xlink:to="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_116f2222-fcbf-4038-8170-6bfd6704ef91" xlink:href="ameh-20211231.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_116f2222-fcbf-4038-8170-6bfd6704ef91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_60aa8b57-e4c7-4fbb-90b7-ce7d15ffd78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:to="loc_us-gaap_ManagementServiceMember_60aa8b57-e4c7-4fbb-90b7-ce7d15ffd78e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_0ab49001-d5da-45d6-8643-5d0f0ca37e22" xlink:href="ameh-20211231.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_0ab49001-d5da-45d6-8643-5d0f0ca37e22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_92227f2d-bb7a-4e24-9e75-9fcd886d4006" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_CounterpartyNameAxis_92227f2d-bb7a-4e24-9e75-9fcd886d4006" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92227f2d-bb7a-4e24-9e75-9fcd886d4006_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_92227f2d-bb7a-4e24-9e75-9fcd886d4006" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92227f2d-bb7a-4e24-9e75-9fcd886d4006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_92227f2d-bb7a-4e24-9e75-9fcd886d4006" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_ce85cdec-d600-496d-a7ce-eee59c8eb898" xlink:href="ameh-20211231.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_ce85cdec-d600-496d-a7ce-eee59c8eb898" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_4f7e8b4d-f2e6-4efe-b8cf-ffc1dc81d926" xlink:href="ameh-20211231.xsd#ameh_CMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:to="loc_ameh_CMSMember_4f7e8b4d-f2e6-4efe-b8cf-ffc1dc81d926" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7bd4abec-0be9-4a96-9532-de6b22afb2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7bd4abec-0be9-4a96-9532-de6b22afb2bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bd4abec-0be9-4a96-9532-de6b22afb2bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7bd4abec-0be9-4a96-9532-de6b22afb2bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7bd4abec-0be9-4a96-9532-de6b22afb2bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d9fbe94-53d2-4f86-b08f-f518e7ef5df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7bd4abec-0be9-4a96-9532-de6b22afb2bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d9fbe94-53d2-4f86-b08f-f518e7ef5df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3ec7d571-6674-403a-b48a-8af67d259cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d9fbe94-53d2-4f86-b08f-f518e7ef5df5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3ec7d571-6674-403a-b48a-8af67d259cca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_95cb7c23-7229-403d-adeb-736d889cd087" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_dei_LegalEntityAxis_95cb7c23-7229-403d-adeb-736d889cd087" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_95cb7c23-7229-403d-adeb-736d889cd087_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_95cb7c23-7229-403d-adeb-736d889cd087" xlink:to="loc_dei_EntityDomain_95cb7c23-7229-403d-adeb-736d889cd087_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_95cb7c23-7229-403d-adeb-736d889cd087" xlink:to="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5cfaf476-2511-4480-9214-5b18c5015ec2" xlink:href="ameh-20211231.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5cfaf476-2511-4480-9214-5b18c5015ec2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ea7a826f-0be3-4709-8485-ae706de54b84" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ea7a826f-0be3-4709-8485-ae706de54b84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f0f2f254-cd43-43b2-8736-1174df9ede90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f0f2f254-cd43-43b2-8736-1174df9ede90" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0f2f254-cd43-43b2-8736-1174df9ede90_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f0f2f254-cd43-43b2-8736-1174df9ede90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f0f2f254-cd43-43b2-8736-1174df9ede90_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4871a918-41e7-4788-9652-137f8b5e1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f0f2f254-cd43-43b2-8736-1174df9ede90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4871a918-41e7-4788-9652-137f8b5e1a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_accb6c5e-e172-441e-b645-abef544c5e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4871a918-41e7-4788-9652-137f8b5e1a8e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_accb6c5e-e172-441e-b645-abef544c5e95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a2176ef9-5213-40b1-933c-326fca4c748e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_OwnershipAxis_a2176ef9-5213-40b1-933c-326fca4c748e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_a2176ef9-5213-40b1-933c-326fca4c748e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_a2176ef9-5213-40b1-933c-326fca4c748e" xlink:to="loc_srt_OwnershipDomain_a2176ef9-5213-40b1-933c-326fca4c748e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e16380f0-f691-4442-a9c2-7a31dbff16ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_a2176ef9-5213-40b1-933c-326fca4c748e" xlink:to="loc_srt_OwnershipDomain_e16380f0-f691-4442-a9c2-7a31dbff16ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_52cb6e99-d12b-40bf-bee7-367df04b06ff" xlink:href="ameh-20211231.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e16380f0-f691-4442-a9c2-7a31dbff16ce" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_52cb6e99-d12b-40bf-bee7-367df04b06ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_63b37aaa-f189-43f8-bd8e-3dac3b360097" xlink:href="ameh-20211231.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_63b37aaa-f189-43f8-bd8e-3dac3b360097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e2a0cbe7-9f1e-454d-9746-a2caf7d83668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e2a0cbe7-9f1e-454d-9746-a2caf7d83668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c58893d0-60b0-48f2-9fc3-c32891f482a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c58893d0-60b0-48f2-9fc3-c32891f482a6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c58893d0-60b0-48f2-9fc3-c32891f482a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c58893d0-60b0-48f2-9fc3-c32891f482a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c58893d0-60b0-48f2-9fc3-c32891f482a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c58893d0-60b0-48f2-9fc3-c32891f482a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fd50baf5-a455-4cae-8c50-b6a1192c1ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:to="loc_us-gaap_InterestRateSwapMember_fd50baf5-a455-4cae-8c50-b6a1192c1ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_b5e434b3-0922-4b98-989a-d9f1290c3246" xlink:href="ameh-20211231.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_b5e434b3-0922-4b98-989a-d9f1290c3246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e093b805-1d08-4a69-889d-55c0a42709b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e093b805-1d08-4a69-889d-55c0a42709b7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_e093b805-1d08-4a69-889d-55c0a42709b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e093b805-1d08-4a69-889d-55c0a42709b7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_e093b805-1d08-4a69-889d-55c0a42709b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_49631aa4-939b-4550-b1f1-7ccbb81ddf39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e093b805-1d08-4a69-889d-55c0a42709b7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_49631aa4-939b-4550-b1f1-7ccbb81ddf39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_958881ce-b2dc-414b-8006-362867d29863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_49631aa4-939b-4550-b1f1-7ccbb81ddf39" xlink:to="loc_us-gaap_CashFlowHedgingMember_958881ce-b2dc-414b-8006-362867d29863" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f933306c-b7f0-4d90-941c-4121e8b28237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_HedgingDesignationAxis_f933306c-b7f0-4d90-941c-4121e8b28237" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f933306c-b7f0-4d90-941c-4121e8b28237_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f933306c-b7f0-4d90-941c-4121e8b28237" xlink:to="loc_us-gaap_HedgingDesignationDomain_f933306c-b7f0-4d90-941c-4121e8b28237_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d8cc9c63-4e64-4af5-bfeb-db00ab678629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f933306c-b7f0-4d90-941c-4121e8b28237" xlink:to="loc_us-gaap_HedgingDesignationDomain_d8cc9c63-4e64-4af5-bfeb-db00ab678629" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a10a3a8a-a98a-4ba2-a092-bcf2d2260d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d8cc9c63-4e64-4af5-bfeb-db00ab678629" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a10a3a8a-a98a-4ba2-a092-bcf2d2260d83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended" id="i8bf710239342484eb6802461cca906ff_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1d0cd67b-a352-4f8a-916e-d4201d783a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1d0cd67b-a352-4f8a-916e-d4201d783a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_731697eb-ba85-4655-b74c-4a94a539bb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_731697eb-ba85-4655-b74c-4a94a539bb49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:to="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:to="loc_srt_ProductsAndServicesDomain_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:to="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_e283be2c-eba6-4b49-9b46-90f173e59b34" xlink:href="ameh-20211231.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_e283be2c-eba6-4b49-9b46-90f173e59b34" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended" id="i2aebd96c67b44a6dbde19079c6b2784f_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1d0cd67b-a352-4f8a-916e-d4201d783a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1d0cd67b-a352-4f8a-916e-d4201d783a72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:to="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:to="loc_srt_ProductsAndServicesDomain_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:to="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_e283be2c-eba6-4b49-9b46-90f173e59b34" xlink:href="ameh-20211231.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_e283be2c-eba6-4b49-9b46-90f173e59b34" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails" xlink:type="extended" id="i3904725fc93e4f7bbbe77a3300d35ef0_BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_566069f8-dd4c-46e8-96ba-ec0e0763029b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f6431ea-4668-41e3-84b8-4aa1a81bdd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_566069f8-dd4c-46e8-96ba-ec0e0763029b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f6431ea-4668-41e3-84b8-4aa1a81bdd10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4dfe6fc3-b5a5-46c8-91ee-c426e637959a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_566069f8-dd4c-46e8-96ba-ec0e0763029b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4dfe6fc3-b5a5-46c8-91ee-c426e637959a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_287ecdf3-7538-4536-8f9c-8efe870e227a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4dfe6fc3-b5a5-46c8-91ee-c426e637959a" xlink:to="loc_srt_MajorCustomersAxis_287ecdf3-7538-4536-8f9c-8efe870e227a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_287ecdf3-7538-4536-8f9c-8efe870e227a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_287ecdf3-7538-4536-8f9c-8efe870e227a" xlink:to="loc_srt_NameOfMajorCustomerDomain_287ecdf3-7538-4536-8f9c-8efe870e227a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_287ecdf3-7538-4536-8f9c-8efe870e227a" xlink:to="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_6db86479-9f9d-4cce-a9f1-00f358a14b4b" xlink:href="ameh-20211231.xsd#ameh_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_CommercialMember_6db86479-9f9d-4cce-a9f1-00f358a14b4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_0bdf15ae-13ae-4037-a40c-3008b95ee70e" xlink:href="ameh-20211231.xsd#ameh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_MedicareMember_0bdf15ae-13ae-4037-a40c-3008b95ee70e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_ef2756b2-6bc0-43a9-874c-d3535410739e" xlink:href="ameh-20211231.xsd#ameh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_MedicaidMember_ef2756b2-6bc0-43a9-874c-d3535410739e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_fa3c5f76-5ec2-436e-98bf-cab01c9a6732" xlink:href="ameh-20211231.xsd#ameh_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_OtherThirdPartiesMember_fa3c5f76-5ec2-436e-98bf-cab01c9a6732" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended" id="i698fdec072a44329b390063b9c5a0eed_BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2a078c6a-ecee-41dc-8a54-1e586d857432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2a667ec2-a1e3-43d3-8f22-284e69da411f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2a078c6a-ecee-41dc-8a54-1e586d857432" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2a667ec2-a1e3-43d3-8f22-284e69da411f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2a078c6a-ecee-41dc-8a54-1e586d857432" xlink:to="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_536fc4dc-1797-4c34-b02f-e630039d589f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_536fc4dc-1797-4c34-b02f-e630039d589f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_536fc4dc-1797-4c34-b02f-e630039d589f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_536fc4dc-1797-4c34-b02f-e630039d589f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_536fc4dc-1797-4c34-b02f-e630039d589f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_536fc4dc-1797-4c34-b02f-e630039d589f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cbec4ae3-3fd9-457b-bcc2-69bc15460dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:to="loc_us-gaap_SalesRevenueNetMember_cbec4ae3-3fd9-457b-bcc2-69bc15460dbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5902f6f0-d4a2-47cc-8447-7e5ef1c5e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:to="loc_us-gaap_AccountsReceivableMember_5902f6f0-d4a2-47cc-8447-7e5ef1c5e01b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_128ba503-993d-4412-b435-aae4601c4693" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:to="loc_srt_MajorCustomersAxis_128ba503-993d-4412-b435-aae4601c4693" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_128ba503-993d-4412-b435-aae4601c4693_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_128ba503-993d-4412-b435-aae4601c4693" xlink:to="loc_srt_NameOfMajorCustomerDomain_128ba503-993d-4412-b435-aae4601c4693_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_128ba503-993d-4412-b435-aae4601c4693" xlink:to="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_ac21959a-4674-417e-bb6e-6d2a7e113892" xlink:href="ameh-20211231.xsd#ameh_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorAMember_ac21959a-4674-417e-bb6e-6d2a7e113892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_6bd83f86-515b-4d10-a204-4e0383537dab" xlink:href="ameh-20211231.xsd#ameh_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorBMember_6bd83f86-515b-4d10-a204-4e0383537dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_d1f4adeb-f658-4a43-9e65-7cbb3297d885" xlink:href="ameh-20211231.xsd#ameh_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorCMember_d1f4adeb-f658-4a43-9e65-7cbb3297d885" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_c17cd928-4442-4bfd-9877-7c3058a4c5b2" xlink:href="ameh-20211231.xsd#ameh_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorDMember_c17cd928-4442-4bfd-9877-7c3058a4c5b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_f3b0b494-268b-46fc-9af6-70f4082f821b" xlink:href="ameh-20211231.xsd#ameh_PayorEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorEMember_f3b0b494-268b-46fc-9af6-70f4082f821b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_35d798db-11f4-451c-98c3-de0d75b001cb" xlink:href="ameh-20211231.xsd#ameh_PayorFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorFMember_35d798db-11f4-451c-98c3-de0d75b001cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7b66b814-b56e-46d7-ae70-fb8623512511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7b66b814-b56e-46d7-ae70-fb8623512511" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_7b66b814-b56e-46d7-ae70-fb8623512511_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7b66b814-b56e-46d7-ae70-fb8623512511" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_7b66b814-b56e-46d7-ae70-fb8623512511_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ef9dcc56-5426-46a7-98ae-3fb3d2dd044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7b66b814-b56e-46d7-ae70-fb8623512511" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ef9dcc56-5426-46a7-98ae-3fb3d2dd044b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a5cf752e-fca3-4b6c-8d7c-52aa2e8edf11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ef9dcc56-5426-46a7-98ae-3fb3d2dd044b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a5cf752e-fca3-4b6c-8d7c-52aa2e8edf11" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended" id="i268bf28b621948849d31d7ff3639284f_BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08fd0ca4-8f46-4597-acf0-3d02b6baad78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08fd0ca4-8f46-4597-acf0-3d02b6baad78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67a0da2b-8566-4866-9d44-5bdfaf10f9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67a0da2b-8566-4866-9d44-5bdfaf10f9af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_dacc3f38-5e2b-48a2-884a-b649bfb0888a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_dacc3f38-5e2b-48a2-884a-b649bfb0888a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6df24f93-d873-43af-8447-835c80319497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_DerivativeAssets_6df24f93-d873-43af-8447-835c80319497" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3492d9a4-d6b6-4da9-8a79-b3e997d715a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3492d9a4-d6b6-4da9-8a79-b3e997d715a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0c96d1cb-cfba-4bcc-98c1-683a5a9c5e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_DerivativeLiabilities_0c96d1cb-cfba-4bcc-98c1-683a5a9c5e0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51932300-1298-43b2-8a51-80b0ca682db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51932300-1298-43b2-8a51-80b0ca682db0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b8ae4f1a-f681-4a74-82bf-e5c9b7792dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b8ae4f1a-f681-4a74-82bf-e5c9b7792dcf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_443f02fc-52f8-4c65-9df6-0e35828f61ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_443f02fc-52f8-4c65-9df6-0e35828f61ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_443f02fc-52f8-4c65-9df6-0e35828f61ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_443f02fc-52f8-4c65-9df6-0e35828f61ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_443f02fc-52f8-4c65-9df6-0e35828f61ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_443f02fc-52f8-4c65-9df6-0e35828f61ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_444a6cbc-f520-4898-97e4-d672b9890857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_444a6cbc-f520-4898-97e4-d672b9890857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9beceeb5-3522-4f94-a7d2-3c64c743a851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9beceeb5-3522-4f94-a7d2-3c64c743a851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_06681590-c210-4c24-a64d-e7b843cfb12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_06681590-c210-4c24-a64d-e7b843cfb12d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c56a1fad-6c58-4fc1-a59b-3afa39143582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c56a1fad-6c58-4fc1-a59b-3afa39143582" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c56a1fad-6c58-4fc1-a59b-3afa39143582_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c56a1fad-6c58-4fc1-a59b-3afa39143582" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c56a1fad-6c58-4fc1-a59b-3afa39143582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c56a1fad-6c58-4fc1-a59b-3afa39143582" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_29509639-d0fc-40f9-b589-0af33f5dd694" xlink:href="ameh-20211231.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_29509639-d0fc-40f9-b589-0af33f5dd694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_63d73659-3eb0-40c6-a1f1-59a1485d2f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:to="loc_us-gaap_WarrantMember_63d73659-3eb0-40c6-a1f1-59a1485d2f82" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended" id="i28d59375e599445eab4e60c2df75afae_BusinessCombinationsandGoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_716dd439-93e2-44f0-9c7c-d2b83e1c3dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_716dd439-93e2-44f0-9c7c-d2b83e1c3dc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d82a14e-2122-4eb7-9e1b-a2f8be2d8498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d82a14e-2122-4eb7-9e1b-a2f8be2d8498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_60b62f50-fac5-4d54-9419-3ee21e466c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_60b62f50-fac5-4d54-9419-3ee21e466c33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0657d5d3-20e6-41b2-9cfc-731c7a246c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0657d5d3-20e6-41b2-9cfc-731c7a246c59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_595ee0bd-b00d-4056-bd37-436df935e56a" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_595ee0bd-b00d-4056-bd37-436df935e56a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130e0bcc-c795-4720-905c-46d27280bbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130e0bcc-c795-4720-905c-46d27280bbd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c218ae8f-07c5-43d4-b39d-9572e54adda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130e0bcc-c795-4720-905c-46d27280bbd1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c218ae8f-07c5-43d4-b39d-9572e54adda3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c218ae8f-07c5-43d4-b39d-9572e54adda3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c218ae8f-07c5-43d4-b39d-9572e54adda3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c218ae8f-07c5-43d4-b39d-9572e54adda3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c218ae8f-07c5-43d4-b39d-9572e54adda3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_1677d433-abab-4c9d-9752-ff1a81a3b587" xlink:href="ameh-20211231.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_1677d433-abab-4c9d-9752-ff1a81a3b587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_4b5499f2-d00a-4621-a6fd-23ec059400ac" xlink:href="ameh-20211231.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_4b5499f2-d00a-4621-a6fd-23ec059400ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_6b701821-887d-48d5-a20e-a4e5d0d683da" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:to="loc_ameh_DmgMember_6b701821-887d-48d5-a20e-a4e5d0d683da" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails" xlink:type="extended" id="i24d6a1c37e6e42789d3d81ab41f063a9_LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66d9ba1b-ecf8-46ae-90da-11b3e1fc8d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66d9ba1b-ecf8-46ae-90da-11b3e1fc8d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_cde2e996-2006-4e3c-b9d8-587f584e3004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_cde2e996-2006-4e3c-b9d8-587f584e3004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_515f8fb1-dc06-44db-82be-bee349a4ba17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_515f8fb1-dc06-44db-82be-bee349a4ba17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_92976c6c-c8e0-4a35-8cf4-94d179d078f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_92976c6c-c8e0-4a35-8cf4-94d179d078f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd539d1c-dc3b-4600-86f0-ccf55fa52525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd539d1c-dc3b-4600-86f0-ccf55fa52525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd539d1c-dc3b-4600-86f0-ccf55fa52525_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd539d1c-dc3b-4600-86f0-ccf55fa52525" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd539d1c-dc3b-4600-86f0-ccf55fa52525_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd539d1c-dc3b-4600-86f0-ccf55fa52525" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_4c1e6a39-2ff2-4373-90a2-0b98e45e38e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_LandMember_4c1e6a39-2ff2-4373-90a2-0b98e45e38e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9d6f3f60-c93b-4d9a-89e8-af6654e46421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_BuildingMember_9d6f3f60-c93b-4d9a-89e8-af6654e46421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_6073dfe5-0862-411f-8a4f-050c45931bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_ComputerEquipmentMember_6073dfe5-0862-411f-8a4f-050c45931bb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_cbe24a96-6c85-4c20-a2c7-e1301277af73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_cbe24a96-6c85-4c20-a2c7-e1301277af73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_20a4f303-b83c-4eb0-a728-a16eefbc1ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_ConstructionInProgressMember_20a4f303-b83c-4eb0-a728-a16eefbc1ce5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8e7fa91b-f7b4-4cfd-a90b-9c0f8df97ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8e7fa91b-f7b4-4cfd-a90b-9c0f8df97ec9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f69b5b4-65e1-4551-be49-076532ef69a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:to="loc_srt_RangeAxis_6f69b5b4-65e1-4551-be49-076532ef69a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f69b5b4-65e1-4551-be49-076532ef69a1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f69b5b4-65e1-4551-be49-076532ef69a1" xlink:to="loc_srt_RangeMember_6f69b5b4-65e1-4551-be49-076532ef69a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f69b5b4-65e1-4551-be49-076532ef69a1" xlink:to="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bbf16eb6-9c6f-4d61-a841-dcfcfb4b2fa9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:to="loc_srt_MinimumMember_bbf16eb6-9c6f-4d61-a841-dcfcfb4b2fa9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7dae121-137e-40c0-b3de-d11e105bac81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:to="loc_srt_MaximumMember_c7dae121-137e-40c0-b3de-d11e105bac81" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i45ceb37f70fb464886145d4b9b14766b_IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a8f8c946-c3b7-4d7e-8cb8-7813207b2e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a8f8c946-c3b7-4d7e-8cb8-7813207b2e8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f7493068-f9a8-49ba-9e0e-0e8b17423105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f7493068-f9a8-49ba-9e0e-0e8b17423105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_83575c63-ffdc-4da5-90b5-e897474ff052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_83575c63-ffdc-4da5-90b5-e897474ff052" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dfa8fa4-16c8-4e2b-9d12-6de5677dce58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dfa8fa4-16c8-4e2b-9d12-6de5677dce58" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9bd9e047-8ce9-4431-b383-9f8b69be19d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3d703b1f-15c4-4a8b-9f95-2f746ba0759f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3d703b1f-15c4-4a8b-9f95-2f746ba0759f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_256fa6c5-ece3-40ed-af4f-9a62ac369043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_256fa6c5-ece3-40ed-af4f-9a62ac369043" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d45c1588-6764-4cec-bfe3-65f3eeedbd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d45c1588-6764-4cec-bfe3-65f3eeedbd85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_72f02616-8261-46da-8036-9f04a4a682f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_913ed00d-b1dc-4f39-9b97-ee692a60d35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_913ed00d-b1dc-4f39-9b97-ee692a60d35f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04585bb6-bbd2-4fa0-bbf7-169378f2df11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04585bb6-bbd2-4fa0-bbf7-169378f2df11" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_44306a32-4c11-4ba7-a4a6-6ea78c86bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_44306a32-4c11-4ba7-a4a6-6ea78c86bc82" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ef2b9ff-f0c0-4e74-9620-21148bee74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ef2b9ff-f0c0-4e74-9620-21148bee74fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_05476c2b-f913-4bad-8ca5-67ead1116d35" xlink:href="ameh-20211231.xsd#ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_05476c2b-f913-4bad-8ca5-67ead1116d35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c77836c6-cef0-4b2b-9e88-10b3b860a067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c77836c6-cef0-4b2b-9e88-10b3b860a067" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c19323e0-d0f8-47b6-a317-4a6d7fd42a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c19323e0-d0f8-47b6-a317-4a6d7fd42a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c19323e0-d0f8-47b6-a317-4a6d7fd42a34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c19323e0-d0f8-47b6-a317-4a6d7fd42a34" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c19323e0-d0f8-47b6-a317-4a6d7fd42a34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ae2d246-0f61-450f-99cd-bb4b2c773a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c19323e0-d0f8-47b6-a317-4a6d7fd42a34" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ae2d246-0f61-450f-99cd-bb4b2c773a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareLicenseMember_2cd58203-e6f0-4d9c-bd05-e5daa7d6ccb2" xlink:href="ameh-20211231.xsd#ameh_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ae2d246-0f61-450f-99cd-bb4b2c773a67" xlink:to="loc_ameh_MedicareLicenseMember_2cd58203-e6f0-4d9c-bd05-e5daa7d6ccb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_97a4338e-48f0-484d-b9dd-bdbc47fb30b6" xlink:href="ameh-20211231.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_NetworkRelationshipsMember_97a4338e-48f0-484d-b9dd-bdbc47fb30b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_5debebed-4237-4e33-b075-409b2ad6ea67" xlink:href="ameh-20211231.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_ManagementContractsMember_5debebed-4237-4e33-b075-409b2ad6ea67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_c783890f-ab4d-420a-bcc2-cc953a88b080" xlink:href="ameh-20211231.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_MemberRelationshipsMember_c783890f-ab4d-420a-bcc2-cc953a88b080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_2cd7aa07-31d7-4a99-8c63-4bcd9efb5592" xlink:href="ameh-20211231.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_PatientManagementPlatformMember_2cd7aa07-31d7-4a99-8c63-4bcd9efb5592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3ac2fb28-756b-4eb2-b10f-b9b0cd3b8631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_us-gaap_TradeNamesMember_3ac2fb28-756b-4eb2-b10f-b9b0cd3b8631" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_337cd2fd-5193-4b8f-bc41-363b94978dbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:to="loc_srt_RangeAxis_337cd2fd-5193-4b8f-bc41-363b94978dbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_337cd2fd-5193-4b8f-bc41-363b94978dbe_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_337cd2fd-5193-4b8f-bc41-363b94978dbe" xlink:to="loc_srt_RangeMember_337cd2fd-5193-4b8f-bc41-363b94978dbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_337cd2fd-5193-4b8f-bc41-363b94978dbe" xlink:to="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db9c0c0b-ace6-45cc-9ccf-cb3cab8009e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:to="loc_srt_MinimumMember_db9c0c0b-ace6-45cc-9ccf-cb3cab8009e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cfd97733-177a-4d0e-9757-1c734e4376d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:to="loc_srt_MaximumMember_cfd97733-177a-4d0e-9757-1c734e4376d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended" id="if6272c20c11f476d97ff9ea668a345dd_IntangibleAssetsNetAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_58ea7112-0be9-4b32-91f3-34fec3ca78b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_58ea7112-0be9-4b32-91f3-34fec3ca78b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b2c2d2d0-84a9-4197-8370-1eac76cde825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b2c2d2d0-84a9-4197-8370-1eac76cde825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_0ba0f174-8358-4950-b675-3c41cfe4e855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_0ba0f174-8358-4950-b675-3c41cfe4e855" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2d592257-6e61-4e51-9a22-88dd6a5352d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2d592257-6e61-4e51-9a22-88dd6a5352d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d592257-6e61-4e51-9a22-88dd6a5352d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2d592257-6e61-4e51-9a22-88dd6a5352d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2d592257-6e61-4e51-9a22-88dd6a5352d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e3a18354-96bb-4154-901f-e428c0103bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2d592257-6e61-4e51-9a22-88dd6a5352d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e3a18354-96bb-4154-901f-e428c0103bb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareLicenseMember_3e2d9620-3c13-4c68-b6f5-ea8ee98e01d4" xlink:href="ameh-20211231.xsd#ameh_MedicareLicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e3a18354-96bb-4154-901f-e428c0103bb7" xlink:to="loc_ameh_MedicareLicenseMember_3e2d9620-3c13-4c68-b6f5-ea8ee98e01d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_978d0a0e-139b-44e2-949d-aeb0861e0d05" xlink:href="ameh-20211231.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_NetworkRelationshipsMember_978d0a0e-139b-44e2-949d-aeb0861e0d05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_67e726a9-7924-4368-afa7-9304bf6fe9bd" xlink:href="ameh-20211231.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_ManagementContractsMember_67e726a9-7924-4368-afa7-9304bf6fe9bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_3ad1dd55-888f-47d2-a078-6321a9192096" xlink:href="ameh-20211231.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_MemberRelationshipsMember_3ad1dd55-888f-47d2-a078-6321a9192096" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_8cf688d2-2a00-428a-93f8-ca4bc2f379e3" xlink:href="ameh-20211231.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_PatientManagementPlatformMember_8cf688d2-2a00-428a-93f8-ca4bc2f379e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_119a1c99-dbbd-4871-830e-f2d72ecc2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_119a1c99-dbbd-4871-830e-f2d72ecc2d9b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesEquityMethodDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails" xlink:type="extended" id="idb01bb9d707441a988aadb835ad3d153_InvestmentsinOtherEntitiesEquityMethodDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c607ded-92ab-495f-a57a-faf11acf3da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c607ded-92ab-495f-a57a-faf11acf3da6" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e4d50514-7dbe-460d-a76c-8ff298bae65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_us-gaap_EquityMethodInvestments_e4d50514-7dbe-460d-a76c-8ff298bae65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentInvestmentInPeriod_2f667802-230d-4e00-b048-da277300cd0c" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentInvestmentInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_ameh_EquityMethodInvestmentInvestmentInPeriod_2f667802-230d-4e00-b048-da277300cd0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b9121e9f-7159-4d55-aaf8-0f1283fbb9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b9121e9f-7159-4d55-aaf8-0f1283fbb9bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_0c06d1db-1ce9-478a-9d04-2b096a39afcc" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_0c06d1db-1ce9-478a-9d04-2b096a39afcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_65616e3b-4e34-4b98-91aa-37b7c52e722b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_65616e3b-4e34-4b98-91aa-37b7c52e722b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated_c0206cac-3336-4bab-b15a-1f082484cf16" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_ameh_EquityMethodInvestmentsConsolidated_c0206cac-3336-4bab-b15a-1f082484cf16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8bee43bc-1fde-4769-9137-e0c02d31579a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2955089f-2daf-4bec-aa60-999b6d17f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c607ded-92ab-495f-a57a-faf11acf3da6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2955089f-2daf-4bec-aa60-999b6d17f9c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_957988b6-461a-468a-ab79-69ae2b9caf12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2955089f-2daf-4bec-aa60-999b6d17f9c6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_957988b6-461a-468a-ab79-69ae2b9caf12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_957988b6-461a-468a-ab79-69ae2b9caf12_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_957988b6-461a-468a-ab79-69ae2b9caf12" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_957988b6-461a-468a-ab79-69ae2b9caf12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_957988b6-461a-468a-ab79-69ae2b9caf12" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_70cdb99a-0dee-43f4-8e2d-d68dffc11801" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_70cdb99a-0dee-43f4-8e2d-d68dffc11801" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_b53beb1e-a83a-4b59-898e-d1155424c4fc" xlink:href="ameh-20211231.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_b53beb1e-a83a-4b59-898e-d1155424c4fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_240c9b65-c167-475b-80c4-6337c7af52d5" xlink:href="ameh-20211231.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_240c9b65-c167-475b-80c4-6337c7af52d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_e629b334-e40d-4929-9aab-4312a7bf8608" xlink:href="ameh-20211231.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_e629b334-e40d-4929-9aab-4312a7bf8608" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_248fd007-543b-4923-98c4-93ca91b4a0e0" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_OneMSOLLCMember_248fd007-543b-4923-98c4-93ca91b4a0e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_09daee45-9996-4e2b-b3e9-4e9752196feb" xlink:href="ameh-20211231.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_09daee45-9996-4e2b-b3e9-4e9752196feb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_de625451-e418-4636-99b9-1d1b44f3184f" xlink:href="ameh-20211231.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_de625451-e418-4636-99b9-1d1b44f3184f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOMember_921c255a-05d1-47b8-88e6-d9f69630874d" xlink:href="ameh-20211231.xsd#ameh_CAIPAMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_CAIPAMSOMember_921c255a-05d1-47b8-88e6-d9f69630874d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended" id="i8fac1def7c74499c9f27ceb75601ce53_InvestmentsinOtherEntitiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_6fb79774-c177-47e7-9c24-9f19ee696d6c" xlink:href="ameh-20211231.xsd#ameh_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_NumberOfEmployees_6fb79774-c177-47e7-9c24-9f19ee696d6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e30f7aa4-6311-4250-be76-d809975b9557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e30f7aa4-6311-4250-be76-d809975b9557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef4556b5-a05e-4a00-80eb-c8362dc99d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef4556b5-a05e-4a00-80eb-c8362dc99d50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_6cafb106-2648-4988-9673-e0249a5ef95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_NotesReceivableNet_6cafb106-2648-4988-9673-e0249a5ef95b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_9b90592a-6ebf-4cf8-99e7-b0d7feb65f0a" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_9b90592a-6ebf-4cf8-99e7-b0d7feb65f0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_d36c6838-b2e6-4ac4-83fe-6c4c84e78d86" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_d36c6838-b2e6-4ac4-83fe-6c4c84e78d86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_46d23916-a149-4665-a614-4dc2fcc6b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_46d23916-a149-4665-a614-4dc2fcc6b5c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1dc7a2d3-d3e5-4c25-b787-60b7b2bab90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_EquityMethodInvestments_1dc7a2d3-d3e5-4c25-b787-60b7b2bab90d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_d587672c-7d63-43b6-98e0-aaba31d933f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_PaymentsForFees_d587672c-7d63-43b6-98e0-aaba31d933f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a273f2a2-db95-45b8-a5ab-ac00f657e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a273f2a2-db95-45b8-a5ab-ac00f657e5c6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_2740a837-2ac7-45b5-ab69-008b31f36219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_MembersCapital_2740a837-2ac7-45b5-ab69-008b31f36219" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_65674773-7991-4647-a45b-008179b562de" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_65674773-7991-4647-a45b-008179b562de" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_a18fa9aa-79d1-4eb2-b78f-831b095e1ff8" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_a18fa9aa-79d1-4eb2-b78f-831b095e1ff8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_32d05bb2-3edc-410e-83db-120381c3e779" xlink:href="ameh-20211231.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_32d05bb2-3edc-410e-83db-120381c3e779" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_f96941b5-8fcb-462e-80e6-2854e3f40c6b" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_f96941b5-8fcb-462e-80e6-2854e3f40c6b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_25f62cb8-90e3-4cdd-9d0b-b12d2223118b" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_25f62cb8-90e3-4cdd-9d0b-b12d2223118b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f6e830e0-23df-432e-958c-d19da37c635e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f6e830e0-23df-432e-958c-d19da37c635e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bd67d673-430e-43fb-b4c8-1392e4a17a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bd67d673-430e-43fb-b4c8-1392e4a17a8d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_ca4b32e0-97fc-47dc-9924-dac4ecd42258" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_ca4b32e0-97fc-47dc-9924-dac4ecd42258" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_25577b87-3659-478d-aac9-45e1cd6cb28f" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_25577b87-3659-478d-aac9-45e1cd6cb28f" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet_52c899f6-df93-4d0c-bc91-0ac488fae7fa" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet_52c899f6-df93-4d0c-bc91-0ac488fae7fa" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f27856c5-ba86-43ba-a8a6-022c9b9a56e4" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f27856c5-ba86-43ba-a8a6-022c9b9a56e4" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_082d9408-426b-4dde-ada7-1d50d3fb2691" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_082d9408-426b-4dde-ada7-1d50d3fb2691" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c8695c4b-f361-46d8-8f63-ca58db11de96" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c8695c4b-f361-46d8-8f63-ca58db11de96" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0f33f24c-af69-45e3-a41d-049782b5ade4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0f33f24c-af69-45e3-a41d-049782b5ade4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0f33f24c-af69-45e3-a41d-049782b5ade4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0f33f24c-af69-45e3-a41d-049782b5ade4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0f33f24c-af69-45e3-a41d-049782b5ade4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0f33f24c-af69-45e3-a41d-049782b5ade4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_910b49fb-2baa-44ac-b88b-2f6bf8ccbcd5" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_910b49fb-2baa-44ac-b88b-2f6bf8ccbcd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9a137396-f41a-4ed8-a865-d057e9659668" xlink:href="ameh-20211231.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9a137396-f41a-4ed8-a865-d057e9659668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_aa81ab12-6f28-459a-a744-f83ea451a0d9" xlink:href="ameh-20211231.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_aa81ab12-6f28-459a-a744-f83ea451a0d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_339a22c4-5b90-4d84-abba-fe3ddecc79b4" xlink:href="ameh-20211231.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_339a22c4-5b90-4d84-abba-fe3ddecc79b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_ca5d0ee1-b5ca-4fb2-b455-6e5da16312a4" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_OneMSOLLCMember_ca5d0ee1-b5ca-4fb2-b455-6e5da16312a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_997cf6f6-222c-4c05-add3-da13a2a605cc" xlink:href="ameh-20211231.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_997cf6f6-222c-4c05-add3-da13a2a605cc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_3b9f1c2b-4e63-4dfc-94f2-e7855dc27a64" xlink:href="ameh-20211231.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_3b9f1c2b-4e63-4dfc-94f2-e7855dc27a64" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_fe2d0ecf-d53f-4f99-80f6-2be7bd6807fa" xlink:href="ameh-20211231.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_CAIPAMSOLLCMember_fe2d0ecf-d53f-4f99-80f6-2be7bd6807fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_96393eb2-6774-4015-b15f-44dde5232d89" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_dei_LegalEntityAxis_96393eb2-6774-4015-b15f-44dde5232d89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_96393eb2-6774-4015-b15f-44dde5232d89_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_96393eb2-6774-4015-b15f-44dde5232d89" xlink:to="loc_dei_EntityDomain_96393eb2-6774-4015-b15f-44dde5232d89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_96393eb2-6774-4015-b15f-44dde5232d89" xlink:to="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_f065fbb7-bf0c-4a43-9614-2233016098fa" xlink:href="ameh-20211231.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_ApcLsmaMember_f065fbb7-bf0c-4a43-9614-2233016098fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_b129a3de-7147-4b5e-81cd-cb8dcfe8a378" xlink:href="ameh-20211231.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_APCAndAPCLSMAMember_b129a3de-7147-4b5e-81cd-cb8dcfe8a378" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b828c75a-b6e2-483d-bfa1-6f67d195ab06" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b828c75a-b6e2-483d-bfa1-6f67d195ab06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_84fdc160-5450-47de-bcb2-ad9f6d48ce5e" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_84fdc160-5450-47de-bcb2-ad9f6d48ce5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_92e7df2f-2056-46af-9259-eebf1806b47e" xlink:href="ameh-20211231.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_92e7df2f-2056-46af-9259-eebf1806b47e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_317d1773-cc84-479f-b200-52f1d661e79b" xlink:href="ameh-20211231.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_317d1773-cc84-479f-b200-52f1d661e79b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6ce30174-c4c8-48bb-9c64-276972f2034a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_srt_OwnershipAxis_6ce30174-c4c8-48bb-9c64-276972f2034a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6ce30174-c4c8-48bb-9c64-276972f2034a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_6ce30174-c4c8-48bb-9c64-276972f2034a" xlink:to="loc_srt_OwnershipDomain_6ce30174-c4c8-48bb-9c64-276972f2034a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_6ce30174-c4c8-48bb-9c64-276972f2034a" xlink:to="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_661da10f-884d-47cd-aa3c-590cafc6c42d" xlink:href="ameh-20211231.xsd#ameh_MediPortalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:to="loc_ameh_MediPortalLLCMember_661da10f-884d-47cd-aa3c-590cafc6c42d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_8831fd7f-8606-4a44-b022-0312049cce4a" xlink:href="ameh-20211231.xsd#ameh_AchievaMedInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:to="loc_ameh_AchievaMedInc.Member_8831fd7f-8606-4a44-b022-0312049cce4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_5943751e-d88c-467c-836a-64bd71eaedaf" xlink:href="ameh-20211231.xsd#ameh_ContractTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_ameh_ContractTypeAxis_5943751e-d88c-467c-836a-64bd71eaedaf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_5943751e-d88c-467c-836a-64bd71eaedaf_default" xlink:href="ameh-20211231.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ContractTypeAxis_5943751e-d88c-467c-836a-64bd71eaedaf" xlink:to="loc_ameh_ContractTypeDomain_5943751e-d88c-467c-836a-64bd71eaedaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_b5d07f66-3e18-4219-a204-5f2da63001c7" xlink:href="ameh-20211231.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ContractTypeAxis_5943751e-d88c-467c-836a-64bd71eaedaf" xlink:to="loc_ameh_ContractTypeDomain_b5d07f66-3e18-4219-a204-5f2da63001c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_72ec3a75-e3d0-4741-9129-c5f7baa5a1c7" xlink:href="ameh-20211231.xsd#ameh_AncillaryServiceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ContractTypeDomain_b5d07f66-3e18-4219-a204-5f2da63001c7" xlink:to="loc_ameh_AncillaryServiceContractMember_72ec3a75-e3d0-4741-9129-c5f7baa5a1c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ade85dd7-35af-44af-b67e-315bedd6a5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ade85dd7-35af-44af-b67e-315bedd6a5be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ade85dd7-35af-44af-b67e-315bedd6a5be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ade85dd7-35af-44af-b67e-315bedd6a5be" xlink:to="loc_us-gaap_RelatedPartyDomain_ade85dd7-35af-44af-b67e-315bedd6a5be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_61882786-10f0-4d4f-ba20-661b2782ea2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ade85dd7-35af-44af-b67e-315bedd6a5be" xlink:to="loc_us-gaap_RelatedPartyDomain_61882786-10f0-4d4f-ba20-661b2782ea2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_60c97309-e65d-41b4-a34f-162c918b0b71" xlink:href="ameh-20211231.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_61882786-10f0-4d4f-ba20-661b2782ea2d" xlink:to="loc_ameh_Dr.ArteagaMember_60c97309-e65d-41b4-a34f-162c918b0b71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193" xlink:to="loc_us-gaap_ReceivableTypeDomain_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a5a7210e-3f93-4adf-8eed-d81d185dc6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193" xlink:to="loc_us-gaap_ReceivableTypeDomain_a5a7210e-3f93-4adf-8eed-d81d185dc6f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_04aa1f7f-ced3-4c0b-9ea8-a7d2d51cafdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a5a7210e-3f93-4adf-8eed-d81d185dc6f8" xlink:to="loc_us-gaap_NotesReceivableMember_04aa1f7f-ced3-4c0b-9ea8-a7d2d51cafdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended" id="i0581335aaf5e4262bc56e45c165ecb15_InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:to="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fa08c9a-1424-4188-9e6f-9effec256625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fa08c9a-1424-4188-9e6f-9effec256625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9e866609-d1a4-4869-ad75-f66da57570f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9e866609-d1a4-4869-ad75-f66da57570f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2fb673c7-df0a-4d07-8043-53edfe40b673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_OtherAssetsCurrent_2fb673c7-df0a-4d07-8043-53edfe40b673" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_40d07b13-dde8-46ae-abe3-cb82f89e089b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_40d07b13-dde8-46ae-abe3-cb82f89e089b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ebf54fa5-8ac8-4b01-ae8e-9afd4b955d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_RestrictedCashCurrent_ebf54fa5-8ac8-4b01-ae8e-9afd4b955d4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b9749a55-9549-4964-9fd4-9a51a659a313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_Assets_b9749a55-9549-4964-9fd4-9a51a659a313" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e80f4cbd-b89e-49c1-8fc0-031d57760d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:to="loc_us-gaap_LiabilitiesCurrent_e80f4cbd-b89e-49c1-8fc0-031d57760d7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c654e34-2ffc-4725-a145-0cc4a5a47f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c654e34-2ffc-4725-a145-0cc4a5a47f85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4baa3c6-1cca-4eb2-baa0-a1d4d21498b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4baa3c6-1cca-4eb2-baa0-a1d4d21498b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:to="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5e11797-c44e-4cd4-92b6-c2eeac7cb879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5e11797-c44e-4cd4-92b6-c2eeac7cb879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0fa68ad5-7323-4ced-aa39-d8b22e4dac89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_CostsAndExpenses_0fa68ad5-7323-4ced-aa39-d8b22e4dac89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7dd8be8f-85a2-47de-81d6-d600388cae80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_OperatingIncomeLoss_7dd8be8f-85a2-47de-81d6-d600388cae80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e9cfd57c-ce9e-4fa1-99c0-a2eee5673e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e9cfd57c-ce9e-4fa1-99c0-a2eee5673e71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a76092c0-4c13-491f-90ba-7e058bbc3266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_ProfitLoss_a76092c0-4c13-491f-90ba-7e058bbc3266" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ec7e4912-74e6-4f44-bc71-a9db5959c6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ec7e4912-74e6-4f44-bc71-a9db5959c6bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_99692d39-51c4-4f68-96c4-12fa116e9151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ec7e4912-74e6-4f44-bc71-a9db5959c6bc" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_99692d39-51c4-4f68-96c4-12fa116e9151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_99692d39-51c4-4f68-96c4-12fa116e9151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_99692d39-51c4-4f68-96c4-12fa116e9151" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_99692d39-51c4-4f68-96c4-12fa116e9151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_45a0c8af-456f-4a1c-81a7-e0c143e7c973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_99692d39-51c4-4f68-96c4-12fa116e9151" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_45a0c8af-456f-4a1c-81a7-e0c143e7c973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_61f33b46-56b3-4e46-99a6-042bd4eef1f0" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_45a0c8af-456f-4a1c-81a7-e0c143e7c973" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_61f33b46-56b3-4e46-99a6-042bd4eef1f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended" id="i59f8a3dab89f488db4398e8ba34b3dd8_LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_26efde99-5eab-41bb-992f-a748848ed7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_NotesReceivableNet_26efde99-5eab-41bb-992f-a748848ed7e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6362129a-81ca-411b-be29-1562ddd825d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6362129a-81ca-411b-be29-1562ddd825d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3f566849-d7ed-4ba8-8d5b-57b417d8fee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3f566849-d7ed-4ba8-8d5b-57b417d8fee6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_2d6c4995-b37a-4106-86ba-85d6c9ca60cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_NotesReceivableGross_2d6c4995-b37a-4106-86ba-85d6c9ca60cd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_8df974ef-4aee-4d94-87d6-91cd829d5949" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_8df974ef-4aee-4d94-87d6-91cd829d5949" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c95c3c6b-cf03-498f-b1be-7d609aab64f1" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c95c3c6b-cf03-498f-b1be-7d609aab64f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss_c7b78999-21ca-4a25-8333-f3ca8cd584de" xlink:href="ameh-20211231.xsd#ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss_c7b78999-21ca-4a25-8333-f3ca8cd584de" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss_e82c5425-9e50-47d9-8a85-c379bcf9d6b9" xlink:href="ameh-20211231.xsd#ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss_e82c5425-9e50-47d9-8a85-c379bcf9d6b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f" xlink:to="loc_us-gaap_ReceivableTypeDomain_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a0febdf4-f46d-4cd8-bebb-c8c0c5178803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f" xlink:to="loc_us-gaap_ReceivableTypeDomain_a0febdf4-f46d-4cd8-bebb-c8c0c5178803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_714d76b9-43ac-4b2e-b36b-fd42921711f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a0febdf4-f46d-4cd8-bebb-c8c0c5178803" xlink:to="loc_us-gaap_NotesReceivableMember_714d76b9-43ac-4b2e-b36b-fd42921711f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fdebb5df-ae10-41d8-90c6-7525a8860963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fdebb5df-ae10-41d8-90c6-7525a8860963" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fdebb5df-ae10-41d8-90c6-7525a8860963_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fdebb5df-ae10-41d8-90c6-7525a8860963" xlink:to="loc_us-gaap_RelatedPartyDomain_fdebb5df-ae10-41d8-90c6-7525a8860963_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fdebb5df-ae10-41d8-90c6-7525a8860963" xlink:to="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_0bf4f4b9-13a7-4c61-81cf-ce7f567f2206" xlink:href="ameh-20211231.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:to="loc_ameh_Pacific6EnterprisesMember_0bf4f4b9-13a7-4c61-81cf-ce7f567f2206" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_c405e09d-e672-4d1f-8018-2e690183ebd5" xlink:href="ameh-20211231.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:to="loc_ameh_AHMCMember_c405e09d-e672-4d1f-8018-2e690183ebd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b8eaf4cf-1818-41c2-b227-37bc0622d31e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_dei_LegalEntityAxis_b8eaf4cf-1818-41c2-b227-37bc0622d31e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b8eaf4cf-1818-41c2-b227-37bc0622d31e_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_b8eaf4cf-1818-41c2-b227-37bc0622d31e" xlink:to="loc_dei_EntityDomain_b8eaf4cf-1818-41c2-b227-37bc0622d31e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_b8eaf4cf-1818-41c2-b227-37bc0622d31e" xlink:to="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_08a2e582-8685-420a-90a3-53278b7709e3" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_NetworkMedicalManagementMember_08a2e582-8685-420a-90a3-53278b7709e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member_43eeeaf0-7e4d-4477-8b2a-4a6c49502aa1" xlink:href="ameh-20211231.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_HealthSourceMSOInc.Member_43eeeaf0-7e4d-4477-8b2a-4a6c49502aa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_2e213893-8a2e-479b-b0ff-3fe397b5d72f" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_2e213893-8a2e-479b-b0ff-3fe397b5d72f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b642a2ba-6144-4165-96c7-ce583eb6a8e7" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b642a2ba-6144-4165-96c7-ce583eb6a8e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_dbe4db5c-64e1-4a90-bfcb-27199bceb30d" xlink:href="ameh-20211231.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_Pacific6EnterprisesMember_dbe4db5c-64e1-4a90-bfcb-27199bceb30d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49129b71-4db7-4427-a766-a0f92071606d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49129b71-4db7-4427-a766-a0f92071606d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_49129b71-4db7-4427-a766-a0f92071606d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49129b71-4db7-4427-a766-a0f92071606d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_49129b71-4db7-4427-a766-a0f92071606d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6587a9ff-e54a-4fbb-9635-e075f72460f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49129b71-4db7-4427-a766-a0f92071606d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6587a9ff-e54a-4fbb-9635-e075f72460f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_afae9664-9b80-4638-932c-47634aed0290" xlink:href="ameh-20211231.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6587a9ff-e54a-4fbb-9635-e075f72460f2" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_afae9664-9b80-4638-932c-47634aed0290" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails" xlink:type="extended" id="i4cfdf56b4a2149829ebadc1cdc31b350_CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a9bed822-5a16-4f16-93eb-ca7e3357cee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a9bed822-5a16-4f16-93eb-ca7e3357cee3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_82fd0e55-6dc7-43d2-82ee-0ccf8cfbba84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_LongTermDebtCurrent_82fd0e55-6dc7-43d2-82ee-0ccf8cfbba84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9931dea0-0668-491e-90fd-d197ace2f511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9931dea0-0668-491e-90fd-d197ace2f511" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0c746a15-fa7c-4230-aae3-301e85a4b8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0c746a15-fa7c-4230-aae3-301e85a4b8c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6f665630-6550-40fa-b55e-30b02a4bf0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:to="loc_us-gaap_CreditFacilityAxis_6f665630-6550-40fa-b55e-30b02a4bf0cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6f665630-6550-40fa-b55e-30b02a4bf0cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6f665630-6550-40fa-b55e-30b02a4bf0cd" xlink:to="loc_us-gaap_CreditFacilityDomain_6f665630-6550-40fa-b55e-30b02a4bf0cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6f665630-6550-40fa-b55e-30b02a4bf0cd" xlink:to="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_0c9aa7ca-803d-4202-8c30-06072eb814a2" xlink:href="ameh-20211231.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:to="loc_ameh_TermLoanAMember_0c9aa7ca-803d-4202-8c30-06072eb814a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a4c16481-aeb0-4f49-bf88-9f300bc7a188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a4c16481-aeb0-4f49-bf88-9f300bc7a188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ae362d05-cc60-4ce0-a3cd-a9091fdda685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ae362d05-cc60-4ce0-a3cd-a9091fdda685" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ae362d05-cc60-4ce0-a3cd-a9091fdda685_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ae362d05-cc60-4ce0-a3cd-a9091fdda685" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ae362d05-cc60-4ce0-a3cd-a9091fdda685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ae362d05-cc60-4ce0-a3cd-a9091fdda685" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_8f6bce13-9e5f-49c6-884d-9705b99a8dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:to="loc_us-gaap_RealEstateLoanMember_8f6bce13-9e5f-49c6-884d-9705b99a8dfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_971beb58-e6cf-4949-8663-6aada69db170" xlink:href="ameh-20211231.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:to="loc_ameh_ConstructionLoanMember_971beb58-e6cf-4949-8663-6aada69db170" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail" xlink:type="extended" id="ibeff2dcf447b4c19a56918910239c8af_CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_b8c53eea-fa7b-4668-9ffb-a1028e0d2bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentTerm_b8c53eea-fa7b-4668-9ffb-a1028e0d2bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cbe69bcf-dd92-4c44-a45d-45e236e37637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cbe69bcf-dd92-4c44-a45d-45e236e37637" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_68a7a761-11bc-4d06-84da-953860df969b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_68a7a761-11bc-4d06-84da-953860df969b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0c4c7e9e-7201-4ad0-a87e-68ed20fe1d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0c4c7e9e-7201-4ad0-a87e-68ed20fe1d27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_d6261abb-6bef-4b2c-9572-20398d841bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_d6261abb-6bef-4b2c-9572-20398d841bd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_931ede27-50a2-41ab-93cc-b02460590597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_931ede27-50a2-41ab-93cc-b02460590597" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_4f6245c7-7cac-43bb-89db-ad3655f3d84a" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_4f6245c7-7cac-43bb-89db-ad3655f3d84a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_37b93273-936b-4e25-960a-6568e30fec6f" xlink:href="ameh-20211231.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_37b93273-936b-4e25-960a-6568e30fec6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0f2dab11-d053-471e-9d23-a999a0e3759f" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0f2dab11-d053-471e-9d23-a999a0e3759f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_60b33b8a-4208-4989-af26-5c2ff25c1f6a" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_60b33b8a-4208-4989-af26-5c2ff25c1f6a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_c8aeed63-29c4-4f46-b464-315fda534fc1" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_c8aeed63-29c4-4f46-b464-315fda534fc1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_5da27ebb-15c0-4fa7-82fb-41fdb5d0a68b" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_5da27ebb-15c0-4fa7-82fb-41fdb5d0a68b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0c404ee4-d96a-4167-9075-29178969b75e" xlink:href="ameh-20211231.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0c404ee4-d96a-4167-9075-29178969b75e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_18e658e8-0bb4-4e57-8140-1894f8f132a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LiabilitiesAssumed1_18e658e8-0bb4-4e57-8140-1894f8f132a5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4b404b7e-f4df-4c5c-a21d-1e6bad1c3dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4b404b7e-f4df-4c5c-a21d-1e6bad1c3dbe" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_93c75bbc-ee6d-466d-8079-87567b6d9d98" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_93c75bbc-ee6d-466d-8079-87567b6d9d98" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_22d027c2-99a5-4774-881f-5d84f2d2b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LongTermDebtCurrent_22d027c2-99a5-4774-881f-5d84f2d2b1a1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_28ae0cd3-88aa-4f58-a7f7-65e2b9175758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_28ae0cd3-88aa-4f58-a7f7-65e2b9175758" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_38823664-6f9c-4208-bc22-9980416b28a4" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_38823664-6f9c-4208-bc22-9980416b28a4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_ea8611da-20f3-49d1-a855-33651fe6a9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_ea8611da-20f3-49d1-a855-33651fe6a9ce" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ff42c780-615f-4eab-a38f-d586fecf45e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ff42c780-615f-4eab-a38f-d586fecf45e6" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_38bd6412-4cb4-4d33-9291-0ca152064e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_InterestExpense_38bd6412-4cb4-4d33-9291-0ca152064e42" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_730549b7-6650-42bb-89fa-82e0380b9d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCredit_730549b7-6650-42bb-89fa-82e0380b9d6b" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6e9c7654-1dd6-4a08-86ef-84ab2d3e7231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6e9c7654-1dd6-4a08-86ef-84ab2d3e7231" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_91020c84-3645-4ce6-8db5-e5274d648916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_91020c84-3645-4ce6-8db5-e5274d648916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_91020c84-3645-4ce6-8db5-e5274d648916_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_91020c84-3645-4ce6-8db5-e5274d648916" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_91020c84-3645-4ce6-8db5-e5274d648916_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_91020c84-3645-4ce6-8db5-e5274d648916" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_55dac4ed-67c9-4ac8-81d8-6b401e771d31" xlink:href="ameh-20211231.xsd#ameh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_CreditAgreementMember_55dac4ed-67c9-4ac8-81d8-6b401e771d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_5cae8bd2-9c8e-48f0-b9e6-f6e931f1f3f3" xlink:href="ameh-20211231.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_AmendedCreditAgreementMember_5cae8bd2-9c8e-48f0-b9e6-f6e931f1f3f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_db979d6c-a829-4043-98c3-282d71c27a43" xlink:href="ameh-20211231.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_ConstructionLoanMember_db979d6c-a829-4043-98c3-282d71c27a43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_4510ab99-6cdd-465b-808e-07e2c67cbca1" xlink:href="ameh-20211231.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_4510ab99-6cdd-465b-808e-07e2c67cbca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1e389d53-ff15-41d6-8b41-6713a6e086f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_CreditFacilityAxis_1e389d53-ff15-41d6-8b41-6713a6e086f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1e389d53-ff15-41d6-8b41-6713a6e086f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1e389d53-ff15-41d6-8b41-6713a6e086f0" xlink:to="loc_us-gaap_CreditFacilityDomain_1e389d53-ff15-41d6-8b41-6713a6e086f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1e389d53-ff15-41d6-8b41-6713a6e086f0" xlink:to="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_7ccb3802-23d3-44b0-9a94-6510822837ac" xlink:href="ameh-20211231.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_ameh_TermLoanAMember_7ccb3802-23d3-44b0-9a94-6510822837ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4eae27a8-4e1d-4fde-980a-7de9ae3aaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4eae27a8-4e1d-4fde-980a-7de9ae3aaf04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_63ca6411-269f-4cba-9d7b-ac37d5c77c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_LetterOfCreditMember_63ca6411-269f-4cba-9d7b-ac37d5c77c31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_d0d921da-d479-4ae4-b169-b80cb47b12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_BridgeLoanMember_d0d921da-d479-4ae4-b169-b80cb47b12a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a66a5483-2e2e-4517-93dd-b50d967dace0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_LineOfCreditMember_a66a5483-2e2e-4517-93dd-b50d967dace0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_1259cce7-b0ba-4f7e-a670-2377f1a27013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_1259cce7-b0ba-4f7e-a670-2377f1a27013" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1ce6de36-75db-418b-ba67-b188b9ce801e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1ce6de36-75db-418b-ba67-b188b9ce801e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1ce6de36-75db-418b-ba67-b188b9ce801e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1ce6de36-75db-418b-ba67-b188b9ce801e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1ce6de36-75db-418b-ba67-b188b9ce801e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1ce6de36-75db-418b-ba67-b188b9ce801e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_90a849ba-edcc-4d7e-85cd-96e254190183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:to="loc_us-gaap_LineOfCreditMember_90a849ba-edcc-4d7e-85cd-96e254190183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_d5d05b02-ba16-49f8-a396-34b4dc9703a3" xlink:href="ameh-20211231.xsd#ameh_ConstructionLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:to="loc_ameh_ConstructionLoanMember_d5d05b02-ba16-49f8-a396-34b4dc9703a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc360b68-51f4-4fc3-b567-e17f8f3efd56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_srt_RangeAxis_bc360b68-51f4-4fc3-b567-e17f8f3efd56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc360b68-51f4-4fc3-b567-e17f8f3efd56_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc360b68-51f4-4fc3-b567-e17f8f3efd56" xlink:to="loc_srt_RangeMember_bc360b68-51f4-4fc3-b567-e17f8f3efd56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc360b68-51f4-4fc3-b567-e17f8f3efd56" xlink:to="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87d05de6-8dc2-45aa-90ef-48c12d603d75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:to="loc_srt_MinimumMember_87d05de6-8dc2-45aa-90ef-48c12d603d75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e52e1f7-132e-4d80-b994-8fe1d6c97eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:to="loc_srt_MaximumMember_7e52e1f7-132e-4d80-b994-8fe1d6c97eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a8543069-1381-4043-8e7e-1040cb3b953b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_dei_LegalEntityAxis_a8543069-1381-4043-8e7e-1040cb3b953b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a8543069-1381-4043-8e7e-1040cb3b953b_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a8543069-1381-4043-8e7e-1040cb3b953b" xlink:to="loc_dei_EntityDomain_a8543069-1381-4043-8e7e-1040cb3b953b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a8543069-1381-4043-8e7e-1040cb3b953b" xlink:to="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9b6b1261-ff0f-4a84-9d52-116fec92dd8b" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9b6b1261-ff0f-4a84-9d52-116fec92dd8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_22a58f56-694c-4c9a-945c-088ec4f9de17" xlink:href="ameh-20211231.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_22a58f56-694c-4c9a-945c-088ec4f9de17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_2321939d-42a0-4477-a271-fbd6e3dcca99" xlink:href="ameh-20211231.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_AMGPropertiesLLCMember_2321939d-42a0-4477-a271-fbd6e3dcca99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_32c1e309-458e-4a2b-b1b3-f593caaac6af" xlink:href="ameh-20211231.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_ZLLPartnersLLCMember_32c1e309-458e-4a2b-b1b3-f593caaac6af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_1a6cb1c7-979f-4e20-b488-6760ef523f2c" xlink:href="ameh-20211231.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_1a6cb1c7-979f-4e20-b488-6760ef523f2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_96a4aca5-e131-4c8d-a142-c263296c5c05" xlink:href="ameh-20211231.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_ApaacoMember_96a4aca5-e131-4c8d-a142-c263296c5c05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_834770b5-6403-4875-afa8-e48e835517af" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_834770b5-6403-4875-afa8-e48e835517af" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5dccdb39-1f06-49d2-be30-228a2acef015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_VariableRateAxis_5dccdb39-1f06-49d2-be30-228a2acef015" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5dccdb39-1f06-49d2-be30-228a2acef015_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_5dccdb39-1f06-49d2-be30-228a2acef015" xlink:to="loc_us-gaap_VariableRateDomain_5dccdb39-1f06-49d2-be30-228a2acef015_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_5dccdb39-1f06-49d2-be30-228a2acef015" xlink:to="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_713b168f-d97e-4718-bee6-5edb7a9fc872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_713b168f-d97e-4718-bee6-5edb7a9fc872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_9ccd1cde-1d0e-4f4f-9fb8-2b14f1d2d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:to="loc_us-gaap_PrimeRateMember_9ccd1cde-1d0e-4f4f-9fb8-2b14f1d2d9eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0db04210-b3bf-4bd1-b19a-27a9a77a9899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0db04210-b3bf-4bd1-b19a-27a9a77a9899" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_25cf9406-9c53-4117-9e87-8fc234630313" xlink:href="ameh-20211231.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0db04210-b3bf-4bd1-b19a-27a9a77a9899" xlink:to="loc_ameh_PreferredBankMember_25cf9406-9c53-4117-9e87-8fc234630313" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c5a7bacd-83a8-4bbd-bdd8-7213d206374c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c5a7bacd-83a8-4bbd-bdd8-7213d206374c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c5a7bacd-83a8-4bbd-bdd8-7213d206374c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c5a7bacd-83a8-4bbd-bdd8-7213d206374c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c5a7bacd-83a8-4bbd-bdd8-7213d206374c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c5a7bacd-83a8-4bbd-bdd8-7213d206374c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_39e1ca75-04a5-4e01-a275-20f9324c75ce" xlink:href="ameh-20211231.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_39e1ca75-04a5-4e01-a275-20f9324c75ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_1159287a-d5b4-4b67-91bd-da0a8d58a62f" xlink:href="ameh-20211231.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:to="loc_ameh_AMGPropertiesLLCMember_1159287a-d5b4-4b67-91bd-da0a8d58a62f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_35491eab-aa73-4389-9854-14b860dc3fa0" xlink:href="ameh-20211231.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:to="loc_ameh_ZLLPartnersLLCMember_35491eab-aa73-4389-9854-14b860dc3fa0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1091335b-f737-4b89-9737-71117a310a85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_srt_StatementScenarioAxis_1091335b-f737-4b89-9737-71117a310a85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_1091335b-f737-4b89-9737-71117a310a85_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_1091335b-f737-4b89-9737-71117a310a85" xlink:to="loc_srt_ScenarioUnspecifiedDomain_1091335b-f737-4b89-9737-71117a310a85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6344e0a3-7709-474d-9c49-897ca3155312" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_1091335b-f737-4b89-9737-71117a310a85" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6344e0a3-7709-474d-9c49-897ca3155312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4538b5d0-b0d1-4706-862f-23c4f37bb582" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6344e0a3-7709-474d-9c49-897ca3155312" xlink:to="loc_srt_ScenarioForecastMember_4538b5d0-b0d1-4706-862f-23c4f37bb582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_82883669-84e4-4130-82ff-da6cf4281f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_82883669-84e4-4130-82ff-da6cf4281f56" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_82883669-84e4-4130-82ff-da6cf4281f56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82883669-84e4-4130-82ff-da6cf4281f56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_82883669-84e4-4130-82ff-da6cf4281f56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0b88f8d3-dbd1-49ec-8ef3-96bce9ec349e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82883669-84e4-4130-82ff-da6cf4281f56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0b88f8d3-dbd1-49ec-8ef3-96bce9ec349e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_80c6709e-0140-4c78-8394-21c02194412e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0b88f8d3-dbd1-49ec-8ef3-96bce9ec349e" xlink:to="loc_us-gaap_SubsequentEventMember_80c6709e-0140-4c78-8394-21c02194412e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="ie396916d2a99442487b0e7b153523b21_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_69c8a5b4-767d-4b7a-bae4-ae03b018b57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_OperatingLossCarryforwards_69c8a5b4-767d-4b7a-bae4-ae03b018b57e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OperatingLossCarryforwardsExpirationPeriod_542b2196-ac41-4c38-8a5f-561f6dccc571" xlink:href="ameh-20211231.xsd#ameh_OperatingLossCarryforwardsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_ameh_OperatingLossCarryforwardsExpirationPeriod_542b2196-ac41-4c38-8a5f-561f6dccc571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OperatingLossCarryforwardsNotSubjectToExpiration_a49f311b-2848-4b54-835f-db8e5738f93b" xlink:href="ameh-20211231.xsd#ameh_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_ameh_OperatingLossCarryforwardsNotSubjectToExpiration_a49f311b-2848-4b54-835f-db8e5738f93b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9cddf629-3d99-4164-83ac-0de64242a5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9cddf629-3d99-4164-83ac-0de64242a5dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_dac00239-c21b-47d5-b6a0-8ed9d0d93267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_dac00239-c21b-47d5-b6a0-8ed9d0d93267" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2718e8ff-348a-436a-9c00-0246fd0f6dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2718e8ff-348a-436a-9c00-0246fd0f6dbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_8116bf85-568b-4c43-b36f-00d18ff8f90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_8116bf85-568b-4c43-b36f-00d18ff8f90e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_8116bf85-568b-4c43-b36f-00d18ff8f90e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_8116bf85-568b-4c43-b36f-00d18ff8f90e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_8116bf85-568b-4c43-b36f-00d18ff8f90e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_8116bf85-568b-4c43-b36f-00d18ff8f90e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bb137867-e315-4db3-9817-f401716b9f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:to="loc_us-gaap_DomesticCountryMember_bb137867-e315-4db3-9817-f401716b9f29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_4bbc303a-9b01-4b43-b89a-d0cd8fc13144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_4bbc303a-9b01-4b43-b89a-d0cd8fc13144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_647c6396-71fc-453e-a70b-ff6faf60bc24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:to="loc_srt_RangeAxis_647c6396-71fc-453e-a70b-ff6faf60bc24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_647c6396-71fc-453e-a70b-ff6faf60bc24_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_647c6396-71fc-453e-a70b-ff6faf60bc24" xlink:to="loc_srt_RangeMember_647c6396-71fc-453e-a70b-ff6faf60bc24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_647c6396-71fc-453e-a70b-ff6faf60bc24" xlink:to="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65b00812-1041-4848-ba83-bab34e394079" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:to="loc_srt_MinimumMember_65b00812-1041-4848-ba83-bab34e394079" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9a3c2d51-ca2b-47d2-a22e-9869d8b53572" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:to="loc_srt_MaximumMember_9a3c2d51-ca2b-47d2-a22e-9869d8b53572" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="ib1d2d45676b74e8395ce0bcd2830247f_MezzanineandStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5f1b442-5208-440d-8e28-25963e3c55e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5f1b442-5208-440d-8e28-25963e3c55e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d2c7b8d-2bce-484e-90d8-46ff24257e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d2c7b8d-2bce-484e-90d8-46ff24257e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_001f0540-6ba4-4993-a935-9d33cffc3977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_001f0540-6ba4-4993-a935-9d33cffc3977" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff52ed46-85eb-4967-86ec-0df36813aeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff52ed46-85eb-4967-86ec-0df36813aeb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_7ae01c20-8b75-49a0-bc85-1b3adf34aaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_7ae01c20-8b75-49a0-bc85-1b3adf34aaa9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfSharesHoldbackPercentage_01bc1134-c382-47be-8f73-9ec8e78b9cf6" xlink:href="ameh-20211231.xsd#ameh_NumberOfSharesHoldbackPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_NumberOfSharesHoldbackPercentage_01bc1134-c382-47be-8f73-9ec8e78b9cf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d5babbc-f7b4-4fc3-b415-07a7f014a44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d5babbc-f7b4-4fc3-b415-07a7f014a44b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationNumberOfSharesHeldBack_d73c0ab5-2d11-4ca8-a7a1-590a8c803a87" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationNumberOfSharesHeldBack"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_BusinessCombinationNumberOfSharesHeldBack_d73c0ab5-2d11-4ca8-a7a1-590a8c803a87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_350521b8-2a55-4602-9848-c460efc8ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_350521b8-2a55-4602-9848-c460efc8ca95" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_76065cd3-aa37-4a28-9a5f-dd4e9d27f753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_SharesIssued_76065cd3-aa37-4a28-9a5f-dd4e9d27f753" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodShareConversionOfNotes_c26784c0-628b-4993-b133-509b1b2c1107" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodShareConversionOfNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_StockIssuedDuringPeriodShareConversionOfNotes_c26784c0-628b-4993-b133-509b1b2c1107" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueConversionOfNotes_2ce57593-d1b6-4f08-8273-5db4c2faaa63" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueConversionOfNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_StockIssuedDuringPeriodValueConversionOfNotes_2ce57593-d1b6-4f08-8273-5db4c2faaa63" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_4ac79b58-cd5b-452d-b38f-184e82deae8a" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_4ac79b58-cd5b-452d-b38f-184e82deae8a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_52a80a36-289b-4b38-bea8-1db91267e119" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_076e3179-8f83-4acd-bb81-dc8f63125599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_076e3179-8f83-4acd-bb81-dc8f63125599" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_03361234-c61f-4a64-be84-234b1b0ba5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_TreasuryStockCommonShares_03361234-c61f-4a64-be84-234b1b0ba5ab" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8ba35598-b287-4536-b3b0-aa15b107dbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_TreasuryStockValue_8ba35598-b287-4536-b3b0-aa15b107dbf7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2286adb6-9dba-492a-b712-4f081e1a7fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2286adb6-9dba-492a-b712-4f081e1a7fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2286adb6-9dba-492a-b712-4f081e1a7fcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2286adb6-9dba-492a-b712-4f081e1a7fcb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2286adb6-9dba-492a-b712-4f081e1a7fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0cea1e2-9c5e-44a0-b4e6-7bdb72c6ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2286adb6-9dba-492a-b712-4f081e1a7fcb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0cea1e2-9c5e-44a0-b4e6-7bdb72c6ccd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_a11f51c8-7abe-4bbb-afa9-3865e9d4f925" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0cea1e2-9c5e-44a0-b4e6-7bdb72c6ccd2" xlink:to="loc_ameh_NetworkMedicalManagementMember_a11f51c8-7abe-4bbb-afa9-3865e9d4f925" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5c72019f-322e-4214-86a9-b62061c54c32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_dei_LegalEntityAxis_5c72019f-322e-4214-86a9-b62061c54c32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5c72019f-322e-4214-86a9-b62061c54c32_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5c72019f-322e-4214-86a9-b62061c54c32" xlink:to="loc_dei_EntityDomain_5c72019f-322e-4214-86a9-b62061c54c32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5c72019f-322e-4214-86a9-b62061c54c32" xlink:to="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_51b5646c-323a-4ec1-a8a6-8a20c30e32be" xlink:href="ameh-20211231.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_APAMHMedicalCorporationMember_51b5646c-323a-4ec1-a8a6-8a20c30e32be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_95db36c7-72a3-4be3-9f21-4363ddf350c9" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_95db36c7-72a3-4be3-9f21-4363ddf350c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_175e88fd-1223-4882-9f6b-98de6266b0b8" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_NetworkMedicalManagementMember_175e88fd-1223-4882-9f6b-98de6266b0b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_c79e0fdc-a5bc-4a43-8ca2-4b91ce3c4cdf" xlink:href="ameh-20211231.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_CDSCMember_c79e0fdc-a5bc-4a43-8ca2-4b91ce3c4cdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baf345c8-c5f8-492a-9ebb-82c37497434b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baf345c8-c5f8-492a-9ebb-82c37497434b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_baf345c8-c5f8-492a-9ebb-82c37497434b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baf345c8-c5f8-492a-9ebb-82c37497434b" xlink:to="loc_us-gaap_RelatedPartyDomain_baf345c8-c5f8-492a-9ebb-82c37497434b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fc33eea4-95e8-4715-8979-e974971f5beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baf345c8-c5f8-492a-9ebb-82c37497434b" xlink:to="loc_us-gaap_RelatedPartyDomain_fc33eea4-95e8-4715-8979-e974971f5beb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8273a123-adb9-440c-b59d-a38960927e89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_fc33eea4-95e8-4715-8979-e974971f5beb" xlink:to="loc_srt_AffiliatedEntityMember_8273a123-adb9-440c-b59d-a38960927e89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6a8bbc04-fe67-4442-bc12-04116ae578f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6a8bbc04-fe67-4442-bc12-04116ae578f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6a8bbc04-fe67-4442-bc12-04116ae578f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6a8bbc04-fe67-4442-bc12-04116ae578f8" xlink:to="loc_us-gaap_ClassOfStockDomain_6a8bbc04-fe67-4442-bc12-04116ae578f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6a8bbc04-fe67-4442-bc12-04116ae578f8" xlink:to="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_50b03cb9-8b43-4f90-87e8-1205e95dc799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_50b03cb9-8b43-4f90-87e8-1205e95dc799" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_d2245353-eb6e-4827-85b4-5d93de609d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_d2245353-eb6e-4827-85b4-5d93de609d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_12d43325-380e-4e3c-aa5f-91c8741cda7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_srt_TitleOfIndividualAxis_12d43325-380e-4e3c-aa5f-91c8741cda7e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_12d43325-380e-4e3c-aa5f-91c8741cda7e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_12d43325-380e-4e3c-aa5f-91c8741cda7e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_12d43325-380e-4e3c-aa5f-91c8741cda7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f534f8b-cfdb-4305-bdeb-dcdd79f7a0f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_12d43325-380e-4e3c-aa5f-91c8741cda7e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f534f8b-cfdb-4305-bdeb-dcdd79f7a0f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FormerShareholdersOfNmmMember_6bfbc6ef-4245-4e69-809a-8b89d8f00783" xlink:href="ameh-20211231.xsd#ameh_FormerShareholdersOfNmmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f534f8b-cfdb-4305-bdeb-dcdd79f7a0f8" xlink:to="loc_ameh_FormerShareholdersOfNmmMember_6bfbc6ef-4245-4e69-809a-8b89d8f00783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c32169ac-cc08-4dd5-b751-850cff4a9b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c32169ac-cc08-4dd5-b751-850cff4a9b42" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c32169ac-cc08-4dd5-b751-850cff4a9b42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c32169ac-cc08-4dd5-b751-850cff4a9b42" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c32169ac-cc08-4dd5-b751-850cff4a9b42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_033372a2-4746-4301-aa4c-92fada388d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c32169ac-cc08-4dd5-b751-850cff4a9b42" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_033372a2-4746-4301-aa4c-92fada388d31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e6b93725-c674-4a91-9363-cee85601f100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_033372a2-4746-4301-aa4c-92fada388d31" xlink:to="loc_us-gaap_PrivatePlacementMember_e6b93725-c674-4a91-9363-cee85601f100" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dc8d539a-32c8-4158-bf51-d137546d19a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dc8d539a-32c8-4158-bf51-d137546d19a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dc8d539a-32c8-4158-bf51-d137546d19a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dc8d539a-32c8-4158-bf51-d137546d19a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dc8d539a-32c8-4158-bf51-d137546d19a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dc8d539a-32c8-4158-bf51-d137546d19a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Warrant1Member_429415fe-f0dd-4420-b16a-f7b43223ef02" xlink:href="ameh-20211231.xsd#ameh_Warrant1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:to="loc_ameh_Warrant1Member_429415fe-f0dd-4420-b16a-f7b43223ef02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Warrant2Member_5e5f6a52-ee93-49eb-85b1-bdbc169a8d02" xlink:href="ameh-20211231.xsd#ameh_Warrant2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:to="loc_ameh_Warrant2Member_5e5f6a52-ee93-49eb-85b1-bdbc169a8d02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_fd547e98-0875-4e24-b6ab-292f8c07eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_VestingAxis_fd547e98-0875-4e24-b6ab-292f8c07eb7a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_fd547e98-0875-4e24-b6ab-292f8c07eb7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_fd547e98-0875-4e24-b6ab-292f8c07eb7a" xlink:to="loc_us-gaap_VestingDomain_fd547e98-0875-4e24-b6ab-292f8c07eb7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_57195727-5078-4c86-94c2-c3872fac0857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_fd547e98-0875-4e24-b6ab-292f8c07eb7a" xlink:to="loc_us-gaap_VestingDomain_57195727-5078-4c86-94c2-c3872fac0857" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7bb6700a-1ad8-443b-b856-f32f21a6676a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_57195727-5078-4c86-94c2-c3872fac0857" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7bb6700a-1ad8-443b-b856-f32f21a6676a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_srt_CounterpartyNameAxis_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b26de6a-fcbe-4083-ad98-4e95e46edabd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b26de6a-fcbe-4083-ad98-4e95e46edabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_1f98aa49-e240-434a-8993-8217d2ff7769" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b26de6a-fcbe-4083-ad98-4e95e46edabd" xlink:to="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_1f98aa49-e240-434a-8993-8217d2ff7769" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended" id="ib0c7a7df823143efa87831051f78764c_StockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b21dd8a5-7579-4daa-9029-057baa28c3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b21dd8a5-7579-4daa-9029-057baa28c3a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94535b1e-ad7e-47d2-b013-6ceb17c78ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94535b1e-ad7e-47d2-b013-6ceb17c78ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d1799c61-ca49-4619-b4b3-20e38dd0afba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d1799c61-ca49-4619-b4b3-20e38dd0afba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17308e19-b07c-4478-a840-db4560939416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17308e19-b07c-4478-a840-db4560939416" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e8e0038-cabd-4c8b-9339-ef45e593f5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e8e0038-cabd-4c8b-9339-ef45e593f5c6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a4aa1d01-e492-4564-bb18-c5f78b9a96e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a4aa1d01-e492-4564-bb18-c5f78b9a96e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_5801564f-f42b-4761-9ebe-6b5fe6e9a558" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_5801564f-f42b-4761-9ebe-6b5fe6e9a558" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fc916fd-be90-4d0d-99d7-1e0c0cad726e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fc916fd-be90-4d0d-99d7-1e0c0cad726e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43721a4c-7a04-432f-ac7a-de71e8f73142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43721a4c-7a04-432f-ac7a-de71e8f73142" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d507d4c6-2c81-4444-b637-333046fbda38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d507d4c6-2c81-4444-b637-333046fbda38" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3ec8dd33-ac3e-4ef6-b2ea-f056d0d5f314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3ec8dd33-ac3e-4ef6-b2ea-f056d0d5f314" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0872b8ca-d80a-472a-940c-5d17cae4b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0872b8ca-d80a-472a-940c-5d17cae4b6a2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_312cc940-faa4-43ae-85cc-52cc0dd98d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_312cc940-faa4-43ae-85cc-52cc0dd98d4c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_794f72ab-6b48-420b-b5de-f6828c5f2266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_794f72ab-6b48-420b-b5de-f6828c5f2266" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2c847da0-2fc8-42d3-89cd-a4a7f4e6c53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2c847da0-2fc8-42d3-89cd-a4a7f4e6c53a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d2dacb-ab8e-4467-ba35-3bae944c531e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d2dacb-ab8e-4467-ba35-3bae944c531e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d8f7888d-717e-4707-9122-100ab8a50bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d8f7888d-717e-4707-9122-100ab8a50bec" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_eed80894-9b2c-4b7b-995a-ab8852dce32b" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_eed80894-9b2c-4b7b-995a-ab8852dce32b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_6e55e2e1-e4ee-4bdc-b32b-fe4ce9699c6d" xlink:href="ameh-20211231.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_6e55e2e1-e4ee-4bdc-b32b-fe4ce9699c6d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_e247d757-1ad9-4af6-81e5-d198cb558c6c" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_e247d757-1ad9-4af6-81e5-d198cb558c6c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_239cc4b7-123c-459b-b8f3-98a8fba6c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_PlanNameAxis_239cc4b7-123c-459b-b8f3-98a8fba6c00a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_239cc4b7-123c-459b-b8f3-98a8fba6c00a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_239cc4b7-123c-459b-b8f3-98a8fba6c00a" xlink:to="loc_us-gaap_PlanNameDomain_239cc4b7-123c-459b-b8f3-98a8fba6c00a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_239cc4b7-123c-459b-b8f3-98a8fba6c00a" xlink:to="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityIncentivePlanTwentyThirteenMember_a731f185-7143-45e8-8a82-323117c955c3" xlink:href="ameh-20211231.xsd#ameh_EquityIncentivePlanTwentyThirteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:to="loc_ameh_EquityIncentivePlanTwentyThirteenMember_a731f185-7143-45e8-8a82-323117c955c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityIncentivePlanTwentyFifteenMember_a1e3b3ef-00cc-45ac-bbbc-31ed023ff3b2" xlink:href="ameh-20211231.xsd#ameh_EquityIncentivePlanTwentyFifteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:to="loc_ameh_EquityIncentivePlanTwentyFifteenMember_a1e3b3ef-00cc-45ac-bbbc-31ed023ff3b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_AwardTypeAxis_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2dca495a-a0c9-4318-88cb-d27a71f10305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2dca495a-a0c9-4318-88cb-d27a71f10305" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e99aa168-972e-454b-ad13-e290190dde67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:to="loc_us-gaap_RestrictedStockMember_e99aa168-972e-454b-ad13-e290190dde67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9a3970a0-7339-49eb-bb13-fdce07debde8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_srt_TitleOfIndividualAxis_9a3970a0-7339-49eb-bb13-fdce07debde8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9a3970a0-7339-49eb-bb13-fdce07debde8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_9a3970a0-7339-49eb-bb13-fdce07debde8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9a3970a0-7339-49eb-bb13-fdce07debde8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_9a3970a0-7339-49eb-bb13-fdce07debde8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_e9a946d5-842c-457a-980b-3ca8c61448b0" xlink:href="ameh-20211231.xsd#ameh_ApcStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:to="loc_ameh_ApcStockOptionMember_e9a946d5-842c-457a-980b-3ca8c61448b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:href="ameh-20211231.xsd#ameh_ExecutiveOfficerAndDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:to="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_173e8d6d-330f-4e5a-b916-aecb6aeba7cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:to="loc_srt_DirectorMember_173e8d6d-330f-4e5a-b916-aecb6aeba7cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_4018ed38-15c8-4708-a7c6-db41168578b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:to="loc_srt_ExecutiveOfficerMember_4018ed38-15c8-4708-a7c6-db41168578b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1be13737-b795-4fad-ab51-dfdef111a8ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_srt_RangeAxis_1be13737-b795-4fad-ab51-dfdef111a8ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1be13737-b795-4fad-ab51-dfdef111a8ea_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1be13737-b795-4fad-ab51-dfdef111a8ea" xlink:to="loc_srt_RangeMember_1be13737-b795-4fad-ab51-dfdef111a8ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1be13737-b795-4fad-ab51-dfdef111a8ea" xlink:to="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_668263b6-c208-4be1-9f39-5054adbfb42c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:to="loc_srt_MinimumMember_668263b6-c208-4be1-9f39-5054adbfb42c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ce82fef-fe54-49c1-957a-c9f86c140c2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:to="loc_srt_MaximumMember_0ce82fef-fe54-49c1-957a-c9f86c140c2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd144b93-b102-4a80-80ae-dc81a36eb814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd144b93-b102-4a80-80ae-dc81a36eb814" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd144b93-b102-4a80-80ae-dc81a36eb814_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd144b93-b102-4a80-80ae-dc81a36eb814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cd144b93-b102-4a80-80ae-dc81a36eb814_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e33f324-9cd0-41ea-b835-33b66d9cb7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd144b93-b102-4a80-80ae-dc81a36eb814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e33f324-9cd0-41ea-b835-33b66d9cb7b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4a2b82b2-1451-4cee-b1ef-5cbd3e082114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e33f324-9cd0-41ea-b835-33b66d9cb7b8" xlink:to="loc_us-gaap_PrivatePlacementMember_4a2b82b2-1451-4cee-b1ef-5cbd3e082114" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c" xlink:to="loc_us-gaap_ClassOfStockDomain_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c" xlink:to="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_14f86bfe-91af-4822-9e5c-8fafcabc4390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_14f86bfe-91af-4822-9e5c-8fafcabc4390" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eff8e550-e33e-48b7-a297-788d42b75ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:to="loc_us-gaap_CommonStockMember_eff8e550-e33e-48b7-a297-788d42b75ace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A11CommonStockWarrantsMember_ec7aba59-4ffe-4fd2-9085-d87c6b90d6fa" xlink:href="ameh-20211231.xsd#ameh_A11CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:to="loc_ameh_A11CommonStockWarrantsMember_ec7aba59-4ffe-4fd2-9085-d87c6b90d6fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A10CommonStockWarrantsMember_2d0857f4-e9cb-49d3-b4e8-d06b78840df0" xlink:href="ameh-20211231.xsd#ameh_A10CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:to="loc_ameh_A10CommonStockWarrantsMember_2d0857f4-e9cb-49d3-b4e8-d06b78840df0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" id="i56275c9f36894e07a322cecfe68046c6_StockBasedCompensationShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_016abb40-4aed-4ed3-911d-d2ad9c8a6b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b5f8158a-2b14-4392-8039-982e918b3cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_016abb40-4aed-4ed3-911d-d2ad9c8a6b82" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b5f8158a-2b14-4392-8039-982e918b3cd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_016abb40-4aed-4ed3-911d-d2ad9c8a6b82" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_663cb67e-7fe7-448d-a76b-351ebe4f3bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:to="loc_us-gaap_AwardTypeAxis_663cb67e-7fe7-448d-a76b-351ebe4f3bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_663cb67e-7fe7-448d-a76b-351ebe4f3bc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_663cb67e-7fe7-448d-a76b-351ebe4f3bc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_663cb67e-7fe7-448d-a76b-351ebe4f3bc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_663cb67e-7fe7-448d-a76b-351ebe4f3bc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6f6ea9da-e3c9-4670-93e2-10d3052d3391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6f6ea9da-e3c9-4670-93e2-10d3052d3391" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_f735cc9b-e90e-415b-a8b3-474bef69315b" xlink:href="ameh-20211231.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:to="loc_ameh_StockAwardsAndUnitsMember_f735cc9b-e90e-415b-a8b3-474bef69315b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:to="loc_dei_LegalEntityAxis_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911" xlink:to="loc_dei_EntityDomain_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_17e0c1ff-4623-4ac8-a6d6-7fd2118aa18b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911" xlink:to="loc_dei_EntityDomain_17e0c1ff-4623-4ac8-a6d6-7fd2118aa18b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_3a99d8d4-2519-43cf-abff-193998fe4305" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_17e0c1ff-4623-4ac8-a6d6-7fd2118aa18b" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_3a99d8d4-2519-43cf-abff-193998fe4305" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended" id="i748379ee45f345c794751f32fffb4198_StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9800b1c-7c51-4111-a9bc-0bb0a000456f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9800b1c-7c51-4111-a9bc-0bb0a000456f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee771886-7326-474a-8220-496d0bc54468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee771886-7326-474a-8220-496d0bc54468" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f2487194-8769-4e20-970f-45ae1a5633f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f2487194-8769-4e20-970f-45ae1a5633f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_515c7469-c6df-4878-82f4-b066d9aee789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_SharePrice_515c7469-c6df-4878-82f4-b066d9aee789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_723edbbb-de3c-414b-b530-d62c8516eb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_723edbbb-de3c-414b-b530-d62c8516eb05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_235814c0-d8be-47f4-b633-8835f50ae671" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_235814c0-d8be-47f4-b633-8835f50ae671" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_468cb248-6221-4083-904d-9be990c5584e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:to="loc_srt_TitleOfIndividualAxis_468cb248-6221-4083-904d-9be990c5584e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_468cb248-6221-4083-904d-9be990c5584e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_468cb248-6221-4083-904d-9be990c5584e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_468cb248-6221-4083-904d-9be990c5584e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fa5f4ec7-ea0f-4a4c-b231-82b6842fe57d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_468cb248-6221-4083-904d-9be990c5584e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fa5f4ec7-ea0f-4a4c-b231-82b6842fe57d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_6e0466de-2fec-4bdc-938c-bcf0319dab0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fa5f4ec7-ea0f-4a4c-b231-82b6842fe57d" xlink:to="loc_srt_ExecutiveOfficerMember_6e0466de-2fec-4bdc-938c-bcf0319dab0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e306e7f-c428-493d-b38f-d2bf194c6d48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:to="loc_srt_RangeAxis_7e306e7f-c428-493d-b38f-d2bf194c6d48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7e306e7f-c428-493d-b38f-d2bf194c6d48_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7e306e7f-c428-493d-b38f-d2bf194c6d48" xlink:to="loc_srt_RangeMember_7e306e7f-c428-493d-b38f-d2bf194c6d48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7e306e7f-c428-493d-b38f-d2bf194c6d48" xlink:to="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aeea8c57-5c7f-44f6-aa76-64e45f523b99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:to="loc_srt_MinimumMember_aeea8c57-5c7f-44f6-aa76-64e45f523b99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_202cf3ea-d479-4a4e-836d-2eef5950b17c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:to="loc_srt_MaximumMember_202cf3ea-d479-4a4e-836d-2eef5950b17c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended" id="i666434a026ef4ff190e482f444aa1a31_StockBasedCompensationSummaryofRestrictedStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a1a78a5-e223-4dd3-a70c-2b9dfcbce5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a1a78a5-e223-4dd3-a70c-2b9dfcbce5b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f58b4251-db47-4593-ac59-585ff8671e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f58b4251-db47-4593-ac59-585ff8671e6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_52541f37-b94f-4f13-9f99-071c448d6d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_52541f37-b94f-4f13-9f99-071c448d6d6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_31b37260-c740-46db-bcda-f811f806a646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_31b37260-c740-46db-bcda-f811f806a646" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65d9acb3-242b-49d7-b757-3a1b91cbd5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2eef2898-6f83-45be-a887-14b528f69cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2eef2898-6f83-45be-a887-14b528f69cee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43e5ab23-fa43-4153-9309-7344e0a4feb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43e5ab23-fa43-4153-9309-7344e0a4feb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1fb7e0d6-61fe-414a-ab99-30e92264f1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1fb7e0d6-61fe-414a-ab99-30e92264f1d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d8e74e00-1d9a-4e58-a76c-620166b5e475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d8e74e00-1d9a-4e58-a76c-620166b5e475" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d9c464c-cf92-434b-bc5d-35d4b5ea61b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d50c34-1a09-422a-a450-b43b87579b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d50c34-1a09-422a-a450-b43b87579b0f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d4052f7-50ea-4006-8008-b4ba9e966666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d50c34-1a09-422a-a450-b43b87579b0f" xlink:to="loc_us-gaap_AwardTypeAxis_8d4052f7-50ea-4006-8008-b4ba9e966666" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d4052f7-50ea-4006-8008-b4ba9e966666_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8d4052f7-50ea-4006-8008-b4ba9e966666" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8d4052f7-50ea-4006-8008-b4ba9e966666_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b792cdd8-4b8d-44ee-94fa-da73762ecc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8d4052f7-50ea-4006-8008-b4ba9e966666" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b792cdd8-4b8d-44ee-94fa-da73762ecc78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6c9b67b-09a8-4675-8769-68d5cc8eb5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b792cdd8-4b8d-44ee-94fa-da73762ecc78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6c9b67b-09a8-4675-8769-68d5cc8eb5ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended" id="id6c0c8bd20ad4a619e47f85950a55235_StockBasedCompensationWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19ccad05-a189-46fb-8756-fb29f31c5b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19ccad05-a189-46fb-8756-fb29f31c5b34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2de95536-625e-40c5-b2a0-e6bc51aa4d4d" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2de95536-625e-40c5-b2a0-e6bc51aa4d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_683669f0-92c7-4926-910a-6f21b102620f" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_683669f0-92c7-4926-910a-6f21b102620f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_d1cea37a-8c1e-43dc-ac6d-30bdfd1bea76" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_d1cea37a-8c1e-43dc-ac6d-30bdfd1bea76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3b297759-3322-4ae8-b024-65f1f28e5795" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3b297759-3322-4ae8-b024-65f1f28e5795" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9757a70a-67e0-4090-b2ee-70b2896524c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9757a70a-67e0-4090-b2ee-70b2896524c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9757a70a-67e0-4090-b2ee-70b2896524c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9757a70a-67e0-4090-b2ee-70b2896524c7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_9757a70a-67e0-4090-b2ee-70b2896524c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9757a70a-67e0-4090-b2ee-70b2896524c7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_86f30f62-47aa-4cd9-9649-248faadafd5b" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_86f30f62-47aa-4cd9-9649-248faadafd5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_f5a2b01b-f595-4527-b997-5b00ccbceea6" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_f5a2b01b-f595-4527-b997-5b00ccbceea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_9d6ea633-306a-4b41-affb-0063b0ac503d" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_9d6ea633-306a-4b41-affb-0063b0ac503d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_47350147-4a1a-49f3-8d76-a1b3dadb76c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:to="loc_srt_RangeAxis_47350147-4a1a-49f3-8d76-a1b3dadb76c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_47350147-4a1a-49f3-8d76-a1b3dadb76c7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_47350147-4a1a-49f3-8d76-a1b3dadb76c7" xlink:to="loc_srt_RangeMember_47350147-4a1a-49f3-8d76-a1b3dadb76c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_47350147-4a1a-49f3-8d76-a1b3dadb76c7" xlink:to="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b86b4ad6-db81-46cd-a875-5238316555dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:to="loc_srt_MinimumMember_b86b4ad6-db81-46cd-a875-5238316555dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_54b36d42-6194-4bf4-a27c-542080ac4242" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:to="loc_srt_MaximumMember_54b36d42-6194-4bf4-a27c-542080ac4242" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="iea571966d8cf4612acb911869f9aea1b_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:href="ameh-20211231.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_2180c712-ceb7-4a00-a748-9d0c6c2de3b4" xlink:href="ameh-20211231.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_2180c712-ceb7-4a00-a748-9d0c6c2de3b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_18f47316-c617-4f0e-92b2-724155bb2026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_18f47316-c617-4f0e-92b2-724155bb2026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_fdb4df43-90c0-45b9-a143-a54147405665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:to="loc_us-gaap_LineOfCredit_fdb4df43-90c0-45b9-a143-a54147405665" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:href="ameh-20211231.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_us-gaap_CreditFacilityAxis_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c" xlink:to="loc_us-gaap_CreditFacilityDomain_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1cf63d3c-892f-49ab-a2f7-3813f5873c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c" xlink:to="loc_us-gaap_CreditFacilityDomain_1cf63d3c-892f-49ab-a2f7-3813f5873c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_971e7254-ab4a-4580-b535-0e1f6b768d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1cf63d3c-892f-49ab-a2f7-3813f5873c8f" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_971e7254-ab4a-4580-b535-0e1f6b768d47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_dei_LegalEntityAxis_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc" xlink:to="loc_dei_EntityDomain_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc" xlink:to="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_b8f676dc-1887-402b-bc0c-f0d22b689670" xlink:href="ameh-20211231.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:to="loc_ameh_ApaacoMember_b8f676dc-1887-402b-bc0c-f0d22b689670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9bc5d0a6-ff87-4c58-b68d-117da20ad96e" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9bc5d0a6-ff87-4c58-b68d-117da20ad96e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_2ee540d2-9626-49a1-a03b-4df0cebb4908" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_2ee540d2-9626-49a1-a03b-4df0cebb4908" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_9b3d8ffd-8cf9-48ed-9fca-761bc53c2281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_9b3d8ffd-8cf9-48ed-9fca-761bc53c2281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_50978fb1-b39c-448c-9c18-f25f002b7b31" xlink:href="ameh-20211231.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9b3d8ffd-8cf9-48ed-9fca-761bc53c2281" xlink:to="loc_ameh_PreferredBankMember_50978fb1-b39c-448c-9c18-f25f002b7b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b1a12291-1514-4e03-946b-92437829e313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b1a12291-1514-4e03-946b-92437829e313" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b1a12291-1514-4e03-946b-92437829e313_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b1a12291-1514-4e03-946b-92437829e313" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b1a12291-1514-4e03-946b-92437829e313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_e2150d22-2f47-454a-a65d-331beddb7f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b1a12291-1514-4e03-946b-92437829e313" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_e2150d22-2f47-454a-a65d-331beddb7f56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_c6bfe1bb-c1b7-46de-9776-55fee6438abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_e2150d22-2f47-454a-a65d-331beddb7f56" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_c6bfe1bb-c1b7-46de-9776-55fee6438abd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="ia0ca7a32b48b429ba91fc09cf68c6611_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_b040968f-ccc7-4562-8165-e991c1046f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_RevenueFromRelatedParties_b040968f-ccc7-4562-8165-e991c1046f8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_9fbf1fd0-4a1f-42c2-ac95-fcdfd7b0d426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_DueFromRelatedParties_9fbf1fd0-4a1f-42c2-ac95-fcdfd7b0d426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ebe5633-00ff-4322-9651-0e7001c08081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ebe5633-00ff-4322-9651-0e7001c08081" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_6d08c234-dc3f-479e-ae56-b3e813a3c9b5" xlink:href="ameh-20211231.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_ameh_PaymentMadeToRelatedParty_6d08c234-dc3f-479e-ae56-b3e813a3c9b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_872f3d7d-480e-4e01-ac66-2cef1339e505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_872f3d7d-480e-4e01-ac66-2cef1339e505" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue_ba344ea5-0994-45b5-aac2-7e6d040469b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_InsuranceServicesRevenue_ba344ea5-0994-45b5-aac2-7e6d040469b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_8acd7e3f-534b-4c9a-b17d-8777a95f539b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_8acd7e3f-534b-4c9a-b17d-8777a95f539b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_28809748-6364-4377-af02-c7a4f5f5398d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_28809748-6364-4377-af02-c7a4f5f5398d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_348b8856-920f-4f72-a839-40a859265dd2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_dei_LegalEntityAxis_348b8856-920f-4f72-a839-40a859265dd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_348b8856-920f-4f72-a839-40a859265dd2_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_348b8856-920f-4f72-a839-40a859265dd2" xlink:to="loc_dei_EntityDomain_348b8856-920f-4f72-a839-40a859265dd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_348b8856-920f-4f72-a839-40a859265dd2" xlink:to="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_4535709e-be95-476d-b2c4-3d1cd26c9d3f" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_NetworkMedicalManagementMember_4535709e-be95-476d-b2c4-3d1cd26c9d3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab4f2bef-e51c-403f-8524-8a645e2e0832" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab4f2bef-e51c-403f-8524-8a645e2e0832" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_0d5d2592-7cb0-4e24-a866-7c6b6f69008a" xlink:href="ameh-20211231.xsd#ameh_ApaAcoIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_ApaAcoIncMember_0d5d2592-7cb0-4e24-a866-7c6b6f69008a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_e1964a25-4243-4226-af67-d50d5d5d5ae6" xlink:href="ameh-20211231.xsd#ameh_SCHCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_SCHCMember_e1964a25-4243-4226-af67-d50d5d5d5ae6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_aea93e5c-199e-4fd2-b71b-75b35605e1a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_srt_TitleOfIndividualAxis_aea93e5c-199e-4fd2-b71b-75b35605e1a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aea93e5c-199e-4fd2-b71b-75b35605e1a4_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_aea93e5c-199e-4fd2-b71b-75b35605e1a4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_aea93e5c-199e-4fd2-b71b-75b35605e1a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_aea93e5c-199e-4fd2-b71b-75b35605e1a4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_000f548a-8735-47d9-b83d-db7cfad6c3ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:to="loc_srt_OfficerMember_000f548a-8735-47d9-b83d-db7cfad6c3ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_61fb335a-dbe1-43ba-8620-ad6092f6064f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:to="loc_srt_DirectorMember_61fb335a-dbe1-43ba-8620-ad6092f6064f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d8c5e04f-f664-40f5-b9c8-f60ab15421ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d8c5e04f-f664-40f5-b9c8-f60ab15421ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d8c5e04f-f664-40f5-b9c8-f60ab15421ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d8c5e04f-f664-40f5-b9c8-f60ab15421ce" xlink:to="loc_us-gaap_RelatedPartyDomain_d8c5e04f-f664-40f5-b9c8-f60ab15421ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d8c5e04f-f664-40f5-b9c8-f60ab15421ce" xlink:to="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_cb4c9bbd-7fe1-4bac-8ba1-0acfa445defa" xlink:href="ameh-20211231.xsd#ameh_ApcShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_ApcShareholdersMember_cb4c9bbd-7fe1-4bac-8ba1-0acfa445defa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_cc7d8eb7-9ff2-49e0-9bd5-0c517a4a8036" xlink:href="ameh-20211231.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_cc7d8eb7-9ff2-49e0-9bd5-0c517a4a8036" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_45db4fc7-2a91-478a-8fdb-8787c403a6f6" xlink:href="ameh-20211231.xsd#ameh_FreseniusMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_FreseniusMember_45db4fc7-2a91-478a-8fdb-8787c403a6f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_d119012e-5139-4a71-bb08-d0da8087b119" xlink:href="ameh-20211231.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_FulgentGeneticsIncMember_d119012e-5139-4a71-bb08-d0da8087b119" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_bb5b32f4-69a8-4a5d-a50f-078d1b94695a" xlink:href="ameh-20211231.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_OneMSOInc.Member_bb5b32f4-69a8-4a5d-a50f-078d1b94695a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_7d80e971-0800-4eaf-a77f-ede103de11a1" xlink:href="ameh-20211231.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_7d80e971-0800-4eaf-a77f-ede103de11a1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_174f2db1-9f7f-4be3-ae70-bb1c01de9ec2" xlink:href="ameh-20211231.xsd#ameh_NumenLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_NumenLLCMember_174f2db1-9f7f-4be3-ae70-bb1c01de9ec2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaFamilyHealthCenterMember_4b1afe8d-9935-4ddd-8465-f285c905a522" xlink:href="ameh-20211231.xsd#ameh_ArroyoVistaFamilyHealthCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_ArroyoVistaFamilyHealthCenterMember_4b1afe8d-9935-4ddd-8465-f285c905a522" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_2e6271c7-2f76-4e4e-9668-4e087a5740d8" xlink:href="ameh-20211231.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_AHMCMember_2e6271c7-2f76-4e4e-9668-4e087a5740d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_52903a6a-6602-4e20-84e9-6a63f81c7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_52903a6a-6602-4e20-84e9-6a63f81c7a33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_52903a6a-6602-4e20-84e9-6a63f81c7a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_52903a6a-6602-4e20-84e9-6a63f81c7a33" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_52903a6a-6602-4e20-84e9-6a63f81c7a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_52903a6a-6602-4e20-84e9-6a63f81c7a33" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_8dec6970-fe05-4d01-ad41-0435340c8b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:to="loc_us-gaap_ServiceMember_8dec6970-fe05-4d01-ad41-0435340c8b23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConsultingServicesMember_d16c5121-7d44-4e07-bfd7-4694b5858944" xlink:href="ameh-20211231.xsd#ameh_ConsultingServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:to="loc_ameh_ConsultingServicesMember_d16c5121-7d44-4e07-bfd7-4694b5858944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_38370fc1-fc46-419c-9ff9-d0d0cc1834d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_srt_ConsolidatedEntitiesAxis_38370fc1-fc46-419c-9ff9-d0d0cc1834d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_38370fc1-fc46-419c-9ff9-d0d0cc1834d1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_38370fc1-fc46-419c-9ff9-d0d0cc1834d1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_38370fc1-fc46-419c-9ff9-d0d0cc1834d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_38370fc1-fc46-419c-9ff9-d0d0cc1834d1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_6a456aa3-e246-4d41-bfba-b77a1e47669c" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_6a456aa3-e246-4d41-bfba-b77a1e47669c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_c9678f7a-31c7-4337-8845-69769e791bb8" xlink:href="ameh-20211231.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:to="loc_ameh_PmiocMember_c9678f7a-31c7-4337-8845-69769e791bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_1174bf10-35a5-4499-b1d3-a478fcbd9777" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:to="loc_ameh_DmgMember_1174bf10-35a5-4499-b1d3-a478fcbd9777" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e2f83ce-dd00-4204-8e52-f7afca6b17f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e2f83ce-dd00-4204-8e52-f7afca6b17f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3e2f83ce-dd00-4204-8e52-f7afca6b17f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e2f83ce-dd00-4204-8e52-f7afca6b17f3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3e2f83ce-dd00-4204-8e52-f7afca6b17f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e2f83ce-dd00-4204-8e52-f7afca6b17f3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_eaab752e-21fa-4a6e-a6a4-d639f897ec7c" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_eaab752e-21fa-4a6e-a6a4-d639f897ec7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_08e2b5ac-1cb0-432f-8d83-9e3e9ba6c7d0" xlink:href="ameh-20211231.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_PmiocMember_08e2b5ac-1cb0-432f-8d83-9e3e9ba6c7d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_207a65b9-d727-4082-8d94-4866f1d41169" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_DmgMember_207a65b9-d727-4082-8d94-4866f1d41169" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_1f9d3aac-6d4b-435c-98b3-2eb815493eb7" xlink:href="ameh-20211231.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_OneMSOInc.Member_1f9d3aac-6d4b-435c-98b3-2eb815493eb7" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="extended" id="iac27ba75aa8c41259982205bd0ab5928_RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_9fece783-139a-403e-bec3-8d0a1f8b9c5b" xlink:href="ameh-20211231.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_9fece783-139a-403e-bec3-8d0a1f8b9c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_858f8ed0-a433-4f90-a611-ac975e7a990f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:to="loc_us-gaap_ManagementFeeExpense_858f8ed0-a433-4f90-a611-ac975e7a990f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_ca7de854-e380-461f-9edf-6185df8c5cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_ca7de854-e380-461f-9edf-6185df8c5cf6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_56f58292-61d0-41a7-9695-fdb8532f1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_56f58292-61d0-41a7-9695-fdb8532f1a60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_811ceabb-b519-4de3-9b61-f0fc29d3b630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_56f58292-61d0-41a7-9695-fdb8532f1a60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_811ceabb-b519-4de3-9b61-f0fc29d3b630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_811ceabb-b519-4de3-9b61-f0fc29d3b630_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_811ceabb-b519-4de3-9b61-f0fc29d3b630" xlink:to="loc_us-gaap_RelatedPartyDomain_811ceabb-b519-4de3-9b61-f0fc29d3b630_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_811ceabb-b519-4de3-9b61-f0fc29d3b630" xlink:to="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_ea0fe21e-ec25-4b97-b294-50fe1c65d1ec" xlink:href="ameh-20211231.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:to="loc_ameh_AHMCMember_ea0fe21e-ec25-4b97-b294-50fe1c65d1ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_63936ec5-7f53-443d-ab20-209ec8e32838" xlink:href="ameh-20211231.xsd#ameh_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:to="loc_ameh_HSMSOMember_63936ec5-7f53-443d-ab20-209ec8e32838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_84f69ff1-b759-463f-856a-2834a939f049" xlink:href="ameh-20211231.xsd#ameh_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:to="loc_ameh_AurionMember_84f69ff1-b759-463f-856a-2834a939f049" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended" id="idc66ddad21e4482cab942fc37ef84271_EarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_f29eabac-ce6d-4ee4-8a61-b1bd62b27dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c94859-b2a5-448d-92f0-c747f8ff791b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_f29eabac-ce6d-4ee4-8a61-b1bd62b27dc5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c94859-b2a5-448d-92f0-c747f8ff791b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_4a66e667-298c-41a7-a961-50a5306090c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_f29eabac-ce6d-4ee4-8a61-b1bd62b27dc5" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_4a66e667-298c-41a7-a961-50a5306090c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eabd965a-fc0f-4f51-a3a0-1cef9416e3df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_4a66e667-298c-41a7-a961-50a5306090c2" xlink:to="loc_dei_LegalEntityAxis_eabd965a-fc0f-4f51-a3a0-1cef9416e3df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_eabd965a-fc0f-4f51-a3a0-1cef9416e3df_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_eabd965a-fc0f-4f51-a3a0-1cef9416e3df" xlink:to="loc_dei_EntityDomain_eabd965a-fc0f-4f51-a3a0-1cef9416e3df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_20c4f093-eeef-467b-ac01-93fefdd6e471" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_eabd965a-fc0f-4f51-a3a0-1cef9416e3df" xlink:to="loc_dei_EntityDomain_20c4f093-eeef-467b-ac01-93fefdd6e471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_73d5ed00-15e9-45c8-ba69-e9dfecf4bd07" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_20c4f093-eeef-467b-ac01-93fefdd6e471" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_73d5ed00-15e9-45c8-ba69-e9dfecf4bd07" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails" xlink:type="extended" id="i1cb5f9ae9ce44b348f32a169ec4fc70f_EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b854a118-96fd-4bf9-a1bc-5ffbb455d857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b854a118-96fd-4bf9-a1bc-5ffbb455d857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c05b277e-859b-4148-8356-ddeedbeb55b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c05b277e-859b-4148-8356-ddeedbeb55b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddf5691c-8f43-44b8-8cce-f3463585046c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddf5691c-8f43-44b8-8cce-f3463585046c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f27b1b73-6b4a-468a-bb5b-8dd11a18823d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f27b1b73-6b4a-468a-bb5b-8dd11a18823d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f27b1b73-6b4a-468a-bb5b-8dd11a18823d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f27b1b73-6b4a-468a-bb5b-8dd11a18823d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f27b1b73-6b4a-468a-bb5b-8dd11a18823d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f27b1b73-6b4a-468a-bb5b-8dd11a18823d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40dafb97-66d2-4932-a108-ef591de61ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40dafb97-66d2-4932-a108-ef591de61ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_68a20235-6a25-4f3a-af97-a4b168a0619a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:to="loc_us-gaap_RestrictedStockMember_68a20235-6a25-4f3a-af97-a4b168a0619a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14f894dc-1fdf-42d8-a2e0-910768651abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14f894dc-1fdf-42d8-a2e0-910768651abb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_14f894dc-1fdf-42d8-a2e0-910768651abb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14f894dc-1fdf-42d8-a2e0-910768651abb" xlink:to="loc_us-gaap_EquityComponentDomain_14f894dc-1fdf-42d8-a2e0-910768651abb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_628bd18e-babf-4ae8-8daa-7285a4e2e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14f894dc-1fdf-42d8-a2e0-910768651abb" xlink:to="loc_us-gaap_EquityComponentDomain_628bd18e-babf-4ae8-8daa-7285a4e2e3ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a36b7052-532f-483c-8d9f-9675e1dbaa61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_628bd18e-babf-4ae8-8daa-7285a4e2e3ab" xlink:to="loc_us-gaap_WarrantMember_a36b7052-532f-483c-8d9f-9675e1dbaa61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_eb980343-7ff7-426c-8d25-acc4449b8a1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:to="loc_srt_TitleOfIndividualAxis_eb980343-7ff7-426c-8d25-acc4449b8a1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eb980343-7ff7-426c-8d25-acc4449b8a1f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_eb980343-7ff7-426c-8d25-acc4449b8a1f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_eb980343-7ff7-426c-8d25-acc4449b8a1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_eb980343-7ff7-426c-8d25-acc4449b8a1f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_18c614c9-b5a9-42e9-a1f3-68887cd1cad5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:to="loc_srt_ManagementMember_18c614c9-b5a9-42e9-a1f3-68887cd1cad5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_d61a69b7-9956-4b51-9268-5fdb80b335dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:to="loc_srt_ExecutiveOfficerMember_d61a69b7-9956-4b51-9268-5fdb80b335dd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails" xlink:type="extended" id="id523166df20345e282504049062b179a_VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:to="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4eb27222-4028-40a3-b8b8-8acac6f37114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4eb27222-4028-40a3-b8b8-8acac6f37114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_00d791bb-6b98-409c-b553-d241ac1ebbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_00d791bb-6b98-409c-b553-d241ac1ebbae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_59b36919-414a-43ef-9d78-2489936c5ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_59b36919-414a-43ef-9d78-2489936c5ff8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e7f4ae3b-2720-4797-84a6-9f9c7760c60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e7f4ae3b-2720-4797-84a6-9f9c7760c60e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_0b81e7a3-9199-4ae4-a1b5-f00a6c593e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_IncomeTaxesReceivable_0b81e7a3-9199-4ae4-a1b5-f00a6c593e10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_4338fe50-a4bb-4692-93cc-bc90f5497e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_4338fe50-a4bb-4692-93cc-bc90f5497e43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_478ec9ad-6ba6-4b6a-b541-5a37d302cc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_478ec9ad-6ba6-4b6a-b541-5a37d302cc2b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_3d39101a-34a7-400d-963a-dc1aa366f2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_3d39101a-34a7-400d-963a-dc1aa366f2c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_ae5a30a1-e4f0-4446-8667-04f4a52b1099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_DueFromAffiliates_ae5a30a1-e4f0-4446-8667-04f4a52b1099" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a05b41d7-e4e1-49d6-b41a-02cffa64034f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_AssetsCurrent_a05b41d7-e4e1-49d6-b41a-02cffa64034f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68f74e9f-8a4f-4f5e-a4d0-732ebebee9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68f74e9f-8a4f-4f5e-a4d0-732ebebee9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2cb5ada-8625-4480-970a-515d378be7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2cb5ada-8625-4480-970a-515d378be7f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1c0ac890-8a28-41af-b626-ec2e72e1923b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_Goodwill_1c0ac890-8a28-41af-b626-ec2e72e1923b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_114062cb-701d-4a6c-b899-3995dc22a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_114062cb-701d-4a6c-b899-3995dc22a94f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_20f6295f-2735-4834-a63d-195af1887c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_OtherLongTermInvestments_20f6295f-2735-4834-a63d-195af1887c92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fe381740-1aa1-48f7-9f02-0267c7cdfbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_EquityMethodInvestments_fe381740-1aa1-48f7-9f02-0267c7cdfbf0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_634232fb-e5e0-4b0c-a554-e66007d46fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_634232fb-e5e0-4b0c-a554-e66007d46fd3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c81d25b5-4c62-4099-8413-9865f1211024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c81d25b5-4c62-4099-8413-9865f1211024" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ae009b-a8ef-4d3b-ad57-a63d4f82a8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ae009b-a8ef-4d3b-ad57-a63d4f82a8d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1817afc7-7a2e-4620-bbce-4f549b035d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1817afc7-7a2e-4620-bbce-4f549b035d3e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_fc33febf-1942-45d4-8640-763144cf8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_AssetsNoncurrent_fc33febf-1942-45d4-8640-763144cf8a43" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6f16cacb-4dce-430f-a8a1-e224cc888989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:to="loc_us-gaap_Assets_6f16cacb-4dce-430f-a8a1-e224cc888989" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_eea2ce66-a4aa-4bc8-b673-9c81f80835da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_eea2ce66-a4aa-4bc8-b673-9c81f80835da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_fa308d34-9ef8-406c-b206-220bf50b691d" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_fa308d34-9ef8-406c-b206-220bf50b691d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_75a88a73-afc5-422f-9e11-82771c42d51a" xlink:href="ameh-20211231.xsd#ameh_MedicalLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_75a88a73-afc5-422f-9e11-82771c42d51a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_83f269d9-3410-4c8e-9a63-71a5a54aa13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_83f269d9-3410-4c8e-9a63-71a5a54aa13d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_6a32d098-97dc-429d-b0d7-6097271c5f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_DividendsPayableCurrent_6a32d098-97dc-429d-b0d7-6097271c5f79" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_12d9c420-0c20-4d27-80ba-c9003728859f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_DueToAffiliateCurrent_12d9c420-0c20-4d27-80ba-c9003728859f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_39b90160-d701-4676-9627-6cd32ee97b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_39b90160-d701-4676-9627-6cd32ee97b23" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46b3f168-3bae-466a-b405-a1681b2a9793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46b3f168-3bae-466a-b405-a1681b2a9793" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b0a0a308-ca4d-4fc6-b509-84036432a485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_LongTermDebtCurrent_b0a0a308-ca4d-4fc6-b509-84036432a485" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a9b8a542-f22f-4e20-90c0-9cc4d20d5a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_LiabilitiesCurrent_a9b8a542-f22f-4e20-90c0-9cc4d20d5a9c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3136617b-b327-48ff-9c52-95171baac0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3136617b-b327-48ff-9c52-95171baac0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bbeb39b3-eb24-4310-967b-fe68b34ddcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bbeb39b3-eb24-4310-967b-fe68b34ddcb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3875b17-1bec-4a40-a129-7c87a87d0d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3875b17-1bec-4a40-a129-7c87a87d0d49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be5d7983-a9db-44f3-80fe-fd6a4ffc2321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be5d7983-a9db-44f3-80fe-fd6a4ffc2321" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_78ca5e77-7b56-4fe5-99e2-c2a09d6e0ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_78ca5e77-7b56-4fe5-99e2-c2a09d6e0ac1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b6c8ef02-c508-435d-82c1-2e8860733e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b6c8ef02-c508-435d-82c1-2e8860733e21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dd194212-19ac-4623-9e3c-a1ee0d807994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_Liabilities_dd194212-19ac-4623-9e3c-a1ee0d807994" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7976fbd1-0c8d-4df2-9d1b-9f5fa279cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7976fbd1-0c8d-4df2-9d1b-9f5fa279cf01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f3958282-0940-40d4-af65-69e186895f89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7976fbd1-0c8d-4df2-9d1b-9f5fa279cf01" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f3958282-0940-40d4-af65-69e186895f89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f3958282-0940-40d4-af65-69e186895f89_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f3958282-0940-40d4-af65-69e186895f89" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f3958282-0940-40d4-af65-69e186895f89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_618aaa9b-648d-4574-96b9-84499eff6093" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f3958282-0940-40d4-af65-69e186895f89" xlink:to="loc_srt_ConsolidatedEntitiesDomain_618aaa9b-648d-4574-96b9-84499eff6093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_58fa011b-5fc2-4a07-8e40-b12f8546443c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_618aaa9b-648d-4574-96b9-84499eff6093" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_58fa011b-5fc2-4a07-8e40-b12f8546443c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="i391353c1a4e34866a9266757a60d40a4_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_caef583e-25d9-4b99-8f1e-2543b2d07b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_caef583e-25d9-4b99-8f1e-2543b2d07b83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_70d77b40-9c2e-4f1c-af12-57c6db511647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_70d77b40-9c2e-4f1c-af12-57c6db511647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e106313c-6e9b-4c6b-bda9-da5f653cb5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e106313c-6e9b-4c6b-bda9-da5f653cb5cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_e9926260-e4e2-40c4-88b4-2576f351e7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_e9926260-e4e2-40c4-88b4-2576f351e7e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_66578ba2-68d6-439c-8474-89e723738bc7" xlink:href="ameh-20211231.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_66578ba2-68d6-439c-8474-89e723738bc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_738f8f6a-382f-47f1-a2a8-af1b1540fb38" xlink:href="ameh-20211231.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_738f8f6a-382f-47f1-a2a8-af1b1540fb38" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_6607d681-c471-4cc1-844a-bcafa4c2c470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_6607d681-c471-4cc1-844a-bcafa4c2c470" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_b66b0b52-62b8-4d35-9528-be50ddad11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_b66b0b52-62b8-4d35-9528-be50ddad11b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dbaf5762-46f7-43fb-a9fe-86577ee42764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dbaf5762-46f7-43fb-a9fe-86577ee42764" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03eb354b-4e51-4b8b-b753-ae6c652cf751" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbaf5762-46f7-43fb-a9fe-86577ee42764" xlink:to="loc_srt_RangeAxis_03eb354b-4e51-4b8b-b753-ae6c652cf751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03eb354b-4e51-4b8b-b753-ae6c652cf751_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_03eb354b-4e51-4b8b-b753-ae6c652cf751" xlink:to="loc_srt_RangeMember_03eb354b-4e51-4b8b-b753-ae6c652cf751_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_03eb354b-4e51-4b8b-b753-ae6c652cf751" xlink:to="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bea5016a-3f2f-4fcc-836e-3de5efef6fd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:to="loc_srt_MinimumMember_bea5016a-3f2f-4fcc-836e-3de5efef6fd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0acfdfe3-ad06-4363-a8da-0430b80b1ca8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:to="loc_srt_MaximumMember_0acfdfe3-ad06-4363-a8da-0430b80b1ca8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended" id="i747fe6b38e974356a8683aca753615c1_SubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92773594-ee19-498d-a24a-05f30deeee25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92773594-ee19-498d-a24a-05f30deeee25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_168115d5-1c60-40f5-b9c5-a179a80effd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_168115d5-1c60-40f5-b9c5-a179a80effd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfDirectContractingEntityPatients_cc13436e-f790-4d08-adce-9a5163ce8786" xlink:href="ameh-20211231.xsd#ameh_NumberOfDirectContractingEntityPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_ameh_NumberOfDirectContractingEntityPatients_cc13436e-f790-4d08-adce-9a5163ce8786" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfRemotePatientMonitoringPatients_20fb0aef-ab49-4895-b913-1943af875982" xlink:href="ameh-20211231.xsd#ameh_NumberOfRemotePatientMonitoringPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_ameh_NumberOfRemotePatientMonitoringPatients_20fb0aef-ab49-4895-b913-1943af875982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7f268446-ceee-42df-8700-27eb47621274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7f268446-ceee-42df-8700-27eb47621274" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7f268446-ceee-42df-8700-27eb47621274_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f268446-ceee-42df-8700-27eb47621274" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7f268446-ceee-42df-8700-27eb47621274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ff33dc-24bc-47d0-bbf1-fcfa19f58e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f268446-ceee-42df-8700-27eb47621274" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ff33dc-24bc-47d0-bbf1-fcfa19f58e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_cba9d53f-cbd3-4b19-9869-99d49bbf31ae" xlink:href="ameh-20211231.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ff33dc-24bc-47d0-bbf1-fcfa19f58e15" xlink:to="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_cba9d53f-cbd3-4b19-9869-99d49bbf31ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_077f216d-56fc-4300-af1b-1ad33f0bc452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_077f216d-56fc-4300-af1b-1ad33f0bc452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_077f216d-56fc-4300-af1b-1ad33f0bc452_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_077f216d-56fc-4300-af1b-1ad33f0bc452" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_077f216d-56fc-4300-af1b-1ad33f0bc452_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6f1261cf-9c1a-41d6-ad41-09a89f8c2c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_077f216d-56fc-4300-af1b-1ad33f0bc452" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6f1261cf-9c1a-41d6-ad41-09a89f8c2c19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8b4f45e7-cf11-4e97-a1e4-a0a4670b6f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6f1261cf-9c1a-41d6-ad41-09a89f8c2c19" xlink:to="loc_us-gaap_SubsequentEventMember_8b4f45e7-cf11-4e97-a1e4-a0a4670b6f34" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>ameh-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56a96635-232a-499f-a03d-15d085375db3,g:3c5e1a1a-f2ce-472c-bc52-288bd5b84a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_122a684d-1d71-4221-a602-03678d45d52b_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_558c8be2-7d39-4076-ad11-46ccce7d94cd_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_bb2b19e5-7f44-4822-8f2d-941ffd0e76ea_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_34ff3d5b-9297-4385-aa1d-811d5506ee1e_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a73481e8-51a5-469b-834d-cebe81589ce8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_99773ffd-4a88-4817-b6fd-c45a9b6520dd_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_dc2f0ee1-2499-4437-8ffd-95c4f586fb9a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_7013fca5-f6b3-4a26-bef3-3dbfa9772fa3_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_9678a67a-78eb-4c7a-9a6e-03319ba5621b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_7e0efb8b-e251-44ce-b263-0e2943c66b1d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicaidMember_f6f72148-2f5f-4731-adf0-842bc7641749_terseLabel_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ameh_MedicaidMember_label_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ameh_MedicaidMember_documentation_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember" xlink:href="ameh-20211231.xsd#ameh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_deb751c0-3e43-47e7-b6ca-c97b3ba5b28f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_2631235f-35d6-4ae0-8716-920227e91a84_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_79869faa-9d11-4c86-95e0-56c55048c33b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableExpectedToBeCollectedPeriod_c17f1be5-da43-414d-b68c-d675904ead14_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableExpectedToBeCollectedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, expected to be collected, period</link:label>
    <link:label id="lab_ameh_AccountsReceivableExpectedToBeCollectedPeriod_label_en-US" xlink:label="lab_ameh_AccountsReceivableExpectedToBeCollectedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Expected to be Collected, Period</link:label>
    <link:label id="lab_ameh_AccountsReceivableExpectedToBeCollectedPeriod_documentation_en-US" xlink:label="lab_ameh_AccountsReceivableExpectedToBeCollectedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Expected to be Collected, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableExpectedToBeCollectedPeriod" xlink:href="ameh-20211231.xsd#ameh_AccountsReceivableExpectedToBeCollectedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableExpectedToBeCollectedPeriod" xlink:to="lab_ameh_AccountsReceivableExpectedToBeCollectedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a69cdb1e-5ffc-404c-8aaf-04cf800913e9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_912ff385-0d75-4377-857d-e33004bdafcb_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_de42c548-e280-4c5f-9acc-6719acb3188e_verboseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_bbd3164f-7faa-43bf-a87e-8da319b05a45_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable - related party</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_0d8c08d4-db42-4b73-bb16-cf4ee2eda3e7_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1e319f6e-636d-419b-9246-3d3b5750f77e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_1635d78d-38ad-4d1b-b450-4ebc92801e9c_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_b0a272c6-5733-4bba-909d-064185f25df3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_a698b179-38b3-449f-ab78-b9c15fd3e9c3_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2400128d-b45f-4137-ac39-d71567d945bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of share available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0a3ad6f8-9066-4423-8a95-b7ce8ce3a3c3_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20fbe3ed-a8f0-40d4-b446-ee06a3d1d25a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2e3e5957-37eb-4b87-8269-626cde581ce7_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommercialMember_adf11560-7a91-4d09-970c-420be4bc0516_terseLabel_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_ameh_CommercialMember_label_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_ameh_CommercialMember_documentation_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember" xlink:href="ameh-20211231.xsd#ameh_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_33fc8975-92c2-4ba6-8e13-178d0e95b49a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_b97387dd-6806-40f2-86a3-10698eead273_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_91cab764-8b1d-425f-829d-b209e1784c2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_83cc7fe5-8cfc-4fb2-9e3b-085cc5f19d2f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_5402244f-0a7f-4ea0-b2cd-611da60b8580_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_9664fb45-fce2-43b1-b44a-0c013674a189_terseLabel_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in millions)</link:label>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_label_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" xlink:href="ameh-20211231.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_8226292c-807b-4cd8-a7f9-cf902fa788a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_618aefa8-0736-426f-bfaf-2ec28c7a1207_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_7b59125c-be3a-4e38-8a00-819493a132ec_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CDSCMember_8812804f-e99a-4532-8edf-25c156d93e3d_terseLabel_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_ameh_CDSCMember_label_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_ameh_CDSCMember_documentation_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember" xlink:href="ameh-20211231.xsd#ameh_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CDSCMember" xlink:to="lab_ameh_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_7db4550b-6740-43ec-a63a-540d62b4992e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_b39e6e8a-7984-4366-888d-5dfdfaaf7ff3_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_e37864fa-a6dc-44fe-a4aa-0647f98b58fc_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares_2de552cd-eae5-4e51-96a1-032c365d06e5_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of equity issuance of preferred shares</link:label>
    <link:label id="lab_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares_label_en-US" xlink:label="lab_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Cost of Equity Issuance of Preferred Shares</link:label>
    <link:label id="lab_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Cost of Equity Issuance of Preferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares" xlink:to="lab_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_e4b98c09-11c5-4a8c-a4b2-0076fa9f4fc9_terseLabel_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy [Policy Text Block]</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:href="ameh-20211231.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c4d91f40-a3e9-4a3f-9830-63c0b9e967ef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_544a6a10-30b8-4a05-9701-ff6e399b0624_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b8803265-7d8d-42d0-a23b-a43c81045e49_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_354b6599-47cf-4eff-af83-2190db175228_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AncillaryServiceContractMember_506ba9eb-d4b1-4f33-b69b-686d688957a1_terseLabel_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract</link:label>
    <link:label id="lab_ameh_AncillaryServiceContractMember_label_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember" xlink:href="ameh-20211231.xsd#ameh_AncillaryServiceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AncillaryServiceContractMember" xlink:to="lab_ameh_AncillaryServiceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_f69bc24c-fc58-4287-89e8-1b4bcaaded03_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_a512170a-cbc0-4508-994d-e98c8cb807a0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_330e3a7f-c2a8-43bf-81a2-41ab3ba67892_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_da0d80d2-6eea-4eef-a3e7-81fecc19f86d_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_309d9b2d-3790-4df8-b4a2-261a0dc4e1f4_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:to="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_8d17e839-f89c-4c30-a4a1-1f9eca9ca7c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_f64e9683-4133-4101-9cfe-af678220337b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d69e9b-79e4-4c62-bff2-1309286b5660_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_79cb0894-ec43-4666-920a-9cf7efdb4417_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d818558d-bb62-492c-9637-8e85b74165c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_430c6c3d-2553-46bb-b7e0-2f311290fd85_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_1516df7f-2f4e-4e4f-9964-37fb39d49cf2_terseLabel_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_label_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made To Related Party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_documentation_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty" xlink:href="ameh-20211231.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_2aafd5d4-d8bc-4eb5-a9e6-e350724a8949_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OperatingLossCarryforwardsExpirationPeriod_dff5c125-afd6-4db7-9d29-4b0b4d7f607d_terseLabel_en-US" xlink:label="lab_ameh_OperatingLossCarryforwardsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, expiration period</link:label>
    <link:label id="lab_ameh_OperatingLossCarryforwardsExpirationPeriod_label_en-US" xlink:label="lab_ameh_OperatingLossCarryforwardsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss CarryForwards Expiration Period</link:label>
    <link:label id="lab_ameh_OperatingLossCarryforwardsExpirationPeriod_documentation_en-US" xlink:label="lab_ameh_OperatingLossCarryforwardsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carry forwards Expiration Period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OperatingLossCarryforwardsExpirationPeriod" xlink:href="ameh-20211231.xsd#ameh_OperatingLossCarryforwardsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OperatingLossCarryforwardsExpirationPeriod" xlink:to="lab_ameh_OperatingLossCarryforwardsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b3b726b4-50ee-463c-b334-610ef565153f_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_ee1ba829-2f73-4cbd-a412-5ec5ba8599cd_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9559740b-c942-4607-9b1e-8942f647aa88_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_b720e5b9-577c-4433-bb9e-14305ae66ebe_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions of preferred returns</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_07b3f683-4727-4a36-b28c-6af2638628b1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityIncentivePlanTwentyThirteenMember_1cbc6437-0fe9-465a-97a0-99a73734a96a_terseLabel_en-US" xlink:label="lab_ameh_EquityIncentivePlanTwentyThirteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Equity Incentive Plan</link:label>
    <link:label id="lab_ameh_EquityIncentivePlanTwentyThirteenMember_label_en-US" xlink:label="lab_ameh_EquityIncentivePlanTwentyThirteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Twenty Thirteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityIncentivePlanTwentyThirteenMember" xlink:href="ameh-20211231.xsd#ameh_EquityIncentivePlanTwentyThirteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityIncentivePlanTwentyThirteenMember" xlink:to="lab_ameh_EquityIncentivePlanTwentyThirteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_90c00076-3def-448e-bd6e-d15ff9cb2368_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a46fc496-31f3-4717-b472-6139f440feee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_31a90e41-82b0-425a-bd5c-f0d82760c06d_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_c8668048-9792-4891-ad40-2cf0efa29d67_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting rights held (more than)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ArroyoVistaFamilyHealthCenterMember_36188eb3-ded9-40a5-bb6e-329b44b8156e_terseLabel_en-US" xlink:label="lab_ameh_ArroyoVistaFamilyHealthCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista Family Health Center</link:label>
    <link:label id="lab_ameh_ArroyoVistaFamilyHealthCenterMember_label_en-US" xlink:label="lab_ameh_ArroyoVistaFamilyHealthCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista Family Health Center [Member]</link:label>
    <link:label id="lab_ameh_ArroyoVistaFamilyHealthCenterMember_documentation_en-US" xlink:label="lab_ameh_ArroyoVistaFamilyHealthCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arroyo Vista Family Health Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaFamilyHealthCenterMember" xlink:href="ameh-20211231.xsd#ameh_ArroyoVistaFamilyHealthCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ArroyoVistaFamilyHealthCenterMember" xlink:to="lab_ameh_ArroyoVistaFamilyHealthCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityIncentivePlanTwentyFifteenMember_d49082bb-e2f6-46ec-bfee-82b7ec0ddf5a_verboseLabel_en-US" xlink:label="lab_ameh_EquityIncentivePlanTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015 Equity Incentive Plan</link:label>
    <link:label id="lab_ameh_EquityIncentivePlanTwentyFifteenMember_label_en-US" xlink:label="lab_ameh_EquityIncentivePlanTwentyFifteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan Twenty Fifteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityIncentivePlanTwentyFifteenMember" xlink:href="ameh-20211231.xsd#ameh_EquityIncentivePlanTwentyFifteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityIncentivePlanTwentyFifteenMember" xlink:to="lab_ameh_EquityIncentivePlanTwentyFifteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8e671cd0-23f6-4d5e-b0de-0a5bfd510448_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentInvestmentInPeriod_5816e748-97d6-4006-bb54-2e2dbde20115_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentInvestmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Investment</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentInvestmentInPeriod_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentInvestmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Investment In Period</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentInvestmentInPeriod_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentInvestmentInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Investment In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentInvestmentInPeriod" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentInvestmentInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentInvestmentInPeriod" xlink:to="lab_ameh_EquityMethodInvestmentInvestmentInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_bbdb6880-daa2-4c8c-80f4-1fc6633f27e7_terseLabel_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_label_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:label id="lab_ameh_CancellationOfRestrictedStockAwards_documentation_en-US" xlink:label="lab_ameh_CancellationOfRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards" xlink:href="ameh-20211231.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CancellationOfRestrictedStockAwards" xlink:to="lab_ameh_CancellationOfRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_28ebd308-8ad3-456c-b51c-dbd70984e65b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_7e01f5c6-b580-441e-b853-815e477f6f05_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_GainLossOnAssumptionOfLoan_dd4fa8bd-19f8-4b17-9576-efa2cc7dd6e2_negatedTerseLabel_en-US" xlink:label="lab_ameh_GainLossOnAssumptionOfLoan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on loan assumption</link:label>
    <link:label id="lab_ameh_GainLossOnAssumptionOfLoan_label_en-US" xlink:label="lab_ameh_GainLossOnAssumptionOfLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Assumption Of Loan</link:label>
    <link:label id="lab_ameh_GainLossOnAssumptionOfLoan_documentation_en-US" xlink:label="lab_ameh_GainLossOnAssumptionOfLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Assumption Of Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnAssumptionOfLoan" xlink:href="ameh-20211231.xsd#ameh_GainLossOnAssumptionOfLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_GainLossOnAssumptionOfLoan" xlink:to="lab_ameh_GainLossOnAssumptionOfLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_8805dccd-c37a-46db-a22c-233b236e49e9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorEMember_13c52e5a-0543-4185-87c8-8355bcdc85b0_terseLabel_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:label id="lab_ameh_PayorEMember_label_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember" xlink:href="ameh-20211231.xsd#ameh_PayorEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorEMember" xlink:to="lab_ameh_PayorEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_9ae888f9-4137-4329-b78d-1631626752c4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_353c2102-89a4-4eba-a86a-27e4481a9b40_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_90693dd2-ac96-4eab-9f5e-9482b61b578f_terseLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional proceeds to be received from sale of equity method investments, if circumstances met</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:href="ameh-20211231.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:to="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_80e61296-ea98-425f-ba35-8b802d885270_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromAffiliates_95395668-6d3e-4218-88e1-a3d5a11dae22_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due from affiliates*</link:label>
    <link:label id="lab_us-gaap_DueFromAffiliates_label_en-US" xlink:label="lab_us-gaap_DueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromAffiliates" xlink:to="lab_us-gaap_DueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_db0f9a20-f9a1-43af-99c4-3474a3b38353_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested as of January 1, 2021</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1972ea3-5d41-42df-9526-6fda4d05f235_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested as of December 31, 2021</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CAIPAMSOMember_b44dc839-c0b7-4d68-b72a-527a3a6ecfaf_terseLabel_en-US" xlink:label="lab_ameh_CAIPAMSOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:label id="lab_ameh_CAIPAMSOMember_label_en-US" xlink:label="lab_ameh_CAIPAMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO [Member]</link:label>
    <link:label id="lab_ameh_CAIPAMSOMember_documentation_en-US" xlink:label="lab_ameh_CAIPAMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOMember" xlink:href="ameh-20211231.xsd#ameh_CAIPAMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CAIPAMSOMember" xlink:to="lab_ameh_CAIPAMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_8c42fa40-e498-4223-9b90-825207db9783_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_54375dbf-eb05-44f2-9e24-e398f2bb01db_terseLabel_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, current, maturity period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="ameh-20211231.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PmiocMember_b064961f-84e4-467b-a6da-a261c6aecf3d_terseLabel_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_ameh_PmiocMember_label_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember" xlink:href="ameh-20211231.xsd#ameh_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_41713121-e965-447b-878a-4cc710309fc4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NoncontrollingInterestSharesDistributed_b95eec50-f1ba-41e0-b602-67e53c7ba71c_terseLabel_en-US" xlink:label="lab_ameh_NoncontrollingInterestSharesDistributed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, shares distributed</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestSharesDistributed_label_en-US" xlink:label="lab_ameh_NoncontrollingInterestSharesDistributed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Shares Distributed</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestSharesDistributed_documentation_en-US" xlink:label="lab_ameh_NoncontrollingInterestSharesDistributed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Shares Distributed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestSharesDistributed" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestSharesDistributed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NoncontrollingInterestSharesDistributed" xlink:to="lab_ameh_NoncontrollingInterestSharesDistributed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_30e3b124-028c-42ad-bd2f-4b7492d3404d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_d4b7744f-0651-4d9a-b487-7a20df197027_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_fac59da4-8157-4569-967c-09a5872a708f_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool surplus or deficits, settlement period after performance year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="ameh-20211231.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_3eabdd88-4949-4280-84b4-2be56f8b4393_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock_6632ed61-ecce-408e-a2e1-5b7b46f70275_terseLabel_en-US" xlink:label="lab_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Property and Equipment, Net</link:label>
    <link:label id="lab_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock_label_en-US" xlink:label="lab_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment Disclosure And Asset Acquisition [Text Block]</link:label>
    <link:label id="lab_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock_documentation_en-US" xlink:label="lab_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment And Asset Acquisition Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" xlink:href="ameh-20211231.xsd#ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" xlink:to="lab_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_7694c72b-0fe6-4df6-9569-6b6bc2fce5d3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_9c568dbc-8644-420f-83c3-85d0df52f603_terseLabel_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember" xlink:href="ameh-20211231.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmendedCreditAgreementMember" xlink:to="lab_ameh_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_686566ba-ca5f-4043-847e-3309c091bcde_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received from equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_66d7b65c-48ff-4975-8711-c8a46a9961b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5a94a8a4-00d0-4dce-8a9e-41b48314df73_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_1e5b389c-642f-4a83-a7c0-5725ceb99141_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_a45ef368-bbf7-4d23-a2cc-5b8659a26784_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_e6d92279-ef7e-49f6-9187-98aa6b18887b_terseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_4137c8c7-b0a5-49c0-b586-f6fa5b47670a_verboseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_d000d183-2dd6-4eb6-9591-0bb7531d25ae_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ebf737d-3c83-4d6e-8f48-2acb1abfae80_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_890aa79c-866d-4235-866e-f981a995231c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash &#8211; long-term - letters of credit</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_7087df4b-7eae-4a9d-a799-4fae6222162a_terseLabel_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_label_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC [Member]</link:label>
    <link:label id="lab_ameh_AMGPropertiesLLCMember_documentation_en-US" xlink:label="lab_ameh_AMGPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG Properties LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember" xlink:href="ameh-20211231.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AMGPropertiesLLCMember" xlink:to="lab_ameh_AMGPropertiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_9f5da557-db0a-4770-bcbc-3aaca7bf7c72_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_bd78937a-4868-49e1-ba91-8cbdcb42d9a4_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities - Equity Method</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_b3eae5e8-7aca-4d5b-bbf8-0bd837b63c33_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_5cc01c6f-556a-4ac7-8127-53ebb46d4676_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_26d7617f-617c-4702-ba2b-2b19d8cc5bb9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_82404ab3-ff8c-409f-9801-0c9b358cc9ef_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Mezzanine Equity, and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_74cee717-2693-4d26-b059-d93e52028d63_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcShareholdersMember_e7c0b3b0-b62f-48b8-ba51-59ba05c11e06_terseLabel_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_ApcShareholdersMember_label_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember" xlink:href="ameh-20211231.xsd#ameh_ApcShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a09cdfd7-8d46-45d1-85ed-109f76344149_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_42672be8-f9c6-4163-bc49-7746be2681e5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_89c1f01c-be5c-422e-bb9f-88c925a6061f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_67bced9d-f988-4896-b1e5-487dd1372fbc_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_29c94693-710e-48e2-b337-d2c385b3abcb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsStateTaxes_13389d14-e868-408f-99ba-54da6944def9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsStateTaxes_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, State Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0d3825b5-c361-405d-9f7e-8c48d6afd4b4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_57d145d3-37c0-488d-b311-f2fb0e8b6207_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds for exercise of options and warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_29af55a1-480e-4876-a6f3-98dc212e29f1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized intangible assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_84f3115d-1c57-4586-a0f0-ed86dc0b1c57_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_6526d563-ebfe-4aa3-b4ff-a7e54de203bc_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_17f92719-94d1-40f5-b7a8-1ba2bf00c3d5_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorAMember_cfb3154e-5d12-4f83-8387-fff4430accc2_terseLabel_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_ameh_PayorAMember_label_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_ameh_PayorAMember_documentation_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember" xlink:href="ameh-20211231.xsd#ameh_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorAMember" xlink:to="lab_ameh_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_f295f792-83d4-427a-8efb-b6e148e2a513_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_dc5322a8-7eae-44d9-9f2a-4d4476639f1d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_fd5ce3a2-2806-482b-bd55-bd33cc6e061d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenue_9094c2f5-2995-4f95-8734-a110806e2065_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_label_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenue" xlink:to="lab_ameh_PaymentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_78c109f3-c35c-4442-80b3-242313c19352_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_be2c764b-e0ac-4c46-ae6c-fe91c234efd0_terseLabel_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CQMC</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_label_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp [Member]</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_documentation_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Critical Quality Management Corp Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember" xlink:href="ameh-20211231.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CriticalQualityManagementCorpMember" xlink:to="lab_ameh_CriticalQualityManagementCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_0def4cf6-0139-428d-9e93-515607141076_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_a1077aa7-c9e1-44d7-954d-d6cdd1e12eae_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_c86ec1f8-69f2-4a23-a418-e55888e8c51c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent equity securities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ae9366df-3117-41b9-a1c4-9e5e0d592615_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfEmployees_c77662b1-efeb-4a4f-beae-d78fd82d830e_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees (more than)</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_label_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_documentation_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees" xlink:href="ameh-20211231.xsd#ameh_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfEmployees" xlink:to="lab_ameh_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_f3baf15e-1d68-4b30-be50-bfebddc2761f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_757a6bcb-5979-4e22-92d3-a66030fb8fc6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of loans receivable - related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4331e783-f0b9-41fd-ab2d-4c0e52d1172c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9173c79f-a6a4-4b98-a816-f82e5d20c057_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_ad6e3eb8-b962-4d18-9a2c-da24aa76b51c_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_52c0c64c-5a9f-49ab-95a8-395cbddc949b_negatedLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_d07f3e37-5b48-4a9f-8db7-8ae885139b49_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_ca890aea-2504-4225-9c63-cdf87e92c5db_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_b974db0b-5a12-4976-a10a-d7e7fa6abe7c_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_3daab79d-0e80-4bde-8484-6bbb649200ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at ending (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5a241fc1-61b8-42df-b45b-65880923642c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable weighted average exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_afcbeaca-2fa8-480c-b730-cd9e6686f120_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_ce6c7d4e-5122-442f-9bb3-26694ace9926_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_084eafa5-da8e-4172-9f9d-8b8b2dd43637_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_5d91ff29-d529-4a9b-a7c6-b92dec9896ec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_95528f7e-4592-4210-bae3-a163f892dfc0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_53e82164-21e5-4832-9167-7cff4a0f39e2_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SharesWarrantsRollForward_3cdd81b3-12bb-420d-b1ad-73245016cd77_terseLabel_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_label_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward" xlink:href="ameh-20211231.xsd#ameh_SharesWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesWarrantsRollForward" xlink:to="lab_ameh_SharesWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_09afae2b-a8ca-4939-b45a-dd5bd3f6cff3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9e999d01-9df7-4a0a-921a-ba56f9cf3c1a_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxAssetsLeaseLiability_97e3dddd-75d0-4598-bf0b-b0f148c9396f_terseLabel_en-US" xlink:label="lab_ameh_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ameh_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_ameh_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_ameh_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_ameh_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxAssetsLeaseLiability" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxAssetsLeaseLiability" xlink:to="lab_ameh_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_568b5204-3f48-47de-8330-dce471c818e9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_14983e21-c93d-4c18-9c93-eb744236ce9f_terseLabel_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_label_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable And Accrued Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:href="ameh-20211231.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:to="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_b4795188-8849-405a-91af-1b54cb68e24c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.001; 100,000,000 shares authorized,44,630,873and 42,249,137 shares outstanding, excluding 10,925,702 and 12,323,164 treasury shares, at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_35ea99b6-830a-4a6c-afad-02bcd7398420_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalLiabilitiesCurrent_6111ed5a-7d4a-4c96-b680-d30c993d3b69_verboseLabel_en-US" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_MedicalLiabilitiesCurrent_3a25eb62-916e-4395-bfe7-0c7226e2192e_terseLabel_en-US" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_MedicalLiabilitiesCurrent_label_en-US" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities, Current</link:label>
    <link:label id="lab_ameh_MedicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_ameh_MedicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalLiabilitiesCurrent" xlink:href="ameh-20211231.xsd#ameh_MedicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalLiabilitiesCurrent" xlink:to="lab_ameh_MedicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxLiabilities481aAdjustment_1352c028-c14d-4c47-bc70-57733b9b84f9_negatedTerseLabel_en-US" xlink:label="lab_ameh_DeferredTaxLiabilities481aAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">481(a) adjustment</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilities481aAdjustment_label_en-US" xlink:label="lab_ameh_DeferredTaxLiabilities481aAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, 481(a) Adjustment</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilities481aAdjustment_documentation_en-US" xlink:label="lab_ameh_DeferredTaxLiabilities481aAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, 481(a) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilities481aAdjustment" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxLiabilities481aAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilities481aAdjustment" xlink:to="lab_ameh_DeferredTaxLiabilities481aAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeDomain_16526d37-788d-46aa-8521-6a504eabada2_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:label id="lab_ameh_ContractTypeDomain_label_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain" xlink:href="ameh-20211231.xsd#ameh_ContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeDomain" xlink:to="lab_ameh_ContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f7afc45e-1f24-4213-9eaf-063c1659e08b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (In dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e85b60ca-ebe3-425b-92e9-d98d5a91b010_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7fec54f0-cbc7-4b99-9500-a094a633d1e6_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_680bc2ff-fad6-4229-b9d9-029e1fcc8250_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaacoMember_76126088-1f31-4c22-b17b-66e07a6a46b1_terseLabel_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO</link:label>
    <link:label id="lab_ameh_ApaacoMember_label_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember" xlink:href="ameh-20211231.xsd#ameh_ApaacoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaacoMember" xlink:to="lab_ameh_ApaacoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_00ddce72-f22c-49ed-8892-1a9bc83b4787_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_9554b60f-4bd2-4383-aeef-57beee6ec8c0_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_e577c3f3-9559-4496-b303-c87581443f4a_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_8cc27e32-9d5d-4d4b-b051-740e51681898_verboseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_7ba075fa-2fba-4303-92e3-47ac8fbf1ffa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_611fa5b8-1e28-42b7-83be-e54c6fb5526c_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e61b7e1b-332d-489c-acf1-100491ae4f16_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_3a5c4350-22b7-4fea-b3be-914769717fb1_terseLabel_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group</link:label>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_label_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember" xlink:href="ameh-20211231.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DiagnosticMedicalGroupMember" xlink:to="lab_ameh_DiagnosticMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_75d0ccc8-bbaf-4a0e-80c3-1aa6fad11d83_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_3edc43d8-1de5-404d-8d86-3e01bd108a6a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_2e4d3479-b004-4757-9401-adaf015dfce5_terseLabel_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant issued during period value stock options exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:href="ameh-20211231.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_8073d5d3-d10a-446f-bc32-3ff6e8a70227_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_9333a9e1-19c8-43cc-961a-1313b5f861a1_negatedTerseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of non-controlling interest</link:label>
    <link:label id="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_label_en-US" xlink:label="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase from Sale of Non-Controlling Interest</link:label>
    <link:label id="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Increase from Sale of Non-Controlling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:to="lab_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_99987dbe-fe76-4bc0-ac03-c7d57ce04fd2_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_25500b63-3437-47d9-b2df-70fbde5af746_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a69e295b-8d95-4a5d-86df-d90e69baffdc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_7b0de6d6-9151-4417-bc4e-5a01dead50d2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_9e2f4c0a-6625-4f64-a19d-335a0e104e1f_terseLabel_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_label_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc. [Member]</link:label>
    <link:label id="lab_ameh_FulgentGeneticsIncMember_documentation_en-US" xlink:label="lab_ameh_FulgentGeneticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fulgent Genetics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember" xlink:href="ameh-20211231.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FulgentGeneticsIncMember" xlink:to="lab_ameh_FulgentGeneticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_61cdd0ac-160f-4fc6-a267-eb29d72150c7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_10b14275-dfd5-4c3f-a357-d90921a8dc80_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherThirdPartiesMember_49c1409e-9b02-4c95-bda2-fd05dbaf0f52_terseLabel_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_label_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember" xlink:href="ameh-20211231.xsd#ameh_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodShareConversionOfNotes_5a20638f-76de-4cff-8e45-fa2ebdd6baf5_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodShareConversionOfNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period share conversion of notes (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodShareConversionOfNotes_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodShareConversionOfNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Share, Conversion Of Notes</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodShareConversionOfNotes_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodShareConversionOfNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock issued during the period upon the conversion of notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodShareConversionOfNotes" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodShareConversionOfNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodShareConversionOfNotes" xlink:to="lab_ameh_StockIssuedDuringPeriodShareConversionOfNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_1a25373c-242c-4e26-b905-9094fe5b9b5f_terseLabel_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_label_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_documentation_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember" xlink:href="ameh-20211231.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APAMHMedicalCorporationMember" xlink:to="lab_ameh_APAMHMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_8cbba6cc-2a72-45f3-886f-58e8a7e89ad4_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_b781a2ec-be26-4139-be75-78748bace995_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccef177d-241b-45fc-a6e3-ce0102943fc3_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c44c0ec3-5bb3-4d8e-93e4-7aa9b7645b99_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Warrant1Member_97f4aa09-5639-48fd-ad40-6ec635c89a05_terseLabel_en-US" xlink:label="lab_ameh_Warrant1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant 1</link:label>
    <link:label id="lab_ameh_Warrant1Member_label_en-US" xlink:label="lab_ameh_Warrant1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Warrant1Member" xlink:href="ameh-20211231.xsd#ameh_Warrant1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Warrant1Member" xlink:to="lab_ameh_Warrant1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_4cafa3aa-b7be-4cc1-a883-6806e4d916df_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_77232c4b-b039-4192-9289-194d14e18821_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb4fa42d-9f62-4c33-9b30-1dbcf251ebaa_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb043c75-981a-4926-a146-4594edd7085e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0af03abe-0d08-484e-b9c5-597e068488dd_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaAcoIncMember_889feb66-b9b4-4f5e-83f7-4f767fa21ee9_terseLabel_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO</link:label>
    <link:label id="lab_ameh_ApaAcoIncMember_label_en-US" xlink:label="lab_ameh_ApaAcoIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APA ACO Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember" xlink:href="ameh-20211231.xsd#ameh_ApaAcoIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaAcoIncMember" xlink:to="lab_ameh_ApaAcoIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2427eeae-9538-452a-a5b2-df0fa99fd1d9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares_55c2eee9-b1f2-4a8c-aa39-fe5a8d35dce8_terseLabel_en-US" xlink:label="lab_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of 50% holdback shares</link:label>
    <link:label id="lab_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares_label_en-US" xlink:label="lab_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase During Period Value Release of Hold Back shares</link:label>
    <link:label id="lab_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares_documentation_en-US" xlink:label="lab_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity impact of the value of stock that has been released during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" xlink:href="ameh-20211231.xsd#ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" xlink:to="lab_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_39a2f851-3176-4a95-bb0e-60e3787239ed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd0aa1db-3273-4b0b-8d22-46f40f73fe49_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7cfeab7a-6604-436a-9bfc-157f06bd0da5_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_4893b810-0901-4a53-96a5-b7070163c592_terseLabel_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC</link:label>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:href="ameh-20211231.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_c7c11dc4-a69e-473d-83fc-98406f8e5cd2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_97c33625-fa34-46e4-ae99-292069818f55_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_eeb4988d-1140-4bfc-8302-78d3e071f03a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_3b93de92-9312-41dd-9310-beca1c07a5e0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_ff34bff2-63cf-4050-b323-af28c7016d2f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_824f5179-e9e6-46cb-b410-8fd370ed1bf2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d9e95469-e23d-4696-9b0d-f4f78e804a59_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ef23c096-8628-43f5-bc6e-ee882839f54d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_fe68dc6e-e8fd-4756-886b-02404fbcfdb8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances on loans receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Fund Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_5c6a18af-8d7b-4a69-86c1-bab283d425c8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_38ee8e83-2287-478c-8781-6a07deca193c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_45d51be1-5fb6-4506-b589-2c8cc3375175_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_5af189cb-44a0-443a-afe4-f2f71ab2c49a_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" xlink:href="ameh-20211231.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_542d2123-866d-4a87-ac1a-475d43bff92f_terseLabel_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMPM</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_label_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_documentation_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:href="ameh-20211231.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:to="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_fbdf835f-5b3f-418e-b91b-73a3f17c14c2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_307d1873-f908-4c04-8a25-825a52184ff5_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual&#160;Life</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_4b30c4fc-01b1-4d78-8677-8d69730f1e6a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_e0b287a0-588c-49bc-b74a-642fa4bce1c5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_03a13ded-3aef-48f1-a4af-5c962c77950f_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_688014e1-2c90-4c65-9c5b-184265e14a0e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_895f9f10-3712-4930-9fd3-06fbe6514c8c_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loan</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_6688ead2-1540-4a84-9060-acecc1f57940_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_82d94a98-3ba6-447a-8aef-6e97b6bb7e6d_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock, within five years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_744e66ff-9165-43a0-b1e4-8bc1eac73ff0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest entities</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_0aaca62c-6e91-41f1-86e6-0f562cc262a8_terseLabel_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial fixed term of amended and restated management and administrative services agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_label_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_documentation_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:href="ameh-20211231.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_cfbe5812-21b7-408d-904b-4c636f858983_terseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Operating Lease Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkRelationshipsMember_7c64bc8a-fc77-4f89-b460-b122c514d7e8_verboseLabel_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_label_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember" xlink:href="ameh-20211231.xsd#ameh_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4bc6f937-82d5-4af8-9389-d681eb077624_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_20ff9ba4-462d-4263-b82f-d4ebfa0e9d0b_terseLabel_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_label_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_ZLLPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_ZLLPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZLL Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember" xlink:href="ameh-20211231.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ZLLPartnersLLCMember" xlink:to="lab_ameh_ZLLPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_6c7f2162-8f38-43b4-8976-5cc1cf273596_terseLabel_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_label_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC [Member]</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersLLCMember_documentation_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:href="ameh-20211231.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersLLCMember" xlink:to="lab_ameh_MedicalPropertyPartnersLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_96ae494d-c1f1-49dd-9489-53914ebe41f7_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, preferred shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_de8c3b85-de32-4475-a14a-efba0a6df0b2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_cb3907c0-fd41-414d-98ec-a28610525b88_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_4935df09-10ee-454b-a1e1-188de6f2e1d8_negatedLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants forfeited (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, cancelled in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8c80cff5-f5a8-4d75-841f-add4634d7b5d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leases, Future Minimum Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_460caff5-e1c1-416e-aa69-86884b668a2d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_79db0420-7234-4438-b38a-4b62a8cec6c2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity attributable to parent</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_386b6ec5-9bd3-4fe1-b540-41beb482d7be_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ae302838-7f54-45f8-bf7e-e42a231de1b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b26b8ef9-2d93-4468-a239-f710dd3d45cc_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b09c46f7-4beb-4b0c-9804-818f2d8f0bc5_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership upon conversion of finance receivable</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage, Upon Conversion</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage, Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_d80e3a50-73d5-4be8-b4ff-8e3b8492b68a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_GainLossOnEquityReceivable_f0028487-bdaa-4446-98d2-9bfb7197ed9b_negatedTerseLabel_en-US" xlink:label="lab_ameh_GainLossOnEquityReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on contingent equity securities</link:label>
    <link:label id="lab_ameh_GainLossOnEquityReceivable_label_en-US" xlink:label="lab_ameh_GainLossOnEquityReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Equity Receivable</link:label>
    <link:label id="lab_ameh_GainLossOnEquityReceivable_documentation_en-US" xlink:label="lab_ameh_GainLossOnEquityReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Equity Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnEquityReceivable" xlink:href="ameh-20211231.xsd#ameh_GainLossOnEquityReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_GainLossOnEquityReceivable" xlink:to="lab_ameh_GainLossOnEquityReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ManagementMember_d9e313a3-f117-4f82-9759-e1e883428382_terseLabel_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management restricted stock awards</link:label>
    <link:label id="lab_srt_ManagementMember_label_en-US" xlink:label="lab_srt_ManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember" xlink:to="lab_srt_ManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_4c962d4c-48be-4f97-b18b-66736b4f6923_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent_6d825fca-2a61-4307-9a2c-ad85de6b4a7e_terseLabel_en-US" xlink:label="lab_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment basis adjustment</link:label>
    <link:label id="lab_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent_label_en-US" xlink:label="lab_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Investment Basis Adjustment, Percent</link:label>
    <link:label id="lab_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent_documentation_en-US" xlink:label="lab_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Investment Basis Adjustment, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" xlink:href="ameh-20211231.xsd#ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" xlink:to="lab_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_30d34941-2189-42a4-b2d8-dab78b332cbb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_7ed28345-0d50-4fb3-9466-b7ba489394e1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_fd399f0c-5608-4315-9aa9-2dec7c91a861_terseLabel_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_label_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC [Member]</link:label>
    <link:label id="lab_ameh_ApolloSunLabsManagementLLCMember_documentation_en-US" xlink:label="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo-Sun Labs Management, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:href="ameh-20211231.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloSunLabsManagementLLCMember" xlink:to="lab_ameh_ApolloSunLabsManagementLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8290637c-62a2-435b-967e-c15487b35b8b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_686737c6-67d1-430f-b620-56a23d8f91e6_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4d887e28-bbd7-4b5f-b864-e0e88154d60f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life (Years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificAmbulatorySurgeryCenterLlcMember_7d05556e-d3f9-4e73-9c1b-ab74591a40e1_terseLabel_en-US" xlink:label="lab_ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PASC</link:label>
    <link:label id="lab_ameh_PacificAmbulatorySurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Ambulatory Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:href="ameh-20211231.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:to="lab_ameh_PacificAmbulatorySurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_e6741766-73ce-43df-afff-27367d5c7468_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_b1d6d2cb-ce84-465f-92ea-59b69a39a435_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ecbe2e70-8e0d-4957-8e7c-5c50682a0063_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_d0a12bc0-588d-4c0d-9091-574feffd08d4_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4ed5d595-a771-4304-b8f9-e74016bbace8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_94fa74bd-5a0f-4a84-8b6a-0e526c628d17_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_cd0bb955-aa61-4db3-ac6f-68b4333f3b2e_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_fc3fcc59-5f6c-4776-9789-712551348c6e_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6a2ba304-0692-4e41-afe5-4534da98e75b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_f0c20f24-d47d-48a7-b9d2-7b597c1dcbd3_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to purchase membership interests</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20211231.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_9812deca-ecb1-4d87-a930-01cdfb05776e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_d3b503dc-682c-439d-b0fa-662e7419a557_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_a584f1d3-4bef-4350-8fe0-ec7594215d4d_terseLabel_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center</link:label>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_label_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:href="ameh-20211231.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOInc.Member_20894e43-5fb5-44d0-8791-7bb90385db50_terseLabel_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc.</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_label_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member" xlink:href="ameh-20211231.xsd#ameh_OneMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOInc.Member" xlink:to="lab_ameh_OneMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9f6c33c3-dfe7-4dee-a701-f4b6b35661a6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value of common stock</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_03fa6985-63b3-464c-adcc-ca4d23515e1c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3bef7c64-8f1d-42e5-b9c6-6478ab79ea3e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_198e24d5-7dec-4abf-876b-a072956846b5_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_6b232175-b757-4454-a591-f39a32a86915_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_a0c228ba-a6e9-4318-b724-8f17ec10670e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_e1849f9c-96ce-48d5-b12d-dac72ca8dbb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_426dabe7-46af-44d9-9b04-57b517e269df_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6a30e68d-f2c5-4a62-ab66-fa3ffcc48b8f_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_15a06775-980b-4a9d-9285-c9aa6920f4ab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_452532b7-32c2-4a8d-87f3-71fd927d8708_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_a2e97c9f-3778-4829-9313-a7a57e8cd91e_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_0cc87a9e-d3ab-4192-96d8-c9efe400a897_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable" xlink:href="ameh-20211231.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_cab059cb-7571-43a9-9f6c-1510ce82e972_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_c856b586-a766-4d2b-9a88-174c938d9592_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share based payment award, warrant exercised, exercise price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:to="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_93e129ba-e4bb-4009-ade1-d8dd7ccdcf3d_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_GainLossOnConsolidationOfEquityMethodInvestment_f9621f7d-bef7-4498-b349-1b54a8bf308f_negatedLabel_en-US" xlink:label="lab_ameh_GainLossOnConsolidationOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on consolidation of equity method investment</link:label>
    <link:label id="lab_ameh_GainLossOnConsolidationOfEquityMethodInvestment_label_en-US" xlink:label="lab_ameh_GainLossOnConsolidationOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Consolidation of Equity Method Investment</link:label>
    <link:label id="lab_ameh_GainLossOnConsolidationOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_ameh_GainLossOnConsolidationOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Consolidation of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment" xlink:href="ameh-20211231.xsd#ameh_GainLossOnConsolidationOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment" xlink:to="lab_ameh_GainLossOnConsolidationOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_8f274ee5-65c8-425a-bd12-66bc50735a98_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_ad2a0d10-d218-4356-90e6-2e091090f616_verboseLabel_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC &#8211; Risk pool earnings net of claims payment</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_label_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_documentation_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:href="ameh-20211231.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:to="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_259a338c-ab59-49d4-a889-457a69b9c957_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares_9c896b13-93e5-4e06-8917-62fdb9a087a3_terseLabel_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends (shares)</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares_label_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Shares, Release Of Hold Back Shares</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares_documentation_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Shares, Release Of Hold Back Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" xlink:to="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7b1858bc-7519-4189-8426-f7e3e55eb64c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_50902964-cba7-4487-ad40-cebf1a20b3cd_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_9d3dca25-7917-4cc5-8b90-b87ef65258b6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_82f46701-82c2-41a7-9139-2021db8b1854_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f9bb3c13-c742-4238-ae0b-cd953901608a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_e29042aa-67bc-4c50-b16b-2581a54eba6d_terseLabel_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account</link:label>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_label_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:to="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_65bf5b32-2cee-4bc9-a810-6a6e693e1acc_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum debt coverage ratio</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ac452035-42ea-426b-b356-24ab912a5ae5_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_cf71a66a-6b13-4b07-8b8f-286ff8f00c37_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b79f540d-5434-4c58-9a7a-cf2ff1aec450_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_abb8187d-6b51-4f8b-b58f-089b3a87f895_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_7ee4c43f-a88c-40b0-8388-4469fe9773fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-controlling interest capital</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3b181722-4185-4454-963a-77cf64f8304f_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_fb0b0f23-81b3-4233-ae10-93595c9cc646_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e947a68d-2dc7-48a0-8999-0e850cf2aefc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_1c6f4746-a90f-4e7b-95e4-a3a403a9a9a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d177f8bb-c4fc-49ec-b4a3-84a559906119_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_aa2d3230-8ffc-440b-89f2-ad6e29a62b2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_84f65cd0-80de-4223-8c0a-b78707f84ebe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_447fb3fc-3fa2-4784-911d-6c0a31383049_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount invested for interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_c4224371-8ada-41c2-9027-55463f230523_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_88061258-ddd4-476d-916c-1dba114849da_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_aa0744ce-55e4-4dc0-b79a-b8cc74d5d6f1_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_87865b92-833e-4e56-9ed7-736e342f5a45_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_56bb608e-d421-4acb-b7c9-5cb8abd275ac_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_14ff24b2-463a-4277-88dd-24a780fc4269_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_e91252bc-215d-4465-a796-231fe12aadd9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_cbbffeb4-ef17-43c2-8507-1542f4a9fd7d_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_4baad808-5c41-4d86-8a81-53b8cfaa237b_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9a59d897-5441-4400-9110-ff9d2bb65434_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2cf620cd-5d73-43c2-9845-0f6b2af163af_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_168a0933-03f2-4f97-8809-7e13b5148f5b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_361f5054-6f09-4263-89fd-c54375565d31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_ee1c9034-1f07-4a69-bea6-d556de6f67e8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8ffddbac-257c-495d-bcbe-f345b3e839a7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_01add230-c493-42ca-b3a2-df12b9880974_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of capital lease obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_48d173a4-e5b7-4b63-a7e6-ba08d27b8582_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_594843e1-adbb-49da-acfc-52806c1c516d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e897d60c-57d9-405a-b55f-7fa488dd9fb6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5177f84a-9a38-4ad1-befe-5474243fab6f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d3f537a1-44d1-4eca-a176-f10ee6251ceb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment/ Disposal</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_43051d61-af17-40db-beed-f32f088ee152_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_0fc4620f-817e-42ef-b100-1524dd3becd7_terseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="ameh-20211231.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_7fdace59-fd77-4ac7-9bdf-9fb7de098bd1_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_aad3e71e-df3e-4479-8248-98d28bc28653_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_462e7d44-bf6b-4308-a8be-371df2a9ab79_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0ab51582-b39f-48c9-b859-40a8e74b7c50_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1146eaa7-fdd0-4eff-93c9-9774d3a70cbb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_3151cc0e-d2f3-4b32-84f7-dc374691f4db_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_6c9f4e23-31ef-493e-a4ca-0b9a2b543b26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_a95bf172-257c-4737-8cf0-daa6ebd005af_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_5409280d-7004-4917-92f7-509df21958ec_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d6192950-14b4-44d4-9d1a-5c9008528e68_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7aac3fb2-bec1-43d2-bb8e-0339aa9969b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_69ec8cb4-34b0-460f-9660-81b28a37db08_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20211231.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_c962613c-ceea-453a-b063-5327b9582f8d_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_e4fc34af-b472-4120-9295-2bcc27fb1f22_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease terms, financing</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:to="lab_us-gaap_LesseeFinanceLeaseTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_8e9ae848-d6c9-4065-ac50-fd281cede0e0_totalLabel_en-US" xlink:label="lab_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite and Indefinite Lived Intangible Assets Acquired</link:label>
    <link:label id="lab_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_documentation_en-US" xlink:label="lab_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite and Indefinite Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired" xlink:href="ameh-20211231.xsd#ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired" xlink:to="lab_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_08e69e36-4940-4caf-9682-90f9560e0a2f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired (see Note 3)</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0e1f1b24-6822-4d72-877f-8b2db37e6526_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_911df755-1ebc-4ce7-a3cd-4d90e21406cf_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="ameh-20211231.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_640e3f4c-0dac-4996-8b22-8d84f45e6403_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_c35bfce9-8e25-448c-9c20-61335cd219fa_verboseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_label_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:to="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_77aff631-32f4-4bc1-8d83-b07b345ee80b_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0a27ac88-0785-4f30-89d9-36ae337750a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_e9e12237-11b3-44bc-aaf1-a6c390ef5283_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_48e27bf6-d4e6-4ffe-90ef-dee374123fbb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_9b7f25c8-753a-4fb8-ab5f-4b1e0ba8ad16_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxAssetsInvestment_1b677075-b481-4a8a-b934-811456dc9dad_verboseLabel_en-US" xlink:label="lab_ameh_DeferredTaxAssetsInvestment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in other entities</link:label>
    <link:label id="lab_ameh_DeferredTaxAssetsInvestment_label_en-US" xlink:label="lab_ameh_DeferredTaxAssetsInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Investment</link:label>
    <link:label id="lab_ameh_DeferredTaxAssetsInvestment_documentation_en-US" xlink:label="lab_ameh_DeferredTaxAssetsInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxAssetsInvestment" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxAssetsInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxAssetsInvestment" xlink:to="lab_ameh_DeferredTaxAssetsInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9ceb089d-ed0f-4b56-8bab-c6967b9a7b6c_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_3bbe8f85-9e28-445c-86bc-17392f114196_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c344222b-3775-471e-8da7-5e3b4fd0b332_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_665c65ed-74f8-45d5-8751-c0731bce0c7f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_f40e7d5f-d96d-490f-9959-1e0a7e9c4f92_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_8511437b-5f8e-40ba-adb0-96406d6104b9_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_d5d520ce-f61c-4dd7-9cef-516b0ef3289a_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f7a6ed0b-2bce-4b1d-87d8-eeb15aa37db7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_74c739b8-0028-4805-bbfc-a075b14bbc79_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_33041f58-012f-4102-8153-d874eb04440e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_60613b0e-922d-49e5-92d1-1fd4456e9e93_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on loan receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.ArteagaMember_b354809e-80d9-4320-b34f-23dec907ce26_terseLabel_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_label_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_documentation_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember" xlink:href="ameh-20211231.xsd#ameh_Dr.ArteagaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.ArteagaMember" xlink:to="lab_ameh_Dr.ArteagaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_01360ad4-99a1-4665-9eb9-c2b8b6f506cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_fb2fb38e-5022-43a3-92bb-ecfa0ef6c61c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f2963c3c-3dd0-4674-bd2e-e74abb82b4c6_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d3235b54-c75e-4d8c-8605-29e0a8e9c814_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APCMG contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fd9b5957-77da-4e74-915e-31ad8bdd7f05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_10fabc54-1f35-4689-9216-446cf6ae9a1f_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_e32a8ad8-9048-48c7-b327-3889694d5ea3_verboseLabel_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember" xlink:href="ameh-20211231.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthCareCapitationRevenueMember" xlink:to="lab_ameh_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_212836cc-6fe5-4b98-aece-0cf79d0f70c2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Expense and Other Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareIncMember_85701fac-07d5-4562-bd51-98d28dde7766_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc</link:label>
    <link:label id="lab_ameh_UniversalCareIncMember_label_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember" xlink:href="ameh-20211231.xsd#ameh_UniversalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_d04a54ee-529f-43c9-be43-1dfb3a9101b2_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_16a402f3-1359-456b-a7ab-be012963edfa_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_ea11380d-4745-4d91-a4c6-2114af558274_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated rate of note of loan receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableStatedInterestRate" xlink:to="lab_ameh_FinanceReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_671b10de-92b9-4b3b-ab61-8e520c84ef2a_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_ea34a9d3-9347-4de5-8416-1cc63d9f46da_totalLabel_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Liabilities Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5b92e0dc-728a-41bf-a81a-9db660411305_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_7b63a39f-b93d-415a-b519-8a3baf1f67cb_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_5ec448e8-a25b-49fc-81d8-19bb2aaea4b8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_f9e98ca0-b470-4ae8-a50e-e8083a02999f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f341d5c3-cb49-41dc-86c8-6a0f8d5315b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_5ae70551-5dba-4290-a5db-26ca2d71f4da_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_be72add1-d092-4ad4-9690-f93d31f211df_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_497dd167-d1e9-40a4-8f10-b1c3f1415506_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8a67de9e-b7c4-4d92-b430-2e0a2927c904_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) income from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_b0ab6f72-7069-4a32-9bad-bd6daae466a5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (income) from equity method investments, net</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e7d88b13-4517-444a-976a-4904c23356dc_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PreferredBankMember_fddfe899-ae4d-411f-891e-80804cca0f8c_terseLabel_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_ameh_PreferredBankMember_label_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember" xlink:href="ameh-20211231.xsd#ameh_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PreferredBankMember" xlink:to="lab_ameh_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.JayMember_0ce9ca20-1742-4687-9b1d-948c2d2f6c5b_terseLabel_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay</link:label>
    <link:label id="lab_ameh_Dr.JayMember_label_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:label id="lab_ameh_Dr.JayMember_documentation_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember" xlink:href="ameh-20211231.xsd#ameh_Dr.JayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.JayMember" xlink:to="lab_ameh_Dr.JayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_65e11717-ea72-416d-8d56-aa37fd6b5442_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_0a65348c-02ee-4dc9-a49a-aa7e37043f04_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_baead5ce-4ace-482d-ac80-29c2e726d8fb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finance Lease, Future Minimum Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_87d6716c-8fae-47cd-84bc-417ceec0a767_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmgIncMember_a177c000-7833-416f-82b0-5cd54313a348_terseLabel_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG</link:label>
    <link:label id="lab_ameh_AmgIncMember_label_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember" xlink:href="ameh-20211231.xsd#ameh_AmgIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3bf28489-f086-4e1e-a854-bd7a05882300_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_24e955ba-9b9d-423a-ae1b-f80783d2e08e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_f901cd2b-d572-4ee2-a6fd-d3c33fabca97_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_516d40fd-2998-4e9a-9e60-87620e30bbbd_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared included in dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_6c996089-0008-4784-bbdf-fd32c01404c7_totalLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receipts, net</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_7c296922-c671-4d81-953a-c2a2b9b4da6c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_657eaf86-aa0b-4bf5-8ab9-d5c02519b926_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_5de4144d-ea97-4e29-ade4-daa47cff2550_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_a65497d8-d123-4921-a719-df4c1bc53a86_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of main reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_77fffd6c-4802-4688-81ca-fd33af2feb69_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_88c7c685-50f7-441f-b873-7293f1be3cb6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_7e9051be-5bdf-45d8-b36a-e5e339a866b6_terseLabel_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_label_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_CAIPAMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_CAIPAMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAIPA MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember" xlink:href="ameh-20211231.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CAIPAMSOLLCMember" xlink:to="lab_ameh_CAIPAMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_cf04a2f4-14e8-49cd-b4f7-38347ab17e60_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MemberRelationshipsMember_d85c2522-00b0-4af7-a5ed-baf3ced3a9fb_verboseLabel_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_label_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember" xlink:href="ameh-20211231.xsd#ameh_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7b582dc1-e6b6-46e0-bfef-aa6149976130_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_71116750-23b0-4925-9096-226e4be44501_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_cb04c68f-701d-4fe9-adf7-9ef34fd9b3d0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Land, Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_0225e730-b7d9-4a6f-a4d1-fbe6ad3f1b91_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_4e7a4708-3883-457a-8691-0564621a533a_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_d14b5c18-6a09-4f56-b08c-97233040306f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_e3c3a8ea-474b-4785-a5ff-d20ea8af5d4a_verboseLabel_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables. Receivables &#8211; Related Parties, and Loan Receivable - Related Party</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_label_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables And Related parties Receivables Policy Text Block [Policy Text Block]</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:href="ameh-20211231.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:to="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityDistributionToNoncontrollingInterest_5c25de9b-261d-48e7-8337-5b32769e2598_negatedTerseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_ameh_TemporaryEquityDistributionToNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_TemporaryEquityDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Distribution to Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_TemporaryEquityDistributionToNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityDistributionToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Distribution to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityDistributionToNoncontrollingInterest" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityDistributionToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityDistributionToNoncontrollingInterest" xlink:to="lab_ameh_TemporaryEquityDistributionToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c0854d81-6c81-46df-af73-acd229e8ce01_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_1763db42-56fb-404c-9533-f80060f257ed_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, cash flow coverage ratio, minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7e922b57-4ed7-4df5-96c8-ec674049e893_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_24a0d2f4-13ae-4fb2-b670-a465b677d42a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_fd8c9015-2b78-4c86-a679-d6050ac14525_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_317a6833-ed74-4fb9-aa93-354c66b41bab_terseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_label_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember" xlink:href="ameh-20211231.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountableHealthCareIPAMember" xlink:to="lab_ameh_AccountableHealthCareIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_08d120a0-8ecd-4142-af7a-008c13bca785_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss (gain) from investment in equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationNumberOfSharesHeldBack_3f54d12d-f9bd-4ba5-9f18-6cd69886676b_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationNumberOfSharesHeldBack" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares held back (in shares)</link:label>
    <link:label id="lab_ameh_BusinessCombinationNumberOfSharesHeldBack_label_en-US" xlink:label="lab_ameh_BusinessCombinationNumberOfSharesHeldBack" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Shares Held Back</link:label>
    <link:label id="lab_ameh_BusinessCombinationNumberOfSharesHeldBack_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationNumberOfSharesHeldBack" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Shares Held Back</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationNumberOfSharesHeldBack" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationNumberOfSharesHeldBack"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationNumberOfSharesHeldBack" xlink:to="lab_ameh_BusinessCombinationNumberOfSharesHeldBack" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_feb30d30-e939-46d5-a3c1-08043f1c0cb1_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash recorded from consolidation of VIE</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_label_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:label id="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_documentation_en-US" xlink:label="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Cash Received from Consolidation of Variable Interest Entity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:to="lab_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_2636ba8b-229c-4fdb-a5e2-08eb7692425a_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of revenue, revenue recognized</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Revenue Recognized</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueRevenueRecognized_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueRevenueRecognized" xlink:to="lab_ameh_PaymentOfRevenueRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_92e4752c-2acc-4ef1-beb6-85e9e07427c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7bd5fbc1-6c47-4c08-bd50-e253e6f68488_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d5daf1a3-af30-4815-bf3d-6edfab8ad5b5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1df95272-4930-4ca6-88d8-4198038a40b7_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_7c04db65-d9d5-44ce-be93-03bcfeeaeb4f_terseLabel_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="ameh-20211231.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_6ada5203-338e-4f3c-83d0-70cccc9cd4ad_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementMember" xlink:to="lab_ameh_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_93eac8be-2214-45ae-a306-4315489d96a6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_38aa403a-e85b-4e25-a3ef-d7d03c2d4e19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_b20d3450-4e6c-4cf5-9714-ae9f023cd0f1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_27c90c24-103c-4663-b2c7-1d3842f745bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f8797fac-267d-4035-8464-64e8d3eef6ff_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_4068b73f-944d-4d8c-afb1-67267efd4d93_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9035ba46-8f3e-4b3c-b8ee-89477b3e8156_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_ae714522-41e2-4cb2-a294-7f26cb25f4af_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_2266f783-c2a4-409b-b1e5-3fec3f1e89ee_netLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_ff70f231-c44c-4575-9eff-f859efebeda7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance cost</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_7cd7f77f-389a-47f4-a65c-2b3e3d4057f2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_43cee018-2a34-4ccd-b3c3-5e5724f8cbb8_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_85f1f83d-8a0c-4bce-ba48-9a100b9edeae_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_48dcce13-a05c-47ba-81e4-8f814df0e642_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_fc98491d-6a22-471a-926d-361048a02c7d_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial interest acquired from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_label_en-US" xlink:label="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:to="lab_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_49412ebe-2ec5-40d1-b6f8-41f714fd3811_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss of disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IssuanceOfFinancingObligationForBusinessCombination_4dedc0d3-449f-47c5-a68e-d92d1ff17ad6_terseLabel_en-US" xlink:label="lab_ameh_IssuanceOfFinancingObligationForBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of financing obligation for business combinations</link:label>
    <link:label id="lab_ameh_IssuanceOfFinancingObligationForBusinessCombination_label_en-US" xlink:label="lab_ameh_IssuanceOfFinancingObligationForBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Financing Obligation for Business Combination</link:label>
    <link:label id="lab_ameh_IssuanceOfFinancingObligationForBusinessCombination_documentation_en-US" xlink:label="lab_ameh_IssuanceOfFinancingObligationForBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Financing Obligation for Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IssuanceOfFinancingObligationForBusinessCombination" xlink:href="ameh-20211231.xsd#ameh_IssuanceOfFinancingObligationForBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IssuanceOfFinancingObligationForBusinessCombination" xlink:to="lab_ameh_IssuanceOfFinancingObligationForBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_dc736749-c7ab-4732-92eb-467852281427_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_6ee8a34a-1eb8-4a6b-be33-59cf10f5e26f_terseLabel_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:href="ameh-20211231.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfRemotePatientMonitoringPatients_e20ac62e-38f1-43e3-95eb-09ccbf3f87f7_terseLabel_en-US" xlink:label="lab_ameh_NumberOfRemotePatientMonitoringPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Remote Patient Monitoring patients</link:label>
    <link:label id="lab_ameh_NumberOfRemotePatientMonitoringPatients_label_en-US" xlink:label="lab_ameh_NumberOfRemotePatientMonitoringPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Remote Patient Monitoring Patients</link:label>
    <link:label id="lab_ameh_NumberOfRemotePatientMonitoringPatients_documentation_en-US" xlink:label="lab_ameh_NumberOfRemotePatientMonitoringPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Remote Patient Monitoring Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfRemotePatientMonitoringPatients" xlink:href="ameh-20211231.xsd#ameh_NumberOfRemotePatientMonitoringPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfRemotePatientMonitoringPatients" xlink:to="lab_ameh_NumberOfRemotePatientMonitoringPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_6fcc4a81-2997-46c1-a3c5-c11dbbc7d049_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio, annual change</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_3cce9844-cd86-4067-bc16-03d42d1f7049_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_be08ef49-88ba-4bd0-9785-9b0fdd1ee7d9_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_c40e7886-0666-4196-b3a6-1756155949c7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_c049f0e4-18a7-4512-be8d-3bde95dd5f38_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c1e86ca8-2551-4048-bcb2-7fe87ce2d6dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, beginning of year</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_73c7adb4-a08f-43e9-8c1d-c80b3fa08f49_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, end of year</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_519205b3-5340-4e24-9fe9-7e4ba7eabb5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_d84d6779-96f9-4ec5-abff-c8aea9d55225_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceServicesRevenue_f3239dfc-3ee5-42fe-8de8-891f651dc16c_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceServicesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool revenue recognized under agreement</link:label>
    <link:label id="lab_us-gaap_InsuranceServicesRevenue_label_en-US" xlink:label="lab_us-gaap_InsuranceServicesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceServicesRevenue" xlink:to="lab_us-gaap_InsuranceServicesRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_a0cdf377-06a4-42bf-b3a0-0892967e8a68_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_09e06d8a-fd3a-43c4-8d6d-0c979ace7ff9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c3cad4e-9ad9-4fce-9a22-17647deb3545_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_19bf4d51-2620-42f8-91d7-6f04475632a1_terseLabel_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General amount of guarantee (as a percent)</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_label_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Financial Guarantee Benchmark Amount</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_documentation_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of financial guarantee on benchmark Medicare expenditure amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:href="ameh-20211231.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:to="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_f8f943dd-bad6-401c-b343-e9bd33f6e083_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_c339dc12-3097-4405-9a43-c6153d8532db_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_5005a78b-5598-4886-9cf8-460c5c0167ba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2e020656-12a7-4951-8be3-d84b068313dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e23730f3-20dd-4bd2-9b54-2b87d4264ef3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_fac4cf12-4ca2-4a0e-869b-d4f986e4ab57_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares by noncontrolling interest (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_4e71ffca-8565-4c6c-bcf4-ec1de9be88cb_terseLabel_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20211231.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_f023c0ad-9215-46fb-bc7a-7306f4462986_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_d726a012-ae5d-45f8-b9bc-c426f3c49c5d_terseLabel_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_label_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_documentation_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember" xlink:href="ameh-20211231.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Pacific6EnterprisesMember" xlink:to="lab_ameh_Pacific6EnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_63009487-b3c4-48a2-833d-bc8ad1870f92_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, equity interest purchase obligation, noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficerMember_4e0668de-6a2c-413a-8264-e9810127b9b7_terseLabel_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer</link:label>
    <link:label id="lab_srt_OfficerMember_label_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficerMember" xlink:to="lab_srt_OfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_6e3a079f-f456-4569-962c-dec1e83f79fd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_fc5ed709-09eb-46c5-935a-cd23fe5d2efa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_1353db13-185f-4e9c-9f6e-00a1c97e92ef_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12a2d459-c41a-43e8-95c2-73f3fdd8551c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_01347d61-4831-4c8e-9edd-84c0fad4c29f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_88b7b486-8c78-4372-be5d-4f6f11f15aad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_5adec81f-4de0-4ede-ab9e-07b13b247d78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3398dec4-1850-4907-9c35-293a26e6ee67_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_bf599adf-07c9-4a57-b6a0-bf394625287f_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_02240d4d-3316-48a0-9f10-f3a1f6c804dc_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_93bb7d61-025c-41e6-93be-2956c063d9a1_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5bad0cec-b940-4eae-a733-99ddb44ad7cd_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_4a8d0594-03a4-4f42-b417-16332189d001_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c07c7b49-364e-43bb-9c4e-f904e822410b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_dbcacd6d-4feb-4382-9b2e-67a5f144014f_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c897e656-def1-46d4-a71b-271165dea146_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_34c96b62-83be-4f11-84cc-3f8159856c09_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized financing cost</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_2108411b-47e7-4edf-a031-c876e57fe3f3_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, amount</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_f5e36238-431d-43fc-8bf8-598671ea28ca_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_e87f23b6-0e4e-40d5-b5d0-83154eb24ab5_verboseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_82c38ac4-e567-4851-940b-017c51b5c8d8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_09fbc138-92a9-4b47-9f85-209def1e3814_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e658b26a-173d-471d-82fc-7ab99fc3fc54_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_24bd117d-6eb5-49a8-ab7a-559e6e042dee_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_0f7b53f0-9b2e-43e9-988c-2d697a46c662_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_71bddacf-3aa3-4a6a-af9a-c8f6b4006246_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_da7861fb-7c73-4f70-b1c5-12ceb6d9124d_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bdb4c642-6e66-474f-b98f-090c76065b67_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b7109fbd-d90f-489b-83f9-1c2925357fb1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_10e2d22c-1f29-4fdb-914c-d965bcac3c83_terseLabel_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract" xlink:href="ameh-20211231.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalCareCostsAbstract" xlink:to="lab_ameh_MedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_09d4d80d-4aa2-435b-b486-37bffac0521d_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_ff5338cc-0aee-4482-9109-a50254a2ab0b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_79ee5cfe-b14d-4b59-ba23-26ad61c701da_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d9bd905c-b490-4d85-b5c9-ba49bca420fd_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8bcffb50-e5b6-463b-b375-90d4f19855b7_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_c635efd4-cdbd-4a3d-8aac-90304265eac5_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_7016c7e3-2931-4962-8345-4b9471b7f450_terseLabel_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_label_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group [Member]</link:label>
    <link:label id="lab_ameh_AccessPrimaryCareMedicalGroupMember_documentation_en-US" xlink:label="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Access Primary Care Medical Group</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:href="ameh-20211231.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccessPrimaryCareMedicalGroupMember" xlink:to="lab_ameh_AccessPrimaryCareMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_a55517e6-fc8b-4254-aa59-7e22598c0b48_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_390f7e9f-285f-4406-ab3e-e4c4e75aeff9_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_631f815d-accf-4643-bab9-c0d1deb94334_verboseLabel_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="ameh-20211231.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_a8763f20-21d6-400e-9c00-061c6ac47662_negatedLabel_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments on bank loan and lines of credit</link:label>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_label_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Bank Loan And Lines Of Credit</link:label>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_documentation_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Bank Loan And Lines Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:href="ameh-20211231.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:to="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_debc963a-f39f-4890-a04e-8371c2ed0b55_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_c933ebbe-c9e1-4001-95d4-3e47297b88f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Goodwill Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_357daba3-f897-4aab-b249-fe91e2e7a5d4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_13bf9806-6586-47db-aa9b-a098a7b07d6e_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward" xlink:to="lab_ameh_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_fa7c3d3e-7421-4546-8c2e-a7b186df082e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_c98a2610-a717-451e-a0f9-35ad8777b7f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfSharesHoldbackPercentage_67a3b4c5-7478-4a91-975f-d135e20edfc1_terseLabel_en-US" xlink:label="lab_ameh_NumberOfSharesHoldbackPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares holdback percentage</link:label>
    <link:label id="lab_ameh_NumberOfSharesHoldbackPercentage_label_en-US" xlink:label="lab_ameh_NumberOfSharesHoldbackPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Shares Holdback, Percentage</link:label>
    <link:label id="lab_ameh_NumberOfSharesHoldbackPercentage_documentation_en-US" xlink:label="lab_ameh_NumberOfSharesHoldbackPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of shares holdback pursuant to the merger agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfSharesHoldbackPercentage" xlink:href="ameh-20211231.xsd#ameh_NumberOfSharesHoldbackPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfSharesHoldbackPercentage" xlink:to="lab_ameh_NumberOfSharesHoldbackPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_7ab3f445-7ff5-46b6-a3fa-fc538c970957_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0e680e00-741d-4e97-ab0d-a71d1909d782_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OperatingLossCarryforwardsNotSubjectToExpiration_62897890-3273-4dc4-a735-3b794984f5a4_terseLabel_en-US" xlink:label="lab_ameh_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_ameh_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_ameh_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_ameh_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_ameh_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="ameh-20211231.xsd#ameh_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_ameh_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ExecutiveOfficerMember_b33735e1-03ff-4c67-88fa-fa762c1fa0f8_terseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executives</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_e1ca2337-0678-48ae-907b-024e5b2ef280_verboseLabel_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive restricted stock awards</link:label>
    <link:label id="lab_srt_ExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ExecutiveOfficerMember" xlink:to="lab_srt_ExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_18af57e1-a3dc-4b88-ae51-190347b79a11_terseLabel_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="ameh-20211231.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_76e93b71-a2ba-4259-8be1-91b326f98c22_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_309dfdd4-6eb5-4bc6-a425-e4bc94d6bcbb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CreditAgreementMember_476a7c4b-f2f3-4ec6-bcc2-3d6add9bfd9c_terseLabel_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_label_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember" xlink:href="ameh-20211231.xsd#ameh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CreditAgreementMember" xlink:to="lab_ameh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_b47f3bdf-4291-4247-a59f-e302a139af3c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_e7a356ec-0b87-4f64-863b-a14415f0855d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashlessExerciseOfStockOptions_3f402118-1e8a-48be-a429-81e48af9b781_verboseLabel_en-US" xlink:label="lab_ameh_CashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashless exercise of warrants</link:label>
    <link:label id="lab_ameh_CashlessExerciseOfStockOptions_label_en-US" xlink:label="lab_ameh_CashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashless Exercise Of Stock Options</link:label>
    <link:label id="lab_ameh_CashlessExerciseOfStockOptions_documentation_en-US" xlink:label="lab_ameh_CashlessExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashless Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashlessExerciseOfStockOptions" xlink:href="ameh-20211231.xsd#ameh_CashlessExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashlessExerciseOfStockOptions" xlink:to="lab_ameh_CashlessExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_e1d27707-17f3-45c9-b33f-5ca11e078235_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal corporate tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_88c5c649-9e8b-4280-a321-acc0651a8156_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax provision at U.S. federal statutory rates</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_76f968fc-0a6e-4456-b053-f392052342be_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_f887749f-5a9b-4954-876e-fee9a424bb55_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee6ac4f2-31d4-4459-b650-a64ad62083da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0e92ad88-9cb2-4f28-9e93-1a9e494819af_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6b69bdc7-9dc7-4c07-bf3a-698c5aa1b5ad_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9eed3d1e-7e13-47e4-adf5-4facbbc0a840_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_32d76780-2818-4aab-99a3-fe82841f7edf_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_5f2605bb-80c3-466a-9298-0a16ede64f1a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bd8ce4e3-5c4f-4d0b-8078-dfc8ebc7284b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3e63f4f1-a1e6-4ce9-be4f-6fd3ce8e683b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0185bfbc-daf1-4162-a2c3-b282a43682ac_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a8b964c7-f76b-4f9f-b457-dfd6ccf723f2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_d8cb42f5-7244-41a0-ae03-7f254cfa9355_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_a84c7575-1b15-4c0d-b3f2-397430b3b660_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ab612001-e810-4fc3-853b-e94a7a39e2d6_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f7299d12-5dcf-4029-96c9-4acf08c7b5f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of fixed assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_7ba9d2d6-c2a7-4970-9318-9f51725192f6_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercisable</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesStockOptions_319f4c09-9324-476b-bdae-d91e2926c322_negatedTerseLabel_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesStockOptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesStockOptions_label_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Stock Options</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesStockOptions_documentation_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesStockOptions" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxLiabilitiesStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilitiesStockOptions" xlink:to="lab_ameh_DeferredTaxLiabilitiesStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_10ad0d10-0ab8-471d-b5ef-8b3ad515f221_totalLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment/ Disposal</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_ab4bfb8a-e6d4-49b3-b7bd-af668645dee7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_f07b43ec-52e9-4a2a-8f68-42e3a19a581a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_36a05618-07b7-451f-8778-01df4fbafa46_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates*</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e73a68e0-8ad9-4667-8b3d-33341c514502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_69a262f7-4c51-43bd-8895-333239b8f706_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a96242d4-b3ad-43f8-a65a-8bb5d8b3c588_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_8124c796-e092-431b-b146-b0c6c133009c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_401fd6b1-10bd-4265-af22-2379ab2a341f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses from transactions with related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_27292a58-2746-4a28-9ad6-e9b6039ecb03_terseLabel_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_label_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units [Member]</link:label>
    <link:label id="lab_ameh_StockAwardsAndUnitsMember_documentation_en-US" xlink:label="lab_ameh_StockAwardsAndUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Awards And Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember" xlink:href="ameh-20211231.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockAwardsAndUnitsMember" xlink:to="lab_ameh_StockAwardsAndUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FormerShareholdersOfNmmMember_92876c2b-91c4-427a-b727-edf867aa404b_terseLabel_en-US" xlink:label="lab_ameh_FormerShareholdersOfNmmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Shareholders of NMM</link:label>
    <link:label id="lab_ameh_FormerShareholdersOfNmmMember_label_en-US" xlink:label="lab_ameh_FormerShareholdersOfNmmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Shareholders of NMM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FormerShareholdersOfNmmMember" xlink:href="ameh-20211231.xsd#ameh_FormerShareholdersOfNmmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FormerShareholdersOfNmmMember" xlink:to="lab_ameh_FormerShareholdersOfNmmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_8b349e33-51c6-4f7d-bbf7-50ac305ee90c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled, forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_97f74f2b-bfa8-406b-b320-c494ebd18c0f_terseLabel_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC</link:label>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_label_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC [Member]</link:label>
    <link:label id="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_documentation_en-US" xlink:label="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orma Health, Inc., and Provider Growth Solutions LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:href="ameh-20211231.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:to="lab_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_51143e25-0029-4e61-944c-159ea488b67c_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsContribution" xlink:to="lab_ameh_EquityMethodInvestmentsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_84219abe-dc2f-4fc9-a827-44bc62681abd_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_7502153c-5612-4f4b-8fb8-45bb23882b44_terseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM and APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California And Network Medical Management [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California And Net work Medical Management [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_8e7af1a3-84ff-456c-9b1b-2e497b892b6b_terseLabel_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloMed</link:label>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:href="ameh-20211231.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_2a3e8fea-240b-4dea-b2eb-05d6f2952b59_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Debt Securities, Trading, Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DmgMember_e9013400-b3ec-4244-ac6d-78ee648e221e_terseLabel_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG</link:label>
    <link:label id="lab_ameh_DmgMember_label_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_198fdeb2-7ece-40ba-b6fa-e609fd8574d8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_88e64de1-2502-43c0-b7ea-5c131cd03c00_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial consolidation gain</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Initial Consolidation, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:to="lab_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_76d30e8c-11e6-491b-bd28-ccae07c9b480_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_4c4aecc1-4370-4213-a867-68f9a7e6330a_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_2e67b247-7252-4419-9cde-dc00ba186cca_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_60528b11-f308-49cb-bb45-a1535ca3117a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Other than Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_85da1094-ca7e-427e-9df2-b0f1eafff006_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_95e3264a-e7b2-4213-ad3b-41514aec7b4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_68a1d8be-564a-4e66-bc2c-55d19b4ddc0b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required annual facility fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_85698bba-1a7c-4f94-914e-bb5ed56ccb55_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_53be93da-377c-4dc5-a1be-cfdefe99af0d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_5d561f74-75ea-46c7-ad62-ad59a7798f6c_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests acquired (in dollars per share)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_005db3e0-ddfd-4220-ab91-944b48271fd9_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire common stock and warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireCommonStockAndWarrants_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:href="ameh-20211231.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:to="lab_ameh_PaymentsToAcquireCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_877883af-8b44-4c8b-b8c8-255f3f8063da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_725fc125-83f7-47fb-bf13-d3402da87693_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_75e325e6-c7db-4599-a62d-125154762a8a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_d00f71b2-899d-49b6-a7d1-0ef3866cb2b1_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_33709b78-7696-44e3-a3b6-119db8fd26de_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_0164c265-7cf7-4ed2-8a30-2e6e0280e2ab_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill and intangible assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_6995a508-a79e-446f-b42f-e415d73ab800_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_bdcbea59-1d40-407d-abb4-01f0dee1d513_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dbd5984d-57e1-4af5-8e63-fb5ca617cc8d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_8906326d-50ca-4e40-97a9-4805f2799c6d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f795df1f-8592-4ca5-a896-d7d35ca2c740_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_beaeefc3-9685-4292-8e7f-5bd3a1102a7e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b588d86d-5ce9-4f27-8fb0-d2bdc6e648ce_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a91eea9e-00e5-4740-85a5-dc9b322dad2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by based payment award outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4aff7965-c58a-42b7-97b5-19c53dca53b8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a54deb72-e5ea-4124-913d-749a74eebc87_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_b1e3d9c0-dd11-4251-9983-36a1683768bf_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tradename/trademarks</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_7a000c61-937b-4709-9382-5b78b0360d3f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MediPortalLLCMember_e92d7632-f096-4957-a828-f002728f7eff_terseLabel_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC</link:label>
    <link:label id="lab_ameh_MediPortalLLCMember_label_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember" xlink:href="ameh-20211231.xsd#ameh_MediPortalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MediPortalLLCMember" xlink:to="lab_ameh_MediPortalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_7709f999-553f-4ff8-a499-d600bc4b54ca_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, equity interest purchase obligation, period to purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_label_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:label id="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Equity Interest Purchase Obligation, Period to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:to="lab_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_1cd7f662-ad39-4218-9984-7a498c8d0f61_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_d597ab33-453f-4985-88b8-0279a84892c3_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_5c6271c7-f5a3-49fa-8bf4-d7a7758ed899_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ebe1d5b8-8344-43ba-a1fa-a8653e479c8f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_cdf4f46a-58f8-4a12-b33d-0a3eb4c92cc4_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants forfeited (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_d302a0e2-3db1-4d60-8cf0-5d8cd7c718da_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived assets written off</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_195b4734-48e9-4785-b96b-ac3996952556_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_A10CommonStockWarrantsMember_ee8a71ae-c7de-4407-8c3d-6f6fdce35028_terseLabel_en-US" xlink:label="lab_ameh_A10CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$10 Common Stock Warrants</link:label>
    <link:label id="lab_ameh_A10CommonStockWarrantsMember_label_en-US" xlink:label="lab_ameh_A10CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$10 Common Stock Warrants [Member]</link:label>
    <link:label id="lab_ameh_A10CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_ameh_A10CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$10 Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A10CommonStockWarrantsMember" xlink:href="ameh-20211231.xsd#ameh_A10CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_A10CommonStockWarrantsMember" xlink:to="lab_ameh_A10CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_93b9e53a-20b2-4e95-90cf-9373b519fbfb_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_cdd9cbf7-3348-4a8b-a597-26a0070b98f8_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants forfeited</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_a0c1f85c-b321-4a71-9412-b8927e105130_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in ownership percentage, finance receivable converted</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_75144616-1e46-4df4-84a0-1dfb5e0057af_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ManagementContractsMember_fd734119-f64e-4146-b510-338abc43f0d2_verboseLabel_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_label_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_documentation_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember" xlink:href="ameh-20211231.xsd#ameh_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_8a793d1c-e8e7-4260-805f-ac8d43e2de0b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_170a020b-20c4-4734-b49e-7909f395d144_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_09795294-dade-44d0-91fd-00699060c842_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_a1b56f53-9d70-4bc7-bb25-8948c205e1d7_terseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA Line of Business</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_4a1fe098-aa9f-4a63-8328-07424da14bb6_verboseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MWNCommunityHospitalLLCMember_beea1331-03b4-4cb2-84c4-084aaaeacad0_terseLabel_en-US" xlink:label="lab_ameh_MWNCommunityHospitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MWN Community Hospital LLC</link:label>
    <link:label id="lab_ameh_MWNCommunityHospitalLLCMember_label_en-US" xlink:label="lab_ameh_MWNCommunityHospitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MWN Community Hospital LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember" xlink:href="ameh-20211231.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MWNCommunityHospitalLLCMember" xlink:to="lab_ameh_MWNCommunityHospitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_52a8c0d0-137c-4dd9-b227-63fc12359f43_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9b0fab1e-ff6b-4884-9a19-42cb55101ef4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities - equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_207e6acb-7e9d-4557-a079-b2e8d684452e_negatedTerseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation of Entity</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Consolidated</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsConsolidated_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Consolidated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsConsolidated" xlink:to="lab_ameh_EquityMethodInvestmentsConsolidated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a2ad9f0e-ec1c-4c14-95cd-8e5a8f274f9b_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_26048ede-a050-47bf-a096-49c04c404c07_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_432458c4-8df3-474b-b3a1-7e4f35ba0e6c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares_0c8eb9ef-701f-4f9e-8a0b-f0a6e7e18ffe_terseLabel_en-US" xlink:label="lab_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of 50% holdback shares (shares)</link:label>
    <link:label id="lab_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares_label_en-US" xlink:label="lab_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase During Period Shares Release of Hold Back Shares</link:label>
    <link:label id="lab_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares_documentation_en-US" xlink:label="lab_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares that have been released during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" xlink:href="ameh-20211231.xsd#ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" xlink:to="lab_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_bc43d69f-b288-480d-8038-a71838630422_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_9ac16344-935d-45f1-bdd8-e286c281f572_negatedLabel_en-US" xlink:label="lab_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments in privately held entities</link:label>
    <link:label id="lab_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_label_en-US" xlink:label="lab_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Investment Privately Held Entity Does Not Report To NAV Per Share</link:label>
    <link:label id="lab_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_documentation_en-US" xlink:label="lab_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Investment Privately Held Entity Does Not Report To NAV Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" xlink:href="ameh-20211231.xsd#ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" xlink:to="lab_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLossOnDerivative_9322ad6c-0391-4ad0-b699-86dc7d0c0650_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss in interest rate swaps</link:label>
    <link:label id="lab_us-gaap_DerivativeLossOnDerivative_label_en-US" xlink:label="lab_us-gaap_DerivativeLossOnDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLossOnDerivative" xlink:to="lab_us-gaap_DerivativeLossOnDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HSMSOMember_48385dd3-3fe5-4945-834a-bc273cd35ee3_verboseLabel_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HSMSOMember_label_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_ameh_HSMSOMember_documentation_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember" xlink:href="ameh-20211231.xsd#ameh_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HSMSOMember" xlink:to="lab_ameh_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a32175b7-1fca-4af7-b6e3-cd4c2bcf12d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_5de9769c-0861-475b-959f-394e92bff80e_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_94d1ad7a-13ea-4cd7-8ce7-e71b54ae78dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_ec737bc2-d570-42d6-8490-3dec4cc176af_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:href="ameh-20211231.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_c9f6d56b-a9b3-4a95-ac7f-c0320eb6b8eb_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability adjustment related to warrant exercises</link:label>
    <link:label id="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices_label_en-US" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment of Warrants Granted for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DefinedContributionPlanServicePeriod_84afa51b-b151-48ed-94de-ad6fe5e154d6_terseLabel_en-US" xlink:label="lab_ameh_DefinedContributionPlanServicePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, service period</link:label>
    <link:label id="lab_ameh_DefinedContributionPlanServicePeriod_label_en-US" xlink:label="lab_ameh_DefinedContributionPlanServicePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Service Period</link:label>
    <link:label id="lab_ameh_DefinedContributionPlanServicePeriod_documentation_en-US" xlink:label="lab_ameh_DefinedContributionPlanServicePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DefinedContributionPlanServicePeriod" xlink:href="ameh-20211231.xsd#ameh_DefinedContributionPlanServicePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DefinedContributionPlanServicePeriod" xlink:to="lab_ameh_DefinedContributionPlanServicePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AurionMember_e34751a9-b973-4168-aa88-c8e89c6f3a2d_verboseLabel_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_ameh_AurionMember_label_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_ameh_AurionMember_documentation_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember" xlink:href="ameh-20211231.xsd#ameh_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AurionMember" xlink:to="lab_ameh_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2cea43a9-534a-4fc1-89d9-bcb1bcef52f7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_dcb4e86d-d653-40be-a832-5e5d4276afca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_8b81d134-a55b-4c2c-98e6-2c32145accd5_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of family practice clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_label_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Family Practice Clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_documentation_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Family Practice Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics" xlink:href="ameh-20211231.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFamilyPracticeClinics" xlink:to="lab_ameh_NumberOfFamilyPracticeClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_3e9e5744-7328-43c3-87dd-8d44f7c8448e_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ebaac9a2-6759-402e-86c6-0db5fa417911_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_4f38379b-7ecc-4dd6-8ca4-033186315744_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_6769bb12-a255-4190-92ae-a21da586f868_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_38a32ff5-1b5f-4ab3-8357-c7ab4975d8b1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_c8ca9fa0-0cbd-4870-9f3f-8598b71afdb9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_92b8d965-ff00-4f09-8992-c38999cac518_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineEquityAbstract_f60691d3-d057-4452-a0b4-66a3daa51348_verboseLabel_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_ameh_MezzanineEquityAbstract_label_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract" xlink:href="ameh-20211231.xsd#ameh_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_74947a8d-eac7-4aca-9f00-e4d3bf2319e8_terseLabel_en-US" xlink:label="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest capital charge</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_label_en-US" xlink:label="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase From Capital Charge</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_documentation_en-US" xlink:label="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase From Capital Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestIncreaseFromCapitalCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:to="lab_ameh_NoncontrollingInterestIncreaseFromCapitalCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_7256143e-4378-494f-bb03-3b14ea802497_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstateLoanMember_9ee250bd-40ff-463f-80f7-7062ab46ea31_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real estate loans</link:label>
    <link:label id="lab_us-gaap_RealEstateLoanMember_label_en-US" xlink:label="lab_us-gaap_RealEstateLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstateLoanMember" xlink:to="lab_us-gaap_RealEstateLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_bbaab6f2-4efe-4b5d-9b5a-349d6f9114c3_terseLabel_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc</link:label>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" xlink:href="ameh-20211231.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2912e884-a0bf-495a-8af7-4e020925dc00_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity, and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_44b9e79c-6702-4aaf-ae7d-105d09771ff9_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_0ca6df76-d0f0-4930-8acd-f9897fc5df30_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of beneficial interest</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_edba66c5-7e80-4803-a692-7fa234069ebb_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated interest coverage ratio</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_08337181-96c4-4cd5-a634-cf2ced03a70e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche one</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6915f561-79d2-4cbd-b9fb-9c20b05ad470_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c7b6bca0-e48a-48df-9d12-db5dcd630417_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorCMember_0ea051fd-13d0-4214-af8e-a5c3fb493bea_terseLabel_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_ameh_PayorCMember_label_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_ameh_PayorCMember_documentation_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember" xlink:href="ameh-20211231.xsd#ameh_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorCMember" xlink:to="lab_ameh_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_f2bf4732-5460-4f8c-beaf-49ec28e1408f_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_670a91da-f538-47c5-9c32-8e854ded4c1b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueConversionOfNotes_b8273599-3223-4457-b28a-f0b50e2191e9_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueConversionOfNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period value conversion of notes</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueConversionOfNotes_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueConversionOfNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Conversion Of Notes</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueConversionOfNotes_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueConversionOfNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of stock issued during the period upon the conversion of notes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueConversionOfNotes" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueConversionOfNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueConversionOfNotes" xlink:to="lab_ameh_StockIssuedDuringPeriodValueConversionOfNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_6d3ad76d-1f5a-4517-ad23-7f9b044faed7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_76a0a695-5af0-40f9-b79e-5707ee7ff75e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfDirectContractingEntityPatients_bd5efff7-4343-46d0-9b49-5f2dcb8fbf56_terseLabel_en-US" xlink:label="lab_ameh_NumberOfDirectContractingEntityPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Direct Contracting Entity patients</link:label>
    <link:label id="lab_ameh_NumberOfDirectContractingEntityPatients_label_en-US" xlink:label="lab_ameh_NumberOfDirectContractingEntityPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Direct Contracting Entity Patients</link:label>
    <link:label id="lab_ameh_NumberOfDirectContractingEntityPatients_documentation_en-US" xlink:label="lab_ameh_NumberOfDirectContractingEntityPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Direct Contracting Entity Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfDirectContractingEntityPatients" xlink:href="ameh-20211231.xsd#ameh_NumberOfDirectContractingEntityPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfDirectContractingEntityPatients" xlink:to="lab_ameh_NumberOfDirectContractingEntityPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConsultingServicesMember_536493f0-7a6f-4a5d-8f43-910969816acc_terseLabel_en-US" xlink:label="lab_ameh_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services</link:label>
    <link:label id="lab_ameh_ConsultingServicesMember_label_en-US" xlink:label="lab_ameh_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:label id="lab_ameh_ConsultingServicesMember_documentation_en-US" xlink:label="lab_ameh_ConsultingServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConsultingServicesMember" xlink:href="ameh-20211231.xsd#ameh_ConsultingServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConsultingServicesMember" xlink:to="lab_ameh_ConsultingServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_10a2f388-953e-4765-9c6d-d5ba6f153cb3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcStockOptionMember_55a236ff-6580-49f5-9b3c-63dddb7638a4_terseLabel_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option</link:label>
    <link:label id="lab_ameh_ApcStockOptionMember_label_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember" xlink:href="ameh-20211231.xsd#ameh_ApcStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcStockOptionMember" xlink:to="lab_ameh_ApcStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SubcontractorIpaRiskPoolPayable_ab6de77b-7aa8-46d6-9f65-d803035d94c5_verboseLabel_en-US" xlink:label="lab_ameh_SubcontractorIpaRiskPoolPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_ameh_SubcontractorIpaRiskPoolPayable_label_en-US" xlink:label="lab_ameh_SubcontractorIpaRiskPoolPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Risk Pool Payable</link:label>
    <link:label id="lab_ameh_SubcontractorIpaRiskPoolPayable_documentation_en-US" xlink:label="lab_ameh_SubcontractorIpaRiskPoolPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of subcontractor IPA risk pool payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIpaRiskPoolPayable" xlink:href="ameh-20211231.xsd#ameh_SubcontractorIpaRiskPoolPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIpaRiskPoolPayable" xlink:to="lab_ameh_SubcontractorIpaRiskPoolPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d924aac3-6d91-4a26-99a6-e15b7ecdd247_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_3ccb2a9c-5ebc-4636-9f8f-b1194509050c_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_7f02b531-8249-4f16-94e5-4a7232226322_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_bef532a9-f82b-4080-8da5-885c5a029386_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4d6a8179-1bbb-4941-8419-7480a145ec45_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_1fec4041-7b9b-4e8f-9559-1ce61ee46b83_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_a62a3016-314f-4df2-8232-53569539ee42_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_117d3bb2-29d2-4639-ba20-5a3deacbaf90_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_d5f37287-62a7-49d1-94b6-2b2d095aa243_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity_c4065656-d7dd-4fd1-b583-d01b1e9743a3_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of options liability to equity</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Liability Reclassified To Equity</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Liability Reclassified To Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" xlink:to="lab_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AHMCMember_b45542cd-1411-4ea6-8c2f-63e944fb3397_terseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_label_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember" xlink:href="ameh-20211231.xsd#ameh_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AHMCMember" xlink:to="lab_ameh_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityRepurchaseOfTreasuryShares_77646318-42b4-434f-85ed-a72fc4c8274b_negatedTerseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityRepurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of treasury shares</link:label>
    <link:label id="lab_ameh_TemporaryEquityRepurchaseOfTreasuryShares_label_en-US" xlink:label="lab_ameh_TemporaryEquityRepurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Repurchase of Treasury Shares</link:label>
    <link:label id="lab_ameh_TemporaryEquityRepurchaseOfTreasuryShares_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityRepurchaseOfTreasuryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Repurchase of Treasury Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityRepurchaseOfTreasuryShares" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityRepurchaseOfTreasuryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityRepurchaseOfTreasuryShares" xlink:to="lab_ameh_TemporaryEquityRepurchaseOfTreasuryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_91935b50-1240-46e2-91f4-1acfd7f88830_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_51a2e679-3b14-466d-8961-368b7a79200f_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_33e40586-db4e-40b7-8eaa-6d86c272639a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_ea59242a-3f74-4870-84ca-77bfa189ba76_terseLabel_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities:</link:label>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_label_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="ameh-20211231.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1c528e33-f21d-4910-8c24-45e55058b215_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled, forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_25a5249a-cef7-4d9d-85f6-87027c0cf923_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1f5b1ea6-99d2-4f5e-a2e2-8279c2c8e312_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss_8c059bfe-afef-4339-9574-ede448c7fdf5_negatedTerseLabel_en-US" xlink:label="lab_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded, loan receivable - related parties</link:label>
    <link:label id="lab_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss_label_en-US" xlink:label="lab_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Noncurrent, Gain (Loss)</link:label>
    <link:label id="lab_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss_documentation_en-US" xlink:label="lab_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Noncurrent, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss" xlink:href="ameh-20211231.xsd#ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss" xlink:to="lab_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5620d8d8-1dd4-4caa-8eaf-db4145926a6e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_49f0818d-622e-47ee-9cfe-5c7d1b381369_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_8b1f68c9-6735-4448-9bf7-90a298697aeb_verboseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, maturity period</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_label_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableTermOfReceivable" xlink:to="lab_ameh_FinanceReceivableTermOfReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract_397584cb-a1c8-4f5f-b474-417513d8ca23_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease cost</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_58ad8c49-de25-41d4-ab24-94f853372e83_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_c61657f1-1960-4549-ab91-d5eebe43254c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FreseniusMember_7b23ea0b-2471-46d9-8b41-424551209706_terseLabel_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:label id="lab_ameh_FreseniusMember_label_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius [Member]</link:label>
    <link:label id="lab_ameh_FreseniusMember_documentation_en-US" xlink:label="lab_ameh_FreseniusMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fresenius</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember" xlink:href="ameh-20211231.xsd#ameh_FreseniusMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FreseniusMember" xlink:to="lab_ameh_FreseniusMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_1a1a9a78-b65c-4099-b85a-20ec06a0d15c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_209490a2-fe94-4ca2-8e6d-7aa970af4d71_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during period new issues</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_545999fb-1454-4be5-9b71-530f7d41a70d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4417708d-e646-447d-82d7-beb59e6a4b28_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_42ff5d09-060d-4e9b-87a5-d348cda7f9e7_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5224b223-1492-4c1f-87a9-371226a6eb51_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Bank Loans, and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_f3db4e71-8959-48fe-9244-1edca0c9bf4b_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for cashless exercise of warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2d91ec2d-ec0e-453c-9127-81be0bddce02_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_ee0ab3f1-c6ec-445d-a20b-9dc00a1c8a46_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_256f5b05-b4ca-4dae-92e2-68b2837bd5b8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet_8cc93018-1abc-47e0-aea8-3b9f618d2afa_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Options Issued, Option To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Options Issued, Option To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:to="lab_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_841a2c3e-b027-43aa-9c6b-c5f6dbacfdb3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_76d7c934-1a72-4fe6-b0a9-8b6319b98871_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_99bbc34b-41bd-4dbe-8d4b-256b06828f09_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of ordinary dividends common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_63cd5c51-3da0-4668-8615-6ef6588ab71b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_acedee97-0341-457b-a64a-53d056462618_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_889e0c56-6051-4007-a788-dea3aebbe3f7_negatedLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_928d2c77-92d8-4728-858a-519d650d64fb_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest costs incurred</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5586ad82-d144-4112-8df5-5ad48e79a392_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased by related party (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_bda0a8d1-d505-454a-9e65-a3e1dbeb1862_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_ae86a9a3-d3c5-4217-ad9b-3d342cbc0a0f_terseLabel_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_label_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_documentation_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:to="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_34edc986-e9df-4c50-99b3-10c5701337bc_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_86de1677-f016-49e6-879c-64638f8e4568_terseLabel_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_label_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member]</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_documentation_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember" xlink:href="ameh-20211231.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CollegeStreetInvestmentLpMember" xlink:to="lab_ameh_CollegeStreetInvestmentLpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0d015f43-53ec-4726-9115-fc90096b08df_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_668ad538-5ecd-4644-a84d-541f881a21a2_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_e87aeb58-e934-4578-b21f-27565a2b144c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_104828bb-be13-4f1d-90a8-ead97a4af512_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c9e75e71-4b2f-4e2e-b19a-97fd4bd95fdc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_c7d13165-5301-4db4-87b6-63171a37d493_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_e3f05e3b-fee8-48a6-977c-3f11a862e869_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_db935c0b-a994-432f-8513-4401a62abc2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_02999cd0-fbd3-4d43-af89-0aca839e11d6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_a02e51e1-30ce-4885-a212-bdd215b2a9c9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash &#8211; short-term</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCMember_98c74c5f-0518-44db-a17e-b509e207276b_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC &#8212; related party</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCMember" xlink:to="lab_ameh_OneMSOLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesNoncurrent_12ce71ff-c2e0-4ee8-ba82-d37025e46087_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesNoncurrent" xlink:to="lab_us-gaap_DueFromRelatedPartiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_50184830-4cf9-47ff-880e-868e5a237a34_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_781b7128-59ec-4759-a205-1627c6c15bf0_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_36695692-d1fd-4e0f-a940-f1cdc159af74_terseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableAbstract_f926f5d2-832a-444f-bdaa-4c00dab2d1fb_terseLabel_en-US" xlink:label="lab_ameh_LoanReceivableAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Abstract]</link:label>
    <link:label id="lab_ameh_LoanReceivableAbstract_label_en-US" xlink:label="lab_ameh_LoanReceivableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableAbstract" xlink:href="ameh-20211231.xsd#ameh_LoanReceivableAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableAbstract" xlink:to="lab_ameh_LoanReceivableAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_9a158c17-f245-47c3-92c9-d3bf8c697475_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2cb613fb-b55f-4486-85cf-53c86d64bfdb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_654e8693-18be-4db5-95c8-6b5801290da8_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_34990fcb-3126-47fd-ac3a-428f60065297_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, fair value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0219e397-7428-4519-819a-a3111c36384b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_8153ecee-7dd4-498e-8243-f2b0c80f9451_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum adjusted consolidated leverage ratio</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_f44a2acc-98dc-4994-8129-b27337580455_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_f381d125-7b8f-4f57-ba40-2a82b4a071f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_d7ade2be-f08c-46bc-902e-5d448de93f5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableTextBlock_11c8ab9b-8502-4350-a0ca-df47ce1cdc5f_terseLabel_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Receivable and Loans Receivable &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_label_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock" xlink:href="ameh-20211231.xsd#ameh_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_a3cdfce2-2f84-4560-ae08-e1d56d23fc2b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_743c8ae9-7c25-4b51-825c-9f96269ec1e2_terseLabel_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_label_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc. [Member]</link:label>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member" xlink:href="ameh-20211231.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthSourceMSOInc.Member" xlink:to="lab_ameh_HealthSourceMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_f172fa02-fa76-4953-9504-2c7e31b54bf9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_e954b965-7f92-4a92-a6cb-8529f8eb0ece_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumenLLCMember_08296a3e-bbf2-4d66-ab5b-be07dac3d54e_terseLabel_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen</link:label>
    <link:label id="lab_ameh_NumenLLCMember_label_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember" xlink:href="ameh-20211231.xsd#ameh_NumenLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumenLLCMember" xlink:to="lab_ameh_NumenLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_5dc5b409-2fb6-4212-9c73-d04c3a742c47_terseLabel_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 and thereafter</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_label_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:label id="lab_ameh_LongTermDebtMaturityAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:href="ameh-20211231.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LongTermDebtMaturityAfterYearFour" xlink:to="lab_ameh_LongTermDebtMaturityAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_00f29cce-87af-4c5e-a792-11ad19b80094_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_75a35ed9-7cdd-4b1f-9d2b-8bea8cf6ae0e_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:href="ameh-20211231.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_caefb4a4-876c-4376-bad9-59bcb2411f79_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SCHCMember_54403e77-fd94-4e23-9a46-69e989c04ecf_terseLabel_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:label id="lab_ameh_SCHCMember_label_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:label id="lab_ameh_SCHCMember_documentation_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember" xlink:href="ameh-20211231.xsd#ameh_SCHCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SCHCMember" xlink:to="lab_ameh_SCHCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6429972b-1c1a-40b9-9760-6aeed7e187e4_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DefinedContributionPlanVestingPeriod_49aa3dc5-148f-464c-8279-2ed33e34c249_terseLabel_en-US" xlink:label="lab_ameh_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit vested estimated year</link:label>
    <link:label id="lab_ameh_DefinedContributionPlanVestingPeriod_label_en-US" xlink:label="lab_ameh_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Vesting Period</link:label>
    <link:label id="lab_ameh_DefinedContributionPlanVestingPeriod_documentation_en-US" xlink:label="lab_ameh_DefinedContributionPlanVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DefinedContributionPlanVestingPeriod" xlink:href="ameh-20211231.xsd#ameh_DefinedContributionPlanVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DefinedContributionPlanVestingPeriod" xlink:to="lab_ameh_DefinedContributionPlanVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_86d257e6-dce5-4d3c-9302-6014907c04da_terseLabel_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</link:label>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:href="ameh-20211231.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:to="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_735c66d6-05f6-420a-ad87-35f76b05e568_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from investment in warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_8f0e6dd7-8ccd-4b5f-a2c0-b8ec307f2858_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_10ee9bd0-5231-47fd-a39f-14673ed584b6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_77ea7326-4bb4-4458-972f-6559469fe867_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_e070ec2a-e65f-42e7-bda3-571b44ee02e5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_68d61d16-05e2-450d-9c8c-6b592a03772d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_c0f1a441-6fbc-4ed2-ba58-0820d15f7e5f_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans receivable &#8212; related parties</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_89c18fa9-7a16-49e9-9fb0-52f2b186cf28_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_978e1a25-e2e8-4649-a987-f1588127968e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c031be6d-737d-4893-82c0-b0d680ce4f50_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_10810fcb-4e85-4934-b815-ddf12c7d64ef_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_63e216ad-709e-43b0-813c-10dbecdeec64_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, common, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReclassificationOfLiabilityForEquity_6028a608-7e79-49e5-9738-0d8005ca8727_terseLabel_en-US" xlink:label="lab_ameh_ReclassificationOfLiabilityForEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of liability for equity shares</link:label>
    <link:label id="lab_ameh_ReclassificationOfLiabilityForEquity_label_en-US" xlink:label="lab_ameh_ReclassificationOfLiabilityForEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Liability For Equity</link:label>
    <link:label id="lab_ameh_ReclassificationOfLiabilityForEquity_documentation_en-US" xlink:label="lab_ameh_ReclassificationOfLiabilityForEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Of Liability For Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReclassificationOfLiabilityForEquity" xlink:href="ameh-20211231.xsd#ameh_ReclassificationOfLiabilityForEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReclassificationOfLiabilityForEquity" xlink:to="lab_ameh_ReclassificationOfLiabilityForEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_c749272d-d244-46d2-b622-467ead680aab_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with business acquisition</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_3f400dc3-af20-41db-8690-99f2cb61c30d_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_d524801f-572d-43b8-878a-70d14f87e9fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_088bc2e3-b12b-409f-b2d8-310f7cf4abb4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_48940b35-7ead-4d08-89f8-28f905d49256_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f0272a67-4e2a-44eb-838e-91e30a39beba_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_dc7e6bbe-356c-4b50-8ce7-2f35f35e3f6f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareMember_2523c70e-aca5-4246-abf4-cfac250384a6_terseLabel_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ameh_MedicareMember_label_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ameh_MedicareMember_documentation_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember" xlink:href="ameh-20211231.xsd#ameh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_b10b033b-50a8-486a-ac95-c116f88e807c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CMSMember_c971acb7-b7f6-480f-a183-6ae98d675bad_terseLabel_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS</link:label>
    <link:label id="lab_ameh_CMSMember_label_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:label id="lab_ameh_CMSMember_documentation_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember" xlink:href="ameh-20211231.xsd#ameh_CMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CMSMember" xlink:to="lab_ameh_CMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_059060a4-6ca1-48a9-a2f3-e5e3c8782b6d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC stock issued in exchange for AMG</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_088e60cd-5f27-4ec0-83b7-005813b663da_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_15f67fd9-5af4-4209-9572-80056fa94ee6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate at end of period</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e496b1ca-5685-49de-9f6c-e1a040ffdf9d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_9ac10d94-4c92-4ca8-99b5-1e9a32c44ac2_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_af62ed54-196f-48e1-9060-af2c232cdf26_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of revenue, monthly amount</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:to="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_83d53164-322d-4a79-940e-f33b3b396017_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityNetIncome_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityNetIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Net Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityNetIncome" xlink:to="lab_us-gaap_TemporaryEquityNetIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSettlement_e0218541-49e1-4107-aecf-20d7e4015f3a_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlement</link:label>
    <link:label id="lab_ameh_RiskPoolSettlement_label_en-US" xlink:label="lab_ameh_RiskPoolSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Settlement</link:label>
    <link:label id="lab_ameh_RiskPoolSettlement_documentation_en-US" xlink:label="lab_ameh_RiskPoolSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">These lines are represents that risk pool settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSettlement" xlink:href="ameh-20211231.xsd#ameh_RiskPoolSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSettlement" xlink:to="lab_ameh_RiskPoolSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3562dff-e8e5-4142-bcf2-bd75d5440e03_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_31af9641-08e2-4daf-b073-c03799a56e35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b442b278-d67e-43b6-a7e5-8a327385cec4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_142dc13b-e9ce-44ee-9324-8af41c73c93a_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (&#8220;APC&#8221;)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_67016610-e480-4557-9961-ebb6cc36ffbf_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount, beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_5a9ea77c-8399-439a-be33-ae213001de72_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary equity, carrying amount, ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityStockSubscription_cf2e6d3d-5ae2-4439-ad0c-4bd658c9e068_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityStockSubscription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscription</link:label>
    <link:label id="lab_ameh_TemporaryEquityStockSubscription_label_en-US" xlink:label="lab_ameh_TemporaryEquityStockSubscription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Subscription</link:label>
    <link:label id="lab_ameh_TemporaryEquityStockSubscription_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityStockSubscription" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Subscription</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityStockSubscription" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityStockSubscription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityStockSubscription" xlink:to="lab_ameh_TemporaryEquityStockSubscription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_8f7efa9a-3b54-413a-b3f3-84b5caef30cb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AchievaMedInc.Member_192f6456-3794-4383-8932-aecbfb6a1cf2_terseLabel_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc.</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_label_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_documentation_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member" xlink:href="ameh-20211231.xsd#ameh_AchievaMedInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AchievaMedInc.Member" xlink:to="lab_ameh_AchievaMedInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_2a619333-b2eb-4675-bbaf-690d9a0cc9bc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_1e37f570-e6cc-4709-b96b-2fbbd47bcfa0_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_64f86b50-e71d-4193-a27a-6e9fb436ecf0_terseLabel_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_label_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:href="ameh-20211231.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_820f874b-f71f-4b98-a725-48cb6335807e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_c86d4d77-5837-415a-8e64-7e7f9f488060_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Warrant2Member_59134e0e-8403-43d5-9dbd-c7edd06002c8_terseLabel_en-US" xlink:label="lab_ameh_Warrant2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant 2</link:label>
    <link:label id="lab_ameh_Warrant2Member_label_en-US" xlink:label="lab_ameh_Warrant2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Warrant2Member" xlink:href="ameh-20211231.xsd#ameh_Warrant2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Warrant2Member" xlink:to="lab_ameh_Warrant2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6e9ad57c-8b9b-4570-bc52-d34e4835856a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_3a83c74b-155e-4e32-b0f0-b137dc7a16cd_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, interest rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:to="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_79c9199f-9df6-45f5-9fb2-cda753a8b6cb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_1ca215ac-1b22-497f-aa6f-49075425e7b5_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_c97945a9-ea3e-4ec3-bb93-d029b21a90a8_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b6c42cb8-6a4d-4fb3-b97b-29168c613b59_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_642a04ac-2ee0-4f35-97d0-479f03bb6d3b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b0dc227f-6d54-4deb-9867-cccdbc7e89bb_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorDMember_95e200a8-5db5-4f2c-88c1-2fc76097f8a9_terseLabel_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_ameh_PayorDMember_label_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember" xlink:href="ameh-20211231.xsd#ameh_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7960eb04-5f52-43b4-8a9f-7ed4fb18bc18_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_2da2eebf-56b6-4008-bc5f-7e08d85db502_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments, Financial Statement Information</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_271ac350-8716-4b5b-b8eb-4067be4d04b0_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_a1ffd890-caa9-4fed-ae9e-cdc050907cbe_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCAP</link:label>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_label_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:href="ameh-20211231.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d28f5f89-901c-4a06-bad2-691f49cfc313_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_db7432e2-cb7f-4671-9083-ab20e53157a8_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:href="ameh-20211231.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_4947b66d-d253-453b-a527-082b0ba32a6b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_dd547717-5325-4d84-9be1-ceb67d462778_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_ccf10b44-1bb0-44f9-8f51-e62abb3d3a09_terseLabel_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC &#8212; related party</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag6MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-6 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:href="ameh-20211231.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag6MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_d1b75952-3dad-4813-be96-063c3da1be22_periodStartLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb317e12-4d91-4699-a41e-e141b7d86303_periodEndLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_daecb68f-6b32-4c87-93a7-92039b0eb16c_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_b2cdc998-103e-4fae-a427-fb4e9b1d7c28_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c0f1e887-0f65-4619-a247-698f00197210_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_00bd82d4-7a85-4908-a7d5-f4ccca17b4b2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a1e0e89d-22ce-4112-a69e-36980e3d8d5f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d0226508-7ae9-4f9d-a661-89e3ca85483a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b1100ec6-d3b5-4fe8-8c64-268581c5e4ab_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_580dc1a1-db43-4d76-80b2-00ce70f21765_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at ending</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00479ebc-13f2-4f09-99be-6bcad81c46be_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_93d39f7e-42b1-4797-b1ae-ca396bd0d209_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3772eaf9-0e22-42f7-9a0c-ff7de4260274_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd013d94-2a0c-4046-8e5e-b2d3ae21ba69_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_355f5c9c-a7a2-4ce6-8f58-ceb4b59ae221_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for cashless exercise of warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Cashless Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Cashless Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_acb0c69a-3a04-4fc4-b69b-3b0d4d4e5135_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_98b4aa5c-b805-4098-a287-3c30c11a0ee4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_b9123063-677b-49d9-8284-75815bdeaf88_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_985c4745-7f54-428e-8cda-131231dcc15a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_4c6b44dc-39df-44c9-9c68-4cc48f67865d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_05dddb8b-5bec-4cf0-acee-949d506f8cf2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_955d3229-b367-4f75-87fd-d65c7868a970_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fdadf970-2399-4688-b6e8-7453052b0c2b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_627f71a7-0425-4eb2-95c2-fff134aa999c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_6bea758c-fab5-45c8-b105-3adee6ef3bd9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance, increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_ebd7afcf-e4e8-4635-9c91-57bdef2bffcb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fees Incurred and Income Received Related to AHMC, HSMSO and Aurion Corporation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_9f80f7e4-95ec-4fdb-bb51-d48a28136fc2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_476582ae-1de5-4f30-912e-d0e0863ea6e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_cb485e29-9ee9-4091-a51a-14c31376b5e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_5dea8bef-9bdc-4527-a659-2961dcaec06f_terseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Discount Rate</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:href="ameh-20211231.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_7cf6ee95-ad97-4290-a154-c351892500b2_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_2a306326-a33e-4c43-b69b-1e181bd62757_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromOtherOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Other Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromOtherOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HoldbackSharesMember_4be5b62d-ca8b-4095-876e-f20c3380717f_terseLabel_en-US" xlink:label="lab_ameh_HoldbackSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares</link:label>
    <link:label id="lab_ameh_HoldbackSharesMember_label_en-US" xlink:label="lab_ameh_HoldbackSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HoldbackSharesMember" xlink:href="ameh-20211231.xsd#ameh_HoldbackSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HoldbackSharesMember" xlink:to="lab_ameh_HoldbackSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_a8f48917-0269-42bf-b994-2cd97dfac652_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_7433048a-0ba7-4930-86ce-28e62e42f5f9_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_374c054e-4a87-44a8-8c04-998140178cee_terseLabel_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ProceedsFromEquityOffering_5bc6eda3-71cd-48de-b2ae-67a4067f5d52_terseLabel_en-US" xlink:label="lab_ameh_ProceedsFromEquityOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock offering</link:label>
    <link:label id="lab_ameh_ProceedsFromEquityOffering_label_en-US" xlink:label="lab_ameh_ProceedsFromEquityOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Offering</link:label>
    <link:label id="lab_ameh_ProceedsFromEquityOffering_documentation_en-US" xlink:label="lab_ameh_ProceedsFromEquityOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromEquityOffering" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromEquityOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ProceedsFromEquityOffering" xlink:to="lab_ameh_ProceedsFromEquityOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_b5aaaf68-2ae6-4761-85e3-1c22b838f5e2_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cashless options, exercises in period (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_a3391562-0915-421f-9a5e-a39fd8c52f80_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_c8ce6a87-ea72-4500-a104-aa3b099652a7_terseLabel_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, percentage of shares acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_label_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:label id="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired_documentation_en-US" xlink:label="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Percentage Of Shares Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:href="ameh-20211231.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:to="lab_ameh_AssetAcquisitionPercentageOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_61367d6d-31ec-48c3-bbf6-5b6e7298d8b5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_e910bbaa-fe76-4456-86a0-973ecb7fbb34_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ab8a9ef1-826e-4a05-af56-799da80d31d6_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_7f0a42ee-eea1-45ce-9083-5c8fdcd0e0fe_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_58637a85-3f55-47f7-ac89-61d081b2cd18_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_baedb2ba-dc51-4ad2-98e3-e16856e56497_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AuditInformationAbstract_6cd7b2e7-0d28-4854-ae9a-6691df5306b7_terseLabel_en-US" xlink:label="lab_ameh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ameh_AuditInformationAbstract_label_en-US" xlink:label="lab_ameh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ameh_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ameh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AuditInformationAbstract" xlink:href="ameh-20211231.xsd#ameh_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AuditInformationAbstract" xlink:to="lab_ameh_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8e89e17c-73af-436f-9468-6b32f2788f28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_a481560e-ab99-4810-a977-d6cc92804385_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due to affiliate*</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_80aecd94-8030-4464-8865-2234dca3a5e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_f1d82887-b9a6-4761-856f-f36fda1b1a6f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_7b2502cd-377a-407e-9230-546d4d5b27de_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_f8673750-ace2-4cb0-a230-204d647b8715_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, cash held in escrow</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ca17d6e0-1073-4ab6-b72f-33b9f6531887_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_169e610e-4aef-42f6-a7d0-06a71baed6a2_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_588bbf2c-3ca3-48e0-bf7f-062732986af7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_77e04516-6156-415e-99ae-b63a5e974e83_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_d866fe99-6bfc-407f-860e-c79f80aad18f_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_515315cd-0ae4-4bfd-a13a-686f1931ef8b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_e0ed3949-5b17-41b2-b4f5-0e6166058dd3_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_1d00bc1c-6bf9-49b3-8720-0104c4221f78_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_666e4210-beeb-437e-ae73-5e668b6c35c5_terseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Lease Term</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="ameh-20211231.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8b23fe1e-420c-448d-bb0d-d46724de162d_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3f6641f1-c3b7-4cfc-923b-6c6e986378db_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_414a4908-76ce-42c3-a416-6b048454fec8_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_1f2ec4d5-3b5e-47c5-b74b-8408b8241a74_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b485f9f3-1454-447b-8945-daf4ac31112a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_de79b8ca-711e-4d31-b6f0-dfb89e6bba96_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_c9e96b3e-432e-4c6f-82da-9565c58d6469_terseLabel_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NGACO</link:label>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_label_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement [Member]</link:label>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_documentation_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:href="ameh-20211231.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:to="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ad765448-dbc9-4cb3-93af-b9a099956a7a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_e756db84-4972-444d-b138-7f557e2a08c7_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorBMember_e1ac09a7-60d4-4543-9dd3-1e9a827266cd_terseLabel_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_ameh_PayorBMember_label_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_ameh_PayorBMember_documentation_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember" xlink:href="ameh-20211231.xsd#ameh_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorBMember" xlink:to="lab_ameh_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_224183fc-864a-4b5e-abe9-5448cb909ea7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_2c700f85-ac1c-4363-8773-f63eedc1dda1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_aa059779-439d-40a5-a12d-6a2a0d4548d7_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period value of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_4a956c50-4357-4967-ac79-1ab0fc77d143_negatedLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised" xlink:href="ameh-20211231.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_671c57d6-ab24-44c0-9219-84ba99a90dd3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_62a4c7c0-ed99-4c4b-a80c-567496ccd426_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_44be802c-55dd-449e-8f78-fa043ca2b0c0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term, performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1a0cdf7e-b5a9-4658-8a3f-52e052deafad_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_20f38651-7785-437d-ad15-1b5937847970_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_32f17a5f-88db-458b-922d-0371b7e4fb08_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_556c0f1f-d81d-451a-9946-0a3f3ba001c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_daf0b8a6-d779-4667-9ee2-4e3178072df5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_e6f9fa8a-972c-4492-99be-e11f45516bb1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_2c5ceacc-cdd5-45cd-b52f-26e620fa5ab9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_26a97a42-1c10-416c-93bb-4f0dda8961ea_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_7bf02b74-4450-4ca3-a19f-83f6c7f691c7_verboseLabel_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:href="ameh-20211231.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_84635ee1-fd1f-42de-8df0-32473e371de2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5dca1b05-4c87-49d3-a144-bc06a9dcb262_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f3069ec1-2a5d-486c-87f5-089e1df59e9a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_4851d54d-55ce-47fb-a5f2-4a8170f3100f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_d77f88e3-1327-4e73-b2c9-5dc4d721b697_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliates</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_034fe810-cdf1-41a9-b696-0111a2f16cfb_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_2d24fdb5-2f2d-44d4-b1dc-30b0104ce72a_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_93db747e-fc48-4659-8f33-9c4f0ea448c8_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_a4b3c007-45b3-4e8d-9ab8-bfe7d246d2bb_terseLabel_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_label_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition [Member]</link:label>
    <link:label id="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MPP, AMG Properties, and ZLL Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:href="ameh-20211231.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:to="lab_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_36fb5511-359c-4193-a368-28b9c3aad93b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsMinorityInterest_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:to="lab_us-gaap_PaymentsOfDividendsMinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7dd9010f-19a6-4fd1-8379-46347b582873_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_9afca650-5db7-452c-93a3-4a2d24776e6a_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_51df4648-1aa3-4fb1-abca-d51dbfb4b889_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_aa4f62b1-dc8c-4ef2-9a51-7315c862affc_terseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:href="ameh-20211231.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_dce356dd-c132-4a27-a80f-ee340bc247b5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_9cda3e7b-e083-47c6-acb5-0ac8bb5d0579_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_c5232381-ccef-46f6-8d40-97cac68832d7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareLicenseMember_c00c6590-0a65-4bd7-8788-d1b16101aae2_terseLabel_en-US" xlink:label="lab_ameh_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_ameh_MedicareLicenseMember_label_en-US" xlink:label="lab_ameh_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare License [Member]</link:label>
    <link:label id="lab_ameh_MedicareLicenseMember_documentation_en-US" xlink:label="lab_ameh_MedicareLicenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare License</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareLicenseMember" xlink:href="ameh-20211231.xsd#ameh_MedicareLicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareLicenseMember" xlink:to="lab_ameh_MedicareLicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fc41b8ef-870a-485b-be63-d98df0bc5989_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation for Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_ab190f86-2efd-4c82-a8fc-eb497b55743a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_b79d2a31-d651-4b94-a86a-ad09b3f6862a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for bad debts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_14111aa1-9c4d-49cc-ad76-53a22bcaa64e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_8ecc1045-3008-419c-a914-3a1370015b7c_terseLabel_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC and APC-LSMA</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_label_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_documentation_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember" xlink:href="ameh-20211231.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APCAndAPCLSMAMember" xlink:to="lab_ameh_APCAndAPCLSMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_9f9e89f0-e72f-4286-a8f7-587530828011_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_73a7fe59-5852-4d0f-85b1-ecb9448e74fb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of financing obligation for business combinations</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_41b5be5a-4c80-46a6-875f-d3a5769edc47_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_b456ecf6-9713-404a-a701-4b1399743e82_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8700746a-f3bd-4da8-a366-c0513d24196a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services, excluding depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8186cb9f-a793-4949-8c26-9c3cf3afae58_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_a1d8870b-5908-4371-822a-2bc77281a361_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_277c4189-9e53-4d30-8b8d-4634a9f9d793_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_8f9163a9-6612-4064-90f9-1322bc3ab62f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cd229cd8-61e4-40fd-ae1d-8fb568a02c5e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_546d02c1-9b5f-4aa3-86f4-1c7a6d392d36_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of options liability to equity</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_059e7114-ee53-4ced-8e60-d9f7a286824c_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of shares by noncontrolling interest</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Noncontrolling Interest</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:to="lab_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_49545874-d1b6-453d-8de2-8e094f021793_terseLabel_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities</link:label>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_label_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities [Member]</link:label>
    <link:label id="lab_ameh_ContingentEquitySecuritiesMember_documentation_en-US" xlink:label="lab_ameh_ContingentEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Equity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember" xlink:href="ameh-20211231.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContingentEquitySecuritiesMember" xlink:to="lab_ameh_ContingentEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_594bf555-08d6-4d34-8a1c-03cc58559cce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_0c27cdca-ce06-455d-855c-316a55a90afd_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares received from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockAmountIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Amount Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_050ec7c4-7529-40f2-b1ea-b7fa154c150c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_752a079f-7960-40fd-8847-4c86490ca968_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_85b6b6bb-902c-49e4-9a9e-203745c33579_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5194e626-20fa-44e0-9f33-def6ac726708_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_3ad205cb-08aa-48d0-9901-234622d6f5e1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f209add4-23f9-42c1-9e6f-2384a1799e92_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_3d32891d-9b1a-48a0-b717-89f3eedf9859_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_34d750c6-b11d-4f16-a4cf-396a6a33f026_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_eced44ac-61f3-459a-950e-5cc39c1572c8_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_b1a94623-f26f-42cb-9cb8-36a27b14b707_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise&#160;Price&#160;Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PatientManagementPlatformMember_aa6ceefe-7468-4c53-bc88-03317eee582f_verboseLabel_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_label_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember" xlink:href="ameh-20211231.xsd#ameh_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_ffc2bfb5-6d03-40dd-8167-116f5a2b7c9b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorFMember_fb1769b7-e95e-4c2b-a223-8555977ddd61_terseLabel_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F</link:label>
    <link:label id="lab_ameh_PayorFMember_label_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:label id="lab_ameh_PayorFMember_documentation_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember" xlink:href="ameh-20211231.xsd#ameh_PayorFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorFMember" xlink:to="lab_ameh_PayorFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_2ae71992-44a1-49a1-b455-9e939471791e_terseLabel_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_label_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:label id="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_documentation_en-US" xlink:label="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:to="lab_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_d0108229-2d83-4b28-996f-c1afa1292ac6_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_fad96830-540b-4295-a52e-5039132d4212_terseLabel_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest</link:label>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_label_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest [Policy Text Block]</link:label>
    <link:label id="lab_ameh_BeneficialInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BeneficialInterestPolicyTextBlock" xlink:href="ameh-20211231.xsd#ameh_BeneficialInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BeneficialInterestPolicyTextBlock" xlink:to="lab_ameh_BeneficialInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_92414d15-fa96-408b-a137-f3d860f7e290_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f19fa0b4-f2f4-4284-b588-925ae121cbfb_netLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_50a703f6-b565-4872-9fc2-4f85e55a6a52_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_A11CommonStockWarrantsMember_72095b54-cffd-444c-9558-d2c11d492f35_terseLabel_en-US" xlink:label="lab_ameh_A11CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_ameh_A11CommonStockWarrantsMember_label_en-US" xlink:label="lab_ameh_A11CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$11 Common Stock Warrants [Member]</link:label>
    <link:label id="lab_ameh_A11CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_ameh_A11CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$11 Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A11CommonStockWarrantsMember" xlink:href="ameh-20211231.xsd#ameh_A11CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_A11CommonStockWarrantsMember" xlink:to="lab_ameh_A11CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cc590704-5158-4c2d-b9e1-493952a082e9_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_66deec87-1e52-46b6-9bde-298a683a673a_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_d0b50a25-5eb9-4131-97bc-3aeb665a62ea_terseLabel_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of payment upon termination of agreement</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_label_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_documentation_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:href="ameh-20211231.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:to="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineMember_e631ec04-3811-40df-b5a9-217534952867_terseLabel_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity&#160;&#8211; Non-controlling Interest&#160;in&#160;APC</link:label>
    <link:label id="lab_ameh_MezzanineMember_label_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember" xlink:href="ameh-20211231.xsd#ameh_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineMember" xlink:to="lab_ameh_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_f4aa58d2-7e95-4d3f-853c-c949ff301acf_terseLabel_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" xlink:href="ameh-20211231.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_2e79bb32-6214-4d1a-8ced-506b3848c219_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_d9d1d035-7328-436b-b168-69ba02c60d75_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_d3aad1b0-ed2d-4602-89ae-5f5f11c4d67e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_09cb337c-e0db-4a7c-bcd3-2f704fe7f83f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_cae4dcf1-ec53-4ec8-9347-b9a8c3caf94d_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_22b54e21-9c68-497e-84b6-54c8a0d73d9b_terseLabel_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc. [Member]</link:label>
    <link:label id="lab_ameh_ClinigenceHoldingsIncMember_documentation_en-US" xlink:label="lab_ameh_ClinigenceHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinigence Holdings, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember" xlink:href="ameh-20211231.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClinigenceHoldingsIncMember" xlink:to="lab_ameh_ClinigenceHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_010da2c1-45c4-4783-aa67-6fada745dc34_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_176f1061-72d4-427b-b561-6f81a920ec29_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5db91c05-4d21-4194-a1d1-ffc63fc8f588_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1c167d87-899c-4074-b289-db6d9e383dfd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_5ea785a3-22bf-4115-b9bc-a0a93dffa4f0_negatedLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9941b8db-274f-4a0f-9dc9-24ba3476a6b7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_4247639b-fc39-4763-b859-2d3b7795af9e_netLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TermLoanAMember_defe2136-8a9f-4ba1-a57f-8e4f723fe3e7_terseLabel_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan</link:label>
    <link:label id="lab_ameh_TermLoanAMember_690640c5-0967-466c-bda4-536731443776_verboseLabel_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan A</link:label>
    <link:label id="lab_ameh_TermLoanAMember_label_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_ameh_TermLoanAMember_documentation_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember" xlink:href="ameh-20211231.xsd#ameh_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TermLoanAMember" xlink:to="lab_ameh_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_056e4225-b3a2-44d9-8b01-946ac4d81042_periodStartLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_738de9ad-3e20-4843-8e3c-3efe8f7fd5d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_fa721619-a9a7-4158-aab3-ca2db9e9582e_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in millions)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_20d64816-b5e1-4ce2-8eee-eb114bed5a8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_86d82d46-e8c9-4988-9e8d-6e5d93ef15ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PrimaryBeneficiaryMember_41d2314b-ecb8-4a62-95c3-32144b043898_terseLabel_en-US" xlink:label="lab_ameh_PrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Beneficiary</link:label>
    <link:label id="lab_ameh_PrimaryBeneficiaryMember_label_en-US" xlink:label="lab_ameh_PrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Beneficiary [Member]</link:label>
    <link:label id="lab_ameh_PrimaryBeneficiaryMember_documentation_en-US" xlink:label="lab_ameh_PrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary Beneficiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrimaryBeneficiaryMember" xlink:href="ameh-20211231.xsd#ameh_PrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PrimaryBeneficiaryMember" xlink:to="lab_ameh_PrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_da5ab97d-4c8e-4406-ab21-0b6e03e03960_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_7835d5c8-9442-4170-a0ac-8a5de925f63a_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e270fa4e-8d2e-4531-8263-9c3c2875c23e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5fa860df-2b65-4153-ab77-5426f9451478_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcLsmaMember_17d565f3-8f96-4b56-8f3e-dcad1957c2ce_terseLabel_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA</link:label>
    <link:label id="lab_ameh_ApcLsmaMember_label_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember" xlink:href="ameh-20211231.xsd#ameh_ApcLsmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_1e299ee5-4d04-4029-a5bc-4a8c790e6818_terseLabel_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC &#8212; related party</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_label_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC [Member]</link:label>
    <link:label id="lab_ameh_Tag8MedicalInvestmentGroupLLCMember_documentation_en-US" xlink:label="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tag-8 Medical Investment Group, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:href="ameh-20211231.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:to="lab_ameh_Tag8MedicalInvestmentGroupLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4b9c2d9a-1049-4c7d-bdec-905b9dd9f986_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d7971808-c3d7-4e29-b6b4-fe22fb735584_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_3fc5357a-fd6e-4260-ab02-e59229d9b1e9_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase additional membership interests (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0d8a4434-bda4-499d-a27f-108d23a620d3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_fef99f06-4b52-4d07-9e73-fe355c6f5bdd_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercises in period (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_d02e7f3d-c2a0-44f3-981e-62f4b3f853db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_84e6a9eb-8a0f-413e-a67c-1be9185d0cea_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_51fee528-aef0-49c0-8777-80e9c1ad1dce_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ExecutiveOfficerAndDirectorMember_e9349280-a44f-4312-8202-220ec68bb887_terseLabel_en-US" xlink:label="lab_ameh_ExecutiveOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Members and Directors</link:label>
    <link:label id="lab_ameh_ExecutiveOfficerAndDirectorMember_label_en-US" xlink:label="lab_ameh_ExecutiveOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Director [Member]</link:label>
    <link:label id="lab_ameh_ExecutiveOfficerAndDirectorMember_documentation_en-US" xlink:label="lab_ameh_ExecutiveOfficerAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Officer And Director</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ExecutiveOfficerAndDirectorMember" xlink:href="ameh-20211231.xsd#ameh_ExecutiveOfficerAndDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ExecutiveOfficerAndDirectorMember" xlink:to="lab_ameh_ExecutiveOfficerAndDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_8c5731ee-ecc5-4b8d-a21f-c59c687c5157_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_8064a31b-a910-40b1-834d-0784981f30d1_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_label_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable [Policy Text Block]</link:label>
    <link:label id="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Cash and Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:href="ameh-20211231.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:to="lab_ameh_FiduciaryCashAndPayablePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b886409d-990e-412f-8269-542d2646c2f5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_82f92048-c38a-4538-91f6-c24d2cb2c674_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisition amounts:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a08df324-a19b-4414-b40e-28e4b68d827b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_3dc5a592-fc6a-4a3f-bdb1-3650edbe2007_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate during period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_66701a0a-9585-4822-8799-802883ef5040_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted" xlink:href="ameh-20211231.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConstructionLoanMember_e6e3eb72-77e5-4529-8bc9-5d577a4794b3_terseLabel_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction loan</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_label_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan [Member]</link:label>
    <link:label id="lab_ameh_ConstructionLoanMember_documentation_en-US" xlink:label="lab_ameh_ConstructionLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember" xlink:href="ameh-20211231.xsd#ameh_ConstructionLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConstructionLoanMember" xlink:to="lab_ameh_ConstructionLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2c91774c-e276-43d7-ab1c-9f145d04a1a0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_93c987a6-1b6a-4a5a-8579-91ae12040250_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss_a909a626-47ef-4c6a-b614-862d8bd6498a_negatedTerseLabel_en-US" xlink:label="lab_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded, loan receivable</link:label>
    <link:label id="lab_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss_label_en-US" xlink:label="lab_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, After Allowance For Credit Loss, Current, Gain (Loss)</link:label>
    <link:label id="lab_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss_documentation_en-US" xlink:label="lab_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, After Allowance For Credit Loss, Current, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" xlink:href="ameh-20211231.xsd#ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" xlink:to="lab_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_0d779b35-15e8-4316-8a86-22ab793d4a9e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of debt and equity issuances</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_1ad65b99-3c41-4e33-8c00-e5347e6b5d58_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_520cf4d5-f257-4115-b3f4-ed6233c3bfc0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_84dc6f28-cf97-42fb-b6da-40257ffa539f_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityShareBasedCompensation_ae7c1451-e916-412c-ba04-22aeecf74967_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ameh_TemporaryEquityShareBasedCompensation_label_en-US" xlink:label="lab_ameh_TemporaryEquityShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Share-based Compensation</link:label>
    <link:label id="lab_ameh_TemporaryEquityShareBasedCompensation_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityShareBasedCompensation" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityShareBasedCompensation" xlink:to="lab_ameh_TemporaryEquityShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_791e69cd-9c8a-404d-9d8d-a2bc7f472b91_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_25d985ad-33e2-4c4e-b0bb-f896e4c4c5c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1a7826ea-04bb-488f-95d8-d80d88cd2de1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_937b405d-bc6a-4d0b-9be9-2264ec13d369_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_13be822c-cbf0-4fe3-8d3a-90a82bbae7de_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amount</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MembersCapital_7a6a4e19-b6b3-4b52-b673-b674f534ecb7_terseLabel_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial capital contributions</link:label>
    <link:label id="lab_us-gaap_MembersCapital_label_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members' Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersCapital" xlink:to="lab_us-gaap_MembersCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_431b8ea0-00a4-4131-9216-1f644d66578d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value, gross liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_5695bd0e-86c6-441f-b0c9-250d888adfbc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_7d3c3836-3019-4e32-b817-c280b5afd4e8_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_6728c9a8-1592-40fb-98ae-f8876765391d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_b5e20b85-ce82-4f47-89d4-01b16cc044c0_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_4f3b8c5a-229d-408e-9716-3aefc31f83b4_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_4c8ed0d4-9bce-48c2-b2e1-926fa36b2fc5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_94ef725f-b045-4c81-974c-09449606160a_terseLabel_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="ameh-20211231.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_1adadd27-e9c0-455b-a49d-a504b32db62a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accruals</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_a60f7545-33ee-4ca1-8f0f-9f1de6c46f32_terseLabel_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, aggregate purchase price, maximum</link:label>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_label_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:label id="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum_documentation_en-US" xlink:label="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Covenant, Aggregate Purchase Price, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:href="ameh-20211231.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:to="lab_ameh_DebtCovenantAggregatePurchasePriceMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_045519ef-aeeb-4bd1-86cf-093c9759bb15_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_3be9960f-280e-4dbd-8149-e7c440fa8af4_terseLabel_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_label_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:href="ameh-20211231.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:to="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment_43606335-0f7a-4cb0-a659-fe9747eceb16_verboseLabel_en-US" xlink:label="lab_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible permanent items</link:label>
    <link:label id="lab_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment_label_en-US" xlink:label="lab_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Federal Rate Adjustment</link:label>
    <link:label id="lab_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment_documentation_en-US" xlink:label="lab_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the effective income tax rate reconciliation of federal rate adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" xlink:href="ameh-20211231.xsd#ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" xlink:to="lab_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeAxis_db4472b2-0875-426b-8352-297421dfd076_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:label id="lab_ameh_ContractTypeAxis_label_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis" xlink:href="ameh-20211231.xsd#ameh_ContractTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeAxis" xlink:to="lab_ameh_ContractTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66cf8c8e-7348-41e6-8990-62696d8ee732_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1f6610c5-a39e-404d-be5d-3fca1315c63d_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_559e5800-26e1-4e41-98ca-26a9573adbbd_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" xlink:href="ameh-20211231.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_ba93e652-1b79-4907-ad35-61125c579166_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionOfDividends_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Accretion of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionOfDividends" xlink:to="lab_us-gaap_TemporaryEquityAccretionOfDividends" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>ameh-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:56a96635-232a-499f-a03d-15d085375db3,g:3c5e1a1a-f2ce-472c-bc52-288bd5b84a32-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/Cover" xlink:type="simple" xlink:href="ameh-20211231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e3d25959-02d1-4210-914c-a87f9f8bcf3c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_DocumentType_e3d25959-02d1-4210-914c-a87f9f8bcf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_26a4227e-107b-430d-9af1-7f2421a650e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_DocumentAnnualReport_26a4227e-107b-430d-9af1-7f2421a650e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ecbab7c5-828a-497a-8a38-816a62ad28da" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_DocumentPeriodEndDate_ecbab7c5-828a-497a-8a38-816a62ad28da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d9ce681f-ffeb-49c0-b35d-7169af7f46db" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_CurrentFiscalYearEndDate_d9ce681f-ffeb-49c0-b35d-7169af7f46db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7108b043-651e-4f70-bc72-7f484190de54" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_DocumentTransitionReport_7108b043-651e-4f70-bc72-7f484190de54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_67b42c29-3ae6-4f38-918b-56113da485e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityFileNumber_67b42c29-3ae6-4f38-918b-56113da485e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c853af1e-e1ca-43b3-b6f7-1d122ee0ee05" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityRegistrantName_c853af1e-e1ca-43b3-b6f7-1d122ee0ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bd2bed08-3459-48af-8e85-aaa49a26053c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bd2bed08-3459-48af-8e85-aaa49a26053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_220f35f3-700d-4352-bb8a-2227bc3456fb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityTaxIdentificationNumber_220f35f3-700d-4352-bb8a-2227bc3456fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2be97f1d-7d39-4a1c-b106-765b76c5a27e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityAddressAddressLine1_2be97f1d-7d39-4a1c-b106-765b76c5a27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_3f1c5e21-ed3a-47b7-a049-26af5099ee9a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityAddressAddressLine2_3f1c5e21-ed3a-47b7-a049-26af5099ee9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_9b6ee212-f78e-4c87-a955-f149ef3f58f3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityAddressCityOrTown_9b6ee212-f78e-4c87-a955-f149ef3f58f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_95faa8e1-2d22-416e-be33-004b5ce91c23" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityAddressStateOrProvince_95faa8e1-2d22-416e-be33-004b5ce91c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d2662342-5a96-45b5-b3a6-c0640fc74fe3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityAddressPostalZipCode_d2662342-5a96-45b5-b3a6-c0640fc74fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b0e29bf8-b68d-41de-b282-1eec348eec80" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_CityAreaCode_b0e29bf8-b68d-41de-b282-1eec348eec80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ca286445-3761-4c34-9d74-f11a70cb1058" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_LocalPhoneNumber_ca286445-3761-4c34-9d74-f11a70cb1058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a313770-dfac-42e4-876e-7fefd13c17ab" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_Security12bTitle_4a313770-dfac-42e4-876e-7fefd13c17ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a22839ed-ec43-4e85-abe8-c8e903d1210c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_TradingSymbol_a22839ed-ec43-4e85-abe8-c8e903d1210c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_de8017e6-ce21-4161-a114-d42d3542b1ee" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_de8017e6-ce21-4161-a114-d42d3542b1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_c89ece03-3ceb-4083-a9f0-9c7247893963" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityVoluntaryFilers_c89ece03-3ceb-4083-a9f0-9c7247893963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_83c6da58-e024-4afc-ab89-a33a89dcd36b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityCurrentReportingStatus_83c6da58-e024-4afc-ab89-a33a89dcd36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_0408e22b-ed23-482e-8d1c-e6608ebf0c19" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityInteractiveDataCurrent_0408e22b-ed23-482e-8d1c-e6608ebf0c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b56c017a-5715-4897-b374-f8acf18c0f98" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityFilerCategory_b56c017a-5715-4897-b374-f8acf18c0f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_01bb6bbb-8024-4f6f-8f89-6fe040533b8b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntitySmallBusiness_01bb6bbb-8024-4f6f-8f89-6fe040533b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_afed41b2-791f-43b5-a885-df27899be870" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityEmergingGrowthCompany_afed41b2-791f-43b5-a885-df27899be870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_fb8d0312-192c-4e2d-be85-5e0fa823264f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_IcfrAuditorAttestationFlag_fb8d0312-192c-4e2d-be85-5e0fa823264f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_52ce20c9-3983-473d-aa06-9af99c14485d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityShellCompany_52ce20c9-3983-473d-aa06-9af99c14485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_e3f5dc51-a87d-4d92-8d84-17aaf71d2b7f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityPublicFloat_e3f5dc51-a87d-4d92-8d84-17aaf71d2b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0e651818-3930-44f7-8908-470b8901e4be" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0e651818-3930-44f7-8908-470b8901e4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b325137f-f2ab-4ca2-bec2-1b76aaa1d600" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_b325137f-f2ab-4ca2-bec2-1b76aaa1d600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ad1b2b5d-26a9-4bc7-9b1d-392b5ed8fb0e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_AmendmentFlag_ad1b2b5d-26a9-4bc7-9b1d-392b5ed8fb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_25589669-60b8-4e42-a022-ba64835221aa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_DocumentFiscalYearFocus_25589669-60b8-4e42-a022-ba64835221aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_79e7ac99-9c87-444a-9765-d7d830123b65" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_DocumentFiscalPeriodFocus_79e7ac99-9c87-444a-9765-d7d830123b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2f25ab8d-764d-4bb5-b460-adf136a7d8b8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a6eda73-8430-4cc2-87c3-3dcd5e871b75" xlink:to="loc_dei_EntityCentralIndexKey_2f25ab8d-764d-4bb5-b460-adf136a7d8b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AuditInformation" xlink:type="simple" xlink:href="ameh-20211231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AuditInformationAbstract_32d9c75d-983a-4a23-adde-2d666a6d8868" xlink:href="ameh-20211231.xsd#ameh_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_75cc218d-6351-47c8-bd61-73e8825f1358" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AuditInformationAbstract_32d9c75d-983a-4a23-adde-2d666a6d8868" xlink:to="loc_dei_AuditorName_75cc218d-6351-47c8-bd61-73e8825f1358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d2983a91-a1ca-4308-ac48-5225ab58f28f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AuditInformationAbstract_32d9c75d-983a-4a23-adde-2d666a6d8868" xlink:to="loc_dei_AuditorLocation_d2983a91-a1ca-4308-ac48-5225ab58f28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d42ae7ea-d47d-4300-8078-42a6e34d6c76" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AuditInformationAbstract_32d9c75d-983a-4a23-adde-2d666a6d8868" xlink:to="loc_dei_AuditorFirmId_d42ae7ea-d47d-4300-8078-42a6e34d6c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_227381e5-240d-4648-a445-9e274b943787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_898b3b8e-ce5d-4b4f-b437-c347f5cd380a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_227381e5-240d-4648-a445-9e274b943787" xlink:to="loc_us-gaap_StatementTable_898b3b8e-ce5d-4b4f-b437-c347f5cd380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_90638b13-cbe2-427e-af15-616c2f5282db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_898b3b8e-ce5d-4b4f-b437-c347f5cd380a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_90638b13-cbe2-427e-af15-616c2f5282db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_90638b13-cbe2-427e-af15-616c2f5282db" xlink:to="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_b1f03a76-6e71-45c3-84f4-cd5b1f94b6d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_b1f03a76-6e71-45c3-84f4-cd5b1f94b6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_fe25947b-e94f-45bc-ba2f-4314293b9fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8cf84ddc-ae63-4236-9cd2-677bfbcb954b" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_fe25947b-e94f-45bc-ba2f-4314293b9fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_898b3b8e-ce5d-4b4f-b437-c347f5cd380a" xlink:to="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:to="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b1ce54eb-0bf6-4252-8f02-b3e5c1495b84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b1ce54eb-0bf6-4252-8f02-b3e5c1495b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_c0863114-563c-4426-955a-9f1389fcb3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_c0863114-563c-4426-955a-9f1389fcb3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_743b59db-74e2-4cbe-947f-a5bf39ccb65f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_743b59db-74e2-4cbe-947f-a5bf39ccb65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33be7faf-744c-44bb-889f-6b94190c1637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_33be7faf-744c-44bb-889f-6b94190c1637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_4e5569d1-d019-40c3-abce-7f6be72da5cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_4e5569d1-d019-40c3-abce-7f6be72da5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8e72f13-07b7-4bd1-a36e-0772b65a70ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8e72f13-07b7-4bd1-a36e-0772b65a70ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5ba85f55-bdb1-4768-9e64-f497f1e38e40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_5ba85f55-bdb1-4768-9e64-f497f1e38e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_020f0983-2f38-466e-9970-4720facdff6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d53abddc-2031-4628-91e9-dc45eff8e5f5" xlink:to="loc_us-gaap_AssetsCurrent_020f0983-2f38-466e-9970-4720facdff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_45c17c51-8846-4366-9f6d-ae782c79e600" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_45c17c51-8846-4366-9f6d-ae782c79e600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1128c689-4efe-4bc1-8742-3f47a4eb1c73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1128c689-4efe-4bc1-8742-3f47a4eb1c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_108f19d3-a5c1-41a5-b067-ea44582d59d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_Goodwill_108f19d3-a5c1-41a5-b067-ea44582d59d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_e0ac4e41-0f43-4c28-87d3-33616337653d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_e0ac4e41-0f43-4c28-87d3-33616337653d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_04f42ecd-57fa-4c41-9a00-e8927b6e06b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesNoncurrent_04f42ecd-57fa-4c41-9a00-e8927b6e06b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_49ad4830-716e-4754-aa44-422842566108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_EquityMethodInvestments_49ad4830-716e-4754-aa44-422842566108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4059a433-6764-481a-9747-8c77a40f6b1b" xlink:href="ameh-20211231.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_4059a433-6764-481a-9747-8c77a40f6b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_3ca11440-5f25-47a1-a117-c6558e782389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_3ca11440-5f25-47a1-a117-c6558e782389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e055c927-9543-4a57-82bd-2aad3e5ad6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e055c927-9543-4a57-82bd-2aad3e5ad6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1f2b2395-b0b4-4541-83f7-9481775c130c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1f2b2395-b0b4-4541-83f7-9481775c130c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3ba47b11-50a1-4cde-8096-452d45bfc4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_54d1a916-81e8-409a-b188-a1ffeaac889c" xlink:to="loc_us-gaap_AssetsNoncurrent_3ba47b11-50a1-4cde-8096-452d45bfc4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_572eece4-1c8e-4818-a99b-15df2a1b12a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b7d4b400-76bc-4c4a-8081-eca2a1445b72" xlink:to="loc_us-gaap_Assets_572eece4-1c8e-4818-a99b-15df2a1b12a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d86fa3a0-01e3-49f8-a76f-657e01cbd98e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c8516e3a-a7dd-4245-aa4b-1103d6ff6545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c8516e3a-a7dd-4245-aa4b-1103d6ff6545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_db377982-c8ee-431a-8cf2-a224da8d17aa" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_db377982-c8ee-431a-8cf2-a224da8d17aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_8be53f89-2588-4648-8ca9-b20702a552a6" xlink:href="ameh-20211231.xsd#ameh_MedicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_8be53f89-2588-4648-8ca9-b20702a552a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_de509132-76c4-4b88-abaa-4b1594344ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_de509132-76c4-4b88-abaa-4b1594344ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_5ae32464-91d7-4e27-a1d9-12d4f7f4e244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_DividendsPayableCurrent_5ae32464-91d7-4e27-a1d9-12d4f7f4e244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_bfbe4f7e-974e-4576-a810-14ff0057036b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_bfbe4f7e-974e-4576-a810-14ff0057036b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_07e9294b-42dd-4c1c-8a4f-088ec983caad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_07e9294b-42dd-4c1c-8a4f-088ec983caad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_7f7cc0d7-51a6-48c9-add1-f08be485ec54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_LongTermDebtCurrent_7f7cc0d7-51a6-48c9-add1-f08be485ec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_410538d3-6809-46b1-bbdd-190170c1d192" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff51d31-621f-4ee4-a746-949cf98f1818" xlink:to="loc_us-gaap_LiabilitiesCurrent_410538d3-6809-46b1-bbdd-190170c1d192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_be509544-16af-41d4-95a8-c3d47cbd5ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_be509544-16af-41d4-95a8-c3d47cbd5ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8805701b-eb03-4d83-81ee-a1a52cbaebbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_8805701b-eb03-4d83-81ee-a1a52cbaebbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbafc726-c85f-4abe-8a85-833139c9dd88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_dbafc726-c85f-4abe-8a85-833139c9dd88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2a2b4d3f-673c-4f38-99f2-cd40cfe0d42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2a2b4d3f-673c-4f38-99f2-cd40cfe0d42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3ab5cf9d-f2a5-46b4-b34f-02ee97abe8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3ab5cf9d-f2a5-46b4-b34f-02ee97abe8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_e44307e8-d1d9-4452-affc-02755b2b3f24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5db21a09-cb2b-4edd-aac0-1664a9ddb605" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_e44307e8-d1d9-4452-affc-02755b2b3f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c3187a61-59fa-4a27-bef1-73c9f8e9bb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_Liabilities_c3187a61-59fa-4a27-bef1-73c9f8e9bb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f1238a4e-d4a9-4450-8991-7a21e70583a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f1238a4e-d4a9-4450-8991-7a21e70583a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_65da6b33-cbaf-4e85-8322-bfd74df7bbd9" xlink:href="ameh-20211231.xsd#ameh_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_ameh_MezzanineEquityAbstract_65da6b33-cbaf-4e85-8322-bfd74df7bbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_95597118-7d3f-4850-a886-aa7f300df5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_65da6b33-cbaf-4e85-8322-bfd74df7bbd9" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_95597118-7d3f-4850-a886-aa7f300df5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_52eb1c83-9c2a-4060-a17a-73e54e238a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_PreferredStockValue_52eb1c83-9c2a-4060-a17a-73e54e238a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_aaeb46bc-4577-4c74-93be-03c6003b6ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_CommonStockValue_aaeb46bc-4577-4c74-93be-03c6003b6ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f49bfd6e-80ea-4661-98b2-8d7929132135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f49bfd6e-80ea-4661-98b2-8d7929132135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b0176a6-a7e3-4018-beff-e506a284966f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1b0176a6-a7e3-4018-beff-e506a284966f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a8d02d1a-560e-4add-9e36-641223bf6f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_StockholdersEquity_a8d02d1a-560e-4add-9e36-641223bf6f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a737bfa5-bdd5-4473-8bc5-17e6a0f595e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_MinorityInterest_a737bfa5-bdd5-4473-8bc5-17e6a0f595e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0165e19-6c5b-46f7-bd5e-5cc9e694558f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_a66afa7a-2df3-4643-9dd6-afc72172c3d1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0165e19-6c5b-46f7-bd5e-5cc9e694558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd83684b-044a-42d4-b7b0-824bd9b361fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2992d0a4-5e16-413a-8af3-5002ea179934" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cd83684b-044a-42d4-b7b0-824bd9b361fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_760db0c2-583f-4bc5-a286-ca0d4f566b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_760db0c2-583f-4bc5-a286-ca0d4f566b58" xlink:to="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3c93d2af-1fc2-4ce3-8db5-83fa816234a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3c93d2af-1fc2-4ce3-8db5-83fa816234a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3c93d2af-1fc2-4ce3-8db5-83fa816234a3" xlink:to="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_c8ae3533-05b2-4bbc-84ce-65b70035057c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_c8ae3533-05b2-4bbc-84ce-65b70035057c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_02ef6ad8-2950-4e00-8da2-4f0dea5bdd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_778b1aea-6620-4a0b-b2ec-c3957b31b7e1" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_02ef6ad8-2950-4e00-8da2-4f0dea5bdd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:to="loc_srt_ConsolidatedEntitiesAxis_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_86e16335-ef7d-48c5-a45f-2863f56920ed" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_388e7d79-fa3b-46e7-b5f8-f865e6da5f0c" xlink:to="loc_srt_ConsolidatedEntitiesDomain_86e16335-ef7d-48c5-a45f-2863f56920ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PrimaryBeneficiaryMember_f9230e60-d2de-425b-94d1-c748842bc64d" xlink:href="ameh-20211231.xsd#ameh_PrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_86e16335-ef7d-48c5-a45f-2863f56920ed" xlink:to="loc_ameh_PrimaryBeneficiaryMember_f9230e60-d2de-425b-94d1-c748842bc64d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a8f4c10c-dfbe-41c5-b19b-790ec660f11f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a8f4c10c-dfbe-41c5-b19b-790ec660f11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ba2c6374-66f2-4a6d-98f1-03ac14306400" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a8f4c10c-dfbe-41c5-b19b-790ec660f11f" xlink:to="loc_us-gaap_EquityComponentDomain_ba2c6374-66f2-4a6d-98f1-03ac14306400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4d4236f8-25e7-4244-b4ea-1007ea378039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ba2c6374-66f2-4a6d-98f1-03ac14306400" xlink:to="loc_us-gaap_CommonStockMember_4d4236f8-25e7-4244-b4ea-1007ea378039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3428ad9f-26fa-4095-bd29-66b843818605" xlink:to="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ef1b3640-374f-420d-ad0b-218e0bd0b8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ef1b3640-374f-420d-ad0b-218e0bd0b8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_14926dc8-c575-4642-8a59-e8af17df4f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_14926dc8-c575-4642-8a59-e8af17df4f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_40847620-5a1b-4821-b707-40dcc9c7767f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockSharesIssued_40847620-5a1b-4821-b707-40dcc9c7767f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4341b2fc-029c-46a5-bfee-ea1723c4f409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4341b2fc-029c-46a5-bfee-ea1723c4f409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8a61e8c3-15ae-4ef5-9234-8a6d86deec95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8a61e8c3-15ae-4ef5-9234-8a6d86deec95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_d52c0473-d3fa-41f6-8c54-f4c53b2025c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_d52c0473-d3fa-41f6-8c54-f4c53b2025c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9e991d17-9e74-4272-af74-55f1c783f677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_SharesOutstanding_9e991d17-9e74-4272-af74-55f1c783f677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_22b2395b-41d2-4295-83f8-111489ace465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_TreasuryStockCommonShares_22b2395b-41d2-4295-83f8-111489ace465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e15d3d46-c9b0-4482-be8c-17f94d589a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_Assets_e15d3d46-c9b0-4482-be8c-17f94d589a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6bc7daab-ed52-4f93-9b9d-4e95284837cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_Liabilities_6bc7daab-ed52-4f93-9b9d-4e95284837cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f07a2d8-011f-4653-86af-68c027fc9546" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_4f07a2d8-011f-4653-86af-68c027fc9546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_8021fdef-f30c-467b-967a-6ee5ea0ebc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8188c879-c6f0-4f11-b0c6-1c6ba8c84416" xlink:to="loc_us-gaap_DueFromAffiliates_8021fdef-f30c-467b-967a-6ee5ea0ebc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a1122f6a-c1ee-4c52-b96d-bb58ca75fa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_54cb586b-f7db-4ecf-989d-5e7d0924b45a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a1122f6a-c1ee-4c52-b96d-bb58ca75fa8f" xlink:to="loc_us-gaap_StatementTable_54cb586b-f7db-4ecf-989d-5e7d0924b45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_407b1c28-00ee-438b-ac81-586457d19d97" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54cb586b-f7db-4ecf-989d-5e7d0924b45a" xlink:to="loc_srt_ProductOrServiceAxis_407b1c28-00ee-438b-ac81-586457d19d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_407b1c28-00ee-438b-ac81-586457d19d97" xlink:to="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_d6eaed30-55ff-4e67-8167-54a744f14003" xlink:href="ameh-20211231.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_d6eaed30-55ff-4e67-8167-54a744f14003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_e071a24a-6bee-469c-816a-8a48a6a1c0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_HealthCareOtherMember_e071a24a-6bee-469c-816a-8a48a6a1c0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_5bbaa7e0-f885-484c-aa2b-4adcec768dab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_ManagementServiceMember_5bbaa7e0-f885-484c-aa2b-4adcec768dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_3823c2a3-abbb-44b1-a4dc-9099dce0a024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_3823c2a3-abbb-44b1-a4dc-9099dce0a024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_330ee679-00a6-4726-bcf3-282c936a517d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ceef02fb-ee8f-4216-92f4-d8f019ab90aa" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_330ee679-00a6-4726-bcf3-282c936a517d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_54cb586b-f7db-4ecf-989d-5e7d0924b45a" xlink:to="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_2a28bed4-0b4a-449a-96b9-4baa91e5be93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_RevenuesAbstract_2a28bed4-0b4a-449a-96b9-4baa91e5be93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b7040f0-f751-47b8-8e77-ff0c3cb9b583" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_2a28bed4-0b4a-449a-96b9-4baa91e5be93" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b7040f0-f751-47b8-8e77-ff0c3cb9b583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9c463b25-7e8a-4c55-a29b-ff7be4f3f7be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9c463b25-7e8a-4c55-a29b-ff7be4f3f7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_01539c08-c140-43ff-9f3a-1a77dd777cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_01539c08-c140-43ff-9f3a-1a77dd777cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_7ea152c5-6a64-4a5c-b023-496c10348df1" xlink:href="ameh-20211231.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_7ea152c5-6a64-4a5c-b023-496c10348df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_ed762f85-8d55-45ad-999e-1ffed7baa787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_ed762f85-8d55-45ad-999e-1ffed7baa787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_00df7ce6-82d6-47e9-b876-550c763cb06b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_00df7ce6-82d6-47e9-b876-550c763cb06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6256ff51-f82c-4fae-b7ef-600aadcca448" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54c17b73-05dc-4a9f-8780-075f9660f905" xlink:to="loc_us-gaap_CostsAndExpenses_6256ff51-f82c-4fae-b7ef-600aadcca448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_44ea14ff-8730-47ef-919e-b7cc8b49e496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_OperatingIncomeLoss_44ea14ff-8730-47ef-919e-b7cc8b49e496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8d46dc7a-46c2-40d9-96a0-0ded72bd77db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_8d46dc7a-46c2-40d9-96a0-0ded72bd77db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f45f40a3-41ac-4c2e-bf1b-5e276ebdb4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_f45f40a3-41ac-4c2e-bf1b-5e276ebdb4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_081530b1-fd95-481b-9761-068c4e269b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_InterestExpense_081530b1-fd95-481b-9761-068c4e269b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d26bef89-e21f-4b2a-9a43-d1eae17c3097" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d26bef89-e21f-4b2a-9a43-d1eae17c3097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_00d25490-abd2-4fa2-b375-87a36079d07c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_00d25490-abd2-4fa2-b375-87a36079d07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_22616674-40ba-450b-b2da-fd33e6b4a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_22616674-40ba-450b-b2da-fd33e6b4a9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e47a9c83-0847-497e-b54b-5bc35234cc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_98e0f909-45a0-417b-be7c-d9bc0b8b90c6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e47a9c83-0847-497e-b54b-5bc35234cc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_154da18e-bb84-4e92-ad05-5ee574bfc97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_154da18e-bb84-4e92-ad05-5ee574bfc97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_923e59e2-223b-4fee-ab7c-5eb03099b8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_923e59e2-223b-4fee-ab7c-5eb03099b8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f691741b-eb17-4b99-aecc-9be44340a504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_ProfitLoss_f691741b-eb17-4b99-aecc-9be44340a504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_38103b60-953b-497e-a7cb-00908a0a899c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_38103b60-953b-497e-a7cb-00908a0a899c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11fae322-ce1b-4d9b-b1e9-ae4a9a20fcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_NetIncomeLoss_11fae322-ce1b-4d9b-b1e9-ae4a9a20fcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a4b56148-04cc-45a7-a7ab-4101bbcb32bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_EarningsPerShareBasic_a4b56148-04cc-45a7-a7ab-4101bbcb32bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4028f2c9-6f8c-4817-8742-984349d0a8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e29eef71-466c-40b3-bf95-aeeb0b90e88d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4028f2c9-6f8c-4817-8742-984349d0a8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c4568956-2245-4294-894e-4e412a08945b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c4568956-2245-4294-894e-4e412a08945b" xlink:to="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b926f8da-1d4e-4b2e-a412-95d85920a180" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b926f8da-1d4e-4b2e-a412-95d85920a180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b926f8da-1d4e-4b2e-a412-95d85920a180" xlink:to="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_194fd3eb-5cdf-4855-b0c2-883b11b961e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_CommonStockMember_194fd3eb-5cdf-4855-b0c2-883b11b961e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3551628d-3bd2-43d6-bddf-ce5a1dfb2aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3551628d-3bd2-43d6-bddf-ce5a1dfb2aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1d01c396-1f30-45a7-9ae0-23c0ebd758a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_RetainedEarningsMember_1d01c396-1f30-45a7-9ae0-23c0ebd758a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_ed4c2a80-3f73-4d19-9873-3e0a538224e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_60d2c6f0-59a5-4423-9351-bb59798c0d17" xlink:to="loc_us-gaap_NoncontrollingInterestMember_ed4c2a80-3f73-4d19-9873-3e0a538224e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_24fd742a-fc88-4b67-81cd-49adf80c4ffc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:to="loc_dei_LegalEntityAxis_24fd742a-fc88-4b67-81cd-49adf80c4ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_55242de6-c819-40ca-a769-e4c32c01ca86" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_24fd742a-fc88-4b67-81cd-49adf80c4ffc" xlink:to="loc_dei_EntityDomain_55242de6-c819-40ca-a769-e4c32c01ca86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_1f5f873c-56b5-487e-8eac-f5fb062dfd8d" xlink:href="ameh-20211231.xsd#ameh_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_55242de6-c819-40ca-a769-e4c32c01ca86" xlink:to="loc_ameh_MezzanineMember_1f5f873c-56b5-487e-8eac-f5fb062dfd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a195dcf4-782f-4b53-845b-ab3b5a29cd91" xlink:to="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fdfc3aa1-66a9-45ee-9fbe-391a61f6dc60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_fdfc3aa1-66a9-45ee-9fbe-391a61f6dc60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityNetIncome_269b1f43-2ee5-495c-b42f-93499b4106ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityNetIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityNetIncome_269b1f43-2ee5-495c-b42f-93499b4106ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityRepurchaseOfTreasuryShares_2358b9a2-e852-452a-9cad-6cced0cb4283" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityRepurchaseOfTreasuryShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityRepurchaseOfTreasuryShares_2358b9a2-e852-452a-9cad-6cced0cb4283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityShareBasedCompensation_d3c295a0-c966-4012-bded-a5777b493ba1" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityShareBasedCompensation_d3c295a0-c966-4012-bded-a5777b493ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityStockSubscription_2e8f1d39-61c5-4015-b5be-2576516030ec" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityStockSubscription"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityStockSubscription_2e8f1d39-61c5-4015-b5be-2576516030ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_29dac533-9037-4c42-ace3-0a28dbb4cf1c" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest_29dac533-9037-4c42-ace3-0a28dbb4cf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityDistributionToNoncontrollingInterest_53087274-547a-46e2-a713-0b94d60430ed" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityDistributionToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityDistributionToNoncontrollingInterest_53087274-547a-46e2-a713-0b94d60430ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1fd2175b-1a98-4d94-9dc4-627c3f79dd90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1fd2175b-1a98-4d94-9dc4-627c3f79dd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares_f6ec5090-b72b-44a7-80da-f510a3936d3e" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares_f6ec5090-b72b-44a7-80da-f510a3936d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAccretionOfDividends_66ec0b5f-31f2-4177-82a3-809c0e89abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionOfDividends"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityAccretionOfDividends_66ec0b5f-31f2-4177-82a3-809c0e89abdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_31668542-1792-4876-9bba-7dc3bbd1d697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_31668542-1792-4876-9bba-7dc3bbd1d697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_5f6409ce-9509-41bd-a110-cae79d15e7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_43077475-9a7d-498c-818a-393900b0ca25" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_5f6409ce-9509-41bd-a110-cae79d15e7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_67a5f58d-fc88-44d5-91d8-c27007ce6ebb" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a8fb396-3168-4e70-98be-4acf88616504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3a8fb396-3168-4e70-98be-4acf88616504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_71ae9aae-b688-4407-9ecd-8cc45c568665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_SharesOutstanding_71ae9aae-b688-4407-9ecd-8cc45c568665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_53c4450d-3c84-4991-ac0b-5b56f8df2269" xlink:href="ameh-20211231.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_53c4450d-3c84-4991-ac0b-5b56f8df2269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_df0c2418-59b8-42f2-8494-05ec3e6a7755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_df0c2418-59b8-42f2-8494-05ec3e6a7755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_2ee5f604-a3a3-47a0-ba28-03f1957b12b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_2ee5f604-a3a3-47a0-ba28-03f1957b12b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_8d328325-b291-4e3d-bcfc-8d936f7f9bb3" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestIncreaseFromCapitalCharge"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NoncontrollingInterestIncreaseFromCapitalCharge_8d328325-b291-4e3d-bcfc-8d936f7f9bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d5b97b8a-d987-434c-9c1a-f0d1d37dbc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_d5b97b8a-d987-434c-9c1a-f0d1d37dbc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_4e902322-9f27-4602-8243-5dc710301b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_4e902322-9f27-4602-8243-5dc710301b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_f50cc8b4-2eb6-4fae-af2c-01c5db16062e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_f50cc8b4-2eb6-4fae-af2c-01c5db16062e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e6610ae7-c151-45d2-a155-3e6f70313789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_e6610ae7-c151-45d2-a155-3e6f70313789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares_5011b84c-3d9e-4ed6-98a4-960b9e5f99a5" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares_5011b84c-3d9e-4ed6-98a4-960b9e5f99a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_96605487-e7ae-4b19-bb94-023a83b0edb5" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares_96605487-e7ae-4b19-bb94-023a83b0edb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4cf79475-b557-4fef-a793-6137effdde5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_4cf79475-b557-4fef-a793-6137effdde5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ebc93773-19ae-4798-84ea-74cc92d588d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_ebc93773-19ae-4798-84ea-74cc92d588d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_2cc6e467-df47-4e82-b988-baf5473a368e" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_2cc6e467-df47-4e82-b988-baf5473a368e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_b925b2a3-1519-4690-9ea8-eec35ca7f172" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_b925b2a3-1519-4690-9ea8-eec35ca7f172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_2247622a-fb44-46d0-b0a6-df9e15826d71" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_2247622a-fb44-46d0-b0a6-df9e15826d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_8c8658bb-7b5c-48cd-980a-47ed41af716a" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_8c8658bb-7b5c-48cd-980a-47ed41af716a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_cb3fd4c3-a32a-493c-9d6b-0591a8d3a16d" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest_cb3fd4c3-a32a-493c-9d6b-0591a8d3a16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_77a152bd-1d6e-465e-a844-67e4b22a2c64" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest_77a152bd-1d6e-465e-a844-67e4b22a2c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_9298794d-8227-4298-a7ae-c4c9fa08fbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_9298794d-8227-4298-a7ae-c4c9fa08fbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_62e52b7b-afce-48ad-b876-8b7c2148435f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_62e52b7b-afce-48ad-b876-8b7c2148435f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c48ff2a8-85b0-43f2-8491-5de17a2aaf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_c48ff2a8-85b0-43f2-8491-5de17a2aaf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity_0d1486c6-e90e-4163-8b27-5b7b5b57b7ba" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity_0d1486c6-e90e-4163-8b27-5b7b5b57b7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares_a6dca88b-0a14-4963-a686-2eaf77a03c27" xlink:href="ameh-20211231.xsd#ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares_a6dca88b-0a14-4963-a686-2eaf77a03c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares_2490f541-9395-4de6-8a1c-669865aadb46" xlink:href="ameh-20211231.xsd#ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares_2490f541-9395-4de6-8a1c-669865aadb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca01b494-61f1-460e-a0c1-6b4743adc916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ca01b494-61f1-460e-a0c1-6b4743adc916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_2b2bdf05-c64e-4908-82de-3b3d6670f228" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_719ddb74-43d6-4c52-b6f1-1d2dcc5eacd6" xlink:to="loc_us-gaap_SharesOutstanding_2b2bdf05-c64e-4908-82de-3b3d6670f228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_41797989-fa55-40a2-8f5e-ad52c170e095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_88ef2361-73ea-479e-b6c7-2a399f593243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_41797989-fa55-40a2-8f5e-ad52c170e095" xlink:to="loc_us-gaap_StatementTable_88ef2361-73ea-479e-b6c7-2a399f593243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_635bae97-4518-4de1-aabb-2f4d6cac4b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_88ef2361-73ea-479e-b6c7-2a399f593243" xlink:to="loc_us-gaap_StatementClassOfStockAxis_635bae97-4518-4de1-aabb-2f4d6cac4b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_326c9722-2996-4ab3-945a-a680bf01bb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_635bae97-4518-4de1-aabb-2f4d6cac4b58" xlink:to="loc_us-gaap_ClassOfStockDomain_326c9722-2996-4ab3-945a-a680bf01bb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HoldbackSharesMember_36ed2cd2-31fb-47b7-9ea4-0302de78470b" xlink:href="ameh-20211231.xsd#ameh_HoldbackSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_326c9722-2996-4ab3-945a-a680bf01bb9f" xlink:to="loc_ameh_HoldbackSharesMember_36ed2cd2-31fb-47b7-9ea4-0302de78470b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e35eb271-1ba3-4972-854f-a5cbb1274fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_88ef2361-73ea-479e-b6c7-2a399f593243" xlink:to="loc_us-gaap_StatementLineItems_e35eb271-1ba3-4972-854f-a5cbb1274fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6885625d-d6d5-4f71-8e65-a3a98727829e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e35eb271-1ba3-4972-854f-a5cbb1274fc4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6885625d-d6d5-4f71-8e65-a3a98727829e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ameh-20211231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_823a6f92-ebcf-47c9-83f1-b01eaafd6b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_823a6f92-ebcf-47c9-83f1-b01eaafd6b90" xlink:to="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_069b3621-43d2-4925-b1a7-77cbddcb31f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_069b3621-43d2-4925-b1a7-77cbddcb31f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b66e8f10-9eef-42e1-bffc-95d4cbfd51b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_069b3621-43d2-4925-b1a7-77cbddcb31f6" xlink:to="loc_us-gaap_RelatedPartyDomain_b66e8f10-9eef-42e1-bffc-95d4cbfd51b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_d9dee59b-03c8-4ef7-b628-684cb4b0c383" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b66e8f10-9eef-42e1-bffc-95d4cbfd51b0" xlink:to="loc_srt_AffiliatedEntityMember_d9dee59b-03c8-4ef7-b628-684cb4b0c383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1df742b7-e97a-4e62-9f6a-a449f67fb5bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:to="loc_srt_CounterpartyNameAxis_1df742b7-e97a-4e62-9f6a-a449f67fb5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77ecaac-f13f-41a3-964c-92c75fcc641c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1df742b7-e97a-4e62-9f6a-a449f67fb5bb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77ecaac-f13f-41a3-964c-92c75fcc641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1a02ddf2-e2ad-4324-ac81-e9616ec7bf93" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c77ecaac-f13f-41a3-964c-92c75fcc641c" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_1a02ddf2-e2ad-4324-ac81-e9616ec7bf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_df4344e9-dcb1-4521-90ed-a2a568632cc4" xlink:to="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_45554ea0-9da4-4167-810f-f33b584bd88d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:to="loc_us-gaap_ProfitLoss_45554ea0-9da4-4167-810f-f33b584bd88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4dfa6d28-a0e2-4b6c-b20f-e78b0b016b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4dfa6d28-a0e2-4b6c-b20f-e78b0b016b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_6fae85bf-96ac-428c-bdd6-5b6e9667c890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_6fae85bf-96ac-428c-bdd6-5b6e9667c890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromOtherOperatingActivities_9c2a2a80-a4ea-4933-99b5-b420756b438b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_ProceedsFromOtherOperatingActivities_9c2a2a80-a4ea-4933-99b5-b420756b438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6a299d5f-942c-46ae-b8dd-8d734531453d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_6a299d5f-942c-46ae-b8dd-8d734531453d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_615ab9fb-b2ae-4197-8ad2-5fd229f02a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_615ab9fb-b2ae-4197-8ad2-5fd229f02a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_0cb81934-ad70-429f-88c6-9eca611679f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_0cb81934-ad70-429f-88c6-9eca611679f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7d6b0cb0-982d-4668-8f1f-274440a4a879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_ShareBasedCompensation_7d6b0cb0-982d-4668-8f1f-274440a4a879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_1650c81c-d035-47a1-ac9a-687d2111bc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_1650c81c-d035-47a1-ac9a-687d2111bc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment_b5da50dd-1f88-4db8-a403-b7cfef66e83e" xlink:href="ameh-20211231.xsd#ameh_GainLossOnConsolidationOfEquityMethodInvestment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_ameh_GainLossOnConsolidationOfEquityMethodInvestment_b5da50dd-1f88-4db8-a403-b7cfef66e83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnEquityReceivable_82f45b1b-8332-422e-b3f9-3063ec5620e9" xlink:href="ameh-20211231.xsd#ameh_GainLossOnEquityReceivable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_ameh_GainLossOnEquityReceivable_82f45b1b-8332-422e-b3f9-3063ec5620e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnAssumptionOfLoan_c61b4065-585f-43b9-b06d-5f58d4dcd00b" xlink:href="ameh-20211231.xsd#ameh_GainLossOnAssumptionOfLoan"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_ameh_GainLossOnAssumptionOfLoan_c61b4065-585f-43b9-b06d-5f58d4dcd00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c1d4d472-0050-4bb8-86ce-a17ed674bc5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c1d4d472-0050-4bb8-86ce-a17ed674bc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_f160b1b5-d0d1-40dd-a406-e6b864d7c7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_f160b1b5-d0d1-40dd-a406-e6b864d7c7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLossOnDerivative_09c92c17-d7c6-4b42-9ac1-e63976aa1640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLossOnDerivative"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_DerivativeLossOnDerivative_09c92c17-d7c6-4b42-9ac1-e63976aa1640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_e0de21ba-616d-4647-a2c8-b1744d727efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_e0de21ba-616d-4647-a2c8-b1744d727efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d8da4566-b1cc-480d-a489-31611fb00b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d8da4566-b1cc-480d-a489-31611fb00b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b91cd6a9-16b2-4205-9fb1-59eee74954da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b91cd6a9-16b2-4205-9fb1-59eee74954da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ca1a3a3-80ad-43d0-80a7-e1aea0252066" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d7364bcf-c4f3-4a60-8b1d-da022bb41565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d7364bcf-c4f3-4a60-8b1d-da022bb41565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a7178a01-5ae2-4a67-8ebc-a6c8ae458e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_a7178a01-5ae2-4a67-8ebc-a6c8ae458e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_65969faa-650c-40cc-b4f1-2020c4379911" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_65969faa-650c-40cc-b4f1-2020c4379911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_cbf78704-a5a6-4c8d-a833-2184a4054c2f" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_cbf78704-a5a6-4c8d-a833-2184a4054c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_65398c8b-19cd-4112-a6ba-d9e36c606cbe" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_65398c8b-19cd-4112-a6ba-d9e36c606cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_053eb185-01e7-4d63-aa49-3f2a46439a16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_053eb185-01e7-4d63-aa49-3f2a46439a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1405e825-0547-47ee-8e1a-20a64df6511b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1405e825-0547-47ee-8e1a-20a64df6511b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_bfec3230-a2b2-4639-a436-e369b6576738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_bfec3230-a2b2-4639-a436-e369b6576738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_c8e3709c-fe82-4c1a-b5b1-cd4cbe7af66a" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_c8e3709c-fe82-4c1a-b5b1-cd4cbe7af66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_43ff7270-bfa2-43fd-83c1-6e91166cb992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_43ff7270-bfa2-43fd-83c1-6e91166cb992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_31e86268-9da5-41f9-a90f-acca84a0a1f0" xlink:href="ameh-20211231.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fa501f9f-e045-490b-8b34-8ce98f5c5c49" xlink:to="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_31e86268-9da5-41f9-a90f-acca84a0a1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_219524dc-dfdf-4db5-8d7a-73d5f81f4826" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_96946721-bd98-4037-8539-6714f33b26ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_219524dc-dfdf-4db5-8d7a-73d5f81f4826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dcccb813-197e-427d-87db-c9bff655b479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_dcccb813-197e-427d-87db-c9bff655b479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8a879fc2-5e3f-4931-8fa6-8bf34b265d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_8a879fc2-5e3f-4931-8fa6-8bf34b265d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_9b671383-79d2-4637-a666-96eafad29bcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_9b671383-79d2-4637-a666-96eafad29bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_0a51badb-3f80-4916-a582-030920329be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_0a51badb-3f80-4916-a582-030920329be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4eb64339-b123-4c6c-867d-e701a69a0672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4eb64339-b123-4c6c-867d-e701a69a0672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_32666862-98a0-4b8c-9246-2fd52feafabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_32666862-98a0-4b8c-9246-2fd52feafabb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c7f0239b-ffd6-46fa-8094-a968b0684685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_c7f0239b-ffd6-46fa-8094-a968b0684685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_e3c8a771-6670-4862-98ac-582454c4aaa1" xlink:href="ameh-20211231.xsd#ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare_e3c8a771-6670-4862-98ac-582454c4aaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_c51be980-4413-4fd2-9cb2-8bad64bf49ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_c51be980-4413-4fd2-9cb2-8bad64bf49ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3c78e442-adbc-4680-9c80-575f5042dae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_3c78e442-adbc-4680-9c80-575f5042dae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fedecce0-ae4d-47ea-8c88-b76ab6944cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fedecce0-ae4d-47ea-8c88-b76ab6944cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_46e2b25d-f292-4070-b4af-8f5007625e9c" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity_46e2b25d-f292-4070-b4af-8f5007625e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a774df7f-aca2-425b-bb4f-b2492164801b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_649dad82-98b6-4ca2-83e1-a8d31ae52920" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a774df7f-aca2-425b-bb4f-b2492164801b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_d4e51417-c07e-42eb-8000-d1e2d65d8322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_d4e51417-c07e-42eb-8000-d1e2d65d8322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_665f2c84-edf0-4214-a5f8-b9ee1cd8ed99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_665f2c84-edf0-4214-a5f8-b9ee1cd8ed99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_546c1e80-cd3f-426b-9821-3cde86acdfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_546c1e80-cd3f-426b-9821-3cde86acdfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_deb1ca99-cd84-4fed-9685-9f5ff58d2e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_deb1ca99-cd84-4fed-9685-9f5ff58d2e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5d403430-e761-47fe-9038-af4e9c05da33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_5d403430-e761-47fe-9038-af4e9c05da33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_5e465a35-0457-47fd-9197-48048a753259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_5e465a35-0457-47fd-9197-48048a753259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_51a187b1-c053-4861-b75e-854f3d2deca5" xlink:href="ameh-20211231.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_51a187b1-c053-4861-b75e-854f3d2deca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_b0745978-9031-45b1-a79d-5b5a54464673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations_b0745978-9031-45b1-a79d-5b5a54464673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ab8a4c48-bef2-459a-9d04-2c9c22d95c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ab8a4c48-bef2-459a-9d04-2c9c22d95c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dff5ad1e-f460-4015-a4af-c189a390f80f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dff5ad1e-f460-4015-a4af-c189a390f80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ProceedsFromEquityOffering_7e0923d0-4dc3-4718-88aa-2998808f4493" xlink:href="ameh-20211231.xsd#ameh_ProceedsFromEquityOffering"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_ameh_ProceedsFromEquityOffering_7e0923d0-4dc3-4718-88aa-2998808f4493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_92db6676-1138-4a99-aea3-dfdca089fc74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_92db6676-1138-4a99-aea3-dfdca089fc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsMinorityInterest_a7ba04cb-2291-439b-91d7-3d2cfd2dd4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsMinorityInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentsOfDividendsMinorityInterest_a7ba04cb-2291-439b-91d7-3d2cfd2dd4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7d8dc122-398f-4d2a-ae78-bdfefac45c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_7d8dc122-398f-4d2a-ae78-bdfefac45c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84ed71ae-6b47-4d47-a4fe-9a6d4b50ccf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3714fe09-dfc8-4ef0-a9e1-a67a35c1b139" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_84ed71ae-6b47-4d47-a4fe-9a6d4b50ccf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87a84fa2-36af-435c-bd33-2179e95a3c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87a84fa2-36af-435c-bd33-2179e95a3c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_753a8c96-5db5-4281-88e0-4a97002bf676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_753a8c96-5db5-4281-88e0-4a97002bf676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3bb71d10-7e87-4f13-b0e8-972e6328dc4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3bb71d10-7e87-4f13-b0e8-972e6328dc4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a3b5c883-f2f1-42e7-8b11-03d29e366e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:to="loc_us-gaap_IncomeTaxesPaid_a3b5c883-f2f1-42e7-8b11-03d29e366e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_ed8fa690-8c6e-443d-b179-ae086f18a7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_8cc88e01-b3a5-472d-8f5a-aec2b0438835" xlink:to="loc_us-gaap_InterestPaidNet_ed8fa690-8c6e-443d-b179-ae086f18a7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IssuanceOfFinancingObligationForBusinessCombination_a570ca69-a0e5-4c96-b587-a9d05ebd81d1" xlink:href="ameh-20211231.xsd#ameh_IssuanceOfFinancingObligationForBusinessCombination"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_IssuanceOfFinancingObligationForBusinessCombination_a570ca69-a0e5-4c96-b587-a9d05ebd81d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashlessExerciseOfStockOptions_63184b90-a513-4606-9b63-9a116babaf4b" xlink:href="ameh-20211231.xsd#ameh_CashlessExerciseOfStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_CashlessExerciseOfStockOptions_63184b90-a513-4606-9b63-9a116babaf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CancellationOfRestrictedStockAwards_615dfe93-3a5f-4948-a7ed-65d05ab5db4b" xlink:href="ameh-20211231.xsd#ameh_CancellationOfRestrictedStockAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_CancellationOfRestrictedStockAwards_615dfe93-3a5f-4948-a7ed-65d05ab5db4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_9675a50a-33bd-4922-909c-9b08029e82f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_9675a50a-33bd-4922-909c-9b08029e82f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_fe1b8389-d69c-43dc-bdd8-df18a271abb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_StockIssued1_fe1b8389-d69c-43dc-bdd8-df18a271abb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReclassificationOfLiabilityForEquity_5de1ef80-2847-4d4a-ba12-f354013466b6" xlink:href="ameh-20211231.xsd#ameh_ReclassificationOfLiabilityForEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_ameh_ReclassificationOfLiabilityForEquity_5de1ef80-2847-4d4a-ba12-f354013466b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_621c3547-b2bd-40e3-83cf-2c0cd4c94c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_621c3547-b2bd-40e3-83cf-2c0cd4c94c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_c5c0b327-9445-4b76-a009-0ec836e4a127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_c5c0b327-9445-4b76-a009-0ec836e4a127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_697709c1-2fa0-429b-b1c9-07ef0b579e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_b9b1b830-bfc6-4034-9d51-e98c223433ea" xlink:to="loc_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset_697709c1-2fa0-429b-b1c9-07ef0b579e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:href="ameh-20211231.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6187f102-eb9d-41bb-bc23-bedad0d148b3" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f612ce4a-a77d-49de-b190-83217e20fa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f612ce4a-a77d-49de-b190-83217e20fa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_71f6bb3a-e1e9-4b03-ae3d-2c4b6ab156a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_71f6bb3a-e1e9-4b03-ae3d-2c4b6ab156a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_d3dc1df9-d1e0-4d3f-b666-f671714046a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_d3dc1df9-d1e0-4d3f-b666-f671714046a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63f894e0-1842-4ab3-8c76-a6eef4aa05a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_2350cbb2-ff4d-4762-9e90-813f84db2991" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_63f894e0-1842-4ab3-8c76-a6eef4aa05a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20211231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_716376cb-b0fe-4635-bbab-479fdae853d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_bd0db0bc-6331-48eb-b3bc-7b70f2ba2888" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_716376cb-b0fe-4635-bbab-479fdae853d0" xlink:to="loc_us-gaap_NatureOfOperations_bd0db0bc-6331-48eb-b3bc-7b70f2ba2888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e080d3c-7a99-42b4-aead-18a8184e87d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:href="ameh-20211231.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4e080d3c-7a99-42b4-aead-18a8184e87d8" xlink:to="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_7df2e56c-2531-49e7-9c12-e8064feaaab8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_dei_LegalEntityAxis_7df2e56c-2531-49e7-9c12-e8064feaaab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7df2e56c-2531-49e7-9c12-e8064feaaab8" xlink:to="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e3f3d371-2386-4b02-978d-8007a8b2c8d6" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_e3f3d371-2386-4b02-978d-8007a8b2c8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_33355393-00a6-4d99-ba7f-6ffa46bfc118" xlink:href="ameh-20211231.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_ApcLsmaMember_33355393-00a6-4d99-ba7f-6ffa46bfc118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_372431c2-6921-4262-b2d4-5e28630bbe59" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_372431c2-6921-4262-b2d4-5e28630bbe59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_ddaae660-72a5-4d82-99e6-bd4aa61b3cf4" xlink:href="ameh-20211231.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AccountableHealthCareIPAMember_ddaae660-72a5-4d82-99e6-bd4aa61b3cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_32dd1a1f-6ebe-44c5-bb7b-15a6b8d0446f" xlink:href="ameh-20211231.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2e65ea2f-7eb4-479b-a77f-275f17965a1d" xlink:to="loc_ameh_AmgIncMember_32dd1a1f-6ebe-44c5-bb7b-15a6b8d0446f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_61a5f976-6769-4000-be5a-199f7a55264b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_61a5f976-6769-4000-be5a-199f7a55264b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_53bc7c2d-5c11-41ee-bf31-424df88aa701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_61a5f976-6769-4000-be5a-199f7a55264b" xlink:to="loc_us-gaap_RelatedPartyDomain_53bc7c2d-5c11-41ee-bf31-424df88aa701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_0809bc3c-a209-4434-ab73-48e72f20bbb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_53bc7c2d-5c11-41ee-bf31-424df88aa701" xlink:to="loc_srt_AffiliatedEntityMember_0809bc3c-a209-4434-ab73-48e72f20bbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_srt_CounterpartyNameAxis_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c0c9fd3c-8f13-41ad-b1c8-35c5c350b7c8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_fa51eeb2-2ee5-4590-8780-87fccc022c7c" xlink:href="ameh-20211231.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:to="loc_ameh_APAMHMedicalCorporationMember_fa51eeb2-2ee5-4590-8780-87fccc022c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_7e01d7b9-5419-4c8a-9f27-a98b25ca373b" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_7e01d7b9-5419-4c8a-9f27-a98b25ca373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_40d76ae9-27cc-4a5d-8c91-76972bed09fe" xlink:href="ameh-20211231.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e4e8b672-650b-4c83-aa9c-2442b19b995f" xlink:to="loc_ameh_Dr.JayMember_40d76ae9-27cc-4a5d-8c91-76972bed09fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_71806c1b-731b-4eaf-839c-da3618ed29c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_71806c1b-731b-4eaf-839c-da3618ed29c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f5969e6-f512-4517-af30-b712f144f3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_71806c1b-731b-4eaf-839c-da3618ed29c3" xlink:to="loc_us-gaap_ClassOfStockDomain_7f5969e6-f512-4517-af30-b712f144f3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4074eeab-11b1-4654-92c1-a9c0964cc73d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7f5969e6-f512-4517-af30-b712f144f3d4" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4074eeab-11b1-4654-92c1-a9c0964cc73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e9d1bae0-1025-4683-a295-d32692e8ff4e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e9d1bae0-1025-4683-a295-d32692e8ff4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_e9d1bae0-1025-4683-a295-d32692e8ff4e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_18f47d46-9e41-4b57-9bad-054e9c3eb9fe" xlink:href="ameh-20211231.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_18f47d46-9e41-4b57-9bad-054e9c3eb9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_c34ab13f-5b1b-4afd-930e-ccdd39852b0c" xlink:href="ameh-20211231.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_c34ab13f-5b1b-4afd-930e-ccdd39852b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_20bb3e9e-9dd8-44c1-8ff9-009836d92157" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_24b401f1-ea9c-4562-b30f-ff63710b254a" xlink:to="loc_ameh_DmgMember_20bb3e9e-9dd8-44c1-8ff9-009836d92157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_b4917ecf-a970-4789-b034-d072eb2a4e22" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_srt_OwnershipAxis_b4917ecf-a970-4789-b034-d072eb2a4e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_b4917ecf-a970-4789-b034-d072eb2a4e22" xlink:to="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_ef5b0c6e-8cfb-4f70-9755-01b05ad124d6" xlink:href="ameh-20211231.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_ef5b0c6e-8cfb-4f70-9755-01b05ad124d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_1b20212c-92fe-4266-80a0-7e4486074afd" xlink:href="ameh-20211231.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:to="loc_ameh_AccountableHealthCareIPAMember_1b20212c-92fe-4266-80a0-7e4486074afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ab23cb91-828f-467e-9cce-078f929daa8f" xlink:href="ameh-20211231.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_5d086b35-edb3-415b-89b0-db021533977c" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ab23cb91-828f-467e-9cce-078f929daa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_10370b42-86c8-4b8e-86fe-e54eacf67bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_10370b42-86c8-4b8e-86fe-e54eacf67bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_10370b42-86c8-4b8e-86fe-e54eacf67bb8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_f2114634-2491-458f-acf1-fd6892215b12" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_f2114634-2491-458f-acf1-fd6892215b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_7390165e-bf26-4b36-9111-f560478c1931" xlink:href="ameh-20211231.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AccountableHealthCareIPAMember_7390165e-bf26-4b36-9111-f560478c1931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_924c16b7-c864-4174-b4df-d280b75e3cf4" xlink:href="ameh-20211231.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AmgIncMember_924c16b7-c864-4174-b4df-d280b75e3cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_002debbc-898e-4486-9d50-8d9ebe66c599" xlink:href="ameh-20211231.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_002debbc-898e-4486-9d50-8d9ebe66c599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_9d0be98e-ee4d-4f03-bfed-0d84d96cfa98" xlink:href="ameh-20211231.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0b22489d-7c58-4271-8470-65eeb9957ae9" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_9d0be98e-ee4d-4f03-bfed-0d84d96cfa98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c47cc8e9-6d14-4dcb-8c50-f2b50b39561e" xlink:to="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ed46056f-069e-4b77-b6ec-e4b733ee09cd" xlink:href="ameh-20211231.xsd#ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:to="loc_ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember_ed46056f-069e-4b77-b6ec-e4b733ee09cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_aba8ab0c-209b-4ca5-a350-d23e6f435998" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_de44bdbc-cbba-463c-b407-a623f18fa4d8" xlink:to="loc_ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember_aba8ab0c-209b-4ca5-a350-d23e6f435998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:href="ameh-20211231.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_43166288-6774-40df-bf37-7b7a7858cd0c" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_bc714c1f-eff7-4a65-8fe5-d4f52a618e75" xlink:href="ameh-20211231.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_bc714c1f-eff7-4a65-8fe5-d4f52a618e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_828913eb-4da7-4ae8-821f-1c7b91dc2f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_NotesReceivableNet_828913eb-4da7-4ae8-821f-1c7b91dc2f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_3ba2ec36-86b4-4af3-8c6a-723572179fed" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_3ba2ec36-86b4-4af3-8c6a-723572179fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_b8b01ccc-484e-4720-b71b-d730c65db305" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_b8b01ccc-484e-4720-b71b-d730c65db305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_a14ab3e0-dc88-4008-9fca-e9f103a5115d" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_a14ab3e0-dc88-4008-9fca-e9f103a5115d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51caeaeb-2ebe-4e77-bbca-3187439cdfe1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_51caeaeb-2ebe-4e77-bbca-3187439cdfe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2cb17494-df77-4db2-8997-9958f7fb2d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2cb17494-df77-4db2-8997-9958f7fb2d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NoncontrollingInterestSharesDistributed_0392d0b2-dba5-4bfa-8cf2-13e683ad7bdc" xlink:href="ameh-20211231.xsd#ameh_NoncontrollingInterestSharesDistributed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_NoncontrollingInterestSharesDistributed_0392d0b2-dba5-4bfa-8cf2-13e683ad7bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a1e31f-f5db-44cd-92d4-ed32db7e70d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_44a1e31f-f5db-44cd-92d4-ed32db7e70d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_76e6b359-e54e-4943-9d88-89323e17655d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_76e6b359-e54e-4943-9d88-89323e17655d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_218ef68f-2a2e-474b-9133-11fc53058501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_218ef68f-2a2e-474b-9133-11fc53058501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_0cceb20b-4232-4b48-a8c3-7594c1b43fbe" xlink:href="ameh-20211231.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_0cceb20b-4232-4b48-a8c3-7594c1b43fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f8351590-3a65-44b1-b1d3-1df1919fdc89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_f8351590-3a65-44b1-b1d3-1df1919fdc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fff04e2b-79b1-4367-a86d-92fbf7fdff4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fff04e2b-79b1-4367-a86d-92fbf7fdff4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_0df8db07-9247-41ba-9efa-f62764a91001" xlink:href="ameh-20211231.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_0df8db07-9247-41ba-9efa-f62764a91001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fd91b28-1889-4243-8721-7a512720a213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_8fd91b28-1889-4243-8721-7a512720a213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f911241a-976b-43ec-843b-5fd74594db56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_f911241a-976b-43ec-843b-5fd74594db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3da97d48-774a-47e1-9b95-f6c9925a6150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_us-gaap_EquityMethodInvestments_3da97d48-774a-47e1-9b95-f6c9925a6150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_164e69ac-25f2-432a-8047-b752ae1ae380" xlink:href="ameh-20211231.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_164e69ac-25f2-432a-8047-b752ae1ae380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_e4ed30bf-3c8c-4850-9637-1abd50035241" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_e4ed30bf-3c8c-4850-9637-1abd50035241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_a8409231-c733-4c84-8736-96ba4d2b5522" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_1f504d74-d8d7-4d94-932b-733b29c6222e" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent_a8409231-c733-4c84-8736-96ba4d2b5522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5a73691c-8a19-4b1c-bba4-f900618b83a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b5fe4e42-8cef-4ab2-9313-db5a548a3254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a73691c-8a19-4b1c-bba4-f900618b83a2" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b5fe4e42-8cef-4ab2-9313-db5a548a3254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_50199d58-18fa-4a2f-89e3-097077ac4958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_50199d58-18fa-4a2f-89e3-097077ac4958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d77ca88f-84e8-4185-a122-4ba164d47427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d77ca88f-84e8-4185-a122-4ba164d47427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_16cf396f-128e-4c0f-b901-1be54ea4d806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_UseOfEstimates_16cf396f-128e-4c0f-b901-1be54ea4d806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_35f2364e-26f0-459b-ac07-969515386274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_35f2364e-26f0-459b-ac07-969515386274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_b4ef2485-5a1f-459f-9c14-f87f3b3eb79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_b4ef2485-5a1f-459f-9c14-f87f3b3eb79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_452bc5eb-2512-4e6c-9bb9-aef83a5a9143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_452bc5eb-2512-4e6c-9bb9-aef83a5a9143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_640719cf-63b6-45ea-8eb3-5e805d364aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_640719cf-63b6-45ea-8eb3-5e805d364aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5e3a6a3e-6a35-4fa9-ba53-04c8008caec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_5e3a6a3e-6a35-4fa9-ba53-04c8008caec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_9578f6e0-580a-4f6d-a159-4340c991604c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_9578f6e0-580a-4f6d-a159-4340c991604c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_4f1c0a25-4e97-4b65-9892-7f9d9bc96886" xlink:href="ameh-20211231.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_4f1c0a25-4e97-4b65-9892-7f9d9bc96886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_d9d51ba2-8865-43e8-a09f-1ca84ee6bbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_d9d51ba2-8865-43e8-a09f-1ca84ee6bbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_150f34e5-177a-4911-8d9f-f95ada1c0cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_150f34e5-177a-4911-8d9f-f95ada1c0cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c04c74db-7212-48fb-ac92-6100825f645a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_c04c74db-7212-48fb-ac92-6100825f645a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2786c154-8a44-4186-a7f9-c056cdcf4207" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2786c154-8a44-4186-a7f9-c056cdcf4207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4833a205-6ff4-45e6-ba9f-c10abdb6bdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_4833a205-6ff4-45e6-ba9f-c10abdb6bdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_eea470f9-aeae-45b9-b876-9cd7691f21ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_eea470f9-aeae-45b9-b876-9cd7691f21ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_732a139a-00bd-4c7c-9c1d-1c0b164ad435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_732a139a-00bd-4c7c-9c1d-1c0b164ad435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_dd44bcde-282e-49cd-9258-f0dd97fde565" xlink:href="ameh-20211231.xsd#ameh_FiduciaryCashAndPayablePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_ameh_FiduciaryCashAndPayablePolicyTextBlock_dd44bcde-282e-49cd-9258-f0dd97fde565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_761036e4-b6f2-4f57-86cf-34e227e6b7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_761036e4-b6f2-4f57-86cf-34e227e6b7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c7d89a6a-b690-4fd1-a10d-d5229bea6e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_c7d89a6a-b690-4fd1-a10d-d5229bea6e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_eb964438-60ef-46df-ba92-61b1f3141829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_eb964438-60ef-46df-ba92-61b1f3141829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_77d64d6d-f81e-4f6a-a1f3-f0ad5ed28be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_77d64d6d-f81e-4f6a-a1f3-f0ad5ed28be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_d73ad47a-3c30-489c-8261-c7ffe4ab7432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_d73ad47a-3c30-489c-8261-c7ffe4ab7432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock_bcc47870-4a89-4059-82a3-cca663b952b7" xlink:href="ameh-20211231.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_ameh_MinorityInterestPolicyPolicyTextBlock_bcc47870-4a89-4059-82a3-cca663b952b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock_71bbb856-cd5a-41f3-abf4-8bc6afe75f70" xlink:href="ameh-20211231.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_ameh_TemporaryEquityPolicyTextBlock_71bbb856-cd5a-41f3-abf4-8bc6afe75f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_61c75d70-1080-43ad-9b7e-3c6586cbde8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_61c75d70-1080-43ad-9b7e-3c6586cbde8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BeneficialInterestPolicyTextBlock_c1f6e072-e562-4de6-92f8-26c577c9d940" xlink:href="ameh-20211231.xsd#ameh_BeneficialInterestPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_ameh_BeneficialInterestPolicyTextBlock_c1f6e072-e562-4de6-92f8-26c577c9d940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5ddc97ff-5a40-4da8-8bd4-09f091a58876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_42da80f1-9518-4927-a89c-5cb6c2c1f5d1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5ddc97ff-5a40-4da8-8bd4-09f091a58876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_403ad24d-bbf4-40f8-ac17-fa25105b21dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c7352ff6-a3a3-4b2e-8057-2dd138ecb30e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403ad24d-bbf4-40f8-ac17-fa25105b21dc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_c7352ff6-a3a3-4b2e-8057-2dd138ecb30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_3c63c672-2134-4907-b621-a375385d62d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403ad24d-bbf4-40f8-ac17-fa25105b21dc" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_3c63c672-2134-4907-b621-a375385d62d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4dc46f7f-c633-4ee2-ba44-274ff655a29b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_403ad24d-bbf4-40f8-ac17-fa25105b21dc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4dc46f7f-c633-4ee2-ba44-274ff655a29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6fcd0d5-3505-48b8-abfe-fa3736564541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:href="ameh-20211231.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6fcd0d5-3505-48b8-abfe-fa3736564541" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_edcdfa51-a276-46f0-b0e6-7311ebde34f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_RangeAxis_edcdfa51-a276-46f0-b0e6-7311ebde34f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_edcdfa51-a276-46f0-b0e6-7311ebde34f4" xlink:to="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_69c30c26-5d68-4746-aee3-3ee656aaea6a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:to="loc_srt_MinimumMember_69c30c26-5d68-4746-aee3-3ee656aaea6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e60b90e2-8b75-4d3b-8c0a-b83f7af70802" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_81219a43-a1f8-4f44-a9e1-a0256b43732d" xlink:to="loc_srt_MaximumMember_e60b90e2-8b75-4d3b-8c0a-b83f7af70802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9072988c-965d-4a61-9423-bdd7e66fee66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9072988c-965d-4a61-9423-bdd7e66fee66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2c7b1a22-91af-4cef-bb98-f6e679de4026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_9072988c-965d-4a61-9423-bdd7e66fee66" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2c7b1a22-91af-4cef-bb98-f6e679de4026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareLicenseMember_06eacc49-24bc-41bb-bbbe-beafe8a5b7f2" xlink:href="ameh-20211231.xsd#ameh_MedicareLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2c7b1a22-91af-4cef-bb98-f6e679de4026" xlink:to="loc_ameh_MedicareLicenseMember_06eacc49-24bc-41bb-bbbe-beafe8a5b7f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e80ca51-161a-442d-a243-a16b4051440e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e80ca51-161a-442d-a243-a16b4051440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e80ca51-161a-442d-a243-a16b4051440e" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_e00bc33f-e0ea-4ded-bc0b-f0e6338ff6e7" xlink:href="ameh-20211231.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:to="loc_ameh_UniversalCareIncMember_e00bc33f-e0ea-4ded-bc0b-f0e6338ff6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_ef4fe18c-1acf-4a7f-9666-2ca62dc10116" xlink:href="ameh-20211231.xsd#ameh_PacificAmbulatorySurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_d1fd5034-cd56-41ce-8fbe-d23ceefdf3b9" xlink:to="loc_ameh_PacificAmbulatorySurgeryCenterLlcMember_ef4fe18c-1acf-4a7f-9666-2ca62dc10116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_687d75f5-2a9a-42de-94e4-745861763e3c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_ProductOrServiceAxis_687d75f5-2a9a-42de-94e4-745861763e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_687d75f5-2a9a-42de-94e4-745861763e3c" xlink:to="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_116f2222-fcbf-4038-8170-6bfd6704ef91" xlink:href="ameh-20211231.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_116f2222-fcbf-4038-8170-6bfd6704ef91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_60aa8b57-e4c7-4fbb-90b7-ce7d15ffd78e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:to="loc_us-gaap_ManagementServiceMember_60aa8b57-e4c7-4fbb-90b7-ce7d15ffd78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_0ab49001-d5da-45d6-8643-5d0f0ca37e22" xlink:href="ameh-20211231.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e13184c1-e31c-495b-b2c6-acff7a56acb9" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_0ab49001-d5da-45d6-8643-5d0f0ca37e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_92227f2d-bb7a-4e24-9e75-9fcd886d4006" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_CounterpartyNameAxis_92227f2d-bb7a-4e24-9e75-9fcd886d4006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_92227f2d-bb7a-4e24-9e75-9fcd886d4006" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClinigenceHoldingsIncMember_ce85cdec-d600-496d-a7ce-eee59c8eb898" xlink:href="ameh-20211231.xsd#ameh_ClinigenceHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:to="loc_ameh_ClinigenceHoldingsIncMember_ce85cdec-d600-496d-a7ce-eee59c8eb898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_4f7e8b4d-f2e6-4efe-b8cf-ffc1dc81d926" xlink:href="ameh-20211231.xsd#ameh_CMSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8e5982f8-2191-4556-be20-b4c5099fc588" xlink:to="loc_ameh_CMSMember_4f7e8b4d-f2e6-4efe-b8cf-ffc1dc81d926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7bd4abec-0be9-4a96-9532-de6b22afb2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7bd4abec-0be9-4a96-9532-de6b22afb2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d9fbe94-53d2-4f86-b08f-f518e7ef5df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7bd4abec-0be9-4a96-9532-de6b22afb2bd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d9fbe94-53d2-4f86-b08f-f518e7ef5df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_3ec7d571-6674-403a-b48a-8af67d259cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6d9fbe94-53d2-4f86-b08f-f518e7ef5df5" xlink:to="loc_us-gaap_CertificatesOfDepositMember_3ec7d571-6674-403a-b48a-8af67d259cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_95cb7c23-7229-403d-adeb-736d889cd087" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_dei_LegalEntityAxis_95cb7c23-7229-403d-adeb-736d889cd087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_95cb7c23-7229-403d-adeb-736d889cd087" xlink:to="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5cfaf476-2511-4480-9214-5b18c5015ec2" xlink:href="ameh-20211231.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5cfaf476-2511-4480-9214-5b18c5015ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ea7a826f-0be3-4709-8485-ae706de54b84" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_2b0cbaca-6a64-4882-8dfe-f9b26499e8d1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ea7a826f-0be3-4709-8485-ae706de54b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f0f2f254-cd43-43b2-8736-1174df9ede90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f0f2f254-cd43-43b2-8736-1174df9ede90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4871a918-41e7-4788-9652-137f8b5e1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f0f2f254-cd43-43b2-8736-1174df9ede90" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4871a918-41e7-4788-9652-137f8b5e1a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_accb6c5e-e172-441e-b645-abef544c5e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4871a918-41e7-4788-9652-137f8b5e1a8e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_accb6c5e-e172-441e-b645-abef544c5e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_a2176ef9-5213-40b1-933c-326fca4c748e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_srt_OwnershipAxis_a2176ef9-5213-40b1-933c-326fca4c748e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e16380f0-f691-4442-a9c2-7a31dbff16ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_a2176ef9-5213-40b1-933c-326fca4c748e" xlink:to="loc_srt_OwnershipDomain_e16380f0-f691-4442-a9c2-7a31dbff16ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_52cb6e99-d12b-40bf-bee7-367df04b06ff" xlink:href="ameh-20211231.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e16380f0-f691-4442-a9c2-7a31dbff16ce" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_52cb6e99-d12b-40bf-bee7-367df04b06ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_cf33ccf0-573c-40cb-aaa6-ddf75ac3b365" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_63b37aaa-f189-43f8-bd8e-3dac3b360097" xlink:href="ameh-20211231.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_63b37aaa-f189-43f8-bd8e-3dac3b360097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e2a0cbe7-9f1e-454d-9746-a2caf7d83668" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a7c1d03f-e6de-4140-86b1-017164cdb4a9" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_e2a0cbe7-9f1e-454d-9746-a2caf7d83668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c58893d0-60b0-48f2-9fc3-c32891f482a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c58893d0-60b0-48f2-9fc3-c32891f482a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c58893d0-60b0-48f2-9fc3-c32891f482a6" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fd50baf5-a455-4cae-8c50-b6a1192c1ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:to="loc_us-gaap_InterestRateSwapMember_fd50baf5-a455-4cae-8c50-b6a1192c1ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_b5e434b3-0922-4b98-989a-d9f1290c3246" xlink:href="ameh-20211231.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0938087c-a3e6-46c8-9ab9-20b2429b1c5d" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_b5e434b3-0922-4b98-989a-d9f1290c3246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e093b805-1d08-4a69-889d-55c0a42709b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e093b805-1d08-4a69-889d-55c0a42709b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_49631aa4-939b-4550-b1f1-7ccbb81ddf39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e093b805-1d08-4a69-889d-55c0a42709b7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_49631aa4-939b-4550-b1f1-7ccbb81ddf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_958881ce-b2dc-414b-8006-362867d29863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_49631aa4-939b-4550-b1f1-7ccbb81ddf39" xlink:to="loc_us-gaap_CashFlowHedgingMember_958881ce-b2dc-414b-8006-362867d29863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f933306c-b7f0-4d90-941c-4121e8b28237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_us-gaap_HedgingDesignationAxis_f933306c-b7f0-4d90-941c-4121e8b28237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d8cc9c63-4e64-4af5-bfeb-db00ab678629" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f933306c-b7f0-4d90-941c-4121e8b28237" xlink:to="loc_us-gaap_HedgingDesignationDomain_d8cc9c63-4e64-4af5-bfeb-db00ab678629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a10a3a8a-a98a-4ba2-a092-bcf2d2260d83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d8cc9c63-4e64-4af5-bfeb-db00ab678629" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a10a3a8a-a98a-4ba2-a092-bcf2d2260d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:href="ameh-20211231.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ebf5ca8b-554f-4b48-a05a-40740ed78262" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3a25b122-6b76-4b36-b75a-3ad086757e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3a25b122-6b76-4b36-b75a-3ad086757e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_50e6f33d-e5d8-4c6c-a881-61267a02de5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_NumberOfReportableSegments_50e6f33d-e5d8-4c6c-a881-61267a02de5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_2bc0a9d4-1bb9-46c0-8d22-a3b5df7ef8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_CashUninsuredAmount_2bc0a9d4-1bb9-46c0-8d22-a3b5df7ef8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_7ad6e4fe-708e-4365-b351-5dd14998abae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_7ad6e4fe-708e-4365-b351-5dd14998abae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_859b03d0-4779-48d7-8a66-a9feab845c97" xlink:href="ameh-20211231.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_859b03d0-4779-48d7-8a66-a9feab845c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4b1c475-b9b5-41dd-a9d9-ebd005252a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d4b1c475-b9b5-41dd-a9d9-ebd005252a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_e8dc6888-bd6f-4589-b416-dbf60677131c" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_e8dc6888-bd6f-4589-b416-dbf60677131c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6b828f5e-1051-484f-a0f0-28e8d079e665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_6b828f5e-1051-484f-a0f0-28e8d079e665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_bf76d84d-e304-4691-a674-e67f6ec045a9" xlink:href="ameh-20211231.xsd#ameh_PaymentsToAcquireCommonStockAndWarrants"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentsToAcquireCommonStockAndWarrants_bf76d84d-e304-4691-a674-e67f6ec045a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_52132803-d4d6-4fa5-bb55-e0bee83d6464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_52132803-d4d6-4fa5-bb55-e0bee83d6464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableExpectedToBeCollectedPeriod_9ed67de2-96b7-4553-b0d8-65f22545f58d" xlink:href="ameh-20211231.xsd#ameh_AccountsReceivableExpectedToBeCollectedPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_AccountsReceivableExpectedToBeCollectedPeriod_9ed67de2-96b7-4553-b0d8-65f22545f58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_423565e9-69a4-4e60-ad90-eb25b4e5f226" xlink:href="ameh-20211231.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_423565e9-69a4-4e60-ad90-eb25b4e5f226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aae8d9ba-a96c-4570-97b8-827f7ea3475e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aae8d9ba-a96c-4570-97b8-827f7ea3475e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_d9a72b09-9a2a-4e52-a0ee-7313a79f0639" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_NumberOfReportingUnits_d9a72b09-9a2a-4e52-a0ee-7313a79f0639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_e8d8cc17-abbe-4352-91a2-75dd514d180a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_e8d8cc17-abbe-4352-91a2-75dd514d180a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc3a19a4-d285-4e19-aa26-46f8267da262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_fc3a19a4-d285-4e19-aa26-46f8267da262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_38d8d894-667d-4816-890a-da5c02fb6ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_38d8d894-667d-4816-890a-da5c02fb6ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_43e79e18-cacd-44ff-acc7-71f25c3f6f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_43e79e18-cacd-44ff-acc7-71f25c3f6f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_1069de2a-3906-433f-8baf-87484d020ac5" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_1069de2a-3906-433f-8baf-87484d020ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d875c887-a90a-4d66-b546-e2e5bcd976ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_d875c887-a90a-4d66-b546-e2e5bcd976ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_b001d594-e73f-407c-8725-dad75e9eda4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_DerivativeAssets_b001d594-e73f-407c-8725-dad75e9eda4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_a6da29e0-6f6f-434c-aa9f-d4fe8571fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_a6da29e0-6f6f-434c-aa9f-d4fe8571fff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e2f70a07-5fd6-431a-9f83-82b445a5307e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_e2f70a07-5fd6-431a-9f83-82b445a5307e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_6d5c1343-39c5-4d36-84af-7bc630bbd1b5" xlink:href="ameh-20211231.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_6d5c1343-39c5-4d36-84af-7bc630bbd1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSettlement_c2d5eca2-d59a-46e2-9718-0b40138fb60f" xlink:href="ameh-20211231.xsd#ameh_RiskPoolSettlement"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_RiskPoolSettlement_c2d5eca2-d59a-46e2-9718-0b40138fb60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_e391a59a-c001-4182-b320-84cab0353ebc" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_e391a59a-c001-4182-b320-84cab0353ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_bc2619d2-6e4c-4aba-880b-85552e053712" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentOfRevenue_bc2619d2-6e4c-4aba-880b-85552e053712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueRevenueRecognized_9cbea239-ed23-4862-8f06-82e217ceb604" xlink:href="ameh-20211231.xsd#ameh_PaymentOfRevenueRevenueRecognized"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_PaymentOfRevenueRevenueRecognized_9cbea239-ed23-4862-8f06-82e217ceb604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5761c35-5f57-4f44-9563-28ca0df96e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5761c35-5f57-4f44-9563-28ca0df96e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5a6e4dee-c9f0-4c16-897b-04d227cba948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5a6e4dee-c9f0-4c16-897b-04d227cba948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0132b656-f9cb-4e9b-950c-acb2fe79e329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_0132b656-f9cb-4e9b-950c-acb2fe79e329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_661e171f-2071-4772-8565-bf1cd5c7ea0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_661e171f-2071-4772-8565-bf1cd5c7ea0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_dd84257a-615c-4643-af60-e548e58eac74" xlink:href="ameh-20211231.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_dd84257a-615c-4643-af60-e548e58eac74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_82e1cc5e-69a9-4857-8563-2d8415db7f68" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_82e1cc5e-69a9-4857-8563-2d8415db7f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_4a76210d-4ab4-434b-9324-1c154ae49f3e" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_4a76210d-4ab4-434b-9324-1c154ae49f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9446d8e9-08de-4b57-b4da-8daa78c3312e" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_491d86e9-6453-45a5-9d48-7242b5abff8e" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_9446d8e9-08de-4b57-b4da-8daa78c3312e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_882e009f-ab3c-4798-8f93-74d96385c6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_882e009f-ab3c-4798-8f93-74d96385c6f4" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_731697eb-ba85-4655-b74c-4a94a539bb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_731697eb-ba85-4655-b74c-4a94a539bb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:to="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4307ef8e-4a03-40ed-a0ae-45b0dc7babeb" xlink:to="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_e283be2c-eba6-4b49-9b46-90f173e59b34" xlink:href="ameh-20211231.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2f951829-bad5-40dd-bf9b-3c173ca45216" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_e283be2c-eba6-4b49-9b46-90f173e59b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_db0ef0be-7bd3-46e2-bbf6-761ed9748a73" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1d0cd67b-a352-4f8a-916e-d4201d783a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_69f98aa3-dd2f-4799-94a4-e19bf383704b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_1d0cd67b-a352-4f8a-916e-d4201d783a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_538a121f-c85c-4f58-a006-33fdd9e6eb60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_4dfe6fc3-b5a5-46c8-91ee-c426e637959a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_538a121f-c85c-4f58-a006-33fdd9e6eb60" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_4dfe6fc3-b5a5-46c8-91ee-c426e637959a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_287ecdf3-7538-4536-8f9c-8efe870e227a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4dfe6fc3-b5a5-46c8-91ee-c426e637959a" xlink:to="loc_srt_MajorCustomersAxis_287ecdf3-7538-4536-8f9c-8efe870e227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_287ecdf3-7538-4536-8f9c-8efe870e227a" xlink:to="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_6db86479-9f9d-4cce-a9f1-00f358a14b4b" xlink:href="ameh-20211231.xsd#ameh_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_CommercialMember_6db86479-9f9d-4cce-a9f1-00f358a14b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_0bdf15ae-13ae-4037-a40c-3008b95ee70e" xlink:href="ameh-20211231.xsd#ameh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_MedicareMember_0bdf15ae-13ae-4037-a40c-3008b95ee70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_ef2756b2-6bc0-43a9-874c-d3535410739e" xlink:href="ameh-20211231.xsd#ameh_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_MedicaidMember_ef2756b2-6bc0-43a9-874c-d3535410739e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_fa3c5f76-5ec2-436e-98bf-cab01c9a6732" xlink:href="ameh-20211231.xsd#ameh_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_34b82771-7e41-46ad-804e-7ca82825f5a6" xlink:to="loc_ameh_OtherThirdPartiesMember_fa3c5f76-5ec2-436e-98bf-cab01c9a6732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_566069f8-dd4c-46e8-96ba-ec0e0763029b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_4dfe6fc3-b5a5-46c8-91ee-c426e637959a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_566069f8-dd4c-46e8-96ba-ec0e0763029b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f6431ea-4668-41e3-84b8-4aa1a81bdd10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_566069f8-dd4c-46e8-96ba-ec0e0763029b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f6431ea-4668-41e3-84b8-4aa1a81bdd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_da153d98-e513-4021-9788-9080250123e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da153d98-e513-4021-9788-9080250123e4" xlink:to="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_536fc4dc-1797-4c34-b02f-e630039d589f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_536fc4dc-1797-4c34-b02f-e630039d589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_536fc4dc-1797-4c34-b02f-e630039d589f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cbec4ae3-3fd9-457b-bcc2-69bc15460dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:to="loc_us-gaap_SalesRevenueNetMember_cbec4ae3-3fd9-457b-bcc2-69bc15460dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_5902f6f0-d4a2-47cc-8447-7e5ef1c5e01b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_111c139a-d59a-43e8-97dc-486a27b9c0bf" xlink:to="loc_us-gaap_AccountsReceivableMember_5902f6f0-d4a2-47cc-8447-7e5ef1c5e01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_128ba503-993d-4412-b435-aae4601c4693" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:to="loc_srt_MajorCustomersAxis_128ba503-993d-4412-b435-aae4601c4693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_128ba503-993d-4412-b435-aae4601c4693" xlink:to="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_ac21959a-4674-417e-bb6e-6d2a7e113892" xlink:href="ameh-20211231.xsd#ameh_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorAMember_ac21959a-4674-417e-bb6e-6d2a7e113892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_6bd83f86-515b-4d10-a204-4e0383537dab" xlink:href="ameh-20211231.xsd#ameh_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorBMember_6bd83f86-515b-4d10-a204-4e0383537dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_d1f4adeb-f658-4a43-9e65-7cbb3297d885" xlink:href="ameh-20211231.xsd#ameh_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorCMember_d1f4adeb-f658-4a43-9e65-7cbb3297d885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_c17cd928-4442-4bfd-9877-7c3058a4c5b2" xlink:href="ameh-20211231.xsd#ameh_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorDMember_c17cd928-4442-4bfd-9877-7c3058a4c5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_f3b0b494-268b-46fc-9af6-70f4082f821b" xlink:href="ameh-20211231.xsd#ameh_PayorEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorEMember_f3b0b494-268b-46fc-9af6-70f4082f821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_35d798db-11f4-451c-98c3-de0d75b001cb" xlink:href="ameh-20211231.xsd#ameh_PayorFMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e7231d20-6aed-494b-9688-d94e9caca9c3" xlink:to="loc_ameh_PayorFMember_35d798db-11f4-451c-98c3-de0d75b001cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_7b66b814-b56e-46d7-ae70-fb8623512511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_7b66b814-b56e-46d7-ae70-fb8623512511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ef9dcc56-5426-46a7-98ae-3fb3d2dd044b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_7b66b814-b56e-46d7-ae70-fb8623512511" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ef9dcc56-5426-46a7-98ae-3fb3d2dd044b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a5cf752e-fca3-4b6c-8d7c-52aa2e8edf11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ef9dcc56-5426-46a7-98ae-3fb3d2dd044b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a5cf752e-fca3-4b6c-8d7c-52aa2e8edf11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2a078c6a-ecee-41dc-8a54-1e586d857432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_ad25bb5f-694f-4caa-9245-8170c21e9ec9" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_2a078c6a-ecee-41dc-8a54-1e586d857432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2a667ec2-a1e3-43d3-8f22-284e69da411f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2a078c6a-ecee-41dc-8a54-1e586d857432" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2a667ec2-a1e3-43d3-8f22-284e69da411f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7cfe858-4d65-4c63-b6f2-7296e5136aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7cfe858-4d65-4c63-b6f2-7296e5136aa3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_443f02fc-52f8-4c65-9df6-0e35828f61ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_443f02fc-52f8-4c65-9df6-0e35828f61ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_443f02fc-52f8-4c65-9df6-0e35828f61ee" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_444a6cbc-f520-4898-97e4-d672b9890857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_444a6cbc-f520-4898-97e4-d672b9890857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9beceeb5-3522-4f94-a7d2-3c64c743a851" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9beceeb5-3522-4f94-a7d2-3c64c743a851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_06681590-c210-4c24-a64d-e7b843cfb12d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d29c5cee-072d-400d-a9d0-7ee3640fc830" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_06681590-c210-4c24-a64d-e7b843cfb12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c56a1fad-6c58-4fc1-a59b-3afa39143582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c56a1fad-6c58-4fc1-a59b-3afa39143582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c56a1fad-6c58-4fc1-a59b-3afa39143582" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContingentEquitySecuritiesMember_29509639-d0fc-40f9-b589-0af33f5dd694" xlink:href="ameh-20211231.xsd#ameh_ContingentEquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:to="loc_ameh_ContingentEquitySecuritiesMember_29509639-d0fc-40f9-b589-0af33f5dd694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_63d73659-3eb0-40c6-a1f1-59a1485d2f82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b5f13fba-d779-44c6-b84d-7ac17d8fa4f5" xlink:to="loc_us-gaap_WarrantMember_63d73659-3eb0-40c6-a1f1-59a1485d2f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d1883fe2-a28c-4332-b8bf-24daed84f69e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08fd0ca4-8f46-4597-acf0-3d02b6baad78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_08fd0ca4-8f46-4597-acf0-3d02b6baad78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67a0da2b-8566-4866-9d44-5bdfaf10f9af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_67a0da2b-8566-4866-9d44-5bdfaf10f9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_dacc3f38-5e2b-48a2-884a-b649bfb0888a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_dacc3f38-5e2b-48a2-884a-b649bfb0888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_6df24f93-d873-43af-8447-835c80319497" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_DerivativeAssets_6df24f93-d873-43af-8447-835c80319497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3492d9a4-d6b6-4da9-8a79-b3e997d715a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3492d9a4-d6b6-4da9-8a79-b3e997d715a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_0c96d1cb-cfba-4bcc-98c1-683a5a9c5e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_DerivativeLiabilities_0c96d1cb-cfba-4bcc-98c1-683a5a9c5e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51932300-1298-43b2-8a51-80b0ca682db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_51932300-1298-43b2-8a51-80b0ca682db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b8ae4f1a-f681-4a74-82bf-e5c9b7792dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_58c2bc89-ba54-40ee-8178-52f1da0695de" xlink:to="loc_us-gaap_FinancialLiabilitiesFairValueDisclosure_b8ae4f1a-f681-4a74-82bf-e5c9b7792dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20211231.xsd#BusinessCombinationsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6979c03a-db71-45b8-b854-d258e26d1c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_072c5193-a39f-4745-8970-985d27fad868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6979c03a-db71-45b8-b854-d258e26d1c38" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_072c5193-a39f-4745-8970-985d27fad868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_04bcbf2c-98e9-4b13-bfea-87be039777f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e37c15ba-d97a-40fa-b803-deca71efce5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_04bcbf2c-98e9-4b13-bfea-87be039777f0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e37c15ba-d97a-40fa-b803-deca71efce5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f9f6d05e-ca21-4c39-aa90-d0e8813e20b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130e0bcc-c795-4720-905c-46d27280bbd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f9f6d05e-ca21-4c39-aa90-d0e8813e20b5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130e0bcc-c795-4720-905c-46d27280bbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c218ae8f-07c5-43d4-b39d-9572e54adda3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130e0bcc-c795-4720-905c-46d27280bbd1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c218ae8f-07c5-43d4-b39d-9572e54adda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c218ae8f-07c5-43d4-b39d-9572e54adda3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccessPrimaryCareMedicalGroupMember_1677d433-abab-4c9d-9752-ff1a81a3b587" xlink:href="ameh-20211231.xsd#ameh_AccessPrimaryCareMedicalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:to="loc_ameh_AccessPrimaryCareMedicalGroupMember_1677d433-abab-4c9d-9752-ff1a81a3b587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloSunLabsManagementLLCMember_4b5499f2-d00a-4621-a6fd-23ec059400ac" xlink:href="ameh-20211231.xsd#ameh_ApolloSunLabsManagementLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:to="loc_ameh_ApolloSunLabsManagementLLCMember_4b5499f2-d00a-4621-a6fd-23ec059400ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_6b701821-887d-48d5-a20e-a4e5d0d683da" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3230550d-91da-4517-86af-eaa4a25c9307" xlink:to="loc_ameh_DmgMember_6b701821-887d-48d5-a20e-a4e5d0d683da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_130e0bcc-c795-4720-905c-46d27280bbd1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_716dd439-93e2-44f0-9c7c-d2b83e1c3dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_716dd439-93e2-44f0-9c7c-d2b83e1c3dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d82a14e-2122-4eb7-9e1b-a2f8be2d8498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_8d82a14e-2122-4eb7-9e1b-a2f8be2d8498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_60b62f50-fac5-4d54-9419-3ee21e466c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_60b62f50-fac5-4d54-9419-3ee21e466c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0657d5d3-20e6-41b2-9cfc-731c7a246c59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0657d5d3-20e6-41b2-9cfc-731c7a246c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_595ee0bd-b00d-4056-bd37-436df935e56a" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_3e6429a7-cbd7-4024-b941-32f65c5e9333" xlink:to="loc_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase_595ee0bd-b00d-4056-bd37-436df935e56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#BusinessCombinationsandGoodwillGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b55d2a77-d33a-4d1f-a46f-5299996cbb82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_e2cdda0e-7fc9-49ca-9cac-039f7303ca2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b55d2a77-d33a-4d1f-a46f-5299996cbb82" xlink:to="loc_us-gaap_GoodwillRollForward_e2cdda0e-7fc9-49ca-9cac-039f7303ca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_44b32efc-c957-4499-a03f-917bc589f6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e2cdda0e-7fc9-49ca-9cac-039f7303ca2b" xlink:to="loc_us-gaap_Goodwill_44b32efc-c957-4499-a03f-917bc589f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_d8eacc2a-a424-42d7-aced-30673a6e3ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e2cdda0e-7fc9-49ca-9cac-039f7303ca2b" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_d8eacc2a-a424-42d7-aced-30673a6e3ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_f0c6bb6d-4800-492f-90ff-549c288d019d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e2cdda0e-7fc9-49ca-9cac-039f7303ca2b" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_f0c6bb6d-4800-492f-90ff-549c288d019d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b9062049-14c5-4c91-9c13-6834c20d8edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_e2cdda0e-7fc9-49ca-9cac-039f7303ca2b" xlink:to="loc_us-gaap_Goodwill_b9062049-14c5-4c91-9c13-6834c20d8edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNet" xlink:type="simple" xlink:href="ameh-20211231.xsd#LandPropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LandPropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3d4abd1-8bbe-4ab2-91d6-1f40c612d67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock_82acfcf3-9e1f-4010-83e8-91651b3654ea" xlink:href="ameh-20211231.xsd#ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3d4abd1-8bbe-4ab2-91d6-1f40c612d67c" xlink:to="loc_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock_82acfcf3-9e1f-4010-83e8-91651b3654ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#LandPropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LandPropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_40cd92fd-06bb-4032-978e-be8ee9bd74f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e25d651-2c10-41f4-b036-5fb5367030cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_40cd92fd-06bb-4032-978e-be8ee9bd74f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3e25d651-2c10-41f4-b036-5fb5367030cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95932bd9-f006-4c6f-8e0f-b4d9ae2e068b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_95932bd9-f006-4c6f-8e0f-b4d9ae2e068b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd539d1c-dc3b-4600-86f0-ccf55fa52525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd539d1c-dc3b-4600-86f0-ccf55fa52525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_dd539d1c-dc3b-4600-86f0-ccf55fa52525" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_4c1e6a39-2ff2-4373-90a2-0b98e45e38e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_LandMember_4c1e6a39-2ff2-4373-90a2-0b98e45e38e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9d6f3f60-c93b-4d9a-89e8-af6654e46421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_BuildingMember_9d6f3f60-c93b-4d9a-89e8-af6654e46421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_6073dfe5-0862-411f-8a4f-050c45931bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_ComputerEquipmentMember_6073dfe5-0862-411f-8a4f-050c45931bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_cbe24a96-6c85-4c20-a2c7-e1301277af73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_cbe24a96-6c85-4c20-a2c7-e1301277af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_20a4f303-b83c-4eb0-a728-a16eefbc1ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_ConstructionInProgressMember_20a4f303-b83c-4eb0-a728-a16eefbc1ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8e7fa91b-f7b4-4cfd-a90b-9c0f8df97ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2912ee8b-9532-4812-a1d2-bba9da06fae4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8e7fa91b-f7b4-4cfd-a90b-9c0f8df97ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f69b5b4-65e1-4551-be49-076532ef69a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:to="loc_srt_RangeAxis_6f69b5b4-65e1-4551-be49-076532ef69a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f69b5b4-65e1-4551-be49-076532ef69a1" xlink:to="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bbf16eb6-9c6f-4d61-a841-dcfcfb4b2fa9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:to="loc_srt_MinimumMember_bbf16eb6-9c6f-4d61-a841-dcfcfb4b2fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7dae121-137e-40c0-b3de-d11e105bac81" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_70669394-2c18-499b-8d50-6d2feb9cfad9" xlink:to="loc_srt_MaximumMember_c7dae121-137e-40c0-b3de-d11e105bac81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2ebff5db-40a4-4901-b6e6-81de8ed8907e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66d9ba1b-ecf8-46ae-90da-11b3e1fc8d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_66d9ba1b-ecf8-46ae-90da-11b3e1fc8d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_cde2e996-2006-4e3c-b9d8-587f584e3004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization_cde2e996-2006-4e3c-b9d8-587f584e3004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_515f8fb1-dc06-44db-82be-bee349a4ba17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_515f8fb1-dc06-44db-82be-bee349a4ba17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_92976c6c-c8e0-4a35-8cf4-94d179d078f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_e5a4a899-084b-496d-a540-4c83fd35a36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_92976c6c-c8e0-4a35-8cf4-94d179d078f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LandPropertyandEquipmentNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LandPropertyandEquipmentNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LandPropertyandEquipmentNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_097f5789-2c73-4f3a-95d6-e232265cd572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_5ec9f87d-a7f2-4a00-b460-3378b22b636f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_097f5789-2c73-4f3a-95d6-e232265cd572" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_5ec9f87d-a7f2-4a00-b460-3378b22b636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a03d1613-ca44-44be-b604-0677aaaa2294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_097f5789-2c73-4f3a-95d6-e232265cd572" xlink:to="loc_us-gaap_DepreciationAndAmortization_a03d1613-ca44-44be-b604-0677aaaa2294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_878d3924-f283-4856-bdd1-42937ff6a6d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8cdd056d-c7e4-45bf-972b-dfb6a4f84ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_878d3924-f283-4856-bdd1-42937ff6a6d5" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8cdd056d-c7e4-45bf-972b-dfb6a4f84ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d9a6906-81c0-416a-95ae-020a30b1563c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_428fb828-6404-4f6c-8071-be5b1e9c3af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d9a6906-81c0-416a-95ae-020a30b1563c" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_428fb828-6404-4f6c-8071-be5b1e9c3af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fe051a93-d475-487f-89e6-43c5a81d0487" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d9a6906-81c0-416a-95ae-020a30b1563c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_fe051a93-d475-487f-89e6-43c5a81d0487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b302dee6-7277-486d-80b8-f61cfa3eb94c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7d9a6906-81c0-416a-95ae-020a30b1563c" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_b302dee6-7277-486d-80b8-f61cfa3eb94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ad911ff-c97d-49e5-a6b8-0018b3938018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ad911ff-c97d-49e5-a6b8-0018b3938018" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c19323e0-d0f8-47b6-a317-4a6d7fd42a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c19323e0-d0f8-47b6-a317-4a6d7fd42a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ae2d246-0f61-450f-99cd-bb4b2c773a67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c19323e0-d0f8-47b6-a317-4a6d7fd42a34" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ae2d246-0f61-450f-99cd-bb4b2c773a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareLicenseMember_2cd58203-e6f0-4d9c-bd05-e5daa7d6ccb2" xlink:href="ameh-20211231.xsd#ameh_MedicareLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0ae2d246-0f61-450f-99cd-bb4b2c773a67" xlink:to="loc_ameh_MedicareLicenseMember_2cd58203-e6f0-4d9c-bd05-e5daa7d6ccb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f3c2e7ea-7eab-4d45-b4f5-1c4024908f46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_97a4338e-48f0-484d-b9dd-bdbc47fb30b6" xlink:href="ameh-20211231.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_NetworkRelationshipsMember_97a4338e-48f0-484d-b9dd-bdbc47fb30b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_5debebed-4237-4e33-b075-409b2ad6ea67" xlink:href="ameh-20211231.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_ManagementContractsMember_5debebed-4237-4e33-b075-409b2ad6ea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_c783890f-ab4d-420a-bcc2-cc953a88b080" xlink:href="ameh-20211231.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_MemberRelationshipsMember_c783890f-ab4d-420a-bcc2-cc953a88b080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_2cd7aa07-31d7-4a99-8c63-4bcd9efb5592" xlink:href="ameh-20211231.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_ameh_PatientManagementPlatformMember_2cd7aa07-31d7-4a99-8c63-4bcd9efb5592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_3ac2fb28-756b-4eb2-b10f-b9b0cd3b8631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_20ad1573-8332-4eb4-a028-873833fe842a" xlink:to="loc_us-gaap_TradeNamesMember_3ac2fb28-756b-4eb2-b10f-b9b0cd3b8631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_337cd2fd-5193-4b8f-bc41-363b94978dbe" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:to="loc_srt_RangeAxis_337cd2fd-5193-4b8f-bc41-363b94978dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_337cd2fd-5193-4b8f-bc41-363b94978dbe" xlink:to="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_db9c0c0b-ace6-45cc-9ccf-cb3cab8009e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:to="loc_srt_MinimumMember_db9c0c0b-ace6-45cc-9ccf-cb3cab8009e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cfd97733-177a-4d0e-9757-1c734e4376d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb7ccc37-967d-431b-af60-8a361aadab30" xlink:to="loc_srt_MaximumMember_cfd97733-177a-4d0e-9757-1c734e4376d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_11995d53-416a-46bd-9f89-e71cd93cec12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a8f8c946-c3b7-4d7e-8cb8-7813207b2e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a8f8c946-c3b7-4d7e-8cb8-7813207b2e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f7493068-f9a8-49ba-9e0e-0e8b17423105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_f7493068-f9a8-49ba-9e0e-0e8b17423105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_83575c63-ffdc-4da5-90b5-e897474ff052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_83575c63-ffdc-4da5-90b5-e897474ff052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dfa8fa4-16c8-4e2b-9d12-6de5677dce58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_2dfa8fa4-16c8-4e2b-9d12-6de5677dce58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9bd9e047-8ce9-4431-b383-9f8b69be19d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsRollForward_3699a8f0-e003-486f-9359-42eb2292205e" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_9bd9e047-8ce9-4431-b383-9f8b69be19d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3d703b1f-15c4-4a8b-9f95-2f746ba0759f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_3d703b1f-15c4-4a8b-9f95-2f746ba0759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_256fa6c5-ece3-40ed-af4f-9a62ac369043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_256fa6c5-ece3-40ed-af4f-9a62ac369043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d45c1588-6764-4cec-bfe3-65f3eeedbd85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d45c1588-6764-4cec-bfe3-65f3eeedbd85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_72f02616-8261-46da-8036-9f04a4a682f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_72f02616-8261-46da-8036-9f04a4a682f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_913ed00d-b1dc-4f39-9b97-ee692a60d35f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_913ed00d-b1dc-4f39-9b97-ee692a60d35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04585bb6-bbd2-4fa0-bbf7-169378f2df11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_04585bb6-bbd2-4fa0-bbf7-169378f2df11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_44306a32-4c11-4ba7-a4a6-6ea78c86bc82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_44306a32-4c11-4ba7-a4a6-6ea78c86bc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ef2b9ff-f0c0-4e74-9620-21148bee74fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRollForward_16ade63a-7010-43ed-b1d6-59988a0a537c" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6ef2b9ff-f0c0-4e74-9620-21148bee74fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_05476c2b-f913-4bad-8ca5-67ead1116d35" xlink:href="ameh-20211231.xsd#ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired_05476c2b-f913-4bad-8ca5-67ead1116d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c77836c6-cef0-4b2b-9e88-10b3b860a067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0ef0beea-265f-44f1-9d52-17847ce6d754" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c77836c6-cef0-4b2b-9e88-10b3b860a067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301cb0de-4fc1-4cfd-b7e8-c437c5d23076" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_301cb0de-4fc1-4cfd-b7e8-c437c5d23076" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2d592257-6e61-4e51-9a22-88dd6a5352d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2d592257-6e61-4e51-9a22-88dd6a5352d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e3a18354-96bb-4154-901f-e428c0103bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_2d592257-6e61-4e51-9a22-88dd6a5352d4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e3a18354-96bb-4154-901f-e428c0103bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareLicenseMember_3e2d9620-3c13-4c68-b6f5-ea8ee98e01d4" xlink:href="ameh-20211231.xsd#ameh_MedicareLicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_e3a18354-96bb-4154-901f-e428c0103bb7" xlink:to="loc_ameh_MedicareLicenseMember_3e2d9620-3c13-4c68-b6f5-ea8ee98e01d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ecdfd38f-0f5b-4cdc-8f3b-b1035b6be701" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_978d0a0e-139b-44e2-949d-aeb0861e0d05" xlink:href="ameh-20211231.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_NetworkRelationshipsMember_978d0a0e-139b-44e2-949d-aeb0861e0d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_67e726a9-7924-4368-afa7-9304bf6fe9bd" xlink:href="ameh-20211231.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_ManagementContractsMember_67e726a9-7924-4368-afa7-9304bf6fe9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_3ad1dd55-888f-47d2-a078-6321a9192096" xlink:href="ameh-20211231.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_MemberRelationshipsMember_3ad1dd55-888f-47d2-a078-6321a9192096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_8cf688d2-2a00-428a-93f8-ca4bc2f379e3" xlink:href="ameh-20211231.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_ameh_PatientManagementPlatformMember_8cf688d2-2a00-428a-93f8-ca4bc2f379e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_119a1c99-dbbd-4871-830e-f2d72ecc2d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_def511bd-019b-4f6e-af27-6532c5dd84fa" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_119a1c99-dbbd-4871-830e-f2d72ecc2d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_13f11f74-9716-4876-9cd1-7334aa552928" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_58ea7112-0be9-4b32-91f3-34fec3ca78b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_58ea7112-0be9-4b32-91f3-34fec3ca78b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b2c2d2d0-84a9-4197-8370-1eac76cde825" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b2c2d2d0-84a9-4197-8370-1eac76cde825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_0ba0f174-8358-4950-b675-3c41cfe4e855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c717627c-ece3-4bbb-b819-6b161f9981cc" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit_0ba0f174-8358-4950-b675-3c41cfe4e855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5ab8d47e-a62d-4787-9985-14abdc533aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5ab8d47e-a62d-4787-9985-14abdc533aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4c028c98-c85d-45b8-82b2-11647ebb83db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4c028c98-c85d-45b8-82b2-11647ebb83db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ee42e1ae-4bce-4e84-be0b-f6855fdbb5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ee42e1ae-4bce-4e84-be0b-f6855fdbb5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3c0b072f-c625-4d8b-b381-8f063280220b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3c0b072f-c625-4d8b-b381-8f063280220b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d54aaf5c-2a2c-4fd6-a8bb-77631f63b45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d54aaf5c-2a2c-4fd6-a8bb-77631f63b45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_75e2c85a-8826-4046-9765-064658f010b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_75e2c85a-8826-4046-9765-064658f010b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12ba83e2-d2e0-4822-aec5-2e25e5e1a801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_782d7448-6cc5-4095-91fc-b66b9745d334" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_12ba83e2-d2e0-4822-aec5-2e25e5e1a801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_210f73e8-4dc9-4be6-86a4-03f625194eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_6b642458-8ea4-4691-ad49-651174cbbc55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_210f73e8-4dc9-4be6-86a4-03f625194eb3" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_6b642458-8ea4-4691-ad49-651174cbbc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c9d2fa4e-674a-409a-937d-bbcd7f91ef76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_242c7712-f9f7-4f70-af22-2f5c64fadd53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_c9d2fa4e-674a-409a-937d-bbcd7f91ef76" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_242c7712-f9f7-4f70-af22-2f5c64fadd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesEquityMethodDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b1bf3e00-dcb1-4133-a5a5-3a7da0df0c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2955089f-2daf-4bec-aa60-999b6d17f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b1bf3e00-dcb1-4133-a5a5-3a7da0df0c42" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2955089f-2daf-4bec-aa60-999b6d17f9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_957988b6-461a-468a-ab79-69ae2b9caf12" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2955089f-2daf-4bec-aa60-999b6d17f9c6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_957988b6-461a-468a-ab79-69ae2b9caf12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_957988b6-461a-468a-ab79-69ae2b9caf12" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_70cdb99a-0dee-43f4-8e2d-d68dffc11801" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_70cdb99a-0dee-43f4-8e2d-d68dffc11801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_b53beb1e-a83a-4b59-898e-d1155424c4fc" xlink:href="ameh-20211231.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_b53beb1e-a83a-4b59-898e-d1155424c4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_240c9b65-c167-475b-80c4-6337c7af52d5" xlink:href="ameh-20211231.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_240c9b65-c167-475b-80c4-6337c7af52d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_e629b334-e40d-4929-9aab-4312a7bf8608" xlink:href="ameh-20211231.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_e629b334-e40d-4929-9aab-4312a7bf8608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_248fd007-543b-4923-98c4-93ca91b4a0e0" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_OneMSOLLCMember_248fd007-543b-4923-98c4-93ca91b4a0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_09daee45-9996-4e2b-b3e9-4e9752196feb" xlink:href="ameh-20211231.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_09daee45-9996-4e2b-b3e9-4e9752196feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_de625451-e418-4636-99b9-1d1b44f3184f" xlink:href="ameh-20211231.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_de625451-e418-4636-99b9-1d1b44f3184f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOMember_921c255a-05d1-47b8-88e6-d9f69630874d" xlink:href="ameh-20211231.xsd#ameh_CAIPAMSOMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_a5c16e9d-c329-44f9-956e-17dde5376a05" xlink:to="loc_ameh_CAIPAMSOMember_921c255a-05d1-47b8-88e6-d9f69630874d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c607ded-92ab-495f-a57a-faf11acf3da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_2955089f-2daf-4bec-aa60-999b6d17f9c6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c607ded-92ab-495f-a57a-faf11acf3da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c607ded-92ab-495f-a57a-faf11acf3da6" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_e4d50514-7dbe-460d-a76c-8ff298bae65e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_us-gaap_EquityMethodInvestments_e4d50514-7dbe-460d-a76c-8ff298bae65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentInvestmentInPeriod_2f667802-230d-4e00-b048-da277300cd0c" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentInvestmentInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_ameh_EquityMethodInvestmentInvestmentInPeriod_2f667802-230d-4e00-b048-da277300cd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b9121e9f-7159-4d55-aaf8-0f1283fbb9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_b9121e9f-7159-4d55-aaf8-0f1283fbb9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_0c06d1db-1ce9-478a-9d04-2b096a39afcc" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_0c06d1db-1ce9-478a-9d04-2b096a39afcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_65616e3b-4e34-4b98-91aa-37b7c52e722b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_65616e3b-4e34-4b98-91aa-37b7c52e722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsConsolidated_c0206cac-3336-4bab-b15a-1f082484cf16" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsConsolidated"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_ameh_EquityMethodInvestmentsConsolidated_c0206cac-3336-4bab-b15a-1f082484cf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_8bee43bc-1fde-4769-9137-e0c02d31579a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_973c962f-1e32-4ba3-bf3a-36c2723693a1" xlink:to="loc_us-gaap_EquityMethodInvestments_8bee43bc-1fde-4769-9137-e0c02d31579a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ed3c1f9b-3e0c-4440-9035-30b3adcb6334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ed3c1f9b-3e0c-4440-9035-30b3adcb6334" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0f33f24c-af69-45e3-a41d-049782b5ade4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0f33f24c-af69-45e3-a41d-049782b5ade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0f33f24c-af69-45e3-a41d-049782b5ade4" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_910b49fb-2baa-44ac-b88b-2f6bf8ccbcd5" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_910b49fb-2baa-44ac-b88b-2f6bf8ccbcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9a137396-f41a-4ed8-a865-d057e9659668" xlink:href="ameh-20211231.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_9a137396-f41a-4ed8-a865-d057e9659668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_aa81ab12-6f28-459a-a744-f83ea451a0d9" xlink:href="ameh-20211231.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_aa81ab12-6f28-459a-a744-f83ea451a0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_339a22c4-5b90-4d84-abba-fe3ddecc79b4" xlink:href="ameh-20211231.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_339a22c4-5b90-4d84-abba-fe3ddecc79b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOLLCMember_ca5d0ee1-b5ca-4fb2-b455-6e5da16312a4" xlink:href="ameh-20211231.xsd#ameh_OneMSOLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_OneMSOLLCMember_ca5d0ee1-b5ca-4fb2-b455-6e5da16312a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_997cf6f6-222c-4c05-add3-da13a2a605cc" xlink:href="ameh-20211231.xsd#ameh_Tag6MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_Tag6MedicalInvestmentGroupLLCMember_997cf6f6-222c-4c05-add3-da13a2a605cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_3b9f1c2b-4e63-4dfc-94f2-e7855dc27a64" xlink:href="ameh-20211231.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_3b9f1c2b-4e63-4dfc-94f2-e7855dc27a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CAIPAMSOLLCMember_fe2d0ecf-d53f-4f99-80f6-2be7bd6807fa" xlink:href="ameh-20211231.xsd#ameh_CAIPAMSOLLCMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_401be458-a163-48c0-8ccc-b218d1b714f2" xlink:to="loc_ameh_CAIPAMSOLLCMember_fe2d0ecf-d53f-4f99-80f6-2be7bd6807fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_96393eb2-6774-4015-b15f-44dde5232d89" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_dei_LegalEntityAxis_96393eb2-6774-4015-b15f-44dde5232d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_96393eb2-6774-4015-b15f-44dde5232d89" xlink:to="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_f065fbb7-bf0c-4a43-9614-2233016098fa" xlink:href="ameh-20211231.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_ApcLsmaMember_f065fbb7-bf0c-4a43-9614-2233016098fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_b129a3de-7147-4b5e-81cd-cb8dcfe8a378" xlink:href="ameh-20211231.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_APCAndAPCLSMAMember_b129a3de-7147-4b5e-81cd-cb8dcfe8a378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b828c75a-b6e2-483d-bfa1-6f67d195ab06" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b828c75a-b6e2-483d-bfa1-6f67d195ab06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_84fdc160-5450-47de-bcb2-ad9f6d48ce5e" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember_be3b7c65-af05-47f0-ad79-3099da2fb6c6" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_84fdc160-5450-47de-bcb2-ad9f6d48ce5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_92e7df2f-2056-46af-9259-eebf1806b47e" xlink:href="ameh-20211231.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_92e7df2f-2056-46af-9259-eebf1806b47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_317d1773-cc84-479f-b200-52f1d661e79b" xlink:href="ameh-20211231.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_d20b817f-4240-4439-9307-a105f93b90e8" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_317d1773-cc84-479f-b200-52f1d661e79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_6ce30174-c4c8-48bb-9c64-276972f2034a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_srt_OwnershipAxis_6ce30174-c4c8-48bb-9c64-276972f2034a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_6ce30174-c4c8-48bb-9c64-276972f2034a" xlink:to="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_661da10f-884d-47cd-aa3c-590cafc6c42d" xlink:href="ameh-20211231.xsd#ameh_MediPortalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:to="loc_ameh_MediPortalLLCMember_661da10f-884d-47cd-aa3c-590cafc6c42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_8831fd7f-8606-4a44-b022-0312049cce4a" xlink:href="ameh-20211231.xsd#ameh_AchievaMedInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_e3202ddf-6e79-4db0-8651-1ef02afe14fd" xlink:to="loc_ameh_AchievaMedInc.Member_8831fd7f-8606-4a44-b022-0312049cce4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_5943751e-d88c-467c-836a-64bd71eaedaf" xlink:href="ameh-20211231.xsd#ameh_ContractTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_ameh_ContractTypeAxis_5943751e-d88c-467c-836a-64bd71eaedaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_b5d07f66-3e18-4219-a204-5f2da63001c7" xlink:href="ameh-20211231.xsd#ameh_ContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeAxis_5943751e-d88c-467c-836a-64bd71eaedaf" xlink:to="loc_ameh_ContractTypeDomain_b5d07f66-3e18-4219-a204-5f2da63001c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_72ec3a75-e3d0-4741-9129-c5f7baa5a1c7" xlink:href="ameh-20211231.xsd#ameh_AncillaryServiceContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeDomain_b5d07f66-3e18-4219-a204-5f2da63001c7" xlink:to="loc_ameh_AncillaryServiceContractMember_72ec3a75-e3d0-4741-9129-c5f7baa5a1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ade85dd7-35af-44af-b67e-315bedd6a5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ade85dd7-35af-44af-b67e-315bedd6a5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_61882786-10f0-4d4f-ba20-661b2782ea2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ade85dd7-35af-44af-b67e-315bedd6a5be" xlink:to="loc_us-gaap_RelatedPartyDomain_61882786-10f0-4d4f-ba20-661b2782ea2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_60c97309-e65d-41b4-a34f-162c918b0b71" xlink:href="ameh-20211231.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_61882786-10f0-4d4f-ba20-661b2782ea2d" xlink:to="loc_ameh_Dr.ArteagaMember_60c97309-e65d-41b4-a34f-162c918b0b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a5a7210e-3f93-4adf-8eed-d81d185dc6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_0e3893f8-b9ac-4d2f-8c8a-c71ca487e193" xlink:to="loc_us-gaap_ReceivableTypeDomain_a5a7210e-3f93-4adf-8eed-d81d185dc6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_04aa1f7f-ced3-4c0b-9ea8-a7d2d51cafdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a5a7210e-3f93-4adf-8eed-d81d185dc6f8" xlink:to="loc_us-gaap_NotesReceivableMember_04aa1f7f-ced3-4c0b-9ea8-a7d2d51cafdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_91b96c58-8277-49b4-aa1b-a0a5535a0c49" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_6fb79774-c177-47e7-9c24-9f19ee696d6c" xlink:href="ameh-20211231.xsd#ameh_NumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_NumberOfEmployees_6fb79774-c177-47e7-9c24-9f19ee696d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_e30f7aa4-6311-4250-be76-d809975b9557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_e30f7aa4-6311-4250-be76-d809975b9557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef4556b5-a05e-4a00-80eb-c8362dc99d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ef4556b5-a05e-4a00-80eb-c8362dc99d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_6cafb106-2648-4988-9673-e0249a5ef95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_NotesReceivableNet_6cafb106-2648-4988-9673-e0249a5ef95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_9b90592a-6ebf-4cf8-99e7-b0d7feb65f0a" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease_9b90592a-6ebf-4cf8-99e7-b0d7feb65f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_d36c6838-b2e6-4ac4-83fe-6c4c84e78d86" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_d36c6838-b2e6-4ac4-83fe-6c4c84e78d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_46d23916-a149-4665-a614-4dc2fcc6b5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_46d23916-a149-4665-a614-4dc2fcc6b5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1dc7a2d3-d3e5-4c25-b787-60b7b2bab90d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_EquityMethodInvestments_1dc7a2d3-d3e5-4c25-b787-60b7b2bab90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_d587672c-7d63-43b6-98e0-aaba31d933f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_PaymentsForFees_d587672c-7d63-43b6-98e0-aaba31d933f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a273f2a2-db95-45b8-a5ab-ac00f657e5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss_a273f2a2-db95-45b8-a5ab-ac00f657e5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_2740a837-2ac7-45b5-ab69-008b31f36219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MembersCapital"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_MembersCapital_2740a837-2ac7-45b5-ab69-008b31f36219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_65674773-7991-4647-a45b-008179b562de" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_65674773-7991-4647-a45b-008179b562de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_a18fa9aa-79d1-4eb2-b78f-831b095e1ff8" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_a18fa9aa-79d1-4eb2-b78f-831b095e1ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_32d05bb2-3edc-410e-83db-120381c3e779" xlink:href="ameh-20211231.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_32d05bb2-3edc-410e-83db-120381c3e779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_f96941b5-8fcb-462e-80e6-2854e3f40c6b" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_f96941b5-8fcb-462e-80e6-2854e3f40c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_25f62cb8-90e3-4cdd-9d0b-b12d2223118b" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_25f62cb8-90e3-4cdd-9d0b-b12d2223118b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f6e830e0-23df-432e-958c-d19da37c635e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_f6e830e0-23df-432e-958c-d19da37c635e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bd67d673-430e-43fb-b4c8-1392e4a17a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bd67d673-430e-43fb-b4c8-1392e4a17a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_ca4b32e0-97fc-47dc-9924-dac4ecd42258" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_ca4b32e0-97fc-47dc-9924-dac4ecd42258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_25577b87-3659-478d-aac9-45e1cd6cb28f" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_25577b87-3659-478d-aac9-45e1cd6cb28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet_52c899f6-df93-4d0c-bc91-0ac488fae7fa" xlink:href="ameh-20211231.xsd#ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet_52c899f6-df93-4d0c-bc91-0ac488fae7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f27856c5-ba86-43ba-a8a6-022c9b9a56e4" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_f27856c5-ba86-43ba-a8a6-022c9b9a56e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_082d9408-426b-4dde-ada7-1d50d3fb2691" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_082d9408-426b-4dde-ada7-1d50d3fb2691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c8695c4b-f361-46d8-8f63-ca58db11de96" xlink:href="ameh-20211231.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_91fe50d4-c628-466f-a399-2bcfd2aa0dd1" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c8695c4b-f361-46d8-8f63-ca58db11de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_378bce4b-8ebb-4490-9e52-08f0632d6d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ec7e4912-74e6-4f44-bc71-a9db5959c6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_378bce4b-8ebb-4490-9e52-08f0632d6d7a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ec7e4912-74e6-4f44-bc71-a9db5959c6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_99692d39-51c4-4f68-96c4-12fa116e9151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ec7e4912-74e6-4f44-bc71-a9db5959c6bc" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_99692d39-51c4-4f68-96c4-12fa116e9151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_45a0c8af-456f-4a1c-81a7-e0c143e7c973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_99692d39-51c4-4f68-96c4-12fa116e9151" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_45a0c8af-456f-4a1c-81a7-e0c143e7c973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_61f33b46-56b3-4e46-99a6-042bd4eef1f0" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_45a0c8af-456f-4a1c-81a7-e0c143e7c973" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_61f33b46-56b3-4e46-99a6-042bd4eef1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_ec7e4912-74e6-4f44-bc71-a9db5959c6bc" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:to="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fa08c9a-1424-4188-9e6f-9effec256625" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7fa08c9a-1424-4188-9e6f-9effec256625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9e866609-d1a4-4869-ad75-f66da57570f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9e866609-d1a4-4869-ad75-f66da57570f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2fb673c7-df0a-4d07-8043-53edfe40b673" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_OtherAssetsCurrent_2fb673c7-df0a-4d07-8043-53edfe40b673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_40d07b13-dde8-46ae-abe3-cb82f89e089b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_40d07b13-dde8-46ae-abe3-cb82f89e089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_ebf54fa5-8ac8-4b01-ae8e-9afd4b955d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_RestrictedCashCurrent_ebf54fa5-8ac8-4b01-ae8e-9afd4b955d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b9749a55-9549-4964-9fd4-9a51a659a313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5de7e343-2342-4b67-99ba-c1e88b0c4ab8" xlink:to="loc_us-gaap_Assets_b9749a55-9549-4964-9fd4-9a51a659a313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e80f4cbd-b89e-49c1-8fc0-031d57760d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:to="loc_us-gaap_LiabilitiesCurrent_e80f4cbd-b89e-49c1-8fc0-031d57760d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c654e34-2ffc-4725-a145-0cc4a5a47f85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7c654e34-2ffc-4725-a145-0cc4a5a47f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4baa3c6-1cca-4eb2-baa0-a1d4d21498b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_93a93dc5-5a62-484f-9912-73efef6ead11" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4baa3c6-1cca-4eb2-baa0-a1d4d21498b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_77bfbece-9e69-4548-b62f-456d7de4b82f" xlink:to="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5e11797-c44e-4cd4-92b6-c2eeac7cb879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c5e11797-c44e-4cd4-92b6-c2eeac7cb879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0fa68ad5-7323-4ced-aa39-d8b22e4dac89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_CostsAndExpenses_0fa68ad5-7323-4ced-aa39-d8b22e4dac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7dd8be8f-85a2-47de-81d6-d600388cae80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_OperatingIncomeLoss_7dd8be8f-85a2-47de-81d6-d600388cae80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e9cfd57c-ce9e-4fa1-99c0-a2eee5673e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e9cfd57c-ce9e-4fa1-99c0-a2eee5673e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a76092c0-4c13-491f-90ba-7e058bbc3266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_1b008d38-817d-4791-b2cd-f0efa4e28220" xlink:to="loc_us-gaap_ProfitLoss_a76092c0-4c13-491f-90ba-7e058bbc3266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20211231.xsd#LoansReceivableandLoansReceivableRelatedParties"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableAbstract_e0404f08-4a10-48b4-942e-49a7fe43e2f9" xlink:href="ameh-20211231.xsd#ameh_LoanReceivableAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock_59537213-f37f-4e94-b6c6-fcbe94d0f5db" xlink:href="ameh-20211231.xsd#ameh_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LoanReceivableAbstract_e0404f08-4a10-48b4-942e-49a7fe43e2f9" xlink:to="loc_ameh_LoanReceivableTextBlock_59537213-f37f-4e94-b6c6-fcbe94d0f5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableAbstract_41bacb6d-16e7-4ad3-a7b2-f23ef4b85f4c" xlink:href="ameh-20211231.xsd#ameh_LoanReceivableAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LoanReceivableAbstract_41bacb6d-16e7-4ad3-a7b2-f23ef4b85f4c" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a0febdf4-f46d-4cd8-bebb-c8c0c5178803" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1e5c60d8-1171-4f6e-93f7-ec5775d25e0f" xlink:to="loc_us-gaap_ReceivableTypeDomain_a0febdf4-f46d-4cd8-bebb-c8c0c5178803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_714d76b9-43ac-4b2e-b36b-fd42921711f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a0febdf4-f46d-4cd8-bebb-c8c0c5178803" xlink:to="loc_us-gaap_NotesReceivableMember_714d76b9-43ac-4b2e-b36b-fd42921711f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fdebb5df-ae10-41d8-90c6-7525a8860963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fdebb5df-ae10-41d8-90c6-7525a8860963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fdebb5df-ae10-41d8-90c6-7525a8860963" xlink:to="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_0bf4f4b9-13a7-4c61-81cf-ce7f567f2206" xlink:href="ameh-20211231.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:to="loc_ameh_Pacific6EnterprisesMember_0bf4f4b9-13a7-4c61-81cf-ce7f567f2206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_c405e09d-e672-4d1f-8018-2e690183ebd5" xlink:href="ameh-20211231.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a6656016-3ae6-4ce8-bd98-ba6531f0c440" xlink:to="loc_ameh_AHMCMember_c405e09d-e672-4d1f-8018-2e690183ebd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_b8eaf4cf-1818-41c2-b227-37bc0622d31e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_dei_LegalEntityAxis_b8eaf4cf-1818-41c2-b227-37bc0622d31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_b8eaf4cf-1818-41c2-b227-37bc0622d31e" xlink:to="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_08a2e582-8685-420a-90a3-53278b7709e3" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_NetworkMedicalManagementMember_08a2e582-8685-420a-90a3-53278b7709e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member_43eeeaf0-7e4d-4477-8b2a-4a6c49502aa1" xlink:href="ameh-20211231.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_HealthSourceMSOInc.Member_43eeeaf0-7e4d-4477-8b2a-4a6c49502aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_2e213893-8a2e-479b-b0ff-3fe397b5d72f" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_2e213893-8a2e-479b-b0ff-3fe397b5d72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b642a2ba-6144-4165-96c7-ce583eb6a8e7" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_b642a2ba-6144-4165-96c7-ce583eb6a8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_dbe4db5c-64e1-4a90-bfcb-27199bceb30d" xlink:href="ameh-20211231.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_408947f7-e42c-4cca-87b0-ccbd7c40bebd" xlink:to="loc_ameh_Pacific6EnterprisesMember_dbe4db5c-64e1-4a90-bfcb-27199bceb30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49129b71-4db7-4427-a766-a0f92071606d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49129b71-4db7-4427-a766-a0f92071606d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6587a9ff-e54a-4fbb-9635-e075f72460f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_49129b71-4db7-4427-a766-a0f92071606d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6587a9ff-e54a-4fbb-9635-e075f72460f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_afae9664-9b80-4638-932c-47634aed0290" xlink:href="ameh-20211231.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6587a9ff-e54a-4fbb-9635-e075f72460f2" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_afae9664-9b80-4638-932c-47634aed0290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_99ec8907-ba02-4488-911a-9101fb903947" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_26efde99-5eab-41bb-992f-a748848ed7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_NotesReceivableNet_26efde99-5eab-41bb-992f-a748848ed7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6362129a-81ca-411b-be29-1562ddd825d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6362129a-81ca-411b-be29-1562ddd825d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3f566849-d7ed-4ba8-8d5b-57b417d8fee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_3f566849-d7ed-4ba8-8d5b-57b417d8fee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_2d6c4995-b37a-4106-86ba-85d6c9ca60cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_us-gaap_NotesReceivableGross_2d6c4995-b37a-4106-86ba-85d6c9ca60cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_8df974ef-4aee-4d94-87d6-91cd829d5949" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_8df974ef-4aee-4d94-87d6-91cd829d5949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c95c3c6b-cf03-498f-b1be-7d609aab64f1" xlink:href="ameh-20211231.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_c95c3c6b-cf03-498f-b1be-7d609aab64f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss_c7b78999-21ca-4a25-8333-f3ca8cd584de" xlink:href="ameh-20211231.xsd#ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss_c7b78999-21ca-4a25-8333-f3ca8cd584de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss_e82c5425-9e50-47d9-8a85-c379bcf9d6b9" xlink:href="ameh-20211231.xsd#ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_de7b0575-d750-4988-846e-a9290347eeb0" xlink:to="loc_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss_e82c5425-9e50-47d9-8a85-c379bcf9d6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20211231.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3ab5cdaa-c73f-448f-ad09-acb943ea1bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_713b17d7-535a-4aa0-9c9c-adf3c189478b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3ab5cdaa-c73f-448f-ad09-acb943ea1bb5" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_713b17d7-535a-4aa0-9c9c-adf3c189478b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e2b5f09f-4bcb-4074-9342-73343fa3258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b630e55b-bc9c-4d64-9d82-99af7465424e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e2b5f09f-4bcb-4074-9342-73343fa3258d" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_b630e55b-bc9c-4d64-9d82-99af7465424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_79a56b36-a627-41af-a243-ba9f98f93018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_79a56b36-a627-41af-a243-ba9f98f93018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_2906ff18-bc86-47f1-8a15-9aec0e560892" xlink:href="ameh-20211231.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_2906ff18-bc86-47f1-8a15-9aec0e560892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIpaRiskPoolPayable_70efbdcb-9232-4b9e-b6f3-6288cf181001" xlink:href="ameh-20211231.xsd#ameh_SubcontractorIpaRiskPoolPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_ameh_SubcontractorIpaRiskPoolPayable_70efbdcb-9232-4b9e-b6f3-6288cf181001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_18e1303e-e0ad-495f-8c88-bf45229357f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_18e1303e-e0ad-495f-8c88-bf45229357f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_74929d5e-9e3d-4d26-b4e9-b629da832403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_74929d5e-9e3d-4d26-b4e9-b629da832403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e5e4128-7a30-4056-a119-ddc0b440c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_1e5e4128-7a30-4056-a119-ddc0b440c59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0a194509-ed39-4922-95dd-901f0cb13779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0a194509-ed39-4922-95dd-901f0cb13779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a1eb7a8f-4ad7-49f3-8a21-b82aecfed68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c8e171b0-4345-40e3-a6a0-1f930352292d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_a1eb7a8f-4ad7-49f3-8a21-b82aecfed68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20211231.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_81073046-9017-4d8a-91be-db77d8d5f2a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_3cf749e7-2d5d-4ef7-bc42-b8eae759859e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_81073046-9017-4d8a-91be-db77d8d5f2a9" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_3cf749e7-2d5d-4ef7-bc42-b8eae759859e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_5389d373-fd3d-447a-aea4-89d12e76e388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6a2ebb1c-2ad9-46fc-8592-9f33a2eb9016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_5389d373-fd3d-447a-aea4-89d12e76e388" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_6a2ebb1c-2ad9-46fc-8592-9f33a2eb9016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_8ab6ee34-fa94-45af-b757-c8de75de567a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_8ab6ee34-fa94-45af-b757-c8de75de567a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6d542df5-ffb4-47e4-9ee8-12e4368af3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6d542df5-ffb4-47e4-9ee8-12e4368af3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_40b5671b-7f99-44eb-a6ef-6dc19f408021" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_40b5671b-7f99-44eb-a6ef-6dc19f408021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract_78562629-2579-4428-b069-f0901afbb949" xlink:href="ameh-20211231.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:to="loc_ameh_MedicalCareCostsAbstract_78562629-2579-4428-b069-f0901afbb949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_428b47c4-d2af-4011-833c-5e7d32ac9918" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_78562629-2579-4428-b069-f0901afbb949" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_428b47c4-d2af-4011-833c-5e7d32ac9918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_a530cafe-8fdc-4524-a9bc-f308748b89fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_78562629-2579-4428-b069-f0901afbb949" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_a530cafe-8fdc-4524-a9bc-f308748b89fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_67d81b7b-8b5c-4cd4-a16c-ccf1ec88866c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_78562629-2579-4428-b069-f0901afbb949" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_67d81b7b-8b5c-4cd4-a16c-ccf1ec88866c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract_04aa4929-6cc6-4a63-9605-75755b18ee08" xlink:href="ameh-20211231.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:to="loc_ameh_PaymentsForMedicalCareCostsAbstract_04aa4929-6cc6-4a63-9605-75755b18ee08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_5172f3c2-777f-47bf-a6f3-377830b61b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_04aa4929-6cc6-4a63-9605-75755b18ee08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_5172f3c2-777f-47bf-a6f3-377830b61b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_3703a857-d25a-42aa-ad89-051612cc796a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_04aa4929-6cc6-4a63-9605-75755b18ee08" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_3703a857-d25a-42aa-ad89-051612cc796a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_263eb989-2e07-457e-bb32-ca397314fcff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_04aa4929-6cc6-4a63-9605-75755b18ee08" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_263eb989-2e07-457e-bb32-ca397314fcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_b0d44387-229b-46a3-96ac-6e1ba2f21069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_b0d44387-229b-46a3-96ac-6e1ba2f21069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2dd3b8b5-e6bf-48be-aa62-e4789c6de676" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_4626698d-fa88-463f-9f68-bf8ec0132ac8" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_2dd3b8b5-e6bf-48be-aa62-e4789c6de676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_56edd7c3-9fe3-4ec6-bec6-73e64d8326bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_5731de04-4b7f-4e98-b4e4-d8c0bc22ad44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_56edd7c3-9fe3-4ec6-bec6-73e64d8326bd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_5731de04-4b7f-4e98-b4e4-d8c0bc22ad44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e554f6b1-4a2a-4ac4-bd4b-0ada3177e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_4d0c42e3-e385-4492-bd1f-e6f7f9f7f578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e554f6b1-4a2a-4ac4-bd4b-0ada3177e0b4" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_4d0c42e3-e385-4492-bd1f-e6f7f9f7f578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_559b2c00-d414-427c-868e-a699c64f9955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e554f6b1-4a2a-4ac4-bd4b-0ada3177e0b4" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_559b2c00-d414-427c-868e-a699c64f9955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_bfe622d3-99f8-490c-9bd1-2dd1302e4a31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_bfe622d3-99f8-490c-9bd1-2dd1302e4a31" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6f665630-6550-40fa-b55e-30b02a4bf0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:to="loc_us-gaap_CreditFacilityAxis_6f665630-6550-40fa-b55e-30b02a4bf0cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6f665630-6550-40fa-b55e-30b02a4bf0cd" xlink:to="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_0c9aa7ca-803d-4202-8c30-06072eb814a2" xlink:href="ameh-20211231.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:to="loc_ameh_TermLoanAMember_0c9aa7ca-803d-4202-8c30-06072eb814a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a4c16481-aeb0-4f49-bf88-9f300bc7a188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d84d5dab-ac22-4bbc-8981-7e4fbbe26c64" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a4c16481-aeb0-4f49-bf88-9f300bc7a188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_ae362d05-cc60-4ce0-a3cd-a9091fdda685" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_ae362d05-cc60-4ce0-a3cd-a9091fdda685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_ae362d05-cc60-4ce0-a3cd-a9091fdda685" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstateLoanMember_8f6bce13-9e5f-49c6-884d-9705b99a8dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealEstateLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:to="loc_us-gaap_RealEstateLoanMember_8f6bce13-9e5f-49c6-884d-9705b99a8dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_971beb58-e6cf-4949-8663-6aada69db170" xlink:href="ameh-20211231.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_295a4835-6c43-4e7b-8b8d-260e9b347ee6" xlink:to="loc_ameh_ConstructionLoanMember_971beb58-e6cf-4949-8663-6aada69db170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_50852d96-e1f2-42f1-80d8-e8843bac6b29" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a9bed822-5a16-4f16-93eb-ca7e3357cee3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a9bed822-5a16-4f16-93eb-ca7e3357cee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_82fd0e55-6dc7-43d2-82ee-0ccf8cfbba84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_LongTermDebtCurrent_82fd0e55-6dc7-43d2-82ee-0ccf8cfbba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9931dea0-0668-491e-90fd-d197ace2f511" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9931dea0-0668-491e-90fd-d197ace2f511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0c746a15-fa7c-4230-aae3-301e85a4b8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_8c82060a-f55b-46f1-91c9-951bcc0dca19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0c746a15-fa7c-4230-aae3-301e85a4b8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8f8a8a95-cfb1-486e-b932-1ca69d3b792a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f48a100f-236b-4efd-a519-0c2ce4b05283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8f8a8a95-cfb1-486e-b932-1ca69d3b792a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f48a100f-236b-4efd-a519-0c2ce4b05283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1a789f2d-69dd-4a6c-b825-8671222867a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8f8a8a95-cfb1-486e-b932-1ca69d3b792a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1a789f2d-69dd-4a6c-b825-8671222867a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_90746c4b-c87c-40de-8907-c22bb8084034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8f8a8a95-cfb1-486e-b932-1ca69d3b792a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_90746c4b-c87c-40de-8907-c22bb8084034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3eb1e6ad-7c26-40dc-b71f-faf01dda6dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8f8a8a95-cfb1-486e-b932-1ca69d3b792a" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_3eb1e6ad-7c26-40dc-b71f-faf01dda6dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LongTermDebtMaturityAfterYearFour_8f16ff38-3f53-4fc7-8667-183dd33558a8" xlink:href="ameh-20211231.xsd#ameh_LongTermDebtMaturityAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8f8a8a95-cfb1-486e-b932-1ca69d3b792a" xlink:to="loc_ameh_LongTermDebtMaturityAfterYearFour_8f16ff38-3f53-4fc7-8667-183dd33558a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_bd270d9d-950f-48bf-8f63-de9758225b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8f8a8a95-cfb1-486e-b932-1ca69d3b792a" xlink:to="loc_us-gaap_LineOfCredit_bd270d9d-950f-48bf-8f63-de9758225b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail" xlink:type="simple" xlink:href="ameh-20211231.xsd#CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2a157ca1-64ad-4698-a256-37ce3501906c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2a157ca1-64ad-4698-a256-37ce3501906c" xlink:to="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_91020c84-3645-4ce6-8db5-e5274d648916" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_DebtInstrumentAxis_91020c84-3645-4ce6-8db5-e5274d648916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_91020c84-3645-4ce6-8db5-e5274d648916" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_55dac4ed-67c9-4ac8-81d8-6b401e771d31" xlink:href="ameh-20211231.xsd#ameh_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_CreditAgreementMember_55dac4ed-67c9-4ac8-81d8-6b401e771d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmendedCreditAgreementMember_5cae8bd2-9c8e-48f0-b9e6-f6e931f1f3f3" xlink:href="ameh-20211231.xsd#ameh_AmendedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_AmendedCreditAgreementMember_5cae8bd2-9c8e-48f0-b9e6-f6e931f1f3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_db979d6c-a829-4043-98c3-282d71c27a43" xlink:href="ameh-20211231.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_ConstructionLoanMember_db979d6c-a829-4043-98c3-282d71c27a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_4510ab99-6cdd-465b-808e-07e2c67cbca1" xlink:href="ameh-20211231.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_953e2f8e-a9de-4a53-9a5a-e410764c155d" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_4510ab99-6cdd-465b-808e-07e2c67cbca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1e389d53-ff15-41d6-8b41-6713a6e086f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_CreditFacilityAxis_1e389d53-ff15-41d6-8b41-6713a6e086f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1e389d53-ff15-41d6-8b41-6713a6e086f0" xlink:to="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_7ccb3802-23d3-44b0-9a94-6510822837ac" xlink:href="ameh-20211231.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_ameh_TermLoanAMember_7ccb3802-23d3-44b0-9a94-6510822837ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_4eae27a8-4e1d-4fde-980a-7de9ae3aaf04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_4eae27a8-4e1d-4fde-980a-7de9ae3aaf04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_63ca6411-269f-4cba-9d7b-ac37d5c77c31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_LetterOfCreditMember_63ca6411-269f-4cba-9d7b-ac37d5c77c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_d0d921da-d479-4ae4-b169-b80cb47b12a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_BridgeLoanMember_d0d921da-d479-4ae4-b169-b80cb47b12a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_a66a5483-2e2e-4517-93dd-b50d967dace0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_LineOfCreditMember_a66a5483-2e2e-4517-93dd-b50d967dace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_1259cce7-b0ba-4f7e-a670-2377f1a27013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_36782fb9-c405-4be3-8f10-d703918fac92" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_1259cce7-b0ba-4f7e-a670-2377f1a27013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1ce6de36-75db-418b-ba67-b188b9ce801e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1ce6de36-75db-418b-ba67-b188b9ce801e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1ce6de36-75db-418b-ba67-b188b9ce801e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_90a849ba-edcc-4d7e-85cd-96e254190183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:to="loc_us-gaap_LineOfCreditMember_90a849ba-edcc-4d7e-85cd-96e254190183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConstructionLoanMember_d5d05b02-ba16-49f8-a396-34b4dc9703a3" xlink:href="ameh-20211231.xsd#ameh_ConstructionLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8fb9564e-e0c9-4284-b9ab-2be31a15b58a" xlink:to="loc_ameh_ConstructionLoanMember_d5d05b02-ba16-49f8-a396-34b4dc9703a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc360b68-51f4-4fc3-b567-e17f8f3efd56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_srt_RangeAxis_bc360b68-51f4-4fc3-b567-e17f8f3efd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bc360b68-51f4-4fc3-b567-e17f8f3efd56" xlink:to="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87d05de6-8dc2-45aa-90ef-48c12d603d75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:to="loc_srt_MinimumMember_87d05de6-8dc2-45aa-90ef-48c12d603d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7e52e1f7-132e-4d80-b994-8fe1d6c97eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_778a8001-7a00-483d-b878-0458a6a44ba0" xlink:to="loc_srt_MaximumMember_7e52e1f7-132e-4d80-b994-8fe1d6c97eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a8543069-1381-4043-8e7e-1040cb3b953b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_dei_LegalEntityAxis_a8543069-1381-4043-8e7e-1040cb3b953b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a8543069-1381-4043-8e7e-1040cb3b953b" xlink:to="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9b6b1261-ff0f-4a84-9d52-116fec92dd8b" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9b6b1261-ff0f-4a84-9d52-116fec92dd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_22a58f56-694c-4c9a-945c-088ec4f9de17" xlink:href="ameh-20211231.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_22a58f56-694c-4c9a-945c-088ec4f9de17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_2321939d-42a0-4477-a271-fbd6e3dcca99" xlink:href="ameh-20211231.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_AMGPropertiesLLCMember_2321939d-42a0-4477-a271-fbd6e3dcca99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_32c1e309-458e-4a2b-b1b3-f593caaac6af" xlink:href="ameh-20211231.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_ZLLPartnersLLCMember_32c1e309-458e-4a2b-b1b3-f593caaac6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_1a6cb1c7-979f-4e20-b488-6760ef523f2c" xlink:href="ameh-20211231.xsd#ameh_Tag8MedicalInvestmentGroupLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_Tag8MedicalInvestmentGroupLLCMember_1a6cb1c7-979f-4e20-b488-6760ef523f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_96a4aca5-e131-4c8d-a142-c263296c5c05" xlink:href="ameh-20211231.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_ApaacoMember_96a4aca5-e131-4c8d-a142-c263296c5c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_834770b5-6403-4875-afa8-e48e835517af" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c30e52b0-f7b1-4584-ac20-0d96a57c9f97" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_834770b5-6403-4875-afa8-e48e835517af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_5dccdb39-1f06-49d2-be30-228a2acef015" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_VariableRateAxis_5dccdb39-1f06-49d2-be30-228a2acef015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_5dccdb39-1f06-49d2-be30-228a2acef015" xlink:to="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_713b168f-d97e-4718-bee6-5edb7a9fc872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_713b168f-d97e-4718-bee6-5edb7a9fc872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_9ccd1cde-1d0e-4f4f-9fb8-2b14f1d2d9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0119e6ac-32bd-478b-b8bd-f895c131db1c" xlink:to="loc_us-gaap_PrimeRateMember_9ccd1cde-1d0e-4f4f-9fb8-2b14f1d2d9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0db04210-b3bf-4bd1-b19a-27a9a77a9899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_c7f7fb71-6ef6-4bf6-ac17-4a11f8eba422" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0db04210-b3bf-4bd1-b19a-27a9a77a9899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_25cf9406-9c53-4117-9e87-8fc234630313" xlink:href="ameh-20211231.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0db04210-b3bf-4bd1-b19a-27a9a77a9899" xlink:to="loc_ameh_PreferredBankMember_25cf9406-9c53-4117-9e87-8fc234630313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_c5a7bacd-83a8-4bbd-bdd8-7213d206374c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_AssetAcquisitionAxis_c5a7bacd-83a8-4bbd-bdd8-7213d206374c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_c5a7bacd-83a8-4bbd-bdd8-7213d206374c" xlink:to="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersLLCMember_39e1ca75-04a5-4e01-a275-20f9324c75ce" xlink:href="ameh-20211231.xsd#ameh_MedicalPropertyPartnersLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:to="loc_ameh_MedicalPropertyPartnersLLCMember_39e1ca75-04a5-4e01-a275-20f9324c75ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AMGPropertiesLLCMember_1159287a-d5b4-4b67-91bd-da0a8d58a62f" xlink:href="ameh-20211231.xsd#ameh_AMGPropertiesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:to="loc_ameh_AMGPropertiesLLCMember_1159287a-d5b4-4b67-91bd-da0a8d58a62f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ZLLPartnersLLCMember_35491eab-aa73-4389-9854-14b860dc3fa0" xlink:href="ameh-20211231.xsd#ameh_ZLLPartnersLLCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_c1a0f397-3972-4633-9aab-1d2d67199e79" xlink:to="loc_ameh_ZLLPartnersLLCMember_35491eab-aa73-4389-9854-14b860dc3fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_1091335b-f737-4b89-9737-71117a310a85" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_srt_StatementScenarioAxis_1091335b-f737-4b89-9737-71117a310a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_6344e0a3-7709-474d-9c49-897ca3155312" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_1091335b-f737-4b89-9737-71117a310a85" xlink:to="loc_srt_ScenarioUnspecifiedDomain_6344e0a3-7709-474d-9c49-897ca3155312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_4538b5d0-b0d1-4706-862f-23c4f37bb582" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_6344e0a3-7709-474d-9c49-897ca3155312" xlink:to="loc_srt_ScenarioForecastMember_4538b5d0-b0d1-4706-862f-23c4f37bb582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_82883669-84e4-4130-82ff-da6cf4281f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_82883669-84e4-4130-82ff-da6cf4281f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0b88f8d3-dbd1-49ec-8ef3-96bce9ec349e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_82883669-84e4-4130-82ff-da6cf4281f56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0b88f8d3-dbd1-49ec-8ef3-96bce9ec349e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_80c6709e-0140-4c78-8394-21c02194412e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0b88f8d3-dbd1-49ec-8ef3-96bce9ec349e" xlink:to="loc_us-gaap_SubsequentEventMember_80c6709e-0140-4c78-8394-21c02194412e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e911a204-5040-49a9-b828-5ff146947aeb" xlink:to="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_b8c53eea-fa7b-4668-9ffb-a1028e0d2bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentTerm_b8c53eea-fa7b-4668-9ffb-a1028e0d2bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cbe69bcf-dd92-4c44-a45d-45e236e37637" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_cbe69bcf-dd92-4c44-a45d-45e236e37637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_68a7a761-11bc-4d06-84da-953860df969b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_68a7a761-11bc-4d06-84da-953860df969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0c4c7e9e-7201-4ad0-a87e-68ed20fe1d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0c4c7e9e-7201-4ad0-a87e-68ed20fe1d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_d6261abb-6bef-4b2c-9572-20398d841bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_d6261abb-6bef-4b2c-9572-20398d841bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_931ede27-50a2-41ab-93cc-b02460590597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_931ede27-50a2-41ab-93cc-b02460590597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_4f6245c7-7cac-43bb-89db-ad3655f3d84a" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_4f6245c7-7cac-43bb-89db-ad3655f3d84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_37b93273-936b-4e25-960a-6568e30fec6f" xlink:href="ameh-20211231.xsd#ameh_DebtCovenantAggregatePurchasePriceMaximum"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtCovenantAggregatePurchasePriceMaximum_37b93273-936b-4e25-960a-6568e30fec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0f2dab11-d053-471e-9d23-a999a0e3759f" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_0f2dab11-d053-471e-9d23-a999a0e3759f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_60b33b8a-4208-4989-af26-5c2ff25c1f6a" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_60b33b8a-4208-4989-af26-5c2ff25c1f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_c8aeed63-29c4-4f46-b464-315fda534fc1" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_c8aeed63-29c4-4f46-b464-315fda534fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_5da27ebb-15c0-4fa7-82fb-41fdb5d0a68b" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum_5da27ebb-15c0-4fa7-82fb-41fdb5d0a68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0c404ee4-d96a-4167-9075-29178969b75e" xlink:href="ameh-20211231.xsd#ameh_AssetAcquisitionPercentageOfSharesAcquired"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_AssetAcquisitionPercentageOfSharesAcquired_0c404ee4-d96a-4167-9075-29178969b75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_18e658e8-0bb4-4e57-8140-1894f8f132a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LiabilitiesAssumed1_18e658e8-0bb4-4e57-8140-1894f8f132a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_4b404b7e-f4df-4c5c-a21d-1e6bad1c3dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_4b404b7e-f4df-4c5c-a21d-1e6bad1c3dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_93c75bbc-ee6d-466d-8079-87567b6d9d98" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum_93c75bbc-ee6d-466d-8079-87567b6d9d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_22d027c2-99a5-4774-881f-5d84f2d2b1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LongTermDebtCurrent_22d027c2-99a5-4774-881f-5d84f2d2b1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_28ae0cd3-88aa-4f58-a7f7-65e2b9175758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_28ae0cd3-88aa-4f58-a7f7-65e2b9175758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_38823664-6f9c-4208-bc22-9980416b28a4" xlink:href="ameh-20211231.xsd#ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum_38823664-6f9c-4208-bc22-9980416b28a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_ea8611da-20f3-49d1-a855-33651fe6a9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_ea8611da-20f3-49d1-a855-33651fe6a9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ff42c780-615f-4eab-a38f-d586fecf45e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_ff42c780-615f-4eab-a38f-d586fecf45e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_38bd6412-4cb4-4d33-9291-0ca152064e42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_InterestExpense_38bd6412-4cb4-4d33-9291-0ca152064e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_730549b7-6650-42bb-89fa-82e0380b9d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCredit_730549b7-6650-42bb-89fa-82e0380b9d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6e9c7654-1dd6-4a08-86ef-84ab2d3e7231" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72e87e29-7f4c-4c63-a4fe-4965d62d8922" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_6e9c7654-1dd6-4a08-86ef-84ab2d3e7231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_49ef278a-d949-4cec-bbd8-d5a9a12c64ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_63ccd8a8-fef5-4e45-8022-e83b1b95a26d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_49ef278a-d949-4cec-bbd8-d5a9a12c64ab" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_63ccd8a8-fef5-4e45-8022-e83b1b95a26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a477fdbd-c632-4308-a3fc-6118317639f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3f9e52f8-4c4c-4147-a40e-7f38a2c89dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a477fdbd-c632-4308-a3fc-6118317639f4" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3f9e52f8-4c4c-4147-a40e-7f38a2c89dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_23599310-f8e0-43ed-a317-b41a7386e4a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a477fdbd-c632-4308-a3fc-6118317639f4" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_23599310-f8e0-43ed-a317-b41a7386e4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_48148b1e-c01d-47f4-b78b-68b35657bee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a477fdbd-c632-4308-a3fc-6118317639f4" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_48148b1e-c01d-47f4-b78b-68b35657bee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesIncomeTaxProvisionBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e086910a-6030-476d-9b1f-4843d590f62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bd3edad-fc46-4b80-b7f2-77a986e702c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e086910a-6030-476d-9b1f-4843d590f62a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bd3edad-fc46-4b80-b7f2-77a986e702c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1f391ed8-0a0f-492f-b712-ad77e135210b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bd3edad-fc46-4b80-b7f2-77a986e702c6" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1f391ed8-0a0f-492f-b712-ad77e135210b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ccb1cc2d-647a-45ee-843d-2bdcf457a938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bd3edad-fc46-4b80-b7f2-77a986e702c6" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ccb1cc2d-647a-45ee-843d-2bdcf457a938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d5626c0d-4a7d-419f-8046-b6ecb39eeb36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_3bd3edad-fc46-4b80-b7f2-77a986e702c6" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d5626c0d-4a7d-419f-8046-b6ecb39eeb36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_55e82486-ecf0-4626-8ec8-20df1c4b949b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e086910a-6030-476d-9b1f-4843d590f62a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_55e82486-ecf0-4626-8ec8-20df1c4b949b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e4685a5a-1df8-4c94-950d-b9f888ab2ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_55e82486-ecf0-4626-8ec8-20df1c4b949b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_e4685a5a-1df8-4c94-950d-b9f888ab2ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c7ed21c4-4e87-41f2-9096-4eef3f92a5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_55e82486-ecf0-4626-8ec8-20df1c4b949b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_c7ed21c4-4e87-41f2-9096-4eef3f92a5b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1b1a239a-1094-4c43-b74d-ff7ba4f7c7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_55e82486-ecf0-4626-8ec8-20df1c4b949b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1b1a239a-1094-4c43-b74d-ff7ba4f7c7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_717abe00-11f7-4b77-8dab-c7e86228cd01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e086910a-6030-476d-9b1f-4843d590f62a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_717abe00-11f7-4b77-8dab-c7e86228cd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9d34b24a-7d9c-4496-85d8-b66ae3223b79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9d34b24a-7d9c-4496-85d8-b66ae3223b79" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_8116bf85-568b-4c43-b36f-00d18ff8f90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_8116bf85-568b-4c43-b36f-00d18ff8f90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_8116bf85-568b-4c43-b36f-00d18ff8f90e" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_bb137867-e315-4db3-9817-f401716b9f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:to="loc_us-gaap_DomesticCountryMember_bb137867-e315-4db3-9817-f401716b9f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_4bbc303a-9b01-4b43-b89a-d0cd8fc13144" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_65569a88-bca5-404d-a94f-021943852973" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_4bbc303a-9b01-4b43-b89a-d0cd8fc13144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_647c6396-71fc-453e-a70b-ff6faf60bc24" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:to="loc_srt_RangeAxis_647c6396-71fc-453e-a70b-ff6faf60bc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_647c6396-71fc-453e-a70b-ff6faf60bc24" xlink:to="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_65b00812-1041-4848-ba83-bab34e394079" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:to="loc_srt_MinimumMember_65b00812-1041-4848-ba83-bab34e394079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9a3c2d51-ca2b-47d2-a22e-9869d8b53572" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e34ca5ff-3334-4514-bcde-452ee2a45ed4" xlink:to="loc_srt_MaximumMember_9a3c2d51-ca2b-47d2-a22e-9869d8b53572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_3370bc6c-4584-4cfb-a9bc-8ba4f6feb0d7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_69c8a5b4-767d-4b7a-bae4-ae03b018b57e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_OperatingLossCarryforwards_69c8a5b4-767d-4b7a-bae4-ae03b018b57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OperatingLossCarryforwardsExpirationPeriod_542b2196-ac41-4c38-8a5f-561f6dccc571" xlink:href="ameh-20211231.xsd#ameh_OperatingLossCarryforwardsExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_ameh_OperatingLossCarryforwardsExpirationPeriod_542b2196-ac41-4c38-8a5f-561f6dccc571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OperatingLossCarryforwardsNotSubjectToExpiration_a49f311b-2848-4b54-835f-db8e5738f93b" xlink:href="ameh-20211231.xsd#ameh_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_ameh_OperatingLossCarryforwardsNotSubjectToExpiration_a49f311b-2848-4b54-835f-db8e5738f93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9cddf629-3d99-4164-83ac-0de64242a5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9cddf629-3d99-4164-83ac-0de64242a5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_dac00239-c21b-47d5-b6a0-8ed9d0d93267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_dac00239-c21b-47d5-b6a0-8ed9d0d93267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2718e8ff-348a-436a-9c00-0246fd0f6dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_24f574df-bf0a-488b-8a53-ecc4458feb56" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2718e8ff-348a-436a-9c00-0246fd0f6dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_efd1a9b5-de3f-47fd-b803-fc2540c2dc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_efd1a9b5-de3f-47fd-b803-fc2540c2dc03" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_711f5f15-6233-4d75-a822-da503fa3a2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_711f5f15-6233-4d75-a822-da503fa3a2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2c5b4252-ed12-4369-8d05-fd7ef82766d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2c5b4252-ed12-4369-8d05-fd7ef82766d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d5dbb015-1c83-433d-b9bd-4c906802a631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_d5dbb015-1c83-433d-b9bd-4c906802a631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_61d64b46-0bbc-48b4-b2c4-63c10adfc4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_61d64b46-0bbc-48b4-b2c4-63c10adfc4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxAssetsInvestment_2f3a9e86-e4f2-4551-ad4a-f03cfb9f18a3" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxAssetsInvestment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_ameh_DeferredTaxAssetsInvestment_2f3a9e86-e4f2-4551-ad4a-f03cfb9f18a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2dbd9939-d20a-4cb4-8a4f-15dac293356c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2dbd9939-d20a-4cb4-8a4f-15dac293356c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxAssetsLeaseLiability_b7cfa947-8fea-477c-9fd4-1cdd382a99e1" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_ameh_DeferredTaxAssetsLeaseLiability_b7cfa947-8fea-477c-9fd4-1cdd382a99e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_686847a2-7a89-4f28-9943-68997536e06e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities_686847a2-7a89-4f28-9943-68997536e06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_81a7f11b-3323-49e0-b397-99f631cf8573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_81a7f11b-3323-49e0-b397-99f631cf8573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_912b0c11-7e4a-485c-b4fe-2db0b2aa01c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_912b0c11-7e4a-485c-b4fe-2db0b2aa01c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7cfd2a7d-579e-49a0-82df-dd4ba018c90e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_7cfd2a7d-579e-49a0-82df-dd4ba018c90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_aa74caa0-dec0-453f-8eca-09f29c660f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_de0fcf23-aa6e-43fa-a877-cf83008035a3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_aa74caa0-dec0-453f-8eca-09f29c660f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_efd1a9b5-de3f-47fd-b803-fc2540c2dc03" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_24a5541f-d7ec-4278-9844-229e0fbd228d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_24a5541f-d7ec-4278-9844-229e0fbd228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c4a575f5-7a21-415e-80cb-77cf9fe7bf3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_c4a575f5-7a21-415e-80cb-77cf9fe7bf3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesStockOptions_1284ca33-ec0b-43b7-93d9-7abdd99a610d" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxLiabilitiesStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:to="loc_ameh_DeferredTaxLiabilitiesStockOptions_1284ca33-ec0b-43b7-93d9-7abdd99a610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c33d5d80-e201-42f6-80bc-362a4da44cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_c33d5d80-e201-42f6-80bc-362a4da44cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_761be998-236d-43d8-9093-722d15be6089" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts_761be998-236d-43d8-9093-722d15be6089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilities481aAdjustment_14ff6801-c902-44d2-9de1-8082a7dc4d35" xlink:href="ameh-20211231.xsd#ameh_DeferredTaxLiabilities481aAdjustment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:to="loc_ameh_DeferredTaxLiabilities481aAdjustment_14ff6801-c902-44d2-9de1-8082a7dc4d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5ce833ec-3e26-475f-b456-c9703f265a86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_911b3ca9-6939-4136-a33d-8cadd701cfc9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_5ce833ec-3e26-475f-b456-c9703f265a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_73fb7584-167d-42fb-9989-caf2605d7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_efd1a9b5-de3f-47fd-b803-fc2540c2dc03" xlink:to="loc_us-gaap_DeferredTaxLiabilities_73fb7584-167d-42fb-9989-caf2605d7ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15cd1a37-55a0-4869-b0b1-bb28455e2cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_15cd1a37-55a0-4869-b0b1-bb28455e2cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1d46a184-87ce-495b-828c-4067ff3a54ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1d46a184-87ce-495b-828c-4067ff3a54ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment_259551cc-3ef5-4275-abee-9b03b1f77392" xlink:href="ameh-20211231.xsd#ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment_259551cc-3ef5-4275-abee-9b03b1f77392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1f219ea1-38ee-437f-9ed9-6e3b05a54ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary_1f219ea1-38ee-437f-9ed9-6e3b05a54ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_44638fb0-4183-4437-8a19-d43702d66002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_44638fb0-4183-4437-8a19-d43702d66002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_40d79e24-8272-4f1c-abb6-59e7ad2ff947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_40d79e24-8272-4f1c-abb6-59e7ad2ff947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent_d972e267-fe36-4796-a11f-766f01d8a00c" xlink:href="ameh-20211231.xsd#ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent_d972e267-fe36-4796-a11f-766f01d8a00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6179b45b-b014-43a3-9798-f41ce7af1442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6179b45b-b014-43a3-9798-f41ce7af1442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ab54f768-0b03-4da3-9c2e-3fd90557d39f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ebc97439-b185-4482-a7b2-43c1a22d496a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_ab54f768-0b03-4da3-9c2e-3fd90557d39f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20211231.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_9beec6cf-cb8b-4b67-bf3e-b6280272d22f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7627576e-5ea0-475c-a43a-816e57e123bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_9beec6cf-cb8b-4b67-bf3e-b6280272d22f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7627576e-5ea0-475c-a43a-816e57e123bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0a38bc73-72ab-425c-876c-b29c4cdb2e20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0a38bc73-72ab-425c-876c-b29c4cdb2e20" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2286adb6-9dba-492a-b712-4f081e1a7fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2286adb6-9dba-492a-b712-4f081e1a7fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0cea1e2-9c5e-44a0-b4e6-7bdb72c6ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2286adb6-9dba-492a-b712-4f081e1a7fcb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0cea1e2-9c5e-44a0-b4e6-7bdb72c6ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_a11f51c8-7abe-4bbb-afa9-3865e9d4f925" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d0cea1e2-9c5e-44a0-b4e6-7bdb72c6ccd2" xlink:to="loc_ameh_NetworkMedicalManagementMember_a11f51c8-7abe-4bbb-afa9-3865e9d4f925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_5c72019f-322e-4214-86a9-b62061c54c32" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_dei_LegalEntityAxis_5c72019f-322e-4214-86a9-b62061c54c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5c72019f-322e-4214-86a9-b62061c54c32" xlink:to="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_51b5646c-323a-4ec1-a8a6-8a20c30e32be" xlink:href="ameh-20211231.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_APAMHMedicalCorporationMember_51b5646c-323a-4ec1-a8a6-8a20c30e32be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_95db36c7-72a3-4be3-9f21-4363ddf350c9" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_95db36c7-72a3-4be3-9f21-4363ddf350c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_175e88fd-1223-4882-9f6b-98de6266b0b8" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_NetworkMedicalManagementMember_175e88fd-1223-4882-9f6b-98de6266b0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_c79e0fdc-a5bc-4a43-8ca2-4b91ce3c4cdf" xlink:href="ameh-20211231.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_66bcf71b-401d-4503-a70d-98a0b0e08138" xlink:to="loc_ameh_CDSCMember_c79e0fdc-a5bc-4a43-8ca2-4b91ce3c4cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baf345c8-c5f8-492a-9ebb-82c37497434b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baf345c8-c5f8-492a-9ebb-82c37497434b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fc33eea4-95e8-4715-8979-e974971f5beb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_baf345c8-c5f8-492a-9ebb-82c37497434b" xlink:to="loc_us-gaap_RelatedPartyDomain_fc33eea4-95e8-4715-8979-e974971f5beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_8273a123-adb9-440c-b59d-a38960927e89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_fc33eea4-95e8-4715-8979-e974971f5beb" xlink:to="loc_srt_AffiliatedEntityMember_8273a123-adb9-440c-b59d-a38960927e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6a8bbc04-fe67-4442-bc12-04116ae578f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6a8bbc04-fe67-4442-bc12-04116ae578f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6a8bbc04-fe67-4442-bc12-04116ae578f8" xlink:to="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_50b03cb9-8b43-4f90-87e8-1205e95dc799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_50b03cb9-8b43-4f90-87e8-1205e95dc799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_d2245353-eb6e-4827-85b4-5d93de609d22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1980b074-62c2-4d79-b8f7-a18dc0c61283" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_d2245353-eb6e-4827-85b4-5d93de609d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_12d43325-380e-4e3c-aa5f-91c8741cda7e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_srt_TitleOfIndividualAxis_12d43325-380e-4e3c-aa5f-91c8741cda7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f534f8b-cfdb-4305-bdeb-dcdd79f7a0f8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_12d43325-380e-4e3c-aa5f-91c8741cda7e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f534f8b-cfdb-4305-bdeb-dcdd79f7a0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FormerShareholdersOfNmmMember_6bfbc6ef-4245-4e69-809a-8b89d8f00783" xlink:href="ameh-20211231.xsd#ameh_FormerShareholdersOfNmmMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1f534f8b-cfdb-4305-bdeb-dcdd79f7a0f8" xlink:to="loc_ameh_FormerShareholdersOfNmmMember_6bfbc6ef-4245-4e69-809a-8b89d8f00783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c32169ac-cc08-4dd5-b751-850cff4a9b42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c32169ac-cc08-4dd5-b751-850cff4a9b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_033372a2-4746-4301-aa4c-92fada388d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c32169ac-cc08-4dd5-b751-850cff4a9b42" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_033372a2-4746-4301-aa4c-92fada388d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_e6b93725-c674-4a91-9363-cee85601f100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_033372a2-4746-4301-aa4c-92fada388d31" xlink:to="loc_us-gaap_PrivatePlacementMember_e6b93725-c674-4a91-9363-cee85601f100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dc8d539a-32c8-4158-bf51-d137546d19a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dc8d539a-32c8-4158-bf51-d137546d19a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dc8d539a-32c8-4158-bf51-d137546d19a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Warrant1Member_429415fe-f0dd-4420-b16a-f7b43223ef02" xlink:href="ameh-20211231.xsd#ameh_Warrant1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:to="loc_ameh_Warrant1Member_429415fe-f0dd-4420-b16a-f7b43223ef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Warrant2Member_5e5f6a52-ee93-49eb-85b1-bdbc169a8d02" xlink:href="ameh-20211231.xsd#ameh_Warrant2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d6071ecb-a514-4d12-aa89-5dd8ccfe8c10" xlink:to="loc_ameh_Warrant2Member_5e5f6a52-ee93-49eb-85b1-bdbc169a8d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_fd547e98-0875-4e24-b6ab-292f8c07eb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_VestingAxis_fd547e98-0875-4e24-b6ab-292f8c07eb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_57195727-5078-4c86-94c2-c3872fac0857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_fd547e98-0875-4e24-b6ab-292f8c07eb7a" xlink:to="loc_us-gaap_VestingDomain_57195727-5078-4c86-94c2-c3872fac0857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7bb6700a-1ad8-443b-b856-f32f21a6676a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_57195727-5078-4c86-94c2-c3872fac0857" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7bb6700a-1ad8-443b-b856-f32f21a6676a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_srt_CounterpartyNameAxis_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b26de6a-fcbe-4083-ad98-4e95e46edabd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_51d086b6-f2ea-4862-8f37-f76c6a1f9f7b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b26de6a-fcbe-4083-ad98-4e95e46edabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_1f98aa49-e240-434a-8993-8217d2ff7769" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b26de6a-fcbe-4083-ad98-4e95e46edabd" xlink:to="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_1f98aa49-e240-434a-8993-8217d2ff7769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1c3b67de-dce7-4150-90f8-c7917f3c5f8b" xlink:to="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5f1b442-5208-440d-8e28-25963e3c55e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5f1b442-5208-440d-8e28-25963e3c55e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d2c7b8d-2bce-484e-90d8-46ff24257e87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4d2c7b8d-2bce-484e-90d8-46ff24257e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_001f0540-6ba4-4993-a935-9d33cffc3977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_001f0540-6ba4-4993-a935-9d33cffc3977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff52ed46-85eb-4967-86ec-0df36813aeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_ff52ed46-85eb-4967-86ec-0df36813aeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_7ae01c20-8b75-49a0-bc85-1b3adf34aaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_7ae01c20-8b75-49a0-bc85-1b3adf34aaa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfSharesHoldbackPercentage_01bc1134-c382-47be-8f73-9ec8e78b9cf6" xlink:href="ameh-20211231.xsd#ameh_NumberOfSharesHoldbackPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_NumberOfSharesHoldbackPercentage_01bc1134-c382-47be-8f73-9ec8e78b9cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d5babbc-f7b4-4fc3-b415-07a7f014a44b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_9d5babbc-f7b4-4fc3-b415-07a7f014a44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationNumberOfSharesHeldBack_d73c0ab5-2d11-4ca8-a7a1-590a8c803a87" xlink:href="ameh-20211231.xsd#ameh_BusinessCombinationNumberOfSharesHeldBack"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_BusinessCombinationNumberOfSharesHeldBack_d73c0ab5-2d11-4ca8-a7a1-590a8c803a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_350521b8-2a55-4602-9848-c460efc8ca95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_350521b8-2a55-4602-9848-c460efc8ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_76065cd3-aa37-4a28-9a5f-dd4e9d27f753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_SharesIssued_76065cd3-aa37-4a28-9a5f-dd4e9d27f753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodShareConversionOfNotes_c26784c0-628b-4993-b133-509b1b2c1107" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodShareConversionOfNotes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_StockIssuedDuringPeriodShareConversionOfNotes_c26784c0-628b-4993-b133-509b1b2c1107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueConversionOfNotes_2ce57593-d1b6-4f08-8273-5db4c2faaa63" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodValueConversionOfNotes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_StockIssuedDuringPeriodValueConversionOfNotes_2ce57593-d1b6-4f08-8273-5db4c2faaa63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_4ac79b58-cd5b-452d-b38f-184e82deae8a" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_4ac79b58-cd5b-452d-b38f-184e82deae8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_52a80a36-289b-4b38-bea8-1db91267e119" xlink:href="ameh-20211231.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_076e3179-8f83-4acd-bb81-dc8f63125599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_076e3179-8f83-4acd-bb81-dc8f63125599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_03361234-c61f-4a64-be84-234b1b0ba5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_TreasuryStockCommonShares_03361234-c61f-4a64-be84-234b1b0ba5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_8ba35598-b287-4536-b3b0-aa15b107dbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5733fbd5-0620-43d2-8841-9dc027186a73" xlink:to="loc_us-gaap_TreasuryStockValue_8ba35598-b287-4536-b3b0-aa15b107dbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1919f939-85cd-4173-a0b5-f1a6527e3abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a8dc7717-6cf9-45d8-ab50-4ddd41afd48c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1919f939-85cd-4173-a0b5-f1a6527e3abd" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a8dc7717-6cf9-45d8-ab50-4ddd41afd48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e362adf3-31e2-4e7e-ac7f-c11f955cc490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d2b3da01-b367-4a3f-9633-e919d4665a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e362adf3-31e2-4e7e-ac7f-c11f955cc490" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d2b3da01-b367-4a3f-9633-e919d4665a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_998d14b9-1422-4a44-983c-3304b8ee3a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e362adf3-31e2-4e7e-ac7f-c11f955cc490" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_998d14b9-1422-4a44-983c-3304b8ee3a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ae70ec66-20da-4c32-8240-a29855648ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e362adf3-31e2-4e7e-ac7f-c11f955cc490" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ae70ec66-20da-4c32-8240-a29855648ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_dedb305f-3383-43a0-a421-082b915942c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e362adf3-31e2-4e7e-ac7f-c11f955cc490" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_dedb305f-3383-43a0-a421-082b915942c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_06b5282b-24a6-44b9-ad72-b76bf286c5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e362adf3-31e2-4e7e-ac7f-c11f955cc490" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_06b5282b-24a6-44b9-ad72-b76bf286c5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ea454fb-c375-4533-a229-a188627da490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5ea454fb-c375-4533-a229-a188627da490" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_239cc4b7-123c-459b-b8f3-98a8fba6c00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_PlanNameAxis_239cc4b7-123c-459b-b8f3-98a8fba6c00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_239cc4b7-123c-459b-b8f3-98a8fba6c00a" xlink:to="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityIncentivePlanTwentyThirteenMember_a731f185-7143-45e8-8a82-323117c955c3" xlink:href="ameh-20211231.xsd#ameh_EquityIncentivePlanTwentyThirteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:to="loc_ameh_EquityIncentivePlanTwentyThirteenMember_a731f185-7143-45e8-8a82-323117c955c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityIncentivePlanTwentyFifteenMember_a1e3b3ef-00cc-45ac-bbbc-31ed023ff3b2" xlink:href="ameh-20211231.xsd#ameh_EquityIncentivePlanTwentyFifteenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fe26e8ec-8d7c-49d0-b84d-ead7ca11c81b" xlink:to="loc_ameh_EquityIncentivePlanTwentyFifteenMember_a1e3b3ef-00cc-45ac-bbbc-31ed023ff3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_AwardTypeAxis_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_10a8a89a-32de-4dcd-ba99-1ae14fe8afa6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2dca495a-a0c9-4318-88cb-d27a71f10305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2dca495a-a0c9-4318-88cb-d27a71f10305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e99aa168-972e-454b-ad13-e290190dde67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_80d0fbff-32b3-4595-a612-43ae65c74d65" xlink:to="loc_us-gaap_RestrictedStockMember_e99aa168-972e-454b-ad13-e290190dde67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_9a3970a0-7339-49eb-bb13-fdce07debde8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_srt_TitleOfIndividualAxis_9a3970a0-7339-49eb-bb13-fdce07debde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_9a3970a0-7339-49eb-bb13-fdce07debde8" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_e9a946d5-842c-457a-980b-3ca8c61448b0" xlink:href="ameh-20211231.xsd#ameh_ApcStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:to="loc_ameh_ApcStockOptionMember_e9a946d5-842c-457a-980b-3ca8c61448b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:href="ameh-20211231.xsd#ameh_ExecutiveOfficerAndDirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_03d6bcc2-b333-484c-8d8d-b0df7b3ca6ae" xlink:to="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_173e8d6d-330f-4e5a-b916-aecb6aeba7cd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:to="loc_srt_DirectorMember_173e8d6d-330f-4e5a-b916-aecb6aeba7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_4018ed38-15c8-4708-a7c6-db41168578b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ExecutiveOfficerAndDirectorMember_1fac1ca0-a154-4968-a52f-adfb16738c74" xlink:to="loc_srt_ExecutiveOfficerMember_4018ed38-15c8-4708-a7c6-db41168578b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1be13737-b795-4fad-ab51-dfdef111a8ea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_srt_RangeAxis_1be13737-b795-4fad-ab51-dfdef111a8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1be13737-b795-4fad-ab51-dfdef111a8ea" xlink:to="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_668263b6-c208-4be1-9f39-5054adbfb42c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:to="loc_srt_MinimumMember_668263b6-c208-4be1-9f39-5054adbfb42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0ce82fef-fe54-49c1-957a-c9f86c140c2a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f1bc03ca-3311-4bac-95b5-c9f6c209a593" xlink:to="loc_srt_MaximumMember_0ce82fef-fe54-49c1-957a-c9f86c140c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_cd144b93-b102-4a80-80ae-dc81a36eb814" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_cd144b93-b102-4a80-80ae-dc81a36eb814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e33f324-9cd0-41ea-b835-33b66d9cb7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_cd144b93-b102-4a80-80ae-dc81a36eb814" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e33f324-9cd0-41ea-b835-33b66d9cb7b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_4a2b82b2-1451-4cee-b1ef-5cbd3e082114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6e33f324-9cd0-41ea-b835-33b66d9cb7b8" xlink:to="loc_us-gaap_PrivatePlacementMember_4a2b82b2-1451-4cee-b1ef-5cbd3e082114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_b2dc1e54-97bd-44f3-a59b-29d9ccc5c70c" xlink:to="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_14f86bfe-91af-4822-9e5c-8fafcabc4390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_14f86bfe-91af-4822-9e5c-8fafcabc4390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eff8e550-e33e-48b7-a297-788d42b75ace" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_7d759a1b-6905-4f01-a088-23fa0b4d631b" xlink:to="loc_us-gaap_CommonStockMember_eff8e550-e33e-48b7-a297-788d42b75ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0040dd9b-fa2c-4dbf-b37d-1bd1bf791956" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A11CommonStockWarrantsMember_ec7aba59-4ffe-4fd2-9085-d87c6b90d6fa" xlink:href="ameh-20211231.xsd#ameh_A11CommonStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:to="loc_ameh_A11CommonStockWarrantsMember_ec7aba59-4ffe-4fd2-9085-d87c6b90d6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_A10CommonStockWarrantsMember_2d0857f4-e9cb-49d3-b4e8-d06b78840df0" xlink:href="ameh-20211231.xsd#ameh_A10CommonStockWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a59d3dfd-4d4e-45cf-92a3-5ebd4443f7bc" xlink:to="loc_ameh_A10CommonStockWarrantsMember_2d0857f4-e9cb-49d3-b4e8-d06b78840df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d8534ed7-1159-44bf-a2ee-a1358341a4d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b21dd8a5-7579-4daa-9029-057baa28c3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b21dd8a5-7579-4daa-9029-057baa28c3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94535b1e-ad7e-47d2-b013-6ceb17c78ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_94535b1e-ad7e-47d2-b013-6ceb17c78ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d1799c61-ca49-4619-b4b3-20e38dd0afba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d1799c61-ca49-4619-b4b3-20e38dd0afba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17308e19-b07c-4478-a840-db4560939416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_17308e19-b07c-4478-a840-db4560939416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e8e0038-cabd-4c8b-9339-ef45e593f5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8e8e0038-cabd-4c8b-9339-ef45e593f5c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a4aa1d01-e492-4564-bb18-c5f78b9a96e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a4aa1d01-e492-4564-bb18-c5f78b9a96e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_5801564f-f42b-4761-9ebe-6b5fe6e9a558" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_5801564f-f42b-4761-9ebe-6b5fe6e9a558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fc916fd-be90-4d0d-99d7-1e0c0cad726e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_4fc916fd-be90-4d0d-99d7-1e0c0cad726e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43721a4c-7a04-432f-ac7a-de71e8f73142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_43721a4c-7a04-432f-ac7a-de71e8f73142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d507d4c6-2c81-4444-b637-333046fbda38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d507d4c6-2c81-4444-b637-333046fbda38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3ec8dd33-ac3e-4ef6-b2ea-f056d0d5f314" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3ec8dd33-ac3e-4ef6-b2ea-f056d0d5f314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0872b8ca-d80a-472a-940c-5d17cae4b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0872b8ca-d80a-472a-940c-5d17cae4b6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_312cc940-faa4-43ae-85cc-52cc0dd98d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_312cc940-faa4-43ae-85cc-52cc0dd98d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_794f72ab-6b48-420b-b5de-f6828c5f2266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_794f72ab-6b48-420b-b5de-f6828c5f2266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2c847da0-2fc8-42d3-89cd-a4a7f4e6c53a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2c847da0-2fc8-42d3-89cd-a4a7f4e6c53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d2dacb-ab8e-4467-ba35-3bae944c531e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c9d2dacb-ab8e-4467-ba35-3bae944c531e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d8f7888d-717e-4707-9122-100ab8a50bec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d8f7888d-717e-4707-9122-100ab8a50bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_eed80894-9b2c-4b7b-995a-ab8852dce32b" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_eed80894-9b2c-4b7b-995a-ab8852dce32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_6e55e2e1-e4ee-4bdc-b32b-fe4ce9699c6d" xlink:href="ameh-20211231.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_6e55e2e1-e4ee-4bdc-b32b-fe4ce9699c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_e247d757-1ad9-4af6-81e5-d198cb558c6c" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd104162-5765-4017-af79-bd0fe8b5265a" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_e247d757-1ad9-4af6-81e5-d198cb558c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6a9dc5e-4e79-4b6d-8c89-0bcc3f955ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6a9dc5e-4e79-4b6d-8c89-0bcc3f955ae4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_663cb67e-7fe7-448d-a76b-351ebe4f3bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:to="loc_us-gaap_AwardTypeAxis_663cb67e-7fe7-448d-a76b-351ebe4f3bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_663cb67e-7fe7-448d-a76b-351ebe4f3bc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_6f6ea9da-e3c9-4670-93e2-10d3052d3391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:to="loc_us-gaap_EmployeeStockOptionMember_6f6ea9da-e3c9-4670-93e2-10d3052d3391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockAwardsAndUnitsMember_f735cc9b-e90e-415b-a8b3-474bef69315b" xlink:href="ameh-20211231.xsd#ameh_StockAwardsAndUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3975c403-03f9-4e36-8afc-1b1e2e74f376" xlink:to="loc_ameh_StockAwardsAndUnitsMember_f735cc9b-e90e-415b-a8b3-474bef69315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:to="loc_dei_LegalEntityAxis_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_17e0c1ff-4623-4ac8-a6d6-7fd2118aa18b" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ba38bc9c-1f21-4ba9-ae49-d665a0dfb911" xlink:to="loc_dei_EntityDomain_17e0c1ff-4623-4ac8-a6d6-7fd2118aa18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_3a99d8d4-2519-43cf-abff-193998fe4305" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_17e0c1ff-4623-4ac8-a6d6-7fd2118aa18b" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_3a99d8d4-2519-43cf-abff-193998fe4305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_016abb40-4aed-4ed3-911d-d2ad9c8a6b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_470fd836-065c-43d6-a755-498da0a146d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_016abb40-4aed-4ed3-911d-d2ad9c8a6b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b5f8158a-2b14-4392-8039-982e918b3cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_016abb40-4aed-4ed3-911d-d2ad9c8a6b82" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b5f8158a-2b14-4392-8039-982e918b3cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15447ba0-0ddd-4d0d-96ff-f7d6bf41c0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c92dcf-0edc-4388-8378-d740f7eaa6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15447ba0-0ddd-4d0d-96ff-f7d6bf41c0d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c92dcf-0edc-4388-8378-d740f7eaa6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2639a920-c3e7-4fbe-847c-e2d743b20a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c92dcf-0edc-4388-8378-d740f7eaa6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2639a920-c3e7-4fbe-847c-e2d743b20a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d4127ee2-a014-4f2c-bcfd-b008030b36cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c92dcf-0edc-4388-8378-d740f7eaa6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_d4127ee2-a014-4f2c-bcfd-b008030b36cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_51c98139-effb-48f2-95ce-238e373d869d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c92dcf-0edc-4388-8378-d740f7eaa6ec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_51c98139-effb-48f2-95ce-238e373d869d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_670a167e-09eb-4997-8c95-6c3be0f1082a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c92dcf-0edc-4388-8378-d740f7eaa6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_670a167e-09eb-4997-8c95-6c3be0f1082a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9896ed9-baa2-4e58-8325-2d30001b211f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_76c92dcf-0edc-4388-8378-d740f7eaa6ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9896ed9-baa2-4e58-8325-2d30001b211f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fc5d77dc-2240-48bc-ae0e-25bbc34e0295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15447ba0-0ddd-4d0d-96ff-f7d6bf41c0d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fc5d77dc-2240-48bc-ae0e-25bbc34e0295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a509b143-3668-421f-a8ac-e82665172d66" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15447ba0-0ddd-4d0d-96ff-f7d6bf41c0d1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a509b143-3668-421f-a8ac-e82665172d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c7c313e-74f9-450e-b30c-31568a51705d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a509b143-3668-421f-a8ac-e82665172d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8c7c313e-74f9-450e-b30c-31568a51705d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fa1e48ba-6c4e-4b66-8d92-65762f7868a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a509b143-3668-421f-a8ac-e82665172d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fa1e48ba-6c4e-4b66-8d92-65762f7868a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_08fec953-c70b-4b84-9ed2-9cd831c0d0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a509b143-3668-421f-a8ac-e82665172d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_08fec953-c70b-4b84-9ed2-9cd831c0d0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2ff9b0d9-e370-43da-a19c-95b87cd5c2db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a509b143-3668-421f-a8ac-e82665172d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2ff9b0d9-e370-43da-a19c-95b87cd5c2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23e50c5e-6232-4069-87a4-5bd411bf55f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_a509b143-3668-421f-a8ac-e82665172d66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23e50c5e-6232-4069-87a4-5bd411bf55f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8157e10a-ad1b-434e-ace4-5b36a1ec337c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15447ba0-0ddd-4d0d-96ff-f7d6bf41c0d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8157e10a-ad1b-434e-ace4-5b36a1ec337c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_936c9114-7b38-4f87-a94b-6a3ac156f5e4" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15447ba0-0ddd-4d0d-96ff-f7d6bf41c0d1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_936c9114-7b38-4f87-a94b-6a3ac156f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_48a1b4bb-7603-4e94-8dae-d6ff5a287727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_936c9114-7b38-4f87-a94b-6a3ac156f5e4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_48a1b4bb-7603-4e94-8dae-d6ff5a287727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fae24d60-6c32-4296-bc89-456e61ba815f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_936c9114-7b38-4f87-a94b-6a3ac156f5e4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_fae24d60-6c32-4296-bc89-456e61ba815f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0a7e5e40-bf1f-4c47-9035-b37ecb354dbe" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15447ba0-0ddd-4d0d-96ff-f7d6bf41c0d1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0a7e5e40-bf1f-4c47-9035-b37ecb354dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c3dd899c-85c3-40c3-ae43-5a03e71ac72a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0a7e5e40-bf1f-4c47-9035-b37ecb354dbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c3dd899c-85c3-40c3-ae43-5a03e71ac72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0f7a87dc-31c6-4c85-9a91-6a578071e653" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0a7e5e40-bf1f-4c47-9035-b37ecb354dbe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0f7a87dc-31c6-4c85-9a91-6a578071e653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2bef46d8-ac7b-432d-bbc6-98d38585bd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_0a7e5e40-bf1f-4c47-9035-b37ecb354dbe" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2bef46d8-ac7b-432d-bbc6-98d38585bd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41bde148-f991-41f7-bde5-717c97bc374b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41bde148-f991-41f7-bde5-717c97bc374b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_468cb248-6221-4083-904d-9be990c5584e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:to="loc_srt_TitleOfIndividualAxis_468cb248-6221-4083-904d-9be990c5584e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fa5f4ec7-ea0f-4a4c-b231-82b6842fe57d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_468cb248-6221-4083-904d-9be990c5584e" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fa5f4ec7-ea0f-4a4c-b231-82b6842fe57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_6e0466de-2fec-4bdc-938c-bcf0319dab0f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_fa5f4ec7-ea0f-4a4c-b231-82b6842fe57d" xlink:to="loc_srt_ExecutiveOfficerMember_6e0466de-2fec-4bdc-938c-bcf0319dab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7e306e7f-c428-493d-b38f-d2bf194c6d48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:to="loc_srt_RangeAxis_7e306e7f-c428-493d-b38f-d2bf194c6d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7e306e7f-c428-493d-b38f-d2bf194c6d48" xlink:to="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_aeea8c57-5c7f-44f6-aa76-64e45f523b99" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:to="loc_srt_MinimumMember_aeea8c57-5c7f-44f6-aa76-64e45f523b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_202cf3ea-d479-4a4e-836d-2eef5950b17c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_36f65dc0-38a1-491d-ac36-d2c6176bf1b9" xlink:to="loc_srt_MaximumMember_202cf3ea-d479-4a4e-836d-2eef5950b17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0980867-c9db-4744-8034-bb61fe7830d9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9800b1c-7c51-4111-a9bc-0bb0a000456f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b9800b1c-7c51-4111-a9bc-0bb0a000456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee771886-7326-474a-8220-496d0bc54468" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ee771886-7326-474a-8220-496d0bc54468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f2487194-8769-4e20-970f-45ae1a5633f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f2487194-8769-4e20-970f-45ae1a5633f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_515c7469-c6df-4878-82f4-b066d9aee789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_SharePrice_515c7469-c6df-4878-82f4-b066d9aee789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_723edbbb-de3c-414b-b530-d62c8516eb05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_723edbbb-de3c-414b-b530-d62c8516eb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_235814c0-d8be-47f4-b633-8835f50ae671" xlink:href="ameh-20211231.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5440b916-79a5-40d8-8cdb-32154a917e72" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_235814c0-d8be-47f4-b633-8835f50ae671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationSummaryofRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a6b8cb1-ba01-48e2-b731-5c6ba6b03d75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d50c34-1a09-422a-a450-b43b87579b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a6b8cb1-ba01-48e2-b731-5c6ba6b03d75" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d50c34-1a09-422a-a450-b43b87579b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8d4052f7-50ea-4006-8008-b4ba9e966666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d50c34-1a09-422a-a450-b43b87579b0f" xlink:to="loc_us-gaap_AwardTypeAxis_8d4052f7-50ea-4006-8008-b4ba9e966666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b792cdd8-4b8d-44ee-94fa-da73762ecc78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8d4052f7-50ea-4006-8008-b4ba9e966666" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b792cdd8-4b8d-44ee-94fa-da73762ecc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f6c9b67b-09a8-4675-8769-68d5cc8eb5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b792cdd8-4b8d-44ee-94fa-da73762ecc78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f6c9b67b-09a8-4675-8769-68d5cc8eb5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_22d50c34-1a09-422a-a450-b43b87579b0f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a1a78a5-e223-4dd3-a70c-2b9dfcbce5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1a1a78a5-e223-4dd3-a70c-2b9dfcbce5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f58b4251-db47-4593-ac59-585ff8671e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f58b4251-db47-4593-ac59-585ff8671e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_52541f37-b94f-4f13-9f99-071c448d6d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_52541f37-b94f-4f13-9f99-071c448d6d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_31b37260-c740-46db-bcda-f811f806a646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_31b37260-c740-46db-bcda-f811f806a646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65d9acb3-242b-49d7-b757-3a1b91cbd5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2a041e5f-0422-4ea3-9266-ac6bb0ebfe19" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_65d9acb3-242b-49d7-b757-3a1b91cbd5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_162a88b8-4701-4e9d-939e-80d4dbc641f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2eef2898-6f83-45be-a887-14b528f69cee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2eef2898-6f83-45be-a887-14b528f69cee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43e5ab23-fa43-4153-9309-7344e0a4feb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_43e5ab23-fa43-4153-9309-7344e0a4feb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1fb7e0d6-61fe-414a-ab99-30e92264f1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1fb7e0d6-61fe-414a-ab99-30e92264f1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d8e74e00-1d9a-4e58-a76c-620166b5e475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d8e74e00-1d9a-4e58-a76c-620166b5e475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d9c464c-cf92-434b-bc5d-35d4b5ea61b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b7f8e8b-d341-419c-925b-6ac7c064fc85" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8d9c464c-cf92-434b-bc5d-35d4b5ea61b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationSummaryofWarrantDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_242d6484-b1cf-442e-a388-2cea96585630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward_725b98fe-474d-4837-8f60-892b5bbeb9f6" xlink:href="ameh-20211231.xsd#ameh_SharesWarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_242d6484-b1cf-442e-a388-2cea96585630" xlink:to="loc_ameh_SharesWarrantsRollForward_725b98fe-474d-4837-8f60-892b5bbeb9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_345adf7a-5cf0-4b7b-a999-0a985adfc011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_725b98fe-474d-4837-8f60-892b5bbeb9f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_345adf7a-5cf0-4b7b-a999-0a985adfc011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted_2f744231-06c6-476d-a9c7-c8fa4361ab52" xlink:href="ameh-20211231.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_725b98fe-474d-4837-8f60-892b5bbeb9f6" xlink:to="loc_ameh_NumberOfWarrantsGranted_2f744231-06c6-476d-a9c7-c8fa4361ab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised_443e79b7-aebc-44fe-8aaa-5774b6c145aa" xlink:href="ameh-20211231.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_725b98fe-474d-4837-8f60-892b5bbeb9f6" xlink:to="loc_ameh_NumberOfWarrantsExercised_443e79b7-aebc-44fe-8aaa-5774b6c145aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_a603bd32-211b-4b24-807a-25df2b720a21" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_725b98fe-474d-4837-8f60-892b5bbeb9f6" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_a603bd32-211b-4b24-807a-25df2b720a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e697f365-dc46-48ac-b967-b4998663c2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_725b98fe-474d-4837-8f60-892b5bbeb9f6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e697f365-dc46-48ac-b967-b4998663c2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_74e984eb-d1ba-4847-b4d4-733b62b4e2a0" xlink:href="ameh-20211231.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_242d6484-b1cf-442e-a388-2cea96585630" xlink:to="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_74e984eb-d1ba-4847-b4d4-733b62b4e2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_1027dcb5-8e3b-4668-a562-614eb93d2c09" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_74e984eb-d1ba-4847-b4d4-733b62b4e2a0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_1027dcb5-8e3b-4668-a562-614eb93d2c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_e88a286b-aecc-4a90-849f-7c5a589cef94" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_74e984eb-d1ba-4847-b4d4-733b62b4e2a0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_e88a286b-aecc-4a90-849f-7c5a589cef94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_2df60ae9-3582-4eb1-b704-918f0c55c00b" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_74e984eb-d1ba-4847-b4d4-733b62b4e2a0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_2df60ae9-3582-4eb1-b704-918f0c55c00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_61bac09f-608c-4c87-9626-4fd45670e175" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_74e984eb-d1ba-4847-b4d4-733b62b4e2a0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_61bac09f-608c-4c87-9626-4fd45670e175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_e89f6dfe-859f-4a4d-aeda-8386a1df038e" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_74e984eb-d1ba-4847-b4d4-733b62b4e2a0" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_e89f6dfe-859f-4a4d-aeda-8386a1df038e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_11d365a9-643d-4bc8-8626-c1c60c891133" xlink:href="ameh-20211231.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_242d6484-b1cf-442e-a388-2cea96585630" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_11d365a9-643d-4bc8-8626-c1c60c891133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_492eef8a-0cf2-4840-b940-18a4d4c0defa" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_11d365a9-643d-4bc8-8626-c1c60c891133" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_492eef8a-0cf2-4840-b940-18a4d4c0defa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_a50779e6-0fc5-401a-8d28-fa8df0423ec4" xlink:href="ameh-20211231.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_242d6484-b1cf-442e-a388-2cea96585630" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_a50779e6-0fc5-401a-8d28-fa8df0423ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_82e96c26-5827-4ac8-94d1-74a2e0e27b4b" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_a50779e6-0fc5-401a-8d28-fa8df0423ec4" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_82e96c26-5827-4ac8-94d1-74a2e0e27b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_fc27fcfc-46e6-4014-9f1f-2618f957820f" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_a50779e6-0fc5-401a-8d28-fa8df0423ec4" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_fc27fcfc-46e6-4014-9f1f-2618f957820f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e091d6ce-fc54-4e2b-a53e-36e73f29d730" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_a50779e6-0fc5-401a-8d28-fa8df0423ec4" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_e091d6ce-fc54-4e2b-a53e-36e73f29d730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_75c3a627-ec49-4076-8da7-b0942fc0efee" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_a50779e6-0fc5-401a-8d28-fa8df0423ec4" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_75c3a627-ec49-4076-8da7-b0942fc0efee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_2b5dafe2-4e52-49cf-a944-a87c79bfc0cb" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_a50779e6-0fc5-401a-8d28-fa8df0423ec4" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_2b5dafe2-4e52-49cf-a944-a87c79bfc0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#StockBasedCompensationWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfda6f2d-222d-4a71-b9ef-4d580b7c54a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bfda6f2d-222d-4a71-b9ef-4d580b7c54a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9757a70a-67e0-4090-b2ee-70b2896524c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9757a70a-67e0-4090-b2ee-70b2896524c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_9757a70a-67e0-4090-b2ee-70b2896524c7" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_86f30f62-47aa-4cd9-9649-248faadafd5b" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_86f30f62-47aa-4cd9-9649-248faadafd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_f5a2b01b-f595-4527-b997-5b00ccbceea6" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_f5a2b01b-f595-4527-b997-5b00ccbceea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_9d6ea633-306a-4b41-affb-0063b0ac503d" xlink:href="ameh-20211231.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5204fec5-2fc8-4132-936e-6cd704cfbac4" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_9d6ea633-306a-4b41-affb-0063b0ac503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_47350147-4a1a-49f3-8d76-a1b3dadb76c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:to="loc_srt_RangeAxis_47350147-4a1a-49f3-8d76-a1b3dadb76c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_47350147-4a1a-49f3-8d76-a1b3dadb76c7" xlink:to="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b86b4ad6-db81-46cd-a875-5238316555dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:to="loc_srt_MinimumMember_b86b4ad6-db81-46cd-a875-5238316555dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_54b36d42-6194-4bf4-a27c-542080ac4242" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb408508-7000-4e94-92fe-45ee2cb1c3ce" xlink:to="loc_srt_MaximumMember_54b36d42-6194-4bf4-a27c-542080ac4242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_71310618-161a-4905-b881-385878871fc2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19ccad05-a189-46fb-8756-fb29f31c5b34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19ccad05-a189-46fb-8756-fb29f31c5b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2de95536-625e-40c5-b2a0-e6bc51aa4d4d" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_2de95536-625e-40c5-b2a0-e6bc51aa4d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_683669f0-92c7-4926-910a-6f21b102620f" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_683669f0-92c7-4926-910a-6f21b102620f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_d1cea37a-8c1e-43dc-ac6d-30bdfd1bea76" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_d1cea37a-8c1e-43dc-ac6d-30bdfd1bea76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3b297759-3322-4ae8-b024-65f1f28e5795" xlink:href="ameh-20211231.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_048715bb-6e2e-4b51-abe6-d85a08188646" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3b297759-3322-4ae8-b024-65f1f28e5795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20211231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9f532224-1302-47b8-9c49-87b3c8209b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b26e4614-f3b2-44eb-a30e-ea5e935f318e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9f532224-1302-47b8-9c49-87b3c8209b3b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_b26e4614-f3b2-44eb-a30e-ea5e935f318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a89fe210-a00b-47aa-bda7-91b5cef051ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:href="ameh-20211231.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a89fe210-a00b-47aa-bda7-91b5cef051ab" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_us-gaap_CreditFacilityAxis_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1cf63d3c-892f-49ab-a2f7-3813f5873c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_9180bd7b-cbd6-4cf4-8f2c-3d992efe4a1c" xlink:to="loc_us-gaap_CreditFacilityDomain_1cf63d3c-892f-49ab-a2f7-3813f5873c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_971e7254-ab4a-4580-b535-0e1f6b768d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1cf63d3c-892f-49ab-a2f7-3813f5873c8f" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_971e7254-ab4a-4580-b535-0e1f6b768d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_dei_LegalEntityAxis_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4a5f9bb8-cfc8-494a-ba3c-cf42c8678acc" xlink:to="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_b8f676dc-1887-402b-bc0c-f0d22b689670" xlink:href="ameh-20211231.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:to="loc_ameh_ApaacoMember_b8f676dc-1887-402b-bc0c-f0d22b689670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9bc5d0a6-ff87-4c58-b68d-117da20ad96e" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_9bc5d0a6-ff87-4c58-b68d-117da20ad96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_2ee540d2-9626-49a1-a03b-4df0cebb4908" xlink:href="ameh-20211231.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4592a0af-b458-41ec-9818-df02393873ae" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_2ee540d2-9626-49a1-a03b-4df0cebb4908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_9b3d8ffd-8cf9-48ed-9fca-761bc53c2281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_be2f8935-e687-4bb5-ac2b-f4b38af6b1d2" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_9b3d8ffd-8cf9-48ed-9fca-761bc53c2281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_50978fb1-b39c-448c-9c18-f25f002b7b31" xlink:href="ameh-20211231.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_9b3d8ffd-8cf9-48ed-9fca-761bc53c2281" xlink:to="loc_ameh_PreferredBankMember_50978fb1-b39c-448c-9c18-f25f002b7b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b1a12291-1514-4e03-946b-92437829e313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b1a12291-1514-4e03-946b-92437829e313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_e2150d22-2f47-454a-a65d-331beddb7f56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b1a12291-1514-4e03-946b-92437829e313" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_e2150d22-2f47-454a-a65d-331beddb7f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_c6bfe1bb-c1b7-46de-9776-55fee6438abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_e2150d22-2f47-454a-a65d-331beddb7f56" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_c6bfe1bb-c1b7-46de-9776-55fee6438abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:href="ameh-20211231.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_db515d5a-512b-40ae-80d6-5e4f7dc93f00" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_2180c712-ceb7-4a00-a748-9d0c6c2de3b4" xlink:href="ameh-20211231.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_2180c712-ceb7-4a00-a748-9d0c6c2de3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_18f47316-c617-4f0e-92b2-724155bb2026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_18f47316-c617-4f0e-92b2-724155bb2026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_fdb4df43-90c0-45b9-a143-a54147405665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_88289d28-b712-4edd-adb1-c784a3fc0ab0" xlink:to="loc_us-gaap_LineOfCredit_fdb4df43-90c0-45b9-a143-a54147405665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20211231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1e247709-9ea0-40dc-895c-ddd751d04e80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_26cc06ec-579f-456c-8628-cbb584542501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1e247709-9ea0-40dc-895c-ddd751d04e80" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_26cc06ec-579f-456c-8628-cbb584542501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0c4b99ed-b1bf-4712-8939-c246ea660281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_6399072d-4103-4640-8bb3-e3b50b6f014e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0c4b99ed-b1bf-4712-8939-c246ea660281" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_6399072d-4103-4640-8bb3-e3b50b6f014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_a6619d2b-8e3b-467c-84d2-179ada1ada42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_a6619d2b-8e3b-467c-84d2-179ada1ada42" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_348b8856-920f-4f72-a839-40a859265dd2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_dei_LegalEntityAxis_348b8856-920f-4f72-a839-40a859265dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_348b8856-920f-4f72-a839-40a859265dd2" xlink:to="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_4535709e-be95-476d-b2c4-3d1cd26c9d3f" xlink:href="ameh-20211231.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_NetworkMedicalManagementMember_4535709e-be95-476d-b2c4-3d1cd26c9d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab4f2bef-e51c-403f-8524-8a645e2e0832" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ab4f2bef-e51c-403f-8524-8a645e2e0832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaAcoIncMember_0d5d2592-7cb0-4e24-a866-7c6b6f69008a" xlink:href="ameh-20211231.xsd#ameh_ApaAcoIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_ApaAcoIncMember_0d5d2592-7cb0-4e24-a866-7c6b6f69008a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_e1964a25-4243-4226-af67-d50d5d5d5ae6" xlink:href="ameh-20211231.xsd#ameh_SCHCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_b45ad6cb-fded-493c-85eb-005934dd099f" xlink:to="loc_ameh_SCHCMember_e1964a25-4243-4226-af67-d50d5d5d5ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_aea93e5c-199e-4fd2-b71b-75b35605e1a4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_srt_TitleOfIndividualAxis_aea93e5c-199e-4fd2-b71b-75b35605e1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_aea93e5c-199e-4fd2-b71b-75b35605e1a4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_000f548a-8735-47d9-b83d-db7cfad6c3ca" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:to="loc_srt_OfficerMember_000f548a-8735-47d9-b83d-db7cfad6c3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_61fb335a-dbe1-43ba-8620-ad6092f6064f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f17c7dae-00c1-42d7-a027-3f102e81285c" xlink:to="loc_srt_DirectorMember_61fb335a-dbe1-43ba-8620-ad6092f6064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d8c5e04f-f664-40f5-b9c8-f60ab15421ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d8c5e04f-f664-40f5-b9c8-f60ab15421ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d8c5e04f-f664-40f5-b9c8-f60ab15421ce" xlink:to="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_cb4c9bbd-7fe1-4bac-8ba1-0acfa445defa" xlink:href="ameh-20211231.xsd#ameh_ApcShareholdersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_ApcShareholdersMember_cb4c9bbd-7fe1-4bac-8ba1-0acfa445defa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_cc7d8eb7-9ff2-49e0-9bd5-0c517a4a8036" xlink:href="ameh-20211231.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_cc7d8eb7-9ff2-49e0-9bd5-0c517a4a8036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FreseniusMember_45db4fc7-2a91-478a-8fdb-8787c403a6f6" xlink:href="ameh-20211231.xsd#ameh_FreseniusMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_FreseniusMember_45db4fc7-2a91-478a-8fdb-8787c403a6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FulgentGeneticsIncMember_d119012e-5139-4a71-bb08-d0da8087b119" xlink:href="ameh-20211231.xsd#ameh_FulgentGeneticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_FulgentGeneticsIncMember_d119012e-5139-4a71-bb08-d0da8087b119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_bb5b32f4-69a8-4a5d-a50f-078d1b94695a" xlink:href="ameh-20211231.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_OneMSOInc.Member_bb5b32f4-69a8-4a5d-a50f-078d1b94695a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_7d80e971-0800-4eaf-a77f-ede103de11a1" xlink:href="ameh-20211231.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_7d80e971-0800-4eaf-a77f-ede103de11a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_174f2db1-9f7f-4be3-ae70-bb1c01de9ec2" xlink:href="ameh-20211231.xsd#ameh_NumenLLCMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_NumenLLCMember_174f2db1-9f7f-4be3-ae70-bb1c01de9ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ArroyoVistaFamilyHealthCenterMember_4b1afe8d-9935-4ddd-8465-f285c905a522" xlink:href="ameh-20211231.xsd#ameh_ArroyoVistaFamilyHealthCenterMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_ArroyoVistaFamilyHealthCenterMember_4b1afe8d-9935-4ddd-8465-f285c905a522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_2e6271c7-2f76-4e4e-9668-4e087a5740d8" xlink:href="ameh-20211231.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_54690f4f-6a60-4b12-bf05-0246a0f7ddd3" xlink:to="loc_ameh_AHMCMember_2e6271c7-2f76-4e4e-9668-4e087a5740d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_52903a6a-6602-4e20-84e9-6a63f81c7a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_52903a6a-6602-4e20-84e9-6a63f81c7a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_52903a6a-6602-4e20-84e9-6a63f81c7a33" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_8dec6970-fe05-4d01-ad41-0435340c8b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:to="loc_us-gaap_ServiceMember_8dec6970-fe05-4d01-ad41-0435340c8b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConsultingServicesMember_d16c5121-7d44-4e07-bfd7-4694b5858944" xlink:href="ameh-20211231.xsd#ameh_ConsultingServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_0814d9a8-198e-4fc8-8e2b-2ffb22079e1b" xlink:to="loc_ameh_ConsultingServicesMember_d16c5121-7d44-4e07-bfd7-4694b5858944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_38370fc1-fc46-419c-9ff9-d0d0cc1834d1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_srt_ConsolidatedEntitiesAxis_38370fc1-fc46-419c-9ff9-d0d0cc1834d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_38370fc1-fc46-419c-9ff9-d0d0cc1834d1" xlink:to="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_6a456aa3-e246-4d41-bfba-b77a1e47669c" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_6a456aa3-e246-4d41-bfba-b77a1e47669c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_c9678f7a-31c7-4337-8845-69769e791bb8" xlink:href="ameh-20211231.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:to="loc_ameh_PmiocMember_c9678f7a-31c7-4337-8845-69769e791bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_1174bf10-35a5-4499-b1d3-a478fcbd9777" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_309a6a12-622f-45c8-a68c-185288011bf9" xlink:to="loc_ameh_DmgMember_1174bf10-35a5-4499-b1d3-a478fcbd9777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e2f83ce-dd00-4204-8e52-f7afca6b17f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e2f83ce-dd00-4204-8e52-f7afca6b17f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_3e2f83ce-dd00-4204-8e52-f7afca6b17f3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_eaab752e-21fa-4a6e-a6a4-d639f897ec7c" xlink:href="ameh-20211231.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_eaab752e-21fa-4a6e-a6a4-d639f897ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_08e2b5ac-1cb0-432f-8d83-9e3e9ba6c7d0" xlink:href="ameh-20211231.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_PmiocMember_08e2b5ac-1cb0-432f-8d83-9e3e9ba6c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_207a65b9-d727-4082-8d94-4866f1d41169" xlink:href="ameh-20211231.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_DmgMember_207a65b9-d727-4082-8d94-4866f1d41169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_1f9d3aac-6d4b-435c-98b3-2eb815493eb7" xlink:href="ameh-20211231.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6e92a957-7ee2-48c2-9f65-f0eb5b00fa28" xlink:to="loc_ameh_OneMSOInc.Member_1f9d3aac-6d4b-435c-98b3-2eb815493eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf58190e-9522-4c85-95d9-2515de673269" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_b040968f-ccc7-4562-8165-e991c1046f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_RevenueFromRelatedParties_b040968f-ccc7-4562-8165-e991c1046f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_9fbf1fd0-4a1f-42c2-ac95-fcdfd7b0d426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_DueFromRelatedParties_9fbf1fd0-4a1f-42c2-ac95-fcdfd7b0d426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ebe5633-00ff-4322-9651-0e7001c08081" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4ebe5633-00ff-4322-9651-0e7001c08081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_6d08c234-dc3f-479e-ae56-b3e813a3c9b5" xlink:href="ameh-20211231.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_ameh_PaymentMadeToRelatedParty_6d08c234-dc3f-479e-ae56-b3e813a3c9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_872f3d7d-480e-4e01-ac66-2cef1339e505" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_872f3d7d-480e-4e01-ac66-2cef1339e505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceServicesRevenue_ba344ea5-0994-45b5-aac2-7e6d040469b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InsuranceServicesRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_InsuranceServicesRevenue_ba344ea5-0994-45b5-aac2-7e6d040469b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_8acd7e3f-534b-4c9a-b17d-8777a95f539b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_8acd7e3f-534b-4c9a-b17d-8777a95f539b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_28809748-6364-4377-af02-c7a4f5f5398d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0097f0ee-138a-4055-8be0-ff440e545000" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_28809748-6364-4377-af02-c7a4f5f5398d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_f588dda1-7a21-4955-977b-f9ab63e52cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_56f58292-61d0-41a7-9695-fdb8532f1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_f588dda1-7a21-4955-977b-f9ab63e52cb1" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_56f58292-61d0-41a7-9695-fdb8532f1a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_811ceabb-b519-4de3-9b61-f0fc29d3b630" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_56f58292-61d0-41a7-9695-fdb8532f1a60" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_811ceabb-b519-4de3-9b61-f0fc29d3b630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_811ceabb-b519-4de3-9b61-f0fc29d3b630" xlink:to="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_ea0fe21e-ec25-4b97-b294-50fe1c65d1ec" xlink:href="ameh-20211231.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:to="loc_ameh_AHMCMember_ea0fe21e-ec25-4b97-b294-50fe1c65d1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_63936ec5-7f53-443d-ab20-209ec8e32838" xlink:href="ameh-20211231.xsd#ameh_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:to="loc_ameh_HSMSOMember_63936ec5-7f53-443d-ab20-209ec8e32838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_84f69ff1-b759-463f-856a-2834a939f049" xlink:href="ameh-20211231.xsd#ameh_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_89bba617-7f0b-44be-956b-11331f9ad91d" xlink:to="loc_ameh_AurionMember_84f69ff1-b759-463f-856a-2834a939f049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_56f58292-61d0-41a7-9695-fdb8532f1a60" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_9fece783-139a-403e-bec3-8d0a1f8b9c5b" xlink:href="ameh-20211231.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_9fece783-139a-403e-bec3-8d0a1f8b9c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_858f8ed0-a433-4f90-a611-ac975e7a990f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:to="loc_us-gaap_ManagementFeeExpense_858f8ed0-a433-4f90-a611-ac975e7a990f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_ca7de854-e380-461f-9edf-6185df8c5cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_485f1645-3755-4e7d-9e8b-f78ea91d6bf9" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_ca7de854-e380-461f-9edf-6185df8c5cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="ameh-20211231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2dc0c5ff-4a48-4426-9caf-1caa6a15559d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_db5dafeb-41e8-427f-8379-d3573e919c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2dc0c5ff-4a48-4426-9caf-1caa6a15559d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_db5dafeb-41e8-427f-8379-d3573e919c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#EmployeeBenefitPlanAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a58f0b0e-6088-41f8-8463-3be573448f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DefinedContributionPlanServicePeriod_d913bc38-6f28-4d2e-baa3-77565a0203ab" xlink:href="ameh-20211231.xsd#ameh_DefinedContributionPlanServicePeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a58f0b0e-6088-41f8-8463-3be573448f84" xlink:to="loc_ameh_DefinedContributionPlanServicePeriod_d913bc38-6f28-4d2e-baa3-77565a0203ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DefinedContributionPlanVestingPeriod_684cdc6e-6287-437f-8f48-776e111ffdf3" xlink:href="ameh-20211231.xsd#ameh_DefinedContributionPlanVestingPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a58f0b0e-6088-41f8-8463-3be573448f84" xlink:to="loc_ameh_DefinedContributionPlanVestingPeriod_684cdc6e-6287-437f-8f48-776e111ffdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_c8e16669-7f1a-43f7-a96f-ede3afee6b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a58f0b0e-6088-41f8-8463-3be573448f84" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_c8e16669-7f1a-43f7-a96f-ede3afee6b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_df085ef9-1892-4145-9399-8974a5168cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e1998df1-d9ad-4d2e-a587-9849bf82f622" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df085ef9-1892-4145-9399-8974a5168cc0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e1998df1-d9ad-4d2e-a587-9849bf82f622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cef165f2-f2cb-45b5-bc6a-c79dc3707754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7257adae-b40d-4e71-8d15-ab99582ce9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cef165f2-f2cb-45b5-bc6a-c79dc3707754" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7257adae-b40d-4e71-8d15-ab99582ce9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_f57b6d85-92f3-4d9b-ad8a-84a61ea57a95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cef165f2-f2cb-45b5-bc6a-c79dc3707754" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_f57b6d85-92f3-4d9b-ad8a-84a61ea57a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_577e72b4-2c93-4837-a25a-7b26bdab39df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_4a66e667-298c-41a7-a961-50a5306090c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_577e72b4-2c93-4837-a25a-7b26bdab39df" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_4a66e667-298c-41a7-a961-50a5306090c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_eabd965a-fc0f-4f51-a3a0-1cef9416e3df" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_4a66e667-298c-41a7-a961-50a5306090c2" xlink:to="loc_dei_LegalEntityAxis_eabd965a-fc0f-4f51-a3a0-1cef9416e3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_20c4f093-eeef-467b-ac01-93fefdd6e471" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_eabd965a-fc0f-4f51-a3a0-1cef9416e3df" xlink:to="loc_dei_EntityDomain_20c4f093-eeef-467b-ac01-93fefdd6e471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_73d5ed00-15e9-45c8-ba69-e9dfecf4bd07" xlink:href="ameh-20211231.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_20c4f093-eeef-467b-ac01-93fefdd6e471" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_73d5ed00-15e9-45c8-ba69-e9dfecf4bd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_f29eabac-ce6d-4ee4-8a61-b1bd62b27dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_4a66e667-298c-41a7-a961-50a5306090c2" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_f29eabac-ce6d-4ee4-8a61-b1bd62b27dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c94859-b2a5-448d-92f0-c747f8ff791b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_f29eabac-ce6d-4ee4-8a61-b1bd62b27dc5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_38c94859-b2a5-448d-92f0-c747f8ff791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_eccccab2-83c9-4dcf-98d8-e9c44b9a39f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ec41a974-cd85-4c62-a90f-c66d9c51563e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eccccab2-83c9-4dcf-98d8-e9c44b9a39f3" xlink:to="loc_us-gaap_EarningsPerShareBasic_ec41a974-cd85-4c62-a90f-c66d9c51563e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2b3877ea-5dc5-4f25-bda1-ae54cd6fcf60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eccccab2-83c9-4dcf-98d8-e9c44b9a39f3" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2b3877ea-5dc5-4f25-bda1-ae54cd6fcf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8683fc7c-364d-4b46-b8f9-064f3cce8df1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eccccab2-83c9-4dcf-98d8-e9c44b9a39f3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8683fc7c-364d-4b46-b8f9-064f3cce8df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_835fdbfc-77c3-45d2-b939-558ae8c18fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_eccccab2-83c9-4dcf-98d8-e9c44b9a39f3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_835fdbfc-77c3-45d2-b939-558ae8c18fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7d4b9b84-56ad-4ec2-921a-fcb0fed0f258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7d4b9b84-56ad-4ec2-921a-fcb0fed0f258" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f27b1b73-6b4a-468a-bb5b-8dd11a18823d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f27b1b73-6b4a-468a-bb5b-8dd11a18823d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f27b1b73-6b4a-468a-bb5b-8dd11a18823d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_40dafb97-66d2-4932-a108-ef591de61ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_40dafb97-66d2-4932-a108-ef591de61ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_68a20235-6a25-4f3a-af97-a4b168a0619a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_db267581-631e-4d7f-a703-e1a7211710d3" xlink:to="loc_us-gaap_RestrictedStockMember_68a20235-6a25-4f3a-af97-a4b168a0619a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14f894dc-1fdf-42d8-a2e0-910768651abb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14f894dc-1fdf-42d8-a2e0-910768651abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_628bd18e-babf-4ae8-8daa-7285a4e2e3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14f894dc-1fdf-42d8-a2e0-910768651abb" xlink:to="loc_us-gaap_EquityComponentDomain_628bd18e-babf-4ae8-8daa-7285a4e2e3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_a36b7052-532f-483c-8d9f-9675e1dbaa61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_628bd18e-babf-4ae8-8daa-7285a4e2e3ab" xlink:to="loc_us-gaap_WarrantMember_a36b7052-532f-483c-8d9f-9675e1dbaa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_eb980343-7ff7-426c-8d25-acc4449b8a1f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:to="loc_srt_TitleOfIndividualAxis_eb980343-7ff7-426c-8d25-acc4449b8a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_eb980343-7ff7-426c-8d25-acc4449b8a1f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ManagementMember_18c614c9-b5a9-42e9-a1f3-68887cd1cad5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:to="loc_srt_ManagementMember_18c614c9-b5a9-42e9-a1f3-68887cd1cad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ExecutiveOfficerMember_d61a69b7-9956-4b51-9268-5fdb80b335dd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f614b672-71b5-48e7-b733-1c46f5f6018a" xlink:to="loc_srt_ExecutiveOfficerMember_d61a69b7-9956-4b51-9268-5fdb80b335dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_67f991c9-066b-488b-8f49-9795e1f03a30" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b854a118-96fd-4bf9-a1bc-5ffbb455d857" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b854a118-96fd-4bf9-a1bc-5ffbb455d857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c05b277e-859b-4148-8356-ddeedbeb55b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_c05b277e-859b-4148-8356-ddeedbeb55b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddf5691c-8f43-44b8-8cce-f3463585046c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_677a2595-3bf9-4fb7-8a95-fa8207200b68" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ddf5691c-8f43-44b8-8cce-f3463585046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20211231.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_031ea895-e7cb-4b3a-89cf-2efef4ad9cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_215108dd-31c8-47c9-af6b-b592c4ce04ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_031ea895-e7cb-4b3a-89cf-2efef4ad9cbb" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_215108dd-31c8-47c9-af6b-b592c4ce04ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20506273-74cd-440c-8b46-920c013d5336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_af8760cb-dec9-443c-b04b-a9f6940feebb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20506273-74cd-440c-8b46-920c013d5336" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_af8760cb-dec9-443c-b04b-a9f6940feebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0256f51-3130-487e-9597-688f7acf875a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7976fbd1-0c8d-4df2-9d1b-9f5fa279cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c0256f51-3130-487e-9597-688f7acf875a" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7976fbd1-0c8d-4df2-9d1b-9f5fa279cf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f3958282-0940-40d4-af65-69e186895f89" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7976fbd1-0c8d-4df2-9d1b-9f5fa279cf01" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f3958282-0940-40d4-af65-69e186895f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_618aaa9b-648d-4574-96b9-84499eff6093" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f3958282-0940-40d4-af65-69e186895f89" xlink:to="loc_srt_ConsolidatedEntitiesDomain_618aaa9b-648d-4574-96b9-84499eff6093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_58fa011b-5fc2-4a07-8e40-b12f8546443c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_618aaa9b-648d-4574-96b9-84499eff6093" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_58fa011b-5fc2-4a07-8e40-b12f8546443c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_7976fbd1-0c8d-4df2-9d1b-9f5fa279cf01" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:to="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4eb27222-4028-40a3-b8b8-8acac6f37114" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4eb27222-4028-40a3-b8b8-8acac6f37114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_00d791bb-6b98-409c-b553-d241ac1ebbae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_00d791bb-6b98-409c-b553-d241ac1ebbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_59b36919-414a-43ef-9d78-2489936c5ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_59b36919-414a-43ef-9d78-2489936c5ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e7f4ae3b-2720-4797-84a6-9f9c7760c60e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_e7f4ae3b-2720-4797-84a6-9f9c7760c60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_0b81e7a3-9199-4ae4-a1b5-f00a6c593e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_IncomeTaxesReceivable_0b81e7a3-9199-4ae4-a1b5-f00a6c593e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_4338fe50-a4bb-4692-93cc-bc90f5497e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_4338fe50-a4bb-4692-93cc-bc90f5497e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_478ec9ad-6ba6-4b6a-b541-5a37d302cc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_478ec9ad-6ba6-4b6a-b541-5a37d302cc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_3d39101a-34a7-400d-963a-dc1aa366f2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_3d39101a-34a7-400d-963a-dc1aa366f2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromAffiliates_ae5a30a1-e4f0-4446-8667-04f4a52b1099" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromAffiliates"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_DueFromAffiliates_ae5a30a1-e4f0-4446-8667-04f4a52b1099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a05b41d7-e4e1-49d6-b41a-02cffa64034f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_259b0879-88f5-42a5-8edf-aa8ee4927a6d" xlink:to="loc_us-gaap_AssetsCurrent_a05b41d7-e4e1-49d6-b41a-02cffa64034f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_68f74e9f-8a4f-4f5e-a4d0-732ebebee9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_68f74e9f-8a4f-4f5e-a4d0-732ebebee9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2cb5ada-8625-4480-970a-515d378be7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f2cb5ada-8625-4480-970a-515d378be7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1c0ac890-8a28-41af-b626-ec2e72e1923b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_Goodwill_1c0ac890-8a28-41af-b626-ec2e72e1923b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedPartiesNoncurrent_114062cb-701d-4a6c-b899-3995dc22a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_DueFromRelatedPartiesNoncurrent_114062cb-701d-4a6c-b899-3995dc22a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_20f6295f-2735-4834-a63d-195af1887c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_OtherLongTermInvestments_20f6295f-2735-4834-a63d-195af1887c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_fe381740-1aa1-48f7-9f02-0267c7cdfbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_EquityMethodInvestments_fe381740-1aa1-48f7-9f02-0267c7cdfbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_634232fb-e5e0-4b0c-a554-e66007d46fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_634232fb-e5e0-4b0c-a554-e66007d46fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c81d25b5-4c62-4099-8413-9865f1211024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c81d25b5-4c62-4099-8413-9865f1211024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ae009b-a8ef-4d3b-ad57-a63d4f82a8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_52ae009b-a8ef-4d3b-ad57-a63d4f82a8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1817afc7-7a2e-4620-bbce-4f549b035d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1817afc7-7a2e-4620-bbce-4f549b035d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_fc33febf-1942-45d4-8640-763144cf8a43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_27e22b84-95da-47a1-9cd0-0be3f6c19d7a" xlink:to="loc_us-gaap_AssetsNoncurrent_fc33febf-1942-45d4-8640-763144cf8a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6f16cacb-4dce-430f-a8a1-e224cc888989" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7576f48b-6371-448f-a287-de89488ed1ad" xlink:to="loc_us-gaap_Assets_6f16cacb-4dce-430f-a8a1-e224cc888989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_eea2ce66-a4aa-4bc8-b673-9c81f80835da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_eea2ce66-a4aa-4bc8-b673-9c81f80835da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_fa308d34-9ef8-406c-b206-220bf50b691d" xlink:href="ameh-20211231.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_fa308d34-9ef8-406c-b206-220bf50b691d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalLiabilitiesCurrent_75a88a73-afc5-422f-9e11-82771c42d51a" xlink:href="ameh-20211231.xsd#ameh_MedicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_ameh_MedicalLiabilitiesCurrent_75a88a73-afc5-422f-9e11-82771c42d51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_83f269d9-3410-4c8e-9a63-71a5a54aa13d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_83f269d9-3410-4c8e-9a63-71a5a54aa13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_6a32d098-97dc-429d-b0d7-6097271c5f79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_DividendsPayableCurrent_6a32d098-97dc-429d-b0d7-6097271c5f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_12d9c420-0c20-4d27-80ba-c9003728859f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_DueToAffiliateCurrent_12d9c420-0c20-4d27-80ba-c9003728859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_39b90160-d701-4676-9627-6cd32ee97b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_39b90160-d701-4676-9627-6cd32ee97b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_46b3f168-3bae-466a-b405-a1681b2a9793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_46b3f168-3bae-466a-b405-a1681b2a9793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_b0a0a308-ca4d-4fc6-b509-84036432a485" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_LongTermDebtCurrent_b0a0a308-ca4d-4fc6-b509-84036432a485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a9b8a542-f22f-4e20-90c0-9cc4d20d5a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_b00d3c95-8825-4e73-a34e-ea94992bae28" xlink:to="loc_us-gaap_LiabilitiesCurrent_a9b8a542-f22f-4e20-90c0-9cc4d20d5a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3136617b-b327-48ff-9c52-95171baac0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3136617b-b327-48ff-9c52-95171baac0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bbeb39b3-eb24-4310-967b-fe68b34ddcb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_bbeb39b3-eb24-4310-967b-fe68b34ddcb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3875b17-1bec-4a40-a129-7c87a87d0d49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b3875b17-1bec-4a40-a129-7c87a87d0d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_be5d7983-a9db-44f3-80fe-fd6a4ffc2321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_be5d7983-a9db-44f3-80fe-fd6a4ffc2321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_78ca5e77-7b56-4fe5-99e2-c2a09d6e0ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_78ca5e77-7b56-4fe5-99e2-c2a09d6e0ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b6c8ef02-c508-435d-82c1-2e8860733e21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_99594c16-2df2-43c3-bb5d-b2d7f31e166e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b6c8ef02-c508-435d-82c1-2e8860733e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_dd194212-19ac-4623-9e3c-a1ee0d807994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_622b6efb-a6ad-45f3-9526-d1c4eb8c115c" xlink:to="loc_us-gaap_Liabilities_dd194212-19ac-4623-9e3c-a1ee0d807994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20211231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4fe722b3-bc5c-445d-92f6-24c128bfc3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_f72d1a20-2d71-44a9-bfae-020d23c74ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fe722b3-bc5c-445d-92f6-24c128bfc3a6" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_f72d1a20-2d71-44a9-bfae-020d23c74ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_c705104e-0d60-4939-a539-d123b8232292" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4fe722b3-bc5c-445d-92f6-24c128bfc3a6" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_c705104e-0d60-4939-a539-d123b8232292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d4dad99e-8913-45b7-b59b-769b691a2dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_08a6a3af-6c71-453f-9121-c0200ee90ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4dad99e-8913-45b7-b59b-769b691a2dd0" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_08a6a3af-6c71-453f-9121-c0200ee90ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_19b1aea0-ae17-44d3-a0ab-8137a92aa7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4dad99e-8913-45b7-b59b-769b691a2dd0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_19b1aea0-ae17-44d3-a0ab-8137a92aa7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_640975c2-4ccf-4fcb-843e-738ed01f68bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d4dad99e-8913-45b7-b59b-769b691a2dd0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_640975c2-4ccf-4fcb-843e-738ed01f68bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d51e6d83-5a04-4cd2-b2eb-d9b3d67248e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_dbaf5762-46f7-43fb-a9fe-86577ee42764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d51e6d83-5a04-4cd2-b2eb-d9b3d67248e4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_dbaf5762-46f7-43fb-a9fe-86577ee42764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03eb354b-4e51-4b8b-b753-ae6c652cf751" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbaf5762-46f7-43fb-a9fe-86577ee42764" xlink:to="loc_srt_RangeAxis_03eb354b-4e51-4b8b-b753-ae6c652cf751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_03eb354b-4e51-4b8b-b753-ae6c652cf751" xlink:to="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bea5016a-3f2f-4fcc-836e-3de5efef6fd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:to="loc_srt_MinimumMember_bea5016a-3f2f-4fcc-836e-3de5efef6fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0acfdfe3-ad06-4363-a8da-0430b80b1ca8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_507d47c2-1224-4bf0-b3f7-836d28af5855" xlink:to="loc_srt_MaximumMember_0acfdfe3-ad06-4363-a8da-0430b80b1ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_dbaf5762-46f7-43fb-a9fe-86577ee42764" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_caef583e-25d9-4b99-8f1e-2543b2d07b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_caef583e-25d9-4b99-8f1e-2543b2d07b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_70d77b40-9c2e-4f1c-af12-57c6db511647" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseTermOfContract1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeFinanceLeaseTermOfContract1_70d77b40-9c2e-4f1c-af12-57c6db511647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e106313c-6e9b-4c6b-bda9-da5f653cb5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_e106313c-6e9b-4c6b-bda9-da5f653cb5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_e9926260-e4e2-40c4-88b4-2576f351e7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_e9926260-e4e2-40c4-88b4-2576f351e7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_66578ba2-68d6-439c-8474-89e723738bc7" xlink:href="ameh-20211231.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_66578ba2-68d6-439c-8474-89e723738bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_738f8f6a-382f-47f1-a2a8-af1b1540fb38" xlink:href="ameh-20211231.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_738f8f6a-382f-47f1-a2a8-af1b1540fb38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_6607d681-c471-4cc1-844a-bcafa4c2c470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_6607d681-c471-4cc1-844a-bcafa4c2c470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_b66b0b52-62b8-4d35-9528-be50ddad11b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a4afb6de-5473-4b11-af77-82b88524610d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_b66b0b52-62b8-4d35-9528-be50ddad11b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1348be07-ca40-47b1-acb0-83328a09825e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_204f452a-c034-442e-a0ac-6b8c771a5a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1348be07-ca40-47b1-acb0-83328a09825e" xlink:to="loc_us-gaap_OperatingLeaseCost_204f452a-c034-442e-a0ac-6b8c771a5a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract_36a69125-3be1-475f-be3d-d13058fefddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1348be07-ca40-47b1-acb0-83328a09825e" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract_36a69125-3be1-475f-be3d-d13058fefddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6807cd9-7224-4dcf-9152-f060ac1f3374" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract_36a69125-3be1-475f-be3d-d13058fefddf" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e6807cd9-7224-4dcf-9152-f060ac1f3374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_1ba3f2fb-ba99-4357-936a-69f38c1d4b16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract_36a69125-3be1-475f-be3d-d13058fefddf" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_1ba3f2fb-ba99-4357-936a-69f38c1d4b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_34338ef6-1316-4fc1-badc-7be6480862ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1348be07-ca40-47b1-acb0-83328a09825e" xlink:to="loc_us-gaap_SubleaseIncome_34338ef6-1316-4fc1-badc-7be6480862ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_1d6815d6-0638-413a-9c40-8015b43be7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1348be07-ca40-47b1-acb0-83328a09825e" xlink:to="loc_us-gaap_LeaseCost_1d6815d6-0638-413a-9c40-8015b43be7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d8c00f64-8881-4858-9190-d5889b4a986b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f6175b7e-c3cf-4da5-a777-f9041d7e4e03" xlink:href="ameh-20211231.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8c00f64-8881-4858-9190-d5889b4a986b" xlink:to="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f6175b7e-c3cf-4da5-a777-f9041d7e4e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1832542e-d0b3-4be5-a3a0-316406b4c930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f6175b7e-c3cf-4da5-a777-f9041d7e4e03" xlink:to="loc_us-gaap_OperatingLeasePayments_1832542e-d0b3-4be5-a3a0-316406b4c930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_3c1b54bc-6ede-4095-8163-9e3d372d57f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f6175b7e-c3cf-4da5-a777-f9041d7e4e03" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_3c1b54bc-6ede-4095-8163-9e3d372d57f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_078d9d1a-3b75-4e24-b3a7-6f49f2c654a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_f6175b7e-c3cf-4da5-a777-f9041d7e4e03" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_078d9d1a-3b75-4e24-b3a7-6f49f2c654a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_413b6d7a-8102-41ba-b282-af988fd67719" xlink:href="ameh-20211231.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8c00f64-8881-4858-9190-d5889b4a986b" xlink:to="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_413b6d7a-8102-41ba-b282-af988fd67719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd609edf-703b-4895-b7dd-3ab241d0b2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_413b6d7a-8102-41ba-b282-af988fd67719" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_fd609edf-703b-4895-b7dd-3ab241d0b2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_a9bb3938-cab3-4099-9a2c-672777e309f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_413b6d7a-8102-41ba-b282-af988fd67719" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_a9bb3938-cab3-4099-9a2c-672777e309f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_57a7185a-2fd5-4422-9900-a6b968db6802" xlink:href="ameh-20211231.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8c00f64-8881-4858-9190-d5889b4a986b" xlink:to="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_57a7185a-2fd5-4422-9900-a6b968db6802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e7da04d7-a3a8-418a-9899-8e3795301ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_57a7185a-2fd5-4422-9900-a6b968db6802" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e7da04d7-a3a8-418a-9899-8e3795301ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_ffd4874d-d628-40af-a44e-421144081213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_57a7185a-2fd5-4422-9900-a6b968db6802" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_ffd4874d-d628-40af-a44e-421144081213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_c393046c-ac52-4092-a516-b068d0114e24" xlink:href="ameh-20211231.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8c00f64-8881-4858-9190-d5889b4a986b" xlink:to="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_c393046c-ac52-4092-a516-b068d0114e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6bc4c777-ca0e-4274-9567-e8ec08a18dba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_c393046c-ac52-4092-a516-b068d0114e24" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6bc4c777-ca0e-4274-9567-e8ec08a18dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_787183eb-c0d1-45c7-879b-67699ddad84b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_c393046c-ac52-4092-a516-b068d0114e24" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_787183eb-c0d1-45c7-879b-67699ddad84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7856db1e-f406-42d1-9dc0-9eb393827f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7856db1e-f406-42d1-9dc0-9eb393827f9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_835652c7-db0e-4a92-b65c-50e983d35686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_835652c7-db0e-4a92-b65c-50e983d35686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4edf2330-dcb9-47cb-8517-20da5f3aefd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4edf2330-dcb9-47cb-8517-20da5f3aefd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_21ed3eee-e5e2-458e-9768-1b37356369be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_21ed3eee-e5e2-458e-9768-1b37356369be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79a71596-3e56-4ef3-9455-bc19fd3d9b61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_79a71596-3e56-4ef3-9455-bc19fd3d9b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f74989e5-6280-4ced-bac3-1e1721d48ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f74989e5-6280-4ced-bac3-1e1721d48ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ab8bbf9e-7a6d-4d16-b17f-68e114da574a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_ab8bbf9e-7a6d-4d16-b17f-68e114da574a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa25a266-fec9-4e57-b37d-8751f8d14bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fa25a266-fec9-4e57-b37d-8751f8d14bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_00e65520-9c53-41c5-ac74-9c10b1db7d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_00e65520-9c53-41c5-ac74-9c10b1db7d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_49a31c1a-d620-453c-ab4c-bf85c1c424af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_OperatingLeaseLiability_49a31c1a-d620-453c-ab4c-bf85c1c424af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f1211c24-27f4-41ca-ac8c-d34842a7bd0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f1211c24-27f4-41ca-ac8c-d34842a7bd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_688475ac-0c1d-411c-a243-37b414ee5490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1651cd2c-4425-4065-b67b-b6bc151f8574" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_688475ac-0c1d-411c-a243-37b414ee5490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7856db1e-f406-42d1-9dc0-9eb393827f9f" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_516eb95f-1041-4b06-977e-1656a6dcd9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_516eb95f-1041-4b06-977e-1656a6dcd9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_165aea29-77f5-4121-a6f0-1c6878b1cc2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_165aea29-77f5-4121-a6f0-1c6878b1cc2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f70d41de-985f-44c7-b0a4-d0f24419f79c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_f70d41de-985f-44c7-b0a4-d0f24419f79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ed0ffa46-3d81-40cd-bc06-2e15bbd0fee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ed0ffa46-3d81-40cd-bc06-2e15bbd0fee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_a2561174-9b64-4aad-89ec-b9a12402ffa7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_a2561174-9b64-4aad-89ec-b9a12402ffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_cb0277ed-ee5f-45dc-a407-3ecbcf34ef34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_cb0277ed-ee5f-45dc-a407-3ecbcf34ef34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d690659e-b4ff-4a2e-8713-53a99c1c271a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_d690659e-b4ff-4a2e-8713-53a99c1c271a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_70d0eeb8-e293-46ec-8f5c-88f7f8b5d41e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_70d0eeb8-e293-46ec-8f5c-88f7f8b5d41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_ede01ed7-beb1-4502-898e-2e55faa60bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiability_ede01ed7-beb1-4502-898e-2e55faa60bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f1926276-6995-4970-a083-da2fbc1c7d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f1926276-6995-4970-a083-da2fbc1c7d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_96c3659d-0218-4356-82d0-acd1ea0d3fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_fbb01ea9-61c7-444f-a98f-a12e2305636e" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_96c3659d-0218-4356-82d0-acd1ea0d3fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1" xlink:type="simple" xlink:href="ameh-20211231.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEvents" xlink:type="simple" xlink:href="ameh-20211231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_72e3b242-c7b7-47a0-8a94-24f29e3b7ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_df6dd2df-fa91-49d2-9188-b3f13acdb91e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_72e3b242-c7b7-47a0-8a94-24f29e3b7ad6" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_df6dd2df-fa91-49d2-9188-b3f13acdb91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20211231.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5c152830-1d0f-436c-983a-f7c4cbd65548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5c152830-1d0f-436c-983a-f7c4cbd65548" xlink:to="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7f268446-ceee-42df-8700-27eb47621274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7f268446-ceee-42df-8700-27eb47621274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ff33dc-24bc-47d0-bbf1-fcfa19f58e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7f268446-ceee-42df-8700-27eb47621274" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ff33dc-24bc-47d0-bbf1-fcfa19f58e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_cba9d53f-cbd3-4b19-9869-99d49bbf31ae" xlink:href="ameh-20211231.xsd#ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_83ff33dc-24bc-47d0-bbf1-fcfa19f58e15" xlink:to="loc_ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember_cba9d53f-cbd3-4b19-9869-99d49bbf31ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_077f216d-56fc-4300-af1b-1ad33f0bc452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_077f216d-56fc-4300-af1b-1ad33f0bc452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_6f1261cf-9c1a-41d6-ad41-09a89f8c2c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_077f216d-56fc-4300-af1b-1ad33f0bc452" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_6f1261cf-9c1a-41d6-ad41-09a89f8c2c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8b4f45e7-cf11-4e97-a1e4-a0a4670b6f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_6f1261cf-9c1a-41d6-ad41-09a89f8c2c19" xlink:to="loc_us-gaap_SubsequentEventMember_8b4f45e7-cf11-4e97-a1e4-a0a4670b6f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_27383d87-f934-47f2-baa0-9cf1b4886a2d" xlink:to="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92773594-ee19-498d-a24a-05f30deeee25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_92773594-ee19-498d-a24a-05f30deeee25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_168115d5-1c60-40f5-b9c5-a179a80effd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_168115d5-1c60-40f5-b9c5-a179a80effd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfDirectContractingEntityPatients_cc13436e-f790-4d08-adce-9a5163ce8786" xlink:href="ameh-20211231.xsd#ameh_NumberOfDirectContractingEntityPatients"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_ameh_NumberOfDirectContractingEntityPatients_cc13436e-f790-4d08-adce-9a5163ce8786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfRemotePatientMonitoringPatients_20fb0aef-ab49-4895-b913-1943af875982" xlink:href="ameh-20211231.xsd#ameh_NumberOfRemotePatientMonitoringPatients"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_80779075-efcc-4743-8604-a9852f300c16" xlink:to="loc_ameh_NumberOfRemotePatientMonitoringPatients_20fb0aef-ab49-4895-b913-1943af875982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ameh-20211231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ameh-20211231_g1.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!_P7X_Y0V?M"?]D_
MF_\ 1T5?QA5_9[_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX
M_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'R!_P7X_Y0V?M"?]D_F_\ 1T5?QA5_9[_P7X_Y0V?M
M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[
M_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!_P7
MX_Y0V?M"?]D_F_\ 1T5?QA5_9[_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &
MFW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB?#W3-#FU3Q%=Z7<V*RWFHG4-UHL%U%'*#"MDI:3&UC/A?N$M].U\X?LK_\
M!/KP=^R9^VO\?OVE/AC9:7IV@_'"V\-7]YHMBK(]OK=E_:B7\WEA BQSK=6L
MN0Q9IFN2RK\I;R'XR_\ !<CP5_PW9)_P38_8<_9YU3XX_%C2X[A_%<5GXEMM
M&T701  9TGOYDES)$2JNJ1,%=UCW&3,:@'W;17Q7^Q/_ ,%LO@G^T_\ M6>)
M_P#@G]\:/AAK7P?^/'A.YFBO/ /B2_@O(-2$48E9K"^APEU^Y(F"E(V:(^8@
M=5<KE?\ !6[_ (+B>"_^"0'B3PM:_&W]ESQ?XCT'QE'<#0/$GAS5K'RI9[<1
M&>!XI9%DC91-&02-K G!.U@ #[IHK\K?C!_P=%>!/#_[)VF?M>_L]_\ !/[X
MJ_$7PFEM;-XU\0JHT_1/"]S.RJMC/J/E3)-<J7B#B-#&C31HT@<E!W'P5_X.
M2OV9OVG/V9=/^*7[+W[._P 2_B-\3[U[J*X^!O@_2!>:SIK6RQF6ZNI4S%!8
MGSH@ETW,K2;$C:1)(T /T:HK\Z?^"/W_  <7? ?_ (*N?&+7?V;[OX'ZY\,O
M'^DZ=-J-GHFK:JE]!J-M#(J3!)A%$R3QEU+0M&/EW$,VQL-_X*B_\'$?PZ_X
M)/?'BS^"'[07[(7CC4!K.EG4O#FO:#K.GR6VHV@E>(N%:0/$X=""C@$94\@Y
MH _1BBORS_::_P"#FRU^!_PI\/?M._#_ /X)L_%;Q?\ !G5C:PWGQ6GN(]-T
MU+J51OBM0\4ANE23?!Y[&&&26-EC=QM9ONW]A;]N3]GW_@HG^S?HO[4/[-?B
M.:^\/ZNSPSVM["(KS3+R/'G6=S&"PCF0D9 +*RLKJS(ZL0#U^BOA[2/^"T=A
M^TG\7_B+\$/^"9?[,.H_'O5/A48XO&6LIXVTWP_HZ7,AF6.WM;BZ9Y;MF>WF
M7S$A\GY,B4AE)P_^"4'_  <$?L\?\%//BQKW[,VI_"C7OA=\5_#T5Q-<^#?$
M%Y'=1W:6\GEW M[E%3?+$WWXGC1MOS+O"N4 /OVBO@W_ (*U?\%U_!/_  2!
M\<>&?#_QT_96\8Z_HOC."Y?PSXE\.ZO8&&Z>V6 W,3122+)$T9N(OO##!LJ3
M@@>*_M?_ /!V=^QY^S+\*_AUXJ\&_!3Q)XW\4^//">G^(K[PG;:K!:)X;M;R
M%9H8;V[VRJ+IHV5Q"B,=A#,4#)N /IG_ (+&_P#!8SX0_P#!'?X/^&?B+\0_
MAEK/C'5?&.LRV&@>'])NDM@XAC62>:6>16$:(KH  K,S2*  -S+[1^PG^V+\
M-OV__P!DKP5^U_\ "33=1LM!\:Z=)<6UCJT:K<6LL-Q+;3POM)4E)X94W X8
M*&'!K\[_ /@M/_P4N_X)_P"J_LB?!GQ]^WQ_P3@\4?$WX3_%S1;#Q1X$U"#6
M[>TN=/NIK"&Z\ES%<17-M,(;D*2C[) &&2!BOJW]EC]O?]B?X6_\$>?#7[>/
MA?X?/\+?@KH/@R2\TWPPMO&TVGVT-U):QVR)&Q62>:=0J_-F228;FRQ- 'U]
M17YOZ5_P7M^,:_L>2?\ !1/Q+_P2K^(8^!]SIMU?:1XG\/>-M)U'4_LT;O''
M<WFF[HWM+9I$(>57F\I?G92N"?LWQ)^V!\&?AG^Q_#^VS\;/$MOX3\%Q^#+3
MQ'JMY>2F46<%Q#'(D0VKNFD+2I&BJNZ1V557+ 4 >IT5^:'A/_@X/^)WQ2_9
M@\4?\% O@]_P3"\:ZU^S_P"$[ZX2_P#&EUXZTZUUBXM+=PES>0:3M?S(H<Y<
M_: !M?GY'V_8W[&/[>O[/W_!0C]F>#]I_P#9(\0-XCTJX2:$Z7=8M;RSU"-
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MG@,7B"(:C(AU.S$3MB&58H\;]K85<CBOW/\ ^"9FF?#K]J_X%_#W]I/XW_\
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MLN>+_$>A>,X[D>'_ !'X<U:Q\J6>W$1GA>*619(V43QD$C:P)P3M8#1^,_\
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M)\4/A_KD6IZ!XCT>VU31-2A5@EW9W$2S0S*& 8!HW5AD X/(%?GS_P $UO\
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MEIGBZ*X;PSXF\*QZ3<6=\]NL!N(]LM_'-$\9N(@?,C4-NRA8 D<I_P $W/\
M@X9^"7[<W[5NO?L&?%WX$:_\'/C+H=_J%C_PBFMZM#J-M>75BT@O+6*ZB5,S
MQ"&5RAC"LD;%7;&*^(_^#Y#_ )$;]F[_ +"WBG_T5I= '[2?LE?M)^#?VQ/V
M:?!/[47P]T;4].T3QUX?@U?2['68XTNX(91E5E$3N@<=]K,/>NO\;Z]KOAGP
MM=Z[X9\$7WB.^MU4V^BZ;<V\,]T2P!"/<R1Q*0"6^=U&%('. ?F;_@AA_P H
M?_V=O^R7:;_Z!7U=0!^5?Q'_ .#LC]DGX2_M%:E^R?X]_8P^.MCX_P!*\3_\
M(_>: ;'0G8:@91$L2R+JAC8,[+M<,4(8,#@YKUW]I#_@O-HG[&'AB#X@_M??
M\$S/VF? OA::X2!_%,OAS0M0L+61VVHL\MGJT@AW'A=W+'  .:_ ;_@IX /^
M#E3Q=@?\W!Z+_P"C[*OZ4/\ @M9K7PMT+_@DM^T/=?&"YLX](E^$VLV]O]N*
MA7U&6U>.P5-W'FF\:W$?^WMH [;]AC_@H5^R3_P4=^$S_&3]DCXK6_B/3+6X
M%MJ]G) ]O?:5<%=PAN;>4!XB1G:V"C@$HS 9KVJOYH?^#*#1/C!-^WC\4/$6
M@17H\#0?"PV_B:4!OLK:@^H6K6"MV\[8E\4[A!+ZU^Y?_!2W_@J?^S!_P2U^
M%6G>/_CY>ZEJ6L^([MK+P9X(\.6ZSZKK]T-NY(8V90J*73?*Q"KO4#<[HC '
MTG17PAJ'_!;*?]GO]I_X=?LQ_P#!1S]DO4O@A/\ %NT5_ 'BD^,[77-+ENMZ
M1M97LL4<1LYE>6%&($L:F:,F0(2X\#_X.BO^"N'[3_["OP+C^ ?[./PE\1:'
M)X^B;3;_ .,MPBQ6EBDD3-)9Z:RMO:\,8;=,0HA4_)ND(:( _4SX9?%+X>?&
M;P?%\0/A9XML]=T2>]O+2#5-/DWPRRVMU+:SA&Z,%FAE3<,JVW*D@@G?K\E_
M^#:O]LGXX2_L#?!']F&W_8$^)3>'(-%UPV_Q?EFLD\/W#)=ZC=* QE,RAY0+
M4$IQ(<GY>:[;X5_\',/P9\>_\%$K'_@FEXJ_9%\?>&/'<_CN7PI?W%]JFGSV
MEE>QNZ,Q>&5O,CRA(9<Y!!% 'Z945^;/_!3?_@Y!^%O_  2K_:1_X9O_ &@O
MV0/'=[=W>CQZQH.LZ)K&G26VIZ?)--"DZAI0\9\R"53&X##;GD%2?K#]L#]M
MB;]E']C6]_;2L_@AK7C'0]'T&/7->TC2-2M;>[LM.,/FR3CSV5)?+!&Y%.XC
M)&<8(![M17Y9_!#_ (.Q?V$OBO\ LV_$W]I#Q-\+?&GA>W^'EUI=E8^'+MK6
MXU'Q+>WT=[)'!9QQ28_=I8S22/(51$^8GC![[_@G[_P7\T+_ (*$_L=?%K]J
MGX8_L?>)H+_X0W&_6?!L?B2TEEOK'[/)<">WN95AC:01PREH2 054!FW"@#]
M#J*_*C]E'_@["_95_:XU[7/ WP[_ &2OBY=>*[/2?M'ACP=HNF0:GJ7B6YW@
M&VMHK=SL")OEDFE*1QQQL2V=JMT__!,W_@Y7^#/[?/[8E]^PM\3OV9/%'P?^
M(0N+ZVT;3?$.II=BZN[-9&N;*<>3"]I=(L4K>6R,#Y3J7#;58 _3"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ^0/\ @OQ_RAL_:$_[)_-_Z.BK^,*O[/?^"_'_
M "AL_:$_[)_-_P"CHJ_C"H _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
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M'=1T>.S\!W=G)KGAJ"YNK>[BADL[J>$W'DRVJQ"2-B&A8L2K_NR ?$'_  7
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M%?VP/@]J6N_#)YYK+QQ\&?&<6&MK>XW+//ILK915E5G;"E[:X#D]7$H^[_\
M@Z>_:'\#>*/^"./[,VE?LG:K<CX2^-]4L;K2CYLA=]/L]*Q8VLY=BY91(2R.
M2WF6X+$LF:])_P""QOP%_;5_X*^?LV>#/V;]=_X(_>(_"WQ[TSQ!:M-\2;_7
M]%D\,Z'9C(NWM]5BNWGGMI@0WV5H0XP#M:2- _TK^U!_P0@\&?'[_@BKX/\
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M'_![C_R>;\&O^R87'_IQFK^@K]D7_DU#X8?]D\T7_P!((:_&'_@Y7_X)??\
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M_9[^%?A'6H-7L_ACH_B:#5?$GBV\@<20?VM>6P-M:6*N$<V<#2/(RXDD  %
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M\8?V0-"M/$?B+X>IJ5EJOA&;48;2>^M+LV[K-;R3ND1:-H&#1LX+"4;<E=K
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M1FUB:ZT2Z\5^*K6UL- GE8>=+%?PW#(]JQ_>M  SEBQ3#.RL ?IW_P $.?\
M@G_\>O\ @F5^PK:_LE_'_P")F@>*;W2?%6HWNB7GAN2X:VM["Y,<H@_?QQL&
M%PURY &/W@.<DX^P:\Y_9;^&_P 8?AK\*(;;]H3XHCQ=XZUB]EU3Q7J=F)(]
M.@NYMN;33X)&)M[*!%2&)3\SB,RR9EED9O1J /G;_@KQ_P HI_VD_P#LA/BS
M_P!-%S7X(_\ !E+_ ,I//B'_ -D&U'_T]:-7[J_\%;K?]H_XC?L2_%#]FO\
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MLS"QN_&O@7Q:NN:?H.H7B6RZQ UM+!+;QS2%8XYOWB.ID94.QE+#<" #K?\
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MX86NFV$>E:]^T'XHOU.L)8HH1I;;3UE<7.IF,$)<,! ) 'D4G*OZ;_P<8_\
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M2@#R#_@]A_Y2.?#+_LB5K_Z>-4K]H_\ @I?_ ,H(/BW_ -FXWO\ Z::_)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'R!_P7X_Y0V?M"?]D_F_\ 1T5?QA5_9[_P7X_Y0V?M"?\ 9/YO_1T5?QA4
M ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!_P7X_Y0V?M"?]D_F_\
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MS\)QRO<QZ=HUQ.L(.[[+%KNGRW!X["%)"?\ 9!H P_&'[>_[</P)_8"\+_\
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M<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\
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MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
M^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU47
MBRSM(?#=Y+#:QHRPDJRH 15RPL+%K&%FLHB3$I),8YXH @_X3'PQ_P!!J#_O
MJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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MUW_V\?\ I\GK]_J "BBB@ HHHH **** /EK_ (*M_P#!/CXE_P#!2?X$:?\
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M%8_B7_D+Z/\ ]?I_]!-;% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!CV7_ ".][_UY1?S-;%8]E_R.][_UY1?S-;% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?('_!?C_E#9^T)_V3^;_T=%7\
M85?V>_\ !?C_ )0V?M"?]D_F_P#1T5?QA4 ?O]_P:;?\I3/VN_\ MX_]/D]?
MO]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !1110 4444 %
M%%% 'E'[<_\ R:/X]_[ +_\ H:UW7PN_Y)GX=_[ 5I_Z)2N%_;G_ .31_'O_
M & 7_P#0UKNOA=_R3/P[_P!@*T_]$I0!NT444 %%%% !1110 4444 %8_B7_
M )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\ 030!L4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %8]E_R.][_ ->47\S6Q6/9?\CO
M>_\ 7E%_,T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6/X'_Y!$O_ %^S?^A5L5C^!_\ D$2_]?LW_H5 &Q1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!F^,?^18O?^N!JYIW_ "#X
M/^N*_P A5/QC_P BQ>_]<#5S3O\ D'P?]<5_D* )J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** ,?Q+_R%]'_Z_3_Z":V*Q_$O_(7T
M?_K]/_H)K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)?\ K]F_]"K8K'\#_P#((E_Z_9O_ $*@#8HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH S?&/_ "+%[_UP-7-._P"0?!_UQ7^0JGXQ
M_P"18O?^N!JYIW_(/@_ZXK_(4 34444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 8_B7_D+Z/_U^G_T$UL5C^)?^0OH__7Z?_036Q0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8]E_R.][
M_P!>47\S6Q6/9?\ ([WO_7E%_,UL4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!\@?\%^/^4-G[0G_ &3^;_T=%7\85?V>_P#!?C_E#9^T)_V3
M^;_T=%7\85 '[_?\&FW_ "E,_:[_ .WC_P!/D]?O]7X _P#!IM_RE,_:[_[>
M/_3Y/7[_ % !1110 4444 %%%% !1110 4444 %%%% 'E'[<_P#R:/X]_P"P
M"_\ Z&M=U\+O^29^'?\ L!6G_HE*X7]N?_DT?Q[_ -@%_P#T-:[KX7?\DS\.
M_P#8"M/_ $2E &[1110 4444 %%%% !1110 5C^)?^0OH_\ U^G_ -!-;%8_
MB7_D+Z/_ -?I_P#030!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8]E_R.][_UY1?S-;%8]E_R.][_ ->47\S0!L4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8_@?_D$2_P#7[-_Z
M%6Q6/X'_ .01+_U^S?\ H5 &Q1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!F^,?\ D6+W_K@:N:=_R#X/^N*_R%4_&/\ R+%[_P!<
M#5S3O^0?!_UQ7^0H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@ HHHH **** "L?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*@#8HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?&/_(L7O_7
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M\I3/VN_^WC_T^3U^_P!0 4444 %%%% !1110 4444 %%%% !1110!Y1^W/\
M\FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_;G_Y-'\>_P#8!?\ ]#6N
MZ^%W_),_#O\ V K3_P!$I0!NT444 %%%% !1110 4444 %8_B7_D+Z/_ -?I
M_P#036Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !6/9?\CO>_]>47\S6Q6/9?\CO>_P#7E%_,T ;%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6/X'_Y!
M$O\ U^S?^A5L5C^!_P#D$2_]?LW_ *%0!L4444 %%%% !1110 4444 %%%%
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MA5_9[_P7X_Y0V?M"?]D_F_\ 1T5?QA4 ?O\ ?\&FW_*4S]KO_MX_]/D]?O\
M5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% !1110 4
M444 >4?MS_\ )H_CW_L O_Z&M=U\+O\ DF?AW_L!6G_HE*X7]N?_ )-'\>_]
M@%__ $-:[KX7?\DS\._]@*T_]$I0!NT444 %%%% !1110 4444 %8_B7_D+Z
M/_U^G_T$UL5C^)?^0OH__7Z?_030!L4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %8]E_R.][_P!>47\S6Q6/9?\ ([WO_7E%_,T
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MKRJ(^3RW_A3XEQ6.?P4$J$/72=9KUE[.#\Z3,>R_Y'>]_P"O*+^9K8K'LO\
MD=[W_KRB_F:V*^5/K HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/D#_ (+\?\H;/VA/^R?S?^CHJ_C"K^SW_@OQ_P H;/VA/^R?S?\ HZ*OXPJ
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MR.][_P!>47\S1_P@^D?\_-[_ .!;5F6OA73I/%-U8-/<[([:-E(N&W9)/4T
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MP7I4MG%*US>9:)2<738Z4 ;M%8__  @^D?\ /S>_^!;4?\(/I'_/S>_^!;4
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MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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MHK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\
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MG_T$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S- &Q1110 4444 %%%% !1110
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M7\S6Q0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'R!_P %^/\
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M% !1110 4444 %8_@?\ Y!$O_7[-_P"A5L5C^!_^01+_ -?LW_H5 &Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!F^,?^18O?^N!
MJYIW_(/@_P"N*_R%4_&/_(L7O_7 U<T[_D'P?]<5_D* )J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q+_R%]'_ .OT_P#H)K8K
M'\2_\A?1_P#K]/\ Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKSS]J[XTP?L]_L[^*_BT77[3I>E.-,1AGS+V0B*W3'<&5TS[9KT.OFO]JO\
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M_P!#6NZ^%W_),_#O_8"M/_1*5PO[<_\ R:/X]_[ +_\ H:UW7PN_Y)GX=_[
M5I_Z)2@#=HHHH **** "BBB@ HHHH *Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]
M'_Z_3_Z": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYF@#8HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_ _P#R")?^OV;_ -"K8K'\
M#_\ ((E_Z_9O_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#-\8_\BQ>_]<#5S3O^0?!_UQ7^0JGXQ_Y%B]_ZX&KFG?\ (/@_
MZXK_ "% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0 4444 %%%% !1110
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M_P!#6NZ^%W_),_#O_8"M/_1*5PO[<_\ R:/X]_[ +_\ H:UW7PN_Y)GX=_[
M5I_Z)2@#=HHHH **** "BBB@ HHHH *Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]
M'_Z_3_Z": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYF@#8HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_ _P#R")?^OV;_ -"K8K'\
M#_\ ((E_Z_9O_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#-\8_\BQ>_]<#5S3O^0?!_UQ7^0JGXQ_Y%B]_ZX&KFG?\ (/@_
MZXK_ "% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0 4444 %%%% !1110
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M_P!#6NZ^%W_),_#O_8"M/_1*5PO[<_\ R:/X]_[ +_\ H:UW7PN_Y)GX=_[
M5I_Z)2@#=HHHH **** "BBB@ HHHH *Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]
M'_Z_3_Z": -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K'LO^1WO?\ KRB_F:V*Q[+_ )'>]_Z\HOYF@#8HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_ _P#R")?^OV;_ -"K8K'\
M#_\ ((E_Z_9O_0J -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#-\8_\BQ>_]<#5S3O^0?!_UQ7^0JGXQ_Y%B]_ZX&KFG?\ (/@_
MZXK_ "% $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% &/XE_Y"^C_ /7Z?_036Q6/XE_Y"^C_ /7Z?_036Q0 4444 %%%% !1110
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MR.][_P!>47\S6Q6/9?\ ([WO_7E%_,T ;%%%% !1110 4444 %%%% !1110
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M[])<OD?)\0_\*&88/*5M.7M:G_7NBU*W_;U5THVZQYO,^BJ***^5/K HHHH
M**** "BBB@#'LO\ D=[W_KRB_F:V*Q[+_D=[W_KRB_F:V* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ^0/^"_'_*&S]H3_LG\W_HZ*OXPJ_L]
M_P""_'_*&S]H3_LG\W_HZ*OXPJ /W^_X--O^4IG[7?\ V\?^GR>OW^K\ ?\
M@TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** /*/VY
M_P#DT?Q[_P!@%_\ T-:[KX7?\DS\._\ 8"M/_1*5PO[<_P#R:/X]_P"P"_\
MZ&M=U\+O^29^'?\ L!6G_HE* -VBBB@ HHHH **** "BBB@ K'\2_P#(7T?_
M *_3_P"@FMBL?Q+_ ,A?1_\ K]/_ *": -BBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K'LO^1WO?^O*+^9K8K'LO^1WO?\ KRB_
MF: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'
M\#_\@B7_ *_9O_0JV*Q_ _\ R")?^OV;_P!"H V**** "BBB@ HHHH ****
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MK8K'LO\ D=[W_KRB_F:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^0/^"_'_*&S]H3_ +)_-_Z.BK^,*O[/?^"_'_*&S]H3_LG\W_HZ*OXP
MJ /W^_X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
MHHHH **** "BBB@ HHHH **** "BBB@#RC]N?_DT?Q[_ -@%_P#T-:[KX7?\
MDS\._P#8"M/_ $2E<+^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I_P"B4H W
M:*** "BBB@ HHHH **** "L?Q+_R%]'_ .OT_P#H)K8K'\2_\A?1_P#K]/\
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M"H _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J
M"BBB@ HHHH **** "BBB@ HHHH **** /*/VY_\ DT?Q[_V 7_\ 0UKNOA=_
MR3/P[_V K3_T2E<+^W/_ ,FC^/?^P"__ *&M=U\+O^29^'?^P%:?^B4H W:*
M** "BBB@ HHHH **** "L?Q+_P A?1_^OT_^@FMBL?Q+_P A?1_^OT_^@F@#
M8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q[+_D
M=[W_ *\HOYFMBL>R_P"1WO?^O*+^9H V**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "L?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV
M;_T*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% &/9?\ ([WO_7E%_,UL5CV7_([WO_7E%_,UL4 %%%%
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;XQ_Y%B]_ZX&KFG?\
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M *&M=U\+O^29^'?^P%:?^B4KA?VY_P#DT?Q[_P!@%_\ T-:[KX7?\DS\._\
M8"M/_1*4 ;M%%% !1110 4444 %%%% !6/XE_P"0OH__ %^G_P!!-;%8_B7_
M )"^C_\ 7Z?_ $$T ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6/9?\CO>_P#7E%_,UL5CV7_([WO_ %Y1?S- &Q1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^!_^01+_P!?LW_H
M5;%8_@?_ )!$O_7[-_Z%0!L4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 9OC'_D6+W_K@:N:=_P @^#_KBO\ (53\8_\ (L7O_7 U
M<T[_ )!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH
M**** "O!_P#@HKX^USP[^SU)\,O!$O\ Q4OQ)U:W\*:"BGG==MLF<XY"B$2
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M^W/_ ,FC^/?^P"__ *&M=U\+O^29^'?^P%:?^B4KA?VY_P#DT?Q[_P!@%_\
MT-:[KX7?\DS\._\ 8"M/_1*4 ;M%%% !1110 4444 %%%% !6/XE_P"0OH__
M %^G_P!!-;%8_B7_ )"^C_\ 7Z?_ $$T ;%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !6/9?\CO>_P#7E%_,UL5CV7_([WO_ %Y1
M?S- &Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MC^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%0!L4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 9OC'_D6+W_K@:N:=_P @^#_KBO\
M(53\8_\ (L7O_7 U<T[_ )!\'_7%?Y"@":BBB@ HHHH **** "BBB@ HHHH
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MIEC20LJO@;@ <#- '0US/Q,^,OPN^#=C:ZG\4/&MEHEO>S&*UEO7($C@9*C
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\
M"8^&/^@U!_WU5S^SM/\ ^?&'_OT*\^_:K^*^C_L]_L\^*_BY):6_VC2M*?\
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M*+^9K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y _X+\?\
M*&S]H3_LG\W_ *.BK^,*O[/?^"_'_*&S]H3_ +)_-_Z.BK^,*@#]_O\ @TV_
MY2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BB
MB@ HHHH **** "BBB@#RC]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I
M7"_MS_\ )H_CW_L O_Z&M=U\+O\ DF?AW_L!6G_HE* -VBBB@ HHHH ****
M"BBB@ K'\2_\A?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z": -BBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K'LO\ D=[W_KRB_F:V*Q[+
M_D=[W_KRB_F: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ K'\#_P#((E_Z_9O_ $*MBL?P/_R")?\ K]F_]"H V**** "BBB@
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M@ HHHH *Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYF@#8HHHH **** "BBB@
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MLCRQ9/E%'!WYG"*YI?S2>LY/SE)N3\V%%%%>6>J%%%% !1110 4444 %%%%
M!1110 4444 8]E_R.][_ ->47\S6Q6/9?\CO>_\ 7E%_,UL4 %%%% !1110
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M^G_T$UL5C^)?^0OH_P#U^G_T$T ;%%%% !1110 4444 %%%% !1110 4444
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M+_D=[W_KRB_F:V*Q[+_D=[W_ *\HOYF@#8HHHH **** "BBB@ HHHH ****
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M_P!<#5S3O^0?!_UQ7^0JGXQ_Y%B]_P"N!JYIW_(/@_ZXK_(4 34444 %%%%
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M#A*>&HJT(148KLHJR7R2"BBBN<Z HHHH **** "BBB@ HHHH **** "BBB@
MHHHH Q[+_D=[W_KRB_F:V*Q[+_D=[W_KRB_F:V* "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ^0/\ @OQ_RAL_:$_[)_-_Z.BK^,*O[/?^"_'_
M "AL_:$_[)_-_P"CHJ_C"H _?[_@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
ME*9^UW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** /*/VY_\
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M+<=^[L?CM\0_B#XO^*WC?4_B+X]UN74=8U>[:XOKN8\NY[ =%4#"JHX50 ,
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M;%8_@?\ Y!$O_7[-_P"A4 ;%%%% !1110 4444 %%%% !1110 4444 %%%%
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M+U[Q+H-SJ>F30:I$RPW1:5@?NC;U-=!_9VG_ //C#_WZ%9'B.RLTU7252TB
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M*!/]=?\ @#Q6MO@?WE@O5\Q_]T'-'^K,:_\ N6-H5?+G]D_NKJDK^C?E</\
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M,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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M_P "_LUZ;XE\;V<<GB7QQ=S^*/$<TD0#-<WK>:H(/*E8O*4KV(:O;O[.T_\
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M-&#+%<?%+Q1(F1TRK:F0?H17W?9V=IIUI%I]A:QP001K'!#"@5(T48"J!P
M  !4E% !1110!Y1^W/\ \FC^/?\ L O_ .AK7=?"[_DF?AW_ + 5I_Z)2N%_
M;G_Y-'\>_P#8!?\ ]#6NZ^%W_),_#O\ V K3_P!$I0!NT444 %%%% !1110
M4444 %8_B7_D+Z/_ -?I_P#036Q6/XE_Y"^C_P#7Z?\ T$T ;%%%% !1110
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MZ31]#45X_I'[?_[%NMX%E^TKX43/3[9J0M__ $;MKJM'_:6_9R\0X_L#X_\
M@F^W?=%IXJLY,]OX9#7G5\ASS#?QL+4CZPDOS1Z=#/\ (L5_!Q=.7I4B_P F
M=M15+2?$OAS7UWZ%X@LKT$9!M+M)!C_@)-7:\R4)0E:2LSU(3A./-%W7D%%%
M%24%%%% !1110 4444 %%%% !117(?&WX\?"C]G;P3+\0?B_XPM](TZ-MD1D
M!:6XD(R(XHU!:1SCHH. "3@ D;X;#8C&8B-"A!SG)V48IMM]DEJV88G%8;!8
M>5?$34(15W*3227=MZ)&[XQ_Y%B]_P"N!JYIW_(/@_ZXK_(5\ ?$C_@NO\/9
MWN=%\"?L_:QJ%E*"BWNJ:Y%9R8]?*2.8?AOKU_\ 9:_X*P_LV_M ZO9> -8%
M[X/U^YV0V=KK;(;:[D/ CBN%.-QZ .$R2 NXG%?9X[PSX[RW O&8C S5-*[:
M<9-+NXQDY)+K=:=3XC >*/ .9X]8/#X^#J-V2:E%-]E*45%M]+/7H?4U%%%?
M"GWP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117C?[5'[=G[/
MW[(MI'!\2O$$UUK-S%YEGX<T>)9KR5,X#L"RK$F?XG9<X.W<017=EV69AF^,
MCA<%2E4J2VC%7?\ PRZMZ+J<&9YIEV38.6+QU6-.G'>4G9?\.^B6KZ'IGB7_
M )"^C_\ 7Z?_ $$UX+^WO++\6_%7PW_8TTR1F7QUXD74/%*1M]W1+ B>96_N
M^8X0*3U9".:^?M3_ ."[/A;4?$5G(/V;M02PM+G?Y_\ PDR&9EQC_5_9]H./
M]NO2?V$_V@/AS^U[^U]X_P#V@UU9;2_M_#UCHG@[PUJ4B+>V^FK^]NIMH)5@
MUQCE"=H.&QN&?TC!<"\5\'NIG69X5PC0@YP=XR_>.T*?P2E;EE)5-;:09^9X
MWC[A'C-4\DRO%JI+$3C":M*/[M7G4^.,;\\8NGI?6:/LB**."-888U1$4*B*
M,!0.@ [4ZBBORG<_6]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#'LO\ D=[W_KRB_F:V*Q[+_D=[W_KRB_F:V* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ^0/^"_'_*&S]H3_LG\W_HZ*OXPJ_L]_P""
M_'_*&S]H3_LG\W_HZ*OXPJ /W^_X--O^4IG[7?\ V\?^GR>OW^K\ ?\ @TV_
MY2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** /*/VY_P#D
MT?Q[_P!@%_\ T-:[KX7?\DS\._\ 8"M/_1*5PO[<_P#R:/X]_P"P"_\ Z&M=
MU\+O^29^'?\ L!6G_HE* -VBBB@ HHHH **** "BBB@ K'\2_P#(7T?_ *_3
M_P"@FMBL?Q+_ ,A?1_\ K]/_ *": -BBBB@ HHHH ***;//#;0O<W,RQQQJ6
MDD=@%50,DDGH!0DVP;20ZBO _B#_ ,%"OA)IOB*7X=? K0M6^*GBQ.#H_@F#
MSX(#G&9[OF&),@@L"^W'(%8?_"E?VW?VE_W_ .T%\7HOACX:G^]X,^',^_4)
M8S_!<:BV=K=01$"C ]!7T]+A;%TJ:K9E..%IO5>TOSR7]VDDZCOT;2AWDCY:
MMQ7@ZM5T,LA+%5%H_9VY(O\ OU6U35NL5)S[09Z#\</VU?V>O@'?#PWXK\9'
M4O$4K;+7PGX<@-]J<\AZ((8\[">WF% ?6O/O[>_X*!?M.?+X9T&Q^!_A2?\
MYB&LQKJ'B&XC/=+?B.V)&00^'4X()KU?X'?LL? 3]G.Q-M\)?AQ8Z=<R+BZU
M613->W.>29+B0F1LGG;G:"> *]!K3^U<CRK3+</[2:_Y>UTI?.-%7IQ_[?=7
MY&?]DY]FVN9XGV4'_P NJ#<?E*L[5)?]PU2^9XO\'_V#/@%\*M>_X3W6-,O?
M&GB]V#W'B_QO=G4;UI!_$GF?)%@YP44,!QN->T445X>89IF.:U_;8RK*I+9<
MSO9=DMDET2LET1[N795EN44/8X*E&G'=\JM=]V]VWU;NWU84445P'H!1110
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MC_N31!A^1J:BOCDW%W1]HTI*S.4UCX#_  .\0Y_M_P"#/A2^SU^V>';:7/\
MWTAKE=8_8:_8YUS/VW]F7P2F[J;3P]!;_P#HI5KU6BO1H9SG&&_@XFI'TG)?
MDSS:^29-BOXV&IR]81?YH\!U;_@EU^P?K#>9/^S_ &D+YRKV6L7UN5/J/+G4
M52_X=>_LU6'_ "*6L^.] Q]S^Q_'-XFWZ;W:OHNBO3CQGQ;&/+]?K-=G4E)?
M<VT>5/@G@^<N;^SZ*?=4X1?WI)GSI_P[SFTWGPG^VO\ ';3L?=A?QYY\*_\
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M=_AYGO&&-X*P56>$C5?);GE6Y9246XIM>SEJTEK=WWZGT717SI_P[/\ @_\
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M+'_X.I_YGT717SI_PP=\0?\ H_GXT?\ A01?_&J/^&#OB#_T?S\:/_"@B_\
MC5']D</?]#*/_@JK_P#(A_;/$7_0LE_X-I?_ "1]%T5\Z?\ #"GQ-@^:R_;\
M^,*L>"9]8AE&/H8^#[T?\,._&#_I(%\5_P#P+M__ (BC^Q\@_P"AG#_P55_^
M0'_;7$/7*Y_^#:/_ ,FCUK]H/XN:?\!O@EXG^,&I0+,F@:/-=16[M@3S 8BB
M)[;Y"BY[;J_!WXA_$'Q?\5O&^I_$7Q[K<NHZQJ]VUQ?7<QY=SV Z*H&%51PJ
M@ 8 %?IU^V=^Q-\8;#]EWQIJY_:_^(GBM-.T@WLWA_6+B%K:[C@=)G#A4!.U
M49QCN@K\K*_I?P)RC)L'EF+Q6&K1K5'-1<E&4;144U&TDGJVV[:.R[:?R]X^
MYSG>,S3"83%4)4:48.2BY1ES2<FG*\&UHDDKZJ[Z/4K9^'GQ!\7_  I\;Z9\
M1? 6MRZ=K&D7:W%C=PGE''8CHRD95E/#*2#D$UC45^[U:5.O2E3J13C)--/5
M-/1IKJF?@-*K5H58U:<G&46FFM&FM4T^C3V/W[_9]^+FG_'GX)>&/C!IL"PI
MK^CPW4MNC9$$Q&)8@>^R0.N>^VNQKP__ ()M^$=8\$?L/?#O0]<B=+B31Y+T
M(_41W-Q+<Q_3Y)5X[5[A7^<.?X7"X+/L7A\,[TX5:D8_X8R:C^"1_IAP]BL5
MCL@PF)Q*M4G2IRE_BE!.7XMA1117D'L!1110 4444 %%%% !1110 4444 %%
M%% !1110!Q_Q8^/GPE^!WV#_ (6CXL_LO^U/-^P_Z!//YOE[-_\ J8VVX\Q.
MN,YXS@UQW_#?/[)G_15__*%?_P#QBO'O^"L'_,@_]Q7_ -LZ^0K*TFO[N.S@
M&7D<*/;WK^7O$7QLXJX1XRQ64X.C1E3I<EG.,W+WJ<)N[52*WD[62TMZGR>.
MSK,J6:O!X:"DVXJ*LVVY)66C6[=D?H9:_MT_LKQ^*;K4G^*6(9+9$1_[$ON2
M"<C'D9K2_P"&^?V3/^BK_P#E"O\ _P",5^?_ (S\.PV%I!>64>$C012X'7T8
M_P"?2N<KXA?21XX:_P!WPW_@%7_Y<=O%-;B'A+.)Y=C(0YDDTTI6:DKW7O;7
MNO5,_82BBBO[8/?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y _X+\?
M\H;/VA/^R?S?^CHJ_C"K^SW_ (+\?\H;/VA/^R?S?^CHJ_C"H _?[_@TV_Y2
MF?M=_P#;Q_Z?)Z_?ZOP!_P"#3;_E*9^UW_V\?^GR>OW^H **** "BBB@ HHH
MH **** "BBB@ HHHH \H_;G_ .31_'O_ & 7_P#0UKNOA=_R3/P[_P!@*T_]
M$I7"_MS_ /)H_CW_ + +_P#H:UW7PN_Y)GX=_P"P%:?^B4H W:*** "BBB@
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MS-;%8]E_R.][_P!>47\S0!L4444 %%%% !1110 4444 %%%% !1110 4444
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M%^/^4-G[0G_9/YO_ $=%7\85?V>_\%^/^4-G[0G_ &3^;_T=%7\85 '[_?\
M!IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0 4444 %%%
M% !1110 4444 %%%% !1110!Y1^W/_R:/X]_[ +_ /H:UW7PN_Y)GX=_[ 5I
M_P"B4KA?VY_^31_'O_8!?_T-:[KX7?\ ),_#O_8"M/\ T2E &[1110 4444
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M *\HOYFMBL>R_P"1WO?^O*+^9H V**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "L?P/\ \@B7_K]F_P#0JV*Q_ __ "")?^OV;_T*
M@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S?&/
M_(L7O_7 U<T[_D'P?]<5_D*I^,?^18O?^N!JYIW_ "#X/^N*_P A0!-1110
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M_P"$9_L7 \S9NW_]-.N?Z?2N&D1XG:.12&4D,#V-?CB\</$]_P#,?_Y2H?\
MRL]WC;)>*>"XX1XBK=5J:D_=C[LU\<-OLW6O6_D?JG\ _BQ_PO'X2Z3\4?[
M_LO^U//_ -!^U>?Y7ESR0_?V+NSY>?NC&<<XS785\L?LD_M6_!+X9_LZ>&_
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MS+U@_>C\TCFQ669A@XJ=:DU%[.WNOTDM'\F:%%%%>Z<(4444 %%%% !1110
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MV?[/&O:ECI]DT9DS_P!_S'7>V7P"^"6GX^S_  IT$XZ&;3(Y/_0P:U[+X?\
M@+3<?V=X(TBWQT\G38DQ^2UR5<-XGXG18G"4E_=I5:C^^52*_P#)2'')%UJO
M_P  C^?.>"ZE_P %%M&DD,?A7X+:Y>MCY1=WUO 3]0ADQ5"?]L[]HO7X]_@_
M]GVUMRWW$NS>W9_\A0H#7T[#;P6R>7;P)&O]U% 'Z4^N&?"?B%B7^^X@:3Z4
M\-3C^+E*7XF3>2K:G5?K5A_[;1B_Q/B/X^?$W]K'X@?"'5]/^*?A9-#T*4P&
M^:+PO/!" +B-DS--(67YPF,#DX'>O /"OAJP%Z-2CU1+D0'A4C( ;MR>N/\
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M6'_QBOMK]D7Q]XM^*'[//A[QSXYU;[=JM]]K^U77D1Q;]EW-&ORQJJC"HHX
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M$W/BSXG>,M0C'WWU7Q.^W\2 M<[J/@']A/PA(TOB+7_#0G'WA?\ BII9#_P
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MFO?=@^&V@1-_?:\NIU_+Y#2_MG/\5_#Q->?_ %ZP,Z:^3Q#<?G=H/[;R*/\
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M\G0]#L[),8VVELD8Q]% JY117OPIPI1Y8))=EH=*22L@HHHJQA1110 4444
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MBB@#'LO^1WO?^O*+^9K8K'LO^1WO?^O*+^9K8H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Y _P""_'_*&S]H3_LG\W_HZ*OXPJ_L]_X+\?\
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M^&J/!;_\>O@?QC/G[OD^&Y#N^F2*/^&G=,DYM?@U\0Y\_=\KPNQW?3+BLO\
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MJFYC^$_AN'/ \W7F;'O\HZ4?VQ^UQ+S'X-\$Q>TNHW#9_(5E_P#"COVGHO\
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MM;[[-=CXTUC_ ()8?V3I<^I?\+V\SR4W;/\ A&,9_'[54UO_ ,$I?M%O'/\
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M=[W_ *\HOYFMBL>R_P"1WO?^O*+^9K8H **** "BBB@ HHHH **** "BBB@
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MT?\ #V[_ ()T?]'2:+_X 7G_ ,9KU/\ X9?_ &:?^C>/ O\ X25G_P#&J/\
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M"J % N.@_*@?M6?LZ&0Q#XNZ/D#))F./SQBOT\_X9?\ V:?^C>/ O_A)6?\
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MZ^^/^'MW_!.C_HZ31?\ P O/_C-=7_PP-^R9_P!$H_\ *[?_ /Q^NH_X9?\
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M_P#AE_\ 9I_Z-X\"_P#A)6?_ ,:H_P"&7_V:?^C>/ O_ (25G_\ &J /+/\
MA[=_P3H_Z.DT7_P O/\ XS1_P]N_X)T?]'2:+_X 7G_QFO4_^&7_ -FG_HWC
MP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\ QJ@#RS_A[=_P3H_Z.DT7_P
M+S_XS1_P]N_X)T?]'2:+_P" %Y_\9KU/_AE_]FG_ *-X\"_^$E9__&J/^&7_
M -FG_HWCP+_X25G_ /&J /+/^'MW_!.C_HZ31?\ P O/_C-'_#V[_@G1_P!'
M2:+_ . %Y_\ &:]3_P"&7_V:?^C>/ O_ (25G_\ &J/^&7_V:?\ HWCP+_X2
M5G_\:H \L_X>W?\ !.C_ *.DT7_P O/_ (S1_P /;O\ @G1_T=)HO_@!>?\
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M+_X 7G_QFO4_^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\
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M_@G1_P!'2:+_ . %Y_\ &:]3_P"&7_V:?^C>/ O_ (25G_\ &J/^&7_V:?\
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MZ31?_ "\_P#C-'_#V[_@G1_T=)HO_@!>?_&:]3_X9?\ V:?^C>/ O_A)6?\
M\:H_X9?_ &:?^C>/ O\ X25G_P#&J /+/^'MW_!.C_HZ31?_   O/_C-'_#V
M[_@G1_T=)HO_ ( 7G_QFO4_^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/
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M\712OINK6Q@O%@E*.4)!X8=#Q6EHVE6F@Z/::'IZL(+*VC@@#MDA$4*N3W.
M*\Y_9>_;2_90_;5\,7WC']E+X_\ AGQYI^EW*V^J2>']265[*1@2BS1\/%N
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M)'(K(^*O[:W[)_P/\:-\/?BS\??#>A:Q!;PW&H65[?@'38)GV0SWC#*V44C
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M[<G% 'J>F?"GPCI'Q1U3XP6<,XUK5]-@L;UVG)C,,1)0!.QR>O>NDID\\%K
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M^'GQZ\*:?J>O>)(9_$/Q%T[4K1+B";7=3NGU*_1DD!#I'=W$B)N'RI%& !M
M'RI_P;0Z)I'AK]C[XN>'- TZ&SL-/_:@\:VUE:6T82."&.:W5$51PJJH  '
M K]!_$GB;PWX-T.Y\3^+_$%CI6FV4?F7FHZE=I!! F<;GD<A5&2.217YP?\
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MW[57QYT;P)/X]NKFV\+77B%98;.YDMQ$9A)=[#!;!1-'S/)&#NX)P< 'Q/\
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MAEG?P'8V E;Q3>7#<BRTN.S=+RYDE(QY$9*MU8!06 !\]?L:>+9/AC_P<?\
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M1^,?B/QUX5N[/X=>!M!E6?7F\0-&RZ?.+"4+=67DW+12R3S1QI#$'>1ECR2
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MT2(RGGEBH&X\GKZU>HH **** (=/T[3])LHM-TJQAMK:! D-O;Q!$C4=E48
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M /%T ??5%? O_"^O^"Q?_1&/_+=A_P#BZ/\ A?7_  6+_P"B,?\ ENP__%T
M??5%? O_  OK_@L7_P!$8_\ +=A_^+H_X7U_P6+_ .B,?^6[#_\ %T ??5%?
M O\ POK_ (+%_P#1&/\ RW8?_BZ/^%]?\%B_^B,?^6[#_P#%T ??5%? O_"^
MO^"Q?_1&/_+=A_\ BZ/^%]?\%B_^B,?^6[#_ /%T ??5%? O_"^O^"Q?_1&/
M_+=A_P#BZ/\ A?7_  6+_P"B,?\ ENP__%T ??5%? O_  OK_@L7_P!$8_\
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MA_\ BZ/^%]?\%B_^B,?^6[#_ /%T ??5%? O_"^O^"Q?_1&/_+=A_P#BZ/\
MA?7_  6+_P"B,?\ ENP__%T ??5%? O_  OK_@L7_P!$8_\ +=A_^+H_X7U_
MP6+_ .B,?^6[#_\ %T ??5%? O\ POK_ (+%_P#1&/\ RW8?_BZ/^%]?\%B_
M^B,?^6[#_P#%T ??5%? O_"^O^"Q?_1&/_+=A_\ BZ/^%]?\%B_^B,?^6[#_
M /%T ??5%? O_"^O^"Q?_1&/_+=A_P#BZ/\ A?7_  6+_P"B,?\ ENP__%T
M??5%? O_  OK_@L7_P!$8_\ +=A_^+H_X7U_P6+_ .B,?^6[#_\ %T ??5%?
M O\ POK_ (+%_P#1&/\ RW8?_BZ/^%]?\%B_^B,?^6[#_P#%T ??5%? O_"^
MO^"Q?_1&/_+=A_\ BZ/^%]?\%B_^B,?^6[#_ /%T ??5%? O_"^O^"Q?_1&/
M_+=A_P#BZ/\ A?7_  6+_P"B,?\ ENP__%T ??5%? O_  OK_@L7_P!$8_\
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MA_\ BZ/^%]?\%B_^B,?^6[#_ /%T ??5%? O_"^O^"Q?_1&/_+=A_P#BZ/\
MA?7_  6+_P"B,?\ ENP__%T ??5%? O_  OK_@L7_P!$8_\ +=A_^+H_X7U_
MP6+_ .B,?^6[#_\ %T ??5%? O\ POK_ (+%_P#1&/\ RW8?_BZ/^%]?\%B_
M^B,?^6[#_P#%T ??5%? O_"^O^"Q?_1&/_+=A_\ BZ/^%]?\%B_^B,?^6[#_
M /%T ??5%? O_"^O^"Q?_1&/_+=A_P#BZ/\ A?7_  6+_P"B,?\ ENP__%T
M??5%? O_  OK_@L7_P!$8_\ +=A_^+H_X7U_P6+_ .B,?^6[#_\ %T ??5%?
M O\ POK_ (+%_P#1&/\ RW8?_BZ/^%]?\%B_^B,?^6[#_P#%T ??5%? O_"^
MO^"Q?_1&/_+=A_\ BZ/^%]?\%B_^B,?^6[#_ /%T ??5%? O_"^O^"Q?_1&/
M_+=A_P#BZ/\ A?7_  6+_P"B,?\ ENP__%T ??5%? O_  OK_@L7_P!$8_\
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M; AA]T =!BNH_P"#6]U;_@A5\#E5@2K>)@P!Z'_A)M5/]: /T HHHH ****
M"BN5^*GP_P#$_P 0-/M+/PQ\4=5\+R6\S/+<:5&C-.",;6WCH.M<3_PS;\6?
M^CNO&/\ X#V_^%>!C\TS?"XETZ& G5BK>\ITDG\ISC+3;5'-4K5X3M&DY+O>
M/ZL]@HKQ_P#X9M^+/_1W7C'_ ,![?_"C_AFWXL_]'=>,?_ >W_PKC_MSB#_H
M55/_  90_P#EIG]9Q7_/E_?'_,^!OCM_R6_QE_V->H_^E,E<I70?%G3[K2?B
MIXFTJ^U26^FMO$%[%->S@![AEG<&1L<;F(R<=S7/U_G'F\I2S;$.2LW.>G;W
MGIIH?E-?6M+U?YA7WS_P3#_Y-ZO_ /L:[G_T1;U\#5]=_L)?"'QSX[^#=YK/
MAOX[Z_X9MT\03Q-I^EQ1-&S"&$F0[QG<0P'_  $5^G^!V)Q6$XZC4P]!UI>S
MG[L7&+Z:WFXK3UN>QP[.<,RO&/,[/33];'V317C_ /PS;\6?^CNO&/\ X#V_
M^%'_  S;\6?^CNO&/_@/;_X5_9O]N<0?]"JI_P"#*'_RT^^^LXK_ )\O[X_Y
MGL%17]C:ZG8S:;?1;X;B)HIDW$;E88(R.1P>U<=\*_A;XR^'^H7=YXG^-&M^
M*([B%4BM]5BC58"#DLNP=3TKMJ]_ 8C$XK#*I7HNE)W]UN,FOG!RCKOHSII2
MG.%Y1Y7VT_0_([]AW]GKPE\</^"U7[:GP$^)OC_XFWWA#X>OX8E\$Z%:?&+Q
M'8PZ,U_9-/<^1]EOXRH+X*@D^7@!-HKM?^"-_P"T5^T1IG_!3W]JK_@G-K7Q
MS\2_%CX4_":ZM+KP?XS\7ZJ^IZCHUS.4\S2)K]\R7)4O/&/-9G5K"3&,L*\?
M^%7[(D?[9G_!9+_@H_\ "W2_C;X\^'VO3Z)X1@\.^*O GC?4])DL+J722%EG
MAL[B*.^C#*H,4X<;6<+L+EJ^@/\ @WJ^,/@SP+\,?%W_  35^)WP7\-?#;X]
M_!/4S;?$?1]$L([;_A+H3M%OXE1@H:[^T1F+S)CN.YHV^1)HD'8:'V5\-/VT
M/V;?B_\ $KQG\&?A]\0)[WQ?\/;6&Y\9>%Y?#]_;ZAID4REX6>WF@21O,4;D
M"*Q<%2H(899\)/VW_P!E/XX^!_&GQ(^''QGTVYT3X<:G>:=X]O\ 4(9M/7P_
M=6D?FW45V+M(F@:).7W@;,'."#CY'_8X9(/^#BO]LB"5@DEQ\-/ ,L*,<&1%
ML=K,!W ) )]37BW["_PW^#/[2_P#_P""E'P9^*7Q0'A_PGXY_:I\6:/=>*M/
M<2BQ^V?9H(+@;?E9!,\9.2$*@[F5<L #]%O /[>/[,GQ)^)>@_![0/%6OVGB
M3Q397%YX9TSQ'X UK2&U:V@C\R:>V>_LX4FB1"I,B,5^>,9RZ YWQ'_X*._L
M>_">;6W\<?$O4H-/\-ZN=*U[Q%9^"=8O-'L=0#B-K.34K>T>T6X$K+$8?-\Q
M96$94.0M?&G[//[1/_!0+]D?]MWX-?L-_P#!63X=^&/B3;^(;S4;/X'?M'^#
M"\$\U[#I\HEMM4M3C;-);,RL0H0L5;]^4::/R_XW']L?_@EG\+OB-\;_ (;6
MWAO]IS]A[QMXGUK7/&7@N[=['Q+X-@U'4)3J7V6;Y?/ACN992=V9%<,2L!#S
MT ?JG\9_VC_A!\ 5T^#XD>(+T:AK'G'1] T#0+W6-5U!85#3/;Z?I\,]U.D8
M9"[)$RIO7<1N&?.+C]H#]F'_ (*"?L>>/M9^!/Q>FU[0H],U+3-7FT#5+_1]
M2TN^@B8O;7"J8+RRF4A=T4@C8J<,I5L'Y!A^.<'Q!_X+\ZQX#U_]I_Q5\-$^
M('[-OAN\^#%UIEGHX.M69NKFXNK5!JMA= 3/)(9#'$$=A:G=N\I ON_P1_8R
M_9L_90^)O[2_B;X8?&+QAXI^(?Q#\,6VN_%0>(;RR:".=H=06TG$-C:6\-O-
M*!<%E5064*Q W*6 /DC]DW01XU_X,^KG6-6U_6X+[2_@EXWUNTO]+U^[LIS>
MV]UK$\;R26\B-,OF %HY"R/_ !*<"OOK_@DD2?\ @E;^S62<D_ 7PCDG_L#6
MM?"?[#Q'_$'7K7/_ #;C\0O_ $9K-?=?_!)'_E%9^S7_ -D%\(?^F:UH W?V
ML?V-=)_;+-CX,^*WQ9\8:9X#M+9VO?"G@GQ%<Z+)K%XS?+)>7EI(D[PQJ!LM
MT9$+NSR>9MC"?.7_  1(^%?Q]^!OBG]HKX-ZW\7_ !3XX^"?A?XI+IOP.U_Q
MGJ[W]Z8HX#_:EM'<2?-+;6]T4ME8?)YUO<XPV\5]M?$?X>>%?BQX)U'X=^.+
M6ZGTG58#!?P6>IW%F\L9(RGFV\B2*#C! 89!(.02*_.C_@EY^Q\__!/[_@J]
M^T#^QC^SAXFUJ;X 7/PTT3Q9#X9OM5EO(O"FO7US/"+.*25F96E@M[B8Y)=H
M_(WE]BL0"S_P3::W_P""SWPV^,7[:?QN\:^*8=/USXC:OX9^"4&@^)KRP7P=
MH5BD<=M?V2V\J*FH2S/)-+<G<Y*(@(C797D=U_P6Y_:.'_!!Z+XM)K%H/VA)
MOBG_ ,*1&O+:H8AXE\\H=3$6-OF?81]HV[=GGG[NSY:]@_X-A=!N?@5_P3I\
M7?LT?$-X]/\ $/P<^,_BCP[XNAN2(_L\T4L<_FMNZ1M'*K*_W2HR"0*_.6R^
M 7CZU_X((Z1^W!=^'[P:"G[>2_&BYB>!MX\.-*-)-QY>-VWS%63./]62_P!T
MYH _1O\ X*+K:_\ !&CP!\&?VR?@KXT\3SV&D_$G2?"_QL3Q#XGO-0_X3#0]
M022.XU"\%Q*X?4(ITCGBN!M92\D>?*8I73>,_B_J?[<W_!:WQ!_P3\U[6M1B
M^%/P+^%EMXA\:>'M-U*:U3Q)XCU%[=K.&]:%E:6T@LYO-6 G8\QW.KA$"\M_
MP<\^%[WX^?L%?#W]E[P XOM>^,/QU\,^'O#D-HP=IC(9YVG&W_EFD<1=I/NJ
MN"2!3_V6O!>H_!/_ (.8OVE[7Q7 T$?QB^"_AOQ3X0GE'RW5OIZVNF72(QX9
MTF4DJ.0I4XQ@T =S^P+\??%?PF_X*<_'[_@E/XF\3ZCK'AOPGHFE^._A'/K.
MH2W=WIVC7L<*7NF-/,S2206]Y,H@WLS)'(8]VU$5?IO]M'P+H/Q _99\>:3K
MTE_$+;PGJ5W9W6EZK<65S:W$=G,8YHIK=TD1U)R"&'-?%G[*_@S5_B5_P<R?
MM+_M :'"\F@?#_X(^'_ M_?)_JGU.]-CJ7DJW1GCCMCO Y0LH."17W7^TV0/
MV;?B$2< >!]6R?\ MSEH ^"/^#?OXW?##X1?\$0? 7[;'[6WQ[N+:[UPZ]-X
MN\=?$/QE<W)D%OKFH6T,8>[E?&(;:-5BC&6*D@%F.?H[4O\ @M%_P2_T>X\#
MVVJ?M>:#;_\ "Q(K*3PO-+I]\(G6\4-:_:I/(V:>94(=%NS"64A@-IS7QU_P
M2.BAN/\ @T<FMYXU='^#/Q/5T89!!U'7\@UYW^T_X-\(Z;_P9>:9%IOAFPME
M;X5^$-186]HB9O'UK36>X.T#]XS,Q9^IW').30!^O7QK^/OPA_9V\,6WB[XP
M^-(=(M;_ %*'3=*@6WEN;O4[Z7/E6EI:P(\]W</ABL,*/(0K$+@$C\WOA-\6
M/A#\6/\ @YZLM9^#GBWQ3<Q+^RSJ1\2Z'XKBUBTN-*U4ZU$64Z?JRI-8;[?[
M*PC6*.-D*.JD-N.Q\7/B]=Q?\'#_ .RIX ^,6J;/#$G[-^JWOP^DU!\0R^*[
MIIH[LH6X,YL;>-!_%B; Y?!Z?QC8Z99_\'37@^^@M88KB\_8PO/M$B* TQ7Q
M'(%W?WB%&,GL,=J /J+X[?\ !1[]CC]FR]U6W^+_ ,5+RRM_#UU%:^*-8TWP
MCJNIZ;X?GE56CBU*^LK6:VTYRKQMMN9(CMD0]'4E_P >_P#@HU^Q9^S%IGA;
M7OC?\<[/1M+\<10/X.UJ/2[R[L-:\X;HDMKJVADAFD=<.L:N7*LK ;64GX&_
MX(J>$[/]O3_@G3XY^ /Q;_;,\>Z7XFB\7>,]"^/7PXL;7PV&@N=0U2_DN6E:
M[TB6]VSPW!_?/,2'65$9?*"I[-\:OV1OV";K_@B5%^Q9H][XD\;?#V:UF\/?
M":>:ZBN]<U'6OM]PNFMITQ6-)&%R,PS +#]E0N[?9_,>@#Z\MOVJO@;=_M )
M^RU!XIOCX]?0(M<;P^?#E^&CTV3>$NY)3!Y4<1>-XM[N!YJ-%_K 4KT2OSK_
M ."#?Q;\5:=>?%3]C[]LR6Y/[57P_P!7MHOBAK&K7PN)O%>C1PK#I&IV<A1"
M]BML40*JC;)(TT@$MVY;]%* "BBB@ HHHH **\WO?@G\0KJ]FNH?VBO$D*22
MLR0I##MC!.0HXZ#I4?\ PHOXC_\ 1R?B?_OQ#_A7RDL\S]2:655'_P!Q*'_R
MT]E9?EK6N,C_ . 5/_D#TRBO,_\ A1?Q'_Z.3\3_ /?B'_"C_A1?Q'_Z.3\3
M_P#?B'_"E_;O$'_0IJ?^#*'_ ,M'_9V6?]!L/_ *G_R!K?M!_%*+X1?"[4/$
M\<JB^D7[-I:'^*X<$*<=PH!<^RFO!/V%?B[+I7B^\^&>NWS-#K3-<V3ROG%T
MHRXR>[H/S0>M<%^TIXDUJX\>W'@BY^(^I^(K31)3$MQ?LH GP!)M"@#@C;D\
MY4]JX#3-2U#1M1@U?2KR2WNK699;>>)L-&ZG(8'L017\G\9>+V8OQ+P^84(.
M-+!-P]GS1?-=VK:Q;B^;X4TVO=C)'[-D7!&%7"E7#5))SKI2YK-6ZPT:3TW:
M:3U:/TMHKQ+X6>#?&GQ2\!:=XXTO]I'Q,BWL&9H!'"3#*.'C)QV8$9[C![UT
M/_"B_B/_ -')^)_^_$/^%?U/@N*<WS'!T\5A\LJ2IU(J46JE"SC)73_B]4S\
M>KY/@<+7E1JXN*E%M-<E31K1KX#TRBO,_P#A1?Q'_P"CD_$__?B'_"C_ (47
M\1_^CD_$_P#WXA_PKI_MWB#_ *%-3_P90_\ EIE_9V6?]!L/_ *G_P @>F5^
M>_\ P7Z_:TU7]E[0?@/I_P 0?%GBCPM\$O&?Q:BTSXW^+O!]Q<V][;:6L#21
M69N+4B>"">0,9F@*S-%;NB'+E6_0.R@DM;.&VFN6F>.)5>9_O2$#!8^YZUY3
M^TKK_P"SEXV\1>'/V,_VE/!FCZ_I7Q?L-5MK+1O$%O%-::C+91PW#VQCD^](
M8FDF0CE?LS,"" 1]7%MQ3:L>,TD]#Y[O_P!A_P"#WBE_A!^T]_P3;^->NVGA
M.U^(.BZGXDT'P;\1KR^\->+]%^TJLCR6[W,EN98'*7'FIM=A#(C[SMV^H_\
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M<TG)IZK5*^Z9Z]17D/\ PWQ^QU_T<%H'_?U__B:/^&^/V.O^C@M _P"_K_\
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MX7,L4DWA^U\:ZOI=I<-&^^,S16%U LVUP&7S V"JD<@87_AOC]CK_HX+0/\
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M %%W_AOC]CK_ *."T#_OZ_\ \31_PWQ^QU_T<%H'_?U__B: .9\(_P#!+/\
M8E\!_LD7_P"PEX1^'/B*Q^$VI0SP7?@Z+XF^(3%Y$S2O-;I*;\S102--*9(4
MD6-RY+*:]._9X_9X^%/[*WPCTCX%?!#2-2T[PKH%JEKHNF:EXDO]4-E;HBI'
M!'+?3S2K$BJJK&'V*!\H%<O_ ,-\?L=?]'!:!_W]?_XFC_AOC]CK_HX+0/\
MOZ__ ,30!B?M'_\ !-_]F7]J'XW^'OVD_'T?C/2?'?AC1VTG2O%'@?XB:OH-
MTMBTK2FW9K"YB#H7=SR,G>021@#TOX-_ CX5? 'P_=>'/A7X6-A'J-\U]J]]
M=W\][?:I=LJHUS>7ET\EQ=S%41?-FD=]J*N<* ./_P"&^/V.O^C@M _[^O\
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M,?"^7QKX2MIQ<6*>(O$%_=ZA:W W;;B/4)9VNUE =UW^;DHQ0Y0E:Q/V0_\
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M7_0$U_\ \'K_ .%?3E% 'S'_ ,.COV.O^@)K_P#X/7_PH_X='?L=?] 37_\
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M_P#X/7_PH_X='?L=?] 37_\ P>O_ (5].44 ?,?_  Z._8Z_Z FO_P#@]?\
MPH_X='?L=?\ 0$U__P 'K_X5].44 ?,?_#H[]CK_ * FO_\ @]?_  H_X='?
ML=?] 37_ /P>O_A7TY10!\Q_\.COV.O^@)K_ /X/7_PH_P"'1W['7_0$U_\
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M .%?3E% 'S'_ ,.COV.O^@)K_P#X/7_PH_X='?L=?] 37_\ P>O_ (5].44
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M'?L=?] 37_\ P>O_ (5].44 ?,?_  Z._8Z_Z FO_P#@]?\ PH_X='?L=?\
M0$U__P 'K_X5].44 ?,?_#H[]CK_ * FO_\ @]?_  H_X='?L=?] 37_ /P>
MO_A7TY10!\Q_\.COV.O^@)K_ /X/7_PH_P"'1W['7_0$U_\ \'K_ .%?3E%
M'S'_ ,.COV.O^@)K_P#X/7_PH_X='?L=?] 37_\ P>O_ (5].44 ?,?_  Z.
M_8Z_Z FO_P#@]?\ PH_X='?L=?\ 0$U__P 'K_X5].44 ?,?_#H[]CK_ * F
MO_\ @]?_  H_X='?L=?] 37_ /P>O_A7TY10!\Q_\.COV.O^@)K_ /X/7_PH
M_P"'1W['7_0$U_\ \'K_ .%?3E% 'S'_ ,.COV.O^@)K_P#X/7_PH_X='?L=
M?] 37_\ P>O_ (5].44 ?,?_  Z._8Z_Z FO_P#@]?\ PH_X='?L=?\ 0$U_
M_P 'K_X5].44 ?,?_#H[]CK_ * FO_\ @]?_  H_X='?L=?] 37_ /P>O_A7
MTY10!\Q_\.COV.O^@)K_ /X/7_PH_P"'1W['7_0$U_\ \'K_ .%?3E% %71-
M(L_#^C6F@Z<K"WL;6.W@#MDA$4*N3W. *M444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!\@?\%^/^4-G[0G_ &3^;_T=%7\85?V>_P#!?C_E
M#9^T)_V3^;_T=%7\85 '[_?\&FW_ "E,_:[_ .WC_P!/D]?O]7X _P#!IM_R
ME,_:[_[>/_3Y/7[_ % !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '
MR!_P7X_Y0V?M"?\ 9/YO_1T5?QA5_9[_ ,%^/^4-G[0G_9/YO_1T5?QA4 ?O
M]_P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&FW_*4S]KO_MX_]/D]?O\ 4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 ?('_!?C_E#9^T)_P!D_F_]
M'15_&%7]GO\ P7X_Y0V?M"?]D_F_]'15_&%0!^_W_!IM_P I3/VN_P#MX_\
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,#<1\O0>M?A;0!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823213608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 16, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,956,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s definitive Proxy Statement for the 2022 annual meeting of the stockholders of the registrant are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) within 120 days of the registrant&#8217;s fiscal year ended December&#160;31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364824125752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst and Young, LLP<span></span>
</td>
<td class="text">BDO USA, LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los Angeles, California<span></span>
</td>
<td class="text">Los Angeles, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364819173288">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 233,097<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,417<span></span>
</td>
<td class="nump">67,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,608<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,376<span></span>
</td>
<td class="nump">49,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,647<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,637<span></span>
</td>
<td class="nump">16,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable - related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">398,782<span></span>
</td>
<td class="nump">338,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,186<span></span>
</td>
<td class="nump">29,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,807<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">253,039<span></span>
</td>
<td class="nump">239,053<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">569<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,715<span></span>
</td>
<td class="nump">43,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">896<span></span>
</td>
<td class="nump">37,075<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,441<span></span>
</td>
<td class="nump">18,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,928<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">453,581<span></span>
</td>
<td class="nump">478,909<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">852,363<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,951<span></span>
</td>
<td class="nump">36,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,783<span></span>
</td>
<td class="nump">50,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">652<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">486<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,629<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">780<span></span>
</td>
<td class="nump">10,889<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115,371<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,127<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">973<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,198<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,917<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,777<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220,992<span></span>
</td>
<td class="nump">257,346<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">336,363<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (&#8220;APC&#8221;)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,510<span></span>
</td>
<td class="nump">114,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.001; 100,000,000 shares authorized,44,630,873and 42,249,137 shares outstanding, excluding 10,925,702 and 12,323,164 treasury shares, at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">310,876<span></span>
</td>
<td class="nump">261,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">143,629<span></span>
</td>
<td class="nump">69,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity attributable to parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">454,550<span></span>
</td>
<td class="nump">330,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,940<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">460,490<span></span>
</td>
<td class="nump">330,911<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">852,363<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $567.0&#160;million and $576.1&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $91.7&#160;million and $88.6&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively. These VIE balances do not include $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823254760">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,630,873<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,925,702<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 852,363<span></span>
</td>
<td class="nump">$ 817,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 336,363<span></span>
</td>
<td class="nump">$ 372,338<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,630,873<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ameh_PrimaryBeneficiaryMember', window );">Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 567,000<span></span>
</td>
<td class="nump">$ 576,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">91,700<span></span>
</td>
<td class="nump">88,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802,800<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliates', window );">Amounts due from affiliates*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 225,100<span></span>
</td>
<td class="nump">$ 22,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $567.0&#160;million and $576.1&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $91.7&#160;million and $88.6&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively. These VIE balances do not include $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822739128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 773,915<span></span>
</td>
<td class="nump">$ 687,180<span></span>
</td>
<td class="nump">$ 560,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of services, excluding depreciation and amortization</a></td>
<td class="nump">596,142<span></span>
</td>
<td class="nump">539,211<span></span>
</td>
<td class="nump">467,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">62,077<span></span>
</td>
<td class="nump">49,116<span></span>
</td>
<td class="nump">41,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts', window );">Depreciation and amortization</a></td>
<td class="nump">17,517<span></span>
</td>
<td class="nump">18,350<span></span>
</td>
<td class="nump">18,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill and intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">675,736<span></span>
</td>
<td class="nump">606,677<span></span>
</td>
<td class="nump">528,198<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">98,179<span></span>
</td>
<td class="nump">80,503<span></span>
</td>
<td class="nump">32,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="num">(4,306)<span></span>
</td>
<td class="nump">3,694<span></span>
</td>
<td class="num">(6,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investment</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">99,839<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,394)<span></span>
</td>
<td class="num">(9,499)<span></span>
</td>
<td class="num">(4,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,571<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="num">(10,745)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income</a></td>
<td class="num">(3,750)<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(20,431)<span></span>
</td>
<td class="nump">97,924<span></span>
</td>
<td class="num">(6,580)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">77,748<span></span>
</td>
<td class="nump">178,427<span></span>
</td>
<td class="nump">25,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">28,454<span></span>
</td>
<td class="nump">56,107<span></span>
</td>
<td class="nump">8,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">49,294<span></span>
</td>
<td class="nump">122,320<span></span>
</td>
<td class="nump">17,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (loss) income attributable to noncontrolling interests</a></td>
<td class="num">(24,564)<span></span>
</td>
<td class="nump">84,454<span></span>
</td>
<td class="nump">3,557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 73,858<span></span>
</td>
<td class="nump">$ 37,866<span></span>
</td>
<td class="nump">$ 14,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 593,224<span></span>
</td>
<td class="nump">$ 557,326<span></span>
</td>
<td class="nump">$ 454,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">111,627<span></span>
</td>
<td class="nump">77,367<span></span>
</td>
<td class="nump">51,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">35,959<span></span>
</td>
<td class="nump">34,850<span></span>
</td>
<td class="nump">34,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">26,564<span></span>
</td>
<td class="nump">12,683<span></span>
</td>
<td class="nump">15,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 6,541<span></span>
</td>
<td class="nump">$ 4,954<span></span>
</td>
<td class="nump">$ 5,209<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817784856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Mezzanine Equity&#160;&#8211; Non-controlling Interest&#160;in&#160;APC</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 225,117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="nump">1,808,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityRepurchaseOfTreasuryShares', window );">Repurchase of treasury shares</a></td>
<td class="num">(283,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityStockSubscription', window );">Stock subscription</a></td>
<td class="nump">754,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with business acquisition</a></td>
<td class="nump">414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares', window );">Cost of equity issuance of preferred shares</a></td>
<td class="num">(878,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends</a></td>
<td class="num">(60,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Reclassification of options liability to equity</a></td>
<td class="nump">1,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Dec. 31, 2019</a></td>
<td class="nump">168,724,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning at Dec. 31, 2018</a></td>
<td class="nump">181,545,000<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 162,723,000<span></span>
</td>
<td class="nump">$ 17,788,000<span></span>
</td>
<td class="nump">$ 999,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at beginning (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,578,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net income</a></td>
<td class="nump">15,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,117,000<span></span>
</td>
<td class="nump">1,749,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(601,581)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Repurchase of treasury shares</a></td>
<td class="num">(7,287,000)<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">(7,286,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestIncreaseFromCapitalCharge', window );">Noncontrolling interest capital charge</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">940,000<span></span>
</td>
<td class="nump">$ 1,599<span></span>
</td>
<td class="nump">940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">418,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">3,233,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,233,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(1,990,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,990,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity', window );">Reclassification of options liability to equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares', window );">Issuance of 50% holdback shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares', window );">Issuance of 50% holdback shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at ending at Dec. 31, 2019</a></td>
<td class="nump">192,335,000<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">159,608,000<span></span>
</td>
<td class="nump">31,905,000<span></span>
</td>
<td class="nump">786,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="nump">83,621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityDistributionToNoncontrollingInterest', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(1,037,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends</a></td>
<td class="num">(137,071,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Dec. 31, 2020</a></td>
<td class="nump">114,237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net income</a></td>
<td class="nump">38,699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,866,000<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Repurchase of treasury shares</a></td>
<td class="num">(301,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(301,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(236,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares', window );">Dividends (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,984,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares', window );">Dividends</a></td>
<td class="nump">85,539,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">87,066,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,532,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised', window );">Shares issued for cashless exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised', window );">Shares issued for cashless exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">11,492,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">11,491,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at ending at Dec. 31, 2020</a></td>
<td class="nump">$ 330,911,000<span></span>
</td>
<td class="nump">$ 42,000<span></span>
</td>
<td class="nump">261,011,000<span></span>
</td>
<td class="nump">69,771,000<span></span>
</td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2020</a></td>
<td class="nump">42,249,137<span></span>
</td>
<td class="nump">42,249,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityNetIncome', window );">Net income</a></td>
<td class="num">$ (27,331,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest', window );">Sale of non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionOfDividends', window );">Dividends</a></td>
<td class="num">(30,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Temporary equity, carrying amount, ending balance at Dec. 31, 2021</a></td>
<td class="nump">55,510,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net income</a></td>
<td class="nump">76,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,858,000<span></span>
</td>
<td class="nump">2,767,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(174,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Repurchase of treasury shares</a></td>
<td class="num">(5,738,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,738,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestIncreaseFromCapitalCharge', window );">Noncontrolling interest capital charge</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">6,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
<td class="num">$ (1,546,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Cancellation of restricted stock awards (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(334,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(334,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">9,061,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">9,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest', window );">Sale of shares by noncontrolling interest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,638,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest', window );">Sale of shares by noncontrolling interest</a></td>
<td class="nump">40,134,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">40,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Investment in non-controlling interest</a></td>
<td class="nump">3,769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,769,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Acquisition of non-controlling interest</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(1,156,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,156,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at ending at Dec. 31, 2021</a></td>
<td class="nump">$ 460,490,000<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="nump">$ 310,876,000<span></span>
</td>
<td class="nump">$ 143,629,000<span></span>
</td>
<td class="nump">$ 5,940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at ending (in shares) at Dec. 31, 2021</a></td>
<td class="nump">44,630,873<span></span>
</td>
<td class="nump">44,630,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Shares, Release Of Hold Back Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NoncontrollingInterestIncreaseFromCapitalCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Increase From Capital Charge</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NoncontrollingInterestIncreaseFromCapitalCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Cashless Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Cashless Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Stock Options Liability Reclassified To Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been released during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been released during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Cost of Equity Issuance of Preferred Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityDistributionToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Distribution to Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityDistributionToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Increase from Sale of Non-Controlling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityRepurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Repurchase of Treasury Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityRepurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Share-based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityStockSubscription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Subscription</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityStockSubscription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity during the period due to unpaid dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityNetIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of net income or loss attributable to temporary equity interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityNetIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364905848472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ameh_HoldbackSharesMember', window );">Holdback shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ameh_HoldbackSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ameh_HoldbackSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364818850184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 49,294<span></span>
</td>
<td class="nump">$ 122,320<span></span>
</td>
<td class="nump">$ 17,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">17,517<span></span>
</td>
<td class="nump">18,350<span></span>
</td>
<td class="nump">18,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance cost</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
<td class="nump">473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherOperatingActivities', window );">Other</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss of disposal of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Impairment of goodwill and intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">6,745<span></span>
</td>
<td class="nump">3,383<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investment</a></td>
<td class="num">(2,193)<span></span>
</td>
<td class="num">(99,839)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_GainLossOnConsolidationOfEquityMethodInvestment', window );">Gain on consolidation of equity method investment</a></td>
<td class="num">(2,752)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_GainLossOnEquityReceivable', window );">Gain on contingent equity securities</a></td>
<td class="num">(4,270)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_GainLossOnAssumptionOfLoan', window );">Gain on loan assumption</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized loss (gain) from investment in equity securities</a></td>
<td class="nump">10,845<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gain from investment in warrants</a></td>
<td class="num">(1,145)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Loss in interest rate swaps</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Impairment of beneficial interest</a></td>
<td class="nump">15,723<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss (income) from equity method investments, net</a></td>
<td class="nump">4,306<span></span>
</td>
<td class="num">(3,694)<span></span>
</td>
<td class="nump">6,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="num">(5,952)<span></span>
</td>
<td class="num">(6,620)<span></span>
</td>
<td class="num">(6,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisition amounts:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivable, net</a></td>
<td class="num">(1,518)<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
<td class="nump">10,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivable, net &#8211; related parties</a></td>
<td class="num">(20,116)<span></span>
</td>
<td class="num">(1,123)<span></span>
</td>
<td class="num">(1,435)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivable</a></td>
<td class="num">(5,351)<span></span>
</td>
<td class="nump">12,589<span></span>
</td>
<td class="num">(15,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,708<span></span>
</td>
<td class="num">(6,432)<span></span>
</td>
<td class="num">(2,756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOperatingLeaseAssets', window );">Right-of-use assets</a></td>
<td class="nump">3,133<span></span>
</td>
<td class="nump">3,325<span></span>
</td>
<td class="nump">2,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,529)<span></span>
</td>
<td class="num">(5,530)<span></span>
</td>
<td class="num">(572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,217<span></span>
</td>
<td class="nump">8,204<span></span>
</td>
<td class="num">(4,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="nump">892<span></span>
</td>
<td class="nump">7,615<span></span>
</td>
<td class="nump">488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="nump">5,279<span></span>
</td>
<td class="num">(8,691)<span></span>
</td>
<td class="num">(2,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(3,621)<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(7,093)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(3,215)<span></span>
</td>
<td class="num">(2,973)<span></span>
</td>
<td class="num">(2,244)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">70,335<span></span>
</td>
<td class="nump">46,163<span></span>
</td>
<td class="nump">13,673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(28,000)<span></span>
</td>
<td class="num">(1,793)<span></span>
</td>
<td class="num">(115,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">67,612<span></span>
</td>
<td class="nump">50,625<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Proceeds from repayment of loans receivable - related parties</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Advances on loans receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(11,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Dividends received from equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired</a></td>
<td class="num">(2,585)<span></span>
</td>
<td class="num">(11,354)<span></span>
</td>
<td class="num">(49,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare', window );">Purchases of investments in privately held entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(491)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">6,375<span></span>
</td>
<td class="nump">52,743<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of investments &#8211; equity method</a></td>
<td class="num">(13,622)<span></span>
</td>
<td class="num">(9,969)<span></span>
</td>
<td class="num">(3,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(19,223)<span></span>
</td>
<td class="num">(1,164)<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity', window );">Cash recorded from consolidation of VIE</a></td>
<td class="nump">5,927<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">16,540<span></span>
</td>
<td class="nump">95,493<span></span>
</td>
<td class="num">(180,631)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(31,089)<span></span>
</td>
<td class="num">(51,319)<span></span>
</td>
<td class="num">(61,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Repayment of term loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Change in non-controlling interest capital</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Borrowings on long-term debt</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayments on long-term debt</a></td>
<td class="num">(201)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RepaymentsOfBankLoanAndLinesOfCredit', window );">Repayments on bank loan and lines of credit</a></td>
<td class="num">(238,125)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations', window );">Payment of capital lease obligations</a></td>
<td class="num">(208)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="num">(102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of stock options and warrants</a></td>
<td class="nump">9,061<span></span>
</td>
<td class="nump">10,802<span></span>
</td>
<td class="nump">3,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of shares</a></td>
<td class="nump">40,134<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ProceedsFromEquityOffering', window );">Proceeds from common stock offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares</a></td>
<td class="num">(5,739)<span></span>
</td>
<td class="num">(537)<span></span>
</td>
<td class="num">(7,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsMinorityInterest', window );">Distribution to non-controlling interest</a></td>
<td class="num">(1,471)<span></span>
</td>
<td class="num">(1,037)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Cost of debt and equity issuances</a></td>
<td class="num">(727)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,771)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(47,748)<span></span>
</td>
<td class="num">(51,696)<span></span>
</td>
<td class="nump">163,331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">39,127<span></span>
</td>
<td class="nump">89,960<span></span>
</td>
<td class="num">(3,627)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of year</a></td>
<td class="nump">193,970<span></span>
</td>
<td class="nump">104,010<span></span>
</td>
<td class="nump">107,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">233,097<span></span>
</td>
<td class="nump">193,970<span></span>
</td>
<td class="nump">104,010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">37,201<span></span>
</td>
<td class="nump">62,002<span></span>
</td>
<td class="nump">20,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">4,158<span></span>
</td>
<td class="nump">8,510<span></span>
</td>
<td class="nump">4,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IssuanceOfFinancingObligationForBusinessCombination', window );">Issuance of financing obligation for business combinations</a></td>
<td class="nump">12,706<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashlessExerciseOfStockOptions', window );">Cashless exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CancellationOfRestrictedStockAwards', window );">Cancellation of Restricted Stock Awards</a></td>
<td class="nump">334<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividend declared included in dividend payable</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReclassificationOfLiabilityForEquity', window );">Reclassification of liability for equity shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Deferred tax liability adjustment related to warrant exercises</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Preferred shares received from sale of equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset', window );">Beneficial interest acquired from sale of equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,723<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">233,097<span></span>
</td>
<td class="nump">193,470<span></span>
</td>
<td class="nump">103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash &#8211; long-term - letters of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash &#8211; short-term</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">233,097<span></span>
</td>
<td class="nump">193,970<span></span>
</td>
<td class="nump">104,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">APC stock issued in exchange for AMG</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CancellationOfRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cancellation of Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CancellationOfRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_GainLossOnAssumptionOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Assumption Of Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_GainLossOnAssumptionOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_GainLossOnConsolidationOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Consolidation of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_GainLossOnConsolidationOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_GainLossOnEquityReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Equity Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_GainLossOnEquityReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IssuanceOfFinancingObligationForBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Financing Obligation for Business Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IssuanceOfFinancingObligationForBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Investment Privately Held Entity Does Not Report To NAV Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Cash Received from Consolidation of Variable Interest Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ProceedsFromEquityOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Equity Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ProceedsFromEquityOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReclassificationOfLiabilityForEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification Of Liability For Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReclassificationOfLiabilityForEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RepaymentsOfBankLoanAndLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Bank Loan And Lines Of Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RepaymentsOfBankLoanAndLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from operating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823179560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Apollo Medical Holdings, Inc. (&#8220;ApolloMed&#8221;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#8220;NMM&#8221;) in December 2017 (the &#8220;2017 Merger&#8221;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed&#8217;s subsidiaries and VIEs include management services organizations (&#8220;MSOs&#8221;), affiliated independent practice associations (&#8220;IPAs&#8221;) and a Next Generation Accountable Care Organization (&#8220;NGACO&#8221;). NMM and Apollo Medical Management, Inc. (&#8220;AMM&#8221;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually. Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#8220;APC&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA (&#8220;Accountable Health Care&#8221;), and Access Primary Care Medical Group (&#8220;APCMG&#8221;) are the affiliated IPA groups that provide medical services. These affiliated IPAs are supported by ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). The Company&#8217;s NGACO operates under the APA ACO, Inc. (&#8220;APAACO&#8221;) brand and participates in the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#8217;s attribution-based risk-sharing model.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, AMH and SCHC. AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly owned subsidiary of ApolloMed in December 2017. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (amending an initial management services agreement that was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) and AP-AMH 2 Medical Corporation (&#8220;AP-AMH 2&#8221;) were formed in May 2019 and July 2021, respectively, as a designated shareholder&#160;professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. ApolloMed makes all the decisions on behalf of AP-AMH and AP-AMH 2 and funds and receives all the distributions from its operations. ApolloMed has the right to receive benefits from the operations of AP-AMH and AP-AMH 2 and has the option, but not the obligation, to cover its losses. Therefore, AP-AMH and AP-AMH 2 is controlled by and consolidated by ApolloMed as the primary beneficiary of this VIE. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $545.0 million loan to AP-AMH, pursuant to a 10-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#8217;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $545.0 million private placement, where AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. During the year ended December&#160;31, 2021 and 2020, APC distributed $55.1 million and $30.4 million, respectively, as preferred returns.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">A $300.0&#160;million private placement, where APC purchased 15,015,015 shares of the Company&#8217;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.  During the year ended December&#160;31, 2020, APC distributed approximately 5.0&#160;million shares of the Company&#8217;s common stock to APC shareholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#8220;Excluded Assets&#8221;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC's ownership in ApolloMed was 19.68% and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.58%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as of December&#160;31, 2021 and 2020, respectively.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, organized by a group of highly qualified physicians, with a surgical center that utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of December&#160;31, 2021, APC owned 44.50% of CDSC&#8217;s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#8217;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and the right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;), and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#8220;MMG&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;), and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA, was acquired by APC-LSMA in May 2019 for an aggregate purchase price of $45.1 million in cash, has been operating in California since 1993, and is a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, Medicare, and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare, and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock they did not already own (comprising 75%) for $7.3 million in cash.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating in three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its networks of doctors and nurse practitioners. In September 2019, APC-LSMA acquired 100% of the aggregate issued and outstanding shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, has the ability to exercise significant influence, but not control over DMG&#8217;s operations. However, in October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $8.5&#160;million at December&#160;31, 2021. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#8220;MPP&#8221;), AMG Properties, LLC (&#8220;AMG Properties&#8221;), and ZLL Partners, LLC (&#8220;ZLL&#8221;) and a 50% interest in each of One MSO, LLC (&#8220;One MSO&#8221;), Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;), and Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;). These entities own buildings that are currently leased to tenants, as well as vacant land that they plan to develop in the future. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate the accounting for the Company&#8217;s investment in Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#8217;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, AP-AMH 2 purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#8220;APCMG&#8221;), a primary care physicians&#8217; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#8220;Sun Labs&#8221;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments-certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $4.2&#160;million at December&#160;31, 2021. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.</span></div>APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820797528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared by management in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of December&#160;31, 2021 and 2020 and consolidated statements of income for the years ended December&#160;31, 2021, 2020 and 2019 include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment, accrual of medical liabilities (IBNR claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors, and historical margins), income tax  valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by it in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements (&#8220;MSA&#8221;). To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company concludes that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 6 &#8211; &#8220;Investments in Other Entities&#8221; for entities that qualify as VIEs but the Company is not the primary beneficiary.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of December&#160;31, 2021 and 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $285.9 million and $294.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of December&#160;31, 2021 and 2020, investments in marketable securities were approximately $53.4 million and $67.7 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to twenty-four months (see fair value measurements of financial instruments below). As of December&#160;31, 2021 and 2020, certificates of deposit amounted to approximately $25.0 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted-average share prices from observable market data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The common stock of a payor partner were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. As of December&#160;31, 2021, the equity securities from the payor partner amounted to $24.0 million. As of December&#160;31, 2020, prior to our payor partner&#8217;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#8220;contingent equity securities&#8221;) for $3.0 million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 - &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#8221; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognized unrealized losses of $10.7 million during the year ended December&#160;31, 2021 in unrealized gain or loss on investments in the accompanying consolidated statements of income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, management fee income, incentive receivables, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements and incentive receivables, management fee income and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s loan receivable - related party consists of promissory notes from payees that are expected to be collected between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5OTk_64bfc1bc-0468-44da-ae64-8adbf345015b">two</span> to four years and accrue interest per annum. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full-risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, FFS reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risks</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by each payor type (in thousands):</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,286</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,596</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,311</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,079</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,596</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third parties</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,985</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,654</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,680</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total net revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties :</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor F</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Land, Property, and Equipment, Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMDk1_890dedd3-9639-4f3d-a087-9691ad4f5456">three</span> to thirty-nine years. Leasehold improvements are amortized on a straight-line basis over the shorter of the terms of the respective leases or the expected useful lives of those improvements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021 are presented below (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020 are presented below (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:31pt">Included in cash and cash equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, and member relationships and are stated at cost, less accumulated amortization, and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization, and impairment losses, and are amortized using the straight-line method.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 350&#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) MSOs, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances. <br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the year ended December 31, 2019, the Company wrote off indefinite-lived intangible assets of approximately $2.0 million related to Medicare licenses, acquired as part of the 2017 Merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom. The write-off is included in impairment of goodwill and intangible assets in the accompanying consolidated statements of income. There was no impairment loss recorded related to goodwill and intangibles during the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8211; Equity Method</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are subject to impairment evaluation. During the years ended December&#160;31, 2019, the Company recognized an impairment loss of approximately $0.3 million related to its investment in Pacific Ambulatory Health Care, LLC as the Company does not believe it will recover its investment balance. Such impairment loss is included in loss from equity method investments in the accompanying consolidated statements of income. There was no impairment loss recorded related to equity method investments for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. The consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fiduciary Cash and Payable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $10.5 million and $9.6 million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 10 - &#8220;Credit Facility, Bank Loan, and Lines of Credit,&#8221; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of December&#160;31, 2021, was $1.1 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement which included the Company purchasing warrants. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of December&#160;31, 2021 was $1.1 million and is presented within other assets in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The Company determined the fair value of the contingent equity security using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $4.3 million and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. The Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company&#8217;s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions on factors, including but not limited to, historical margin, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared-risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk-share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MDUx_13452d7a-ce48-4cb1-9932-b9a62aad18dd">two</span> performance years through December&#160;31, 2019, which was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MTA3_7004a731-22ef-4a6d-af57-dbde08754dca">two</span> additional renewal years through December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company submitted to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company obtained CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk-share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency, in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 9 - &#8220;Medical Liabilities&#8221;), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there was any excess AIPBPs for the performance year and the excess is refunded to CMS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared-risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit for the performance year and therefore this shared-risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $21.8 million and $19.8 million in risk pool savings, related to the 2020 and 2019 performance years, respectively, and has recognized such savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be eligible in receiving AIPBP under the NGACO Model for performance year 2021, with the effective date of the performance year beginning January 1, 2021. For performance year 2021, the Company received monthly AIPBP payments at a rate of approximately $7.7 million per month from CMS. The monthly AIPBP received by the Company for performance year 2020 was approximately $7.2 million per month. The Company has received approximately $92.4 million in total AIPBP for the year ended December&#160;31, 2021 of which $59.2 million has been recognized as revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors, such as hours staffed, patient visits, or collections per visit, against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients, and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company does not have any contract assets since all obligations have been performed when revenue was recognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. As of December&#160;31, 2021, the Company&#8217;s contract liability balance was $16.8 million, of which $16.3 million was related to the Company&#8217;s NGACO. Contract liability was $13.0&#160;million as of December&#160;31, 2020, of which $12.6&#160;million was related to NGACO. Contract liability is presented within the accounts payable and accrued expenses in the accompanying consolidated balance sheets. Approximately $0.4 million of the Company&#8217;s contracted liability accrued in 2020 has been recognized as revenue during the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to the holders of the Company&#8217;s common stock by the weighted-average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted-average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 17 &#8212;  &#8220;Earnings Per Share&#8221; for a discussion of shares treated as treasury shares for accounting purposes.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of December&#160;31, 2021 and 2020, APC&#8217;s shares were not redeemable nor was it probable the shares would become redeemable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and ROU asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under twelve month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020 was&#160;$15.7&#160;million and was included in other assets in the accompanying consolidated balance sheets. The beneficial interest was the result of a gross margin provision in the stock purchase agreement, which entitled UCAP to potentially receive additional cash and preferred shares (cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale, were held in an escrow account) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varied dependent upon the gross margin as compared to the target but cannot exceed the amounts that were in the escrow account. Additionally, the stock purchase agreement included a tangible net equity provision that could have resulted in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. The Company determined the fair value of the beneficial interest using an income approach, which included significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value, which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment was defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7&#160;million was written off and expensed in other income in the accompanying consolidated statements of income during the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently assessing the impact of that adoption of ASU 2021-08 will have on the Company&#8217;s consolidated financial statements. <br/><br/>With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820845768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations and Goodwill</a></td>
<td class="text">Business Combinations and Goodwill<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APCMG</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $2.0 million. As part of the transaction, the Company paid $1.0 million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#8217;s financial performance for fiscal year 2022 (&#8220;APCMG contingent consideration&#8221;). The APCMG contingent consideration is met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#8220;EBITDA&#8221;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sun Labs</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DMG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of APCMG, Sun Labs, and DMG have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of goodwill activity for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820768296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Land, Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock', window );">Land, Property and Equipment, Net</a></td>
<td class="text">Land, Property, and Equipment, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land, property, and equipment, net consisted of (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 39</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company had finance leases totaling $1.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd $0.4 million, respectively, included in land, property, and equipment, net in the accompanying consolidated balance sheets.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span> $2.3 million and $2.0 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment And Asset Acquisition Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820835512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,814&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89,544)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, network relationships, management contracts, member relationships, patient management platform, and tradename/trademarks had weighted-average remaining useful lives of 10.5 years, 8.5 years, 8.3 years, 0.9 years, and 15.9 years, respectively. Amortization expense was $15.4 million, $16.0 million and $16.3 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2019, the Company wrote off indefinite-lived intangible assets of $2.0 million related to Medicare licenses it acquired as part of the 2017 Merger. The Company will no longer utilize these licenses and as such the Company will not receive future economic benefits. There was no impairment loss recorded related to intangibles for the year ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands):</span></div><div style="margin-top:17pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,661&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,908&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820783848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Other Entities</a></td>
<td class="text">Investments in Other Entities<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.336%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contribution</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidation of Entity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,943)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One MSO, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; IPA Line of Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino, and Tulare Counties through its network of approximately 2,400 independently contracted primary care physicians and specialist providers. LMA&#8217;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net, and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#8217;s IPA line of business. NMM has a management services agreement with LMA. In December 2020, the Company exercised its option to convert a promissory note totaling $6.4&#160;million due from Dr. Arteaga into an additional 21.25% interest in LMA&#8217;s IPA line of business. As a result, APC-LSMA&#8217;s interest in LMA&#8217;s IPA line of business increased to 46.25%. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4&#160;million, which resulted in APC-LSMA owning a 25% interest in LMA as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the year ended December&#160;31, 2021, APC recorded net loss of $5.8 million from its investment in LMA as compared to a net income of $0.3 million for the year ended December&#160;31, 2020, in the accompanying consolidated statements of income. The investment balance was $3.0 million and $13.0 million at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s unaudited summarized balance sheets at December&#160;31, 2021 and 2020 and unaudited summarized statements of operations for the years ended December&#160;31, 2021, 2020, and 2019 are as follows (in thousands):</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020<br/>(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2021<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2019<br/>(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,071)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,071)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMIOC was incorporated in 2004 in the state of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at their facilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership in PMIOC.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract APC paid PMIOC fees of $2.4 million and $2.2 million for the years ended December&#160;31, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. During the year ended December&#160;31, 2021, APC recorded net income of $0.3 million from its investment as compared to net income of $17,000 for the year ended December&#160;31, 2020 in the accompanying consolidated statements of income and has an investment balance of $1.7 million and $1.4 million at December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounted for its 40% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, had the ability to exercise significant influence, but not control over DMG&#8217;s operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#8217;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; therefore DMG is consolidated. As a result of the consolidation, the Company recognized a gain of $2.8 million for the year ended December&#160;31, 2021 in other income in the accompanying consolidated statement of income, representing the difference between the fair value and the carrying value of the previously held noncontrolling interest in DMG on the date of consolidation.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, and prior to consolidation of DMG, APC recorded income from this investment of $0.3 million as compared to income of $0.3 million during the year ended December&#160;31, 2020 in the accompanying consolidated statements of income.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), a related party, APC and NMM, entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owns 50%, 25%, and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s&#160;25%&#160;membership interest in 531 W. College, LLC for approximately&#160;$8.3 million. Subsequently, APC has a&#160;50%&#160;ownership in 531 W. College LLC. APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, APC recorded losses from its investment in 531 W. College LLC of $0.2 million and loss of $0.4 million, respectively, in the accompanying consolidated statements of income. During the year ended December&#160;31, 2021 and 2020, APC contributed $0.2 million and $1.0&#160;million, respectively, to 531 W. College, LLC as part of its 50% interest.  The accompanying consolidated balance sheets include the related investment balance of $17.2 million</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $17.2 million, respectively, related to APC's investment at December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One MSO LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in One MSO LLC (&#8220;One MSO&#8221;) for $2.4&#160;million. APC accounts for its investment in One MSO under the equity method of accounting as APC has the ability to exercise significant influence, but not control over One MSO&#8217;s operations. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. During the year ended December&#160;31, 2021, APC recorded income from this investment of $0.5 million in the accompanying consolidated statements of income. The investment balance was $2.9 million and $2.4 million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, APC purchased a 50% member interest in Tag-6 Medical Investment Group, LLC (&#8220;Tag 6&#8221;) for $4.5 million and a 50% member interest in Tag-8 Medical Investment Group, LLC (&#8220;Tag 8&#8221;) for $2.1 million. Tag 6 leases their building to tenants and Tag 8 has vacant land with plans to develop medical offices in the future. In April 2021, the Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company for the year ended December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in Tag 6 under the equity method of accounting as APC has the ability to exercise significant influence, but not control over Tag 6&#8217;s operations. Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. During the year ended December&#160;31, 2021, APC recorded income from this investment of $0.3 million in the accompanying consolidated statements of income. The investment balance was $4.8 million and $4.5 million as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAIPA MSO, LLC</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, ApolloMed purchased a 30% interest in CAIPA MSO, LLC for $11.7 million. CAIPA MSO, LLC (&#8220;CAIPA MSO&#8221;) is a New York-based management services organization affiliated with Chinese-American IPA d.b.a. Coalition of Asian-American IPA , a leading independent practice association serving the greater New York City area.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#8217;s operations. During the year ended December&#160;31, 2021, ApolloMed recorded income from this investment of $0.3 million in the accompanying consolidated statements of income. The investment balance was $12.0 million as of December&#160;31, 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented approximately 2.8% ownership. APC also received a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjU2_c963fd5b-c811-4093-81f8-04122b4eaed7">five</span>-year warrant to purchase 270,000 membership interests. A <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzEx_0992ad4a-a700-4f32-8ee4-5af8a166e27a">five</span>-year option to purchase an additional 380,000 membership interests and a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzgy_218c2412-51ed-4adf-8fb2-fba58a465401">five</span>-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date, however, the Company did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December&#160;31, 2021 and 2020, there were no observable price changes to APC&#8217;s investment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase up to 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction, NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5&#160;million is included in &#8220;Investment in a privately held entities&#8221; in the accompanying consolidated balance sheets as of December&#160;31, 2021. As NMM does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December&#160;31, 2021 and 2020, there were no observable price changes to NMM&#8217;s investment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820729912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Receivable and Loans Receivable - Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableAbstract', window );"><strong>Loan Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loans Receivable and Loans Receivable &#8211; Related Parties</a></td>
<td class="text">Loans Receivable and Loans Receivable &#8211; Related Parties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loans Receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific6</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, NMM received a promissory note from Pacific6 Enterprises (&#8220;Pacific6&#8221;) totaling $0.5&#160;million as a result of the sale of the Company&#8217;s 33.3% interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan Receivable &#8212; Related Party</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AHMC Healthcare Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC Healthcare Inc. (&#8220;AHMC&#8221;), a related party of the Company, (the &#8220;AHMC Note&#8221;) for a principal sum of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of December&#160;31, 2021, the total principal of $4.0&#160;million remains outstanding. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable and loan receivable &#8212; related parties under the CECL model by assessing the party&#8217;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and </span></div>estimates an expected credit loss based on the remittance schedule of the note. No losses were recorded for loan receivable and loan receivable &#8212; related parties as of December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820734536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor IPA payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820814312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical Liabilities<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,118)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820954664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loans, and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loans, and Lines of Credit<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction loan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized financing cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Long-term debt </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of December&#160;31, 2021 and 2020, the carrying value was not materially different from fair value, as the interest rates on the Company&#8217;s debt approximated rates currently available to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amended Credit Agreement</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#8220;Amended Credit Agreement&#8221; and the credit facility thereunder, the &#8220;Amended Credit Facility&#8221;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#8220;Credit Facility&#8221;), in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400 million, which includes a letter of credit sub-facility of up to $25 million and a swingline loan sub-facility of $25 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;) between the Company, NMM and Truist Bank remain in effect.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.35% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio.  As of December&#160;31, 2021, the interest rate on the Credit Agreement was 1.71%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0 million, the maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Loans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company purchased 100% of MPP, AMG Properties, and ZLL. As a result of the purchase, the Company assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively, on the day of acquisition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MPP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $6.1 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AMG Properties</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $0.7 million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ZLL</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $0.6 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#8220;Prime Rate.&#8221; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Construction Loan</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#8220;Construction Loan&#8221;). Tag 8 is a VIE consolidated by the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Construction Loan allows Tag 8 to borrow up to $10.7&#160;million with a maturity date of December 1, 2022 (&#8220;Construction Loan Term&#8221;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#8220;Permanent Loan Term&#8221;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of December&#160;31, 2021, the likelihood of the construction being completed by the maturity date is remote. The outstanding balance as of December&#160;31, 2021 was $0.6 million and was recorded as current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#8217;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7 million related to its entry into the Amended Credit Facility.  Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related Credit Facility and the costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility.  As of December&#160;31, 2021 and 2020, unamortized deferred financing costs were $4.3 million and $4.6 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the years ended December&#160;31, 2021, 2020, and 2019 was 2.06%, 3.48%, and 3.39%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the years ended December&#160;31, 2021, 2020, and 2019 of $1.2 million, $1.4 million, and $0.5 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, APC amended its promissory note agreement with Preferred Bank (&#8220;APC Business Loan Agreement&#8221;), which is affiliated with one of the Company&#8217;s board members, to modify loan availability to $4.1 million. This further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019 securing APC&#8217;s obligations to NMM under, and as required pursuant to, that certain Management Services Agreement dated as of July 1, 1999, as amended.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#8217;s board members, totaling $14.8&#160;million for the benefit of CMS. In September 2019, these letters were terminated with Preferred Bank and reissued under the Credit Agreement. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS. As of December&#160;31, 2021, there were no outstanding letters of credit and the Company had $25.0 million available under the Amended Credit Facility.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820786296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,952)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,620)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,793)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates. As of December&#160;31, 2021, the Company had federal and California net operating loss carryforwards of approximately $97.9 million and $120.8 million, respectively. The federal and California net operating loss carryforwards will expire at various dates from 2027 through 2040; however, $77.7 million of the federal operating loss do not expire and can be carried forward indefinitely. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company&#8217;s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three years&#8217; period since the last ownership change. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets (liabilities) as of December&#160;31, 2021 and 2020 are shown below (in thousands). A valuation allowance of $22.4 million and $15.5 million as of December&#160;31, 2021 and 2020, respectively, has been established against the Company&#8217;s deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $6.8 million in 2021.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for bad debts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in other entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481(a) adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,373)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,195)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,127)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,959)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December&#160;31:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision at U.S. federal statutory rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable interest entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective tax rate is different from the federal statutory rate of 21% due primarily to state taxes, change in valuation allowance, and permanent adjustments. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act was enacted and signed into law. The CARES Act, among other things, permits net operating loss carryovers and carrybacks and modifications on the limitation of business interests.  As of December&#160;31, 2021, the Company does not expect the CARES Act to result in any material impact on the Company&#8217;s effective tax rate. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021 and 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div>The Company is subject to U.S. federal income tax, as well as income tax in California. The Company and its subsidiaries&#8217; state&#160;and federal income tax returns are open to audit under the statute of limitations for the years ended December&#160;31, 2017 through December&#160;31, 2020 and for the years ended December&#160;31, 2018 through December&#160;31, 2020, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820797528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders&#8217; Equity</a></td>
<td class="text">Mezzanine and Stockholders&#8217; Equity<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Mezzanine Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">APC</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature (see Note 2 &#8212; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221;) of APC&#8217;s shares of common stock is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interests in mezzanine or temporary equity. APC&#8217;s shares were not redeemable and it was not probable that the shares would become redeemable as of December&#160;31, 2021, 2020 and 2019.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. This investment was eliminated in consolidation. In relation to the issuance of APC Series A Preferred Stock, APC incurred $0.9 million in cost (see Note 1 &#8212; &#8220;Description of Business&#8221;). </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Stockholders&#8217; Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock &#8211; Series A</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2015, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 1,111,111 units, each unit consisting of one share of ApolloMed&#8217;s Series A Preferred Stock and a common stock warrant to purchase one share of ApolloMed&#8217;s common stock at an exercise price of $9.00 per share. NMM paid ApolloMed an aggregate of $10.0 million for the units.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock &#8211; Series B</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 555,555 units, each unit consisting of one share of ApolloMed&#8217;s Series B Preferred Stock and a common stock warrant to purchase one share of ApolloMed&#8217;s common stock at an exercise price of $10.00 per share. NMM paid ApolloMed an aggregate $5.0 million for the units.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2017 Share Issuances and Repurchases</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, ApolloMed completed its business combination with NMM following the satisfaction or waiver of the conditions set forth in the Merger Agreement, pursuant to which Merger Subsidiary merged with and into NMM, with NMM surviving as a wholly owned subsidiary of ApolloMed.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2017 Merger and as of the effective time of the 2017 Merger (the &#8220;Effective Time&#8221;):</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">each issued and outstanding share of NMM common stock was converted into the right to receive such number of shares of common stock of ApolloMed that results in the former NMM shareholders who did not dissent from the 2017 Merger (&#8220;former NMM Shareholders&#8221;) having a right to receive an aggregate of 30,397,489 shares of common stock of ApolloMed, subject to the 10% holdback pursuant to the Merger Agreement;</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ApolloMed issued to former NMM Shareholders each former NMM Shareholder&#8217;s pro rata portion of (i) warrants to purchase an aggregate of 850,000 shares of common stock of ApolloMed, exercisable at $11.00 per share, and (ii) warrants to purchase an aggregate of 900,000 shares of common stock of ApolloMed, exercisable at $10.00 per share; and</span></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">ApolloMed held back an aggregate of 3,039,749 shares of common stock issuable to former NMM Shareholders, representing 10% of the total number of shares of ApolloMed common stock issuable to former NMM Shareholders, to secure indemnification rights of AMEH and its affiliates under the Merger Agreement (the &#8220;Holdback Shares&#8221;). The Holdback Shares were issued and outstanding as of December&#160;31, 2021. The first tranche of 1,519,805 shares were issued in December 2018 and the remaining 1,511,380 were issued in December 2019, net of shares repurchase.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares of common stock issuable to former NMM shareholders in the exchange were 25,675,630 (net of 10% holdback and Treasury Shares). The 10% holdback shares were released to all the former NMM shareholders based on their respective pro rata ownership interest in NMM at the Effective Time without regard to whether the former NMM shareholders are providing any services to the Company at the time of this distribution. This holdback accommodation was made as indemnification protection to the accounting acquiree (ApolloMed), and as such, is not considered compensatory. At the time when these holdback shares were issued to the former NMM shareholders, the Company recorded the stock issuance with a reduction to additional paid-in capital to properly reflect the shares outstanding.&#160;</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon consummation of the 2017 Merger, the Company issued 520,081 shares of its common stock with a fair value of approximately $5.4 million from the conversion of a convertible promissory note issued by the Company in 2017.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, 140,954 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the Merger Agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, NMM did not pay any dividends.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid dividends of $29.9 million, $136.6 million and $60.0 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, CDSC paid distributions of $1.5 million, $2.1 million and $2.6 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned 10,925,702 shares of ApolloMed&#8217;s common stock as of December&#160;31, 2021, and 12,323,164 shares of ApolloMed&#8217;s common stock as of December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1 &#8212; &#8220;Description of Business&#8221;).</span></div>During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board, of which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of December&#160;31, 2020, the brokerage account only held shares of ApolloMed, as such the brokerage account totaling $7.7 million was recorded as treasury shares. As of April 2021, the brokerage account has been closed.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821351896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Incentive Plans</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2017 Merger, the Company assumed ApolloMed&#8217;s 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;), pursuant to which 500,000 shares of the Company&#8217;s common stock were reserved for issuance thereunder. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of December&#160;31, 2021, there were no shares available for future grants under the 2013 Plan.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the 2017 Merger, the Company assumed ApolloMed&#8217;s 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;), pursuant to which 1,500,000 shares of the Company&#8217;s common stock were reserved for issuance thereunder. In addition, shares that are subject to outstanding grants under the Company&#8217;s 2013 Plan, but that ordinarily would have been restored to such plans reserve due to award forfeitures and terminations, were rolled into and become available for awards under the 2015 Plan. The 2015 Plan provides for awards, including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. The 2015 Plan was approved by ApolloMed&#8217;s stockholders at ApolloMed&#8217;s 2016 annual meeting of stockholders that was held in September 2016. As of December&#160;31, 2021, 2020, and 2019, there were approximately 1.7 million, 0.1 million and 0.5 million shares available for future grants under the 2015 Plan, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans in 2021, 2020, and 2019 and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense related to total share-based payments outstanding as of December&#160;31, 2021 was $21.3&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, stock options were exercised for 40,000 and 0.1 million shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $0.2 million and $0.3 million, respectively. The exercise price was $5.20 per share for the exercises during the year ended December&#160;31, 2021 and ranged from $2.10 to $5.00 per share for the exercises during the year ended December&#160;31, 2020. During the year ended December&#160;31, 2021, no stock options were exercised pursuant the cashless exercise provision. The total intrinsic value of stock options exercised was $2.8 million, $1.8 million, and $2.7 million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. The intrinsic value of stock options is defined as the difference between the Company&#8217;s stock price on the exercise date and the grant date exercise price. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company granted 0.1 million five-year stock options to certain ApolloMed executives with exercise price ranging from $23.24-$80.00. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2021, 2020, and 2019 was $32.63, $9.89, and $11.33, respectively. The options granted during the year ended December&#160;31, 2021 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.45% - 81.10%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.19% - 1.15%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.86-37.82</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s unvested restricted stock award activity for the year ended December&#160;31, 2021 consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted  Average <br/>Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.96</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,202</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.73</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,910)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.03</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,204)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.88</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,507</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$37.84</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to employees and executives, which are earned based on service conditions. The awards will vest over a period of six months to three years in accordance with the terms of those plans. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the year ended December&#160;31, 2021, the Company granted restricted stock awards for employees totaling 0.3 million shares with a weighted-average grant-date fair value of $50.73. The  weighted-average grant-date fair value of restricted stock awards granted during the years ended December&#160;31, 2020, and 2019 was $17.56 and $18.65, respectively. The total fair value of restricted stock awards, as of their respective vesting dates during the years ended December&#160;31, 2021, 2020, and 2019 were $1.1 million, $1.4 million, and $0, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants, to purchase 1,111,111 shares of ApolloMed common stock, issued to NMM in connection with the Series A Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $9.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants, to purchase 555,555 shares of ApolloMed common stock, issued to NMM in connection with the Series B Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $10.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock warrants, to purchase 850,000 shares, for $11.00 per share, and 900,000 shares, for $10.00 per share, of ApolloMed common stock, issued to former NMM shareholders on a pro-rata basis in connection with the Merger, may be exercised at any time after issuance and through December 8, 2022, subject to adjustment in the event of stock dividends and stock splits. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise&#160;Price&#160;Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br/>Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>Per<br/>Share</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.00 &#8211; $11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, common stock warrants were exercised for 0.9&#160;million and 1.2 million shares of the Company&#8217;s common stock, respectively, which resulted in proceeds of approximately $8.8 million and $10.5 million, respectively. The exercise price ranged from $9.00 to $10.00 per share during year ended December&#160;31, 2021 and December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820848360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care (&#8220;DMHC&#8221;). The Company must comply with a minimum working capital requirement, tangible net equity (&#8220;TNE&#8221;) requirement, cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. At December&#160;31, 2021 and 2020, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount of 2% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS and $0 remain outstanding as of December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and Alpha Care established irrevocable standby letters of credit with Preferred Bank for a total of $0.3 million and $3.8 million, respectively, for the benefit of certain health plans (see Note 10 &#8212; &#8220;Credit Facility, Bank Loan, and Lines of Credit&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows, or results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820957160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, NMM earned approximately $18.7 million, $16.9 million, and $17.3&#160;million, respectively, in management fees, of which $7.0 million and $2.3 million, remained outstanding, at December&#160;31, 2021 and 2020 respectively, from LMA, which is accounted for under the equity method based on 25% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $2.4 million, $2.2 million, and $2.7&#160;million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $0, $6.0 million, and $7.8&#160;million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;). In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $0.7 million, $0.5 million, $0.4&#160;million, respectively, to Advance Diagnostic Surgery Center for services as a provider. Advance Diagnostic Surgery Center shares common ownership with certain board members of APC. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $0.1 million, $0.1 million, and $0.1&#160;million respectively, to Fresenius and their subsidiaries for services as a provider. During the year ended December&#160;31, 2021 and 2020, APAACO paid approximately $0.7 million and $0.7 million, respectively, to Fresenius and their subsidiaries for services as a provider. One of the Company&#8217;s board members is an officer of Fresenius and their subsidiaries. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, APC paid approximately $2.0 million and $0.3 million, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shares common a board member with the Company starting in 2019. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, NMM paid approximately $1.3 million and $1.4 million, respectively, to One MSO, Inc. (&#8220;One MSO&#8221;) for an office lease. One MSO is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 6 &#8212; &#8220;Investments in Other Entities&#8221;). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, the Company paid approximately $0, $0.3 million, and $0.5&#160;million respectively, to Critical Quality Management Corp (&#8220;CQMC&#8221;) for an office lease. As of December 31, 2020, the office lease has ended. CQMC shares common ownership with certain board members of APC (see Note 19 &#8212; &#8220;Leases&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, SCHC paid approximately $0.4 million, $0.4 million, and $0.4&#160;million respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC (see Note 19 &#8212; &#8220;Leases&#8221;).</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021 and 2020, APC paid approximately $15.4 million and $0, respectively, to Arroyo Vista Family Health Center (&#8220;Arroyo Vista&#8221;) for services as a provider. The CEO of Arroyo Vista became a board member with the Company in 2021. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;), Aurion Corporation (&#8220;Aurion&#8221;), and AHMC for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion Corporation (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:69.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC &#8211; Risk pool earnings net of claims payment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipts, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the years ended December&#160;31, 2021, 2020, and 2019, the Company has recognized risk pool revenue under this agreement of $60.1 million, $42.6&#160;million, and $49.3&#160;million, respectively, of which $58.4 million and $45.3 million, remain outstanding as of December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, APC paid an aggregate of approximately $34.8 million, $33.1 million, and $30.8&#160;million, respectively, to shareholders of APC for provider services, which included approximately $8.5 million, $9.0 million, and $8.8&#160;million, respectively, to shareholders who are also officers of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2021, 2020, and 2019, NMM paid approximately $44,000, $0.1 million, and $0.2&#160;million to an ApolloMed board member, Matthew Mazdyasni, for consulting services.  </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including Dr. Thomas Lam, ApolloMed&#8217;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable and line of credits from related parties, see Note 6 &#8212; &#8220;Investments in Other Entities,&#8221; Note 7 &#8212; &#8220;Loans Receivable &#8212; Related Parties,&#8221; and Note 10 &#8212;  &#8220;Credit Facility, Bank Loan, and Lines of Credit,&#8221;  respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820930136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit PlanNMM has a qualified 401(k) plan that covers substantially all employees who have completed at least six months of service and meet minimum age requirements. Participants may&#160;contribute a portion of their compensation to the plan, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Participants become fully vested after six years of service. NMM matches a portion of the participants&#8217; contributions. NMM&#8217;s matching contributions for the years ended December&#160;31, 2021 and 2020 were approximately $0.4 million and $0.4 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820747992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per ShareBasic net income per share is calculated by dividing net income by the weighted-average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period. Diluted net income per share is calculated using the weighted-average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for preferred stock and the treasury stock method for options and common stock warrants.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, 2020, and 2019, APC held 10,925,702, 12,323,164 and 17,290,317 shares, respectively, of ApolloMed's common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share (see Note 12 &#8212; &#8220;Mezzanine and Shareholders&#8217; Equity&#8221;). The non-controlling interests in APC are allocated their share of ApolloMed&#8217;s income from APC&#8217;s ownership of ApolloMed common stock and this is included in the net income attributable to non-controlling interests on the consolidated statements of income. Therefore, none of the shares of ApolloMed held by APC are considered outstanding for the purposes of basic or diluted earnings per share computation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,828,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,527,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,708,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,403,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,448,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,403,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,828,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,527,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,708,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,403,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,448,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,403,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821336600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies &#8212; Variable Interest Entities&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8212; related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in a privately held entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investment in affiliates include APC&#8217;s investment in ApolloMed, which is reflected as treasury shares and eliminated upon consolidation. Amount due to, or due from, affiliates are payables and receivables with ApolloMed&#8217;s subsidiaries and consolidated VIEs. As a result, these balances are eliminated upon consolidation and are not reflected on ApolloMed&#8217;s consolidated balance sheets as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364905930280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms ranging from seven months to eight years, some of which may include options to extend the leases for up to ten years, and some of which may include options to terminate the leases within one year. As of December&#160;31, 2021 and December&#160;31, 2020, assets recorded under finance leases were $1.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases was $0.6 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Other information related to leases was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.27 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.26 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company does not have additional operating or finance leases that have not yet commenced.</span><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, physicians&#8217; offices, and certain equipment. These leases have remaining lease terms ranging from seven months to eight years, some of which may include options to extend the leases for up to ten years, and some of which may include options to terminate the leases within one year. As of December&#160;31, 2021 and December&#160;31, 2020, assets recorded under finance leases were $1.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases was $0.6 million and $0.4 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Other information related to leases was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.27 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.26 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company does not have additional operating or finance leases that have not yet commenced.</span><span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820843128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Orma Health, Inc., and Provider Growth Solutions LLC (together, "Orma Health")</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Company announced that it acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#8220;Orma Health&#8221;) in accordance with an agreement between ApolloMed, Orma, and certain equity holders of Orma Health. Per the agreement, the purchase price consists of $2.0 million in cash and shares. Through its suite of AI-driven solutions, Orma Health currently serves over 4,000 aligned Medicare beneficiaries in a Direct Contracting Entity (&#8220;DCE&#8221;) and over 2,500 patients in California, Nevada, Arizona, and Texas through its remote patient monitoring ("RPM") platform.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823272296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared by management in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets as of December&#160;31, 2021 and 2020 and consolidated statements of income for the years ended December&#160;31, 2021, 2020 and 2019 include the accounts of (1) ApolloMed, ApolloMed&#8217;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#8217;s consolidated subsidiary, APCMG; (3) AMM&#8217;s consolidated VIEs, SCHC and AMH; (4) NMM&#8217;s VIE, APC; (5) APC&#8217;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#8217;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment, accrual of medical liabilities (IBNR claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors, and historical margins), income tax  valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Interest Entities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by it in accordance with the consolidation guidance. The evaluation considers all of the Company&#8217;s variable interests, including equity ownership, as well as management services agreements (&#8220;MSA&#8221;). To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company has a variable interest in the legal entity &#8211; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#8217;s net assets.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A legal entity is determined to be a VIE if it has any of the following three characteristics:</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity does not have sufficient equity to finance its activities without additional subordinated financial support;</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or</span></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#8217;s economic performance, as evidenced by:</span></div><div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Substantive participating rights in day-to-day management of the entity&#8217;s activities; or</span></div><div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Substantive kick-out rights over the party responsible for significant decisions;</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The obligation to absorb the entity&#8217;s expected losses; or</span></div><div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The right to receive the entity&#8217;s expected residual returns.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company concludes that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable interest model</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#8211; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#8217;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; to the consolidated financial statements for information on the Company&#8217;s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 6 &#8211; &#8220;Investments in Other Entities&#8221; for entities that qualify as VIEs but the Company is not the primary beneficiary.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text">Reportable SegmentsThe Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Restricted CashRestricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of December&#160;31, 2021 and 2020, investments in marketable securities were approximately $53.4 million and $67.7 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to twenty-four months (see fair value measurements of financial instruments below). As of December&#160;31, 2021 and 2020, certificates of deposit amounted to approximately $25.0 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted-average share prices from observable market data.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#8220;Clinigence&#8221;). The common stock of a payor partner were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#8220;UCI&#8221;) in April 2020. As of December&#160;31, 2021, the equity securities from the payor partner amounted to $24.0 million. As of December&#160;31, 2020, prior to our payor partner&#8217;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#8220;contingent equity securities&#8221;) for $3.0 million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 - &#8220;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#8221; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recognized unrealized losses of $10.7 million during the year ended December&#160;31, 2021 in unrealized gain or loss on investments in the accompanying consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock', window );">Receivables. Receivables &#8211; Related Parties, and Loan Receivable - Related Party</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables, Receivables &#8211; Related Parties, and Loan Receivable - Related Party</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, management fee income, incentive receivables, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements and incentive receivables, management fee income and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s loan receivable - related party consists of promissory notes from payees that are expected to be collected between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5OTk_64bfc1bc-0468-44da-ae64-8adbf345015b">two</span> to four years and accrue interest per annum. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full-risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, FFS reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div>Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#8220;CECL&#8221;) model.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risks</a></td>
<td class="text">Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Land, Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Land, Property, and Equipment, Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMDk1_890dedd3-9639-4f3d-a087-9691ad4f5456">three</span> to thirty-nine years. Leasehold improvements are amortized on a straight-line basis over the shorter of the terms of the respective leases or the expected useful lives of those improvements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FASB Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts, and member relationships and are stated at cost, less accumulated amortization, and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization, and impairment losses, and are amortized using the straight-line method.</span></div>Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 350&#8221;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three reporting units (1) MSOs, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</span></div>At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities - Equity Method</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8211; Equity Method</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity method investments are subject to impairment evaluation. During the years ended December&#160;31, 2019, the Company recognized an impairment loss of approximately $0.3 million related to its investment in Pacific Ambulatory Health Care, LLC as the Company does not believe it will recover its investment balance. Such impairment loss is included in loss from equity method investments in the accompanying consolidated statements of income. There was no impairment loss recorded related to equity method investments for the years ended December&#160;31, 2021 and 2020.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical LiabilitiesAPC, Alpha Care, Accountable Health Care, and APCMG (&#8220;consolidated IPAs&#8221;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. The consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryCashAndPayablePolicyTextBlock', window );">Fiduciary Cash and Payable</a></td>
<td class="text">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Financial Instruments</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Swap Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#8217;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 10 - &#8220;Credit Facility, Bank Loan, and Lines of Credit,&#8221; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of December&#160;31, 2021, was $1.1 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  </span></div><div style="margin-top:11pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement which included the Company purchasing warrants. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of December&#160;31, 2021 was $1.1 million and is presented within other assets in the accompanying consolidated balance sheets.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The Company determined the fair value of the contingent equity security using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company </span></div>considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $4.3 million and is presented within prepaid and other current assets in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. The Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company&#8217;s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions on factors, including but not limited to, historical margin, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared-risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk-share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MDUx_13452d7a-ce48-4cb1-9932-b9a62aad18dd">two</span> performance years through December&#160;31, 2019, which was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MTA3_7004a731-22ef-4a6d-af57-dbde08754dca">two</span> additional renewal years through December&#160;31, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company submitted to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company obtained CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#8217;s in-network contracted providers are paid by APAACO. The Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk-share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency, in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 9 - &#8220;Medical Liabilities&#8221;), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there was any excess AIPBPs for the performance year and the excess is refunded to CMS. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared-risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit for the performance year and therefore this shared-risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $21.8 million and $19.8 million in risk pool savings, related to the 2020 and 2019 performance years, respectively, and has recognized such savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December&#160;31, 2021 and 2020, respectively.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to be eligible in receiving AIPBP under the NGACO Model for performance year 2021, with the effective date of the performance year beginning January 1, 2021. For performance year 2021, the Company received monthly AIPBP payments at a rate of approximately $7.7 million per month from CMS. The monthly AIPBP received by the Company for performance year 2020 was approximately $7.2 million per month. The Company has received approximately $92.4 million in total AIPBP for the year ended December&#160;31, 2021 of which $59.2 million has been recognized as revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors, such as hours staffed, patient visits, or collections per visit, against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients, and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company does not have any contract assets since all obligations have been performed when revenue was recognized. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div>Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based CompensationThe Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#8217;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share (&#8220;EPS&#8221;) is computed by dividing net income attributable to the holders of the Company&#8217;s common stock by the weighted-average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted-average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 17 &#8212;  &#8220;Earnings Per Share&#8221; for a discussion of shares treated as treasury shares for accounting purposes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interests</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text">Mezzanine EquityPursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and ROU asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under twelve month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BeneficialInterestPolicyTextBlock', window );">Beneficial Interest</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Beneficial Interest<br/><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020 was&#160;$15.7&#160;million and was included in other assets in the accompanying consolidated balance sheets. The beneficial interest was the result of a gross margin provision in the stock purchase agreement, which entitled UCAP to potentially receive additional cash and preferred shares (cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale, were held in an escrow account) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varied dependent upon the gross margin as compared to the target but cannot exceed the amounts that were in the escrow account. Additionally, the stock purchase agreement included a tangible net equity provision that could have resulted in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. The Company determined the fair value of the beneficial interest using an income approach, which included significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value, which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment was defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#8217;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7&#160;million was written off and expensed in other income in the accompanying consolidated statements of income during the year ended December&#160;31, 2021.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the FASB issued ASU) No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2021-08&#8221;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently assessing the impact of that adoption of ASU 2021-08 will have on the Company&#8217;s consolidated financial statements. <br/><br/>With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations, and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BeneficialInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BeneficialInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryCashAndPayablePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiduciary Cash and Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryCashAndPayablePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49178521&amp;loc=d3e9162-115647<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823176232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by each payor type (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.144%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.002%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,333&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,340&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,286</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271,596</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,002</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283,311</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269,079</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,596</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third parties</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,985</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,654</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,680</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">773,915&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,618&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text">The Company had major payors that contributed the following percentages of net revenue:<div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.326%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor A</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Less than 10% of total net revenues</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties :</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:73.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.778%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor F</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2021 are presented below (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent equity securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,497&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APCMG contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2020 are presented below (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.098%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:31pt">Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821362712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of Goodwill Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of goodwill activity for the years ended December&#160;31, 2021 and 2020 (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820870200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Land, Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Land, Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land, property, and equipment, net consisted of (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Useful Life (Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,937&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer software</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 39</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property, and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,890&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364824125368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,814&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89,544)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2021, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite lived assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,150&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,749&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,814&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,563)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,997&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,606)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">805&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,729&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(104,922)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, intangible assets, net consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:19.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.682%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Useful<br/>Life<br/>(Years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>January 1,<br/>2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment/<br/>Disposal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross<br/>December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net<br/>December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortized intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Network relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,761&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,715)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Member relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,234)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,270)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tradename/trademarks</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(156)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(89,544)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,985&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands):</span></div><div style="margin-top:17pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,661&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,414&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,908&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364905876312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments, Financial Statement Information</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in other entities &#8211; equity method consisted of the following (in thousands):</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.336%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Initial Investment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allocation of Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contribution</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consolidation of Entity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LaSalle Medical Associates &#8211; IPA Line of Business</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,413&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostic Medical Group</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,943)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">531 W. College, LLC &#8211; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">One MSO, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,910&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-6 Medical Investment Group, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tag-8 Medical Investment Group, LLC &#8212; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,768)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CAIPA MSO, LLC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,306)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,711)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s unaudited summarized balance sheets at December&#160;31, 2021 and 2020 and unaudited summarized statements of operations for the years ended December&#160;31, 2021, 2020, and 2019 are as follows (in thousands):</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020<br/>(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,571)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,834&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,090&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.764%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2021<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2020<br/>(unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>December 31, 2019<br/>(unaudited)</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,964&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,071)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,071)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821350088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other accruals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subcontractor IPA payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due to related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,798&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Total accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,951&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,143&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820956328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">348,273&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,590&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(291,243)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(261,062)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,056)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(342,474)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,118)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,783&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,330&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821478840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s debt balance consists of the following (in thousands):</span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real estate loans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction loan </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,705&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: unamortized financing cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,605)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Long-term debt </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,211&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s debt for the years ending December 31:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.181%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,965&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364906107400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes consisted of the following (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,657)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,952)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,620)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,793)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total provision for income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,454&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets (liabilities) as of December&#160;31, 2021 and 2020 are shown below (in thousands). A valuation allowance of $22.4 million and $15.5 million as of December&#160;31, 2021 and 2020, respectively, has been established against the Company&#8217;s deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $6.8 million in 2021.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax assets </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for bad debts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in other entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized Gain </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,351)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,763)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,117)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,888)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481(a) adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(985)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,373)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,195)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,127)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,959)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation for Provision for Income Taxes</a></td>
<td class="text">The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December&#160;31:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:57.318%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision at U.S. federal statutory rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible permanent items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable interest entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment basis adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817608888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock-based compensation expense recognized under all of the Company&#8217;s stock plans in 2021, 2020, and 2019 and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands): </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,745&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text">The Company&#8217;s outstanding stock options consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled, forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,826)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,965&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, the Company granted 0.1 million five-year stock options to certain ApolloMed executives with exercise price ranging from $23.24-$80.00. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2021, 2020, and 2019 was $32.63, $9.89, and $11.33, respectively. The options granted during the year ended December&#160;31, 2021 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: </span></div><div style="margin-top:17pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75.45% - 81.10%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.19% - 1.15%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:17pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.86-37.82</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock Activity</a></td>
<td class="text">The Company&#8217;s unvested restricted stock award activity for the year ended December&#160;31, 2021 consisted of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.276%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of <br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted  Average <br/>Grant-Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of January 1, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262,419</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$17.96</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,202</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.73</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,910)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.03</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,204)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.88</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested as of December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541,507</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$37.84</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at January&#160;1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,878,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858,583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,803)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.665%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise&#160;Price&#160;Per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual&#160;Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants<br/>Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise&#160;Price<br/>Per<br/>Share</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10.00 &#8211; $11.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.94</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820730472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Income Received Related to AHMC, HSMSO and Aurion Corporation</a></td>
<td class="text">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion Corporation (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:69.757%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC &#8211; Risk pool earnings net of claims payment</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,908&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO &#8211; Management fees, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(629)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aurion &#8211; Management fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receipts, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,977&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,515&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364820863384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.029%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,828,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,527,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,708,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,403,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,448,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,403,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.589%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,828,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,527,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,708,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,029&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,384,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,403,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,448,430&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,403,279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364911929480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Variable Interest Entities</a></td>
<td class="text">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#8217;s other consolidated VIEs were not considered significant.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,863&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8212; related parties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts due from affiliates*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans receivable &#8211; related parties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,145&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in a privately held entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; long-term</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,070,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,591&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,684&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.999%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Investment in affiliates include APC&#8217;s investment in ApolloMed, which is reflected as treasury shares and eliminated upon consolidation. Amount due to, or due from, affiliates are payables and receivables with ApolloMed&#8217;s subsidiaries and consolidated VIEs. As a result, these balances are eliminated upon consolidation and are not reflected on ApolloMed&#8217;s consolidated balance sheets as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364905922696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense and Other Information Related to Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(784)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,407&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Other information related to leases was as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">208&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Remaining Lease Term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.27 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.26 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-Average Discount Rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Operating Leases, Future Minimum Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Finance Lease, Future Minimum Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.520%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.225%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years ending December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">443&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,244&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease obligations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,827&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,198&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">973&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364812626680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 31, 1999</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>clinic </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions of preferred returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,585<span></span>
</td>
<td class="nump">$ 11,354<span></span>
</td>
<td class="nump">$ 49,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,715<span></span>
</td>
<td class="nump">$ 43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Business combination, equity interest purchase obligation, period to purchase</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent', window );">Business combination, equity interest purchase obligation, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Business combination, equity interest purchase obligation, period to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | AP-AMH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Term of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableStatedInterestRate', window );">Stated rate of note of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate', window );">Interest rate in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Initial fixed term of amended and restated management and administrative services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MPP, AMG Properties, and ZLL Asset Acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | ApolloMed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.68%<span></span>
</td>
<td class="nump">22.58%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Concourse Diagnostic Surgery Center, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NoncontrollingInterestSharesDistributed', window );">Noncontrolling interest, shares distributed | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity | AP-AMH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distributions of preferred returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,100<span></span>
</td>
<td class="nump">$ 30,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity | AP-AMH | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Alpha Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Accountable Health Care IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | AMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Maverick Medical Group, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Dr. Jay | Accountable Health Care IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFederallyQualifiedHealthPlans', window );">Number federally qualified health plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AmgIncMember', window );">AMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFamilyPracticeClinics', window );">Number of family practice clinics | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Period to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Modifications, Subsequent Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NoncontrollingInterestSharesDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Shares Distributed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NoncontrollingInterestSharesDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFamilyPracticeClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Family Practice Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFamilyPracticeClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364813360808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,900,000<span></span>
</td>
<td class="nump">$ 294,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Amount of short-term marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,417,000<span></span>
</td>
<td class="nump">67,695,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,024,000<span></span>
</td>
<td class="nump">67,637,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Marketable securities - equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,745,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after performance year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of main reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,534,000<span></span>
</td>
<td class="nump">9,642,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSettlement', window );">Risk pool settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,800,000<span></span>
</td>
<td class="nump">19,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueMonthlyAmount', window );">Payment of revenue, monthly amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueRevenueRecognized', window );">Payment of revenue, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,798,000<span></span>
</td>
<td class="nump">12,988,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Voting rights held (more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember', window );">Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Contingent equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenue', window );">Payment of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities | Interest Rate Swap | Cash Flow Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value, gross liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | UCAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">67,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember', window );">Clinigence Holdings, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireCommonStockAndWarrants', window );">Payments to acquire common stock and warrants</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_CMSMember', window );">CMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport', window );">Expected period of payment upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember', window );">PMPM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember', window );">NGACO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="nump">12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care Inc | UCAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash', window );">Contingent consideration, cash held in escrow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares', window );">Contingent consideration, preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue', window );">Contingent consideration, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care Inc | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional proceeds to be received from sale of equity method investments, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember', window );">PASC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit', window );">Indefinite-lived assets written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableExpectedToBeCollectedPeriod', window );">Accounts receivable, expected to be collected, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Marketable securities, current, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableExpectedToBeCollectedPeriod', window );">Accounts receivable, expected to be collected, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Marketable securities, current, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableExpectedToBeCollectedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Expected to be Collected, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableExpectedToBeCollectedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueMonthlyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Monthly Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueMonthlyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>These lines are represents that risk pool settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 35<br> -Paragraph 32<br> -URI http://asc.fasb.org/extlink&amp;oid=124268079&amp;loc=d3e32787-111569<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset lacking physical substance and having a projected indefinite period of benefit to fair value. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_ClinigenceHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_CMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_CMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificAmbulatorySurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364824384392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details) - NGACO<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Term, performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Term, performance obligation</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2020-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364819193896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Payor Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 773,915<span></span>
</td>
<td class="nump">$ 687,180<span></span>
</td>
<td class="nump">$ 560,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">138,333<span></span>
</td>
<td class="nump">108,851<span></span>
</td>
<td class="nump">107,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">307,286<span></span>
</td>
<td class="nump">271,596<span></span>
</td>
<td class="nump">226,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">283,311<span></span>
</td>
<td class="nump">269,079<span></span>
</td>
<td class="nump">192,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 44,985<span></span>
</td>
<td class="nump">$ 37,654<span></span>
</td>
<td class="nump">$ 34,680<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817573608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net revenue | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net revenue | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="nump">13.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net revenue | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">11.90%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net revenue | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">15.30%<span></span>
</td>
<td class="nump">16.90%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Gross receivables | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">43.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Gross receivables | Payor F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">36.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364824265944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">$ 114,665<span></span>
</td>
<td class="nump">$ 115,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">25,024<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">28,393<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">173,497<span></span>
</td>
<td class="nump">183,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember', window );">Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">114,665<span></span>
</td>
<td class="nump">115,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">25,024<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">24,123<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">163,812<span></span>
</td>
<td class="nump">183,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level&#160;1 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">5,415<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Interest rate swaps</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Contingent Equity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ameh_ContingentEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364812536712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember', window );">Access Primary Care Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">APCMG contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember', window );">Apollo-Sun Labs Management, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Business combination, equity interest purchase obligation, period to purchase</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_DmgMember', window );">DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase', window );">Business combination, equity interest purchase obligation, period to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Equity Interest Purchase Obligation, Period to Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccessPrimaryCareMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_ApolloSunLabsManagementLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822621336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Goodwill Roll Forward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning Balance</a></td>
<td class="nump">$ 239,053<span></span>
</td>
<td class="nump">$ 238,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions</a></td>
<td class="nump">13,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending Balance</a></td>
<td class="nump">$ 253,039<span></span>
</td>
<td class="nump">$ 239,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364813284616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Land, Property and Equipment, Net - Schedule of Land, Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, gross</a></td>
<td class="nump">$ 73,568<span></span>
</td>
<td class="nump">$ 48,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(20,382)<span></span>
</td>
<td class="num">(18,188)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property, and equipment, net</a></td>
<td class="nump">$ 53,186<span></span>
</td>
<td class="nump">29,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, gross</a></td>
<td class="nump">$ 20,937<span></span>
</td>
<td class="nump">9,604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, gross</a></td>
<td class="nump">$ 21,661<span></span>
</td>
<td class="nump">15,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, gross</a></td>
<td class="nump">$ 3,589<span></span>
</td>
<td class="nump">3,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, gross</a></td>
<td class="nump">$ 15,358<span></span>
</td>
<td class="nump">13,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, gross</a></td>
<td class="nump">$ 4,901<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, gross</a></td>
<td class="nump">$ 7,122<span></span>
</td>
<td class="nump">$ 6,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364825716072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Land, Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817069752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Indefinite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(104,922,000)<span></span>
</td>
<td class="num">(89,544,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">80,657,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">187,729,000<span></span>
</td>
<td class="nump">176,529,000<span></span>
</td>
<td class="nump">$ 176,529,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">82,807,000<span></span>
</td>
<td class="nump">86,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired', window );">Additions</a></td>
<td class="nump">11,200,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment/ Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance, Gross</a></td>
<td class="nump">143,930,000<span></span>
</td>
<td class="nump">143,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="nump">6,749,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment/ Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Ending Balance, Gross</a></td>
<td class="nump">150,679,000<span></span>
</td>
<td class="nump">143,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(84,865,000)<span></span>
</td>
<td class="num">(73,169,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 65,814,000<span></span>
</td>
<td class="nump">$ 70,761,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance, Gross</a></td>
<td class="nump">$ 22,832,000<span></span>
</td>
<td class="nump">$ 22,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment/ Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Ending Balance, Gross</a></td>
<td class="nump">22,832,000<span></span>
</td>
<td class="nump">22,832,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(13,563,000)<span></span>
</td>
<td class="num">(11,715,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 9,269,000<span></span>
</td>
<td class="nump">$ 11,117,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance, Gross</a></td>
<td class="nump">$ 6,696,000<span></span>
</td>
<td class="nump">$ 6,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="nump">2,301,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment/ Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Ending Balance, Gross</a></td>
<td class="nump">8,997,000<span></span>
</td>
<td class="nump">6,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(4,606,000)<span></span>
</td>
<td class="num">(3,234,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 4,391,000<span></span>
</td>
<td class="nump">$ 3,462,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance, Gross</a></td>
<td class="nump">$ 2,060,000<span></span>
</td>
<td class="nump">$ 2,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment/ Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Ending Balance, Gross</a></td>
<td class="nump">2,060,000<span></span>
</td>
<td class="nump">2,060,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,682,000)<span></span>
</td>
<td class="num">(1,270,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 378,000<span></span>
</td>
<td class="nump">$ 790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Tradename/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life (Years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRollForward', window );"><strong>Amortized intangible assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Beginning Balance, Gross</a></td>
<td class="nump">$ 1,011,000<span></span>
</td>
<td class="nump">$ 1,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment/ Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Ending Balance, Gross</a></td>
<td class="nump">1,011,000<span></span>
</td>
<td class="nump">1,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(206,000)<span></span>
</td>
<td class="num">(156,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">805,000<span></span>
</td>
<td class="nump">855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward', window );"><strong>Indefinite-lived Intangible Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Additions</a></td>
<td class="nump">2,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Ending Balance</a></td>
<td class="nump">$ 2,150,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite and Indefinite Lived Intangible Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364812511736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 16.0<span></span>
</td>
<td class="nump">$ 16.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">10 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average useful life</a></td>
<td class="text">15 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit', window );">Indefinite-lived assets written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset lacking physical substance and having a projected indefinite period of benefit to fair value. Excludes financial assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MedicareLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817564792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 13,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">11,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">10,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">9,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">8,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">26,908<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 80,657<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817097464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Equity Method (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">$ 43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">11,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="num">(4,306)<span></span>
</td>
<td class="nump">$ 3,694<span></span>
</td>
<td class="num">$ (6,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">1,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="num">(4,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="num">(6,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">41,715<span></span>
</td>
<td class="nump">43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">13,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="num">(5,831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="num">(4,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">3,034<span></span>
</td>
<td class="nump">13,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">1,719<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">2,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="num">(2,943)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="num">(208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">17,230<span></span>
</td>
<td class="nump">17,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">2,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">2,910<span></span>
</td>
<td class="nump">2,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">4,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">4,830<span></span>
</td>
<td class="nump">4,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember', window );">Tag-8 Medical Investment Group, LLC &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">1,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="num">(3,768)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentInvestmentInPeriod', window );">Initial Investment</a></td>
<td class="nump">11,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsConsolidated', window );">Consolidation of Entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 11,992<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentInvestmentInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Investment In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentInvestmentInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Consolidated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364810226296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>provider</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,306,000)<span></span>
</td>
<td class="nump">$ 3,694,000<span></span>
</td>
<td class="num">$ (6,901,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,715,000<span></span>
</td>
<td class="nump">43,292,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,898,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MediPortal LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares', window );">Membership interests purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Payments to purchase membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest', window );">Membership interests acquired (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption', window );">Term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests', window );">Options to purchase additional membership interests (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet', window );">Number of warrants available to purchase, contingent upon the portal completion date (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">NMM | AchievaMed, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears', window );">Percentage of voting common stock, within five years</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment', window );">Duration of investment</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost', window );">Investment amount</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees (more than) | provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,831,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,034,000<span></span>
</td>
<td class="nump">$ 13,047,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business | APC and APC-LSMA | Dr. Arteaga | Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion', window );">Ownership upon conversion of finance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,800,000)<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business | APC | Dr. Arteaga | Notes Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease', window );">Increase in ownership percentage, finance receivable converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719,000<span></span>
</td>
<td class="nump">$ 1,413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC | Ancillary Service Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,613,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss', window );">Initial consolidation gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(208,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,230,000<span></span>
</td>
<td class="nump">17,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party | NMM and APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200,000)<span></span>
</td>
<td class="num">$ (400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,200,000<span></span>
</td>
<td class="nump">$ 17,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party | College Street Investment LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,910,000<span></span>
</td>
<td class="nump">$ 2,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember', window );">One MSO, LLC &#8212; related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,830,000<span></span>
</td>
<td class="nump">$ 4,516,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember', window );">Tag-6 Medical Investment Group, LLC &#8212; related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember', window );">Tag-8 Medical Investment Group, LLC &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember', window );">Tag-8 Medical Investment Group, LLC &#8212; related party | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Loss) income from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember', window );">CAIPA MSO, LLC | ApolloMed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage, Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Options Issued, Option To Purchase Additional Interests, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MediPortalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MediPortalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_AchievaMedInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_AchievaMedInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag6MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_CAIPAMSOLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364813518680">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 233,097<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,608<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">852,363<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and stockholders&#8217; deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115,371<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">460,490<span></span>
</td>
<td class="nump">330,911<span></span>
</td>
<td class="nump">192,335<span></span>
</td>
<td class="nump">$ 181,545<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">852,363<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">773,915<span></span>
</td>
<td class="nump">687,180<span></span>
</td>
<td class="nump">560,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">675,736<span></span>
</td>
<td class="nump">606,677<span></span>
</td>
<td class="nump">528,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98,179<span></span>
</td>
<td class="nump">80,503<span></span>
</td>
<td class="nump">32,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,750)<span></span>
</td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">3,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,294<span></span>
</td>
<td class="nump">122,320<span></span>
</td>
<td class="nump">17,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,619<span></span>
</td>
<td class="nump">9,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">3,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loans receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">696<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,834<span></span>
</td>
<td class="nump">17,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and stockholders&#8217; deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,405<span></span>
</td>
<td class="nump">21,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(20,571)<span></span>
</td>
<td class="num">(4,499)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity, and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,834<span></span>
</td>
<td class="nump">17,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">204,061<span></span>
</td>
<td class="nump">186,964<span></span>
</td>
<td class="nump">194,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220,132<span></span>
</td>
<td class="nump">185,724<span></span>
</td>
<td class="nump">205,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(16,071)<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
<td class="num">(11,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (loss) income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (16,071)<span></span>
</td>
<td class="nump">$ 1,248<span></span>
</td>
<td class="num">$ (11,133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $567.0&#160;million and $576.1&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $91.7&#160;million and $88.6&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively. These VIE balances do not include $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364818806040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loans Receivable and Loans Receivable - Related Parties - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
<th class="th"><div>Dec. 18, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss', window );">Loss recorded, loan receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss', window );">Loss recorded, loan receivable - related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">NMM | MWN Community Hospital LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember', window );">Pacific6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Notes Receivable | Pacific6 | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Notes Receivable | AHMC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Note receivable, amount</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableInterestRateStatedPercentage', window );">Note receivable, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, After Allowance For Credit Loss, Current, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notes Receivable, Related Parties, Noncurrent, Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922352-210448<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI http://asc.fasb.org/extlink&amp;oid=124267575&amp;loc=SL82922355-210448<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (1)<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1404<br> -Paragraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823224056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accounts payable and other accruals</a></td>
<td class="nump">$ 9,583<span></span>
</td>
<td class="nump">$ 9,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">3,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIpaRiskPoolPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">878<span></span>
</td>
<td class="nump">1,378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">2,301<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">16,798<span></span>
</td>
<td class="nump">12,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">10,107<span></span>
</td>
<td class="nump">6,970<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 43,951<span></span>
</td>
<td class="nump">$ 36,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIpaRiskPoolPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of subcontractor IPA risk pool payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIpaRiskPoolPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364819121240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of year</a></td>
<td class="nump">$ 50,330<span></span>
</td>
<td class="nump">$ 58,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquired (see Note 3)</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">347,720<span></span>
</td>
<td class="nump">309,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="nump">553<span></span>
</td>
<td class="num">(3,258)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">348,273<span></span>
</td>
<td class="nump">306,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(291,243)<span></span>
</td>
<td class="num">(261,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(51,231)<span></span>
</td>
<td class="num">(54,056)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(342,474)<span></span>
</td>
<td class="num">(315,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="num">(521)<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of year</a></td>
<td class="nump">$ 55,783<span></span>
</td>
<td class="nump">$ 50,330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364819036168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 187,965<span></span>
</td>
<td class="nump">$ 245,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of debt</a></td>
<td class="num">(780)<span></span>
</td>
<td class="num">(10,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized financing cost</a></td>
<td class="num">(4,268)<span></span>
</td>
<td class="num">(4,605)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">182,917<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember', window );">Real estate loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">7,396<span></span>
</td>
<td class="nump">7,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember', window );">Construction loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion of debt</a></td>
<td class="num">(600)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="nump">$ 180,000<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RealEstateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821556552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">6,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LongTermDebtMaturityAfterYearFour', window );">2026 and thereafter</a></td>
<td class="nump">180,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 187,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LongTermDebtMaturityAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Maturity, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LongTermDebtMaturityAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364809003352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 01, 2023</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Issuance of financing obligation for business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,000<span></span>
</td>
<td class="nump">10,889,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,965,000<span></span>
</td>
<td class="nump">245,705,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,394,000<span></span>
</td>
<td class="nump">$ 9,499,000<span></span>
</td>
<td class="nump">$ 4,733,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG Properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | ZLL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AssetAcquisitionPercentageOfSharesAcquired', window );">Asset acquisition, percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">MPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Minimum debt coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember', window );">MPP | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Minimum debt coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember', window );">AMG Properties | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum', window );">Minimum debt coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember', window );">ZLL | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember', window );">Construction loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000,000<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtCovenantAggregatePurchasePriceMaximum', window );">Debt covenant, aggregate purchase price, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum', window );">Maximum adjusted consolidated leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.06%<span></span>
</td>
<td class="nump">3.48%<span></span>
</td>
<td class="nump">3.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange', window );">Consolidated leverage ratio, annual change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Revolver loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Commitment fee</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.175%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Revolver loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Revolver loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Bridge Loan | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Standby Letters of Credit | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Standby Letters of Credit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction loan | Tag-8 Medical Investment Group, LLC &#8212; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum', window );">Debt instrument, covenant, cash flow coverage ratio, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember', window );">Construction loan | Tag-8 Medical Investment Group, LLC &#8212; related party | LIBOR | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember', window );">APC Business Loan Agreement | Line of Credit | APC | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AssetAcquisitionPercentageOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage Of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AssetAcquisitionPercentageOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtCovenantAggregatePurchasePriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Covenant, Aggregate Purchase Price, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtCovenantAggregatePurchasePriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Incremental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_MedicalPropertyPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AMGPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ZLLPartnersLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ConstructionLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Tag8MedicalInvestmentGroupLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821763400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 22,801<span></span>
</td>
<td class="nump">$ 43,572<span></span>
</td>
<td class="nump">$ 9,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">11,605<span></span>
</td>
<td class="nump">19,155<span></span>
</td>
<td class="nump">5,925<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">34,406<span></span>
</td>
<td class="nump">62,727<span></span>
</td>
<td class="nump">14,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(3,794)<span></span>
</td>
<td class="num">(4,963)<span></span>
</td>
<td class="num">(3,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2,158)<span></span>
</td>
<td class="num">(1,657)<span></span>
</td>
<td class="num">(3,285)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="num">(5,952)<span></span>
</td>
<td class="num">(6,620)<span></span>
</td>
<td class="num">(6,793)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total provision for income taxes</a></td>
<td class="nump">$ 28,454<span></span>
</td>
<td class="nump">$ 56,107<span></span>
</td>
<td class="nump">$ 8,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364812560792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 22,351<span></span>
</td>
<td class="nump">$ 15,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, increase</a></td>
<td class="nump">$ 6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_OperatingLossCarryforwardsExpirationPeriod', window );">Net operating loss carryforwards, expiration period</a></td>
<td class="text">2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_OperatingLossCarryforwardsExpirationPeriod', window );">Net operating loss carryforwards, expiration period</a></td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 97,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">77,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 120,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_OperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carry forwards Expiration Period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_OperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822459544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State taxes</a></td>
<td class="nump">$ 2,379<span></span>
</td>
<td class="nump">$ 3,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,864<span></span>
</td>
<td class="nump">3,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Allowance for bad debts</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxAssetsInvestment', window );">Investment in other entities</a></td>
<td class="nump">3,289<span></span>
</td>
<td class="nump">702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">28,992<span></span>
</td>
<td class="nump">20,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">4,208<span></span>
</td>
<td class="nump">4,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities', window );">Unrealized Gain</a></td>
<td class="nump">3,007<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">44,597<span></span>
</td>
<td class="nump">35,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(22,351)<span></span>
</td>
<td class="num">(15,517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">22,246<span></span>
</td>
<td class="nump">20,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(777)<span></span>
</td>
<td class="num">(661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangible assets</a></td>
<td class="num">(23,763)<span></span>
</td>
<td class="num">(24,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilitiesStockOptions', window );">Stock options</a></td>
<td class="num">(1,641)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(4,117)<span></span>
</td>
<td class="num">(4,888)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts', window );">Debt issuance cost</a></td>
<td class="num">(988)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilities481aAdjustment', window );">481(a) adjustment</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(985)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(31,373)<span></span>
</td>
<td class="num">(31,195)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred liabilities</a></td>
<td class="num">$ (9,127)<span></span>
</td>
<td class="num">$ (10,959)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxAssetsInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxAssetsInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilities481aAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, 481(a) Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilities481aAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilitiesStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilitiesStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364813301144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax provision at U.S. federal statutory rates</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes net of federal benefit</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">8.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment', window );">Non-deductible permanent items</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary', window );">Variable interest entities</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(2.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent', window );">Investment basis adjustment</a></td>
<td class="num">(2.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Effective income tax rate</a></td>
<td class="nump">36.90%<span></span>
</td>
<td class="nump">31.30%<span></span>
</td>
<td class="nump">31.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the effective income tax rate reconciliation of federal rate adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Investment Basis Adjustment, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817170088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfSharesHoldbackPercentage', window );">Number of shares holdback percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by based payment award outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,965<span></span>
</td>
<td class="nump">725,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodShareConversionOfNotes', window );">Stock issued during period share conversion of notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueConversionOfNotes', window );">Stock issued during period value conversion of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,089<span></span>
</td>
<td class="nump">$ 51,319<span></span>
</td>
<td class="nump">$ 61,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember', window );">Allied Pacific of California Brokerage Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by based payment award outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,380<span></span>
</td>
<td class="nump">1,519,805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_Warrant1Member', window );">Warrant 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_Warrant2Member', window );">Warrant 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_FormerShareholdersOfNmmMember', window );">Former Shareholders of NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,675,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APAMHMedicalCorporationMember', window );">AP-AMH | Affiliated Entity | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued during period new issues</a></td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Interest costs incurred</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,900<span></span>
</td>
<td class="nump">$ 136,600<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,925,702<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Payments of ordinary dividends common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_NetworkMedicalManagementMember', window );">NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,397,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfSharesHoldbackPercentage', window );">Number of shares holdback percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationNumberOfSharesHeldBack', window );">Number of shares held back (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,039,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationNumberOfSharesHeldBack">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number Of Shares Held Back</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationNumberOfSharesHeldBack</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfSharesHoldbackPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of shares holdback pursuant to the merger agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfSharesHoldbackPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodShareConversionOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of stock issued during the period upon the conversion of notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodShareConversionOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueConversionOfNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueConversionOfNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ameh_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_Warrant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ameh_Warrant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_FormerShareholdersOfNmmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_FormerShareholdersOfNmmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817288984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 08, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod', window );">Cashless options, exercises in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.74<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32.63<span></span>
</td>
<td class="nump">$ 9.89<span></span>
</td>
<td class="nump">$ 11.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod', window );">Warrants exercises in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Warrant issued during period value stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="nump">$ 10.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares)</a></td>
<td class="nump">555,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares)</a></td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | $10 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares)</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable weighted average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Share-based compensation arrangement by share based payment award, warrant exercised, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="nump">9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable weighted average exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Share-based compensation arrangement by share based payment award, warrant exercised, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember', window );">APC Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds for exercise of options and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executives | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Executives | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Board Members and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.73<span></span>
</td>
<td class="nump">$ 17.56<span></span>
</td>
<td class="nump">18.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (In dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ameh_EquityIncentivePlanTwentyThirteenMember', window );">2013 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ameh_EquityIncentivePlanTwentyFifteenMember', window );">2015 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of share available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued During Period Value Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_A11CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ameh_A11CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ameh_A10CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ameh_A10CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_ExecutiveOfficerAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_ExecutiveOfficerAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ameh_EquityIncentivePlanTwentyThirteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ameh_EquityIncentivePlanTwentyThirteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ameh_EquityIncentivePlanTwentyFifteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ameh_EquityIncentivePlanTwentyFifteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821035032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 6,745<span></span>
</td>
<td class="nump">$ 3,383<span></span>
</td>
<td class="nump">$ 1,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">2,480<span></span>
</td>
<td class="nump">1,763<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 4,265<span></span>
</td>
<td class="nump">$ 1,620<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ameh_StockAwardsAndUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364819047288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">813,965<span></span>
</td>
<td class="nump">725,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">137,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(40,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options canceled, forfeited or expired (in shares)</a></td>
<td class="num">(9,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">813,965<span></span>
</td>
<td class="nump">725,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">618,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">66.29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Options canceled, forfeited or expired (in dollars per share)</a></td>
<td class="nump">3.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">22.74<span></span>
</td>
<td class="nump">$ 13.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 10.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">2 years 1 month 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 37.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823003368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details) - Executives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">75.45%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.19%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock</a></td>
<td class="nump">$ 12.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.15%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock</a></td>
<td class="nump">$ 37.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822631240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Activity (Details) - Restricted stock awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of January 1, 2021 | shares</a></td>
<td class="nump">262,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares) | shares</a></td>
<td class="nump">332,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(39,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(13,204)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested as of December 31, 2021 | shares</a></td>
<td class="nump">541,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant-Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 17.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value granted (in dollars per share) | $ / shares</a></td>
<td class="nump">50.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">17.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">29.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 37.84<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822463480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Warrant (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesWarrantsRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,878,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(858,583)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Warrants forfeited (in shares)</a></td>
<td class="num">(17,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,001,740<span></span>
</td>
<td class="nump">1,878,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageExercisePriceWarrantsRollForward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding (in dollars per share)</a></td>
<td class="nump">$ 10.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">10.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod', window );">Warrants forfeited (in dollars per share)</a></td>
<td class="nump">9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Warrants outstanding balance</a></td>
<td class="text">11 months 8 days<span></span>
</td>
<td class="text">1 year 7 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value (in millions)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Warrants granted</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">41.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Warrants forfeited</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">$ 63.1<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageExercisePriceWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedAverageExercisePriceWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364818717496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="nump">$ 10.39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">515,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual&#160;Life</a></td>
<td class="text">11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">515,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">486,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual&#160;Life</a></td>
<td class="text">11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">486,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">1,001,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual&#160;Life</a></td>
<td class="text">11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">1,001,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823267080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount', window );">General amount of guarantee (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="nump">$ 187,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member', window );">Alpha Care | Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">14,800,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financial guarantee on benchmark Medicare expenditure amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PercentageOfFinancialGuaranteeBenchmarkAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364812946968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 6,375<span></span>
</td>
<td class="nump">$ 52,743<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember', window );">CQMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceServicesRevenue', window );">Risk pool revenue recognized under agreement</a></td>
<td class="nump">60,100<span></span>
</td>
<td class="nump">42,600<span></span>
</td>
<td class="nump">49,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Remaining outstanding under agreement</a></td>
<td class="nump">$ 58,400<span></span>
</td>
<td class="nump">45,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">17,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from related parties</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | One MSO, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | Director | Consulting Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses from transactions with related party</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | One MSO, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Provider services | PMIOC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Provider services | DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">7,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">$ 34,800<span></span>
</td>
<td class="nump">33,100<span></span>
</td>
<td class="nump">30,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | APC | Provider services | PMIOC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | APC | Provider services | DMG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Advance Diagnostic Surgery Center | Provider services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Fresenius | Provider services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Fulgent Genetics, Inc. | Provider services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Arroyo Vista Family Health Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Officer | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">8,500<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApaAcoIncMember', window );">APAACO | Fresenius | Provider services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_SCHCMember', window );">SCHC | Numen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related party</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.1,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ameh_ConsultingServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ameh_ConsultingServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FreseniusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_FulgentGeneticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaFamilyHealthCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ArroyoVistaFamilyHealthCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaAcoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaAcoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_SCHCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_SCHCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822554008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Receipts, net</a></td>
<td class="nump">$ 45,977<span></span>
</td>
<td class="nump">$ 27,515<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet', window );">AHMC &#8211; Risk pool earnings net of claims payment</a></td>
<td class="nump">46,908<span></span>
</td>
<td class="nump">28,767<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">(629)<span></span>
</td>
<td class="num">(949)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember', window );">Aurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">$ (302)<span></span>
</td>
<td class="num">$ (303)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Services Revenue, Capitation, And Claims Payment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364905934968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DefinedContributionPlanServicePeriod', window );">Defined contribution plan, service period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DefinedContributionPlanVestingPeriod', window );">Employee benefit vested estimated year</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer discretionary contribution amount</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DefinedContributionPlanServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Service Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DefinedContributionPlanServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DefinedContributionPlanVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DefinedContributionPlanVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823092696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">10,925,702<span></span>
</td>
<td class="nump">12,323,164<span></span>
</td>
<td class="nump">17,290,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364823210296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 0.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">43,828,664<span></span>
</td>
<td class="nump">36,527,672<span></span>
</td>
<td class="nump">34,708,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted (in shares)</a></td>
<td class="nump">45,403,085<span></span>
</td>
<td class="nump">37,448,430<span></span>
</td>
<td class="nump">36,403,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817554040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Summary of Shares Included in Diluted Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">43,828,664<span></span>
</td>
<td class="nump">36,527,672<span></span>
</td>
<td class="nump">34,708,429<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">45,403,085<span></span>
</td>
<td class="nump">37,448,430<span></span>
</td>
<td class="nump">36,403,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">819,151<span></span>
</td>
<td class="nump">717,029<span></span>
</td>
<td class="nump">1,384,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">495,618<span></span>
</td>
<td class="nump">182,999<span></span>
</td>
<td class="nump">295,672<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Management restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">23,824<span></span>
</td>
<td class="nump">7,242<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | Executive restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">235,828<span></span>
</td>
<td class="nump">13,488<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822919480">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 233,097<span></span>
</td>
<td class="nump">$ 193,470<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,417<span></span>
</td>
<td class="nump">67,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,608<span></span>
</td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">69,376<span></span>
</td>
<td class="nump">49,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,647<span></span>
</td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,637<span></span>
</td>
<td class="nump">16,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">398,782<span></span>
</td>
<td class="nump">338,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">82,807<span></span>
</td>
<td class="nump">86,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">253,039<span></span>
</td>
<td class="nump">239,053<span></span>
</td>
<td class="nump">$ 238,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,715<span></span>
</td>
<td class="nump">43,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,441<span></span>
</td>
<td class="nump">18,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,928<span></span>
</td>
<td class="nump">18,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">453,581<span></span>
</td>
<td class="nump">478,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">852,363<span></span>
</td>
<td class="nump">817,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,951<span></span>
</td>
<td class="nump">36,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">55,783<span></span>
</td>
<td class="nump">50,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">652<span></span>
</td>
<td class="nump">4,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">486<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,629<span></span>
</td>
<td class="nump">3,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">780<span></span>
</td>
<td class="nump">10,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">115,371<span></span>
</td>
<td class="nump">114,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,127<span></span>
</td>
<td class="nump">10,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">973<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,198<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">182,917<span></span>
</td>
<td class="nump">230,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,777<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">220,992<span></span>
</td>
<td class="nump">257,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">336,363<span></span>
</td>
<td class="nump">372,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">161,762<span></span>
</td>
<td class="nump">126,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,066<span></span>
</td>
<td class="nump">67,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,251<span></span>
</td>
<td class="nump">5,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">62,180<span></span>
</td>
<td class="nump">46,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,833<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,734<span></span>
</td>
<td class="nump">14,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loans receivable &#8212; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliates', window );">Amounts due from affiliates*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,598<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">305,766<span></span>
</td>
<td class="nump">261,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,547<span></span>
</td>
<td class="nump">27,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,282<span></span>
</td>
<td class="nump">69,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,656<span></span>
</td>
<td class="nump">109,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesNoncurrent', window );">Loans receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">89<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">802,821<span></span>
</td>
<td class="nump">225,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,715<span></span>
</td>
<td class="nump">43,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in affiliates*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">405<span></span>
</td>
<td class="nump">36,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,953<span></span>
</td>
<td class="nump">6,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,219<span></span>
</td>
<td class="nump">17,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,070,687<span></span>
</td>
<td class="nump">539,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,376,453<span></span>
</td>
<td class="nump">801,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,591<span></span>
</td>
<td class="nump">12,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,534<span></span>
</td>
<td class="nump">9,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalLiabilitiesCurrent', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,000<span></span>
</td>
<td class="nump">37,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">556<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Amount due to affiliate*</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">110<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">780<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">68,821<span></span>
</td>
<td class="nump">89,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">9,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">193<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,950<span></span>
</td>
<td class="nump">5,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,114<span></span>
</td>
<td class="nump">7,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,614<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,853<span></span>
</td>
<td class="nump">22,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 91,674<span></span>
</td>
<td class="nump">$ 111,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company&#8217;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $567.0&#160;million and $576.1&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $91.7&#160;million and $88.6&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively. These VIE balances do not include $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 18 &#8211; &#8220;Variable Interest Entities (VIEs)&#8221; for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.11)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822430952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization associated with finance leases</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms, operating</a></td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Remaining lease terms, financing</a></td>
<td class="text">7 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Remaining lease terms, operating</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseTermOfContract1', window );">Remaining lease terms, financing</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364825481640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 6,025<span></span>
</td>
<td class="nump">$ 6,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract', window );"><strong>Finance lease cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease expense</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(852)<span></span>
</td>
<td class="num">(784)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 5,407<span></span>
</td>
<td class="nump">$ 5,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364822631528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 6,083<span></span>
</td>
<td class="nump">$ 5,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">6 years 3 months 7 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">3 years 3 months 3 days<span></span>
</td>
<td class="text">3 years 8 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted-Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">4.53%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364821527240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">2,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">2,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">19,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">3,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">15,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">2,629<span></span>
</td>
<td class="nump">$ 3,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">13,198<span></span>
</td>
<td class="nump">15,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease obligations</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease obligations</a></td>
<td class="nump">$ 973<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140364817540008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - Orma Health, Inc., and Provider Growth Solutions LLC - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($) </div>
<div>patient</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred | $</a></td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfDirectContractingEntityPatients', window );">Number of Direct Contracting Entity patients</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfRemotePatientMonitoringPatients', window );">Number of Remote Patient Monitoring patients</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfDirectContractingEntityPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Direct Contracting Entity Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfDirectContractingEntityPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfRemotePatientMonitoringPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Remote Patient Monitoring Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfRemotePatientMonitoringPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>ameh-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ameh="http://www.apollomed.net/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ameh-20211231.xsd" xlink:type="simple"/>
    <context id="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icc6ae380313d4f9e9297cfdbf9b997ac_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib7afb98c0185462db67289bfa9ee20c8_I20220216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2022-02-16</instant>
        </period>
    </context>
    <context id="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8759c801140b4316acf0688d1a7d8073_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib3a3083cbe3b4707adbb02b65c588a45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34d8f20402a94db18c5d908913c78e54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0648fafc89a544e7a200bb47e8fe8e6e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iae936f11a7bb4e4c99d3fe13851ffc0b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i830aa1f9bb124cffa1eb7bbc0aff0ad3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic0bca0ca7ef34b17b7aa1fbeb535bbf0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id541469a4a79478381a9bc7f4f5a6536_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb259c5215b44e0591d9d9fe4eca90e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i612cc8b6b50c4dd986466df93d1b6382_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6dc831eca8c24ab395130475d7b38dd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idea8035697aa431d99f99268b6c7d832_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2efb609fa90049de89473edcbce394a5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i872c7cf84d474bde9cbecebf6dc0d987_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2292f34b157f4b3b842835c609844787_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id823cee670274003a572be40978abfb9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38935258fdd640ccbf3015940e510e1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iea80e278e3444cafa519677345773d02_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69d3506ad61545a28e82fbaea4860bd7_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i238ec269dd2b4e39bf78ffb28244ae9f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5dc7a8bb404d44d6a025101ce145ebcb_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1890ce55fe054d5fb8532b6899d89386_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i64bc2b851e8049a69e6c4252d1789f5a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i51d91826c13e48f9ac3b196f1709cf0c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i69343d65ad324809810e1b1eda1dbc7d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:HoldbackSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6084317bda0d48f9b2293ce7324d000d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibae93612a82b454fad4c214ad4fbe93f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59f1b5c490b84fb7bcd0e27816f8a1fd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic665959fd8094aba83a52190f5ce2a29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7108c557e599411aa1a3345423fbcaf2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2666f9aebddc43b295ec38700190d8f9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd090b6a4d07450b83ab3ba19b8a8b82_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idcca7582879a462a8ca400618dab2e16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbb14ec4c3d04df498362b3ff2649443_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3ebd2bb3cc9f4ccfb1e9e646ea718b5a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6b34f542dee746a88ed1f03df4889be3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i76474cb8ad064d37a1739d166c60efc9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c0752ab08774f379384a68ffb9687d6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i346e155972b041b3a6f575e701ef481d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92f73d2de50b4e529703a74542535701_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i02229923c53147db941db9c29b48ab30_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic922097b0d6044c2893f7d407499ba35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1c75cb4bf9e4ad79f118905ac2df40d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0088a70f180a4664865e2acb1ce90bce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i97a105ebf2734bc999cb1eda989a2bf9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ca318fe85484ec8995fd60b38993065_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f341ffb85ca4a0a9602302c5c3d5969_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0a787853fb4e44ab97a431b68a27e17f_D19990701-19990731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-07-01</startDate>
            <endDate>1999-07-31</endDate>
        </period>
    </context>
    <context id="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i075d8ca8fc3540c08520741050fea395_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia2b7ab46ec1f4230b17c5bc1355ea969_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibb9136ad4e1240bd8120581c09a56b83_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic93862edf0d94e38a0905a9d5e2a7e97_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i730fecde417c468e90d3113624967018_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia7b9267d39a0457aa1e20e58ddb345e4_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9d2380fc33084f94b7a593212ef66566_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i439aed610b4a4563872164ecdf084f75_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica1cde9ee4cb4494b58321188ad95db5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4bb40e84ae24fb4b5080af0965a1437_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8c3dd0689a5341d584d1b40693f33ff1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5742adc9978b45aaa40335db8f9111dd_D20190531-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="i45ba50ac0812478a8bf374d9030b66b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i82f8e127a67545b3bdfa58cfd22513c0_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i2f4a82d79e57442f9d6db8a9a608f3ff_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="ide47e2643c3c4ee5a76d35bfdd8a6db7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8e95cb40b2041898bc0dd250b3bf3a3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6eb95e4e08f44ee1bbc425d9152ac541_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i971fe048ecb4482193d9bb6633606328_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i38c118bd8bb54e4d9429b7ddcd63c503_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa8a8f6914b344759eab7b2e8596a641_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i47097cefe18c427f8543ad5cd7663066_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fb44b3ad67c4065a24264c841b2285a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MPPAMGPropertiesAndZLLAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iff99085ba68941a1a5742e3e59299a26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2bb290c80ed04d9284ae72a27d2b780d_I20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="i6e863e59c64443d08c0faadab68620e3_I20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="ie58240bdc60b46879e56e7842cd94022_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i843561394b2844a9b8120f9bad1daee3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56fd8a6fc7d245bdbb1e814caed96cee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d60f7810f154d9185d11b65f7a20684_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f06cfd6220a4db180cc0a47fb336fc4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i302d9a0e032749edb6f74c01755fae4b_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="iac5f8642c01d4d23bd5b08e841100c8c_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:ClinigenceHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if2fdbacce1904cf3912b442f8c709d96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i32f8e0c168ce444ca00cbd5129aa617a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0587413f1c6a47c099219d283492a39a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16b60c8d266045aa80eb56cf8c52109f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i745de55cc97343cf9f5cd4dd3f327d33_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56c70a6d6fd1473aa3326d1e1d7c1a0b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id30a014ea9a543089265dbe3894f75f9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i68bb08ba38e94f7bb612b424801b2a5c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29d8221e56424d85ab5b7cc79c7ebe1e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i022a5fa7aae74c619acb43e67e97eda4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e2e545c192042c0a652056f20110ef6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8391dd985bc48f89be89e25c7043816_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9926274bc8d84660ae987c991d85aa80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic4300a3b054a47eb9093ebb87d484b6d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic95b069367b24fd890ebdca632ea58eb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8ce2f24276fa40f1bac2f8b82eb3561d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5c991f317b8a4c638731da2d2c41fbf7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i943dfe63e2ab45ca9f085402af19715d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fc1a4e79592432dbc61f090c132bdce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2ca388db64744f11a4ecfa00deef6721_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i056d175194ad41b1a26e434846bc2bb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic80816a284004c57bc9d57607f50fae6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idc61efd9b3fb4b72af24435b0ac021d3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2f42dcbfcf6e414f9c2f53ca2fd539fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib36036ab49044648a373020e6e50c5c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8b6bca11224045aab99c0deaf9679a62_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i43b900167e4147608494071af8a327e5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9e05dc98d4304124b10db253c8d59d8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i213a44cfc3bd4b5682c262ca824b12b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c0aa3b01d794603ada2fd543a712bb9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a462e81bf45445cb29240d95de98506_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1797fd6783dd4f6a8e55c48ac402e7d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ice50008825b6453b900419be6e538d60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f29656902d24bac845ed6c3e1313c72_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ameh:ContingentEquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i724f9c4c78a84bb5b1cf0f0c80000aa7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a44a937b1d142b3bfe3aa76130e4ed1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e0046d91fd144e69bc896e9a3d03eb3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifb3ead10c02740de85a4ae1939f70f28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8cc51db51b6476f9350d45ef801fbe2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i015c75fcf61d4986bcc5f227b6c412de_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i62aa39d44086415d845d34f0d7dc7a73_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i144871d547d04bfcb5651aa2b05ed3f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iba8abaa0013749f6a54d7e3495c4052d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificAmbulatorySurgeryCenterLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i04a8b2897992491a9bba33dd880b5e6f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f20c7ee23624be2a07a0c15e0ad0c80_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfa29991cc184f5ab71a9689f9e7cbb3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i889c185a8f9149ea80fad8d3964a0104_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2020-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id558792183dd45c2a570c57e2912737a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i332f5bcb413946b09f9ee77d790f9a78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86e83dd845b24aafb3a23652cf069056_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icd3bc75cd44b41e18d64665e42101205_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i2125de0047684f7088debca1f678a717_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i1ee954aec3cb404a92c9fa15cd03d7f5_D20210731-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-31</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i839af06b2bf7483780595e14fb317ba9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccessPrimaryCareMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if75a131bd7e744b5a823cd87fdb684fe_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:ApolloSunLabsManagementLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="id201e64241bd4df388bd1b11f4019ca1_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:DmgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="ie51111a66dda4ebb9aba6212e6167b7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia31747ce9de543bc82b00188c7aa83e7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0b2e1de018d94f24b2a76496127751c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9e99a95143da4c8eaf2dd4d3559ccdbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5051abc09bc4fa69a0f957f3c5b0241_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie4f0ad5790334506970900a82f46c08f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i487033aa27ad4f9b9271e75aa8aa3a91_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaff2efa428034a01ba020fb02de6fc10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifea711226dc146e9810f79de10c986d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9c77143a62554eab971843dd2d16ee2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27538f0196b542fc85d8c25bf235059d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia5c3bdf2fd4b4890ae012255fe841f5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i024a6dcb30a242cb813e9f1ccb581b12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i676fdea1181f4e9193158b995298022b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53efa605f72144cf9c19b468aa9c14af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2582d81f93dc42f1a148af1c328393bb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88445e03e6ca41139c3da34cf3553c19_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf6b316b9ec34ba09028e2941bda64c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b75bb3419b74b6db04ab86aac159bb2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icc4cabdf561f47f68984b36789e4965c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i42823650eb854b4f9ee2477d31236773_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib13a44368edd4777a7c9cfc306a21f2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MedicareLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d8e768a8482425ba021a05970238a2f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i008c29b02c5e4ce5a69883a33d891ded_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2878f7db1e942a9b61dbbd3d355573f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9cdc0c8a020740599e30d4e0c3298af2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia10dba65880142848189a35b3d649ae5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35497baacaae4c5f8085541195e2dbab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab7fa92aa24446d18fe184c6400b9ba3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i52ebf6aeee1a415ca258abe927ecdc64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia464591a552f4ad4a88bc800875941fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if9eee87a655349b195602787d695ad5b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i40c3a0315be548acb27758e893a56720_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i749dc1caa7f94b5a8d9ae541374197c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb8f4c6415114fdab30e95d035c48f77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e30d0a130514a509245b1d72aa48f0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i74208b2350a54619bb22d219854dc476_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f9f2d34982748f39594f8bbf5d26296_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i49479cdc0b20425392e36614906e56d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic77befc8ecf64d6390b3232a58d0202f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i503c88657b144f3aab4aa1799044b19f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefca0b3acca84ef39bac26666af72183_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibc7ce9f2aefb4de8b0e4a49738897718_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b87107110124a33ad3ed49dca12817e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f9c8db35dd1455cbb9efcf67a63698b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i110382789db14433b603074a67e42a36_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13903951d2fc4cb3a6f3cc653bc12796_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i898d05e125bd4e44b591badacf6f75fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i731e915d69124743b66363b19a199dda_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4ca09a27d4e24e43ac205809e114b053_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f6c47496c364a6b8c27c34e249b3a21_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cce677040344f7c94c12092ed289604_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i273a684a3d8b492283839a5d9ccc76b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifa85536a036b46379cea77c234a086b4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibbf87ab1f75b4885966e552286174dd2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c28398a7a274eb28a70bc44722ecef4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id52e19518ae34e748e1b53e56a606015_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id249748cb92647bcb3ae2fe466c5b254_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0412a16b622b47b881cd9067167d397e_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="i198ab6e687c84de2a822e8318e6dfb6d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idbbeb1f862bf450891db9fb5dfd9a221_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8cb8cf60062647d29f8c59848644f427_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i03f22c6e36ab4bd4853b9f3b723fc918_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic37f82250e404856a1dcea1915c8a4f9_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="iee587da7f4aa43ada9b4e8471a61bc94_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c187ffabbda44aca5a5d84550b8aa79_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib555dbec242444c28b4456bb93f2b6f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic9a36e1a441145a19e883235e84ce38a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if37956fe79bf4000a19ec8e8571ca1cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i18d99fc8fa9b454a8bd0c6ed6faa3ba9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5061a26c78b5403a92ef0a14467a0063_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdc98f3cf1ce4c1d8a0b83f75ea36297_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iad767e257dc04de09097654e8d9ea038_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0d13a567771417b82eab2d872ffeddd_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i00e772255fe246ffa225f111f36bbee4_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="id948340a0f0b4857bed7bfd4a5db9f4c_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="ib63764ca4e84414c81bcc395ce6a0848_I20190423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="ief1111e9e2a048a785ec584e3a23c0db_I20190423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="ib8eb23240eab47278ba31489ec5f4074_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie652a00fea2c45bba68f168cd6fd0326_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4819e77fc964fe284f83cd52ffd9bed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ice49c40a4d0b40009b5fc8fabf4890d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i28a5796b7a274d6dac1cfafd9d65e199_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1154256fe1de45f59c9c10c10c8ab21b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic23531b109fe425ea37a2b8d6a5e782b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0037e84ba38f4a3e9dfb06a8532434cb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag6MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8e6770db7ed467b9bfa172bb05c7567_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id671637d094b4da9baff3726eb0bb9ef_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i8fd1339411804f9e8ee4a8aaa22a5cc7_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i100c286c449b435198ed0d3c17cfbda1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2ab282e08eee4f75b09eb011582c6e08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:CAIPAMSOLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i81be945f4a484abab03ca823d400fb2d_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="id0caec3bea3f4eaa9e7ff87ad11adae8_D20190701-20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="ib53fcc8b36514b66982fc74e646bd81d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieef9d826ba6d40728e8ea8794c1ba388_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i604b63e710a74052bd5134a326c3b521_I20181218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="ie2dacf52383a475da0334f0ba9ad8b31_I20181218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="i3069a2df4dba45069c16005bfe7c95a9_I20181218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-18</instant>
        </period>
    </context>
    <context id="idb1195755b784aa8b53f18c076ac879d_I20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="i2c9d54cb427946a28f7ce5949115e202_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i3f1e6664f4ef468db3a85b5fe37e8ad0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ec0825cadd340a0b4abec77e08752ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1018ea938faa4df890ec9e0a02e9cd39_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i805098d929664b258e9e02430e3446f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2087645dd294b50b435fd15e8f370f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i79361bf90da942189dd476704c690d21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6eba764439774dedac07edaac463b53b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RealEstateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife653c4fcbb243abb96d4ba2a5ef5c68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9caf120fa2d4bb9a623a159c3d8cb6b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iae23f71d35ba49afac259c7ec4de8fd2_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ief487b48631e4a36972039b3bafdc0c5_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i00679cfa5a534ce9a92bdb137b52ec50_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="ie551eb427ed34af7aa4c793742c0e19a_I20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-16</instant>
        </period>
    </context>
    <context id="i0a6bb0cac4404e838f3cb21cb1f78f8a_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i87ee29c5cb344aa98db576466c4bfb91_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="id3d5ec03a2b04b30a66a4a30c5784f2b_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="idfb4fbfb2ec34149b57c0fb417d25c41_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="ibf89debf8d114314b44b8b7514c5ed0e_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i4b9c42d5297743dda47552322302b667_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i6900356a9b954339b957ad128fe7fb9e_D20210616-20210616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-16</startDate>
            <endDate>2021-06-16</endDate>
        </period>
    </context>
    <context id="i5ac4990f656442ea8b9d9d247491dc90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c7dc17bcbe04fb4904d893562ad225d_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e78513b2a054c24a539e76d8c9ed784_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i61742fc5636f4d02a62b8ec226f2b8a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib09048f44b5646e98a8d38401a6e9317_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iabfdc0514ad04c73ab76b77f6739e8e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i447604f483784ad082efe8790195e57c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d459770fc824dfd85b90f08dcfec692_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MedicalPropertyPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9b39ded9aa144fe959c2e5f7e0cdc81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i031524a8f2864901a900ba1a85eaecbf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6b9e264b58ec4372891355322134a590_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AMGPropertiesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie560514b2ee1454a9f9e0ab9ae48bb1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86ab3861fcda413d815e58a991ea9bf7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i92cd58fb0c7d4588b4469022555c03b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ZLLPartnersLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9bd4ffb9558045b08ca6250bddb77123_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i7511f70c51f546fab2df45ef49ea60d1_D20230101-20231201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-01</endDate>
        </period>
    </context>
    <context id="i22b6c0d320cb4d01aef31c88d0405025_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ConstructionLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Tag8MedicalInvestmentGroupLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4df55a8afb084316ae481f2b066f353f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib42cdd50cdf8449ea72386bfca57f57e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i53c301d60fb84feb86e40458baac030a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7f03a46a00b3442fa2d6f0b063116153_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7d5181abc61c4949b5e2bb84d79457b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia61a2888862d4451867b421f57199890_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1dbe830985b3456088798fdc58aa9daf_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i92adc7af35ce442586e7f832696d8083_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i718ff6d9aae440bfbe2ebdfa0389b7f9_I20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="if827ee4c779a4b57ab9eeeb719e06b2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f6447a0def84811a339a66cb7ac0e7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87791bdb507743179b1b6187068193d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a226f12905c46efbbd050421af8eea6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i87bcea25b6704ede86f7f3a191ef629d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icdc79f5d00754b61ab7e3baaf585df20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7f59b7851384b0d91511c5a20b67577_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8e116c4ba416435f84ab15341357ee49_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="id187f254b8f044069cf6e62f7dd23492_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="id8f27f189d204a99bb6fbd309638d302_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="ic9bf49749cfa4149bfcc21376770c3d7_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i736e3fec90114a5aa4409b6b2e10ee3d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i6be868f31ad04ccd92b62a8b53e31994_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:Warrant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="idafaa881ac7c4f0ea1acfd5e7bac657c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id6c9410eee65468595d358150c9017de_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9926c974cf3347f388bb822becf71f99_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:FormerShareholdersOfNmmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36c4f94c659e40378bce5560a8288c13_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1eff2864c695401fb93686780342c192_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i601de355c37d4e38a5ea8fffe8e17e9d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i81990f1f745c424ca090209239fb9e19_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i011724573aa749b2834cc036d67d7006_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i40fc578ddc114d17b7d8aa16f28a9b27_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id5cc5d815cc04d21bef7fb998c409f3d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i163cc47f491d41b392adbb6959d8f774_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04943825157d4043aa0fb2fe8723b079_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4774888a4f484996ad1923628b04af51_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificofCaliforniaBrokerageAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5005e6c965ce49078328bedec974e062_I20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyThirteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-08</instant>
        </period>
    </context>
    <context id="i0a44ec4586564a71b632ebd24b41a548_I20171208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-08</instant>
        </period>
    </context>
    <context id="iec9540bba78a40aa9b698767130e5df9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f37aecb480c4ca4bdaabd1cc01c6d74_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69e0bb8c26da401f981101891ef4858c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ameh:EquityIncentivePlanTwentyFifteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife5a872d4cb64a1795a11e4a6a81b2cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35d0316c954743c68575e89e641ec7ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92bee5c5555f4c9bb28b959713ee742c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i55c7e2bb01da4cb8a05eeb09f96b7145_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ida71012f2abb40c3bb3b97875ac19fd1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia48d331e72ef4c45922e796a5ec33fe2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ameh:StockAwardsAndUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id34b814b72a749ff9980e038fe3de780_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e60e144eae847ee8431a5c5918fdb83_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id2b2b020931f4f90afee0ac9784f1f61_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0f05771c561640aaab3a2c2c0e44330b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bb2c1e084a049cd8af7b6044a0c177e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibef63d60b9e947eead74bdfd0b22345e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie160814e72a34eebb359d61571716c26_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e9c3a5ed3424d31b9ae24620d3bb654_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i31c542aee5d1477695e59726049c8b71_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ExecutiveOfficerAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc47b22c80ae4ba5a6046042c4073438_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie31caf7183734c75a34b0c38fefd09f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife3ade634e3f411d8ff9d287f7f6ccfc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i88ed9f8ac2bd41ad84ee70e5cec56071_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i670fb4a8ae4c408681d8b085578171d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic130048652fd4ae89ae9be7d998b753c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2b029890b2714cffb3297481713b140b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i21f1ff2005de4e06ab13d40c18783c14_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia49fab4addb846b78532141505ad76c8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id39d667c80e24f60a2821321e2d966cc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9eae915be53045f6bb1b2c554e86ccb5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifebcbe81b7cb4bb1b35b8f52f712e985_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0fafa1dea0849b1b343ca69489e8c78_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1d3bbb3ca7dd4c24bc7e516e958c13e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7edf78b63c6f4e08805f86b4036d2e81_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A11CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="i5f12986e0b9048669859a5f857899013_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A11CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="i779a53f850a8409dbd4e696d526532c9_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A10CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="ie312f8b83db04cdcb3b524d5a3a6ba12_I20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ameh:A10CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-31</instant>
        </period>
    </context>
    <context id="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66cd6792e85c49d7a61ed092edae091c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia90a6c2a97b64a389f5c927fc93bf96a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if46b72f6abf844e9879f71846c8b9b66_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i08aaa85087aa4345a9007df6c4591fd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b537ba452f949228e951dcdfcef32e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i53187ce216524aa3b307b37805167d6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3b1cfd32fb714d1b80f4201a5deed2a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5bab33a21a0648868b28fc7d50f54158_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d72bc8610fd48128d879bda262dfe43_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ie254787cc84c48bd84c74b128e2266d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15d1c54ce99042c1b561ab2ee11ee78e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i129f6a3461cf4f1ab4901b6a723c2efa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9270b7467dd044688bc0a7eb2e2ca95b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2b387c30626438ebb40b9bca7610e32_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4e46c773fc154de4bf33cdae598f28cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b8910f127dd44bf93a735ed77e16ac9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic79962b6add548d1a0a0800ef768b995_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63281dcdd4a140dbb747619db7d8c8a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i70d92535c55249a8847213ad5c2a502c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4bad5438ff3a4f74a3d70bcaa21c6c0f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia5679f2c797347059c1225b32fbb6b13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie849991976b847cf90334bfe31a52480_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icf99075624e6433ba75a5f77dc805f15_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib13f9af073384d4c9e1929dc51068830_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic2133589307c47dcbdf2e41c006a5957_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e8615520d1c460abd7740668e7eccb7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bcb63ad4a3840f5972376ef0ad45c77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c960befa3cb4c8481200d45bd9ea49e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id3bb44ce70f74f858de6d865daacc078_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66a2b156a58d4e41b8c652fbfc2b1dc3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i725de084f7484bf2b557e23683209c2f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48ce8008a9aa413bbc0d854c5c099a7b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ad1a32d47d24ebd9e398feacbdef5da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FreseniusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaAcoIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i345508df7f534ec186d436d698300127_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i17a3d24c34e24e4bbb0b52e9864a691c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:FulgentGeneticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if2e413d93a45413e867b6c43dcbcb16f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i56618b59636c41de889fa82a7f480457_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i885597d6544c4e3abef7773242454b2b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i962c50aee1e348aba05114edeaee56c5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72264584776344db971c065a8fce37ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9f3ec8accf2446a924e82c4b5f8ccfb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia561e5c258f2485694a76848bb8b6a1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e4b1ef0f59e450b996daa00631fb6ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i413b4eb991864312abee85b2aa4136a2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icaf783f1db0c4787a4a69fb6282d4e02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaFamilyHealthCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iac72b50c95e94fc09e52a827a55332b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ArroyoVistaFamilyHealthCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia53e8f382a2e4439b60240b8915724ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1cd656c250ce4150a6a1a1fceb8542ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie2192a286cf646ccab3788f074402528_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i134932193dfa499ca1b1effba3b95a14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia409ec0563224e55807090c8d3e6ede7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9cdce4ca78b41e0a57fc6795290012c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24ec1d618774465c8dea886fe213dfe7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2a2b3509507d4d48912d14647a92e623_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic3a8211eb68b4df0b319ce09e3b1f902_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i30eb97f7c32744b7b15f7e0871ad0fbb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8a4c5277f7fe49faac858648aba110d4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i14d6fef6bdcd4ea5849d94a4db61a9e0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i75f1a347fb7b4952812981c95e91f55d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id64373440d04487abfcbb1c9c106cd2a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibea0b347dab449ca8628a24054c9a91c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib376d31c4e7c47d1adb2a6a237f9cc09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09eece4c427740f687d9a6fadb11f1ff_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i802eb21bde26452ba2c3f5659cee4c04_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ameh:ConsultingServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i65dded2172ef422fb17e1d0fce8b7249_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i69c49049ebbc47528adaa662d73d39ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib2e7d052ba2b4395b0f60a17ae65a0f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic14cb455ba05463cb1678b216ef7075f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3ae3db4ca1e34c708b94c52c71ad2914_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd421eb1df5c49939ff1803196eb2a86_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i208f479f75974f779de286c45d4474bf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6adcc0aa230f41fd87e0b1d0454f2be7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0f8971b99a7041a48f19c1d1278bc25b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib0f8d61c8ab544a5b3f23e1be85c5358_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia44bf6e3eefc4f64a56179122b3b4d22_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7308475feed14b639f9c04dfe2ffc4d7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i28dfed083b894f49a515b929d24e2c7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i283b7bc3b0dc4508af91c59f486c2adf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8994136231a429187388373d060ea08_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ia9cc68c974834aefa2ce53b34b45264a_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:OrmaHealthIncAndProviderGrowthSolutionsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>ameh:plan</measure>
    </unit>
    <unit id="clinic">
        <measure>ameh:clinic</measure>
    </unit>
    <unit id="segment">
        <measure>ameh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>ameh:unit</measure>
    </unit>
    <unit id="provider">
        <measure>ameh:provider</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>ameh:financial_ratio</measure>
    </unit>
    <unit id="patient">
        <measure>ameh:patient</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV8zLTEtMS0xLTA_0f3855e7-9d58-4a94-97a8-b7baf56faa84">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV80LTEtMS0xLTA_66f4422f-a161-43df-9c71-cb88caaa3a17">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV81LTEtMS0xLTA_b8a923d9-c53b-4c7f-a284-3b7d225c7afa">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl80L2ZyYWc6MDExZGI2YzIyNDZjNGQ1MGFkOTE2NzJiMWZkZmYyMDkvdGFibGU6ZDBlYjFiODc1ZmFkNDIzODhkZWQ2ZjFmOGE0NDI2YWUvdGFibGVyYW5nZTpkMGViMWI4NzVmYWQ0MjM4OGRlZDZmMWY4YTQ0MjZhZV82LTEtMS0xLTA_7b75b2fb-c44a-47cb-8511-b8bdd4a83b29">0001083446</dei:EntityCentralIndexKey>
    <ameh:AccountsReceivableExpectedToBeCollectedPeriod
      contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5OTk_64bfc1bc-0468-44da-ae64-8adbf345015b">P2Y</ameh:AccountsReceivableExpectedToBeCollectedPeriod>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMDk1_890dedd3-9639-4f3d-a087-9691ad4f5456">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="icfa29991cc184f5ab71a9689f9e7cbb3_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MDUx_13452d7a-ce48-4cb1-9932-b9a62aad18dd">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i889c185a8f9149ea80fad8d3964a0104_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MTA3_7004a731-22ef-4a6d-af57-dbde08754dca">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjU2_c963fd5b-c811-4093-81f8-04122b4eaed7">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption
      contextRef="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzEx_0992ad4a-a700-4f32-8ee4-5af8a166e27a">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzgy_218c2412-51ed-4adf-8fb2-fba58a465401">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzY0OQ_c2588d0e-53b8-4fa3-9a93-34c4f0d89c10">Subsequent Events&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%"&gt;Orma Health, Inc., and Provider Growth Solutions LLC (together, "Orma Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the Company announced that it acquired 100% of the capital stock of Orma Health, Inc., and Provider Growth Solutions, LLC (together, &#x201c;Orma Health&#x201d;) in accordance with an agreement between ApolloMed, Orma, and certain equity holders of Orma Health. Per the agreement, the purchase price consists of $2.0 million in cash and shares. Through its suite of AI-driven solutions, Orma Health currently serves over 4,000 aligned Medicare beneficiaries in a Direct Contracting Entity (&#x201c;DCE&#x201d;) and over 2,500 patients in California, Nevada, Arizona, and Texas through its remote patient monitoring ("RPM") platform.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ic8994136231a429187388373d060ea08_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzYwNDczMTM5NTUzNTg_091ab6eb-48a1-4381-b862-a1ee2bf1ba85"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia9cc68c974834aefa2ce53b34b45264a_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzEwOTk1MTE2MzEzNDQ_648e4a1f-7151-473b-91b2-25a96b7739a1"
      unitRef="usd">2000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfDirectContractingEntityPatients
      contextRef="ic8994136231a429187388373d060ea08_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzYwNDczMTM5NTUzNjQ_87ae507c-2078-472f-a2f5-f8ba9b5909a3"
      unitRef="patient">4000</ameh:NumberOfDirectContractingEntityPatients>
    <ameh:NumberOfRemotePatientMonitoringPatients
      contextRef="ic8994136231a429187388373d060ea08_I20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMjYvZnJhZzo2ZGY4OTNjZjhhMzI0OTNmODQxOTgzN2JkMTdmODFkNi90ZXh0cmVnaW9uOjZkZjg5M2NmOGEzMjQ5M2Y4NDE5ODM3YmQxN2Y4MWQ2XzYwNDczMTM5NTUzNzE_d63830c0-700c-4182-89a6-4a73428dc93d"
      unitRef="patient">2500</ameh:NumberOfRemotePatientMonitoringPatients>
    <dei:DocumentType
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQy_88abd94d-5de3-4675-adbd-bf3bb33c4c2b">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YzE5MTNmYTZmZjAyNDhmNmE0NjU2Mzc2OGYxZDY2ZDAvdGFibGVyYW5nZTpjMTkxM2ZhNmZmMDI0OGY2YTQ2NTYzNzY4ZjFkNjZkMF8wLTAtMS0xLTA_160594e0-d191-493d-a955-e101f2d61326">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8xMjk_50a026c9-9901-4c95-b593-8a1f70fcda51">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8xMjk_54cbf30a-1dfc-4779-a53d-ef8d4aae6291">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YmMzNmI2NmVkNTEzNDgxYWJiOWVkNmY1YTdhODVlY2QvdGFibGVyYW5nZTpiYzM2YjY2ZWQ1MTM0ODFhYmI5ZWQ2ZjVhN2E4NWVjZF8wLTAtMS0xLTA_100f84c9-6a28-4792-9baf-dcf58d4b8178">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQz_c0d4075a-6de3-494f-87bd-74824d9fcb8b">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTUx_451c3301-6f43-42b5-977f-d5c154efb700">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YTM1NThlYWVjYzFjNGVkZjg1OTRmODNjZDIzNWYwNDAvdGFibGVyYW5nZTphMzU1OGVhZWNjMWM0ZWRmODU5NGY4M2NkMjM1ZjA0MF8wLTAtMS0xLTA_de96649b-7b65-4a3c-8e7d-cf0f822c6e5d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6YTM1NThlYWVjYzFjNGVkZjg1OTRmODNjZDIzNWYwNDAvdGFibGVyYW5nZTphMzU1OGVhZWNjMWM0ZWRmODU5NGY4M2NkMjM1ZjA0MF8wLTItMS0xLTA_18a187ac-bbd1-41a2-8ba4-52a6e530aa5e">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTUz_8d4ff6d3-7bab-4754-87d8-fa43f8db4a69">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTM3_88f2b622-9624-456f-b97c-def50cbbcf5c">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ2_2a72b214-d4c1-4114-8102-4e890aa717cb">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTM4_38cfafde-de9c-4666-b569-8ce0c81633db">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTM5_47e9e876-0621-4c19-b5ac-fdcdb962ad73">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTU0_38bc7908-03f4-45e2-8432-0bbc1e1edbc4">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ3_af933a54-e871-45d0-95d3-ab01a262e1db">282-0288</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6NDMzMzcyMzcxODA4NDUwNTgxOWM2ZTUzZWY0YzU2YTYvdGFibGVyYW5nZTo0MzMzNzIzNzE4MDg0NTA1ODE5YzZlNTNlZjRjNTZhNl8xLTAtMS0xLTA_20902b9b-5fb8-4c1a-b35a-e0db943d9d01">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6NDMzMzcyMzcxODA4NDUwNTgxOWM2ZTUzZWY0YzU2YTYvdGFibGVyYW5nZTo0MzMzNzIzNzE4MDg0NTA1ODE5YzZlNTNlZjRjNTZhNl8xLTItMS0xLTA_66a529a4-0096-4841-a93b-4aa886bdd84e">AMEH</dei:TradingSymbol>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl82MDQ3MzEzOTU2NDI1_5d7ee590-28b7-4854-8ebe-864d02e374d7">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ5_a6c8df7a-8054-46f0-bf81-44a95f3dbbfc">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTU1_14d417aa-a489-4234-8228-35f155f9962e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTUw_37c2694d-481c-4982-9781-41efa46363fe">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6Mjc1ZjFhMTEyMTBhNDQyZDhhNTRmZGZmYmMyZjk1ZWUvdGFibGVyYW5nZToyNzVmMWExMTIxMGE0NDJkOGE1NGZkZmZiYzJmOTVlZV8wLTAtMS0xLTQzNDEy_92f1bb77-9b44-4844-ae64-aa6b5dcc635d">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6Mjc1ZjFhMTEyMTBhNDQyZDhhNTRmZGZmYmMyZjk1ZWUvdGFibGVyYW5nZToyNzVmMWExMTIxMGE0NDJkOGE1NGZkZmZiYzJmOTVlZV8xLTMtMS0xLTA_3ff54b88-bbb1-4837-a0e1-64c8080dde23">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGFibGU6Mjc1ZjFhMTEyMTBhNDQyZDhhNTRmZGZmYmMyZjk1ZWUvdGFibGVyYW5nZToyNzVmMWExMTIxMGE0NDJkOGE1NGZkZmZiYzJmOTVlZV8yLTMtMS0xLTA_408f923b-7c28-44d4-8eee-ce690ff1d791">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQ1_89a7e5d3-a71d-4e46-9c64-bf6efdb5ef42">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQw_152a17bd-5ca5-40a2-90e0-6afbdbe55c40">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="icc6ae380313d4f9e9297cfdbf9b997ac_I20210630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8yODYy_35612549-cd38-4d52-882e-6de746e6f7b9"
      unitRef="usd">2400000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ib7afb98c0185462db67289bfa9ee20c8_I20220216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zMDE5_276a2d17-7d80-4c6c-ac9c-7da38eac87d4"
      unitRef="shares">55956280</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xL2ZyYWc6MDZhYTUyNzBjNjEwNGZmOThkNjBkY2ZkOTk0ZjFmMjYvdGV4dHJlZ2lvbjowNmFhNTI3MGM2MTA0ZmY5OGQ2MGRjZmQ5OTRmMWYyNl8zNTQx_acbb21e0-4e75-4f2b-9678-c1dad389a73c">Portions of the registrant&#x2019;s definitive Proxy Statement for the 2022 annual meeting of the stockholders of the registrant are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such Proxy Statement will be filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) within 120 days of the registrant&#x2019;s fiscal year ended December&#160;31, 2021.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMwODI_1f3fcea7-3c9d-4dea-9876-bde9d46cc155">Ernst and Young, LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMxMTM_e6f71d57-65d0-462b-89e1-027c49af7aff">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMxMjg_6f16572d-f835-45d8-8ca2-e1279d92d9e7">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorFirmId
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85NC9mcmFnOjYyOGZmYWUxNTVjNjRlODlhNGFhOGY4MGQ1MThkYzU4L3RhYmxlOjJmZjQzMjE5OTllZjQyZWJiZWRlNDNjNGY3NDM0MjRlL3RhYmxlcmFuZ2U6MmZmNDMyMTk5OWVmNDJlYmJlZGU0M2M0Zjc0MzQyNGVfMi0wLTEtMS00NzAxMi90ZXh0cmVnaW9uOjhhZGVkYWExZmI2OTQ4ZjE5MzgxNjJlYzMwMzA5ODJmXzYwNDczMTM5NTMxNjA_a60f5916-53e1-480c-9bcb-37b9c6b63ffa">243</dei:AuditorFirmId>
    <dei:AuditorLocation
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl85Ny9mcmFnOjdkNWE3MDBkNjRkYTRkYmQ5ZTljNDQyMDI5ZDc3ZTViL3RhYmxlOmUwODUyMDRmYWJjNTRmNThhNGYxMjljNjE0ZGFmYTc3L3RhYmxlcmFuZ2U6ZTA4NTIwNGZhYmM1NGY1OGE0ZjEyOWM2MTRkYWZhNzdfNC0wLTEtMS02NDIzOS90ZXh0cmVnaW9uOjkzNDgyZDdmMzg1ZjQ1OTU4MmVhMmM2OGU1Y2UxNzcwXzYwNDczMTM5NTI4MTg_e61aa64e-6a34-4469-bd34-6050f12beebe">Los Angeles, California</dei:AuditorLocation>
    <dei:AuditorLocation
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDAvZnJhZzpmYTNmNGI5NDE3YTg0YmQ2YTQyZmQ3ZDJlZjliOTZkNC90YWJsZTo5NDlmNzg0OWQ1ZDE0OWJiOTY5MTRiODQ0ZWIwM2ZiMC90YWJsZXJhbmdlOjk0OWY3ODQ5ZDVkMTQ5YmI5NjkxNGI4NDRlYjAzZmIwXzQtMC0xLTEtNjQyNDcvdGV4dHJlZ2lvbjpmZGY2M2ZlZjQ1NmM0OTY2YTc4ZDBmYWEzYTFiODAxMF82MDQ3MzEzOTUyODE4_139d0156-ac4d-4e93-b74d-5947d46af551">Los Angeles, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzktMi0xLTEtMA_340b52d2-4e6e-4388-ac0b-9957196958b9"
      unitRef="usd">233097000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzktNC0xLTEtMA_f61b8ac7-e297-4b22-b2f0-a88f2be0ad33"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzExLTItMS0xLTA_ac0bf856-b3aa-450e-9b7c-95e5d625cedb"
      unitRef="usd">53417000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzExLTQtMS0xLTA_df627b0a-ab1a-48f8-a38a-4c6faf6049c2"
      unitRef="usd">67695000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEyLTItMS0xLTA_509470f9-312e-4a58-b623-c4fbc8638427"
      unitRef="usd">10608000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEyLTQtMS0xLTA_24c074b3-0de7-497e-b778-6a4ddc1323a4"
      unitRef="usd">7058000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEzLTItMS0xLTA_6c097f24-f330-45c1-b1bd-370e829a2f8f"
      unitRef="usd">69376000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzEzLTQtMS0xLTA_d12458ed-42ba-4fca-b703-2ac977716fd7"
      unitRef="usd">49260000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE0LTItMS0xLTA_1d97999e-a7ae-4c3e-b141-d7debffd6923"
      unitRef="usd">9647000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE0LTQtMS0xLTA_d58e93c0-28c7-489b-9b94-9d44071702a1"
      unitRef="usd">4297000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE1LTItMS0xLTA_10cbf361-0c74-47e1-b4b9-f35719905c88"
      unitRef="usd">18637000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE1LTQtMS0xLTA_64984d77-9ff9-4a13-999e-b620a7e994f2"
      unitRef="usd">16797000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE2LTItMS0xLTA_682bea18-6fe7-443b-be80-18755bba0c7f"
      unitRef="usd">4000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE2LTQtMS0xLTA_d5c31590-286a-44a4-a838-f3eaa4435f3e"
      unitRef="usd">0</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE4LTItMS0xLTA_b37ccd2b-6b13-4128-b578-965b2aa3ed56"
      unitRef="usd">398782000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzE4LTQtMS0xLTA_2cb063c7-b7fe-4d12-b9fa-100d57f03459"
      unitRef="usd">338577000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIxLTItMS0xLTA_66bf8581-9d31-461c-a161-b4a11fdc4fac"
      unitRef="usd">53186000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIxLTQtMS0xLTA_b53c01c7-b4bd-47af-bf0c-b92587572391"
      unitRef="usd">29890000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIyLTItMS0xLTA_bbcb79ec-3c83-4394-9986-4b8c250acb1b"
      unitRef="usd">82807000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIyLTQtMS0xLTA_e56feb02-8654-410e-82fa-ca0d27359950"
      unitRef="usd">86985000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIzLTItMS0xLTA_31994818-98fa-4198-820e-4b3a43fe7944"
      unitRef="usd">253039000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzIzLTQtMS0xLTA_7281d788-bfcc-494b-8edd-6da1e56e3b58"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI0LTItMS0xLTA_cb6810f9-3bfb-4820-9a1d-0a4774ebfb94"
      unitRef="usd">569000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI0LTQtMS0xLTA_35390c7f-f7f8-4583-a70b-7e6d5e90c8e4"
      unitRef="usd">480000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI1LTItMS0xLTA_178a7031-d3ae-4cfa-8311-a049a82fc3d2"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:NotesReceivableRelatedPartiesNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI1LTQtMS0xLTA_03595b8e-b0a3-4dfe-9c1a-955872190e62"
      unitRef="usd">4145000</us-gaap:NotesReceivableRelatedPartiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI2LTItMS0xLTA_2af51476-b530-4e21-b5d2-1eb56938133b"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI2LTQtMS0xLTA_fd905bda-e37e-4c15-addf-f28be0ac23c0"
      unitRef="usd">43292000</us-gaap:EquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI3LTItMS0xLTA_88cb9631-ac38-466f-84b4-cf2b33d28bd5"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI3LTQtMS0xLTA_a32e7292-bae1-4421-a044-edbc5fb301d7"
      unitRef="usd">37075000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI4LTItMS0xLTA_03a8415b-b804-4af5-bda9-c372a29d84eb"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI4LTQtMS0xLTA_dc7db8fb-c8e7-4711-98bf-d794c0f84f1b"
      unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI5LTItMS0xLTA_a3c12cf9-b685-4bd0-ae95-876b9d1ee3e8"
      unitRef="usd">15441000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzI5LTQtMS0xLTA_834f5de9-0e18-40fa-8ee3-0c102a0b00a9"
      unitRef="usd">18574000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMwLTItMS0xLTA_4aa9ad5c-528b-490a-b032-2abc5f749f0a"
      unitRef="usd">5928000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMwLTQtMS0xLTA_d46ccab1-ce3c-4560-94ac-26ba355e60fd"
      unitRef="usd">18915000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMyLTItMS0xLTA_3c3cd6b7-c5eb-40ac-880d-7605d2554a6c"
      unitRef="usd">453581000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzMyLTQtMS0xLTA_d461ce1d-cb87-404e-a4cc-233be6ba5c79"
      unitRef="usd">478909000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTItMS0xLTA_7bcc9575-21a7-4a27-a77e-32e7a3454581"
      unitRef="usd">852363000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTQtMS0xLTA_d2add495-3187-4214-9620-f3aacb32a074"
      unitRef="usd">817486000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzktMi0xLTEtMA_3732b2f1-ef5d-46c6-b6b9-591677048ef3"
      unitRef="usd">43951000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzktNC0xLTEtMA_ca173616-1fef-4777-aeca-e9837aaf4aa1"
      unitRef="usd">36143000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEwLTItMS0xLTA_c523ae19-94b6-4ab2-9107-7a6974aa5ef0"
      unitRef="usd">10534000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEwLTQtMS0xLTA_6e08c140-ef6b-4272-9015-d08cb566e18c"
      unitRef="usd">9642000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:MedicalLiabilitiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzExLTItMS0xLTA_408d62c8-60c1-4627-9e0b-94ee8d552ede"
      unitRef="usd">55783000</ameh:MedicalLiabilitiesCurrent>
    <ameh:MedicalLiabilitiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzExLTQtMS0xLTA_57d3a797-90fa-493b-8068-a7b388628f26"
      unitRef="usd">50330000</ameh:MedicalLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEyLTItMS0xLTA_292ce126-4440-4517-a393-ca38b7813474"
      unitRef="usd">652000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEyLTQtMS0xLTA_2000cd92-2696-4772-a45d-a261b15e1da4"
      unitRef="usd">4224000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEzLTItMS0xLTA_156faffa-3305-42c7-ac8b-4a608a23e9d0"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzEzLTQtMS0xLTA_a3eb0311-dc93-48eb-8851-a0470161149c"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE0LTItMS0xLTA_7590c5f0-b732-43a8-a088-e1af8ee2f5ec"
      unitRef="usd">486000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE0LTQtMS0xLTA_cb46f684-a21c-42f2-b38f-05746416b96b"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE1LTItMS0xLTA_ddb71357-96b7-4bd9-90eb-1ec1c3c1d5c9"
      unitRef="usd">2629000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE1LTQtMS0xLTA_71e0b7e4-4aea-4de4-ad41-1f1212591d0f"
      unitRef="usd">3177000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE2LTItMS0xLTA_1d0f5829-2995-4993-b717-6600671db2c3"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE2LTQtMS0xLTA_14bba95e-37fa-4f95-8a85-97ec355b6825"
      unitRef="usd">10889000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE4LTItMS0xLTA_b3c11552-d39e-4f97-8d8e-de2d5b889acd"
      unitRef="usd">115371000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzE4LTQtMS0xLTA_aea1bd2a-c711-44d2-84ac-cd43d29830ec"
      unitRef="usd">114992000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIxLTItMS0xLTA_96975791-398e-45c8-946a-5e24909d77e6"
      unitRef="usd">9127000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIxLTQtMS0xLTA_421493fe-31b6-47ec-9809-42764a8f83ac"
      unitRef="usd">10959000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIyLTItMS0xLTA_8e0c8a2b-f23e-412d-be9e-4f6949f1c83d"
      unitRef="usd">973000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIyLTQtMS0xLTA_2bf18304-7c4d-41b3-a418-1a16a1116c44"
      unitRef="usd">311000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIzLTItMS0xLTA_9de3aa1d-d7b6-4f2e-a98d-cbe541b1f75a"
      unitRef="usd">13198000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzIzLTQtMS0xLTA_88ac1981-3830-4dd0-871e-081634d96198"
      unitRef="usd">15865000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI0LTItMS0xLTA_55d2a1d8-1605-4e20-9829-1bd2ae2235f0"
      unitRef="usd">182917000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI0LTQtMS0xLTA_23608805-65c0-4001-9c9c-08d82a60e2ef"
      unitRef="usd">230211000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTItMS0xLTQzOTA5_ed8bae1c-5822-419e-bb3f-328689e69e6e"
      unitRef="usd">14777000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTQtMS0xLTQzOTA5_086c1b9a-ce42-4d99-a358-878d741c23be"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTItMS0xLTA_72fef86f-e773-400b-bfa4-35dde7591f16"
      unitRef="usd">220992000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI2LTQtMS0xLTA_34b37a2e-cdd4-4b1b-b59c-329817e222f4"
      unitRef="usd">257346000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTItMS0xLTA_88f8d027-0dcd-4f98-8e05-61d92fffcfaf"
      unitRef="usd">336363000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTQtMS0xLTA_a79fca52-6e1e-45fb-b0a3-d2e1a70dd11d"
      unitRef="usd">372338000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMwLTItMS0xLTA_f7fe8067-6ec8-412a-bfac-6513a9f9afe5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMwLTQtMS0xLTA_f9ad7a83-dedc-4228-a77c-6610340d0f46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMzLTItMS0xLTA_37f068df-676c-43a4-a91f-f65d85edd9d9"
      unitRef="usd">55510000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzMzLTQtMS0xLTA_b467bfa5-d693-473a-aa29-ee4a362408d5"
      unitRef="usd">114237000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80MA_62a05e33-45a9-4925-9fb6-8849c7c46302"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80MA_95f704da-f016-4ed1-95f0-a9c7118838f1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80NA_37d40ccc-3ca3-4ffd-a850-448e5050cb74"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV80NA_c3e67ba0-71a3-4065-a546-168e2b1780bb"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMDY_2faff5dc-5e2d-4d94-8847-feea8942a5ef"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMDY_c03bd823-b3da-419f-9589-b1082e5c9bcc"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMjA_b3f0634e-dd24-493b-ab8a-3811ce0c25b8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTAtMS0xLTAvdGV4dHJlZ2lvbjoyY2RhN2FjZjM2NGU0ZmQ3YjhlOWZlMzk0MWE2N2U3ZV8xMjA_f3eb6abe-648c-41f2-a921-3bfdc2d8c620"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i8759c801140b4316acf0688d1a7d8073_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTItMS0xLTA_c074c4a8-e5e1-4eac-bc69-6d8671da5142"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i4d023fd0ad184f8f8c6b0a7fbd1fcc6e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM2LTQtMS0xLTA_b35f3463-0af3-4cd2-a952-73f182c300e0"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80MA_5ad718a2-c4c5-4615-8c7c-6851d824416f"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80MA_cc867601-49d9-4901-aa33-56aaf2b960ed"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80NA_08f3498b-b42c-40d0-a626-bf84e47386f6"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV80NA_1429f82e-e3d1-47d1-a7c2-780b09620beb"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMDY_18617bd7-db40-46d9-9d0c-7d56187baa6c"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMDY_7e3cd650-718e-409d-959e-5d01851105f3"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMjA_33fe03d3-68d3-4deb-8411-5b3bac0f3a88"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTAtMS0xLTAvdGV4dHJlZ2lvbjoyYTVlZDM0NjQ3ZTQ0YzczODQyZjlmMGM1Nzc5OTRkOV8xMjA_c8477edf-61d7-4ed7-8dce-5e9ed7ebb3db"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i40dc5d98948f44f4a00a909ee4e75e4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTItMS0xLTA_c5cc5717-cc6a-4f5b-8ba3-686ba3824154"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib3a3083cbe3b4707adbb02b65c588a45_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM3LTQtMS0xLTA_bc2a3cdf-5ca1-4e12-8e26-45d196e8aed6"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yOA_8ee43eeb-53dc-487b-9f87-1c3de2567414"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yOA_bbf05a51-7384-4c18-a716-562cbf1aa42e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8zMg_adb1ae0a-18fa-4e2c-becf-3832a54762b6"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8zMg_dfe68d70-8f61-4644-b7e9-a7887e37778e"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesOutstanding
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yNzQ4Nzc5MDY5NjE2_a7068b7b-27b9-4bdf-b895-c174ffeea017"
      unitRef="shares">44630873</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8yNzQ4Nzc5MDY5NjIw_94b841c7-790e-4130-a5d4-76153a4f9ec1"
      unitRef="shares">42249137</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF85NA_cc893a97-9d2a-485e-94f5-8266e81085d6"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTAtMS0xLTAvdGV4dHJlZ2lvbjoxNTZhZjMyYTk3OGU0MzJiODczMjNiOTQyODhkYTI2NF8xMDE_60a5da2b-b4a4-47b9-ba13-61156b91303f"
      unitRef="shares">12323164</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTItMS0xLTA_202f9ecc-5e63-45bd-8bf8-1628b8dfda3b"
      unitRef="usd">45000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM4LTQtMS0xLTA_c4ad7c59-5d98-4a81-993b-a10be0cac045"
      unitRef="usd">42000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM5LTItMS0xLTA_62353f04-0901-4c1c-a0d0-52e74640fa1a"
      unitRef="usd">310876000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzM5LTQtMS0xLTA_782ea5af-828d-47d5-b865-c608aa97a100"
      unitRef="usd">261011000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQwLTItMS0xLTA_4e47237d-7fe1-4ff1-bdb5-1dd06cef9ee5"
      unitRef="usd">143629000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQwLTQtMS0xLTA_550f866a-0996-41e2-afeb-724868d98a39"
      unitRef="usd">69771000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQxLTItMS0xLTA_ce69675f-1678-42e0-9867-afe03841033b"
      unitRef="usd">454550000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQxLTQtMS0xLTA_24fde083-7e4d-4295-91ac-c77b3ebcf9cc"
      unitRef="usd">330824000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQzLTItMS0xLTA_a34fdc46-83bc-457b-8dca-cfd79c5ecabd"
      unitRef="usd">5940000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQzLTQtMS0xLTA_67d80690-cd5b-49bb-81e6-af07f8929375"
      unitRef="usd">87000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ1LTItMS0xLTA_12d5fc04-7f45-4284-90e5-d1554b36231a"
      unitRef="usd">460490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ1LTQtMS0xLTA_39caddb9-3b7d-495d-9b01-4b12122c1836"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ3LTItMS0xLTA_5b4c320a-ec5d-41d5-b671-bf66bc7826ea"
      unitRef="usd">852363000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzQ3LTQtMS0xLTA_59ddecac-ea69-48a7-ba7d-13e77f82e6ac"
      unitRef="usd">817486000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNzU_15ac2327-2a6b-4756-8ecc-ac30caaf82ad"
      unitRef="usd">567000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNjE_7e4532d7-54c5-4276-a66e-1c733b53e0f4"
      unitRef="usd">576100000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNzk_5f7068f2-9104-4622-aa44-0b4d75001561"
      unitRef="usd">91700000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNjU_9ca6ccda-be3e-489c-bb22-1caa7b2cc359"
      unitRef="usd">88600000</us-gaap:Liabilities>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkwOTk_89b6cbf2-f3b3-4a52-b753-20b494c5737d"
      unitRef="usd">802800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkxMzQ_6ce4175b-d598-4e59-8859-db7a7362bd2f"
      unitRef="usd">6600000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DueFromAffiliates
      contextRef="ie28b1a4e25004f8d9ff2e1f8e26f009e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyMzY_1eecbd2c-b343-4cb9-b7b1-f7ea12b05532"
      unitRef="usd">225100000</us-gaap:DueFromAffiliates>
    <us-gaap:DueFromAffiliates
      contextRef="i34d8f20402a94db18c5d908913c78e54_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzEwOTk1MTE2MjkyNDg_a8f82e76-6e41-41b3-a97e-7475630c62dd"
      unitRef="usd">22700000</us-gaap:DueFromAffiliates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0648fafc89a544e7a200bb47e8fe8e6e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzYtMi0xLTEtMA_dc10b9fe-4a72-4542-8033-f2d942c5b3e5"
      unitRef="usd">593224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae936f11a7bb4e4c99d3fe13851ffc0b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzYtNC0xLTEtMA_23a24c89-29f7-454d-a539-d2dfd82f42a0"
      unitRef="usd">557326000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i830aa1f9bb124cffa1eb7bbc0aff0ad3_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzYtNi0xLTEtMA_09916749-db7b-4726-9cc5-b727c7b7a397"
      unitRef="usd">454168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0bca0ca7ef34b17b7aa1fbeb535bbf0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzctMi0xLTEtMA_3a626d50-d2f5-4f24-b0c5-306dd9cc213b"
      unitRef="usd">111627000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id541469a4a79478381a9bc7f4f5a6536_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzctNC0xLTEtMA_f9702bab-7059-4039-b455-a494201ed3e2"
      unitRef="usd">77367000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb259c5215b44e0591d9d9fe4eca90e5_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzctNi0xLTEtMA_685477d5-4fce-43e4-b197-94289f6d4004"
      unitRef="usd">51098000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i612cc8b6b50c4dd986466df93d1b6382_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzgtMi0xLTEtMA_f70deaa9-f02a-4875-9505-ec00e337b30b"
      unitRef="usd">35959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dc831eca8c24ab395130475d7b38dd7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzgtNC0xLTEtMA_599e6972-601e-4bcf-aff8-a079bf94a0e1"
      unitRef="usd">34850000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idea8035697aa431d99f99268b6c7d832_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzgtNi0xLTEtMA_0f5896c8-721d-4cd5-9c11-b7c6ed515be6"
      unitRef="usd">34668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2efb609fa90049de89473edcbce394a5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzktMi0xLTEtMA_b88b5624-00b2-43f5-b094-499aa82f1ae9"
      unitRef="usd">26564000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i872c7cf84d474bde9cbecebf6dc0d987_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzktNC0xLTEtMA_e26604a9-dbe4-4af0-9b3e-4df4f251a1fe"
      unitRef="usd">12683000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2292f34b157f4b3b842835c609844787_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzktNi0xLTEtMA_c196c91f-7330-4b1e-88df-39ac499a661d"
      unitRef="usd">15475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id823cee670274003a572be40978abfb9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEwLTItMS0xLTA_fc5c032f-1751-4749-b4dd-d5fdc0dc9eef"
      unitRef="usd">6541000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i38935258fdd640ccbf3015940e510e1d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEwLTQtMS0xLTA_af46794c-b4d8-47d2-b7a4-ae284c282f34"
      unitRef="usd">4954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea80e278e3444cafa519677345773d02_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEwLTYtMS0xLTA_babb4322-8d56-40b1-a1f4-035a41cfb566"
      unitRef="usd">5209000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEyLTItMS0xLTA_61083131-0994-4bbe-bd94-e3933e9128c1"
      unitRef="usd">773915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEyLTQtMS0xLTA_173a1fef-1ef8-45ee-91e5-d4733592b28b"
      unitRef="usd">687180000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzEyLTYtMS0xLTA_2b2bdab3-a1ca-48bd-ae80-12f8195d25f6"
      unitRef="usd">560618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE1LTItMS0xLTA_83a0dfef-fb1b-422f-ba77-3eb3b28603b5"
      unitRef="usd">596142000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE1LTQtMS0xLTA_423db96f-7fa6-408d-a123-0908fcc48f0e"
      unitRef="usd">539211000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE1LTYtMS0xLTA_ac02ab18-0546-4046-8ea8-c0d85752770e"
      unitRef="usd">467805000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE2LTItMS0xLTA_4f4704b1-2588-4556-b2d1-07b906038e7e"
      unitRef="usd">62077000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE2LTQtMS0xLTA_e7de7e6e-31e5-46ab-8e47-9ff88f68d144"
      unitRef="usd">49116000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE2LTYtMS0xLTA_b9cb7348-a903-422f-835e-e072961dcaa9"
      unitRef="usd">41482000</us-gaap:GeneralAndAdministrativeExpense>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE3LTItMS0xLTA_1f3827d0-8719-4536-bb33-316aaefff8df"
      unitRef="usd">17517000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE3LTQtMS0xLTA_777e79da-f677-4dd8-ac91-d23145fcae6b"
      unitRef="usd">18350000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE3LTYtMS0xLTA_88eca1aa-b65c-4b8a-9797-0f1bccfc81fd"
      unitRef="usd">18280000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE4LTItMS0xLTUzNDQ0_eb2469d5-dfa1-4298-92ec-44252a9d7d62"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE4LTQtMS0xLTUzNDQ3_6efe2edb-ab88-4d82-ad9d-66acc6092ab0"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE4LTYtMS0xLTUzNDUw_7c7be6e5-6882-40b1-9026-1a11a09f4df5"
      unitRef="usd">-1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE5LTItMS0xLTUzNDQ0_f858590a-fe9e-40b5-9460-227bbee3f767"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE5LTQtMS0xLTUzNDQ3_dfa5c0e2-d7b9-4dd5-b0ca-b479be8b3387"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzE5LTYtMS0xLTUzNDUw_0e0fa775-be03-497b-b52d-7a7fea453ad9"
      unitRef="usd">1994000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:CostsAndExpenses
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIxLTItMS0xLTA_6a964ee1-8e00-4a65-840c-914b4dce2172"
      unitRef="usd">675736000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIxLTQtMS0xLTA_dbdbf9fa-1cfd-4bc1-81ac-9b9309a9581d"
      unitRef="usd">606677000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIxLTYtMS0xLTA_3b9292c3-dafb-4963-8e8b-478b6826ec56"
      unitRef="usd">528198000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIzLTItMS0xLTA_ae8512aa-be76-485e-a90a-d28012a9aa92"
      unitRef="usd">98179000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIzLTQtMS0xLTA_d20bd7a1-56d9-42c5-8980-2336be4fb0bc"
      unitRef="usd">80503000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzIzLTYtMS0xLTA_c344a049-4453-41f0-babe-68acf3a68b95"
      unitRef="usd">32420000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI2LTItMS0xLTA_0b21e403-ca66-4a17-82d7-66b1c7da7d4a"
      unitRef="usd">-4306000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI2LTQtMS0xLTA_9e6f038c-2e08-4bd6-889b-3409cd4032a7"
      unitRef="usd">3694000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI2LTYtMS0xLTA_f47c81d7-6783-46ec-9b11-afc1ca898050"
      unitRef="usd">-6901000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI3LTItMS0xLTA_5e240719-2bd2-47a6-93a1-a7fc904c11ce"
      unitRef="usd">2193000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI3LTQtMS0xLTA_a4cdd048-ef34-43e8-8014-bb31bf854d0d"
      unitRef="usd">99839000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI3LTYtMS0xLTA_61ef4cc0-6189-418e-b7cc-957298461135"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:InterestExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI4LTItMS0xLTA_adf3cd62-62fb-45e0-bb0d-20cda211077d"
      unitRef="usd">5394000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI4LTQtMS0xLTA_f6ef636d-2efa-45a0-9449-1f7277459f83"
      unitRef="usd">9499000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI4LTYtMS0xLTA_2ff258cc-48b6-4144-b75a-0262f6925086"
      unitRef="usd">4733000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI5LTItMS0xLTA_b9915b1e-1d8c-456a-85ee-ab06d751efca"
      unitRef="usd">1571000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI5LTQtMS0xLTA_9ce1a328-aac0-4157-ac0e-db310b33986b"
      unitRef="usd">2813000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzI5LTYtMS0xLTA_a6570573-578a-4a13-a944-313c58f14627"
      unitRef="usd">2024000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMwLTItMS0xLTA_a5d9c22c-178b-4e34-865e-2774f4c23d49"
      unitRef="usd">-10745000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMwLTQtMS0xLTA_ed9781fa-5a61-489c-8e78-a3d8ce3858d7"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMwLTYtMS0xLTA_f90392e7-692f-48a0-882f-b43b2311644f"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMxLTItMS0xLTQ3NDMy_16702a52-8a7e-43c2-be06-fd53d799e251"
      unitRef="usd">-3750000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMxLTQtMS0xLTQ3NDQ1_ec54a2e4-1cd4-46ef-9407-de487b71906c"
      unitRef="usd">1077000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMxLTYtMS0xLTQ3NDU3_67a362d4-18f7-40aa-b206-58b0d8ea62eb"
      unitRef="usd">3030000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMyLTItMS0xLTA_e80add7d-5cd6-4f7c-ac23-1f1158d066ba"
      unitRef="usd">-20431000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMyLTQtMS0xLTA_40258d9a-dfb9-40ac-850c-cdad5689e605"
      unitRef="usd">97924000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzMyLTYtMS0xLTA_9c88a544-543f-4931-b153-872719f47701"
      unitRef="usd">-6580000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM0LTItMS0xLTA_f71ca901-8258-4d7b-aa88-256b83e74bf8"
      unitRef="usd">77748000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM0LTQtMS0xLTA_9458415c-8666-4118-bea1-36ec552c318c"
      unitRef="usd">178427000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM0LTYtMS0xLTA_a5f95df5-2ffa-45cd-a46c-d7b853a0f68a"
      unitRef="usd">25840000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM2LTItMS0xLTA_8b315dda-f5c9-46a4-88fe-eb141f2a9732"
      unitRef="usd">28454000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM2LTQtMS0xLTA_8f3f6360-bd24-4e27-825c-5f0873bd6e69"
      unitRef="usd">56107000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM2LTYtMS0xLTA_7028b4db-47d4-48bc-9a98-c16a190bdae4"
      unitRef="usd">8167000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM4LTItMS0xLTA_364a6d8b-e6a1-491e-b729-106ef48da381"
      unitRef="usd">49294000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM4LTQtMS0xLTA_9c0d78b7-74ff-47c5-9cd2-17ac348fd930"
      unitRef="usd">122320000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzM4LTYtMS0xLTA_2036d44f-6c20-4cdf-a93d-1a3e35611e19"
      unitRef="usd">17673000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQwLTItMS0xLTA_605a91ad-5fa8-4738-b18b-df4a9838cb0b"
      unitRef="usd">-24564000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQwLTQtMS0xLTA_7c7e5be8-ba0a-4408-ad2e-da6a7e16b89c"
      unitRef="usd">84454000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQwLTYtMS0xLTA_0fcbab2c-e0b4-4ded-a0fc-e19251e3a05e"
      unitRef="usd">3557000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQyLTItMS0xLTA_f4f699f5-c108-491d-9687-30876c8d763f"
      unitRef="usd">73858000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQyLTQtMS0xLTA_18cf4aff-4a0d-406b-9b90-c3083b9ec680"
      unitRef="usd">37866000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQyLTYtMS0xLTA_1d08cd35-2a74-4a7e-889a-31596adf83f5"
      unitRef="usd">14116000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTItMS0xLTA_57ed5f7a-186e-4c00-af0b-ec15e458aee2"
      unitRef="usdPerShare">1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTQtMS0xLTA_5ca414fe-74d9-43ba-b1e3-515192dd333c"
      unitRef="usdPerShare">1.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTQtMS0xLTA_d102e43f-969b-4c76-961f-55c29d2b6f56"
      unitRef="usdPerShare">1.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ0LTYtMS0xLTA_a02d5581-b5fb-4f54-b286-f3fa06c0bd5a"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTItMS0xLTA_4cc08e02-a9ed-4aba-ac19-153240ebe555"
      unitRef="usdPerShare">1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTQtMS0xLTA_2017a725-0eaa-4ad2-a164-a319967f755c"
      unitRef="usdPerShare">1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTQtMS0xLTA_476da3fc-2223-4d51-a0be-020e1ff9ed13"
      unitRef="usdPerShare">1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDYvZnJhZzo4NzI2ZmY1ZDU3MGM0YTU1YTljNjRjNzg1YmE5Y2U5MC90YWJsZTphNzQ3NWI3NDI2ZGM0YzMzOWU1OWU5YjEyNDYyODM0Yi90YWJsZXJhbmdlOmE3NDc1Yjc0MjZkYzRjMzM5ZTU5ZTliMTI0NjI4MzRiXzQ2LTYtMS0xLTA_20cc52cf-b0e7-43a0-a18b-bc467a36b65e"
      unitRef="usdPerShare">0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i69d3506ad61545a28e82fbaea4860bd7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTEtMS0xLTA_8d4436fd-7433-4140-bf75-8a3f3e4762e2"
      unitRef="usd">225117000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i238ec269dd2b4e39bf78ffb28244ae9f_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTMtMS0xLTA_a7dfb47b-1540-4bb1-8c50-12efe32c3614"
      unitRef="shares">34578040</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i238ec269dd2b4e39bf78ffb28244ae9f_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTUtMS0xLTA_2a4d680a-38bf-49ce-ba01-a9fed2ed949a"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5dc7a8bb404d44d6a025101ce145ebcb_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTctMS0xLTA_876ed514-e797-4e35-9531-5cca877fcc27"
      unitRef="usd">162723000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1890ce55fe054d5fb8532b6899d89386_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTktMS0xLTA_94f0d888-57fd-4e11-ba94-bd92e79570f6"
      unitRef="usd">17788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i64bc2b851e8049a69e6c4252d1789f5a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTExLTEtMS0w_ecbf0b9b-34ae-4fd2-b3c6-a976abef2a0f"
      unitRef="usd">999000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69d3506ad61545a28e82fbaea4860bd7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE3LTEzLTEtMS0w_f7475fae-bd8b-4969-8ac0-8d9810298ddc"
      unitRef="usd">181545000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTEtMS0xLTA_9ea76744-a018-4d48-b81d-ee968c7a031a"
      unitRef="usd">1808000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i51d91826c13e48f9ac3b196f1709cf0c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTktMS0xLTA_f7d5164c-8808-418b-aa4f-0255dd3ee0c9"
      unitRef="usd">14117000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTExLTEtMS0w_d3680d64-d16e-4490-83aa-c38cc680188d"
      unitRef="usd">1749000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE4LTEzLTEtMS0w_0f53bcfc-95e1-4c23-89f1-fef1e69d022b"
      unitRef="usd">15866000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:TemporaryEquityRepurchaseOfTreasuryShares
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTEtMS0xLTA_86809fca-bedf-450e-8719-996763d853b5"
      unitRef="usd">283000</ameh:TemporaryEquityRepurchaseOfTreasuryShares>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTMtMS0xLTA_7a6ad25e-c966-4c9b-a883-4a8cb0ea96c6"
      unitRef="shares">601581</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTUtMS0xLTA_f7366558-46da-4a6a-a4c6-d0cc76eb3ab9"
      unitRef="usd">1000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTctMS0xLTA_a4149d43-7ed5-4d33-845e-707d97185b60"
      unitRef="usd">7286000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzE5LTEzLTEtMS0w_777213ef-8451-47db-ae23-70965fdd8780"
      unitRef="usd">7287000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIwLTMtMS0xLTA_922abf92-72c6-4eab-aae3-0bd8df23d3c5"
      unitRef="shares">418619</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIwLTctMS0xLTA_59bc7973-6e34-4861-8a0c-34e36762035f"
      unitRef="usd">3233000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIwLTEzLTEtMS0w_34696a84-a5ab-4dac-9ba8-4b803f7e2a6a"
      unitRef="usd">3233000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:TemporaryEquityShareBasedCompensation
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTEtMS0xLTA_2a50aada-9ced-41d2-9843-71147fbe355c"
      unitRef="usd">607000</ameh:TemporaryEquityShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTMtMS0xLTA_be04a136-4774-48c7-ac1f-6c344f5df033"
      unitRef="usd">1599</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTctMS0xLTA_687475a9-ad33-4274-af3d-6a261bc93442"
      unitRef="usd">940000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIxLTEzLTEtMS0w_45ae7619-2d3f-4f88-8bba-ed9bcd0fe781"
      unitRef="usd">940000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ameh:TemporaryEquityStockSubscription
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIyLTEtMS0xLTA_d786a1ae-7a32-4e26-a031-600a1c3d3e0a"
      unitRef="usd">754000</ameh:TemporaryEquityStockSubscription>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzIzLTEtMS0xLTA_7bebdb00-bdff-4dfb-8366-2d9581552fd2"
      unitRef="usd">414000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <ameh:TemporaryEquityCostOfEquityIssuanceOfPreferredShares
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI0LTEtMS0xLTA_87f1352d-68af-4ed2-a1c5-3312a90e92da"
      unitRef="usd">-878000</ameh:TemporaryEquityCostOfEquityIssuanceOfPreferredShares>
    <ameh:NoncontrollingInterestIncreaseFromCapitalCharge
      contextRef="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI1LTExLTEtMS0w_b65f740b-f218-4f99-9099-dd9c505e924b"
      unitRef="usd">28000</ameh:NoncontrollingInterestIncreaseFromCapitalCharge>
    <ameh:NoncontrollingInterestIncreaseFromCapitalCharge
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI1LTEzLTEtMS0w_12567bb8-e6eb-41ac-a3bf-dfe6186035d7"
      unitRef="usd">28000</ameh:NoncontrollingInterestIncreaseFromCapitalCharge>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI2LTEtMS0xLTA_92dc8ead-70e1-42e4-8b7b-a3c2f15d7409"
      unitRef="usd">60000000</us-gaap:TemporaryEquityAccretionOfDividends>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i76452835af3f4e6facc0877e5561c9fd_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI2LTExLTEtMS0w_2fe6f790-ad52-49a4-8d5f-49737eaf8999"
      unitRef="usd">1990000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI2LTEzLTEtMS0w_130d153e-c425-43ea-85c4-5e8296916bdf"
      unitRef="usd">1990000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI3LTEtMS0xLTA_13d7a4dd-476c-4071-ae63-d6f72e494f06"
      unitRef="usd">1185000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <ameh:StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI3LTEzLTEtMS0w_950ab715-7a4a-4b23-b3c9-aa7d5aac003c"
      unitRef="usd">0</ameh:StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i69343d65ad324809810e1b1eda1dbc7d_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTAtMS0xLTAvdGV4dHJlZ2lvbjo3MmZjZWMzMDI2Y2M0MzhjYTMzODA5MWI0ZjZkZmUzNF82MDQ3MzEzOTUyODA2_5d69c990-acaf-43ed-b3f4-fee3ebdf1686"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <ameh:StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares
      contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTMtMS0xLTA_fd170b49-c144-47cb-a68a-cc9b8ef6086b"
      unitRef="shares">1511380</ameh:StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares>
    <ameh:StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares
      contextRef="iab77660d2c7e4a4ea1f4b90b59389e79_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTUtMS0xLTA_774c3994-6cbe-42f5-8020-0b731eafbb71"
      unitRef="usd">2000</ameh:StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares
      contextRef="iee80ed1c0a474f08ac99d58003afa37b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTctMS0xLTA_1cc8aa00-e427-4559-8f3c-22bb42f43fc0"
      unitRef="usd">-2000</ameh:StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTEtMS0xLTA_c84dcca8-8f11-4f79-ad90-7a0adc702a70"
      unitRef="usd">168724000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="ibae93612a82b454fad4c214ad4fbe93f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTMtMS0xLTA_85f91c4e-112c-497a-9966-2869abb24b97"
      unitRef="shares">35908057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibae93612a82b454fad4c214ad4fbe93f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTUtMS0xLTA_672e125a-bd10-41d2-b1e1-248530c47173"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59f1b5c490b84fb7bcd0e27816f8a1fd_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTctMS0xLTA_d5ee432f-4f99-4187-af56-f1497d46d40d"
      unitRef="usd">159608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic665959fd8094aba83a52190f5ce2a29_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTktMS0xLTA_bd5cc407-3930-48c2-ab7b-de14c1f501a6"
      unitRef="usd">31905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7108c557e599411aa1a3345423fbcaf2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTExLTEtMS0w_d02474a1-9fb4-4e32-ac58-243a09154495"
      unitRef="usd">786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI5LTEzLTEtMS0w_1b7d8094-a80c-4964-9410-41f7ce022071"
      unitRef="usd">192335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEtMS0xLTA_43dbf99a-08d7-49b6-a8d5-e5df25c1fc11"
      unitRef="usd">83621000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i2666f9aebddc43b295ec38700190d8f9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTktMS0xLTA_1db3f453-9bb5-4d19-83a5-0de1a525091f"
      unitRef="usd">37866000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="icd090b6a4d07450b83ab3ba19b8a8b82_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTExLTEtMS0w_ed00ea1c-5d8a-48b6-b1b6-0343f8af76b5"
      unitRef="usd">833000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEzLTEtMS0w_b62c06f3-6964-4780-9114-06f954c90ca8"
      unitRef="usd">38699000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTMtMS0xLTA_84439b25-255f-44cd-ad3a-f21a8213c7d4"
      unitRef="shares">16897</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTUtMS0xLTA_107b4188-b6ae-4a1e-991c-fc9ccf78cf2a"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTctMS0xLTA_00774938-9a10-4211-afe9-0ed7dc3dc800"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMxLTEzLTEtMS0w_9cdb9786-1ca3-4a51-959f-8eb5e0c72d2e"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <ameh:TemporaryEquityDistributionToNoncontrollingInterest
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMyLTEtMS0xLTA_7d67ebc4-9098-47b8-a337-4cd66d7c872b"
      unitRef="usd">1037000</ameh:TemporaryEquityDistributionToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMzLTMtMS0xLTA_d53facc5-ccf4-480f-a75c-634948e7a480"
      unitRef="shares">66788</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMzLTEzLTEtMS0w_7d40a125-7fdd-4c34-9f46-c6ac20177eab"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTMtMS0xLTA_d430e59a-e56a-4bc4-a8c1-79d461dcd807"
      unitRef="shares">66517</ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised>
    <ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTEzLTEtMS0w_7d8c6b96-3e3c-4e33-86b7-4e25cca61bcc"
      unitRef="usd">0</ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTMtMS0xLTA_90b77d89-d6a4-4ca8-ba15-9a0b70e45b5e"
      unitRef="shares">1240622</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTUtMS0xLTA_b85e1883-752f-4fde-b1fb-1dc3e4fe70d0"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTctMS0xLTA_f41f6888-cec9-4099-b969-7dcad768112e"
      unitRef="usd">11491000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTEzLTEtMS0w_bdd1df14-2c53-4440-8d43-92dd9d23b6da"
      unitRef="usd">11492000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM2LTctMS0xLTA_143f55a7-6df1-4c79-86ce-24c2d29f4102"
      unitRef="usd">3383000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM2LTEzLTEtMS0w_aa44240e-5bdf-49c3-8ba1-2afaa64ae8dd"
      unitRef="usd">3383000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTctMS0xLTQzMDIy_c947f5f7-1445-4d00-b454-08c50bd348a1"
      unitRef="usd">236000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzI4LTEzLTEtMS00MzA1NQ_8498e83c-14fc-414a-b2c7-b89cd8e08ba1"
      unitRef="usd">236000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEtMS0xLTQyOTg5_d84bc3e9-7549-4200-bf52-a384302194db"
      unitRef="usd">137071000</us-gaap:TemporaryEquityAccretionOfDividends>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTMtMS0xLTQzMDAw_31345a7b-9534-45c7-95e6-a8bd1419036c"
      unitRef="shares">4984050</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="ic3d603c3475d480088e42e0e2f39bf0f_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTUtMS0xLTQzMDEx_3e4d57be-5e4d-424e-b861-9bd73b909e48"
      unitRef="usd">5000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="i7a4b58840d6d4c3eb9b0533c522db9ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTctMS0xLTQzMDIy_63fd8214-1d0f-443d-93bb-04ba64f0d785"
      unitRef="usd">87066000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="icd090b6a4d07450b83ab3ba19b8a8b82_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTExLTEtMS00MzA0NA_55f180b2-3942-422f-87f6-c3deab808e37"
      unitRef="usd">-1532000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMwLTEzLTEtMS00MzA1NQ_60330767-2213-4ab8-9692-4c36fbdf9aa4"
      unitRef="usd">85539000</ameh:NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTEtMS0xLTA_87d3b574-25e6-4c89-858a-e588517abb6e"
      unitRef="usd">114237000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="idcca7582879a462a8ca400618dab2e16_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTMtMS0xLTA_fd44811f-11ae-44a1-970a-2d3553438d4a"
      unitRef="shares">42249137</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcca7582879a462a8ca400618dab2e16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTUtMS0xLTA_2dc0286b-b12e-4da5-a214-8893fa99c503"
      unitRef="usd">42000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idbb14ec4c3d04df498362b3ff2649443_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTctMS0xLTA_61133e4e-2738-4906-b918-3d5ddf5413df"
      unitRef="usd">261011000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ebd2bb3cc9f4ccfb1e9e646ea718b5a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTktMS0xLTA_42011c94-eafa-4eef-af5a-b923034c6c1b"
      unitRef="usd">69771000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b34f542dee746a88ed1f03df4889be3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTExLTEtMS0w_1eae3f9d-bac3-4146-91bd-c0aedd85baee"
      unitRef="usd">87000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTEzLTEtMS0w_8a8cba26-4aec-43a8-afeb-d787c112b50c"
      unitRef="usd">330911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TemporaryEquityNetIncome
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTEtMS0xLTQzMjAy_5c1a0cd7-b016-47b3-82ba-4921c0a2861e"
      unitRef="usd">-27331000</us-gaap:TemporaryEquityNetIncome>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i76474cb8ad064d37a1739d166c60efc9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTktMS0xLTQzMjI1_2049e2bf-501c-49b9-8efb-d509eec8ba24"
      unitRef="usd">73858000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTExLTEtMS00MzIzMg_96984807-3f59-4f16-8486-1fe482d89db7"
      unitRef="usd">2767000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTEzLTEtMS00MzI0OA_30e749cd-c55f-4ec9-91ad-251ea074ff34"
      unitRef="usd">76625000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i3c0752ab08774f379384a68ffb9687d6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTEtMS0xLTQzMjAy_cb7a674a-4ace-4d22-acdb-9fb0b107acf4"
      unitRef="usd">1546000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTExLTEtMS00MzIzMg_17588ab5-dcae-49e3-b163-1e6e4e93f6fd"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTEzLTEtMS00MzI0OA_2fb3d2c3-c3d4-4824-906a-4e710f5de0fd"
      unitRef="usd">75000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ameh:TemporaryEquityIncreaseFromSaleOfNonControllingInterest
      contextRef="i3c0752ab08774f379384a68ffb9687d6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM2LTEtMS0xLTQzMjAy_cbd8b5ac-5ee7-447c-a088-7f49e6d1e128"
      unitRef="usd">-150000</ameh:TemporaryEquityIncreaseFromSaleOfNonControllingInterest>
    <ameh:StockIssuedDuringPeriodSharesNoncontrollingInterest
      contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMyLTMtMS0xLTUyOTUx_3daa9a94-5d82-4985-bf2d-c42ea3b36dca"
      unitRef="shares">1638045</ameh:StockIssuedDuringPeriodSharesNoncontrollingInterest>
    <ameh:StockIssuedDuringPeriodValueNoncontrollingInterest
      contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM3LTUtMS0xLTQzMjEx_e1d81529-7af2-45e0-92d3-c4f7e6debcd4"
      unitRef="usd">2000</ameh:StockIssuedDuringPeriodValueNoncontrollingInterest>
    <ameh:StockIssuedDuringPeriodValueNoncontrollingInterest
      contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM3LTctMS0xLTQzMjE4_107d827c-9b47-42bc-8287-7dfe1ecbe392"
      unitRef="usd">40132000</ameh:StockIssuedDuringPeriodValueNoncontrollingInterest>
    <ameh:StockIssuedDuringPeriodValueNoncontrollingInterest
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM3LTEzLTEtMS00MzI0OA_6f0857de-22b4-45a2-b36b-03f1b2ccfa17"
      unitRef="usd">40134000</ameh:StockIssuedDuringPeriodValueNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzMzLTMtMS0xLTUyOTUx_6b9082ff-654c-47db-b45e-64157c5adbcb"
      unitRef="shares">29973</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM4LTEzLTEtMS00MzI0OA_7cd4d52a-02ef-423d-ac4c-50e409e7ff70"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM0LTMtMS0xLTUyOTUx_e3595b4c-ff08-45fe-ad34-c86e39a5adae"
      unitRef="shares">898583</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTUtMS0xLTQzMjEx_4b783af0-8019-429e-a1e8-3e2eea3c17a8"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTctMS0xLTQzMjE4_1dacdfb1-104f-4bd7-9d35-351e73841312"
      unitRef="usd">9060000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTEzLTEtMS00MzI0OA_0de5765c-2153-4652-917b-17e9268afb14"
      unitRef="usd">9061000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM1LTMtMS0xLTUyOTUx_2808664d-7cd0-4e06-ba0f-b2e7adc8e0f0"
      unitRef="shares">174158</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQwLTctMS0xLTQzMjE4_f3cff771-9545-4976-9140-b59128f39a20"
      unitRef="usd">5738000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQwLTEzLTEtMS00MzgyMw_43128f32-6606-4834-b68b-e98319aaab33"
      unitRef="usd">5738000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQxLTctMS0xLTQzMjE4_7217597e-d4bb-4daa-bf5d-a2e4117fdeca"
      unitRef="usd">6745000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQxLTEzLTEtMS00MzI0OA_99a81ab0-32af-47db-9c1c-27aa92cd136f"
      unitRef="usd">6745000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQyLTExLTEtMS00MzIzMg_667cb577-a24f-4f19-85bf-2f0f66eaba2d"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQyLTEzLTEtMS00MzI0OA_bc3d1a20-7433-48ae-9425-e5f36409cf2c"
      unitRef="usd">3769000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQzLTExLTEtMS00MzIzMg_26582e1a-3f0c-4834-9fad-7966f7dff667"
      unitRef="usd">500000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQzLTEzLTEtMS00MzgyMw_dbf7cd9d-5f0e-4d59-bc76-847c928cc6f7"
      unitRef="usd">500000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="i346e155972b041b3a6f575e701ef481d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzM5LTMtMS0xLTUyOTUx_4a30706c-c9b4-4a1e-918e-8a22c3034fa6"
      unitRef="shares">10707</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="i92f73d2de50b4e529703a74542535701_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ0LTctMS0xLTQzMjE4_e1ae1282-01b0-47aa-bd77-eaf2d3f8548b"
      unitRef="usd">334000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ0LTEzLTEtMS00MzgyMw_edd0afe7-bd5a-4f3f-9a32-c13d3bdd4dee"
      unitRef="usd">334000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <ameh:NoncontrollingInterestIncreaseFromCapitalCharge
      contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ1LTExLTEtMS00MzIzMg_eaccd5f4-b652-4687-88b6-e28df821d908"
      unitRef="usd">48000</ameh:NoncontrollingInterestIncreaseFromCapitalCharge>
    <ameh:NoncontrollingInterestIncreaseFromCapitalCharge
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ1LTEzLTEtMS00MzI0OA_fe4c64b6-8afe-4b84-920c-a9a4119166d3"
      unitRef="usd">48000</ameh:NoncontrollingInterestIncreaseFromCapitalCharge>
    <us-gaap:TemporaryEquityAccretionOfDividends
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ2LTEtMS0xLTQzMjAy_a0890f9b-9c4a-49d4-aceb-4ef474ed759a"
      unitRef="usd">30000000</us-gaap:TemporaryEquityAccretionOfDividends>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3f5d46dca8ba4dcfb496d751c5a83ce8_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ2LTExLTEtMS00MzIzMg_994dd97c-446c-4aed-affd-26618c164b15"
      unitRef="usd">1156000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ2LTEzLTEtMS00MzI0OA_96912cfd-3aaf-463a-ab0d-865edf58c67a"
      unitRef="usd">1156000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTEtMS0xLTQzMjY0_b533dcd0-dd00-41d1-893e-d724d40c0f0a"
      unitRef="usd">55510000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="i02229923c53147db941db9c29b48ab30_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTMtMS0xLTQzMjY5_90eaebea-6956-4cf6-9697-0a89a5b42fb1"
      unitRef="shares">44630873</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i02229923c53147db941db9c29b48ab30_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTUtMS0xLTQzMjcy_63c00680-89b8-49b9-9a8e-6d893be327cb"
      unitRef="usd">45000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic922097b0d6044c2893f7d407499ba35_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTctMS0xLTQzMjc3_da8b87e5-d117-46e5-b200-4812d78023ea"
      unitRef="usd">310876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie1c75cb4bf9e4ad79f118905ac2df40d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTktMS0xLTQzMjgy_12847355-b80b-4a54-b472-cd4bac3a1580"
      unitRef="usd">143629000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0088a70f180a4664865e2acb1ce90bce_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTExLTEtMS00MzI4Nw_65f5cb90-6e1d-4353-87f0-5679ac665023"
      unitRef="usd">5940000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDkvZnJhZzo0NmI2NjMzZGQ2OGE0NTE3YjZjZjFmZDUzZmNhN2EyNS90YWJsZTo4N2JjNTllOGVkZjA0NzM4YTgyNDkwNzc2Y2RlNzVmOC90YWJsZXJhbmdlOjg3YmM1OWU4ZWRmMDQ3MzhhODI0OTA3NzZjZGU3NWY4XzQ4LTEzLTEtMS00MzI5Mg_46139da2-a5df-450e-b259-8bafffeb967f"
      unitRef="usd">460490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYtMi0xLTEtMA_88660091-9e1c-48b8-ac42-c1588dcece84"
      unitRef="usd">49294000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYtNC0xLTEtMA_15c1140b-1318-4da1-8cd8-c7f8c7c3462d"
      unitRef="usd">122320000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYtNi0xLTEtMA_1f6f70b7-eddc-4dd7-90b9-df2fa0d496e0"
      unitRef="usd">17673000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgtMi0xLTEtMA_75da68a3-1462-4bf1-9d61-253ad5e36bcc"
      unitRef="usd">17517000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgtNC0xLTEtMA_1f6cf19b-54fe-45ed-adbb-880a83dca202"
      unitRef="usd">18350000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgtNi0xLTEtMA_ddbc09d7-2faa-48d5-9a3c-fe569073c4ad"
      unitRef="usd">18280000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzktMi0xLTEtMA_af5a6647-4b11-43fd-afe4-00c52203a57c"
      unitRef="usd">1078000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzktNC0xLTEtMA_c4c8206f-cb4c-4a08-ab12-91c5e216451e"
      unitRef="usd">1347000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzktNi0xLTEtMA_e6900b18-f550-4640-8f30-2ea09326118c"
      unitRef="usd">473000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTItMS0xLTU2OTY2_0fa5180f-93b1-4d51-80ce-6535b0708d6b"
      unitRef="usd">189000</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTQtMS0xLTU2OTc3_f23dd644-797b-4e20-8157-af65b77167d7"
      unitRef="usd">0</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:ProceedsFromOtherOperatingActivities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTYtMS0xLTU2OTg0_363ace60-ee59-4df7-b9fa-5ea5c2bd3731"
      unitRef="usd">0</us-gaap:ProceedsFromOtherOperatingActivities>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTItMS0xLTA_aa63e8bd-0ca1-40a8-a4f7-542e71710a3d"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTQtMS0xLTA_76cb9fcd-e68e-4c1d-9913-75e612e9fdf3"
      unitRef="usd">-91000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEwLTYtMS0xLTA_08f0f1e9-5997-4398-9319-6da179746e78"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzExLTItMS0xLTA_a0244f3f-4e65-4996-8359-3fc8743d2c11"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzExLTQtMS0xLTA_aca69346-bd5b-4e1c-bd25-1ef76089fb4a"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzExLTYtMS0xLTA_4528f48c-c13b-4997-b4aa-f29fb570eeb2"
      unitRef="usd">1994000</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEyLTItMS0xLTA_83c5bcc6-044a-4cc3-a3f4-a706606f536d"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEyLTQtMS0xLTA_d3c7ed50-3f35-4d78-b7d9-0446cef578a7"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEyLTYtMS0xLTA_987026d0-250d-4fa7-9052-675764f29939"
      unitRef="usd">-1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEzLTItMS0xLTA_657f6baf-c8a9-4e1f-8234-36bb11ff2718"
      unitRef="usd">6745000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEzLTQtMS0xLTA_ecdb4789-cabf-4857-b940-f209951e5cc5"
      unitRef="usd">3383000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzEzLTYtMS0xLTA_ecee3514-8b9e-4d1b-838d-ce0741db3b2f"
      unitRef="usd">1547000</us-gaap:ShareBasedCompensation>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE0LTItMS0xLTA_1d4a9367-cf74-4394-b2f7-241118001b5e"
      unitRef="usd">2193000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE0LTQtMS0xLTA_3f03564a-7124-48bf-9f84-adfee4a716c3"
      unitRef="usd">99839000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE0LTYtMS0xLTA_ba085385-9253-4699-b9ad-ab07dc08646c"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <ameh:GainLossOnConsolidationOfEquityMethodInvestment
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTItMS0xLTYzNTU0_9c6d6043-3b8f-482a-a6d2-3d1383c3948b"
      unitRef="usd">2752000</ameh:GainLossOnConsolidationOfEquityMethodInvestment>
    <ameh:GainLossOnConsolidationOfEquityMethodInvestment
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTQtMS0xLTYzNTY0_e846b6f3-2e90-4e08-919b-0e0815093d11"
      unitRef="usd">0</ameh:GainLossOnConsolidationOfEquityMethodInvestment>
    <ameh:GainLossOnConsolidationOfEquityMethodInvestment
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTYtMS0xLTYzNTcy_76fc422e-a6a1-444f-b3bf-43fce9d91b06"
      unitRef="usd">0</ameh:GainLossOnConsolidationOfEquityMethodInvestment>
    <ameh:GainLossOnEquityReceivable
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTItMS0xLTU3MDEw_468a9240-8629-4ae8-bb58-01c4c5dad57c"
      unitRef="usd">4270000</ameh:GainLossOnEquityReceivable>
    <ameh:GainLossOnEquityReceivable
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTQtMS0xLTU3MDE5_9915e51d-4060-4bdc-909e-aa4b1dacd193"
      unitRef="usd">0</ameh:GainLossOnEquityReceivable>
    <ameh:GainLossOnEquityReceivable
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTYtMS0xLTU3MDI2_3468426b-ea30-47f3-a76c-197156e75b3a"
      unitRef="usd">0</ameh:GainLossOnEquityReceivable>
    <ameh:GainLossOnAssumptionOfLoan
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE1LTItMS0xLTA_0eb6401b-2e94-4925-bb6f-8c9d1a981f69"
      unitRef="usd">0</ameh:GainLossOnAssumptionOfLoan>
    <ameh:GainLossOnAssumptionOfLoan
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE1LTQtMS0xLTA_34ae5eb0-f89d-4786-9129-e1e03ea6acaf"
      unitRef="usd">0</ameh:GainLossOnAssumptionOfLoan>
    <ameh:GainLossOnAssumptionOfLoan
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE1LTYtMS0xLTA_56dcc0e8-443c-4856-a5df-4ef1dfb2d701"
      unitRef="usd">2250000</ameh:GainLossOnAssumptionOfLoan>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTItMS0xLTA_debbcfa5-cf08-4fee-b16b-faf2895ab38a"
      unitRef="usd">-10845000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTQtMS0xLTA_e5aed621-da1e-48f9-a4fd-e334b54756f3"
      unitRef="usd">-11000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE2LTYtMS0xLTA_9c6fbbd8-de15-441e-b504-4388e80e0c00"
      unitRef="usd">9000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTItMS0xLTY0OTM2_02de63fd-f6f4-4676-b111-a2e56a477027"
      unitRef="usd">-1145000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTQtMS0xLTY0OTQz_09f486c3-36d6-47bc-9b07-766c3afa587b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTYtMS0xLTY0OTUw_49169aac-b0c1-476a-9254-ac06946a7593"
      unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE5LTItMS0xLTU3MTA2_9df39dd6-36ef-4d10-aed8-c08bbd48c02a"
      unitRef="usd">1071000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE5LTQtMS0xLTU3MTE1_86b121e9-56ed-43ae-805f-1a03fd757dbe"
      unitRef="usd">0</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE5LTYtMS0xLTU3MTI0_a899051e-20a2-4204-b1dc-fbbc5ab0f9d7"
      unitRef="usd">0</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTItMS0xLTU3MTA2_806eb04e-e689-407c-89b4-7b6f960b7c9e"
      unitRef="usd">15723000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTQtMS0xLTU3MTE1_a5976b33-a4ed-4c52-b686-f2f5e9350e1c"
      unitRef="usd">0</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTYtMS0xLTU3MTI0_6f43403b-428c-495a-8d4f-2ba536501fa8"
      unitRef="usd">0</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE3LTItMS0xLTA_abf87456-59b2-47e0-881b-705191cf7acb"
      unitRef="usd">-4306000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE3LTQtMS0xLTA_b24c97ec-21b5-4608-9df0-c7cf97947fa0"
      unitRef="usd">3694000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE3LTYtMS0xLTA_f3272d99-73eb-487e-a6c9-2bf0d88b18a2"
      unitRef="usd">-6901000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE4LTItMS0xLTA_932ed0c8-b882-4b79-bef9-e54b527c1433"
      unitRef="usd">-5952000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE4LTQtMS0xLTA_5eb90734-523d-4cd2-ae50-89e3c6cd5421"
      unitRef="usd">-6620000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzE4LTYtMS0xLTA_c7b381f2-4e16-46af-a3ee-13ae3ef526d0"
      unitRef="usd">-6801000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTItMS0xLTA_cd9839ca-c59b-4dbf-b923-7768263c4171"
      unitRef="usd">1518000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTQtMS0xLTA_eb982cf3-cd9f-4838-9154-e7c56f857c3c"
      unitRef="usd">-4134000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIwLTYtMS0xLTA_1c55b5bb-a585-40ea-aaf8-9aaae69ab725"
      unitRef="usd">-10714000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIxLTItMS0xLTA_47c996fe-b903-44b0-aaca-868b8a0736a0"
      unitRef="usd">20116000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIxLTQtMS0xLTA_ec23a801-0439-47f6-84fb-6b6a997d6c0d"
      unitRef="usd">1123000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIxLTYtMS0xLTA_fe552626-0cdb-46b2-944a-775c7dc2a431"
      unitRef="usd">1435000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIyLTItMS0xLTA_4ff33b26-4b7b-4a6a-9dbd-b6cb28fd7964"
      unitRef="usd">5351000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIyLTQtMS0xLTA_b3f1164c-edf3-4b41-af5d-af1f560939d1"
      unitRef="usd">-12589000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIyLTYtMS0xLTA_ab086b46-6958-48cd-b7aa-5ee5817a55bf"
      unitRef="usd">15079000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIzLTItMS0xLTA_122d457c-8679-4cb3-8290-876079cacc3c"
      unitRef="usd">-2708000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIzLTQtMS0xLTA_9b94ecf1-728e-49e7-9932-04d8abc74062"
      unitRef="usd">6432000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzIzLTYtMS0xLTA_a60eedb2-aad2-4185-99f0-eedde6ded6fe"
      unitRef="usd">2756000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI0LTItMS0xLTA_ebf70a61-1c6d-4baa-9218-ef9364555b1a"
      unitRef="usd">3133000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI0LTQtMS0xLTA_218c7b23-f32f-4319-90ef-297a9d591a84"
      unitRef="usd">3325000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI0LTYtMS0xLTA_ec034afb-d6dd-4b97-93f6-0934f9b2a25d"
      unitRef="usd">2480000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI1LTItMS0xLTA_c7c52027-8b0e-4e19-b4f0-eb26319a2759"
      unitRef="usd">1529000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI1LTQtMS0xLTA_b64c3339-a9a5-4dc4-8811-0ffcc8c6dd11"
      unitRef="usd">5530000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI1LTYtMS0xLTA_a5fb729b-0b31-419c-b07a-8cb9cba2eeae"
      unitRef="usd">572000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI2LTItMS0xLTA_e3058d93-b427-4b3d-940d-c22b0ff76dfd"
      unitRef="usd">3217000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI2LTQtMS0xLTA_186ab10e-15e1-4f97-8b60-1a3af093ac82"
      unitRef="usd">8204000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI2LTYtMS0xLTA_250bf5e3-fd1e-45f6-b372-c0eede20a521"
      unitRef="usd">-4883000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI3LTItMS0xLTA_838bb5e3-1af9-4fbb-86cf-d04252dd171c"
      unitRef="usd">892000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI3LTQtMS0xLTA_656e3755-2ed7-418f-98aa-b15c53643946"
      unitRef="usd">7615000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI3LTYtMS0xLTA_030f76f0-e25b-457f-84fc-79bdf6c9bfc9"
      unitRef="usd">488000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI5LTItMS0xLTA_267fae67-b112-4b5d-b6db-9acd525187e4"
      unitRef="usd">5279000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI5LTQtMS0xLTA_ed86b2fb-6df8-4cfb-aa0b-da035168ef11"
      unitRef="usd">-8691000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzI5LTYtMS0xLTA_373a1dd7-dbe0-4e34-bb9d-6316487a5ac3"
      unitRef="usd">-2392000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMwLTItMS0xLTA_b35d5474-3553-46e9-82da-6db88f476473"
      unitRef="usd">-3621000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMwLTQtMS0xLTA_bae9541f-159d-4f8b-9038-cb623cc258b3"
      unitRef="usd">-304000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMwLTYtMS0xLTA_a350e291-1115-4b49-89dc-aa12665a0299"
      unitRef="usd">-7093000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMxLTItMS0xLTA_445055b0-6814-4eac-acfe-9edea3b71999"
      unitRef="usd">-3215000</ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities>
    <ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMxLTQtMS0xLTA_f4c4bcee-1751-4afb-9a77-1ba5d89c2ed5"
      unitRef="usd">-2973000</ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities>
    <ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMxLTYtMS0xLTA_a87bd63b-1b2e-4c6c-bced-b76d8dbe4377"
      unitRef="usd">-2244000</ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMyLTItMS0xLTA_badeaad9-6a23-4b04-b639-b5da80f1323f"
      unitRef="usd">70335000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMyLTQtMS0xLTA_236467a2-d958-44f2-910a-3326a32e3a01"
      unitRef="usd">46163000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzMyLTYtMS0xLTA_23c96cc1-dc83-4c2b-81e4-97306cbe59b4"
      unitRef="usd">13673000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM1LTItMS0xLTA_b12d2744-c460-4ae8-8493-082fb6acd2de"
      unitRef="usd">28000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM1LTQtMS0xLTA_3f2c1992-527b-4d48-937a-745c4c41f527"
      unitRef="usd">1793000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM1LTYtMS0xLTA_f5764a14-6bb5-449e-9293-8c3daa245432"
      unitRef="usd">115402000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM2LTItMS0xLTA_39e6ab10-5c87-455d-821a-2f805a252621"
      unitRef="usd">67612000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM2LTQtMS0xLTA_6a6dfa58-a11d-4a8b-b981-7b047b3b8ff5"
      unitRef="usd">50625000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM2LTYtMS0xLTA_963cc66a-ddde-476d-96d7-3f3a083bbd2b"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM3LTItMS0xLTA_b033a112-9de6-4d72-9c47-2be7cf47cf6c"
      unitRef="usd">56000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM3LTQtMS0xLTA_e999fa07-5b53-44e2-8a25-617f69425a67"
      unitRef="usd">16500000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM3LTYtMS0xLTA_71839a22-ea0e-4f75-8d1f-cd338edd17da"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM4LTItMS0xLTA_e42a1793-0a9d-481d-a4a3-80b911756809"
      unitRef="usd">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM4LTQtMS0xLTA_160f4b40-1dd8-4c29-9091-3d2cb8a635f6"
      unitRef="usd">145000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM4LTYtMS0xLTA_2fa1d2d4-8eee-4030-adc9-f73ed2035800"
      unitRef="usd">11425000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM5LTItMS0xLTA_aeca5254-a55d-4eab-b7cb-772728f5763d"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM5LTQtMS0xLTA_cfc78184-8bf0-4491-8c20-ebc886f49bad"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzM5LTYtMS0xLTA_48f38cd1-b668-4c0d-9af9-14ac02885414"
      unitRef="usd">240000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQwLTItMS0xLTA_49cdf276-ea60-4ff8-9c7d-266a05704b28"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQwLTQtMS0xLTA_ff44f449-4baf-4a76-87d3-279150832a48"
      unitRef="usd">50000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQwLTYtMS0xLTA_ce1d9e09-b8bf-4897-8711-b0ca29fc0958"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQxLTItMS0xLTA_177bced4-99b3-4ac0-ac51-f2052f7cbb92"
      unitRef="usd">2585000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQxLTQtMS0xLTA_ecbacba5-53d0-4756-8a0a-b904b6a5cbde"
      unitRef="usd">11354000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQxLTYtMS0xLTA_3c1d5150-ea4c-4aa3-8a01-ea1f187861c9"
      unitRef="usd">49403000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQyLTItMS0xLTA_4b04c28f-8414-4816-bb5b-f7530964bfcf"
      unitRef="usd">0</ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare>
    <ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQyLTQtMS0xLTA_83556d04-64e5-440c-a459-2404af5334d7"
      unitRef="usd">0</ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare>
    <ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQyLTYtMS0xLTA_204a2143-e7be-4af8-97dd-fe7ebb03cc48"
      unitRef="usd">491000</ameh:PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQzLTItMS0xLTA_7a8e151f-e9e5-4f78-977a-36a137359bab"
      unitRef="usd">6375000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQzLTQtMS0xLTA_8009109f-3455-4ae4-896a-b0bcff2add66"
      unitRef="usd">52743000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQzLTYtMS0xLTA_7cd48b62-7da8-402e-85e9-802f751e0757"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ0LTItMS0xLTA_91e91337-2691-401e-bdb2-c4905b3af458"
      unitRef="usd">13622000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ0LTQtMS0xLTA_c209acf4-ddda-477f-890c-2098e4ea960c"
      unitRef="usd">9969000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ0LTYtMS0xLTA_f27b6c50-8e3f-4a1e-8c1a-3fd51a1e3e2f"
      unitRef="usd">3108000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ1LTItMS0xLTA_4e9a701e-705c-439e-8d0f-9f6129de127b"
      unitRef="usd">19223000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ1LTQtMS0xLTA_18688269-9945-47f9-9d5e-7473ba53be5a"
      unitRef="usd">1164000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ1LTYtMS0xLTA_c75b351d-53f0-490c-98e9-7ca7f79fb203"
      unitRef="usd">1042000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTItMS0xLTU3NDA1_dd84942c-3895-4e89-a674-9d14fc6fc7b1"
      unitRef="usd">5927000</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTQtMS0xLTU4Nzk2_60029cf7-9c82-4ce0-b06c-c16c42006aa2"
      unitRef="usd">0</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTYtMS0xLTU4Nzk2_8a3d0468-62e6-4529-813d-df42ba266a51"
      unitRef="usd">0</ameh:ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ2LTItMS0xLTA_6b7a749f-b650-4d96-ab94-13590c46c7d7"
      unitRef="usd">16540000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ2LTQtMS0xLTA_67cb02a6-ee4c-43a5-8ce5-39ce103a1cba"
      unitRef="usd">95493000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ2LTYtMS0xLTA_5f61cbff-9185-4aae-94ed-479f3dc2421a"
      unitRef="usd">-180631000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ5LTItMS0xLTA_148ccf24-a888-4d28-a64b-d27b297ab86f"
      unitRef="usd">31089000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ5LTQtMS0xLTA_dc78c088-8f54-4cb6-9e38-d09ec26316e3"
      unitRef="usd">51319000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzQ5LTYtMS0xLTA_15516c4b-e828-428e-806d-6a475134d3e1"
      unitRef="usd">61717000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTItMS0xLTA_fdd69168-0f03-4433-aed7-40f0a00db0b4"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTQtMS0xLTA_4d96ca10-1b56-4df2-bd51-905abc39c807"
      unitRef="usd">9500000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUwLTYtMS0xLTA_1d5e9836-7e11-4ea1-a1d7-3589966f90ca"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUxLTItMS0xLTA_98c4dd11-db3f-486a-a1ab-4024ca97ae34"
      unitRef="usd">48000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUxLTQtMS0xLTA_f650067b-f857-4904-9b9c-b0e310600b03"
      unitRef="usd">0</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUxLTYtMS0xLTA_31e439aa-70ed-4faf-9a7f-08bd08067f12"
      unitRef="usd">28000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUyLTItMS0xLTA_82c5e328-b49b-448c-8b95-fe161c906a35"
      unitRef="usd">569000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUyLTQtMS0xLTA_3649b35b-0b02-464c-b9a8-eb13d8c8cfb1"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUyLTYtMS0xLTA_0c90e499-8daa-49e6-98da-586022bced3e"
      unitRef="usd">250000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUzLTItMS0xLTA_b40bb9b4-1e41-4181-b0f6-25c6259f055b"
      unitRef="usd">180000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUzLTQtMS0xLTA_68df605b-5c9f-4773-9210-1479a39a67b7"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzUzLTYtMS0xLTA_95d42e71-14b4-4676-97e8-11c76f736c40"
      unitRef="usd">39600000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU0LTItMS0xLTA_62d20c84-e553-4e4a-9e81-d0bbcf84159c"
      unitRef="usd">201000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU0LTQtMS0xLTA_306d7379-3810-4d19-a356-a898e37acad5"
      unitRef="usd">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU0LTYtMS0xLTA_51059f19-3a07-4fab-bf6d-a9cac0ee58a3"
      unitRef="usd">2375000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <ameh:RepaymentsOfBankLoanAndLinesOfCredit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU1LTItMS0xLTA_c617f686-7afa-4445-9e25-2965289f97d2"
      unitRef="usd">238125000</ameh:RepaymentsOfBankLoanAndLinesOfCredit>
    <ameh:RepaymentsOfBankLoanAndLinesOfCredit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU1LTQtMS0xLTA_5545d094-afa2-485f-9858-8ba5755fcd8f"
      unitRef="usd">0</ameh:RepaymentsOfBankLoanAndLinesOfCredit>
    <ameh:RepaymentsOfBankLoanAndLinesOfCredit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU1LTYtMS0xLTA_e300cc29-dc59-433e-81b6-7ec61e713111"
      unitRef="usd">52640000</ameh:RepaymentsOfBankLoanAndLinesOfCredit>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU2LTItMS0xLTA_7c042160-0de0-4c06-9822-a93cd1728347"
      unitRef="usd">208000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU2LTQtMS0xLTA_6ee6d21d-83bc-4d8b-94db-2662f62b5d9c"
      unitRef="usd">105000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU2LTYtMS0xLTA_7b0e59ca-ebb1-4ec0-afdb-6401ae3ea86e"
      unitRef="usd">102000</us-gaap:RepaymentsOfDebtAndCapitalLeaseObligations>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU3LTItMS0xLTA_df35bd02-2b1b-4eec-a79b-dfa671e7c4ad"
      unitRef="usd">9061000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU3LTQtMS0xLTA_6f05d726-e78a-4b78-bb74-fd1c04955b87"
      unitRef="usd">10802000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU3LTYtMS0xLTA_ea1aa591-fe1a-4c53-8f3a-030fce9e870c"
      unitRef="usd">3123000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTItMS0xLTU3NTAw_3076c026-92a6-4400-b699-accec6d7cbb2"
      unitRef="usd">40134000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTQtMS0xLTU3NTA5_4bf9be6c-0edc-4b8b-b4ae-c88af42fb463"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTYtMS0xLTU3NTE2_0f208076-c3f7-4ad7-bee9-716248c867d8"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ameh:ProceedsFromEquityOffering
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU4LTItMS0xLTA_7a21b9c2-3076-4a9e-a24d-045c3f0d0047"
      unitRef="usd">0</ameh:ProceedsFromEquityOffering>
    <ameh:ProceedsFromEquityOffering
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU4LTQtMS0xLTA_6dee4a75-7796-43e9-862a-659dd8399bb5"
      unitRef="usd">0</ameh:ProceedsFromEquityOffering>
    <ameh:ProceedsFromEquityOffering
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU4LTYtMS0xLTA_3ae3ea0b-ed19-458d-92fc-aaad49947893"
      unitRef="usd">755000</ameh:ProceedsFromEquityOffering>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU5LTItMS0xLTA_56038668-e4df-4330-8f05-c407d886e9df"
      unitRef="usd">5739000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU5LTQtMS0xLTA_a333b64c-b3d7-4dc7-805f-fd4129ae6f59"
      unitRef="usd">537000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzU5LTYtMS0xLTA_5e7894f1-0246-4a0e-b474-8c473042682d"
      unitRef="usd">7570000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYwLTItMS0xLTA_270f4c2c-e49d-4992-a7dd-3af1bdeab221"
      unitRef="usd">1471000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYwLTQtMS0xLTA_7cd48175-2f83-430d-ae57-0a9114f03ab3"
      unitRef="usd">1037000</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentsOfDividendsMinorityInterest
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYwLTYtMS0xLTA_6e661260-15fa-42b5-8f41-1e4485036e23"
      unitRef="usd">0</us-gaap:PaymentsOfDividendsMinorityInterest>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYxLTItMS0xLTA_b8f467a2-3dc0-4e4c-9838-d4e3a53657e7"
      unitRef="usd">727000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYxLTQtMS0xLTA_2fe0311a-8d94-412a-af8c-0c411b111ef0"
      unitRef="usd">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYxLTYtMS0xLTA_af9d2101-3252-4d18-b82c-4f49644cc08d"
      unitRef="usd">5771000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYyLTItMS0xLTA_dee493d3-c8df-4ddf-816d-55d78354babb"
      unitRef="usd">-47748000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYyLTQtMS0xLTA_915097eb-f203-4b4c-9c2b-24919155b800"
      unitRef="usd">-51696000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzYyLTYtMS0xLTA_d870a776-0b13-4780-ab25-40ff3517c542"
      unitRef="usd">163331000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTItMS0xLTA_ed0f24f9-b817-4546-8896-ecd75d7aedf9"
      unitRef="usd">39127000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTQtMS0xLTA_9d467e06-8a78-48f1-b1e5-e3ab0331e3af"
      unitRef="usd">89960000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY0LTYtMS0xLTA_f6867771-19d3-47b7-8f58-c3a7142038a7"
      unitRef="usd">-3627000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY2LTItMS0xLTA_2e1bfa09-6030-49d8-bb90-f9f2528b52ff"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY2LTQtMS0xLTA_f84fb3af-a26b-45df-aff7-99f8a452788a"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i69d3506ad61545a28e82fbaea4860bd7_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY2LTYtMS0xLTA_e632fcaa-2b50-4c9a-9460-5c58730f393f"
      unitRef="usd">107637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY4LTItMS0xLTA_d5bb75d3-4f73-462c-8e07-c3bb13f2f9b7"
      unitRef="usd">233097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY4LTQtMS0xLTA_ae8b7388-30a6-4cb7-a1de-c2bf0e6913c9"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzY4LTYtMS0xLTA_e15ac8b7-6324-4326-a2f6-bc9762947b75"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcxLTItMS0xLTA_d87628a3-f8e2-4ca5-8119-9725a49f0d90"
      unitRef="usd">37201000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcxLTQtMS0xLTA_f0debaf3-4533-4ea2-a02f-a8fdb4172ab7"
      unitRef="usd">62002000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcxLTYtMS0xLTA_2d418ce8-9d26-4fd6-8b6c-75b4b9a28453"
      unitRef="usd">20200000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcyLTItMS0xLTA_83e0b772-3614-42ad-bc24-b1b9989ae630"
      unitRef="usd">4158000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcyLTQtMS0xLTA_0cfca526-c20f-4b74-a394-d713397afb9e"
      unitRef="usd">8510000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzcyLTYtMS0xLTA_a904a0f2-6c45-4213-b36b-652a5b381df9"
      unitRef="usd">4258000</us-gaap:InterestPaidNet>
    <ameh:IssuanceOfFinancingObligationForBusinessCombination
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgyLTItMS0xLTY5NTA0_85472788-0b68-4d12-94a5-be786ecb237c"
      unitRef="usd">12706000</ameh:IssuanceOfFinancingObligationForBusinessCombination>
    <ameh:IssuanceOfFinancingObligationForBusinessCombination
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgyLTQtMS0xLTY5NTEy_57114cd8-cae8-43a9-a53e-f92574517387"
      unitRef="usd">0</ameh:IssuanceOfFinancingObligationForBusinessCombination>
    <ameh:IssuanceOfFinancingObligationForBusinessCombination
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgyLTYtMS0xLTY5NTE5_65fc8ddc-bf8b-41f6-9868-666af3f7b49d"
      unitRef="usd">0</ameh:IssuanceOfFinancingObligationForBusinessCombination>
    <ameh:CashlessExerciseOfStockOptions
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc1LTItMS0xLTA_eaa050b7-5a09-4fe7-96fe-f7fb61a43e12"
      unitRef="usd">0</ameh:CashlessExerciseOfStockOptions>
    <ameh:CashlessExerciseOfStockOptions
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc1LTQtMS0xLTA_9894246c-107f-48f6-b374-baafac9befab"
      unitRef="usd">599000</ameh:CashlessExerciseOfStockOptions>
    <ameh:CashlessExerciseOfStockOptions
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc1LTYtMS0xLTA_981ea7b2-ac0c-4494-ab83-61452b0f9af6"
      unitRef="usd">0</ameh:CashlessExerciseOfStockOptions>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgzLTItMS0xLTU3NTQx_276eac04-43ee-4008-a2c2-944715054530"
      unitRef="usd">334000</ameh:CancellationOfRestrictedStockAwards>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgzLTQtMS0xLTU3NTQ4_bbad32a7-4b8d-472d-832e-69a3778b463a"
      unitRef="usd">0</ameh:CancellationOfRestrictedStockAwards>
    <ameh:CancellationOfRestrictedStockAwards
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1XzgzLTYtMS0xLTU3NTU4_b2897ac8-48d8-4c26-83c3-3b593ab52165"
      unitRef="usd">0</ameh:CancellationOfRestrictedStockAwards>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc2LTItMS0xLTA_1f16de84-37ce-43ca-9f3d-4c88b121b786"
      unitRef="usd">71000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc2LTQtMS0xLTA_3c141b79-fabe-4960-a9f2-80f8c8c61d63"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc2LTYtMS0xLTA_822da011-eac7-487f-9150-909b79427814"
      unitRef="usd">271000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:StockIssued1
      contextRef="i97a105ebf2734bc999cb1eda989a2bf9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc3LTItMS0xLTA_5964342b-e227-45c1-b43b-f5f2a45bd6ff"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i3ca318fe85484ec8995fd60b38993065_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc3LTQtMS0xLTA_a091681e-a415-4957-afcc-fac768cd81a2"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="i3f341ffb85ca4a0a9602302c5c3d5969_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc3LTYtMS0xLTA_dbe345d3-6ab1-404f-8d8b-7633a839bc0d"
      unitRef="usd">414000</us-gaap:StockIssued1>
    <ameh:ReclassificationOfLiabilityForEquity
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc5LTItMS0xLTA_519a2c6b-68a8-4efc-8308-78f4385dd7f1"
      unitRef="usd">0</ameh:ReclassificationOfLiabilityForEquity>
    <ameh:ReclassificationOfLiabilityForEquity
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc5LTQtMS0xLTA_2d5c98db-c19a-43bf-9182-4826f745ad6f"
      unitRef="usd">0</ameh:ReclassificationOfLiabilityForEquity>
    <ameh:ReclassificationOfLiabilityForEquity
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzc5LTYtMS0xLTA_36717fec-fee7-4c6c-ab2e-831cf4376316"
      unitRef="usd">1185000</ameh:ReclassificationOfLiabilityForEquity>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg0LTItMS0xLTA_2041d872-b333-4c5f-979c-1543a9336b0c"
      unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg0LTQtMS0xLTA_127f619f-066d-4a2b-b2e1-927bcbd9c37a"
      unitRef="usd">690000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg0LTYtMS0xLTA_6ba9b5b8-99f6-469d-a06d-938a21b0f416"
      unitRef="usd">0</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg1LTItMS0xLTA_0baf88b1-c17c-4609-bcf1-87d66223066f"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg1LTQtMS0xLTA_709d2026-2871-4d40-b41d-25193186f1f6"
      unitRef="usd">36179000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg1LTYtMS0xLTA_b477f5f2-0792-4d25-a851-85ce08716450"
      unitRef="usd">0</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg2LTItMS0xLTA_87f6a958-0158-467b-804e-37c8fa5f4bf6"
      unitRef="usd">0</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg2LTQtMS0xLTA_2e7f9dc8-ddbb-41bc-8dec-0e9568cd40e6"
      unitRef="usd">15723000</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZToyNzM1MGVkZGYyN2U0MDdlYjZhMzZmNGEyNzRjNjJiNS90YWJsZXJhbmdlOjI3MzUwZWRkZjI3ZTQwN2ViNmEzNmY0YTI3NGM2MmI1Xzg2LTYtMS0xLTA_4be5112f-e52f-41a2-ac01-42594f8f5859"
      unitRef="usd">0</us-gaap:ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzItMS0xLTEtMA_d639ae01-f4d2-46b6-88f8-5f5ecb6c49d7"
      unitRef="usd">233097000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzItMy0xLTEtMA_50ac3082-0bb0-44b2-9f8f-8477c3bff218"
      unitRef="usd">193470000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzItNS0xLTEtMA_be83bca8-99cf-4605-8f43-d745294d07f5"
      unitRef="usd">103189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzMtMS0xLTEtMA_69bff7b8-79f2-4c4c-91bb-f7b97804f557"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzMtMy0xLTEtMA_621abcbb-d512-48b7-9540-27a2f0587a43"
      unitRef="usd">500000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzMtNS0xLTEtMA_b2901397-fd52-4887-8126-da8debf73eef"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzQtMS0xLTEtMA_0e5608ad-0a67-4c4a-982b-03cd78ca3242"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzQtMy0xLTEtMA_abb7a0e0-0fb8-4918-accb-1ae0a254c461"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzQtNS0xLTEtMA_905385e5-70e9-4ace-bdaf-ece43f2cee8f"
      unitRef="usd">75000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzUtMS0xLTEtMA_9e5c19ca-3b05-459b-902a-24c351070b16"
      unitRef="usd">233097000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzUtMy0xLTEtMA_7dce339c-6f82-4bfb-8331-052434afad09"
      unitRef="usd">193970000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTIvZnJhZzo1MjczYWU3ODJjMzg0NmNiYjBjMTdlZTM1NGEyMDFhNC90YWJsZTozNjY4ZDBmMGMzY2I0NjJlODQxMDBhYjZlZmU3MjU4OS90YWJsZXJhbmdlOjM2NjhkMGYwYzNjYjQ2MmU4NDEwMGFiNmVmZTcyNTg5XzUtNS0xLTEtMA_b8e7557a-a898-452d-8bb2-1b474c6bda94"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzE1NDI4_9212eaa5-b7c3-4c8b-b4c1-d46d672a2fba">Description of Business&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Apollo Medical Holdings, Inc. (&#x201c;ApolloMed&#x201d;) is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high-quality care to patients in a cost-effective manner. ApolloMed was merged with Network Medical Management (&#x201c;NMM&#x201d;) in December 2017 (the &#x201c;2017 Merger&#x201d;). As a result of the 2017 Merger, NMM became a wholly owned subsidiary of ApolloMed, and the former NMM shareholders own a majority of the issued and outstanding common stock of ApolloMed and maintain control of the board of directors of ApolloMed. Unless the context dictates otherwise, references in these notes to the financial statements, the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; and similar words are references to ApolloMed and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#x201c;VIEs&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headquartered in Alhambra, California, ApolloMed&#x2019;s subsidiaries and VIEs include management services organizations (&#x201c;MSOs&#x201d;), affiliated independent practice associations (&#x201c;IPAs&#x201d;) and a Next Generation Accountable Care Organization (&#x201c;NGACO&#x201d;). NMM and Apollo Medical Management, Inc. (&#x201c;AMM&#x201d;) are the administrative and managerial services companies for the affiliated physician-owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually. Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA (&#x201c;APC&#x201d;), Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), Accountable Health Care IPA (&#x201c;Accountable Health Care&#x201d;), and Access Primary Care Medical Group (&#x201c;APCMG&#x201d;) are the affiliated IPA groups that provide medical services. These affiliated IPAs are supported by ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). The Company&#x2019;s NGACO operates under the APA ACO, Inc. (&#x201c;APAACO&#x201d;) brand and participates in the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program&#x2019;s attribution-based risk-sharing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, and hospitalists. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMM, a wholly owned subsidiary of ApolloMed, manages affiliated medical groups, AMH and SCHC. AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly owned subsidiary of ApolloMed in December 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC was incorporated in 1992 for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (&#x201c;HMOs&#x201d;) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#x201c;PMPM&#x201d;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (amending an initial management services agreement that was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a VIE of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#x2019;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AP-AMH Medical Corporation (&#x201c;AP-AMH&#x201d;) and AP-AMH 2 Medical Corporation (&#x201c;AP-AMH 2&#x201d;) were formed in May 2019 and July 2021, respectively, as a designated shareholder&#160;professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH and AP-AMH 2. ApolloMed makes all the decisions on behalf of AP-AMH and AP-AMH 2 and funds and receives all the distributions from its operations. ApolloMed has the right to receive benefits from the operations of AP-AMH and AP-AMH 2 and has the option, but not the obligation, to cover its losses. Therefore, AP-AMH and AP-AMH 2 is controlled by and consolidated by ApolloMed as the primary beneficiary of this VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $545.0 million loan to AP-AMH, pursuant to a 10-year secured loan agreement (the &#x201c;AP-AMH Loan&#x201d;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable, (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&#x2019;s assets. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $545.0 million private placement, where AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock which entitle AP-AMH to receive preferential, cumulative dividends that accrue on a daily basis. During the year ended December&#160;31, 2021 and 2020, APC distributed $55.1 million and $30.4 million, respectively, as preferred returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;A $300.0&#160;million private placement, where APC purchased 15,015,015 shares of the Company&#x2019;s common stock and in  connection therewith, the Company granted APC certain registration rights with respect to the purchased shares.  During the year ended December&#160;31, 2020, APC distributed approximately 5.0&#160;million shares of the Company&#x2019;s common stock to APC shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed licensed to AP-AMH the right to use certain tradenames for specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee is also payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the series of transactions, in September 2019, APC and AP-AMH entered into a Second Amendment to the Series A Preferred Stock Purchase Agreement clarifying the term excluded assets (&#x201c;Excluded Assets&#x201d;). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#x2019;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing, or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment, or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii), and (iii). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC's ownership in ApolloMed was 19.68% and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.58%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as of December&#160;31, 2021 and 2020, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concourse Diagnostic Surgery Center, LLC (&#x201c;CDSC&#x201d;) was formed in March 2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California, organized by a group of highly qualified physicians, with a surgical center that utilizes some of the most advanced equipment in Eastern Los Angeles County and San Gabriel Valley. The facility is Medicare-certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of December&#160;31, 2021, APC owned 44.50% of CDSC&#x2019;s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#x2019;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA Designated Shareholder Medical Corporation (&#x201c;APC-LSMA&#x201d;) was formed in October 2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC-LSMA. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and the right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#x2019;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#x201c;LMA&#x201d;), Pacific Medical Imaging and Oncology Center, Inc. (&#x201c;PMIOC&#x201d;), Diagnostic Medical Group (&#x201c;DMG&#x201d;), and AHMC International Cancer Center, a Medical Corporation (&#x201c;ICC&#x201d;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, Inc. (&#x201c;MMG&#x201d;), Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), Accountable Health Care IPA, a Professional Medical Corporation (&#x201c;Accountable Health Care&#x201d;), and AMG, a Professional Medical Corporation (&#x201c;AMG&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care, an IPA, was acquired by APC-LSMA in May 2019 for an aggregate purchase price of $45.1 million in cash, has been operating in California since 1993, and is a risk-bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, Medicare, and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care provides quality healthcare services to its members through three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare, and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock they did not already own (comprising 75%) for $7.3 million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMG is a network of family practice clinics operating in three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its networks of doctors and nurse practitioners. In September 2019, APC-LSMA acquired 100% of the aggregate issued and outstanding shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;DMG is a professional medical California corporation and a complete outpatient imaging center. APC accounted for its 40% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, has the ability to exercise significant influence, but not control over DMG&#x2019;s operations. However, in October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE of the Company and is consolidated by the Company. In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $8.5&#160;million at December&#160;31, 2021. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 100% interest in each of Medical Property Partners, LLC (&#x201c;MPP&#x201d;), AMG Properties, LLC (&#x201c;AMG Properties&#x201d;), and ZLL Partners, LLC (&#x201c;ZLL&#x201d;) and a 50% interest in each of One MSO, LLC (&#x201c;One MSO&#x201d;), Tag-6 Medical Investment Group, LLC (&#x201c;Tag 6&#x201d;), and Tag-8 Medical Investment Group, LLC (&#x201c;Tag 8&#x201d;). These entities own buildings that are currently leased to tenants, as well as vacant land that they plan to develop in the future. MPP, AMG Properties, and ZLL are 100% owned subsidiaries of APC and are included in the consolidated financial statements. In April 2021, Tag 8 entered into a loan agreement with MUFG Union Bank N.A. with APC as their guarantor, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in Tag 8. Based on the reevaluation and in accordance with relevant accounting guidance, it was concluded that Tag 8 is a VIE and is consolidated by APC. One MSO and Tag 6 are accounted for as equity method investments as APC has the ability to exercise significant influence, but not control over the operations of the entity. These purchases are deemed Excluded Assets that are solely for the benefit of APC and its shareholders. As such, any income pertaining to APC&#x2019;s interests in these properties has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation, and consequently will not affect net income attributable to ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, AP-AMH 2 purchased an 80% equity interest (on a fully diluted basis) in Access Primary Care Medical Group (&#x201c;APCMG&#x201d;), a primary care physicians&#x2019; group focused on providing high-quality care to senior patients in the northern California cities of Daly City and San Francisco. As a result, APCMG is consolidated by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Apollo Medical Holdings, Inc. acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Clinical Laboratories (&#x201c;Sun Labs&#x201d;) for an aggregate purchase price of $4.0 million. Sun Labs is a Clinical Laboratory Improvement Amendments-certified full-service lab that operates across the San Gabriel Valley in Southern California. In accordance with relevant accounting guidance, Sun Labs is determined to be a VIE of the Company and is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. The purchase of the remaining equity value is considered a financing obligation with a carrying value of $4.2&#160;million at December&#160;31, 2021. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;APAACO, jointly owned by NMM and AMM, began participating in the NGACO Model in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk-sharing model.</us-gaap:NatureOfOperations>
    <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
      contextRef="i0a787853fb4e44ab97a431b68a27e17f_D19990701-19990731"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzM4NjA_b17a91f4-68ce-4be0-a2fe-f31e3bad1fc8">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>
    <us-gaap:NotesReceivableNet
      contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzUxNjA_1349d560-53ff-44c4-8601-863124513c16"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="i075d8ca8fc3540c08520741050fea395_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzE1NDMw_9615e901-80ae-41aa-b0da-53fe9e5382fa">P10Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableStatedInterestRate
      contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzUyNjY_080e80fd-69a8-4231-8834-58b94b01d32d"
      unitRef="number">0.10</ameh:FinanceReceivableStatedInterestRate>
    <ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate
      contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzU5Njc_86f6d9df-000a-415c-97a6-3188c861b10f"
      unitRef="number">0.1075</ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate>
    <us-gaap:NotesReceivableNet
      contextRef="ia8eba5e3ecc24775b615ff1f59f368ba_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDY0Mjc_1349d560-53ff-44c4-8601-863124513c16"
      unitRef="usd">545000000</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia2b7ab46ec1f4230b17c5bc1355ea969_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwMTQ_117325c0-1706-4c31-aff6-d862d4e43593"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibb9136ad4e1240bd8120581c09a56b83_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDYyNzE_452a9cff-dbf9-4fa9-889e-4106b892be14"
      unitRef="usd">55100000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ic93862edf0d94e38a0905a9d5e2a7e97_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDYyNzg_886295b5-6723-4cb4-b569-6fd9fece5cce"
      unitRef="usd">30400000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NotesReceivableNet
      contextRef="i730fecde417c468e90d3113624967018_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzI3NDg3NzkxMDcwMDg_2328d2fb-8951-4405-aba3-2f8e111f6b47"
      unitRef="usd">300000000</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ia7b9267d39a0457aa1e20e58ddb345e4_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzY3NjY_a409c6c1-3808-496b-9363-9dce35352bc4"
      unitRef="shares">15015015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ameh:NoncontrollingInterestSharesDistributed
      contextRef="i9d2380fc33084f94b7a593212ef66566_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzQzOTgwNDY1MzgyNTg_759c68a1-1f01-4b31-97e2-6be680412d4e"
      unitRef="shares">5000000</ameh:NoncontrollingInterestSharesDistributed>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i439aed610b4a4563872164ecdf084f75_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzg5MDQ_ad64d8b5-7caf-4055-a734-90965963f070"
      unitRef="number">0.1968</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ica1cde9ee4cb4494b58321188ad95db5_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzg5MTE_dacf40a0-a20a-4bb3-8791-06e42f7225eb"
      unitRef="number">0.2258</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie4bb40e84ae24fb4b5080af0965a1437_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzk0MzQ_53ea1069-caa7-4d50-9a5d-bd8c3d8cc039"
      unitRef="number">0.4450</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i8c3dd0689a5341d584d1b40693f33ff1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwODY5_6e3475de-6088-4aa4-be78-304f2af3cb84"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i5742adc9978b45aaa40335db8f9111dd_D20190531-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzExMjE4_ee35d1ff-5fc7-4859-b5f6-7222bdc097f5"
      unitRef="usd">45100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <ameh:NumberOfFederallyQualifiedHealthPlans
      contextRef="i45ba50ac0812478a8bf374d9030b66b3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTQwMDE5NzE_a47bfe56-394c-4a5d-8dda-60a013b90712"
      unitRef="plan">3</ameh:NumberOfFederallyQualifiedHealthPlans>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i82f8e127a67545b3bdfa58cfd22513c0_I20190831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyNTE0_95cc4058-1061-40f5-8ee2-1c781bc351a0"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i2f4a82d79e57442f9d6db8a9a608f3ff_D20190801-20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyNTIy_629f5308-da29-4040-9e4d-6c180343c172"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfFamilyPracticeClinics
      contextRef="ide47e2643c3c4ee5a76d35bfdd8a6db7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyNjE1_c1983def-355b-44b2-80e7-81533de27c55"
      unitRef="clinic">3</ameh:NumberOfFamilyPracticeClinics>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ia8e95cb40b2041898bc0dd250b3bf3a3_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyODY2_6b40bfd0-852e-44ff-863a-1ca73b31cf16"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i6eb95e4e08f44ee1bbc425d9152ac541_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyOTQ0_bd6ed291-3dfd-444e-a15b-d3fc228d29b7"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i971fe048ecb4482193d9bb6633606328_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEyOTU5_66f2bfff-e1a7-4021-883a-c14c938e60e6"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i38c118bd8bb54e4d9429b7ddcd63c503_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTQwMDE5NjA_b7968eec-e02c-4ace-9bc9-8d15c2c6b25e"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="iaa8a8f6914b344759eab7b2e8596a641_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTQwMDE5NTQ_0b18c766-f9a1-442d-aba8-2db1fec23571">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <us-gaap:EquityMethodInvestments
      contextRef="i47097cefe18c427f8543ad5cd7663066_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTM5Nzk_fa7743a4-55db-4371-8ba2-725802128385"
      unitRef="usd">8500000</us-gaap:EquityMethodInvestments>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i8fb44b3ad67c4065a24264c841b2285a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzY5NTg_44f5cfb7-3ff0-42bf-a01b-42b482591154"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="iff99085ba68941a1a5742e3e59299a26_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzY5NjQ_36039ab4-aac6-436f-bbc2-d57a2e1e4d09"
      unitRef="number">0.50</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i8fb44b3ad67c4065a24264c841b2285a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzY5Njk_3f732b57-6214-45f9-9306-bd917037df5f"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i2bb290c80ed04d9284ae72a27d2b780d_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTQ1ODA_d9f80b33-4e73-452a-a351-a81037df4c39"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i6e863e59c64443d08c0faadab68620e3_I20210801"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTQ1NzY_bb685719-718a-4c24-84cf-51668fa85550"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTQ1NzI_53b60b2f-24e7-4ab9-8b92-7c4b1fd26ff5"
      unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzYwNDczMTM5NzcwMjc_e458a269-aa50-4e6e-ab43-986f96d2b287">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent
      contextRef="ie58240bdc60b46879e56e7842cd94022_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMTgvZnJhZzo1NjZhYWYyMjRjZmQ0MzU2OGExOGU4N2Q0ZjhkZDRiYy90ZXh0cmVnaW9uOjU2NmFhZjIyNGNmZDQzNTY4YTE4ZTg3ZDRmOGRkNGJjXzEwOTk1MTE2NTM5NzE_f724b504-8ea2-4ca5-b19f-5ec2b4511c08"
      unitRef="usd">4200000</ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQx_426180ea-c9c7-4acd-b0c3-305299f003a0">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared by management in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of December&#160;31, 2021 and 2020 and consolidated statements of income for the years ended December&#160;31, 2021, 2020 and 2019 include the accounts of (1) ApolloMed, ApolloMed&#x2019;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; (3) AMM&#x2019;s consolidated VIEs, SCHC and AMH; (4) NMM&#x2019;s VIE, APC; (5) APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment, accrual of medical liabilities (IBNR claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors, and historical margins), income tax  valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by it in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements (&#x201c;MSA&#x201d;). To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company concludes that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 6 &#x2013; &#x201c;Investments in Other Entities&#x201d; for entities that qualify as VIEs but the Company is not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash. As of December&#160;31, 2021 and 2020, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $285.9 million and $294.9 million, respectively. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of December&#160;31, 2021 and 2020, investments in marketable securities were approximately $53.4 million and $67.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to twenty-four months (see fair value measurements of financial instruments below). As of December&#160;31, 2021 and 2020, certificates of deposit amounted to approximately $25.0 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted-average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#x201c;Clinigence&#x201d;). The common stock of a payor partner were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#x201c;UCI&#x201d;) in April 2020. As of December&#160;31, 2021, the equity securities from the payor partner amounted to $24.0 million. As of December&#160;31, 2020, prior to our payor partner&#x2019;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#x201c;contingent equity securities&#x201d;) for $3.0 million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 - &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#x201d; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recognized unrealized losses of $10.7 million during the year ended December&#160;31, 2021 in unrealized gain or loss on investments in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables, Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, management fee income, incentive receivables, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements and incentive receivables, management fee income and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s loan receivable - related party consists of promissory notes from payees that are expected to be collected between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5OTk_64bfc1bc-0468-44da-ae64-8adbf345015b"&gt;two&lt;/span&gt; to four years and accrue interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full-risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, FFS reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risks&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by each payor type (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,286&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,596&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,311&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,079&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,654&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt"&gt;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Land, Property, and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMDk1_890dedd3-9639-4f3d-a087-9691ad4f5456"&gt;three&lt;/span&gt; to thirty-nine years. Leasehold improvements are amortized on a straight-line basis over the shorter of the terms of the respective leases or the expected useful lives of those improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2021 are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2020 are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:31pt"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts, and member relationships and are stated at cost, less accumulated amortization, and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization, and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 350&#x201d;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) MSOs, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances. &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the year ended December 31, 2019, the Company wrote off indefinite-lived intangible assets of approximately $2.0 million related to Medicare licenses, acquired as part of the 2017 Merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom. The write-off is included in impairment of goodwill and intangible assets in the accompanying consolidated statements of income. There was no impairment loss recorded related to goodwill and intangibles during the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2013; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#x201c;Income (loss) from equity method investments&#x201d; and also is adjusted by contributions to and distributions from the investee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are subject to impairment evaluation. During the years ended December&#160;31, 2019, the Company recognized an impairment loss of approximately $0.3 million related to its investment in Pacific Ambulatory Health Care, LLC as the Company does not believe it will recover its investment balance. Such impairment loss is included in loss from equity method investments in the accompanying consolidated statements of income. There was no impairment loss recorded related to equity method investments for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, and APCMG (&#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. The consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fiduciary Cash and Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them. The fiduciary cash balance of $10.5 million and $9.6 million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, is presented within prepaid expenses and other current assets and the related payable is presented as fiduciary payable in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 10 - &#x201c;Credit Facility, Bank Loan, and Lines of Credit,&#x201d; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of December&#160;31, 2021, was $1.1 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement which included the Company purchasing warrants. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of December&#160;31, 2021 was $1.1 million and is presented within other assets in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The Company determined the fair value of the contingent equity security using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $4.3 million and is presented within prepaid and other current assets in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. The Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company&#x2019;s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions on factors, including but not limited to, historical margin, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared-risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk-share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO and CMS entered into a NGACO Model Participation Agreement (the &#x201c;Participation Agreement&#x201d;) with an initial term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MDUx_13452d7a-ce48-4cb1-9932-b9a62aad18dd"&gt;two&lt;/span&gt; performance years through December&#160;31, 2019, which was extended for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MTA3_7004a731-22ef-4a6d-af57-dbde08754dca"&gt;two&lt;/span&gt; additional renewal years through December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company submitted to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company obtained CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk-share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency, in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 9 - &#x201c;Medical Liabilities&#x201d;), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there was any excess AIPBPs for the performance year and the excess is refunded to CMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared-risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit for the performance year and therefore this shared-risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $21.8 million and $19.8 million in risk pool savings, related to the 2020 and 2019 performance years, respectively, and has recognized such savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to be eligible in receiving AIPBP under the NGACO Model for performance year 2021, with the effective date of the performance year beginning January 1, 2021. For performance year 2021, the Company received monthly AIPBP payments at a rate of approximately $7.7 million per month from CMS. The monthly AIPBP received by the Company for performance year 2020 was approximately $7.2 million per month. The Company has received approximately $92.4 million in total AIPBP for the year ended December&#160;31, 2021 of which $59.2 million has been recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors, such as hours staffed, patient visits, or collections per visit, against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s contracted physicians and employed physicians are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients, and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company does not have any contract assets since all obligations have been performed when revenue was recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. As of December&#160;31, 2021, the Company&#x2019;s contract liability balance was $16.8 million, of which $16.3 million was related to the Company&#x2019;s NGACO. Contract liability was $13.0&#160;million as of December&#160;31, 2020, of which $12.6&#160;million was related to NGACO. Contract liability is presented within the accounts payable and accrued expenses in the accompanying consolidated balance sheets. Approximately $0.4 million of the Company&#x2019;s contracted liability accrued in 2020 has been recognized as revenue during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#x2019;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is computed by dividing net income attributable to the holders of the Company&#x2019;s common stock by the weighted-average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted-average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 17 &#x2014;  &#x201c;Earnings Per Share&#x201d; for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements. As of December&#160;31, 2021 and 2020, APC&#x2019;s shares were not redeemable nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and ROU asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under twelve month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Beneficial Interest&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020 was&#160;$15.7&#160;million and was included in other assets in the accompanying consolidated balance sheets. The beneficial interest was the result of a gross margin provision in the stock purchase agreement, which entitled UCAP to potentially receive additional cash and preferred shares (cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale, were held in an escrow account) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varied dependent upon the gross margin as compared to the target but cannot exceed the amounts that were in the escrow account. Additionally, the stock purchase agreement included a tangible net equity provision that could have resulted in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. The Company determined the fair value of the beneficial interest using an income approach, which included significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value, which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment was defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#x2019;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7&#160;million was written off and expensed in other income in the accompanying consolidated statements of income during the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued ASU) No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-08&#x201d;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently assessing the impact of that adoption of ASU 2021-08 will have on the Company&#x2019;s consolidated financial statements. &lt;br/&gt;&lt;br/&gt;With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUy_61cdeb6f-7152-4fd4-8fc3-c22e16f1ec06">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared by management in accordance with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU0_9cb51c38-9ffd-4b31-9109-56082f2742c7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets as of December&#160;31, 2021 and 2020 and consolidated statements of income for the years ended December&#160;31, 2021, 2020 and 2019 include the accounts of (1) ApolloMed, ApolloMed&#x2019;s consolidated subsidiaries, NMM, AMM, and APAACO, and its VIEs, AP-AMH, AP-AMH 2, Sun Labs, and DMG; (2) AP-AMH 2&#x2019;s consolidated subsidiary, APCMG; (3) AMM&#x2019;s consolidated VIEs, SCHC and AMH; (4) NMM&#x2019;s VIE, APC; (5) APC&#x2019;s consolidated subsidiaries, Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), MPP, AMG Properties, ZLL, and its VIEs, CDSC, APC-LSMA, ICC, and Tag 8; and (6) APC-LSMA&#x2019;s consolidated subsidiaries, Alpha Care, Accountable Health Care, and AMG.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY1_bd08c6e4-3bb2-410a-8aea-869f641856f7">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combinations and goodwill valuation and impairment, accrual of medical liabilities (IBNR claims), determination of full-risk and shared-risk revenue and receivables (including constraints, completion factors, and historical margins), income tax  valuation allowance, share-based compensation, and right-of-use assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ1_3fa4ef03-943b-4999-96a2-85031f5551d1">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, as circumstances indicate the need for reconsideration, the Company evaluates each legal entity that is not wholly owned by it in accordance with the consolidation guidance. The evaluation considers all of the Company&#x2019;s variable interests, including equity ownership, as well as management services agreements (&#x201c;MSA&#x201d;). To fall within the scope of the consolidation guidance, an entity must meet both of the following criteria:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity has a legal structure that has been established to conduct business activities and to hold assets; such entity can be in the form of a partnership, limited liability company, or corporation, among others; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The Company has a variable interest in the legal entity &#x2013; i.e., variable interests that are contractual, such as equity ownership, or other financial interests that change with changes in the fair value of the entity&#x2019;s net assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity does not meet both criteria above, the Company applies other accounting guidance, such as the cost or equity method of accounting. If an entity does meet both criteria above, the Company evaluates such entity for consolidation under either the variable interest model if the legal entity meets any of the following characteristics to qualify as a VIE, or under the voting model for all other legal entities that are not VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A legal entity is determined to be a VIE if it has any of the following three characteristics:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity does not have sufficient equity to finance its activities without additional subordinated financial support;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The entity is established with non-substantive voting rights (i.e., where the entity deprives the majority economic interest holder(s) of voting rights); or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The equity holders, as a group, lack the characteristics of a controlling financial interest. Equity holders meet this criterion if they lack any of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The power, through voting rights or similar rights, to direct the activities of the entity that most significantly influence the entity&#x2019;s economic performance, as evidenced by:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Substantive participating rights in day-to-day management of the entity&#x2019;s activities; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:135pt;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;Substantive kick-out rights over the party responsible for significant decisions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The obligation to absorb the entity&#x2019;s expected losses; or&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:90pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The right to receive the entity&#x2019;s expected residual returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company concludes that any of the three characteristics of a VIE are met, the Company will conclude that the entity is a VIE and evaluate it for consolidation under the variable interest model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable interest model&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If an entity is determined to be a VIE, the Company evaluates whether the Company is the primary beneficiary. The primary beneficiary analysis is a qualitative analysis based on power and economics. The Company consolidates a VIE if both power and benefits belong to the Company &#x2013; that is, the Company (i) has the power to direct the activities of a VIE that most significantly influence the VIE&#x2019;s economic performance (power), and (ii) has the obligation to absorb losses of, or the right to receive benefits from, the VIE that could potentially be significant to the VIE (benefits). The Company consolidates VIEs whenever it is determined that the Company is the primary beneficiary. Refer to Note 18 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; to the consolidated financial statements for information on the Company&#x2019;s consolidated VIE. If there are variable interests in a VIE but the Company is not the primary beneficiary, the Company may account for the investment using the equity method of accounting, refer to Note 6 &#x2013; &#x201c;Investments in Other Entities&#x201d; for entities that qualify as VIEs but the Company is not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU5_30cf1bc5-003d-4610-8ea1-02bd10d7e9c2">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the acquisition method of accounting for all business combinations, which requires assets and liabilities of the acquiree to be recorded at fair value, to measure the fair value of the consideration transferred, including contingent consideration, to be determined on the acquisition date, and to account for acquisition-related costs separately from the business combination.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU2_3ae599a9-e4b3-40e1-84dc-d5fb7dcfebef">Reportable SegmentsThe Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYzODg_8469423e-85d6-431d-a79e-73052ff9ddf4"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzY2NjU_e9a81eb5-5bcd-4c79-a9fd-53d4c49827c8"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDM4_24cc35b9-6111-412f-9f4f-1cb9148f6828">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents, and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzc4NTg_e9cbe513-a188-4b95-b5f4-046cb09127c1"
      unitRef="usd">285900000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzc4NjU_8e2c23a4-c62e-4ecd-9980-d1ffc85931ee"
      unitRef="usd">294900000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU3_b9e5e7d7-a648-4b4b-99da-ae27ab693624">Restricted CashRestricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYy_19be3e6a-94e8-4011-8ad7-bc59d73bb9a0">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable securities consist of equity securities and certificates of deposit with various financial institutions. The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of December&#160;31, 2021 and 2020, investments in marketable securities were approximately $53.4 million and $67.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certificates of deposit are reported at par value, plus accrued interest, with maturity dates from four months to twenty-four months (see fair value measurements of financial instruments below). As of December&#160;31, 2021 and 2020, certificates of deposit amounted to approximately $25.0 million and $67.6 million, respectively. Investments in certificates of deposit are classified as Level 1 investments in the fair value hierarchy.&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities are reported at fair value. These securities are classified as Level 1 in the valuation hierarchy, where quoted market prices from reputable third-party brokers are available in an active market and unadjusted. The trading volume of certain equity securities we hold is low, thus resulting in our determination that such equity securities do not have an active market with buyers and sellers ready to trade. Accordingly, we classify such equity securities as Level 2 in the valuation hierarchy, and their valuation is based on weighted-average share prices from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities held by the Company are primarily comprised of common stock of a payor partner that completed its IPO in June 2021 and Clinigence Holdings, Inc. (&#x201c;Clinigence&#x201d;). The common stock of a payor partner were acquired as a result of UCAP selling its 48.9% ownership interest in Universal Care, Inc. (&#x201c;UCI&#x201d;) in April 2020. As of December&#160;31, 2021, the equity securities from the payor partner amounted to $24.0 million. As of December&#160;31, 2020, prior to our payor partner&#x2019;s IPO, the related investment balance was included in investments in privately held entities at its cost basis of $36.2 million in the accompanying consolidated balance sheets. In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement in which ApolloMed purchased shares of common stock, warrants, and potentially additional common stock if certain metrics are not met (&#x201c;contingent equity securities&#x201d;) for $3.0 million. The common stock is included in investments in marketable securities and the warrants and contingent equity securities are classified as derivatives and included in other assets and prepaid expenses and other current assets, respectively, in the accompanying consolidated balance sheets. See Note 2 - &#x201c;Basis of Presentation and Summary of Significant Accounting Policies - Derivative Financial Instruments&#x201d; in the accompanying consolidated financial statements for information on the treatment of the derivative instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recognized unrealized losses of $10.7 million during the year ended December&#160;31, 2021 in unrealized gain or loss on investments in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzg2Njg_4dbba808-3316-4da0-b05c-8a4693263905"
      unitRef="usd">53400000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzg2NzU_a7b5aecc-67fc-4577-8326-d83bf92518f4"
      unitRef="usd">67700000</us-gaap:MarketableSecuritiesCurrent>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i843561394b2844a9b8120f9bad1daee3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2NTU_ce4cb9af-4339-4bc0-940d-d1c80b805aaa">P4M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i56fd8a6fc7d245bdbb1e814caed96cee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2NzY_3a9cfc6b-6c02-4e4c-89af-0a2695103cef">P24M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8d60f7810f154d9185d11b65f7a20684_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2MDg_38e12ae8-f90c-4d56-81d3-ffb881e12443"
      unitRef="usd">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5f06cfd6220a4db180cc0a47fb336fc4_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2Mjk_e54d2da6-314c-4ae5-ba53-984564e0d86f"
      unitRef="usd">67600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2ODI_2c07a05a-0345-48c0-ae72-b3dd42d0e5ff"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2NzA_94333efe-ecc5-4b23-9f41-528188dbc8c4"
      unitRef="usd">24000000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk2ODY_6587b830-5e4e-43a0-ac14-d189470e6a36"
      unitRef="usd">36200000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <ameh:PaymentsToAcquireCommonStockAndWarrants
      contextRef="iac5f8642c01d4d23bd5b08e841100c8c_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk4ODQ_9f624d72-c51b-49a6-88f2-96a34544046e"
      unitRef="usd">3000000</ameh:PaymentsToAcquireCommonStockAndWarrants>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2ODk5MDM_b09bc795-d9ec-45cf-ba22-5a4ef6316ac6"
      unitRef="usd">-10700000</us-gaap:UnrealizedGainLossOnInvestments>
    <ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY2_958ad082-f1b9-499f-ab64-0e7caa8f0659">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables, Receivables &#x2013; Related Parties, and Loan Receivable - Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, management fee income, incentive receivables, and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements and incentive receivables, management fee income and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s loan receivable - related party consists of promissory notes from payees that are expected to be collected between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5OTk_64bfc1bc-0468-44da-ae64-8adbf345015b"&gt;two&lt;/span&gt; to four years and accrue interest per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full-risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2020 APAACO performance year to be administered following instructions from CMS, FFS reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop-loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends, and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (&#x201c;CECL&#x201d;) model.</ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock>
    <ameh:AccountsReceivableExpectedToBeCollectedPeriod
      contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjMwMTg_0320ae9f-af8a-42c8-90ba-52e7760fee43">P4Y</ameh:AccountsReceivableExpectedToBeCollectedPeriod>
    <ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwNjI5ODY_0a674dc8-5dcd-486d-9b63-7286e99f767e">P18M</ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYw_656258e1-ba6c-4696-9de6-1a98f4a497de">Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUz_7898db7d-0dcd-4896-abdb-c58c39b0de68">The following table presents disaggregated revenue generated by each payor type (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.144%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,286&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271,596&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,002&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283,311&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269,079&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,985&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,654&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,680&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;773,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2fdbacce1904cf3912b442f8c709d96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzItMS0xLTEtMA_5546a221-f158-4efc-a0ca-ec24c7b47da1"
      unitRef="usd">138333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32f8e0c168ce444ca00cbd5129aa617a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzItMy0xLTEtMA_5b2392ed-218b-4763-97ad-fa286318e8c2"
      unitRef="usd">108851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0587413f1c6a47c099219d283492a39a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzItNS0xLTEtMA_7ce5dc71-caeb-4d3f-bdb0-3a956f4a7777"
      unitRef="usd">107340000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16b60c8d266045aa80eb56cf8c52109f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzMtMS0xLTEtMA_51db2d11-7134-4113-82e7-18c283714685"
      unitRef="usd">307286000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i745de55cc97343cf9f5cd4dd3f327d33_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzMtMy0xLTEtMA_264d665c-f28e-4c3d-bcda-3c4806c833a7"
      unitRef="usd">271596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56c70a6d6fd1473aa3326d1e1d7c1a0b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzMtNS0xLTEtMA_7e669411-9464-43ce-ab4c-6b8229f81cc5"
      unitRef="usd">226002000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id30a014ea9a543089265dbe3894f75f9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzQtMS0xLTEtMA_30bbfb58-49c5-41db-940f-ce3fb2db5e79"
      unitRef="usd">283311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68bb08ba38e94f7bb612b424801b2a5c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzQtMy0xLTEtMA_3ddbb0d5-4416-4007-9c59-24f0319e0fcf"
      unitRef="usd">269079000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29d8221e56424d85ab5b7cc79c7ebe1e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzQtNS0xLTEtMA_fd94ed5b-55c3-4ced-ac47-f59b6675fa64"
      unitRef="usd">192596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i022a5fa7aae74c619acb43e67e97eda4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzUtMS0xLTEtMA_96c9f81b-f3d6-410e-aaca-efc369431ff7"
      unitRef="usd">44985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e2e545c192042c0a652056f20110ef6_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzUtMy0xLTEtMA_43b5a36e-257c-4eca-abfe-cd6b73bc6378"
      unitRef="usd">37654000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8391dd985bc48f89be89e25c7043816_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzUtNS0xLTEtMA_256e8833-8935-47ba-9d5c-89b1c3bfd2db"
      unitRef="usd">34680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzYtMS0xLTEtMA_5b924c4b-551d-4f16-a05f-bc56881cd37a"
      unitRef="usd">773915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzYtMy0xLTEtMA_dbc09a1a-7c76-44c6-8111-7c70d1bffb6d"
      unitRef="usd">687180000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo0YzQwNTBiOGFlMDI0ZjYwOGIyMzZkMGE3NzAxNmQzNS90YWJsZXJhbmdlOjRjNDA1MGI4YWUwMjRmNjA4YjIzNmQwYTc3MDE2ZDM1XzYtNS0xLTEtMA_2ed3be24-a2a9-483e-bbb7-98348dc2546e"
      unitRef="usd">560618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ3_81dd4573-812a-4162-873e-360cb2d3b525">The Company had major payors that contributed the following percentages of net revenue:&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt"&gt;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of net receivables and receivables - related parties :&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.778%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9926274bc8d84660ae987c991d85aa80_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzItMS0xLTEtMA_c3a32d8c-fbcc-471b-9981-137e03a85996"
      unitRef="number">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic4300a3b054a47eb9093ebb87d484b6d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzItMy0xLTEtMA_a127c576-55fa-4f9b-bddf-9c63f75530c0"
      unitRef="number">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic95b069367b24fd890ebdca632ea58eb_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzItNS0xLTEtMA_85b59674-a74d-46a4-901d-9fa1e1b063f5"
      unitRef="number">0.136</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8ce2f24276fa40f1bac2f8b82eb3561d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzMtMy0xLTEtMA_47f4ecb0-138d-41b5-bc95-5841bfdab7d2"
      unitRef="number">0.109</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5c991f317b8a4c638731da2d2c41fbf7_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzMtNS0xLTEtMA_ac55de94-96d2-4991-b341-f051b971f6f9"
      unitRef="number">0.134</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i943dfe63e2ab45ca9f085402af19715d_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzUtMS0xLTEtMA_4a421631-6dbd-4b9a-b2e2-61e9a6b89798"
      unitRef="number">0.119</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5fc1a4e79592432dbc61f090c132bdce_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzUtMy0xLTEtMA_e37f9a47-11dd-40f5-be02-f090421e31c6"
      unitRef="number">0.131</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2ca388db64744f11a4ecfa00deef6721_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzUtNS0xLTEtMA_0f84895e-415c-4302-ba33-8527942bde1c"
      unitRef="number">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i056d175194ad41b1a26e434846bc2bb8_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzYtMS0xLTEtMA_a4100da3-66ac-4f06-9a09-326a058d64d5"
      unitRef="number">0.153</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic80816a284004c57bc9d57607f50fae6_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzYtMy0xLTEtMA_4cc99dba-b52e-49a6-b080-aa9261e6bbff"
      unitRef="number">0.169</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idc61efd9b3fb4b72af24435b0ac021d3_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTowNmZlNTlmNjFjZTA0Yjc0YTM5ODZmZjBmYzU4M2ZkOS90YWJsZXJhbmdlOjA2ZmU1OWY2MWNlMDRiNzRhMzk4NmZmMGZjNTgzZmQ5XzYtNS0xLTEtMA_f48da1a6-00f6-4a3d-8eb2-191e19cbc7fb"
      unitRef="number">0.129</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2f42dcbfcf6e414f9c2f53ca2fd539fb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzItMi0xLTEtMA_1e623e96-dd8c-4598-a3b6-dde8050c16e1"
      unitRef="number">0.450</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib36036ab49044648a373020e6e50c5c9_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzItNC0xLTEtMA_86eb3e20-50a6-4436-9d7b-9378ec1648c0"
      unitRef="number">0.439</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8b6bca11224045aab99c0deaf9679a62_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzMtMi0xLTEtMA_c1677e66-4e5e-4561-a830-cb6e69d8480b"
      unitRef="number">0.300</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i43b900167e4147608494071af8a327e5_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTpiNTYwNjdlNDAxZDk0NWNhYTI2NzNlNzExM2E3YWY5Yi90YWJsZXJhbmdlOmI1NjA2N2U0MDFkOTQ1Y2FhMjY3M2U3MTEzYTdhZjliXzMtNC0xLTEtMA_423208e9-8226-4743-978a-3de3dcc1b702"
      unitRef="number">0.365</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ4_71795ca2-ba1c-4daa-9716-cfa8b0991d46">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Land, Property, and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land is carried at cost and is not depreciated as it is considered to have an indefinite useful life.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, including leasehold improvements, are carried at cost less accumulated depreciation and amortization. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMDk1_890dedd3-9639-4f3d-a087-9691ad4f5456"&gt;three&lt;/span&gt; to thirty-nine years. Leasehold improvements are amortized on a straight-line basis over the shorter of the terms of the respective leases or the expected useful lives of those improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maintenance and repairs are charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation and amortization is removed from the accounts, and any related gain or loss is included in the determination of consolidated net income.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEzMTAx_c7bdf9c4-75ab-438c-a4fb-ee58aa9b5b53">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDM5_31f4b501-8fd5-45a0-a705-5116e84eaabe">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash and cash equivalents, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FASB Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014;Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014;Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014;Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUw_db16492f-b6e0-45be-8812-13b90a61301d">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2021 are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APCMG contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2020 are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.098%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:31pt"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtMi0xLTEtMA_c29c3b12-ef9d-44df-910d-d4422a31fa13"
      unitRef="usd">114665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtNC0xLTEtMA_b6d3f0bd-3ad6-4f29-8989-0a17f9d3fe4a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtNi0xLTEtMA_eac7cad0-da30-4d22-85c4-5d60f8b6f9e6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzMtOC0xLTEtMA_0c9dbaea-d772-4611-a1f3-5a640a09a2a5"
      unitRef="usd">114665000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtMi0xLTEtMA_a8c5261c-e432-4045-aa41-e00c75da6f6f"
      unitRef="usd">25024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtNC0xLTEtMA_97b5a64e-6112-4801-b0b1-13fb042f19ab"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtNi0xLTEtMA_8a748026-a879-4d10-96bf-2bb4892f1186"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzQtOC0xLTEtMA_56f7be8f-5d5f-47c0-81cd-9580ddb9dddf"
      unitRef="usd">25024000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtMi0xLTEtMA_0afb0f42-a956-4611-9c57-304eca7e278f"
      unitRef="usd">24123000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtNC0xLTEtMA_81617f2c-5b7e-4e82-a540-65dc291b33e2"
      unitRef="usd">4270000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtNi0xLTEtMA_252473d4-a0e9-4193-b509-f083eaf917e6"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzUtOC0xLTEtMA_69b1f1d2-086d-45d3-83a7-36d1157e597c"
      unitRef="usd">28393000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DerivativeAssets
      contextRef="i3a462e81bf45445cb29240d95de98506_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtMi0xLTEtNTMwOTA_b24a0e41-1eba-4ccb-bbe1-4aaded4b1b4f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1797fd6783dd4f6a8e55c48ac402e7d7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNC0xLTEtNTMwOTA_41e66566-e7ea-46db-bc4f-8cdf744b11a3"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ice50008825b6453b900419be6e538d60_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNi0xLTEtNTMwOTA_16023222-42a3-45aa-a462-35e35f9e66ec"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i9f29656902d24bac845ed6c3e1313c72_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtOC0xLTEtNTMwOTA_a28d4ca0-07e0-4726-b398-6223291097b5"
      unitRef="usd">4270000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i724f9c4c78a84bb5b1cf0f0c80000aa7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtMi0xLTEtMzUyODM_9ff52430-378b-4658-bf31-27bd591b59b7"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0a44a937b1d142b3bfe3aa76130e4ed1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNC0xLTEtMzUyODM_e346e88b-1484-4efd-bbc1-20316012f450"
      unitRef="usd">1145000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i0e0046d91fd144e69bc896e9a3d03eb3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtNi0xLTEtMzUyODM_4dc524c8-41ce-4a0f-89bd-40c1d9d9682c"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ifb3ead10c02740de85a4ae1939f70f28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzYtOC0xLTEtMzUyODM_aa318c2b-5328-4022-ba5b-21e11e676f16"
      unitRef="usd">1145000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctMi0xLTEtMA_05830bdc-c5a4-4f99-be8c-260eaa58247b"
      unitRef="usd">163812000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctNC0xLTEtMA_ebc1b2e5-2324-4baf-8e65-3e885be94dcd"
      unitRef="usd">5415000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctNi0xLTEtMA_bddfcca9-0d80-4b08-914d-2c3732842b5f"
      unitRef="usd">4270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzctOC0xLTEtMA_67d9fb28-bbc3-4c7a-aa44-8828ee31d64f"
      unitRef="usd">173497000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTItMS0xLTM1OTQw_bc42dc28-f2e5-4562-8a6b-22c0e9093250"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTQtMS0xLTM1OTQw_502467ef-ecfe-445f-ae95-718bfeedecd2"
      unitRef="usd">1071000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTYtMS0xLTM1OTQw_456fccbb-9033-4a9b-8f4a-8c3240e47239"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEwLTgtMS0xLTM1OTQw_be701af8-bab8-4e58-bba2-43101f525257"
      unitRef="usd">1071000</us-gaap:DerivativeLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTItMS0xLTM1OTQw_de7a41d0-bcc7-43d8-9ea2-c9b93aa52ed3"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTQtMS0xLTM1OTQw_39a04386-4b3f-4668-b513-4231d3d8044e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTYtMS0xLTM1OTQw_687d70c5-215d-4a2a-8d74-3da03ea3dd56"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzExLTgtMS0xLTM1OTQw_035088a4-2f6e-4a81-8295-e8c162122793"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i9e05dc98d4304124b10db253c8d59d8a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTItMS0xLTM1OTQw_1291d9a5-8e29-4c7b-972e-4f4e6c308cd9"
      unitRef="usd">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTQtMS0xLTM1OTQw_39663233-6d40-4d74-94a2-02a221c8aef5"
      unitRef="usd">1071000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i0c0aa3b01d794603ada2fd543a712bb9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTYtMS0xLTM1OTQw_43d5283b-bd11-48c7-b0dc-dbd092804f9a"
      unitRef="usd">1000000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTo4YTkzZDE0YTVkNWU0MWZiYTVhYjVjMzkyNzhhZjI4ZC90YWJsZXJhbmdlOjhhOTNkMTRhNWQ1ZTQxZmJhNWFiNWMzOTI3OGFmMjhkXzEyLTgtMS0xLTM1OTQw_d59df8d8-ebe1-4dd2-bf70-497c1ee6dc47"
      unitRef="usd">2071000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtMi0xLTEtMA_1549e8c7-9183-4b28-8f04-5ffb19336f89"
      unitRef="usd">115769000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtNC0xLTEtMA_1901292d-8ee1-4c61-9d19-56ad9a6b7c37"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtNi0xLTEtMA_3f914980-27be-4603-afb3-c03a88d6d04b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzMtOC0xLTEtMA_2823d9fa-1c12-4d54-891b-f834da00b5de"
      unitRef="usd">115769000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtMi0xLTEtMA_7651e59b-5731-4692-b94c-332ed6a12bf5"
      unitRef="usd">67637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtNC0xLTEtMA_230380fa-e443-4187-af1a-917afc54ef91"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtNi0xLTEtMA_9d62f5dd-d56f-429f-82a6-cd6d4d271214"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzQtOC0xLTEtMA_0b52df7b-700c-4841-8748-37d5f6b6da3f"
      unitRef="usd">67637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtMi0xLTEtMA_d3c47864-0a77-4905-bc40-6baac845d70e"
      unitRef="usd">58000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtNC0xLTEtMA_497cd5e1-edec-4ef1-a861-a57c97efd2a9"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtNi0xLTEtMA_dc2fd3a8-660d-4312-b6bd-61ece7fcc765"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzUtOC0xLTEtMA_a69d7040-5ae0-40e7-8174-cd2d2b6ae72d"
      unitRef="usd">58000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic8cc51db51b6476f9350d45ef801fbe2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctMi0xLTEtMA_921a345e-66bd-4e74-bebd-fde788ccdd84"
      unitRef="usd">183464000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i01d4ebb041104a03b9d6fb5a7abe3abf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctNC0xLTEtMA_2c148842-788c-477e-8c99-8f22eef12ebd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="icd5b2bd9b50f4e3bbc477c88c8dfbb70_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctNi0xLTEtMA_119c85c8-94d0-46ef-8334-274698319d93"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90YWJsZTplNGRiZTBlOWJmZDE0MWZiYjliMzJhZGVjYjg0ODRjMi90YWJsZXJhbmdlOmU0ZGJlMGU5YmZkMTQxZmJiOWIzMmFkZWNiODQ4NGMyXzctOC0xLTEtMA_c9f66049-ce89-4116-bbcb-bc42b4f6479e"
      unitRef="usd">183464000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYz_4c648f0f-1749-4360-b572-bace857cde67">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts, and member relationships and are stated at cost, less accumulated amortization, and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization, and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU1_e21027ca-daf3-41e0-80dc-83b97fc27d66">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 350&#x201d;), goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three reporting units (1) MSOs, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments, and assumptions management believes are appropriate in the circumstances.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE4MDgy_98cf7b9f-88d5-4632-bd0b-536f498b9abd"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i015c75fcf61d4986bcc5f227b6c412de_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5NTAz_6b9edfef-247a-41b3-9580-b52ea7a0245b"
      unitRef="usd">2000000</us-gaap:IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_3a4d9bd2-30bb-41c5-ae06-87d54c23f6ee"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_7e3120c8-6608-4f95-a4d3-7404e957db55"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_c53a5281-0b5f-45dc-b67a-8ff0e68f6e78"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzE5OTU4_e7796800-1cb0-4d29-9efa-75eaae8212f9"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDUx_82935112-09b6-4c0c-8a29-3a0e36fbba29">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2013; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#x201c;Income (loss) from equity method investments&#x201d; and also is adjusted by contributions to and distributions from the investee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity method investments are subject to impairment evaluation. During the years ended December&#160;31, 2019, the Company recognized an impairment loss of approximately $0.3 million related to its investment in Pacific Ambulatory Health Care, LLC as the Company does not believe it will recover its investment balance. Such impairment loss is included in loss from equity method investments in the accompanying consolidated statements of income. There was no impairment loss recorded related to equity method investments for the years ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report net asset value are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i62aa39d44086415d845d34f0d7dc7a73_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzIxMTcy_6fdb310d-293d-4e9a-82a0-d113cd1f95bb"
      unitRef="usd">300000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="i144871d547d04bfcb5651aa2b05ed3f2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzIxNDE4_c5f47e1f-5aad-40b6-95d7-aef7f812fb6c"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="iba8abaa0013749f6a54d7e3495c4052d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzIxNDE4_f7b59d94-9c9b-4b42-97cc-987676df3b61"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY3_35fa464e-d834-4e6d-8478-9f42a5b039b2">Medical LiabilitiesAPC, Alpha Care, Accountable Health Care, and APCMG (&#x201c;consolidated IPAs&#x201d;) and APAACO are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. The consolidated IPAs and APAACO provide integrated care to HMOs, Medicare, and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services, excluding depreciation and amortization, expense in the accompanying consolidated statements of income.An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimated IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting accrual are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <ameh:FiduciaryCashAndPayablePolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2ODg_2b45e38a-6a8e-4d4b-91fb-37c82bd4bcac">Fiduciary Cash and PayableThe consolidated IPAs collect cash from health plans on behalf of their sub-IPAs and providers and pass the money through to them.</ameh:FiduciaryCashAndPayablePolicyTextBlock>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI2MDQ_227188fb-7dcc-4906-a586-fd5a3eb75c74"
      unitRef="usd">10500000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI2MTk_7d6e69d8-6147-409c-8b5c-87e010f6ef6f"
      unitRef="usd">9600000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMjE2ODk_91be1f33-7987-4894-96f8-cc01ca9d7de6">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Rate Swap Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to interest rate risk on its floating-rate debt. The Company has entered into interest rate swap agreements to effectively convert its floating-rate debt to a fixed-rate basis. The principal objective of these contracts is to eliminate or reduce the variability of the cash flows in interest payments associated with the Company&#x2019;s floating-rate debt, thus reducing the impact of interest rate changes on future interest payment cash flows. Refer to Note 10 - &#x201c;Credit Facility, Bank Loan, and Lines of Credit,&#x201d; for further information on our debt. Interest rate swap agreements are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as interest expense in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the interest rate swap agreements was determined using Level 2 inputs. The fair value of the derivative instrument as of December&#160;31, 2021, was $1.1 million and is presented within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, ApolloMed and Clinigence entered into a stock purchase agreement which included the Company purchasing warrants. The purchased warrants are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The warrants are classified as a Level 2 instrument as the estimated fair value of the warrants were determined using the Black-Scholes option pricing model and inputs from observable market data. The fair value of the derivative instrument as of December&#160;31, 2021 was $1.1 million and is presented within other assets in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the common stock and warrants purchased under the stock purchase agreement between ApolloMed and Clinigence, ApolloMed is entitled to additional common stock if Clinigence does not pay NMM management fees exceeding a threshold by the end of December 31, 2022. The contingent equity securities are considered derivatives but are not designated as hedging instruments. Changes in the fair value on these contracts are recognized as unrealized gain or loss on investments in the accompanying consolidated statements of income.  The Company determined the fair value of the contingent equity security using a probability-weighted model which includes significant unobservable inputs (Level 3). Specifically, the Company &lt;/span&gt;&lt;/div&gt;considered various scenarios of recognizing management fees and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $4.3 million and is presented within prepaid and other current assets in the accompanying consolidated balance sheets.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i04a8b2897992491a9bba33dd880b5e6f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI3Mzc_afbc67a9-ee51-46ad-a73f-5c8aa55b1325"
      unitRef="usd">1100000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeAssets
      contextRef="i213a44cfc3bd4b5682c262ca824b12b3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE2OTI4Mzc_401bcf6e-5fa4-483e-ba17-4abd645bd9dd"
      unitRef="usd">1100000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="i9f29656902d24bac845ed6c3e1313c72_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzEwOTk1MTE3MTE2NDQ_06a10e6e-2bd0-4019-a7bf-1a3db239c2e6"
      unitRef="usd">4300000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQy_8e0e1610-5ba0-4ffd-baf7-a58c3e64c280">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients. The Company recognizes incremental costs of obtaining a contract with amortization periods of one year or less as expense when incurred and records within general and administrative expenses, recognizes revenue in the amount of consideration to which the Company has a right to invoice the customer if that amount corresponds directly with the value to the customer of the Company&#x2019;s services completed to date, and does not recognize an adjustment for the effects of a significant financing component as the period between the time of service and time of payment is typically one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees, and risk sharing. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full-risk capitation arrangements with certain health plans and local hospitals, which are administered by a third-party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging, and paying for professional risk. Under a full-risk pool-sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions on factors, including but not limited to, historical margin, IBNR completion factors, and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared-risk arrangements relating to the provision of institutional services to enrollees and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared-risk arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared-risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk-share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared-risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period, but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO and CMS entered into a NGACO Model Participation Agreement (the &#x201c;Participation Agreement&#x201d;) with an initial term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MDUx_13452d7a-ce48-4cb1-9932-b9a62aad18dd"&gt;two&lt;/span&gt; performance years through December&#160;31, 2019, which was extended for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM0MTA3_7004a731-22ef-4a6d-af57-dbde08754dca"&gt;two&lt;/span&gt; additional renewal years through December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company submitted to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company obtained CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation-like AIPBP payments from CMS on a monthly basis to pay claims from in-network providers. The Company records such AIPBPs received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS, while claims from APAACO&#x2019;s in-network contracted providers are paid by APAACO. The Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk-share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency, in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO AIPBP revenues monthly. Excess AIPBPs over claims paid, plus an estimate for the related IBNR claims (see Note 9 - &#x201c;Medical Liabilities&#x201d;), are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there was any excess AIPBPs for the performance year and the excess is refunded to CMS. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS shall assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared-risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop-loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit for the performance year and therefore this shared-risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $21.8 million and $19.8 million in risk pool savings, related to the 2020 and 2019 performance years, respectively, and has recognized such savings as revenue in risk pool settlements and incentives in the accompanying consolidated statements of income for the years ended December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to be eligible in receiving AIPBP under the NGACO Model for performance year 2021, with the effective date of the performance year beginning January 1, 2021. For performance year 2021, the Company received monthly AIPBP payments at a rate of approximately $7.7 million per month from CMS. The monthly AIPBP received by the Company for performance year 2020 was approximately $7.2 million per month. The Company has received approximately $92.4 million in total AIPBP for the year ended December&#160;31, 2021 of which $59.2 million has been recognized as revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative, and other non-medical services provided by the Company to IPAs, hospitals, and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly, or annual basis. The revenue may include variable arrangements measuring factors, such as hours staffed, patient visits, or collections per visit, against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues as revenue in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., ten years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the professional component of charges for medical services rendered by the Company&#x2019;s contracted physicians and employed physicians are billed and collected from third-party payors, hospitals, and patients. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and is recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges, less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients, and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether the patients, to whom services are provided, in the period are insured and the contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions, and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company does not have any contract assets since all obligations have been performed when revenue was recognized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable aging, and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly as revenues are recognized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i9f20c7ee23624be2a07a0c15e0ad0c80_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzI4NjQ1_43f41697-22ca-4bda-8e9b-1bc7d70f77b9">one year</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM3MzU0_fa8739a8-edf3-4579-a81a-49aaa547222e">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM3NjE0_98051a56-25d0-498b-a025-56678ce3d3a5">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="icbd01c9241b94ee2ac1425c57fcd0ce5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM3NzM3_98051a56-25d0-498b-a025-56678ce3d3a5">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RiskPoolSettlement
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM5MDU1_aad9ede4-a96e-440e-aff2-f71c9690e2fa"
      unitRef="usd">21800000</ameh:RiskPoolSettlement>
    <ameh:RiskPoolSettlement
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NjY3NDM_0a72e636-8ea8-454a-b5a8-6fe4db28e897"
      unitRef="usd">19800000</ameh:RiskPoolSettlement>
    <ameh:PaymentOfRevenueMonthlyAmount
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM5ODIz_c80292cd-02d1-4a9d-84f0-e325df42329f"
      unitRef="usd">7700000</ameh:PaymentOfRevenueMonthlyAmount>
    <ameh:PaymentOfRevenueMonthlyAmount
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NjY5ODU_a622e132-7077-4537-b5dd-6d637b09a3ea"
      unitRef="usd">7200000</ameh:PaymentOfRevenueMonthlyAmount>
    <ameh:PaymentOfRevenue
      contextRef="id558792183dd45c2a570c57e2912737a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQwMTkz_13acfef4-b215-4c7e-939b-58906a304678"
      unitRef="usd">92400000</ameh:PaymentOfRevenue>
    <ameh:PaymentOfRevenueRevenueRecognized
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQwMjQy_07be0074-0fc8-420e-82a2-845aead33e68"
      unitRef="usd">59200000</ameh:PaymentOfRevenueRevenueRecognized>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i612cc8b6b50c4dd986466df93d1b6382_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQyNjU5_418b6cb2-3efa-4759-9eae-49736a06565c">ten years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQ4OTc4_67879eb7-12b9-4c19-8ad9-38bae44b2fec"
      unitRef="usd">16800000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i332f5bcb413946b09f9ee77d790f9a78_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQ4OTkx_d9d172d1-247a-484a-9d1e-6a3dcc592264"
      unitRef="usd">16300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3Njc4NzQ_636c169a-d5b6-4f3a-ae24-a10b3136f006"
      unitRef="usd">13000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i86e83dd845b24aafb3a23652cf069056_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3Njc4ODE_799da796-e345-46ac-9a3c-13415a68efa0"
      unitRef="usd">12600000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id558792183dd45c2a570c57e2912737a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzQ5MjU2_1e9a649a-370d-4e58-aedc-d2c74b3880ee"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY0_15867157-3b18-48cf-9279-cc36a65b86b8">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions, and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQz_92024f40-377e-4302-96d1-f29744b311b6">Share-Based CompensationThe Company maintains a stock-based compensation program for employees, non-employees, directors, and consultants. The value of share-based awards is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for forfeitures as they occur. From time to time, the Company issues shares of its common stock to its employees, directors, and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules. The fair value of options granted are determined using the Black-Scholes option pricing model and include several assumptions, including expected term, expected volatility, expected dividends, and risk-free rates. The expected term is presumed to be the midpoint between the vesting date and the end of the contractual term. The expected stock price volatility is determined based on an average of historical volatility. The expected dividend yield is based on the Company&#x2019;s expected dividend payouts. The risk-free interest rate is based on the U.S. Constant Maturity curve over the expected term of the option at the time of grant.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDYx_55bc0846-750d-41ab-ab95-c222a2b97063">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share (&#x201c;EPS&#x201d;) is computed by dividing net income attributable to the holders of the Company&#x2019;s common stock by the weighted-average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted-average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 17 &#x2014;  &#x201c;Earnings Per Share&#x201d; for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <ameh:MinorityInterestPolicyPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQ0_c3b49834-41ee-4be8-872c-441a85184651">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Non-controlling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to non-controlling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</ameh:MinorityInterestPolicyPolicyTextBlock>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzUyMTg2_f60390d1-9a26-4fde-9559-17c99f90d69a"
      unitRef="number">0.50</us-gaap:VariableInterestEntityOwnershipPercentage>
    <ameh:TemporaryEquityPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDU4_1d215ef6-5fb8-499d-a031-1686c84be58f">Mezzanine EquityPursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase its shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes non-controlling interests in APC as mezzanine equity in the consolidated financial statements.</ameh:TemporaryEquityPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDQw_7b8e2192-e343-425c-966a-7274526ce4d8">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at its inception. The expected term of the lease used for computing the lease liability and ROU asset and determining the classification of the lease as operating or financing may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The Company elected practical expedients for ongoing accounting that is provided by the new standard comprised of the following: (1) the election for classes of underlying asset to not separate non-lease components from lease components, and (2) the election for short-term lease recognition exemption for all leases under twelve month term. The present value of the lease payments is calculated using a rate implicit in the lease, when readily determinable. However, as most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate to determine the present value of the lease payments for the majority of its leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <ameh:BeneficialInterestPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMzAzNjk_93404ca9-bed9-4e86-9cf9-fd87c486f8a2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Beneficial Interest&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, when UCAP, a 100% owned subsidiary of APC, sold its 48.9% ownership interest in UCI, APC received a beneficial interest in the equity method investment sold, pursuant to the terms of the stock purchase agreement. The estimated fair value of such interest in April 2020 was&#160;$15.7&#160;million and was included in other assets in the accompanying consolidated balance sheets. The beneficial interest was the result of a gross margin provision in the stock purchase agreement, which entitled UCAP to potentially receive additional cash and preferred shares (cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale, were held in an escrow account) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varied dependent upon the gross margin as compared to the target but cannot exceed the amounts that were in the escrow account. Additionally, the stock purchase agreement included a tangible net equity provision that could have resulted in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. The Company determined the fair value of the beneficial interest using an income approach, which included significant unobservable inputs (Level 3). Specifically, the Company utilized a probability-weighted discounted cash flow model using a risk-free treasury rate to estimate fair value, which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account, and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment was defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020, below a target gross margin unless such deficit is within a specific dollar amount. In June 2021, UCI&#x2019;s gross margin for the year ended December 31, 2020, was assessed and beneficial interest was concluded to not be collectible. The $15.7&#160;million was written off and expensed in other income in the accompanying consolidated statements of income during the year ended December&#160;31, 2021.&lt;/span&gt;</ameh:BeneficialInterestPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="icd3bc75cd44b41e18d64665e42101205_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1Mzg_1e2d2e70-7f01-433e-a6a2-0417b2c39b25"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1NDY_98c7dd62-55ce-4824-bf97-90c3b47c2461"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="i2125de0047684f7088debca1f678a717_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1NjM_6d67a8a6-208e-46cb-94b6-1c5b24533eeb"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationCash
      contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1OTg_c5afd403-856f-4090-be11-daa9fce97cff"
      unitRef="usd">15600000</ameh:EquityMethodInvestmentSaleContingentConsiderationCash>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares
      contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1Njk_216d532e-ba24-49d3-bc97-fa2f3895de3a"
      unitRef="usd">6400000</ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue
      contextRef="i302d9a0e032749edb6f74c01755fae4b_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ1ODM_86ceb07f-d47a-44b6-9b11-110d2650da56"
      unitRef="usd">22000000</ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="i2125de0047684f7088debca1f678a717_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzM4NDgyOTA3NzQ2MjY_6d67a8a6-208e-46cb-94b6-1c5b24533eeb"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzU3NDY4_99e2ce53-8e5b-4f61-a2fc-48414285e347">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued ASU) No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-08&#x201d;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently assessing the impact of that adoption of ASU 2021-08 will have on the Company&#x2019;s consolidated financial statements. &lt;br/&gt;&lt;br/&gt;With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMjQvZnJhZzo5YzUzMThmYTM2Zjc0ODFjODMxZTdlZjhmMGM0Yjk3YS90ZXh0cmVnaW9uOjljNTMxOGZhMzZmNzQ4MWM4MzFlN2VmOGYwYzRiOTdhXzYwNDczMTQwMzY4Njg_2bbf2363-1bf6-4661-9945-b3063cf3b5d4">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In December 2019, the FASB issued ASU) No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standard discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2021-08&#x201d;). This ASU requires the entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606 as if it had&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;originated the contracts. The amendments in this ASU are effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. The Company is currently assessing the impact of that adoption of ASU 2021-08 will have on the Company&#x2019;s consolidated financial statements. &lt;br/&gt;&lt;br/&gt;With the exception of the new standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations, and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTYyNDQy_8d76b077-dab4-4353-b0d6-f17f5251017b">Business Combinations and Goodwill&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;APCMG&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company acquired an 80% equity interest (on a fully diluted basis) in APCMG for an aggregate purchase price of $2.0 million. As part of the transaction, the Company paid $1.0 million in cash and the remaining amount will be paid out in cash as a contingent consideration related to APCMG&#x2019;s financial performance for fiscal year 2022 (&#x201c;APCMG contingent consideration&#x201d;). The APCMG contingent consideration is met if gross revenue and earnings before interest, taxes, and depreciation, and amortization (&#x201c;EBITDA&#x201d;) targets exceed a threshold for fiscal year 2022. The Company determined the fair value of the contingent consideration using a probability-weighted model that includes significant unobservable inputs (Level 3). Specifically, the Company considered various scenarios of gross revenue and EBITDA and assigned probabilities to each such scenario in determining fair value. As of December&#160;31, 2021, the contingent consideration is valued at $1.0 million and was included within other long-term liabilities in the accompanying consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sun Labs&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company acquired 49% of the aggregate issued and outstanding shares of capital stock of Sun Labs for an aggregate purchase price of $4.0 million. As Sun Labs was concluded to be a VIE and the Company is the primary beneficiary, Sun Labs is consolidated by the Company. The Company is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating Sun Labs as a VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;DMG&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; DMG is consolidated by Apollo.  In addition, APC-LSMA is obligated to purchase the remaining equity interest within three years from the effective date. As the financing obligation is embedded in the non-controlling interest, the non-controlling interest is recognized in other long-term liabilities in the accompanying consolidated balance sheets. The Company recognized goodwill as a result of consolidating DMG as a VIE. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired companies were allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of APCMG, Sun Labs, and DMG have been included in the Company&#x2019;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of goodwill activity for the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i2bb290c80ed04d9284ae72a27d2b780d_I20210731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzMx_d9f80b33-4e73-452a-a351-a81037df4c39"
      unitRef="number">0.80</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i1ee954aec3cb404a92c9fa15cd03d7f5_D20210731-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3Mzk3_8304f57e-db49-4c9b-806e-68a304440cdf"
      unitRef="usd">2000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i1ee954aec3cb404a92c9fa15cd03d7f5_D20210731-20210731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzQ2_a94a7624-5e12-4ca8-a6a1-e0828f218492"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i839af06b2bf7483780595e14fb317ba9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzYx_1007b08e-89bc-4d47-b3a5-c0d3dd9d1d45"
      unitRef="usd">1000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i6e863e59c64443d08c0faadab68620e3_I20210801"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzI1_bb685719-718a-4c24-84cf-51668fa85550"
      unitRef="number">0.49</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i4a90dada50974fc1a89ab41d8073f777_D20210801-20210801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV8xMDk5NTExNjM3MzE5_53b60b2f-24e7-4ab9-8b92-7c4b1fd26ff5"
      unitRef="usd">4000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="if75a131bd7e744b5a823cd87fdb684fe_D20210801-20210831"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTYyNDU5_8ccd2a48-5d40-4391-b1ab-24acd4a27006">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase
      contextRef="id201e64241bd4df388bd1b11f4019ca1_D20211001-20211031"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTczNTIx_95d49a5c-828f-4b9e-b40d-c793e4afbbaf">P3Y</ameh:BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGV4dHJlZ2lvbjpiODA2YjcxYjFjMDk0NGU2ODEwNWFmODgwZGZkMWM3NV82MDQ3MzEzOTYyNDQz_671a4c0d-48c5-4ebf-ab89-532c2b2ec78c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of goodwill activity for the years ended December&#160;31, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN18yLTEtMS0xLTM2ODc2_75984b42-3079-4f87-8d6e-93e0df9b120e"
      unitRef="usd">238505000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN18zLTEtMS0xLTM2ODc2_95dde043-d68f-4752-8b78-8d08a450b3f7"
      unitRef="usd">548000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN180LTEtMS0xLTM2ODc2_01f4c9aa-969a-4c64-a4d8-345b4ae52990"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN181LTEtMS0xLTM2OTIw_0e0a0e76-3976-49d6-b661-d1a0b8f037c3"
      unitRef="usd">13986000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTAzL2ZyYWc6YjgwNmI3MWIxYzA5NDRlNjgxMDVhZjg4MGRmZDFjNzUvdGFibGU6OTg2NWMwMThlNDZjNGFlN2I4ODAyZTViZDUxMWQwMzcvdGFibGVyYW5nZTo5ODY1YzAxOGU0NmM0YWU3Yjg4MDJlNWJkNTExZDAzN182LTEtMS0xLTM2ODc2_e022cee6-b25a-4885-b6e1-e8ab5c1867a0"
      unitRef="usd">253039000</us-gaap:Goodwill>
    <ameh:PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzEzMzU_c971e637-8a3e-4e5a-8e96-6efe82100f66">Land, Property, and Equipment, Net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land, property, and equipment, net consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 39&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company had finance leases totaling $1.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd $0.4 million, respectively, included in land, property, and equipment, net in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.1 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt; $2.3 million and $2.0 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income.</ameh:PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzEzMzY_7d91630f-762b-4e78-b454-8c38045afc33">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land, property, and equipment, net consisted of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Useful Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 39&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property, and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ie51111a66dda4ebb9aba6212e6167b7f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzItMy0xLTEtMA_8ff543a5-4b51-4b74-9f0a-cdde73096af0"
      unitRef="usd">20937000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ia31747ce9de543bc82b00188c7aa83e7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzItNS0xLTEtMA_2470a8e8-fc00-4ca1-9200-a0c72a72165b"
      unitRef="usd">9604000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0b2e1de018d94f24b2a76496127751c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzMtMS0xLTEtMA_d871d5ee-0ff8-4b09-b448-5e6725fd9731">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i9e99a95143da4c8eaf2dd4d3559ccdbc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzMtMy0xLTEtMA_90ae3882-aac3-4baa-b764-986c723c808e"
      unitRef="usd">21661000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ib5051abc09bc4fa69a0f957f3c5b0241_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzMtNS0xLTEtMA_a5d1dd1b-f9b6-4109-b55a-86ede47a7ed5"
      unitRef="usd">15097000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie4f0ad5790334506970900a82f46c08f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjdhZmIxNTQyMmNhMzQ2YWU4MjQwMGIwN2E3ZDI0NjNjXzQ_5101f659-fad5-4219-9a59-add06b216022">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i487033aa27ad4f9b9271e75aa8aa3a91_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtMS0xLTEtMC90ZXh0cmVnaW9uOjdhZmIxNTQyMmNhMzQ2YWU4MjQwMGIwN2E3ZDI0NjNjXzk_ddb23984-c33e-46c9-80a4-5f8a0ff82fb0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iaff2efa428034a01ba020fb02de6fc10_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtMy0xLTEtMA_ff33bf9e-1f27-4781-af86-edfd964d82b7"
      unitRef="usd">3589000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ifea711226dc146e9810f79de10c986d4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzQtNS0xLTEtMA_a36c3dc0-fb8c-4f3a-ad01-00486076e532"
      unitRef="usd">3104000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i9c77143a62554eab971843dd2d16ee2a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmZiMzBlOWQ0MjA0ZjQ2OWI5NDU0M2I4MzY3YmQ3OTkwXzQ_96727fe5-d4e0-4c81-8b76-6b1b263a97b4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i27538f0196b542fc85d8c25bf235059d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmZiMzBlOWQ0MjA0ZjQ2OWI5NDU0M2I4MzY3YmQ3OTkwXzk_8f92f411-74a1-43be-a1da-adae3006c76c">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="ia5c3bdf2fd4b4890ae012255fe841f5d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtMy0xLTEtMA_af0e3a3b-5ec9-4d54-999f-abfd07198148"
      unitRef="usd">15358000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i024a6dcb30a242cb813e9f1ccb581b12_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzUtNS0xLTEtMA_69d56dac-00ff-4667-8a50-dce338a10dd7"
      unitRef="usd">13116000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i676fdea1181f4e9193158b995298022b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzYtMy0xLTEtMA_c4c4d2b0-d56c-4c91-85e0-d51c83dee4f0"
      unitRef="usd">4901000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i53efa605f72144cf9c19b468aa9c14af_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzYtNS0xLTEtMA_92639b8b-1565-4170-b92f-058bf153d535"
      unitRef="usd">435000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i2582d81f93dc42f1a148af1c328393bb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctMS0xLTEtMC90ZXh0cmVnaW9uOjkyYTY5MzhhYmE2NzRmYjk4NzBiMTMwMGRlZDA1MmUxXzQ_6c716e2f-9932-4dd4-9fef-d50036f6a61b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i88445e03e6ca41139c3da34cf3553c19_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctMS0xLTEtMC90ZXh0cmVnaW9uOjkyYTY5MzhhYmE2NzRmYjk4NzBiMTMwMGRlZDA1MmUxXzk_6e6f129f-2293-4263-8aa6-e59bce851a0e">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="iaf6b316b9ec34ba09028e2941bda64c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctMy0xLTEtMA_c48caf8a-22e0-403f-8b50-7014b4f9be5a"
      unitRef="usd">7122000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i9b75bb3419b74b6db04ab86aac159bb2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzctNS0xLTEtMA_d7d7be2b-dad9-4ac1-bb04-7a7cd5393acd"
      unitRef="usd">6722000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzktMy0xLTEtMA_fdb80711-aec9-43fe-b174-d24af883a9a4"
      unitRef="usd">73568000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzktNS0xLTEtMA_bfe010e3-8467-4e9e-b3c9-606eac142ed9"
      unitRef="usd">48078000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzExLTMtMS0xLTA_0cec4cd3-d9df-4cec-aa3c-00f54786e95a"
      unitRef="usd">20382000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzExLTUtMS0xLTA_a77922c0-1a66-45e8-9e00-50f8693cad8e"
      unitRef="usd">18188000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzEzLTMtMS0xLTA_4fec9ca3-e7e1-409d-ade4-362a78ed1c1a"
      unitRef="usd">53186000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90YWJsZTo5MmRhMTkxZTFmNDg0NGFiYjI2Mzk5NjBhMTk3OTg2OC90YWJsZXJhbmdlOjkyZGExOTFlMWY0ODQ0YWJiMjYzOTk2MGExOTc5ODY4XzEzLTUtMS0xLTA_8a829b91-923d-4024-a855-37ef8fb7c581"
      unitRef="usd">29890000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzE2NA_a3878f45-4b46-4af2-8ce1-453e0810dc34"
      unitRef="usd">1300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzE3MQ_93a8d47c-a2e4-487e-b409-be4d2a1aa6dd"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:DepreciationAndAmortization
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzMwOQ_0cdd7fe4-7a71-4e98-9d70-fb4834a9c19e"
      unitRef="usd">2100000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzMxMw_0f4da910-b6e1-45af-8141-b9125159dbd3"
      unitRef="usd">2300000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzYvZnJhZzpiZDg0MjI4YzdjZmU0YjRkODYxZWQ0ZGJmZTBiYjkyMC90ZXh0cmVnaW9uOmJkODQyMjhjN2NmZTRiNGQ4NjFlZDRkYmZlMGJiOTIwXzMyMA_b4b29705-8cac-4667-828f-e04032b2c598"
      unitRef="usd">2000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgzMQ_c648c200-6037-4d07-8c2e-1563d16638a0">Intangible Assets, Net&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, intangible assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Useful&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment/&lt;br/&gt;Disposal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, intangible assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Useful&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;January 1,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment/&lt;br/&gt;Disposal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(89,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, network relationships, management contracts, member relationships, patient management platform, and tradename/trademarks had weighted-average remaining useful lives of 10.5 years, 8.5 years, 8.3 years, 0.9 years, and 15.9 years, respectively. Amortization expense was $15.4 million, $16.0 million and $16.3 million for the years ended December&#160;31, 2021, 2020, and 2019, respectively, which is included in depreciation and amortization in the accompanying consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2019, the Company wrote off indefinite-lived intangible assets of $2.0 million related to Medicare licenses it acquired as part of the 2017 Merger. The Company will no longer utilize these licenses and as such the Company will not receive future economic benefits. There was no impairment loss recorded related to intangibles for the year ended December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgyOQ_6af7fcb7-71e5-4f67-ac39-a4b7e8790345">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, intangible assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Useful&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment/&lt;br/&gt;Disposal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, intangible assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Useful&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;January 1,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment/&lt;br/&gt;Disposal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(89,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgzMg_71a7eb1e-8862-48f5-b6bf-086dca249d09">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2021, intangible assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Useful&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment/&lt;br/&gt;Disposal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite lived assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(104,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, intangible assets, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.682%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Useful&lt;br/&gt;Life&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;January 1,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment/&lt;br/&gt;Disposal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Network relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11,715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Member relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,234)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:20.25pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tradename/trademarks&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(156)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(89,544)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="icc4cabdf561f47f68984b36789e4965c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMy0xLTEtMzgyNjk_a9ad7429-af1e-4f47-b65c-937ab3ba5867"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired
      contextRef="i42823650eb854b4f9ee2477d31236773_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNS0xLTEtMzgyNjk_4a9d4b3f-fb7d-447c-a3e5-e9634807a9ed"
      unitRef="usd">2150000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i42823650eb854b4f9ee2477d31236773_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNy0xLTEtMzgyNjk_cecb69ab-0fea-4ffc-ac15-afd081f516c1"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib13a44368edd4777a7c9cfc306a21f2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItOS0xLTEtMzgyNjk_1bdd7b57-3cde-4c6d-a483-8d4c6edb7311"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib13a44368edd4777a7c9cfc306a21f2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMTMtMS0xLTM4MjY5_60ad6736-9813-44f1-8f86-cb7f60e60653"
      unitRef="usd">2150000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6d8e768a8482425ba021a05970238a2f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY1YTc3MWYxMTc0NjQxNGJiZGQ4MGY2YzRlNDFkYWQzXzQ_23d62e82-cdec-45a5-bbf3-b679972e3cf9">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i008c29b02c5e4ce5a69883a33d891ded_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMS0xLTEtMC90ZXh0cmVnaW9uOjY1YTc3MWYxMTc0NjQxNGJiZGQ4MGY2YzRlNDFkYWQzXzc_4b91ef55-c9ed-4743-a1b3-5bb20d735419">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMy0xLTEtMA_1c87a8b1-35df-4ebf-9e3b-f3ab1d62c45e"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNS0xLTEtMA_a603b0f5-bcc0-41e4-94be-8038547c9c49"
      unitRef="usd">6749000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItNy0xLTEtMA_05b0f68f-e9a6-44d7-8894-1623d1b1db40"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9cdc0c8a020740599e30d4e0c3298af2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItOS0xLTEtMA_8a54b6e1-b4e8-4bde-9df2-de54dbbfb1b2"
      unitRef="usd">150679000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9cdc0c8a020740599e30d4e0c3298af2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMTEtMS0xLTA_8e558860-25f9-4377-8297-0331180db034"
      unitRef="usd">84865000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9cdc0c8a020740599e30d4e0c3298af2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzItMTMtMS0xLTA_26a42293-3060-45ab-91f3-fe6c650ffcd6"
      unitRef="usd">65814000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMS0xLTEtMA_582d129f-cf1e-47ff-9a26-39493c12ad72">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMy0xLTEtMA_93063574-0ef3-4afa-b4df-f5da484e15e0"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtNS0xLTEtMA_d7fb117f-6cdb-498a-8428-b4a68f0ea422"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtNy0xLTEtMA_30f96a20-90fc-4bf6-b5b5-521fd247b09c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iab7fa92aa24446d18fe184c6400b9ba3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtOS0xLTEtMA_2dedbb13-ce07-478a-84bc-4992358b14fa"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iab7fa92aa24446d18fe184c6400b9ba3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMTEtMS0xLTA_10159ef3-efc6-406f-a8a2-077dc08bc8ca"
      unitRef="usd">13563000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iab7fa92aa24446d18fe184c6400b9ba3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzMtMTMtMS0xLTA_8c32b23c-e4da-4494-aaf1-7ea5e01b8e0e"
      unitRef="usd">9269000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMS0xLTEtMA_1d6375a5-8b1e-44d8-8b40-c0e378f38810">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMy0xLTEtMA_9d6c5257-6d51-4ae3-b895-6adf00d747b6"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtNS0xLTEtMA_0fd30855-fea0-421f-9034-e9eee6c22fb2"
      unitRef="usd">2301000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtNy0xLTEtMA_6dd6a72d-d8b8-49bb-a076-7c693c940e09"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtOS0xLTEtMA_1325898a-b322-4eba-aa37-d0b3773cc8dc"
      unitRef="usd">8997000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMTEtMS0xLTA_6bef57d5-7bc2-4125-8da0-6c8393f4826f"
      unitRef="usd">4606000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic45ea78bd2cb4bcfb003cf52affd5fa5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzQtMTMtMS0xLTA_ff4ef54f-b68f-4cf6-9609-23203ac6d020"
      unitRef="usd">4391000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMS0xLTEtMA_562f28a8-425a-4644-8d29-7185388817e8">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMy0xLTEtMA_79d3fb1f-79cf-4409-b121-ae3de6a3fc7a"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtNS0xLTEtMA_b0e4584b-7573-4a10-91d2-f5bd8060ef84"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtNy0xLTEtMA_360e0140-5f04-4e2c-9ba9-22ae0de9935d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtOS0xLTEtMA_541f9c9c-1f5e-4a6b-ba18-a53e36cfdb1e"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMTEtMS0xLTA_c9ec5497-d164-4360-accf-48b8ab739832"
      unitRef="usd">1682000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2e1cbd0b700b49c4ac2b6ac4009607c1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzUtMTMtMS0xLTA_a471e4cf-a3b7-40c8-b2fe-076e3cba6bd7"
      unitRef="usd">378000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMS0xLTEtMA_6f8ff2a1-d156-4fcc-801a-bcb9883573d8">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMy0xLTEtMA_5e9b1d0d-9e0f-4e5f-b657-e764a80ae2a4"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtNS0xLTEtMA_832fb8eb-f960-4885-847b-ec2873a0b75e"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i99be5fe66af74ef1b2baf74ef315c7e0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtNy0xLTEtMA_6d2f2d8b-fcee-4e7e-a79c-78313e342593"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia464591a552f4ad4a88bc800875941fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtOS0xLTEtMA_5bb183ce-1ce2-4786-91cf-f4efdfde6630"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia464591a552f4ad4a88bc800875941fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMTEtMS0xLTA_a1869fc8-cb4b-4822-bf57-ae7a5bca46a9"
      unitRef="usd">206000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia464591a552f4ad4a88bc800875941fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzYtMTMtMS0xLTA_3178d6f8-0be3-45e7-baa3-00245dbaf117"
      unitRef="usd">805000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctMy0xLTEtMA_18a1c350-83f3-4204-99a8-09a98b73413e"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <ameh:FiniteAndIndefiniteLivedIntangibleAssetsAcquired
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctNS0xLTEtMA_dd719470-a90a-44e0-8f94-00cc1ec8425a"
      unitRef="usd">11200000</ameh:FiniteAndIndefiniteLivedIntangibleAssetsAcquired>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctNy0xLTEtMA_1c756da4-5328-433c-b0d2-3c483938f620"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctOS0xLTEtMA_3cc6216f-f6c7-40bc-8537-a9ba0af2d6cb"
      unitRef="usd">187729000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctMTEtMS0xLTA_e2e0be01-da13-41cb-89fd-4ebe59b043c6"
      unitRef="usd">104922000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTpiZTcwNGY1YWUzMjM0ZTQ1OTQ5YjBmZTBhMGZjODJmNC90YWJsZXJhbmdlOmJlNzA0ZjVhZTMyMzRlNDU5NDliMGZlMGEwZmM4MmY0XzctMTMtMS0xLTA_20fba9ef-ca9e-4cc6-915a-f17b3a181a32"
      unitRef="usd">82807000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if9eee87a655349b195602787d695ad5b_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzOTczNmQ4ZDJjYjQyZDE4ZTdkMTBlNmI1NzljNjU0XzQ_ad617aca-6ea1-4a34-a155-5f8725e3beba">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i40c3a0315be548acb27758e893a56720_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMS0xLTEtMC90ZXh0cmVnaW9uOmEzOTczNmQ4ZDJjYjQyZDE4ZTdkMTBlNmI1NzljNjU0Xzc_d9b42f8a-4f8f-4773-82f2-b29a3fc68915">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i749dc1caa7f94b5a8d9ae541374197c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMy0xLTEtMA_70546750-f77e-45d5-8612-cde48ff89bba"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="icb8f4c6415114fdab30e95d035c48f77_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzItNS0xLTEtNDkxNTM_2cbb58c2-8d56-4a52-8c77-7c9bf8621840"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="icb8f4c6415114fdab30e95d035c48f77_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzItNy0xLTEtNDkxNTg_622b73eb-42b4-4ce5-b6ff-0c63b979a42f"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtOS0xLTEtMA_40998102-1d6a-42be-b071-73ad5b0d0bf9"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMTEtMS0xLTA_54e94b16-a70c-466b-929d-5490f63fdb81"
      unitRef="usd">73169000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib2878f7db1e942a9b61dbbd3d355573f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtMTMtMS0xLTA_97311d2e-266a-4461-bbb7-8503c9397e07"
      unitRef="usd">70761000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMS0xLTEtMA_78af7b01-46b1-42a1-b363-adcc04816fca">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4e30d0a130514a509245b1d72aa48f0f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMy0xLTEtMA_62a0e1da-4e53-4505-a5d8-9b1000e979c4"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzMtNS0xLTEtNDkxNTM_c948be29-6ab7-4935-9faa-2ee942c23628"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="id1f2ba6b38fd4c61863f1e0397e91bcd_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzMtNy0xLTEtNDkxNTg_5138100f-9e99-4d7b-bd3a-d7ebee8af209"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtOS0xLTEtMA_16cbba03-25b6-48bd-a94f-46abdab0afcd"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMTEtMS0xLTA_fa307bc4-e75d-4189-b34f-5e55024b3939"
      unitRef="usd">11715000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i35497baacaae4c5f8085541195e2dbab_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtMTMtMS0xLTA_f1c2adb9-a160-444d-8649-4fcd0b2e498f"
      unitRef="usd">11117000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMS0xLTEtMA_18b347db-ccec-4fc4-8810-00d03b8e3e8c">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i74208b2350a54619bb22d219854dc476_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMy0xLTEtMA_1b60a6d7-c7af-434f-bdd2-37339ee09c2e"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtNS0xLTEtNDkxNTM_3b727f66-f507-4ae7-8b40-0e621392a359"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="idd1a7e93dda94debaeb41f6185acae92_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzQtNy0xLTEtNDkxNTg_92b2ce84-b8a3-4e47-9852-4fbefd529048"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtOS0xLTEtMA_f02198ee-5b07-4ded-9119-8c7ff6ae7ff0"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMTEtMS0xLTA_886dfaae-4d85-4c85-94d6-aadf8c2815ad"
      unitRef="usd">3234000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i891c2dd4d61f4103a58b7821ed5d6ffe_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtMTMtMS0xLTA_68888c2b-3815-4a9e-9f97-aa82d3464280"
      unitRef="usd">3462000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMS0xLTEtMA_d97d1453-c25b-4f83-bef1-65c178a28819">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5f9f2d34982748f39594f8bbf5d26296_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMy0xLTEtMA_5c8ddbf2-be70-4f14-9b19-b8662550742b"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtNS0xLTEtNDkxNTM_89097c67-84bc-499b-a5d7-5396853fa76c"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i32e43b4b19b54697bad45722056bd0c9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzUtNy0xLTEtNDkxNTg_f3b21171-fcff-4e8c-b72b-f24c4983fd75"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctOS0xLTEtMA_39610e8d-aa47-4118-b17d-491e32f95c19"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMTEtMS0xLTA_aac91326-7596-4087-93ff-f31a82889891"
      unitRef="usd">1270000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i52ebf6aeee1a415ca258abe927ecdc64_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctMTMtMS0xLTA_b721a62f-e2bc-47cc-9b21-5f0a48bd4295"
      unitRef="usd">790000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMS0xLTEtMA_376c1087-ce76-4bc4-92ac-e8d363aa232f">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i49479cdc0b20425392e36614906e56d6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMy0xLTEtMA_d77d1af6-3928-44f4-b2f2-a79fa12f63d2"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtNS0xLTEtNDkxNTM_c0fc46df-293b-42cb-ad20-10ba10207e48"
      unitRef="usd">0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i0ec17bec093842a29a10ee0dd5c885ef_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzYtNy0xLTEtNDkxNTg_3eaeacbe-a61b-41d3-b4f4-e8772d4094ac"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtOS0xLTEtMA_0d8f9bd9-329d-46bf-9e40-8d36d72bb2d4"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMTEtMS0xLTA_c6314eb7-a807-4c84-aade-bcf2a82decd4"
      unitRef="usd">156000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7ac39a81fa0c434faff0d01f6dd0fe46_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzgtMTMtMS0xLTA_709a29dc-2ab1-4720-8c26-857567c0bc9f"
      unitRef="usd">855000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktMy0xLTEtMA_29e94972-488f-4961-813d-e17b0dceb255"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <ameh:FiniteAndIndefiniteLivedIntangibleAssetsAcquired
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctNS0xLTEtNDkxNTM_12273b92-68d2-4a83-93cf-30d209a19366"
      unitRef="usd">0</ameh:FiniteAndIndefiniteLivedIntangibleAssetsAcquired>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzctNy0xLTEtNDkxNTg_c197f5ee-9253-4d65-bbc0-1b5dfe0a700d"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktOS0xLTEtMA_7f1bea48-91d1-43a3-bed1-ee26bbc5b9a6"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktMTEtMS0xLTA_9ad49649-92ce-4574-b5b2-da85f85a29bd"
      unitRef="usd">89544000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTo1ZDk5M2M3ZWVlMWI0NWYyODc0NjIxMjJkZDVlNmI2MC90YWJsZXJhbmdlOjVkOTkzYzdlZWUxYjQ1ZjI4NzQ2MjEyMmRkNWU2YjYwXzktMTMtMS0xLTA_95337d6d-8c5f-42df-bcf4-ed5983e213c7"
      unitRef="usd">86985000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8629053ba27846d8b7000bb1cbacfe00_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1MTM_cf44962c-ca56-4d58-9d23-ab15751e202e">P10Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia10dba65880142848189a35b3d649ae5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1MTg_376e80e5-8ea1-4b40-aad5-475081927056">P8Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i95ea5217f2b34aaf91592581250193f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1MjM_438c83d5-28be-476b-a11f-dd69718da00b">P8Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7a10a8288113455ca4b5f70c9d3eecd1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1Mjg_7467267e-2578-4e95-98e5-b2c0caf89fa0">P0Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic77befc8ecf64d6390b3232a58d0202f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzI3NDg3NzkwNzE1Mzc_72dfffa9-4b68-4349-8a93-544f88877688">P15Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzIwNg_61d97354-52b1-4b4c-be60-85fe44090e53"
      unitRef="usd">15400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzIxMA_93a434eb-1288-4c36-add7-7f2ebc9d8eee"
      unitRef="usd">16000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzIxNw_2e80cf9a-a02b-463a-b513-d7a8faa6d2e0"
      unitRef="usd">16300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i015c75fcf61d4986bcc5f227b6c412de_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzQ2Mg_f1a4c320-4f20-48cb-ae6b-26440a60aef0"
      unitRef="usd">2000000</us-gaap:IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90ZXh0cmVnaW9uOjVkYTFhYjVlYTAwZDQ0YjNiZTVjNDFmMGM5OGZhN2NlXzgzMA_4660ceea-32a2-4c23-b0fa-b45e35cfb2dd">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the years ending December 31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzItMS0xLTEtMA_6854a938-25f0-4c98-963d-3d6c57cf9031"
      unitRef="usd">13708000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzMtMS0xLTEtMA_cd3f0656-3fdd-4e24-97ab-e19dad9665ef"
      unitRef="usd">11661000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzQtMS0xLTEtMA_5f245be4-d741-4227-9684-a9c1285b9c6d"
      unitRef="usd">10596000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzUtMS0xLTEtMA_bdcf1c78-01d9-4d54-afd7-4af85c2fec6a"
      unitRef="usd">9414000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzYtMS0xLTEtMA_395d02aa-6e3d-4964-8e24-03289e854cb5"
      unitRef="usd">8370000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzctMS0xLTEtMA_f47a629f-22b2-4cbf-a277-9fddb9089c79"
      unitRef="usd">26908000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMzkvZnJhZzo1ZGExYWI1ZWEwMGQ0NGIzYmU1YzQxZjBjOThmYTdjZS90YWJsZTozZDk4NTUzODg1NWE0MTIwYWM5MjZmMTViNGI5NWU0MS90YWJsZXJhbmdlOjNkOTg1NTM4ODU1YTQxMjBhYzkyNmYxNWI0Yjk1ZTQxXzgtMS0xLTEtMA_e3d37887-f16a-4d1e-9d22-893d4ade8894"
      unitRef="usd">80657000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE1OTQ0_a1b924ba-e09a-40bd-bba7-f8980808eaec">Investments in Other Entities&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in other entities &#x2013; equity method consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.336%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidation of Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2014; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2014; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-8 Medical Investment Group, LLC &#x2014; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2014; IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA was founded by Dr. Albert Arteaga in 1996 and operates as an IPA delivering high-quality care to patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino, and Tulare Counties through its network of approximately 2,400 independently contracted primary care physicians and specialist providers. LMA&#x2019;s patients are primarily served by Medi-Cal, but are also served by Blue Cross, Blue Shield, Molina, Health Net, and Inland Empire Health Plan. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#x2019;s IPA line of business. NMM has a management services agreement with LMA. In December 2020, the Company exercised its option to convert a promissory note totaling $6.4&#160;million due from Dr. Arteaga into an additional 21.25% interest in LMA&#x2019;s IPA line of business. As a result, APC-LSMA&#x2019;s interest in LMA&#x2019;s IPA line of business increased to 46.25%. In September 2021, APC-LSMA sold 21.25% of its interest in LMA back to Dr. Arteaga for $6.4&#160;million, which resulted in APC-LSMA owning a 25% interest in LMA as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#x2019;s operations. For the year ended December&#160;31, 2021, APC recorded net loss of $5.8 million from its investment in LMA as compared to a net income of $0.3 million for the year ended December&#160;31, 2020, in the accompanying consolidated statements of income. The investment balance was $3.0 million and $13.0 million at December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s unaudited summarized balance sheets at December&#160;31, 2021 and 2020 and unaudited summarized statements of operations for the years ended December&#160;31, 2021, 2020, and 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2021&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2020&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMIOC was incorporated in 2004 in the state of California. PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry, and digital mammography at their facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership in PMIOC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract APC paid PMIOC fees of $2.4 million and $2.2 million for the years ended December&#160;31, 2021 and 2020, respectively. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#x2019;s operations. During the year ended December&#160;31, 2021, APC recorded net income of $0.3 million from its investment as compared to net income of $17,000 for the year ended December&#160;31, 2020 in the accompanying consolidated statements of income and has an investment balance of $1.7 million and $1.4 million at December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounted for its 40% investment in DMG, under the equity method of accounting as APC-LSMA, a designated shareholder professional corporation, had the ability to exercise significant influence, but not control over DMG&#x2019;s operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2021, DMG entered into an administrative services agreement with a subsidiary of the Company, causing the Company to reevaluate the accounting for the Company&#x2019;s investment in DMG. Based on the reevaluation and in accordance with relevant accounting guidance, DMG is determined to be a VIE and the Company is the primary beneficiary; therefore DMG is consolidated. As a result of the consolidation, the Company recognized a gain of $2.8 million for the year ended December&#160;31, 2021 in other income in the accompanying consolidated statement of income, representing the difference between the fair value and the carrying value of the previously held noncontrolling interest in DMG on the date of consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, and prior to consolidation of DMG, APC recorded income from this investment of $0.3 million as compared to income of $0.3 million during the year ended December&#160;31, 2020 in the accompanying consolidated statements of income.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;531 W. College LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, College Street Investment LP, a California limited partnership (&#x201c;CSI&#x201d;), a related party, APC and NMM, entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC, and NMM, each owns 50%, 25%, and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#x2019;s&#160;25%&#160;membership interest in 531 W. College, LLC for approximately&#160;$8.3 million. Subsequently, APC has a&#160;50%&#160;ownership in 531 W. College LLC. APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, APC recorded losses from its investment in 531 W. College LLC of $0.2 million and loss of $0.4 million, respectively, in the accompanying consolidated statements of income. During the year ended December&#160;31, 2021 and 2020, APC contributed $0.2 million and $1.0&#160;million, respectively, to 531 W. College, LLC as part of its 50% interest.  The accompanying consolidated balance sheets include the related investment balance of $17.2 million&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $17.2 million, respectively, related to APC's investment at December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;One MSO LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, using cash comprised solely of Excluded Assets, APC purchased a 50% membership interest in One MSO LLC (&#x201c;One MSO&#x201d;) for $2.4&#160;million. APC accounts for its investment in One MSO under the equity method of accounting as APC has the ability to exercise significant influence, but not control over One MSO&#x2019;s operations. One MSO owns an office building in Monterey Park, California that is leased to tenants, including NMM. During the year ended December&#160;31, 2021, APC recorded income from this investment of $0.5 million in the accompanying consolidated statements of income. The investment balance was $2.9 million and $2.4 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tag-6 Medical Investment Group, LLC and Tag-8 Medical Investment Group, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, APC purchased a 50% member interest in Tag-6 Medical Investment Group, LLC (&#x201c;Tag 6&#x201d;) for $4.5 million and a 50% member interest in Tag-8 Medical Investment Group, LLC (&#x201c;Tag 8&#x201d;) for $2.1 million. Tag 6 leases their building to tenants and Tag 8 has vacant land with plans to develop medical offices in the future. In April 2021, the Company reevaluated Tag 8 as a VIE since APC is a guarantor on the loan agreement between Tag 8 and MUFG Union Bank N.A. Based on the reevaluation, Tag 8 is a VIE and is consolidated by the Company for the year ended December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in Tag 6 under the equity method of accounting as APC has the ability to exercise significant influence, but not control over Tag 6&#x2019;s operations. Tag 6 shares common ownership with certain board members of APC and as such is considered a related party. During the year ended December&#160;31, 2021, APC recorded income from this investment of $0.3 million in the accompanying consolidated statements of income. The investment balance was $4.8 million and $4.5 million as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, ApolloMed purchased a 30% interest in CAIPA MSO, LLC for $11.7 million. CAIPA MSO, LLC (&#x201c;CAIPA MSO&#x201d;) is a New York-based management services organization affiliated with Chinese-American IPA d.b.a. Coalition of Asian-American IPA , a leading independent practice association serving the greater New York City area.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ApolloMed accounts for its investment in CAIPA MSO under the equity method of accounting as ApolloMed has the ability to exercise significant influence, but not control over CAIPA MSO&#x2019;s operations. During the year ended December&#160;31, 2021, ApolloMed recorded income from this investment of $0.3 million in the accompanying consolidated statements of income. The investment balance was $12.0 million as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investment in privately held entities that do not report net asset value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MediPortal, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented approximately 2.8% ownership. APC also received a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjU2_c963fd5b-c811-4093-81f8-04122b4eaed7"&gt;five&lt;/span&gt;-year warrant to purchase 270,000 membership interests. A &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzEx_0992ad4a-a700-4f32-8ee4-5af8a166e27a"&gt;five&lt;/span&gt;-year option to purchase an additional 380,000 membership interests and a &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzgy_218c2412-51ed-4adf-8fb2-fba58a465401"&gt;five&lt;/span&gt;-year warrant to purchase 480,000 membership interests were contingent upon the portal completion date, however, the Company did not exercise the option after completion of the portal. As APC does not have the ability to exercise significant influence, and lacks control over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December&#160;31, 2021 and 2020, there were no observable price changes to APC&#x2019;s investment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AchievaMed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#x201c;AchievaMed&#x201d;), entered into an agreement in which NMM would purchase up to 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction, NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5&#160;million is included in &#x201c;Investment in a privately held entities&#x201d; in the accompanying consolidated balance sheets as of December&#160;31, 2021. As NMM does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative, which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. During the year ended December&#160;31, 2021 and 2020, there were no observable price changes to NMM&#x2019;s investment.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE1OTQz_ca9f4320-dca0-4ef4-874b-cba36774422a">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in other entities &#x2013; equity method consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.379%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.336%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Initial Investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contribution&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consolidation of Entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,943)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;One MSO, LLC &#x2014; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-6 Medical Investment Group, LLC &#x2014; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tag-8 Medical Investment Group, LLC &#x2014; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,768)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;CAIPA MSO, LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s unaudited summarized balance sheets at December&#160;31, 2021 and 2020 and unaudited summarized statements of operations for the years ended December&#160;31, 2021, 2020, and 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.128%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.764%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2021&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2020&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;December 31, 2019&lt;br/&gt;(unaudited)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i503c88657b144f3aab4aa1799044b19f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMi0xLTEtMA_251e155c-7107-40c7-aaed-958d697a77ed"
      unitRef="usd">13047000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtNC0xLTEtMA_ba11a932-4754-4b18-b159-47463f953363"
      unitRef="usd">0</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtNi0xLTEtMA_be3a43d2-2155-421d-afda-b1aca2aadd67"
      unitRef="usd">-5831000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtOC0xLTEtMA_6969388b-612a-40ed-bf40-6e477e3b9201"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMTAtMS0xLTA_50a27dd3-363d-4953-a69d-d0f01b4a40b9"
      unitRef="usd">4182000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i2459cf5a4c3147b99dff3a86cbc01e96_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMTItMS0xLTQwMTU1_8c9dac0b-1ec5-4d38-bb07-94217f2296b8"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="iefca0b3acca84ef39bac26666af72183_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEtMTItMS0xLTA_5fa147f4-ac93-47f9-b762-88dd25b3caf3"
      unitRef="usd">3034000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ibc7ce9f2aefb4de8b0e4a49738897718_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMi0xLTEtMA_874a825c-a349-4e03-800e-b3ac8191d1c7"
      unitRef="usd">1413000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItNC0xLTEtMA_e4ba2a3a-9523-4743-bffb-72a8a058d3cf"
      unitRef="usd">0</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItNi0xLTEtMA_aa3a3475-85f3-491b-9387-c4f8dec2eb85"
      unitRef="usd">306000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItOC0xLTEtMA_1d89126a-c1db-480e-8bc0-78f1cb62267e"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMTAtMS0xLTA_aaa1b398-4999-4ecc-bda7-8905fd54005b"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ia9534796412d4ee5a16af99d793be44e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMTItMS0xLTQwMTU1_a8b00320-4643-4a87-9570-e5a4acd60bd0"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i1b87107110124a33ad3ed49dca12817e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzItMTItMS0xLTA_457d000e-b58d-479b-914a-6a5c35d55abd"
      unitRef="usd">1719000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9f9c8db35dd1455cbb9efcf67a63698b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMi0xLTEtMA_bd5265f4-8d3b-40fb-af57-4178b0a2a355"
      unitRef="usd">2613000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtNC0xLTEtMA_e4f4d448-4292-409a-9241-bce1b325d451"
      unitRef="usd">0</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtNi0xLTEtMA_48968667-06ff-4b10-8719-40b89858fc56"
      unitRef="usd">330000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtOC0xLTEtMA_2d45c62e-b62a-4eb7-a742-61e38f1475e9"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMTAtMS0xLTA_2b99ffe5-cc79-4401-b924-a2a5ccd9dbdd"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzMtMTItMS0xLTQwMTU1_2f88959e-47ca-4f67-8b16-96415be18e28"
      unitRef="usd">2943000</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i110382789db14433b603074a67e42a36_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMTItMS0xLTA_b88ffec8-c385-43fe-bf28-587e65d45444"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i13903951d2fc4cb3a6f3cc653bc12796_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMi0xLTEtMA_486f6d43-8e38-4b98-8877-09b11439bb93"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtNC0xLTEtMA_710745f0-b7bf-4b69-8f3f-13a52ee08660"
      unitRef="usd">0</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtNi0xLTEtMA_a16cd3fc-1809-403f-a489-78de4696867a"
      unitRef="usd">-208000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtOC0xLTEtMA_3e365a85-fd83-4570-9c8c-53049925ec52"
      unitRef="usd">238000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMTAtMS0xLTA_3011ae91-0f19-46e0-a005-64c785a2d568"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i499adfa0929b4d5c89ec3edcbee63481_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzQtMTItMS0xLTQwMTU1_522a7047-a85a-486d-b331-07641bb7a2aa"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i898d05e125bd4e44b591badacf6f75fe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMTItMS0xLTA_79a1a533-8c91-42e5-a581-695085dfc9a4"
      unitRef="usd">17230000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i731e915d69124743b66363b19a199dda_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMi0xLTEtMA_dccf423f-b40a-408b-b2b6-cf850ba02d1e"
      unitRef="usd">2395000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctNC0xLTEtMA_6431e20a-6507-44da-b654-7281c7972938"
      unitRef="usd">0</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctNi0xLTEtMA_70e9b72a-2727-46e7-9e9d-a6c87c7b67df"
      unitRef="usd">515000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctOC0xLTEtMA_962259e6-683c-49c8-bb26-15e6ad9aab69"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMTAtMS0xLTA_55b94877-628f-47bf-8644-4a504442d2c0"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzUtMTItMS0xLTQwMTU1_aed32c55-fd45-45cf-bcc3-8391b0ecfe7a"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i4ca09a27d4e24e43ac205809e114b053_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMTItMS0xLTA_1da0603d-db61-4ef3-b0f8-091976d7f0c7"
      unitRef="usd">2910000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9f6c47496c364a6b8c27c34e249b3a21_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMi0xLTEtMA_ca3df851-10e6-44cd-bcd5-52610d708bc5"
      unitRef="usd">4516000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNC0xLTEtMA_251147df-f8b7-4f86-90ac-a39403e7852e"
      unitRef="usd">0</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNi0xLTEtMA_be550ee2-87cb-4f2b-a363-e2c0a923a03f"
      unitRef="usd">314000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtOC0xLTEtMA_0987abd2-4e41-4d5e-9d6d-1470035aead9"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTAtMS0xLTA_44fe348b-52b3-4601-860b-26c7fdadea12"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzYtMTItMS0xLTQwMTU1_5719b627-f29f-4e67-8709-eb510fcf236f"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i6cce677040344f7c94c12092ed289604_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTItMS0xLTA_208e6637-a7d4-46ac-96a2-5f08eb79d3ad"
      unitRef="usd">4830000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i273a684a3d8b492283839a5d9ccc76b3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktMi0xLTEtMA_e57df2ec-d4f3-44ec-90bb-a00d85c2f5f0"
      unitRef="usd">2108000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktNC0xLTEtMA_f0d3e852-a980-4670-b4cb-1968a08d07ba"
      unitRef="usd">0</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktNi0xLTEtMA_1eda32ef-66ea-4b7c-8f12-201c683d79be"
      unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktOC0xLTEtMA_e4117537-b6c5-4053-be9b-ed6649355c21"
      unitRef="usd">1660000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktMTAtMS0xLTA_328a2fa6-4498-4260-8cd4-7c53666677c1"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ifa85536a036b46379cea77c234a086b4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzctMTItMS0xLTQwMTU1_479848b5-749f-4c85-9510-0d951c2b2be1"
      unitRef="usd">3768000</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="ibbf87ab1f75b4885966e552286174dd2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzktMTItMS0xLTA_362f7e27-be5b-4b3f-9a34-31e46f3a6d4f"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i0c28398a7a274eb28a70bc44722ecef4_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMi0xLTEtNDAyMjE_1dd118de-fc4a-420f-b645-c9070ec924d6"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNC0xLTEtNDAxNTU_b44d9802-7f5d-4a8e-85f7-63c2cb320b4d"
      unitRef="usd">11724000</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtNi0xLTEtNDAxNTU_3c15e62b-8ba9-4122-89db-88d621352756"
      unitRef="usd">268000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtOC0xLTEtNDAxNTU_4bf0433c-1fc6-4a4b-b927-2c6a4d932cee"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTAtMS0xLTQwMTU1_c2ed90fe-dfab-4426-b88e-d29e0a75c105"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="id52e19518ae34e748e1b53e56a606015_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTItMS0xLTQwMTU1_109a63a0-6256-4436-9b1f-63a323f1916d"
      unitRef="usd">0</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="id249748cb92647bcb3ae2fe466c5b254_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzgtMTQtMS0xLTQwMjIx_25fadf36-d2a9-4b38-93ab-c5585291ca81"
      unitRef="usd">11992000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTItMS0xLTA_c59c9edc-cb80-4c3f-b609-e4912b02e8f1"
      unitRef="usd">43292000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentInvestmentInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTQtMS0xLTA_e6f59e4a-65d4-4c02-938d-13c92fb59747"
      unitRef="usd">11724000</ameh:EquityMethodInvestmentInvestmentInPeriod>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTYtMS0xLTA_5dbb6578-2516-4e2a-a770-c9bba3f36e5f"
      unitRef="usd">-4306000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTgtMS0xLTA_2e53b0f4-c4d5-4f44-b51c-4d517fae3780"
      unitRef="usd">1898000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTEwLTEtMS0w_33cf6d68-d331-4cfd-9077-9234b4b958d7"
      unitRef="usd">4182000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <ameh:EquityMethodInvestmentsConsolidated
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzEwLTEyLTEtMS00MDE1NQ_a14d2562-e33d-45b4-9108-22fcbee684c7"
      unitRef="usd">6711000</ameh:EquityMethodInvestmentsConsolidated>
    <us-gaap:EquityMethodInvestments
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTplMDdkODEyNTY1N2Q0NDI2OTkwZjJmOWU3MWEzZGRkYS90YWJsZXJhbmdlOmUwN2Q4MTI1NjU3ZDQ0MjY5OTBmMmY5ZTcxYTNkZGRhXzExLTEyLTEtMS0w_b391b4b6-93cf-430b-a275-c7576f87593b"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <ameh:NumberOfEmployees
      contextRef="iefca0b3acca84ef39bac26666af72183_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2Nzg4MTc_19ba5978-ecde-452c-9c0a-00b84468cd2d"
      unitRef="provider">2400</ameh:NumberOfEmployees>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i0412a16b622b47b881cd9067167d397e_I20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzg4MQ_36c716b5-3f0a-48ae-9878-1edb81e519dd"
      unitRef="usd">5000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i198ab6e687c84de2a822e8318e6dfb6d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzg5MA_804699e2-aa96-4d49-ab7b-54e8647238d1"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NotesReceivableNet
      contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNzg_68f33184-2e12-4aac-9a17-97ed1600f127"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease
      contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMjE_938d426f-abf9-49db-b1d5-42998dafc370"
      unitRef="number">0.2125</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion
      contextRef="idbbeb1f862bf450891db9fb5dfd9a221_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzY1OTcwNjk3OTQyMjc_1a6dbfe8-34cc-4105-9ec5-4caf537eaac0"
      unitRef="number">0.4625</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease
      contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2NzkyNzg_938d426f-abf9-49db-b1d5-42998dafc370"
      unitRef="number">0.2125</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease>
    <us-gaap:NotesReceivableNet
      contextRef="i7752aa181d2b43d7b454c8fdbaa54b71_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2NzkzMjk_68f33184-2e12-4aac-9a17-97ed1600f127"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i198ab6e687c84de2a822e8318e6dfb6d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2NzkzNzA_804699e2-aa96-4d49-ab7b-54e8647238d1"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i8cb8cf60062647d29f8c59848644f427_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0ODI_17fadfae-3dd1-4201-8810-03d0a18bcde2"
      unitRef="usd">-5800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i03f22c6e36ab4bd4853b9f3b723fc918_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE1NDE_52709f84-2a2a-46e8-adf5-bdedf5128c28"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="iefca0b3acca84ef39bac26666af72183_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE2NDk_02bfe176-9238-47cd-8612-aa1d10955994"
      unitRef="usd">3000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i503c88657b144f3aab4aa1799044b19f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE2NTY_8c5177b8-40e2-43d3-94d3-5a5db2c14895"
      unitRef="usd">13000000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzMtMi0xLTEtMA_435d8344-1853-4696-9e9d-038c31a27c84"
      unitRef="usd">6619000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzMtNC0xLTEtMA_fe793263-bba5-4965-9dc8-6ac4b48c5e91"
      unitRef="usd">9350000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzQtMi0xLTEtMA_a400689c-d1af-4078-9524-ed523793f089"
      unitRef="usd">2269000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzQtNC0xLTEtMA_2363d141-b48a-419e-bc67-a9edcdf090f7"
      unitRef="usd">3918000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzUtMi0xLTEtMA_180734b9-72b1-4652-90e7-d4fe42f64a8f"
      unitRef="usd">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzUtNC0xLTEtMA_2dc2b3a6-fb20-4a26-802a-d4d250e0cbc1"
      unitRef="usd">881000</us-gaap:OtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzYtMi0xLTEtMA_88d73897-6285-4682-99bb-5755b4487a68"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzYtNC0xLTEtMA_bdbbcbeb-998d-4ed2-a332-00e9fb7b4e7b"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzctMi0xLTEtMA_61bf8089-7282-4b54-963b-faa1fa709aa0"
      unitRef="usd">696000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzctNC0xLTEtMA_4d0d4dbf-f4e9-441e-aa52-70eeb6c5477d"
      unitRef="usd">691000</us-gaap:RestrictedCashCurrent>
    <us-gaap:Assets
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzktMi0xLTEtMA_1bf3d245-b458-4263-8e91-85380b45575f"
      unitRef="usd">11834000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzktNC0xLTEtMA_15adfa21-8f8d-4809-a377-5c93daabb321"
      unitRef="usd">17090000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEyLTItMS0xLTA_3ce74770-4e77-4ac8-a43b-723232cc8efd"
      unitRef="usd">32405000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEyLTQtMS0xLTA_ecb09a0e-5cf1-4d6d-b98f-58b28f11c878"
      unitRef="usd">21589000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEzLTItMS0xLTA_74e8f03f-e24e-489a-af1d-6adc4c68b186"
      unitRef="usd">-20571000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzEzLTQtMS0xLTA_7f5b04b1-2705-4de3-8292-85f4905ab34d"
      unitRef="usd">-4499000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzE1LTItMS0xLTA_ea5bc264-e4ca-4726-b00a-138a0f6bc5c9"
      unitRef="usd">11834000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i71ba5fb68e5e49f6855f73f475e4c3b6_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkMjE0OWJkNzJlZmU0YTE2OWUyNGUyYzVlNWMwMDk5ZS90YWJsZXJhbmdlOmQyMTQ5YmQ3MmVmZTRhMTY5ZTI0ZTJjNWU1YzAwOTllXzE1LTQtMS0xLTA_ce585ead-df4e-4d86-b8b9-695e7f64ab3f"
      unitRef="usd">17090000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzItMi0xLTEtMA_57dd5cc0-6853-450a-92ae-65c6092a5c8c"
      unitRef="usd">204061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzItNC0xLTEtMA_21bf2cc0-8750-44b9-b668-229ff65050bb"
      unitRef="usd">186964000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzItNi0xLTEtMzk5NDg_e23f7af1-9b99-468f-ab9d-989f1c996129"
      unitRef="usd">194020000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzMtMi0xLTEtMA_34da640e-9941-4eaa-bb07-f14eee7ef585"
      unitRef="usd">220132000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzMtNC0xLTEtMA_2dc71281-d029-4b33-b7fb-947e72bbaa47"
      unitRef="usd">185724000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzMtNi0xLTEtMzk5NDg_d3fc6b0e-f0f4-4b8e-aebb-4f9e761a4a9d"
      unitRef="usd">205153000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzUtMi0xLTEtMA_4e3247d2-bde9-467c-be19-596d84999eee"
      unitRef="usd">-16071000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzUtNC0xLTEtMA_131b906e-e9dc-4a60-bf21-f732b904388d"
      unitRef="usd">1240000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzUtNi0xLTEtMzk5NTU_32e65700-6509-427e-9d74-a76527c052f2"
      unitRef="usd">-11133000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzctMi0xLTEtMA_29712c70-c502-4836-9990-1bac01c743be"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzctNC0xLTEtMA_326634bb-2f94-42e3-89dc-ea0acc0f30f5"
      unitRef="usd">8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzctNi0xLTEtMzk5NTU_8e6b9606-f758-436c-abe2-473e4b15909c"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="i2e7a5e9230ca46429efe5db436f4baf2_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzEzLTItMS0xLTA_3cf89d73-503c-4faf-8947-9650ce0c4bb2"
      unitRef="usd">-16071000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2292702d1aad45aa97a69ec6c2dd4a27_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzEzLTQtMS0xLTA_78ffe9de-2af4-4bff-ac66-a055072ffea6"
      unitRef="usd">1248000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i022d329a5e684ed4839cd07ec1ba5854_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90YWJsZTpkN2UyYzk5NDQzYTA0OWQyODBhOWI5YzJkYTg2MDVmYy90YWJsZXJhbmdlOmQ3ZTJjOTk0NDNhMDQ5ZDI4MGE5YjljMmRhODYwNWZjXzEzLTYtMS0xLTM5OTU1_53509845-9c2a-48ea-9ca0-39f176a9af4e"
      unitRef="usd">-11133000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ic37f82250e404856a1dcea1915c8a4f9_I20150731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzIzODE_536336a2-c5df-44ec-a629-ade3b34dcaaa"
      unitRef="usd">1200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic37f82250e404856a1dcea1915c8a4f9_I20150731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzIzOTA_6bfb0f34-4deb-477c-98ea-ab96530e585a"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsForFees
      contextRef="iee587da7f4aa43ada9b4e8471a61bc94_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI2MjI_0801b47b-3b85-4706-8e2f-d2fa3b05b02e"
      unitRef="usd">2400000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i2c187ffabbda44aca5a5d84550b8aa79_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI2Mjk_80c47b9a-4006-4e93-9fa5-9ef0ef301f43"
      unitRef="usd">2200000</us-gaap:PaymentsForFees>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib555dbec242444c28b4456bb93f2b6f5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI5MDg_88dafe2b-8082-47d0-8f0b-f2105dbd6def"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic9a36e1a441145a19e883235e84ce38a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzI5NTg_16a2b07c-0723-4bba-924c-b1abf7025568"
      unitRef="usd">17000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if37956fe79bf4000a19ec8e8571ca1cc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzMwNzA_537499d8-30d4-44aa-ba80-26535ee0a070"
      unitRef="usd">1700000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i18d99fc8fa9b454a8bd0c6ed6faa3ba9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzMwNzc_96a0cc53-18e5-42b9-89cb-3990975d9ca7"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i5061a26c78b5403a92ef0a14467a0063_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzcwNjc_5e2389f7-e40c-4fe3-aba8-2c4db27c6188"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss
      contextRef="i12a34479c0d9431082347eef5e6503c7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzM4NDgyOTA3NjE0MDU_14c6ee7f-a180-4bdd-9b2b-e9d471a87045"
      unitRef="usd">2800000</us-gaap:VariableInterestEntityInitialConsolidationGainOrLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibdc98f3cf1ce4c1d8a0b83f75ea36297_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzczMjU_a4837707-f0a8-4feb-bc0a-97b8bf1eac5e"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iad767e257dc04de09097654e8d9ea038_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODc2NjI_597e093b-415a-43a3-98a4-df34abeb34f6"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib0d13a567771417b82eab2d872ffeddd_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk4Nzc_9da2a9b9-7bf9-42f3-ba2f-07461d6aaf67"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i00e772255fe246ffa225f111f36bbee4_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk4ODE_35096f50-9390-4c61-aa70-f9775a9ed220"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id948340a0f0b4857bed7bfd4a5db9f4c_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk4ODg_e74d3ff9-6365-4b1b-aff8-e0db021f88f1"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MembersCapital
      contextRef="ib0d13a567771417b82eab2d872ffeddd_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk5NjQ_264e5574-a8e7-4a43-8961-8a8018ec3540"
      unitRef="usd">16700000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i00e772255fe246ffa225f111f36bbee4_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk5Njg_6a54cf6d-abde-42b5-ab4b-37c86e99f0b0"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="id948340a0f0b4857bed7bfd4a5db9f4c_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1Xzk5NzY_5faa2be1-adff-4f09-b194-aa15e753e8bb"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib63764ca4e84414c81bcc395ce6a0848_I20190423"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNjEz_6a04ad4b-dfc7-4dcd-a723-af7f3fed6ea6"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ib63764ca4e84414c81bcc395ce6a0848_I20190423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNjc3_10ed5da4-1e9e-48f7-ab9e-a113435c8b32"
      unitRef="usd">8300000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ief1111e9e2a048a785ec584e3a23c0db_I20190423"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwNzA1_5f648cfe-070c-4e8b-a975-39ca7e8c0945"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ib8eb23240eab47278ba31489ec5f4074_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMjQw_b5fba5e7-f9e3-4e14-a184-94f7393ffe73"
      unitRef="usd">-200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie652a00fea2c45bba68f168cd6fd0326_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMjQ3_3ac52a65-c6cd-43cd-a902-27ca9448846d"
      unitRef="usd">-400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ie4819e77fc964fe284f83cd52ffd9bed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE3MDY0Mjc_28a0a292-6ce6-4059-938e-585fbfb8bd28"
      unitRef="usd">200000</ameh:EquityMethodInvestmentsContribution>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="ice49c40a4d0b40009b5fc8fabf4890d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExMzg3_094bb598-450b-4f54-9dfb-0b85fe5ea354"
      unitRef="usd">1000000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i28a5796b7a274d6dac1cfafd9d65e199_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExNDQ5_6c4e5303-4600-4fa4-b36f-66d354b7796b"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i1154256fe1de45f59c9c10c10c8ab21b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExNTUw_4fa7c5bb-3c91-444c-92fd-2da8f7bacef0"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i28a5796b7a274d6dac1cfafd9d65e199_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzExNTU3_63b88aec-56d4-4c06-8b79-287a6d373c7c"
      unitRef="usd">17200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic23531b109fe425ea37a2b8d6a5e782b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEyNjc0_4a073ca8-f558-4cab-88d4-ffaffcbf2648"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i731e915d69124743b66363b19a199dda_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEyNzI4_05d22591-1e40-4271-9922-f52d784e41fe"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3f10c53f93ed4367baff7a7469d0435c_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODM3OTQ_2ce1e51a-9380-409a-a67c-9260d124c152"
      unitRef="usd">500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i4ca09a27d4e24e43ac205809e114b053_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODM3OTA_115342c8-9da0-404a-ba1d-9747fb5f8026"
      unitRef="usd">2900000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i731e915d69124743b66363b19a199dda_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODM3NzQ_ce2e8f81-03b1-45a0-9d14-7ec90b31ead4"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0037e84ba38f4a3e9dfb06a8532434cb_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEyOTY1_1a1cff1f-8f35-446e-9445-3d95ff592219"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i9f6c47496c364a6b8c27c34e249b3a21_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzMDM3_fc73ee7e-8182-4194-858d-4b734e74d0e0"
      unitRef="usd">4500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if8e6770db7ed467b9bfa172bb05c7567_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzMDc3_af885500-1e30-409a-8b50-290289353ff5"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i273a684a3d8b492283839a5d9ccc76b3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzMTQ5_754cc19e-fc9d-427d-8c80-cf54adf221db"
      unitRef="usd">2100000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie004f56332464ba79436fde5a8bf3124_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODQzOTQ_1324167b-de7d-441b-876b-e81ea35ce40e"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6cce677040344f7c94c12092ed289604_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODQzOTg_3a6563e4-bf20-4b57-b411-5c64e8ec2eef"
      unitRef="usd">4800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i9f6c47496c364a6b8c27c34e249b3a21_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODQ0MDI_91c7e000-99f0-4346-9169-e31c04e6e5c8"
      unitRef="usd">4500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id671637d094b4da9baff3726eb0bb9ef_I20210831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODEzODA_4b6eba8f-524c-4f6e-b9ff-8804bbe6c7a0"
      unitRef="number">0.30</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="i8fd1339411804f9e8ee4a8aaa22a5cc7_I20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODEzOTY_520fe6ad-11eb-49a5-9f3a-6319131db338"
      unitRef="usd">11700000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i100c286c449b435198ed0d3c17cfbda1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODMxNjY_709d2570-cf5d-42fe-acf2-ef9cb336019e"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2ab282e08eee4f75b09eb011582c6e08_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEwOTk1MTE2ODMxMjA_590c2c3e-a0d1-4a5a-b2e3-39b9f3b893af"
      unitRef="usd">12000000</us-gaap:EquityMethodInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares
      contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNDcx_7559bfbd-81d3-4236-af42-ffc2a3ba765b"
      unitRef="shares">270000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares>
    <ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNTU2_18eec776-cf91-454d-8243-e008653a3b0e"
      unitRef="usd">400000</ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest
      contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNTYy_27bd608e-7fe3-4dfd-bc24-706f2e462194"
      unitRef="usdPerShare">1.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjIy_67040b99-33d6-4063-a751-b513b66ab140"
      unitRef="number">0.028</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNjg0_44b2dba9-7a7f-45d9-b7f3-93f5983b26ed"
      unitRef="shares">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests
      contextRef="i53dfe9f595bc42e0b920a5129a920134_D20180501-20180531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzNzUy_5616b2c9-4daa-4b02-abfc-f42b638f2a0e"
      unitRef="shares">380000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests>
    <ameh:EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet
      contextRef="ib35744eb8b2a4654a6e7d576a8beb03e_I20180531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzEzODEw_b9646671-07d9-4b36-868a-bc4c24fd8652"
      unitRef="shares">480000</ameh:EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears
      contextRef="i81be945f4a484abab03ca823d400fb2d_I20190701"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0NTM2_a12a2f54-5a91-4549-a80c-a063dfa67bf5"
      unitRef="number">0.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment
      contextRef="id0caec3bea3f4eaa9e7ff87ad11adae8_D20190701-20190701"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0NjMw_5fab91f5-a299-480b-b981-10954978fc6f">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="i81be945f4a484abab03ca823d400fb2d_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0Njgw_5f47b626-baa6-47c0-ae32-3478accb7216"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i81be945f4a484abab03ca823d400fb2d_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0Njg5_e4bdeb18-bfeb-4b88-84a9-5bd2bc5fea32"
      unitRef="number">0.10</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="ib53fcc8b36514b66982fc74e646bd81d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNDUvZnJhZzo4Mzk1ZTAyNGUwMGY0ZDBiYmY5MDEzMDgwZDllMjM5NS90ZXh0cmVnaW9uOjgzOTVlMDI0ZTAwZjRkMGJiZjkwMTMwODBkOWUyMzk1XzE0NzM2_c417c850-bc9a-45d3-bcc7-8e08662dc305"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:LoanReceivableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzMwMjU_483db4b1-8768-4537-b112-20fce918ec7e">Loans Receivable and Loans Receivable &#x2013; Related Parties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loans Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pacific6&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, NMM received a promissory note from Pacific6 Enterprises (&#x201c;Pacific6&#x201d;) totaling $0.5&#160;million as a result of the sale of the Company&#x2019;s 33.3% interest in MWN. Interest accrues at a rate of 5% per annum and is payable monthly through the maturity date of December 1, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan Receivable &#x2014; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AHMC Healthcare Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, APC entered into a promissory note with AHMC Healthcare Inc. (&#x201c;AHMC&#x201d;), a related party of the Company, (the &#x201c;AHMC Note&#x201d;) for a principal sum of $4.0&#160;million with a maturity date of April 2022. The contractual interest rate on the AHMC Note is 3.75% per annum. The AHMC Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. As of December&#160;31, 2021, the total principal of $4.0&#160;million remains outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the outstanding loan receivable and loan receivable &#x2014; related parties under the CECL model by assessing the party&#x2019;s ability to pay by reviewing their interest payment history quarterly, financial history annually, and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and &lt;/span&gt;&lt;/div&gt;estimates an expected credit loss based on the remittance schedule of the note. No losses were recorded for loan receivable and loan receivable &#x2014; related parties as of December&#160;31, 2021.</ameh:LoanReceivableTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="ieef9d826ba6d40728e8ea8794c1ba388_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzE3Nzc_d70cd624-a636-4e9b-835f-c9b645b713b1"
      unitRef="usd">500000</us-gaap:NotesReceivableNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i604b63e710a74052bd5134a326c3b521_I20181218"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzEwOTk1MTE2MzMyNTc_208b7eb1-ced0-446e-9282-c7dd88ade3be"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ie2dacf52383a475da0334f0ba9ad8b31_I20181218"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzEwOTk1MTE2MzMyNTc_40ad2811-6607-4d89-86dc-08c2140b1c6a"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i3069a2df4dba45069c16005bfe7c95a9_I20181218"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzEwOTk1MTE2MzMyNTc_48938be1-844f-43e5-8f70-42908f284f65"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idb1195755b784aa8b53f18c076ac879d_I20201030"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzE4Njg_da6a8a65-bc2d-400f-9128-6c043385be5b"
      unitRef="number">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="i2c9d54cb427946a28f7ce5949115e202_I20201031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzIxMjc_ffe7d83a-9f9e-41c2-a3a8-9cdf8722e796"
      unitRef="usd">4000000</us-gaap:NotesReceivableGross>
    <ameh:FinanceReceivableInterestRateStatedPercentage
      contextRef="i2c9d54cb427946a28f7ce5949115e202_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzIyMzk_b9a6a5ea-0289-42f4-9d73-eddaee4b1b72"
      unitRef="number">0.0375</ameh:FinanceReceivableInterestRateStatedPercentage>
    <us-gaap:NotesReceivableGross
      contextRef="i3f1e6664f4ef468db3a85b5fe37e8ad0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzI0NDg_65548fbd-d376-406b-87f1-78201c6a8fe3"
      unitRef="usd">4000000</us-gaap:NotesReceivableGross>
    <ameh:NotesReceivableRelatedPartiesNoncurrentGainLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzI5MTk_60fcd83c-052b-430b-b6db-17b62eb1eb9f"
      unitRef="usd">0</ameh:NotesReceivableRelatedPartiesNoncurrentGainLoss>
    <ameh:FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTEvZnJhZzozN2U2OWVhZmIzM2M0MTczODFkZTIxYjU1ZDJjZmNmZS90ZXh0cmVnaW9uOjM3ZTY5ZWFmYjMzYzQxNzM4MWRlMjFiNTVkMmNmY2ZlXzI5MTk_6ef6e9c2-6c66-4c6b-a3ad-bae9bded7568"
      unitRef="usd">0</ameh:FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90ZXh0cmVnaW9uOjI0N2NjNzVhNDlhZjQ0MzhhOWQxMDNmNTFiYjgzNDQ3XzEyOA_73e8bfca-68cc-41e4-a610-648badddd0e6">Accounts Payable and Accrued Expenses&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90ZXh0cmVnaW9uOjI0N2NjNzVhNDlhZjQ0MzhhOWQxMDNmNTFiYjgzNDQ3XzEyOQ_c02ccb7c-7938-4e59-bb77-65b41b1cac93">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and other accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due to related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzItMi0xLTEtMA_01190d73-7dc2-4bac-b56a-550ed30a4748"
      unitRef="usd">9583000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzItNC0xLTEtMA_b7e51871-612a-4f60-abd9-c17bad91ae76"
      unitRef="usd">9554000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzMtMi0xLTEtMA_92d1943d-a72f-4383-a03a-2e5e0455bb00"
      unitRef="usd">2697000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzMtNC0xLTEtMA_1f17b22d-c601-4c65-b5fa-55c6fae46aa3"
      unitRef="usd">3541000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SubcontractorIpaRiskPoolPayable
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzQtMi0xLTEtMA_c6be5cd4-fa30-48d3-a5e0-9bbaff8ee7f3"
      unitRef="usd">1587000</ameh:SubcontractorIpaRiskPoolPayable>
    <ameh:SubcontractorIpaRiskPoolPayable
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzQtNC0xLTEtMA_9b41d4b3-8391-478e-a4e8-0e3651eb0236"
      unitRef="usd">1662000</ameh:SubcontractorIpaRiskPoolPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzUtMi0xLTEtMA_d002a8e2-5f14-4467-adc0-cd5014b3afb9"
      unitRef="usd">878000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzUtNC0xLTEtMA_474a2228-fe23-4c18-b053-a6f00f4d8720"
      unitRef="usd">1378000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzYtMi0xLTEtMA_b5408c74-bac8-4d51-b52a-294212cb541f"
      unitRef="usd">2301000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzYtNC0xLTEtMA_59694f5a-0a15-43e1-8029-db4ee7253cc8"
      unitRef="usd">50000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzctMi0xLTEtMA_05d06ba3-7811-4677-a9b2-c60f42ea4a23"
      unitRef="usd">16798000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzctNC0xLTEtMA_32ac2f7d-90c3-476d-b075-926055a4fcea"
      unitRef="usd">12988000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzgtMi0xLTEtMA_e8cf10cf-5da4-4e6e-98c3-2181a7520a9e"
      unitRef="usd">10107000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzgtNC0xLTEtMA_f83872fd-44e7-4f46-a119-b34b07d4c80c"
      unitRef="usd">6970000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzktMi0xLTEtMA_9448564e-0a40-49ae-a5cb-ef16b3563c6e"
      unitRef="usd">43951000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNTcvZnJhZzoyNDdjYzc1YTQ5YWY0NDM4YTlkMTAzZjUxYmI4MzQ0Ny90YWJsZToxNDc3YjI1ZDk4NDI0NThjYWM0MzZlNmM1ODU4MGRhNS90YWJsZXJhbmdlOjE0NzdiMjVkOTg0MjQ1OGNhYzQzNmU2YzU4NTgwZGE1XzktNC0xLTEtMA_d899c1dd-dd61-406d-91b9-08496c1743d5"
      unitRef="usd">36143000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90ZXh0cmVnaW9uOmUwNWEyZGIyNTFiNjQ3MjhiYjg1YWJiM2NlNmMwMThkXzEwNg_b8d7aa7f-6317-43e2-aeb1-763ff8fb2f79">Medical Liabilities&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90ZXh0cmVnaW9uOmUwNWEyZGIyNTFiNjQ3MjhiYjg1YWJiM2NlNmMwMThkXzEwNw_c3997010-6854-4f1c-881b-8f1082cca390">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;347,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,258)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;348,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(291,243)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(261,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(342,474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzItMi0xLTEtMA_637886bc-89ce-4003-a89e-6b568d3b6e2d"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6084317bda0d48f9b2293ce7324d000d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzItNC0xLTEtMA_5b92b1b4-3290-4ada-84d0-863b3e0b7f3a"
      unitRef="usd">58725000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzMtMi0xLTEtMA_6c5336e0-2089-463f-ae50-9822f918293b"
      unitRef="usd">175000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzMtNC0xLTEtMA_1a7edcae-741d-4d7a-b8e2-d5420f7c2291"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzUtMi0xLTEtMA_ae51292b-1398-4efa-b4fe-59f6100c7f63"
      unitRef="usd">347720000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzUtNC0xLTEtMA_6e2e1aae-de92-470a-ab5e-d2f98ac8300a"
      unitRef="usd">309848000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzYtMi0xLTEtMA_417866ca-95a7-4750-b1fa-282033aebbad"
      unitRef="usd">553000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzYtNC0xLTEtMA_f925f62c-bc3c-4c87-8cb1-9e48dadfc4c4"
      unitRef="usd">-3258000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzctMi0xLTEtMA_771211a2-b47c-415a-9e2a-e2ce6cb59e8e"
      unitRef="usd">348273000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzctNC0xLTEtMA_1f3fcb6d-55ae-4ff8-8331-1f14b1f4d174"
      unitRef="usd">306590000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzktMi0xLTEtMA_ed9c1c6e-9880-4fd5-9738-228ee5f10712"
      unitRef="usd">291243000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzktNC0xLTEtMA_297c9c7d-eb4e-4b9e-871b-530651c53e68"
      unitRef="usd">261062000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEwLTItMS0xLTA_1fba9335-71e9-45a4-8329-c3161ad348ea"
      unitRef="usd">51231000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEwLTQtMS0xLTA_5aae7917-de2c-4c99-b49b-06a378c48259"
      unitRef="usd">54056000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzExLTItMS0xLTA_437c5e99-28b1-411a-a661-36a70fa46b2c"
      unitRef="usd">342474000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzExLTQtMS0xLTA_e4141672-0473-4616-8d81-89f7be3c0f28"
      unitRef="usd">315118000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEyLTItMS0xLTA_c15310fe-8027-4396-823b-36c0bb20ae59"
      unitRef="usd">-521000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzEyLTQtMS0xLTA_c3ba0374-9ce2-40c3-a291-e48b362bc02e"
      unitRef="usd">133000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzE0LTItMS0xLTA_ec7b1dc6-1aa8-41c5-acc3-d4c4baa52673"
      unitRef="usd">55783000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjAvZnJhZzplMDVhMmRiMjUxYjY0NzI4YmI4NWFiYjNjZTZjMDE4ZC90YWJsZToxM2NkZjAzYzEwOWM0NzcyOGZiZDVjYWU5ZGZiNzM3MC90YWJsZXJhbmdlOjEzY2RmMDNjMTA5YzQ3NzI4ZmJkNWNhZTlkZmI3MzcwXzE0LTQtMS0xLTA_0d1b2112-7ce5-411f-9111-0cec1eba34c7"
      unitRef="usd">50330000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4ODA4_d9c46b2b-79c1-49b6-a890-752c803cf6d8">Credit Facility, Bank Loans, and Lines of Credit&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction loan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized financing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Long-term debt &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of our long-term debt was determined using Level 2 inputs primarily related to comparable market prices. As of December&#160;31, 2021 and 2020, the carrying value was not materially different from fair value, as the interest rates on the Company&#x2019;s debt approximated rates currently available to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amended Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2021, the Company entered into an amended and restated credit agreement (the &#x201c;Amended Credit Agreement&#x201d; and the credit facility thereunder, the &#x201c;Amended Credit Facility&#x201d;) with Truist Bank, in its capacity as administrative agent for the lenders, issuing bank, swingline lender and lender, Truist Securities, Inc., JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Preferred Bank, Royal Bank of Canada, and Fifth Third Bank, National Association, in their capacities as joint lead arrangers and/or lenders, and the lenders from time to time party thereto, to, among other things, amend and restate that certain credit agreement, dated September 11, 2019, by and among the Company, Truist Bank, and certain lenders thereto (the credit facility thereunder, the &#x201c;Credit Facility&#x201d;), in its entirety. The Amended Credit Agreement provides for a five-year revolving credit facility to the Company of $400 million, which includes a letter of credit sub-facility of up to $25 million and a swingline loan sub-facility of $25 million. The revolving credit facility will be used to, among other things, refinance certain existing indebtedness of the Company and certain subsidiaries, finance certain future acquisitions and investments, and provide for working capital needs and other general corporate purposes. Under the Amended Credit Agreement, the terms and conditions of the Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;) between the Company, NMM and Truist Bank remain in effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay an annual agent fee of $50,000 and an annual facility fee of 0.175% to 0.35% on the available commitments under the Amended Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#x2019;s leverage ratio. The Company will pay fees for standby letters of credit at an annual rate equal to 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. The Company is also required to pay customary fees between the Company and Truist Bank, the lead arranger of the Amended Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, amounts borrowed under the Amended Credit Agreement bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of from 1.25% to 2.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread of 0.25% to 1.50%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio.  As of December&#160;31, 2021, the interest rate on the Credit Agreement was 1.71%. Borrowings under the Amended Credit Agreement may be prepaid at any time without penalty. If LIBOR ceases to be reported under the Amended Credit Agreement, the Company will use the secured overnight financing rate or the Company and the Agent will agree to an alternative rate of interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated total net leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter, provided that for any fiscal quarter during which the Company or certain subsidiaries consummate a permitted acquisition or investment, the aggregate purchase price is greater than $75.0 million, the maximum consolidated total net leverage ratio may temporarily increase by 0.25 to 1.00 to 4.00 to 1.00. The Company must maintain a minimum consolidated interest coverage ratio of not less than 3.25 to 1.00 as of the last day of each fiscal quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the lenders under the Amended Credit Agreement a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, certain of the lenders under the Amended Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking, cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Real Estate Loans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company purchased 100% of MPP, AMG Properties, and ZLL. As a result of the purchase, the Company assumed $6.4 million, $0.7 million, and $0.7 million of existing loans held by MPP, AMG Properties, and ZLL, respectively, on the day of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MPP&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, MPP entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $6.1 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying MPP. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. MPP must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AMG Properties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, AMG Properties entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $0.7 million with a variable interest rate of 0.30% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. AMG Properties must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ZLL&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, ZLL entered into a loan agreement with East West Bank with a maturity date of August 5, 2030. As of December&#160;31, 2021, the principal on the loan is $0.6 million with a variable interest rate of 0.50% less than the independent index, which is the daily Wall Street Journal &#x201c;Prime Rate.&#x201d; If the index is not available, East West Bank may designate a substitute index after notifying AMG Properties. Monthly payments on the principal and any accrued interest rate not yet paid began in September 2020. ZLL must maintain a Debt Coverage Ratio (defined as net operating income divided by current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Construction Loan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, Tag 8 entered into a construction loan agreement with MUFG Union Bank N.A. (&#x201c;Construction Loan&#x201d;). Tag 8 is a VIE consolidated by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Construction Loan allows Tag 8 to borrow up to $10.7&#160;million with a maturity date of December 1, 2022 (&#x201c;Construction Loan Term&#x201d;). Interest rate is equal to an index rate determined by the bank. Monthly interest payments began on May 1, 2021, or can become part of the principal and bear interest. If construction is completed and, there are no events of default or substantial deterioration in the financial condition of Tag 8 or APC, guarantor on the loan agreement, at the maturity date of the Construction Loan Term, the loan shall convert to an amortizing loan with an extended maturity date of December 1, 2032 (&#x201c;Permanent Loan Term&#x201d;). Upon conversion to the Permanent Loan Term, monthly principal and interest payments shall be made beginning January 1, 2023. From January 1, 2023 until December 1, 2023, the interest rate will be 2.0% per annum in excess of the LIBOR rate. As of December&#160;31, 2021, the likelihood of the construction being completed by the maturity date is remote. The outstanding balance as of December&#160;31, 2021 was $0.6 million and was recorded as current portion of long-term debt in the accompanying consolidated balance sheets. Once the loan converts to the Permanent Loan Term, APC, as Tag 8&#x2019;s guarantor, must maintain a Cash Flow Coverage Ratio (defined as consolidated EBITDA minus unfinanced capital expenditures and distributions paid divided by the sum of current portion of long-term debt, plus interest expense) of not less than 1.25 to 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. In June 2021, the Company recorded additional deferred financing costs of $0.7 million related to its entry into the Amended Credit Facility.  Deferred financing costs are recorded as a direct reduction of the carrying amount of the related debt liability using straight-line amortization. The remaining unamortized deferred financing costs related Credit Facility and the costs related to the Amended Credit Facility are amortized over the life of the Amended Credit Facility.  As of December&#160;31, 2021 and 2020, unamortized deferred financing costs were $4.3 million and $4.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s average effective interest rate on its total debt during the years ended December&#160;31, 2021, 2020, and 2019 was 2.06%, 3.48%, and 3.39%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the years ended December&#160;31, 2021, 2020, and 2019 of $1.2 million, $1.4 million, and $0.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, APC amended its promissory note agreement with Preferred Bank (&#x201c;APC Business Loan Agreement&#x201d;), which is affiliated with one of the Company&#x2019;s board members, to modify loan availability to $4.1 million. This further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019 securing APC&#x2019;s obligations to NMM under, and as required pursuant to, that certain Management Services Agreement dated as of July 1, 1999, as amended.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO established an irrevocable standby letter of credit with Preferred Bank, which is affiliated with one of the Company&#x2019;s board members, totaling $14.8&#160;million for the benefit of CMS. In September 2019, these letters were terminated with Preferred Bank and reissued under the Credit Agreement. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS. As of December&#160;31, 2021, there were no outstanding letters of credit and the Company had $25.0 million available under the Amended Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4ODA5_c838e21c-035f-479c-bf1a-4b20e306fcf9">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s debt balance consists of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.315%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term loan&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real estate loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction loan &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: unamortized financing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Long-term debt &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1ec0825cadd340a0b4abec77e08752ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzItMS0xLTEtMA_7bcdc06c-2a41-40bf-a443-67714d87d18d"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1018ea938faa4df890ec9e0a02e9cd39_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzItMy0xLTEtMA_e7247fa8-4135-4022-bfaf-0d355dd96b86"
      unitRef="usd">178125000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i805098d929664b258e9e02430e3446f0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzMtMS0xLTEtMA_b7caa316-a062-4309-a20c-be56f3061815"
      unitRef="usd">180000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id2087645dd294b50b435fd15e8f370f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzMtMy0xLTEtMA_23366b77-8aec-43c1-a4fa-c97cd3f1e2e4"
      unitRef="usd">60000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i79361bf90da942189dd476704c690d21_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzQtMS0xLTEtMA_80015cbf-b99c-44cf-877e-af3b3d525c52"
      unitRef="usd">7396000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6eba764439774dedac07edaac463b53b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzQtMy0xLTEtMA_eb1c3e88-c5d1-445c-8239-b0d4d0471f99"
      unitRef="usd">7580000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ife653c4fcbb243abb96d4ba2a5ef5c68_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMS0xLTEtMzk0MjU_3d2d0cda-076a-46e9-b48d-0cd148700554"
      unitRef="usd">569000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia9caf120fa2d4bb9a623a159c3d8cb6b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMy0xLTEtMzk0MDI_47d8b03c-e3c5-4dfc-968a-a1ef251bfc94"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMS0xLTEtMA_7b4bd3c1-2e69-4e00-8a87-0f6202d2a5f7"
      unitRef="usd">187965000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzUtMy0xLTEtMA_e08adbf0-dc6c-49f7-b889-db5b313c404f"
      unitRef="usd">245705000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzctMS0xLTEtMA_55ed9ed1-1cc4-47ab-b96d-0aa5357fe78f"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzctMy0xLTEtMA_95fe82a2-7487-41ed-b3e6-865692bf2179"
      unitRef="usd">10889000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzgtMS0xLTEtMA_03c459b5-7753-42e4-bc62-0d6a0aa5fc19"
      unitRef="usd">4268000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzgtMy0xLTEtMA_0aaf8b44-4568-48d4-b84b-5d70df56a608"
      unitRef="usd">4605000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzEwLTEtMS0xLTA_e42025c3-d993-4798-bc40-e4accc22838e"
      unitRef="usd">182917000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTpiODFjZjIwYTFiNDA0Yzc1YTM4YjdhOWVjZTI4Y2M0Yy90YWJsZXJhbmdlOmI4MWNmMjBhMWI0MDRjNzVhMzhiN2E5ZWNlMjhjYzRjXzEwLTMtMS0xLTA_16f8273d-2f42-4614-9569-5abc9a4b9421"
      unitRef="usd">230211000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4NzAy_315468d3-9d10-40bc-a305-a637f5ba8371">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s debt for the years ending December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.181%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzEtMS0xLTEtMA_7a9f9d1e-9103-44ed-90f3-a805af11dddf"
      unitRef="usd">780000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzItMS0xLTEtMA_a1b96c38-fc3c-4a8e-8b2b-e8035c14095a"
      unitRef="usd">215000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzMtMS0xLTEtMA_156b9b04-f79e-45da-b72b-280925ff5033"
      unitRef="usd">222000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzQtMS0xLTEtMA_d4c6bc28-c710-4364-9d45-cb58533efd19"
      unitRef="usd">6748000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <ameh:LongTermDebtMaturityAfterYearFour
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzUtMS0xLTEtMA_9511bf16-efce-4a67-9315-716a946c7fdc"
      unitRef="usd">180000000</ameh:LongTermDebtMaturityAfterYearFour>
    <us-gaap:LineOfCredit
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90YWJsZTowYzM4M2NjNGM0NGE0ZWMwOGQ0OTFlNDZiYThjNTQ0OS90YWJsZXJhbmdlOjBjMzgzY2M0YzQ0YTRlYzA4ZDQ5MWU0NmJhOGM1NDQ5XzctMS0xLTEtMA_1143fda7-eb85-4587-84ac-fe6c6a87c049"
      unitRef="usd">187965000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="iae23f71d35ba49afac259c7ec4de8fd2_D20210616-20210616"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI2Mzg4Mjc5MTc4MTEx_bce93083-241b-4039-a3f4-925b086798ac">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ief487b48631e4a36972039b3bafdc0c5_I20210616"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI3NDg3NzkxNTcyNTI_88d31634-c6cc-486b-87c4-f7f89336de7f"
      unitRef="usd">400000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i00679cfa5a534ce9a92bdb137b52ec50_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI3NDg3NzkxNTcyNzI_5b2ab0cc-db7d-492a-941d-fd17b842eeb7"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ie551eb427ed34af7aa4c793742c0e19a_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzI3NDg3NzkxNTcyOTI_c8ab868b-d8d0-420f-8072-3c8ec04349ae"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="i0a6bb0cac4404e838f3cb21cb1f78f8a_D20210616-20210616"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0NDk_0e960bbb-9b68-40e1-aee2-3714b548adef"
      unitRef="usd">50000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i87ee29c5cb344aa98db576466c4bfb91_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0MTY_96d9718b-8a20-457f-9eae-585141293241"
      unitRef="number">0.00175</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="id3d5ec03a2b04b30a66a4a30c5784f2b_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0MjQ_22f5017e-0469-40f0-8c9c-6032c4b2d846"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="idfb4fbfb2ec34149b57c0fb417d25c41_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0MzI_4a75c0d6-3aba-40c2-b977-9de29edba3c8"
      unitRef="number">0.0125</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ibf89debf8d114314b44b8b7514c5ed0e_D20210616-20210616"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODM0Mzk_9e09fc7d-a978-44d1-abff-94fd63b0ae7d"
      unitRef="number">0.0250</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i4b9c42d5297743dda47552322302b667_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4MTI_d1bc5745-c61d-4db1-9aa7-e1357dd07d26"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6900356a9b954339b957ad128fe7fb9e_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4MTk_6eb8bbd4-a32f-46c3-8cb8-24f401848ff1"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i87ee29c5cb344aa98db576466c4bfb91_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4Mjc_0d46bd89-34f5-4d5a-8793-dbf2398214d4"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="id3d5ec03a2b04b30a66a4a30c5784f2b_D20210616-20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODY4MzQ_0816d05e-597f-444a-abf3-38fd43c1ba55"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i5ac4990f656442ea8b9d9d247491dc90_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2ODUxNTk_f7378fde-4b85-4f6f-b70e-f209befbb634"
      unitRef="number">0.0171</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <ameh:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwNDQ_472497d5-6a96-4375-9bc3-e212cc263ddc"
      unitRef="financial_ratio">2</ameh:DebtInstrumentNumberOfKeyFinancialRatios>
    <ameh:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2MDQ_7075e6d3-ba1d-4668-a15f-7447f9a5dc11"
      unitRef="number">3.75</ameh:DebtInstrumentCovenantLeverageRatioMaximum>
    <ameh:DebtCovenantAggregatePurchasePriceMaximum
      contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2Mjg_334b04bf-b378-478b-95ab-52ffea7f684a"
      unitRef="usd">75000000</ameh:DebtCovenantAggregatePurchasePriceMaximum>
    <ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange
      contextRef="i4c7dc17bcbe04fb4904d893562ad225d_I20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2NDQ_18cf4965-457b-43ed-9ba4-bcb31c515286"
      unitRef="number">0.25</ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange>
    <ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum
      contextRef="i42f3a03d8ac94ab9a73b30a6748eb246_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2NTA_f6cdec4b-3fa4-4939-b814-59a45ab3375c"
      unitRef="number">4.00</ameh:DebtInstrumentCovenantLeverageRatioAdjustedMaximum>
    <ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2OTk2MTg_b3570f22-ec9e-4993-bd20-907638ed5b02"
      unitRef="number">3.25</ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i1e78513b2a054c24a539e76d8c9ed784_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzExNzcy_7cc85422-e161-4dc1-8a11-1a8064a97511"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="i61742fc5636f4d02a62b8ec226f2b8a3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzExNzcy_d0a54315-9028-46e1-94a4-0842efb35f3b"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <ameh:AssetAcquisitionPercentageOfSharesAcquired
      contextRef="ib09048f44b5646e98a8d38401a6e9317_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzExNzcy_dc849d56-f132-42c5-b724-4b41d0db1351"
      unitRef="number">1</ameh:AssetAcquisitionPercentageOfSharesAcquired>
    <us-gaap:LiabilitiesAssumed1
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzQzOTgwNDY1OTM0MzI_40851bae-daa7-4e70-8bfc-5cad28554d37"
      unitRef="usd">6400000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzQzOTgwNDY1OTM0NjI_21753228-15fd-4a69-a454-e7cf750cf738"
      unitRef="usd">700000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzQzOTgwNDY1OTM0NDc_6cd29518-94a7-4c2c-8c44-1d63384dfe5d"
      unitRef="usd">700000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iabfdc0514ad04c73ab76b77f6739e8e4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjA2MzI_9e23406e-dcc3-4e9a-b4aa-bab67007d64e"
      unitRef="usd">6100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i447604f483784ad082efe8790195e57c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEyMTI0_b8120e70-e7ef-48cd-a472-9d43f8907358"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i8d459770fc824dfd85b90f08dcfec692_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEyNTcy_0fba27fb-ed18-4941-b496-b847d181b35a"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if9b39ded9aa144fe959c2e5f7e0cdc81_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjA2NDA_6ae64aa4-7abb-4f18-85b4-f31ca70b98f2"
      unitRef="usd">700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i031524a8f2864901a900ba1a85eaecbf_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEyNzk5_fc84d4e0-e0d4-483e-aa4c-387744a97a7c"
      unitRef="number">-0.0030</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i6b9e264b58ec4372891355322134a590_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEzMjY5_978c3841-61ad-4001-8757-f4137729a7d0"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie560514b2ee1454a9f9e0ab9ae48bb1e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjA2MzY_2cbe2272-7790-474e-8138-30eec44d489c"
      unitRef="usd">600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i86ab3861fcda413d815e58a991ea9bf7_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEzNDg0_859ed44b-9313-4b06-a507-bf2320280009"
      unitRef="number">-0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum
      contextRef="i92cd58fb0c7d4588b4469022555c03b1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEzOTQz_a1e172d7-6d3b-471d-b8cb-6bf6a6c33730"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantDebtCoverageRatioMinimum>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9bd4ffb9558045b08ca6250bddb77123_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwNDg_3ea4325b-356f-4327-af2a-f87744211e9c"
      unitRef="usd">10700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7511f70c51f546fab2df45ef49ea60d1_D20230101-20231201"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwNjM_11e01621-8e0c-46c4-b1a5-aa6910874cd7"
      unitRef="number">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LongTermDebtCurrent
      contextRef="ife653c4fcbb243abb96d4ba2a5ef5c68_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE3MDI3Njk_7aaf5169-2af4-494f-b88a-e0d542ae9625"
      unitRef="usd">600000</us-gaap:LongTermDebtCurrent>
    <ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum
      contextRef="i22b6c0d320cb4d01aef31c88d0405025_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzYwNDczMTQwMjcwODM_383a54ac-fd1b-4431-aa04-568d305c01f4"
      unitRef="number">1.25</ameh:DebtInstrumentCovenantCashFlowCoverageRatioMinimum>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i4df55a8afb084316ae481f2b066f353f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjM3ODU_419affc3-91fe-4b4e-b0e4-a9168893634e"
      unitRef="usd">6500000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="ib42cdd50cdf8449ea72386bfca57f57e_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjM5MTE_1bcb2dc5-7ac8-45b3-a059-0c5361ea48c9"
      unitRef="usd">700000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i53c301d60fb84feb86e40458baac030a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQzNjY_fba73297-453a-4602-a668-043e1fa62606"
      unitRef="usd">4300000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i7f03a46a00b3442fa2d6f0b063116153_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQzNzQ_8fa9a6af-5116-460e-99fe-11c29a89f368"
      unitRef="usd">4600000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ1Mjg_22fc3c6b-0e8c-4460-b579-05fa19d94754"
      unitRef="number">0.0206</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i7d5181abc61c4949b5e2bb84d79457b5_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ1MzM_63a15327-897e-4bd9-8780-b9aca970487f"
      unitRef="number">0.0348</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="ia61a2888862d4451867b421f57199890_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ1NDI_390fd46d-a1e5-45fd-afeb-e5e1e989335b"
      unitRef="number">0.0339</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="i22c976f65ce9442e9368b7c4c91bdfb4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ3MTQ_7c8041d1-0025-4176-adda-56192e48d181"
      unitRef="usd">1200000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7d5181abc61c4949b5e2bb84d79457b5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ3MTk_97e3adf9-8203-4494-9422-32d33c7c04e8"
      unitRef="usd">1400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia61a2888862d4451867b421f57199890_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE2NjQ3Mjg_2e79c0c7-a902-4b34-9086-53035fcc22fe"
      unitRef="usd">500000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1dbe830985b3456088798fdc58aa9daf_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE2MDQw_929d13a9-9e81-4ce6-b34f-ef5ab78da242"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i92adc7af35ce442586e7f832696d8083_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3MjM3_a607c56e-4c80-4b2d-be56-00a778f7d8e0"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i718ff6d9aae440bfbe2ebdfa0389b7f9_I20200731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3NzM3_4eba0672-ecfd-4864-a338-56b6e9a586df"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i92adc7af35ce442586e7f832696d8083_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3ODEw_019b1969-0c59-4caf-98e4-46aecc8480aa"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i00679cfa5a534ce9a92bdb137b52ec50_I20210616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzEwOTk1MTE3MDgzNzM_5b2ab0cc-db7d-492a-941d-fd17b842eeb7"
      unitRef="usd">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if827ee4c779a4b57ab9eeeb719e06b2a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE3OTYz_ab2ce96d-8399-409d-b73a-ee63231405c7"
      unitRef="usd">300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i7f6447a0def84811a339a66cb7ac0e7e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4Nzg0_c9be7d7f-10d6-4b9f-b44b-952a3989ec1a">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i87791bdb507743179b1b6187068193d1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4NDAw_40043666-454c-4927-ac65-542a89614f3b"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i0a226f12905c46efbbd050421af8eea6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjMvZnJhZzpiMmQ3NjQ5MTM0ZDU0MTZiOTJjYmE3YjM4NmMyYzNkZC90ZXh0cmVnaW9uOmIyZDc2NDkxMzRkNTQxNmI5MmNiYTdiMzg2YzJjM2RkXzE4ODMw_30ac672b-45dc-4928-ba83-2c605f185f3b">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjM_0f6e0f49-e74a-4482-b12b-71558c1ea3f5">Income Taxes&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates. As of December&#160;31, 2021, the Company had federal and California net operating loss carryforwards of approximately $97.9 million and $120.8 million, respectively. The federal and California net operating loss carryforwards will expire at various dates from 2027 through 2040; however, $77.7 million of the federal operating loss do not expire and can be carried forward indefinitely. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company&#x2019;s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three years&#x2019; period since the last ownership change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets (liabilities) as of December&#160;31, 2021 and 2020 are shown below (in thousands). A valuation allowance of $22.4 million and $15.5 million as of December&#160;31, 2021 and 2020, respectively, has been established against the Company&#x2019;s deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $6.8 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for bad debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in other entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481(a) adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision at U.S. federal statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable interest entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment basis adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective tax rate is different from the federal statutory rate of 21% due primarily to state taxes, change in valuation allowance, and permanent adjustments. On March 27, 2020, the Coronavirus Aid, Relief and Economic Security (&#x201c;CARES&#x201d;) Act was enacted and signed into law. The CARES Act, among other things, permits net operating loss carryovers and carrybacks and modifications on the limitation of business interests.  As of December&#160;31, 2021, the Company does not expect the CARES Act to result in any material impact on the Company&#x2019;s effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021 and 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;The Company is subject to U.S. federal income tax, as well as income tax in California. The Company and its subsidiaries&#x2019; state&#160;and federal income tax returns are open to audit under the statute of limitations for the years ended December&#160;31, 2017 through December&#160;31, 2020 and for the years ended December&#160;31, 2018 through December&#160;31, 2020, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjQ_f4357106-4639-4a43-9a7b-0af4876abd9d">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provision for income taxes consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.184%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,952)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,620)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzMtMS0xLTEtMA_6abc794c-4f4a-45ef-8f93-9c8f71fbb8f7"
      unitRef="usd">22801000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzMtMy0xLTEtMA_36217449-3f08-44e5-b028-a6c95d6bb533"
      unitRef="usd">43572000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzMtNS0xLTEtMA_a3908c2c-ff4d-4ded-a2db-331ac0829e19"
      unitRef="usd">9035000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzQtMS0xLTEtMA_5ce6adcb-d984-4d4d-8c94-96369bac5a5a"
      unitRef="usd">11605000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzQtMy0xLTEtMA_cce94d04-8ebc-4c5a-9a48-64a91ea87893"
      unitRef="usd">19155000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzQtNS0xLTEtMA_a25a7360-ab35-4529-b9fe-21a676b42a12"
      unitRef="usd">5925000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzUtMS0xLTEtMA_1266cd5d-1e3d-4b93-a0cf-f6a03e0d2c74"
      unitRef="usd">34406000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzUtMy0xLTEtMA_25e3a624-046e-4dca-bb96-63334a376881"
      unitRef="usd">62727000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzUtNS0xLTEtMA_3aebe2a0-9af3-4b5c-b147-cb0e80737900"
      unitRef="usd">14960000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzgtMS0xLTEtMA_a92b92e7-a322-40d4-b83f-7cb45a619bc8"
      unitRef="usd">-3794000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzgtMy0xLTEtMA_bc2f85ee-056e-4751-a5b0-8147c3a75cee"
      unitRef="usd">-4963000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzgtNS0xLTEtMA_09f94f90-7d00-434a-9926-5a6b63e390e0"
      unitRef="usd">-3508000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzktMS0xLTEtMA_6d861a1a-9c19-4bee-aa5a-5b360aea1835"
      unitRef="usd">-2158000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzktMy0xLTEtMA_6f4fde12-93ba-4bb1-af81-1afef10f897b"
      unitRef="usd">-1657000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzktNS0xLTEtMA_97ef0c29-08e2-4fee-98b0-d9569a77bc8e"
      unitRef="usd">-3285000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEwLTEtMS0xLTA_9adf337b-7ea3-4709-bc65-d7c1adc83fdb"
      unitRef="usd">-5952000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEwLTMtMS0xLTA_0eeadb54-dcf3-4be7-8b24-d08741a0e058"
      unitRef="usd">-6620000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEwLTUtMS0xLTA_77eb39f5-22bb-4512-b0c2-b9fadc89040b"
      unitRef="usd">-6793000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEyLTEtMS0xLTA_8420e38a-d00c-4a0e-be18-0bf753295c76"
      unitRef="usd">28454000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEyLTMtMS0xLTA_e75e547c-a55b-4b89-b3a6-57a4354e5766"
      unitRef="usd">56107000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTphNGMzOTVmOWE2NjA0ZmU0YmJlYThmYjRkYzE2M2ZjZS90YWJsZXJhbmdlOmE0YzM5NWY5YTY2MDRmZTRiYmVhOGZiNGRjMTYzZmNlXzEyLTUtMS0xLTA_5e0c4d17-e0e8-4965-b76b-0b6ee0179a2d"
      unitRef="usd">8167000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i87bcea25b6704ede86f7f3a191ef629d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzQ2NQ_91adb713-f687-40d3-b31a-5248e9e34749"
      unitRef="usd">97900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="icdc79f5d00754b61ab7e3baaf585df20_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzQ3Mg_a34d2694-d38c-49e6-9cd0-8b2eceb85d33"
      unitRef="usd">120800000</us-gaap:OperatingLossCarryforwards>
    <ameh:OperatingLossCarryforwardsExpirationPeriod
      contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzU4NA_df79133d-e965-4571-92d0-a2b812181303">2027</ameh:OperatingLossCarryforwardsExpirationPeriod>
    <ameh:OperatingLossCarryforwardsExpirationPeriod
      contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzU5NQ_0e246985-664d-4d51-a439-62fafab7c0bf">2040</ameh:OperatingLossCarryforwardsExpirationPeriod>
    <ameh:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i87bcea25b6704ede86f7f3a191ef629d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzYwOA_7ad8a54e-987d-404b-a2f0-94c2bb17587c"
      unitRef="usd">77700000</ameh:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjU_8dfb6f7a-41b4-4402-b93d-265fd097deb3">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets (liabilities) as of December&#160;31, 2021 and 2020 are shown below (in thousands). A valuation allowance of $22.4 million and $15.5 million as of December&#160;31, 2021 and 2020, respectively, has been established against the Company&#x2019;s deferred tax assets related to loss entities the Company cannot consolidate under the federal consolidation rules, as realization of these assets is uncertain. Valuation allowance increased by $6.8 million in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Allowance for bad debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in other entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized Gain &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,763)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,888)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481(a) adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(985)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,127)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzExMDc_81cd0083-a45f-468b-a6bd-41113bd70fe3"
      unitRef="usd">22400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzExMTQ_878dc2f9-6fa2-41d7-97c1-5edd28cbe168"
      unitRef="usd">15500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzEwOTk1MTE2MzA1MTU_64d0dcd6-08e5-479b-896d-cba244ba68df"
      unitRef="usd">6800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzItMS0xLTEtMA_ec9633a2-d9cf-465c-acb5-051b979d54ff"
      unitRef="usd">2379000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzItMy0xLTEtMA_d6564b1d-8cb1-427d-b867-5412741b3e33"
      unitRef="usd">3932000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzMtMS0xLTEtMA_1e4575b5-38f2-4833-bba0-0a3797ac6e07"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzMtMy0xLTEtMA_1293660d-14b7-4ca5-a743-e2f79ae7fab7"
      unitRef="usd">461000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzQtMS0xLTEtMA_44b9ff01-144a-4e6b-84f5-31c043ec7bfe"
      unitRef="usd">1864000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzQtMy0xLTEtMA_0d4b6561-ed0d-43a5-9e1c-4b2aa461ed28"
      unitRef="usd">3905000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzUtMS0xLTEtMA_432b8c27-841e-49f9-8286-2fe0dcfe272b"
      unitRef="usd">153000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzUtMy0xLTEtMA_45704d2e-c132-4fed-a556-187e7054645b"
      unitRef="usd">351000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <ameh:DeferredTaxAssetsInvestment
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzYtMS0xLTEtMA_e7632a4e-00dd-4f09-8fbc-983ba676ce1d"
      unitRef="usd">3289000</ameh:DeferredTaxAssetsInvestment>
    <ameh:DeferredTaxAssetsInvestment
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzYtMy0xLTEtMA_dca62591-8e21-443a-a8fb-9290bdddc375"
      unitRef="usd">702000</ameh:DeferredTaxAssetsInvestment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzctMS0xLTEtMA_7789a718-dbad-4fb5-9569-2f60bf212e06"
      unitRef="usd">28992000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzctMy0xLTEtMA_ba3f8264-420d-4b26-b8c0-34c9038949c7"
      unitRef="usd">20758000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <ameh:DeferredTaxAssetsLeaseLiability
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMS0xLTEtNjE4MjU_4356378c-8e51-4d0d-9778-7550e02aa895"
      unitRef="usd">4208000</ameh:DeferredTaxAssetsLeaseLiability>
    <ameh:DeferredTaxAssetsLeaseLiability
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMy0xLTEtNjE4MjU_b7445d1f-aaa0-463c-9828-c3b4d0f44ad6"
      unitRef="usd">4979000</ameh:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMS0xLTEtNjE1NDk_8c35e0d9-f887-4109-8959-6d88e36a6e77"
      unitRef="usd">3007000</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>
    <us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzgtMy0xLTEtNjE1NTg_cc753911-ac35-49c1-83ff-fc1bf7012a9f"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsUnrealizedLossesOnTradingSecurities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzktMS0xLTEtMA_442746d7-591b-4a63-9b9f-a3e7ebfa75d5"
      unitRef="usd">705000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzktMy0xLTEtMA_d2e42df3-6dc2-43f2-963d-64dda1fb79f3"
      unitRef="usd">665000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEwLTEtMS0xLTA_f6664662-2d6d-4bdc-8bc4-bd9ace3df6ad"
      unitRef="usd">44597000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEwLTMtMS0xLTA_eabc9534-e39f-4695-9014-e36e20062334"
      unitRef="usd">35753000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzExLTEtMS0xLTA_4e52eca5-1b91-41ef-a681-092fcab2e3a3"
      unitRef="usd">22351000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzExLTMtMS0xLTA_00e3f12e-d1cc-4eb7-aa18-648c5bc3dd5d"
      unitRef="usd">15517000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEyLTEtMS0xLTA_8346165d-f4f6-419e-8db5-a21166011c5f"
      unitRef="usd">22246000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzEyLTMtMS0xLTA_5f056547-100a-4167-8c50-871ccfaee41e"
      unitRef="usd">20236000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE1LTEtMS0xLTA_7f869d9e-4862-45c0-a3d1-5cae03c6138e"
      unitRef="usd">777000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE1LTMtMS0xLTA_a9afc550-58b3-4a01-9d4a-c0e04d989ea4"
      unitRef="usd">661000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE2LTEtMS0xLTA_4f8c3625-7d1f-4630-a15f-c7fd634c4768"
      unitRef="usd">23763000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE2LTMtMS0xLTA_fb580bbe-af92-43bd-a000-e623aac84860"
      unitRef="usd">24661000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ameh:DeferredTaxLiabilitiesStockOptions
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTEtMS0xLTYxNTc1_6a86b0f0-7db4-418c-aaf0-4296d6deb6eb"
      unitRef="usd">1641000</ameh:DeferredTaxLiabilitiesStockOptions>
    <ameh:DeferredTaxLiabilitiesStockOptions
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTMtMS0xLTYxNTc5_74de4634-488a-454c-a4dd-865efa00732c"
      unitRef="usd">0</ameh:DeferredTaxLiabilitiesStockOptions>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE3LTEtMS0xLTA_8f746060-75eb-40fb-8e33-712cdee9e6ec"
      unitRef="usd">4117000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE3LTMtMS0xLTA_8127722e-bca7-4dce-b88f-8dacbe2ee92c"
      unitRef="usd">4888000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTEtMS0xLTY0NjM0_6f75f34d-7154-4d09-b1d0-2f95e763a7da"
      unitRef="usd">988000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTMtMS0xLTY0NjQx_7175135a-a2be-4d0f-8cf4-f2560f489fa7"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts>
    <ameh:DeferredTaxLiabilities481aAdjustment
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTEtMS0xLTA_d32f3cf9-ff1b-432b-8eb4-cb1213942b7c"
      unitRef="usd">87000</ameh:DeferredTaxLiabilities481aAdjustment>
    <ameh:DeferredTaxLiabilities481aAdjustment
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzE4LTMtMS0xLTA_337973a2-3b2e-450a-8184-036450995843"
      unitRef="usd">985000</ameh:DeferredTaxLiabilities481aAdjustment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTEtMS0xLTA_31a425a0-6b66-40f7-8d7f-d859b98d7c04"
      unitRef="usd">31373000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIwLTMtMS0xLTA_8caefb56-f8a3-43d6-965e-ab61c3ebae8c"
      unitRef="usd">31195000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIyLTEtMS0xLTA_77d92a11-b0b4-44b7-a71d-949b27a669ec"
      unitRef="usd">9127000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZToxNmQzMjM4NGQyZjc0MmM2OWIwOGExN2ZlNDZiOWNjZS90YWJsZXJhbmdlOjE2ZDMyMzg0ZDJmNzQyYzY5YjA4YTE3ZmU0NmI5Y2NlXzIyLTMtMS0xLTA_798a09d0-c6b3-44cd-89a4-eefb75cabf65"
      unitRef="usd">10959000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzI3MjI_86c684ef-0935-44e3-bd61-fabce78b1f3d">The provision for income taxes differs from the amount computed by applying the federal income tax rate as follows for the years ended December&#160;31:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax provision at U.S. federal statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable interest entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment basis adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzMtMS0xLTEtMA_3dc1dea3-1ef9-4ab3-b00d-a09b17a5068e"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzMtMy0xLTEtMA_fd14e995-81fc-4290-b7f9-4ed0ea6283af"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzMtNS0xLTEtMA_c2b6b610-e581-4a73-b24a-f4bde0bc6001"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzQtMS0xLTEtMA_6b71ec27-447a-4e02-bad4-59b2af3206ca"
      unitRef="number">0.078</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzQtMy0xLTEtMA_dbe757e0-7219-48dc-a8e2-64db0bcddce8"
      unitRef="number">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzQtNS0xLTEtMA_21d19fd7-ad31-4589-b1da-8b5ea2bace54"
      unitRef="number">0.081</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzUtMS0xLTEtMA_f2ab874c-d821-4e23-bf0f-6547efa2bc67"
      unitRef="number">0.037</ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment>
    <ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzUtMy0xLTEtMA_c925b342-e01f-4bce-ba90-513cc104e1bb"
      unitRef="number">0.003</ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment>
    <ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzUtNS0xLTEtMA_05c7daaa-16d3-426a-8bcc-2be83566ef27"
      unitRef="number">0.033</ameh:EffectiveIncomeTaxRateReconciliationFederalRateAdjustment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzYtMS0xLTEtMA_84946b73-4e5e-491c-abfc-d6c1a3810481"
      unitRef="number">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzYtMy0xLTEtMA_58dfa5c1-7d74-49b4-8a77-50d03b3e5986"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzYtNS0xLTEtMA_9e707250-7d46-44b3-8488-8d0081f15f82"
      unitRef="number">-0.027</us-gaap:EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzctMS0xLTEtMA_b7f4185c-c73b-4b83-8d3c-f25b38994455"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzctMy0xLTEtMA_5626f2e6-5f8b-4bd9-86b3-043a85a87b79"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzctNS0xLTEtMA_cb81403f-d0c9-48c4-b0b0-76864b8f5f89"
      unitRef="number">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzgtMS0xLTEtMA_9fde4756-337f-4191-8cf6-1436165f0bd9"
      unitRef="number">0.089</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzgtMy0xLTEtMA_abf47d1a-4c57-4204-aa5a-871978112141"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzgtNS0xLTEtMA_a503a658-4a9b-4034-a27d-4fb01cd88800"
      unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMS0xLTEtNjgwOTY_28afcf5c-d9eb-471f-acf1-7decbd4c1fb7"
      unitRef="number">-0.021</ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent>
    <ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMy0xLTEtNjgxMDM_c626a244-6f5e-4824-9a0e-eb5f4a2adac4"
      unitRef="number">0</ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent>
    <ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktNS0xLTEtNjgxMTA_7e89138a-779a-40a1-bba8-e55352a50c35"
      unitRef="number">0</ameh:EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMS0xLTEtMA_596626dd-3c55-422f-8231-80dbede29deb"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktMy0xLTEtMA_4bdc093b-9aab-424b-8b29-c8be5963572d"
      unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzktNS0xLTEtMA_938e1009-7484-4443-8943-d79ecf8f5110"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzExLTEtMS0xLTA_ffe1f62f-fce1-4325-a893-985af7e4f8e6"
      unitRef="number">0.369</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzExLTMtMS0xLTA_e4399dd3-9f01-49df-b4ac-2c7f0ef6a834"
      unitRef="number">0.313</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90YWJsZTo4ZmEyNGYyZjQ1M2M0MzU4ODk3NTE1NjQxMjM3Y2Q3Yy90YWJsZXJhbmdlOjhmYTI0ZjJmNDUzYzQzNTg4OTc1MTU2NDEyMzdjZDdjXzExLTUtMS0xLTA_83027a0a-16ce-4775-bebb-08c30591dda3"
      unitRef="number">0.316</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNjkvZnJhZzoxYmUyZDc3MWNkMmY0YTA5OTNhMTU0YThiNzQyYzkxNS90ZXh0cmVnaW9uOjFiZTJkNzcxY2QyZjRhMDk5M2ExNTRhOGI3NDJjOTE1XzE2MjI_d21f3a2f-175c-4edc-a6b2-0db7f7c1a409"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzgwNDk_5255caef-4ad0-4eac-9f5b-23f933e7235f">Mezzanine and Stockholders&#x2019; Equity&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;APC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the redemption feature (see Note 2 &#x2014; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies&#x201d;) of APC&#x2019;s shares of common stock is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as non-controlling interests in mezzanine or temporary equity. APC&#x2019;s shares were not redeemable and it was not probable that the shares would become redeemable as of December&#160;31, 2021, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. This investment was eliminated in consolidation. In relation to the issuance of APC Series A Preferred Stock, APC incurred $0.9 million in cost (see Note 1 &#x2014; &#x201c;Description of Business&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock &#x2013; Series A&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2015, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 1,111,111 units, each unit consisting of one share of ApolloMed&#x2019;s Series A Preferred Stock and a common stock warrant to purchase one share of ApolloMed&#x2019;s common stock at an exercise price of $9.00 per share. NMM paid ApolloMed an aggregate of $10.0 million for the units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock &#x2013; Series B&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, ApolloMed entered into an agreement with NMM pursuant to which ApolloMed sold to NMM, and NMM purchased from ApolloMed, in a private offering of securities, 555,555 units, each unit consisting of one share of ApolloMed&#x2019;s Series B Preferred Stock and a common stock warrant to purchase one share of ApolloMed&#x2019;s common stock at an exercise price of $10.00 per share. NMM paid ApolloMed an aggregate $5.0 million for the units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2017 Share Issuances and Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, ApolloMed completed its business combination with NMM following the satisfaction or waiver of the conditions set forth in the Merger Agreement, pursuant to which Merger Subsidiary merged with and into NMM, with NMM surviving as a wholly owned subsidiary of ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2017 Merger and as of the effective time of the 2017 Merger (the &#x201c;Effective Time&#x201d;):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;each issued and outstanding share of NMM common stock was converted into the right to receive such number of shares of common stock of ApolloMed that results in the former NMM shareholders who did not dissent from the 2017 Merger (&#x201c;former NMM Shareholders&#x201d;) having a right to receive an aggregate of 30,397,489 shares of common stock of ApolloMed, subject to the 10% holdback pursuant to the Merger Agreement;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;ApolloMed issued to former NMM Shareholders each former NMM Shareholder&#x2019;s pro rata portion of (i) warrants to purchase an aggregate of 850,000 shares of common stock of ApolloMed, exercisable at $11.00 per share, and (ii) warrants to purchase an aggregate of 900,000 shares of common stock of ApolloMed, exercisable at $10.00 per share; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt"&gt;ApolloMed held back an aggregate of 3,039,749 shares of common stock issuable to former NMM Shareholders, representing 10% of the total number of shares of ApolloMed common stock issuable to former NMM Shareholders, to secure indemnification rights of AMEH and its affiliates under the Merger Agreement (the &#x201c;Holdback Shares&#x201d;). The Holdback Shares were issued and outstanding as of December&#160;31, 2021. The first tranche of 1,519,805 shares were issued in December 2018 and the remaining 1,511,380 were issued in December 2019, net of shares repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares of common stock issuable to former NMM shareholders in the exchange were 25,675,630 (net of 10% holdback and Treasury Shares). The 10% holdback shares were released to all the former NMM shareholders based on their respective pro rata ownership interest in NMM at the Effective Time without regard to whether the former NMM shareholders are providing any services to the Company at the time of this distribution. This holdback accommodation was made as indemnification protection to the accounting acquiree (ApolloMed), and as such, is not considered compensatory. At the time when these holdback shares were issued to the former NMM shareholders, the Company recorded the stock issuance with a reduction to additional paid-in capital to properly reflect the shares outstanding.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon consummation of the 2017 Merger, the Company issued 520,081 shares of its common stock with a fair value of approximately $5.4 million from the conversion of a convertible promissory note issued by the Company in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, 140,954 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the 2017 Merger, as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the Merger Agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the 2017 Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the 2017 Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, NMM did not pay any dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, APC paid dividends of $29.9 million, $136.6 million and $60.0 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, CDSC paid distributions of $1.5 million, $2.1 million and $2.6 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC owned 10,925,702 shares of ApolloMed&#x2019;s common stock as of December&#160;31, 2021, and 12,323,164 shares of ApolloMed&#x2019;s common stock as of December&#160;31, 2020, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1 &#x2014; &#x201c;Description of Business&#x201d;).&lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board, of which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of December&#160;31, 2020, the brokerage account only held shares of ApolloMed, as such the brokerage account totaling $7.7 million was recorded as treasury shares. As of April 2021, the brokerage account has been closed.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ib7f59b7851384b0d91511c5a20b67577_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzY0NA_de9adf20-f6ec-4961-917c-07420deb572d"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib7f59b7851384b0d91511c5a20b67577_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxNw_58b06fa0-1b82-4b7b-a873-a93cf2a42a79"
      unitRef="usd">545000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8e116c4ba416435f84ab15341357ee49_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3Xzg2Nw_975348d8-51be-42b0-b90e-29568c522073"
      unitRef="usd">900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzExMTU_f51acdd4-cfcb-4a77-9a29-796e269e4b63"
      unitRef="shares">1111111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id187f254b8f044069cf6e62f7dd23492_I20151031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzEzMDA_76826167-68b2-44d1-bf66-1142418a2762"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzEzNDk_d8c3f4f6-60c3-4592-b0a1-a88c3a21657f"
      unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzE1NjY_6e88f9f3-e517-476b-9108-36431d0e232e"
      unitRef="shares">555555</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id8f27f189d204a99bb6fbd309638d302_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzE3NTE_a30ad749-c8ba-4448-9b6d-c8eb3239951b"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzE3OTc_912cd240-ffde-4bac-9ed8-ea5119700106"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic9bf49749cfa4149bfcc21376770c3d7_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI1NDE_7b516bf3-69e7-4275-a596-06fc15780db7"
      unitRef="shares">30397489</us-gaap:StockRepurchasedDuringPeriodShares>
    <ameh:NumberOfSharesHoldbackPercentage
      contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI1OTY_d6bc1d20-d2ab-4cdb-8236-fa8910e91c36"
      unitRef="number">0.10</ameh:NumberOfSharesHoldbackPercentage>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i736e3fec90114a5aa4409b6b2e10ee3d_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI3Nzc_d8f58ecc-c795-4825-9a80-bc02b14cf1b1"
      unitRef="shares">850000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i736e3fec90114a5aa4409b6b2e10ee3d_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI4MzI_e5b71eb9-4a18-49b5-a92e-d3c8d8ed1b86"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6be868f31ad04ccd92b62a8b53e31994_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI4OTI_3a5e29e9-f5b7-4b2d-b36f-83bff6aa7b5b"
      unitRef="shares">900000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6be868f31ad04ccd92b62a8b53e31994_I20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI5NDc_2f7c8ea1-0330-4eee-b855-1d409d8cda67"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:BusinessCombinationNumberOfSharesHeldBack
      contextRef="ic9bf49749cfa4149bfcc21376770c3d7_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzMwMDE_d49cceaf-1ac3-4248-bda4-54c371c3a141"
      unitRef="shares">3039749</ameh:BusinessCombinationNumberOfSharesHeldBack>
    <ameh:NumberOfSharesHoldbackPercentage
      contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzMwNzc_06019460-5a1b-4a0c-b12a-67e0874648bb"
      unitRef="number">0.10</ameh:NumberOfSharesHoldbackPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="idafaa881ac7c4f0ea1acfd5e7bac657c_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzMzNjQ_7c9701d7-e8b5-4f06-8fa9-066ded080c0b"
      unitRef="shares">1519805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id6c9410eee65468595d358150c9017de_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM0MjE_72777726-47c0-481c-b98b-19f0dc4d297f"
      unitRef="shares">1511380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharesIssued
      contextRef="i9926c974cf3347f388bb822becf71f99_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM1NjQ_acfd6cea-343b-4d0b-87df-cb35f9043599"
      unitRef="shares">25675630</us-gaap:SharesIssued>
    <ameh:NumberOfSharesHoldbackPercentage
      contextRef="i36c4f94c659e40378bce5560a8288c13_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM1NzU_da514a9c-3199-49e7-9082-9b6bc770c9a8"
      unitRef="number">0.10</ameh:NumberOfSharesHoldbackPercentage>
    <ameh:NumberOfSharesHoldbackPercentage
      contextRef="i36c4f94c659e40378bce5560a8288c13_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM2MTM_da514a9c-3199-49e7-9082-9b6bc770c9a8"
      unitRef="number">0.10</ameh:NumberOfSharesHoldbackPercentage>
    <ameh:StockIssuedDuringPeriodShareConversionOfNotes
      contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzQzMjE_1b7ce519-9db0-41fa-98d9-18dee0bd6987"
      unitRef="shares">520081</ameh:StockIssuedDuringPeriodShareConversionOfNotes>
    <ameh:StockIssuedDuringPeriodValueConversionOfNotes
      contextRef="i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzQzODY_e14be780-2372-420d-8288-11c3547697e8"
      unitRef="usd">5400000</ameh:StockIssuedDuringPeriodValueConversionOfNotes>
    <ameh:StockIssuedDuringPeriodSharesMerger
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzQ0OTY_9dbc1ca5-8847-4c56-b4de-e05a135b4970"
      unitRef="shares">140954</ameh:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i1eff2864c695401fb93686780342c192_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxMDY_c7c9fd67-944f-4075-9178-fa8117fd4daf"
      unitRef="usd">29900000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i601de355c37d4e38a5ea8fffe8e17e9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxMTA_0d04389c-1d55-4df8-b643-9d1c1dfb4137"
      unitRef="usd">136600000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i81990f1f745c424ca090209239fb9e19_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcxMTc_ce2893db-2794-458c-8aef-464ffc38cd1d"
      unitRef="usd">60000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i011724573aa749b2834cc036d67d7006_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzM4NDgyOTA3MDgwMTM_18828d0d-9563-4cd8-9c01-bb9102215f8f"
      unitRef="usd">1500000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i40fc578ddc114d17b7d8aa16f28a9b27_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcyMDQ_93b0103c-bd60-45a3-899d-f70fcdd7f5a3"
      unitRef="usd">2100000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="id5cc5d815cc04d21bef7fb998c409f3d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcyMTE_8f1d6521-a156-4e07-a198-a078489c1fdc"
      unitRef="usd">2600000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i163cc47f491d41b392adbb6959d8f774_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzcyNTQ_4a8f6990-b1b9-46ea-9cfc-5a1e95ca0f3d"
      unitRef="shares">10925702</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i04943825157d4043aa0fb2fe8723b079_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzczMDY_795d041e-fd78-4493-ad90-b3fcea98984b"
      unitRef="shares">12323164</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i4774888a4f484996ad1923628b04af51_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xNzUvZnJhZzo2MWJjNDViMjNkODE0OWE3OTk2MmVmOGMyNDMxMzNiNy90ZXh0cmVnaW9uOjYxYmM0NWIyM2Q4MTQ5YTc5OTYyZWY4YzI0MzEzM2I3XzI3NDg3NzkwNzg5NTY_1e947b9f-bd94-497a-9941-9514a9aaf4c5"
      unitRef="usd">7700000</us-gaap:TreasuryStockValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODg_cbafba91-4f4b-4d6d-b09f-a18fcc3b04cd">Stock-Based Compensation&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2017 Merger, the Company assumed ApolloMed&#x2019;s 2013 Equity Incentive Plan (the &#x201c;2013 Plan&#x201d;), pursuant to which 500,000 shares of the Company&#x2019;s common stock were reserved for issuance thereunder. The Company issues new shares to satisfy stock option and warrant exercises under the 2013 Plan. As of December&#160;31, 2021, there were no shares available for future grants under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the 2017 Merger, the Company assumed ApolloMed&#x2019;s 2015 Equity Incentive Plan (the &#x201c;2015 Plan&#x201d;), pursuant to which 1,500,000 shares of the Company&#x2019;s common stock were reserved for issuance thereunder. In addition, shares that are subject to outstanding grants under the Company&#x2019;s 2013 Plan, but that ordinarily would have been restored to such plans reserve due to award forfeitures and terminations, were rolled into and become available for awards under the 2015 Plan. The 2015 Plan provides for awards, including incentive stock options, non-qualified options, restricted common stock, and stock appreciation rights. The 2015 Plan was approved by ApolloMed&#x2019;s stockholders at ApolloMed&#x2019;s 2016 annual meeting of stockholders that was held in September 2016. As of December&#160;31, 2021, 2020, and 2019, there were approximately 1.7 million, 0.1 million and 0.5 million shares available for future grants under the 2015 Plan, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans in 2021, 2020, and 2019 and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APC stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized compensation expense related to total share-based payments outstanding as of December&#160;31, 2021 was $21.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, stock options were exercised for 40,000 and 0.1 million shares, respectively, of the Company&#x2019;s common stock, which resulted in proceeds of approximately $0.2 million and $0.3 million, respectively. The exercise price was $5.20 per share for the exercises during the year ended December&#160;31, 2021 and ranged from $2.10 to $5.00 per share for the exercises during the year ended December&#160;31, 2020. During the year ended December&#160;31, 2021, no stock options were exercised pursuant the cashless exercise provision. The total intrinsic value of stock options exercised was $2.8 million, $1.8 million, and $2.7 million during the years ended December&#160;31, 2021, 2020, and 2019, respectively. The intrinsic value of stock options is defined as the difference between the Company&#x2019;s stock price on the exercise date and the grant date exercise price. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company granted 0.1 million five-year stock options to certain ApolloMed executives with exercise price ranging from $23.24-$80.00. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2021, 2020, and 2019 was $32.63, $9.89, and $11.33, respectively. The options granted during the year ended December&#160;31, 2021 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Executives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.45% - 81.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.19% - 1.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.86-37.82&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s unvested restricted stock award activity for the year ended December&#160;31, 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted  Average &lt;br/&gt;Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,202&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,910)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,204)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,507&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$37.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock awards to employees and executives, which are earned based on service conditions. The awards will vest over a period of six months to three years in accordance with the terms of those plans. The grant date fair value of the restricted stock awards is that day&#x2019;s closing market price of the Company&#x2019;s common stock. During the year ended December&#160;31, 2021, the Company granted restricted stock awards for employees totaling 0.3 million shares with a weighted-average grant-date fair value of $50.73. The  weighted-average grant-date fair value of restricted stock awards granted during the years ended December&#160;31, 2020, and 2019 was $17.56 and $18.65, respectively. The total fair value of restricted stock awards, as of their respective vesting dates during the years ended December&#160;31, 2021, 2020, and 2019 were $1.1 million, $1.4 million, and $0, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock warrants, to purchase 1,111,111 shares of ApolloMed common stock, issued to NMM in connection with the Series A Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $9.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock warrants, to purchase 555,555 shares of ApolloMed common stock, issued to NMM in connection with the Series B Preferred Stock investment in ApolloMed were subject to exercise through March 30, 2021, for $10.00 per share, subject to adjustment in the event of stock dividends and stock splits. As part of the 2017 Merger between NMM and ApolloMed, such warrants were distributed to former NMM shareholders on a pro-rata basis utilizing the percentage of shares of NMM held by each shareholder prior to the 2017 Merger date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock warrants, to purchase 850,000 shares, for $11.00 per share, and 900,000 shares, for $10.00 per share, of ApolloMed common stock, issued to former NMM shareholders on a pro-rata basis in connection with the Merger, may be exercised at any time after issuance and through December 8, 2022, subject to adjustment in the event of stock dividends and stock splits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&#160;Price&#160;Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrants&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.00 &#x2013; $11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, common stock warrants were exercised for 0.9&#160;million and 1.2 million shares of the Company&#x2019;s common stock, respectively, which resulted in proceeds of approximately $8.8 million and $10.5 million, respectively. The exercise price ranged from $9.00 to $10.00 per share during year ended December&#160;31, 2021 and December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i5005e6c965ce49078328bedec974e062_I20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE4NQ_97bb7c98-3707-425c-9845-810073fbf38a"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i0a44ec4586564a71b632ebd24b41a548_I20171208"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU2OA_ac6dfdcd-b8da-493c-aae3-fc1fe31245e1"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iec9540bba78a40aa9b698767130e5df9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEyNDk_6e2977a2-731b-4807-995d-bf419dc5e645"
      unitRef="shares">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9f37aecb480c4ca4bdaabd1cc01c6d74_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEyNTM_a7a221b9-85f4-4a08-b54b-387193ecdcc5"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i69e0bb8c26da401f981101891ef4858c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEyNjA_42cebe11-386f-469c-9c97-65df956ae4e2"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODQ_3e6e3be0-4ef9-41c7-a56a-99c9f0f86b9b">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the stock-based compensation expense recognized under all of the Company&#x2019;s stock plans in 2021, 2020, and 2019 and associated with the issuance of restricted shares of common stock and vesting of stock options that are included in general and administrative expenses in the accompanying consolidated statements of income recognized (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;APC stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife5a872d4cb64a1795a11e4a6a81b2cd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzItMi0xLTEtMA_58c06697-12f6-448a-98c6-3fd673016d49"
      unitRef="usd">2480000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i35d0316c954743c68575e89e641ec7ec_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzItNC0xLTEtMA_98be9e2d-cbba-440c-bb2c-38c6208a148a"
      unitRef="usd">1763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92bee5c5555f4c9bb28b959713ee742c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzItNi0xLTEtMA_0b22f73b-320d-4154-9d7c-19eaae913f7f"
      unitRef="usd">688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55c7e2bb01da4cb8a05eeb09f96b7145_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzMtMi0xLTEtMA_a4c1e645-a5ef-4c45-9b25-6883d73c8725"
      unitRef="usd">4265000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida71012f2abb40c3bb3b97875ac19fd1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzMtNC0xLTEtMA_b25578d1-d14b-43b2-a17a-96f8aae1ce18"
      unitRef="usd">1620000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia48d331e72ef4c45922e796a5ec33fe2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzMtNi0xLTEtMA_386c9a7a-d7c0-4b27-838a-38a11ace4a86"
      unitRef="usd">252000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id34b814b72a749ff9980e038fe3de780_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzQtMi0xLTEtMA_132523f3-8506-4d13-b03d-5db392b5e807"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e60e144eae847ee8431a5c5918fdb83_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzQtNC0xLTEtMA_7cbe370a-429f-44cd-abae-03db4815c4f7"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2b2b020931f4f90afee0ac9784f1f61_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzQtNi0xLTEtMA_0b3c5f46-3001-409a-a7fc-ed65ee8711ca"
      unitRef="usd">607000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzUtMi0xLTEtMA_592a5d0c-96ab-4b10-9dfe-211a97e7d9ea"
      unitRef="usd">6745000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzUtNC0xLTEtMA_e6defa17-d4f0-46c0-8361-3606b484c989"
      unitRef="usd">3383000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplZDA5NzY0MTVhMTY0YzJiOTZmY2FlOTFkMWJlZjBiNC90YWJsZXJhbmdlOmVkMDk3NjQxNWExNjRjMmI5NmZjYWU5MWQxYmVmMGI0XzUtNi0xLTEtMA_f83d48bc-8a77-43f2-9149-2879221d83a9"
      unitRef="usd">1547000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="iec9540bba78a40aa9b698767130e5df9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzg4Mjc_71902771-1896-42e4-aa42-ee469c20b02a"
      unitRef="usd">21300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODU_5e5ffd9a-550e-45b5-85c6-0b72664cbb66">The Company&#x2019;s outstanding stock options consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled, forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItMS0xLTEtMA_bf4c3922-400a-456b-b633-a9eb6b0a330d"
      unitRef="shares">725864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItMy0xLTEtMA_90092442-8d58-416e-85bf-b5e717ac42fe"
      unitRef="usdPerShare">13.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItNS0xLTEtMA_0e43e1f2-c7dc-43b9-821f-9b72feb0291d">P3Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzItNy0xLTEtMA_29e7648d-0236-4e97-8b63-29596e836478"
      unitRef="usd">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzMtMS0xLTEtMA_7b75c285-cef5-4560-a03d-0acd620846fe"
      unitRef="shares">137927</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzMtMy0xLTEtMA_a21ab59f-96d6-45c9-9ba2-331ccfb1413d"
      unitRef="usdPerShare">66.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzQtMS0xLTEtMA_cf815231-1ecb-432e-b085-9d6b1e6dac01"
      unitRef="shares">40000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzQtMy0xLTEtMA_65cadc40-c09a-4e82-90cc-d738ca131a81"
      unitRef="usdPerShare">5.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzQtNy0xLTEtMA_52d01090-6680-48ab-bdd2-5064d1109bf1"
      unitRef="usd">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzUtMS0xLTEtMA_d3a2ecd4-945a-469e-a528-8c7a740ca48d"
      unitRef="shares">9826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzUtMy0xLTEtMA_9dad1865-85a2-4c05-914d-b4388a054329"
      unitRef="usdPerShare">3.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtMS0xLTEtMA_cdea8806-8aec-4f26-ae71-88ce39d0f36e"
      unitRef="shares">813965</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtMy0xLTEtMA_1a72a61d-5e2d-4cb9-92e3-aca63780b178"
      unitRef="usdPerShare">22.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtNS0xLTEtMA_387b9ee0-5f6f-454d-8d8a-60c3b6c895e2">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzYtNy0xLTEtMA_6a1d8054-99b4-4b07-99ce-e0f56d38a94b"
      unitRef="usd">41600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtMS0xLTEtMA_e3337537-1bdb-43df-8eab-2049ec3cd6a2"
      unitRef="shares">618006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtMy0xLTEtMA_32c9ff46-b67a-4290-b530-eb61fd55ca33"
      unitRef="usdPerShare">10.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtNS0xLTEtMA_69ff41a1-6233-465b-8602-bbdcbe3a7c66">P2Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTplNWE0N2M0MGVlOGE0Mjc4OGY3M2FhYWRkMjhlNDE1ZC90YWJsZXJhbmdlOmU1YTQ3YzQwZWU4YTQyNzg4ZjczYWFhZGQyOGU0MTVkXzgtNy0xLTEtMA_d19a2fb0-36b9-4078-834d-7665e9fddacd"
      unitRef="usd">37100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE4NjA_f7fe8e61-d59f-4fb1-97bf-d11e956ac7b6"
      unitRef="shares">40000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE4Njc_f7d89983-428e-4b65-b269-9440ef5249fe"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0f05771c561640aaab3a2c2c0e44330b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE5Njc_5ed8fd1c-326c-409b-8736-c97a310c1674"
      unitRef="usd">200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8bb2c1e084a049cd8af7b6044a0c177e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzE5NzQ_72c7fed2-d180-42f5-a313-85fe570fdd64"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibef63d60b9e947eead74bdfd0b22345e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIwMzA_e9e80a0c-5376-444c-ab9a-c536fea63b95"
      unitRef="usdPerShare">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ie160814e72a34eebb359d61571716c26_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIxMDI_6ed70609-6271-469c-b65b-6073549fe550"
      unitRef="usdPerShare">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i3e9c3a5ed3424d31b9ae24620d3bb654_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIxMDg_abc0330e-3d6b-477f-b4a5-b8a567d52486"
      unitRef="usdPerShare">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjUzMzA_c24bb71c-cc3f-4418-9c48-2481365ccd47"
      unitRef="shares">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3MDE_0be8bbce-bac9-48b4-8279-a8605df97428"
      unitRef="usd">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3MTY_0a168b46-b5d1-42a1-87b5-26fadfde08b6"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3MzI_26dcc813-1c64-4d94-951b-d04cab59b82c"
      unitRef="usd">2700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODY_21046691-19b0-4b87-9b23-6950b096345e">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, the Company granted 0.1 million five-year stock options to certain ApolloMed executives with exercise price ranging from $23.24-$80.00. The weighted-average grant-date fair value of options granted during the years ended December&#160;31, 2021, 2020, and 2019 was $32.63, $9.89, and $11.33, respectively. The options granted during the year ended December&#160;31, 2021 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Executives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75.45% - 81.10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.19% - 1.15%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:17pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.86-37.82&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzIzMTk_b6689eca-3391-46ed-a98e-5a78f8435e2f"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i31c542aee5d1477695e59726049c8b71_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzU1ODc_36447cc8-b1ac-4bbf-a746-4bbfb1ea9f79">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibc47b22c80ae4ba5a6046042c4073438_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI0NTI_eaf1a502-f4da-46f0-971a-528a2bde9126"
      unitRef="usdPerShare">23.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie31caf7183734c75a34b0c38fefd09f8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzY5ODU_b0b1a509-206b-44a3-906f-1be72368d1de"
      unitRef="usdPerShare">80.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzcxODE_07e57571-425b-4d3b-a571-3c17aeca91c1"
      unitRef="usdPerShare">32.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzcxODY_ca9b6eef-a7b8-4e25-b6fd-331274860394"
      unitRef="usdPerShare">9.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzM4NDgyOTA3MDkzNDI_84da59df-cdb4-41ff-b432-1fc36dcf2c75"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzEtNC0xLTEtMA_245246f8-2cdb-438a-a733-ea98226c40a4">P3Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ife3ade634e3f411d8ff9d287f7f6ccfc_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzItNC0xLTEtMC90ZXh0cmVnaW9uOjgzMDdkMGNlMGY1ZDRiNWViNjE2NjEzZTEyNGZkZTUyXzk4OTU2MDQ2NTAwMjI_59b16b3c-3683-400f-8b39-e6e67c2330a9"
      unitRef="number">0.7545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i88ed9f8ac2bd41ad84ee70e5cec56071_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzItNC0xLTEtMC90ZXh0cmVnaW9uOjgzMDdkMGNlMGY1ZDRiNWViNjE2NjEzZTEyNGZkZTUyXzk4OTU2MDQ2NTAwMzI_faf95ee5-eabc-48b4-a6db-3beae5a08490"
      unitRef="number">0.8110</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ife3ade634e3f411d8ff9d287f7f6ccfc_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzMtNC0xLTEtMC90ZXh0cmVnaW9uOmE2M2U5ZDY2Y2NiMzRhMWQ4OGU5ZTY3NjRlNTYwN2ZjXzk4OTU2MDQ2NTAwMTk_2292b82f-f37c-4f11-bdd2-6dae6dd4905e"
      unitRef="number">0.0019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i88ed9f8ac2bd41ad84ee70e5cec56071_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzMtNC0xLTEtMC90ZXh0cmVnaW9uOmE2M2U5ZDY2Y2NiMzRhMWQ4OGU5ZTY3NjRlNTYwN2ZjXzk4OTU2MDQ2NTAwMjg_bb25dba3-f5a7-4778-a25a-a81f61bcdc43"
      unitRef="number">0.0115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="ibc47b22c80ae4ba5a6046042c4073438_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzQtNC0xLTEtMC90ZXh0cmVnaW9uOmQxZmM5ODdmMjc3YTRkNzZhNDExNDJlZjFiYWE1OGZiXzk4OTU2MDQ2NTAwMTk_5058b813-b3d3-4a22-afbf-aeb62ae0c076"
      unitRef="usdPerShare">12.86</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="ie31caf7183734c75a34b0c38fefd09f8_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzQtNC0xLTEtMC90ZXh0cmVnaW9uOmQxZmM5ODdmMjc3YTRkNzZhNDExNDJlZjFiYWE1OGZiXzk4OTU2MDQ2NTAwMzE_ad6e49d7-b693-475f-9641-034cddb5b6c3"
      unitRef="usdPerShare">37.82</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzUtNC0xLTEtMA_452022ba-2fde-460d-a11b-a0de7c51bcb2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZToxNzM1NzA2MTgwN2Y0MDkwYThlNjdkNDhhOWUxNjE2MS90YWJsZXJhbmdlOjE3MzU3MDYxODA3ZjQwOTBhOGU2N2Q0OGE5ZTE2MTYxXzYtNC0xLTEtMA_b08dc655-9b55-4690-a7c0-8325edf73707"
      unitRef="number">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjAwOTk_b8efc1bf-c23a-4e55-b43c-7793da8ce351">The Company&#x2019;s unvested restricted stock award activity for the year ended December&#160;31, 2021 consisted of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.276%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Number of &lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted  Average &lt;br/&gt;Grant-Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;262,419&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$17.96&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;332,202&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.73&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,910)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.03&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,204)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541,507&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$37.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i670fb4a8ae4c408681d8b085578171d6_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzItMS0xLTEtNDEyMjQ_7f8f5cfc-c933-45c8-8a52-04c9c0b8903b"
      unitRef="shares">262419</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i670fb4a8ae4c408681d8b085578171d6_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzItMy0xLTEtNDEyMjQ_0526b7d3-3820-4321-a439-9fce2e628b57"
      unitRef="usdPerShare">17.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzMtMS0xLTEtNDEyMjQ_25925ee8-f19f-4860-8eb6-514f6f232174"
      unitRef="shares">332202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzMtMy0xLTEtNDEyMjQ_26436a31-df54-4a3f-8729-5ae7202ad9ed"
      unitRef="usdPerShare">50.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzQtMS0xLTEtNDEyMjQ_81fdafb4-bf87-4c5e-bcea-c0f3b5e9c0fb"
      unitRef="shares">39910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzQtMy0xLTEtNDEyMjQ_5c3458fa-9dec-4f62-8365-e529ea4394cf"
      unitRef="usdPerShare">17.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzUtMS0xLTEtNDEyMjQ_c3f4ca23-f3f0-4e3f-8728-e5ea8e805d72"
      unitRef="shares">13204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ieaedd64b71184c4e98c7374ac8285088_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzUtMy0xLTEtNDEyMjQ_9a410f64-344e-464c-9869-89f5c58dc89f"
      unitRef="usdPerShare">29.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic130048652fd4ae89ae9be7d998b753c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzYtMS0xLTEtNDEyMjQ_1f6e937a-6f1c-46a2-a085-208bfc7d382d"
      unitRef="shares">541507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic130048652fd4ae89ae9be7d998b753c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo4YmZjMzJmMGNlODg0YTVjOWM3ODE5OTIwNDdmYzk4Yy90YWJsZXJhbmdlOjhiZmMzMmYwY2U4ODRhNWM5Yzc4MTk5MjA0N2ZjOThjXzYtMy0xLTEtNDEyMjQ_277c12f7-ded8-4a10-a207-262600eb78ee"
      unitRef="usdPerShare">37.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i2b029890b2714cffb3297481713b140b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjYzODk_df7649ae-cea3-4bae-8c6d-3e0cbb2b3110">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i21f1ff2005de4e06ab13d40c18783c14_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzYwNDczMTM5NjY0MDk_59792be8-a3a4-49e8-8e12-a981250120ec">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia49fab4addb846b78532141505ad76c8_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3NDU_e07f471e-f262-460f-be0a-b8987b3408d8"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia49fab4addb846b78532141505ad76c8_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzc3NDk_0864ec7b-e082-4478-a257-37941034ef11"
      unitRef="usdPerShare">50.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id39d667c80e24f60a2821321e2d966cc_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzg3MDc_eff4dc0c-cdc2-4a3b-8c98-815fb32582fe"
      unitRef="usdPerShare">17.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9eae915be53045f6bb1b2c554e86ccb5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2Mzg3MTE_4ecbdfaf-c49c-48bb-84d9-538cf38dff95"
      unitRef="usdPerShare">18.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ifebcbe81b7cb4bb1b35b8f52f712e985_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyNDg_ad816c33-ec49-4417-8468-3104c0c537f1"
      unitRef="usdPerShare">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic0fafa1dea0849b1b343ca69489e8c78_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyNjQ_043548b1-4d2a-4477-b8ad-a306713e871b"
      unitRef="usdPerShare">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1d3bbb3ca7dd4c24bc7e516e958c13e6_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyODA_5681813e-5b67-4e29-b166-1d65ecaa7c36"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1c3b89e15c2a46a8b1584061df39bce7_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzUwODk_f51acdd4-cfcb-4a77-9a29-796e269e4b63"
      unitRef="shares">1111111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id187f254b8f044069cf6e62f7dd23492_I20151031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzUyODk_76826167-68b2-44d1-bf66-1142418a2762"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i1b739b484d69489e8fc9a13e8e90ec54_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzU2MzE_6e88f9f3-e517-476b-9108-36431d0e232e"
      unitRef="shares">555555</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id8f27f189d204a99bb6fbd309638d302_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2MzkyOTQ_a30ad749-c8ba-4448-9b6d-c8eb3239951b"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7edf78b63c6f4e08805f86b4036d2e81_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0MzA_eefd38e7-9499-4ddf-9bbc-948da4bbebc9"
      unitRef="shares">850000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5f12986e0b9048669859a5f857899013_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0Mzk_a90c3b61-2cd1-4c1b-8ceb-be7ae76804ef"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i779a53f850a8409dbd4e696d526532c9_D20160301-20160331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0NDk_f17d8ed2-d140-4c6a-99e0-d75f63c85174"
      unitRef="shares">900000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie312f8b83db04cdcb3b524d5a3a6ba12_I20160331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzEwOTk1MTE2NDE0NTg_fe232e03-0664-4628-aac9-fa47be996e03"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzY1OTcwNjk3NzU4NTY_5f1f1544-ad2e-407b-8580-d3c09c34ae43">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:17pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,878,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858,583)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.665%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.229%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&#160;Price&#160;Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrants&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;br/&gt;Per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$10.00 &#x2013; $11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtMS0xLTEtNDEwNzk_7f8a3c29-1abb-4267-ab69-3e98c17c3720"
      unitRef="shares">1878126</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtMy0xLTEtNDEwNzk_403b923c-0bea-4916-89b7-f6e1d0988640"
      unitRef="usdPerShare">10.39</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtNS0xLTEtNDEwNzk_5ee34dee-9dfd-4d6e-ab62-5e0f9f9b7a6b">P1Y7M17D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzgtNy0xLTEtNDEwNzk_632b200f-7d49-48bd-a1db-cebe5189f469"
      unitRef="usd">14800000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsGranted
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzktMS0xLTEtNDEwNzk_c303967d-2f5e-43c7-9499-8744e29c3978"
      unitRef="shares">0</ameh:NumberOfWarrantsGranted>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzktMy0xLTEtNDEwNzk_4daecf76-bea8-45d5-9343-7996259d1e60"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod>
    <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzktNy0xLTEtNDEwNzk_74947ae2-31e8-47e8-9b84-eb2a8450822d"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsExercised
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEwLTEtMS0xLTQxMDc5_14531960-6531-416b-9a85-0c5227224a93"
      unitRef="shares">858583</ameh:NumberOfWarrantsExercised>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEwLTMtMS0xLTQxMDc5_5b3bdf0d-f3ea-4368-bade-5950e2e07c16"
      unitRef="usdPerShare">10.30</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod>
    <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEwLTctMS0xLTQxMDc5_f58c4035-286c-41db-8a1b-d2222775c61a"
      unitRef="usd">41100000</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>
    <ameh:ClassOfWarrantOrRightCancelledInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzExLTEtMS0xLTQxMDc5_2de8235a-1982-467e-a30e-a0c07b430dd6"
      unitRef="shares">17803</ameh:ClassOfWarrantOrRightCancelledInPeriod>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzExLTMtMS0xLTQxMDc5_fb115bfc-7256-43ff-bca1-d2b9bcbe4304"
      unitRef="usdPerShare">9.72</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod>
    <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzExLTctMS0xLTQxMDc5_1f03caea-b221-4547-8c87-5b977281f6f9"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTEtMS0xLTQxMDc5_e1d6e842-2714-44ef-9438-717409c7d2db"
      unitRef="shares">1001740</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTMtMS0xLTQxMDc5_b06254b7-a58c-4d0e-a280-6a648f3aeda5"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTUtMS0xLTQxMDc5_8c9cf0ac-25d8-4511-992e-873051a9237f">P0Y11M8D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo0ZTJiMDA1MjM2ZDU0ZTY5OTRmN2I1MDhjZDc2YzE4Zi90YWJsZXJhbmdlOjRlMmIwMDUyMzZkNTRlNjk5NGY3YjUwOGNkNzZjMThmXzEzLTctMS0xLTQxMDc5_6084b169-4c90-44f7-bfa9-951dda3f0965"
      unitRef="usd">63100000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtMC0xLTEtNDEwNzk_de5e45a0-c67d-43fc-ad38-60a9193443c3"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i66cd6792e85c49d7a61ed092edae091c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtMi0xLTEtNDEwNzk_fbfac083-b9fc-4957-a8f1-c86db5208c78"
      unitRef="shares">515176</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i66cd6792e85c49d7a61ed092edae091c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtNC0xLTEtNDEwNzk_02a6ae1c-31e8-4015-bf5b-d04dc9391387">P0Y11M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtNi0xLTEtNDEwNzk_39f4f0b1-2c30-4766-92b8-46a8c3afbae3"
      unitRef="shares">515176</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzMtOC0xLTEtNDEwNzk_46e90052-a854-4215-95e9-1c1fc3fb7cea"
      unitRef="usdPerShare">10.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtMC0xLTEtNDEwNzk_9afec95c-004f-47d3-ab26-affd87f7f1d4"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="ia90a6c2a97b64a389f5c927fc93bf96a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtMi0xLTEtNDEwNzk_efc96c41-4dac-4cd6-83e4-8ee46edfd351"
      unitRef="shares">486564</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="ia90a6c2a97b64a389f5c927fc93bf96a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtNC0xLTEtNDEwNzk_bbdf5577-29ee-4e88-9452-683001af1ab9">P0Y11M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtNi0xLTEtNDEwNzk_2c076080-ef7d-4328-8895-d1dc8fdce795"
      unitRef="shares">486564</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i5ad034bfd2ef46c99ae8959ef0d62b81_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzQtOC0xLTEtNDEwNzk_db1685fa-c825-4752-b63f-12413de96f9f"
      unitRef="usdPerShare">11.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if46b72f6abf844e9879f71846c8b9b66_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtMC0xLTEtNDEwNzkvdGV4dHJlZ2lvbjpmNThkZTM5NDQ5M2Q0MTNkOGNhMjBjMDhmNmEyMmY3M180_ede00109-c2ea-43c2-9fcb-f3c31354e40c"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i08aaa85087aa4345a9007df6c4591fd1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtMC0xLTEtNDEwNzkvdGV4dHJlZ2lvbjpmNThkZTM5NDQ5M2Q0MTNkOGNhMjBjMDhmNmEyMmY3M185_f22f7081-762e-4737-9d68-c51e979221cd"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i3b537ba452f949228e951dcdfcef32e0_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtMi0xLTEtNDEwNzk_0eba1fa5-7395-4479-bfbf-5208e3d9efa9"
      unitRef="shares">1001740</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i3b537ba452f949228e951dcdfcef32e0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtNC0xLTEtNDEwNzk_fcbb35e1-cfe0-4468-b54e-b9784063bb2b">P0Y11M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i53187ce216524aa3b307b37805167d6b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtNi0xLTEtNDEwNzk_665c41e2-3177-4217-9d21-4365b24be5f5"
      unitRef="shares">1001740</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i53187ce216524aa3b307b37805167d6b_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90YWJsZTo3Y2NjN2MzYjM0MTY0NDNlYTYwMWU4ODFhM2ZhZmRjZS90YWJsZXJhbmdlOjdjY2M3YzNiMzQxNjQ0M2VhNjAxZTg4MWEzZmFmZGNlXzYtOC0xLTEtNDEwNzk_47ec9143-06f1-45a2-982f-96b85c46cd89"
      unitRef="usdPerShare">10.49</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYyODI_ebb300db-cbf3-4e65-bbe4-f9180b127ada"
      unitRef="shares">900000</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYyOTA_c44977f3-b97d-4a8b-bed6-1354ece5b593"
      unitRef="shares">1200000</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYzODk_584a387d-d7cb-4ea0-8de7-f230eafb0ed7"
      unitRef="usd">8800000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzYzOTc_badc2701-661d-4637-a73b-8abfaa45dcbc"
      unitRef="usd">10500000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i3b1cfd32fb714d1b80f4201a5deed2a1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NDc_3b76a9ef-2052-434a-ac1d-e5e9d3784b1c"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i18b3dd4fa9ea494c8e4664eadd46fe86_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NDc_c5a936ac-ce7d-45a9-97bb-b4c37b15711b"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="ib0c6887e9a0e48769c6c40b88779c532_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NTQ_1989b4f2-501f-46cb-887c-e0e7f782890c"
      unitRef="usdPerShare">10.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i5bab33a21a0648868b28fc7d50f54158_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTkvZnJhZzpmZWRiODY4OGM5MTg0ZjQ2OWZkMzAzMGU4MjI5NjFhOS90ZXh0cmVnaW9uOmZlZGI4Njg4YzkxODRmNDY5ZmQzMDMwZTgyMjk2MWE5XzI3NDg3NzkwNzY0NTQ_274f5fd2-4a7c-453b-bf9e-121610a74ad7"
      unitRef="usdPerShare">10.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzM4Mjg_90df191e-5bfc-4486-b6d2-cb70ebecfdbe">Commitments and Contingencies&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a risk-bearing organization, the Company is required to follow regulations of the Department of Managed Health Care (&#x201c;DMHC&#x201d;). The Company must comply with a minimum working capital requirement, tangible net equity (&#x201c;TNE&#x201d;) requirement, cash-to-claims ratio, and claims payment requirements prescribed by the DMHC. TNE is defined as net assets less intangibles, less non-allowable assets (which include amounts due from affiliates), plus subordinated obligations. At December&#160;31, 2021 and 2020, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the Company&#x2019;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount of 2% of the Company&#x2019;s benchmark Medicare Part A and Part B expenditures. In August 2020, $14.8&#160;million of the irrevocable standby letters of credit were released by CMS and $0 remain outstanding as of December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and Alpha Care established irrevocable standby letters of credit with Preferred Bank for a total of $0.3 million and $3.8 million, respectively, for the benefit of certain health plans (see Note 10 &#x2014; &#x201c;Credit Facility, Bank Loan, and Lines of Credit&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ameh:PercentageOfFinancialGuaranteeBenchmarkAmount
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzE4NjE_a1c0e148-6bb3-444e-b4e3-9d3aac0ddd2f"
      unitRef="number">0.02</ameh:PercentageOfFinancialGuaranteeBenchmarkAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5d72bc8610fd48128d879bda262dfe43_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzE5NDg_dcb2b55d-a422-44ed-9e13-cdb3eeb7f77a"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCredit
      contextRef="i92adc7af35ce442586e7f832696d8083_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzE5NTI_019b1969-0c59-4caf-98e4-46aecc8480aa"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="ie254787cc84c48bd84c74b128e2266d7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzIwNjM_bd32a70e-c571-4040-99cb-06d9a9cf3961"
      unitRef="usd">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i15d1c54ce99042c1b561ab2ee11ee78e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODEvZnJhZzo2NjAxYjYzZDM0MTc0N2I0ODQyMzI3NmJlYzIxZDExMS90ZXh0cmVnaW9uOjY2MDFiNjNkMzQxNzQ3YjQ4NDIzMjc2YmVjMjFkMTExXzIwNzA_d746ed28-4e43-47bc-b761-e62f63c9ad4d"
      unitRef="usd">3800000</us-gaap:LineOfCredit>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQyOTg_88b60b0f-334a-4ee2-9acd-bd558f3566e9">Related-Party Transactions&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, NMM earned approximately $18.7 million, $16.9 million, and $17.3&#160;million, respectively, in management fees, of which $7.0 million and $2.3 million, remained outstanding, at December&#160;31, 2021 and 2020 respectively, from LMA, which is accounted for under the equity method based on 25% equity ownership interest held by APC (see Note 6 &#x2014; &#x201c;Investments in Other Entities&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $2.4 million, $2.2 million, and $2.7&#160;million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 6 &#x2014; &#x201c;Investments in Other Entities&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $0, $6.0 million, and $7.8&#160;million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 6 &#x2014; &#x201c;Investments in Other Entities&#x201d;). In October 2021,  DMG was consolidated by Apollo. As such, DMG is no longer a related party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $0.7 million, $0.5 million, $0.4&#160;million, respectively, to Advance Diagnostic Surgery Center for services as a provider. Advance Diagnostic Surgery Center shares common ownership with certain board members of APC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, APC paid approximately $0.1 million, $0.1 million, and $0.1&#160;million respectively, to Fresenius and their subsidiaries for services as a provider. During the year ended December&#160;31, 2021 and 2020, APAACO paid approximately $0.7 million and $0.7 million, respectively, to Fresenius and their subsidiaries for services as a provider. One of the Company&#x2019;s board members is an officer of Fresenius and their subsidiaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, APC paid approximately $2.0 million and $0.3 million, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shares common a board member with the Company starting in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, NMM paid approximately $1.3 million and $1.4 million, respectively, to One MSO, Inc. (&#x201c;One MSO&#x201d;) for an office lease. One MSO is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 6 &#x2014; &#x201c;Investments in Other Entities&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, the Company paid approximately $0, $0.3 million, and $0.5&#160;million respectively, to Critical Quality Management Corp (&#x201c;CQMC&#x201d;) for an office lease. As of December 31, 2020, the office lease has ended. CQMC shares common ownership with certain board members of APC (see Note 19 &#x2014; &#x201c;Leases&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, SCHC paid approximately $0.4 million, $0.4 million, and $0.4&#160;million respectively, to Numen, LLC (&#x201c;Numen&#x201d;) for an office lease. Numen is owned by a shareholder of APC (see Note 19 &#x2014; &#x201c;Leases&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021 and 2020, APC paid approximately $15.4 million and $0, respectively, to Arroyo Vista Family Health Center (&#x201c;Arroyo Vista&#x201d;) for services as a provider. The CEO of Arroyo Vista became a board member with the Company in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;), Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion Corporation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AHMC &#x2013; Risk pool earnings net of claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the years ended December&#160;31, 2021, 2020, and 2019, the Company has recognized risk pool revenue under this agreement of $60.1 million, $42.6&#160;million, and $49.3&#160;million, respectively, of which $58.4 million and $45.3 million, remain outstanding as of December&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, APC paid an aggregate of approximately $34.8 million, $33.1 million, and $30.8&#160;million, respectively, to shareholders of APC for provider services, which included approximately $8.5 million, $9.0 million, and $8.8&#160;million, respectively, to shareholders who are also officers of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2021, 2020, and 2019, NMM paid approximately $44,000, $0.1 million, and $0.2&#160;million to an ApolloMed board member, Matthew Mazdyasni, for consulting services.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, affiliates wholly owned by the Company&#x2019;s officers, including Dr. Thomas Lam, ApolloMed&#x2019;s Co-CEO and President, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#x2019;s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments, loans receivable and line of credits from related parties, see Note 6 &#x2014; &#x201c;Investments in Other Entities,&#x201d; Note 7 &#x2014; &#x201c;Loans Receivable &#x2014; Related Parties,&#x201d; and Note 10 &#x2014;  &#x201c;Credit Facility, Bank Loan, and Lines of Credit,&#x201d;  respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i129f6a3461cf4f1ab4901b6a723c2efa_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEwMg_6fb2cb20-a6cb-47fc-b18a-aebb7a589686"
      unitRef="usd">18700000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i9270b7467dd044688bc0a7eb2e2ca95b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEwNg_841e80df-cb97-4e0d-bc54-4c85cf16d8f8"
      unitRef="usd">16900000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ic2b387c30626438ebb40b9bca7610e32_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExNA_977116e8-f0fe-44be-a0cd-600609e460c6"
      unitRef="usd">17300000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i4e46c773fc154de4bf33cdae598f28cd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE2MQ_4d011b9c-1daf-46f5-8014-f2a9b3e437cf"
      unitRef="usd">7000000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i7b8910f127dd44bf93a735ed77e16ac9_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE2OA_eac5e704-458e-40a6-8eb7-edaec02e9278"
      unitRef="usd">2300000</us-gaap:DueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic79962b6add548d1a0a0800ef768b995_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI4Nw_9d73444b-b927-4b9b-b98b-28c4406a16b6"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i63281dcdd4a140dbb747619db7d8c8a4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQwNg_a15b7470-d44d-4bcc-8125-bb60a1858750"
      unitRef="usd">2400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i70d92535c55249a8847213ad5c2a502c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQxMA_d50c1c61-4b28-4bd0-bd13-1fbf8e649f9d"
      unitRef="usd">2200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i4bad5438ff3a4f74a3d70bcaa21c6c0f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQxOA_ea8d8a58-1670-4d08-9e7f-b19fd4edb6c6"
      unitRef="usd">2700000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia5679f2c797347059c1225b32fbb6b13_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzUyNA_e0d4592e-2b79-436a-a5e2-59922bf87235"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie849991976b847cf90334bfe31a52480_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzY0Mw_92a49d59-e074-4226-b85e-88a62188a4ea"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="icf99075624e6433ba75a5f77dc805f15_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzY0Nw_e68bcb44-9e69-4def-880b-f567a1ad1b00"
      unitRef="usd">6000000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ib13f9af073384d4c9e1929dc51068830_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzY1NQ_0575fcef-a6cf-4e7b-975c-7f7c7c8891f3"
      unitRef="usd">7800000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic2133589307c47dcbdf2e41c006a5957_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzc1OQ_57cd94c4-395b-4efc-a800-b0459f6ceed1"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8e8615520d1c460abd7740668e7eccb7_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzg3OA_786bfaa6-75ac-4fb6-b458-1250ab5a481a"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i0bcb63ad4a3840f5972376ef0ad45c77_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzg4Mg_a457f919-f5f9-43e9-bd81-45aff224c2e1"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3c960befa3cb4c8481200d45bd9ea49e_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2Xzg4Ng_d4af4412-1046-4153-8b57-3be55dfcd70d"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id3bb44ce70f74f858de6d865daacc078_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExMjY_bcd66abc-0102-41ae-80e9-9d36f2070076"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i66a2b156a58d4e41b8c652fbfc2b1dc3_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExMzA_0c88c1d6-712d-4c5d-89a5-d215626580c9"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i725de084f7484bf2b557e23683209c2f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzExMzg_2ea73476-0e49-417d-bda1-963c306dc753"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i48ce8008a9aa413bbc0d854c5c099a7b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEyNzg_aa3a6abd-3720-48d4-9b19-ff8e8720c3db"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i9ad1a32d47d24ebd9e398feacbdef5da_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzEyODU_09575f02-f3df-49de-8f92-33a533eb9b2a"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i345508df7f534ec186d436d698300127_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE1MTE_57ffb23f-4ff5-44a0-aa70-fdd3d6417530"
      unitRef="usd">2000000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i17a3d24c34e24e4bbb0b52e9864a691c_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE1MTg_6b9fd8bc-6b7b-4466-b96d-f13d7893bde4"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if2e413d93a45413e867b6c43dcbcb16f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE5NTM_9feb2c4a-6477-4d4e-8bb3-b2641f969f77"
      unitRef="usd">1300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i56618b59636c41de889fa82a7f480457_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzE5NjA_5bfe38a8-c05e-45f1-9f14-fa777d08df06"
      unitRef="usd">1400000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i885597d6544c4e3abef7773242454b2b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM4NDgyOTA3MDIyOTk_8f4e1805-2fb1-4f81-8a75-42b4d111e0b6"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i962c50aee1e348aba05114edeaee56c5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzIyNDg_d41aabcf-1225-4fc7-888c-afb6ef2d67b6"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i72264584776344db971c065a8fce37ec_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzIyNTI_5813e428-0f94-471f-adbd-10351313adcb"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id9f3ec8accf2446a924e82c4b5f8ccfb_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzIyNjA_275bb6bb-f4db-4fcd-a183-5e1039f80c2d"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia561e5c258f2485694a76848bb8b6a1b_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI0ODY_fb9bc4ae-001a-4554-a0b8-cd3ad7735edd"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3e4b1ef0f59e450b996daa00631fb6ca_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI0OTA_7d6a3532-4490-4412-b6e2-6ebc056b5413"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i413b4eb991864312abee85b2aa4136a2_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI0OTg_dc745c45-7b04-4ebd-b8f6-f8453f5bbbad"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="icaf783f1db0c4787a4a69fb6282d4e02_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI3NDg3NzkwNzU4MDU_3bfc3518-fe63-4519-93f7-47b8fa120e31"
      unitRef="usd">15400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iac72b50c95e94fc09e52a827a55332b6_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI3NDg3NzkwNzU4MTM_4bb4c1d8-fdc6-49b7-a0ff-c5d57d120e00"
      unitRef="usd">0</ameh:PaymentMadeToRelatedParty>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzQyOTk_7ea9ec52-8923-4c20-9f6b-7e34161c5545">The following table sets forth fees incurred and income received related to AHMC, HSMSO, and Aurion Corporation (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.103%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AHMC &#x2013; Risk pool earnings net of claims payment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(629)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receipts, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="ia53e8f382a2e4439b60240b8915724ee_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzItMS0xLTEtMA_d1e1547b-862a-4c2b-b353-38f2f6ad1e91"
      unitRef="usd">46908000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i1cd656c250ce4150a6a1a1fceb8542ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzItMy0xLTEtMA_843ccc78-21da-4154-9264-ec21652c5784"
      unitRef="usd">28767000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <us-gaap:ManagementFeeExpense
      contextRef="ie2192a286cf646ccab3788f074402528_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzMtMS0xLTEtMA_c594be8f-23b3-49cd-929a-2618c1eebbc6"
      unitRef="usd">629000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i134932193dfa499ca1b1effba3b95a14_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzMtMy0xLTEtMA_a89378cb-d7a1-40d7-a776-bad331b58345"
      unitRef="usd">949000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ia409ec0563224e55807090c8d3e6ede7_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzQtMS0xLTEtMA_543559b4-1c74-48a2-a622-521419c08dce"
      unitRef="usd">302000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="id9cdce4ca78b41e0a57fc6795290012c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzQtMy0xLTEtMA_61fc3a7d-ae8a-405a-8fa5-df029958866c"
      unitRef="usd">303000</us-gaap:ManagementFeeExpense>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzYtMS0xLTEtMA_6eb10aab-2026-405c-9b6d-a4c527c03e8e"
      unitRef="usd">45977000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90YWJsZTo1MGE0ZTYxMzk2OTM0OTc4OGJkYWE5OGZiMWRjYzMxNi90YWJsZXJhbmdlOjUwYTRlNjEzOTY5MzQ5Nzg4YmRhYTk4ZmIxZGNjMzE2XzYtMy0xLTEtMA_d2b678cc-b5e5-4a39-aa1f-a84dfef74738"
      unitRef="usd">27515000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:InsuranceServicesRevenue
      contextRef="ia53e8f382a2e4439b60240b8915724ee_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyNTk_0309d818-b599-43af-b20d-b24677268d15"
      unitRef="usd">60100000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i1cd656c250ce4150a6a1a1fceb8542ce_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyNjM_ff886b14-fcfb-4152-8c3b-86737abc666c"
      unitRef="usd">42600000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:InsuranceServicesRevenue
      contextRef="i24ec1d618774465c8dea886fe213dfe7_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyNzE_09d9a446-2b59-4da5-ae56-6384a160bea4"
      unitRef="usd">49300000</us-gaap:InsuranceServicesRevenue>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i2a2b3509507d4d48912d14647a92e623_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMyOTg_a992eec3-4119-4ac8-9604-99dba4f535f4"
      unitRef="usd">58400000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="ic3a8211eb68b4df0b319ce09e3b1f902_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzMzMDU_ba3226ac-e6c6-44ff-a943-9fd1e777420c"
      unitRef="usd">45300000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i30eb97f7c32744b7b15f7e0871ad0fbb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM0Mzk_e2f64f33-e646-437a-babf-5058d1038f60"
      unitRef="usd">34800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8a4c5277f7fe49faac858648aba110d4_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM0NDM_9bb2d060-2add-4b20-b229-f76c3c717050"
      unitRef="usd">33100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i14d6fef6bdcd4ea5849d94a4db61a9e0_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM0NTE_ff6d31c8-6895-411e-a51d-603b6c3e2798"
      unitRef="usd">30800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i75f1a347fb7b4952812981c95e91f55d_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM1NDQ_53d2af10-8a48-4db5-b76b-f2747c4d43bc"
      unitRef="usd">8500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id64373440d04487abfcbb1c9c106cd2a_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM1NDg_3095872f-1ca4-40dd-8548-d51cc9a237a5"
      unitRef="usd">9000000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ibea0b347dab449ca8628a24054c9a91c_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM1NTY_fc8bb9c1-291a-45d1-9534-c382e932902c"
      unitRef="usd">8800000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib376d31c4e7c47d1adb2a6a237f9cc09_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM2Nzc_4370249b-925b-47ed-bf8c-deeacbc35892"
      unitRef="usd">44000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i09eece4c427740f687d9a6fadb11f1ff_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzM2ODQ_be48e8a7-3d98-429b-ad71-e5de8f3329b8"
      unitRef="usd">100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i802eb21bde26452ba2c3f5659cee4c04_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xODcvZnJhZzo0MzE5OGRkZTRmNTY0NTljOTNlMjg2OGNjMzdhOTI0Ni90ZXh0cmVnaW9uOjQzMTk4ZGRlNGY1NjQ1OWM5M2UyODY4Y2MzN2E5MjQ2XzI3NDg3NzkwNzQ1ODc_a0bf4204-221b-40f1-9d4e-c750de0ae1c1"
      unitRef="usd">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzUzOA_e8be5673-3045-42fe-904b-f4ca457c392b">Employee Benefit PlanNMM has a qualified 401(k) plan that covers substantially all employees who have completed at least six months of service and meet minimum age requirements. Participants may&#160;contribute a portion of their compensation to the plan, up to the maximum amount permitted under Section 401(k) of the Internal Revenue Code. Participants become fully vested after six years of service. NMM matches a portion of the participants&#x2019; contributions. NMM&#x2019;s matching contributions for the years ended December&#160;31, 2021 and 2020 were approximately $0.4 million and $0.4 million.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <ameh:DefinedContributionPlanServicePeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzEzMQ_6b97b83a-7078-4297-b96b-62d49f11a5cc">P6M</ameh:DefinedContributionPlanServicePeriod>
    <ameh:DefinedContributionPlanVestingPeriod
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzM3OA_31e638b1-7b90-4718-b631-532e091d4544">P6Y</ameh:DefinedContributionPlanVestingPeriod>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzUyOQ_fffae937-c93c-4738-89f8-eaf08a6d2e8c"
      unitRef="usd">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xOTMvZnJhZzoxYjFjOGI2MjQ1NTk0NzZlYjA3MDYyYTA3ZjA0NjE0NS90ZXh0cmVnaW9uOjFiMWM4YjYyNDU1OTQ3NmViMDcwNjJhMDdmMDQ2MTQ1XzUzNg_c1526416-1aa1-44ca-b55b-07aa046324c8"
      unitRef="usd">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzIwOTI_6e38cbb7-4565-4479-81c9-4753d6b234e8">Earnings Per ShareBasic net income per share is calculated by dividing net income by the weighted-average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period. Diluted net income per share is calculated using the weighted-average number of common and potentially dilutive common shares outstanding during the period, using the as-if converted method for preferred stock and the treasury stock method for options and common stock warrants.&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, 2020, and 2019, APC held 10,925,702, 12,323,164 and 17,290,317 shares, respectively, of ApolloMed's common stock, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share (see Note 12 &#x2014; &#x201c;Mezzanine and Shareholders&#x2019; Equity&#x201d;). The non-controlling interests in APC are allocated their share of ApolloMed&#x2019;s income from APC&#x2019;s ownership of ApolloMed common stock and this is included in the net income attributable to non-controlling interests on the consolidated statements of income. Therefore, none of the shares of ApolloMed held by APC are considered outstanding for the purposes of basic or diluted earnings per share computation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,828,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,527,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,708,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,403,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,448,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,403,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,828,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,527,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,708,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Executive restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,403,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,448,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,403,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1eff2864c695401fb93686780342c192_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzEyODc_27a9991b-b6f8-44c5-a422-b3060ea73603"
      unitRef="shares">10925702</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i601de355c37d4e38a5ea8fffe8e17e9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzEyOTE_c7efd69d-ce76-4fec-93dd-9141a5b2fe09"
      unitRef="shares">12323164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i81990f1f745c424ca090209239fb9e19_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzEyOTg_13242a22-43a8-40a7-8303-e42cdb699a4e"
      unitRef="shares">17290317</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzIwOTM_54af8444-1fdf-494e-8f99-35bfa0bf13de">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.029%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,828,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,527,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,708,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,403,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,448,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,403,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzMtMi0xLTEtMA_91661981-9b3e-4269-b352-b364cfa604d6"
      unitRef="usdPerShare">1.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzMtNC0xLTEtMA_2cce4aa0-32ca-4db1-9f87-169d2c28d4e7"
      unitRef="usdPerShare">1.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzMtNi0xLTEtMA_cf430905-2116-4b07-9af5-811596da5d34"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzQtMi0xLTEtMA_7b991bf8-2142-4a6a-9f72-c4d0c4d587d4"
      unitRef="usdPerShare">1.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzQtNC0xLTEtMA_33cbb798-6d3a-4cd8-9984-a516d2ce0248"
      unitRef="usdPerShare">1.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzQtNi0xLTEtMA_27dd02d1-1640-4059-a955-afc2ff7ba7bb"
      unitRef="usdPerShare">0.39</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzUtMi0xLTEtMA_daf8ec0a-2d39-4896-b4d0-c868e996bbc3"
      unitRef="shares">43828664</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzUtNC0xLTEtMA_a65d3dff-49c2-443d-bb8c-2fed854f2306"
      unitRef="shares">36527672</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzUtNi0xLTEtMA_8d2ca12c-b759-43d3-a7ea-27e909ec9fb7"
      unitRef="shares">34708429</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzYtMi0xLTEtMA_e14602e1-8369-4d19-8904-4aa6d7afe516"
      unitRef="shares">45403085</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzYtNC0xLTEtMA_bd9658fc-8506-424e-a00a-e90373e6b0d2"
      unitRef="shares">37448430</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTpjMWVmZjcxOGU4OTQ0MDg2YjZlOWJhMDI4YjQ3NWM1MS90YWJsZXJhbmdlOmMxZWZmNzE4ZTg5NDQwODZiNmU5YmEwMjhiNDc1YzUxXzYtNi0xLTEtMA_179d0ba7-64ed-4557-92cc-8a16f1011e09"
      unitRef="shares">36403279</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90ZXh0cmVnaW9uOjJkZTE1MTQzNDY1YzRlNDE5OGNhYjM1ZDhkNmRmZjE4XzIwOTE_c35852ed-4de1-4bdc-a592-3911786f43b9">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.589%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.603%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.606%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,828,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,527,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,708,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,384,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Management restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Executive restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,403,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,448,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,403,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzMtMi0xLTEtMA_0c3bd503-6876-4b38-bf81-f47b6b9c49be"
      unitRef="shares">43828664</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzMtNC0xLTEtMA_b770a8b0-162f-4156-b0ac-6b3c077858ad"
      unitRef="shares">36527672</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzMtNi0xLTEtMA_9880718f-c2be-4012-8c98-db366763cb0b"
      unitRef="shares">34708429</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i65dded2172ef422fb17e1d0fce8b7249_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzUtMi0xLTEtMA_46ab2610-f9e4-4df2-ae33-912528b50307"
      unitRef="shares">495618</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i69c49049ebbc47528adaa662d73d39ec_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzUtNC0xLTEtMA_d216bc2d-f234-4542-a833-e4d7a81b6be5"
      unitRef="shares">182999</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib2e7d052ba2b4395b0f60a17ae65a0f2_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzUtNi0xLTEtMA_d20e6707-279e-4d13-af4e-13e4d9cd5c3f"
      unitRef="shares">295672</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ic14cb455ba05463cb1678b216ef7075f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzYtMi0xLTEtMA_4d9ae896-1d86-4578-a921-3524e63146e2"
      unitRef="shares">819151</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3ae3db4ca1e34c708b94c52c71ad2914_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzYtNC0xLTEtMA_71f7ab8a-3eb0-4101-8a46-25865990ea94"
      unitRef="shares">717029</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ibd421eb1df5c49939ff1803196eb2a86_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzYtNi0xLTEtMA_cf6db97b-a709-4041-a0dd-a18d5891cba9"
      unitRef="shares">1384078</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i208f479f75974f779de286c45d4474bf_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzctMi0xLTEtMA_068705d6-9865-45b2-8c01-bb5ead79bc28"
      unitRef="shares">23824</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6adcc0aa230f41fd87e0b1d0454f2be7_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzctNC0xLTEtMA_6a29ab2f-9614-479e-84fd-d0324f1c266a"
      unitRef="shares">7242</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0f8971b99a7041a48f19c1d1278bc25b_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzctNi0xLTEtMA_cacbe718-022b-47e6-b4ab-54bef7395f88"
      unitRef="shares">15100</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ib0f8d61c8ab544a5b3f23e1be85c5358_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzgtMi0xLTEtMA_73927943-bff5-4fb1-86fc-9ed78a7fc734"
      unitRef="shares">235828</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ia44bf6e3eefc4f64a56179122b3b4d22_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzgtNC0xLTEtMA_d5cbc438-4f87-4fd5-a410-08dc07b68bbf"
      unitRef="shares">13488</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7308475feed14b639f9c04dfe2ffc4d7_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzgtNi0xLTEtMA_a97fe5fc-c30a-407c-8ddd-0b994757d148"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzktMi0xLTEtMA_eba3dc58-77ab-490f-a0ed-b97a4a4d57ba"
      unitRef="shares">45403085</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzktNC0xLTEtMA_84948431-3a69-41d2-a06c-1bd7b2d91b09"
      unitRef="shares">37448430</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i274fcf58ba484973ae71b511a3d81f82_D20190101-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDUvZnJhZzoyZGUxNTE0MzQ2NWM0ZTQxOThjYWIzNWQ4ZDZkZmYxOC90YWJsZTo4Y2RjOWY1OWUyYmM0NTVmYWRlODMyMzQwYmY1YjdiNC90YWJsZXJhbmdlOjhjZGM5ZjU5ZTJiYzQ1NWZhZGU4MzIzNDBiZjViN2I0XzktNi0xLTEtMA_675c402b-ac7d-4697-8dca-9da68956b1b0"
      unitRef="shares">36403279</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90ZXh0cmVnaW9uOmVjOTJkOWQ0ZTU5MzQ1ZjBhZDJmZjNlYzI0NmM5ZmQ1XzE2ODg_69a88e0e-ded8-4ad3-b283-fde032ac5a48">Variable Interest Entities (VIEs)&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#x2013; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies &#x2014; Variable Interest Entities&#x201d; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2014; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due from affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in a privately held entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Investment in affiliates include APC&#x2019;s investment in ApolloMed, which is reflected as treasury shares and eliminated upon consolidation. Amount due to, or due from, affiliates are payables and receivables with ApolloMed&#x2019;s subsidiaries and consolidated VIEs. As a result, these balances are eliminated upon consolidation and are not reflected on ApolloMed&#x2019;s consolidated balance sheets as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90ZXh0cmVnaW9uOmVjOTJkOWQ0ZTU5MzQ1ZjBhZDJmZjNlYzI0NmM5ZmQ1XzE2ODk_f849d48b-dcd7-45cd-aea5-582f175a426a">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of ApolloMed have no recourse, and liabilities to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the general credit of ApolloMed, as the primary beneficiary of the VIEs. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands). The assets and liabilities of the Company&#x2019;s other consolidated VIEs were not considered significant.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2014; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts due from affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;261,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loans receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in a privately held entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash &#x2013; long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,070,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.999%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*Investment in affiliates include APC&#x2019;s investment in ApolloMed, which is reflected as treasury shares and eliminated upon consolidation. Amount due to, or due from, affiliates are payables and receivables with ApolloMed&#x2019;s subsidiaries and consolidated VIEs. As a result, these balances are eliminated upon consolidation and are not reflected on ApolloMed&#x2019;s consolidated balance sheets as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzYtMi0xLTEtMA_7a66ea3c-b19d-4fd0-8cdf-e9e31130e6d0"
      unitRef="usd">161762000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzYtNC0xLTEtMA_a5887ff5-9472-49fb-8525-63cea47cb14f"
      unitRef="usd">126158000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzgtMi0xLTEtMA_04e8a08a-62e7-4de9-8d99-7950b27f06c4"
      unitRef="usd">49066000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzgtNC0xLTEtMA_0664e2b5-49c5-4c1a-aad4-8e30ea1977bf"
      unitRef="usd">67637000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzktMi0xLTEtMA_a11670fc-5d2a-4348-bd05-f7df42e2a91a"
      unitRef="usd">7251000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzktNC0xLTEtMA_692d452a-8ace-44ac-8869-73cbe1bd4fed"
      unitRef="usd">5155000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEwLTItMS0xLTA_2fff612a-f295-4803-a51a-950c093fdd6d"
      unitRef="usd">62180000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEwLTQtMS0xLTA_808b0bfc-7e0d-4f42-bbec-067a395ade7c"
      unitRef="usd">46718000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTItMS0xLTYyMDUy_41d4189c-3d36-48fe-b595-d7dfb48277ff"
      unitRef="usd">1342000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTQtMS0xLTYyMDU5_12e69afc-eee3-4f30-8a77-3719a4ccadb6"
      unitRef="usd">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTItMS0xLTA_2639a89c-df3c-444c-a006-810c2136d217"
      unitRef="usd">1833000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzExLTQtMS0xLTA_fa7416b0-d369-4ffd-9a9d-32fc6480a81b"
      unitRef="usd">1084000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEyLTItMS0xLTA_bd9c973b-9eec-4244-8b40-dae2d60ba1e7"
      unitRef="usd">11734000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzEyLTQtMS0xLTA_ae24daec-8374-4fef-9839-913627e1825c"
      unitRef="usd">14863000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE0LTItMS0xLTA_be8663a6-8374-42fb-add7-7df32fd88228"
      unitRef="usd">4000000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE0LTQtMS0xLTA_d11d7e34-d620-47cf-a45d-b326ae4e84ea"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:DueFromAffiliates
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE1LTItMS0xLTYxNzA2_1e11a221-02cd-4d28-85bf-d98197262ac1"
      unitRef="usd">6598000</us-gaap:DueFromAffiliates>
    <us-gaap:DueFromAffiliates
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE1LTQtMS0xLTYxNzEz_17cbbb53-de0a-4815-8a27-2c3d75ce908a"
      unitRef="usd">0</us-gaap:DueFromAffiliates>
    <us-gaap:AssetsCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE2LTItMS0xLTA_05dcc9df-b6c1-4e44-89c4-6399a180e152"
      unitRef="usd">305766000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE2LTQtMS0xLTA_429aa5c6-fe9b-4130-a13e-f9996244b03e"
      unitRef="usd">261615000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE5LTItMS0xLTA_5349c34d-0deb-48d6-8b4f-83f73936e334"
      unitRef="usd">49547000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzE5LTQtMS0xLTA_c110aafd-7aa9-45e5-891d-a3a12fcb3811"
      unitRef="usd">27599000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIwLTItMS0xLTA_0ef26c3e-f3bd-48dd-9f74-530c95f1808c"
      unitRef="usd">58282000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIwLTQtMS0xLTA_7423cde0-911d-436a-9c77-d2480b2dd641"
      unitRef="usd">69250000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIxLTItMS0xLTA_ed7a8233-f63e-425a-b689-703d08a5c081"
      unitRef="usd">109656000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIxLTQtMS0xLTA_8870ab32-36de-4358-86e2-5d1abda801f6"
      unitRef="usd">109460000</us-gaap:Goodwill>
    <us-gaap:DueFromRelatedPartiesNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIyLTItMS0xLTA_de27dfdf-f06e-482c-90b2-ab8aee9e8700"
      unitRef="usd">89000</us-gaap:DueFromRelatedPartiesNoncurrent>
    <us-gaap:DueFromRelatedPartiesNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIyLTQtMS0xLTA_ef0f81ec-0e82-4674-8620-057d44c1f41e"
      unitRef="usd">4145000</us-gaap:DueFromRelatedPartiesNoncurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIzLTItMS0xLTA_6d488e4a-1cc8-4ec0-a582-520113e11d62"
      unitRef="usd">41715000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzIzLTQtMS0xLTA_8a1dad74-ff18-4b79-af26-d14afd80693a"
      unitRef="usd">43516000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI0LTItMS0xLTA_93869503-cd64-4e31-b63c-4fd8fd2f2c0b"
      unitRef="usd">405000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI0LTQtMS0xLTA_409b4d35-b3c3-4971-a632-aadef1d7c3e8"
      unitRef="usd">36584000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:OtherLongTermInvestments
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI1LTItMS0xLTA_177a3824-3c3c-4080-8177-dc5a0a93ae22"
      unitRef="usd">802821000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI1LTQtMS0xLTA_2de187f5-be7b-43c5-89d2-985d269729d5"
      unitRef="usd">225144000</us-gaap:OtherLongTermInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI2LTItMS0xLTA_dee712d2-2721-4b31-b696-93f6ffc62a97"
      unitRef="usd">0</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI2LTQtMS0xLTA_31bcbe2b-f348-4d2f-b649-b3eaa10b9fe8"
      unitRef="usd">500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI3LTItMS0xLTA_74a98b8e-bfa2-4712-8a94-8587ce176216"
      unitRef="usd">4953000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI3LTQtMS0xLTA_8229e421-08fc-496c-9308-17e4bf9a14b7"
      unitRef="usd">6298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI4LTItMS0xLTA_7dfa2f6c-53d5-4b86-89ad-61be3e39f230"
      unitRef="usd">3219000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzI4LTQtMS0xLTA_bfe1ba4c-ee9a-4bb9-87e4-55ccc6922cd0"
      unitRef="usd">17177000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMwLTItMS0xLTA_e37ffff5-4e85-4de1-8b49-55bc5eaf65a1"
      unitRef="usd">1070687000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMwLTQtMS0xLTA_7d0207f2-f2e0-4277-a10c-00353b771b80"
      unitRef="usd">539673000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMyLTItMS0xLTA_ca5cd44a-3715-4c33-9ca4-a08a81752f56"
      unitRef="usd">1376453000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzMyLTQtMS0xLTA_6962958f-1087-4219-9c8d-313db2a70631"
      unitRef="usd">801288000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM1LTItMS0xLTA_15ed6d54-e1bd-49ce-8e29-f3f6ed5d171b"
      unitRef="usd">11591000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM1LTQtMS0xLTA_7bb09b93-86e4-47c5-907b-3502a238e461"
      unitRef="usd">12963000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM2LTItMS0xLTA_d6952d7c-9ad1-4b79-b275-949655a1e7a0"
      unitRef="usd">10534000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM2LTQtMS0xLTA_77e5d803-16fc-4160-a3eb-114a8cf6c0be"
      unitRef="usd">9642000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:MedicalLiabilitiesCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM3LTItMS0xLTA_851ee1c0-c7c6-4677-baa2-87db41481fbf"
      unitRef="usd">44000000</ameh:MedicalLiabilitiesCurrent>
    <ameh:MedicalLiabilitiesCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM3LTQtMS0xLTA_1a3da0bc-0ce9-488c-b88c-28ad27777400"
      unitRef="usd">37684000</ameh:MedicalLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM4LTItMS0xLTA_04ab771c-8b86-4c83-a9f4-3f8237d2ce04"
      unitRef="usd">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM4LTQtMS0xLTA_cb15f39f-36d6-4d57-8aba-c9cf2cb916ee"
      unitRef="usd">4225000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM5LTItMS0xLTA_06fddcfb-835a-4904-83ff-c2a3fd7f1416"
      unitRef="usd">556000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzM5LTQtMS0xLTA_a014d574-5679-4a5c-ada9-a977b5e093d7"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQwLTItMS0xLTA_998391fd-d0ec-4ed2-bce7-12aeaeb40e92"
      unitRef="usd">0</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQwLTQtMS0xLTA_e5308b06-c5ed-48ae-bc15-7e06a5c21328"
      unitRef="usd">22698000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQxLTItMS0xLTA_9e539bac-ec6f-4a84-8bb8-2dc8ee615612"
      unitRef="usd">110000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQxLTQtMS0xLTA_1cb27c40-12a0-43a4-bc87-ed792bf337a7"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQyLTItMS0xLTA_db55c82d-13ea-4f60-8a14-31f04e400497"
      unitRef="usd">1250000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQyLTQtMS0xLTA_dc0cea5f-dfd8-44a4-aa4e-311c15a6c22b"
      unitRef="usd">1242000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQzLTItMS0xLTA_ed99c436-821f-4da1-b13a-f4842f4df7ce"
      unitRef="usd">780000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQzLTQtMS0xLTA_37fd52a6-7cab-4c1c-b219-62279489f9ba"
      unitRef="usd">201000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ1LTItMS0xLTA_58292372-0010-46b5-b169-3951b30d287f"
      unitRef="usd">68821000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ1LTQtMS0xLTA_dc6834e6-be72-41fc-869f-cbb227ad7fdc"
      unitRef="usd">89242000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ4LTItMS0xLTA_83846aa3-933a-4f7c-9db4-fb313f5f2751"
      unitRef="usd">1982000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ4LTQtMS0xLTA_86b44ad1-f808-4b4c-8291-7ce29831602a"
      unitRef="usd">9144000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ5LTItMS0xLTA_ca2b4568-214f-45e6-ae75-a5bf0016adf1"
      unitRef="usd">193000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzQ5LTQtMS0xLTA_54a059fd-c746-45f4-95cc-41e55ba1b879"
      unitRef="usd">311000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUwLTItMS0xLTA_324ab5b6-585e-4614-a237-675d8bb26b9e"
      unitRef="usd">3950000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUwLTQtMS0xLTA_f6842ca3-d374-4a24-bdfb-a839d7f7c8b2"
      unitRef="usd">5242000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUyLTItMS0xLTA_d8aff236-f42e-4335-bfe5-586d257fc5c0"
      unitRef="usd">7114000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUyLTQtMS0xLTA_331ffecf-b431-41bb-ba93-8ca843ddc680"
      unitRef="usd">7379000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUzLTItMS0xLTQ0MjE2_b91e53e8-893a-4e2a-ace3-d82e69f18dcd"
      unitRef="usd">9614000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzUzLTQtMS0xLTQ0MjI3_0f63a850-30d2-4a47-91c6-cfaf46db7a23"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU0LTItMS0xLTA_99ea0fec-ef07-4e36-90cc-c0369ed9488c"
      unitRef="usd">22853000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU0LTQtMS0xLTA_d4c84644-186a-4e5a-82b0-2895f2039d95"
      unitRef="usd">22076000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i28dfed083b894f49a515b929d24e2c7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU2LTItMS0xLTA_497fd46c-123c-4f17-8bb8-6ca5683c714b"
      unitRef="usd">91674000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic0f403ad8d2e44f5acf821af7d302d5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMDgvZnJhZzplYzkyZDlkNGU1OTM0NWYwYWQyZmYzZWMyNDZjOWZkNS90YWJsZTo5NmM5NDNmNTE1OTk0MDdmYjc5ZThmYWY4MjIwOWI0OC90YWJsZXJhbmdlOjk2Yzk0M2Y1MTU5OTQwN2ZiNzllOGZhZjgyMjA5YjQ4XzU2LTQtMS0xLTA_243ec097-d0f5-42f4-9772-1ad29b4490bd"
      unitRef="usd">111318000</us-gaap:Liabilities>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMzA_9f7042e8-66cd-47c3-9cad-09448798c7bd">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms ranging from seven months to eight years, some of which may include options to extend the leases for up to ten years, and some of which may include options to terminate the leases within one year. As of December&#160;31, 2021 and December&#160;31, 2020, assets recorded under finance leases were $1.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases was $0.6 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.27 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.26 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company does not have additional operating or finance leases that have not yet commenced.&lt;/span&gt;&lt;span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMzE_4a3155ed-f08b-40e3-88da-6bb2a3e8f3a6">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, physicians&#x2019; offices, and certain equipment. These leases have remaining lease terms ranging from seven months to eight years, some of which may include options to extend the leases for up to ten years, and some of which may include options to terminate the leases within one year. As of December&#160;31, 2021 and December&#160;31, 2020, assets recorded under finance leases were $1.3 million and $0.4 million, respectively, and accumulated depreciation associated with finance leases was $0.6 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.27 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.26 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company does not have additional operating or finance leases that have not yet commenced.&lt;/span&gt;&lt;span style="background-color:#ffff00;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="i283b7bc3b0dc4508af91c59f486c2adf_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4Mg_18b81b0d-fa87-467a-9d3a-6a47b47a12dd">P7M</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i283b7bc3b0dc4508af91c59f486c2adf_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4Mg_1b7463d1-fc0e-4bd1-803f-f911a97d89b0">P7M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeFinanceLeaseTermOfContract1
      contextRef="ibef63d60b9e947eead74bdfd0b22345e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4OA_612810fc-17d3-4dbb-a746-443bdb1ba28e">P8Y</us-gaap:LesseeFinanceLeaseTermOfContract1>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ibef63d60b9e947eead74bdfd0b22345e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzE4OA_7a7ad439-6ed3-42a6-9104-ddb7a63bad44">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzI1Nw_2b4a27a6-5173-46cf-b8f3-877f79a7aa03">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzI1Nw_394f0bff-a876-4a2c-9937-7a19d3ca7e1e">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzMzMA_5bc8f1df-6b07-42e4-a2ee-b154e9521cad">P1Y</ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzMzMA_da373d40-64b5-4f33-9fb8-d6a7e7135031">P1Y</ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzM5Mw_a3878f45-4b46-4af2-8ce1-453e0810dc34"
      unitRef="usd">1300000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzQwMA_93a8d47c-a2e4-487e-b409-be4d2a1aa6dd"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzQ4Mg_a06c46e0-78ec-4823-9432-67c7a0c43b3e"
      unitRef="usd">600000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzQ4OQ_b8d599ea-62d6-4afc-abaa-818c09018a8a"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMzI_bbad78e7-e36c-42b2-8a1d-9bbbb985d26e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(784)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average Remaining Lease Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.27 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.26 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted-Average Discount Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzItMS0xLTEtMA_bd99ac84-3761-4fa6-8933-37e4ac4a8ef1"
      unitRef="usd">6025000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzItMy0xLTEtMA_d57fa590-4496-4dd2-a5a1-eee7fcbf576b"
      unitRef="usd">6589000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzUtMS0xLTEtMA_cc41ee65-a969-4065-a679-ea7b7c766a65"
      unitRef="usd">208000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzUtMy0xLTEtMA_40e0405c-256b-49f9-a302-0a577965ecd5"
      unitRef="usd">105000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzYtMS0xLTEtMA_d4679480-3c7d-413c-856b-1633f3d16b9e"
      unitRef="usd">26000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzYtMy0xLTEtMA_ffbb2be4-5cc3-4478-ad18-02093cfd2a85"
      unitRef="usd">14000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzgtMS0xLTEtMA_c3559adf-b600-46d5-be35-14841c8d4185"
      unitRef="usd">852000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzgtMy0xLTEtMA_14c89557-ee9c-43e8-9921-a540b06a31eb"
      unitRef="usd">784000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzEwLTEtMS0xLTA_4b2c659b-714a-4e24-b56a-5e59a866b6e5"
      unitRef="usd">5407000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZToyYjA1MDUwNjlhYTg0ODc3YTg0MzYxZjMyY2U2ODJiZi90YWJsZXJhbmdlOjJiMDUwNTA2OWFhODQ4NzdhODQzNjFmMzJjZTY4MmJmXzEwLTMtMS0xLTA_14ef86b0-0b41-49b5-ba60-505a94697412"
      unitRef="usd">5924000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzUtMS0xLTEtMA_b19101df-fa47-460a-be81-96e00194ac6c"
      unitRef="usd">6083000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzUtMy0xLTEtMA_500e844e-99f1-4b22-97c2-ed292e7c746b"
      unitRef="usd">5804000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzYtMS0xLTEtMA_4c3e4fea-37de-4ef5-a54b-b73a8ff84835"
      unitRef="usd">26000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzYtMy0xLTEtMA_b45d3762-0d75-420f-8c51-780dc4458d31"
      unitRef="usd">14000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzctMS0xLTEtMA_ab849d55-5b7c-4c51-8196-952e4649d2b1"
      unitRef="usd">208000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzctMy0xLTEtMA_d4706a3a-8047-4592-9ef1-e2b4866f85e6"
      unitRef="usd">105000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzEwLTEtMS0xLTA_fe6becd9-b8b5-41ed-8f14-25babf4883a4"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzEwLTMtMS0xLTA_71f5a787-2e47-4e46-94b5-4c11d1988b4d"
      unitRef="usd">7652000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzExLTEtMS0xLTA_c6c8a4f3-4117-4659-a5f6-178391a1f6e0"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzExLTMtMS0xLTA_4a7cadea-59a9-48cb-b279-ad3720e49657"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE3LTEtMS0xLTA_52e1c7e7-7185-4f2d-a0b7-3cea5d2f71a1">P6Y3M7D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE3LTMtMS0xLTA_45c7b31c-bb02-4fba-941c-269498290a10">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE4LTEtMS0xLTA_f91b18e6-82df-4c73-8dd1-bca880321681">P3Y3M3D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzE4LTMtMS0xLTA_25a4de0d-1f18-4149-af52-6b4a3c38e1f7">P3Y8M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIyLTEtMS0xLTA_62788bbe-bf1e-40a2-87e8-0f5142f22a23"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIyLTMtMS0xLTA_b519aac9-75cb-4343-be1a-c7c89c1767ec"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIzLTEtMS0xLTA_99ef301d-8383-482b-bcde-0992da424ec3"
      unitRef="number">0.0453</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i15daea0fb86f4e9087b3958e4c3f97dd_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTo4M2YzZTNhZjVhOWI0NDMyODllNTJjZjI4ODRlOTY1NS90YWJsZXJhbmdlOjgzZjNlM2FmNWE5YjQ0MzI4OWU1MmNmMjg4NGU5NjU1XzIzLTMtMS0xLTA_2599ae6c-ec17-4e9f-8aa7-74013dfaece9"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMjg_6a935754-2490-431d-8d14-94de40b9cde5">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90ZXh0cmVnaW9uOmUzZjdlMzMyZjQ2YzQ0ZmM5OTUwZDQ4MDJjODkyMjRiXzEwMjk_1dd5222d-f19a-4e47-8399-479820bc4931">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;br/&gt;Future minimum lease payments under non-cancellable leases as of December&#160;31, 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.225%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEtMS0xLTEtMA_badc122f-1d16-4d86-a82d-5a24d64d28c0"
      unitRef="usd">3543000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEtMy0xLTEtMA_f9f5730c-b860-499e-8a71-e9dad5afc209"
      unitRef="usd">543000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzItMS0xLTEtMA_ea471196-013f-4c4c-91d1-f60f1b9297d6"
      unitRef="usd">3303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzItMy0xLTEtMA_b07b967c-cf34-4625-9a98-74d58638035b"
      unitRef="usd">443000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzMtMS0xLTEtMA_38b3719f-e5f7-4d6f-85e4-2655daa78f4c"
      unitRef="usd">2940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzMtMy0xLTEtMA_d69d707f-ce8c-473d-aab0-0f18f341978d"
      unitRef="usd">377000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzQtMS0xLTEtMA_ba3a1779-22df-4d71-b36f-a7cc4a966261"
      unitRef="usd">2648000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzQtMy0xLTEtMA_7dab60ce-2856-4111-a504-27c24f28b47a"
      unitRef="usd">214000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzUtMS0xLTEtMA_2bc16039-c172-47cf-9c24-30e0b9475329"
      unitRef="usd">2070000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzUtMy0xLTEtMA_f7c92222-0e0e-480b-ab99-304eda4662fb"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzYtMS0xLTEtMA_0122c610-1b94-4f9f-8245-386479df623a"
      unitRef="usd">4740000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzYtMy0xLTEtMA_f59a2451-d92b-48d4-bba5-b6f705361963"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzgtMS0xLTEtMA_cf2c815d-a238-4048-8191-27dda641e43a"
      unitRef="usd">19244000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzgtMy0xLTEtMA_b5911dd4-0152-4342-99e4-b1f0a9941fbc"
      unitRef="usd">1577000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzktMS0xLTEtMA_ae1ba630-1be1-47bf-9dfd-b3585dc26306"
      unitRef="usd">3417000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzktMy0xLTEtMA_97c7c603-c88c-494b-8a3f-f4dcb27f2d98"
      unitRef="usd">118000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEwLTEtMS0xLTA_41f5ea67-8d0e-4dfb-a3b1-1e3920d61508"
      unitRef="usd">15827000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEwLTMtMS0xLTA_cd828c1d-8d01-460e-a915-a677f471ebff"
      unitRef="usd">1459000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzExLTEtMS0xLTA_aa25d78c-812d-451c-91cb-bfe1de119ce5"
      unitRef="usd">2629000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzExLTMtMS0xLTA_4be1210a-0890-4f31-9ab1-c3890a892f90"
      unitRef="usd">486000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEyLTEtMS0xLTA_5c581a85-0411-4105-9627-d7ea65be4964"
      unitRef="usd">13198000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i88eaaac5b8bf4609a5884bfad9cf117e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8yMTQvZnJhZzplM2Y3ZTMzMmY0NmM0NGZjOTk1MGQ0ODAyYzg5MjI0Yi90YWJsZTpjZDU0YzUwYTk0ZjQ0NTQyYmMzN2VmZWJhMWZmNmE5Ny90YWJsZXJhbmdlOmNkNTRjNTBhOTRmNDQ1NDJiYzM3ZWZlYmExZmY2YTk3XzEyLTMtMS0xLTA_75154cc0-6c8b-438b-ad77-5df297f627d1"
      unitRef="usd">973000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTItMS0xLTA_7bcc9575-21a7-4a27-a77e-32e7a3454581"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTItMS0xLTA_7bcc9575-21a7-4a27-a77e-32e7a3454581"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTQtMS0xLTA_a79fca52-6e1e-45fb-b0a3-d2e1a70dd11d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTQtMS0xLTA_a79fca52-6e1e-45fb-b0a3-d2e1a70dd11d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTQtMS0xLTA_d2add495-3187-4214-9620-f3aacb32a074"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTQtMS0xLTA_d2add495-3187-4214-9620-f3aacb32a074"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTItMS0xLTA_88f8d027-0dcd-4f98-8e05-61d92fffcfaf"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTItMS0xLTA_88f8d027-0dcd-4f98-8e05-61d92fffcfaf"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company&#x2019;s consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#x2019;s consolidated VIEs totaling $567.0&#160;million and $576.1&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively, and total liabilities of the Company&#x2019;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $91.7&#160;million and $88.6&#160;million as of December&#160;31, 2021 and December&#160;31, 2020, respectively. These VIE balances do not include $802.8&#160;million of investment in affiliates and $6.6&#160;million of amounts due from affiliates as of December&#160;31, 2021 and $225.1&#160;million of investment in affiliates and $22.7&#160;million of amounts due to affiliates as of December&#160;31, 2020 as these are eliminated upon consolidation and not presented within the consolidated balance sheets. See Note 18 &#x2013; &#x201c;Variable Interest Entities (VIEs)&#x201d; for further detail.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTItMS0xLTA_7bcc9575-21a7-4a27-a77e-32e7a3454581"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTQtMS0xLTA_a79fca52-6e1e-45fb-b0a3-d2e1a70dd11d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZTo1NDIwOTEzMzYwYmU0MjQ3OWZlODFjYWViZWFiM2EyNi90YWJsZXJhbmdlOjU0MjA5MTMzNjBiZTQyNDc5ZmU4MWNhZWJlYWIzYTI2XzM0LTQtMS0xLTA_d2add495-3187-4214-9620-f3aacb32a074"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90YWJsZToxMWJhNmY5ZTkyYjk0MjEwOTMzZTkzNzExZjM1NDYwZC90YWJsZXJhbmdlOjExYmE2ZjllOTJiOTQyMTA5MzNlOTM3MTFmMzU0NjBkXzI4LTItMS0xLTA_88f8d027-0dcd-4f98-8e05-61d92fffcfaf"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjc5NmQ2MmMyZWI2NzRiOGM5ZWRkNDhkNzhlYmYxZjk2L3NlYzo3OTZkNjJjMmViNjc0YjhjOWVkZDQ4ZDc4ZWJmMWY5Nl8xMDMvZnJhZzo2YzYyMGFlNTYyYzg0Mzk0YjM3MDM1M2JkOTZjYTVjYi90ZXh0cmVnaW9uOjZjNjIwYWU1NjJjODQzOTRiMzcwMzUzYmQ5NmNhNWNiXzY0OQ_8ee7c054-ac2b-4708-a874-28bb5920ca00"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>107
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?W<5'%L#]\9WP==Z[YK8J<REO+<WD^B\Y5E&/.&AL1 ,_CWP,4\2BP0\_BU
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M%^#WA91F>V,'V'U_NO@/4$L#!!0    ( )**7%0=;*043P(  +4&   8
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK971;ILP%(9?Q>(Z"@&2;*T($DE:
M+5*Z18VZ:9IVX< )6,4VL\UHWWZV(2R9",K%;L#']O]Q_H,YA#47KS('4.B-
M%DPNG%RI\MYU99(#Q7+,2V!ZY<@%Q4J'(G-E*0"G5D0+UY],YB[%A#E1:.=V
M(@IYI0K"8">0K"C%XGT)!:\7CN><)IY)EBLSX49AB3/8@WHI=T)';D=)"04F
M"6=(P''AQ-[]:F[VVPU?"=3R;(R,DP/GKR;8I MG8A*" A)E"%C??L,*BL*
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MH4-<UY?)LNW^14^#;7""LG6K9#44!@554??_I]^&@3BF !D*D$D!S!P%Z%"
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M,CO+SAZ46)O3W8502D3F-F#49U(+P/A20)SR!^V@^(_"[?]02P,$%     @
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M\3@RJVXG*K#&UT8%QV2@9D2Z&$'^8L3#-N/Y6BI[_PV^L8NO640Z48%YI.)
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M^$C5AM<S:.NY,;R44VF_J&Y\[[1S>I2*EZU89U 2UHSXK3V',X%_>T$0M(+
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M#_=[W]\/6^Z'L/>YKKIMZWVHUFQ]VL E?_B1 3XR>(^=+:8L_\4CZ+6'?8R
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MXB'PC4W:)0 SJI#/KF,(E;0(9\LI)VSR>K<3M7O]H&TVK.%F$R0UGZ^8AZ0
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M-6L$@/^^J>ON^(>XP?B6J:O_ 5!+ P04    " "2BEQ4XS,\W607  "O1P
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MZ[W1"VAYI7Y#'F"V8K27NI#J#R@06G='Y$($6]8G1&WXI4^Q\85_XCO]:4*
M7<I%HF*R"+Z]>+%?'L0@2R7^[&QZCJR+N.1Y*R&$YF:+Q!"):P>J83ZOW+OB
M0 *<"O#W*HI]INHUPGUOV6M4J(C,C4M#L2$O;85+W\KOV1E>SH[>7\TO0-U8
M/KK*JB]W%Z]D[P%-^E#TK?>=I_^,$M7_1X5**Z)S8_:4J(06(@^I(F4;,*IG
M=3M8F)*=DU"*&NW:4YK:4Y;B(;"T9RR4J5C$L=K"M=W"%XHB"3]3M=K%J=;4
MHMN.;QUE0>:.J(Z'&TF"(DT8&G;Q2.TC(YL!4K_&.[.LD10:*'?W$U+-RTOU
MN-"UM\K%;97[U;?(]'%9Q6OT-N>?OR/=99<?=*-]':#= (?F3&A:E<U='F2\
MUU=D?:,V!N.9#4:\3WHXB>,Z8?V[6D9)B0 ?X"MY8C0XQM$$Q^7\W8=LD"?S
MI_MG9UZFR1D_=O-V/@-(/PS ;)J1Y>KB>7?/I+R;92,ID;:<#Q!I'=?PR-)G
M 46J5<TU-;V*CW>.'<USG/\YHTKW&K'ZLG&F^9LO YHN.<TN.?&-XPD;ZQAJ
M9KH\:COXKE1*YD)9@)2EX CCJ[.\AD+AH';K"5N?A3%-%O;:T:02I!L 3IX]
M>QQ+DWH\%YTWJO,0/(T@C*Q!S%5E2DE<OPRL9[/(J;"<]2SS"9386=)IF&AG
MZH216WZV=YN"MIP#<2KE#^G#YIW:? HZ:]M2G["GQB';,6^VLVD/DH,CD/91
MF)NBB?VZ1D[.I;40H0F=7U("]PHNP9*\22,]SF3]S-D3%01"^/>"%)G&D*C-
M0-U%L4Y[9L^F!Q6"69L6^F$HLG8<#Y&H$/-\:Z!J_?A(/322W_%C2*"F.'=?
MJ(J?,K8%;A&+4C,Z31H)<^)D.\EXW?+4'^Y[&ENMAVX31WGV<"JOEW!GTI,W
M((=_#14Y<# /F:4(?R2"/'XZ5+VE B[.*P=X3O8,N<L(;+^+VSOS&'*/K7KM
M9[["S!KW;BZ&%7*46[6.8(*#K>!XP=!$">M!5C-/U8-1W$T[M@A;2L[W=47O
M0_$$C7I(32'H/&U^<OZU=,&_>C)]O&M/:(CJC0_ $G=Y<FV;IHZES^S&)D=(
M7G-+I2U\WXV*.WLE&*=$_HZLBXP'NOXH&W_+N9W(OD<;)<P,/$HO-N1-;'\O
M)E_9RN ][6LXL94[$O+&CP'L*4[M,$K\Y&XY[L#+ H=X1Q$.B,*,.9F>[C)&
MBN99S3Q$UGGQ%H%\X-[>J9A,0+/PR(^(A[XA81NF":V/9R3U];,QHJY4U6JE
M&7J&ZV?Q-PUED1--0ZR^@%2;?MWR*P_9! 5L4HK,OSAUF>Q+"<TGXK\S>>X'
MK);58'A4(W1XXPL9U-7U 1;'U'GG^6U[0Z\(3<:9%B7%1.M;XR_W&VW1.Q-M
M6=5MHJ@[MU.*DXS!T,L_)%J2[$82AEFJW;K=+9Y,U0OV"+Z_%R$&(;!?.O3B
MQ>V>0R\2?.PF!MD2&;LI2RNLS2-^GUSY8GH(CL8F<J=.R1>(AHF=3<KBT@M.
MA(BD'!%LF,/:A<PO7X4[D%,C_0X#8F2C4P;HV0Q+U7&56;92&/=T>IXZ8?WM
M:@N78;+!LS%<2Z]W+4Q9IBIITS9'(?D26QRZGG?]2I"0A+8KJ8O%7+!JF]41
MU\,K*SIETR@Y"0%S2EY[RAFI*Q8:?NE3#&<VF4FE1!%JMF7>&Y&.(WNM6 5V
MBNF3G0Z>ST;R'(2GL[$S1.<(V:&W8-.E[OJ&Q_+S6N3\\C)+*2"X?CU/9.<+
MQ[^-LX/_?/_^ 'C\LO/.S?D!?#\TAJ9^Q]O]PW3:+WIU]&U*+),J^ZPIWXRU
MZMLQHK3]Z1=L?SH:O8 .Q/>D*'Y8#%8J^:FE4 P=]93!O$IZZ=2KH,G77M[0
MNC%51?]>:S:_E01)TDOGMR ;>>>&B_A!OI9#/W301O#J-H\"_>GTF)KNO#.6
ME9LX(&Z\4'GX(Y'=]UZ<Q&<0SLH;>:;-;@=J9YB%=7W^Z^LWU!6!CK[0S4?U
MT_1B*K^DRH?M8#LU-8O;[I]FYQGCO]S26YFI! $]19F70AT..$)=]U !U MX
M$$[U+3-H'$QHMQ,JC.IS[E )^$_Y^]L#8NP6N#,5=""8'WFSJ"1VE[>Z?E$C
MO"T+7/*5O5PDN5\\:JQ?.!Y)F?B1G8*Z"1MI$;-HM*,!S5$'KA<4HX(P99 ]
M6@@'37HWX];A2]^TC=U>7Y-+#><]58Y)+.6!+Z+M/"##^864TA%.!\3#>SAA
M%BE[ES4,#H=V@I^/R^Q[HYY"I7==^$.>1I$WH4M;#>)JG'7\'O&??/5LPO'Q
MWG=9/*E]ATA2?]:B5 O9^PJU,]#\;O0FM3C?;C?W484-N?U+C5MQXRH4 5[3
M&Q76%>WHI6?VA1)I?2YXBJDED_G.%^UC^G+V["_)7JX&7#,,(+_7"Q*AMLO?
MM*45^"&]_G"OJE<:8YFJ ,%7.FZ=ME7O:N*4V.4X(>"RGAG)TE%XLZ+2"]'?
M] )_P5,4K#JWFG('T]DOGA;/+_+71<^_9.O_I6+FLRPA_I>-F??][8Y'V1]1
MX;^Y0'\JQDF%4/Z>2GP:_QK-A?P1EK1<_I3-7'?(Y1W"M26VTA#C VE'A2]]
MN^$_R;)H^[ZM^>/::'",%N#W9=OVX0L=$/]&SX__"U!+ P04    " "2BEQ4
M]W$&I (I  ">AP  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6SE?6ES
MVU:VX%]!>9PIJ0NB16JQO,15LAPG>F4EJBCI5S-3\P$D+LD;@P"#13+[U\]9
M[P("LIS7W3-5\R&Q2%[<Y=RS;WC[4-6?F[4Q;?)E4Y3-]\_6;;M]_>)%LUB;
M3=9,JJTIX9=E56^R%C[6JQ?-MC993@]MBA>SX^/S%YO,EL_>O:7O;NMW;ZNN
M+6QI;NNDZ3:;K-Z]-T7U\/VSZ3/]XE>[6K?XQ8MW;[?9RMR9]O?M;0V?7KA9
M<KLQ96.K,JG-\OMGE]/7[T]Q/ WXNS4/3?!W@B>95]5G_'"=?__L&#=D"K-H
M<88,_KDW5Z8H<"+8QI\RYS.W)#X8_JVS?Z2SPUGF66.NJN(_;=ZNOW]V\2S)
MS3+KBO;7ZN$G(^<YP_D65='0_Y,''GO^ZEFRZ)JVVLC#L(.-+?G?[(O (7C@
MXGCD@9D\,*-]\T*TRP]9F[U[6U</28VC83;\@XY*3\/F;(F7<M?6\*N%Y]IW
M[[/&-DFU3&YKTYBRS1A699[<\37A;W=V5=JE761EFUPN%E57MK9<);=581?6
M-&]?M+ 3G._%0E9]SZO.1E:=SI*;JFS73?)#F9L\GN %',&=8Z;G>#][=,8/
M9C%)3J9I,CN>31^9[\3!Y83F.QF9;^"8R?^ZG#=M#7CTOQ]9X-0M<$H+G/Z;
M ?_HJDCBKYMMMC#?/]OBNO6]>?9/V4HR/,EO:P.$MZ@VVZS<X?A%53;P2)ZU
M)D^6MLS*A<V*I('Q!FB];9)U=F^2N3%E CO<9C6,F^\ Y4O@$3@BL25-6>?P
MK %R:=?)RI2FSHIBA[^8+<Z=^3UN:PNK; O8)3S;PI9^+RV.N<-5:=.7&U/#
MV9*#__[?+F:SXS>_3^XFR8^7E[?T>?KF< +G<K/  U?N''K,Z&3SK*#=$6$V
M24;/ (Z:S=S4#D\)QO#',?T131  !)Z$E:N-28 'T_9W)JN;Q"#I[$^:^AEG
MQ]-7^&S1Y88>%*#0G ?3P^1R6Q5%=6/RU/^))YZ^?-/T]M/-&YO;K(:[3I.?
M;V[@"?P?+G-Y>WEY]0O_;6'ROU__ &,N;X\N;W[2?Y-9"MA4)I^R><,C/]S\
M^"8YF!VZ 5]9>(=37=%#)X>X^/!X7OSNZJ<KWMO-3_# Z2%NV3T 8V@R^.4,
MU[]ZRID!9^Y-W0"R7@%2 @W\V=G&TO7?9G4+" B#/GVZ\CATY=$G36YN;Q%D
M/P(>@42M6YKS?W[ZU ?;U8>[*]K<T:>[F\LTN;ZZXB&_9:ODX@W]>7!^Z$8\
M9>N7Q7:=T;93I=UL7ICD)Y,50#W\ T/KQTGR>V,0/WYH6KLA^D#L9EID;(<?
MVS["#Y(R3EF;@@;DMED45=/53(7P,&H4MMTQ!3N"@P< L#@J(/FV@D^?36+<
MGG#JK %58HM;:F!#69MDRR4(>]H<;+>JB0]L',;#>".[*FPVMX7%6Z#/?G<X
M$#:'C -7'GN&5\&S?QLXQO96FWM3=K(;\P5TK@8^Y%V-#,P_1.P,6%653R*.
M#.QLT^"M_T$ J.#/Q?H1<"E3 /4!]2,^V(XWLC#V'M$#$ <^5(#TP<]%5:Z.
M"J"$G/$6,*E<640FAE2:S+L&A$Z#"+F9 QAX01R\JJK\P19%<I\5G1<R%H2#
MK1%$*3*HN@.HP4H;D\/9B@CL!]?O?_XU6129W31 4[EI#>!0Z=!RV17%46V;
MSS1QLT;IP9\%OH*2[HC) 4-"11.(=S@2G )%5F%HWB5(_*H6KK6VH)+5M#&0
MC"M;XCZ$/;?9E_!HP$X?4 BDO)$C5!YSFA@NE\;PE#4JCD?5\JAK3(1O!AX(
MCS]);CQ)&%X)J0G&C]\T 1G^OZKPC'.2TGA#J_ HB'# *E!BX?,5(%SMS^U!
M1'C>U35M .!5;>P"Y-"]K:M2+A >1U*%C>1_@/K*F/^P-@Q'WM_"UHMN Y0!
M"P*2VP72R"2Y;. "6Z1!O"Q/,+9.#%$VX%16EE4+ZH&[>P I,1!@4 O;,% 7
M+>(0\!!0S1$/NP(I'*:H$P12;4E56-;5!J:OFD?XRB3Y._!08I;7)3P) T%E
M;1D;?]D';8JB/CZ>+1&/6Q; I4'F &(<*0LLF]S4@@GXZQ7K2<'=F@S(N# K
MO"-<=L>,#NX0P?"PKO @U4/)2I(=5(YBYH2HN>HL_3XAUFX\SNJ>&L1>96RR
M*R=H[A4B5B 2H0AR[Y;W5#=KNR6(/(#5A?\&+!UU3XOPR5:U$0:IDO/F[M+K
M7;]5@#E%06<1]:U9@ C=Y[OAT1 3%60;P$-@)V#AS@&S];DEZCL/1/BU):1X
MG="JYV\8+/SP&K:=R14 >^@6A*!T"_@3*:H  P"(!64O1]X+.\IAG.>$9'IZ
M80-#X.)RH?4WPJMY.4!PQ&XY*(I(DES)5E0,@FAA-Z2_*F_8):)AIPF@%MP^
MB IE,!O 3R;HAI6'\(R*<'S(O8O5;40(2'@P?9/8B9FD \@@HKBFFR%S"8@Q
MY4/",OOX 5L6AN.$9F^RQ1J$C& S_^TT^26(#F*Z#A]XFPY;2Z-"?))<+P.L
MR"O#5.0Q0Q$AR>8@]F*:S+;; B^0MQI8%Q[C](B,E0 ^.)D<=V. T>1TE>[)
MH?T\;2^>/X2HLZ2[#XFA PL!MF!IRSC!_@UOJMP O)?[][QARZ7<#1 ,R#.X
M5]@>\,U%@PC])URR7>X20B32KV$WO#XM7!&L>#7<*/$7VE>P*,+780]>#:K$
M(!?BC0'S"Y@_K WT0FOB,2R3Y>"VVS5PFO[F!XG>X089HTVW7**1BT*/KQ,6
M960U)'T#^D8<K3HX09Z3;8!<HYL#/T8M)58,NRUJ=&^&UK=-Q%,(\<NJ/$*U
M'L0*.K(4I*0]H!Y#Y B"MC8!&0"DP/J]-XR4F^P/$/CPK9/=#@^0(9GZH#E$
ML$53'[[!JXPVR4#@1UCD9<FJKCID3=GB,Q- #T>(BQ%'@/O V?>I?9+\$,W,
MU !<OU%J )QF5-WQ0D/7'%_HMGHP-5(/;&^U[@$-SM4 *RVR6KY)\69SL#[$
MB@@N-N(NC*4;I/'&:^$@BFVY!%:$>#' BAS40=DB=RK+*?CA'H0N?$ A[K=_
M%UPVLG] P6T6;A]88)[MCMKJ"/X)9>LP)_2'B6XT7.:S77P^0O15 -T+_>+Z
M.]2HMJ@A( =9$O"\!9*+^M7$"%T!#J^8&P%HP?BOZOD@;$ #79!,JX!9-WLX
M1QO"*5AY'X:OS@'[M#FK@""M2^;\(0.%BR#[1]F-1Z-!'L'(BQP&&1/P\I@=
MDTVC4_*,;43+\BQ:=L*YD4^-\>M'&'6@CO8X>"1*1CGDF!@!MN%DA/YJF6<
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MU0= @4"K0Z"I7& -+S0V07O>V*:I@$Z B:GD C%CPAC\V/KP >P" QCQ4(%
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M1=W _\=O@9<6:X#]H08,O!5$/B19YP-LW$BG; .].1E^].SRY\@GM!*:GGV
MZ."S@F.@$<F\Q"'(?UIM3,4.' YT0"96!$RA 5*5D>N;X/0X8*!'E(<?X;!.
MV+<]*-]"A1<52MBWT.>$MF;WE!T16@U.XV>V)O,\(<,^LCVK52%3W>O(_G@.
M>6#:&/%69I[;RZ;9X1@[UF!.GGW3,6#H%,K[Z+Z)Q>H#'MBL+R4(Q]MS6:L
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MF 6@AWD^"%9U?H;NE:6)[)<-/8&HG0'MUTK9L^ "C(_JYA]02P,$%     @
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M1"HD':__OD-*UKK-9E$@+Q(YES-G.,/A_*3-)WM =/#8U,HNHH-S[2Q);'G
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M5 YM0*[JH:2F"6B#IPM)%OC-#[-,?"'#ZC$Z_A?%<[U^WI[*$HPC)D=P72S
M,=X@O:A5ZKMPN-3 UW1)+X:26<13CMY1_:_M$S]=T/DE,9(G'9T"XFGAF4T<
MQ,O\4>3&6R\@*X@3R,1='('B+"_]G/L&H>E803^U"*F\(7;BNV3K.D1AT-8'
M*K\QDD]2_,PG$'>\T7HEM/5PGBW^.(TD;GVR'9/V4W@7#A8076F=-H>.=##
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MJ0"T#&W \WD)M<(/8M"^E'W[7U!+ P04    " "2BEQ4HDFOU14+  "3(P
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MF,$XRJQ0J0R/>E:RJKM@' Q%^RZ+E*>%O0J.'>AU!K8:931FR*=->Q2FK[/
M@]:RQ-WLB4X!U+I2?9*4[I N&BJ;OW>0@9(T?*-X(0UZ+Q$K'EA--\B6V'_
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M7T&#$:8"<A$3HG>MIS[&;V6EZ-IGK,WD1SC$R$:"R'^.^;Y!T#03GL7YD ;
M5Y;)8RX(;'ZT;LM3%IB'Z9 ,Y[BF$*3*H)U$W[Y/7[+JN)K M=0<P$%]K;\4
MA2V00WLQ=W[I* XPB!^B&O;TWY<9J&"O-IM"<T8%-6"C S/&3\9@&!NX\ZX1
M#3A"P#Z8_(+(J'WA<.T"#V ZL%>\/0^^6RI57H"QU"$Y(3Q!]V;C>6?7<N,\
M\=%+[Q<D!M'GIO4M<HP9WA3Z-.RGY,/@P3Z,QS1J/5,9WZ=EG/)">?RCX&I=
MR-AZ$DP4[#WH+A#9+=SWG#X:A%+CQHL+DIV-Y,CD:.>0'EO+P?ZO3=[C8YDG
M$JJ2>A?0M8FDTU2P?PEPJUS<2GN1T/-M&-&60/*NJ^ICA*1Q@KHU41G5[I"P
MW8&8UN']D3)(K2:[>D)O:$06&OE.0[+DF11O?64R+,$'/-R2$YCH#H0S:698
M)B8_A/" RGZ*@)EJ2P"SMJ/Q8CS,H6G^HQ?VCC%+$-Y(;;C#9E(9^HOMT[7#
MFQ8BB5>"HE!MFJ\+!Q EP?3ZUL-"('EX37OJL\7TX$M1HWS%W\."X)$]?30:
M5H=/;HOTI6F_/7VONY.^XO"K-8[.)C^^&8%%^1M8NHFNY>].*Q>C:_@2K1L3
M.VW \[5#V\XWI&#X$'G];U!+ P04    " "2BEQ4]FVX,2,(  #!&P  &0
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M!Y#<0L3NN;8K]IOFJ>$.+W/6L2B?1G7"4M9E(2O8(:L;L*E*;6S8SVD$45-
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M]5Q;\AF3GE+U31C0IN4E#+H;E\L=RMZ53Y&=/MZ5?AR6]%@^71.A@Z2**Y.
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M'@Y:6%;<!Z/BQJK,?:29*6M5XBYCX,@X- #?SQ4Z7]Z0@NJKW<7?4$L#!!0
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M[PBZ8,#WE;5T$$* X<NT^ %02P,$%     @ DHI<5!39\YX!!0  _ P  !D
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M8N8?2*/K2)5J"J""=YX&K*[H+'\4Y&@]-0;FJ$TQAK>ZZIC;*^AWCB'^@^I
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M/2U/AA5J%;Z5C]Q-EC-T_>2Y<$_NG8&R,1HS.?WI*.:36\#B),/O;+[L6'X
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MJ!? ZASFHF9UQJ%TAS'A().JD7B$@YS/1<:U!TVQTB(3K-8__9!&X>3-9HM
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MD\;(R@X+SO "IP.X/Y?2]!-BL'XZOOX'4$L#!!0    ( )**7%2D J>%70,
M "8'   9    >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;*55;6_;-A#^*P?M
M!2G@6;+B=%EK&W"<;$W1;$;2;1^&?:"ILT2$(A7R9"?]]3U2BN(5;=!B7R3R
M>/?<<\>[XVQOW:VO$ GN:VW\/*F(FE=IZF6%M?!CVZ#ADZUUM2#>NC+UC4-1
M1*-:IWF6O4QKH4RRF$79VBUFMB6M#*X=^+:NA7LX0VWW\V22/ JN55E1$*2+
M62-*O$'ZLUD[WJ4#2J%J-%Y9 PZW\V0Y>74V#?I1X2^%>W^PAA#)QMK;L+DL
MYDD6"*%&20%!\&^'*]0Z #&-NQXS&5P&P\/U(_JO,7:.92,\KJS^6Q54S9/3
M! K<BE;3M=V_P3Z>DX GK?;Q"_M.-_\E =EZLG5OS QJ9;J_N._S<&!PFGW!
M(.\-\LB[<Q19G@L2BYFS>W!!F]'"(H8:K9F<,N%2;LCQJ6([6MRT&X]W+1J"
MBQU__2PEA@V'J>PASCJ(_ L0DQRNK*'*PX4IL/@O0,I\!E+Y(ZFS_%G$<Y1C
M.)Z,(,_RR3-XQT.0QQ'O^&N#A'^6&T^.2^+?9^"G _PTPD__3PZ_$0+^X)*#
M-R@T52.X-'(\ F$*6#N[4P4Z^(U)4@4W5K>AO#V\>[>"([(E4H5N!,D!0/*"
M$>"M,"WW74AJ/@+6@I6M&V$>&-C8UD@L6"H(%'&SW+7*L6"293^ W49U*1I%
M0@,7I;P-PF_E./J4Y(_?G>9Y]OH )THFKU^ "ATKK2L$$^.F8!S!HM(AUB%-
M&Z0]HH%E8[6V5UB,(IV.@41'/)" 4ZKH 2JKF8[_A/(8ULPQ!#:@=FEI6B<K
M[G1HG&+?DIDK3]'\^WR<<1MJ'28*.Y#"5]&CKX1#/X;WE;-M67$./0\Z11BL
MEI<_%8Z'CP'_E(H#)MSHSK%[_0 >W0[9U8ZI34=9EH'0JC1\$QRBDNR$(S>X
M55()IU@SY G.^:XD\7V:6-3*E-R+%$(_ZE-\OKH84AOX1@?YZ(0=-()4+#F&
M6K$WGO1&<2)_QYTH^+]TZH,U?6;?X[WPG*6G*!W6EL/L4:"V1I%U@<)1<KV^
MXMIKM*#P?(P_UVOIP>RJT95Q0GM.>FNH&V.#='@$EMWL>U+O7I KX4K%G:!Q
MRZ;9^.>3!%PWE;L-V29.PHTEGJMQ6?%#ABXH\/G6<B3])C@8GL;%1U!+ P04
M    " "2BEQ4'JF9L>9$  !E]   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6SE?6ESV\:VX%]!>7)GI"I*EN38L>,D5;*R^965J*+XOIJ9F@\@V91P
M#0(, $IF?OV<O4]CH60G=V:JYD-BD01Z.7WZ[,LW]W7SH;T-H<L^KLNJ_?;)
M;==MOG[ZM%W<AG7>'M>;4,$OJ[I9YQU\;&Z>MILFY$MZ:5T^/3LY>?%TG1?5
MD^^^H>^NFN^^J;==653AJLG:[7J=-[LWH:SOOWUR^D2_^*VXN>WPBZ???;/)
M;\)UZ-YOKAKX]-1&61;K4+5%765-6'W[Y/STZS?/Z 5ZXI]%N&_=WQEN95[7
M'_##V^6W3TYP1:$,BPZ'R.&?NW 1RA)'@G7\(8,^L3GQ1?^WCOXC;1XV,\_;
M<%&7_UDLN]MOG[Q\DBW#*M^6W6_U_<]!-O0<QUO494O_S^[EV9,GV6+;=O5:
M7H85K(N*_\T_"B >\\*9O'!&Z^:):)7?YUW^W3=-?9\U^#2,AG_05NEM6%Q1
MX:E<=PW\6L![W7=O\K9HLWJ5736A#567,ZRJ97;-YX2_71<W5;$J%GG59>>+
M1;VMNJ*ZR:[JLE@4H<T.]*_#;YYVL"@<^NE"%O"&%W VL8#3L^RRKKK;-ONA
M6H9E.L!3V(UMZ4RW].9L[XC?A\5Q]NQTEIV=G)WN&>^9@>@9C?=L8KRQ'?_/
M\WG;-8!2_VO/!%_:!%_2!%]^RAF,0?(SALE^OPV ^HMZO<FK'>YA45<M;&.9
M=V&9K8HJKQ9%7F8M/!_@NG5M=IO?A6P>0I7!1=_D#3PWWP'257!-\8FLJ&C(
M9@GO!D#8[C:["55H\K+<X2]A@V/G$6Z;IH!9-B5 #M[M8$GOJP*?N<99:='G
MZ]  AF4'__6_O#P[.WG]_OCZ./OI_/R*/I^^/CS> ^GG!NGG>T%T%=<!4UX8
M)";@_=F#$=030,_SDH!%-[7-<GH',#6LYZ$Q;*6+!W^<T!_) .Y\X$V8N5Z'
M#*@R07,7\J;- EZ@X:"S..+9R>DK?+?<+@.]*&=$8QZ<'F;GF[HLZ\NPG,4_
M\0!.OWK=]M:SG;?%LL@;N ZS[)?+2W@#_X?3G%^=GU_\RG\7,/@_W_X SYQ?
M'9U?_JS_9F<S(#%5]BZ?M_SD]Y<_O<X.S@[M@0<FWN%0%_32LT.<?/QYGOSZ
MXN<+7MOES_#"EX>X9'L!GJ'!X)?G./_%8_8,*'P7FA;NS@7<$2",?VR+MJ#C
MO\J;#NX#//3NW45$Z8N(S;/L\NH*0?837%?@L4U'8_Z/=^_Z8+OX_OJ"%G?T
M[OKR?):]O;C@1W[/;[*7K^G/@Q>']L1CEGY>;FYS6O9,"7H^+T/V<\A+N,S\
M T/KIWWW[H7=NQ=[K\K[-B"&_=!VQ1HO_-AE^[01Z(8Q>>(;!S]V_4LW2MUP
M6TTHZ8%ET2[*NMTV3)C@991SBF['1,UH$+P AXM/.2K8U?#I0\B"K0F'SEL0
M<#:XI!86E'=9OEJ!!$*+@^76#9'&M=TZ>#[(JLHBGQ=E@9A G^/J\$%8'-)2
MG'GJ'9X%]_YIX)A:6Q/N0K65U82/( FV\&&Y;9"FQY>(P@/UKI?'B:@ %'[=
M(N;]BP!0PY^+VSW@4L($,@T*;;RQ'2]D$8H[1%% 7OA0P\5S/Y=U=7-4PFU<
M\MT!;*YN"D1HAM0LFV];0*@6+\5Z#F#@"?'AF[I>WA=EF=WEY39*/P7PRZ)!
M$,V02#9;@!K,M Y+V%N9@/W@[9M??LL695ZL6[C7R] %P*'*T'*U+<NCIF@_
MT,#M+3)4_BSP%92T+68'# GEUB!HP)9@%\C%RT#CKD#VJ!NAG+<%R(D-+0Q$
MMINBPG4(B^CRCWYK0-+OD1'->"%'*-$N:6 X7'J&AVQ0FCVJ5T?;-B3X%N %
MO_WC[#)>B< SX6V"YZ=/FH ,_[^I<8]S$ESPA&[\5A#A@%PAU\3W:T"X)NX[
M@HCP?-LTM " 5[TN%L +[XJFKN0 X76\JK"0Y;] IF;,O[\-#$=>WZ)H%MLU
MW R8$)"\6. =.<[.6SC #N\@'E:\,$63!;K9@%-Y5=4=2$QV]@!2(B! H!9%
MRT!==(A#0$- 7T \W)9XPV&()D,@-05)3ZNF7L/P=;N'KNRCR%\91?YJ+SW]
M)W "(OEO*Y@;I@+QNZ,#':/-GSM6]NOPH&<H_*3 +BJ\51V+)%5 4@6"#=YS
MT/Z6H1&\Q%\O6)!UF!9R("IEN$&,P6EW3'8!H_!0[F]K!&M]7[$46XQ*KRFI
MQ(MRLRWH]V-B-"'>(%U3BW=)R:RLRECOG4*D$(@D"(N\I.,U->UML2&(W(-B
MBO\Z!M.&YJY ^.0W31!RK;+$Y?6Y"<;9[S7@<5G27D2^;A<@5 RY@-\:W@L%
MV1IN!1"W %@,]TS?6Z$$>$]DJ"D(1;_.:-87KQDL_/(M+#N7(P!BM5W0=:%3
MP)](DP 8 $ *$'^7R E@14MX+M)ETLXCZX-'X."60GE>"^?@Z>"ZX5V3C2+#
M)CZ:;43H(HB6Q9H4#*54NTQ4H%D&J 6G#XQ+R=T:\)/)2\OBE-^C(AQO<G"P
MNHP$ 0D/3E]GQ7$XGHT@@P@&#9T,J9% &F:\29AFB!^P9"%_QL)[@RUN@>4)
M-O/?IFJM@)$1"S!\X&4:ME9!18KC[.W*8<6R#GR+(F8H(F3Y')AP>B?SS:;$
M ^2E.O4O8IQND;$2P <[D^VN Y"])1VEO3FVGL>M)=('CSHK.GM_&;:@,\$2
M"EHR#C \X76]# #OU?"<UZS+5;N1"P/<%<X5E@=4?-$B0O\!AURL=ADA$FD<
ML!J>GR:N"58\&RZ4Z NMRTV*\#7LP:-!)0&X5+HP('Z.%<'<<%]H3MQ&P==R
M=-G=+5":_N)'+[WA!ED+VNUJA9819,%\G# I(VL@6<#=;\31>@L[6"Y)6T*J
ML9T#/4:9*153MQN4+U^/S5^T"4TAQ*_JZ@@5'6 K:.M3D)(L@U(574=@^TUP
MUP @M6G@:4;*=?XO$#_@6Y,D# ^0((7FH#U$L"5#'[[&HTP6R4#@5YCEY=E-
M4V^1-.6+#WP!>CA"5(PH IP'CCZ\[<?9#\G(?!N ZK=Z&P"G&55W/-'8,:<'
MNJGO0X.W!Y9W<]L#&NRK!5):YHU\,\.378(N)#J-.]B$NC"6KO&.MU$G %9<
M5"L@18@7(Z3(H ZB'YF<F4_!#W? =.$#,O&X_&MWV$C^ 04WN5\^D,!EOCOJ
MZB/XQ_/6<4H8-Y.<J)_F0['X<(3HJP"ZD_N+\^]0OMN@A( 49$7 B_K04H3!
M-D7H&G#XAJD1@#:?MW4S'X4-R,,+XFDU$.MV@'.T(!R"58EQ^.H8L,YBR0(I
M<.N**;\GH' 0I(TIN8EH-$HC&'F1PB!A EJ>DF/2L'1('K%+[K*\BWJF4&ZD
M4U/T>@^A/L[^.4'!$U8R22&GV B0#>,1^FO!- /(!UG*YZ$*2 7A[V.Q3PQ^
M@"7DY0[U'=HT\02TU-Z%^ OK9+!9NID,%+D7[7$BE#CUOHT$GIAC?)=G[U 0
M0T49-^LWH<**2,WI_@^*0V(6G=*)O;>?5_"XBP]/[KWUV0'-=\C:VT'A%C)Z
M8?A2P"J(K79C]\$ @4K63%<A\A/I8YNZ0_P@30P0PE]>@1J^<* #'>XY#>3+
MI&(&)!!%U\<XO0*/P:7?PHHA_PNL+SM]:6<FRL >!>P UW$HJH)NXF&K$%Z\
MHF*G'YDQJE$]IV]H52H") #)P(CDB\H7 7&^'>P?I8D)&*18N<YW*B2:";RH
M@(639B^6A"ZRX3'1$NU('JHO^D!]:P/2JG^EVZ]P58#B[*E<YJ0\0H%/V^<^
MU?ZEJ?8O]_N!5*>Z<+:N,:W^,X9)\'W;BM"4.]/W&*Q-G!TUPZ%(5H",;C;6
M"?.FL!^:##D0$VVT$C3H]P#81TV'I)1UR-NMR'I#)2@Q+F2@A54MX$.#KH_$
M_*9&U[XQHNX9?.2*>%C@O9BI/NL1UCUTI+9H5(= 6V&+=HBFH# *M7V(\LH0
MY=7>$_Z-K+=T0:_##6'Z&)I\\B >1]"UP=P)K7YJ,:;'6WZ<K_8M>1X62#6
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MAOS.\R7@SYQBG2GW+9#_G\SSZBR*/_ B[P%JM^0?F0W#@$%DJ)8"+1<69V,
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M0<]IFQB+38F2_&/V("3/LQ#*P5-=U )F0S7 "[86#RD)ZF*FB4?>WPN%)O
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MW+EU;6:H"$:-=0QQ1EK\CAJ8[<^'8!A4EB<[MOR)3 KV;:#1# U&^7)<\+1
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MQ<]W 5,^1A'[,2^.-PILN<A!4K& W,UEH#Z1W#+9ZJN-R=2"!OS"MA7MBP4
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MY["L>8"B]0Y\OC3&[39>H!_)LS]02P,$%     @ DHI<5$YF;"X3 P  : 8
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MN*'G$8U7H/.5UNZP\ ZZ!W?^/U!+ P04    " "2BEQ4PX:X'#4&  "=#@
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MU/\.O<.J&+FS7AL E5);..VS+P?RAJH%@(&'\PT[2OU\3!?23NGQ]SA[>2#
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M$Z7/XM!C41"%)_C%@]&QY1<?,WK!E;BXMT;?\2=@S+"I4KR;"_O\[^F]-@J
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M*O=W@WLQ<FD_\>^E,;*UCPO!,4$3 <YG4IK^A00,__G<_ %02P,$%     @
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MO!R=*Z8.G)YNBGMR#6X&/0]4.8Y*P<C<C8"=-#10W#:A"8[*&M#Y7DIS$FR
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M&^%%KJM*MZJS_+O@C=OZM< OPLAA*ZNMMU$944NG36=A3ZAO &3+[P13&JT
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M##&DLZ8_L!Y)4(L5^A<Z41Q&3PIUJB\O/;G*A=<XK=6IU'NQ%H9Z-R(S+CP
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M4R2 ];76;G@A ^,_&:[^!U!+ P04    " "2BEQ4!E_O'7H$  "G#   &0
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MLC\IJ-P".[^0TFP[[LY9__8,?P%02P,$%     @ DHI<5!JX@!"- @  H@8
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M&J<]ET2WUWI XJ;OX *IR4,'3/  I>Y6<1RY2_>GE$?(K,>/ "(461S;I"
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M&7/?/  X*2[G&#74M=+7=-"-XKSYJ*&N:X@U%&2C.&TG:$-=[GS-!>LHCET
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M8M-^7)MD:<HF@?W]J2CJEXLF0'?:]NJ_4$L#!!0    ( )**7%3[?!#U;@L
M %M+   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;+V<6W/;MA* _PK'
MIZ>3S,02 =Y;QS..[21.[<83MZ</9\X#0L$2IQ2IDI1<S_3''X"DM) )+N@;
M7ZR+@<4"6'R[6 (ZNLN+/\L%YY7U]S+-RO<'BZI:_32=EO&"+UDYR5<\$_^Y
MS8LEJ\3'8CXM5P5GL[K2,IU2V_:G2Y9D!\=']7?7Q?%1OJ[2)./7A56NETM6
MW'_@:7[W_H <;+_XELP7E?QB>GRT8G-^PZO?5]>%^#3=29DE2YZ529Y9!;]]
M?W!"?OJ%4"IKU$7^D_"[4GEOR;Y\S_,_Y8>+V?L#6ZK$4QY74@83+QM^RM-4
MBA**_-5*/=@U*BNJ[[?2/]:]%[WYSDI^FJ=_)+-J\?X@/+!F_):MT^I;?O>9
MMSWRI+PX3\OZKW77EK4/K'A=5OFRK2PT6"99\\K^;D="J4!)3P7:5J /*CA^
M3P6GK> \;"'JJ>"V%=RA*GEM!6]H!;^MX ^M$+05@J$5PK9".+1"U%:(AE8@
M]G;F[,%5=I/=&%UC);6)G;&*'1\5^9U5R/)"GGQ3VVE=7UA6DLDU=5,5XK^)
MJ%<=7V0;7E9BD52EE636UVK!"^L\JY(JX:5U:)W,9HFT?99:%UFSA.5*>'/&
M*Y:DY=NC:26TD+*F<=OBAZ9%VM/BEW4ZL6SRSJ(VB7Z_.;/>_*"3<HI+N6+W
MEM,("5LA/UA3JURP@I?-7XW0,USH&8\GK51*6JFK(M\D,UYHI)T/EV;W=_3C
M8"G8<'W"I9RLYYV>::1\-DA9%1.+.B9=+DP&D E=[+VYTTCY,L",VG'Q^J7\
M,GQTJ5;*5"RHW:JBNU5%:[%.C]@;X?IFZY1;^:UU_M<ZJ>ZM*UXM\IFEKK?_
M7HIJUD7%E^7_D$:=7:-.W:C;T^B;R[PLWXI5'.=+;MT6^=+B3=O+INT$VM:M
MC49Z4$N7KGAS?.@ZMF_;]M%THYI]MZ#C1VZGW$>-0#^RB5IPKZ/NKJ,NVM$'
MS,IK9O$MLW[\5T@)^7F_[[K^-HWXBGHN"8C7[:^FH$,CVML/;]</#^W':9Y5
M1?)]+8FJ4]#KM$O"*.QMUM\UZZ/-GER?6O\(>YPEUWE1";!?7IXBYA?LQ ;C
MV7RX:S1$^W+%E]]Y42Z2E;"$B@OJBS96ZR)>B#!K9KT1YM$X@[>BR[UNX33L
MC#0-[-Z!CG;*1:ARU^R^Z725[W02]MC56*=2U%D\<H7UJ41L\/?VXT>,Q6+"
MBG; 9GF:LD(,HUA5]9#)L0/GJO7539N1:JH3KT=5)30AJ*I?[[)64Z%*+$92
M!/G:UG$Q=!+:_T9LC0#5"44E_<:+I33O.U84+*NTNN 2/.N>B['%M '<$YSW
MOZ[E3"KZE(/MO94\U. )D)G@:-Z.4+[J@=JI0<"  0*\$IRO7VLE]I<?@WA6
MMQ*'CV 7SDZ(C"# F>!TULPJVXA0FWT7:%5Z\LZ*A?M(LKE8%]9Z)6)RX0:M
M54-T$0&L4EY'ZC-6\>&]\KNN#NL5^ 82X+VZNA(-G\2+A&^8<#WOA%.()]@L
M@P<@X7A^AP#;"0[W@7#Z8!!#[(F-THD"V2E.]NN='G(H-KDT#FD)2V$%8B<9
M__E.["ZKA3"%VV3#=>NLT=C0C&?4& !/<3*?K8MF.RGTA>!4JQ,NR$P-JH3N
M.*+!:BRVS-<]^M".>_;VW7,3PIG+[6L)\*<X_"_9#4N%T<LP+A8K_J0L\S@1
M:QT"X(OK$ZNV>C&Z']:E>%>B(P20I^YX*XX"SBF.<R C%W3+[[GHZYME7@@L
M+E@FP8;LU<]H%]C4[9T'P#7%<?W<35<K?F^3Y(5._R:) G,ISMP7VB:UK>QY
M.MOI;O?.VX)J5XACNT%_5X#Q% _S33NEMKK:=%^; 'B*D_F)*TRZ.;'!NKRY
M.L'V]$!UQQXQE0!H=G"BGM3H:ZU7; QN\V(7)>G2+*VX+NAZYL$!'CLXC\'1
M(NV?&810S^"T'"7+\BKD;>V"93/Y>BCM0WQU5DRLDZ+B;,[$IU]S*>4;CWFR
MD?$>IB_0VAF1U@[0VC$$W[MIJX-3$:QNQ.?6V=\F&<MB;A4]76WS3'@+KC^A
M'CJG0'$'I_BSYA33 &#MC)@]<0"L#@[69^<,N^ 5[DL3"9UK2CH8'X#3SFMR
M^AE+T 6&NR,RW 6&NX,8+AI-<Z;SF^=NE]H^EF9R@=JN*8J."RXWW#+RT&R5
MWFD8T$)"N!NMK@;"$P,-7""\BQ/^FL7);1+O+.IBR>9R+_4C6ZY^MKZ*M9+F
M\WOKE$M_9-S)NDI:>T12NT!J%^?H<QG@:E(A^X\-]A4#*KLXE5\JS]]-:I"
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M5;ZJ?W_G>UY5^;)^N^!LQ@M90/S_-L^K[0?YDSZ[W],Z_C]02P,$%     @
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MPS[TS*H>N\NAFW>$X"C&?H\_XL:!\',6M!5L"_)941O_P6]J0+AQ(/P:"ZK
M^^]TS_..E#V."_?"2G9NZWYH+^=?B%Q2KA"#A<%Y9Y'9:;*\[Y8-+=;%E?%!
M:',!+1Y7YAL!I TPXPLA]%/#WD+KKX[9/U!+ P04    " "2BEQ4'=!; 6@"
M   <!@  &0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R%E5UOVC 4AO^*
M%?6BE1CY )*L"I%*4;5)K525=KN8=F&2$V+AQ,P^*>V_G^VD$1NA<$'\<=[W
M.8?8AV0OY%:5 $C>*EZKN5,B[JY=5V4E5%2-Q0YJO5,(65'44[EQU4X"S:VH
MXF[@>:%;458[:6+7'F6:B 8YJ^%1$M54%97O"^!B/W=\YV/AB6U*- MNFNSH
M!E: +[M'J6=N[Y*S"FK%1$TD%'/GQK]>Q";>!OQ@L%<'8V(J60NQ-9/O^=SQ
M3$+ (4/C0/7C%6Z!<V.DT_C3>3H]T@@/QQ_N=[9V7<N:*K@5_"?+L9P[L4-R
M*&C#\4GLOT%7S\SX98(K^TWV7:SGD*Q1**I.K#.H6-T^Z5OW.QP( O^$(.@$
M@<V[!=DLEQ1IFDBQ)])$:S<SL*5:M4Z.U>:EK%#J7:9UF-Y*R!F2.YHQSO!]
M1!:TWI)[06LU(K3.R;T6*"(*TD5^(2M],/*&@UE\H-A(ADR'7"X!*>/JBEP0
M5I/G4C1*&ZC$19VGH;E9E].BS2DXD=,2LC&9^",2>('_LEJ2RXNK?UU<765?
M:M"7&EC;R4G;-9(E4QD7JI% ?MVL%4I]+'Y_8C[IS2?6?'K"7*<:#%7:JB*K
M,A?D-8UB+W%?!U#3'C4]AYH,H5I5>( *_-DP:M:C9N=0TR'4[!AERA]"A3TJ
M/(>:#:'"(U083>-A5M2SHG.LT!YN+$%WL@)!#J&C([0?>_HS#(][>/PI_%D@
MY4.X^.BH^''T-?S_%;H'E]WTS0<J-ZQ6A$.AA=XXTB]'MKVHG:#8V?N_%JB[
MB1V6NGV#- %ZOQ "/R:FI?1_".E?4$L#!!0    ( )**7%1N=H58T0H  )-#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;+6<>V_;.!+ OPKANQYZ
M0&J3>FLO"1 [39NNLQLDNW? '0X'VF8<767)U2-I@/WP2TJR*4744"JB_6-C
M-^1P..3\.,-'3I_CY&OZR%B&ON_"*#V;/&;9_J?9+%T_LAU-I_&>1?PW#W&R
MHQG_FFQGZ3YA=%-4VH4S V-GMJ-!-#D_+?[M-CD_C?,L#")VFZ TW^UH\C)G
M8?Q\-B&3PS_<!=O'3/S#[/QT3[?LGF6_[V\3_FUVE+()=BQ*@SA""7LXFUR0
MGVZ(4=0HBOPS8,]I[3,2?5G%\5?QY7IS-L%")1:R=29D4/[CB2U8& I17)%O
ME=3)L5%1L?[Y(/VJZ#WOS8JF;!&'_PHVV>/9Q)N@#7N@>9C=Q<^?6=4C6\A;
MQV%:_!\]5V7Q!*WS-(MW566NP2Z(RI_T>V6)6@7>474%HZI@O*I K(X*9E7!
M?%7!=#HJ6%4%JZ]*=E7![EO!J2HX??O@5A7<OBUX506O;P6_JN#WK4#P8>1P
M[RK'P>X]VN0PW.3U>'=7.0PX*49\5L[%8B)?THR>GR;Q,TI$>2Y/?"B\H:C/
MYV\0"<^]SQ+^VX#7R\X7"=L$&;JBZR ,LI<3-*?15[2,:92>(!IMT))72%'\
M@*J2']#%AO_D3D=#=!V5[! N^/Z2930(_WXZR[A>0OIL7>DP+W4P.G3XDD=3
M1)P39&"#_'Y_B=[_525E 4NY9.LIPJ208BJJ7_:H;I*&$@]!1*-U0,/_):*/
M"J$?^PO%W3V[ZBV%^-U2/FFL3*.C?0Q%]<\]!LG$ND&ZAJ5<[),^4K[ 4N[9
M_B@%,.O/&EWR;9_!6>KL$O:1<M.C1P0#0SSCCGWT;N/HW48AUNR<.:N,.VF:
M)3E?;3/T'^'-Z#ICN_2_@'CS*-XLQ%L=XJ_3-.<.P@0>*E^)MBA>A<&V9 *G
M UKEJ4!(BM;Q;L4+B5^D*O\LVW*+MD3 \73N6%C\=SI[JKM<NYRK*':E+=;H
MLG7LL@5V>9$GB;#D/DZ*'O*>AW&T_9"Q9,<#AE6FZEDITJFKXBDZUBY&L.?Y
MG3K;1YUM4.??XHRSNDLYN]VJY_J.W=:O7=*P;!?;G0HZ1P4=>!Y%W'PLS1#[
MSB/2E*G4=%J-VZ9OM95T6L/N6[[?GA[M<I9KFIU=<8]=<<&N+(^30?Q&3(]U
ML6ZJNN3VL'Q#">^HA <J<7&[0'^@F]M;P,?]HRQ_#(00+ ,0#"N;ICQ!H>MO
M>9 6<<4)VK-DS=OBF8,P8/I(^>0H2W!;*E=AN F"\13C=Y"ZM7B)]+#MQ<TG
M=)OP_(E3@*608(EJ,@JKB80U@6G])H:&F^AA: E: I.V-/2_ETM(FD0@L4>Q
MKD08@1GV)M:%F^AA78DI G,*A@.1I"'>*':5^"$^J"C/3!BBNSCGPKD5NU:Q
M2DHC>B# >F](/ADP/&Z"*-CEY>+.8Y@GEH@![4H(+BMI@D@2ZU/#[E!#<L>
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M$ -;M0AUJ2C)G5/!PSB*!F%!F @F(W=VH28CN3*<"7JAD%X5!5&_3BB7ZW&
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M[W ,:&KX"DZE_46'[MMI&J"BE8HW1[#VH"&L^\=/1R%. ,EL ) > >G/@,D
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ME58)E79[F/9@D@N)FL3,-J65]O&SG1!2 ADOE?H"MG//\3WWQ,[M;QA_%C&
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M@7J_9DQ^WN@OJ'X8F?T&4$L#!!0    ( )**7%0$MV4].@,  /L*   9
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MD8M;T(PGZA(-*JN47<6V3$9JZ&H$-=NY80$US:%H#91/R9W(=*S(ERR"Z+V
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MW55EMUO=^((P$_3[#>?J^& 6*%OI^1]02P,$%     @ DHI<5%<)[9_^ P
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MXPIH L(LT.\7G*O=P !4=VK3?P!02P,$%     @ DHI<5%3:MA]^ P  R T
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MI<%C>35<XU4+E#7 YRLIS</$!F@O;[/O4$L#!!0    ( )**7%2SL#@DOP8
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MQC8#/ZQL?P?E '9](Z793]P&_3]&_@]02P,$%     @ DHI<5/ N\) 5 P
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M,FD \'PAA'ZY,1LTT_+X?U!+ P04    " "2BEQ4:XM+!]@+  #</   &0
M 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6RUFVUSVS82Q[\*QO5TVIO$(@#B
M@8WCF=I.>IGI0R9I>R]N[@5-01:G%*F2E!U_^P-(6J"(!2CY<F\22UJ ?X#@
M_G:QQ.5C5?_5K)5JT9=-439OS]9MN_UAL6BRM=JDS46U5:7^9575F[35'^O[
M1;.M5;KL&FV*!8DBOMBD>7EV==E]][&^NJQV;9&7ZF.-FMUFD]9/UZJH'M^>
MX;/G+S[E]^O6?+&XNMRF]^JS:O_8?JSUI\6^EV6^46635R6JU>KMV8_XAW>2
MF :=Q9^Y>FQ&?R,SE+NJ^LM\^+!\>Q891:I066NZ2/5_#^I&%87I2>OX>^CT
M;']-TW#\]W/O[[O!Z\'<I8VZJ8I_Y<MV_?9,GJ&E6J6[HOU4/?Y3#0-BIK^L
M*IKN7_0XV$9G*-LU;;49&FL%F[SL_T^_#!-Q3 ,R-""3!CCV-*!# WIL@WAH
M$!_;@ T-NJ$O^K%W$W>;MNG595T]HMI8Z][,']WL=ZWU?.6E62B?VUK_FNMV
M[=6?:9VG=X5"'\I6U:IIT;NRS=M<->B[/S^\:[Y'K]&[(M=73ENU1']L]<V]
MJ<JF*O)EVMWJ#V56[);ZMP\E^C'+JLTV+9_R\GYDIG^\3HNTS!3Z;)3JOF]5
MF^9%U_T?GV_1=^??HW.4E^CW=;5KTG+97"Y:/3PC<I$-0[GIAT(\0[E5V06B
M^!4B$<% \]OCFT= \W='-\?)8?.%OB?[&T/V-X9T_5%/?S>[NE9EB]*FT1,6
MZ)#N.Z1=A[&OP[19(SVS*#-_J+]W^4-:Z"N ,]UW);JNC*]YN"*41HFX7#R,
M9]0UPPF-171H]@XPBRB6R=[L8$#Q?D!Q<$ ?R@>]7C=FDO3"T6[N+[VFS%)N
M5+:KNS4,#:WOE(_$,!KCZ<A<*RYXPF#%;*^8!15_4IG2LZXU-J]0J5I('G,N
MC",>R8D\UTI$3,+J^%X=/TD=^O8;23!^HWE0=,_P-JW;)T@S=R<KH8)/-+M6
M<4)X!(L6>]$B*/JW=JUJK7 O'=(GG"LG/)[><=<H)J,%?Z!.[M7)H+J/M=JF
M^1*I+QKLC?:IYOFK.LE9X/GN54MW)4A.I[(!*RY\NI.][B2H^_>J38LC)";.
MQ6DBA203C8 9E4QX1.+(LBL*^LA?J_)U2.1AMR,DXAG'TJ;E?6Y<2=^K]V$=
M.AJ/3!(93>\19,83Z?$FV"("DZ#0GZIJ^9@7!2B-.-<DC$8TF6H#[&@2,3KQ
MX8/=(1(DBWR#L%C"82Y9-]X8/]X_'>HY"'GV0897[1/:J'9=+<'Q4O?YQ0*S
MZ7 !,TH2XAF%91$.P^B3'D.=9\9-&KZ""EVF1%-U )PBCX?$ECHXC)W?MJK6
ML9H.R0JE8VI4F^#Y=;5ZO6M4X.'& (I8'..I9L!,/]RQ1[6E$0[CJ/?L 7DN
M3UA"IJ $K'3@@7VKUF('A[G3>\ARQ@$-2@&T,,JD,Y. G9!)Y(F3L*40#F.H
M%^L5>#W3_-_X/^"P7/1(1BBGTV$!=EC$DGN&92&%DZ-"Y$)G,'D!!'R'@;?%
M"HF"XS59S,ZXHVWZU 64AMIIEM4[95$.S<C0[Z%S2=CT/@-FE..8PO-!++=(
MF%OO\^4NRW6Z;\0>C  4ZT():[<?3\6Z9CIX\OA+,LINPNCZ12WS3"]*[[T;
M1+IT8DS(Z1*#S"*=L'A46C:1.3;I?%:A-OVBPG/I4H6S:10$&,6$>/PDL>0A
M8?+<Y@_Y4I7+H#Z *VP:GP-&L2]&(18^) R?]WG9)?X]>N9NM\N2L9\8=$(I
MDF]!6MR0&=Q,(#FGU.4*X60:7 %6%/OB7F+A0V:2GA.UNEP1<AIZ $8XDKX<
MG5CVD&/8D\VYZD$ID,U@1H7C02&[./&%<<0BA821,LXHCL,*M5BA8:S<JI72
M/2^-.]EW#N;3U 5$@HFS^>):X2AAGCM&+4;H'$8\3VR_*U"M]G=S6]5F"Q <
M H -,77;@!'%V*/?HH6&T1)X.DX:@<L43'$R#3 A,R:YQV_2T6Y=&#T_5^7]
MZU;5&[14=^U)PEW.8$D29XL+L",T(MX;8(E$PT3J(_=B/X"9AYZZW,&Q$([<
M4/ITJ-3"B8;AY$;Q<UI=]A 2C1W/(!:P8X+&GIB76DS1,*9ZQ6&5US-]>.)Y
M"L!*1_-./ _9"4*I9_N16JS1,-8\M8BG5^ACG9LR%KI6I5KE78P;<LD63E1^
MI4UV2Q :WCH[;9O=W1G#' ON+"? CG#LV_&-+9/B,)->NH<.)#I)Q*>1&F#&
MQ7@+\U"U)50<)M0Q^^BQRQ9!G%0,L&*8>9QW;!$4AQ'T\JWTV,4))]B)U@"S
MF OL6P^6.O$)"8_=50>5 IBA\73E E8>KQV/ZC['\&5FSS\&J"+IU)=!5I'T
MY&2QY4H<YLK_M.\? _D-%DYB#IGI9,FSBQ!;PL1A.OQ<I>7XWO=KEQRN79]?
M &H\4>0L7M?*MR8L.^(P.W[<]!L>RYU"J[K:H'2UTH34@IM_@$K==(<S)[@#
MK'Q*+7/B4Q*BP#)P<QP:,>$Z6==.HX'[MCAC2[+X^%QH%I#,(H>%D?.S?A9>
MH6U=Z3"]?>J>#$/)K8&0ORH* 8<Y-3S C B6>%(B9H'#OE9%B % D<2IB %F
M/"',L[B8!0][>46( 9E*E'!G'PBVBWV56F;APN92&LBSX*,\"W,Y(J>[+8!-
MC&-?S=[BAIWRGH'U*Z!,ER<RTK=_&G< =D1')[&'/&STAD&8/%^IFL: C3B@
MF@:9488]60ZS#&)A!OFF''3E#(*.HQ1(6CCSD9Y9[K P=XZH^[$01 9UKHFW
M[L<L:5B8-"^L^S$7*-K73B,GP(J3Q!. ,@L=%DZ?YJI^#'B7@&#'$P#YDO!N
MO'+++AYFURE5/PYMSXF(RRFT $-&$RX\D1RWU.)A:LV4_6XX4 &B@L?.O08,
M982)]+UP9''%CWO)[;BM5FY)P\.D>7$%CP-)#6;)U'U#9B3QQ=[<HH:'47-:
M!8]#R8M;P0/,_!4\;DG#PZ0YLH+' 40 .0%@II>BSS_ST3MM<R0YKH+'0SG)
M(!'@C(:V1Z$E" \3Y)CZ'0?XX,1M@)&W?L<M1'@8(GUBU>55;651#)*8NTQP
M)A'(5@CW<8-;;O P-TXJ,W( #]A1"ACYRHS"$D2$"7)BZ4X $!FG";U4T,KW
MA O+#Q'FQZE:@1TW9^,*,"*1I^(@+$=$..TYJ<@H@"TVZ8;H@)E,_+-JV23H
M5RXQ"LL/,?,NP-$E1@&P(W'25, J\28IPJ)#O/"=@%/*7 +8_TJFD0M@Y*TP
M"@L5\>)W!4X: 9"3).[##;SGYE^&H_>FP]AY>7U1 *\38#R-.B K*CP[,<+B
M2,SD-*?5%H6+FX2[6D/<.A1J@22.>87ZA-*B<'E#B'1B<= L$IZ46UHPR6-2
MFQF-0Q_BP!]P,9U/P QC3'WE"6F(=/B-]?PR[/GA6N;U3*O?UPK=]">5NBT1
M\:9!V?BXTMUP7*GICROE_1DGI!??D$]U&<5HMLRSD[>37LP!J@MD+G94YZ-T
M35\I;5&6ENA.(9VN+U%5%D\F M._MCJAJ>Z*_+X[@-5=NIT;D)'27\&XK7/&
MQ47T[3>81V\V>5%T1_;T@,Z9X!=X\GUW@5N5J<V=JOO?GD]9=8W GZ)7J%;-
M5G7G (NG5YUE.UUCQTM?535Z7.?9&F6:;WE;U0U:5OKY:M$Z?5!F5[':U4T7
MI)H>[U6I?70Q6#]?9SO4D>]L'=G\=)[@"P',AI07_/\P&=V2T%+UP)[7PGXP
MSXOA7$;D0AY>W"PQS\98KY=/Y>H6J;\P,C^:<YW?3-?#K I"II,YD3'.(X(B
M(O-CV\U56BND[#G$G3F'F!V<0S37-C.XU5.ME6FCQ[Q=:WUM^/F[0)^50K]6
MK4)8[G=(S?\D>C-[/+*ST_9F?:YV=4>G97>V\0**Z!:CDYH;5=]W1V3->M>3
MTQ_EVW^[/X9[W9U6G7XO\0^W$OI%^S[]2W=@=6$OT9_[_26M[W/M,0JUTI>+
M+DQX5/=':?L/;;7MSHK>56U;;;H_URI=JMH8Z-]7E9ZGX8.YP/Y \]5_ 5!+
M P04    " "2BEQ4/,FQ'5L#  !E#   &0   'AL+W=O<FMS:&5E=',O<VAE
M970X-BYX;6RU5VUOVS80_BN$T \)X%FB_)84MH$D7K$"-18DZ/9AV =&.MM$
M^:*15)SVU^](.9+;V8QGH%\DOMP]]]R=>#Q-M]I\L1L 1UZD4':6;)RKWJ>I
M+38@F>WK"A3NK+21S.'4K%-;&6!E4)(BS;-LG$K&53*?AK5[,Y_JV@FNX-X0
M6TO)S-=;$'H[2VCRNO# UQOG%]+YM&)K> 3WN;HW.$M;E))+4)9K10RL9LD-
M?7]')UXA2/S!86OWQL2[\J3U%S_Y6,Z2S#," 87S$ Q?SW '0G@DY/'/#C1I
M;7K%_?$K^H?@/#KSQ"S<:?$G+]UFEEPEI(05JX5[T-O?8.?0R.,56MCP)-M&
M=CQ.2%%;I^5.&1E(KIHW>]D%8D^!'E/(=PKYCPK#(PJ#G<(@.-HP"VXMF&/S
MJ=%;8KPTHOE!B$W01F^X\FE\= 9W.>JY^2? &%CR"[DI2^X#RP3AJOD\?)@O
M%N 8%_8213X_+LC%NTOR#B7(D@N! G::.J3AP=)B9_*V,9D?,4ESLM3*;2SY
M5950?@^0(O_6B?S5B=L\BKB HD\&M$?R+*<'"-V=KIY%Z S:F X"WN!H3*T%
MZ)$0VQY9@"T,KT(X__J$LN2C VG_CE@:MI:&P=+PB*7?*S"8)[4FPMLBNK'B
M-($7!ZHD%W6%L\M#28HCTXQ\!69LA.2H)3F*0GW@BJD"SJ 8QSV!XKBE./X_
M<>P1!P8/6W,$<(_KLD?XBK"J$KQ@3P(.T8W;H(%MA.RD)3LY/9YG4HU;>)/J
M54OU*@IT@P?!62SWA39XU$F-!]Z0U;X#!PM(@SH*J/XB>I[3_F":/N^?Z?_*
M9/UA*_,=W>N6[G6<;E'4LA;,(54FM7'\6Q-79JTN>%C?<K<YP8/K ^S&/WAP
M2.:(!S3KZGD6]6')%9>UC"2/[MT-]"<7,IIWMO(H[P?P34=7ROQG;7M8+G8G
M\^ ]$X><$!GNF1B_KJ;3P3G\FB_A&+\XY"G\NIN Q@OVDKV\E?>N8-/1S\Y[
M5WEIO"R>E?<XY-6;]P+M:BV-E\*STAZ'C-!+]QHY"68=^EM+"ETKU_1T[6K;
M0]^$SC'MQ)L&?,G,FBN+M%>HFO4GF'+3]+3-Q.DJM(5/VF&3&88;_ \ XP5P
M?Z6U>YUX ^V?Q?Q?4$L#!!0    ( )**7%3E</%&TP(  .H'   9    >&PO
M=V]R:W-H965T<R]S:&5E=#@W+GAM;(U56V_:,!3^*U;4AU9:FPN$A J0N+1:
MI5:K2KL]3'LPR8%8=>S,-J7;KY\OD%$(V5YB^_B<[WS?B>TSV'#Q*@L A=Y+
MRN30*Y2JKGU?9@646%[Q"IC>67)18J678N7+2@#.;5!)_2@(>GZ)"?-& VM[
M%*,!7RM*&#P*)-=EB<6O"5"^&7JAMS,\D56AC,$?#2J\@CFHE^I1Z)5?H^2D
M!"8)9TC <NB-P^MIW_A;AZ\$-G)OCHR2!>>O9G&7#[W $ (*F3((6 ]O, 5*
M#9"F\7.+Z=4I3>#^?(=^:[5K+0LL8<KI-Y*K8NBE'LIAB==4/?'-9]CJB0U>
MQJFT7[1QODGDH6PM%2^WP9I!29@;\?NV#GL!8>]$0+0-B X#NB<".MN CA7J
MF%E9,ZSP:"#X!@GCK=',Q-;&1FLUA)F_.%="[Q(=IT;WH&L@T26:\K+B#)B2
MB"^1-:.;=WU8]'@^ X4)E1?:[V4^0^=G%^@,$8:>"[Z6F.5RX"M-QD#ZV3;Q
MQ"6.3B0.(_3 F2HDNF$YY!\!?*VBEA+MI$RB5L099%>H$WY"41"%#82F_Q\>
MM-#IU)7M6+Q.>V6_CQ=2"7U:?[1@=FO,KL7LGL#\4H' BK 5HO8'95RJIM([
ME,2BF'O\-NH%43SPW_;+T> 4I_W:Z0/!N"88MXJ^)0RS#$[2^P#:JT%[K:K'
M)1>*_,;VWNO#Z<#!'<XF^0ZNMZ<L"M(#]<<^81 WBT]JGDDKSSNF0(!42--T
M'"G!"T*)(M!X0Y)CGKT#FL<N8;>995JS3%M9SM<+1XZPC)>-]4N/DEZF<73
MK,$I24]PZ]?<^JW<GKG"]!]GNW]T;.-ND!R0:W#J1X?D_+UGLP2QLMU$ZL1K
MIMRS4UOKAC6V[_2!?:(;F>L[?V%<%WS 8D68U)*6&C*X2O3U$:ZSN(7BE7V<
M%USII]Y."]V,01@'O;_D7.T6)D'=WD=_ %!+ P04    " "2BEQ4S[E'SY,#
M  "=#   &0   'AL+W=O<FMS:&5E=',O<VAE970X."YX;6RE5VV/FS@0_BLC
MU)-:Z3:\)81=)9%VDU97Z:JNLNWULP-#L IV:IO-[K\_VQ#R1FC:?DFPF7EX
MGIG!,TRV7'R7.:*"E[)@<NKD2FWN7%<F.99$#O@&F;Z3<5$2I9=B[<J-0)):
MI[)P \^+W))0YLPF=N]1S":\4@5E^"A 5F5)Q.L#%GP[=7QGM[&DZUR9#7<V
MV9 U/J'ZNGD4>N6V*"DMD4G*&0C,ILZ]?S?W1\;!6OQ'<2L/KL%(67'^W2P^
MIE/',XRPP$09"*+_GG&.16&0-(\?#:C3/M,X'E[OT#]8\5K,BDB<\^(;354^
M=6('4LQ(5:@EW_Z#C2!+,.&%M+^P;6P]!Y)**EXVSII!25G]3UZ:0!PX!,,+
M#D'C$)PZC"XXA(U#:(76S*RL!5%D-A%\"\)8:S1S86-CO;4:RDP:GY30=ZGV
M4[-_4<= P@U\5CD*^,CJRC 17F)!%*:@.#16;Q>H""WD.VW_]6D!;]^\@S=
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MT( A2=+L@WO[4;S>I^+-[U^CWU!+ P04    " "2BEQ4EXJ[',     3 @
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M=GC)SY8_V-S^!%!+ 0(4 Q0    ( )**7%0'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ DHI<5'S@
M 0GN    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ DHI<5)E<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "2BEQ4ER#-;KT&  "+
M&@  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ DHI<5!ULI!1/ @  M08  !@              ("!  \
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( )**7%2TDSOS
M'PL  "PO   8              " @841  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "2BEQ41Z[/$PX&  !=&   &
M@(':'   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ DHI<
M5/ HU"]"!P  11\  !@              ("!'B,  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( )**7%0;QGM_#0H  (4W   8
M      " @98J  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "2BEQ4HX'0M"$"  !V!   &               @('9-   >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ DHI<5 4"2(O0#@  <4H  !@
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M970Q,BYX;6Q02P$"% ,4    " "2BEQ4@D;R#GL%  #;#0  &0
M    @(%CD@  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M )**7%3U*9TG)A   ! S   9              " @168  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ DHI<5(F*0]I*!   ]0D  !D
M             ("!<J@  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "2BEQ4 C3.9\@"  !4!@  &0              @('SK   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( )**7%1=:[PV+ ,
M  0'   9              " @?*O  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ DHI<5 R^>6%@$0  "3@  !D              ("!
M5;,  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "2BEQ4
MP<1"+G<(  #V$P  &0              @('LQ   >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( )**7%0M^_"\\0D  * =   9
M      " @9K-  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ DHI<5*))K]45"P  DR,  !D              ("!PM<  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "2BEQ4YTY6QH0(  "4%
M&0              @($.XP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( )**7%3V;;@Q(P@  ,$;   9              " @<GK  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ DHI<5 ,?89X*
M P  I08  !D              ("!(_0  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "2BEQ4%-GSG@$%  #\#   &0
M@(%D]P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( )**
M7%01E]&\;P@  -T4   9              " @9S\  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ DHI<5-M':HRB!0  1A8  !D
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M=#,Q+GAM;%!+ 0(4 Q0    ( )**7%1.9FPN$P,  &@&   9
M  " @2!< 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MDHI<5$/^6T%T!   HA   !D              ("!:E\! 'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "2BEQ4CM@*Z3D%  !%#   &0
M            @($59 $ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( )**7%3@:\&@V0(  $,&   9              " @85I 0!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ DHI<5,/@5B ^ P
M!0<  !D              ("!E6P! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "2BEQ4(;"W*6P#  !\!P  &0              @($*
M< $ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( )**7%3#
MAK@<-08  )T.   9              " @:US 0!X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ DHI<5%^'S@O)!@  _Q$  !D
M     ("!&7H! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )**7%0:TU/LX @  -$O   9              "
M@6V3 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ DHI<
M5*;]\9H0"@  U30  !D              ("!A)P! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " "2BEQ4=.S:87<"  !P!P  &0
M        @('+I@$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( )**7%3T\._(8 ,  .D+   9              " @7FI 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ DHI<5.)CPJQ> P  L0X
M !D              ("!$*T! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " "2BEQ4>;F,]@4&  !<)   &0              @(&EL $
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( )**7%1A_E8$
M;0,   (-   9              " @>&V 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ DHI<5!JX@!"- @  H@8  !D
M ("!A;H! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "2
MBEQ4$2FX;OP$   9&P  &0              @(%)O0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( )**7%2V<K]PD0(  'D&   9
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M970U-RYX;6Q02P$"% ,4    " "2BEQ4^WP0]6X+  !;2P  &0
M    @(&'V@$ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M )**7%3Y]X:9K <  "<@   9              " @2SF 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ DHI<5*04,!*S P  YPX  !D
M             ("!#^X! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " "2BEQ4(G:>4PP#  !#"0  &0              @('Y\0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( )**7%2^:<.NF0,
M /H+   9              " @3SU 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ DHI<5-& 0F!? P  @0P  !D              ("!
M#/D! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "2BEQ4
M'=!; 6@"   <!@  &0              @(&B_ $ >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( )**7%1N=H58T0H  )-#   9
M      " @4'_ 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ DHI<5*K=HL4W P  HPH  !D              ("!20H" 'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " "2BEQ46_1/8G(#   E#0
M&0              @(&W#0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( )**7%3KNVO\>P0   D1   9              " @6 1 @!X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ DHI<5 )BD9.:
M P  ( X  !D              ("!$A8" 'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " "2BEQ44CC3T1H'  !P(@  &0
M@('C&0( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( )**
M7%3-Z<)YT <  "@M   9              " @30A @!X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ DHI<5#<_)S(5 P  2@L  !D
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M=#<V+GAM;%!+ 0(4 Q0    ( )**7%17">V?_@,  %\3   9
M  " @4(\ @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @
MDHI<5%3:MA]^ P  R T  !D              ("!=T " 'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6Q02P$"% ,4    " "2BEQ4L[ X)+\&  #1)0  &0
M            @($L1 ( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4
M Q0    ( )**7%2O$+1@]@(  %D)   9              " @2)+ @!X;"]W
M;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ DHI<5!I8%ER0 @
M@ 8  !D              ("!3TX" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX
M;6Q02P$"% ,4    " "2BEQ4IIF6 X,"   ]!@  &0              @($6
M40( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( )**7%3P
M+O"0%0,   L)   9              " @=!3 @!X;"]W;W)K<VAE971S+W-H
M965T.#,N>&UL4$L! A0#%     @ DHI<5+#D/ZW8 P  .0\  !D
M     ("!'%<" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )**7%2V2)KJQ@,  "\/   9              "
M@:!Q @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ DHI<
M5/5>!8:W @  >@8  !D              ("!G74" 'AL+W=O<FMS:&5E=',O
M<VAE970Y,"YX;6Q02P$"% ,4    " "2BEQ4/];>S2H#   ,$P  #0
M        @ &+> ( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )**7%27BKL<
MP    !,"   +              "  >![ @!?<F5L<R\N<F5L<U!+ 0(4 Q0
M   ( )**7%2ED%]0H 8  ' [   /              "  <E\ @!X;"]W;W)K
M8F]O:RYX;6Q02P$"% ,4    " "2BEQ4YN*DT* "   %-0  &@
M    @ &6@P( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M" "2BEQ4PH ,:SH"  !H,P  $P              @ %NA@( 6T-O;G1E;G1?
@5'EP97-=+GAM;%!+!08     8@!B .4:  #9B (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>486</ContextCount>
  <ElementCount>708</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>189</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Business Combinations and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</Role>
      <ShortName>Business Combinations and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2115104 - Disclosure - Land, Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LandPropertyandEquipmentNet</Role>
      <ShortName>Land, Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119105 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Investments in Other Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntities</Role>
      <ShortName>Investments in Other Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Loans Receivable and Loans Receivable - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedParties</Role>
      <ShortName>Loans Receivable and Loans Receivable - Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2131108 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2134109 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2137110 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2150113 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2159114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2161115 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2165116 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2167117 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2172118 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2175119 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2181120 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables</Role>
      <ShortName>Business Combinations and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2316303 - Disclosure - Land, Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LandPropertyandEquipmentNetTables</Role>
      <ShortName>Land, Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/LandPropertyandEquipmentNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Investments in Other Entities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables</Role>
      <ShortName>Investments in Other Entities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2335307 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2351310 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/StockBasedCompensation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2362311 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2368312 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2373313 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2376314 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Payor Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Payor Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Business Combinations and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Business Combinations and Goodwill - Goodwill Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails</Role>
      <ShortName>Business Combinations and Goodwill - Goodwill Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Land, Property and Equipment, Net - Schedule of Land, Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails</Role>
      <ShortName>Land, Property and Equipment, Net - Schedule of Land, Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Land, Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LandPropertyandEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Land, Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Investments in Other Entities - Equity Method (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails</Role>
      <ShortName>Investments in Other Entities - Equity Method (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Investments in Other Entities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Investments in Other Entities ??? Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>Investments in Other Entities ??? Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Loans Receivable and Loans Receivable - Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Loans Receivable and Loans Receivable - Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2436419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities - Schedule of Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2439420 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2440421 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail</Role>
      <ShortName>Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Provision (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2445424 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2446425 - Disclosure - Income Taxes - Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2447426 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2449427 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock Based Compensation - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails</Role>
      <ShortName>Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Stock-Based Compensation - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2460435 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2464437 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions - Schedule of Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2466438 - Disclosure - Employee Benefit Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2469439 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2470440 - Disclosure - Earnings Per Share - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails</Role>
      <ShortName>Earnings Per Share - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2471441 - Disclosure - Earnings Per Share - Summary of Shares Included in Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share - Summary of Shares Included in Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2474442 - Disclosure - Variable Interest Entities (VIEs) - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2477443 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2478444 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2479445 - Disclosure - Leases - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2480446 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ameh-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2482447 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ameh-20211231.htm">ameh-20211231.htm</File>
    <File>ameh-20211231.xsd</File>
    <File>ameh-20211231_cal.xml</File>
    <File>ameh-20211231_def.xml</File>
    <File>ameh-20211231_lab.xml</File>
    <File>ameh-20211231_pre.xml</File>
    <File>ameh-20211231xexx141.htm</File>
    <File>ameh-20211231xexx211.htm</File>
    <File>ameh-20211231xexx231.htm</File>
    <File>ameh-20211231xexx232.htm</File>
    <File>ameh-20211231xexx311.htm</File>
    <File>ameh-20211231xexx312.htm</File>
    <File>ameh-20211231xexx313.htm</File>
    <File>ameh-20211231xexx32.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ameh-20211231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1440">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ameh-20211231.htm": {
   "axisCustom": 1,
   "axisStandard": 45,
   "contextCount": 486,
   "dts": {
    "calculationLink": {
     "local": [
      "ameh-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ameh-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ameh-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ameh-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 998,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 8,
    "http://www.apollomed.net/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 16
   },
   "keyCustom": 142,
   "keyStandard": 566,
   "memberCustom": 105,
   "memberStandard": 58,
   "nsprefix": "ameh",
   "nsuri": "http://www.apollomed.net/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.apollomed.net/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Business Combinations and Goodwill",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwill",
     "shortName": "Business Combinations and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2115104 - Disclosure - Land, Property and Equipment, Net",
     "role": "http://www.apollomed.net/role/LandPropertyandEquipmentNet",
     "shortName": "Land, Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119105 - Disclosure - Intangible Assets, Net",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Investments in Other Entities",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntities",
     "shortName": "Investments in Other Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Loans Receivable and Loans Receivable - Related Parties",
     "role": "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedParties",
     "shortName": "Loans Receivable and Loans Receivable - Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131108 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134109 - Disclosure - Medical Liabilities",
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "shortName": "Medical Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137110 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Income Taxes",
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://www.apollomed.net/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Mezzanine and Stockholders' Equity",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150113 - Disclosure - Stock Based Compensation",
     "role": "http://www.apollomed.net/role/StockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159114 - Disclosure - Commitments and Contingencies",
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161115 - Disclosure - Related Party Transactions",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2165116 - Disclosure - Employee Benefit Plan",
     "role": "http://www.apollomed.net/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2167117 - Disclosure - Earnings Per Share",
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172118 - Disclosure - Variable Interest Entities (VIEs)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "shortName": "Variable Interest Entities (VIEs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2175119 - Disclosure - Leases",
     "role": "http://www.apollomed.net/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2181120 - Disclosure - Subsequent Events",
     "role": "http://www.apollomed.net/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NotesAndLoansReceivableNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Business Combinations and Goodwill (Tables)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables",
     "shortName": "Business Combinations and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2316303 - Disclosure - Land, Property and Equipment, Net (Tables)",
     "role": "http://www.apollomed.net/role/LandPropertyandEquipmentNetTables",
     "shortName": "Land, Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Investments in Other Entities (Tables)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables",
     "shortName": "Investments in Other Entities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335307 - Disclosure - Medical Liabilities (Tables)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "shortName": "Medical Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.apollomed.net/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351310 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362311 - Disclosure - Related Party Transactions (Tables)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "shortName": "Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2368312 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2373313 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2376314 - Disclosure - Leases (Tables)",
     "role": "http://www.apollomed.net/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ie58240bdc60b46879e56e7842cd94022_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ameh:BusinessCombinationEquityInterestPurchaseObligationNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Payor Type (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Payor Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "if2fdbacce1904cf3912b442f8c709d96_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i9926274bc8d84660ae987c991d85aa80_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i9926274bc8d84660ae987c991d85aa80_D20210101-20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Company's Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
     "shortName": "Business Combinations and Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i839af06b2bf7483780595e14fb317ba9_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i15daea0fb86f4e9087b3958e4c3f97dd_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Business Combinations and Goodwill - Goodwill Roll Forward (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails",
     "shortName": "Business Combinations and Goodwill - Goodwill Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88957c4b067b480aab3feadf03f79f9d_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Land, Property and Equipment, Net - Schedule of Land, Property and Equipment, Net (Details)",
     "role": "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails",
     "shortName": "Land, Property and Equipment, Net - Schedule of Land, Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Land, Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LandPropertyandEquipmentNetAdditionalInformationDetails",
     "shortName": "Land, Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Intangible Assets, Net - Schedule of Future Amortization Expense (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Schedule of Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i15daea0fb86f4e9087b3958e4c3f97dd_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Investments in Other Entities - Equity Method (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails",
     "shortName": "Investments in Other Entities - Equity Method (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentInvestmentInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Investments in Other Entities - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
     "shortName": "Investments in Other Entities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ib35744eb8b2a4654a6e7d576a8beb03e_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Investments in Other Entities \u2014 Summarized Balance Sheets and Statements of Income (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "shortName": "Investments in Other Entities \u2014 Summarized Balance Sheets and Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i3fe54b8d3c6a404180f70fdf3eaaeea0_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i69d3506ad61545a28e82fbaea4860bd7_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i69d3506ad61545a28e82fbaea4860bd7_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "ameh:NotesReceivableRelatedPartiesNoncurrentGainLoss",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Loans Receivable and Loans Receivable - Related Parties - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
     "shortName": "Loans Receivable and Loans Receivable - Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ameh:NotesReceivableRelatedPartiesNoncurrentGainLoss",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i15daea0fb86f4e9087b3958e4c3f97dd_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
     "shortName": "Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i6084317bda0d48f9b2293ce7324d000d_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439420 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility Information (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Schedule of Credit Facility Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440421 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesAssumed1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Detail)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
     "shortName": "Credit Facility, Bank Loans, and Lines of Credit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesAssumed1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - Income Taxes - Income Tax Provision (Benefit) (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails",
     "shortName": "Income Taxes - Income Tax Provision (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445424 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsStateTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446425 - Disclosure - Income Taxes - Deferred Tax Assets (Liabilities) (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets (Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsStateTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447426 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i69343d65ad324809810e1b1eda1dbc7d_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i69343d65ad324809810e1b1eda1dbc7d_D20190101-20191231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:NumberOfSharesHoldbackPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449427 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i0fa1aaf01eb041dc9c7fb082bb953674_D20171201-20171231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:NumberOfSharesHoldbackPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Stock Based Compensation - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
     "shortName": "Stock-Based Compensation - Options, Assumptions Under Black-Scholes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i5f3cfa7d97204877bf2a3a6a5c1621f4_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i670fb4a8ae4c408681d8b085578171d6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i670fb4a8ae4c408681d8b085578171d6_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i15daea0fb86f4e9087b3958e4c3f97dd_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Stock-Based Compensation - Summary of Warrant (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
     "shortName": "Stock-Based Compensation - Summary of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Stock-Based Compensation - Warrants (Details)",
     "role": "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails",
     "shortName": "Stock-Based Compensation - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ib0b3aa90d8224dc5b9bcb0eac668320c_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460435 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i962c50aee1e348aba05114edeaee56c5_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ameh:PaymentMadeToRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464437 - Disclosure - Related Party Transactions - Schedule of Related Party Transactions (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions - Schedule of Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:DefinedContributionPlanServicePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466438 - Disclosure - Employee Benefit Plan - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails",
     "shortName": "Employee Benefit Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:DefinedContributionPlanServicePeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i1eff2864c695401fb93686780342c192_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469439 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i1eff2864c695401fb93686780342c192_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470440 - Disclosure - Earnings Per Share - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails",
     "shortName": "Earnings Per Share - Basic Net Income (loss) Per Share is Calculated Using Weighted Average Number of Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471441 - Disclosure - Earnings Per Share - Summary of Shares Included in Diluted Earnings Per Share (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails",
     "shortName": "Earnings Per Share - Summary of Shares Included in Diluted Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ic14cb455ba05463cb1678b216ef7075f_D20210101-20211231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2474442 - Disclosure - Variable Interest Entities (VIEs) - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Details)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails",
     "shortName": "Variable Interest Entities (VIEs) - Eliminated Upon Consolidation Included In Accompanying Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i28dfed083b894f49a515b929d24e2c7a_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477443 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478444 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2479445 - Disclosure - Leases - Other Information Related to Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2480446 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details)",
     "role": "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases After Adoption of 842 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "i88eaaac5b8bf4609a5884bfad9cf117e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20211231.htm",
      "contextRef": "ia072c9973dc04a18aa780e5b59499cfb_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2482447 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 189,
   "tag": {
    "ameh_A10CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$10 Common Stock Warrants",
        "label": "$10 Common Stock Warrants [Member]",
        "terseLabel": "$10 Common Stock Warrants"
       }
      }
     },
     "localname": "A10CommonStockWarrantsMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_A11CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "$11 Common Stock Warrants",
        "label": "$11 Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "A11CommonStockWarrantsMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AHMCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AHMC [Member]",
        "terseLabel": "AHMC"
       }
      }
     },
     "localname": "AHMCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AMGPropertiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AMG Properties LLC",
        "label": "AMG Properties LLC [Member]",
        "terseLabel": "AMG Properties"
       }
      }
     },
     "localname": "AMGPropertiesLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APAMHMedicalCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AP-AMH Medical Corporation [Member]",
        "label": "AP-AMH Medical Corporation [Member]",
        "terseLabel": "AP-AMH"
       }
      }
     },
     "localname": "APAMHMedicalCorporationMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APCAndAPCLSMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "APC And APC-LSMA [Member]",
        "label": "APC And APC-LSMA [Member]",
        "terseLabel": "APC and APC-LSMA"
       }
      }
     },
     "localname": "APCAndAPCLSMAMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccessPrimaryCareMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Access Primary Care Medical Group",
        "label": "Access Primary Care Medical Group [Member]",
        "terseLabel": "Access Primary Care Medical Group"
       }
      }
     },
     "localname": "AccessPrimaryCareMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountableHealthCareIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accountable Health Care IPA [Member]",
        "terseLabel": "Accountable Health Care IPA"
       }
      }
     },
     "localname": "AccountableHealthCareIPAMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsPayableAndAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable And Accrued Expenses [Member]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsReceivableExpectedToBeCollectedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Expected to be Collected, Period",
        "label": "Accounts Receivable, Expected to be Collected, Period",
        "terseLabel": "Accounts receivable, expected to be collected, period"
       }
      }
     },
     "localname": "AccountsReceivableExpectedToBeCollectedPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_AchievaMedInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AchievaMed, Inc. [Member]",
        "label": "AchievaMed, Inc. [Member]",
        "terseLabel": "AchievaMed, Inc."
       }
      }
     },
     "localname": "AchievaMedInc.Member",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "label": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "terseLabel": "Additional proceeds to be received from sale of equity method investments, if circumstances met"
       }
      }
     },
     "localname": "AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_AdvanceDiagnosticSurgeryCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Diagnostic Surgery Center [Member]",
        "terseLabel": "Advance Diagnostic Surgery Center"
       }
      }
     },
     "localname": "AdvanceDiagnosticSurgeryCenterMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AggregateintrinsicvalueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in millions)"
       }
      }
     },
     "localname": "AggregateintrinsicvalueAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allied Pacific Of California And Net work Medical Management [Member].",
        "label": "Allied Pacific Of California And Network Medical Management [Member]",
        "terseLabel": "NMM and APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaAndNetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlliedPacificOfCaliforniaIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allied Pacific Of California IPA",
        "label": "Allied Pacific Of California IPA [Member]",
        "terseLabel": "APC",
        "verboseLabel": "APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlliedPacificofCaliforniaBrokerageAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allied Pacific of California Brokerage Account [Member]",
        "label": "Allied Pacific of California Brokerage Account [Member]",
        "terseLabel": "Allied Pacific of California Brokerage Account"
       }
      }
     },
     "localname": "AlliedPacificofCaliforniaBrokerageAccountMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlphaCareMedicalGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alpha Care Medical Group, Inc. [Member]",
        "label": "Alpha Care Medical Group, Inc. [Member]",
        "terseLabel": "Alpha Care"
       }
      }
     },
     "localname": "AlphaCareMedicalGroupInc.Member",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmgIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AMG, Inc [Member]",
        "terseLabel": "AMG"
       }
      }
     },
     "localname": "AmgIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AncillaryServiceContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ancillary Service Contract [Member]",
        "terseLabel": "Ancillary Service Contract"
       }
      }
     },
     "localname": "AncillaryServiceContractMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaAcoIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APA ACO Inc [Member]",
        "terseLabel": "APAACO"
       }
      }
     },
     "localname": "ApaAcoIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaacoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APAACO [Member]",
        "terseLabel": "APAACO"
       }
      }
     },
     "localname": "ApaacoMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Business Loan Agreement [Member]",
        "terseLabel": "APC Business Loan Agreement"
       }
      }
     },
     "localname": "ApcBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcLsmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC LSMA [Member]",
        "terseLabel": "APC LSMA"
       }
      }
     },
     "localname": "ApcLsmaMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Shareholders [Member]",
        "terseLabel": "APC"
       }
      }
     },
     "localname": "ApcShareholdersMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "APC Stock Option [Member]",
        "terseLabel": "APC Stock Option"
       }
      }
     },
     "localname": "ApcStockOptionMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloMedicalHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Apollo Medical Holdings, Inc [Member]",
        "terseLabel": "ApolloMed"
       }
      }
     },
     "localname": "ApolloMedicalHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloSunLabsManagementLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apollo-Sun Labs Management, LLC",
        "label": "Apollo-Sun Labs Management, LLC [Member]",
        "terseLabel": "Apollo-Sun Labs Management, LLC"
       }
      }
     },
     "localname": "ApolloSunLabsManagementLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ArroyoVistaFamilyHealthCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arroyo Vista Family Health Center",
        "label": "Arroyo Vista Family Health Center [Member]",
        "terseLabel": "Arroyo Vista Family Health Center"
       }
      }
     },
     "localname": "ArroyoVistaFamilyHealthCenterMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AssetAcquisitionPercentageOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Percentage Of Shares Acquired",
        "label": "Asset Acquisition, Percentage Of Shares Acquired",
        "terseLabel": "Asset acquisition, percentage of shares acquired"
       }
      }
     },
     "localname": "AssetAcquisitionPercentageOfSharesAcquired",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]",
        "terseLabel": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "xbrltype": "stringItemType"
    },
    "ameh_AurionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Aurion Member",
        "label": "Aurion [Member]",
        "verboseLabel": "Aurion"
       }
      }
     },
     "localname": "AurionMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BeneficialInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beneficial Interest",
        "label": "Beneficial Interest [Policy Text Block]",
        "terseLabel": "Beneficial Interest"
       }
      }
     },
     "localname": "BeneficialInterestPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "label": "Business Combination, Equity Interest Purchase Obligation, Noncurrent",
        "terseLabel": "Business combination, equity interest purchase obligation, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationNoncurrent",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "label": "Business Combination, Equity Interest Purchase Obligation, Period to Purchase",
        "terseLabel": "Business combination, equity interest purchase obligation, period to purchase"
       }
      }
     },
     "localname": "BusinessCombinationEquityInterestPurchaseObligationPeriodToPurchase",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_BusinessCombinationNumberOfSharesHeldBack": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Number Of Shares Held Back",
        "label": "Business Combination, Number Of Shares Held Back",
        "terseLabel": "Number of shares held back (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfSharesHeldBack",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_CAIPAMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAIPA MSO, LLC",
        "label": "CAIPA MSO, LLC [Member]",
        "terseLabel": "CAIPA MSO, LLC"
       }
      }
     },
     "localname": "CAIPAMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CAIPAMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CAIPA MSO",
        "label": "CAIPA MSO [Member]",
        "terseLabel": "CAIPA MSO, LLC"
       }
      }
     },
     "localname": "CAIPAMSOMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CDSCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CDSC [Member]",
        "label": "CDSC [Member]",
        "terseLabel": "CDSC"
       }
      }
     },
     "localname": "CDSCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CMSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CMS [Member]",
        "label": "CMS [Member]",
        "terseLabel": "CMS"
       }
      }
     },
     "localname": "CMSMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CancellationOfRestrictedStockAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cancellation of Restricted Stock Awards",
        "label": "Cancellation of Restricted Stock Awards",
        "terseLabel": "Cancellation of Restricted Stock Awards"
       }
      }
     },
     "localname": "CancellationOfRestrictedStockAwards",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid For Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CashlessExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless Exercise Of Stock Options",
        "label": "Cashless Exercise Of Stock Options",
        "verboseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "CashlessExerciseOfStockOptions",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantOrRightCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant or right, cancelled in period",
        "label": "Class Of Warrant Or Right Cancelled In Period",
        "negatedLabel": "Warrants forfeited (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Warrants Exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued in Period",
        "label": "Class Of Warrant Or Right Issued In Period",
        "verboseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual\u00a0Life"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Warrants outstanding balance"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights exercised in period.",
        "label": "Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights forfeited in period.",
        "label": "Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights granted in period.",
        "label": "Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights outstanding.",
        "label": "Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "periodEndLabel": "Warrants outstanding (in dollars per share)",
        "periodStartLabel": "Warrants outstanding (in dollars per share)",
        "terseLabel": "Weighted Average Exercise\u00a0Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period",
        "verboseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights forfeited during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period",
        "verboseLabel": "Warrants forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights granted during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period",
        "verboseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClinigenceHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinigence Holdings, Inc.",
        "label": "Clinigence Holdings, Inc. [Member]",
        "terseLabel": "Clinigence Holdings, Inc."
       }
      }
     },
     "localname": "ClinigenceHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CollegeStreetInvestmentLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "College Street Investment LP [Member].",
        "label": "College Street Investment LP [Member]",
        "terseLabel": "College Street Investment LP"
       }
      }
     },
     "localname": "CollegeStreetInvestmentLpMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:CommercialMember",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ConcourseDiagnosticSurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concourse Diagnostic Surgery Center, LLC [Member]",
        "terseLabel": "Concourse Diagnostic Surgery Center, LLC"
       }
      }
     },
     "localname": "ConcourseDiagnosticSurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ConstructionLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction Loan",
        "label": "Construction Loan [Member]",
        "terseLabel": "Construction loan"
       }
      }
     },
     "localname": "ConstructionLoanMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ConsultingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting Services [Member]",
        "label": "Consulting Services [Member]",
        "terseLabel": "Consulting Services"
       }
      }
     },
     "localname": "ConsultingServicesMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContingentEquitySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Equity Securities",
        "label": "Contingent Equity Securities [Member]",
        "terseLabel": "Contingent Equity Securities"
       }
      }
     },
     "localname": "ContingentEquitySecuritiesMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Axis]",
        "terseLabel": "Contract Type [Axis]"
       }
      }
     },
     "localname": "ContractTypeAxis",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract Type [Domain]",
        "terseLabel": "Contract Type [Domain]"
       }
      }
     },
     "localname": "ContractTypeDomain",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CriticalQualityManagementCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_Critical Quality Management Corp Member",
        "label": "Critical Quality Management Corp [Member]",
        "terseLabel": "CQMC"
       }
      }
     },
     "localname": "CriticalQualityManagementCorpMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DebtCovenantAggregatePurchasePriceMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Covenant, Aggregate Purchase Price, Maximum",
        "label": "Debt Covenant, Aggregate Purchase Price, Maximum",
        "terseLabel": "Debt covenant, aggregate purchase price, maximum"
       }
      }
     },
     "localname": "DebtCovenantAggregatePurchasePriceMaximum",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DebtInstrumentCovenantCashFlowCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Cash Flow Coverage Ratio, Minimum",
        "terseLabel": "Debt instrument, covenant, cash flow coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCashFlowCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantDebtCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Debt Coverage Ratio, Minimum",
        "terseLabel": "Minimum debt coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Minimum consolidated interest coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioAdjustedMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Adjusted Maximum",
        "terseLabel": "Maximum adjusted consolidated leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioAdjustedMaximum",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "terseLabel": "Consolidated leverage ratio, annual change"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioIncrementalChange",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Maximum consolidated leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentNumberOfKeyFinancialRatios": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Number Of Key Financial Ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "terseLabel": "Number of key financial ratios"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_DeferredTaxAssetsInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets Investment",
        "verboseLabel": "Investment in other entities"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestment",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DeferredTaxLiabilities481aAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, 481(a) Adjustment",
        "label": "Deferred Tax Liabilities, 481(a) Adjustment",
        "negatedTerseLabel": "481(a) adjustment"
       }
      }
     },
     "localname": "DeferredTaxLiabilities481aAdjustment",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DeferredTaxLiabilitiesStockOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Stock Options",
        "label": "Deferred Tax Liabilities, Stock Options",
        "negatedTerseLabel": "Stock options"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesStockOptions",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DefinedContributionPlanServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Service Period",
        "label": "Defined Contribution Plan, Service Period",
        "terseLabel": "Defined contribution plan, service period"
       }
      }
     },
     "localname": "DefinedContributionPlanServicePeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_DefinedContributionPlanVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Vesting Period",
        "label": "Defined Contribution Plan, Vesting Period",
        "terseLabel": "Employee benefit vested estimated year"
       }
      }
     },
     "localname": "DefinedContributionPlanVestingPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs",
        "label": "Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DiagnosticMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diagnostic Medical Group [Member]",
        "terseLabel": "Diagnostic Medical Group"
       }
      }
     },
     "localname": "DiagnosticMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DmgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DMG [Member]",
        "terseLabel": "DMG"
       }
      }
     },
     "localname": "DmgMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.ArteagaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Arteaga [Member]",
        "label": "Dr. Arteaga [Member]",
        "terseLabel": "Dr. Arteaga"
       }
      }
     },
     "localname": "Dr.ArteagaMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.JayMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dr. Jay [Member]",
        "label": "Dr. Jay [Member]",
        "terseLabel": "Dr. Jay"
       }
      }
     },
     "localname": "Dr.JayMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EffectiveIncomeTaxRateReconciliationFederalRateAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the effective income tax rate reconciliation of federal rate adjustment.",
        "label": "Effective Income Tax Rate Reconciliation, Federal Rate Adjustment",
        "verboseLabel": "Non-deductible permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationFederalRateAdjustment",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Investment Basis Adjustment, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Investment Basis Adjustment, Percent",
        "terseLabel": "Investment basis adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationInvestmentBasisAdjustmentPercent",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityIncentivePlanTwentyFifteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Twenty Fifteen [Member]",
        "verboseLabel": "2015 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlanTwentyFifteenMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EquityIncentivePlanTwentyThirteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Incentive Plan Twenty Thirteen [Member]",
        "terseLabel": "2013 Equity Incentive Plan"
       }
      }
     },
     "localname": "EquityIncentivePlanTwentyThirteenMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Increase",
        "terseLabel": "Increase in ownership percentage, finance receivable converted"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageIncrease",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage, Upon Conversion",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage, Upon Conversion",
        "terseLabel": "Ownership upon conversion of finance receivable"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentInvestmentInPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Investment In Period",
        "label": "Equity Method Investment, Investment In Period",
        "terseLabel": "Initial Investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentInvestmentInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Options Issued, Option To Purchase Additional Interests, If Circumstances Met",
        "label": "Equity Method Investment, Options Issued, Option To Purchase Additional Interests, If Circumstances Met",
        "terseLabel": "Number of warrants available to purchase, contingent upon the portal completion date (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentOptionsIssuedOptionToPurchaseAdditionalInterestsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageDisposed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Disposed",
        "label": "Equity Method Investment, Ownership Percentage Disposed",
        "terseLabel": "Ownership interest disposed"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageDisposed",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "terseLabel": "Contingent consideration, cash held in escrow"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationCash",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "terseLabel": "Contingent consideration, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationFairValue",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "terseLabel": "Contingent consideration, preferred shares"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationPreferredShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsConsolidated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Consolidated",
        "label": "Equity Method Investments, Consolidated",
        "negatedTerseLabel": "Consolidation of Entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentsConsolidated",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Contribution",
        "label": "Equity Method Investments, Contribution",
        "terseLabel": "Contribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentsContribution",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option",
        "label": "Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option",
        "terseLabel": "Term of option"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "terseLabel": "Duration of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "terseLabel": "Membership interests acquired (in dollars per share)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "terseLabel": "Options to purchase additional membership interests (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "terseLabel": "Percentage of voting common stock, within five years"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "terseLabel": "Membership interests purchased (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_ExecutiveOfficerAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Officer And Director",
        "label": "Executive Officer And Director [Member]",
        "terseLabel": "Board Members and Directors"
       }
      }
     },
     "localname": "ExecutiveOfficerAndDirectorMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FiduciaryAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Fiduciary Accounts Payable Current",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "FiduciaryAccountsPayableCurrent",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiduciaryCashAndPayablePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiduciary Cash and Payable",
        "label": "Fiduciary Cash and Payable [Policy Text Block]",
        "terseLabel": "Fiduciary Cash and Payable"
       }
      }
     },
     "localname": "FiduciaryCashAndPayablePolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_FinanceReceivableInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Interest Rate, Stated Percentage",
        "label": "Finance Receivable, Interest Rate, Stated Percentage",
        "terseLabel": "Note receivable, interest rate"
       }
      }
     },
     "localname": "FinanceReceivableInterestRateStatedPercentage",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "label": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "FinanceReceivableModificationsSubsequentDefaultInterestRate",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Stated Interest Rate",
        "label": "Finance Receivable, Stated Interest Rate",
        "terseLabel": "Stated rate of note of loan receivable"
       }
      }
     },
     "localname": "FinanceReceivableStatedInterestRate",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableTermOfReceivable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Receivable, Term Of Receivable",
        "label": "Finance Receivable, Term Of Receivable",
        "terseLabel": "Term of receivable",
        "verboseLabel": "Note receivable, maturity period"
       }
      }
     },
     "localname": "FinanceReceivableTermOfReceivable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, After Allowance For Credit Loss, Current, Gain (Loss)",
        "label": "Financing Receivable, After Allowance For Credit Loss, Current, Gain (Loss)",
        "negatedTerseLabel": "Loss recorded, loan receivable"
       }
      }
     },
     "localname": "FinancingReceivableAfterAllowanceForCreditLossCurrentGainLoss",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite and Indefinite Lived Intangible Assets Acquired",
        "label": "Finite and Indefinite Lived Intangible Assets Acquired",
        "totalLabel": "Additions"
       }
      }
     },
     "localname": "FiniteAndIndefiniteLivedIntangibleAssetsAcquired",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiveThreeOneW.CollegeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Five Three One W. College LLC [Member]",
        "terseLabel": "531 W. College, LLC \u2013 related party"
       }
      }
     },
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FormerShareholdersOfNmmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Former Shareholders of NMM [Member]",
        "terseLabel": "Former Shareholders of NMM"
       }
      }
     },
     "localname": "FormerShareholdersOfNmmMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FreseniusMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fresenius",
        "label": "Fresenius [Member]",
        "terseLabel": "Fresenius"
       }
      }
     },
     "localname": "FreseniusMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_FulgentGeneticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fulgent Genetics, Inc.",
        "label": "Fulgent Genetics, Inc. [Member]",
        "terseLabel": "Fulgent Genetics, Inc."
       }
      }
     },
     "localname": "FulgentGeneticsIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_GainLossOnAssumptionOfLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Assumption Of Loan",
        "label": "Gain (Loss) On Assumption Of Loan",
        "negatedTerseLabel": "Gain on loan assumption"
       }
      }
     },
     "localname": "GainLossOnAssumptionOfLoan",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_GainLossOnConsolidationOfEquityMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Consolidation of Equity Method Investment",
        "label": "Gain (Loss) on Consolidation of Equity Method Investment",
        "negatedLabel": "Gain on consolidation of equity method investment"
       }
      }
     },
     "localname": "GainLossOnConsolidationOfEquityMethodInvestment",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_GainLossOnEquityReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Equity Receivable",
        "label": "Gain (Loss) on Equity Receivable",
        "negatedTerseLabel": "Gain on contingent equity securities"
       }
      }
     },
     "localname": "GainLossOnEquityReceivable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_HSMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "xxx_HSMSO Member",
        "label": "HSMSO [Member]",
        "verboseLabel": "HSMSO"
       }
      }
     },
     "localname": "HSMSOMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthCareCapitationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_HealthCareCapitationRevenueMember",
        "label": "Health Care Capitation Revenue [Member]",
        "verboseLabel": "Capitation, net"
       }
      }
     },
     "localname": "HealthCareCapitationRevenueMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthSourceMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Source MSO Inc. [Member]",
        "label": "Health Source MSO Inc. [Member]",
        "terseLabel": "HSMSO"
       }
      }
     },
     "localname": "HealthSourceMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HoldbackSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Holdback Shares [Member]",
        "terseLabel": "Holdback shares"
       }
      }
     },
     "localname": "HoldbackSharesMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_IncreaseDecreaseInMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.",
        "label": "Increase (Decrease) In Medical Liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase in operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents increase in lease liabilities.",
        "label": "Increase (Decrease) In Other Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLeaseLiabilities",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial fixed term of amended and restated management and administrative services agreement.",
        "label": "Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement",
        "terseLabel": "Initial fixed term of amended and restated management and administrative services agreement"
       }
      }
     },
     "localname": "InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "label": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "verboseLabel": "AHMC \u2013 Risk pool earnings net of claims payment"
       }
      }
     },
     "localname": "InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share .",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "terseLabel": "Investments in privately held entities"
       }
      }
     },
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IssuanceOfFinancingObligationForBusinessCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Financing Obligation for Business Combination",
        "label": "Issuance of Financing Obligation for Business Combination",
        "terseLabel": "Issuance of financing obligation for business combinations"
       }
      }
     },
     "localname": "IssuanceOfFinancingObligationForBusinessCombination",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LasalleMedicalAssociatesIpaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LaSalle Medical Associates IPA [Member]",
        "terseLabel": "LaSalle Medical Associates \u2013 IPA Line of Business",
        "verboseLabel": "LaSalle Medical Associates"
       }
      }
     },
     "localname": "LasalleMedicalAssociatesIpaMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities:"
       }
      }
     },
     "localname": "LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-Average Discount Rate"
       }
      }
     },
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Lease Term"
       }
      }
     },
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "terseLabel": "Finance lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "terseLabel": "Operating lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LoanReceivableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Receivable [Abstract]",
        "terseLabel": "Loan Receivable [Abstract]"
       }
      }
     },
     "localname": "LoanReceivableAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "xbrltype": "stringItemType"
    },
    "ameh_LoanReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Receivable",
        "label": "Loan Receivable [Text Block]",
        "terseLabel": "Loans Receivable and Loans Receivable \u2013 Related Parties"
       }
      }
     },
     "localname": "LoanReceivableTextBlock",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_LongTermDebtMaturityAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Maturity, After Year Four",
        "label": "Long-Term Debt, Maturity, After Year Four",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturityAfterYearFour",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_MPPAMGPropertiesAndZLLAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MPP, AMG Properties, and ZLL Asset Acquisition",
        "label": "MPP, AMG Properties, and ZLL Asset Acquisition [Member]",
        "terseLabel": "MPP, AMG Properties, and ZLL Asset Acquisition"
       }
      }
     },
     "localname": "MPPAMGPropertiesAndZLLAssetAcquisitionMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MWNCommunityHospitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MWN Community Hospital LLC [Member]",
        "terseLabel": "MWN Community Hospital LLC"
       }
      }
     },
     "localname": "MWNCommunityHospitalLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ManagementContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Management Contracts",
        "label": "Management Contracts [Member]",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementContractsMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MarketableSecuritiesCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities, Current, Maturity Period",
        "label": "Marketable Securities, Current, Maturity Period",
        "terseLabel": "Marketable securities, current, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_MaverickMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maverick Medical Group, Inc [Member]",
        "terseLabel": "Maverick Medical Group, Inc"
       }
      }
     },
     "localname": "MaverickMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MediPortalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MediPortal LLC [Member]",
        "terseLabel": "MediPortal LLC"
       }
      }
     },
     "localname": "MediPortalLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicaidMember",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Care Costs [Abstract]",
        "label": "Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "MedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MedicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of medical liabilities (due within one year or within the normal operating cycle if longer) disclosed in the balance sheet.",
        "label": "Medical Liabilities, Current",
        "terseLabel": "Medical liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "MedicalLiabilitiesCurrent",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_MedicalPropertyPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Property Partners LLC",
        "label": "Medical Property Partners LLC [Member]",
        "terseLabel": "MPP"
       }
      }
     },
     "localname": "MedicalPropertyPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare License",
        "label": "Medicare License [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "MedicareLicenseMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:MedicareMember",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MemberRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Relationships",
        "label": "Member Relationships [Member]",
        "verboseLabel": "Member relationships"
       }
      }
     },
     "localname": "MemberRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MezzanineEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEZZANINE EQUITY [Abstract]",
        "verboseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "MezzanineEquityAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine [Member]",
        "terseLabel": "Mezzanine Equity\u00a0\u2013 Non-controlling Interest\u00a0in\u00a0APC"
       }
      }
     },
     "localname": "MezzanineMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MinorityInterestPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minority Interest Policy.",
        "label": "Minority Interest Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestPolicyPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NetworkMedicalManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management, Inc. [Member]",
        "verboseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Network Medical Management [Member]",
        "terseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Network Relationships",
        "label": "Network Relationships [Member]",
        "verboseLabel": "Network relationships"
       }
      }
     },
     "localname": "NetworkRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NextGenerationACOModelParticipationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Next Generation ACO Model Participation Agreement [Member]",
        "label": "Next Generation ACO Model Participation Agreement [Member]",
        "terseLabel": "NGACO"
       }
      }
     },
     "localname": "NextGenerationACOModelParticipationAgreementMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Shares, Release Of Hold Back Shares",
        "label": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Shares, Release Of Hold Back Shares",
        "terseLabel": "Dividends (shares)"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodSharesReleaseOfHoldBackShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares",
        "label": "Noncontrolling Interest, Decrease From Distributions To Noncontrolling Interest Holders And Stock Repurchased During Period, Value, Release Of Hold Back Shares",
        "terseLabel": "Dividends"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDistributionsToNoncontrollingInterestHoldersAndStockRepurchasedDuringPeriodValueReleaseOfHoldBackShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NoncontrollingInterestIncreaseFromCapitalCharge": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Increase From Capital Charge",
        "label": "Noncontrolling Interest, Increase From Capital Charge",
        "terseLabel": "Noncontrolling interest capital charge"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromCapitalCharge",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NoncontrollingInterestSharesDistributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Shares Distributed",
        "label": "Noncontrolling Interest, Shares Distributed",
        "terseLabel": "Noncontrolling interest, shares distributed"
       }
      }
     },
     "localname": "NoncontrollingInterestSharesDistributed",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NotesReceivableRelatedPartiesNoncurrentGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes Receivable, Related Parties, Noncurrent, Gain (Loss)",
        "label": "Notes Receivable, Related Parties, Noncurrent, Gain (Loss)",
        "negatedTerseLabel": "Loss recorded, loan receivable - related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesNoncurrentGainLoss",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NumberOfDirectContractingEntityPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Direct Contracting Entity Patients",
        "label": "Number of Direct Contracting Entity Patients",
        "terseLabel": "Number of Direct Contracting Entity patients"
       }
      }
     },
     "localname": "NumberOfDirectContractingEntityPatients",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Employees",
        "label": "Number Of Employees",
        "verboseLabel": "Number of employees (more than)"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFamilyPracticeClinics": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Family Practice Clinics",
        "label": "Number Of Family Practice Clinics",
        "terseLabel": "Number of family practice clinics"
       }
      }
     },
     "localname": "NumberOfFamilyPracticeClinics",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Federally Qualified Health Plans",
        "label": "Number Of Federally Qualified Health Plans",
        "terseLabel": "Number federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfRemotePatientMonitoringPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Remote Patient Monitoring Patients",
        "label": "Number of Remote Patient Monitoring Patients",
        "terseLabel": "Number of Remote Patient Monitoring patients"
       }
      }
     },
     "localname": "NumberOfRemotePatientMonitoringPatients",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfSharesHoldbackPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of shares holdback pursuant to the merger agreement.",
        "label": "Number Of Shares Holdback, Percentage",
        "terseLabel": "Number of shares holdback percentage"
       }
      }
     },
     "localname": "NumberOfSharesHoldbackPercentage",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Warrants Granted",
        "label": "Number Of Warrants Granted",
        "verboseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numen LLC [Member]",
        "terseLabel": "Numen"
       }
      }
     },
     "localname": "NumenLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, Inc. [Member]",
        "label": "One MSO, Inc. [Member]",
        "terseLabel": "One MSO, Inc."
       }
      }
     },
     "localname": "OneMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC",
        "label": "One MSO, LLC [Member]",
        "terseLabel": "One MSO, LLC \u2014 related party"
       }
      }
     },
     "localname": "OneMSOLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC",
        "label": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "One MSO, LLC, Tag-6 Medical Investment Group, LLC, and Tag-8 Medical Investment Group, LLC"
       }
      }
     },
     "localname": "OneMSOLLCTag6MedicalInvestmentGroupLLCAndTag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OperatingLossCarryforwardsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carry forwards Expiration Period.",
        "label": "Operating Loss CarryForwards Expiration Period",
        "terseLabel": "Net operating loss carryforwards, expiration period"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "ameh_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "terseLabel": "Net operating loss carryforwards, not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_OrmaHealthIncAndProviderGrowthSolutionsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orma Health, Inc., and Provider Growth Solutions LLC",
        "label": "Orma Health, Inc., and Provider Growth Solutions LLC [Member]",
        "terseLabel": "Orma Health, Inc., and Provider Growth Solutions LLC"
       }
      }
     },
     "localname": "OrmaHealthIncAndProviderGrowthSolutionsLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh:OtherThirdPartiesMember",
        "label": "Other Third Parties [Member]",
        "terseLabel": "Other third parties"
       }
      }
     },
     "localname": "OtherThirdPartiesMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Pacific6EnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific6 Enterprises [Member]",
        "label": "Pacific6 Enterprises [Member]",
        "terseLabel": "Pacific6"
       }
      }
     },
     "localname": "Pacific6EnterprisesMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificAmbulatorySurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pacific Ambulatory Surgery Center, LLC [Member]",
        "terseLabel": "PASC"
       }
      }
     },
     "localname": "PacificAmbulatorySurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificMedicalImagingAndOncologyCenterIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]",
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc."
       }
      }
     },
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PatientManagementPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Management Platform",
        "label": "Patient Management Platform [Member]",
        "verboseLabel": "Patient management platform"
       }
      }
     },
     "localname": "PatientManagementPlatformMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentMadeToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit/Duration (Amount paid to related party in relation to providing services",
        "label": "Payment Made To Related Party",
        "terseLabel": "Payments to related party"
       }
      }
     },
     "localname": "PaymentMadeToRelatedParty",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Investment Privately Held Entity Does Not Report To NAV Per Share",
        "label": "Payment Of Investment Privately Held Entity Does Not Report To NAV Per Share",
        "negatedLabel": "Purchases of investments in privately held entities"
       }
      }
     },
     "localname": "PaymentOfInvestmentPrivatelyHeldEntityDoesNotReportToNAVPerShare",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue",
        "label": "Payment Of Revenue",
        "terseLabel": "Payment of revenue"
       }
      }
     },
     "localname": "PaymentOfRevenue",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueMonthlyAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue, Monthly Amount",
        "label": "Payment Of Revenue, Monthly Amount",
        "terseLabel": "Payment of revenue, monthly amount"
       }
      }
     },
     "localname": "PaymentOfRevenueMonthlyAmount",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Of Revenue, Revenue Recognized",
        "label": "Payment Of Revenue, Revenue Recognized",
        "terseLabel": "Payment of revenue, revenue recognized"
       }
      }
     },
     "localname": "PaymentOfRevenueRevenueRecognized",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Medical Care Costs [Abstract]",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_PaymentsToAcquireCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Common Stock And Warrants",
        "label": "Payments To Acquire Common Stock And Warrants",
        "terseLabel": "Payments to acquire common stock and warrants"
       }
      }
     },
     "localname": "PaymentsToAcquireCommonStockAndWarrants",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Payments to purchase membership interests"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PayorAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor A [Member]",
        "label": "Payor A [Member]",
        "terseLabel": "Payor A"
       }
      }
     },
     "localname": "PayorAMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor B [Member]",
        "label": "Payor B [Member]",
        "terseLabel": "Payor B"
       }
      }
     },
     "localname": "PayorBMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor C [Member]",
        "label": "Payor C [Member]",
        "terseLabel": "Payor C"
       }
      }
     },
     "localname": "PayorCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payor D [Member]",
        "terseLabel": "Payor D"
       }
      }
     },
     "localname": "PayorDMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payor E [Member]",
        "terseLabel": "Payor E"
       }
      }
     },
     "localname": "PayorEMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorFMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payor F [Member]",
        "label": "Payor F [Member]",
        "terseLabel": "Payor F"
       }
      }
     },
     "localname": "PayorFMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PerMemberPerMonthManagedCareContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per-Member-Per-Month Managed Care Contract [Member]",
        "label": "Per-Member-Per-Month Managed Care Contract [Member]",
        "terseLabel": "PMPM"
       }
      }
     },
     "localname": "PerMemberPerMonthManagedCareContractMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PercentageOfFinancialGuaranteeBenchmarkAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financial guarantee on benchmark Medicare expenditure amount.",
        "label": "Percentage Of Financial Guarantee Benchmark Amount",
        "terseLabel": "General amount of guarantee (as a percent)"
       }
      }
     },
     "localname": "PercentageOfFinancialGuaranteeBenchmarkAmount",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_PmiocMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PMIOC [Member]",
        "terseLabel": "PMIOC"
       }
      }
     },
     "localname": "PmiocMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PreferredBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Bank [Member]",
        "terseLabel": "Preferred Bank"
       }
      }
     },
     "localname": "PreferredBankMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PrimaryBeneficiaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Beneficiary",
        "label": "Primary Beneficiary [Member]",
        "terseLabel": "Primary Beneficiary"
       }
      }
     },
     "localname": "PrimaryBeneficiaryMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "label": "Proceeds from Cash Received from Consolidation of Variable Interest Entity",
        "terseLabel": "Cash recorded from consolidation of VIE"
       }
      }
     },
     "localname": "ProceedsFromCashReceivedFromConsolidationOfVariableInterestEntity",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ProceedsFromEquityOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Equity Offering",
        "label": "Proceeds from Equity Offering",
        "terseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "ProceedsFromEquityOffering",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant And Equipment And Asset Acquisition Disclosure",
        "label": "Property, Plant And Equipment Disclosure And Asset Acquisition [Text Block]",
        "terseLabel": "Land, Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureAndAssetAcquisitionTextBlock",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Receivables and receivables from related parties.",
        "label": "Receivables And Related parties Receivables Policy Text Block [Policy Text Block]",
        "verboseLabel": "Receivables. Receivables \u2013 Related Parties, and Loan Receivable - Related Party"
       }
      }
     },
     "localname": "ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReclassificationOfLiabilityForEquity": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Of Liability For Equity",
        "label": "Reclassification Of Liability For Equity",
        "terseLabel": "Reclassification of liability for equity shares"
       }
      }
     },
     "localname": "ReclassificationOfLiabilityForEquity",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_RepaymentsOfBankLoanAndLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayments Of Bank Loan And Lines Of Credit",
        "label": "Repayments Of Bank Loan And Lines Of Credit",
        "negatedLabel": "Repayments on bank loan and lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfBankLoanAndLinesOfCredit",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "terseLabel": "Expected period of payment upon termination of agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_RiskPoolSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "These lines are represents that risk pool settlement.",
        "label": "Risk Pool Settlement",
        "terseLabel": "Risk pool settlement"
       }
      }
     },
     "localname": "RiskPoolSettlement",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "terseLabel": "Risk pool surplus or deficits, settlement period after performance year"
       }
      }
     },
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_SCHCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCHC",
        "label": "SCHC [Member]",
        "terseLabel": "SCHC"
       }
      }
     },
     "localname": "SCHCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period",
        "terseLabel": "Cashless options, exercises in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in millions)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "terseLabel": "Warrants exercises in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "terseLabel": "Share-based compensation arrangement by share based payment award, warrant exercised, exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_SharesWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Warrants [Roll Forward]",
        "label": "Shares, Warrants [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "SharesWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SpecialtyCapitationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of specialty capitation payable current.",
        "label": "Specialty Capitation Payable Current",
        "verboseLabel": "Capitation payable"
       }
      }
     },
     "localname": "SpecialtyCapitationPayableCurrent",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockAwardsAndUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Awards And Units",
        "label": "Stock Awards And Units [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "StockAwardsAndUnitsMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_StockIssuedDuringPeriodShareConversionOfNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock issued during the period upon the conversion of notes.",
        "label": "Stock Issued During Period, Share, Conversion Of Notes",
        "terseLabel": "Stock issued during period share conversion of notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareConversionOfNotes",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Cashless Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Cashless Warrants Exercised",
        "terseLabel": "Shares issued for cashless exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to merger.",
        "label": "Stock Issued During Period, Shares, Merger",
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesNoncontrollingInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Noncontrolling Interest",
        "label": "Stock Issued During Period, Shares, Noncontrolling Interest",
        "terseLabel": "Sale of shares by noncontrolling interest (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Cashless Warrants Exercised",
        "label": "Stock Issued During Period, Value, Cashless Warrants Exercised",
        "terseLabel": "Shares issued for cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCashlessWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringPeriodValueConversionOfNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of notes.",
        "label": "Stock Issued During Period Value Conversion Of Notes",
        "terseLabel": "Stock issued during period value conversion of notes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfNotes",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringPeriodValueNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Noncontrolling Interest",
        "label": "Stock Issued During Period, Value, Noncontrolling Interest",
        "terseLabel": "Sale of shares by noncontrolling interest"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Stock Options Liability Reclassified To Equity",
        "label": "Stock Issued During Period, Value, Stock Options Liability Reclassified To Equity",
        "terseLabel": "Reclassification of options liability to equity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsLiabilityReclassifiedToEquity",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents number of share issued exercise of option and warrants during the period",
        "label": "Stock issued during the period shares of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents value of stock issued during the period",
        "label": "Stock issued during the period value of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been released during the period.",
        "label": "Stock Repurchase During Period Shares Release of Hold Back Shares",
        "terseLabel": "Issuance of 50% holdback shares (shares)"
       }
      }
     },
     "localname": "StockRepurchaseDuringPeriodSharesReleaseOfHoldBackShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been released during the period.",
        "label": "Stock Repurchase During Period Value Release of Hold Back shares",
        "terseLabel": "Issuance of 50% holdback shares"
       }
      }
     },
     "localname": "StockRepurchaseDuringPeriodValueReleaseOfHoldBackShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SubcontractorIpaRiskPoolPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of subcontractor IPA risk pool payable current.",
        "label": "Subcontractor IPA Risk Pool Payable",
        "verboseLabel": "Subcontractor IPA payable"
       }
      }
     },
     "localname": "SubcontractorIpaRiskPoolPayable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_Tag6MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-6 Medical Investment Group, LLC",
        "label": "Tag-6 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-6 Medical Investment Group, LLC \u2014 related party"
       }
      }
     },
     "localname": "Tag6MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Tag8MedicalInvestmentGroupLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tag-8 Medical Investment Group, LLC",
        "label": "Tag-8 Medical Investment Group, LLC [Member]",
        "terseLabel": "Tag-8 Medical Investment Group, LLC \u2014 related party"
       }
      }
     },
     "localname": "Tag8MedicalInvestmentGroupLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_TemporaryEquityCostOfEquityIssuanceOfPreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Cost of Equity Issuance of Preferred Shares",
        "label": "Temporary Equity, Cost of Equity Issuance of Preferred Shares",
        "terseLabel": "Cost of equity issuance of preferred shares"
       }
      }
     },
     "localname": "TemporaryEquityCostOfEquityIssuanceOfPreferredShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_TemporaryEquityDistributionToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Distribution to Noncontrolling Interest",
        "label": "Temporary Equity, Distribution to Noncontrolling Interest",
        "negatedTerseLabel": "Distribution to noncontrolling interest"
       }
      }
     },
     "localname": "TemporaryEquityDistributionToNoncontrollingInterest",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_TemporaryEquityIncreaseFromSaleOfNonControllingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Increase from Sale of Non-Controlling Interest",
        "label": "Temporary Equity, Increase from Sale of Non-Controlling Interest",
        "negatedTerseLabel": "Sale of non-controlling interest"
       }
      }
     },
     "localname": "TemporaryEquityIncreaseFromSaleOfNonControllingInterest",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity [Policy Text Block]",
        "label": "Temporary Equity [Policy Text Block]",
        "verboseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_TemporaryEquityRepurchaseOfTreasuryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Repurchase of Treasury Shares",
        "label": "Temporary Equity, Repurchase of Treasury Shares",
        "negatedTerseLabel": "Repurchase of treasury shares"
       }
      }
     },
     "localname": "TemporaryEquityRepurchaseOfTreasuryShares",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_TemporaryEquityShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Share-based Compensation",
        "label": "Temporary Equity, Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "TemporaryEquityShareBasedCompensation",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_TemporaryEquityStockSubscription": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Subscription",
        "label": "Temporary Equity, Stock Subscription",
        "terseLabel": "Stock subscription"
       }
      }
     },
     "localname": "TemporaryEquityStockSubscription",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A [Member]",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term loan",
        "verboseLabel": "Term loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareAcquisitionPartnersLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Acquisition Partners, LLC [Member]",
        "terseLabel": "UCAP"
       }
      }
     },
     "localname": "UniversalCareAcquisitionPartnersLlcMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Universal Care Inc [Member]",
        "terseLabel": "Universal Care Inc"
       }
      }
     },
     "localname": "UniversalCareIncMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Warrant1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant 1 [Member]",
        "terseLabel": "Warrant 1"
       }
      }
     },
     "localname": "Warrant1Member",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Warrant2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant 2 [Member]",
        "terseLabel": "Warrant 2"
       }
      }
     },
     "localname": "Warrant2Member",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range One [Member]",
        "verboseLabel": "Warrant Exercise Price Range One"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeOneMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Three [Member]",
        "verboseLabel": "Warrant Exercise Price Range Three"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeThreeMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Exercise Price Range Two [Member]",
        "verboseLabel": "Warrant Exercise Price Range Two"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeTwoMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Issued During Period Value Stock Options Exercised",
        "label": "Warrant Issued During Period Value Stock Options Exercised",
        "terseLabel": "Warrant issued during period value stock options exercised"
       }
      }
     },
     "localname": "WarrantIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WeightedAverageExercisePriceWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "label": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WeightedaverageremainingcontractualtermyearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "WeightedaverageremainingcontractualtermyearsAbstract",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ZLLPartnersLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZLL Partners LLC",
        "label": "ZLL Partners LLC [Member]",
        "terseLabel": "ZLL"
       }
      }
     },
     "localname": "ZLLPartnersLLCMember",
     "nsuri": "http://www.apollomed.net/20211231",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r781",
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r778"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.apollomed.net/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r425",
      "r637",
      "r638",
      "r641",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r148",
      "r309",
      "r314",
      "r320",
      "r543",
      "r544",
      "r551",
      "r552",
      "r644",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r148",
      "r309",
      "r314",
      "r320",
      "r543",
      "r544",
      "r551",
      "r552",
      "r644",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r78",
      "r80",
      "r145",
      "r146",
      "r326",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]",
        "terseLabel": "Executives",
        "verboseLabel": "Executive restricted stock awards"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r227",
      "r404",
      "r409",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r228",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management restricted stock awards"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r325",
      "r364",
      "r436",
      "r439",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r683",
      "r752",
      "r755",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r325",
      "r364",
      "r436",
      "r439",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r683",
      "r752",
      "r755",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r227",
      "r404",
      "r409",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]",
        "terseLabel": "Officer"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r225",
      "r404",
      "r407",
      "r684",
      "r751",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r225",
      "r404",
      "r407",
      "r684",
      "r751",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r325",
      "r364",
      "r415",
      "r436",
      "r439",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r683",
      "r752",
      "r755",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r325",
      "r364",
      "r415",
      "r436",
      "r439",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r683",
      "r752",
      "r755",
      "r776",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r79",
      "r80",
      "r145",
      "r146",
      "r326",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r158",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r158",
      "r163",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r158",
      "r163",
      "r303",
      "r437",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r228",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and other accruals"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Gross receivables"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r38",
      "r229",
      "r230"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Receivables, net",
        "verboseLabel": "Receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r68",
      "r144",
      "r638",
      "r641"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Receivables, net \u2013 related parties",
        "verboseLabel": "Receivables, net \u2013 related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r27",
      "r704",
      "r730"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r58"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r39",
      "r481",
      "r647"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r478",
      "r479",
      "r480",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentOfWarrantsGrantedForServices": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for noncash service expenses paid for by granting of warrants.",
        "label": "Adjustment of Warrants Granted for Services",
        "terseLabel": "Deferred tax liability adjustment related to warrant exercises"
       }
      }
     },
     "localname": "AdjustmentOfWarrantsGrantedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r442",
      "r475",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r94",
      "r125",
      "r345",
      "r611"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance cost"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r125",
      "r275",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r140",
      "r207",
      "r217",
      "r223",
      "r246",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r543",
      "r551",
      "r599",
      "r645",
      "r647",
      "r702",
      "r728"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r73",
      "r140",
      "r246",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r543",
      "r551",
      "r599",
      "r645",
      "r647"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "netLabel": "Current assets",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r586"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r140",
      "r246",
      "r309",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r543",
      "r551",
      "r599",
      "r645"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets",
        "verboseLabel": "Non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r233",
      "r235",
      "r260",
      "r710"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities \u2013 certificates of deposit"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r444",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r570",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BridgeLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place.",
        "label": "Bridge Loan [Member]",
        "terseLabel": "Bridge Loan"
       }
      }
     },
     "localname": "BridgeLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r435",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r435",
      "r438",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r528",
      "r529",
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r528",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of shares transferred in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r527",
      "r530",
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "APCMG contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations and Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "verboseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r149",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "verboseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r46",
      "r127"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market accounts"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r128",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r118",
      "r127",
      "r133"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of year",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r118",
      "r600"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r137",
      "r140",
      "r166",
      "r167",
      "r168",
      "r170",
      "r172",
      "r181",
      "r182",
      "r183",
      "r246",
      "r309",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321",
      "r362",
      "r363",
      "r367",
      "r371",
      "r599",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r389",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise\u00a0Price\u00a0Per Share (in dollars per share)",
        "verboseLabel": "Exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants (in shares)",
        "verboseLabel": "Number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding (in shares)",
        "periodStartLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r389",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r63",
      "r302",
      "r714",
      "r735"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r304",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r35",
      "r647"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value $0.001; 100,000,000 shares authorized,44,630,873and 42,249,137 shares outstanding, excluding 10,925,702 and 12,323,164 treasury shares, at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r227",
      "r596",
      "r597",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r227",
      "r596",
      "r597",
      "r762",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r227",
      "r596",
      "r597",
      "r762",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r187",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r192",
      "r193",
      "r227",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r190",
      "r192",
      "r193",
      "r194",
      "r596",
      "r598",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r227",
      "r596",
      "r597",
      "r769"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of beneficial interest received as consideration for transferring noncash financial asset. Includes, but is not limited to, trade receivable in securitization transaction.",
        "label": "Consideration Received for Beneficial Interest Obtained for Transferring Financial Asset",
        "verboseLabel": "Beneficial interest acquired from sale of equity method investment"
       }
      }
     },
     "localname": "ConsiderationReceivedForBeneficialInterestObtainedForTransferringFinancialAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Other Entities - Equity Method"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r550",
      "r554",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "verboseLabel": "Variable Interest Entities"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r391",
      "r392",
      "r405"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Preferred shares received from sale of equity method investment"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r99",
      "r684"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of services, excluding depreciation and amortization"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r505",
      "r512"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r505",
      "r512",
      "r514"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r505",
      "r512"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r191",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r136",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r339",
      "r346",
      "r347",
      "r349",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility, Bank Loans, and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r139",
      "r148",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r352",
      "r353",
      "r354",
      "r355",
      "r612",
      "r703",
      "r707",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r28",
      "r350",
      "r707",
      "r727"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Total debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r322",
      "r352",
      "r353",
      "r610",
      "r612",
      "r613"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount of debt"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r60",
      "r342",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Interest rate during period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r60",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate on loan receivable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r61",
      "r139",
      "r148",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r352",
      "r353",
      "r354",
      "r355",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r61",
      "r139",
      "r148",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r352",
      "r353",
      "r354",
      "r355",
      "r379",
      "r382",
      "r383",
      "r384",
      "r609",
      "r610",
      "r612",
      "r613",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Revolving credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r335",
      "r351",
      "r352",
      "r353",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized financing cost"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r614"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Remaining outstanding under agreement"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r506",
      "r512"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r141",
      "r506",
      "r512",
      "r513",
      "r514"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r31",
      "r32",
      "r495",
      "r705",
      "r726"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r487",
      "r488"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r141",
      "r506",
      "r512"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r496"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.",
        "label": "Deferred Tax Assets, State Taxes",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsStateTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "verboseLabel": "Allowance for bad debts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedLossesOnTradingSecurities": {
     "auth_ref": [
      "r503"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from unrealized loss on investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Deferred Tax Asset, Debt Securities, Trading, Unrealized Loss",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedLossesOnTradingSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r497"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r488",
      "r498"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from debt issuance costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs",
        "negatedTerseLabel": "Debt issuance cost"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Acquired intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesDeferredTaxAssetsLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer discretionary contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EmployeeBenefitPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r125",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r125",
      "r204"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r76",
      "r77",
      "r80",
      "r595"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Contingent equity securities"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r75",
      "r80",
      "r81",
      "r573",
      "r665"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value, gross liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r80",
      "r571",
      "r574",
      "r576",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r568",
      "r571",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r76",
      "r77",
      "r80",
      "r595"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r572"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Loss on Derivative",
        "terseLabel": "Loss in interest rate swaps"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r565",
      "r566",
      "r568",
      "r569",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r404",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregated Revenue by Payor Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r58"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable",
        "verboseLabel": "Dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r27",
      "r30",
      "r706",
      "r729"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividend declared included in dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromAffiliates": {
     "auth_ref": [
      "r638",
      "r640",
      "r737"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership.",
        "label": "Due from Affiliates",
        "terseLabel": "Amounts due from affiliates*"
       }
      }
     },
     "localname": "DueFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r144",
      "r312",
      "r314",
      "r315",
      "r319",
      "r320",
      "r321",
      "r638",
      "r712",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r47",
      "r144",
      "r312",
      "r314",
      "r315",
      "r319",
      "r320",
      "r321",
      "r638"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due after one year (or one business cycle).",
        "label": "Due from Related Parties, Noncurrent",
        "terseLabel": "Loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r25",
      "r144",
      "r638",
      "r764"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Amount due to affiliate*"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r52",
      "r144",
      "r312",
      "r314",
      "r315",
      "r319",
      "r320",
      "r321",
      "r638"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r92",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r164",
      "r166",
      "r170",
      "r171",
      "r172",
      "r177",
      "r178",
      "r584",
      "r585",
      "r718",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r92",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r166",
      "r170",
      "r171",
      "r172",
      "r177",
      "r178",
      "r584",
      "r585",
      "r718",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r173",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r173",
      "r175",
      "r176",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r142",
      "r490",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal corporate tax rate",
        "verboseLabel": "Tax provision at U.S. federal statutory rates"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r490",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary": {
     "auth_ref": [
      "r490",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity in earnings (loss) of unconsolidated subsidiaries exempt from income taxes.",
        "label": "Effective Income Tax Rate Reconciliation, Equity in Earnings (Losses) of Unconsolidated Subsidiary, Percent",
        "terseLabel": "Variable interest entities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationEquityInEarningsLossesOfUnconsolidatedSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r490",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r490",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r490",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income taxes net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r490",
      "r515"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r85",
      "r86",
      "r87",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r180",
      "r249",
      "r378",
      "r385",
      "r478",
      "r479",
      "r480",
      "r508",
      "r509",
      "r583",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r756",
      "r757",
      "r758",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Amount invested for interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r2",
      "r140",
      "r246",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r2",
      "r140",
      "r246",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the equity method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value subject to the equity accounting method. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment.",
        "label": "Equity Method Investment, Other than Temporary Impairment",
        "terseLabel": "Impairment of investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest",
        "verboseLabel": "Investment, ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r95",
      "r96",
      "r125"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of equity method investment",
        "terseLabel": "Gain on sale of equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "negatedTerseLabel": "Sale"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r48",
      "r208",
      "r243"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "verboseLabel": "Investments in other entities \u2013 equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "verboseLabel": "Investments in Other Entities"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "verboseLabel": "Schedule of Equity Method Investments, Financial Statement Information"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r593"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Marketable securities \u2013 equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "terseLabel": "Investment in affiliates*"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r593"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable securities - equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r241",
      "r742"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Unrealized loss (gain) from investment in equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r125",
      "r357"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Gain from investment in warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r586",
      "r587",
      "r588",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r586",
      "r587",
      "r588",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r337",
      "r352",
      "r353",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r431",
      "r587",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r337",
      "r416",
      "r418",
      "r423",
      "r431",
      "r587",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r337",
      "r352",
      "r353",
      "r416",
      "r418",
      "r423",
      "r431",
      "r587",
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r337",
      "r352",
      "r353",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r431",
      "r587",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r337",
      "r352",
      "r353",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r431",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r592",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r617",
      "r624",
      "r633"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r619",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r616",
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease obligations"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Finance Lease, Future Minimum Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease obligations",
        "verboseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r618",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r615"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets recorded under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "auth_ref": [
      "r617",
      "r624"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "terseLabel": "Accumulated amortization associated with finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization [Abstract]",
        "terseLabel": "Finance lease cost"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAfterAccumulatedAmortizationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r617",
      "r624",
      "r633"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of lease expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r630",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r629",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r251",
      "r253",
      "r254",
      "r255",
      "r257",
      "r261",
      "r262",
      "r263",
      "r264",
      "r348",
      "r376",
      "r582",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r536",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r536",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r276",
      "r280",
      "r284",
      "r288",
      "r685",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r284",
      "r686"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "periodEndLabel": "Ending Balance, Gross",
        "periodStartLabel": "Beginning Balance, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r276",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r284",
      "r685"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Finite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Amortized intangible assets:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss of disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r265",
      "r267",
      "r647",
      "r701"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Impairment of goodwill and intangible assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r271",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r125",
      "r266",
      "r269",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r770",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "verboseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOtherMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.",
        "label": "Health Care, Other [Member]",
        "terseLabel": "Risk pool settlements and incentives"
       }
      }
     },
     "localname": "HealthCareOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Fee-for-service, net"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r568",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r125",
      "r289"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "totalLabel": "Impairment/ Disposal"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r125",
      "r289"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment/ Disposal"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r125",
      "r289"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r292",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets and Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r89",
      "r207",
      "r216",
      "r219",
      "r222",
      "r224",
      "r699",
      "r716",
      "r720",
      "r743"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r90",
      "r125",
      "r205",
      "r243",
      "r715",
      "r739"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss (income) from equity method investments, net",
        "netLabel": "Allocation of Income (Loss)",
        "terseLabel": "(Loss) income from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]",
        "verboseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r491",
      "r493",
      "r500",
      "r510",
      "r516",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r143",
      "r161",
      "r162",
      "r206",
      "r489",
      "r511",
      "r517",
      "r744"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Total provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/IncomeTaxesIncomeTaxProvisionBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r485",
      "r486",
      "r493",
      "r494",
      "r499",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r121",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r69",
      "r713",
      "r738"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income taxes receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivable, net \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of acquisition amounts:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedTerseLabel": "Other receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r279",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r279",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Indefinite-lived Intangible Assets [Roll Forward]",
        "terseLabel": "Indefinite-lived Intangible Assets [Roll Forward]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset lacking physical substance and having a projected indefinite period of benefit to fair value. Excludes financial assets and goodwill.",
        "label": "Indefinite-lived Intangible Assets, Written off Related to Sale of Business Unit",
        "verboseLabel": "Indefinite-lived assets written off"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ameh_FiniteAndIndefiniteLivedIntangibleAssetsAcquired",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.",
        "label": "Indefinite-lived Intangible Assets Acquired",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceServicesRevenue": {
     "auth_ref": [
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.",
        "label": "Insurance Services Revenue",
        "terseLabel": "Risk pool revenue recognized under agreement"
       }
      }
     },
     "localname": "InsuranceServicesRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r274",
      "r282"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r88",
      "r203",
      "r608",
      "r611",
      "r719"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r115",
      "r120",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r101",
      "r202"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in affiliates"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r631",
      "r633"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r631"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense and Other Information Related to Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseTermOfContract1": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Term of Contract",
        "terseLabel": "Remaining lease terms, financing"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Operating Leases, Future Minimum Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r622"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Remaining lease terms, operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56",
      "r140",
      "r218",
      "r246",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r544",
      "r551",
      "r552",
      "r599",
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r43",
      "r140",
      "r246",
      "r599",
      "r647",
      "r709",
      "r733"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, mezzanine equity, and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 deficit",
        "verboseLabel": "Liabilities, Mezzanine Equity, and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Issuance of financing obligation for business combinations"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r59",
      "r140",
      "r246",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r544",
      "r551",
      "r552",
      "r599",
      "r645",
      "r646",
      "r647"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r28",
      "r29",
      "r140",
      "r246",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r544",
      "r551",
      "r552",
      "r599",
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities",
        "verboseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r746",
      "r749"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical liabilities, end of year",
        "periodStartLabel": "Medical liabilities, beginning of year"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "terseLabel": "Acquired (see Note 3)"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r748"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedLabel": "Current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r748"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedLabel": "Prior periods"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Medical Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r28",
      "r707",
      "r727"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Long-term line of credit",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r54",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "terseLabel": "Commitment fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Required annual facility fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Term of facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate at end of period"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r54",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r54",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "LIBOR"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: current portion of debt",
        "terseLabel": "Current portion of long-term debt",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r148",
      "r307",
      "r341"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r148",
      "r307",
      "r341"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r148",
      "r307",
      "r341"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r148",
      "r307",
      "r341"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "netLabel": "Long-term debt",
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs",
        "verboseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r61",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r639"
     ],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "negatedLabel": "Management fees"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementServiceMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business.",
        "label": "Management Service [Member]",
        "terseLabel": "Management fee income",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r7",
      "r57"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Amount of short-term marketable securities",
        "verboseLabel": "Investment in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "terseLabel": "Initial capital contributions"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r71",
      "r140",
      "r246",
      "r309",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321",
      "r599",
      "r708",
      "r732"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Dividends",
        "terseLabel": "Distributions of preferred returns"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r385",
      "r541",
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r184",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r118",
      "r123",
      "r126"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r82",
      "r83",
      "r87",
      "r91",
      "r126",
      "r140",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r169",
      "r207",
      "r216",
      "r219",
      "r222",
      "r224",
      "r246",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r585",
      "r599",
      "r717",
      "r740"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Apollo Medical Holdings, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r82",
      "r83",
      "r87",
      "r161",
      "r162",
      "r547",
      "r562"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net (loss) income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r386",
      "r525",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r386",
      "r541",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Investment in non-controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r385",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r36",
      "r229",
      "r230",
      "r711"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Loan receivable - related party",
        "verboseLabel": "Loans receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Loans receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r231",
      "r250",
      "r254",
      "r256",
      "r258",
      "r259",
      "r792",
      "r793",
      "r794"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of financing receivable.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Note receivable, amount"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Notes Receivable"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r38",
      "r229",
      "r256"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Amount of loan"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r68",
      "r144",
      "r638"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "verboseLabel": "Loans receivable \u2014 related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesNoncurrent": {
     "auth_ref": [
      "r18",
      "r37",
      "r144",
      "r638"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due after 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Noncurrent",
        "terseLabel": "Loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of main reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r207",
      "r216",
      "r219",
      "r222",
      "r224"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r625",
      "r633"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r616"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Operating lease liabilities, net of current portion",
        "terseLabel": "Long-term lease obligations",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesAfterAdoptionof842Details",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r620",
      "r627"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r630",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r629",
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r501"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r125",
      "r297"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Impairment of beneficial interest"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r72",
      "r647"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r48",
      "r736"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Investment in affiliates"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 6.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other (loss) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "negatedTerseLabel": "Cost of debt and equity issuances"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Fees paid"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r122",
      "r748"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedTerseLabel": "Dividends paid",
        "terseLabel": "Payments of ordinary dividends common stock"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsMinorityInterest": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests.",
        "label": "Payments of Ordinary Dividends, Noncontrolling Interest",
        "negatedTerseLabel": "Distribution to non-controlling interest"
       }
      }
     },
     "localname": "PaymentsOfDividendsMinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Interest costs incurred"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r108",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Payments for business acquisition, net of cash acquired",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchases of investments \u2013 equity method"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r234"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r107",
      "r637"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-term Loans to Related Parties",
        "negatedTerseLabel": "Advances on loans receivable"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r415",
      "r417",
      "r423",
      "r424",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r444",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r34",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r34",
      "r647"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r8",
      "r44",
      "r45"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r104",
      "r637"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.",
        "label": "Proceeds from Collection of Long-term Loans to Related Parties",
        "terseLabel": "Proceeds from repayment of loans receivable - related parties"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r105",
      "r117"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "verboseLabel": "Dividends received from equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from sale of shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-term Debt",
        "verboseLabel": "Borrowings on long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherOperatingActivities": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from operating activities classified as other.",
        "label": "Proceeds from Other Operating Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromOtherOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "verboseLabel": "Change in non-controlling interest capital"
       }
      }
     },
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of fixed assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r82",
      "r83",
      "r87",
      "r116",
      "r140",
      "r153",
      "r161",
      "r162",
      "r207",
      "r216",
      "r219",
      "r222",
      "r224",
      "r246",
      "r309",
      "r310",
      "r311",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r540",
      "r546",
      "r548",
      "r562",
      "r563",
      "r585",
      "r599",
      "r720"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r295",
      "r617",
      "r624"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r74",
      "r296",
      "r624"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property and equipment, net",
        "totalLabel": "Land, property, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r20",
      "r294",
      "r615"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r50",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r296",
      "r647",
      "r722",
      "r734"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Land, property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r296",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Land, Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Land, Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful Life (Years)",
        "verboseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r93",
      "r252"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealEstateLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan to finance the purchase of real estate, including but not limited to, land or building.",
        "label": "Real Estate Loan [Member]",
        "terseLabel": "Real estate loans"
       }
      }
     },
     "localname": "RealEstateLoanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r359",
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "terseLabel": "Reclassification of options liability to equity"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r425",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r425",
      "r637",
      "r638",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r637"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "totalLabel": "Receipts, net"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r425",
      "r637",
      "r641",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r635",
      "r636",
      "r638",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.",
        "label": "Repayments of Debt and Lease Obligation",
        "negatedTerseLabel": "Payment of capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-term Debt",
        "negatedTerseLabel": "Repayments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r133"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r4",
      "r16",
      "r133",
      "r766",
      "r768"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash \u2013 short-term"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r10",
      "r24",
      "r133",
      "r766",
      "r767",
      "r768"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash \u2013 long-term - letters of credit"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r10",
      "r24",
      "r133",
      "r767"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r40",
      "r385",
      "r481",
      "r647",
      "r731",
      "r759",
      "r760"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r249",
      "r478",
      "r479",
      "r480",
      "r508",
      "r509",
      "r583",
      "r756",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r200",
      "r201",
      "r215",
      "r220",
      "r221",
      "r225",
      "r226",
      "r227",
      "r403",
      "r404",
      "r684"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyPayorTypeDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r98",
      "r312",
      "r314",
      "r315",
      "r319",
      "r320",
      "r321",
      "r765"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Term, performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolver loan"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditScheduleofCreditFacilityInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r628",
      "r633"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r628",
      "r633"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r192",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "verboseLabel": "Net revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoansReceivableandLoansReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Schedule of Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Components of Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r166",
      "r167",
      "r170",
      "r172",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of Effective Income Tax Rate Reconciliation for Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r442",
      "r474",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r2",
      "r140",
      "r245",
      "r246",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r276",
      "r283",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r276",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r271",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Summary of Goodwill Activity"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r287",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Medical Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r50",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LandPropertyandEquipmentNetScheduleofLandPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r639",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsScheduleofRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Schedule of Fees Incurred and Income Received Related to AHMC, HSMSO and Aurion Corporation"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r444",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r449",
      "r461",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Restricted Stock Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r65",
      "r137",
      "r181",
      "r182",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r371",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r389",
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r543",
      "r544",
      "r551",
      "r552",
      "r553",
      "r555",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r553",
      "r555",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "verboseLabel": "Schedule of Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Reportable Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "netLabel": "Series A Preferred Stock",
        "verboseLabel": "Series A Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series B Preferred stock); 1,111,111 issued and zero outstanding"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock",
        "verboseLabel": "Series B Preferred stock, par value $0.001; 5,000,000 shares authorized (inclusive of Series A Preferred stock); 555,555 issued and zero outstanding"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Provider services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested as of December 31, 2021",
        "periodStartLabel": "Unvested as of January 1, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested (in dollars per share)",
        "periodStartLabel": "Unvested (in dollars per share)",
        "terseLabel": "Unvested (In dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant-Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of share available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable weighted average exercise price (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r463"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options exercised",
        "verboseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Options canceled, forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled, forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r451",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "terseLabel": "Share-based compensation arrangement by based payment award outstanding (in shares)",
        "verboseLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r441",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofRestrictedStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche one"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r444",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Market value of common stock"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r469",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationOptionsAssumptionsUnderBlackScholesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at ending (in shares)",
        "periodStartLabel": "Balance at beginning (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r305",
      "r306",
      "r537",
      "r763"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r33",
      "r34",
      "r35",
      "r137",
      "r140",
      "r166",
      "r167",
      "r168",
      "r170",
      "r172",
      "r181",
      "r182",
      "r183",
      "r246",
      "r309",
      "r314",
      "r315",
      "r316",
      "r320",
      "r321",
      "r362",
      "r363",
      "r367",
      "r371",
      "r378",
      "r599",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r67",
      "r85",
      "r86",
      "r87",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r162",
      "r180",
      "r249",
      "r378",
      "r385",
      "r478",
      "r479",
      "r480",
      "r508",
      "r509",
      "r583",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r756",
      "r757",
      "r758",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r180",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r130",
      "r131",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "APC stock issued in exchange for AMG"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r378",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares purchased by related party (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "auth_ref": [
      "r34",
      "r35",
      "r378",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "negatedLabel": "Cancellation of restricted stock awards (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r378",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r35",
      "r378",
      "r385",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r34",
      "r35",
      "r378",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Stock issued during period new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r34",
      "r35",
      "r378",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "negatedTerseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r34",
      "r35",
      "r378",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r34",
      "r35",
      "r385",
      "r443",
      "r462"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r67",
      "r378",
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r34",
      "r35",
      "r378",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Stock repurchased during period (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r35",
      "r41",
      "r42",
      "r140",
      "r232",
      "r246",
      "r599",
      "r647"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Stockholders' equity attributable to parent"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r86",
      "r140",
      "r150",
      "r151",
      "r152",
      "r154",
      "r160",
      "r246",
      "r249",
      "r385",
      "r478",
      "r479",
      "r480",
      "r508",
      "r509",
      "r538",
      "r539",
      "r561",
      "r583",
      "r599",
      "r601",
      "r602",
      "r606",
      "r757",
      "r758",
      "r797"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at ending",
        "periodStartLabel": "Balance at beginning",
        "terseLabel": "Stockholders\u2019 deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r138",
      "r363",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r385",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Mezzanine and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r626",
      "r633"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r607",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r607",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r607",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r607",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r648",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/StockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionOfDividends": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity during the period due to unpaid dividends.",
        "label": "Temporary Equity, Accretion of Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "TemporaryEquityAccretionOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r64",
      "r140",
      "r246",
      "r599"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Temporary equity, carrying amount, ending balance",
        "periodStartLabel": "Temporary equity, carrying amount, beginning balance",
        "terseLabel": "Non-controlling interest in Allied Physicians of California, a Professional Medical Corporation (\u201cAPC\u201d)"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityNetIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of net income or loss attributable to temporary equity interest.",
        "label": "Temporary Equity, Net Income",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "TemporaryEquityNetIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Shares issued in connection with business acquisition"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Tradename/trademarks"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r348",
      "r376",
      "r582",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, common, shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r35",
      "r378",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Repurchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r66",
      "r387",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r378",
      "r385",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "negatedLabel": "Repurchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r185",
      "r186",
      "r188",
      "r189",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance, increase"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Variable Interest Entities (VIEs)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityInitialConsolidationGainOrLoss": {
     "auth_ref": [
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gain (loss) recognized on initial consolidation of a variable interest entity (VIE) when the VIE is not a business (as defined).",
        "label": "Variable Interest Entity, Initial Consolidation, Gain (Loss)",
        "terseLabel": "Initial consolidation gain"
       }
      }
     },
     "localname": "VariableInterestEntityInitialConsolidationGainOrLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Voting rights held (more than)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r543",
      "r544",
      "r551",
      "r552",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsEliminatedUponConsolidationIncludedInAccompanyingConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoansandLinesofCreditAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofCompanysFinancialInstrumentsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r165",
      "r172"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares of common stock outstanding - diluted (in shares)",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails",
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r164",
      "r172"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareBasicNetIncomelossPerShareisCalculatedUsingWeightedAverageNumberofSharesDetails",
      "http://www.apollomed.net/role/EarningsPerShareSummaryofSharesIncludedinDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=124268079&loc=d3e32787-111569"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.11)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4616395-111683"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.1,4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "720",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=49178521&loc=d3e9162-115647"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r778": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r779": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r780": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r781": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r782": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r783": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r784": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r785": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r786": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r787": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r788": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r789": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r790": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r791": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r792": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1404"
  },
  "r793": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(1)"
  },
  "r794": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r795": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r796": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001628280-22-004291-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-22-004291-xbrl.zip
M4$L#!!0    ( )**7%1^<3CM@B0% %B],P 1    86UE:"TR,#(Q,3(S,2YH
M=&WLO6UW4\>R+OK]_ I?SCWW[#U&G/1+]1L[*V>8U\4Z&!,@R88O&57=U;9
MEKPD&3"__E9+,F!"@HEE:TYAUAJ.I#DUYU0_]?)4=W75C__G[>%PZS5/IH/Q
MZ!\W]/?JQM;_^>G'_V=[^[]O/7FX=6><CP]Y--NZ/6&<<=EZ,Y@=;/U6>/IJ
MJT[&AUN_C2>O!J]Q>WO^G=OCHY/)8/]@MF64,9\<G-QT'I/WUFT;:W ;4JK;
MJ&S9UJZHZ&QPA>QW^S=M=JQ1XW8UF;<AF+Q-V9EM$R,51Q'0FN_*S9!\\28;
M)A^ 8DY<"L02(E/5-?EVVX.9_#KYA:/IS>/I]C[BT3]N',QF1S=_^*'BE+X?
M3_9_6![X01Y9;RN];?6-Q5?>G_KFS9OOW]CYR3JE],/;=MGE23<';\^<]Y8F
MP_F91FG[PV T'(RX#>7IZ6_E@U=_?N5V],.59Y^_](>K_C";X&A:QY-#G F
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MR#\U:=@^Q?S''Q8?_OC#XM(T+B<__5@&K[>FLY,A_^-&&4R/AGAR<S0>L3S
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M>G!<BX'-9%S*SFA'PH"42[HDB1DDDLL2U['KM8%="X[KL:M>FYPC>7(J0Y$
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M"4T(+\5@HO@N")E380<2+T5#,GXQYH 8+8?N!K3=1&:%&<5D6$NT(G%K@FJ
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M7;68C7)1)=8:2+G-G^F]&KU<Y72!SV) D\_62\A!,9N0;4,O"9<U'6[QN2+
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M%S^.9>6]V.6%Q]_9G_!*YP\[P38^S8[UV_K]V/YU=NR94R]2OZ!"# 316\V
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MCG9WZG=K:TU@GHQ$L,.D+\_."/^&Y5]Q25%V@E(:HJ84N%;"U!$XP^*\BGO
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M1(X>N\ 0*0:\,GCP2^[^*R,\\@N&D ;S4V"]<JOGWFWVE_*6M<>P1B2- 1S
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M2T]/KM#S3/.IG4.M@VI"Y3 *:V2G<R*DAC :!"2>;RDH -Q2 '@T(XI0=+0
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MNN@O? M!M:+)Q8(6%K(*8B#G$'%G0\PB;NO,])G T@OAJRF.HVP;D\^=,P5
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MB&:\(X^_P1,R;PH3RA.!BK1"RQ.L\UT""DXO_*\&G:))/QJ%F=0 &QPX8M=
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MQ_FQ>%.GJFU#7CY]/2;M,7R_U@22X._R@]WWP":%U"_N"ZE_0 +Q],5=L6<
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M31E"G&L:K^U&V*[SLS,*KWL8C,^>N"N$EYCMRKSE=T#_A(I1$RIQ<P0/S:;
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MFN)S!/\,XXH %^L/J4RYSA!WF8_[+;V(Y'GL2U$^)UVYY(D)_3?(5T6.C&\
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MS\A]/WD??O)0JZT4'QSGS! \UP!)W\_8GSEC><="0KUJ+G P&H&D]%U3:73
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M6DK:BO=G_;+A4R4<;=U664_,/N%U= M8-CW=Q]3Y[WO 8T[#]2)%=MS88C]
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MB-RPX*M@[&!/8!4,X=Q$OH9[$'E!XU]6PAI_N6'I4#93%]DV!A398?3Z5BP
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M<Z$+PP>LA*N;@0_SO>*3V8!C;A^EIAJK%9C V=!QC>/J//&-S.(M,7TW/(L
M_$B7!^<_;*&2+J?YE,'Y$BF[O!,S!@G8E@K:!I6Y2PBD[TL6BH$6SL%MP.>'
M]A3CI);T8BMPF&2@76PB>8=)!V!/?S7+"VI]T2NK4@%/O 9P'[B*G2J.;[8M
MU?F8\:!H(N9@-*.QCH3$H8D5\:(0_EHL#,6C:&&)Y9*A]U1KRR"W_$%W34]
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M\'_2A3RGWW%-_"#A.HFG9-"K):+%1_5,VVD34.OD5NHR,.L$E6N"'V[+T?R
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M*ZP*-5$8CJ;))M-&(F3@5\"VI/%20)O8,V(>/Q,'#98VEEMV:  EV1'HASF
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M+:[FF3"XEF[RLWV\H6C%NU]JDT\,#/*X#S-&GDXLG"L\'T;V74<5L(U0=PO
M-SHD^1$D(Z+/X5&F<<\VXYN%38\Q[XM.J AQPG.$(9C1&!57\V2"S-*(X\%G
M0= T655@N%'M-/C2)>MRDFZY4*"GDU+-F.^VHJL(C<E-.;Z!\*EO=^UG=V6A
M\B!HN<<ST6#D=:3!QLPR-9.=DU&3@]T=&^6X]NT!T>:ERUQ#_HQ\(^PER@KU
M1<<4ZAW27]7/E:LB7#UT0 )>42^QKZ'9W,Z"Z5.11Z#'=[>E"T3I)6E8 HC,
M19<&!RPRZ\K.)F$4;7!5J6<0!WPES[@&X 9+S](#^OTZOHO5VYF*;IP1(%EV
M7]TFZPG)83+ATL#AELT8N45I"8,(7WB^UALBVG*SP8Q&=L*YMAF2D=Q+;1H.
M=#.F4[?^Z=Z\%#NB>^U'%^ J$]7X"ZO/&VAZ.G1E9D$_ ?'T>&9.7NI-(LKY
M6JDP191EIC!^F[81AIT%]#[8^G(Q](G=ZG^YY5Y= 6"9?P*-7U60](EEI0S<
MC@-\_5;\ 3#QW8D@/ITG&?G2>3W194X8B'P<8E>1V5R%^/XJBXXGFUITW*AE
MNW0,_^%/BKGU2,=5Z'8%U*]DQ2UP%UZZ)=T[A_'!/W\*"8"(N$Q)[&MR][)A
M^%8L^"'E263_Z!AQIO(/[JX50E#*X[A'#;^ZPW^[([ZQ5&)^UTFR@3+[O?.J
MHH 5A\5/B>0>4(ZIF"F-9IF/.SJ"[OMJ3'U!!R0E:,%%6PMR$[W'@W0*=IR3
MO_6>$&X6__)HW14_Q!'&S ARA(2'9&O_'?<[>S<W/.7\"\QQR<6CK_[*T<'1
M(0TK@.IT-!":$ZX1$N0?L1C<J?WMT^/3_:?_\7\.3P]^G%!S@V8_V/-8./8Z
M].*$MM8<'U%TR(0&;1PWW+Z'PPE*Z*BJTC/+>+G+S:9D9VF 50K>CXMV?GLI
MVK)JO\[IR?Y)]#9N(5U3PX0="]*(( >^+*B_">X;"/>489O&*NEEIH2V?%B1
MI16'C/.ZW))/GLR>^\G1XSP7>=);(5,4J]DX+2)5Z,K/=R6#MF3@EF/X_N0P
MN2=6/&;LHYH^D,X<@W6W)?D68TB%4U0*%,%OIO!NK\B:V]+9(M,DVQ'E<O7;
M;(C%A>>YD@H2B*RJ2"S5W/83.57,9B1!>^B[XH-E6&8U(R()C2'5)O@'[B.W
M![V,C02HPL&!M&%0-I3L^L -F79<HN* \4(&832KE8B 7K9S:!@U7Q:$23:L
M7D0:R&U;[:BA#,ER"1M,#ZG$#/(X.C(A*R/+(_>-1=V>J"(3H?/)\S^_QV+M
M$1O8\PG0?JS[K!0VP-NQ=1]&;5S/T.YNJ$DT)O>L!^H-*)FKPDLX>C#@)YL6
MVXXQ6]$(RN_;F361)4)#YE8=I1!F1=P,7ZGVK-<1N96>R]!W0CK4-/J$WZDU
M[Q&2_V*#;M-JV%WN)\$0][+$4Y#W$8I+>R?]>D_S)!-?X8Z2+S/,>$PSZL:*
M6R.#75?SZ^YE"=0\]3 X)QKRZ4BX@V0&VVX%WSHXA>Y*G@],LQ="N!45H-QW
M:%9B3]'32_B/A5*+[PTWAHOUXR@5*26 .DI+NW?Q&I&]*S3>\@.3%]OM(OG;
MVK<@C!ZQ#O)7W \/XH?V2P#SPGDBJ76A60F=C'R,S%@=L"%?&^>B)N6()Z<B
MR@IF^F$=;US"(^6SD5+>M8:\Y6\:9Y8MJ\]ENN,0UM(W_92!OFC.8;]/ ,4I
M4_%3Y\5MO'L=RZ=B@);[S/N]?W2E%'U9@4FPN1\%1*/S,8W6!*@JRC]!:@Y5
M5O]N'A#1OV/>:I,J9LHG0Q]2D$<2T;1HIVU$"X+D%[L$W%TJ!$S-DCE+M%KI
M%R#:VKB$0K1:->,)TL)9OK$R:/N.5TVLQ82*O@1@:IEN)2))[25JW*A%Z39Q
M=/'RRI0YGZ8.Z7NT01/E9EZG;MFKC&7(GW/\J80UW.2&<BY51/X@7VOJ[.DD
M'Q"GGQM:^2?G!:E1&"E!MV]N\@I&[8FO'+S]G]<O]@Z??X>DN:R,H(TL0BQ0
M\Q-.#K'YBKFB4I.TJVAEAZNWP=]""Q'[4U*F#\,J%:K]WD\AHTY?U<J5_XEV
M)\:=7-U,3DJ]&Z-CM<39STB"ACA!#)FB%I$@N-$60^FXQ9\Z^X.&$8R'J=&*
MUOG\L(>F.3RC4'@6=_[^^D!#T+RD<)63 "I*JX+Q 6E5\:Y X*^.L_O??ME<
M2\<D7QQ.]):X*>N[=C%+,Z_CM:UB<A^S"-;F9J\<S7O/]RF?1US;LJZ#8=R2
M^5G>"]%].':!+X4!P;+L:;F(^[_(Y*:<@ =UFPXYXZ_GBT4H_?K^TG@^4&R>
M(R69U78JF@Y1#:^#'+T/UV?=T_.#:<Z44F0+!B!B)KI.AV&=Q9FPTR,DT!C'
MU4!>R(9MK<6GB*ZW;W_S@"X_'II",\H.[0W!UIWK[_:D=Q^Y2T9KNUL;!O5F
M#IW# 1',+P?88\\ A9,JNC*=6V!_D16P*D:569WO6#:[S-9C.:.1UFLX2E1_
MU8T?3:)[HDHHRJ5P&W"@V9TA>S$/WA[)%C(.I!WY**!#+-^X.RK=Z_#X,D/;
MG#WJW#/WB?7GROMT$HMQTK9JI/;=T')^0HNV_ARB%E5QP9OX%(P].3<DK-DK
M%\JM")H/*@S1<7C>[UOK'>F.VJ-01JC4$>R!4\+<M!]^;4>>?^MS)_-#R:)K
MPNP@@FONRP9/Y5-%O)X]![S0O\?J*21NU>5(@J2/SP8C32'6R"T(J3?2BAX9
M*@9_,TY:"]$/X"S#[+ZIP"TY8-8&TEE<SJQNJT3FB)Q:"<]=)3>JY)[N*KF?
M4EG$HL1DT?F\]KU"A"8EM$'OGZ&!0=T=9(1,4.+.AOEJ8^P3!8)&_%@3+Y0X
MH_2*Y*NQ6XA^]38#\Z.DGGV26=(O-D5$+M*/# C3^@#%*V8,[D*Z7\>!>VWD
M%%8N$*7!:AV/+%-E6B(C(CY.P"LB7/6(+4)]<8[^45K"?T+,(Y! HOZ!=AE#
MOA<Z7$+>AD'J6S(HJWJQ4^HD:#736@@9E%QTKVE>!'J/Y33P^(R"9Q"UC2+O
M*MDB',#,TR?="LXIN4>CVGMX1)@(;"EWQ\Q=#Y/2=\X!8OBC@\,C8=;S!+E!
M9I.^&DE25\I"QWJF%972R.,6-I#K63$D%YOMBS/(&8?)C4>ANVD<CZ%JS3W2
MX:ZXF7LB!G%F04!:2*#G>VMG"B74'C3;;+5CU8A%NGQ7>G U#3YQ09%8W3WN
MPYE+4O$"I>5X3NRRM.S/J3>CX$/G4J1$<+&6JO@OER\N]"X"\W:K_&J65JD[
M,Y:QQSV.Z5MD7@Y/"!2 3*DV6L3TPJF[R<>F]PLG[R!VZY,=E]$$G>MY%&EV
M+?B.#^R9AQ,K \6S=@F?,^2:NWSAPD)LX./#!#4:TJ;HUYZX;A@:'C1OW+MD
M9IY73$'TDA/-@[OX*5^]U"?BVB 8Q'WC+LI]U-@F37#=KPV.*@K[,LLQ<7BT
MQVBR2_-6_\N@'NB(*@I;AV#9+8@9H,CB6I4L=!_@,BJY?;<>*Y:ZJ[7'\+#E
MGBR[OW1UA=XZYX:51% AQX3;;2&S!2N<%WY=7<M>'!%<(.0,I;VJL@QL:HJ9
M*MRM=:UH@-XV:@KC\RIS^RJ7S/?R@RK(HC/FN"% B_NOPX/$[;(>-NCR>AA^
M[)E:,>YRK!CHUH(JJN700L552D:+L%Q,4FM2:<?W>4S-@RRKV2'D-F]A>J4-
M=_WR\B!R%G8 0-5.QM5RO=+-I)H"K1CW5YVMCHZ&UFKT&:Z03XT8?.ETCUE\
ME]",JNMD*^S]+(U:..2=" F/J[6(";6J%<4'2%BQ;D':^^^B_+CWWYD;)R7W
MIU5X05(=957DJ>\8#RE^=O;'G(DT1;^67,O ,W7S>%D\TS_-;\SV]$HS49*Z
M06$&[)"<IC.UAJ 7'$;9- -%AL%N1,S;VT%3TCH(% ASZ>2%Y:<V8 C.:WM'
MN L_D]4D9S@4$3+?P$;=9N0J>^DX2=3;*R&1@B&K9_U)WJ".CY?)!$N I!A1
MQ%4^RXO.CM?&?/([WIKB"MKFD#RD4JFVS?O>A?B2>CL,"O=F(>L[% .8HYM-
MKI%>4>M%L\I!ZAC&^5HA]B@N&%E-S;AVYT=IM$P8'>7K%JT:VIL0GO#M;WE$
M0+[HD*%O*Z;$D#NM;_7;*\I=^/NRFFO]$P8>/'K./8+QRM..&(I&?-%@7,I>
MU%"='X:/-=,!;7HC3=8U(];N0:;:Z5[2)!W,0=]B;46WKXUFQ^IW?L*$I%A3
MXA\;9+1HFHQ22N*RWHIW7(@#R<B[?B=9B(D;#?JTP[#$ZE'W;>F1+BU.&6GJ
MN,,GB37!)2B=2>[8Z[*(@D@XPEKGMQYHE@@## 7$\.$!&IV5N#9(<D%OU?JD
MHI^HK>DOC%2^0&!R1*D?KT/$;G)'=WB70YMH;V6J02AM9<T(Q01V89\95W\Z
M'<_M+U (O&#@R(4L#_K92_(;[GS1\L7%R\!"42BR#G*VW#0-,E(3$_\R+ON2
MA;PT *.N6^D]*)CU-^%A>,)O.+X3S+^XVAT7X>_3QEYTY[=3+$ "W/"0D..N
M.#;UV$) S<TM[7"#.@W\ U_^[]%1'/%),[+P)> T<-^Q5[VTL^2.2%VM'>OP
M^.#D<'3T2=;A7#;#K<-E%%_733.M?_C^^]P3DNP/)O7^57GS/>0'OA^6@QF9
MK>^OIL/!'F"<>V8![M6SR20E!O0E[_>7[S.-SIR?F:E]C.>8*:$HO8W#-J8H
M86]%\ F1&FS.S=-Y$P+D&Z:_54I@.M1)SM5MD@\94V/0R3/L@U^ ,VP![!DR
MGD!'WBG)4^&B\[EGIN=TJ_>=NU'^;VQ5N=<YZM%\]0ON[78[6!($NF;QTY?G
M%Z_BG<:H3/^AW$JJQU?D:$9>31EHP=@X'8O>1<1UXL:QJ$UF&R^ACX_;K'><
M=!^I7QO9WKO@.UYXWVY+R@%KIEM_I4A5PU0QJ!YJ'%2[W-$#,"M!3WW]OJER
M 5D+<7M>A A5E) E2&)G'RP6G7(X!%V857.! /)3"*85*,PNL=#9J72[MNL(
M81QQ-^SJV;:>?;:K9__9,7Q/"2B(1 @- Y:E]@9?N_BM"<O:LWHP2)QW$7!+
MLHE4][6EO8@&$A7*"U_]F%4#;@Q6;![2FPHOUV ?,'5SM2?HF6*WS@W3.*CR
MU/?8YPC;LN** 5=*&9&&]EE3*''G[E[M[&33@*.'B_+^01"2U6;\&N78Q;#Y
M?D%W1A.W&;$#-D(#28!']^]9D\7I- 1+XRS4=L*5[77ARM.IUW!(]\=LR#F6
M<+$2),U6H'K?I-QZX"#UW#_^+G;65P_EEAP=JVA*HTRD0B&0%-.D;2RX[3OM
MN@1-O'1MH+OA6O)M(<TQ<OUA:U731\)-@2T494$X?32<E]:+!'[#0P228]]0
M4K<7^2W67D3 *A@-7,SHZNK5$I\32^W'FA<)/0B=OY64:I71;A#O5W1I9<.'
M[X* B[\O5B(SK0AE%1L,WAT=1[JH9U@56/[VDIE[)(M:%XMZU&F_O(DF-5X,
M>>C(I;PJ.8:&'E?7(;,5N?O$*E?>8Q^Q.>(0ALU/)OC@%?M%^EG-"B;6!@E_
M#+!'BS512=:GY&55H"%1'D(NH6P%RR:^]TJSN8S7+82Q)XP'"ZNVWRZ4SW40
MI#SA%MMU-E:<8HFB(+2LRF+/]DY%#,+[%(T!MW)%#.JA%N%1W$AG$--EQS#3
MWY<-<U1XP0&&;-(-]N.UU$$\\]&R*_%.<O%L-- U7-Z.<DD=+3XR/+>%\(/Z
MI1,OR7F;!6MJ:4SG-?HXBRQS'5VN[+*"/18UN$DUHRAMU7$!S5</O?+C_>G?
M.U.9R4+^.IP"!H3/0@W*&,W]X&:Q<$3+H3-VF'VW=<XITR_U-5 8+Q0+)K:Y
M;.SUU>C(CB35.I4#T>@<6!79O!I5M@[5B=NL<Z.T*[>M6BO"2FIQD:J(+X-M
M#=1Q.1='+;+99(24.)!%T=2SZ-#%[2+=+$B8%RW8BZ>MHS*.7)8"Y>9T=>T3
M\:31$QD#UWW)H"4Z*F<%#@9L[9N\E!56W*V8^+@";MYSD-_D8RWC#2IJ!:3
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M<TJ'"UW5C+L<1(-4Z-;H3F9=*90!JY\7E'_K19/9H'6$RKZ,(!AG-RET>7W
M8\EE0U2-#DU5C$"W;N(SD("7&C@ PEQ^'G9E3=4XJH#AQ[Y(9L&MM-+ ,I)A
MZ_G65&>A)NY ?IR.Y#^[O#X/9V2-1F?LI*^+-:'MP6M:8MP9YE:&+O6 O(2M
MVI+16^5XM )E=3N6OWJ/2)O-*-KQ"\9<:+I3VH5=E$F$J2"HCJ!,0I8UCIBT
MW[E]]D&AW3Y:7"OBSG.R<FKL^;&!#70;BXQWXU,AE .Y E#&<!#QH\^8,(EB
M"US?/8;(_PVS4<8U%*W=#JE7EW-)!(4LE&P.OA':!;G@"0$8RS44NJ:,M:$
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M'^]' GGPI:WBPCBI^QW?TY8<]MZG-T$%[P('4FV.1#F._/GXGF(..LWH*]0
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M[\8L#'U@]TGB"ZH^3&<#K\'?<!AQ!EP)L#*U6QV-VF',>$+\(K:O,*QB7(I
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M&FFCRFY)E7U!146"J= $8&0E1AW?]J9(E$X:X3)(\6CG-(6BK:6)-B\HJ)(
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MJLFE)I>:7-9*X&V;_>XMDS3VAEPV2?%X8-+9/@RQ>G?KX?@TZ+$E?NZ?R3J
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M0(S12$+3^-KXW#!P!FY9,;7GQDC -L=C0;U2N+LD<:=54$PQQ@6<AI\DX 3
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M$6Q1HRAQ?#N.O;''QA&]1FT32V1#LTB%"U5].H\XA54['F[,S]B):CM?.A9
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MW-X\/W^7*WZ_VJ"%@!9F_!;&,X(DZ#8GH&0ZJ 3&V4N_GOQVDK]U\K_G*Z>
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ME_&0-#(0B*PXV6IM6;Q08Q/Z"G+'! ;1(_P*1]'@AH(1= 8OQ.$TZS[V "=
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M6/\GCT:8L$+OL %E4\:3I'XF?-;JG9SLX+L%6G/L@/BO@Z9#[C/3D)L"ION
M:!IP6T7@*BVA"%6$H6*92T+*"X W*\;(SV%QP-*19/J&Q@DQ>&;+?#9)#.PG
MA2>"TG392^$([3_2150:$,VH3S@WCKR&:)BY=(FR>-K<$Z!7@TP!5>B%S#V1
MK$E- >*;'&<R.S:/SX7H(HBB<!1&+/_G^G*D? *DLO$7?)("4>B;B.3. /N
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MA)!T41_.=.Q,QA+:NZDC*E[.Y#-M%I[4$TA=W2'$OCI^R8MU*LN4>?(:@D&
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M3=BYB)*J:"3&H9)>VM"HL7F!NG)1EDI%.*IR R;7M\78I,Q3E[?:E'Z'BFQ
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M#9>7QI8K=QF(*@^5;W;QE!%53]#1)U6]%0%/H\PSAJ5WR)L;R?+AQ0*VZT!
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MVZ#S_3EQ%W\;-AM\[:WZ9_AUZ6^KANTW>H/U1OV95LRK!K@@@/_G6?M9J>/
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M0G#')$RP75F#%=#D9L8^S%LA:X$4Z?,FC/EY,@MA/#UA3$0P,Q[6L3.(.15
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M<D_6,UC[%C9UFQ/2I%J]*3P(M-3)DYN7ZEUFG/&@$\4<4VMX<$3G[D)8&\+
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M;F5-:M4D>E9IAX4@EHH@J.+))Z&=Y9J#D+!1$2<(L2QHDG0QG1>0(":F,S"
M"S:WL2 ^GSUP =FH,2(T:6)$H")ETUGBIB2S2EF<.T$LHV6]I$4S%^(FE\M@
MO[Z [>Y1[-MA;F$2?QS%[N">)4EJUM9]Z:_QS%*W-WJ#JL?L.'5[5'E_)!=
M<QSU8VZ8=];ZR![VX,Y/JU^4_.Z%\C+E>=Y-KWJ]D)L?OAO/]KM>)Q0I.$,I
M2*:=29I9'+*MF!QQB%.:D+-*(18= SM18N:JNJVR23BM4?I707/=74(%S8^%
MYHGGAU,6G)$)J61S3%2#80<SA;#!.GG/=<(1T,Q,$_BXH'EYT3QS_TU!\V.A
M>>*FL1Y3ZXA&6/",9OA#1ZN1QT$+):A2&<U<JJ;&)37[R6#Y*G;!BNZ,K(]P
MV.ZV!\-^U;/S<:SJ9Y_G-7-#9#RC0'3K%^9S:S2=A?%FR'ATVAKAB2O,'<R3
MT#ER)21R-!"$E3,8;!$=%3">I$VL'ESOKV1NUA?1,S=&"J(?%=$3BR2J )B5
M$;$<@>;2.M P7"&3DM9)ZD!X3L4V34*6L,-"0?3<#)*"Z$=%]%3>M?%.,:Z1
M-9B-/(::B8@BJ# C2?#6&D T:7+]8(=A*7=S7VANEKC(PILC\,?!B^F)A)\[
M,?^066]J/B?9,U._W$V;T0VW!X-CV_4Q^V\&A11G2(ILVG AB6FJ D9:$0.&
M"P/#Q3$&JD=:"Q26=$@K:T0U!2F%RI<8^S,S7 KV:X[]B8FCE(K*!(N25 KQ
M$$ :>4-0@,GE(GD;96Y%HIOLX44^"_;KB_V9F3@%^S7'_L08TCIZ2ZQ%3@J/
MN-,6&644PHDX[Y.'B0\5]NG#,^U+A.:^('[3[WUK#S)\ 0>-T#MVPW3<:5CO
MX1F')3JS&.;0F>?G?#;_ZO4WQW.Y/I[*BTR7VC]B0*>QWRLD=S>2XQ/CYOUI
M:_,M_A0=Y=($@4*R!'%J-#(T N=Q*J@U005)5X#2-"7T98W\/@7/=35Q"IX?
M%<]OI_',/LF8(HW!(>MRJ#5HBFPP 4D)VZ+$AEJ'"YX7%<^_/:[=,H 'AI_N
MC^QBDSP4WOM3\'[__5-N!1UE%$AJ0'95'<=@*A&Q,+'8)!Z2 ,.DR>35RKV_
ME_C,W &Z?7ADV_VJG5HO-3[W>N%[N],9]X<>VN[GMNO$AAT,XCWMD^*V>;+L
ML?%DKG?#]OE4YG/-P\FD%UTS&^(35^R4I(46!EN4HHF9^ 0R7&)$J7(N1A"I
M4LU,UQ1W;'UQ/?L<LH+KQ\3U)7LE)"L\CA0%Y4R.LN2&(]XBQY5Q43O&=,'U
M<\#U[#/)[HSK8JT\%-R7K!4<<;)* :1CSBDSRB$G:$#**N!L+I@-)ELKQM2I
MF=!,*HXL0KV!<HVYU%^HM8$ZJN7YH -,,]S2GG$IKKF46<B'.,>9TL43-\.]
M;?O'A4J=UD@>(T$Z8HRXE0)ICCTRA#L>?*1$T94UJ413L0>??K@K4A9(T#YC
M],^E+$-!__S0/\D+#"ZX9))%Q*>0FW\##Q +Z'>&86.-T+FQEL2R*1]^FK&@
M?QG1/Y<R#@7]\T/_)#.0.4,-]0P%FQR8M)*!"M#PD]).:BJC%[G&)M5-8AY<
M8_.QT+^,%N_\RE>6FYQYC<U:&]+7U]C<KGHV-E*_=]CHC>IM]KI/;E O][XY
M<YOYO%#J:#9?]P9EZYSEUGDZ;3;;J 6A.:D^*HFX%C&?-;8H4 T&CC76&C";
M#>R<ZL&MG4JDI[XHGKGM6U \=Q1/F;\4NZ L04(&@SCU FFC,:*,21=Y<MCY
ME36-FP*7YO%+C.*9V[ %Q7-'\<2,]8QSBSD F N&.$D8.>LBDMKZQ*S4SHB5
M-4:;G-;P@-M2&:KE&L\N-'M#UX;A0>PW?AO'9G]OM"L>G*M%6:XQFVL\LX.W
MO^7-^6R!CEP@\?\>MX<GC<,X/.CE7/=O<3#,&5;E%.Y\3_G,P"5RPRF?B0S+
MW;VVJOG=J:9W>S*[1:'-4*%=J)F*'2618X:\E1+!U"JD:5!(2D>\"E8%;G.S
M>X:OIA@\R4F?@NVZ^TD*HI\ T1//B8D2YDY[1"/6B+L@$4RQ0XQCXP- G5H%
M-E=3/CP;ML"ZQEOV_ [F%H _ < G3I7$E=<D[]%*,\1ES$E!A"";//$V>TD%
M7EF339C;>FS9S^QP[BO;[C8 FP-8X?EX[DTV2PGB+E00]WJ>^R?"L)S&D"<]
M,^)N=[,]..H-,L<5 IP9 5XHERHBY3A72J4N4,25E<@P"P2HDC>8>T)\7%FC
M36)*:&B)$3YSPZ4@_&D1/K%A+/<A8*Y13(PCSJ)&&A.>JR(3E[3@ 8>5-6.:
MFI4<CB6&^,RCOP^#>#F1_P!T3PP826+BWF,DB3:($QV14QZL&*&HT5P2PD0=
M#^,_L_#+-@"Q#P@Y.\990BQU#[%<=M.,YJ_TM)D]G_$+&:<A,1\D19+FPQHB
M8A J., T^6!AIK!2H%9$DUWC<2TQE*4 [QR"* 6\<P3OQ-1(,B;))* U)@O@
MM1@9S@TB25&EN#!),S UFD#"!;S+"=Z96QD%O',%[\22H"E1H<%TX-I)L"0X
M!TM"6(0I;,724(&US-D+BI4ZI4]J0CQ"DN&S=Y;,P8 X<Y",(KYGLUGX;(9\
M)J8M"6<,$8Y$1((&4A/2(BUB1!:$95""Q.1MKF0FU-70;G%[+@V2YV!-%"0_
M!I*GLK!\!/U(-;+68U F0B'X(:+@&,&.,:-S6S?:U*3$*)<8R7,P+0J2'P/)
M$QO#2J&P4 P)I6W.D&;(&C T&&%>Z$2XI"HC&=,:5A=]+K&*]]W^.(;7Z/0&
M@YQ^50Z'+%#DXH9,T\FT3D*S)<=T+J2W\_U"2$,$XRGUB*A<=2HRCK04$667
M:.*>LL!S267<5%S4P[-28%UW(^1.8"ZI%@_ \<0,B<$H$)H6"2L)XMIXI*,"
MJP3TIX],"QUFU_>@H+F^:)ZY(5+0_%AHGCKY83 S-"HD#4V 9HN1UO"3X\S!
MA!')>:HCFF<:]:BY)3(NK]"9.KI>PAX+:GY4<]GJ=7L7:P:5L.[L>6ZJ\CU\
MW^;.R2<B%:964*2MBH@S3W-_%XE2$"PH8R(5))]C5>)JZ:#;6R#%>5I?S3+[
M"GX%SX^(Y[=3>'Y+/D4ON*61(^(#S\=6$S(<*QA@KI53(#ZES[%-/+-R]@74
M-03U[ OZ%5 _(JCWIT#]GGV2RC)) <]$)X4XSF5W*6S2,+\XZ&@EC2YOTIB5
M^G[E&D]^C>6J[_>SUFN]:ZO\-1O=^.1U!Y:M(TL];-6R S[&#G@R'22+8).$
MH (2/DC$D_+(>LH0280(';"4SJZL4=SD["&56.X*FP62NLM&!4]IW!8">"0"
MF$37.*: <V-12+FK.+8>:8$]\L$&(;6)$HN5-:.:9F:Y084%ZL\"]:C25OC@
MD?A@?RKI5VLK.$>"LX2X800Y(AC2BBIB$E<*DUR93>@9N*Q+N[;2"6VA;G*Y
MC.^?MFMS$2@V-H[ZO6_M0=X!X)]G=<R']L?3=T1?P%WU:4_"35<\W8#O:G>/
M8?QVSSOR_5G-^.A]>WF&MWX,^Q8PTN[:_LGV,!X.8$/.=]GO=3K5EEP2]V>^
M&^-I\SPIXBU()Z1!I2,>E$/6:HVHD$ZSJ+A+>F5-J:;BLVJANJ "?+G98,X%
MS@L;U)@-I@[D<:$Y$6"AR]SH@!"-7+0$L=Q+65#/B,[A9Z6;G)8 ]!+3P1R.
MY!4Z6! ZF#K5)Y(1(0E$4U7VQP=DN?0(5((6S.(D=?;=BZ;F)7)=KO'DUU@N
MX_EZ$G]3S.5E,I=AIQM[G/^,W9C:93>;Y6YVH8N7=HR($"Q*PAO$I>5(ZQ11
M=(231"W,+87=#+2MJ-,A]8+DQ3!U"Y+GC.2)F:H3R^4H,7*!<L0CS?WXP&H5
M"6O%7)!1FI4U(9L$%RMUB9$\)RNU('G.2)Y8F I3[7APB*M\WD$[CXPU&GDB
M+<R<"S;RE37=)+).0"X&YC.]QG(9F-='9UMQGI5(YYOF5#MK_7_FEK!R!\ZJ
M^2X^<\OZ3;\'FW;V-9>->X8;]X5V#DQR*X-V*,)&C;@AN3T--8A@&1/7P3)-
M5M:X:=*'=]!=L*S.0G&%XN;M<B@4-R^*FZY.BX/23B&P,A,8*%X@XP-%1%G/
MN$[!,+RR1BAM,CJK\%?AN,)Q=7KPIW3&%(Z;%\=-]0;!3 ;.$Y*>8L1]2,@:
M%A#,6F1"$A))+F&IFE+-J@1W2<E_6"(Y@V$)O6/7B75.=U^NNUPNO\_U5)_]
M/A<JLC7L<-AON^.AS>,S[#6Z%]*OX%VC_*N2>+"PQ^'C<)*7MSXUVWN]DFHW
M[XWX[85:TA(+:X@-2"2KP=A@&CFB'0J)6Z.9]@[G5AB\*>1#^F.6:&9]!?3L
M#[L7>#\MO">^!.45,'8$4%ML$>=8(QMH1,%*JR*13AN_LJ9YR3U:;HS/W$@N
M&']BC$]L:9R\LXYZ%+'CB(<8D(7?(3"AJ2"162QB+O,F1,EEJ-NQZW*3Y0#[
M?5(DKMC(ZT= M[W&3@SY9AO_Z77R4PV:#6#IU:=(J'@&SO;E]*?//"WB@E0H
M,F"&,N!"P;O$DS0F">0)J'QN2$!&:H48UDIZ'91D:65-L:862WBBOM#1DM+1
M?+T3A8YF2T<3SP/1/G&;$Q@L#HACZ9!Q!B,/?,2<B5YJ#%:):FHI"QT5.EH0
M.IJO(Z70T6SI:.(D(0%K'YA U"H.G*0B@IW%(D:$D;"=:);$RAKA34+J1$=+
M[B6Y% <OMSB_6WP._I$MV^]FKT?C* )D#FP_-JI^>^1EP]E!VQ<_2-GI;][I
MW\3^N[QF9NL/H9<W_+-%>O9U?^:5>;ZWX[*WWV9OOU!+4*@81%(6$2TCXAYC
M9!-V*'HB(A?:QDAA;U^5ID8[>Z&?0C^WH9\'^C\*_<R)?B:>#N$M)SQ%I'@P
MB#-GD2.1(4$$,30$QI@O4[^44Q\(IC&7DS?2.-AYE(2?2$)">&H"=3()F7<>
M?#6YIFQ%92M:L*WH@;ZOPD=SXJ.IPIF8!B$T04XDX*,D.')42Y18LEAZ[(*P
M*VMXE5]M>55\7.4:I:K)8[JD0KMS/(RA.*7*5EP[I]3F:&V6S?ANF_&%NI_<
M>ZPCILB:&!"W8!=:3PPB@E&.HXM"B,HM-:L3KL46* 2T+&ZI0D#W):"W4X?L
MB;**"H2CM4!  :B(2(XL(\9(E900]71,E<E_^.1S)8-ER2-**4,\"((L=A'!
M?$22$FQ)A%6NJ:NF8-F.RG:T8-O1O%U3A9'NRTC3-5^\%]0GY'!4B#.+83O2
M#CG/I;),.IG/J>%55J<P;>6C^*,Z9@-_A_:WM?^%/\Z^^M#V/[>[HV-*]")C
M^)@//LX/0=457[2'\&W^YYBB&5/O8FQ8[WN'<#<GN8I&MS>$[QOV,HZJXU46
MUG<CM;NVZ]NV W<,OSB$AS@OL_'([I/JMB='ERX/_?AMG*XJ 9<ZZ@W:>:F\
MZ,>.';:_Q9??VV%X<,8H4Q\<S>\+//F(=3   .\;/_*(T_K3253ZXG!,_YEO
MMZ(D9620U-/HI.).>]CI ]=!Z>@2249^(MBLG'WJX-SM>F0_1^3ZT7Y%-L$C
MOK"=[_9DL/+'Q04/J_W2R%\>M-'0K/VOZ\-'K[G=Z^$C1M[>ZCC;^415&6XP
MN!U[-(@OSGYX&=J#HXX]>='N5D-4?>CE^%KCV<TW=@G7U22.7I[<\RH>W??8
M"SG^YO'+J]5+E]AF]!K%JU*P&U_&J^3&UWYV6;,J";_757_^&N/W^V2YUW*O
MY5Z?YE[5K:YZ;0R%3^I=W#=6<H/(P8\K<GX:6EE_L_OZ]6YC9VMS>V/]=>,_
MNZ\WMUNOWC4;VZV-2[KAH4,U>LY:!98V=EOO=E]O;Z[O;6TVWNW!7SM;K;UW
MC=V_8$0^?EQO;;>V&NNM_-KNQO^7!V?KGW=5Z$F];&R]?;^]MW]!3R_7Z/S6
M[C:&![UCN$88-!OQAX^YC$ 5?P.E:W^_[MDO1Z#E3R+0MPF*]GO?;_I8W4;Q
M>D-\)YZ>6K"#8R7FMO[O<7MX,C+%QC',ZO>M7A=-%7RI?G=6]67T[G9W]/?Z
MFXU;1#OO$&]>B+<N_#)8AYO-AI+M5'/[QK8#.IO2#7N4;= 93>O"#]4_<6CA
MEV$$F+$3J?K';^O>'Q\>=[*97?UB,Z:V;P^OU-![KD/W,QHI8S0:HW?#GO]Z
MT.N 73P8[^53U'R;/8T]<$^[[5O-@H[P1N_PL#?FMFJT1S_N'@\'0] 2>6$N
MZ@[VQ"MB83&71>-M:@TO[0BL'_:.N[/BX"=;]_?.65R$<."?MF.[/I<%:_QM
MN\>V?](@S48.==TZ:/*KRFM+'22]V\,O;OCT4MA4FL $EC9((KBP5$=-D[/1
M<BVQ"^K3-BPA_>LB%GOQ\*C7AU4W$B(;MM_/0:81<6QW?><X#]Z;7C_?T&VJ
MA2Y,)8RO9V%8W#J$ZW_9.?WXZBW=?;6%6WM;;/_+1_C?7X<?-]^??CQL';3H
MUDGKW5D8ML=;].\OK;U.9_<57/_+.FZ=[O#]O<\GK<VOWUNGGN[3?SJMTW\/
M=S<NA6&_?&;[ASLY7 OW\\_ASN9;MG-Z<+"[N8UW]]99ZQ2^]]5[UOJPS_][
MNL5>[VU-FA@'SIE, 2G.&.*$8^22$DA;EECD2M)\6I92T23DP05#[X2K>2>)
MW#:?_6?5@A_.D@M$&)6_;' YU8+IZ"DP1Z".1V9@\>B4'-64<QM-NIXSMEM_
M72:-D;":4M:WP_S3IUXL"N9W)N>"5$B.*X> YC'BSA&DO<"(T)@BHYY)PE?6
M&&\*I9N8/[BKV"+!O@BB(H@>2&Y7!=&THV:DB>ZC@HK.N3/GO9^DFUD>I,86
M,>T2XL;'W 2!(&M2##0&PXT%SA.%ZPK7/4NN$\$KJYWCF(-)$*3%5!!,?"1<
M1.?=8W-=,?AF281^8O I&8,@'$5E%()=32 C&$'">ZN52MY3M;)&)&TJ^N"C
M:(4-"QO6YZGOP(9$&^RC$"EBP8-(3@M&G=3&!&V8EH4-%YD-OTZZ:_.$@]8:
M"94"L"$A( L-1RX8"@0I%$ZRZCRK](/+Y!<R+&18GZ>^2UR .T^! 4G4&,PD
M::+TG H:B-(F"5O,X)KSW=:/L<O_^Z?H7<+..,2XC8BG0)%C7H(=K*1U,5&+
MT\J:,0\^=578KK!=?9[Z":*@1?K5D@I/SZDP*:Y$ A9T03O$C31(6X^1#D83
M3(T.P8/VTZ0)ZV AZ'"Y2FC=W"!^U/7NQA2DTM]UUFU)+F5TG'<I*>PT0W;B
MTWD9)EHE%>?(PF:#>. :.4T"BM%([97%C%@@IZ;&2]B^;<F17.5JTY=EFLHT
ME6DJT_0\INDNH4@2#-%4>L(BU\E8SQPQ,A&%C4_8WUJ^P!\'%UNJW<<$6^^&
M2_JGR)[9RIZ)/SZI((CD'FF=V];F@D#6\H0P%2($%B/V9MR8K4[MZPL%S)@"
ME.2":B9L8HE'F6RNGJI4%$(2;U(H%+!D%##EH@Y,:APD1X'D!D[<8*29M<@S
M[7.?6*)UR*:/XG4J#58HH*Y.C$(!"T(!$]<L3H(YGSPR(A+$/65(FT10BHE$
M:0*FU $%B)JUBWX.9PO_B4?'?7]@!['12XUA/]K!<?]D5$SEYG.QMSA$LX!L
M]MN3T=DE*II,RF[:&T_)N_%QG<)#=^$A<>%P'*@-D[Q%+H:$N, 1:44,RO6R
M)<P;D)1860.=>H6#KM3QN",%+,K)MZ4"[;4'W*Q32DH<J%>16QXM2=P9[(1A
MVD1E?H';:TZZG0,T!XA'*%WW .-^KBA<SKS-$LJ3,V_*2ANHB,@;*4%1&(>L
MU@QQJ[W#T1KIY<J:Q*0I]-4:Z 7."PCGJWOP [%\35QT&LK_VLYQ/$/R&]NO
M_KT3AP>]4';A.T/W_91/D$DIA$9<AMRX0EIDN9<H8.^5C(Y9EWV"!;3+"=H8
M-8Z!>&PY2&BLK3<F"(TQL\DRY>8(VF+?SQ+1DS-(N4.R"9RAW*H=\<# O.>P
M-RNL@E%$"R?QRIIJ4GW5NB^HKBVJ[Q>)+=-4IJE,4TV<2V6/?&+?T\0'KI2B
MA,64MT:"N I@L48*>R8V4J00M-+C3?)J)/Q)-LGGD'T\<M<TVH/!<>Z/T^LW
MXH_8]^V1-[QWE$=_T+#=T/AN^WT[U2_GF03X2C;60DS34_E J^!%M:EL5Q#:
M/.[#R.T=Q#?P'+TP+@*6ML:@VDV[%:36N^'#&$_%13J['6?[^[2+U%!J73(4
M*>HE@EG.N5>1(>R"#HFRP+Q86>-$-R4IF1>+AOA"S LQ34_A&/L%*5=R?P:<
M7*R VW+RQ%,FC/,*##HD(^.(:TF0MM@CQB.32E+,1%I98TW*EK!M_))#O3!R
MF:8R30N?65HVSOILG%/N,\:ED59S9 48,CQ8CXRS&G&G,4LJ4BMM_7;.YY!!
M6AGYR-E!S,]X>!2[ YN'_9DEC]8E=[2:CC_S;&Q,348AG[N1SX_IO%%J!;8V
M6&1\#(B30)'1.=S]_[/WKTUM7=D6,/Q75-1YJ_I4::;79:Z;<QZJB.UT^ZG8
M.(G3_?A\H=;55@=+'$G8P;_^74N )0PD!FU@"\VJ;H*1D;?VW&.L.>:5<S0E
M9*E4;,5F72U4H*1<#T';?>'H)4]CQ<VX#L44+.T2XLM@:<@,/9<:T)@FS*,!
M'WD!'25B4:DP*5N3FNILDAJ!O-^*C\S47R[NO(;P-E1,#M4-V789!M6VS6KS
M#GRK%<3J#X,O,H'V0O,07>5<L;/K.EM50R FKB4SD9DVS4P/63)(1^)]Q!B6
M 4Y4U62:.Q!)%L!B+=@0/.3D0DRL9&-YW\[$K2@1;#@8S([#+$Y'1[<.;%(F
M9NW YJ*_=L4.Q#<WXYN3U9AF,E9[[C,8+P5@%AK:$%+0C'D>99*9^9U=H[!'
MV13*G%*"F\Q$9B(SD9G(3&0F,M-C-=/6U,U\Z3T;C9N4&N=3C?5I-'\_",>S
M^DNSV<"W7LW9B(IJ'G))QI_%P^JG7;Q"X]EN*$D_KTI2$W)(@3$(J13 5 )8
MJ36(Y)3E2HF21&M86EN24AQ[(\X3,A.9B<Q$9B(SD9G(3&2FAS73-N0ZGTYF
M\S;X)"\4ST*:^G%<S$(YFN:2I].J5-<8#;ZY$9%[GMXTJQ^X?O=GZ=!FJ_UR
MMHGVS%#[Y?6YF6A<^&WT*+LP+MP4+I5(H*VO>C0G 9Y'!5)RX1W+3B2_LVO-
MY8V-WSZOB4*;&W&.D)G(3&0F,A.9B<Q$9B(S47;TKF_RQ:UM@]'9VK9!]$>C
MN3\<Q/=^_"YO63KTP8,@%*LB,Y&9R$QD)C(3F6D3S?1P2[NO7,/[8AS;:H+\
MXW3RX>FI:_?TO9^^RQ2YOEGDFE_8N1VT*@99@"*X!2S.@6/U2THN*J:R$QC:
MIDNJI'J\\.UXX3;!]Z[AN^P%YD)I$X*%K', Y#Z"EZ% *EESJYE4R?0,OMN0
M'G\V^CA*>9PH^?UP9=A[L3).NXC]\L4<-':U0R82JREP)U*TV2<P+'- D1%L
M,*&R412%5Q9"YMKDPV%] "D+OCF(?O 0-IF)S$1F(C.1F<A,:WB;G86HSKW-
MEZ/Q9-HJ*L\$[K.\%+C/1K/Y=!2.%TL!WTRN5L3_G!RF/"67M&N7=!G;$E4$
M%^,8^*0$H//5)TVJ0%,;)OMBG6O[XX?.D4OZ2&'?N<@DV/<4]BLQ,<D25S)#
M1*$ 9?9@5410V0JG'=<AE5[!?ANJ='[)\=#/9J-2+V@!VI6MN8<C'T:'K8]D
M/CGK*-FR<IV'9+2O+3/;+U\B:6\FKW-EJ7$>ST^#:D1;'=*67 V@<9F,QY0
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M&5C+ QBFZAD6B_$QM+%6DND>!6<(W[W?*$*X?@!<+UL[@L#H3(X@JI,*J-L
MWFI-B"869QR:XEE;>J@=]J-*G"#=/[U"1W9_H+UL_BA2&)&< R-SU3'6M"F\
MT54)4UBR-E3O3+2]Q-6V/3JRMRV?\BR7/)WF-)C[/RAULJ$='^=&/&6\-_Z/
M/-L;I_K?I_6'(R*Y3DD.5W6)DR(G%BT$:ZLN"<9!R,5!5AB4,)&CE#N[:NAH
M,\ACA?7=M983K.\7UDM9HG)PS$@$)63+IB0!/BL&UF49=4P*!6^^BQ8]&:5#
ML.YAOSG!NA>P7DJ2:(*LQJL'=>8:4/L"7N8,O%I7YJ*$3JS!VEXA26A"UCT
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M0(1L8L'Z?QVKAZ-IEN/CA?&=*I@;P)A43)<87YGJZ)PKE:NA,K,$Q"S >J%
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M]4=.I^F5_'_'H_G)X$.>OY^DLUZL!9XHD;)9VF0E,O-\8=.7"Y.^^&+1+T_
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M0V>L-Y#?'E)X?#%B);A?<SR>YO0L!]ISVGT)[MY!24D[KBVPZEL"HI3@<S*
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M4"]NL>;LP=<T/7+"N]/D1XN[5+Y[>FK;GYII]Y>6)7*[&;E=6+ADJKE$]3N
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MO@'/!-D;0G:I);R4,BQV>LAD %,T8)DJ4!)RX7S61;D*66D(L(\3L-TG,>@
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M9P=3,QQ/YQ.X/S9MP:B-'XXO>X-1-+>@X@^:R=#=XW[N\>RH]E!2+]3 (BS
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M8;+0\6F1F&J[AW<($!PKD#4> @>>C_*9L?@+;[!7TOZ]&EF8(G0SVC19)<5
ME048J$=")3V\'."3P"X1G=H664O #RH\*];*QX<%>#.?#89P/W!L6O7HH313
MV4^8(A:@WN BH%(8W@LU19*:WA]C0&>C4X<<DGN8Z18K0M["Z[U4&N#@L/=O
M-1RZJ^B.>&5BR2C,0,6L1- YBJ,-P,L8 #N#69.3MUO^I21B:PC<@K.TV\QB
M QU+]J?=:^0XPO=(C'$W2^I E5GB!%,N95Z#)4U$HCQN)HJRK.@V\/NSI!_A
MOF].>(8<M;DD1JF",,L3(A6W1%MA,OB_23*YM</8-E^7R8L:6.IM#."I0,(3
M(WB-1FXHCRX+<-9>L:&VJ2$-N565] UET MC7UL'O5"#5BMN?6E51]:N=:Y>
M>J5T:\6%7UOJ?#W?]K.M@^9='717![VA#OK&NN;E.F@ Z2E-"\;!.\R-EY[2
MW LK>%)(N-=&,?CNSC+YX^W!+NRZ=6GQVU91[O6%S?&[&Q#6D9F-R^!;>EWY
M\D9.G!LJE[]'X;+JH8T>N365RW$NXE[2%"H/:J2PN5XY?K-?52@O?&M-Q?*:
M:N5 -MU\9W%#:VJ(0W0:K/-$E_7#]13>4,R\/*9SA21J5XMO7<M"I O&\FYX
MHXC0(ND4<M26@UHWC0$>XM8]*J-A+>*LBC#J>OZDIA2ZE.K%^N>UQ<^!1NIV
M9<\(B4.93XD&KMKK5[XCOLOR>N ;K6.\6HZ0(CTLJFB P>THY1_J+:+R6ALK
M4-WB,_VCT<-^S;);7?_J/%+6XP0<C4QDIJ\<I@7BU=<'KXY:_+LM/VL]Y>U^
M0WA;LN7^\V"O%P['(\%=".6.4)FJYUU/)?MJK\4D6\]M. '!J9TVI9ZWA/\(
M.6V2"T"@&:.6"V8I^ .YS'R6>4_7P_\U&2_+:8UKH/]O5Z_50M?L9^@"O+@\
MVG_/3W*7L8);1_)$",*48D2[0I L83Y5/C-:A/Y7:SV 5NRVJ8L[4$C@9CXN
M2N*2_!ZTY?%AV*-OQ7I]-X;I@Y=WNVGSDJM8[598__'@CWKN^R6%8S_ B/H4
MI;7++)"EE'1KS<%JE7F$9MR$F,A=<BAYP5)EL;&.T(PK$-<DR[C5PDM*J;5E
M@AS/R@0Y?E,2].NR1O1XO!M?I6K\@MEQLR,?&O.5+]FE#&TP)9\//KQ@)\[!
M2E#O"?>F($QP233W.2G2--76)++P?&N'79L4C^=<H14\HB+MW*AUGC=8(#Z'
M50+QH5)F=0FO6NP+TR8,;9\M-N2U"RBESAJ(I.<QG!&^V^[%TK"*M+@CV_S0
M-7V::KC)ESBAP^#\C1R:39!QNVTB*\[H+Y$/L\V8V>X"TZ+/1/K#&?(A!GQ5
MPLD6LS':, )3^X^*AKV/A\#GL%V&JIHJHACG>1]/IE^ 21J@K8R$IC7%^Y_A
M6!A3,ZIPY6\(,) D'%EQD$(OHJ8U5/9/,<=AP^X39+%YLY(,'F%C"$JA;*.T
ME40VPW')E'R.AN^JFDLPF H#R>MBP?!12\XJ\4*9:EA,&^+R*$UU*R(TR>?C
MT/4 IBQ-*@+$36]3\VRO$:UVJDW@"RSEH1K<1M..NK)\@LNUXHDRB: I*X02
MVF<%LS+)$IWG.KL1 <;TSP NC_SO#EX6B?W?5%'[^$Y(5#A=)0(!:UX3@3S?
M=.?+PWWSY>#XS>7!_@N.A4Z*%=H[GI-,,@/PD%LBK%6 %E5",RV3@J9;.[#:
MSJT:=5\M0>OD9,%4AJXK\^%L@(7:(&9V#IYG\*S:+E=EGJZS2DO\S7&IKWJ_
MEYT#JE8-@>5S=WX*5F,EV:AR82I$$_QMAPS4P5ZW.!":])V%F#=^XPK<?AL2
M;M00E-0&CO#>3\A<!7L3?OF.7E$H3$@+E1<<]"/3UBLNC+=IBG6Y25DS(A9U
M(EU&.16H"4@FQG\;;^C(_WL\:Z5*3QN\\XS=HZO#XQ?)B>3&L(0+0I.<$I9X
M3H1S*:&F$%2;C%.5;.VL8R*(3,-WP;:I9TJDMI .4"Y+O;0Y %LE%;AF'ES@
M$MN*JOA#W(1MJU7?:WCL,?"*NT#XY;@AQ*8=MMTL!Z^N3O)4>IXE@EB52I #
MEA#IF"6YH2+)6&9H 7:PV,YNA+9/$>8<O"R#J@W0B ]J&H!%(N+I(ES?*/SQ
MZB7YMXX5+LUA,C/#G..JR&W&M;=6*-"$#0? &_?_,,#7Y?CVXO"Z?7^3D']X
M04\,E2*SSI.,<TT8TRD1B2N(H#R#OZ>%X7SC9G\>R)G&)<=-R.M=@_$QAM(
MR@7_*_9CFH+(-^U[VO"RV?#7^"OQ@*!"!TWKRS:7=2F]8>.VX]B:$;\W"JDJ
M49)Q\*YD U^3E[P$$>[,+03;B6:)3A-&A13:)-:F/(%MW6<JNY%;J-O-OU[
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M PO8ZPX/#DI>E(,^[).G\$I(^3_ %MU5"1C.\N%+^'[O8&P=TE/U_J5@ )/
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M,?OZM?CW^G=[E*]V^YCCQDC0IO@>N)5U\*Y%R! VL)(C*1(=&LQU+JOJ5S^
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MD9[T,7=3X;K>?8\/D5R,3,0UM<3I[SXB,8&O436ML3@JQE9W&$JS[M6&KN/
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M:P=J=JG*AE2N"%(CZ:,M$NR[H=WPXR]>I-H/478FBQ<*;<!E&N>Y^]P+XPU
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MGW=KG=O]:8:KX$!2S%=UI3FR6Y)'MKV=6IOBULA#(PM!J%TZ6I<K$QARR=0
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M1FBR*4ZAY5=+Z95]E2 (<Y%FK2AT##B>\MM5;3F59"_^-&G*K.%;@4,%)U]
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M#GY$5KF7&C?NY?<519MDS\&F"T4,4D1;L-_ DM/<)R2(E#I9+83 *VM\+E1
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M*M/*&F]+/.L=-LTZKU@--DF/A7/=).F1$@>VXPFYW#C.?9+(2&P0910SZV7
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MPWWCW'.]B/=??/\B[]F'P2!<]OK]QJU8G#0^JD>[J8F&&T41USHA;B1!FK"
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M'$7!:I&TL-0XL%JU:0M^?[S(1KPVXK41KTMBM7;C>6.S?F=Y.BDA,((Q%61
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MF!B69'/NSW/NAYT]SK37# Z::@=>G9(.64(2"D$:172P()GSN;/'G+L"AB\
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MULF@U1^<P&>MB_->'S@C7S.LW;G@_6%K> $RXGSVZG-8EX] -*UT<7X!2XI
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M%P-4A+4V/L"]; /5B%L,GKARQI(<4P87AD?B(O6$TF"EU#8FGK"3/LCU!>(
M@I;R?H8_ND/8>]Q8_!5.G>C#@^Z/17-_YVC0!K7N#BJY&NS#-H#D#H:-B5 ,
MEAJ@(97*FU\'IX)<?;JZ%*AD W3OQTAW$"_(>]]I-L+!L'H7B$5OZ@V_=0Y
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M *)^+>HO4MN:42:Y/>I?B;..JCDUPU[\OM/KX'R:<3,AP,#2CNWAN;8<3WR
M?B&O\4K.=(\#4(W.J? \1 G"O;.5SYB 77:++X: S<O]FP*O.O,Z=S*&DU97
M<=(J$++E+1&SD<90(C-P,.FC)5Z*0 P7\-\8;2[IS3N!,]/N/6QU\8HH:BAZ
MH5 T+U^PAJ*'AJ)/)U"48Z#.TPR>8&%$)IU(<+8090.WA;%H#99SL::RBW22
M[=7[&I^?U+=XF<GH?ST*[;JBL?_TAHX:**]V8^< G^''7A^7LSP<]MOAH.IE
MN-%;ZW7'HP]PYM[J>,I$#91S!,KC:<YF9+:%BD(REYE(ZSSQA26B?8HR:AN8
MU0"4M*G,Q43WA59YSRAT7RO]' A.K?3/2.E/V9$I*E 9&.&&*F!'61#+'2=6
M%>FH\D%(<-1D4[J+Y.A)=/Z%!\SKNI871&%'%2^=10B:W_2Y\>Z..T=?DQ!Y
MB3&+.SV#Q3;Z3QM?7>ZFBX:_-N)S-.)LFKEGKT+D6A(@:9Y(PS4)E'K"A/6T
MZ!!5='.NO)E)5Q:\-*?&OE>+?0\0T*VQ[Q&P[]2!B5E9E7TBJ6#4(EG /AL<
MT4YE@]U!@BASKOMY%.RKR/,OE5?\[OE-,?I\9N#3^LG IUO-H7EF8U D76+<
M/J/)(LK5BWV@F2VRGMDR-\RY?,C()LX4_8"#XJKI(O4(E\=\NM=/=*F?[KV>
M+G/SGI=3!S[K13YF='81JT__SC]R]^".):?UF9_7>>:'9^-5=ES0Z*66W.62
M50I2Z"*#+[R:2\\F<^EOU3"CDD(<2O\>TYNPA*_MX<Y[4)C>7NY_^#G.B>(A
M(?A?VO _7T?(8(UC:."[6EOY=+RYL4S7OWXZ6E_Y;6?]ZZK://[S^^;&-F^M
M_+.W>70A9" P-+"^\9VNK:SMM%8^J6\KJ[+UQP>UN=N!M?^]L[ZR>;CV]=ON
M?XY7I\\I*I.2BI$274V14=03QWTF6D5-X2<5;<0Z!]FD>I%.]->@58/6M:#%
M'3>4)^9]DLI[9[QV.>K(4Y*>FPJTZ 2T;M5'I :M)P6MZ3:K+!2.H&6-HD1B
M/^2@M26PZ:5H114-X<T[9G73Z?IT=0U:SP6T*.=)< =L2UN9D[3"Q41-CIB8
ML4HB:#$W!BWF:M!:?-":,*WJN[:W,A?%^,*("\YA.]5"?'")..L*B\YIQC$Y
M[8!N\04\F?W23V=^^+F?NX.'.9)YJ\+:5]%,=NX.Y?O>8(BIYLGVU1@V/PP[
M,W-4R.2UI)DX)QF1V7L2 C6D,)ES-KF E0)OD=,F$WR!S@_5*KSH[E6MP@^I
MPF='5!C&+2.)<F @00@23 G$29,-#\%[:=!W4DW#[^T[U2J\N"H\=V>C5N$'
M5>%SGD02)>H IKC0(D&/;28^AT!D<=EHYJ5W"0.WJLF46" ]GLN1E0=(FM_G
M&@^7%*T7.??,[?/T3%>[L;>7&__J] :#_VF4?F^OT;M82%@;RH<X!SH'?_6*
M Z'C6E \VXG;^Q=L;FTUYV<USXQ.E%EP:1(G(6'?<FTB"9DYHIQ.5CKGP(,%
MXJN;]%XGNFO*N[B4=^Y>:ZV_#ZR_TSU-!0N.ZDRR2Y%(KRD)A3-2C.#P"RFL
M!<++FEPNT@"C6H?G;8WGX+?6UOB)M'G:A]WXLB5XULI02K2B8)*YR<0E(XDW
M6G$3J>*%5T<UF;CHPCZ)29Y+W?&">:_U-6YQC5?B9E;CH!OM"O]JK_)9)4&K
MK5OK=7MGK=@X&GO6D)7VSYS(<>[W:ALVDPT[,Z>..\-X-)1$13D!(J()N)&4
M !&)E$4C10"/LNIJPG^M.>D+UN6Y^Y4WZ'*MLS/I[)07*;C60H9 >'$2*">V
M^$)_,GOJ8Z1%T*+>O+.UMKY<;9U[XK.VO(^CQ>>\1YMU<)IJ4@R.V!(Z$A\R
M&&(CL@Q,.>KB(IK?.@-:+_(1,Z"3IB @_/GZ-;V.=]:/JWY<]>-:D'>^DK#:
M6AZ.@VKC"HZGF/GTJCO[W>D9++;+LQ@E+!_[O=(>UKFR^7H[9X<1B%BL2T80
M144DLOA"K).&.*UHS#3*$/C\2E<6JIMIC7DUYBU(4+9&NH="NJD)#+:4[%(F
MW%=5[:40'[4FGBI%#8=?>CTJ\IE7B+9&NQKM%A7M%J,LJL:]A\*]S3'NM=3Z
MQA>VI82BSDI%7.2>2)L]_.0I$:XPH[T#2,SS*X=ZJL;-N'"4W';WH#J]\#2M
MG*LKOFT/8='QQN;.;]Y]]+%=VK'1R@GOM;&ZYV&=V]4(D_4NKFO[J/&^:K+9
M;*QVX]*M>COS2R,7CP\VHUMLK:Z_;QSZ016IZ.]C(^N<X!\-8$D2_Q[N8 MJ
M>!7;6+^'-0,:=-M^J3'ZZ'Z_]Z.=8$&QM[??SSNY.VC_R(W4]MO='MQ9;+3'
M3PU6^*,=X9T'@^J?>$W2*P2^@/C^L#',<:=;/=/)M7M@^?N#Q@ZLE_S? 7SU
M\&CZPB<7'!S$G0;<0NOOU5]:?R\W&Q\_;/SR?J/9P/]W#V('FX[NX2;"_3<;
M!YUAWP]0.9IPN6T4A\9/TO='@V8C]+JP>+P)[)4R[!\UJ]V>O&W/[^WUMOM^
M?^>HX8?X;-K]1@$Q&36^?X8"L-IM_'G0.1K1*+ 1JME8_OB>_/6YM5S=^6@G
M*AFOY&+8:_C&8,?W<V/_H!]W_" W_'8_5ZW.&X<[\+9P='J)=O=''J!$_=<,
M5BT*4RSGBF9)I57:LQ2S!_.EHO6R.!Q)P( 9GC-FZKP-&PT>:.7A3B^M5@O!
M12YOPW*W0?CPZ.KMC)M^IL;MVW]V:-S[I^N_NH/UW>WC]8U_.JT5G"BP?/AM
M]^_OK3_^;,.:#EL;K4,P=M]Q4@%>_S_'J\?K*Q_ -FDAM.<DJE2(E#D2K[DC
M/F6!8]&B]QYLT]+%K@\-$-4.;C,\7A"8*S<?GGC(_;GL/[_=]J\?=@%4=MK[
M'W,?&R3[[=/2&L)?XT:#!Z9#";0(<+Y2#D0:$XE#)N*#TTI0'# !&WW)&8O_
M;O0FSQ.-1846SQ % :^FT&['@P6#12QW =@[OG_4^#PR-8U)/ZW&L+>=JZK9
M">)=L(8_*L \L5$@]"'O^$Y!,XI?!T":NSCD,>=J0@3:V?T.W,/X#4N-+SA,
MHGK]FH7@I?9]>[+T,K[:+'";87M-\J9([Z7PR;L@LY6&><U"=/*F,/$%W/WH
MCZK!%[_W^K_GV[8$>(48RUN[JUO44A:D"40$JT#UJ"8V\T(2+UX$J@+EP/_Y
MTL6V'"<8BY([RX;SR*PIQ8>0O)0^>N55 A=$T6"]-^ZF(%F]X7??\.];ED;8
M;@>^'H6]EMD)XHH'_R\7FHN@K$B!&WZ#445<. )B.P 828 TDU;Z(R8WF051
MR09N8K/1SX/]#!?ZD3O L"O$BQ%8\'!07:\]'(S96L7D)F#>.#A!H5S94R#2
M:% 19,:?KURB075%H(/56T>CH(XJD/L)=K8-+!$##>A.^>KJI7.0NQ'8>#@8
M-KJ]86,\\[:!P#GZZO%DR,'4F?>EQLI!'[]O<O?7WGQ%9>&^(SJ]J=$]S<?.
MB)!!*95"CEQR*67D-DBI= A.%!YT43<@)#VO+Z='S;!)X^4\I=:BJ[0(KK>]
M96WR)?- ++58_9<HL84&4F ?8*^23KF\>4>7+L9,3K4(^RF<$WL_<F0]VFX0
MWKN+3'1>Z,P 7QF3"LAKME9PH<"PQBRLGSD1,4>9H:]09M8VMK<8N#*! K>E
MA@LB0\"VYS*2P'PHAG*EM!T-2J,7F>X9T+T.=N@D:H+P"*+4/4+  N&HJOJJ
M\,K@S&RPL8 A4B-^ O&<$LC@@1/&F<6O"..4+MFX4,#.4!3 :+-5AD7/8KQB
MHNDM7>@:FZZ0L];AVO$RN,U&.I<L$32!2R6Q8:*WE'#PI53.U%-#T6TV\Z-T
MS";G2K0%R;N2WH9$H\Y)%P\LTKLKICC6^WW__8Y;3GL:HQ*$V0P4G@='K(O
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M_FUC]>?F[A?V;>7/W6][:WO?+@!D2WS;V(0U_;ZWN=LZWCS^]!- 4+:^_@V
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M[B?:.M[96?_ZZ6=K96UO;>/W]N;N]O':RB=137I<WC(BVU"B)]K&2"3+6%3
M*-'2!A"ME&C6YZN>L$\B52PFZKQ43CB5D[;::$<=3:J<K^*:;$ACO"/CXVO5
MGC0^@*GO#NY4K77C.MX]L*1]'C./]7(;F=M8K*K!)Q"W3UN1<CR $8EQPA*9
ME2,A&$.T"I(%%GUTXKSX/(O\Q(F,[T_)N!_+>![+^&@25U69/.:J!9V;RI7_
M5U7BW3N 1:3!_[R]C6>C*FP?5E]WXN6"D>L3N.N.WQ_DMY,??DWMP7[''[UM
M=ZNU5Q_Z=7RML6N,_O2/#%8.",CXF5:/=_3KL:/HW))5 GG^L __3Y,O'KN1
M2Y4+\,LP7?R=84M.7_UKNL3N^#LE^)T^>=UB&5O2PCRGQ;I;7?:7:M=&.P>R
M@3)6U7.<A! J-O&6-E@E6Y/KS>>M?/\GOOFB,WY>[$82]_B\I0J"G*2[)ZSN
M1!7G\C""C]^W^X 5B8SOJ%3_^?5Y/R5ZYBF-Q>Q<Q(Z- >L116^,AY6]V!\V
MJI!+8_)T%N4K;U#*BQ(38\[72PRZ T\D+Q?L([W2/O;P3,S(2H*'?0L]N_%1
MG-^?61XA;3R'!_E?YQ_33+<X?6M]O.I"W=LL1[)M]MY'%<![D1H< &6M#,4G
MH.Z,F7Q%SO!"Z>)%XKZ.0GF1O8_C-[?+)XIGRNXWO_XY^+;1^[FV$L7F[BK[
MMO)=KJT R]_8V=W\V@)V_ZVSMM=BZRM?9.N/OW?PH&7UF?_\N1/V4F=]%P]/
MIG9K]Y_OZQO;M+7[B:W_L;:S>?SI>&WO"]\\_B+7-K8/O_WQ@?WG>'78:M.?
M?VU\&+:6MRACX+0904R*G$@09Q*4]D0IFI.@7AIIW[QS364O5D..PPKW4 Q$
MZAD5I(:I&J9NGB*CDL^>EF!UD=E1:X)PRF8917$FI2MFC]8PM5 PM?;^!*:"
MR8I9PXAFW.-H-DI\2(Y$9@(8'^:ST15,J8NMS9\.IF9FF#?[) N'..^K%D*5
M0HXYYIT(Y;D[OY+P\]F>WJ6H_:RA[;X,K,JA?=[/F/<>'IWNWACB:B";.Y"U
MIOF6XXDY*1+QAN/A$RN(I\(3GE6F4JD0*#93;VIW<:K@C$!V.9@\*-^JM?B1
M"$JMQ8^OQ5-TA!7@'9R#S&K*,%NNP&LJZ#5%77R6VGOQYIUH*LD62(M?0\#K
M\T&8%/GW^M5<T_NPDAO\QUOAV6U]R6>-9_-A)=-[M[KO_VX/OG_L]3IC4*O1
M;'YH]FF:DT0=LHI)@A0)2J1-P$F C1 7</ZXS=D40#/65/;>G&3Q8D"U#L^7
MD]0Z_'@Z/,5(7) LR2"(%=@?V-A,O,R6T(Q]#W.@7&C48:WY NGP:PB0?.SW
M"I[PJ,; E)SOEG"K/:O'SU!AC'=Z]W[/4X'>&JIF@*HOTW0C4<J]S9RHPB3V
MR#'$ITA)3(HR@#!?@GOSSIJ+\^3J ,B+4=,Y9FBN5=.:;LQ/AZ?HAC32<\XM
M*9D+(B-V?*8*_ 9=*"TR6<,IT@VQ4%K\&@(@*P?5H=!SYR?JZ,=SX!RP=QN]
MLP?7:B";.Y!M3I.1H"2UT4@"HFN)3-5<6^X)=Y(S'N'7K& ^1M![1W+KV,?B
M:O"\Z,AU&EPKZ4Q*.L4VE--.%N4)]4QAQSY&+.6.I"!S-ER)&.VEPX_JR,:#
MEGZ, WV-SFDA5!W<> Y$8[)S.,;D_<$ [CWW)]5L1S7EF#N:Q3,EMRI1';P@
MIAKSKHTAW@6.N>0B>?;@66&Z13>-6R3GJ5;F!>4<M3(_MC)/41/!?>3%).)H
M%$0:G4B@1A''-57*RQ*S!V7F36<729E?0R1D<M0=9S?E[J"JCZKC(,^!GGS8
MV^_TCO*DAT]=9_^0<+8]S4VRA9VBL1"P39+(C/,++  ;9Y9YHSCU+F-GM":C
M=2W("];D>7&36I,?59.GB$FQPAI>$I$R&R(!CXEGS)$@)!"4)*.E\<T[W72F
M#IL\KAI.]V3:J%KX^MMT,7F(R,I-GQL?JA]W*A&PJ:EW@ O$I_3KE4?N7_3!
MR7D^FA=C+Q[N7'A]UO(1+,?W,T>4I+1*RTRHEY1(YS/Q*@:2"]-!*"VB!@XH
M1=.I>9UNF(<R/7%<JX;2&DH7BGK74/I$4#I%PI-U+K*42$J:8:/_1!P+CE K
MG8[,2)%PU)AN,GGO]AH+ *45>_^E:G(WW5+^3'O)RUK,CW3RW?^&_B_O+G;@
MNV7C5DV?=^-6]U2-6T]R!;_W^K\?# _Z^2.(13SZ+7=S:0\'@!Q?NON^G=YW
M?'MO$7NX[BZ/@6&_TUKY9Z>U]S<H*X# +@##\:I$,%C[BDTQUW:_;7S;;:U\
MD-_>GVNJN??E<.WKAZ-O?ZP>80/-M=U/HK6[@XTT&8!!N\77$"0.6QL[WW&H
MX-KV5@#Q@\==B!;,8%4")QY'?QHM2K$E\&+<^1ZNX'3+6."#N6C)?/+6@Z/N
ME=')<&73^2:<D_[[?TUGV&?NV'KCMSY>Q]9I89N6*A"R\0\).XIB+_YQB]K7
M*%R'6U' $Z?8$=@J261AD5C+ K&%4<MC],+19]FQ=>.2"<=[8RF?JB.I>[;6
M/5M?8<_6%]JF]#;-7.]>2?+B'U_=Y;7N\GI==*%UT7XV&R&#P>JBO00#>I1]
MOV[T6G=0?/0HU#3?OYGI/XLPU!T=@DD8"LC^]V^[R\>;.)K^:PL^$X_6__C6
M_K;RS^[FUR_J&_R\=MP2K?<7PE#'F_SOO=;*VFYK8UEM'G\2^'W?]O[\OO9U
M;>?;1N?[M[U5T3J.A^>:O (_LU8'<"%<S#C"7!!O728Z*&V3"#KSA/7S32$6
M*1E<8U2-4==AE*96"F9"\C1)6US@W(F8C> RP2(KC&*NQJC%Q:CI,S[!\<""
M)(([2J1/GEC81F*U""+38(KP@%&V:?C%6<YUP<K#%M+^WT$;9V'_:Y#S:$*V
M^)_ZH,]#0ML]9R9>CW&WB[O^AD//\V!0[?YH=N^@!KB9 .Y,YU<=E1 Z4]@P
M'%6O12$^*TJ<Y;PX9L%VA3?OV"63ZNLS/R]&KZUURD09J#9!6NI]$"7[5*@H
MQA67*KVF$[V>T;^ZCU[?,!:UUO?;Z?MTCUAO<HH^$R-9(C(93P)V/4I*<EI,
M!++*L!BTFG>Z0#K_&@)FF(#J=7'>-P;')NFGZ/L9;GD KT[:IPQ[C5BI4:,]
M&B"=WC[H$:+G?HTYT>%*<,VB"]&H>*JQ#Q_OI9H//RL^_/E@?[^3T2SZSFIW
M9/U@#6!%/_9[L*/85'UP@,W55[N#@S[.%?_23;E_V&\/<W]2.+>9?1TQ>$0#
M>Z:/(+!GQAT/A F'0VT+&%A9,E&N:!"P:(K&)NS2- V_=UBS)M6+"PYS)]4U
M.#Q/<)ABWSKSS#RP[Y0=)])03WQ0\$_PM:V/5E#J 1RH:UKY @_F/PL"]1%X
M4W],G^H.A:^*/U5;?SN K#%P!@P\T]M0,F.UCIXXY0U@H*(D,&!)W'(JA,\A
M>$S[JA<XV?.%:_Z_'I<=#>"&X:>GPX":),T/(*9[!#BNBN:1A"@BD=$:8F-@
MQ&5I$XA(E%'B&"NN+E*D"PG 9Y1M'2FY6'!Z-.H-<#$X^=21IGN<55T\)'U>
M.=G5<1!Z]&M6 ^/\@/%,BT9C&&R@YR1( \#(%'"HS#W)/&8=8<>SS1A:LDUN
MYGQP<[%/N=<X\2QRO#5./"!.G)D#*DH,.A&E?":R%$NL$(RPPB2X6C(Q@P2*
MZJ9R\PI!/\(1[A>>_?WHC_:JW"]H19W\K9._=?)WP4,8"\"\1R]_Q'>>9G=J
MPSI'PWJF!U5.+K)8=1^U% QK4@2VWQ+.;<ZJ, H$_<T[[EB37](YY?:QB3JM
MN\!JOP!$NE;[AU?[*3[-G8DNFD1RD,"G@\O$&A:( @JM6%0B:PMJKUF37C+'
M]DG4OD[8UFF;%\]Y3E(U=2QAGMCWX?"OC=5AZS/B'P83@G="*&)8=D0J+XD5
MW)$HF&8^"6EQE(0"RB,N]MU\DG1,K?4OFO+46O]@6O_I1.N5]]DX9N!A<LS!
M.D>"=(%0[86Q45JN'&B];%*E%T/K7V$2%O7FJ6,\+RJ=\J1,:!+_!4C\JS<8
M9 1#_*$N/'E(U/LYS76D,%%EP#IN R.2,4^\UHP([0TM7NK (R98>5,:>7]'
MK\ZMOA0PF#M!JL'@B<#@E )ER233AA,JC2!2,TULLHQ85TS((M+"+8 !4TW&
M[E.(5B=0Y]40Y$0WZBC0PG.?*XIW9W<,/U9QO]5N[&<_R"MY]'>-?+,AW]$T
M#8I,"49+QG'FV$+< ?)Q$8 &11H"ISY7SA^OXSW/2+^?5[BGUNHY:?4IGXDB
M>"J,)"YF3B0.!O;<,9*E#4+S$"G'(9IBD<[=7-%46%[35/A1&C;?YQKSZD^\
M8(M\#0SSTH[&N9N>LI?QM9-U;N5Z+]QCGKF1Z&S/X 79Z?F,-ZP[C3Z1?:;3
MK#M'$UB*FC#O+9$L*N(C&.DD@8IYK[@V L_%-HV=EXF>26\6O%]RC8.O%@?K
MKO#/'P=/_12:6$"K14S,"I,PA3C&&*$Q1Y:#%S*:.;>%?Q0<?)@QA&<](XDC
MH/9[H_Z9;ZL3(^T?>3SY::Q74Y\:WS ]_8@/0/4/AE=_Y,*(FL>'AVI@%_O_
MV7O3ICB.;5WXKU3PGOV&'=')SGFPSR4""\D'7S=8$K(W^D+D"(V:;DX/DN#7
MWY55/=(-8J:!\HZ-H(>JK,RUGGS6RC40/#\9LS]OTI^1K8V_=32Q,T_M842N
M%^T79!,\XR^V_<V>]=?^/=_(J]49CTGF@(%5G[+-T]RKK!@;,?_3;6>9!@MF
MN^/7K].NK+S/JCQ-+OC=S\E0;[J=TCPMDZ/>M3JVXUOP>!\'\,+\8< %"5GR
M@*O=BY/@IVK&N17=8!4[;#;'NUNK>0([S/%[T=QKXL];GW!S[W-K=^^/X_V3
MMVS_N,EW8 S[Y[";+31!W#Z#Z]*=K2_?F^<PKKWWWW=.MD7S9*>UOQ=:S?-#
MNG\.XZ$?<A-$OKNUR0_ P,JQ  XIXPGBQLG<N00C):C7F/DD@[[88S,&(6/D
M-"C).6/1TDB8UQ&SF'Q,\6+;Q#<]T--!\<[ZDI(TBM]LYTOQ9Q?DIU'83BC^
MS/62L^>A^N0M&G#^>$@7'D$!EJK$.#6,1\5UC-I((H%F:6F56UN97H_E%7]I
M#>!V_AJ*=6&N%Z;ND7J0=N!G-9312%JQ_\IU31QXS72DQ"/,1$(<- [!WFT1
M=Q1'AF7RR;R8EJ,!<+9PMIV+$HU[C?;OI=4H49?LW8_;?138T3JN&-*-VX^R
M=4;$0_3>9%0^2*/0V_5*_>%@GZI1Z//L4GF=)I^O9C+NW++S0=/W'^YD[#$&
M^:#5!U;:3[D7>R=%&YCI73(=7YI+=MDCOAR/:_184^'AX1C'%CMN7?1*1:S!
M!G+VNB=/V:[<[O2!M65+_8WM]<Y@LC9/8"('SZ#[R^TH<>5</6WM;KT[_GR\
M_6U_[UUK9VL3[Y][LK_7Y/O'X0CN>?QY;YOOTR;>/[O@7#W9YLU_X(K'OQTU
M_]G&S:T/QSOG?Q\USX]:._0M/-].NPGCWC__<%RVW/PXK2#F/)@JTB-J.1BN
MV"5DP?1#4BG"@U:!Z+"*W5_N*0*BQJ.7BD>8Z&@-T\E:'I(V.'H3 9AH-#XP
M<]T3H.OCT>J>^#P34#J;5E51E*M4GGDS :!$*5CX-B$<F! A&.FTS"WH=(/<
MO<GFZM586&E\^1"_=MLPH*7TKHZ8G43B8(&-#H8:*;FC0D= '\H9CHQSF?#]
M\Z$:?^Z"/\U94N24MY81B2R6%,&B&60I]LA%(1/#DF@B '\T;H"\K5!P;!WW
M?L]:'"B8+Y+#GD,-=P*L&B92("+JQ!1.I&81*Z?%4Q9!&9/2*86TC1ZTV!,P
M;9)%WBA@@(E$&OG:AEPU)7X-_J$/T;:+V,\'\B6/N#P][V56E[L!!"G#)'')
MX& -IT2;$+B2"G,OX35*:B*Q6A#T?I9(:(R)\"XA9PQ $/<)::4BLHDY%@05
M7M"U#=5@9K%FRK/WK=0Z/-9A&9TM(RJ,4CS$8#U6\--Z+ID3S-4T8N5T>,89
MX8AG46OD12"@P\+GW%>#' X\8*Y(,B;KL-"KU+SS-;@B<IP?Z$*E?IE&%+4_
MXC((2E$*YGGRSE'.K'-&!NXLM2(FX:6^'QI1H\P-4.;3E"F<?\'-XT\'+-"
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MSXPO/Q[^:)B5@%Y3XBZ1M(E@P6A;<-&S]2('6UXF[L5IK_NU%6#JLYS9XLK
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MMC<X>UX/>HEOXJ\WQ6^CCA'+$PI6X:%^E$,PFW=$3!DQ!(2GXBW9W#[M=4^
MXG1[9SFD)EY,(/BK-R9#9?[ .%)U86ZF'3+&$:LSB5^33AFANFBW,Q-R.^\D
M<%W;"\5).>)^(_M23KH!)G 4QUME?57G3#<,MR?!1<VPT0+T6$BLM3(Z!2^T
MM2;8,I( 8-40_(,@TF4=D$>=KR9=>M_84WAG<%9C[258F[M(?CLPU 3"K$$F
M:H*XCQ+!XB04D[!.Z6 II]F#?WD9NGS<"1*6AKVR 4G9,6?4I^=TV#OM]B>2
MEJ/E';Q7BFS5Z.4**5X6CU &BSH0Q3@8Y&XQ.82ME()JCP=*.#[JG3:3;+=B
M9]H*^9)&0%D/JS9 DT9#<)L\.OA,LE]S-'LJFQ%5X[9+FA<58=RZ-7?'=+E]
MT%3U26F,@ E2C2(G/?[U9J)S70=09:MP/7CLR7U&C]4?MQ@.>4K'#94:52_.
M<2.=YJ3##-QVU"GFXMBJV-HRO1W& V3&E+&+(S1Z$9OCQY&(_#D5D0HHGE\;
MI<V_-C??[!8@J1;DHW]49G(4+=@+OG9]F?L]KP]3=5BV<]S3;I#7 :3W1FE6
MU :O;&)@1X,9+;2,*FE&I9%!8\U^&.Q9X_X]XC[PZB8[L!(K+V0$R-<8B#4-
MR$4AP;ZV2NFD@HXY896O+SK]YA.NQMX8%SLQM<K8F3?-CV64V$7B Q_KQPEV
ME[$A5<[45!(OD)V,?KTXZJXV;0UVL258>;>YVFTWLO6)3DGFLF@@G=@E%VET
M(5G,M'$JF5',B:K%\U'$<^<<Q)-'9[%4N;%B[HN@)4>6,8V$=#(:"Q 2TK7$
M<TP]+@7-_BQJQC)DK!W+EEGPD5*2?Y@9 U\JO_G@D+BL]<)4Y.9%*K6^QX#.
M8Z_[JJ5I=^OMMP- 'T>,+,,1#2">3<CHR!&7-GJORS8H:QN=[B+'G4U06I27
M<7#>./[UR-[,SX1!Q(U/5EC!@'H;:ZC+O864$S1Z@<<QK436R/.H>4N'YX!"
M!\)1Z[#W*#@%( 0ZBPPG(:=+*)?[>467L^ZN:CT^K9)R>6?+2>SE2M+O'SIH
M9NGI-6&VRM&>9A.W.E5]F#&?L*,0A!L>UR1-58S<*V4L=T)99V)>(V(BEK"6
MMP'56IMNC;Q[^^<'UE' -1F09@:0%QN@F8I9%*-DL X<"Z_*BI:7:] 2@CDV
M>8^B;8,HG;9!A*NHZ\N%KHR)'@Y Y@<YT DLX$EZ^+C9;VD&E]9R*833'(:1
M#.X,3T!-_,4 5<FYLCC$!!M)[J+$C)72.V4]CBHN/2/\L;R]_7[:JI+OQ\?7
M,W(&ZNI_"</>MVXO]&/G]0D7WSD_Q ?>N*B"2HC@(,&&,0FYLH:6H)89;:(G
ML*UGXS8?%8\E;+2*&]E%!!/;+U+.K*\*+(!]TBE+(>3=?-3S-TY6HG2BY,CW
M,NNQ+%_5FJ94SH)8=BR%K[-9-!>N4KENJL;'I>D^SL^?&D2W"KY[XNV@?7J4
M$USSK-UN5[A@_\WLF5<X"N^P96C8*PAP+H&5XHPHX(E.$JVPU,2P<$E-[)J!
M/91:;VU^.P#9XDQ*T&C!?:9="EDO!<JYXMI(PLL6JFR)Z?=<]@QL<PM>0@UL
M?US&Y%S  G-*;-(Q6EGO&0\A7+M;S6\'#(,L*>I N$(I7!HYJQFB7F*1B*[Z
M\[Z0/6-YF'^Y\ I(F:2>1B<5=V5?[\!U4#JZ1)*1!T2:M6N8(J=9Y#N'J!W3
MX!?!Q[M1JZP_^0O*KUROYMCM+_QPN]SR$P9"UBLGT.+/JY3^5FUW+X:1Y+"Y
M/?M]J]7W[6X?1&T/KO];N^N_/+E"?QDI=/?[_LFGK)BL^<_.E^;)/M[?VQ2[
M>SM'S;U/\/M1:^?\/2CTE^\['R\H]/&[UN>]/V L_OL^?7_V^?C#47/KBVC2
MM]]W]CX<[?Z^S7:V_CC>W7M+_G.^G1W9!SC)B!,W*"IN$>>:(D= O1410GL2
M+4OB8GNZZ+5DVB5L8*?Q!H.5F"@UPL?,V)5: _;B[6F.YN\-8S[#+Z,58=YS
M6Y-Y1)B7YZ4)!#^^W?SP&'8YW,@*33 /+'OB<Z:!](0HFK"=M ]_*#'[Z(&U
M#=MY?^F>G'9SQ9/^;IH(WRB(Z;=J;]W+M.YU2^'[@\294 3G%#@&9J[E#!FK
M',(V<:VD=<&$BU+U+!P\?_6Z7UO],:4:A>T.LB*4X;VM?GGB76U7*2<299Y;
M_%1& '>'<.?0__F7ZV"^*.%\,+(11AEE/6#_"!ZU;4_[\9?Q+[^&5A_HV]DO
MK4XYX/)+OXZN-4I#R[EKN79/IFVCB2SGM'I[FI2UCJO$K$$/_A_&=QZ]O5Z^
M]>]!6'Q/XG4BU*5OP[N7OG?596%KD<3<ZK)7OR?8Y3>]PV")OMUEGVBP_%J7
M_7<I#)5 @,QEV?T_:VQMF@98$I-?<$%*F1U?;_)1(A8^2T^_YT\OILE=%-)*
M/A^?V)1:L+\DH+Y@I#'1W_N8G>E'1_I=@M[IH"AS!8K\E+\^KVG+V^C<%-WV
M<:\S9]9_.>QUAYV 1H^7RO]^?4&3B:\SF;>?AWJ6\RP3<Q.MOG1"KGCL;+BM
MU$./ZC8^B'3=EX ]J) ^[T'>6$2]!T-K545T@6Z7(OHNPJ38]D41O<DCXN(Y
M/.A_W>D19Q^MEZ^Z4L]VDT2CVQCK,T?7[*+I/L*XD1PM&.O7.WE@S]2*W__G
MC_[GO=.CG=^;Y[M[?Y_L_E,V7L*?3^"S)W^TX?,G^\<?ONSGX'?Z^?CS^#O_
M^>/(G83V[LE;O'_>%#LPCOV]?=K<^G#R>>]#:__D;[#Z/[=V?O]PW-S;/_]\
MLM/^SWEST/R(O_^Y]W;0S!T]G5<F'U>D[(82,2&=#$/&ZZ1(<@[^@6V7-C1>
MC*2_4*'E%AJ1(?2&FG$CT+YPRXO 7^/3"\4GK8U0/K>C4JZ,DG,L11L29DF9
M9,*/TF!K?'I2?#J;X!.3E"C.#<J%;!#G42"'J496>B."=$XPMK;!64.HQ13J
M&I]J?%I-?***)Y]R>4BN.= H&Q5Q(@=A!4V2IC]*U*[QZ2GQ:6?*GRPS6'OJ
M44H\(!YB0)8&AQ@CUF--321F;<,T,%O,]'XZ>'I97I/EVEA63+O49T)O]K!+
MP?59(]!#67#EM&]VPI]=7^/0@^+0^UD[3O@H;? .!:,YX!" D?:YY(ADTH"(
M"RMLC@!I2'QG(%H.!@_*DZ[KP'OU:OU0AD^MUH^HUE/SQ^<"7@%SI*/SB(,:
M(P.4$4EN<Y]KK;0!\X>8!A&U6K]@M7XH>Z%6Z\=3ZUFK@0JKF,0(X#E7,:0&
MN5Q^G!(KE<PQ=(2N;8B&6=+!Z.FT^JX'6;=2[]$UKG7L]C)U_Z&8^B5QD;72
MWY_2?YJEZ(1*Z8,(B$06<M97;C7C$TK28A9QH%[QM0W&&WQ)@>+;^0JNK35/
M[.>LD>!)R7V-!(^!!%-63T5D5E*.,,^%;(*W*#=X19(QQBU34N>BL)(V%+VL
M;7B-!*\:"1[*'JB1X!&08,80@(5SD5H,5GUBP F$1XYPA;S#46/%E,%E-:N&
MD8NU.E84"49FPH6N/*3*>WN"B+WZ&M>XQLL*4EP>1SMNN'BK0-KK[EOU-5['
M\>(E$:\OW&7YT^/Z+?KPP/#;8N.42I%':U"3E@<G+8>SCHQ<[<W0J)!EE"*.
M T=.LX24=UQ828SS>FV#-919[&WP<WT<\1)T^QX\$;5NKXYN3UT3SM.D18P(
MES5VE2#("H>1!JO$,ZL$;/MK&]D>6:Q\5NOVB]#M>_ MU+J],KH]XVS @,P\
M&8Q4P!AQQBTRADH$>[:3+#*#<^ELUA!XL4+5D^CVRS)*[SM,\;HQX,\;C1[>
MBIB+@:@QZ<$QZ<M<_EG0DE@"2.2)0=P!\[!66"0<D]A&6' FUC9H@XB[8-+J
M97;4&OZ(MD2MX8^NX5.+0B:>0B04&>8L:+@#BR)I@HA-,1&<M%%N;8,TI%@\
MZZPU_$5H^,-;%+6&/[:&S]@51L6$/34(ZT@13["'&^TP"D9(8Y5R7L=L5U"]
M&,WX)!I^U_.)NS@/7EK0PFIQ^5KU'USUWWXKU;Y4?]!](&J,*8=4M QQA0UR
MN>9U4)[8X#5+P961S&(Q/?O&/H65"6*J\>"9,/\:#QX%#YH3/, 1%M )CH(O
M YJB0MI1^!-KQ8G%$0N]MB$;DB[&,]5X\,KQX.'MA!H/'@4//DWP0*GHF$D"
M4>IR[P)"D0-;(:<[97I@,,<NXX$R]W">^%2AC>)&H8W/(8+K)5WC-42C[94]
MA$XO+7I^2TT:%25GH"ZA.\PESJ^]$ZW<%%V_\M"MYF"U=^&G3#>L]]R'WW//
M9FURS2F.3%L@W=@C#J0;N4@TPBXIP7(##R77-JAN<+$8H'>[].(;Z<H3L_$:
M^VKL>ZP$RQK['@7[IOZ'J$047'EDA0![PVF#'+,2"64Y$SP*)0'[A&P0?.?4
MRAK[:NQ[.=AW[RFE-?8]"O9-?2TB8L\#42CBJ!$W4B"GI />)V/$1!E+P]J&
M;A#YK*"OM-__73;+VICI#SG7RVY9O\AK=6\<:0O/?;=.N_VR">HOO=B&RWR-
MTW9;695FOC5Z8#S]BG7];GLXN/PK"WU5'A\11DT@^85>FS,_CR:NK5-["%9#
M+]HOR"88[2^V_<V>]=?^/=\'K=497UW"ZJ_\PV^>YE9O13.&+&W%_W3;63K[
MC0*PZE9MJY_T:7:Z [C8H%N\Z79*7V?NI%J\:W5LQ[?@\<J@F-SBM[]LQ9>V
M?/QA"\<++1\QXS$J;9QWBG,AC!#)8TTLI9HI;]:>1[? W$TYMXS,G7"'_3RI
MN5EMR[JR/7%Q$@='W;)=H/4>8'"0>P4N]!6T_:(?RW;*@Z/<%'?SXYM"<;Q>
M?)HT []XR09LH*.VX:-K]"*\5/7%S=UV;3^W*>P4H97@<['CX3,N#K[%V*E:
M%TX6NS]>[,)VRJN57RZ;0ML^C*M?OCX>0 O>R4W)#XO8@1V@NG_1@TOTUXO-
M\EOC1FK5SL!(H\CNGD9YV_%<'=E0I"J9H[S\&UA,>/Y.RQ8=F(KN:<QM@.$N
M[6Z_7WC;ZYW!V]]L+U0#.SWM=;_#OC^([;,;MC]W/EHJG%28PP"T3"HQ"[0D
M)DG!4%O:_AR)BQQE=SS"/V& ;V;']UQZG3]VW]#W=.?]@2$V.$482E*KG '*
MP,HB%@G*=321<<5SU6NU;BYO=9[EY29+[H,'&UP$C)7@3A+K5&3.6J"L(B2*
MZR5_L"5GS<,#RWB@TG 4F,[]QZ-$Q@><3_<!*!RL06[$ '!Z17O[1M&+_=/H
M,[=JGU5-[&\+'V4/\;+1>"SLH/AJ>ZWNL%_V&Q]U.;^JV3#1CH7 DS71<L.]
MCEQ*'H&M<ID 3:YH-@P_CJX0HL5>]J],6C[QG<V#D)0AC 44LQ7"A2+(4) 6
M2YTFE&C","M[)JJ%3O6#([ T#H^N7#Z'O=1:16-QS'V*C9>>8P<O*>,%H_7R
MW7[Y!. [CI1+HP4"I<A=#7(6,&<&29IL N#UV*6\?!Q?7+Y?BZ/NMPCV7.-1
M]_,?K"HPY8]#=PS(L]>=KG"-]\M%8/_;[N:!LD%;P7,HMP(1P-R!\B:, "RI
M<T0)K?S:AE+KB[Z$R18_[J\]@O@+>!ZZ1:<[F& XX+\'YN]B"?0MH*2CU0,N
M#2RY!<)3;AI_#7O]H06>"X;/=K:^.G#I#R!R8)0 ,0VQ^!C+<?0+IFEY7:99
M(_/Z\8!&]/7___\T)>K7_K+-IAP.\/+6X,*^<V+/\AC;K9-6ILTM8+&%'YX,
M*X]!X8]LYS!F^M_]UHF]_E'K--_UI N/.(#W"H'_572]AX> +6QPU,I$Z"R#
M7HS%6>YC/!I5<5KB3P$DW<?*>+#]P<Q5JSNM%_.VW16@>:N#W7GN]-$?Q3!L
MQ]TT#JC:L]\W2_,B)U],C8N][*W9@UO_UN[Z+Z].@[99\_C3@0[) 8Y9Q(GC
MB'.<PYY@3Z12I("-"M&QM2("SIQF'TEO&)^)N?P1AM!*+9^U$ S@TVXG.QDN
MTZY9$W=LB_XT8XC^G"WG2PW.4A/S85MI&_=A=\D8T>Y^*WYJ91L82!]\HO\S
MF*U  MLC9X9MPR=LUARX\(TV(AVMM5XX[1*7V%BA-7?)!M 00E2\KI6QH!]_
MC\>V.1Y:O?TL5YZWWYM;_D 3L"ZP9D \1$)<:MA_I(.=B!#"7% XQ<P@Z?IB
M",.M34PB@HT6)P?T@T>#@94P(\ V\"R!NE8L9/'4MU[\>UW\O?<'6NG@:0+"
MF2R%)0\*&>4)$C$$JKV+1&HP-L7Z8D+9=/&O RKS%FFC.++9OQ8[@,KYP*'5
MA_VNL(>VU8&]][K@5AX?Y)>Z%9< <*P\;K.N,P#/S'[\U'4+DCGV$XX9T_3=
M_$0]V'G[C?Q@O0C;P'GU:H6Z0&Y&=V_UX4(^]@8PZ/7B[R60"(P"+I ]B^YF
M7K>[AH8M*,JB7EQ4G3<ER]GN;)YDOVNM-9=HS;?=O2^DN?>6-L\WX=]/!V"W
MX>"#S#F98( KXY V,B#O+.7<60GD9&U#7N&LR1PVK^*USD5&$="9]4W/R,JS
M0> D;7O:C[^,?_DUM/JG;7OV2ZM3,HOR2[^.KC4Z6,NG<1?.!$OR4[T].F8R
M9ET+ED^:1L&]HQN/#J'6RT.H"R>9U7N*KDM#+WT;KY-+W[OJLH2L2Z9N==FK
MWQ/L@09KKG79'P10WR!P^XJ0ZNHD;:7JQ6;IOT:MV/NLR?ML)@;/3<S+*M1T
M=?7@V9W^+I6$KY6L\M0)%3<?Y#UE6U2A972=BI41BROJ=]TNR>(5Q-*]S%"Y
M6SH)%B+D%NS$4ICVLBR]ABBY[G<8VWGSN,EW?L\,UV,8)]W]9_O;[N_ <NGG
M]L[6Y];N/SN+47+';^GGK>99\_P0?][ZXZ2Z]K[8/][D^WMO68ZVVSG9%OLT
M1\EMSQ8<B]Y(QL"JS(N%N!0>6>\$PH(XHTP0/.6CC093BV?7S[ZA8HU(+Q21
M;NFYJA'IR1!I6B M2"&Y([EALR.(4Q40+*-"@A.J.'$LYL@*UC!LL83*\VT&
M^?QX7M=_*;JGY<GB*ZO7N@K4"'X9OS;*)\B>5/BW\A]VPBB]H/_QR/;B;]F]
M.?N!-]W^!>]A:GV/ 9W'7K<&KQN!5W.NJ67D0@G@3TPGBKAF##EG,<(6")2R
M7D:LUC9*=SG]]9XZ6-5%'E=0\1^,@=R+XM<*?C,%/YOI6FN8E#@@PIU"W%N!
MK.(,19J4L5'E<+"U#2[)"BGW:_-!;7K?&\:00ZFR?MR.GES7!'S6*/6(].1#
MA,?Y&G-@5+D^<*71.LW$2=5&U?W!UOM97L*Y,REA K#%+>)1.J1Y II"/.8L
M>N52S%6GM;RO$A@KY.:I]?T)6$FM[X^O[U.:@@-W4DB"8@"NPAG0%!.)1]Q1
M:X&=Q$#+GG0&+X8,U4Z41R,JDQBDG#WI; "E<X/:G;*J?&6\7.^ZO:WNT W2
ML+U99<#V:["Z$5A]FB,GC#KMJ0)*0B+B)AFDJ9:(IHB#3Y$JFEMBB,62F+7#
MY,6H]A-3DUJU[U&UISR$"X5YH!%YPLI>&"%7HI*(:!45%EQR :K-1.TN>3HE
MW>Z +@S*6@DY3VMP%'N3&.W:=?)05*1,T5P J^E:U*;1_4'2_ES$BY*,6AX1
MQ@%,HX2!;23GD=',6:FDCR14[7E>8,1+K;_WQ3=^K+^UBMY,16="0+R55!B"
M=*0$<<XLLJ"CR%"#70C!,R76-A2N T">3M5VKJY(4OLP'MV'<==*/C5070>H
M_"R74$H;JXA&P=G,)9Q N<D?HDEBERBA$5>EQ8VY,U;5SHO5U>D'<U[4.OU(
M.CTE'\ZRI*GDB--\=.*H1$Y[C!CW!C-MN/$JYWPUU)(>W+77XK&T\\^<LCVM
M(%D[*A[745%.__@D]ZP&H_L#H\,)P=@Y?LMSX1S.A&1*>S"'!)A#^437 /-
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MXH8$3APSU ;GP(PU02>E^/QH1SS-C\/E*ZLWX,2ZX,B-K+BS]^F @YTHP71
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MB"YCL.*A<YYCU5[?">QR"I@G#&.NI: I<!NUL=&XJ((QVBG!_/P$]3J(XL>
M_/T9K8LD&0U3%LE$P%B3EB*+M0"QKUWR*C!-LQ^7DW6!9YM!OG09DQ^(C>\3
M2'$_9JX#*7X(1IX^D%'*$YH4(&/0B%N"D:58(2JIQ#@ZI6.LZE/,6D^SNMLH
M2VPFG^/NV5.O)>MJ;[I#9F]!)DV)XX\G9^W.983'Y^XKUUWOUAL71RU_U+"Y
M[[SMY@87)<$J-YR%@7W+3?!@)4-)1>E5O38&=[UHM=N-S">-#K!'PS;.BKNA
MA!G?D!%&':9&&^RH(MRGY!@UBN<0*N8(QW?*"*O;+CY]=MC^U>[6UX.0E.0
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MON0($2YYI*B08/:EA)RW!'009W+G)&#T7+9L0]$5<C?7G%X?^_TPV[0:5M\
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M.=HYWOS^9>^0-__:OOIR\MO)EP\[[?]>-?O-]Y,U/$(4D0N+D<\%U3A+'MG
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MV.<.7#;O]P*IH9H&'C&M^>QR+1S;V3ID.^??3W?./_/6UN<#YI)G@FB4HF3
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M_GWDCD-G]]OGT_T]8.+?ML]W]_9%Z_RCV#D_Y/O'?Q[M9Y9^_.'GU^*9VSE
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MQ:?R(91^]+W#+LQ'*-ZF3"7LEZ@P*0;7GCFLDL=UO_(6C\LJ$Q?A[+ITBOI
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M'AD6 C*$$RL<31&;;$:;C+(FD5>XHQE9[K=,-#$&@^=9='T'1]=B ZO!4&8
M52(QMR3>U,ODJ9?)X0%A-&\VT5RJ * $6X4TPPQ% /_@I#&6Q^R&-ZG!348N
MUY"J2/05QY8G>2+_9]X[&)^G**IS #4K0O>#&:9<LO+,D7.ZR*A;I.2<C/K
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M;=NU3.X'0&U$6U'OK5O_[%U@Y9_0XLVS'KIGIUIH+\'*]Z1,:ZUX?+DGI[E
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M'R35SZ+Z,^;QMB1XR3F?IJ&KZU-)0[-HZ"KE&'2^@A!:9Y/#5 FV^17 %N6
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M*AL7KMCUA\[O^O/.2X(!_&KU.NU?_C]02P,$%     @ DHI<5+7^X^"S)0
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ME!MOQJE')JW)#20(YO"Y,\4?0H"[(RSXE;@Q!91=?SHCWCR\8X#19GB\AE'
M\U'"[\JS&X]2RL*-\S8/6^Z$A9.A6\G8.08<O26&CUB2"?PQM!93L')S.$RF
M3GS>L#8OL"A< L#2_>S[SE?FZH<Z57BD/EKX3XD:F'KC\R@Y65.D1S*E*U'7
MC::%3>HI:S1;)5X.)<D.T@\F7^WMN+HVZ$,NLUMMGF%0E\Y'7Y4^!Z3_/@-9
M[_S@*PF<+=-?TH.<^NTV3T6H3_W%G]BEE?1YD,1_@)7IBT3V.?QY^WO,9JAO
M/-%(F[PR'/*3]:)1-&@1VP]6BH]3;H'Q!PMP'JF#*UOS4%5CDA^HEZVB#J2D
MU"&>IY*%QMNR3NQ2?R1I5%>V;JL_N:1]#Q9^??*?6ND0T,#18)>C ,Z39BNZ
MU[KXY?QP!>;R.OQP5+L6A+^'D7MC!O*Q$X8T"NN<N&6P\I/V0Z/HG\NP6 +-
MH1VO)<M8\UBMQB ]3IOGK:+B4TZ.0SQ#2U8U.\M6?ZPK$-="+I6&S4:[4<C+
MJ:#F\I%8:'24A)H4J1%37A/]D>3?E^1;T7;JXI43&12=@A>QDLA'U49O0]_%
M$:QD9^H'$?O&!WK[-J->6#LBOUDO<LJWVHV"N:NUO46_5KYC*^GY0%GAE881
MCV QKQ=-:'#K12RJDW(M02'5>3&D5PCHY9!9S+,X.BO%=Z1+_:1G)2*Y(GS1
M*K-+)#0Z3'VX:HW1P([FCS2:^+6]\O6PRN7E9;M18L_(R'AJB5XLT<U1."Y1
M8$O*T%KHY91^WV[4W+!'U4B+Y"*AA'VCSC5Q,?]S,*&4I[DLKMJ&:*_80.3M
M<<(ZO<H9Y*K=J'?J6O_UGU=P6O^WE8W%2@9CB=&(A)O%>(09A2,Z2!9Z\(D7
M9GEOL#8KWSQ3%TN+]DE02\^JBU>N?'UH%"/S'%\N98_3M?#EJ95T9"4]'6E;
M18/M1 BVV*=4-+3.VXUM\<3Q5,FS39)U&/;)/"$A?!/$U$E,3WUF4&.2;OM6
MHU%,R4AQ6@E23N($;6H<'](F5ZYQ31-,%Y_4$FLU6T5K68MRAVB1*9<\\T0I
MF]:5U[OH6RZW6^W&>IMZQ3FFR4X'*, ?J8,5C1X8>6%N/?=8":A<1+<;Q5R.
M!(F5PW+0JU]3 E<BD(O<BU911RZAQ"$*V.**9E*M^%M=$;H>=KF0O&PW=+;5
MBD@L)?<!"L!N  L1W1$;%V%^3;POW 9 8P33>?V1:*!?Y4P3GUQ4OF\4TYP$
MH)6B_L%"Y,)B^4$8+]@!O]'#6QZ)N+KH-85K/:QRB7O5*IHG=0EZB.)8DP:9
M%%T&V, [L?V>Y6+\0[NY\99?D?$KX ?OK:A-TD<2Q<%:!_T6NI*R2_N\W2SD
M 6W(+MD0CMQ133*)&W+;W"'K2LX=C7:SD$"T!G?(/9V'Q!PB[#,D;[4R%#(8
MJ;K7QKN^Q= 5#S1Q\,-<Z-H)(:N04I6LW6H5W1'Y13]$=2NWAHL_^X'_RO"9
MP6OJ05^U+PK5P2F7:NUVLR0Y+D>Q_$=KT8?UIZ27/Q_DN99;_RUE=^CAD]/R
MHMTL2=Q9HN4QSE9&PQLZH@$<T/!!9(-NX(ZJB59.T<MVLR1!9XFB:2=\?Z99
MZ+F.#GZ#+F06L/L2<=:FJP*CG*3OV\V2E)HEDF92%CI8.3\/D):/]-LWXH$B
MS1.9?/O+Q'<=&B29C37\Q%(T<FWRJE&\/;! F*0T92C_F.1#'HF4K.Y6#LD-
MNI!OR0_M9DGH1D7<XVF:IS]?H6L"T%C[BH+AC8BU:5L!+MV4%^>-XL4.CLCB
MF*P\JH,G14W+3XI$:@1>-%K%0$L560[1("Q?VJV(R#502T7C!>8 E]+RM(26
M1X&HI/)@0@):^';-2W,;="&G>JO=++AQ*G<P_(0]EC'$(5^6JR#.HCHF_MSC
M#P)U[(B]@D*Q)?)K]""G?KO=*I??Y7L^7SR3\XCHTTH[/5)_L5IB94*PTN.I
M^/,7#U3*:Y?87P8VZ)?US=*-.Y+SPD6[5?"B2W@AZ?<'*]>SQ;NV>-^G2>='
MGBCNUV<:1@&S(RJ,FQU)!44O<FZX;+<*5K">9,BZ383$43I4T^@W$@3$JQT4
MJ(=53NGW[5:Y::6D=-+-D:Z+]4E69$NB?16;G(Y7[58A)""A8XK\(*D':S%E
MXF(C\1RL5,^\,?5J/2DGPR%W9GQH%&]=Y[!Q-]02OB-EMO9\U[KXI7OO\KS=
M*@1OI!0]&M!YHN=N*LZ' :;RV%R?U*9J)0+I1KQL-(J7XO,7%N=6'MF1('5S
M2A1HI+[%RV:KF-5339Q#]"Y6+>]6!.5:R.52LM5N%>*A$HH>1:0&K;,4V*H6
MVR*\?D]R+FBW6X40G)0+\DFV,@%P@%QQ.YVY_IS2)$.K[Q+].%P9K/RXO&@4
M2X2D6*P$C85X#IL"6Q&_=?'*]]QENU6([912[BATEXA+ @]4]K!/ Q[XT*?>
M*J!\8[UO% MLI"CP:4D1=CG@A:^I=U: R_7-JU8Q[Z=(A$/4,U>7<SL"K@Y2
MN73[T&X58I@EE#N*-@E-\<4\^XE&(@41EG'Q"PN[R8"I\TL(,+]1-I[ A\XK
M#<B8/L73%QKX(]ZXMK:YZW%(.>?]>;M=B'^6<@X?%J\;FU8PPZ'].=>&A58V
M/HL/T$I':"5#M,08>?R4C_+(>K *61B;KPDLL!L[U&'>#7-C6+W5]INRV+K]
MR5FIT6X7W!6EK)0/H@LF2$> -?:2,92>/ ?(*[^2@.%Y>^]%%"82I<4'?[V_
MU6< *1*I9O:^V2B6T$G162F^7)%;1'FDCUC:FDJ;!BJI O>^U2KFB"II=8CZ
MG&RE;UTVQ>?WX(R=^5[7]T+?90X?<"JF[CTL",5?O04)E359J45:5TQ_WU')
MA3G>E:O/2B#P%^.T<*#6TD@S.7_O6?G!6OG1KM90/42I_T!)G>*'27.Y)+]H
M%.O\","#6]BZ;Q#F@>0B^+)5C&P+\$.4LV+FF=')-BCVJD8EEV@@THH/00K*
M+-G%[,#M8K$FF"OC>Z*(-O]FS;1M/6QRREW!851)N0PU?ZH1OS[H5&RQ,+Q0
M><[#DT2-(E_\O!X5-9'*B?FAW2YD'"R(*>JKYSU3:;@K\A=B]&")*I[H>02T
MTWC:)W.>6<,3CI]\ST:5R<43)I&4(]#1.H[/\Y+]T56[N1[1M]2IE"FNSMOM
M0EQMP13)RT3)$*QT#$FJ-8SB-!M&"L4'8J4C0<D 8SFRSH94K/%VW9:[/;+/
MOK)\XY>0_A[#!&Y?<=GT$WI7 :7&"5XY+][#6:"P!(X#7O?MW)BL@U2^Y;"X
M@Y)>!QMP^O'L+?Q(9C.T)? ;\=GS?#%V_A5\0UW^+@PG.)G2R3]R&;.=E=Q<
M;CR>6.0EC )B1Y].HB"&SQ[ +>4,5\!YS.42+H5[>PE<]G%& ^8[..Y/)TX<
M)-?80Z!CQ*(8/_T<^/'LTPDV=Z*/$V@9V/$+O8_H],2*.*! A5=>O#%^C^A.
MSBKGR#/R[\,PILY-C###">WS<8A@0&]T^P:=L)#V1LF-/L])<_7S"S B;KA8
M@0VQ;F%YV$=67!017U$O"HX<3Z'>Z(YY\ =,H/?BLC'O\LX/KN,0B^NA(?6"
M[C4^D(JE6 M7G040O[T(+]VG$SLI<%QC7:9@L44DF.NPRXS:C+C1O$MF3&R?
MI A_-PX":%K-$FI(]:R9%T8$FW[72:=*RM#OV+_'+*"B"L> VDF!S=]8-/'C
MZ)D2A[EXH8T&Z':%J=P1%OQ*W)CFGJZJ7**M]V,N&Z%\>*:S.+ GH.()&9$7
M$&!HHN[7&WWV7><:KX[RK^4"9RV$^Y8U@L;WL.AP3+Q23'H;?H6_YW<,U%[J
M/5(,T5<=-;K06Y^E$P6G^%?XT?&GA'D:,QW2Z<P/@$'$H/N^R^SYD+Y%URX0
MKY*T*K =3BU*>]&FHWB%,MN$^;\$.U;.4Q_!!MO:H2^[V]4BFZ0W>J93/Z)]
M& '\_.B#RN;S[2B^J-[$VO U#HH:,V5>1,<TT)AH%Y1,AAH=16F":1&P ^4;
M50IBPNY,M*^&?!JKK4P8>7G5D0X.=,R;7L^S)LD9V_E* B<I&;"2MY5JIOV
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M(IEYYTN:=:A*D:V!P(3Y\LCZK4;T_=:D42^]OJZ^;5#1VH29;)(CESR)A7:
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M:^YKV^PZG"HYCUI+1GY-[2A*B$.B/XPSQ7 M,V";M)E-$>X_IUJHJL];[K5
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M;'@O0S*9^]JFE6&.]4[;1.9#Y"Q'THI1*KCE>]W'KM8;3.LV6KV+"/L^+=_
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ME63:I>0Q,)L%;4(Y1>83\;#(:'A4P5C19H++*C3[Y.EO+>T&XPR7,9V5A6Z
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MK CWI9Z0)T"/#"0Q4EG-C!8@8K4-?QN"DS4N>XN[XKR;.WC*<-\5HMF*]%U
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M&9XSHR$[HCC#-X,&1IP0D0BTYZ*7T<AN>TNG)(][CSY)@Z>?@!]J^N!I#/>
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MC(>&9.4KRC(!R6VDC(H0?F;N/V?N[:/ 83+W!?"T*$87L10=1VW1S,R*@+<
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M9&V@&@IHL)%\@F\POH8W*)9UEGB9Y_3Z>C9'N--?_USMC<76Q__2[_[/\ZB
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M[*D#9FMT7OQ&>D: G'F*64H3T+!W7FG'K&.4"U=FMW1-SWCL^36O(&^CV^B
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ME"1WZXC/7!,5><Y<19;U(<?%8\_\,1AQB( ?\L UX,':O"G?W\)%)12XT7J
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MHF*^",ZRXRH(7R"%/G<SQUR:N#D#-I%R[]+$+J6H/)=,JJR8UI'3 1<TLW1
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M[F9P3X%#_?74(;=L,?_?\-/%-'V V:IC],P!<E%;!OCH3'VOR,D3\8:)J(!
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M+7[I@ <DS\G+I)P.3JM.&='#,9Z*8]-9.YUY=+4ZAB#J&@Z]C^DP\<]>6GR
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MG:/=468C8)".UPYQ&MIM(\$^3R+JUG(C_7H)S*LB;<B!*2TXT\DC"^1L,B?
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M7^88WW\L_60NP[]65NWB 7AY_O?C']HECMJU9G4.!%?MXED3OBH@SL>OO$U
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M=A!NS(:^(WYF,1TO\W$06S'RAB*\U%+O:W#!HCJ;]AQGM*&AX*J#BK3RT-:
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M3[VE*KU4OK2EY/FD?:"I0>4M=<W$8Y/KY;1.-Y!1QX3UL&RI5P@*R4^1=I)
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MU5' Q"IIU9175%U#0U*#>/Z)_)98Z>-[@?4 X$3K86^TYP+:IC *\6<5'+G
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M/&J6>MU<::I;X*%!0FEE=>[DC:\!X.-QYZD--JH<I8]!42(K1)H^918GR5:
M/E8P%.C>Q;322PY;U(:B#4I/CKE/.A^,]]2Q]PPQ>Q7G=*'\P-@)CP:W"Z7X
M<3=F#!R.TM*>Z6V<N^:ZSJ_;DJ*#Z5]+58\[VTK8;.J[]<-3;4.YLG+?\TNU
MV@M[,>D4Z*Q&3H#8?!NCQW6_HUD;T:A=+>B#:ODEQU^=U#OD5)"6@=U@>AQ"
MDZ[JX4H<#T[MDKD*3&'P6@V5T-346_,/%>UHY7U:F UU$YV=^NLA=-"Q2">U
M9IF]0;(5OQ$18%MSKD<',,AOI@U>5PW6\<[BKH;Z_4B]>S<L?YOB4-70H.'8
MK[*.]1]/-9HDQQH^66]"H5W!0/NHXZ+,"$XQVPN=[/T<2AVVZ#-^ QL7^=0]
M O<F^_)U)^*#'07;.RZ&AQA9%?PX8 L5^G97J=]XN7;?8\$V#!1%9.<'-Y!9
M&K*8E9!<RCWRF"SB8$E/XF1UHRYNJTQNQ<"[\(APS&KSJ,Z%R# BQ2#-E[%$
MON8HR4.XJQ_ZW%R'V>'TU&U/W@9[W^SF<WBZ469-HN&CX^G[G!/30GKFL?.[
M(ADX9*-G@Y(\W .9N*-4#R<&>Q[JO^@AZCZXU-7JM["@G&YW.N?0JY?)='TY
M;6\[(??*@(P;ZPN8*7#4$[8[AQ0=#A59O70.-L71IH[:5=ZYNV974*!Z@G/^
MJ/XZ4!6$@O&I@O,H6>/OAE7,U5S-<RX&SBK:-(57YW1\Z B.B2HZ^259-'[9
M'7?^"7$Q!#]:15C=-CB'NO$H50[IYP*8(#"8!&OTI(511=CVM8-93@RQ!&/1
M I_@QW,A+S(N*NC<XG/SJ'A:47Q%@;)HTMI2$TMXYXC_#5L1SI960$2::,0U
M**]$T\T@#*Q2TQ*#:W,])QP SN 3=V=G1#[R__YT=D'-N-_FG#.MO"13PTZG
M\K3@LVA3".6/J<QN^#6=E(RM!!-5./F(-&SC&N]4 7L6P+GKG)KS]>JN--\
M TZZ\0;ZG7DFWOW;.M7VKF0U@&<OYC<J%(UC9V+'9I%6K#CXQ2SM(KX2SWYB
M5\0%Q@RA&J1P6'J1"H6N;MHV,6/1*<Q!VA').DZ.D:\Q63[:A+%IY;JY?/:W
M/9'&;CK7^$(+)0YTYE^H//_BA-?:IS3%B>/U^^.9J[M(/Y!!U-]DT)H_9C3
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M54,I,W8(58=Z91"8GHX;U$ =;5U?^&1Z;%,U'FF9EY@PO'&#.JN]9F2Z\GY
M*X6QR--/H"\,0]2/VMBY3)5_BA76V'&K63!7<>-]8<)PUZOX"U254F1U]=V^
M'965=X0B15CY;^:9:3(!@ JP?S#I6W8*"7WD-%KBH23C(^1M-=IS*\$NO3N#
M"$V8/76!_Y@*W,C0>Y<6Z]9J-H/D^LUE_A8%#KSSW6 <.KKRG8H.@ $;Y"^
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M4O5GX=4K@^^6GUDA_]EU,W]HI!\+KA_[LF$WHIN75H])BYHC,!>]F&_@J7Z
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M,N^:^KK8/4^JYC&LA*32B"ED>,C*,7$L.<>/H[ZRSD"VM65UATZ<EN7CV-W
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MZR=EL16!'3_BXW*JZ8%RQ]00$^UG9*>W#'56YGF-H2O+^]?^$\^!@=^TMC%
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MPKWF82<.D1^1IA@@VG965\NJ!QN=_./ZON5+385.LZ18^7.G0PL_OTM!W\\
MS\1;OO=\+?SVL]G.6_[YLY%:#!"G(Q&]"MP\Z_&FVL-H;9/[QS@#A'XUP/R
MFW "4(=0U6$+S^FCZ*'3(T9HZWZ^9 ;H1!GYXY@*L6LM2:;*;<_=K_^,[9W:
MU9.L&!ME8"IM;RH,7_.2!Q%:=C4?VC.G@*GQH5D228J+#)#]%_E/:*.3D_"
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M;G1IO.RQ9?"XC=Y^3-33_3GR#O@%4$VCSJ)MTQQ795.49%2#;:$\EB=WR):
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M-W:(7$U/U[P [P5DB= PM-RS5.RGG%P%)8N$R62Y.D<5UA<L^3[WB!XT/AV
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MR>,ZAC=[7J#JTM':&>'NVS*J*G4M!2,46=5NK7?>[G=>*M(KJ*?IIUGY2#D
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M^K\@>GW9FQ'V !0;R5!;-H.P[N.(.>S]-&F*W6'*0BI;%B%6VT2S>SXD>[R
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M// R5>I116]%WUNOR2^8*#)/?>XIO-7\TZK+YP_8OOO.0/S^5H"BWOD;\3?
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MR 96VNM+'\\%O^SJD]#0/21U.#G:3X]K1]<"(; +$EAF"TCO@L[[[8*TQE%
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M3N6*8UYC);?<IO+,VF>;"4R@LP=O-"UTA-AYMC9539?XO;FQ"_H<A!U4JE"
M'4YG%1%X1(]<^9#X:SN*9G^3L<461^W')/)T!)LX5UB1ULNSSC'"/#ML'8/\
MUO?.NQP\'R-$F9M5F,=>H^&8TA VWTGJ.HF <*5I4QI)3J3M%IOP8L\;<J&?
M?VT1M$-']S\_GS=@O=:>,"\XQEL."G"<]R>WH-F"[:Q2)FRV?[S&A96!//US
M!2AFG 3>+Y!6,V[.Y8<7V@8K:JK++DL_D9\L04F/3S2)>C4PY8>I&23U3%3@
M#"&WNV-&6,_.QN0<XPI\P8)V(+(@X@ZKV=XU,?3Y9/P,K_C7\X&_E,(?Z'0\
M$,;IK1+LZ:@?2&X+AJ,;,X ZR33*MV"/V<O58\067W7+KG];:9.T.I?+JYR8
M<-(+Q0%8P!'P2B%-A3Q=2%6Q!G)097"<]_ <ECJ?."O,>Z-I+^'71\'^XVA6
M14B8]@_7>;6?/4G;.=SZ )3HN0N29_?CJ%8SB5(>OS;G<%R:$&*)HP"C-TW.
M-KA%,OA-GOV)Y\FU(9,Q^9I(IV,5X?V_NYD*#<3/L [PQ^ZV?@6$ZEFT^ :$
M &E'4RLQ[X FN1<='[L.IJ4<]O*=L.+IN8S\W;H'@:!^KDA!$7]QLL*6\_!F
MJ&]7 ]6VTU"Z/K* \J/SK:V,OVLRGW\09:UB[_G7\K+*14& (BG&GA?5UH^2
MO*G7!W4KFG%@/;FY:9CH/!:&<9&='],:->?]])"9^B7MI$2,GQ?BK88M_9D*
M^Y MZUDR:OX^@-L%G=5#G.+<208R.;YF$%6.6F0;@W8J9L&4;<91)N^8_HP0
M!WJ1E8H/CR6%JC32X-29^_K>81"ALXOSJ@6/"T+?+59H6#%:PSQ,NM=9,P6?
MA($C?VJH>'HBQVVO(%R!26H-^7Q!5A*F;0K5,;V?EI^ <-1OM,V(U2''A%3&
M5!I=^>"NXI35>8G_@\JA%@&V8 EMOHPF3+\(= ;0_ /)WCB*(AE/<_D."-=F
M70X^>%U7([RA=U)LSD_D"?A6/!E,M<?PPG-(8TS11VQ^>>K611UM?(XP,#N[
MOY#Z2NTF7NGA_A<F_IYT!J3@HY]"5%'DG2!N H0X#27 9NW>)]$X#I_&N I?
M=QS#'F7NHX&?!;P/R?]H'TD6/K $7C0P++=Y5IJO%.BB[N\T>?2] %NHF/46
M:0H_3;<=0XJR>U%BFRC^:<#09J@ED*;1X0,>*:]MJO_0.*H\5-MG=#WIR6Q(
M95K8GU,J<T.*]L():*IS;\@,H*Y.<69P"FP;K$72SQBXT]7>31JC< MF:G;-
MXAM>XP(_1YCGG[#YM-YKHU@0(?/>BLW/(NZ"Q&_,4&':E'T,;X3#8. '6DHW
M3!P(Z<ROEZY,VWBAL-SD97P\#P_("1J?#C]T:]^W+;O,QI?"0YRE*,"TK4[X
MT8VI#6E,7_)ZR6\7K-RPVH@^2B1$?,HN_*Z>B&5SV8MI]X4"E_-7]A79*#J?
MTP4%  <94<A><*UVIW<(T0J/3LU_ "S@Z4=C*^$:G4C)D0U!'PW+JY41]1YE
M=2UK9VP<%P[I105L8WW1'/9"K(3(@(F=*2O"9)P2PFF$*4P=85K59G0B3PR_
MJO$?@LU1F1\6\\5BFZ9C JY$53RHK=9YF54J[RXY-HV ,D28@@.XT/XD2#TZ
M!\=)Z*E*IX"VBB#"^S1JN^"E98N&^I$JZ*66HJ#K&1>'0UN6 ZP>,KM/7[8Y
MA-_S^QW7#/('NMYP);@"'MX-YN:4[RMC)=X:%T4 \E9;4UBC*E+6W6_=8<FX
MZ*&XVL.GM(.&XN<8)8VX>QUH04[-OZJ]N@D%#C:TF3I=^5PP/T^&2MC>OGW[
M8-3A>S3+=^[/<C1M5'.C]+_\G8;$-ATP,T2U'=I4M.W:JKZ!-1QAQI"WS4Z^
M?QGW\V>(J^NP[<%FRX48CYZ;O+Y;9Q3W:[SF_(#GE">;UYEJY!Q_;%KM -=O
M%$GMA_WF2^&!__.=@\83X V54\9V02)Z#%O( 83C#X3VX99O:S^#'4OTB)FA
MH;,OE[WLF;JP3O3.:0R'5Q)-<8!K?$Z?+N+XX>'BN!=NE3%?(W)11[_K#(<Z
M]EVN@U\:+)UKGH94FB:DT_YV^,QD0#8B?3B,L34&12UARS:0^UF*8YDHJM(,
M4R.'$9X*^>W,09W[.;SI5SG*O1/5G[_5S>R/QYY&]<!H^:RLZ!SVXQZOL@BP
M5 2C2IU<D59;2;GLN5C58AXC,583IT3*B]QOV2W_-/-YI'[_V'9WX=?+?=5"
M%_J^1]_;*BH(0CI!/88V44]=9R#4BY!MP\I=$$/N#VK#XC-"$.K-;H?R(L)G
M<8F1!?W)[-/+'/GL1>S%@W>\'/5NMLO8/%B5_7F. QVX)'=0\>//7<2S2YR$
MS4?S:]#-TC+8@NDP#7O/HFZA[[>^86363YOJL6[&/K+@Y++_F\4<=T$')FF!
M[.SE+@@@#&-+L@I9C1W@C6/_!_8;7L76I.^"T-JK.=M%;8[0<<+2/=W@AD%8
M,EDMW?^GY2_?!!TC!:4?W0@-P'-6.V4G:6HAC:T7@CR239:TKMIT*W&.2\SM
M_7#75*,>@^)*[2!_^%H6??SQ"];HK!KVUIWLYM_?"RX_)T59/:$/;T!4<+XS
M$\OM4 4(L0Y:7]%JGX:% (6Q).$4#"D-(5[L@;A&4\PTUH5.Z&V964W 9H\)
M$%^K;L.Y#-(I*"('0]6Z4D3+46WVJ!L80-V@CM;?@9,RDV"J-=4V45&93.A;
M;,7KWV.ZC]?UTC S.EY/M$W\^J[?#>$[F?D! P:<&8>L&-=1;?XX(H?'"43@
MLK F0"S&_A7<4E@(J&PM,AS9>*9YO&S(VCTP^3OYR&K)@;<'G%+DW=M7CGM@
M.2@[,1I[ M!MQ1U >'.PRP_@!16*APIB39GB(WT-';'@\Q^R)]EBOR\-PLA7
MKA:_9P_*9GQ[^N=T@<&V6-"#>W+@ (0>JQ;"<<U=D%A+(#60M-7!MXJ 4NFC
M\FA9N ]4>&9R2<[?Z2C<G3(?KPH[:3G'^\Y+\ABO;QY"E=6P"PJ 9)OQT"HZ
M<E+ LAN3+\1)7151%7#Z+L@A.=04 ;D;#"Z\*SG>;%VP/\THEGBS[3OOJ6TP
M_91_(EM(@_51^4F"S6WJ<*M.>^8M?XMJPC>>6WP@M)./%D. :0CH,FR9W)Q<
M^A@A"Y31SL!1[4@CUEN$>\D4O-+^]I%J1N#$RP1BZ+;[WGY9HX/\B8U/[K1R
M;WBV0AIR5GIHZF2?1&K,&9H++IAL+S'AY0,/O$@#Q^E7':P+"5)95RN:6%TA
MV;PZ?^PB!TS#N^[\%HKL0 %'5E=BJ$6AH<S;-.W+B?;4Z?<153$=+DB^46V]
M&,4SI[+>S8U4490&P_:^JY9!S)P,\)5UF--"!#-,V(,0JH/V!)@^!>@S.$FM
MS=U,$? CV^%28?KRD/B96E2B0)O)V(?%M;30.ENGK!J;F]_>G;VOZ8Q#.I;G
M]+(-P9-@-E\@M9ELV+4+2AZ=EF=50'Q7Y>%HCS&3 &)S0PQ8## 0M')XO 0-
M*/RU3LJ>=[>9>B:)%_L@LC[ LX3N0A$@))Y6R6$B\) L,/@Z1.GVX(8@]YG/
MH_K>YKX.PZ98= 7>=&11QO]XC_@QF'='F.QZ1@Z!F^[+L7$"LKO(;!2YE^E3
MZ#-0,JROI>M:>.:']D:LK2TV04T[]-;;JRT?GUE[#UJK7*LX4.;),R>#-&JC
M\; %UM_!A:&L"J8S==!,&=F'E6\!3MXM=_]-7':YOC1/7OJQO](W8F^_:O(Y
M!7/%I#=3S5_/8%>I5G0=5B$D0#@-5XM+P\IPHBPE'7F0>8[:6=],<X GK_6\
MS+Z7XN!ITV%@D$>=[#LBO>_)%2F'=V=^EL696;,>18C.0@'=I06W'W6L, &*
M-C$_:[/9EJ4-;?[X?'IR*D2\:\T&=DBO=Q[D822@PG'NY_R,93:?J@U'5Q=V
MG__S1U3I=B-U=NMH'16]8F+%-!^K"N<@LEF:P"[(,D1_"\H4LV([NC/T.?AP
M'S6%_:PJB#N27LW*BD!/:HX#NN2&3K1,<!%W;?V]S]2*!(1%^*N>=SZZB(\^
M/A[6CUI.OI;7&GPHT&Q2='V\'<$!F7NM 5?:%A&6C@K")$;/=.Z")(!9(CJ)
M??1X(?4TE%;T?FNK_ @10L@;_&FS;AL*B[@\X88HNOOY^XG)SM@Z&IBTD(34
MA*L[ I&S&9YO-EZX<.]C2D6_Z"SLE54Y.C_Y)??(J3:N9'/E.3&-]1(V7Q0#
M#&&*,]C\GQEGV%V0FI2TNC=8D!=3;]#$73@95N<..T0M_QP;;G+H^]'#UP."
MKS9\>CJ7'\3,^D77$!& 4.W*.=&=T(\P #H9P<PP&B;==WBS/Y6 2T;RF;\$
M"M;:$(K%;J6W)Z$36BVOW[RVU>W1:U /STV-2QT+B%(<8THMT+/!5//?6"VU
MZB!(D WVZ"ZH_:'<&J$X%9[??^3N22F#;;0O.&BR(; (^:<_[W,B6S!I( RY
M#]5FC/!FZ"'.P3<XQ9BI /23<X2 )OE<%8;)H*T".R1L4=[JV$?<U#$=OCTX
MHYM8+OC.&)M7I13Y4QH);I'C1T[;TE[-J\<WY CIE=@8*OD8AJY+^G^'_,C=
M!47,QT$L.97HU7((9TV"J#QMZ$EU(B;+Q-XT^1%-W8:*Z^J@":>MZ@L#%_5,
MS56S9QU:I,4^Q9X].F1$_B3O;MNCA"@_ZFV8R=9>0C48,J4:.CB(N"_&8^0:
MX$35)@4TI"*"213#RP4_3&S(IA84PG?YT:0G9;4)WV'Z5]7]OD4:?SHOT,LA
M$6;2GX%MQCZ$*2N_!41F^ !XVAC>3(DZ9Y"I6*XCNQ#<-;-]_6&'=RGC[2?5
M>'M67HOT:Z;XWTY)7' ,5+)UP(J60<0E,YU(?+_ 6C^P1?5- 4,J2K)# :JO
MYXXZ95X=X EG[&'&TJ!_CS7K[UX%#D/26NQ?+RO)4XO2RH!5DL+.]V*MJ>D7
M)3[=_#Z+62;?AFSV?9[[JCS]K4<AV73241)9R*I%"+QDGF'E(:)*EX>@'5HM
MZF^\)Z:"HZLZG_15==P+EYE/#XFT$1UYGB 3#I5"?F4?^,$^C&K[AJ[%4;B*
MV]>"P,)L7@#5VK#5PWZS>7K8[TW4L2G9V>SQ5>['FB^)#Z%WV</^PA,-9%%U
M$!SLTK,+:C *XB;F (:KLY%XX?M0ZGDP%W(27-?0W9P1\OG6\C"\N1LJP@P(
MO^,OM3-?''K ]\\OQ#7YH!_7,@/2<[FN&^V<OLQQW$%4F_9&3 [WY UTW7PB
MC%-;Q32.FFCK-<52TT9IYSQ8;^U5KA<%G%646FEWM[YJ\'RL&TJU_EW\B6-@
M*[6&(OT(5")$_,=@LCF/X]B:8-0,!4*<X5W$40/FGTD5D@H% F!)2)$1-T_"
MH>NTS2K](B*%>ROS6R?ZS<\[E^Q R,^($(!!3:'?HW8V9'!*])#BH=%=T.44
MNZ&7GE%A89NG%\-_>7AXM.:83N%)Z7A^D_L:(I_VYO2MWI^1,A-A_NV(+7I7
MATXLTJ+9?;-E:"Y9=32!T\FC6L?UJJXL.THY52Q]?>0&:V!H\(X>F?4_LE1J
M,%M-"R=O_H12;^V"5MX0A3,]ROL/V# ,EQIPPJ4C8)%><G-YP>F/29]T"^7A
M R@IM=9?U&B4S/AB'HH:,9:X^K(N62.C?[Q]G2)V*&Y8DJ80'XF")\GTK)PD
MQ)F] BB[H'U*K&S(]=XIEQGR+JC3ME<#)>QM$4+.\K.C9E>^6<2"BYQ=LK4N
M['P=#0DU^MH26C]OG3TALG'W\"Y(B1-S)=#JP)7.<KBG#S!#^]YO.<2\+2%,
MI-PP/;[V!^^QGOP[E[!$D#U88.5EW/7>JU*#J^XQ.AY'3"\2KV%]AA!?F!D!
MW#08_1OM3SXYJ,5[UE1@=@R?(0\53$Y8</BA/=<8[+%JG;=UD_H3/&/2D>+N
M*(MX^69E1N[OWGNU93;O$^D5]Y)IX%'7C/#UND+\#%]%P9+&YW#'4>S,K::0
MX&')+%7?.[H'6C4A 6?_S 2N*\69M=2SWF+W3[$'^!A:YN3"V=FQ@4-C\O@%
M?#ZI9-A_6NR/S46E*[>EL\C3?W@*LJ1W6B]_%L,9<W1-1$DQG2M\$%=8.;B;
M/6'V%&<.N7"MSR G5U="!=):7$NL^/&E-^[=D3A+U[CIN.=MUD?K8>N]#6&>
M&Y?_KT8HC;Y5)!_S;-/G@B4P0:/C06ENC>K1 Z?]]LX=F7VYR('2[1E SB[(
M2IV,8M"$ =>OMB;](P7NSE:[H-M_L?2$.])C]!.'-A$E(=O<PT<PNKN@)&D:
MF)UMSR$Z6QPR7\*6@':@=HP@G,PRDXIJSZ>OBJ &RBO8!XIW0;U6K!=YJ(&;
M$"H_FAE?Q3!G7LX@2;=3SG70OK[:L6 8Y*4 [Q5$*A3;X[P81S%[64G(X[UE
M<.PZJ:@9T2=4VQ?NOX:]'5%R7">F2;B/I^H6M+8B3;\R1^DG_- "V:R"K&$G
MYB3V$_HQ3KU5+)0?1,QJ-/EE?X.HUV?K,%@GHQ][;,TVIM(]SS.*?%,OK.)@
M_(JY)!/=Y:-]7;NCQ<SWK)#>!SO\Q+K%NC>AOCI,NY!D9_!YO =<X^\EFN1U
MU%7PLLWWILOS-2[+@G+V=H1@4P^(;1!&#' GSL@A+E.E7LQF:=,?TG2T5F0+
MN!14\4=(L^J*_Z.][XQJ8FO#C:(BO1=ID28" B(@*B5@ 1$Q(DH5HG 4 2$B
M(B AHR"]"1Q!40F*2 >E]TA7$&G22PIR% B'!"2,I-WA6_>NN^YWOKODQ[?N
MNC_\,8M%5C+SS'[?_;S/,WO/WD]$LF:YF^X@J*_8D&P8^ CBV,P3D$M!AI.?
M$W1;ACJNKG2GYEW0L/7.Y3ORT15!7CO+O->,?- Z^EBFMK;@5.6HJHW,0-G]
M']V:GS@PTBDF%(N<-!J"!48S]_][ZY?BEF;V<F O;?[GH]6G@.<UW ]9(>;V
M/ YL[[UKV%!(1V+Q/C8.=+=^+-<\5 \Q3N1D/HPH#=>17]F7R-:FAG7T-BU5
MI[_53W%Z%G]!+9SG*__U&[R?!ESJ%7L>H_N-]JM4541-^*0_G8V]]!?0I,BU
M,[ENT<V.<6:1 ZO(2&P\1>H;ZZ/_2;V>7#:/DJ(8N/AHR;9+TFR\\GNNR1D*
MW?1(6S[M[K7O^%%4A=[VW3O"+KOXVQ0IZ%F9"&4M<V"0=HR840<>PBO7F6+H
M6;<&+Y(1*N:8=A[9AKL%+U*FTVA 9DDM:90;IR\'J-:E<ZO[__5F]"I_#./S
M=#-D>78&0W6O@0Y E'V-Z0,.,(XBM? )C4>)1@V]"AN[(SZZ2VWWJ=PA4B]]
MMF*[.:R39P>_PU]]2ZZ,79M;;4:$8 U!;OK'S:F]3&^:#%.=1NA(5&LS-6'A
M#*9/+6MI]S(CA<>E5%_0<Y3T=M4F5N,.G>[)WD"31Y<D.#"!S=5Y"FA2FV]@
M<,?Y52(C<8*FDI9DI"3HUOF3\@V,SI^*MW!1_RLQW7+H94V3?>K$85NCHN+F
M/\RRW8V7Z2K@4ZK":CN^HFQ)CZ&,L1LA4>]&4C\O.K-*3%6#TSJETN;U+$WC
MLBZ]*0D,T30W+:U/>[U4^3/]7<?A5;G;KQ#?@0=8;6PWKL:PS>0D1AG$D_IB
MW*13V'UA )$@%DNV_-@:'W_4W'(G4H/T0#ZF#/(%#P%1K!K0(L^!><%C452H
ML"5B?/(F,<;@I-$4M@\NS#0O.JG%5,M;%/VX<RK(S><VK5-MY=5>'O35RP_D
M22D(+].=F*.@*N-P,'<;O!QHZ7$14#Y'S8@D1I^D4D0+,N5-117%CLA5?_L\
M+YMQ^VMJT'GNK\E,$3'Z)?2D$9O'9W8Y'B_"@?GH)#K#VWV$Y,&TL_W-^YP@
MOR2N=X/FK*+EM\P]V=QSX+25=OG)$P570D76:IBRT8Q =C^.>AX%[O-+IL73
MG^.6V.H#C4B -(\YZ6LO.;JWVM'-J.;B-D.R!]^A^WNRKW=:E:5#O#6-&DLC
M]BU!TGQ'#0T7A3T(1G<EOUR$2S=:>Y0%AYJ!:47S=V5>E/JNG]"7S- M[;+7
M(-W]&7>+$:6[,4FU(V:THL:[2-?CJ=9$AS:67NN,&'4M;[S2E^]TC4B+KX*U
MG&#QIT^?/[=75.CI'K#:"]<"6OPY,-]E7G8GOERU^2ED'8/;VF@8RU$B]:\\
M,G[[_.W+"VYR Z]_5IF<V5YXTDXU/YCTB ,KRB)+M>U0JH6#2F64+@;O=(\_
MXQJDNZEV\"0.#*[?4Z+M*F-C1$YN'_E24NGU@IR2D+YK9,(Z-#M??$\&ZW+"
MQ:L1#M_U:]+Y[F3>7#\?FY<X813D7W_J\B[%>X\,M<,,A9Q!,6(?)8((C#>P
M^;Z1$3+L[F,2-=$8K5GT.-O&>E8MZL[IA\XW[XW2&VWG,Z+$6T\%^,N@'L%D
M(YMZ9N\D.7()L7E^%GEQ8%1'@BR[GU!9TX40#HX#=@4'D4M?4I>)?T>^#DY?
M/1=]XNU0]L./Q2ZL](L=K$\U?&H3+G=20JSE;N;O1LM'L/F\:*M$ E.$B[S>
MCI=<3%D$Y-F"3-LOI@*3/D'V'\X5%7<%RDG6%Z=X>#UR.7/MBKG3OBK,_5*S
M-3QX.*^E/OH]&O+"4I2,V=,V9;'-LM@A-Z7J8:U]TD%567Q'M71@QD_>).@I
M Z*EEA(_AVE\]#M@/ W!W@TP;+"3V#W]VNC*,!_Z&![,>3DY^1*])"3D3'AF
MI3W+7N'.FGOR@^=F[W->&(L'8H1X$'"#_AS#?G"#L1K9$N!ZAS,^%BL?7'&\
M&AP*+88\#,@T&RR[YF)CN11K7)QXRS/S:/:?^P]3&I3Y]NCB!DM,V3V7WD9<
M'"J]X!/ZQ-YQ7\*<J_3V8I.8O:/?+)ER#45"B9!F1(*7<#PO#%XXS"*3F(K9
MH""?_32K(" POR5H>U=20T[-]5G0W*3HAUJ+@@QR5[#.:2HF:-^UP3L-H09/
MHP_MSKDXA6T(,(-G3'"W,2!G$I$=B+Z_/(N0-GQ0@O?<2<,H\*/E%J+/V'@P
MCLNB*OGL_"$S673]YV'*5)#O=*\WT-*??@P?SH%=QS^$/&6S' A)LV9QFF >
M;;5M1NY+%9(';.; SH:6:"_PS1I4AD_\X7#!(S%"I.X,U>)<"#X&ZEFF\DR(
M@",*UY)W8,Y&V&<@H^D644M2IV@F[#3#S/KV,WH&#ZG=#H+CQR>1.\+-E)]!
M7TX&/(#[^(IU2@4U%.(E@9N-MI(O#9=T2"Z6OCYD[9JB$W/Z#I_?GP!"],TK
M9)BDH&V/=N\(W[;QC)PLRQ1FI3;O\9HG^][Z7G_ P2KO._WA%&$&Y7K&*75B
M1E5T:F;JJ&#K_A$K%Q]A04%=P!.8#*!?914:X,6"D<2:]K:@LF#MN;VTH,BU
M$E&&Q?"/ZX%347^UV4;Q/;ET7]4UAW?LB)H$K88I(42>91INKOF$_;"ATXY/
MFNAK0^[R8<O2HEYD@_BSR3:ZDV#<'Q6G!RV^E/CY#KR.EOS>:4*</E2T/Z@O
M&YREV[ 2\-=P$WF=N!IX%P<V(4OFCL>$ E3XY?C.6]Z#\P7R?1'%HNI^<^FC
MUF^KX(HK*2I'[E[GY9E<N7]OY 547&Q9$54V06WUI\JZ#DNZZ=#V]!NKD0N8
MFH4=I&FTW:J"KI=7B4G^4.DU+^44"8]:=TJ"E(H(ZA!4]2\WZGCE 2UV^"MX
MZ?&%C=:^ HSSL"_ZYJ1KO8^ZJ(F)\V')1,4'\M:&RQ)<+[I4:"@-[/1R&!D!
M*A+>$V+PO)4"7*2REA!3-? P.A+!?S,WPVY8\6V:K6<XI-TOUCZ-OWQ(ZG$)
MZ6S[I^Y1,9C_&H$I03]-8/.:0_G 5E=*@1Q3GO,>[MJA\R(_:68*T;,(\ !W
M*Y(/@G;AY>;*B+VYP>&R-G!24DX9F.,$52:="\^M\H$;8\[CYMZ*#S(=+SF#
M/;<*K\PHF^];"X0?PW"!'ZFR="7HMR3L!$3D S3WU5/4JK)PYNZ1<C#:J7G8
MTU!*\O8Y.KU V29 3^_I'XY*_&:$JN.EW*]G^@3*F/*GY$;U#MQ 7'EE_>$]
MOY#T.S6U,3'P$G)LU:P?C2?.$B:%VH,R#5Y/1$:WH;9;>H2IUE>.S&MG-;OG
MI/PI],X09G%7^QXOC(&D>[)* $_XI!2QHVR)AV' =!S"V!$9=?L2#9Y=2A7A
M?_3<6F[@<X&*8-.9TX7OA?W#><@_<*!Z#<6\&%QOY<"$M-B'I;6- [ C;KM&
M#. "WG<S=6+]++?+&]EGC1_0F4[F?8M4Q"0VE.O]U"%/VY&1$0AB*H%ZJ<2(
M&'IYXO($=D1!_52$3?=/F3L;44\5<BMUII%OG]T?(^XUB<0^!^.&V#QMC,O8
M5CP/^RC3@EH=0=:).L8' NT$@:MQI%'*O==GWGJ-T.>Y<DP^I-MZ:X5,*X><
M?<BLW#:/D '0\/$@HE1"&5N>:4:;R?,OFY>1'JGJE6W-$ARN8I0HGW,_/N-V
M*G=BRN"Y5A5-I47\H3L/[^F\63RX_QM%B]I'OS[(@=U$R[&_N(F^!;U*G?D2
MQ3J0^<OQMA?\RV?T=SG-\?,^2>&/Z[Z8O_?!ZC+4'-+!8N1UIG@;/9TZ2G$E
M-?&U9*D-:#7J7F4<QSC1E"][&\J\Z';\5"WI[)>YJM6HQ'?ID57(/N69[<]"
M$Z10#[""LB%0I?^(%!FW5OJ@-!28K"4=42DD<_K]@\DL;.6VC25J&IL7R>#'
MW 5[R< X@V2YI)B] $E?S^A=3>1$#8-,U:%*2G;(C)>'H[_LF7B-:"V^P^/;
M%31T^( 6:[P[3@KC3/W6(@M/T!M;9.O%?J6:C3+5"^?ONJF=@J7E$MR<.WP*
MMO.^9>B7^_'GWMZM]I4 'A"*]C45!EKP$X1X4T%0<*+;1RC:5&@HT.N'_&&1
MN\9'# 2,EJH+.P2_GQ4X>.?6P%((WW8^!U_:$-V.E8+W71Y?)F4LZ=)RV+P[
M:6I=IER0^XN[ T@Q];]4SC<:7D<YS"B]LPX:J@Q62PU*O[J[6B!-_9)ZD]0-
M[IE+-#6FY!#;*B@<04% 6N35SK :E"C0XHOXFA&LS&Y;AV_L/<\]BN,%H/]]
MV.\E@0U%3>Q;4W$.[*,V=91U_P ']N.X/>N7$[ P#_[CY$#4^#)3:I9]?IQQ
M'!A'0%1O>0K5*0'#<F! RQO"RI]]$\OL&<2/GR;0)PY$(::,+P>F?I95RH$M
MS7)@R+31Y;5?7GIS3J5H-/M<//D;JY(#&QS77"YD3D',$,*\"=I2D?0T,*<0
M8T_K38I&A^F_<[;&M/-<=COZKQW3-R=+EBER8%$@*PG_G5@IQ-C@P#:GL1#@
M[T99<I+070$H#BPV6\CM56,T6W:6#OGQG/!^Q#)D>&CZ0!L&VX7Z<<N9F\4"
MV/ONF[@X#-[I!<[4]U<529<6+_O.\#5X#=VV$2NPM^#.W_O(\F79!_2D!YO'
MG_:,CJ5=6X_%BH$.MC1DN-KCW/*ZH:L^\25'>=2Z:Q/- RK]_[I_\3Z/QKD)
MEO*O 9;5$).,/Q^1E=6H/9EW[NZWAV5>+IZ!A:D-%:O#>J0CRVW,9\FW#N8D
M^$FH3[?Z5\V&#2$MI:X%SN58DK7CB8 ,F.RD($==CUBS9IGCW,><O%:L==$V
M<;D52W$L0:@MW8$676-/(F+/&'L 7^D7S7H1E(==;S/=4[NW5Z[]BNOE;8\B
MS565$0=OZOEJ;-NH^%53-2_&&_M_#H[6S.+FB78,_F+_[*^ -.0=W(&+=LXF
MLM6]\)VM"EQ?GQ_-;(,GM!N?+6B^H7UI]YMJWP"KCWF%PYI_/UW\X@ IY?_S
MI,D@.AGJE$E\9AP8OFQS&A&I:YF[S-8-LL,"-(8\,-!R [Z^QH&!F0A2,\*C
M;..(%A>;C>? Q,RD\-[+8[-$[J4JZM^(AX3*Y.C $H^VV!#Y+YGG,F9M7"SC
MR(Y?K93U $]7,T\>E1L+Y9*\W_>8*1L0@H-:ZU&13%TT2?[0XH7TP1'"QR17
M2Z>ZQOIKWS+JLBPS+;XM5Z2ODQO[?ID_1S9E%_4L? Q.MP'GR.A)/=+HPZIE
M@> N-R\_YC5RTPDR(>9-O-W.^ J"95!^4^."H&-(?O>+=RA1J)3R M=U(@#9
M9CAV0+G339FV'+T&B+('W+0:ONC;P#OO58<'$H3Z5+1\;HW0K$5NH'H?G_IB
MKJ*L^_3@2\OO04S#+DH@U$%W9@.$40Z,?.,?20?S"XZGGV-E,AT81Q"42+)0
M.%:A%G3?D+N'8"JJ(2^]M=[?^M-?Q2?Q&6^1IO8>IQ/ATER742TX4$V'TDNU
M=J%V-KUV!FO:#X&2^^+?'P07NS*S&KBC1%ZM /WN35DG(]M/ME=<Z7Y785$J
M$O?B'\$<^$<083FS?:!:!B67ID-_TP\Y+:1T,*+=CFE-'8X?OV&J7 W&ETZ4
M)!9%B9K+%TL5W'Q7>W<FRWYT.GU7QN;030B[VQF^Y LP[GAAA6GB*/$J&R.&
MT7F:+O2S\CYW%:=3SYP-YJL8!^]8"(>X.6KLMG4 _BUM+/_1:EQ<G3BJ#6+<
MHP.0"R1,&!X?PC@0"5)@_8@F6M8;$&2&%-[@:D^QX.VBCU'\E*U>GW<\0.3Y
M4W>[N2L\ ;A:-A[:2:@XANTR) BJ#9GN*4W9]R=;C%H3LR8@R5/\VM[)]VN8
M*7F/JA47_DEI[U]2MQGQHAY;X"\!+13=A)6%03*.]3'4@@GOUTU5J3N'7TO6
M'!.*-S8'BO9<C<P)3LEKS'(:4SXAJ_T',=LDP E7S4U19!QDS^ @#B!=P Z[
M\0XW6I$"#ERP(3%0,@L;KKEM%HQ9O5-7 [?W5KV_MLIUI3#E@S1J"Z'S3$!<
M21ZW)!M2Z@PI5VEZI(<S&B#:X/EA_)C" 9I"3N%'<7^- Z:NP]/M&;KZ5\5S
M7K]\E%"P(S68 QMS8/-H,G8#+4?6!*Q1K,=LP8^YBS(E3\KK1@T2_9;M&I,^
MF-(\^6LN' T7:''L4NB?N]A,+K3T_#4)*(040OU(#KBB94D/ITDMJ>4Q-8=_
MN 9TWMZ#"<@%T9WU;Y[E@%D7K'3RYT=&>7Q#:BNDK)1U/[@FQ,T]P9UD00%$
MCP-L'A8U52<<58YKNTKJW:FRNB_.Y@QYQ2?VME50.MGRMK5>=?_Q\*7(/:__
M>X7G7MP*? NMOK:@^6$+.3R:O[6B^,#TWV:38-. 7U'RRE^&W\?7/ET[:TDO
MJ?LZA[X:ZEKCP_"8+;R586*IX]N ;^/ )N'/#-;[F&)";)L%#HS=V8!CB:!=
MT;^FJ+"@Z!E>#BS_^?$*9!G#Q\)VCGX9)U&%KTP?F>BZZP"=>KRVS'?I:*7W
M5#7AK[ZMM"T^T#1A;2&.W2UOT>EK2IIS_!:;<S<\*/;]%7.-[R>4 ]K4=RB8
M[VI\]LL8'>V+0%"M"6-M="SKI?$IQD7F/JIAW!T"/+CY4EJ'VUX<&1?S]Z2C
M1LNCRQT!^5;\"Z]AA=\O.<S!U#M0X.:6>3/0K=Y 3<B:L8J;E9F'ON2 CTF)
M!^<G=!(Q.K.N'N9?E"H/]'XUKK\V7??4-$CVCYG##3K3[H)Y6V#VV\#FF,IC
MX!UR296V;,EZ@U7#&(\()?QX(:+O514FUNF<E3G1G)G8='.YHZ3=G2[<I7IM
MNA%35H=USB.5@2IPIEA?JYL<F$LR$:.'5D=US9K,?>+ 1/;&.S8E>/,9M]I'
M*<IU'R#MT"AT^6FFD;_DVK4%5.;46;HPR$.=[9J1!Y_TD?%B/@K\Y;65U%.C
M21C?_$7/MOX^Z3AT.:O<ZW W[8'L9=.?W9)(/8]#61=&V3R6#+GQ8, !!- O
M@VM!G7;G'QNC,6SX9<S)X6_]@=;SI39?^@R>UQS(NIR6II*^6,UC931[Z[1)
MQA: !7!@-0BF&!<=4F;A2<$NEM2N)0^J,\$5$/C01VIRZ]P(Y6/MKY[N$>BH
MR'EHY*";ZJ%Z\7%W@0RP$T_,@I<C*#2&_@)0CFQ)C@HRE:>ZU7P[W"#YF&QS
MG'#^2^X3C1[CC82 DMGNA<)(YM*D^%Y%F&W0K_,+M[G6/R38W5';V!^E.+"W
M&0^Q<F!<%^EP+C_5%3RF$]NLJ!LBIE]F4'\&_6G 7-E&/54\Q>/VU_+,'\OC
ML_1@T(ZAB5$>--V)$1XTT#)JK=]9Z/R]_GHNV9IU?MSEE8;ECML$I'Z1J$9A
M\57Z?OA^B9Y?*K#^76I+<"AW":RG@#<\D:W >LT,@R?\P,F#'I:^:F=HE@_8
M2MX; H-CE27J-=??UL4<DPHR3GCQ5=0"]@,? 6PWE<!LH[)&HTTE0,<QRWR"
M ;TL+ @P6:(7W.W.'S7,R$"J=DQUV$KU9EJ&Y1<]W\^5O 7BXD5)(H@X>#D'
MUHF4!>/)W+%,W9(Q5/ 0,KRMZUVP9Z=,>@J:7'3CXFM;[_/C?3*N2PF5+L^E
M='5CGW3>=7B#I.:1$OO:=H%JB+9IB4:YC3T#SUJ[SL8SC.=G'-+HR(JE%29.
M\^L*K08MW7'K'Y?/^4<HM]F1N#>'X^E_@&JS6EQ=65+4F;K\!5.AP;DA8_X9
M35I4;G$7*51=7.61UP !J3&Q*]%>Z?N.*%7'^!!OX3LX>> :$(&JM"@B$<29
M9@-H(DWHH?8;7&N6!I5>%?#&N][:!IYQK"W01^FTTN.#Y<>MDLR*FER\9V5_
MF53'< _@%5VM0N-Y+14@G/CM8=13K[!"9,'"J(-4FNO,0OW#K_JC-1D.@JO3
M4Z?-IO5+_SZ>_UE\&WH62NUM['ZX8!4\$B'F/CS7OQ8:HK6FZ2O5/KIQMD;X
MHVPG39\NUJ;=:7G% 2MHWFFF'+^%P G:D3*8HCET1="0<6@1_JZF32=Z9O^@
MJ?3B2(9]9O+#O6 1V:+F\+IJ[R?=BH5=IY7__*CV).40]RK\EE&2.XV;*>I)
M%Z,Y4!Y[,7B#XTFX6&VVZ'B(#YI8AU4/3J:0CWQ-<GSIR>Y?=1-/W3^MZ*F;
MLU\C>_3JKY6#'&%S#&A' RL>X5T6/B,.BM$:2%DOB[VP7+76R3M\Q((K+AP;
MB3Z44FT=9ELJ0$1H>-XI%LI0,%\9\G-H(X J#A1%ZK?9OR,8%QR9.L-K0(RI
MW(#8V2&,"[E,9J&^:O%5]\K/BIZ@ &57FPQ>!?<YT2,#AS6VN?9M@:V"EY>@
MW-JQN5Z]"_8+OE*U:PE!"Z![6V%<"HX PI=OL!7Q0R5KK;J]<TW% UU';PI\
MS3_DL1ZY.&5LRY!A]REH@T^IJ^3/N20!BTE[T([O%)5-L*"YY>5Y31S3%_"[
MI,]PB:%\_238SUZ18@VLL)=[+FY!9.AT$*CGA,:%NN!5T]%+A#)0S(T#BRQ[
MX_5N?L1-\RT873K^A)+F+XF[7M-D??U^QNT!Z;BC[DZ.J3Y31?]-$?-?%EAD
MX 8BSA:C!+KF!V<=O8@ZC;\^"'D3B;9P\=G:\WRX:P:_9LU17";IW9.IZFHX
MG\/XQ>>7/4S=_"R&Z^K0LE7UP]YWB O]+^,CS_1_2W#V,ZPYY*KCZ;/6#Y9Z
MY=8^SLNR#[I[X.]OJK%?4T,S?<-*?IFZJ$]"W]]/-O1R8"O1'-A=A"L'%E.'
M_AG.@77C6)]6RL80Y"ZZ5)Q?LZ3WZ)&JX573%[74# W\H>3U?NP-[GL;G[<@
MH3!$;<G.6YZ";>IE<1NM;P@J=4=EXD?3IU:;7E#^KO1R.;&*5?Z\W[/N];O*
M[PPUE;H,0X.)00Z,WS?0[]GBERV)5A]*WXZUA17<!)JNPGK*@=UT219TQ0Z@
M!)^ATEH-Q::#K]]8"VU0K^PIP!1/FQL4O[/F7U ZGYH3=;9ZD*?780N)PJ_#
M [08XCWE^<C1T>R#8-]Y6E]R51_WE$%7A J801.Z.)K=KZ9Q<<JY)<2HO4;V
MW,X>S;,YKR.>D]FC.*J5SE@$?0QLR&;W$Z38<.\-H%U'P$QKLQ!J=CA,*)3(
M<=U5\HE7]_"T;7KK<N#E$\W][D+H+1"/3A*>F(R@GD/$$BKH+QGZS).L3/VE
MH+:)ZE?UZ;E L7=0AO/P2';!7,F/S,H*@Q\9VPZ%VS^I;O5@/"SQP?80-A\W
M0)7G&'BBF"D-\I'@PC?HIDH'.3"_15MP]I+K==I5_KTG\G-;ISKDS*=4_$_'
M/)N*W#E58_5K;'OP[Y*98AGT$Q#S8&Y(S8BP4DSA/@KB VN:'W5T])V,0TJ\
M[9$!2IUE1VJ:&S/U'Z?O;TFYJ,N[RV=J2S9%EKXYK1"-[0:JNY*,X33KV: H
M@^^-#D1)'%M$1R+8NO->>F2!U[PIP4"4W!J,\[GI]CHEHC*Q%V<!:E*Y28:4
M-5)/,C]3C5KP+FF#,KU0LYX9V;'&+KA]Z?R4F]NTE6K'UTF)_RTM4K>0);NQ
MVNP67$5T9S+<FR#&M'RY.&%?1S:1T5+NJ)D1IB7EOC*,N0/6A-P=)7<&1PYF
M!YT*^A23>DSSX76[[UD*()+:U@KP^S;S!J-)?R=>(S),I+TD9Z1JACQ<=E-V
M8!W&3TJ/SX4 ZF>OA)M+O-^"_$*WXD U%*6 BNXPE:&A(HWAQ:XU#[+3X=$;
MZ!B,:_Y"NH)8TDG=VB%?OV^IFB?FTD3+]]\@LP;%D[^6W=H2@0JZ06+[*D/"
MB?TEF>$]&:S9L4BS<-GFH0,5=)(O^.0S_<HVNOV)_)\60H^1J78]'[C]0DH0
MD\ILG@8&G$V@W[//8#AC$*/&=AXO%W079,X]%6J7#["IK&Y,=!6=N_*N*4KG
MJ+V5^)F+M8+O%6R\?WW/.Y$3UFR>)8;*OW;7_((J7U_2I3:C9, S$_[^[EE*
MM)VLF9<^MPQ]:Y//I]]M<#(+<F7[G=$]\:>JC]B_<M6)W89ZN]Z&$&&J@]S4
M,S,"1IWV@ <MK+,),"T(+'$)00O7U&;.3V=NDTO=_U!$6A \[Q0[C_]UPG;<
M1! ?P*EG&N#ASM&451T**2B$9#WYM;[Z[9=&=/'ECZ\?U[H\4,#IU_CNP\F>
MSJZ?K,3Z<3_%<RFD;;[J!##$,5=H.FUXJ6 "*:D<W2R&>$J=_Y$<<^SOIPK1
M.CWU-UY5-,7I:5)<5^HK/GZFWWS^ [$%\?F,!@6PBR'+'L3),M48%DQ/\&0@
ML"=8YZROGL7(KJ8POVMO/0_)&E5&W;%>O$WY=+7623CCEKG@^YKW4 5'CNN1
M\$L29/Q$5PM6@G8)UPZ7&\_-BS<^B54#H^R_O#S]T%8EQ0K;3U;9YMXJI,G5
M,V%6@MQ"*?W,PB&(S_'O.#!*4^#L)"Z"(&"P7XR<R)I>;Y<U 3KK.VM\REQ=
M/9?TIEP6' +:5[IY',)>/K6Z<.:YPS,VY#ZI)Q#@/@0EEI:+-6;RLU[@*]8:
MK'_J5+KX0,Z40'"\,7HNURW4R#IV1EJU35B%KVY;J[B<0_&O$XQ;;18)JDI1
MY&G<]#=?\#<!"8S(*M._U-D<379R'UTF#:U]B;RDQ,#BY!:]PJILS<3:%^X6
M['U\X6BO+'MW&J3%!JC07<V3A<:-+%FX,E_C;>02NZ49I?X#C2&E+EH,GD_S
M_*EM]U*K&F^GSJ,;/EI<O_+LQ9,-8 MB+]"4FY6%%0&YB FHBJ3'I*=K\)T=
MKZH?W4&(>Z_?&^RYXKYB4USN+=JK,B#-MDGZ=)B6X- '+U]F"N/8/&$,.0P:
M.<%'-*20]3DPX0G7GL!7 B?:@];IF?HKZ@Z9@Q-_><;MX4U]99,[<$XX7\6A
M[%?/>_JYRQS:<507Y$_5&<B?OF5UL6,DEO'_&+]( XC%J$I4BU B3@BCF@OU
MO+0\GPS)8Y]6ICO<*6=/N\-T/\AYQL$8720D,W59 !C;WL>!G51%CW"WXJ!S
MRT#GWHECQYPA_(?],_]M/ZQ'B'^\-5_$,/D/"S!F"Q&6_[F.&7/;/Q<\^^5%
MMS?[CG!@Q#_QY88Q!L^:0FT'JH;\PP)5V^<,:F -[ZZ_[^)2&1V\>)[[$T#]
MO@PUX?U,#HPMA-J<YQ=MN=G$.Z"(4^]!G(HZ9VL&UX72- </\<UV*)M!D\UW
MP.3EH0[4+P8U9PO4L2/#CIZ"8;HX,,&DS0SA@8)!A#I6:S)X)V@SB<QL  Z,
MNXPM\6-.?-LJG'G,:),6LO=!U!4!78D701H@0"':9@"EE0(>=!CZ\S>VW]A^
M8_N-[3>VW]A^8_N-;1.;Q!T;I;ZV#8,W$7F:?*&RCDM$P7%%D>.ER(#[&L/_
M:X6N__O!_0%.127_/.&YQ,.!_<%&L^0E .E+K*S--Q7^;?VQ\]S+Z_]I?A 6
M!GWYW^<2_?+"OX_?0?C_ZO@O! %0PU.M\> !G38TJ$Q@B@O1X\ 4FC+Q[[I9
M:6./4M1\]<B$//.@24-'$5+][J$$8?/.G=APH!V-*.]C2:^W"S'W%P.M]Q'H
M_+)V.)CXC>[$@>4H@)!%BY1(WEQK0:21W8/XX4$01E!?0;:<%\9J?H47!LB&
MN'%/=D(HF9LM;H\@63(M5AD'.+"!9 QD EOCNIC[N>@;<4QS#BQF!KB&V]!=
MCH&#MH[0:>$TV3Y*!0=F84+C@LZG":=F"TTN:-*XV<HAK'3@>U?S7H!TRH,M
M_AOD;Y"_0?X&^1OD;Y"_0?X&^1OD;Y"_0?X_!HGGP/XY;K)NS>8]RH%Q>V'[
MX-7?*$8T33J26D-)F;41.D\;C2+85 Y7"=P>/.WK^D(VM%"@'=/$78*5[.?F
MC/\/4$L#!!0    ( )**7%1;8Q(X2.$!  W6$P 5    86UE:"TR,#(Q,3(S
M,5]L86(N>&ULW+UYD]RZM2?X?W\*C#WQXGHBX<L%) &[W^NH6Y)L34LJM23;
MW7%C(@.KQ+Y9F?7(3"W^] -PR3V9 !-DT?TBWG6IBB3.^8'\X1S@+/_UOWU_
M7("OLBCSU?+??Q?^,?@=D$N^$OGR\[__[F^?7D'\N__V'__EO_S7_PO"__G+
MAS?@Q8IO'N5R#>X+2==2@&_Y^@OXAY#E;T 5JT?PCU7Q6_Z50O@?U4WWJZ<?
M1?[YRQI$010=_[7X4Y)2DJ9Q J,XHA 1HB -8@'#1 0XB;-$L'CV^4\Q3V1(
M0PI5Q"5$6<0AXTD$(XR92!A&-(ZJAR[RY6]_,O]AM)1 *[<LJW_^^^^^K-=/
M?_KYYV_?OOWQ.RL6?UP5GW^.@B#^N;WZ=\WEWT^N_Q975X>$D)^KOVXO+?-S
M%^K'AC__S[=O/O(O\I'"?%FNZ9*; <K\3V7URS<K3M<5YE?E A>O,/^"[670
M_ J&$8S#/WXOQ>_^X[\ 4,-1K!;R@U3 _._?/KR^."3YV5SQ\U)^-C/[7A;Y
M2GQ<TV+]AC*YT-)73UO_>)+__KLR?WQ:R/9W7PJISC]V410'3S52$B-EF!HI
M?W]IL)]O$-^3O.M363T(5ZG[SI>,79B^\R;N)\T/<GB!]X:Y6>3ZA7JY%&.]
MN]NA;A9]>(E]O1:K-5V,\%KLAMD3>6%^\4;_U QC'M1!IM4X#77OB2J_K^52
MR)HM#QX-<O'OO],_S3<E_$SIT_SCYDEK9=8^NKBGY9=7B]6WUTNU*AXK(K]C
MY;J@?#T/HXBF&.DE3&0A1%$40IH&$0SB-,,")2*)V'R]?=7G<@G_]K&5JAJZ
MU[B_<\!A?>%[+F2YVA1\MQ(^+LXM;WIE,VLA_GE)'V7Y1)L;M/#&:*CU^8]]
ML8'(2[Y8E1L] %@IP+4:0&D]0+Y3Y+_^O$/ WVPLG@OCQ8CP&I&!D1GL"0U^
M;<7^_RY"N^(' BZ,4;(JCH%:\;Y [;[]4NM8H:1HR2HUFT=JR*+P9[E8E^UO
MH/D-#,+&D/F]Z]@_G[P]=T6K)RWXE<EKKOB9K[3%]K2&!_-H+-R; %FO;GKQ
MZFG2(OX.K HA"VVQGU'WY&-YMUK+\DXO4"NZ+#](+K4)SA92&PCOM):;HM#C
MSY,$<\QD!#,1$XB"+(54A)K!4LZYS 1!7+CPELV@4R.M2E90;(5UXR0KF.T(
MR3=X [/1JWRI'1SM,X*=K#- E9XS<+?0[[1Q?X!^K8W;*/(U>+,JRQG8Z>*/
MH5R0\TI/5@./RDTN4!P3D].];JQ4%NOY._TR/:BW]'^OBOM-N5X]RN+%ZI'F
MRSEC$0N)3&"F$(((1Q'$*A*0H% I$<@LE=2&ACI'F1KOM-*!7VOY+J_8#DAV
M,XTW? :F%GMHK*G"2O4N;M /V.,%_:]C3N@>8102L%*R_>KM+NYG?+R1:_T)
M/:B:^=_*1R:+>8R4BD7"((E(!E&,$TAI*" .0Y$D02IE*%V,C7.#3.TCKV4T
M_D\MI9MQ<19&.V/B5G &_L*/<0&_UB)Z=%NZ$/!J!)P=:-1%OTO5XT6^\]I^
M7_O'+[20O]!2BOO5XY-<EK4?4Q1ZQBL_YY<?NTO>TQ_F5W??:"%>_N<F7_]X
MO=0.3W7 4#ZLO\CBTQ>Z?'@RCRC_+LNU%*^7]7;;G&8QPJ'$, EIHIT4PB".
MD8!<,HG#!!,N\?QD8_'Z3L!(\EM]?W:[L#Z_Q5I(\%.^!*51L_R#X[;,6--O
MN:\SI=D<:6/(Z /-@9  ^TJ#/:T!^P'VKVLT!Y7J,U K#_:T!Y7Z8*WU!PT
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M:L0AT[R591@RPL-$B5@;3;';)I_ER-/;ZOME512K;_GR<PFT [70LD)-:(]
M:&E=BT/9@6]',0, .C#?M!+7[81;F8V_6B>-O-EB^Z(+VQYUHYR0\EP_RF[L
MD>M(.0%R6D_*[?:1<Q/?;<RY4^.PEG=?:;XP#NBK55%E2LPC% 1AI#U"[0<J
MB,(X@Y3'!(HL3%+3#2]A3G4.AA)T:B96+:[Y7*M<04!;@:M=^\]52,GX[26N
MS;;EAN $YG#H_<';T_UV;T!3YN_NX!6H-)Y XI[EG$PC%>^:L/\:R766D'M+
ME[,=KV>O!UI^,?]OG/BO="&K9 KM2N8F;\+\X6XI#G^Q=V6=5_%ZR0L3>?Q"
MUO^K_[W8F'"JE]_Y%Z/=![J6+Y62?#T/:$Q%JK#VU=-4&]M1##$E"609EYC+
MF,;:V%YO>V5?;WXPJOA.R]2%ON*>(X% WH@/?A*- G\PW6Q,=^I9W:-:[C2>
M5?T6BBT@U06.K2O&?6'LUK3IO@8#KW3WU317K;-?[D_S3MGZCV;:CW]W<$,-
M GB]?9M:'/Y0!9754( 6"V#  #4:'EMT/,LL^NWU,:X*XS8->9;I.>D^\CQ2
MC.S8;?/;[[33^5BGQ;>IC7]?+?1C3($R(^<\"A23L1208A5 % BDO3V40BF#
ME,8B%%%"1ZHH8R_U]/:^MMF]7[>"CN36.<SUP![>,/,W?6=O5XL%[&F^E_&]
M4[Y:^2;@^+E/U31\0 >Y_S7<0?>)\.89]ABZ9S>NO:W.MW3=%&7[()]J8<H'
M];[0?DC^1!>OE_]+TN+3M]4\THM20I(,QIGIO<%P!G&4$IA&*1<RP2&7F5.;
MKAY"3&U?47]-L6.WKC[0VRT30P,Z,.]71RB?VB.4&6A4^#$#1E:@A?78XNL&
MJ/SV_NHCR+A-P6Z ZJ1;V"W/ZI/ZOGI\E(6)IV@RQZA089BD <PH"2$2 8$D
M"SA$4< D8CQ(PM2ZYM/QTZ=&3COY7!*7CR'KYIZ;@1AZ/V4K6I_J]2=@N&1C
MWP#*F!7LC^7TE1A]0?WN!.?CFT9,5+X@[V'"\:6+^D;#U;V-/M'O>\6R_[):
MB6_Y8G&W%*_U*[#\G+.%L0CENCS^]SR.%<<D2R")N$EHHRG$,HQAF&$12)(P
M1.A\*3^;E+I/+K%S-PIF];*3^F4_$6^X%_Z._^<F+ZKV\*V\@%8"N\;8W3IQ
M=A;=./,P5L1>TVW-](7>T\9L1V\GXZY[,GI$[7D"T'-PWZU2C1P#Z G$TU!!
M7P_NQ[^G^\9WG!<;:3:45X]2BR5+[9]7R5F,9#'.A( I#E*( A5!G%+-M$%*
ML)141)EC5*'#Z-/;7:UE!&LC)'BJI73C4!?P[=AR($ 'YL4S)W3FO+<!N!(:
MO+\"L#,O]H#**P.ZC#\JU_4 YIC5^CQBY-.HAW9OT1BSI=2\6A^D?3(Q#IID
MM1->YKRN4$]"3EF6(HA9*+2CG"B((R(@BP(BM9V)>&25A#:FT%/SQ!O1@6QD
MMZSI.^H\XYCS3,D$8FZJFRH602)C!@.<<)ZHD(A(C73L.-!,C[,R_BO,]<#'
MC@/-W_3/'1]V!XV-ZF8IKY6O_)Q:\\FTB>@Q4=,X=701_%_CV+''5'@[=^PS
M=L_H5%FL<Y7K%UJ6#^J%?%J5^;K96TU0$$4(*1C03$$D::!M#*X=KC 4- T8
M3G#@8FATC#4U^V!?5!.BW@CK&,C9@:T=X7M";.@M_?-@>:R2YX"'WV##CO'&
MC0R\KOA)&)_%+7U:NGS^7%3[PWE+0U^K  E65@4\YR1-M:F*$JBXC$P%O= $
MRU$8\"",TPS1$-LWH;XRV-188RONL651I3(]YHN%877+9"8KM"W. CUB.#"/
M7(;OUU9:7Q4W+4'I;OIQY1DCMOFPT^:PL8?E/3WCF6192OFFWG4I>9%7!LV;
M?"E?K^5C.<=1E$8DXA '&8.("PRUC4$@5R2(%,TPIJ%3Z%+W>%,CBEK<6=M6
M8D]D\*L1&E12.]8]NX:YG<GA$<F!Z>)6$-UCE.R@\1N.=&7,<2./[  X"3*R
MO*WGGNN&E?(_-Z9,SE?]GT_Z*2]6IJSX/ TQE8IB&&1Q"E&4*L@453"2/,(\
MHV$4.,5'7AQI:O2R$Q14D@(C*OBU%M:UFN)%>"WWK'R -O1&4S^\W+>%KF'A
M=R_GXFCC;L!<4_IDU^3J#?T3<?^VU*;.II#B[M&T-9MG+"%AE'#(9$PADC&&
MF 8!Q"%!)*9AK+G":8OC=(RID4,M%1"-DT[;1GSRNZG#(05X]>+U/6A4 (O\
MT7G;XPS.EML=MZ$W]#9'E0FZE0_4 OI-SKR@O?<,RN-Q1D]SO*#HN5S$2Y?V
M"3]^\?&^V8##.(QP@!24A.@O/XDCB*70QD'"PR05)):QL \\WCYW:E^[D<PE
MOG8'D,760C^UA_Y,M5"]0HMWJKL$%?>"8*PF3590.(81GRC<'4"\NWS$T.$3
M&0^#AD__W,^BT(14K/-_5K/XH$Y"2C/!4)($#*89"B"*)8<TU69&@@*11@P1
M$CE5C>\>;FK,LR]MU;MZ63H&I%V!U\ZF\ ?:T+N?^WBMU)!!N':8>#4ZK@PY
MJOUAI_ZQ*6)Y5T\F:>+@7^7+?"W?Y%_E2:CM4>NTOY52;19O<B7G+"8RE9C"
MC&"D>29-(<98P$0HH2A5F7(KU'N+,%-CH6T#0MHT(-Q4HFJ_1KFRT2U39,E5
M(P$_-).U21VU'G!A%#GELS/ME&MUP)NNR7%G.P^H^N7"6P0:ERD]0'?"HSZ>
MV</W.XT";OK,[64ZS&6<X10IJ@TUP2%"2D***#4USS-%,$NPX@ZM(6W&=/EP
MQPF8;-L>+G9".OA15CA;.)>^L1N8],YE#;Q>;EM(OAD.2P=OU3>F(_FQG[[(
MLU7XQ*8P-=/6^L^%?#+FF?[74UUG+5]6OZ?;F ):[WMJR_KQ]/W^HR?OV 7@
M3K_9ZD'C>=0N>AWXVDXW]F#U3_)13SPM?M0],NY7Y;KMHK&K)OV^:/+:Z@J?
M\TC()#&1C)+*!"*9A)"D5"_5<<3C-!%!*JVZ?/:68&I6LA':?!FR$AOD>]74
MGUK)FU+,#NS5:VXL5H:A$1]XI=B*#VJ99Z"%O_[W03'[K1I-E>2AX7=83(:>
MAK$6ET&FPVW9N 7*SF6DUX/'6U9NT?M@F;GI03V6G;?Y<F5*(6G/19IBOW5C
ME>/V/A(Q@GE 8!ARO<Y0S+4WP2(8!%FJ*%%(<?M86*LAI[:PO-,OP6JYUN,M
MC&W6RNY"8W906RP;W@$<>)UHY=VBUJ>M4E\\'=8![[B.1/R7\/7E"SCATLGB
M=D\:C[:=-#O@:;<[^^VE/V@/D!I7L(HX/-I+>I&75;R+J=GX7NHW:;F><R1(
MJ%  :2R)INE808+C *8Q#QB1),VD4P\75P&F1MI;^<'"*.!8BL<9?KN]\2%!
M'9C(=W@VH<HG^]ZM_%7MVZI4O%'!WQ9X7_"\;GL["S'J5G=?B(ZWMWL_I^?!
MX7*=BWRQ,>W]/DK>%'!\^=W46Y?"--4RJ:>;=7-L^9(62]-]3@]>&<%->%Z"
M$$UI&, X8%@S8)"8*HPA5"J5,2$L2"/D=(+H0ZJIT>*^4J#<:M6_396?N;,\
M6AQ[1H8^8]R?C)U"H-6H;@NXIU/ET#=:&8*M'?B9]RA.KT#[/7;T(MFXYX\^
MP3PYB/3Z\)XQZ<8YIGS]CWS]Y7Y3KE>/LFAWQG]\D%_E<B,_2+[ZO,S_*<6<
M81S$49K 3&!3^D=HFS6*&:0HYC@,4"*1U89"O^&G1LB-@*#82N@8J.X&OAW1
M#@?IP(S:"@Z^:<E!*_IL>W+YP_0\J@'_<!UP]^CW7KCY#8QW$V'<F/E>\)R$
MT_=[2O_$/$VPM/CQD9K>]A_7VK<W+>OG<8)8FA#M:V?<%!91"E*%8QB%)! L
MS)(HPJZ)>6='FAIC&?&JCI=&0/"K$;%'.MYY4.WHR0M4 S.1$TJ]DO Z$?">
MA'=^M-&3\#J5/I>$UWV#EVS=TK*2Q;7;I_3V'B63EEZK5]@",60F:3ENB0M;
ME:_DD9Y>WZ?ZS9+GBX7Y*F3Q->>R75#;BEE!RBB1# K$0HA4'$.6$@93G(H4
M8Y)D=F4M+,::VM*VE18TXH)67I=R-]WP6ASR^0-M\ V,2WCYSMBR@Z2[U$WW
M(T:L=&.ERV&A&[M;;FX848<NOY/KN=*?/(\0AXHG6'OIIB\7D1B&##%.J9 B
M<&K!?&X0I\]_I$;)HHV-6=/OMW9QV*%I9QC<BM' 7_M!KX4V_<%@ILU<4^*J
MJ6NZ6*R^F5B50?HMG. R5 N%W4#/U17A1-6.1@>GU_:C@E\V9;Z497F_>F3Y
MLJ[TN135TZN4AS*O?N5F[[H]=$(O?"LXV).\ZI%=R0[VA!_$/.Z'F]</PE&$
M43^5?O <?T0]G]*_>HM^^K7&U,?MJ*O(DCE-PBC, @HYXP%$28 A(4A 23#'
MG.$@HX%;*?5;Q''Y3,?)^#EJ7.]>[Z7WS%ANJH^$]M!;[%J^B@2K'_8D-5OK
M!S-PX:H> 8"]RM#<BK7W>C6]!1J]L,VMT)VK@'/S,V^S:/;)O-J^CP,9FY+@
M/*+8E/A5$(<T@BBD+&8TS3")7+;O+XPSM1V.K4ES:+RX[^%?PM7-)+P!K;%L
M/P>@>EMX%V 8Q)0['NM9;+8+"E\RSBY=WM\*>Z6=U+]*\3E??F[K)=% X$!$
M,)725-&3RH329IH5E.0\) JG5K6T.D>9&AU4J[.1$C1BNEM-ITC:FT,WX3.&
MG;,/S1"M +HP\&Y_G(XTNF%Q4=ES%L/EBWL<>KS2SIT6\X/D4ML7;"'?KD3=
M6<"4L]\=L[R0BFX6ZS:VWP2YSN. ",(B >.,:,]+* P9TK9"E(::-#B2H;**
M++U5D*FQQS;GI#"YZ4VRNJR*SZZ4V4DU"CB<G-PR1Q;'*B,A/S O-5J G1HS
M<*#(#.R=WC:ZS';Y04:=D>;$(?]JI+D9*2MKT#ER.SCS &SGJ=HMSQ_OR,T#
M"@?G<3Z>U[N[<-WN\VZS_E*EH;W3$E6N%Q9A)G%,H,*$0\3CP-3]"6&HB.24
M<)IQIWX4EX>:WD+4MK4%6UEGP$C;R[?MP-C.MO6#W, +27_0^C0&OH*'[S[
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M4Y%V_[I&]3H5;[8K>+15'U3Z5S4V08/ #&PQT#]6*'@TQ<>>.+]6_FC2C^M
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M5-7NW+.]ZT=,/3N5\C#S[,S??;81G:,P"^-06[J2I,96TA\6SC"%B/,L#.*
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M!0^8^76OSB'[HTR->YKN%]565],'UXC9LU7( 9YV+',S2@.3RJX]B 9H)^$
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MF#"$(3)?/Q8L@YA*C),P)@P1-_?JRHC3\[$:@>N&DP<B]^P[>0US.XKPB./
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MY7Q_/VZZX]P\Q1#A:I'S7);;4+4 (TD53:"@6$(49A$DB@B(&6:1$"A.8Z<
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M,0C"/X,P"&9!_?_M:3'=K+^LBOR?4LP0FJ5Q,,-9;)@'1;,(D5D89V?*$,V
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MBJ@X@FEA1/)(&D&B1 JC7#&99S'BV"EU_[B)J9'E[>/R>5%7<33G&=W(\02
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M$CPMEW.@>\GD2U6;ZGFU(]V:O$, YM=7%F'OX/@/3'H;^T'G &@]N %;'VZ
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MHZQ1?^NTN9@L$BI$#$5$$CTG,J49<OVI*Y**-%9)' M'09_^!J?VS>]FZ+Z
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MYUKWMI_]G,/5W5:_8$<,Y:O>_KM9B'8/ "<RE#CF$)- K92HEA8@",.<A$%
M<\$%$69[9X8]3F__K+5Y3_4(U&8#9;?%'5\#P/M9P .(GDGA''I#W_@U!Z?W
MUJ]!,^/=_#7W:>?VK\5C;BNC.J7C1K;]W"SKS.\F),"<,1'&D 1JW8,R2B .
M!8)8XA!Q&8@46:V 3O8TN=B@SG)1(7;WO2^7S1T(JQCA/,!FRYA!8/,=-;@B
M9KTL.8O&H,N/T[V-NLPXZ_3^<N+\ XYD42ZJ0GV\WJ)9Z\F7RS=B(63!"C+O
M%.1OZ(H4B_H?Z[MV>FNX6-RWFSID7E\KF4F68Y2''*9$'^UE(8%YE'(8IV&
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M2D5,@BR74*(D54OP5 MVJA>3"ZTE'TOU3W;YOSV=3>T-7=NJ<S.TM: VU[F
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M25F0QCPGH=FRR;>ITUM<;>RS4'?T/J+]3#2E4?+,:;4+H/8!;/NYO04%WKR
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MC5("PRSF$&4AASB2#&:$YKEDL60)LA6QL3-A>BL@O06[6,VU3EWYI).<-OZ
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MC!X;1'WK3K52*[M)DK&8QP)F2,V_*$$IQ"P24%%OB%,N QQ9594YT<_4:/=
M9TH;:B60=PY8PXV#R^'RO6G@@M2EHES[./B4Y5KW]9K"7/L.GY'F.OBX&RFL
MH[Y:[D#+V,R8BKJB- P4 81J79^$B@H"F<,X(1QG648S::7'=]C%U*A@L^9J
M!$VT%I<=!1R!T>SMOPP<SR_^!I=6L>1M'S#6;_QIWP=]V8]T,^I[?MK-_5>\
MYY,.*Z\OS_K>TXVL17:K?Y9S3@G[\U8L=<%(<B]F:49BBEBB)OX,0T3R$.99
M(B$/XT1$@>"2&;WH1KU-[9UO[-7[X%5M,7AH309/:YLMU@IGP398;PT)H6=F
M:-&[D8V6> 4Z:Z_ K1?X+!9:0\(X7K*&:J[9/'P06]_ H]_/YV7U3%08MBKK
M3S^*Y;T:"W*_%+6X\<\#K<U,<>Q=F9UM9+QUF:D_.ZLRXX?<PB\M"/JLZ$XO
M_IX>UXJKLXS06"*DJ%G*!**4II#$DD#)DABS/ ORQ$B2_$P_4R/ESDQ0E7*E
MEKR6,ARGT#0+Q0; R#/KKN%9F^A!'/D,#(.&9J?Z&C4^.^/P?I!V[N-N1/"U
M$?Z])<O5R]V2+"I]QE<NJG=%Q>:EUJW?)"0$(L6!" (5MX4<(I%GD-" Z_4:
M#_,@YQF.[ 1 +7JW>1W&NDW2:";7UH-M\^W8PV8(S!C%$ZR>6>8TGF!C./C#
M2[J( V*#$I)-_Z.2E ,P^\3ETH3#LG.SB"VKZBU9+E]DLWU=?2E7WY[I_Q%L
M=5>^_^NI6#;!?!KA/-,YJG&D*[QQAA23Q0F,:9:C'".9$*,\$J?>IQ8!Z72!
M3:*'&I9*R\-OO+@"BW(%JL:1IOIYYXK%<LMZC Q6KSZ1'V^?2P/^=A=P7<6S
MM1_<E>#]*(!;K'=] C_2^G?H ;!;Z+H"V+OPM6YTO(6PJ[\["V/G1NPO.KS_
M2[#G5?%=W$A9,+'LZ@;%L9HFA)K&8RDA8FD&,=9K9)*E$0LE":21 M/I+J8V
M.:RM-(QL>\ 3(2.1 A &J=[[Q43 /,@H#"(D$AH)&>' ; TQ#'SC+!76=FY?
M*J^T@A,@]7?W8ES[)\IAL/(\&VY :BT<<)/A/  7WQDYT?QH%T;ZW=N^+7+F
MDRY'/MMI?NJG^;/6M+UM:F!LBY+=E;N29)U8UO6"WXG'IW))EB]-0LHLQ$0F
MF:)9$G,&$<48$I&$,,R#&&4J1B>AQ2G1\ 9.C:2_K#.Y;<X_/ R<R8G3ZPZ'
M[T.J_=3K*[#V$;1.[DKUW9V4ZJOOS:Y=;77^7GF ;<[$7G>@1UI&O-Z 6YZL
M^1N-_L,X#_V.>'[G#[7=(S^/_;@=#KP34N@:@(U9=^0OM:P2BTJ\$0LAB]4L
M2T4>TTQ-T1$E6HLVAYBJ&3L/:1RE,L<LBFR*QISISVK&':%J3&?N^@(5^4MO
MBVF+P4^TL?D?=F<!YQ WV_\?$$?/4^4:PI8^E:W@?0?AFW,06F_S&P(SZ-;^
MN3Y'W<XW!&!_"]_T,3>:N5V63 A>?5#F_DYTG?955W2]FL5!SB7G"*:"ZDH#
M+(5$,0T4ZL<<\90R:E7SKJ^SJ87TG:U #Z2BEL;,.C>GWCLH6QU+K0+TH_'%
M\NRQ%WHSLAD*4,],LXME:RA86SH<QYC@,2C!]'8X*KN8N+Y/+4;/.&Q)-#(W
MUUUR6KM-AK*49 Q1*",90R04FU#&(ACSE'">4\ES9KRI<+2+J7%(8R186VFQ
M=CP.H<'R_F)@/'/!/B8N54>.@V.Q-+X8I)$6M_9@V2U*>W'H758>?W*\A6&O
MY3M+N_Y/ND5-_Q3\7BW^WHFJN%_4WX%6.XJB3,:42[4@RT/U!\H@27()11Q$
M)(QS(F,CCCO7T=28KK43;!EJJ<EU%EJSB&@(P#PSH!-6UJ'0.2 &#8-.=C9J
M"'3.Y?WPY^SG'85W=.'/:_:OYZ(JZNTC?2]49"1.4L%@0'$&D4P1Q+HT)0D1
M"A,9X"2Q*MYYK).ID4)M(]@RTNFF[5$XS<C@4I \$X$U/O9Z+ST #*O7<JRC
M<?56>EP]T$OI^ZS+>H=4#W-15=WBZ4;6%:+:"@6S6"(=/V$8"DP@PE3H;90<
MXE @3&1.,QQ:U 7H[VUZ"1B=O3N;*'9;)B8HFZR-!D/.]R*I@ZRSM+YU5^\[
MM<8.AYO-LFDP_,9:/[GC:+F0,D*F?T75W\2(2RLC7W;76&:/N,53[Z446IY*
MK'? OY*5V-7-OUY]$*I%,O^FOE+/:J!>=CX\$R&/LBS(8)CIO:>Z;'H<2Y@P
M$H8BR' 4&ZDC#VC3U**UUEC RJ4^QEPU9VKZ![MX;8CAPI@E+$4YS$5=:!,'
MD,0J\"",!6D2$APFJ=UMIY$';)R959_8U6J1E0X>R0K\^O.WGX%L![+JO*@'
MT?)P8HA1- O21QX9SS/WVIOM4U5M(]CUZ$H/5_?*K;W:?VA]LWZX)<& < ^Z
M@AC"KE$7' ,"N;\^&;)IQSF7+!?%XKY27[_Z%OQM.2_8R^8N9);*/,62P8"D
M B*4I) &2:R+#T1!$L4HHL*2H/M[G![YOB%5P>KCWW?%_%DGE7<NZ)>VT<BP
MY-PSH!ORZ7! ^N;* [P4W]76@C_:_WJY<&J(T+#T=J;/<:G+#( #6C)\S(UR
M[I:$BT>R_%/7NZK_\D5_=]K#/8EQEJ%<1>Q:)1;E"8(X4]0CA<@)BA U+&]B
MU-O40O.-L37?U'\%M;UV!-,/L1F]# :<9W(YC9D'_0PC4 ;ED_X>1V43(^?W
MN<3L(3<F61>+_2R(ON)>:ZJN?_G/0D5-2_;PTIXK"J$KV<E((<R1#F5R2--$
M+3A31'@:!3CFQ(99K'J?&M-L56U>6UJ_/U^N?W,\T+4;#3,2\H:Q9U*Z#%YK
M6G*":5":LK-@5-IR F>?QMP:<:.UG3L*LT#D$>$8PYS1""K^4C^)/(8AR07*
M$0YS(FWR_W=:MZ*E$;+]-_?K -F^RK,JP?53.9^7X+/@!2/S6I-0QZCU+:#3
MJG@& )LQD3-LGIGFL 3)]1YPMRJ"'W)CZ2@2@Y+);@^CDL51Y_;)X/B'AM!H
M_EK</ZQNY*^5J(^N9RE-<\I9!G/]!V)!!JF,"4QSS!)"0IH0JVR2WMZF%J/L
M*S<OM;FPE/!9_85HBRV71?U8YT+PF(<"9B*,(<H$@H1K@49)&*4L(!@9JB8,
MCO8X&UTCXVW&NX-AZ)F'#^2TOW;H*6-!;:TO<>T3H'C4V=[O\14EMT\XWZ^^
M?>HAQSWTH\4]O@HR+_XM^"\J(-3SQ,WB75$]E169S^*(9VF& QCA$#?%]?)<
MU]H3.,(HE)G@TNJ0VM* J1&]ME"77%>FU3E#HBE,\]@4IBG6'EGNLML.2R*C
M-$@HA3A@:@)(4P+S*,<P(&$JN$B1#,FL+45_]\JCDS>C<V#-_^\'R?!LQ.,;
MX?NPY$15)C6CM.:#>BC::%^-2.?$@ <GCO ->Y)B:\2X1RN.$!V<M;BV<YG:
MP!WYJY[ZJM-2;S/*,1-(Q#!A2$+$ \V,&89<,BPHR]1<974KV*+OJ<U09Y0[
MW?0'3,; C.X\(>N9Z=:Z!#H+IK'["O2I10ZO46 !F!>] I/^7T6[P *84SH&
M-DTX!MZ/3_/R18A6_/A306@QKXN;OGU>ZDVO62S26*JX#9)0I! QD4,J%)FE
MDL=,8)'BV(K"SO8X->*Z9FSYK%XQ5CYJ,0D+:5MSD U#LB&A\QV#M;;"92N7
MOF7M%6CM'3#<,H5FV/CJ;*_C!E2F(!Q$4,8/.IXR%XMB)3X5W[4TRTI]30HZ
M;_8-*O5V/3\^U]U>/VH-J7\WERN"$"=44@8Y4=R#PC2")%)K2AKAB* X57^R
M;B5I>-AL;83#,M(_%W6&@FU++8^9[8?#\*S9#\0C'3C7QL/:>K Q?QU666-O
M?P;M#-^P!]'V9HQ[&NT,T\&1M'M+]C+=7U7[HLT?(YCF*6(9E%E*(9*YA!0E
MF5H7\I0QF46QC$RUN;?:G5KH5)MFF0NS#U4_\UP @&<ZT;GF1;6J3]JW,AX&
M3%TYX?O%"M';;8XF"WW$D6TMZ&/_[%CFFST(_CP7-_(S63TOZRCG1GXJ%_=W
M8OGX3M#572U>N4XEYYA1%,D$9A%"*A(A 20BB&$FHP0Q2?+8+IW6UH"IO=2=
M_7H'>^.!_ELKP?.!Z)L7IO*_SN-B%I+X1-LW@YP$6IL/U5@_ NT ^..N$>OU
M<0' %;]AZY';&C%NH7)'B XJF+NVXTB$XK[9)W_2X8U6\-57%/8OTA"LPI0D
M2V!(PT2GSW!(8YT!G&<H#FA,T]0RI<.HW^FE=C3VUB]:ZX%E*H<9WH:L-C2&
MOJFLL1>L#1[G]I(53,,REE'/X]*4#1@'W&3UL!TA<5',WB]6*F+0*8'-C7JU
MU-(!M'A;/B]6RY>W)1<S0M-0.1Y"@<- +9I8#'$24RAR1#(2YR+BJ4D@9MC?
MU.*NQF2P8_-5?1]:10A+T%H.M.EFQ&2*>S\E>4#3]];T $ :4Y$E/$=(J!+L
MY_OR^W^IEFK^^1?2/\+FQYIT3/L8A6XL'>Z(QO:QRR6\OQ$=:JG?/(GEZN56
M?45T98)UV>*9S*(\YV$$$\XD1$&4PSQE.42$R0"SC"9F]=,<^IX:]>R*4G?I
M2[+X2W"GK%:;83 +B#R!ZYF)=G']UN+:6:YB)&W[57WK:6V^'P5P0\R\"8*?
MZ__5],$-@>F3"S=MPD5-;ZY>OQO9"I+?+.NLW%992B]59ADE.5=Q$601R2#*
MLP#F<8AA+I,PBY(PCZ11S&34V]1HJS5T+6E6+]Y^*A:@TE?R*\.:)V9 ]]/4
MX/!Y)J;:5"T UQ4@N%DVV?C;4 X)GXVRWH PCJ6M5\-9;N L6SBOC/"TU-<S
MQ*=?8>]<(R-J[!GZLZNR9_J0 ^EN96=M94KLRIB&N40L4!%C'"&(]"$?Y41
MGH<BRJ.4Q5%DD0=OV*U#OL(8:>_?MHO 6)"& <X&K#L0;*^0S[F3,>6J:&H
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M=/U>PE(.,RQ$BK"(HE 81S[K9J=&6N\^_V(C"+]&QR"2<?+9-YE\_F7HV.3
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M49<!Z*<RS[!ZIC(G1(U)ZP)L^DA+-;M%6.IO^V3ETN\H9'4!(!U97=*$<T%
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M[.@!?JLT&:9QP(5HAJ6O[2G+N"2UEP'VBHKVPL?UX:AB"U;3W-H##_;\5IL
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MLCJ7LI$X,(P7'PSJ#><;G_9QA37$V9VC&/4XD+/_G+<^97-4*X>C,\?OZ^=
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MYHR(7YCLF-:= ;"]&\8+;1V3<R]H=?2"GN&HNN-F\PKIA&N4VW92*+.T$D1
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MK9*;?B5-X+'].[A?@E97L%5V>TKP"MP8-W=78?OP*4RX1^AX"A,_4G3YK5\
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MM,[0KC'K2E3V MW-(0H(Y<!&ST@*[)L.&EE!(^PP@5-'7,+6SY\9<]SR>3<
M7E7/.]YVZ;:K2M8TRQ>.8H)(:BR+T!2BW!@:0B(%24849DF:LQ3UVVOMC#(U
MH[*S/:AZ@ #V!UM)3QMR'$_?K51/E,;;/]5$6N&;-75",-!.:7>D-]H>'5'V
M])[HV,6].\5^4\:.%-:D_*-8/RY?UE\5D\7\YWME(PK%PJZN.UVAVK."9=MH
M[E;7O%NSG,0\CQ,",:U.]6$*61)A&&=)+C(18ZXCS_ZPH62;FJ&IYZY\+)Y!
MT7;GVR'[NZ2_:[#I=-C-O=TD#1U8KEMY;C4#C6J@T0WL*@>V[>QV3BX;)VK3
MW?-6-^2";S>=WCU;WV):Q^W4.N+T]NG-&GH"'#JR!AMR[#ZLH;$ZTGTU^! ]
M5NR;A;"%5>J]JO][L[AM#\E5[.!U/<8LS3**,VK9=+6$2$4:,HHBJ&,AS3I,
MF<Z=G'>/,:>VPFZ(_%_,]^E3$^6#L\,2&1Z]@9>^5F#P2ROR?QBK!S92-XT2
MK@>"U&.9"@_M2,O/5\O47U:%]46+MO'XMH>/Y]4_U6]M*-(3/[0ZUPK'1XVW
M!OCIMF?;/6_M8;-MI/+K)DYYS<TFCHGU3-,DTU@FD*0)@P@A#;EDYB<119+Q
MQ)AN]ZS3\3&F9I.ME& K)OBM%=0GSW("3@=3?#E( YO>'OCXV8!N!#J_^1.W
MCO>-=\N^]TV?N=2_3.WZ118&UB_FZ3/*8DQ$G$.=( Q1+E)($T&A3+DF(J,Y
MRK%K6=K.<Z?VK3:B 2N;>]'9+E#=7^0%Z@_\%3II[E5"=D3/WB5CN\\:K43L
MB *[)6''?NW_D;U;?E<K1WO^ZOH)O3^57$%M]TEM>[]%^T\;[3TZJL3NFW3\
M@K[GHLOJF&3#&U/.$L&S.-4<<HRU\;A(!@D6&N)4D$QFB&O)?<X&'0[@9<)'
M.QO4<#]Y)K%>@9=A9,].I3 F7-ESGQA2+ C,."91G%#CLWIUKKT(O#'*L,/
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MN*E]C.:]R*H\Q_I1K12SHGI%Z<^AZY33"(C9X-F-Q0.TP@(K[15HY;T"E<3
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M_V,YBR,21UIPL\,GV'C,*8*<Q!A*J>-$Y#)#RG.;WTN.Z1EY\Q*FWI4:/2;
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MS^/F)_(!XRBUD-?+8235-/9);;XMY8?%=]5D'%K;N/HZK'Z62Y8KQ35 F&,
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M5 00@2'(,4$D$TA!TZ=W.,3X SABD$1;5)%MC"O>QDN\RM ADDJ1L0Q(#@L
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MF_A;SY@JW]%TC)H:<(2&CHO:&YH.^%KZ9%_\-EITF!+=H>C%#6'R%6+<(*5
MB(["D$+;\2//]6HSNU\MY;/8W*V^J-7W2J@Z+P35)-6E@L93MN?C6G+ .<J
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MC+\^J^]J\;S+M&*\2KU</=;9#_B\>JA-79LS5!C/ZFOU:!ZYTU_,OZXUJP_
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M+</I7VKI=]O#KSR*#G$B8XW-P#90K<9!KMV[55*K<I.<';*D&:V]M\8:&(\
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MLUF66&'FDR8V.M@C)(@].DNO+_<- +;KT5U<" <_H3N%7O+35N:D$_K\UF#
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M^\]:*UO]4FT=P\]LHSXKJT-]U=!\%G6)@&T9]YD6,./$V%>D3!F !'' %2Z
MI#8](1>(NAYEQA!G>N>9^[4NMOKL[XY8E9)#G1*]7#4U9]?=;[L7?%W$JT;7
MS90;:\0&YO"@H6J*E"16GZ16*&:1@@BXQBUD<(U XQ8[B #=44&$&&V&4?1_
ML55EV^M"%7]>;*K-C_M590RP'V_40NE*5.;'[FR/9S35!(-<:6FS)N: $2V
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MJ9 $X$Q!,YFU!$QE$A#-$28LS052GI& 407TF0PC!0ONZ5>G)B[_DJA:3\\
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M[*2_27: [Q1(WHT!N8=A.2CT(UF;L8? SQ8-1K#70/5O=3RK-5CC U,VO)6
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M&+6<SK&D+ZOGG'@BY 8;>R"?E*P$F^_*&O^R6CX_??SXMIMV*J=4*9OA+(4
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M6ORIM3[M+C;;JN"Y_>\^*H[G (-@/?2!@(&YIIS[?9C_VL&\%3ZYO0RS_]F
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M$"_F"%_&PZ?Q<@(CZ043QE"2LH]$<I H!#S;3(:<F(C,^/TS%G=7W0X"#2=
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MBJ#N\31&Q#Y*2]!A0?.D;.9V_\34G46':6U4%08[R;,-*+P9S\^.TRA)[L&
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M'TJ.OJ!2GKC,A'4Y(DN/O>;>'5Z/$#6LX],_J/J2?Q-6ZR#&TK-W\0$BX/Y
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MOZ\8N>SB?W!6"O6.I^ON/J>EDQ3J;KF<C\-%UZC]TZP<T+@UD"3\\,_'4_3
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M^J:DB)1&$!NB(LR ]C0KIVI-2+Q#R;!Q;$,@VTM%3=JR740Y\I1I!<P1'55
M$6:#_"L@*D8'VDFE;*59][W0/^R[E8;@/  <&K"S3^7%1C%9H:T,A$KIRT,?
M28()E%@N0W)!:);K'.]/4=;,@ZL7N7#>7SF]@>W/K^Y)_"U^H_M1]Y/R7WV
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MD/3P5%I-$^_:'ROG<6=)+H@3BI66I<XX&VEBE=RH/]K YV>I>ZN!S\^1?0,
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M FLO50P/K-NNPD>(%_-.1&^^OA__-IW?<15&D2$+TG!"J<(P*Z EMCH"\<Q
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MS<&S?YTVX4Z^7B^\8N^3_X;BFB;\^Q"_.4:.@F,Q:>\(TZ$D"Z@B+@=&E ,
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MG^/!B]) (WIJ78Y&UK%63]+69J5*[5NOGG351,SPP$W>96+[LM!FY$WP5,9
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M!Y9UD6S>S77]3-],HHN,IUI$[Q1%+5:L*QLC9"M9,CI'R;J==QT6&UMI>0O
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M\V&V6Y%YBF:<31!D32HUR8$/T1,NHE#"1YYTFVS,QZ@:]FSL3_</@NI(18P
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MD<S^.:-M-LD^6!&9!Q]$G=.B:V8*(EC)9;"^,-,HV?I^>L:?U-'B+?0@;8S
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MT<>*M?V]= Y<R^P=H.8UEXA,C+>.-AQS3&A&JL/GEH).0J_US)LDE=J6;7/
MA2QTC+J \:I0)!L">*$T.&Y9$AP]IC:9M_?3,]J[Z'T0<4\;CF-%/X+C_PX7
M+W^^Q%GZ1AO^]_75FI;D*:F<@%MOB1^I(#)1@/PD(L=G[7R;-O!/438LJ/K0
M_E. .D85HX36CIMM;,<Y3USZL.T9*:OO8XD]Y4P0-OK$XJF@]2ME(X/643AX
M$F1'*&4$(*LEE\NMK_$!=YF8*6)2@7Q;6;*O0RPCQ$3AOO&QUOL:EF.;CMSW
MDC,V.!VC\7G?XA]%0[2[ Z.WG&A/&\L4!ED% <JF1.&2LF!18^%)(^-M;E<>
MHFC86Y6F6.I%">-[V.?"Q:"9!.]E'2S%!40E-82 M!-X4L9W*N]L^;!_.L <
M[B;U(-[1/NFC%9)GP< $)"9\[4YA* [)7J%/(06?^L/(\WC2WTNOG9[T]Q'R
MT$] ZVN2%UO[%VA+^$U;=:M <8L0HT$P602+G$OG._>:OOK4,3[E[Z6A>1_B
M&H6>7^[R#V)VLC@#FNL(*G,&03!B 9ET4DN;0[>TC9N?.L8G_./T?(BX1J'G
M5UO",R\J9(Q0C*XW[XJ,'!H--L4H!?E+SG4;J'+S4\?X>'^<G@\1URCT_'H7
M!G&;LA=$LU+DM\:2P3M+?FN23+N@DHY[V.W7XWVD/T[/AXAK%'K^;9=2(".+
MQ#4(XV(=EIW AUIUQXIB3A0G;@>)C^GYMSWTW'M7MY9Z/D1<H]#SFRWA4F?K
M78[ R2*!TIP(=TE"1I:MKK,3TQYZ?K.'GGOOEM92SX>(:P0WB?=<N]8:FDW+
MDFA,=%Q!U.1(*I,M!+0,2G1&2,V%YOQ7S;=[!-D1-6S!\FG>/PY2P!BQM*[&
MVFZNXG-*FMQ6)4S-:+.T+0*"+%%FD3-3C6KE'R%J;#?4!RK^R1?:P[0P!D!M
M#?0=EG8QKT[%:H%04I#D.YD$+ML$6H0@T&$NK0S4XX2-#%B' N VL'K4QAC
M=9N-=U?I:2(PZY*I^6A(VX]GXB1H!1RU,]EIJVZG'+<R5N_VRBOM/0 ZY;EW
MF/C'"*3K<0N<>#'&UISK4),.E<P27!$"A%-H? Z*W,330.D&52.S3P=J_BE
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MAA?O'4\G+\-\MU<[KE%T^&QSE7"8FD8 O5TJT".\_1NG9]]JWC=95[+M-[I
M:8?!TFD(+-::YR@IS.!%@E0%DTS!NMCF??,8JD<;'1Z(H?E "AT#>&]4(MQ-
M+YI$089>9 9.47RCN+=T"E@&'$.R)F5THDU1W>-TC3;D[ F _2EE!!![XI7D
MWXOI:H7$9UD'3)B_SK^$>A"]O%R2-)?+?](_G; 86.%TZ#BI:Q\HS2 :JT$F
MQ5-!A4X/TL:K$_6C#7O[@>O)%?Q<)UH_.-V[U6CK)Q<\01[C?DP/DG5G'04U
M2CDP*:VGY>AZ9B<"H(G>*IUEHS&Z)\VZ>ZPT\:YV/I FOOZ!YS_P_7RV^K:<
MZ!!=5I8"3",H(+3. ID%#5R%F).6,H0V227'T?V<LO/VP>$^A:<]:W<4=TO[
M\?O_,"R^_C&?J,2$2]Y!<IK8U-&!$U$ YX:8C]')W.;.Z2!RAW5SQXK=0W3Y
M7"%+&,0)HA+( ];Y2O0+.@41681BR"<J.4:=3YYT\!C!P[J[HX;MWOI\IL!]
M,[]<3&1BD5E1(!E!LLTNUGY^'%QA1@K'A&!C,;:5WF%?F<8,V[VU^5Q12W]W
MDK4*H>@$(HC:CB,;"(["86N-Y,7(J/3)'PD>H7?8]ZI1HW9?;8[@KFP_+E\4
M6OF*5:M1D"L4P#EA2+K*@+=& S/*:-JEG/;O"(#["]'#-F49*WH/U^O8#6]M
M1,-%#$ZB@"RP#K06 @*21 4*C9H<(W?ZO.ZN_8&:M6H9!13WU<Z(Z\=_X')5
M4VB6T]G'U3=<_#9;35=3//"*]<%/Z^O^M!NY/5V._O9?E]/5S_>X^C;/-Y8F
MZ/U_\^EL]2_ZAL"VO$*;X*Q8B8Z<OE2?--& ,T$!DX5<0>X5QC8]7?<D]%B[
M]<!RU_OO*RG@)?V+WR<F&B64=N"0!*&,YQ"R\F TYU:E&%.CYZCN- Y[\=D2
M8[<M6B.]C?J5Z2&#L4[1Z=G*;3^SM:V[C_2!+%[R692@$(Q5H9ZO-=/29B!\
M9%L\Q]*H#<,X+-[U?A%*)&NY@.*+I?#)LII?*$!02&54"3GKDYK^9VK=]L%3
M1^MVF(Z>I4V[*8&C7LKW6:"UM7N2J8%,7^2Q2&0,<HH<%)<2@@X:9+ YL%Q8
M4FT::I[8]%TGO#ZTP=;)KL)KS9PO('(HU2])$()AX+V/)G/:O*G-2="-ON=E
M!O?!UL/=9WK3U\!3Y)_BZ.Z?XCI#?UTVZ[7USD5#/BRO,Y%=@! M.;(^H(@^
MA<([;=-.,\>/H70L/6CZ0\U\ !4.#-6'^-A6H02=N$&?(4E1!W<5#UX;!&YS
M1BVM"=UFK'8"X^.T# .WTV)AWD0Q0Q>\OPO+<'Z.FS8GYR^6RWF:AA4NWWX/
MVY(DRU*.GGQGEA%!R:(HC!<9LG&YE,3YG8OC!\H-GUQJ.!3UJ=!Y,^D.C95/
M(4W+-&VY>7L1SJ:S,W([/L[2_'Q^]O,521D7;V=IRUO4,F+D",%)VEY1>W#>
M(63.M59")552)^3LN? P"5PM<=12\D.CZO4TG,WFR]45>_]8S"^_;QD1BB5R
M!C20X"C*MCJ"(W\5C)0VV5"TR-V:;CRVRC"94RWQTIM,AP9'?8I=IV]]G.&_
M__:*(GT\PW?O7FU902-\E%(!*I9!>9*2#R&2'>4BV%B<8:X3/!Y?9Y@<I98
MZ5&N0T.$.'C_Y>,U[4*YDAFSH)6,E78)WA&\O4S!\Z@"0]8)$[<^>)B4GY8@
M.$9R0VO]:S@SN^/PRME?6[EK?IC/ 5'I&E":S>#M*&MY*'JK!?>F8.R$A Z+
M#9-2TQ(=?4MX!(AQ3_&3R?!II3G9/>XH(*Q#ZWSTP#/!7Q7)G2I=$?/48L-D
MOC1&3*\2'AHQKUZ\_?2"+.2N-YG@26A-H9K.G/RF6OG@T$#VQ7@CF;.J6T^O
M7S]WF)E!+7%PA-Q&D SZY.7ENZOR79\,LQDS>%&=(Z\+!&T#E% X#ZG(' 9Z
MIGBW5W^3$[1*[?TBN+&ZAK8]#S#S^<8<+V]E\D84X%A'O,4@(18*]Z5)P@II
MO S=+N:>7FODSPD'JGC>3MXCL&,/<#1!E3737('-$>D$I@ O6%/[OQ;A70QH
M-#8Q6@\0- RVFBB]6P[)7AHX<C[REU58K%I9HYM??5HO-Q'%&.N8 "'KQ4%]
M=8Y,.<A!6"L92YEUN_+MNN(PYUM+]+03^ B,TMM9FE_@N_ER^8:$^= &B9X+
MCN0/6*[)\ZR=.T,H#ECAPLD2XYWNN;VUG>E WC#7Q:<P6/UKYXC)V<W,UG+=
M27@:+]=SP%EBY&+F"#S5BPM;VWMFID!$YDV0/I3;W0GW\Z)N+C;,/?) QNIP
M,8_ 3MW/TI?Y>7X5%HN?]?7M8GXY6TV,-A0DU^M2E(J$YAUX'DAH-MJD!5HA
MVE1;=Z5PF&OKX=RK(W5TA,$Z6W?9:AK^T99:SL^GN:XT24PPDT("*:6ILJOC
M&W0 7I@3RJE4>+?&X1T6&^9Z>T#+=9B8AT?/4[%'G;^M9$Q$?IU':(VGO2 M
M(!EHD277UK?I:G*,,]7[+?B0T=\^&C@R^OMME@<I'>A_CNU!*[4N)CCY5-M]
M,[\QR\2+CR )7*"48N"9U"!9E"&G:%IUV!MG58'GT9M4RQ I-@;EHZ+ A4<(
M+&@M=6!)^?^I*FB K0.K"O;1UW.N*F!%RB)4@E#H,% :)03%,S#EK1-1AXR=
MMNG_5!7LC9J^J@KV4>&XJPH4XQ%KK7;@1H)RB8%+*4$4W&4>+5>EOQ*7OV15
MP5Y8Z%Y5L(]BAGZ]?#KOW7,6E2\11*1(7"F*KZ)S]&TQL1!?,75,['V^505[
M*72_JH)]I#LT5O;-;?>!HB7I#115BW8PDP"=T9"9MNB-]L9TR_G]JU05'(RC
MEI(?&E6/9L"'X'B(7( IPI&%]@&"50J*DQB4YH%EWPE"S[*JX&"\]";3H<'Q
M1/:[E'6Z?%*@HV>UYR9YD#$&*"ASQI0L^91_Y:J"@P'2HUR'ALCMW/@4=&:(
M'*).9/M*%!"5UF!0YRHF+D(W3#R7JH*#07",Y(;6>I><=^]M*J88$*+V-DU,
M0\A9 C$C@PB&Z8X/QL^YJN!@=/0MX1$@YLF<=QE]X4G4]\<JK%P2>)(/H'5:
MYR1L,-ULQW.N*C@&,;U*>&C$[++CKZDO*,A"I@)9RT(6TGMPK,(_HHW9.&9+
MZ(2/.Q\]VMJ"@]%PG/0&U'W&Z>0=GH7S]>O1STW_"2.]1#H0C;4*2":Z/BT3
M$ZI66 @ILGOL06*)Z6]G\Q]_IX]>7[7]EZI?PN;+-2KN6?19% 0<<H=[K( '
MQL:&ZMV 8<&BXY8(%8H\925]'6MO:;<P73Q9.X:/S2?M!HR;*PYS27:TRN8]
MR&_H\^#%]_1N>;&[N2O,Z!*CA5CJLUI0$KSABEPA*1DWS+N.9\$O'SN<>@]7
MR[P7&0VNW4^O7LPR_?KNR_L7N^X<7/@@,P(=<[9VYT!P/&5(T>54T 5IN]U@
MWO/APYCW'C5]I+P&U_?Y^13S]F;U8WD5SJ=EOIA- W'U 5=_S!>_;YW9]V$6
MSK >>CLV44:;# 4[A2(>90NCL,=ZD,S['$2)YG;3PX=@<3 -P]Q9]HB>TTA_
MM""KOO&6'2=<LCI -"C(P9:9K&7@0&&US=SK$-F18+I::\ "KE/INQ/&#A/^
MT%AZ2$S7SSY.E9SH6 6M-.U&2X8X)G+00BW@SA2[X>V"P0>@].12 Q9S#8&D
M?D4_Z!":36R^N?#_LEH@WJA5>[=[(O(";2ZB$#1T[;D8"GBA/2#&PATS4=EN
M0'IBH6$>5OH[Q?J4X]#FY<4ZH78+\?^8G^?I[&QY#7#)R2!:*R$E1]&>]04B
MT0!:%)Z-X6A]MQ8]CZ\SS"M+G_%/;U(<./OLXQ\S^IQOT^_K8-\DI(B-XORD
MDJ.#,D;PR5 D9XVWH@@F5:=JA$[)9K\L/>RTU,:IC(<+>2SHV&X8E*3'G L8
M@C"H'!DXHSEP+$R$@IS.Q_[Q,73VX1'JNP\$!\ARZ%.C6KI/\T4=5W9UST]V
M+).A+."<JK/24Z;-(!-HSU(HR20ENK5?NN?#1Z#K0[0T[U%D0ZO\!0D)?X3W
M=3Y>^MO._W62ETP'IC/,U)L^!9$) 4QRP91/"6^?#P^Y!_=\^G )?;TI_6BA
M#:WU=8UX2*NO])?7UDY[):WF"-FY1+ZM3>"D"6!4S)9CP!RZ=>"[_<G#SIEN
M>. ?+\<Q@6"[(Z+.S!9C0&)M$RBXAT#@!5U$#D8RQI/=&P9#GNL]:.DA?1\@
MLJ$U_F*6IN?G8?'S"RY^3!/NV-DUQ1>89+ :4.9Z[:$X>"X\)%UL#$&'KMI_
M?)V1(.$0_<W;"',$G3<^XWFMA/\4%JN?7Q=AMB1.2"/+ES]O_F2]>T)&IW.V
M0):Q/A#3+]%8))]>1\S9!/JM2W2P=SUG=QJ'G1/?\-1IK*Z1 7&[10UW)")G
M@'SJFL"LB /:HT!^=J0_%QANAR - #?D*=9:ZX^ ZP 5#'W*O5[\[<5BA>%L
ME[A@6/)6,@]H-,5CO&XT21QP(Y+G+K)HNW7LO/W)XT'#(6J:]R6S$5B-%RG5
MGD/+#_,5+M_-:6N\F.4WTUF@0WIV]AD33G]4HUMWRN[K*W>0H71>%@?1!W('
MLZ 8+KD R?(4E+/(?9NYK\=0/4R.^@F/N).I= 3P_96#JT;@P0K.R&87+T&%
M3#P@9@I:>.9DW),ICV4C'G/LW:5F6%-W.BS<.0J/5,P(P+46VC4CNQD2BG9B
ML0429EFK/2)X# Z"S2)KDDS);9RJ>\D9^B0]5LOSOD4^ MSLT_^;%]0L*TBF
M5J$:4\A;\!Y$3"6+$%C.O F8>N[(WWN%S@G/RT;J&MJ;_W!9]PXQ=?']?/X3
M<3DQ)5I?L]03KT*R:,$GH< 7[A&--]ETJP2\\]$C;[1SH +GO4EST%RGQSMF
MO3@[6ZR;.;Z:+U<3E*S8$.IP/<Y!"<T@HC5DNYGW5D>OM6UBCSH0-_)*H.-
MUDI)(S@.[V?IZDWQ$RY25>093K HK4W49+8UDN? _G_VWJS)K=Q8%_TK)\X[
M;,Q#Q'DIJ5NV[E6W*B39CGU?& D@(7%WB91)EKKE7W\2)&MB38OD M>JOMO1
MEDI5$I'#AT0FD -GGF-DR2LK<PHA&WY"]#U XLC3<%IB\%B%C0").][EK[B:
M6'(>H^"62:M)3L%[%JQ3#+G4 0R68-KTP[Y/R\A??/O!UI$J&-JI>E@VK^?T
MY6))FGI?-L$UWK#XP+YY.TL+A"6YK3%P$R0PB[%08$.Q=@CD2$2>7<%H3>'=
M\D7ZI6ODKT ]N',#ZO'/ >%_?)O/;O[-)"N;K%>>18DUAR=IYE5!9FL2H$;G
MLS^FM_MQU(W\QG<T<#Y"IR,XW+L-@]$V2Q6$92!TJ"(FWZ76XNJ<9$F)?)G4
MIJ=R?Z-ZAKMKZ<<%Z%]1(T#?8VR(G!S(V@Q(H:&301H6G7?,\NBBC$ '1YO;
MXF,0UGN'E5$$,/LI8P28.H<?:[K?S!=OZHU3-MY9)Q-SN3:A4=&RX)$S@ A*
MY*!4:?/<ND-()PR%%XZA8X0_ NS\$Q;3>LR_K2U123*;NJZWL^EJ"A<W\V)(
M9W^#Z>S]HIKC"4BGB@3)<@RT/TST# Q$!HGS8HU#LUO1WQ/ #J&VVYTS?^$P
M;*['$6!U\\JW? W?IBNXF$BG.7CEF(3D*O5T\D<;&.<^*E&4E:*-BW:7CF[X
M>JF/&CW(?IR![-TQ?M98IVNEJ0M!D&BT8T!<57Z$"]%8F;N5</<U+5&\U >*
M)B(?!X0^8KI<K"<D_6M*G%VN/B#DZ<6/GY"6^4J!,]G?-S!=_!,N+O$6V^>7
MB_0%EB3QCU](161WA2\0 (CU3*S7KF#D7Q8*FT7DP: HNXE'3Z*M+[JZ ?.E
MOEH,K<BA,7SEJ'Z:GR62P@*/D\5$R<Q-)(X5YL1T3>3QJ@Y"E5QYD10ZUZW9
M?,^$=4/Q2WT?&5R50\/X.%:W;LR7Z;<K1WDKP7Q>)T)LOC4IP08MR*?Q)452
MC,3Z7&F9]$:C*IHGVZU[QPF([0;W/\$CS'A4_@*WP$./\M(4*Q/%?(%CS9;,
MN8ZNKE-@99:2<"Q\,Y0?FC(A_@3/+R=5W C"]G_!8@&;D8L?II^_K);O+U?+
M%<QJLY]/Q/&D6/2*(V=2Y<*THKT7C$\LBY!!N635;B.VG@+YYRCK!LF7_L[2
MJWY&@+?7%[!<OB];MMXOUDQ=Y67>;+[7==98?O7CBOWM7UQ.8K8NU\0234S3
M+X5V5FU1(U20J$$X\&V>8HXDO!M:7_J;S2FU.WSKP:-<G_??UL6K;Y?+R_4(
M]J_OR^9;DP0ZTC;F++B2:O_%Q$*0FF5(&E/64IH37$ \2E\W)+_4EZ.Q*/8%
MNK&W='!'!IL_?)I?7=#<GF"^<?"7Y#49YZ)W3%D32#2^-HU*ZT&F(F6;HO3=
M.O"<ENYNV>PO]?EJ[$ 8QQZYEV*])\MOR^OI(EU^K5Y=0HJ(5Q,CDP^A6);7
MQ7>9)Q93(*^$#(7W!;#K;)Y6%';#_4M]5AN/<L>!\(-OY!?S;_-%E<B\7(?*
M5Z*9SOXYIU\^OYY__3J??5S-TV_UTZ>S.L_QOQ 6RTF1SAN;#(O@;<W6  8>
M+.-2IA #&+L[HK[-2\QQ;'3;*W^"%\67 ).7O:%^NERL@?.^W'QSPKW,0?/:
MO<M&5@<6,<C@F,BD2XJ@I W=^KOT3ULWZ/__^,WR:(6^;#S?K8A,W@:3=&1%
MV9ISD#WSQ2J6P/@<A<@8]BD_Z(6H;@A^T>^50ZFP-^C^G[_>4PZ)Y;?UC]8_
MJ?_J Y;_57__QX>W=SX?UDWNOV+^RPQ7F\^_Q=UT]G[U!1?K?#T2S<?+KU]A
M,?T/YE=P41VZCU\05TN8Y8^T[GJ,QG)>-JGQ)#B87BSO<KN<?OUV\6RN4K\$
M_/5&$+LBVM)Q#[*G%0K^L<)9QOR_FR3OG\WR_S.?SE;_I#]<$O]G<;EN5#E1
MSL>$A%6/D<RL#IP%-))Q7[A5,MOL.HT!Z"NI_S%"FS<RV33?P.10!R&9T[50
MJ-0&SLD)!B%'$TQ(-J8FXNA&W[#-*5IB:^].)OOK:P3O/@_S\NN<S,)5^C->
MS^S=S.0,-LBL C,B:6+0UHIB^DK( D)8#,*TZ:JS-ZDC;YQR %XZE>+TI;R7
MALZK:=*U(9&O[44-^5H:1&)>D)N./ FMT-4.DL/C<PS]ZQK#YQBP'J#+H4.N
M=["LSZ?;N4QGR^4\38FEY=MOU]U+15$J:LN,C8III*]"J!<B6L:L$8LHO%,@
M]>Q2+PA7AVAZWDSLH^@EM4=TZ5PL$1.2&V/K8XSV+%JYEF)VF3P=+\LPWN&[
MO5K<#3UC_IA3N)&Z1G#\TFZBB/':>S89'2JMF%1:,AVMHXT4@26!WD>>-,0V
MK5_OTC%RM^Y ;>_V&3Y<]", SFM8?J$@K/Y6I?0=+M9AV>HU+!8_IK//Z]NJ
MB2O ?0K A);D38C:FPC)^@<L!9,TUDK3!$^=R!NXM_ 1^M]-_NI=&2- V%7O
MY3O=KEY?+JIL)P&]M98'E@40+YYV'V1G6+$V@W'&\2+;&*HGJ!KV'.P13[V)
M?A3.UOK.=".=*Q[JE&:GDF.Y<*B9 (YY3K(R"G-!S>M/F\#G/BW#MD3L$31'
MBGD$%F?=7(_LZ+K1^X/8UYQXB$*QG+$^]0 R^AC%4CWH?4#N=^<7]]GN\"G2
MANU^V".,^E7"* S0!W(<%]-$(7$]H:_8P%B,+F"8ASKH-9+2 3VYDE"RKDUH
M*7)M@J4'R1FV9V&/^#E>V".P1!MY3&)PM86G8<'4)E[!UO;8F7X!(\": $HT
M&A"S7G_8QG]]^C/[B_-P$,SK3-X^0/!N"G%ZL7[I/:M/NO/TVY?Y!0E]N8E+
MKT43% 25DV$&+(G&:_+IUS<=B@@O%B&+-N\U72D<^051/_%\$W6-P!;=XNO:
MFGI>=(J913IN:2,E4>N#>1TYG(USEF?7Q@VZ3\NP,7P;G3\.K$,4, ((W1?,
MVUFZN*R5E.>;_-.SU:8#SGH6SGSSD+ B*N@3/U\7H[MD:]6Y9K*LJWBDJ=TM
M#>.)K+\![8IO<YO4#_W#6L&30'4 18\ WL^)=D(N)H!*EHF48-L/!X 34UEG
M*73PL4UCP.<H&_;RX=36\WCEC, KW*3S72?X7<M(1,Y]5IYYX3+MF2!8E"FS
MPK& 1NFE;#/\XQ&"7LRHCV-\OCZ4,9(KBN\XN\3:4?IJGGC-1GY]N5P1@XN?
M_]A:\1I)T7_Y$_PQ20:%<,&QI#76?AL42<EH69*(D%R*?K?356\7&'L3.ZR;
MV M,[MUSM-78_K ,&UC.<-7/"^-\N<[S_/F/;S@C'B:\@/60#9E]6?N[8"U0
M58%E'Z5$G2'Y-GC;I6181ZX%F(Z2]0@\L/??L);S5!?RJCG^Q&4B%FO700.R
MUOPC229;EBT1X'T""J+:O/'<)V;8P[ %8HZ5^ @\J?6#%44@\[NL;/? !$,J
M%$PGEK#&V 4$.9T48P,92S26?,_=Z>U]OA$^2M>P#SU-H-2?'D;A2YTOYF6Z
MVG02=Y8'2<3J),B,!D&!"X_ ''+C8TQ*VC:!WPT-PS[LM,#+@?+MS>+T7?6V
M\]()]]X^/^!%S:<]AT6-8N_RTZVN;=\E^JE<.XJQ(VO3-IG#M-S-:M?@0ZZY
M+K7,%P1!QT=R@[6L]ZC@"FJ%LG1KT?OPYQ^78W[G(S^1%%[1SWZ;F&"4DP3R
MHAS%IA@T1:G)LI(B?9UY,;E;5\I'%A@F0.I+2W?SQ7L0X6A+9/?<4[<;HY3Y
MXNN:@",*9/M<?A CTUT@#0V0%A%2M)D)BX[PG14#%R4K4F'1T9NBNTT2[]<
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MH(WT-S)D7NU6:XWEPC(%M;(W(>W6'.@7L$;1ODI:MS%G]VD9VI:UT?H3X#I
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MS]![K2(D&V6KB\!'2!KE^;P/'NY?>/0A_!&<QW=96$_!ML5:8Q5GUM0Q%KP
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MO,,5?=C5\]:6!ZL26"T$DS84IE,$%K*K3124RR8YEQHU^GJ(FF%CG][1<[3
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MAT8OSX\0U U +W3(T&%B'QUZ:F_A2?3)*$1@!5QDVEK/0BF1@>#2(\\RQE,
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MC_!*.*M"T2_-N'Q,7S!?7M2S<O[UVWQ6;P_>E^L%MS[[*YQAF6YJ\F\PKTI
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MEQ5ZSZC;FZU3="(H64"(AF54I7:OR"QZKEA)TFB>9$Z\<>)&@TX$MQHDW>]
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M!>8^S)RB^#*2E=%DSZ+PADXY+QFX6.LQD@#RFG2P+VX,=!_US,(DVI[*,6.
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MHW@4<-U=?M,[G/OL^]JENMZ[2&0/8?8@M:L%%K6YHF4*/'>E#K*-C(7FV'U
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M3^<G/_X[X\G9USO&+'$"2W8)?.UII8@-X)314&I8T#.-6@Q,[7AYL4&@<,<
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MFZ2Z0-[WO#C/OQ)K;VUMGM>SP!3SQA6(L8:,M"'=R>DP9N]YY$R9X@85#^\
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M @RO 2*.EGSS&AM*P6DI"D?3YF7A-4[?V09;XTS?V49\_1H"C[6P<YS'C"%
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M)K7O,6KZL7Q& ]AHS-\>0OX"0HO\I6ZKY66Y>9.Z/#0OA_LCVI2=5I"EHSO
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M<2]'YGV'^+G*B.,.$7T 4QLT*6T5>!,\.*6\SZ48Y@>5_NR,H*G3<L:1[PN
MV8'9'03='P]-?%S-:^GUQ3Q TM^K'Y</_]H59)R.E"Y1@$)FP65B7>"B.*U,
M-;H/&&MZBLZ^H+8+,@9%D$814[<@O/5((40PN9 GMRF0UD62J2 ,)!Y5#BYR
MK@^)NO>]];8<_U9L(9D.@/9FO<ZW3%"KB3/*T8F4EM?VA06P#N1+V7GE7$X<
M&]5_WZ%C6N-J5!'?KV+=G=]=I$Y<T/_V?%49>1//TCXP9TESNZ)!U=:7KLYL
M1W0Y*R\LFI:PN4?.Q-6J>TCX4;#LP^SM,>,O,+/(9Z/@Y2VNOY(37/]?+4[Y
MCB<;E_?L+:Y6-7#T=SPYSS,Z-L(*01<SJS-D&4H(KCZ&8\1H"G&.-QI?/(2\
M'O"T%PB6K672A6KZ#5?_S&=5<=\4]UZR;<98JIUWZ10&7S?C(P2M)22A.$:>
M0\ V33Z?(6KB8NC18346_[L 4PUNG].I^)1CIA-"F_H]GUWMAI@DC>>^9I#5
M$:^YD/UH'0CEO)<FZE+:)$<_1]6T257CPVDT"4Q^!S[<R:8NH<YB6-T^)-D6
MA5D&(+W+0)&7LAE-1FZ)C[:^XQG61DD-)'#:Y/M#(&Q_N72AO"[:C7_&/_.M
MO<U8<#Q;NL;IW/A:!JQJFK:&PAC2B?$R\S9=Z1XE9Q"8]/& :7^>=Q -^'#V
M-:]NR%_?TKA*2E>R9K5U20!EO  O(UWCT;.BE;=9M>F6]31-@R!DC@="(W&_
M"Q7T<96_X3S]\N>WO%AG\C8VF[O#LYFR+L<ZW-H$K#5S!LDH5!PT2ILD$S&*
M-ME& X@;A"U[/-@:6QY=@.SWY5E^\?:627K..()4:,GU8 F\D0@I<D1I3!&Q
M3='.$.H&P<P=#\Q&ET@7./OY/->^AV]*F9_,:4/K&68Z% PY9%7()%3*@*LC
MLI@B4U&+P)D?E(*P-:@>D#((0?YX$+0?KSNPH>[J5&0Z*)XL$9\Y*)\,T)\1
M2)N6@D8QJ=KTSM_^-KNQ1/M'R>Y,'JV,:E^$_+Y<Q/L<L5F(VO;:ZX3D:!+F
M?4P,6,BRF,A]LFU2$9^BJ(<0Y8@O*7NRO /E\G&U_)979S\^GB!M8I%J_/Y;
MS2(D7V%F7+$J^P(.U68^;"9W@?9BI<B!_C=[;..B/4=5#X\G^\K]@2T]DA Z
M -0[$L;BRYQLM4M6Y;.+5L_SQ9?_6B[3O^<G)S,RR()&XI,S8C/4D(&W#$%S
MG:1U(=M&D^"&4->#CAH98*,+I0.@7=/-(\/H/*,#4M\5.18(1AC(460K,O="
MMO'ZMP),XX>2D0&S$W,[ ,6EL7_73;SAS8QSQ0SA'"SC"12:",%Y#](3DZ(0
MZ!M9SR\0UL-+R,@0&E,4'2!K$]YZOUQ\^9Q7I^\6W_-%!Y#U3+!BA-<%A)6U
M[Y=4@$8FX%YCX;75FQ=-(/4413T\A(R,I5&8WP&(+MKI_I;/OB[3[6V4+!VW
MB@%'8@LY(A9\88+\36.CC:F$TFCDY^,$]? 0,C*$QF!]%['#BXW<9,3\^OWW
M.?D,M3OA\OSL4\8T/_GQ<R;0UHI+,OE^Q?GJ(@/+2"6D* &RS@Q48!%0:P79
M&,9L4J8T&E"S.\T]/)LT06)S 7:@[FY&6-34P%MW?W0\"1TNQS0KYFN)!I?@
MG=&%"\Z9:).>^11%/3R;C RS49C?A<;[\"VO2!:++^\SKO.GVA'K0_G;^L*7
MG6F!F3$? %TNH)*DWR5M-W: *DZ@2VWNSF?)ZN$596PC;#0Q](&JF_?JVUX)
M&0-8H@6+(H,R@D$(,=>XF_*!29UDFY2Y1\GIXIFEA2V_%]\[N-D>T%^BE"6'
M0IZ'$G5.L@)GR*JT1G*E8G'8*)MI-\@<5WQ\+VYW\SXW,X6;B+6U6:K(EJR0
MLJS/T$*H&)US?EB;@1TQTD.8<L2WMZW8V0$(WL\QS$]N%S%<,R,PEF3T&IRK
MD?=L):!4&3)ZY;T(F$6;]/^G:9KV$:1EP>1(<NCA$KI,-_^(/RJSR(>DOUF=
M$QT/MCC+&44D-Q%0(:G?$!T$0_OSY T4QQQ=L(TR 883.>W+[EBX>*(F8&PA
M38B_VJYL]NL\G6_Z(=S;X-5>"DKFDJ3[/I=:H%7#^X(9$(*%HEDPGM^KX'W8
M!6W(0M,JJI%!,SIGIT;);SG-(UV@#[%N-3J'E2DEUF0M46@_G(,3UI(6%TES
M'(2/)Y>8UMYI@8QQN-G'S555X*T2EZN-.%F$\<F#5)R!BBZ#1R/!<M2H22UR
MF5K=4X^3-.W3;+M;:00!=!''^;F.9\J+=%]-&I0B,>_ VQ3I2/@$@24+AGDK
MZ%#H8AME5#].T+3/LHUP- ;S^T#1>?Z\O,X1O]H&%\F3]F3 8BW43,*"8P$A
M>B+""N>T;Y8N\I"<:5]E6R%H;\9W<)]=-.',F\#X%9]^7%>G^. 9-PR2)4$K
M8PUX0QLR,4F1L[=!M D-/D?5M.^JC; TFABZ4$EWWUL>[$>9( LW#B3QA/93
MB^L4TX#T=SP(]'98R\D]W[UV E:SE]1&P!I1%%U ZRJ5ZN<<KBN" T-6/4N(
MJ!*H$@T$S>K;,)-&28'*#1H/NWT0\B$QT[Z>-@+1ODSO SD/?4^LXY6U$E"J
MVZDR7=B>1?HE1KJX6=+HV[2.W#6"V.R]M!5P]N-Y7V\?CSP->J^]BMR J(TS
ME8P20M#D,8ADB^29&]/FS?U9LJ8-'QWH!61/:71@>O]\N>QU*./V[C*9?5P:
MPVV (,G84ZX4.B1:$+>XY0$QLD8-2%\@K)O'CGTA<-^?&U$>'<#K49?B5B9"
M"#F09R$A!Z&(59QTL*'=E6Q<D"JE&-I$F5X@K)MGD9'A-:8\NC"HGG M;F])
M.JL#M\!#CJ!0,7(LA <;G45G$TNJ#<1>)*V;%Y:103:N3+J V6WGX_8^LD[6
M.S)&?0J@%)D1CI4,)1E4I40A19LI/(_3T\U;R\B &H'[7:#HH@[K,3;-K(NH
ML[5@@S;DR68-WF<!42#SR62&L0V2GJ:IFQ>7L=73.%+HP+IZ?!/!1)=K#5;4
MS!%OB"U.1 XB.V>8E3*W4DH[H^@0KRYCZZ2]>=]78&&64LT&Y@*XQUA3R,DE
MSC+2Q9PS2XY9[]L4%=TB8MH+[$!!@ZTXW>V4^8UMM]-PSLO_<IRIF8^1,=(X
MRXM/7RL+N@TL 8!41-0D-45'VXM"NH,TB'"A1(EMIA;?I6/O(Y_7ZYQO^X&W
MYM,6*Q)'P4@A;M+*T4,HF($)EH2,5F%L](CQ#%43AWIV1\$#'3 6ZWLP/39[
MN>OIW=I-M$QSIHC\9!@H+SV@IE\2:8'@R# 7C;HZ/$_7Q&&=L:$T"OM' U.;
M&^:Q:?;;W#.7__V8M\UC)+6Y<Y)*F,@# >>Y)(LC6 C:![#&USQE%*E1<>[8
M=PY][>UR?;;AW U,F2-+2F(!$ZO.T[* YT1/)*7'<O8L-^K;\01!7=TTV\C^
MH7K8G^&=7C+7X<3?\*QV@/AQ;XO<!XX9&6#FEK1JDH , S@N+7J!:)N9:5L3
MV]5UM!_>V@JJ RP^^G+RQ-:,8M[J.M<TQMIS,M*NE,Q@I<N)\6)<:--2;PLB
M)WY\& ][K033N5WT)J5Y_132)\IR=;KY[L_Y#.<G>UA+SWYU3!MJ./F-+"O-
MLTE.@D:F" Y)0! Y0/)!)F.%<KE1M*N!-[_YYL]Y'5?S;Y6/%U-U4\"B;>U1
M8PHI6%D#5[[0&3/:VIR5L*;5%I\DJB\+:PL,/'[C[<_X"6^V.@S\$RZ^Y,V@
M>29SD%H%4%F3:1A<@& UW<G91*-%+%8/>C6@K]Y""OWI/DKN+#LU'D82XG)?
MCO8 @ZO)[+43FJ4[DHN: A(*@R")!4Z:)!PQQ>E!,<#A0+A8>!HH["&R^T+?
M@7\3B_VW^6)^>GYZ27C(J!DW"+*(C7$4*\T99,J::"NFI$&>TR#!WUEZ8M'O
M(KCE&%R<-"EA0SK^>8MTAK&DD@GNB1E2>89^YQ("4Y(%QP*/.*B/RC  W%YZ
M&D=X- #LS,4._-K'[\#WUX^>J+ $DS)H9<DU"YP#%DM,$<$Y+93AK$T"\ N$
M31T[&==R:"&-;L!U-RY4$[D^E+?+Q841'C'3P2(?7.CD:4>UG6;A]8]*!I&8
M#:Y-'=[+M/5HG.X(A0'QNCWDT@W2;L>"[NZ'SRQ+U@95BWQJB\3"(_&+"] V
MFA0TYT:UF3OX(FD]JK(Q<3:65+J!V;U6KGF1_XTG=6>SS)F17$8PV8?:(9@<
MB(0>$NIBM(Q!QY:WY9.$31WM/:PJVU4BW0#L]HFYM1D^R]X+(PRKD_5J\^FH
MP+F@2"M;4Z3FV>8VQ0S/TS5QXOE!-=C.\IBZF=A3ES[MK?+K8U[-E^E=>?/M
MV\D\;BQ90Q:K"RC N%1=&4^^K+*T19^MD%:Z<']4[Q--QK9>>N+<\P: .H (
M^@#8_=O^Z;T1]<65&BIQ-51B"[%1H*L&0.!:L1*DVP)>@Q>>."6]+;C:L+^#
MF_&.#K[7/=\89I-Q'**J>2TQ<CHE"B%$+*BBH+]NDTCT#%$3MPAJ>">.)8F^
M0?4FQO/3\\WTM3>GR]79_'\VPIL%8P(+FC0RL:I.:M"U"L!!R)JEA(GST":U
M=7M:)VXF- T$QY!;Y[D?;Y>GWY8+^N!Z639_\\N?W_*BLGG/](^7/CQF!LA6
MFVB3!,*E<B$S6]L',;H! R$P!@9.2N&0>2=TH\XIHR:!W+4G:]KG3#!5E!8(
MD4D%2HE<D^O("0XNVDTO4MNFJ=!#6J:.HNXL\>?+VK=F<^>W7:%EGE"=U]R3
M!HWG0H,,F2YWJPMI3YD@<<FT*[FDU*:?YYZ$3QU@'0V"AQ1@YWB]?;5GXYB-
MR8/=/-RF6-/:Z:8OS-2*[2*E;9/I-I# :57@04&S!6!WE6!GP+RN%KXP7V8\
M8$W]"!#0^UH";L$3"\'X(EWDB0S=-@4(SQ UK0+L!8#[2*H#T/UQ'DXNME%;
M@\VDDM+E8H!+7GM5D*<=,$6P(1OEF#,"VQ09W*5CZI>ET>[6/=B[/3C\!3@6
M^4M%_><1GX^N3%->HS Z&6!&DKO+)8*/Q!3'N Z*3I(M;286;6?X-WP4&@T9
MNS&U\\X-FRXX[VYJ+S[EC0(^6U[\>.]0PL#OCQE1V&5+C:I+7&2LF/H8Z.I4
M=.W(G/$,DG;.!X7>F3:Z>9S PN8YH8X]_HCS].MR=:>V:G[S_>O]%L.M#C9#
ME+6N*J$&M-9"\4SQ9+/*3+X$FVT7[2JNL(W [SS:M.)R!_;*W7C)1_QQ6H-]
M,^ZDT#52DEBH8=],NY#(",E&,1-4]/(0 Z>OZ)D&1FUE_VS@:B=!= "GQRSY
MR[U\6%P7?LYDY$&K4/-]4J[CV34X;C8=EI*T(FE;VK2P&4;?-)[80>'60%"=
MP>_C:KZ(\V]X<GV6F'7))X[DHMK:GUXH"!(MF*)\$=%H-:QT8B_4/2!K&M]L
M,K#M)Y;ILV<>AD?6'P+9K(O:#OR7/^/76JMRQ= /X63^92/+6QV%N PF6:2#
MQ 2Y)P$A""< BW>N)&,M]X/,L/UIZ2KDOK-U=F"9=*#F[FWVT;T^T>=C1KMA
M/J<"ELE ;":-'FQ*(#$(.L@LB-BFE&,/HB<T_PX-KN4TDCX24#_:1J0.B@G2
MRSI@J-K(S'OP*,AFL8)NJ"R9+VV*1G8F>4(#\P@ O;^4NS 3_I'K7G-Z\YW.
MYY?\*9_25F\G%%\S5%NTW&D$49*N&0H"O&<,T 1O7 K&,3'<)!B\;E>O OM=
M_VUXW8%6O*O<7]PFGV6;D*ED:YB@1K\=@G>U+C!+Z[5DO%7ZQ[:43GVI-X+,
MLV&=D>77 3YOZ^H!NRLE*6=5@F0$[8YA 50J@R)-IA1S7/#V<V)'PF;#^_DP
MV&PHNQXOX)_GZ[@\7YQ]PK-\S;]()@53)@+6 5UD59 9H[F!P(A[C#:6A=KY
MZGULQ:X>7$>]=/?F;P?J[%EU?7N#'_,JUED2)D05:QPL(JM'P2KPVEC(+D?F
MD-,1;/."ORVEG5VW^X-EFXMV7\EU@,QGE/5CN[..K@69 T26:A/A:,%9'\A;
M,M[72@JGVG<W'0F5A[MH1T=E0ZEU7O[RZ_G9^2I?MMVZBO7_;4$"K9-X*E-.
M:H'CY86TR3!,RTWQT;(X)?9.;1EI_3%37UJPI$UJC'7:I, S%%7;8PD"HT]U
M]'+>A&"$+;Z-$]FRYN;6Z]85\W\^OSGFW&@>DZA#'NKT:F8TA#I5,]!%P34O
M3C?*3]^&RJ[R:;9!R;#QDR.(IH.K^ME&Z[?V]SL=WL__SB??\V_+Q=G7]<Q)
M71M86DBAFB1(-TTP.H)FV3N9Z*=N@K;XSU \+1S;86B;SOEC"?2(@/O_9EQ]
M_O=RIG(J0DKR%V/PH&SMU*ZY)935QCT2<TF-AAAN1^BT[]S=P707\1T;.@EN
M>29X3C+G#%G7QC_:9?#6..!!6CI[TOC0JG1X2U*G?8KI$Z%;B_#(,/KK\GPU
MLQXMU]Z S'68;:[C*I4FED;N2Y+)!S.]"JV43ANW[!*A6POPV  Z_YYGQ2KO
M?-9@A&.@8DX0,$K@F5O!DW(!6S:S&T[IM-W(^@3HM@(\(H!NXB/7F\3@0B@^
M@T630*4:GN.V@'&9\YJL:E6K0KH=R)VVMUEW4-U=E$>$UUE!H5$8 R5'7V=7
M6" ;)H&SE8V)JY!:CNU]F<)I>Z%UA\JM!-;#F/CG]O6W1;I\;LCIES\C_=,W
MI_5/,\:RT5K4ULY:@N)1 \;Z%!8Y"SP%F_P$+M)3Y$[;*ZT/B(XBR@X4YU-I
MR\JCY)%C33-A=?QI! PJ0B"611Z54'B(!+;M<G7]T6-N#'%TH 6?V,;;\U7E
M]JQPP7D4"H0MJIX1I#/B(B2IG!)H0V*':+EVGZYA<73V6D&VBW3ZU6#U,?=R
M0\8Y935&8)&3+<OKX 2A)$@;%%<Y:^4/44;]"&G#$'?\3S?CRJ@#T#U6'/$$
MWTH(C&?T8'BLPYM5 ?2.?N$B"\EJ]+2-;3><QJXJ$/=YSVXDEDX!]^RCI^8F
M!Z\+<*;J?$;BI;<V QUC0RY]3+X<#G;]OEZW0LR0R=MCB6_2V8A#=WCUW$D;
MP(S"@[6%KA&R-0!-8<"C<=8%'J-HWQBUVU?J3N"XB[".!X6;)\UB65(\9?".
M3IE2Q,/ 4$%B12C%?;&^C0\RF,1I7Z-[0N+6 CL:+&X>+S-MH: R(%.M_V Q
M08BD\$7F.I"W5<C\G0R*T[\Z=X3$K<5U/$#<//H(;3BOP<I@R/-'3'5X4H3@
MB8&*"=IVFQ+^H11.^[K<$Q"W%==1 /'N$V0,3)#)FX#.$RE\G2*@8A9DCB$6
M69,\VK<J[_P5N1-([BZX(W"M9\EX9K3/$%2A_:#(X"R7H"5Z'WD4EK=):WB)
MLFG?BCO!WE;BZ>!MY-']//F<2$8ORSDXR,)+4(;4NRN:?G'%%A<TF<0'#./T
M^2(\)1!'$5RO2I!,W4SL2N1IY5 K(9D@"\-E,G6U+HB&!3R@DSSM&_"4*-M*
M$+WJN)OWQ3H(V!HPWFM0WC) YB0D%"60OK:)'Q!4?;S]3@FN7>32J\:Z]:+H
M391D%B0@,+@ZLL2 $XGV%!.QCR59#AE5Z>;-=TJD[2B=_X@:^]F]^H3#5]G/
M>(=U]O?9<EUI_]>=I?;'>5CG?YT3.;]\KS3MPO<'WQB'<\^3-E*7@?N+W+R\
MBRR#4 *B#73>+3)PZ!4(582G'UE,;0J?GZ)HA#%0=[[[F3CX$_V#?\Y2,2F)
M5*"@)WO*)P&>.P=!%BY)!P7?R*UZDJ1IG\%'P<0C8Z)&8'^WVO\!SU*:UX_B
MR:W!.GMT4-GJ^VWTS_ MM=9-.G(MG&3 $RMD+Y@(WDF$8J.*(1FM59NI 0?2
M39_K73@35CJ97.WG7X?DVB(@(-9<\L*#<LZ@2(?8Y8::3C72-DAX02-MS_0.
M_)Z?SM?S18TSQ7^=S]>;X_GFS_EZ1G0;IY2!6 NU5=6NSC(&PN:@K!%<-.J<
M\P1!7<%G!TDOQV=[I^BIOUWE_/.R=AN=.5F*E"G2%1\B,8F<LA *AQ(+<E^T
MR[R-W_PB:=,B:A0 # #5[M*8NMWK!S(0_COCR=G7=XOX9I$^KI;?YR24_UHM
M_WWV]8_ER?FF@_W[]V]_RZ<AKV8QH$]:%B"]7<=J<4^JW- O/BE/VY0<7[22
M=EJY/R3M(?7EH430@?JZK];I/]L<0F;I&'*30)M"#).U]S+I=."8I"PL1*7%
M00RG2X*FS2(=_?(;@^U]HN?RP)G"A>%UE'HMLE,\&<"D2. >G2\NBGA_'%0[
M_/1PV8TB\)=!M /W^X/1I29U016ELP4Z3QQ4]A:09P7(4!G+@FF5KO0H.=W!
M9Q=1/P^@'?C>'WC>DR7P[BR?KF>.SI9G5D,NL=[Y2H(S3-4G%RT*G;3(#Q)]
MO:9HVOSSUG?8;HSO $"/6(^7C:OQ2_Y0_KZL=997PT37EX9EFGEAK=1>0<YD
MXRGO4BVP1&":MIC(=<GB8&[= 'J[TE\[8N5E9V]LP74$S[?+TS!?;"3VECR.
MZH1L_O!YA8OU!65\QHWC7"=="XH8*%8T!%\[9G!+]P'+I:0V@VBVH;(K6WY<
M*(XNI*E#$+^?5YO@0_F9CDX\HSUM8L9TKGY9G&W21L_F-9@\BY%+)4V&0CP$
ME9@C,R1F\'6F@(S9V?L]GI^(/ Q<L*N[=#\,->-S+]CYE$^79_ER"[\M%W/Z
M;VAGUWL2K 2&N=0.+/YRHJ?G$KA7$HNSVKMA<P('+CAM]54[[(S)Y_:/Q)<_
MJ+\$7.?_^__X_P%02P,$%     @ DHI<5 Y%2@39$   I50  !@   !A;65H
M+3(P,C$Q,C,Q>&5X>#$T,2YH=&WM7%MSVS86?M]?@3JSK3TCRY9C)XZ=9L:U
MG<8S:9)-W*3[M .1H(28)%B E*+^^CT7@*2NOC0;.VOW(;4H$@0.SOG.=R[0
M\Q].WAZ?__O=J1B662K>_?[+Z[-CL;:YM?7I\?'6ULGYB7AU_MMKL=O=[HES
M*W.G2VURF6YMG;Y9$VO#LBP.MK;&XW%W_+AK[&#K_/T6#K6[E1KC5#<NX[47
MS_$*_*MD_.(?SW_8W!0G)JHRE9<BLDJ6*A:5T_E ?(J5NQ";F_ZN8U-,K!X,
M2[&SO;,C/AE[H4>2OR]UF:H789SG6_SY^1:]Y'G?Q),7SV,]$CK^>4WW]N-^
MW-N6^T_Z:C=ZFNSWDKUX;Z^7/-Y]MIOL)/_IP22WX'9^QI635/V\ENE\<ZCP
M_0=/GG6?[A7EX5C'Y?"@M[W]SS6Z]<7SQ.0EO,_"\_PG#S,W6*F^E)LRU8/\
M((()*[O&SX;O(Y,:>_!HF_X[Q&\V$YGI='+PT[G.E!-OU%B\-YG,?^HXV(=-
MIZQ.^$:G_U(P*9@??1SSG)_".*G.55A#;P=G??3N[>O7;\5OIR=GQT>OQ:NW
MKT_.WOSZH2/.WAQWI]>P:GUW<&7';T].Q=N7XO3\U=GQA^]D*;L+E[(N8U.@
M61P55J>B]ZP#%M#;W[CVQ._:<A?MW"%-(U:1L1+!Y:#*8V7QKK479WEI35Q%
M>'WI,C)I!V"JI2D.>D5YI95//W)8R#@&_-E,50);TMUK72+\.=CI[N#%EL ^
M5Z[4R80O:9AQ7AX\?E*__AMJS.-]T)CSH1*_&&EC81)QHJV*2F,=?C@J3)H:
M\9N*=213\<JDN"X'!I]'7;%>PH,_/MK?V=D^/#99(?,)?>H=;HBA="(H8CG4
M#O X5CCD*7R*'#X+%^N'8U4_F1@K=.E$'";2@<<2'2F8DLQACO!6*U16I&:B
M0 CK($ ]TG$ETW32@5O"J'[R[Z0MP[QH !!K"B/KD<+[YV_6RH7)=(4X<N!?
M8!'P4J5S''\BP+#R2!<@$?5%114.%>;8:7V9Z%S"G_#7@B]E%)DJ+]%S^6\%
M+#PRJ+0P/[@7/A:P:),[_#^()<.;G08-D%8D54Z:#4*Q2CB3J9)T0J;."*L2
M92V*W@C8B-8^?5"YAH%?UE-[ZV7;]6N^$?9-V\ V&L$MH=]YK6NH@7VE<A"&
M!"'*?CH10!' _E@NL0+0$F-K\D%L4+*H&W"]L"8S)>CCWOZ\,/X&;$S):&__
MQD"QV=N_-:0@'7ER^..CWI/M!?^^,KER)0E2H9F#>H%"(P1W!.A]6N%B21O#
MUT.X-V4; (LH*[05*V11@%(CPS-YDNJH)##2Z&5P_+XJQ[BQ;!UH2_!"V+9$
M.4<$$[8\)7?@AKH 8]Y[]K"3U]O)EU6:=D0B-> 0(%4%WE5U!"(,6!&*F_RL
M*^%/,"P%8.VBU+@*H$BCQ17&E@S7L6?9B$(2= .^'&A70CA0 D"FL**Q+H>$
M=J[J9XC\I>F0DGP ;+4:\9A&.OT2@;H,%)AWEFG::KH.+V2?4%1]4!90FBRK
M<E OAL=, ACT)S1B[:46:<3W!727;""N--6 \8KDBR8%LJ&]&IB1LCGN"5A*
M*L?@8&V5>B'#[E3>=OZW=G.7A8>$"-U 43+H,*2@3A-^&209(%!KP)V#87@@
M:CMLC0:N$ZU(/9'K7$60.[-TDL'EEH04&-M(&Z\1^*DF<Z0>J#/W4D6.F+[)
MODYU.2'2*F/DB&AQH"&UF.;CXLO7^MU'7EW1H@*GWM<?,Q5X",56N.7I,(2H
MO?I20+3BN7S$(O7Q /HT;45<T<V>4V%0,R3I>U=-^(_>KRHSXQC2!N!7)_4N
M>9(F0&43JQ3\8S+X1U8QNW 5J0+WN%OO97@""1I,Q/'D\#8U0\68(]C8>5^-
M+%"YRT@@WOMU66 ' R&D*95SC,H#2A]:# 2D3F&\U(R76^LJ5>MU>SMSNN8O
MWBR[\K7?]@VQ ?1X)38 .,R2D]=$0M[7).1]0T(>T&(%6IR1R:(I 6SH:,+^
MN::Y:)01BGKB.6":MGG@"NK786-MA@\V!I97P/?:NSUXGY+14+13+00%Y KI
MKW06 M!XK?:Y"YT5!LV1^;E;.:FN. -K1V2,X!($)O.O'FM<XM3+5PSH <)3
MNB8?0^ #L2I]R&198GI$'(% 9UX&,OVS@N5P&J9OJK*6KY>/9;PJ+& ,WD80
M!P/!K'A2>$LS)>&&IDIC2@,1UHM,97U,#273\<O^3N_IH1-5 3L#4\SE0"&A
MOQE\?17=O[]X1H#6\E!GWD,]0-<JZ,K;24WF,9]-WW.9CKB$"%4.XU@3B\]5
M/*!B(+,C *Z2S-XG0SD]@!?&<N(Z'(PI\/6>!^$^N1GK E,/V=+ /-K$(Z22
MU1>-SXX);" @G$TWDX'6P!F>ID0'OJSF,8@(@F7LK;V#J VSAUM,37X8;@*@
M)/ALP^PN6<]+>$Q]D> )% A(+%H5@ C %69Z<$7Y[(+PQ5-S!-"*E!ZAC)M%
M+E5?O_5[3U@M ?.I%'S  #Q2<[71\&#?E*7)#K:;1V3?F;0JYQ^YI)S*_PYM
M$WT-U&8?*.#%IDQ !@<R1169?OU7K>)^-1N^)9/MJUPEP FPLH->O$K+H&F+
M==]O6:.FM4*"A2U50BI@2*N=CT.6F58?R_[ ]9NTRPSE]Z2'*) J=6G L%R%
M_IE,#&0)5@9_U0,AM\BY#L,)Q2D+T+S4J3< ?9':NN4R,/W/7&IJWA(0BY"
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M*FZ0LY%B\_,S)J9$L+<%,6J]:37JS5&U'30;(3\Y:;=XF[4#%D51JUYC_PK
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M?.5N@O^<Z(7F%.:I-()U=5>B$3C8H7)&YZ;P+%<BMJ\%4&C=_O7!>0V;WA)
M4-+4\,[BRRD4OE32>4<D#DBNTVFN/I\Q'&&*!13(6#Z*&] WYUZTV^56M86.
M6+#>LL7 N8]EYV/%LLVV=KG1;.ULK9:#G6U_IK4.C<'NKO^SVG+0K'UWK;5F
MN5%O_Q"UC?WFH.*BYB,'V# I3=X6ZH4EPEU.Z=32>Q)L3[Z/$.+!\?R7*-QB
MNN@.^^OD)O=_BVOYRLBQ#LX1=T))%E8>K.L;R=^Y_IZ/=(:_Q]9.BN[NUQY3
ML'"Q2AQ/V4?T)YF-UZ\:4';<Y\J]$_(=8;$V9UM7T9NGS/-.T3>/+754Z5O0
MB_S@H(*UZV+06K3^+U/\,\UB3Y5Z$\$CTK_G88:,B%S[+:^CY3<:=A+,W?O\
M:U;WG]6C&W^R#AQU8UZ/-Z>RXGC4%N*V\R+>%M9WB*2WXJ\'NXO*Y_\%4$L#
M!!0    ( )**7%07?''F>@@  -LL   8    86UE:"TR,#(Q,3(S,7AE>'@S
M,3(N:'1M[5IK<QHY%OV^OT)#:C-V%>^'']AQ%<&D0FW&=MED,O-I2W2KC=;J
M5H^D!K._?HZDQH"!"5XG7N*:?"#0NKJZCZ-[C^0^_>G\LCOX_:I'1B86Y.KS
M^T_]+BF4*I4OC6ZE<CXX)Q\'OWPBS7*U1@:*)IH;+A,J*I7>18$41L:D[4IE
M,IF4)XVR5+>5P77%JFI6A)2:E4,3%LY.[1-\,AJ>_>/TIU*)G,L@BUEB2* 8
M-2PDF>;)+?D2,GU'2J5<JBO3J>*W(T/JU7J=?)'JCH^I'S?<"'8VTW-:\;]/
M*VZ1TZ$,IV>G(1\3'KXK\&IU6#TX/J+-*&+-@ZAYU#QD08!OK7JCQNK!OVLP
ML@)Q/T>;J6#O"C%/2B-FUV\WZ^7#5FI.)CPTHW:M6OUGP8F>G48R,5A/8;[_
MZM6L*J/J%OJ,3-NU.C09=F]*5/#;I.U<+'A5,_% "JG:;ZKNWXD=*44TYF+:
M_GG 8Z;)!9N0:QG3Y.>B1EI*FBD>>4'-_\M@(Q9Q/R?>A4/H$3QA,Y=J=>M$
M[W[$A]R01JU<7_9@@^W59=L#!)^IES?^L GCN[WK0?]#O]L9]"\OR.4'<G7=
MO^CVKSJ?2.^W7O?SH/]K#X\AT;O^X9R[^GQ]\[ES,2"#RQ_.]IM>UZ6D4:W;
MM P^]LA-Y_I]YZ)W4[K\[5/O=]+I#NQ(O5K=#G:/MLQ_,FUX-/WN[C77;II^
MD;Q'+0QE0FYX7"0!4]8:8D;4O'W3.CK9VJ64AB$*7TFPR+0;!VN=](]X$B*C
M[5+],/W^M6*]V[7RS*^77WTY4K7C<LN&H4]&=,R(8F/.)N@B9L0UH4F248&'
MJ52&($<?I(I)K5KZ%Y$1Z:12"$E^82$/(/51"JM6%TD_"<I(WO$K35Y]YY+W
MGFJD#/F)I^0ND1/!PEM6]#G,DQ=*F)!(T 2L0'F"W$Y)EAB5,7@ XN X!+)*
M28Q?BB.C$0WP2!$9HZT9Z>56!!(6,*VIFEJ1F-XQK+N@4^-9"&.PI' $!&M8
M@8 K$ Z()9@.2T*FR&3$@Q'1F?V8SY\PQ7(EUH&8:P%F8DG.A)L1'-0I"YR!
M5F\*TV0(-\>8%I+A=#$,KQB5C1\'E8Q$/$'>+83F>2X"DA#'L%H8YTF$FD,M
M5<;W0&0A= )+"TDM H=<B2E) 06+8HMN(>8PS1&B'RV-G1 Z#EZT$IF  + I
M 2"WG';V!%2/2"3D1,^ J]@MUP9-RQ!J'WJ[865Q 7]Z9LR*M:\8@LV=@^!@
M*5]OWQS5:X<G.@=9SC5L(9%1Q/%S3^^[9/8)5<S!!C#@0\%L>@D#5H>"ZY&=
M8<5BU%%;2^WOD.M 2)UAGJVP2@J/GU3)@(5XK,D>X!(RX,]CHG<?C&ARRT@'
MQ>LZ$Y"H-6BIUMICWHI:*_2__$]N66CB<6OU$UOA%N#LX65MV7JA:&FA" M9
M/Q^#'!*6&SR#CC5;NPW</;J_,\AME8]K-A#G3"-4R*!KAU^'5]%VZH!F>OLI
MMF4.&:"2K^2;L,P4%*",C;EVQ1%2+'%Z+"N?E]7%TJR8H Y[>1>>XZ>8EVT[
MR%%B88N6@H?NKD)G0\U#3A6W#G#/%5RS2*RF3-O^[7:K=LW>E5*I&0PR*-UV
M4DH!^B 3U'8 N.6,F/, S/"L8I$,X=N064$4:<QGX3.*\LYC>[A+V&XT5[&]
M=6%;@?CV)7%KI&-WC'EH 4RU3*BM_50#_):F6E13%<X0!LQS.N2"FZGE!NN6
MM?O-@='AS&^5)=$%FNM:S'WN4)JI%#C7CLL$@52A,\ 1WEN6@*((P!TC++7[
MR(J S'M(8[_Q%%7^-8,ZV"50^X+=&U.1N:IF,\ZB")23CY$KO88Z/E"1+:JT
M_[F>33H,8R(JK/:<=2@SL]F";?H(?9!FEI!'7S]6D>&,ZKMMR7PD8(^#H%W@
ME<(PW"48YK759W@5*?; GQ-!-[(6CD^HJ)8+R"#(E,7#0N-=HS66VN"YO4B%
M+FUOB_[(T+>A>F_#E C 1JU[))T;CD,9<W<5R?(5U;ZW:D3U TNQ5=)M!!:Z
M]N'BD9?V*1'\CHG\XN*1?/'9(7HF^'?]M-=Z/:<]=_49SC9.<5[.;'5=!.^\
MLEGX/8&XK-#B!^LHJ+&12C]P!?< *N.8&\/87_2.H00;L>,AAWU.R1X@CE*M
M;2O _Y:@S_8E^R/C,-_MP2P)W!7'_M^'NA?E"!T!RH=@<0#0GJWM*3W@#'#)
M^_S#X6K"Z)UMW)X"NM;MR*N[CYU=43T)A/DYR-]LK*F -,1$S1X*X$; YI07
M4X Z,-.B9P\:U$%G,3"#*#EG\L:S]C+OM3.#'3QU=4  (H7R4@04F"N* ).[
M4L]15_3]DR=C*<;,-M&$WN9_&5!Y'65Q*N24870RDKYRTB5, X/?A&&4-R+C
MT9L$."BY:]RVOX08LY5W"V83A](8&;>K\RETJ*7(S.J4K[R.X#]':J8Y19Q*
M0^RKNQ*-X&";B@F=ZL*+O 6Q?B] H7'GUP?G%0Z])4!0T%2S]NS+"1I?*NBT
MS1,')#?I)%>?1\RN,+8-%&0L7\4MZ(=S+XZ/RX?50^N(@?4FG"V<^UAV/E9,
MN#IV7&ZV#C>.5LNUC6-_I;6!P=KFJ?^SVG*M5?_F6NNM<K-Q_%W4-K>+0<5E
MS6<.V- I3=X5&H4YPEU-:=?3>U);7WP?(<2#X^7?FW";Z;PSZ"V3F]S_-:[E
M.R/'.IPC[H:2S*S<6==7BK]S_0,;JLS^/;9^5'2O>VT1@IF+5>)XRC:B/T@T
MWKYIHNVXS\573;XA+)9BMG87'3PGSAM%#QY;ZJC24]!K^<%.)6M3@OXO4?V1
M M>5I>Z(LXCT[EF061)$+OTI]^\X/B6.>U?^^AQ$="62^ZNAK#BRM(:=;7S!
M;@VUVT5F6_&O_;H7D,_^!%!+ P04    " "2BEQ4VI!R)FL(  "4+   &
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M@($82N[22SBP.I3"C-P,)S9&'76UU/UFPD12F0SS7(752@;\I%I%G.&Q(7N
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MCC!@7M"AD,+.'#?8M*S;;QZ,'F=AJZR(+M%<WV+N<H?23*? N?%<)HJ49MX
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MGB@MT;!'B=HN\M1*>%_7OSE\\CM02P,$%     @ DHI<5!=?^5)Y!0  J"X
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M,C,Q+FAT;5!+ 0(4 Q0    ( )**7%2U_N/@LR4  $B_ 0 1
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M2P$"% ,4    " "2BEQ4#D5*!-D0  "E5   &               @ '$PPH
M86UE:"TR,#(Q,3(S,7AE>'@Q-#$N:'1M4$L! A0#%     @ DHI<5,5L!>T
M!0  /40  !@              ( !T]0* &%M96@M,C R,3$R,S%X97AX,C$Q
M+FAT;5!+ 0(4 Q0    ( )**7%0UO .L$P0  !L5   8              "
M 0G:"@!A;65H+3(P,C$Q,C,Q>&5X>#(S,2YH=&U02P$"% ,4    " "2BEQ4
M9BU;EA$#  #N"@  &               @ %2W@H 86UE:"TR,#(Q,3(S,7AE
M>'@R,S(N:'1M4$L! A0#%     @ DHI<5%8WTS"3"    RT  !@
M     ( !F>$* &%M96@M,C R,3$R,S%X97AX,S$Q+FAT;5!+ 0(4 Q0    (
M )**7%07?''F>@@  -LL   8              "  6+J"@!A;65H+3(P,C$Q
M,C,Q>&5X>#,Q,BYH=&U02P$"% ,4    " "2BEQ4VI!R)FL(  "4+   &
M            @ $2\PH 86UE:"TR,#(Q,3(S,7AE>'@S,3,N:'1M4$L! A0#
M%     @ DHI<5!=?^5)Y!0  J"X  !<              ( !L_L* &%M96@M
H,C R,3$R,S%X97AX,S(N:'1M4$L%!@     /  \ ^P,  &$!"P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
